<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39635529</PMID><DateRevised><Year>2024</Year><Month>12</Month><Day>05</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>The complement system in lipid-mediated pathologies.</ArticleTitle><Pagination><StartPage>1511886</StartPage><MedlinePgn>1511886</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1511886</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1511886</ELocationID><Abstract><AbstractText>The complement system, a coordinator and facilitator of the innate immune response, plays an essential role in maintaining host homeostasis. It promotes clearance of pathogen- and danger-associated molecular patterns, regulates adaptive immunity, and can modify various metabolic processes such as energy expenditure, lipid metabolism, and glucose homeostasis. In this review, we will focus on the intricate interplay between complement components and lipid metabolism. More precisely, we will display how alterations in the activation and regulation of the complement system affect pathological outcome in lipid-associated diseases, such as atherosclerosis, obesity, metabolic syndrome, age-related macular degeneration, and metabolic dysfunction-associated steatotic liver disease. In addition to that, we will present and evaluate underlying complement-mediated physiological mechanisms, observed both <i>in vitro</i> and <i>in vivo</i>. Our manuscript will demonstrate the clinical significance of the complement system as a bridging figure between innate immunity and lipid homeostasis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Alic, Dendinovic and Papac-Milicevic.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alic</LastName><ForeName>Lejla</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medical Biochemistry, Faculty of Medicine, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dendinovic</LastName><ForeName>Kristina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurophysiology and Neuropharmacology, Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papac-Milicevic</LastName><ForeName>Nikolina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurophysiology and Neuropharmacology, Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">complement</Keyword><Keyword MajorTopicYN="N">complement system</Keyword><Keyword MajorTopicYN="N">innate immunity</Keyword><Keyword MajorTopicYN="N">lipid metabolism</Keyword><Keyword MajorTopicYN="N">lipid-mediated pathologies</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>5</Day><Hour>5</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39635529</ArticleId><ArticleId IdType="pmc">PMC11614835</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1511886</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Binder CJ, Papac-Milicevic N, Witztum JL. Innate sensing of oxidation-specific epitopes in health and disease. Nat Rev Immunol. (2016) 16:485&#x2013;97. doi:&#xa0;10.1038/nri.2016.63</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2016.63</ArticleId><ArticleId IdType="pmc">PMC7097710</ArticleId><ArticleId IdType="pubmed">27346802</ArticleId></ArticleIdList></Reference><Reference><Citation>Alic L, Binder CJ, Papac-Milicevic N. The OSE complotype and its clinical potential. Front Immunol. (2022) 13:1010893. doi:&#xa0;10.3389/fimmu.2022.1010893</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1010893</ArticleId><ArticleId IdType="pmc">PMC9561429</ArticleId><ArticleId IdType="pubmed">36248824</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhivaki D, Kagan JC. Innate immune detection of lipid oxidation as a threat assessment strategy. Nat Rev Immunol. (2022) 22:322&#x2013;30. doi:&#xa0;10.1038/s41577-021-00618-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00618-8</ArticleId><ArticleId IdType="pmc">PMC8454293</ArticleId><ArticleId IdType="pubmed">34548649</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotamisligil GS. Foundations of immunometabolism and implications for metabolic health and disease. Immunity. (2017) 47:406&#x2013;20. doi:&#xa0;10.1016/j.immuni.2017.08.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2017.08.009</ArticleId><ArticleId IdType="pmc">PMC5627521</ArticleId><ArticleId IdType="pubmed">28930657</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Chen Y, Pei H. C1q and central nervous system disorders. Front Immunol. (2023) 14:1145649. doi:&#xa0;10.3389/fimmu.2023.1145649</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1145649</ArticleId><ArticleId IdType="pmc">PMC10076750</ArticleId><ArticleId IdType="pubmed">37033981</ArticleId></ArticleIdList></Reference><Reference><Citation>Beltrame MH, Catarino SJ, Goeldner I, Boldt AB, de Messias-Reason IJ. The lectin pathway of complement and rheumatic heart disease. Front Pediatr. (2014) 2:148. doi:&#xa0;10.3389/fped.2014.00148</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2014.00148</ArticleId><ArticleId IdType="pmc">PMC4300866</ArticleId><ArticleId IdType="pubmed">25654073</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastellos DC, Hajishengallis G, Lambris JD. A guide to complement biology, pathology and therapeutic opportunity. Nat Rev Immunol. (2024) 24:118&#x2013;41. doi:&#xa0;10.1038/s41577-023-00926-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-023-00926-1</ArticleId><ArticleId IdType="pubmed">37670180</ArticleId></ArticleIdList></Reference><Reference><Citation>Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I - molecular mechanisms of activation and regulation. Front Immunol. (2015) 6:262. doi:&#xa0;10.3389/fimmu.2015.00262</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2015.00262</ArticleId><ArticleId IdType="pmc">PMC4451739</ArticleId><ArticleId IdType="pubmed">26082779</ArticleId></ArticleIdList></Reference><Reference><Citation>Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B, et al. . Molecular intercommunication between the complement and coagulation systems. J Immunol. (2010) 185:5628&#x2013;36. doi:&#xa0;10.4049/jimmunol.0903678</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0903678</ArticleId><ArticleId IdType="pmc">PMC3123139</ArticleId><ArticleId IdType="pubmed">20870944</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekassy ZD, Kristoffersson AC, Rebetz J, Tati R, Olin AI, Karpman D. Aliskiren inhibits renin-mediated complement activation. Kidney Int. (2018) 94:689&#x2013;700. doi:&#xa0;10.1016/j.kint.2018.04.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2018.04.004</ArticleId><ArticleId IdType="pubmed">29884545</ArticleId></ArticleIdList></Reference><Reference><Citation>Donado CA, Jonsson AH, Theisen E, Zhang F, Nathan A, Rupani KV, et al. . Granzyme K drives a newly-intentified pathway of complement activation. bioRxiv. (2024). doi:&#xa0;10.1101/2024.05.22.595315</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.05.22.595315</ArticleId></ArticleIdList></Reference><Reference><Citation>Irmscher S, Doring N, Halder LD, Jo EAH, Kopka I, Dunker C, et al. . Kallikrein cleaves C3 and activates complement. J Innate Immun. (2018) 10:94&#x2013;105. doi:&#xa0;10.1159/000484257</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000484257</ArticleId><ArticleId IdType="pmc">PMC6757171</ArticleId><ArticleId IdType="pubmed">29237166</ArticleId></ArticleIdList></Reference><Reference><Citation>Elvington M, Liszewski MK, Atkinson JP. Evolution of the complement system: from defense of the single cell to guardian of the intravascular space. Immunol Rev. (2016) 274:9&#x2013;15. doi:&#xa0;10.1111/imr.2016.274.issue-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.2016.274.issue-1</ArticleId><ArticleId IdType="pmc">PMC5108576</ArticleId><ArticleId IdType="pubmed">27782327</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey S, Maharana J, Li XX, Woodruff TM, Shukla AK. Emerging insights into the structure and function of complement C5a receptors. Trends Biochem Sci. (2020) 45:693&#x2013;705. doi:&#xa0;10.1016/j.tibs.2020.04.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2020.04.004</ArticleId><ArticleId IdType="pubmed">32402749</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarantonello A, Revel M, Grunenwald A, Roumenina LT. C3-dependent effector functions of complement. Immunol Rev. (2023) 313:120&#x2013;38. doi:&#xa0;10.1111/imr.v313.1</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.v313.1</ArticleId><ArticleId IdType="pmc">PMC10092904</ArticleId><ArticleId IdType="pubmed">36271889</ArticleId></ArticleIdList></Reference><Reference><Citation>Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol. (2009) 9:729&#x2013;40. doi:&#xa0;10.1038/nri2620</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2620</ArticleId><ArticleId IdType="pubmed">19730437</ArticleId></ArticleIdList></Reference><Reference><Citation>King BC, Blom AM. Intracellular complement: Evidence, definitions, controversies, and solutions. Immunol Rev. (2023) 313:104&#x2013;19. doi:&#xa0;10.1111/imr.v313.1</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.v313.1</ArticleId><ArticleId IdType="pmc">PMC10086947</ArticleId><ArticleId IdType="pubmed">36100972</ArticleId></ArticleIdList></Reference><Reference><Citation>King BC, Renstrom E, Blom AM. Intracellular cytosolic complement component C3 regulates cytoprotective autophagy in pancreatic beta cells by interaction with ATG16L1. Autophagy. (2019) 15:919&#x2013;21. doi:&#xa0;10.1080/15548627.2019.1580515</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2019.1580515</ArticleId><ArticleId IdType="pmc">PMC6526805</ArticleId><ArticleId IdType="pubmed">30741587</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiss MG, Papac-Milicevic N, Porsch F, Tsiantoulas D, Hendrikx T, Takaoka M, et al. . Cell-autonomous regulation of complement C3 by factor H limits macrophage efferocytosis and exacerbates atherosclerosis. Immunity. (2023) 56:1809&#x2013;24.e10. doi:&#xa0;10.1016/j.immuni.2023.06.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2023.06.026</ArticleId><ArticleId IdType="pmc">PMC10529786</ArticleId><ArticleId IdType="pubmed">37499656</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulak K, Kuska K, Colineau L, McKay M, Maziarz K, Slaby J, et al. . Intracellular C3 protects beta-cells from IL-1beta-driven cytotoxicity via interaction with Fyn-related kinase. Proc Natl Acad Sci U S A. (2024) 121:e2312621121. doi:&#xa0;10.1073/pnas.2312621121</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2312621121</ArticleId><ArticleId IdType="pmc">PMC10895342</ArticleId><ArticleId IdType="pubmed">38346191</ArticleId></ArticleIdList></Reference><Reference><Citation>Liszewski MK, Kolev M, Le Friec G, Leung M, Bertram PG, Fara AF, et al. . Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation. Immunity. (2013) 39:1143&#x2013;57. doi:&#xa0;10.1016/j.immuni.2013.10.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2013.10.018</ArticleId><ArticleId IdType="pmc">PMC3865363</ArticleId><ArticleId IdType="pubmed">24315997</ArticleId></ArticleIdList></Reference><Reference><Citation>Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT. Complement system part II: role in immunity. Front Immunol. (2015) 6:257. doi:&#xa0;10.3389/fimmu.2015.00257</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2015.00257</ArticleId><ArticleId IdType="pmc">PMC4443744</ArticleId><ArticleId IdType="pubmed">26074922</ArticleId></ArticleIdList></Reference><Reference><Citation>Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, et al. . Atherosclerosis. Nat Rev Dis Primers. (2019) 5:56. doi:&#xa0;10.1038/s41572-019-0106-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-019-0106-z</ArticleId><ArticleId IdType="pubmed">31420554</ArticleId></ArticleIdList></Reference><Reference><Citation>Geertinger P, Sorensen H. Complement as a factor in arteriosclerosis. Acta Pathol Microbiol Scand A. (1970) 78:284&#x2013;8. doi:&#xa0;10.1111/j.1699-0463.1970.tb03303.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1699-0463.1970.tb03303.x</ArticleId><ArticleId IdType="pubmed">5507253</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollander W, Colombo MA, Kirkpatrick B, Paddock J. Soluble proteins in the human atherosclerotic plaque. With spectral reference to immunoglobulins, C3-complement component, alpha 1-antitrypsin and alpha 2-macroglobulin. Atherosclerosis. (1979) 34:391&#x2013;405. doi:&#xa0;10.1016/0021-9150(79)90064-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0021-9150(79)90064-9</ArticleId><ArticleId IdType="pubmed">92993</ArticleId></ArticleIdList></Reference><Reference><Citation>Niculescu F, Rus H. Complement activation and atherosclerosis. Mol Immunol. (1999) 36:949&#x2013;55. doi:&#xa0;10.1016/S0161-5890(99)00117-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0161-5890(99)00117-0</ArticleId><ArticleId IdType="pubmed">10698349</ArticleId></ArticleIdList></Reference><Reference><Citation>Niculescu F, Rus HG, Vlaicu R. Immunohistochemical localization of C5b-9, S-protein, C3d and apolipoprotein B in human arterial tissues with atherosclerosis. Atherosclerosis. (1987) 65:1&#x2013;11. doi:&#xa0;10.1016/0021-9150(87)90002-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0021-9150(87)90002-5</ArticleId><ArticleId IdType="pubmed">2955791</ArticleId></ArticleIdList></Reference><Reference><Citation>Oksjoki R, Kovanen PT, Pentikainen MO. Role of complement activation in atherosclerosis. Curr Opin Lipidol. (2003) 14:477&#x2013;82. doi:&#xa0;10.1097/00041433-200310000-00008</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00041433-200310000-00008</ArticleId><ArticleId IdType="pubmed">14501586</ArticleId></ArticleIdList></Reference><Reference><Citation>Oksjoki R, Laine P, Helske S, Vehmaan-Kreula P, Mayranpaa MI, Gasque P, et al. . Receptors for the anaphylatoxins C3a and C5a are expressed in human atherosclerotic coronary plaques. Atherosclerosis. (2007) 195:90&#x2013;9. doi:&#xa0;10.1016/j.atherosclerosis.2006.12.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2006.12.016</ArticleId><ArticleId IdType="pubmed">17234193</ArticleId></ArticleIdList></Reference><Reference><Citation>Seifert PS, Hansson GK. Complement receptors and regulatory proteins in human atherosclerotic lesions. Arteriosclerosis. (1989) 9:802&#x2013;11. doi:&#xa0;10.1161/01.ATV.9.6.802</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.ATV.9.6.802</ArticleId><ArticleId IdType="pubmed">2480105</ArticleId></ArticleIdList></Reference><Reference><Citation>Seifert PS, Hansson GK. Decay-accelerating factor is expressed on vascular smooth muscle cells in human atherosclerotic lesions. J Clin Invest. (1989) 84:597&#x2013;604. doi:&#xa0;10.1172/JCI114204</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI114204</ArticleId><ArticleId IdType="pmc">PMC548921</ArticleId><ArticleId IdType="pubmed">2474572</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlaicu R, Niculescu F, Rus HG, Cristea A. Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. Atherosclerosis. (1985) 57:163&#x2013;77. doi:&#xa0;10.1016/0021-9150(85)90030-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0021-9150(85)90030-9</ArticleId><ArticleId IdType="pubmed">3910058</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbone F, Valente A, Perego C, Bertolotto M, Pane B, Spinella G, et al. . Ficolin-2 serum levels predict the occurrence of acute coronary syndrome in patients with severe carotid artery stenosis. Pharmacol Res. (2021) 166:105462. doi:&#xa0;10.1016/j.phrs.2021.105462</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2021.105462</ArticleId><ArticleId IdType="pubmed">33513354</ArticleId></ArticleIdList></Reference><Reference><Citation>Fumagalli S, Perego C, Zangari R, De Blasio D, Oggioni M, De Nigris F, et al. . Lectin pathway of complement activation is associated with vulnerability of atherosclerotic plaques. Front Immunol. (2017) 8:288. doi:&#xa0;10.3389/fimmu.2017.00288</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00288</ArticleId><ArticleId IdType="pmc">PMC5352714</ArticleId><ArticleId IdType="pubmed">28360913</ArticleId></ArticleIdList></Reference><Reference><Citation>Vengen IT, Enger TB, Videm V, Garred P. Pentraxin 3, ficolin-2 and lectin pathway associated serine protease MASP-3 as early predictors of myocardial infarction - the HUNT2 study. Sci Rep. (2017) 7:43045. doi:&#xa0;10.1038/srep43045</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep43045</ArticleId><ArticleId IdType="pmc">PMC5316974</ArticleId><ArticleId IdType="pubmed">28216633</ArticleId></ArticleIdList></Reference><Reference><Citation>Madsen HO, Videm V, Svejgaard A, Svennevig JL, Garred P. Association of mannose-binding-lectin deficiency with severe atherosclerosis. Lancet. (1998) 352:959&#x2013;60. doi:&#xa0;10.1016/S0140-6736(05)61513-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(05)61513-9</ArticleId><ArticleId IdType="pubmed">9752823</ArticleId></ArticleIdList></Reference><Reference><Citation>Poppelaars F, Gaya da Costa M, Berger SP, Assa S, Meter-Arkema AH, Daha MR, et al. . Strong predictive value of mannose-binding lectin levels for cardiovascular risk of hemodialysis patients. J Transl Med. (2016) 14:236. doi:&#xa0;10.1186/s12967-016-0995-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-016-0995-5</ArticleId><ArticleId IdType="pmc">PMC4974702</ArticleId><ArticleId IdType="pubmed">27495980</ArticleId></ArticleIdList></Reference><Reference><Citation>Vengen IT, Madsen HO, Garred P, Platou C, Vatten L, Videm V. Mannose-binding lectin deficiency is associated with myocardial infarction: the HUNT2 study in Norway. PloS One. (2012) 7:e42113. doi:&#xa0;10.1371/journal.pone.0042113</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0042113</ArticleId><ArticleId IdType="pmc">PMC3407165</ArticleId><ArticleId IdType="pubmed">22848725</ArticleId></ArticleIdList></Reference><Reference><Citation>Kieninger-Grafitsch A, Vogt S, Ribi C, Dubler D, Chizzolini C, Huynh-Do U, et al. . No association of complement mannose-binding lectin deficiency with cardiovascular disease in patients with Systemic Lupus Erythematosus. Sci Rep. (2020) 10:3693. doi:&#xa0;10.1038/s41598-020-60523-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-60523-3</ArticleId><ArticleId IdType="pmc">PMC7048794</ArticleId><ArticleId IdType="pubmed">32111865</ArticleId></ArticleIdList></Reference><Reference><Citation>Saevarsdottir S, Oskarsson OO, Aspelund T, Eiriksdottir G, Vikingsdottir T, Gudnason V, et al. . Mannan binding lectin as an adjunct to risk assessment for myocardial infarction in individuals with enhanced risk. J Exp Med. (2005) 201:117&#x2013;25. doi:&#xa0;10.1084/jem.20041431</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20041431</ArticleId><ArticleId IdType="pmc">PMC2212774</ArticleId><ArticleId IdType="pubmed">15623574</ArticleId></ArticleIdList></Reference><Reference><Citation>Meziani S, Ferrannini G, Bjerre M, Hansen TK, Ritsinger V, Norhammar A, et al. . Mannose-binding lectin does not explain the dismal prognosis after an acute coronary event in dysglycaemic patients. A report from the GAMI cohort. Cardiovasc Diabetol. (2022) 21:129. doi:&#xa0;10.1186/s12933-022-01562-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-022-01562-0</ArticleId><ArticleId IdType="pmc">PMC9270763</ArticleId><ArticleId IdType="pubmed">35804351</ArticleId></ArticleIdList></Reference><Reference><Citation>Bashore AC, Yan H, Xue C, Zhu LY, Kim E, Mawson T, et al. . High-dimensional single-cell multimodal landscape of human carotid atherosclerosis. Arterioscler Thromb Vasc Biol. (2024) 44:930&#x2013;45. doi:&#xa0;10.1161/ATVBAHA.123.320524</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.123.320524</ArticleId><ArticleId IdType="pmc">PMC10978277</ArticleId><ArticleId IdType="pubmed">38385291</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui HK, Tang CJ, Gao Y, Li ZA, Zhang J, Li YD. An integrative analysis of single-cell and bulk transcriptome and bidirectional mendelian randomization analysis identified C1Q as a novel stimulated risk gene for Atherosclerosis. Front Immunol. (2023) 14:1289223. doi:&#xa0;10.3389/fimmu.2023.1289223</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1289223</ArticleId><ArticleId IdType="pmc">PMC10764496</ArticleId><ArticleId IdType="pubmed">38179058</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo S, Mao X, Li X, Ouyang H, Gao Y, Ming L. Serum complement C1q activity is associated with obstructive coronary artery disease. Front Cardiovasc Med. (2021) 8:618173. doi:&#xa0;10.3389/fcvm.2021.618173</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.618173</ArticleId><ArticleId IdType="pmc">PMC8116493</ArticleId><ArticleId IdType="pubmed">33996933</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa N, Fujie S, Horii N, Uchida M, Toyama Y, Inoue K, et al. . Aging-induced elevation in circulating complement C1q level is associated with arterial stiffness. Exp Gerontol. (2019) 124:110650. doi:&#xa0;10.1016/j.exger.2019.110650</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exger.2019.110650</ArticleId><ArticleId IdType="pubmed">31279001</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishida K, Nakagawa Y, Kobayashi H, Mazaki T, Yokoi H, Yanagi K, et al. . High serum C1q-binding adiponectin levels in male patients with acute coronary syndrome. Cardiovasc Diabetol. (2014) 13:9. doi:&#xa0;10.1186/1475-2840-13-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1475-2840-13-9</ArticleId><ArticleId IdType="pmc">PMC3893390</ArticleId><ArticleId IdType="pubmed">24400991</ArticleId></ArticleIdList></Reference><Reference><Citation>Li QX, Ma XT, Shao QY, Yang ZQ, Liang J, Yang LX, et al. . Association of serum complement C1q with cardiovascular outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention. J Geriatr Cardiol. (2022) 19:949&#x2013;59. doi:&#xa0;10.11909/j.issn.1671-5411.2022.12.001</Citation><ArticleIdList><ArticleId IdType="doi">10.11909/j.issn.1671-5411.2022.12.001</ArticleId><ArticleId IdType="pmc">PMC9807401</ArticleId><ArticleId IdType="pubmed">36632200</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni XN, Yan SB, Zhang K, Sai WW, Zhang QY, Ti Y, et al. . Serum complement C1q level is associated with acute coronary syndrome. Mol Immunol. (2020) 120:130&#x2013;5. doi:&#xa0;10.1016/j.molimm.2020.02.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2020.02.012</ArticleId><ArticleId IdType="pubmed">32120180</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S, Nishihira K, Yamashita A, Fujii T, Onoue K, Saito Y, et al. . Involvement of enhanced expression of classical complement C1q in atherosclerosis progression and plaque instability: C1q as an indicator of clinical outcome. PloS One. (2022) 17:e0262413. doi:&#xa0;10.1371/journal.pone.0262413</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0262413</ArticleId><ArticleId IdType="pmc">PMC8794146</ArticleId><ArticleId IdType="pubmed">35085285</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson G, Truedsson L, Sturfelt G, Oxelius VA, Braconier JH, Sjoholm AG. Hereditary C2 deficiency in Sweden: frequent occurrence of invasive infection, atherosclerosis, and rheumatic disease. Med (Baltimore). (2005) 84:23&#x2013;34. doi:&#xa0;10.1097/01.md.0000152371.22747.1e</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.md.0000152371.22747.1e</ArticleId><ArticleId IdType="pubmed">15643297</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavusoglu E, Eng C, Chopra V, Ruwende C, Yanamadala S, Clark LT, et al. . Usefulness of the serum complement component C4 as a predictor of stroke in patients with known or suspected coronary artery disease referred for coronary angiography. Am J Cardiol. (2007) 100:164&#x2013;8. doi:&#xa0;10.1016/j.amjcard.2007.02.075</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2007.02.075</ArticleId><ArticleId IdType="pubmed">17631062</ArticleId></ArticleIdList></Reference><Reference><Citation>Engstrom G, Hedblad B, Janzon L, Lindgarde F. Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: a population-based cohort study. Eur J Cardiovasc Prev Rehabil. (2007) 14:392&#x2013;7. doi:&#xa0;10.1097/01.hjr.0000244582.30421.b2</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.hjr.0000244582.30421.b2</ArticleId><ArticleId IdType="pubmed">17568238</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Yin J, Shao K, Yang L, Liu W, Wang Y, et al. . High serum complement component C4 as a unique predictor of unfavorable outcomes in diabetic stroke. Metab Brain Dis. (2021) 36:2313&#x2013;22. doi:&#xa0;10.1007/s11011-021-00834-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11011-021-00834-0</ArticleId><ArticleId IdType="pubmed">34480681</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer J, Rajczy K, Hegyi L, Fulop T, Mohacsi A, Mezei Z, et al. . C4B*Q0 allotype as risk factor for myocardial infarction. BMJ. (1994) 309:313&#x2013;4. doi:&#xa0;10.1136/bmj.309.6950.313</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.309.6950.313</ArticleId><ArticleId IdType="pmc">PMC2540879</ArticleId><ArticleId IdType="pubmed">8086869</ArticleId></ArticleIdList></Reference><Reference><Citation>Nityanand S, Hamsten A, Lithell H, Holm G, Lefvert AK. C4 null alleles and myocardial infarction. Atherosclerosis. (1999) 143:377&#x2013;81. doi:&#xa0;10.1016/S0021-9150(98)00329-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9150(98)00329-3</ArticleId><ArticleId IdType="pubmed">10217367</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorensen H, Dissing J. Association between the C3F gene and atherosclerotic vascular diseases. Hum Hered. (1975) 25:279&#x2013;83. doi:&#xa0;10.1159/000152736</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000152736</ArticleId><ArticleId IdType="pubmed">1184013</ArticleId></ArticleIdList></Reference><Reference><Citation>Muscari A, Massarelli G, Bastagli L, Poggiopollini G, Tomassetti V, Volta U, et al. . Relationship between serum C3 levels and traditional risk factors for myocardial infarction. Acta Cardiol. (1998) 53:345&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">10063429</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai G, Li L, Chen Y, Huang H, Yu L, Xu L. Complement C3 gene polymorphisms are associated with lipid levels, but not the risk of coronary artery disease: a case-control study. Lipids Health Dis. (2019) 18:217. doi:&#xa0;10.1186/s12944-019-1163-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12944-019-1163-8</ArticleId><ArticleId IdType="pmc">PMC6905069</ArticleId><ArticleId IdType="pubmed">31829184</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoudary SR, Chen X, McConnell D, Brooks MM, Billheimer J, Orchard TJ. Associations of HDL subclasses and lipid content with complement proteins over the menopause transition: The SWAN HDL ancillary study: HDL and complement proteins in women. J Clin Lipidol. (2022) 16:649&#x2013;57. doi:&#xa0;10.1016/j.jacl.2022.07.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacl.2022.07.015</ArticleId><ArticleId IdType="pmc">PMC11218699</ArticleId><ArticleId IdType="pubmed">35987805</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez-Diaz M, Rodriguez-Gonzalez D, Heras-Recuero E, Gomez-Bernal F, Quevedo-Abeledo JC, Gonzalez-Rivero AF, et al. . The Relationship between the complement system and subclinical carotid atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther. (2024) 26:127. doi:&#xa0;10.1186/s13075-024-03360-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-024-03360-3</ArticleId><ArticleId IdType="pmc">PMC11229295</ArticleId><ArticleId IdType="pubmed">38978073</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima C, Takei T, Ogawa T, Nitta K. Serum complement C3 predicts renal arteriolosclerosis in non-diabetic chronic kidney disease. J Atheroscler Thromb. (2012) 19:854&#x2013;61. doi:&#xa0;10.5551/jat.12286</Citation><ArticleIdList><ArticleId IdType="doi">10.5551/jat.12286</ArticleId><ArticleId IdType="pubmed">22863782</ArticleId></ArticleIdList></Reference><Reference><Citation>Leban N, Jraba K, Chalghoum A, Hassine S, Elhayek D, Denden S, et al. . Polymorphism of C3 complement in association with myocardial infarction in a sample of central Tunisia. Diagn Pathol. (2013) 8:93. doi:&#xa0;10.1186/1746-1596-8-93</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1746-1596-8-93</ArticleId><ArticleId IdType="pmc">PMC3931526</ArticleId><ArticleId IdType="pubmed">23764154</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Yang N, Gao C. Is plasma C3 and C4 levels useful in young cerebral ischemic stroke patients? Associations with prognosis at 3 months. J Thromb Thrombolysis. (2015) 39:209&#x2013;14. doi:&#xa0;10.1007/s11239-014-1100-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-014-1100-7</ArticleId><ArticleId IdType="pubmed">24938594</ArticleId></ArticleIdList></Reference><Reference><Citation>Aragam KG, Jiang T, Goel A, Kanoni S, Wolford BN, Atri DS, et al. . Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. Nat Genet. (2022) 54:1803&#x2013;15. doi:&#xa0;10.1038/s41588-022-01233-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-022-01233-6</ArticleId><ArticleId IdType="pmc">PMC9729111</ArticleId><ArticleId IdType="pubmed">36474045</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge X, Xu C, Liu Y, Zhu K, Zeng H, Su J, et al. . Complement activation in the arteries of patients with severe atherosclerosis. Int J Clin Exp Pathol. (2018) 11:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6957963</ArticleId><ArticleId IdType="pubmed">31938082</ArticleId></ArticleIdList></Reference><Reference><Citation>Henes JK, Groga-Bada P, Schaeffeler E, Winter S, Hack L, Zdanyte M, et al. . C5 variant rs10985126 is associated with mortality in patients with symptomatic coronary artery disease. Pharmgenomics Pers Med. (2021) 14:893&#x2013;903. doi:&#xa0;10.2147/PGPM.S307827</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/PGPM.S307827</ArticleId><ArticleId IdType="pmc">PMC8312322</ArticleId><ArticleId IdType="pubmed">34321906</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Lopez D, Roldan-Montero R, Garcia-Marques F, Nunez E, Jorge I, Camafeita E, et al. . Complement C5 protein as a marker of subclinical atherosclerosis. J Am Coll Cardiol. (2020) 75:1926&#x2013;41. doi:&#xa0;10.1016/j.jacc.2020.02.058</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.02.058</ArticleId><ArticleId IdType="pubmed">32327104</ArticleId></ArticleIdList></Reference><Reference><Citation>Niculescu F, Niculescu T, Rus H. C5b-9 terminal complement complex assembly on apoptotic cells in human arterial wall with atherosclerosis. Exp Mol Pathol. (2004) 76:17&#x2013;23. doi:&#xa0;10.1016/j.yexmp.2003.10.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexmp.2003.10.002</ArticleId><ArticleId IdType="pubmed">14738864</ArticleId></ArticleIdList></Reference><Reference><Citation>Si W, He P, Wang Y, Fu Y, Li X, Lin X, et al. . Complement complex C5b-9 levels are associated with the clinical outcomes of acute ischemic stroke and carotid plaque stability. Transl Stroke Res. (2019) 10:279&#x2013;86. doi:&#xa0;10.1007/s12975-018-0658-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12975-018-0658-3</ArticleId><ArticleId IdType="pmc">PMC6395518</ArticleId><ArticleId IdType="pubmed">30173313</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimoto K, Inoue T, Oku K, Mori T, Kusuda M, Handa K, et al. . Relation of C4b-binding protein to athero-sclerosis of the descending thoracic aorta. Artery. (1996) 22:101&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">8864252</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin M, Gottsater A, Nilsson PM, Mollnes TE, Lindblad B, Blom AM. Complement activation and plasma levels of C4b-binding protein in critical limb ischemia patients. J Vasc Surg. (2009) 50:100&#x2013;6. doi:&#xa0;10.1016/j.jvs.2008.12.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvs.2008.12.033</ArticleId><ArticleId IdType="pubmed">19563958</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicaud V, Francomme C, Ruidavets JB, Luc G, Arveiler D, Kee F, et al. . Lack of association between complement factor H polymorphisms and coronary artery disease or myocardial infarction. J Mol Med (Berl). (2007) 85:771&#x2013;5. doi:&#xa0;10.1007/s00109-007-0185-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-007-0185-2</ArticleId><ArticleId IdType="pubmed">17396242</ArticleId></ArticleIdList></Reference><Reference><Citation>Pai JK, Manson JE, Rexrode KM, Albert CM, Hunter DJ, Rimm EB. Complement factor H (Y402H) polymorphism and risk of coronary heart disease in US men and women. Eur Heart J. (2007) 28:1297&#x2013;303. doi:&#xa0;10.1093/eurheartj/ehm090</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehm090</ArticleId><ArticleId IdType="pubmed">17483111</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofat R, Casas JP, Kumari M, Talmud PJ, Ireland H, Kivimaki M, et al. . Genetic variation in complement factor H and risk of coronary heart disease: eight new studies and a meta-analysis of around 48,000 individuals. Atherosclerosis. (2010) 213:184&#x2013;90. doi:&#xa0;10.1016/j.atherosclerosis.2010.07.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2010.07.021</ArticleId><ArticleId IdType="pubmed">20708732</ArticleId></ArticleIdList></Reference><Reference><Citation>Volcik KA, Ballantyne CM, Braun MC, Coresh J, Mosley TH, Boerwinkle E. Association of the complement factor H Y402H polymorphism with cardiovascular disease is dependent upon hypertension status: The ARIC study. Am J Hypertens. (2008) 21:533&#x2013;8. doi:&#xa0;10.1038/ajh.2007.81</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajh.2007.81</ArticleId><ArticleId IdType="pmc">PMC2674647</ArticleId><ArticleId IdType="pubmed">18292760</ArticleId></ArticleIdList></Reference><Reference><Citation>Zee RY, Diehl KA, Ridker PM. Complement factor H Y402H gene polymorphism, C-reactive protein, and risk of incident myocardial infarction, ischaemic stroke, and venous thromboembolism: a nested case-control study. Atherosclerosis. (2006) 187:332&#x2013;5. doi:&#xa0;10.1016/j.atherosclerosis.2005.09.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2005.09.009</ArticleId><ArticleId IdType="pubmed">16229850</ArticleId></ArticleIdList></Reference><Reference><Citation>Irmscher S, Zipfel SLH, Halder LD, Ivanov L, Gonzalez-Delgado A, Waldeyer C, et al. . Factor H-related protein 1 (FHR-1) is associated with atherosclerotic cardiovascular disease. Sci Rep. (2021) 11:22511. doi:&#xa0;10.1038/s41598-021-02011-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-02011-w</ArticleId><ArticleId IdType="pmc">PMC8602345</ArticleId><ArticleId IdType="pubmed">34795372</ArticleId></ArticleIdList></Reference><Reference><Citation>Schepers A, de Vries MR, van Leuven CJ, Grimbergen JM, Holers VM, Daha MR, et al. . Inhibition of complement component C3 reduces vein graft atherosclerosis in apolipoprotein E3-Leiden transgenic mice. Circulation. (2006) 114:2831&#x2013;8. doi:&#xa0;10.1161/CIRCULATIONAHA.106.619502</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.106.619502</ArticleId><ArticleId IdType="pubmed">17145993</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdeguer F, Castro C, Kubicek M, Pla D, Vila-Caballer M, Vinue A, et al. . Complement regulation in murine and human hypercholesterolemia and role in the control of macrophage and smooth muscle cell proliferation. Cardiovasc Res. (2007) 76:340&#x2013;50. doi:&#xa0;10.1016/j.cardiores.2007.06.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardiores.2007.06.028</ArticleId><ArticleId IdType="pubmed">17673191</ArticleId></ArticleIdList></Reference><Reference><Citation>Alic L, Papac-Milicevic N, Czamara D, Rudnick RB, Ozsvar-Kozma M, Hartmann A, et al. . A genome-wide association study identifies key modulators of complement factor H binding to malondialdehyde-epitopes. Proc Natl Acad Sci U S A. (2020) 117:9942&#x2013;51. doi:&#xa0;10.1073/pnas.1913970117</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1913970117</ArticleId><ArticleId IdType="pmc">PMC7211993</ArticleId><ArticleId IdType="pubmed">32321835</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser DA, Tenner AJ. Innate immune proteins C1q and mannan-binding lectin enhance clearance of atherogenic lipoproteins by human monocytes and macrophages. J Immunol. (2010) 185:3932&#x2013;9. doi:&#xa0;10.4049/jimmunol.1002080</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1002080</ArticleId><ArticleId IdType="pmc">PMC3334294</ArticleId><ArticleId IdType="pubmed">20833838</ArticleId></ArticleIdList></Reference><Reference><Citation>Palinski W, Horkko S, Miller E, Steinbrecher UP, Powell HC, Curtiss LK, et al. . Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest. (1996) 98:800&#x2013;14. doi:&#xa0;10.1172/JCI118853</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI118853</ArticleId><ArticleId IdType="pmc">PMC507491</ArticleId><ArticleId IdType="pubmed">8698873</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudnick RB, Chen Q, Stea ED, Hartmann A, Papac-Milicevic N, Person F, et al. . FHR5 binds to laminins, uses separate C3b and surface-binding sites, and activates complement on malondialdehyde-acetaldehyde surfaces. J Immunol. (2018) 200:2280&#x2013;90. doi:&#xa0;10.4049/jimmunol.1701641</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1701641</ArticleId><ArticleId IdType="pubmed">29483359</ArticleId></ArticleIdList></Reference><Reference><Citation>Veneskoski M, Turunen SP, Kummu O, Nissinen A, Rannikko S, Levonen AL, et al. . Specific recognition of malondialdehyde and malondialdehyde acetaldehyde adducts on oxidized LDL and apoptotic cells by complement anaphylatoxin C3a. Free Radic Biol Med. (2011) 51:834&#x2013;43. doi:&#xa0;10.1016/j.freeradbiomed.2011.05.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2011.05.029</ArticleId><ArticleId IdType="pubmed">21683785</ArticleId></ArticleIdList></Reference><Reference><Citation>Weismann D, Hartvigsen K, Lauer N, Bennett KL, Scholl HP, Charbel Issa P, et al. . Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature. (2011) 478:76&#x2013;81. doi:&#xa0;10.1038/nature10449</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10449</ArticleId><ArticleId IdType="pmc">PMC4826616</ArticleId><ArticleId IdType="pubmed">21979047</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillotte KL, Horkko S, Witztum JL, Steinberg D. Oxidized phospholipids, linked to apolipoprotein B of oxidized LDL, are ligands for macrophage scavenger receptors. J Lipid Res. (2000) 41:824&#x2013;33. doi:&#xa0;10.1016/S0022-2275(20)32391-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-2275(20)32391-9</ArticleId><ArticleId IdType="pubmed">10787443</ArticleId></ArticleIdList></Reference><Reference><Citation>Foreman KE, Vaporciyan AA, Bonish BK, Jones ML, Johnson KJ, Glovsky MM, et al. . C5a-induced expression of P-selectin in endothelial cells. J Clin Invest. (1994) 94:1147&#x2013;55. doi:&#xa0;10.1172/JCI117430</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI117430</ArticleId><ArticleId IdType="pmc">PMC295185</ArticleId><ArticleId IdType="pubmed">7521884</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilgore KS, Schmid E, Shanley TP, Flory CM, Maheswari V, Tramontini NL, et al. . Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation. Am J Pathol. (1997) 150:2019&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858311</ArticleId><ArticleId IdType="pubmed">9176395</ArticleId></ArticleIdList></Reference><Reference><Citation>Lozada C, Levin RI, Huie M, Hirschhorn R, Naime D, Whitlow M, et al. . Identification of C1q as the heat-labile serum cofactor required for immune complexes to stimulate endothelial expression of the adhesion molecules E-selectin and intercellular and vascular cell adhesion molecules 1. Proc Natl Acad Sci U S A. (1995) 92:8378&#x2013;82. doi:&#xa0;10.1073/pnas.92.18.8378</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.92.18.8378</ArticleId><ArticleId IdType="pmc">PMC41160</ArticleId><ArticleId IdType="pubmed">7545301</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsinjon T, Gasque P, Chan P, Ischenko A, Brady JJ, Fontaine MC. Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J. (2003) 17:1003&#x2013;14. doi:&#xa0;10.1096/fj.02-0737com</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.02-0737com</ArticleId><ArticleId IdType="pubmed">12773483</ArticleId></ArticleIdList></Reference><Reference><Citation>Hertle E, van Greevenbroek MM, Arts IC, van der Kallen CJ, Geijselaers SL, Feskens EJ, et al. . Distinct associations of complement C3a and its precursor C3 with atherosclerosis and cardiovascular disease. The CODAM study. Thromb Haemost. (2014) 111:1102&#x2013;11. doi:&#xa0;10.1160/TH13-10-0831</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH13-10-0831</ArticleId><ArticleId IdType="pubmed">24500020</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller YI, Shyy JY. Context-dependent role of oxidized lipids and lipoproteins in inflammation. Trends Endocrinol Metab. (2017) 28:143&#x2013;52. doi:&#xa0;10.1016/j.tem.2016.11.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2016.11.002</ArticleId><ArticleId IdType="pmc">PMC5253098</ArticleId><ArticleId IdType="pubmed">27931771</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, Jiang J, Yan D, Li D, Li W, Ma Y, et al. . Pentraxin 3 promotes oxLDL uptake and inhibits cholesterol efflux from macrophage-derived foam cells. Exp Mol Pathol. (2014) 96:292&#x2013;9. doi:&#xa0;10.1016/j.yexmp.2014.03.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexmp.2014.03.007</ArticleId><ArticleId IdType="pubmed">24675235</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulanco MC, Cosman J, Ho MM, Huynh J, Fing K, Turcu J, et al. . Complement protein C1q enhances macrophage foam cell survival and efferocytosis. J Immunol. (2017) 198:472&#x2013;80. doi:&#xa0;10.4049/jimmunol.1601445</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1601445</ArticleId><ArticleId IdType="pmc">PMC5173410</ArticleId><ArticleId IdType="pubmed">27895181</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan Y, Zhang X, Zhang X, Lin J, Shu X, Man W, et al. . Inhibition of macrophage-derived foam cells by Adipsin attenuates progression of atherosclerosis. Biochim Biophys Acta Mol Basis Dis. (2022) 1868:166533. doi:&#xa0;10.1016/j.bbadis.2022.166533</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2022.166533</ArticleId><ArticleId IdType="pubmed">36064133</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Chan M, Yu L, Wang W, Qiang L. Adipsin deficiency does not impact atherosclerosis development in Ldlr(-/-) mice. Am J Physiol Endocrinol Metab. (2021) 320:E87&#x2013;92. doi:&#xa0;10.1152/ajpendo.00440.2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.00440.2020</ArticleId><ArticleId IdType="pmc">PMC8194410</ArticleId><ArticleId IdType="pubmed">33135458</ArticleId></ArticleIdList></Reference><Reference><Citation>Nissila E, Hakala P, Leskinen K, Roig A, Syed S, Van Kessel KPM, et al. . Complement factor H and apolipoprotein E participate in regulation of inflammation in THP-1 macrophages. Front Immunol. (2018) 9:2701. doi:&#xa0;10.3389/fimmu.2018.02701</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02701</ArticleId><ArticleId IdType="pmc">PMC6260146</ArticleId><ArticleId IdType="pubmed">30519244</ArticleId></ArticleIdList></Reference><Reference><Citation>Mevorach D, Mascarenhas JO, Gershov D, Elkon KB. Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med. (1998) 188:2313&#x2013;20. doi:&#xa0;10.1084/jem.188.12.2313</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.188.12.2313</ArticleId><ArticleId IdType="pmc">PMC2212421</ArticleId><ArticleId IdType="pubmed">9858517</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatia VK, Yun S, Leung V, Grimsditch DC, Benson GM, Botto MB, et al. . Complement C1q reduces early atherosclerosis in low-density lipoprotein receptor-deficient mice. Am J Pathol. (2007) 170:416&#x2013;26. doi:&#xa0;10.2353/ajpath.2007.060406</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2007.060406</ArticleId><ArticleId IdType="pmc">PMC1762701</ArticleId><ArticleId IdType="pubmed">17200212</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis MJ, Malik TH, Ehrenstein MR, Boyle JJ, Botto M, Haskard DO. Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation. (2009) 120:417&#x2013;26. doi:&#xa0;10.1161/CIRCULATIONAHA.109.868158</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.109.868158</ArticleId><ArticleId IdType="pmc">PMC2761224</ArticleId><ArticleId IdType="pubmed">19620499</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthijsen RA, de Winther MP, Kuipers D, van der Made I, Weber C, Herias MV, et al. . Macrophage-specific expression of mannose-binding lectin controls atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation. (2009) 119:2188&#x2013;95. doi:&#xa0;10.1161/CIRCULATIONAHA.108.830661</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.108.830661</ArticleId><ArticleId IdType="pubmed">19380618</ArticleId></ArticleIdList></Reference><Reference><Citation>Helmy KY, Katschke KJ, Jr., Gorgani NN, Kljavin NM, Elliott JM, Diehl L, et al. . CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell. (2006) 124:915&#x2013;27. doi:&#xa0;10.1016/j.cell.2005.12.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2005.12.039</ArticleId><ArticleId IdType="pubmed">16530040</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Nanda V, Direnzo D, Ye J, Xiao S, Kojima Y, et al. . Clonally expanding smooth muscle cells promote atherosclerosis by escaping efferocytosis and activating the complement cascade. Proc Natl Acad Sci U S A. (2020) 117:15818&#x2013;26. doi:&#xa0;10.1073/pnas.2006348117</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2006348117</ArticleId><ArticleId IdType="pmc">PMC7354942</ArticleId><ArticleId IdType="pubmed">32541024</ArticleId></ArticleIdList></Reference><Reference><Citation>Niyonzima N, Halvorsen B, Sporsheim B, Garred P, Aukrust P, Mollnes TE, et al. . Complement activation by cholesterol crystals triggers a subsequent cytokine response. Mol Immunol. (2017) 84:43&#x2013;50. doi:&#xa0;10.1016/j.molimm.2016.09.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2016.09.019</ArticleId><ArticleId IdType="pubmed">27692470</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilely K, Rosbjerg A, Genster N, Gal P, Pal G, Halvorsen B, et al. . Cholesterol crystals activate the lectin complement pathway via ficolin-2 and mannose-binding lectin: implications for the progression of atherosclerosis. J Immunol. (2016) 196:5064&#x2013;74. doi:&#xa0;10.4049/jimmunol.1502595</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1502595</ArticleId><ArticleId IdType="pubmed">27183610</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilely K, Fumagalli S, Rosbjerg A, Genster N, Skjoedt MO, Perego C, et al. . C-reactive protein binds to cholesterol crystals and co-localizes with the terminal complement complex in human atherosclerotic plaques. Front Immunol. (2017) 8:1040. doi:&#xa0;10.3389/fimmu.2017.01040</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01040</ArticleId><ArticleId IdType="pmc">PMC5581807</ArticleId><ArticleId IdType="pubmed">28900428</ArticleId></ArticleIdList></Reference><Reference><Citation>Samstad EO, Niyonzima N, Nymo S, Aune MH, Ryan L, Bakke SS, et al. . Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release. J Immunol. (2014) 192:2837&#x2013;45. doi:&#xa0;10.4049/jimmunol.1302484</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1302484</ArticleId><ArticleId IdType="pmc">PMC3985066</ArticleId><ArticleId IdType="pubmed">24554772</ArticleId></ArticleIdList></Reference><Reference><Citation>Niyonzima N, Samstad EO, Aune MH, Ryan L, Bakke SS, Rokstad AM, et al. . Reconstituted high-density lipoprotein attenuates cholesterol crystal-induced inflammatory responses by reducing complement activation. J Immunol. (2015) 195:257&#x2013;64. doi:&#xa0;10.4049/jimmunol.1403044</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1403044</ArticleId><ArticleId IdType="pubmed">26026058</ArticleId></ArticleIdList></Reference><Reference><Citation>Niyonzima N, Rahman J, Kunz N, West EE, Freiwald T, Desai JV, et al. . Mitochondrial C5aR1 activity in macrophages controls IL-1beta production underlying sterile inflammation. Sci Immunol. (2021) 6:eabf2489. doi:&#xa0;10.1126/sciimmunol.abf2489</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abf2489</ArticleId><ArticleId IdType="pmc">PMC8902698</ArticleId><ArticleId IdType="pubmed">34932384</ArticleId></ArticleIdList></Reference><Reference><Citation>Herman AB, Tsitsipatis D, Anerillas C, Mazan-Mamczarz K, Carr AE, Gregg JM, et al. . DPP4 inhibition impairs senohemostasis to improve plaque stability in atherosclerotic mice. J Clin Invest. (2023) 133:e165933. doi:&#xa0;10.1172/JCI165933</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI165933</ArticleId><ArticleId IdType="pmc">PMC10266795</ArticleId><ArticleId IdType="pubmed">37097759</ArticleId></ArticleIdList></Reference><Reference><Citation>Wezel A, de Vries MR, Lagraauw HM, Foks AC, Kuiper J, Quax PH, et al. . Complement factor C5a induces atherosclerotic plaque disruptions. J Cell Mol Med. (2014) 18:2020&#x2013;30. doi:&#xa0;10.1111/jcmm.2014.18.issue-10</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.2014.18.issue-10</ArticleId><ArticleId IdType="pmc">PMC4244017</ArticleId><ArticleId IdType="pubmed">25124749</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravastrand CS, Steinkjer B, Halvorsen B, Landsem A, Skjelland M, Jacobsen EA, et al. . Cholesterol crystals induce coagulation activation through complement-dependent expression of monocytic tissue factor. J Immunol. (2019) 203:853&#x2013;63. doi:&#xa0;10.4049/jimmunol.1900503</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1900503</ArticleId><ArticleId IdType="pmc">PMC6680065</ArticleId><ArticleId IdType="pubmed">31270150</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis RD, Jackson CL, Morgan BP, Hughes TR. The membrane attack complex of complement drives the progression of atherosclerosis in apolipoprotein E knockout mice. Mol Immunol. (2010) 47:1098&#x2013;105. doi:&#xa0;10.1016/j.molimm.2009.10.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2009.10.035</ArticleId><ArticleId IdType="pmc">PMC2862291</ArticleId><ArticleId IdType="pubmed">19959238</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu G, Hu W, Shahsafaei A, Song W, Dobarro M, Sukhova GK, et al. . Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex. Circ Res. (2009) 104:550&#x2013;8. doi:&#xa0;10.1161/CIRCRESAHA.108.191361</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.108.191361</ArticleId><ArticleId IdType="pmc">PMC4267695</ArticleId><ArticleId IdType="pubmed">19131645</ArticleId></ArticleIdList></Reference><Reference><Citation>Selle J, Asare Y, Kohncke J, Alampour-Rajabi S, Shagdarsuren G, Klos A, et al. . Atheroprotective role of C5ar2 deficiency in apolipoprotein E-deficient mice. Thromb Haemost. (2015) 114:848&#x2013;58. doi:&#xa0;10.1160/TH14-12-1075</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH14-12-1075</ArticleId><ArticleId IdType="pubmed">26084965</ArticleId></ArticleIdList></Reference><Reference><Citation>Shagdarsuren E, Bidzhekov K, Mause SF, Simsekyilmaz S, Polakowski T, Hawlisch H, et al. . C5a receptor targeting in neointima formation after arterial injury in atherosclerosis-prone mice. Circulation. (2010) 122:1026&#x2013;36. doi:&#xa0;10.1161/CIRCULATIONAHA.110.954370</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.110.954370</ArticleId><ArticleId IdType="pubmed">20733098</ArticleId></ArticleIdList></Reference><Reference><Citation>Manthey HD, Thomas AC, Shiels IA, Zernecke A, Woodruff TM, Rolfe B, et al. . Complement C5a inhibition reduces atherosclerosis in ApoE-/- mice. FASEB J. (2011) 25:2447&#x2013;55. doi:&#xa0;10.1096/fj.10-174284</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.10-174284</ArticleId><ArticleId IdType="pubmed">21490292</ArticleId></ArticleIdList></Reference><Reference><Citation>Emmens RW, Wouters D, Zeerleder S, van Ham SM, Niessen HWM, Krijnen PAJ. On the value of therapeutic interventions targeting the complement system in acute myocardial infarction. Transl Res. (2017) 182:103&#x2013;22. doi:&#xa0;10.1016/j.trsl.2016.10.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2016.10.005</ArticleId><ArticleId IdType="pubmed">27810412</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiss MG, Binder CJ. The multifaceted impact of complement on atherosclerosis. Atherosclerosis. (2022) 351:29&#x2013;40. doi:&#xa0;10.1016/j.atherosclerosis.2022.03.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2022.03.014</ArticleId><ArticleId IdType="pubmed">35365353</ArticleId></ArticleIdList></Reference><Reference><Citation>Maffia P, Mauro C, Case A, Kemper C. Canonical and non-canonical roles of complement in atherosclerosis. Nat Rev Cardiol. (2024) 21:743&#x2013;61. doi:&#xa0;10.1038/s41569-024-01016-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-024-01016-y</ArticleId><ArticleId IdType="pubmed">38600367</ArticleId></ArticleIdList></Reference><Reference><Citation>Denisenko YK, Kytikova OY, Novgorodtseva TP, Antonyuk MV, Gvozdenko TA, Kantur TA. Lipid-induced mechanisms of metabolic syndrome. J Obes. (2020) 2020:5762395. doi:&#xa0;10.1155/2020/5762395</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/5762395</ArticleId><ArticleId IdType="pmc">PMC7491450</ArticleId><ArticleId IdType="pubmed">32963827</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest. (2000) 106:171&#x2013;6. doi:&#xa0;10.1172/JCI10583</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI10583</ArticleId><ArticleId IdType="pmc">PMC314317</ArticleId><ArticleId IdType="pubmed">10903330</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, et al. . Metabolic syndrome: updates on pathophysiology and management in 2021. Int J Mol Sci. (2022) 23:786. doi:&#xa0;10.3390/ijms23020786</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23020786</ArticleId><ArticleId IdType="pmc">PMC8775991</ArticleId><ArticleId IdType="pubmed">35054972</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Chi X, Wang Y, Setrerrahmane S, Xie W, Xu H. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduct Target Ther. (2022) 7:216. doi:&#xa0;10.1038/s41392-022-01073-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-01073-0</ArticleId><ArticleId IdType="pmc">PMC9259665</ArticleId><ArticleId IdType="pubmed">35794109</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajjan R, Carter AM, Somani R, Kain K, Grant PJ. Ethnic differences in cardiovascular risk factors in healthy Caucasian and South Asian individuals with the metabolic syndrome. J Thromb Haemost. (2007) 5:754&#x2013;60. doi:&#xa0;10.1111/j.1538-7836.2007.02434.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2007.02434.x</ArticleId><ArticleId IdType="pubmed">17408409</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Gonzalez M, Gomez-Bernal F, Quevedo-Abeledo JC, Fernandez-Cladera Y, Gonzalez-Rivero AF, Lopez-Mejias R, et al. . The complement system is linked to insulin resistance in patients with systemic lupus erythematosus. Clin Exp Rheumatol. (2024) 42:115&#x2013;21. doi:&#xa0;10.55563/clinexprheumatol/t2k0hn</Citation><ArticleIdList><ArticleId IdType="doi">10.55563/clinexprheumatol/t2k0hn</ArticleId><ArticleId IdType="pubmed">37706313</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Tang Q, Wen J, Tang Y, Huang D, Huang Y, et al. . Elevated serum complement factors 3 and 4 are strong inflammatory markers of the metabolic syndrome development: a longitudinal cohort study. Sci Rep. (2016) 6:18713. doi:&#xa0;10.1038/srep18713</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep18713</ArticleId><ArticleId IdType="pmc">PMC4698666</ArticleId><ArticleId IdType="pubmed">26726922</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng G, Zhu Q, Shao J, Zhang Q, Liu L, Wu H, et al. . Comparing the diagnostic ability of inflammatory markers in metabolic syndrome. Clin Chim Acta. (2017) 475:1&#x2013;6. doi:&#xa0;10.1016/j.cca.2017.09.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2017.09.023</ArticleId><ArticleId IdType="pubmed">28974361</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson B, Hamad OA, Ahlstrom H, Kullberg J, Johansson L, Lindhagen L, et al. . C3 and C4 are strongly related to adipose tissue variables and cardiovascular risk factors. Eur J Clin Invest. (2014) 44:587&#x2013;96. doi:&#xa0;10.1111/eci.2014.44.issue-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.2014.44.issue-6</ArticleId><ArticleId IdType="pubmed">24754458</ArticleId></ArticleIdList></Reference><Reference><Citation>Onat A, Hergenc G, Can G, Kaya Z, Yuksel H. Serum complement C3: a determinant of cardiometabolic risk, additive to the metabolic syndrome, in middle-aged population. Metabolism. (2010) 59:628&#x2013;34. doi:&#xa0;10.1016/j.metabol.2009.09.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2009.09.006</ArticleId><ArticleId IdType="pubmed">19913840</ArticleId></ArticleIdList></Reference><Reference><Citation>Bratti LOS, do Carmo IAR, Vilela TF, Wopereis S, de Moraes ACR, Borba BGM, et al. . Complement component 3 (C3) as a biomarker for insulin resistance after bariatric surgery. Clin Biochem. (2017) 50:529&#x2013;32. doi:&#xa0;10.1016/j.clinbiochem.2017.02.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinbiochem.2017.02.006</ArticleId><ArticleId IdType="pubmed">28188738</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillian AD, McMullen MR, Sebastian BM, Roychowdhury S, Kashyap SR, Schauer PR, et al. . Mice lacking C1q are protected from high fat diet-induced hepatic insulin resistance and impaired glucose homeostasis. J Biol Chem. (2013) 288:22565&#x2013;75. doi:&#xa0;10.1074/jbc.M113.465674</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.465674</ArticleId><ArticleId IdType="pmc">PMC3829343</ArticleId><ArticleId IdType="pubmed">23788643</ArticleId></ArticleIdList></Reference><Reference><Citation>Peake PW, Kriketos AD, Campbell LV, Shen Y, Charlesworth JA. The metabolism of isoforms of human adiponectin: studies in human subjects and in experimental animals. Eur J Endocrinol. (2005) 153:409&#x2013;17. doi:&#xa0;10.1530/eje.1.01978</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/eje.1.01978</ArticleId><ArticleId IdType="pubmed">16131604</ArticleId></ArticleIdList></Reference><Reference><Citation>Hertle E, Stehouwer CD, van Greevenbroek MM. The complement system in human cardiometabolic disease. Mol Immunol. (2014) 61:135&#x2013;48. doi:&#xa0;10.1016/j.molimm.2014.06.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2014.06.031</ArticleId><ArticleId IdType="pubmed">25017306</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Navarrete JM, Fernandez-Real JM. The complement system is dysfunctional in metabolic disease: Evidences in plasma and adipose tissue from obese and insulin resistant subjects. Semin Cell Dev Biol. (2019) 85:164&#x2013;72. doi:&#xa0;10.1016/j.semcdb.2017.10.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2017.10.025</ArticleId><ArticleId IdType="pubmed">29107169</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Real JM, Straczkowski M, Vendrell J, Soriguer F, Perez Del Pulgar S, Gallart L, et al. . Protection from inflammatory disease in insulin resistance: the role of mannan-binding lectin. Diabetologia. (2006) 49:2402&#x2013;11. doi:&#xa0;10.1007/s00125-006-0381-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-006-0381-6</ArticleId><ArticleId IdType="pubmed">16955210</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowalska I, Fernandez-Real JM, Straczkowski M, Kozlowska A, Adamska A, Ortega F, et al. . Insulin resistance is associated with decreased circulating mannan-binding lectin concentrations in women with polycystic ovary syndrome. Diabetes Care. (2008) 31:e20. doi:&#xa0;10.2337/dc07-1872</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc07-1872</ArticleId><ArticleId IdType="pubmed">18375421</ArticleId></ArticleIdList></Reference><Reference><Citation>Stienstra R, Dijk W, van Beek L, Jansen H, Heemskerk M, Houtkooper RH, et al. . Mannose-binding lectin is required for the effective clearance of apoptotic cells by adipose tissue macrophages during obesity. Diabetes. (2014) 63:4143&#x2013;53. doi:&#xa0;10.2337/db14-0256</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db14-0256</ArticleId><ArticleId IdType="pubmed">25008177</ArticleId></ArticleIdList></Reference><Reference><Citation>Manco M, Fernandez-Real JM, Equitani F, Vendrell J, Valera Mora ME, Nanni G, et al. . Effect of massive weight loss on inflammatory adipocytokines and the innate immune system in morbidly obese women. J Clin Endocrinol Metab. (2007) 92:483&#x2013;90. doi:&#xa0;10.1210/jc.2006-0960</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2006-0960</ArticleId><ArticleId IdType="pubmed">17105839</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Lu J, Chen X, Yu H, Zhang L, Bao Y, et al. . Low serum levels of the innate immune component ficolin-3 is associated with insulin resistance and predicts the development of type 2 diabetes. J Mol Cell Biol. (2012) 4:256&#x2013;7. doi:&#xa0;10.1093/jmcb/mjs032</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jmcb/mjs032</ArticleId><ArticleId IdType="pubmed">22679101</ArticleId></ArticleIdList></Reference><Reference><Citation>Engstrom G, Hedblad B, Eriksson KF, Janzon L, Lindgarde F. Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes. (2005) 54:570&#x2013;5. doi:&#xa0;10.2337/diabetes.54.2.570</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diabetes.54.2.570</ArticleId><ArticleId IdType="pubmed">15677517</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Gomez D, Eisenmann JC, Warnberg J, Gomez-Martinez S, Veses A, Veiga OL, et al. . Associations of physical activity, cardiorespiratory fitness and fatness with low-grade inflammation in adolescents: the AFINOS Study. Int J Obes (Lond). (2010) 34:1501&#x2013;7. doi:&#xa0;10.1038/ijo.2010.114</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ijo.2010.114</ArticleId><ArticleId IdType="pubmed">20531354</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips CM, Kesse-Guyot E, Ahluwalia N, McManus R, Hercberg S, Lairon D, et al. . Dietary fat, abdominal obesity and smoking modulate the relationship between plasma complement component 3 concentrations and metabolic syndrome risk. Atherosclerosis. (2012) 220:513&#x2013;9. doi:&#xa0;10.1016/j.atherosclerosis.2011.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2011.11.007</ArticleId><ArticleId IdType="pubmed">22138144</ArticleId></ArticleIdList></Reference><Reference><Citation>Volp AC, Barbosa KB, Bressan J. Triacylglycerols and body fat mass are possible independent predictors of C3 in apparently healthy young Brazilian adults. Nutrition. (2012) 28:544&#x2013;50. doi:&#xa0;10.1016/j.nut.2011.08.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nut.2011.08.014</ArticleId><ArticleId IdType="pubmed">22206689</ArticleId></ArticleIdList></Reference><Reference><Citation>Muscari A, Antonelli S, Bianchi G, Cavrini G, Dapporto S, Ligabue A, et al. . Serum C3 is a stronger inflammatory marker of insulin resistance than C-reactive protein, leukocyte count, and erythrocyte sedimentation rate: comparison study in an elderly population. Diabetes Care. (2007) 30:2362&#x2013;8. doi:&#xa0;10.2337/dc07-0637</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc07-0637</ArticleId><ArticleId IdType="pubmed">17595349</ArticleId></ArticleIdList></Reference><Reference><Citation>van Greevenbroek MM, Jacobs M, van der Kallen CJ, Vermeulen VM, Jansen EH, Schalkwijk CG, et al. . The cross-sectional association between insulin resistance and circulating complement C3 is partly explained by plasma alanine aminotransferase, independent of central obesity and general inflammation (the CODAM study). Eur J Clin Invest. (2011) 41:372&#x2013;9. doi:&#xa0;10.1111/j.1365-2362.2010.02418.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2362.2010.02418.x</ArticleId><ArticleId IdType="pubmed">21114489</ArticleId></ArticleIdList></Reference><Reference><Citation>Wlazlo N, van Greevenbroek MM, Ferreira I, Feskens EJ, van der Kallen CJ, Schalkwijk CG, et al. . Complement factor 3 is associated with insulin resistance and with incident type 2 diabetes over a 7-year follow-up period: the CODAM Study. Diabetes Care. (2014) 37:1900&#x2013;9. doi:&#xa0;10.2337/dc13-2804</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc13-2804</ArticleId><ArticleId IdType="pubmed">24760264</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Lu HL, Zhang J, Yu HY, Wang HW, Zhang MX, et al. . Relationships among acylation stimulating protein, adiponectin and complement C3 in lean vs obese type 2 diabetes. Int J Obes (Lond). (2006) 30:439&#x2013;46. doi:&#xa0;10.1038/sj.ijo.0803173</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijo.0803173</ArticleId><ArticleId IdType="pubmed">16302015</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez-Mijares A, Jarabo-Bueno MM, Lopez-Ruiz A, Sola-Izquierdo E, Morillas-Arino C, Martinez-Triguero ML. Levels of C3 in patients with severe, morbid and extreme obesity: its relationship to insulin resistance and different cardiovascular risk factors. Int J Obes (Lond). (2007) 31:927&#x2013;32. doi:&#xa0;10.1038/sj.ijo.0803543</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijo.0803543</ArticleId><ArticleId IdType="pubmed">17264851</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamane Y, Chung Chan C, Lavallee G, Morin N, Xu LJ, Huang J, et al. . The C3a anaphylatoxin receptor is a key mediator of insulin resistance and functions by modulating adipose tissue macrophage infiltration and activation. Diabetes. (2009) 58:2006&#x2013;17. doi:&#xa0;10.2337/db09-0323</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db09-0323</ArticleId><ArticleId IdType="pmc">PMC2731537</ArticleId><ArticleId IdType="pubmed">19581423</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Z, Sniderman AD, Cianflone K. Acylation-stimulating protein (ASP) deficiency induces obesity resistance and increased energy expenditure in ob/ob mice. J Biol Chem. (2002) 277:45874&#x2013;9. doi:&#xa0;10.1074/jbc.M207281200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M207281200</ArticleId><ArticleId IdType="pubmed">12244109</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisette A, Poursharifi P, Oikonomopoulou K, Munkonda MN, Lapointe M, Cianflone K. Paradoxical glucose-sensitizing yet proinflammatory effects of acute ASP administration in mice. Mediators Inflamm. (2013) 2013:713284. doi:&#xa0;10.1155/2013/713284</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/713284</ArticleId><ArticleId IdType="pmc">PMC3666230</ArticleId><ArticleId IdType="pubmed">23737652</ArticleId></ArticleIdList></Reference><Reference><Citation>Munkonda MN, Lapointe M, Miegueu P, Roy C, Gauvreau D, Richard D, et al. . Recombinant acylation stimulating protein administration to C3-/- mice increases insulin resistance via adipocyte inflammatory mechanisms. PloS One. (2012) 7:e46883. doi:&#xa0;10.1371/journal.pone.0046883</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0046883</ArticleId><ArticleId IdType="pmc">PMC3466186</ArticleId><ArticleId IdType="pubmed">23056509</ArticleId></ArticleIdList></Reference><Reference><Citation>Wamba PC, Mi J, Zhao XY, Zhang MX, Wen Y, Cheng H, et al. . Acylation stimulating protein but not complement C3 associates with metabolic syndrome components in Chinese children and adolescents. Eur J Endocrinol. (2008) 159:781&#x2013;90. doi:&#xa0;10.1530/EJE-08-0467</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/EJE-08-0467</ArticleId><ArticleId IdType="pubmed">18805911</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Navarrete JM, Martinez-Barricarte R, Catalan V, Sabater M, Gomez-Ambrosi J, Ortega FJ, et al. . Complement factor H is expressed in adipose tissue in association with insulin resistance. Diabetes. (2010) 59:200&#x2013;9. doi:&#xa0;10.2337/db09-0700</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db09-0700</ArticleId><ArticleId IdType="pmc">PMC2797922</ArticleId><ArticleId IdType="pubmed">19833879</ArticleId></ArticleIdList></Reference><Reference><Citation>Somani R, Richardson VR, Standeven KF, Grant PJ, Carter AM. Elevated properdin and enhanced complement activation in first-degree relatives of South Asian subjects with type 2 diabetes. Diabetes Care. (2012) 35:894&#x2013;9. doi:&#xa0;10.2337/dc11-1483</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc11-1483</ArticleId><ArticleId IdType="pmc">PMC3308267</ArticleId><ArticleId IdType="pubmed">22338105</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauvreau D, Roy C, Tom FQ, Lu H, Miegueu P, Richard D, et al. . A new effector of lipid metabolism: complement factor properdin. Mol Immunol. (2012) 51:73&#x2013;81. doi:&#xa0;10.1016/j.molimm.2012.02.110</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2012.02.110</ArticleId><ArticleId IdType="pubmed">22387270</ArticleId></ArticleIdList></Reference><Reference><Citation>Coan PM, Barrier M, Alfazema N, Carter RN, Marion de Proce S, Dopico XC, et al. . Complement factor B is a determinant of both metabolic and cardiovascular features of metabolic syndrome. Hypertension. (2017) 70:624&#x2013;33. doi:&#xa0;10.1161/HYPERTENSIONAHA.117.09242</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.117.09242</ArticleId><ArticleId IdType="pmc">PMC5548512</ArticleId><ArticleId IdType="pubmed">28739975</ArticleId></ArticleIdList></Reference><Reference><Citation>Phieler J, Chung KJ, Chatzigeorgiou A, Klotzsche-von Ameln A, Garcia-Martin R, Sprott D, et al. . The complement anaphylatoxin C5a receptor contributes to obese adipose tissue inflammation and insulin resistance. J Immunol. (2013) 191:4367&#x2013;74. doi:&#xa0;10.4049/jimmunol.1300038</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1300038</ArticleId><ArticleId IdType="pmc">PMC3817864</ArticleId><ArticleId IdType="pubmed">24043887</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah DS, McNeilly AD, McCrimmon RJ, Hundal HS. The C5aR1 complement receptor: A novel immunomodulator of insulin action in skeletal muscle. Cell Signal. (2024) 113:110944. doi:&#xa0;10.1016/j.cellsig.2023.110944</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2023.110944</ArticleId><ArticleId IdType="pubmed">37890688</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjerre M, Kistorp C, Hansen TK, Faber J, Lip GY, Hildebrandt P, et al. . Complement activation, endothelial dysfunction, insulin resistance and chronic heart failure. Scand Cardiovasc J. (2010) 44:260&#x2013;6. doi:&#xa0;10.3109/14017431.2010.484506</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/14017431.2010.484506</ArticleId><ArticleId IdType="pubmed">20524927</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghaben AL, Scherer PE. Adipogenesis and metabolic health. Nat Rev Mol Cell Biol. (2019) 20:242&#x2013;58. doi:&#xa0;10.1038/s41580-018-0093-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-018-0093-z</ArticleId><ArticleId IdType="pubmed">30610207</ArticleId></ArticleIdList></Reference><Reference><Citation>Global BMIMC, Di Angelantonio E, Bhupathiraju Sh N, Wormser D, Gao P, Kaptoge S, et al. . Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet. (2016) 388:776&#x2013;86. doi:&#xa0;10.1016/S0140-6736(16)30175-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)30175-1</ArticleId><ArticleId IdType="pmc">PMC4995441</ArticleId><ArticleId IdType="pubmed">27423262</ArticleId></ArticleIdList></Reference><Reference><Citation>Bluher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. (2019) 15:288&#x2013;98. doi:&#xa0;10.1038/s41574-019-0176-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41574-019-0176-8</ArticleId><ArticleId IdType="pubmed">30814686</ArticleId></ArticleIdList></Reference><Reference><Citation>Loos RJF, Yeo GSH. The genetics of obesity: from discovery to biology. Nat Rev Genet. (2022) 23:120&#x2013;33. doi:&#xa0;10.1038/s41576-021-00414-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41576-021-00414-z</ArticleId><ArticleId IdType="pmc">PMC8459824</ArticleId><ArticleId IdType="pubmed">34556834</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenzuela PL, Carrera-Bastos P, Castillo-Garcia A, Lieberman DE, Santos-Lozano A, Lucia A. Obesity and the risk of cardiometabolic diseases. Nat Rev Cardiol. (2023) 20:475&#x2013;94. doi:&#xa0;10.1038/s41569-023-00847-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-023-00847-5</ArticleId><ArticleId IdType="pubmed">36927772</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol. (2021) 320:C375&#x2013;C91. doi:&#xa0;10.1152/ajpcell.00379.2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00379.2020</ArticleId><ArticleId IdType="pmc">PMC8294624</ArticleId><ArticleId IdType="pubmed">33356944</ArticleId></ArticleIdList></Reference><Reference><Citation>Reilly SM, Saltiel AR. Adapting to obesity with adipose tissue inflammation. Nat Rev Endocrinol. (2017) 13:633&#x2013;43. doi:&#xa0;10.1038/nrendo.2017.90</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrendo.2017.90</ArticleId><ArticleId IdType="pubmed">28799554</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook KS, Groves DL, Min HY, Spiegelman BM. A developmentally regulated mRNA from 3T3 adipocytes encodes a novel serine protease homologue. Proc Natl Acad Sci U S A. (1985) 82:6480&#x2013;4. doi:&#xa0;10.1073/pnas.82.19.6480</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.82.19.6480</ArticleId><ArticleId IdType="pmc">PMC390740</ArticleId><ArticleId IdType="pubmed">3901003</ArticleId></ArticleIdList></Reference><Reference><Citation>Choy LN, Rosen BS, Spiegelman BM. Adipsin and an endogenous pathway of complement from adipose cells. J Biol Chem. (1992) 267:12736&#x2013;41. doi:&#xa0;10.1016/S0021-9258(18)42338-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)42338-1</ArticleId><ArticleId IdType="pubmed">1618777</ArticleId></ArticleIdList></Reference><Reference><Citation>Cianflone K, Maslowska M. Differentiation-induced production of ASP in human adipocytes. Eur J Clin Invest. (1995) 25:817&#x2013;25. doi:&#xa0;10.1111/j.1365-2362.1995.tb01690.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2362.1995.tb01690.x</ArticleId><ArticleId IdType="pubmed">8582446</ArticleId></ArticleIdList></Reference><Reference><Citation>White RT, Damm D, Hancock N, Rosen BS, Lowell BB, Usher P, et al. . Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue. J Biol Chem. (1992) 267:9210&#x2013;3. doi:&#xa0;10.1016/S0021-9258(19)50409-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(19)50409-4</ArticleId><ArticleId IdType="pubmed">1374388</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Wright W, Bernlohr DA, Cushman SW, Chen X. Alterations of the classic pathway of complement in adipose tissue of obesity and insulin resistance. Am J Physiol Endocrinol Metab. (2007) 292:E1433&#x2013;40. doi:&#xa0;10.1152/ajpendo.00664.2006</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.00664.2006</ArticleId><ArticleId IdType="pubmed">17244723</ArticleId></ArticleIdList></Reference><Reference><Citation>Pomeroy C, Mitchell J, Eckert E, Raymond N, Crosby R, Dalmasso AP. Effect of body weight and caloric restriction on serum complement proteins, including Factor D/adipsin: studies in anorexia nervosa and obesity. Clin Exp Immunol. (1997) 108:507&#x2013;15. doi:&#xa0;10.1046/j.1365-2249.1997.3921287.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2249.1997.3921287.x</ArticleId><ArticleId IdType="pmc">PMC1904692</ArticleId><ArticleId IdType="pubmed">9182900</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei JN, Li HY, Sung FC, Lin CC, Chiang CC, Carter AM, et al. . Obesity and clustering of cardiovascular disease risk factors are associated with elevated plasma complement C3 in children and adolescents. Pediatr Diabetes. (2012) 13:476&#x2013;83. doi:&#xa0;10.1111/j.1399-5448.2012.00864.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-5448.2012.00864.x</ArticleId><ArticleId IdType="pubmed">22487122</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahebekhtiari N, Saraswat M, Joenvaara S, Jokinen R, Lovric A, Kaye S, et al. . Plasma proteomics analysis reveals dysregulation of complement proteins and inflammation in acquired obesity-A study on rare BMI-discordant monozygotic twin pairs. Proteomics Clin Appl. (2019) 13:e1800173. doi:&#xa0;10.1002/prca.201800173</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prca.201800173</ArticleId><ArticleId IdType="pubmed">30688043</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaye S, Lokki AI, Hanttu A, Nissila E, Heinonen S, Hakkarainen A, et al. . Upregulation of early and downregulation of terminal pathway complement genes in subcutaneous adipose tissue and adipocytes in acquired obesity. Front Immunol. (2017) 8:545. doi:&#xa0;10.3389/fimmu.2017.00545</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00545</ArticleId><ArticleId IdType="pmc">PMC5432622</ArticleId><ArticleId IdType="pubmed">28559893</ArticleId></ArticleIdList></Reference><Reference><Citation>Flier JS, Lowell B, Napolitano A, Usher P, Rosen B, Cook KS, et al. . Adipsin: regulation and dysregulation in obesity and other metabolic states. Recent Prog Horm Res. (1989) 45:567&#x2013;80. doi:&#xa0;10.1016/B978-0-12-571145-6.50017-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-571145-6.50017-0</ArticleId><ArticleId IdType="pubmed">2682848</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt KA, Claffey KP, Wilkison WO, Spiegelman BM, Ross SR. Independent regulation of adipose tissue-specificity and obesity response of the adipsin promoter in transgenic mice. J Biol Chem. (1994) 269:28558&#x2013;62. doi:&#xa0;10.1016/S0021-9258(19)61941-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(19)61941-1</ArticleId><ArticleId IdType="pubmed">7961801</ArticleId></ArticleIdList></Reference><Reference><Citation>Plubell DL, Wilmarth PA, Zhao Y, Fenton AM, Minnier J, Reddy AP, et al. . Extended multiplexing of tandem mass tags (TMT) labeling reveals age and high fat diet specific proteome changes in mouse epididymal adipose tissue. Mol Cell Proteomics. (2017) 16:873&#x2013;90. doi:&#xa0;10.1074/mcp.M116.065524</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.M116.065524</ArticleId><ArticleId IdType="pmc">PMC5417827</ArticleId><ArticleId IdType="pubmed">28325852</ArticleId></ArticleIdList></Reference><Reference><Citation>Dusserre E, Moulin P, Vidal H. Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues. Biochim Biophys Acta. (2000) 1500:88&#x2013;96. doi:&#xa0;10.1016/S0925-4439(99)00091-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0925-4439(99)00091-5</ArticleId><ArticleId IdType="pubmed">10564721</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabrielsson BG, Johansson JM, Lonn M, Jernas M, Olbers T, Peltonen M, et al. . High expression of complement components in omental adipose tissue in obese men. Obes Res. (2003) 11:699&#x2013;708. doi:&#xa0;10.1038/oby.2003.100</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/oby.2003.100</ArticleId><ArticleId IdType="pubmed">12805391</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowell BB, Napolitano A, Usher P, Dulloo AG, Rosen BS, Spiegelman BM, et al. . Reduced adipsin expression in murine obesity: effect of age and treatment with the sympathomimetic-thermogenic drug mixture ephedrine and caffeine. Endocrinology. (1990) 126:1514&#x2013;20. doi:&#xa0;10.1210/endo-126-3-1514</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/endo-126-3-1514</ArticleId><ArticleId IdType="pubmed">2307116</ArticleId></ArticleIdList></Reference><Reference><Citation>Milek M, Moulla Y, Kern M, Stroh C, Dietrich A, Schon MR, et al. . Adipsin serum concentrations and adipose tissue expression in people with obesity and type 2 diabetes. Int J Mol Sci. (2022) 23:2222. doi:&#xa0;10.3390/ijms23042222</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23042222</ArticleId><ArticleId IdType="pmc">PMC8878597</ArticleId><ArticleId IdType="pubmed">35216336</ArticleId></ArticleIdList></Reference><Reference><Citation>Peake PW, O&#x2019;Grady S, Pussell BA, Charlesworth JA. Detection and quantification of the control proteins of the alternative pathway of complement in 3T3-L1 adipocytes. Eur J Clin Invest. (1997) 27:922&#x2013;7. doi:&#xa0;10.1046/j.1365-2362.1997.2090759.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2362.1997.2090759.x</ArticleId><ArticleId IdType="pubmed">9395788</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldo A, Sniderman AD, St-Luce S, Avramoglu RK, Maslowska M, Hoang B, et al. . The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis. J Clin Invest. (1993) 92:1543&#x2013;7. doi:&#xa0;10.1172/JCI116733</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI116733</ArticleId><ArticleId IdType="pmc">PMC288301</ArticleId><ArticleId IdType="pubmed">8376604</ArticleId></ArticleIdList></Reference><Reference><Citation>Cianflone K, Roncari DA, Maslowska M, Baldo A, Forden J, Sniderman AD. Adipsin/acylation stimulating protein system in human adipocytes: regulation of triacylglycerol synthesis. Biochemistry. (1994) 33:9489&#x2013;95. doi:&#xa0;10.1021/bi00198a014</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi00198a014</ArticleId><ArticleId IdType="pubmed">8068623</ArticleId></ArticleIdList></Reference><Reference><Citation>Cianflone KM, Sniderman AD, Walsh MJ, Vu HT, Gagnon J, Rodriguez MA. Purification and characterization of acylation stimulating protein. J Biol Chem. (1989) 264:426&#x2013;30. doi:&#xa0;10.1016/S0021-9258(17)31275-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(17)31275-9</ArticleId><ArticleId IdType="pubmed">2909530</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalant D, MacLaren R, Cui W, Samanta R, Monk PN, Laporte SA, et al. . C5L2 is a functional receptor for acylation-stimulating protein. J Biol Chem. (2005) 280:23936&#x2013;44. doi:&#xa0;10.1074/jbc.M406921200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M406921200</ArticleId><ArticleId IdType="pubmed">15833747</ArticleId></ArticleIdList></Reference><Reference><Citation>Maslowska M, Sniderman AD, Germinario R, Cianflone K. ASP stimulates glucose transport in cultured human adipocytes. Int J Obes Relat Metab Disord. (1997) 21:261&#x2013;6. doi:&#xa0;10.1038/sj.ijo.0800396</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijo.0800396</ArticleId><ArticleId IdType="pubmed">9130021</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray I, Parker RA, Kirchgessner TG, Tran J, Zhang ZJ, Westerlund J, et al. . Functional bioactive recombinant acylation stimulating protein is distinct from C3a anaphylatoxin. J Lipid Res. (1997) 38:2492&#x2013;501. doi:&#xa0;10.1016/S0022-2275(20)30034-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-2275(20)30034-1</ArticleId><ArticleId IdType="pubmed">9458273</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno M, Hirata T, Enomoto M, Araki T, Ishimaru H, Takahashi TA. A putative chemoattractant receptor, C5L2, is expressed in granulocyte and immature dendritic cells, but not in mature dendritic cells. Mol Immunol. (2000) 37:407&#x2013;12. doi:&#xa0;10.1016/S0161-5890(00)00067-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0161-5890(00)00067-5</ArticleId><ArticleId IdType="pubmed">11090875</ArticleId></ArticleIdList></Reference><Reference><Citation>Paglialunga S, Fisette A, Yan Y, Deshaies Y, Brouillette JF, Pekna M, et al. . Acylation-stimulating protein deficiency and altered adipose tissue in alternative complement pathway knockout mice. Am J Physiol Endocrinol Metab. (2008) 294:E521&#x2013;9. doi:&#xa0;10.1152/ajpendo.00590.2007</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.00590.2007</ArticleId><ArticleId IdType="pubmed">18160458</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Harmelen V, Reynisdottir S, Cianflone K, Degerman E, Hoffstedt J, Nilsell K, et al. . Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation-stimulating protein and insulin. J Biol Chem. (1999) 274:18243&#x2013;51. doi:&#xa0;10.1074/jbc.274.26.18243</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.26.18243</ArticleId><ArticleId IdType="pubmed">10373426</ArticleId></ArticleIdList></Reference><Reference><Citation>Cianflone K, Xia Z, Chen LY. Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim Biophys Acta. (2003) 1609:127&#x2013;43. doi:&#xa0;10.1016/S0005-2736(02)00686-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0005-2736(02)00686-7</ArticleId><ArticleId IdType="pubmed">12543373</ArticleId></ArticleIdList></Reference><Reference><Citation>Circolo A, Garnier G, Fukuda W, Wang X, Hidvegi T, Szalai AJ, et al. . Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA. Immunopharmacology. (1999) 42:135&#x2013;49. doi:&#xa0;10.1016/S0162-3109(99)00021-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0162-3109(99)00021-1</ArticleId><ArticleId IdType="pubmed">10408374</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray I, Havel PJ, Sniderman AD, Cianflone K. Reduced body weight, adipose tissue, and leptin levels despite increased energy intake in female mice lacking acylation-stimulating protein. Endocrinology. (2000) 141:1041&#x2013;9. doi:&#xa0;10.1210/endo.141.3.7364</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/endo.141.3.7364</ArticleId><ArticleId IdType="pubmed">10698180</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray I, Sniderman AD, Havel PJ, Cianflone K. Acylation stimulating protein (ASP) deficiency alters postprandial and adipose tissue metabolism in male mice. J Biol Chem. (1999) 274:36219&#x2013;25. doi:&#xa0;10.1074/jbc.274.51.36219</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.51.36219</ArticleId><ArticleId IdType="pubmed">10593909</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessels MR, Butko P, Ma M, Warren HB, Lage AL, Carroll MC. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc Natl Acad Sci U S A. (1995) 92:11490&#x2013;4. doi:&#xa0;10.1073/pnas.92.25.11490</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.92.25.11490</ArticleId><ArticleId IdType="pmc">PMC40427</ArticleId><ArticleId IdType="pubmed">8524789</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsunaga H, Iwashita M, Shinjo T, Yamashita A, Tsuruta M, Nagasaka S, et al. . Adipose tissue complement factor B promotes adipocyte maturation. Biochem Biophys Res Commun. (2018) 495:740&#x2013;8. doi:&#xa0;10.1016/j.bbrc.2017.11.069</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2017.11.069</ArticleId><ArticleId IdType="pubmed">29137982</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Banoy N, Guseh JS, Li G, Rubio-Navarro A, Chen T, Poirier B, et al. . Adipsin preserves beta cells in diabetic mice and associates with protection from type 2 diabetes in humans. Nat Med. (2019) 25:1739&#x2013;47. doi:&#xa0;10.1038/s41591-019-0610-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0610-4</ArticleId><ArticleId IdType="pmc">PMC7256970</ArticleId><ArticleId IdType="pubmed">31700183</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesavre PH, Hugli TE, Esser AF, Muller-Eberhard HJ. The alternative pathway C3/C5 convertase: chemical basis of factor B activation. J Immunol. (1979) 123:529&#x2013;34. doi:&#xa0;10.4049/jimmunol.123.2.529</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.123.2.529</ArticleId><ArticleId IdType="pubmed">458145</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo JC, Ljubicic S, Leibiger B, Kern M, Leibiger IB, Moede T, et al. . Adipsin is an adipokine that improves beta cell function in diabetes. Cell. (2014) 158:41&#x2013;53. doi:&#xa0;10.1016/j.cell.2014.06.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.06.005</ArticleId><ArticleId IdType="pmc">PMC4128197</ArticleId><ArticleId IdType="pubmed">24995977</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Ma M, Ippolito GC, Schroeder HW, Jr., Carroll MC, Volanakis JE. Complement activation in factor D-deficient mice. Proc Natl Acad Sci U S A. (2001) 98:14577&#x2013;82. doi:&#xa0;10.1073/pnas.261428398</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.261428398</ArticleId><ArticleId IdType="pmc">PMC64724</ArticleId><ArticleId IdType="pubmed">11724962</ArticleId></ArticleIdList></Reference><Reference><Citation>Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, Zhang BB, et al. . Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology. (2002) 143:998&#x2013;1007. doi:&#xa0;10.1210/endo.143.3.8662</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/endo.143.3.8662</ArticleId><ArticleId IdType="pubmed">11861525</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, et al. . Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. (2002) 8:731&#x2013;7. doi:&#xa0;10.1038/nm724</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm724</ArticleId><ArticleId IdType="pubmed">12068289</ArticleId></ArticleIdList></Reference><Reference><Citation>Marangoni RG, Masui Y, Fang F, Korman B, Lord G, Lee J, et al. . Adiponectin is an endogenous anti-fibrotic mediator and therapeutic target. Sci Rep. (2017) 7:4397. doi:&#xa0;10.1038/s41598-017-04162-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-04162-1</ArticleId><ArticleId IdType="pmc">PMC5493638</ArticleId><ArticleId IdType="pubmed">28667272</ArticleId></ArticleIdList></Reference><Reference><Citation>Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol. (2003) 149:331&#x2013;5. doi:&#xa0;10.1530/eje.0.1490331</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/eje.0.1490331</ArticleId><ArticleId IdType="pubmed">14514348</ArticleId></ArticleIdList></Reference><Reference><Citation>Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. (2011) 11:98&#x2013;107. doi:&#xa0;10.1038/nri2925</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2925</ArticleId><ArticleId IdType="pubmed">21233852</ArticleId></ArticleIdList></Reference><Reference><Citation>Raynor LA, Pankow JS, Duncan BB, Schmidt MI, Hoogeveen RC, Pereira MA, et al. . Novel risk factors and the prediction of type 2 diabetes in the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care. (2013) 36:70&#x2013;6. doi:&#xa0;10.2337/dc12-0609</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc12-0609</ArticleId><ArticleId IdType="pmc">PMC3526210</ArticleId><ArticleId IdType="pubmed">22933437</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiorentino TV, Hribal ML, Andreozzi F, Perticone M, Sciacqua A, Perticone F, et al. . Plasma complement C3 levels are associated with insulin secretion independently of adiposity measures in non-diabetic individuals. Nutr Metab Cardiovasc Dis. (2015) 25:510&#x2013;7. doi:&#xa0;10.1016/j.numecd.2015.02.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.numecd.2015.02.007</ArticleId><ArticleId IdType="pubmed">25813686</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueredo A, Ibarra JL, Bagazgoitia J, Rodriguez A, Molino AM, Fernandez-Cruz A, et al. . Plasma C3d levels and ischemic heart disease in type II diabetes. Diabetes Care. (1993) 16:445&#x2013;9. doi:&#xa0;10.2337/diacare.16.2.445</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diacare.16.2.445</ArticleId><ArticleId IdType="pubmed">8432215</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer U, Herder C, Sugiri D, Strassburger K, Schikowski T, Ranft U, et al. . Traffic-related air pollution and incident type 2 diabetes: results from the SALIA cohort study. Environ Health Perspect. (2010) 118:1273&#x2013;9. doi:&#xa0;10.1289/ehp.0901689</Citation><ArticleIdList><ArticleId IdType="doi">10.1289/ehp.0901689</ArticleId><ArticleId IdType="pmc">PMC2944089</ArticleId><ArticleId IdType="pubmed">20504758</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujita T, Hemmi S, Kajiwara M, Yabuki M, Fuke Y, Satomura A, et al. . Complement-mediated chronic inflammation is associated with diabetic microvascular complication. Diabetes Metab Res Rev. (2013) 29:220&#x2013;6. doi:&#xa0;10.1002/dmrr.v29.3</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dmrr.v29.3</ArticleId><ArticleId IdType="pubmed">23280928</ArticleId></ArticleIdList></Reference><Reference><Citation>Siezenga MA, Chandie Shaw PK, van der Geest RN, Mollnes TE, Daha MR, Rabelink TJ, et al. . Enhanced complement activation is part of the unfavourable cardiovascular risk profile in South Asians. Clin Exp Immunol. (2009) 157:98&#x2013;103. doi:&#xa0;10.1111/j.1365-2249.2009.03959.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2009.03959.x</ArticleId><ArticleId IdType="pmc">PMC2710597</ArticleId><ArticleId IdType="pubmed">19659775</ArticleId></ArticleIdList></Reference><Reference><Citation>Koistinen HA, Vidal H, Karonen SL, Dusserre E, Vallier P, Koivisto VA, et al. . Plasma acylation stimulating protein concentration and subcutaneous adipose tissue C3 mRNA expression in nondiabetic and type 2 diabetic men. Arterioscler Thromb Vasc Biol. (2001) 21:1034&#x2013;9. doi:&#xa0;10.1161/01.ATV.21.6.1034</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.ATV.21.6.1034</ArticleId><ArticleId IdType="pubmed">11397716</ArticleId></ArticleIdList></Reference><Reference><Citation>Golec E, Ekstrom A, Noga M, Omar-Hmeadi M, Lund PE, Villoutreix BO, et al. . Alternative splicing encodes functional intracellular CD59 isoforms that mediate insulin secretion and are down-regulated in diabetic islets. Proc Natl Acad Sci U S A. (2022) 119:e2120083119. doi:&#xa0;10.1073/pnas.2120083119</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2120083119</ArticleId><ArticleId IdType="pmc">PMC9214515</ArticleId><ArticleId IdType="pubmed">35666870</ArticleId></ArticleIdList></Reference><Reference><Citation>Krus U, King BC, Nagaraj V, Gandasi NR, Sjolander J, Buda P, et al. . The complement inhibitor CD59 regulates insulin secretion by modulating exocytotic events. Cell Metab. (2014) 19:883&#x2013;90. doi:&#xa0;10.1016/j.cmet.2014.03.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2014.03.001</ArticleId><ArticleId IdType="pubmed">24726385</ArticleId></ArticleIdList></Reference><Reference><Citation>Golec E, Rosberg R, Zhang E, Renstrom E, Blom AM, King BC. A cryptic non-GPI-anchored cytosolic isoform of CD59 controls insulin exocytosis in pancreatic beta-cells by interaction with SNARE proteins. FASEB J. (2019) 33:12425&#x2013;34. doi:&#xa0;10.1096/fj.201901007R</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201901007R</ArticleId><ArticleId IdType="pmc">PMC6902737</ArticleId><ArticleId IdType="pubmed">31412214</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahren B, Havel PJ, Pacini G, Cianflone K. Acylation stimulating protein stimulates insulin secretion. Int J Obes Relat Metab Disord. (2003) 27:1037&#x2013;43. doi:&#xa0;10.1038/sj.ijo.0802369</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijo.0802369</ArticleId><ArticleId IdType="pubmed">12917708</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez A, Pio R, Lopez J, Cuttitta F. Expression of the adrenomedullin binding protein, complement factor H, in the pancreas and its physiological impact on insulin secretion. J Endocrinol. (2001) 170:503&#x2013;11. doi:&#xa0;10.1677/joe.0.1700503</Citation><ArticleIdList><ArticleId IdType="doi">10.1677/joe.0.1700503</ArticleId><ArticleId IdType="pubmed">11524230</ArticleId></ArticleIdList></Reference><Reference><Citation>Laudisi F, Spreafico R, Evrard M, Hughes TR, Mandriani B, Kandasamy M, et al. . Cutting edge: the NLRP3 inflammasome links complement-mediated inflammation and IL-1beta release. J Immunol. (2013) 191:1006&#x2013;10. doi:&#xa0;10.4049/jimmunol.1300489</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1300489</ArticleId><ArticleId IdType="pmc">PMC3718202</ArticleId><ArticleId IdType="pubmed">23817414</ArticleId></ArticleIdList></Reference><Reference><Citation>Asgari E, Le Friec G, Yamamoto H, Perucha E, Sacks SS, Kohl J, et al. . C3a modulates IL-1beta secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation. Blood. (2013) 122:3473&#x2013;81. doi:&#xa0;10.1182/blood-2013-05-502229</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2013-05-502229</ArticleId><ArticleId IdType="pubmed">23878142</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitagawa K, Rosen BS, Spiegelman BM, Lienhard GE, Tanner LI. Insulin stimulates the acute release of adipsin from 3T3-L1 adipocytes. Biochim Biophys Acta. (1989) 1014:83&#x2013;9. doi:&#xa0;10.1016/0167-4889(89)90244-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0167-4889(89)90244-9</ArticleId><ArticleId IdType="pubmed">2679882</ArticleId></ArticleIdList></Reference><Reference><Citation>Atanes P, Ruz-Maldonado I, Pingitore A, Hawkes R, Liu B, Zhao M, et al. . C3aR and C5aR1 act as key regulators of human and mouse beta-cell function. Cell Mol Life Sci. (2018) 75:715&#x2013;26. doi:&#xa0;10.1007/s00018-017-2655-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-017-2655-1</ArticleId><ArticleId IdType="pmc">PMC5769825</ArticleId><ArticleId IdType="pubmed">28921001</ArticleId></ArticleIdList></Reference><Reference><Citation>Moini JAR, Miller C, Samsam M. Perspective on economics and obesity. Global Health Complications Obes. (2020), 411&#x2013;23. doi:&#xa0;10.1016/B978-0-12-819751-6.00018-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-819751-6.00018-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Dashty M, Motazacker MM, Levels J, de Vries M, Mahmoudi M, Peppelenbosch MP, et al. . Proteome of human plasma very low-density lipoprotein and low-density lipoprotein exhibits a link with coagulation and lipid metabolism. Thromb Haemost. (2014) 111:518&#x2013;30. doi:&#xa0;10.1160/TH13-02-0178</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH13-02-0178</ArticleId><ArticleId IdType="pubmed">24500811</ArticleId></ArticleIdList></Reference><Reference><Citation>Xin Y, Hertle E, van der Kallen CJH, Vogelzangs N, Arts ICW, Schalkwijk CG, et al. . C3 and alternative pathway components are associated with an adverse lipoprotein subclass profile: The CODAM study. J Clin Lipidol. (2021) 15:311&#x2013;9. doi:&#xa0;10.1016/j.jacl.2021.01.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacl.2021.01.011</ArticleId><ArticleId IdType="pubmed">33612457</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada T, Ohama T, Takafuji K, Kanno K, Matsuda H, Sairyo M, et al. . Shotgun proteomic analysis reveals proteome alterations in HDL of patients with cholesteryl ester transfer protein deficiency. J Clin Lipidol. (2019) 13:317&#x2013;25. doi:&#xa0;10.1016/j.jacl.2019.01.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacl.2019.01.002</ArticleId><ArticleId IdType="pubmed">30745272</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, et al. . Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest. (2007) 117:746&#x2013;56. doi:&#xa0;10.1172/JCI26206</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI26206</ArticleId><ArticleId IdType="pmc">PMC1804352</ArticleId><ArticleId IdType="pubmed">17332893</ArticleId></ArticleIdList></Reference><Reference><Citation>Haapasalo K, van Kessel K, Nissila E, Metso J, Johansson T, Miettinen S, et al. . Complement factor H binds to human serum apolipoprotein E and mediates complement regulation on high density lipoprotein particles. J Biol Chem. (2015) 290:28977&#x2013;87. doi:&#xa0;10.1074/jbc.M115.669226</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.669226</ArticleId><ArticleId IdType="pmc">PMC4661410</ArticleId><ArticleId IdType="pubmed">26468283</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin C, Ackermann S, Ma Z, Mohanta SK, Zhang C, Li Y, et al. . ApoE attenuates unresolvable inflammation by complex formation with activated C1q. Nat Med. (2019) 25:496&#x2013;506. doi:&#xa0;10.1038/s41591-018-0336-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0336-8</ArticleId><ArticleId IdType="pmc">PMC6420126</ArticleId><ArticleId IdType="pubmed">30692699</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlesworth JA, Peake PW, Campbell LV, Pussell BA, O&#x2019;Grady S, Tzilopoulos T. The influence of oral lipid loads on acylation stimulating protein (ASP) in healthy volunteers. Int J Obes Relat Metab Disord. (1998) 22:1096&#x2013;102. doi:&#xa0;10.1038/sj.ijo.0800733</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ijo.0800733</ArticleId><ArticleId IdType="pubmed">9822948</ArticleId></ArticleIdList></Reference><Reference><Citation>Foghmar C, Brons C, Pilely K, Vaag A, Garred P. Complement factors C4 and C3 are down regulated in response to short term overfeeding in healthy young men. Sci Rep. (2017) 7:1235. doi:&#xa0;10.1038/s41598-017-01382-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-01382-3</ArticleId><ArticleId IdType="pmc">PMC5430872</ArticleId><ArticleId IdType="pubmed">28450702</ArticleId></ArticleIdList></Reference><Reference><Citation>Halkes CJ, van Dijk H, de Jaegere PP, Plokker HW, van der Helm Y, Erkelens DW, et al. . Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: effects of expanded-dose simvastatin. Arterioscler Thromb Vasc Biol. (2001) 21:1526&#x2013;30. doi:&#xa0;10.1161/hq0901.095276</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/hq0901.095276</ArticleId><ArticleId IdType="pubmed">11557683</ArticleId></ArticleIdList></Reference><Reference><Citation>Meijssen S, van Dijk H, Verseyden C, Erkelens DW, Cabezas MC. Delayed and exaggerated postprandial complement component 3 response in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. (2002) 22:811&#x2013;6. doi:&#xa0;10.1161/01.ATV.0000014079.98335.72</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.ATV.0000014079.98335.72</ArticleId><ArticleId IdType="pubmed">12006395</ArticleId></ArticleIdList></Reference><Reference><Citation>Onat A, Uzunlar B, Hergenc G, Yazici M, Sari I, Uyarel H, et al. . Cross-sectional study of complement C3 as a coronary risk factor among men and women. Clin Sci (Lond). (2005) 108:129&#x2013;35. doi:&#xa0;10.1042/CS20040198</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20040198</ArticleId><ArticleId IdType="pubmed">15487975</ArticleId></ArticleIdList></Reference><Reference><Citation>van Oostrom AJ, Alipour A, Plokker TW, Sniderman AD, Cabezas MC. The metabolic syndrome in relation to complement component 3 and postprandial lipemia in patients from an outpatient lipid clinic and healthy volunteers. Atherosclerosis. (2007) 190:167&#x2013;73. doi:&#xa0;10.1016/j.atherosclerosis.2006.01.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2006.01.009</ArticleId><ArticleId IdType="pubmed">16488421</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleh J, Wahab RA, Farhan H, Al-Amri I, Cianflone K. Plasma levels of acylation-stimulating protein are strongly predicted by waist/hip ratio and correlate with decreased LDL size in men. ISRN Obes. (2013) 2013:342802. doi:&#xa0;10.1155/2013/342802</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/342802</ArticleId><ArticleId IdType="pmc">PMC3901980</ArticleId><ArticleId IdType="pubmed">24533222</ArticleId></ArticleIdList></Reference><Reference><Citation>van Greevenbroek MM, Ghosh S, van der Kallen CJ, Brouwers MC, Schalkwijk CG, Stehouwer CD. Up-regulation of the complement system in subcutaneous adipocytes from nonobese, hypertriglyceridemic subjects is associated with adipocyte insulin resistance. J Clin Endocrinol Metab. (2012) 97:4742&#x2013;52. doi:&#xa0;10.1210/jc.2012-2539</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2012-2539</ArticleId><ArticleId IdType="pmc">PMC3513546</ArticleId><ArticleId IdType="pubmed">23055543</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujita T, Fujioka T, Murakami T, Satomura A, Fuke Y, Matsumoto K. Chylomicron accelerates C3 tick-over by regulating the role of factor H, leading to overproduction of acylation stimulating protein. J Clin Lab Anal. (2007) 21:14&#x2013;23. doi:&#xa0;10.1002/jcla.20158</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcla.20158</ArticleId><ArticleId IdType="pmc">PMC6649021</ArticleId><ArticleId IdType="pubmed">17245758</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Van Oort MM, Yao M, van der Horst DJ, Rodenburg KW. Insulin and chromium picolinate induce translocation of CD36 to the plasma membrane through different signaling pathways in 3T3-L1 adipocytes, and with a differential functionality of the CD36. Biol Trace Elem Res. (2011) 142:735&#x2013;47. doi:&#xa0;10.1007/s12011-010-8809-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12011-010-8809-8</ArticleId><ArticleId IdType="pubmed">20721637</ArticleId></ArticleIdList></Reference><Reference><Citation>Alper CA, Johnson AM, Birtch AG, Moore FD. Human C&#x2019;3: evidence for the liver as the primary site of synthesis. Science. (1969) 163:286&#x2013;8. doi:&#xa0;10.1126/science.163.3864.286</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.163.3864.286</ArticleId><ArticleId IdType="pubmed">4883617</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin X, Gao B. The complement system in liver diseases. Cell Mol Immunol. (2006) 3:333&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">17092430</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillebrandt S, Wasmuth HE, Weiskirchen R, Hellerbrand C, Keppeler H, Werth A, et al. . Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet. (2005) 37:835&#x2013;43. doi:&#xa0;10.1038/ng1599</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1599</ArticleId><ArticleId IdType="pubmed">15995705</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic dysfunction-associated steatotic liver disease (MASLD): A state-of-the-art review. J Obes Metab Syndr. (2023) 32:197&#x2013;213. doi:&#xa0;10.7570/jomes23052</Citation><ArticleIdList><ArticleId IdType="doi">10.7570/jomes23052</ArticleId><ArticleId IdType="pmc">PMC10583766</ArticleId><ArticleId IdType="pubmed">37700494</ArticleId></ArticleIdList></Reference><Reference><Citation>Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. . Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. (2018) 15:11&#x2013;20. doi:&#xa0;10.1038/nrgastro.2017.109</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2017.109</ArticleId><ArticleId IdType="pubmed">28930295</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. . The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. (2018) 67:328&#x2013;57. doi:&#xa0;10.1002/hep.29367</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.29367</ArticleId><ArticleId IdType="pubmed">28714183</ArticleId></ArticleIdList></Reference><Reference><Citation>Loomba R, Schork N, Chen CH, Bettencourt R, Bhatt A, Ang B, et al. . Heritability of hepatic fibrosis and steatosis based on a prospective twin study. Gastroenterology. (2015) 149:1784&#x2013;93. doi:&#xa0;10.1053/j.gastro.2015.08.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2015.08.011</ArticleId><ArticleId IdType="pmc">PMC4663110</ArticleId><ArticleId IdType="pubmed">26299412</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. (2010) 53:372&#x2013;84. doi:&#xa0;10.1016/j.jhep.2010.04.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2010.04.008</ArticleId><ArticleId IdType="pubmed">20494470</ArticleId></ArticleIdList></Reference><Reference><Citation>Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol. (2013) 10:627&#x2013;36. doi:&#xa0;10.1038/nrgastro.2013.149</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2013.149</ArticleId><ArticleId IdType="pubmed">23958599</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia Q, Li C, Xia Y, Zhang Q, Wu H, Du H, et al. . Association between complement C3 and prevalence of fatty liver disease in an adult population: a cross-sectional study from the Tianjin Chronic Low-Grade Systemic Inflammation and Health (TCLSIHealth) cohort study. PloS One. (2015) 10:e0122026. doi:&#xa0;10.1371/journal.pone.0122026</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0122026</ArticleId><ArticleId IdType="pmc">PMC4391843</ArticleId><ArticleId IdType="pubmed">25856141</ArticleId></ArticleIdList></Reference><Reference><Citation>Ursini F, Russo E, Mauro D, Abenavoli L, Ammerata G, Serrao A, et al. . Complement C3 and fatty liver disease in Rheumatoid arthritis patients: a cross-sectional study. Eur J Clin Invest. (2017) 47:728&#x2013;35. doi:&#xa0;10.1111/eci.2017.47.issue-10</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.2017.47.issue-10</ArticleId><ArticleId IdType="pubmed">28796299</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu C, Chen Y, Xu L, Miao M, Li Y, Yu C. Serum complement C3 levels are associated with nonalcoholic fatty liver disease independently of metabolic features in Chinese population. Sci Rep. (2016) 6:23279. doi:&#xa0;10.1038/srep23279</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep23279</ArticleId><ArticleId IdType="pmc">PMC4814815</ArticleId><ArticleId IdType="pubmed">27029598</ArticleId></ArticleIdList></Reference><Reference><Citation>Yesilova Z, Ozata M, Oktenli C, Bagci S, Ozcan A, Sanisoglu SY, et al. . Increased acylation stimulating protein concentrations in nonalcoholic fatty liver disease are associated with insulin resistance. Am J Gastroenterol. (2005) 100:842&#x2013;9. doi:&#xa0;10.1111/j.1572-0241.2005.40838.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2005.40838.x</ArticleId><ArticleId IdType="pubmed">15784030</ArticleId></ArticleIdList></Reference><Reference><Citation>Rensen SS, Slaats Y, Driessen A, Peutz-Kootstra CJ, Nijhuis J, Steffensen R, et al. . Activation of the complement system in human nonalcoholic fatty liver disease. Hepatology. (2009) 50:1809&#x2013;17. doi:&#xa0;10.1002/hep.23228</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.23228</ArticleId><ArticleId IdType="pubmed">19821522</ArticleId></ArticleIdList></Reference><Reference><Citation>Segers FM, Verdam FJ, de Jonge C, Boonen B, Driessen A, Shiri-Sverdlov R, et al. . Complement alternative pathway activation in human nonalcoholic steatohepatitis. PloS One. (2014) 9:e110053. doi:&#xa0;10.1371/journal.pone.0110053</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0110053</ArticleId><ArticleId IdType="pmc">PMC4192551</ArticleId><ArticleId IdType="pubmed">25299043</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Z, Fan X, Yao J, Tomlinson S, Yuan G, He S. The role of complement in nonalcoholic fatty liver disease. Front Immunol. (2022) 13:1017467. doi:&#xa0;10.3389/fimmu.2022.1017467</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1017467</ArticleId><ArticleId IdType="pmc">PMC9562907</ArticleId><ArticleId IdType="pubmed">36248852</ArticleId></ArticleIdList></Reference><Reference><Citation>Bavia L, Cogliati B, Dettoni JB, Ferreira Alves VA, Isaac L. The complement component C5 promotes liver steatosis and inflammation in murine non-alcoholic liver disease model. Immunol Lett. (2016) 177:53&#x2013;61. doi:&#xa0;10.1016/j.imlet.2016.07.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2016.07.014</ArticleId><ArticleId IdType="pubmed">27477770</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang K, Lu S, Li D, Liu M, Jin H, Lei B, et al. . Blockade of C5aR1 alleviates liver inflammation and fibrosis in a mouse model of NASH by regulating TLR4 signaling and macrophage polarization. J Gastroenterol. (2023) 58:894&#x2013;907. doi:&#xa0;10.1007/s00535-023-02002-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00535-023-02002-w</ArticleId><ArticleId IdType="pmc">PMC10423130</ArticleId><ArticleId IdType="pubmed">37227481</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim J, Iyer A, Suen JY, Seow V, Reid RC, Brown L, et al. . C5aR and C3aR antagonists each inhibit diet-induced obesity, metabolic dysfunction, and adipocyte and macrophage signaling. FASEB J. (2013) 27:822&#x2013;31. doi:&#xa0;10.1096/fj.12-220582</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.12-220582</ArticleId><ArticleId IdType="pubmed">23118029</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. . Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. (2014) 2:e106&#x2013;16. doi:&#xa0;10.1016/S2214-109X(13)70145-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(13)70145-1</ArticleId><ArticleId IdType="pubmed">25104651</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleckenstein M, Keenan TDL, Guymer RH, Chakravarthy U, Schmitz-Valckenberg S, Klaver CC, et al. . Age-related macular degeneration. Nat Rev Dis Primers. (2021) 7:31. doi:&#xa0;10.1038/s41572-021-00265-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-021-00265-2</ArticleId><ArticleId IdType="pubmed">33958600</ArticleId></ArticleIdList></Reference><Reference><Citation>Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. (2000) 45:115&#x2013;34. doi:&#xa0;10.1016/S0039-6257(00)00140-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0039-6257(00)00140-5</ArticleId><ArticleId IdType="pubmed">11033038</ArticleId></ArticleIdList></Reference><Reference><Citation>Catala A. An overview of lipid peroxidation with emphasis in outer segments of photoreceptors and the chemiluminescence assay. Int J Biochem Cell Biol. (2006) 38:1482&#x2013;95. doi:&#xa0;10.1016/j.biocel.2006.02.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2006.02.010</ArticleId><ArticleId IdType="pubmed">16621670</ArticleId></ArticleIdList></Reference><Reference><Citation>Papac-Milicevic N, Busch CJ, Binder CJ. Malondialdehyde epitopes as targets of immunity and the implications for atherosclerosis. Adv Immunol. (2016) 131:1&#x2013;59. doi:&#xa0;10.1016/bs.ai.2016.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.ai.2016.02.001</ArticleId><ArticleId IdType="pmc">PMC5892703</ArticleId><ArticleId IdType="pubmed">27235680</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiegand RD, Giusto NM, Rapp LM, Anderson RE. Evidence for rod outer segment lipid peroxidation following constant illumination of the rat retina. Invest Ophthalmol Vis Sci. (1983) 24:1433&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">6618806</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang MK, Binder CJ, Miller YI, Subbanagounder G, Silverman GJ, Berliner JA, et al. . Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J Exp Med. (2004) 200:1359&#x2013;70. doi:&#xa0;10.1084/jem.20031763</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20031763</ArticleId><ArticleId IdType="pmc">PMC2211955</ArticleId><ArticleId IdType="pubmed">15583011</ArticleId></ArticleIdList></Reference><Reference><Citation>Curcio CA. Complementing apolipoprotein secretion by cultured retinal pigment epithelium. Proc Natl Acad Sci U S A. (2011) 108:18569&#x2013;70. doi:&#xa0;10.1073/pnas.1115497108</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1115497108</ArticleId><ArticleId IdType="pmc">PMC3219100</ArticleId><ArticleId IdType="pubmed">22065764</ArticleId></ArticleIdList></Reference><Reference><Citation>Horkko S, Bird DA, Miller E, Itabe H, Leitinger N, Subbanagounder G, et al. . Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest. (1999) 103:117&#x2013;28. doi:&#xa0;10.1172/JCI4533</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI4533</ArticleId><ArticleId IdType="pmc">PMC407862</ArticleId><ArticleId IdType="pubmed">9884341</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards AO, Ritter R, 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science. (2005) 308:421&#x2013;4. doi:&#xa0;10.1126/science.1110189</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1110189</ArticleId><ArticleId IdType="pubmed">15761121</ArticleId></ArticleIdList></Reference><Reference><Citation>Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, et al. . Complement factor H variant increases the risk of age-related macular degeneration. Science. (2005) 308:419&#x2013;21. doi:&#xa0;10.1126/science.1110359</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1110359</ArticleId><ArticleId IdType="pubmed">15761120</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritsche LG, Igl W, Bailey JN, Grassmann F, Sengupta S, Bragg-Gresham JL, et al. . A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet. (2016) 48:134&#x2013;43. doi:&#xa0;10.1038/ng.3448</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3448</ArticleId><ArticleId IdType="pmc">PMC4745342</ArticleId><ArticleId IdType="pubmed">26691988</ArticleId></ArticleIdList></Reference><Reference><Citation>Geerlings MJ, de Jong EK, den Hollander AI. The complement system in age-related macular degeneration: A review of rare genetic variants and implications for personalized treatment. Mol Immunol. (2017) 84:65&#x2013;76. doi:&#xa0;10.1016/j.molimm.2016.11.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2016.11.016</ArticleId><ArticleId IdType="pmc">PMC5380947</ArticleId><ArticleId IdType="pubmed">27939104</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark SJ, McHarg S, Tilakaratna V, Brace N, Bishop PN. Bruch&#x2019;s membrane compartmentalizes complement regulation in the eye with implications for therapeutic design in age-related macular degeneration. Front Immunol. (2017) 8:1778. doi:&#xa0;10.3389/fimmu.2017.01778</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01778</ArticleId><ArticleId IdType="pmc">PMC5742201</ArticleId><ArticleId IdType="pubmed">29312308</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark SJ, Ridge LA, Herbert AP, Hakobyan S, Mulloy B, Lennon R, et al. . Tissue-specific host recognition by complement factor H is mediated by differential activities of its glycosaminoglycan-binding regions. J Immunol. (2013) 190:2049&#x2013;57. doi:&#xa0;10.4049/jimmunol.1201751</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1201751</ArticleId><ArticleId IdType="pmc">PMC3672945</ArticleId><ArticleId IdType="pubmed">23365078</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark SJ, Schmidt CQ, White AM, Hakobyan S, Morgan BP, Bishop PN. Identification of factor H-like protein 1 as the predominant complement regulator in Bruch&#x2019;s membrane: implications for age-related macular degeneration. J Immunol. (2014) 193:4962&#x2013;70. doi:&#xa0;10.4049/jimmunol.1401613</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1401613</ArticleId><ArticleId IdType="pmc">PMC4225158</ArticleId><ArticleId IdType="pubmed">25305316</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark SJ, Higman VA, Mulloy B, Perkins SJ, Lea SM, Sim RB, et al. . His-384 allotypic variant of factor H associated with age-related macular degeneration has different heparin binding properties from the non-disease-associated form. J Biol Chem. (2006) 281:24713&#x2013;20. doi:&#xa0;10.1074/jbc.M605083200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M605083200</ArticleId><ArticleId IdType="pubmed">16787919</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark SJ, Perveen R, Hakobyan S, Morgan BP, Sim RB, Bishop PN, et al. . Impaired binding of the age-related macular degeneration-associated complement factor H 402H allotype to Bruch&#x2019;s membrane in human retina. J Biol Chem. (2010) 285:30192&#x2013;202. doi:&#xa0;10.1074/jbc.M110.103986</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.103986</ArticleId><ArticleId IdType="pmc">PMC2943316</ArticleId><ArticleId IdType="pubmed">20660596</ArticleId></ArticleIdList></Reference><Reference><Citation>Laine M, Jarva H, Seitsonen S, Haapasalo K, Lehtinen MJ, Lindeman N, et al. . Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol. (2007) 178:3831&#x2013;6. doi:&#xa0;10.4049/jimmunol.178.6.3831</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.178.6.3831</ArticleId><ArticleId IdType="pmc">PMC4853917</ArticleId><ArticleId IdType="pubmed">17339482</ArticleId></ArticleIdList></Reference><Reference><Citation>Molins B, Fuentes-Prior P, Adan A, Anton R, Arostegui JI, Yague J, et al. . Complement factor H binding of monomeric C-reactive protein downregulates proinflammatory activity and is impaired with at risk polymorphic CFH variants. Sci Rep. (2016) 6:22889. doi:&#xa0;10.1038/srep22889</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep22889</ArticleId><ArticleId IdType="pmc">PMC4785391</ArticleId><ArticleId IdType="pubmed">26961257</ArticleId></ArticleIdList></Reference><Reference><Citation>Raychaudhuri S, Iartchouk O, Chin K, Tan PL, Tai AK, Ripke S, et al. . A rare penetrant mutation in CFH confers high risk of age-related macular degeneration. Nat Genet. (2011) 43:1232&#x2013;6. doi:&#xa0;10.1038/ng.976</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.976</ArticleId><ArticleId IdType="pmc">PMC3225644</ArticleId><ArticleId IdType="pubmed">22019782</ArticleId></ArticleIdList></Reference><Reference><Citation>Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI, et al. . A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A. (2005) 102:7227&#x2013;32. doi:&#xa0;10.1073/pnas.0501536102</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0501536102</ArticleId><ArticleId IdType="pmc">PMC1088171</ArticleId><ArticleId IdType="pubmed">15870199</ArticleId></ArticleIdList></Reference><Reference><Citation>Hageman GS, Hancox LS, Taiber AJ, Gehrs KM, Anderson DH, Johnson LV, et al. . Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: characterization, ethnic distribution and evolutionary implications. Ann Med. (2006) 38:592&#x2013;604. doi:&#xa0;10.1080/07853890601097030</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890601097030</ArticleId><ArticleId IdType="pmc">PMC1905836</ArticleId><ArticleId IdType="pubmed">17438673</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes AE, Orr N, Esfandiary H, Diaz-Torres M, Goodship T, Chakravarthy U. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat Genet. (2006) 38:1173&#x2013;7. doi:&#xa0;10.1038/ng1890</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1890</ArticleId><ArticleId IdType="pubmed">16998489</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jong S, Gagliardi G, Garanto A, de Breuk A, Lechanteur YTE, Katti S, et al. . Implications of genetic variation in the complement system in age-related macular degeneration. Prog Retin Eye Res. (2021) 84:100952. doi:&#xa0;10.1016/j.preteyeres.2021.100952</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2021.100952</ArticleId><ArticleId IdType="pubmed">33610747</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagerness JA, Maller JB, Neale BM, Reynolds RC, Daly MJ, Seddon JM. Variation near complement factor I is associated with risk of advanced AMD. Eur J Hum Genet. (2009) 17:100&#x2013;4. doi:&#xa0;10.1038/ejhg.2008.140</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejhg.2008.140</ArticleId><ArticleId IdType="pmc">PMC2985963</ArticleId><ArticleId IdType="pubmed">18685559</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallam TM, Marchbank KJ, Harris CL, Osmond C, Shuttleworth VG, Griffiths H, et al. . Rare genetic variants in complement factor I lead to low FI plasma levels resulting in increased risk of age-related macular degeneration. Invest Ophthalmol Vis Sci. (2020) 61:18. doi:&#xa0;10.1167/iovs.61.6.18</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.61.6.18</ArticleId><ArticleId IdType="pmc">PMC7415286</ArticleId><ArticleId IdType="pubmed">32516404</ArticleId></ArticleIdList></Reference><Reference><Citation>Java A, Baciu P, Widjajahakim R, Sung YJ, Yang J, Kavanagh D, et al. . Functional analysis of rare genetic variants in complement factor I (CFI) using a serum-based assay in advanced age-related macular degeneration. Transl Vis Sci Technol. (2020) 9:37. doi:&#xa0;10.1167/tvst.9.9.37</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/tvst.9.9.37</ArticleId><ArticleId IdType="pmc">PMC7453046</ArticleId><ArticleId IdType="pubmed">32908800</ArticleId></ArticleIdList></Reference><Reference><Citation>Maller JB, Fagerness JA, Reynolds RC, Neale BM, Daly MJ, Seddon JM. Variation in complement factor 3 is associated with risk of age-related macular degeneration. Nat Genet. (2007) 39:1200&#x2013;1. doi:&#xa0;10.1038/ng2131</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng2131</ArticleId><ArticleId IdType="pubmed">17767156</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon O, Hallam TM, Patel S, Harris CL, Menny A, Zelek WM, et al. . The rare C9 P167S risk variant for age-related macular degeneration increases polymerization of the terminal component of the complement cascade. Hum Mol Genet. (2021) 30:1188&#x2013;99. doi:&#xa0;10.1093/hmg/ddab086</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddab086</ArticleId><ArticleId IdType="pmc">PMC8212764</ArticleId><ArticleId IdType="pubmed">33783477</ArticleId></ArticleIdList></Reference><Reference><Citation>Seddon JM, Yu Y, Miller EC, Reynolds R, Tan PL, Gowrisankar S, et al. . Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration. Nat Genet. (2013) 45:1366&#x2013;70. doi:&#xa0;10.1038/ng.2741</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2741</ArticleId><ArticleId IdType="pmc">PMC3902040</ArticleId><ArticleId IdType="pubmed">24036952</ArticleId></ArticleIdList></Reference><Reference><Citation>Shughoury A, Sevgi DD, Ciulla TA. Molecular genetic mechanisms in age-related macular degeneration. Genes (Basel). (2022) 13:1233. doi:&#xa0;10.3390/genes13071233</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes13071233</ArticleId><ArticleId IdType="pmc">PMC9316037</ArticleId><ArticleId IdType="pubmed">35886016</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Ven JP, Nilsson SC, Tan PL, Buitendijk GH, Ristau T, Mohlin FC, et al. . A functional variant in the CFI gene confers a high risk of age-related macular degeneration. Nat Genet. (2013) 45:813&#x2013;7. doi:&#xa0;10.1038/ng.2640</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2640</ArticleId><ArticleId IdType="pubmed">23685748</ArticleId></ArticleIdList></Reference><Reference><Citation>Yates JR, Sepp T, Matharu BK, Khan JC, Thurlby DA, Shahid H, et al. . Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med. (2007) 357:553&#x2013;61. doi:&#xa0;10.1056/NEJMoa072618</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa072618</ArticleId><ArticleId IdType="pubmed">17634448</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Li S, Hu S, Yu J, Xiang Y. Association between genetic variation of complement C3 and the susceptibility to advanced age-related macular degeneration: a meta-analysis. BMC Ophthalmol. (2018) 18:274. doi:&#xa0;10.1186/s12886-018-0945-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12886-018-0945-5</ArticleId><ArticleId IdType="pmc">PMC6199710</ArticleId><ArticleId IdType="pubmed">30352574</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun C, Zhao M, Li X. CFB/C2 gene polymorphisms and risk of age-related macular degeneration: a systematic review and meta-analysis. Curr Eye Res. (2012) 37:259&#x2013;71. doi:&#xa0;10.3109/02713683.2011.635401</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/02713683.2011.635401</ArticleId><ArticleId IdType="pubmed">22440158</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakkinstian A, McEvoy M, Chakravarthy U, Chakrabarti S, McKay GJ, Ryu E, et al. . The association between complement component 2/complement factor B polymorphisms and age-related macular degeneration: a HuGE review and meta-analysis. Am J Epidemiol. (2012) 176:361&#x2013;72. doi:&#xa0;10.1093/aje/kws031</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kws031</ArticleId><ArticleId IdType="pmc">PMC6483268</ArticleId><ArticleId IdType="pubmed">22869612</ArticleId></ArticleIdList></Reference><Reference><Citation>Aredo B, Li T, Chen X, Zhang K, Wang CX, Gou D, et al. . A chimeric Cfh transgene leads to increased retinal oxidative stress, inflammation, and accumulation of activated subretinal microglia in mice. Invest Ophthalmol Vis Sci. (2015) 56:3427&#x2013;40. doi:&#xa0;10.1167/iovs.14-16089</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.14-16089</ArticleId><ArticleId IdType="pmc">PMC4464010</ArticleId><ArticleId IdType="pubmed">26030099</ArticleId></ArticleIdList></Reference><Reference><Citation>Armento A, Honisch S, Panagiotakopoulou V, Sonntag I, Jacob A, Bolz S, et al. . Loss of Complement Factor H impairs antioxidant capacity and energy metabolism of human RPE cells. Sci Rep. (2020) 10:10320. doi:&#xa0;10.1038/s41598-020-67292-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-67292-z</ArticleId><ArticleId IdType="pmc">PMC7316856</ArticleId><ArticleId IdType="pubmed">32587311</ArticleId></ArticleIdList></Reference><Reference><Citation>Borras C, Canonica J, Jorieux S, Abache T, El Sanharawi M, Klein C, et al. . CFH exerts anti-oxidant effects on retinal pigment epithelial cells independently from protecting against membrane attack complex. Sci Rep. (2019) 9:13873. doi:&#xa0;10.1038/s41598-019-50420-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-50420-9</ArticleId><ArticleId IdType="pmc">PMC6761137</ArticleId><ArticleId IdType="pubmed">31554875</ArticleId></ArticleIdList></Reference><Reference><Citation>Armento A, Ueffing M, Clark SJ. The complement system in age-related macular degeneration. Cell Mol Life Sci. (2021) 78:4487&#x2013;505. doi:&#xa0;10.1007/s00018-021-03796-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-021-03796-9</ArticleId><ArticleId IdType="pmc">PMC8195907</ArticleId><ArticleId IdType="pubmed">33751148</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullins RF, Schoo DP, Sohn EH, Flamme-Wiese MJ, Workamelahu G, Johnston RM, et al. . The membrane attack complex in aging human choriocapillaris: relationship to macular degeneration and choroidal thinning. Am J Pathol. (2014) 184:3142&#x2013;53. doi:&#xa0;10.1016/j.ajpath.2014.07.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2014.07.017</ArticleId><ArticleId IdType="pmc">PMC4215023</ArticleId><ArticleId IdType="pubmed">25204844</ArticleId></ArticleIdList></Reference><Reference><Citation>Pauly D, Agarwal D, Dana N, Schafer N, Biber J, Wunderlich KA, et al. . Cell-type-specific complement expression in the healthy and diseased retina. Cell Rep. (2019) 29:2835&#x2013;48 e4. doi:&#xa0;10.1016/j.celrep.2019.10.084</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.10.084</ArticleId><ArticleId IdType="pmc">PMC6911814</ArticleId><ArticleId IdType="pubmed">31775049</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullins RF, Dewald AD, Streb LM, Wang K, Kuehn MH, Stone EM. Elevated membrane attack complex in human choroid with high risk complement factor H genotypes. Exp Eye Res. (2011) 93:565&#x2013;7. doi:&#xa0;10.1016/j.exer.2011.06.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exer.2011.06.015</ArticleId><ArticleId IdType="pmc">PMC3206185</ArticleId><ArticleId IdType="pubmed">21729696</ArticleId></ArticleIdList></Reference><Reference><Citation>Heesterbeek TJ, Lechanteur YTE, Lores-Motta L, Schick T, Daha MR, Altay L, et al. . Complement activation levels are related to disease stage in AMD. Invest Ophthalmol Vis Sci. (2020) 61:18. doi:&#xa0;10.1167/iovs.61.3.18</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.61.3.18</ArticleId><ArticleId IdType="pmc">PMC7401663</ArticleId><ArticleId IdType="pubmed">32176267</ArticleId></ArticleIdList></Reference><Reference><Citation>Keenan TD, Toso M, Pappas C, Nichols L, Bishop PN, Hageman GS. Assessment of proteins associated with complement activation and inflammation in maculae of human donors homozygous risk at chromosome 1 CFH-to-F13B. Invest Ophthalmol Vis Sci. (2015) 56:4870&#x2013;9. doi:&#xa0;10.1167/iovs.15-17009</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.15-17009</ArticleId><ArticleId IdType="pubmed">26218915</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39635018</PMID><DateRevised><Year>2024</Year><Month>12</Month><Day>05</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1878-5077</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The EPMA journal</Title><ISOAbbreviation>EPMA J</ISOAbbreviation></Journal><ArticleTitle>Application of ChatGPT-4 to oculomics: a cost-effective osteoporosis risk assessment to enhance management as a proof-of-principles model in 3PM.</ArticleTitle><Pagination><StartPage>659</StartPage><EndPage>676</EndPage><MedlinePgn>659-676</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13167-024-00378-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Oculomics is an emerging medical field that focuses on the study of the eye to detect and understand systemic diseases. ChatGPT-4 is a highly advanced AI model with multimodal capabilities, allowing it to process text and statistical data. Osteoporosis is a chronic condition presenting asymptomatically but leading to fractures if untreated. Current diagnostic methods like dual X-ray absorptiometry (DXA) are costly and involve radiation exposure. This study aims to develop a cost-effective osteoporosis risk prediction tool using ophthalmological data and ChatGPT-4 based on oculomics, aligning with predictive, preventive, and personalized medicine (3PM) principles.</AbstractText><AbstractText Label="WORKING HYPOTHESIS AND METHODS" NlmCategory="UNASSIGNED">We hypothesize that leveraging ophthalmological data (oculomics) combined with AI-driven regression models developed by ChatGPT-4 can significantly improve the predictive accuracy for osteoporosis risk. This integration will facilitate earlier detection, enable more effective preventive strategies, and support personalized treatment plans tailored to individual patients. We utilized DXA and ophthalmological data from the Korea National Health and Nutrition Examination Survey to develop and validate osteopenia and osteoporosis prediction models. Ophthalmological and demographic data were integrated into logistic regression analyses, facilitated by ChatGPT-4, to create prediction formulas. These models were then converted into calculator software through automated coding by ChatGPT-4.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">ChatGPT-4 automatically developed prediction models based on key predictors of osteoporosis and osteopenia included age, gender, weight, and specific ophthalmological conditions such as cataracts and early age-related macular degeneration, and successfully implemented a risk calculator tool. The oculomics-based models outperformed traditional methods, with area under the curve of the receiver operating characteristic values of 0.785 for osteopenia and 0.866 for osteoporosis in the validation set. The calculator demonstrated high sensitivity and specificity, providing a reliable tool for early osteoporosis screening.</AbstractText><AbstractText Label="CONCLUSIONS&#xa0;AND EXPERT RECOMMENDATIONS IN THE FRAMEWORK OF 3PM" NlmCategory="UNASSIGNED">This study illustrates the value of integrating ophthalmological data into multi-level diagnostics for osteoporosis, significantly improving the accuracy of health risk assessment and the identification of at-risk individuals. Aligned with the principles of 3PM, this approach fosters earlier detection and enables the development of individualized patient profiles, facilitating personalized and targeted treatment strategies. This study also highlights the potential of AI, specifically ChatGPT-4, in developing accessible, cost-effective, and radiation-free screening tools for advancing 3PM in clinical practice. Our findings emphasize the importance of a holistic approach, incorporating comprehensive health indices and interdisciplinary collaboration, to deliver personalized management plans. Preventive strategies should focus on lifestyle modifications and targeted interventions to enhance bone health, thereby preventing the progression of osteoporosis and contributing to overall patient well-being.</AbstractText><AbstractText Label="SUPPLEMENTARY INFORMATION" NlmCategory="UNASSIGNED">The online version contains supplementary material available at 10.1007/s13167-024-00378-0.</AbstractText><CopyrightInformation>&#xa9; The Author(s), under exclusive licence to European Association for Predictive, Preventive and Personalised Medicine (EPMA) 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Joon Yul</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Yonsei University, Wonju, South Korea.</Affiliation><Identifier Source="ROR">https://ror.org/01wjejq96</Identifier><Identifier Source="GRID">grid.15444.30</Identifier><Identifier Source="ISNI">0000 0004 0470 5454</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Eoksoo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Electronics and Telecommunications Research Institute (ETRI), Daejeon, South Korea.</Affiliation><Identifier Source="ROR">https://ror.org/03ysstz10</Identifier><Identifier Source="GRID">grid.36303.35</Identifier><Identifier Source="ISNI">0000 0000 9148 4899</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Tae Keun</ForeName><Initials>TK</Initials><Identifier Source="ORCID">0000-0003-0890-8614</Identifier><AffiliationInfo><Affiliation>Department of Ophthalmology, Hangil Eye Hospital, 35 Bupyeong-Daero, Bupyeong-Gu, Incheon, 21388 South Korea.</Affiliation><Identifier Source="GRID">grid.517973.e</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>EPMA J</MedlineTA><NlmUniqueID>101517307</NlmUniqueID><ISSNLinking>1878-5077</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AI</Keyword><Keyword MajorTopicYN="N">Advanced healthcare</Keyword><Keyword MajorTopicYN="N">ChatGPT-4</Keyword><Keyword MajorTopicYN="N">Cost-effective holistic approach&#xa0;</Keyword><Keyword MajorTopicYN="N">Health risk assessment</Keyword><Keyword MajorTopicYN="N">Individualized patient profile</Keyword><Keyword MajorTopicYN="N">Multi-level diagnostics</Keyword><Keyword MajorTopicYN="N">Oculomics</Keyword><Keyword MajorTopicYN="N">Ophthalmology</Keyword><Keyword MajorTopicYN="N">Osteopenia</Keyword><Keyword MajorTopicYN="N">Osteoporosis</Keyword><Keyword MajorTopicYN="N">Personalized treatment strategies</Keyword><Keyword MajorTopicYN="N">Predictive preventive personalized medicine (PPPM&#xa0;/&#xa0;3PM)</Keyword><Keyword MajorTopicYN="N">Radiation-free screening tool</Keyword></KeywordList><CoiStatement>Conflict of interestTKY is an advisory board member of MediWhale and has received consultant fees as part of the standard compensation package. The remaining authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>5</Day><Hour>5</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39635018</ArticleId><ArticleId IdType="pmc">PMC11612069</ArticleId><ArticleId IdType="doi">10.1007/s13167-024-00378-0</ArticleId><ArticleId IdType="pii">378</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shevroja E, Cafarelli FP, Guglielmi G, Hans D. DXA parameters, trabecular bone score (TBS) and bone mineral density (BMD), in fracture risk prediction in endocrine-mediated secondary osteoporosis. Endocrine. 2021;74:20&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8440280</ArticleId><ArticleId IdType="pubmed">34245432</ArticleId></ArticleIdList></Reference><Reference><Citation>Reginster J-Y, Burlet N. Osteoporosis: a still increasing prevalence. Bone. 2006;38:4&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16455317</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattui SE, Saag KG. Fracture mortality: associations with epidemiology and osteoporosis treatment. Nat Rev Endocrinol. 2014;10:592&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pubmed">25091729</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf6;zen T, &#xd6;z&#x131;&#x15f;&#x131;k L, Ba&#x15f;aran N&#xc7;. An overview and management of osteoporosis. Eur J Rheumatol. 2017;4:46&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5335887</ArticleId><ArticleId IdType="pubmed">28293453</ArticleId></ArticleIdList></Reference><Reference><Citation>Richy F, Gourlay M, Ross PD, Sen SS, Radican L, De Ceulaer F, et al. Validation and comparative evaluation of the osteoporosis self-assessment tool (OST) in a Caucasian population from Belgium. QJM. 2004;97:39&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">14702510</ArticleId></ArticleIdList></Reference><Reference><Citation>Smets J, Shevroja E, H&#xfc;gle T, Leslie WD, Hans D. Machine learning solutions for osteoporosis&#x2014;a review. J Bone Miner Res. 2021;36:833&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">33751686</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo TK, Kim SK, Kim DW, Choi JY, Lee WH, Oh E, et al. Osteoporosis risk prediction for bone mineral density assessment of postmenopausal women using machine learning. Yonsei Med J. 2013;54:1321&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3809875</ArticleId><ArticleId IdType="pubmed">24142634</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang PC, Jha A, Xu W, Song Z, Jamp P, Teuteberg JJ. Cloud-based machine learning platform to predict clinical outcomes at home for patients with cardiovascular conditions discharged from hospital: clinical trial. JMIR Cardio. 2024;8: e45130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10943420</ArticleId><ArticleId IdType="pubmed">38427393</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Wang Z, Duan N, Zhu G, Schwarz EM, Xie C. Osteoblast&#x2013;osteoclast interactions. Connect Tissue Res. 2018;59:99&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5612831</ArticleId><ArticleId IdType="pubmed">28324674</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan C, Shi Y, Yuan L, Lv D, Sun B, Wang J, et al. Mitochondrial quality control and its role in osteoporosis. Front Endocrinol (Lausanne). 2023;14:1077058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9922754</ArticleId><ArticleId IdType="pubmed">36793284</ArticleId></ArticleIdList></Reference><Reference><Citation>Koklesova L, Mazurakova A, Samec M, Kudela E, Biringer K, Kubatka P, et al. Mitochondrial health quality control: measurements and interpretation in the framework of predictive, preventive, and personalized medicine. EPMA J. 2022;13:177&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9096339</ArticleId><ArticleId IdType="pubmed">35578648</ArticleId></ArticleIdList></Reference><Reference><Citation>Koklesova L, Mazurakova A, Samec M, Biringer K, Samuel SM, B&#xfc;sselberg D, et al. Homocysteine metabolism as the target for predictive medical approach, disease prevention, prognosis, and treatments tailored to the person. EPMA J. 2021;12:477&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8581606</ArticleId><ArticleId IdType="pubmed">34786033</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Y, Xiao X, Zhang X, Yi D, Li T, Hao Q, et al. Mediterranean diet in the targeted prevention and personalized treatment of chronic diseases: evidence, potential mechanisms, and prospects. EPMA J. 2024;15:207&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11147989</ArticleId><ArticleId IdType="pubmed">38841625</ArticleId></ArticleIdList></Reference><Reference><Citation>Babenko B, Traynis I, Chen C, Singh P, Uddin A, Cuadros J, et al. A deep learning model for novel systemic biomarkers in photographs of the external eye: a retrospective study. The Lancet Digital Health. 2023;5:e257&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">36966118</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Li C, Shi D, Wang H, Shang X, Wang W, et al. Integrating oculomics with genomics reveals imaging biomarkers for preventive and personalized prediction of arterial aneurysms. EPMA J. 2023;14:73&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9971392</ArticleId><ArticleId IdType="pubmed">36866161</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim BR, Yoo TK, Kim HK, Ryu IH, Kim JK, Lee IS, et al. Oculomics for sarcopenia prediction: a machine learning approach toward predictive, preventive, and personalized medicine. EPMA J. 2022;13:367&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9437169</ArticleId><ArticleId IdType="pubmed">36061832</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan YY, Kang HG, Lee CJ, Kim SS, Park S, Thakur S, et al. Prognostic potentials of AI in ophthalmology: systemic disease forecasting via retinal imaging. Eye and Vis. 2024;11:17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11071258</ArticleId><ArticleId IdType="pubmed">38711111</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner SK, Fu DJ, Faes L, Liu X, Huemer J, Khalid H, et al. Insights into systemic disease through retinal imaging-based oculomics. Trans Vis Sci Tech. 2020;9:6&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7343674</ArticleId><ArticleId IdType="pubmed">32704412</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo TK, Kim SH, Kwak J, Kim HK, Rim TH. Association between osteoporosis and age-related macular degeneration: the Korea National Health and Nutrition Examination Survey. Invest Ophthalmol Vis Sci. 2018;59:AMD132&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">30372730</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson RB, Reffatto V, Bundy JG, Kortvely E, Flinn JM, Lanzirotti A, et al. Identification of hydroxyapatite spherules provides new insight into subretinal pigment epithelial deposit formation in the aging eye. Proc Natl Acad Sci USA. 2015;112:1565&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4321314</ArticleId><ArticleId IdType="pubmed">25605911</ArticleId></ArticleIdList></Reference><Reference><Citation>Pepe J, Cipriani C, Tedeschi M, Curione M, Parravano M, Varano M, et al. Retinal micro-vascular and aortic macro-vascular changes in postmenopausal women with primary hyperparathyroidism. Sci Rep. 2018;8:16521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6224616</ArticleId><ArticleId IdType="pubmed">30410012</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeng Y-T, Lin S-Y, Hu H-Y, Lee OK, Kuo L-L. Osteoporosis and dry eye syndrome: A previously unappreciated association that may alert active prevention of fall. PLoS ONE. 2018;13:e0207008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6218084</ArticleId><ArticleId IdType="pubmed">30395639</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun CC, Huang T-S, Fu T-S, Lee C-Y, Chen B-Y, Chen F-P. Association of age-related macular degeneration on fracture risks among osteoporosis population: a nationwide population-based cohort study. BMJ Open. 2020;10: e037028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7500305</ArticleId><ArticleId IdType="pubmed">32948557</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi JY, Yoo TK. New era after ChatGPT in ophthalmology: advances from data-based decision support to patient-centered generative artificial intelligence. Ann Transl Med. 2023;11:337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10477620</ArticleId><ArticleId IdType="pubmed">37675304</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Wu R, He J, Xiang Y. Evaluating ChatGPT-4.0&#x2019;s data analytic proficiency in epidemiological studies: a comparative analysis with SAS, SPSS, and R. J Glob Health. 2024;14:04070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10978058</ArticleId><ArticleId IdType="pubmed">38547497</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhail MA, Mathew SS, Khalil A, Berengueres J, Shah SJH. &#x201c;Will I be replaced?&#x201d; Assessing ChatGPT&#x2019;s effect on software development and programmer perceptions of AI tools. Sci Comput Program. 2024;235: 103111.</Citation></Reference><Reference><Citation>Choi JY, Yoo TK. Development of a novel scoring system for glaucoma risk based on demographic and laboratory factors using ChatGPT-4. Med Biol Eng Comput. 2024;</Citation><ArticleIdList><ArticleId IdType="pubmed">39129037</ArticleId></ArticleIdList></Reference><Reference><Citation>Barot M, Gokulgandhi MR, Mitra AK. Mitochondrial dysfunction in retinal diseases. Curr Eye Res. 2011;36:1069&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516173</ArticleId><ArticleId IdType="pubmed">21978133</ArticleId></ArticleIdList></Reference><Reference><Citation>Brennan LA, Kantorow M. Mitochondrial function and redox control in the aging eye: Role of MsrA and other repair systems in cataract and macular degenerations. Exp Eye Res. 2009;88:195&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683477</ArticleId><ArticleId IdType="pubmed">18588875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JS, Kim M, Kim SW. Prevalence and risk factors of epiretinal membrane: data from the Korea National Health and Nutrition Examination Survey VII (2017&#x2013;2018). Clin Experiment Ophthalmol. 2022;50:1047&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">36073108</ArticleId></ArticleIdList></Reference><Reference><Citation>Kweon S, Kim Y, Jang M, Kim Y, Kim K, Choi S, et al. Data resource profile: the Korea National Health and Nutrition Examination Survey (KNHANES). Int J Epidemiol. 2014;43:69&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3937975</ArticleId><ArticleId IdType="pubmed">24585853</ArticleId></ArticleIdList></Reference><Reference><Citation>Looker AC, Melton LJ, Borrud LG, Shepherd JA. Lumbar spine bone mineral density in US adults: demographic patterns and relationship with femur neck skeletal status. Osteoporos Int. 2012;23:1351&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">21720893</ArticleId></ArticleIdList></Reference><Reference><Citation>Park EJ, Joo IW, Jang M-J, Kim YT, Oh K, Oh HJ. Prevalence of osteoporosis in the Korean Population Based on Korea National Health and Nutrition Examination Survey (KNHANES), 2008&#x2013;2011. Yonsei Med J. 2014;55:1049&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4075366</ArticleId><ArticleId IdType="pubmed">24954336</ArticleId></ArticleIdList></Reference><Reference><Citation>Diab DL, Watts NB. Diagnosis and treatment of osteoporosis in older adults. Endocrinol Metab Clin North Am. 2013;42:305&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">23702403</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon KC, Choi W, Lee HS, Kim S-D, Kim S-H, Kim CY, et al. An overview of ophthalmologic survey methodology in the 2008&#x2013;2015 Korean National Health and Nutrition Examination Surveys. Korean J Ophthalmol. 2015;29:359&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4668250</ArticleId><ArticleId IdType="pubmed">26635451</ArticleId></ArticleIdList></Reference><Reference><Citation>Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol. 1995;39:367&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">7604360</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SH, Lee JS, Heo H, Suh Y-W, Kim S-H, Lim KH, et al. A nationwide population-based study of low vision and blindness in South Korea. Invest Ophthalmol Vis Sci. 2015;56:484&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">25525165</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang KH, Shin D, Ryu IH, Kim JK, Lee IS, Koh K, et al. Association between cataract and fatty liver diseases from a nationwide cross-sectional study in South Korea. Sci Rep. 2024;14:77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10761897</ArticleId><ArticleId IdType="pubmed">38167592</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhury MZI, Turin TC. Variable selection strategies and its importance in clinical prediction modelling. Fam Med Community Health. 2020;8: e000262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7032893</ArticleId><ArticleId IdType="pubmed">32148735</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin D, Choi H, Kim D, Park J, Yoo TK, Koh K. Code-free machine learning approach for EVO-ICL vault prediction: a retrospective two-center study. Translational Vision Science &amp; Technology. 2024;13: 4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10996943</ArticleId><ArticleId IdType="pubmed">38564200</ArticleId></ArticleIdList></Reference><Reference><Citation>Taipale J, Mikhailova A, Ojamo M, N&#xe4;ttinen J, V&#xe4;&#xe4;t&#xe4;inen S, Gissler M, et al. Low vision status and declining vision decrease health-related quality of life: results from a nationwide 11-year follow-up study. Qual Life Res. 2019;28:3225&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6863947</ArticleId><ArticleId IdType="pubmed">31401749</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemet AY, Hanhart J, Kaiserman I, Vinker S. Are cataracts associated with osteoporosis? Clin Ophthalmol. 2013;7:2079&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3804595</ArticleId><ArticleId IdType="pubmed">24204110</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang D, Borchman D, Yappert MC, Vrensen GFJM, Rasi V. Influence of age, diabetes, and cataract on calcium, lipid-calcium, and protein-calcium relationships in human lenses. Invest Ophthalmol Vis Sci. 2003;44:2059&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">12714644</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg RK, Urs VL, Agarwal AA, Chaudhary SK, Paliwal V, Kar SK. Exploring the role of ChatGPT in patient care (diagnosis and treatment) and medical research: a systematic review. Health Promot Perspect. 2023;13:183&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10558973</ArticleId><ArticleId IdType="pubmed">37808939</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, Yang C. Is ChatGPT a Good geospatial data analyst? Exploring the integration of natural language into structured query language within a spatial database. ISPRS Int J Geo Inf. 2024;13: 26.</Citation></Reference><Reference><Citation>Martins J, Branco F, Mamede H. Combining low-code development with ChatGPT to novel no-code approaches: a focus-group study. Intelligent Systems with Applications. 2023;20: 200289.</Citation></Reference><Reference><Citation>Patterson EJ, Bounds AD, Wagner SK, Kadri-Langford R, Taylor R, Daly D. Oculomics: a crusade against the four horsemen of chronic disease. Ophthalmol Ther. 2024;13:1427&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11109082</ArticleId><ArticleId IdType="pubmed">38630354</ArticleId></ArticleIdList></Reference><Reference><Citation>Savitz DA, Wellenius GA. Can Cross-sectional studies contribute to causal inference? It depends. American Journal of Epidemiology. 2023;192:514&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">35231933</ArticleId></ArticleIdList></Reference><Reference><Citation>Seibel MJ, Cooper MS, Zhou H. Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives. Lancet Diabetes Endocrinol. 2013;1:59&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">24622268</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson J, McBride K, O&#x2019;Connor M. Drugs associated with cataract formation represent an unmet need in cataract research. Front Med. 2022;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9420850</ArticleId><ArticleId IdType="pubmed">36045926</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39634790</PMID><DateRevised><Year>2024</Year><Month>12</Month><Day>05</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2329-0501</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>12</Day></PubDate></JournalIssue><Title>Molecular therapy. Methods &amp; clinical development</Title><ISOAbbreviation>Mol Ther Methods Clin Dev</ISOAbbreviation></Journal><ArticleTitle>Preclinical evaluation of NG101, a potential AAV gene therapy for wet age-related macular degeneration.</ArticleTitle><Pagination><StartPage>101366</StartPage><MedlinePgn>101366</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101366</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.omtm.2024.101366</ELocationID><Abstract><AbstractText>Age-related macular degeneration (AMD) is a leading cause of vision loss in individuals over the age of 55. Approximately 10%-15% of AMD patients develop choroidal neovascularization (CNV), leading to wet AMD (wAMD), which accounts for nearly 90% of AMD-related blindness. Inhibition of vascular endothelial growth factor (VEGF) is the standard treatment for wAMD. However, the frequent administration of the current treatment imposes a significant burden on wAMD patients. Therefore, there is an unmet need for treatments that require less-frequent administration. Here, we present findings on the safety and efficacy of NG101, a recombinant adeno-associated virus (rAAV) vector encoding aflibercept, an anti-VEGF agent, for wAMD therapy. A single subretinal injection of NG101 effectively reduced CNV lesion leakage and size at doses as low as 1&#xa0;&#xd7;&#xa0;10<sup>6</sup> in mouse and 3&#xa0;&#xd7;&#xa0;10<sup>9</sup> viral genomes per eye in cynomolgus monkeys. In cynomolgus monkeys, NG101-derived aflibercept expression in ocular tissues persisted for 1 year post-injection, indicating sustained therapeutic potential. Biodistribution analysis revealed that NG101 was primarily localized in ocular tissues. Only mild and transient ocular inflammatory responses were observed. Overall, these findings suggest that NG101, with its efficacy at low doses and sustained expression, is a promising therapeutic candidate for wAMD.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shim</LastName><ForeName>Juwon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neuracle Genetics Inc., Seoul 02841, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Youyoung</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Neuracle Genetics Inc., Seoul 02841, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bak</LastName><ForeName>Jeongyun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neuracle Genetics Inc., Seoul 02841, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Sunhwa</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neuracle Genetics Inc., Seoul 02841, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kyungwon</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neuracle Genetics Inc., Seoul 02841, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Yoon Hyung</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Neuracle Genetics Inc., Seoul 02841, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Hoon Young</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Neuracle Genetics Inc., Seoul 02841, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Joo Seok</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Neuracle Genetics Inc., Seoul 02841, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Ther Methods Clin Dev</MedlineTA><NlmUniqueID>101624857</NlmUniqueID><ISSNLinking>2329-0501</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AAV</Keyword><Keyword MajorTopicYN="N">CNV</Keyword><Keyword MajorTopicYN="N">aflibercept</Keyword><Keyword MajorTopicYN="N">age-related macular degeneration</Keyword><Keyword MajorTopicYN="N">gene therapy</Keyword><Keyword MajorTopicYN="N">preclinical study</Keyword><Keyword MajorTopicYN="N">promoter</Keyword><Keyword MajorTopicYN="N">subretinal injection</Keyword></KeywordList><CoiStatement>H.Y.K., S.S., K.L., and J.S.H. have filed a patent application for CAT311 promoter (PCT/KR2021/008693). All authors are employees of Neuracle Genetics. Additionally, all authors, except Y.K., hold shares in Neuracle Genetics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>5</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39634790</ArticleId><ArticleId IdType="pmc">PMC11615598</ArticleId><ArticleId IdType="doi">10.1016/j.omtm.2024.101366</ArticleId><ArticleId IdType="pii">S2329-0501(24)00182-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fleckenstein M., Keenan T.D.L., Guymer R.H., Chakravarthy U., Schmitz-Valckenberg S., Klaver C.C., Wong W.T., Chew E.Y. Age-related macular degeneration. Nat. Rev. Dis. Primers. 2021;7:31. doi: 10.1038/s41572-021-00265-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-021-00265-2</ArticleId><ArticleId IdType="pubmed">33958600</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Fortmann S.D., Shen J., Wielechowski E., Tretiakova A., Yoo S., Kozarsky K., Wang J., Wilson J.M., Campochiaro P.A. AAV8-antiVEGFfab Ocular Gene Transfer for Neovascular Age-Related Macular Degeneration. Mol. Ther. 2018;26:542&#x2013;549. doi: 10.1016/j.ymthe.2017.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2017.12.002</ArticleId><ArticleId IdType="pmc">PMC5835120</ArticleId><ArticleId IdType="pubmed">29292162</ArticleId></ArticleIdList></Reference><Reference><Citation>Pugazhendhi A., Hubbell M., Jairam P., Ambati B. Neovascular Macular Degeneration: A Review of Etiology, Risk Factors, and Recent Advances in Research and Therapy. Int. J. Mol. Sci. 2021;22 doi: 10.3390/ijms22031170.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22031170</ArticleId><ArticleId IdType="pmc">PMC7866170</ArticleId><ArticleId IdType="pubmed">33504013</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovach J.L., Schwartz S.G., Flynn H.W., Jr., Scott I.U. Anti-VEGF Treatment Strategies for Wet AMD. J.&#xa0;Ophthalmol. 2012;2012 doi: 10.1155/2012/786870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/786870</ArticleId><ArticleId IdType="pmc">PMC3317200</ArticleId><ArticleId IdType="pubmed">22523653</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiser S.M., Arepalli S., Ehlers J.P. Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration. J.&#xa0;Exp. Pharmacol. 2021;13:905&#x2013;912. doi: 10.2147/JEP.S259298.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JEP.S259298</ArticleId><ArticleId IdType="pmc">PMC8488047</ArticleId><ArticleId IdType="pubmed">34616189</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen Q.D., Das A., Do D.V., Dugel P.U., Gomes A., Holz F.G., Koh A., Pan C.K., Sepah Y.J., Patel N., et al. Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020;127:963&#x2013;976. doi: 10.1016/j.ophtha.2019.12.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2019.12.031</ArticleId><ArticleId IdType="pubmed">32107066</ArticleId></ArticleIdList></Reference><Reference><Citation>Grishanin R., Vuillemenot B., Sharma P., Keravala A., Greengard J., Gelfman C., Blumenkrantz M., Lawrence M., Hu W., Kiss S., Gasmi M. Preclinical Evaluation of ADVM-022, a Novel Gene Therapy Approach to Treating Wet Age-Related Macular Degeneration. Mol. Ther. 2019;27:118&#x2013;129. doi: 10.1016/j.ymthe.2018.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2018.11.003</ArticleId><ArticleId IdType="pmc">PMC6319194</ArticleId><ArticleId IdType="pubmed">30528929</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiss S., Oresic Bender K., Grishanin R.N., Hanna K.M., Nieves J.D., Sharma P., Nguyen A.T., Rosario R.J., Greengard J.S., Gelfman C.M., Gasmi M. Long-Term Safety Evaluation of Continuous Intraocular Delivery of Aflibercept by the Intravitreal Gene Therapy Candidate ADVM-022 in Nonhuman Primates. Transl. Vis. Sci. Technol. 2021;10:34. doi: 10.1167/tvst.10.1.34.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/tvst.10.1.34</ArticleId><ArticleId IdType="pmc">PMC7846953</ArticleId><ArticleId IdType="pubmed">33532145</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai C.M., Estcourt M.J., Himbeck R.P., Lee S.Y., Yew-San Yeo I., Luu C., Loh B.K., Lee M.W., Barathi A., Villano J., et al. Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates. Gene Ther. 2012;19:999&#x2013;1009. doi: 10.1038/gt.2011.169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gt.2011.169</ArticleId><ArticleId IdType="pubmed">22071974</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke X., Jiang H., Li Q., Luo S., Qin Y., Li J., Xie Q., Zheng Q. Preclinical evaluation of KH631, a novel rAAV8 gene therapy product for neovascular age-related macular degeneration. Mol. Ther. 2023;31:3308&#x2013;3321. doi: 10.1016/j.ymthe.2023.09.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2023.09.019</ArticleId><ArticleId IdType="pmc">PMC10638048</ArticleId><ArticleId IdType="pubmed">37752703</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., Tai P.W.L., Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat. Rev. Drug Discov. 2019;18:358&#x2013;378. doi: 10.1038/s41573-019-0012-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-019-0012-9</ArticleId><ArticleId IdType="pmc">PMC6927556</ArticleId><ArticleId IdType="pubmed">30710128</ArticleId></ArticleIdList></Reference><Reference><Citation>Naso M.F., Tomkowicz B., Perry W.L., 3rd, Strohl W.R. Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. BioDrugs. 2017;31:317&#x2013;334. doi: 10.1007/s40259-017-0234-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40259-017-0234-5</ArticleId><ArticleId IdType="pmc">PMC5548848</ArticleId><ArticleId IdType="pubmed">28669112</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J., Zhou W., Zhang Y., Zidon T., Ritchie T., Engelhardt J.F. Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination. J.&#xa0;Virol. 1999;73:9468&#x2013;9477. doi: 10.1128/JVI.73.11.9468-9477.1999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.73.11.9468-9477.1999</ArticleId><ArticleId IdType="pmc">PMC112981</ArticleId><ArticleId IdType="pubmed">10516055</ArticleId></ArticleIdList></Reference><Reference><Citation>Penaud-Budloo M., Le Guiner C., Nowrouzi A., Toromanoff A., Ch&#xe9;rel Y., Chenuaud P., Schmidt M., von Kalle C., Rolling F., Moullier P., Snyder R.O. Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle. J.&#xa0;Virol. 2008;82:7875&#x2013;7885. doi: 10.1128/JVI.00649-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00649-08</ArticleId><ArticleId IdType="pmc">PMC2519600</ArticleId><ArticleId IdType="pubmed">18524821</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurya S., Sarangi P., Jayandharan G.R. Safety of Adeno-associated virus-based vector-mediated gene therapy-impact of vector dose. Cancer Gene Ther. 2022;29:1305&#x2013;1306. doi: 10.1038/s41417-021-00413-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41417-021-00413-6</ArticleId><ArticleId IdType="pubmed">35027711</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertl H.C.J. Mitigating Serious Adverse Events in Gene Therapy with AAV Vectors: Vector Dose and Immunosuppression. Drugs. 2023;83:287&#x2013;298. doi: 10.1007/s40265-023-01836-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-023-01836-1</ArticleId><ArticleId IdType="pubmed">36715794</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan Y.K., Wang S.K., Chu C.J., Copland D.A., Letizia A.J., Costa Verdera H., Chiang J.J., Sethi M., Wang M.K., Neidermyer W.J., Jr., et al. Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses. Sci. Transl. Med. 2021;13 doi: 10.1126/scitranslmed.abd3438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abd3438</ArticleId><ArticleId IdType="pmc">PMC8409505</ArticleId><ArticleId IdType="pubmed">33568518</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartman R.R., Kompella U.B. Intravitreal, Subretinal, and Suprachoroidal Injections: Evolution of Microneedles for Drug Delivery. J.&#xa0;Ocul. Pharmacol. Ther. 2018;34:141&#x2013;153. doi: 10.1089/jop.2017.0121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jop.2017.0121</ArticleId><ArticleId IdType="pmc">PMC5963636</ArticleId><ArticleId IdType="pubmed">29206556</ArticleId></ArticleIdList></Reference><Reference><Citation>Ail D., Malki H., Zin E.A., Dalkara D. Adeno-Associated Virus (AAV) - Based Gene Therapies for Retinal Diseases: Where are We? Appl. Clin. Genet. 2023;16:111&#x2013;130. doi: 10.2147/TACG.S383453.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/TACG.S383453</ArticleId><ArticleId IdType="pmc">PMC10239239</ArticleId><ArticleId IdType="pubmed">37274131</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalkara D., Kolstad K.D., Caporale N., Visel M., Klimczak R.R., Schaffer D.V., Flannery J.G. Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol. Ther. 2009;17:2096&#x2013;2102. doi: 10.1038/mt.2009.181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2009.181</ArticleId><ArticleId IdType="pmc">PMC2814392</ArticleId><ArticleId IdType="pubmed">19672248</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalkara D., Byrne L.C., Klimczak R.R., Visel M., Yin L., Merigan W.H., Flannery J.G., Schaffer D.V. In&#xa0;vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci. Transl. Med. 2013;5 doi: 10.1126/scitranslmed.3005708.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3005708</ArticleId><ArticleId IdType="pubmed">23761039</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotterman M., Beliakoff G., Croze R., Vazin T., Schmitt C., Szymanski P., Leong M., Quezada M., Holt J., Barglow K., et al. Directed Evolution of AAV Targeting Primate Retina by Intravitreal Injection Identifies R100, a Variant Demonstrating Robust Gene Delivery and Therapeutic Efficacy in Non-Human Primates. bioRxiv. 2021 doi: 10.1101/2021.06.24.449775. Preprint at.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.24.449775</ArticleId></ArticleIdList></Reference><Reference><Citation>Seitz I.P., Michalakis S., Wilhelm B., Reichel F.F., Ochakovski G.A., Zrenner E., Ueffing M., Biel M., Wissinger B., Bartz-Schmidt K.U., et al. Superior Retinal Gene Transfer and Biodistribution Profile of Subretinal Versus Intravitreal Delivery of AAV8 in Nonhuman Primates. Invest. Ophthalmol. Vis. Sci. 2017;58:5792&#x2013;5801. doi: 10.1167/iovs.17-22473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.17-22473</ArticleId><ArticleId IdType="pubmed">29117317</ArticleId></ArticleIdList></Reference><Reference><Citation>Holash J., Davis S., Papadopoulos N., Croll S.D., Ho L., Russell M., Boland P., Leidich R., Hylton D., Burova E., et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA. 2002;99:11393&#x2013;11398. doi: 10.1073/pnas.172398299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.172398299</ArticleId><ArticleId IdType="pmc">PMC123267</ArticleId><ArticleId IdType="pubmed">12177445</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart M.W. Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug. Br. J. Ophthalmol. 2012;96:1157&#x2013;1158. doi: 10.1136/bjophthalmol-2011-300654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjophthalmol-2011-300654</ArticleId><ArticleId IdType="pmc">PMC3432488</ArticleId><ArticleId IdType="pubmed">22446028</ArticleId></ArticleIdList></Reference><Reference><Citation>Trichonas G., Kaiser P.K. Aflibercept for the treatment of age-related macular degeneration. Ophthalmol. Ther. 2013;2:89&#x2013;98. doi: 10.1007/s40123-013-0015-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40123-013-0015-2</ArticleId><ArticleId IdType="pmc">PMC4108145</ArticleId><ArticleId IdType="pubmed">25135809</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadopoulos N., Martin J., Ruan Q., Rafique A., Rosconi M.P., Shi E., Pyles E.A., Yancopoulos G.D., Stahl N., Wiegand S.J. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171&#x2013;185. doi: 10.1007/s10456-011-9249-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10456-011-9249-6</ArticleId><ArticleId IdType="pmc">PMC3338918</ArticleId><ArticleId IdType="pubmed">22302382</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Wang Z., Zhang F., Zhu R., Bi J., Wu J., Zhang H., Wu H., Kong W., Yu B., Yu X. Enhancing Transgene Expression from Recombinant AAV8 Vectors in Different Tissues Using Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Element. Int. J. Med. Sci. 2016;13:286&#x2013;291. doi: 10.7150/ijms.14152.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.14152</ArticleId><ArticleId IdType="pmc">PMC4829541</ArticleId><ArticleId IdType="pubmed">27076785</ArticleId></ArticleIdList></Reference><Reference><Citation>Majowicz A., Maczuga P., Kwikkers K.L., van der Marel S., van Logtenstein R., Petry H., van Deventer S.J., Konstantinova P., Ferreira V. Mir-142-3p target sequences reduce transgene-directed immunogenicity following intramuscular adeno-associated virus 1 vector-mediated gene delivery. J.&#xa0;Gene Med. 2013;15:219&#x2013;232. doi: 10.1002/jgm.2712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jgm.2712</ArticleId><ArticleId IdType="pubmed">23658149</ArticleId></ArticleIdList></Reference><Reference><Citation>Worner T.P., Bennett A., Habka S., Snijder J., Friese O., Powers T., Agbandje-McKenna M., Heck A.J.R. Adeno-associated virus capsid assembly is divergent and stochastic. Nat. Commun. 2021;12:1642. doi: 10.1038/s41467-021-21935-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21935-5</ArticleId><ArticleId IdType="pmc">PMC7955066</ArticleId><ArticleId IdType="pubmed">33712599</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno M.R., Tabitha T.S., Nirmal J., Radhakrishnan K., Yee C.H., Lim S., Venkatraman S., Agrawal R. Study of stability and biophysical characterization of ranibizumab and aflibercept. Eur. J. Pharm. Biopharm. 2016;108:156&#x2013;167. doi: 10.1016/j.ejpb.2016.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpb.2016.09.003</ArticleId><ArticleId IdType="pubmed">27615995</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelfman C.M., Grishanin R., Bender K.O., Nguyen A., Greengard J., Sharma P., Nieves J., Kiss S., Gasmi M. Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema. J.&#xa0;Ocul. Pharmacol. Ther. 2021;37:181&#x2013;190. doi: 10.1089/jop.2021.0001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jop.2021.0001</ArticleId><ArticleId IdType="pmc">PMC8060718</ArticleId><ArticleId IdType="pubmed">33835848</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiss S., Grishanin R., Nguyen A., Rosario R., Greengard J.S., Nieves J., Gelfman C.M., Gasmi M. Analysis of Aflibercept Expression in NHPs following Intravitreal Administration of ADVM-022, a Potential Gene Therapy for nAMD. Mol. Ther. Methods Clin. Dev. 2020;18:345&#x2013;353. doi: 10.1016/j.omtm.2020.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtm.2020.06.007</ArticleId><ArticleId IdType="pmc">PMC7341454</ArticleId><ArticleId IdType="pubmed">32671137</ArticleId></ArticleIdList></Reference><Reference><Citation>Busbee B., Boyer D.S., Khanani A.M., Wykoff C.C., Pieramici D.J., Regillo C., Danzig C.J., Joondeph B.C., Major J., Hoang C., et al. Phase 1 Study of Intravitreal Gene Therapy with ADVM-022 for neovascular AMD (OPTIC Trial) Investigative Ophthalmology Vis. Sci. 2021;62:352.</Citation></Reference><Reference><Citation>Nork T.M., Dubielzig R.R., Christian B.J., Miller P.E., Miller J.M., Cao J., Zimmer E.P., Wiegand S.J. Prevention of experimental choroidal neovascularization and resolution of active lesions by VEGF trap in nonhuman primates. Arch. Ophthalmol. 2011;129:1042&#x2013;1052. doi: 10.1001/archophthalmol.2011.210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archophthalmol.2011.210</ArticleId><ArticleId IdType="pubmed">21825187</ArticleId></ArticleIdList></Reference><Reference><Citation>Haryadi R., Ho S., Kok Y.J., Pu H.X., Zheng L., Pereira N.A., Li B., Bi X., Goh L.T., Yang Y., Song Z. Optimization of heavy chain and light chain signal peptides for high level expression of therapeutic antibodies in CHO cells. PLoS One. 2015;10 doi: 10.1371/journal.pone.0116878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0116878</ArticleId><ArticleId IdType="pmc">PMC4338144</ArticleId><ArticleId IdType="pubmed">25706993</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossniklaus H.E., Kang S.J., Berglin L. Animal models of choroidal and retinal neovascularization. Prog. Retin. Eye Res. 2010;29:500&#x2013;519. doi: 10.1016/j.preteyeres.2010.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2010.05.003</ArticleId><ArticleId IdType="pmc">PMC2962694</ArticleId><ArticleId IdType="pubmed">20488255</ArticleId></ArticleIdList></Reference><Reference><Citation>Avery R.L., Castellarin A.A., Steinle N.C., Dhoot D.S., Pieramici D.J., See R., Couvillion S., Nasir M.A., Rabena M.D., Maia M., et al. Systemic Pharmacokinetics and Pharmacodynamics of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab. Retina. 2017;37:1847&#x2013;1858. doi: 10.1097/IAE.0000000000001493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IAE.0000000000001493</ArticleId><ArticleId IdType="pmc">PMC5642319</ArticleId><ArticleId IdType="pubmed">28106709</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick Z., Leborgne C., Barbon E., Masat E., Ronzitti G., van Wittenberghe L., Vignaud A., Collaud F., Charles S., Simon Sola M., et al. Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction. Mol. Ther. Methods Clin. Dev. 2018;9:119&#x2013;129. doi: 10.1016/j.omtm.2018.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtm.2018.02.003</ArticleId><ArticleId IdType="pmc">PMC5948224</ArticleId><ArticleId IdType="pubmed">29766022</ArticleId></ArticleIdList></Reference><Reference><Citation>Krader C.G. Novel Gene Therapy for Neovascular AMD Showing Efficacy,&#xa0;Safety. 2021. https://www.ophthalmologytimes.com/view/novel-gene-therapy-for-neovascular-amd-showing-efficacy-safety</Citation></Reference><Reference><Citation>Whitehead M., Osborne A., Yu-Wai-Man P., Martin K. Humoral immune responses to AAV gene therapy in the ocular compartment. Biol. Rev. Camb. Philos. Soc. 2021;96:1616&#x2013;1644. doi: 10.1111/brv.12718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/brv.12718</ArticleId><ArticleId IdType="pubmed">33837614</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S., Kang I.K., Kim J.H., Jung B.K., Park K., Chang H., Lee J.Y., Lee H. Relationship Between Neutralizing Antibodies Against Adeno-Associated Virus in the Vitreous and Serum: Effects on Retinal Gene Therapy. Transl. Vis. Sci. Technol. 2019;8:14. doi: 10.1167/tvst.8.2.14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/tvst.8.2.14</ArticleId><ArticleId IdType="pmc">PMC6467092</ArticleId><ArticleId IdType="pubmed">31016068</ArticleId></ArticleIdList></Reference><Reference><Citation>Campochiaro P.A., Avery R., Brown D.M., Heier J.S., Ho A.C., Huddleston S.M., Jaffe G.J., Khanani A.M., Pakola S., Pieramici D.J., et al. Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study. Lancet. 2024;403:1563&#x2013;1573. doi: 10.1016/S0140-6736(24)00310-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(24)00310-6</ArticleId><ArticleId IdType="pubmed">38554726</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanani A.M., Hershberger V.S., Kay C.N., Hu A., Eichenbaum D.A., Jaffe G.J., Chung C., Honarmand S., Nien C., Lee S. Interim results for the Phase 1/2 PRISM Trial evaluating 4D-150, a dual-transgene intravitreal genetic medicine in individuals with neovascular (wet) age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2023;64:5055.</Citation></Reference><Reference><Citation>Gong Y., Li J., Sun Y., Fu Z., Liu C.H., Evans L., Tian K., Saba N., Fredrick T., Morss P., et al. Optimization of an Image-Guided Laser-Induced Choroidal Neovascularization Model in Mice. PLoS One. 2015;10 doi: 10.1371/journal.pone.0132643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0132643</ArticleId><ArticleId IdType="pmc">PMC4498645</ArticleId><ArticleId IdType="pubmed">26161975</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39632990</PMID><DateRevised><Year>2024</Year><Month>12</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5454</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Dec</Month><Day>04</Day></PubDate></JournalIssue><Title>Eye (London, England)</Title><ISOAbbreviation>Eye (Lond)</ISOAbbreviation></Journal><ArticleTitle>Bifocal retinal degeneration observed on ultra-widefield autofluorescence in some cases of CRX-associated retinopathy.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41433-024-03522-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Variants in CRX are associated with dominantly inherited retinopathy with considerable phenotypic variability. Many patients have central retinal degeneration; in some patients, we have observed an additional focus of degeneration in the nasal retina. This study explores this phenotypic association amongst patients with CRX-associated disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective review was conducted for all patients with dominant CRX-associated retinopathy at two UK centres. Analysis focused on patients with available ultra-widefield autofluorescence imaging and aimed to identify those with a specific bifocal degeneration pattern involving the nasal retina in both eyes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sixty patients were identified, with ultra-widefield fundus imaging available for 50 patients. Of these, six male patients aged 26-74 years displayed a distinct pattern characterised by central retinal degeneration and an additional discrete area of altered autofluorescence in the nasal periphery. Pattern and full-field ERGs indicated macular dysfunction in all 6 cases, with generalised cone (n&#x2009;=&#x2009;2) or cone and rod (n&#x2009;=&#x2009;4) system involvement, with a locus that appeared to be post-phototransduction. The CRX variants found in these patients included missense variants (n&#x2009;=&#x2009;2), frameshifting variants (n&#x2009;=&#x2009;3), and a CRX whole gene deletion (n&#x2009;=&#x2009;1), with no clear genotype-phenotype correlation identified.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We report a distinct pattern of bifocal retinal degeneration in some cases of CRX-associated retinopathy (12% in our cohort), not typically seen in other forms of inherited retinal disease. Recognising such phenotypes can guide genetic investigations or their interpretation, facilitating molecular diagnoses for effective family counselling, given the autosomal dominant inheritance and phenotypic variability of CRX-associated retinopathy.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Siying</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1122-8396</Identifier><AffiliationInfo><Affiliation>National Institute of Health Research Biomedical Research Centre at Moorfields Eye Hospital and The UCL Institute of Ophthalmology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UCL Institute of Ophthalmology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arno</LastName><ForeName>Gavin</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-6165-7888</Identifier><AffiliationInfo><Affiliation>National Institute of Health Research Biomedical Research Centre at Moorfields Eye Hospital and The UCL Institute of Ophthalmology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UCL Institute of Ophthalmology, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Greenwood Genetic Center, Greenwood, SC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robson</LastName><ForeName>Anthony G</ForeName><Initials>AG</Initials><Identifier Source="ORCID">0000-0002-8391-6123</Identifier><AffiliationInfo><Affiliation>National Institute of Health Research Biomedical Research Centre at Moorfields Eye Hospital and The UCL Institute of Ophthalmology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UCL Institute of Ophthalmology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schiff</LastName><ForeName>Elena R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>National Institute of Health Research Biomedical Research Centre at Moorfields Eye Hospital and The UCL Institute of Ophthalmology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UCL Institute of Ophthalmology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohamed</LastName><ForeName>Moin D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, St Thomas' Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michaelides</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Institute of Health Research Biomedical Research Centre at Moorfields Eye Hospital and The UCL Institute of Ophthalmology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UCL Institute of Ophthalmology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Webster</LastName><ForeName>Andrew R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>National Institute of Health Research Biomedical Research Centre at Moorfields Eye Hospital and The UCL Institute of Ophthalmology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UCL Institute of Ophthalmology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahroo</LastName><ForeName>Omar A</ForeName><Initials>OA</Initials><Identifier Source="ORCID">0000-0003-1254-0832</Identifier><AffiliationInfo><Affiliation>National Institute of Health Research Biomedical Research Centre at Moorfields Eye Hospital and The UCL Institute of Ophthalmology, London, UK. o.mahroo@ucl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UCL Institute of Ophthalmology, University College London, London, UK. o.mahroo@ucl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, St Thomas' Hospital, London, UK. o.mahroo@ucl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>5045/46</GrantID><Agency>Fight for Sight UK</Agency><Country/></Grant><Grant><GrantID>205174/Z/16/Z</GrantID><Agency>Wellcome Trust (Wellcome)</Agency><Country/></Grant><Grant><GrantID>206619/Z/17/Z</GrantID><Agency>Wellcome Trust (Wellcome)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eye (Lond)</MedlineTA><NlmUniqueID>8703986</NlmUniqueID><ISSNLinking>0950-222X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>5</Day><Hour>4</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39632990</ArticleId><ArticleId IdType="doi">10.1038/s41433-024-03522-2</ArticleId><ArticleId IdType="pii">10.1038/s41433-024-03522-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen S, Wang QL, Nie Z, Sun H, Lennon G, Copeland NG, et al. Crx, a novel Otx-like paired-homeodomain protein, binds to and transactivates photoreceptor cell-specific genes. Neuron. 1997;19:1017&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80394-3</ArticleId><ArticleId IdType="pubmed">9390516</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa T, Morrow EM, Cepko CL. Crx, a novel otx-like homeobox gene, shows photoreceptor-specific expression and regulates photoreceptor differentiation. Cell. 1997;91:531&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)80439-0</ArticleId><ArticleId IdType="pubmed">9390562</ArticleId></ArticleIdList></Reference><Reference><Citation>Freund CL, Gregory-Evans CY, Furukawa T, Papaioannou M, Looser J, Ploder L, et al. Cone-rod dystrophy due to mutations in a novel photoreceptor-specific homeobox gene (CRX) essential for maintenance of the photoreceptor. Cell. 1997;91:543&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)80440-7</ArticleId><ArticleId IdType="pubmed">9390563</ArticleId></ArticleIdList></Reference><Reference><Citation>Yahya S, Smith CEL, Poulter JA, McKibbin M, Arno G, Ellingford J, et al. Late-onset autosomal dominant macular degeneration caused by deletion of the CRX gene. Ophthalmology. 2023;130:68&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2022.07.023</ArticleId><ArticleId IdType="pubmed">35934205</ArticleId></ArticleIdList></Reference><Reference><Citation>Hull S, Arno G, Plagnol V, Chamney S, Russell-Eggitt I, Thompson D, et al. The phenotypic variability of retinal dystrophies associated with mutations in CRX, with report of a novel macular dystrophy phenotype. Investig Ophthalmol Vis Sci. 2014;55:6934&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.14-14715</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaroop A, Wang QL, Wu W, Cook J, Coats C, Xu S, et al. Leber congenital amaurosis caused by a homozygous mutation (R90W) in the homeodomain of the retinal transcription factor CRX: direct evidence for the involvement of CRX in the development of photoreceptor function. Hum Mol Genet. 1999;8:299&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/8.2.299</ArticleId><ArticleId IdType="pubmed">9931337</ArticleId></ArticleIdList></Reference><Reference><Citation>Robson AG, Frishman LJ, Grigg J, Hamilton R, Jeffrey BG, Kondo M, et al. ISCEV standard for full-field clinical electroretinography (2022 update). Doc Ophthalmol. 2022;144:165&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10633-022-09872-0</ArticleId><ArticleId IdType="pubmed">35511377</ArticleId><ArticleId IdType="pmc">9192408</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson DA, Bach M, McAnany JJ, &#x160;u&#x161;tar Habjan M, Viswanathan S, Robson AG. ISCEV standard for clinical pattern electroretinography (2024 update). Doc Ophthalmol. 2024;148:75&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10633-024-09970-1</ArticleId><ArticleId IdType="pubmed">38488946</ArticleId><ArticleId IdType="pmc">10954931</ArticleId></ArticleIdList></Reference><Reference><Citation>Robson AG, Nilsson J, Li S, Jalali S, Fulton AB, Tormene AP, et al. ISCEV guide to visual electrodiagnostic procedures. Doc Ophthalmol. 2018;136:1&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10633-017-9621-y</ArticleId><ArticleId IdType="pubmed">29397523</ArticleId><ArticleId IdType="pmc">5811581</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho ER, Robson AG, Arno G, Boon CJF, Webster AA, Michaelides M. Enhanced S-cone syndrome: spectrum of clinical, imaging, electrophysiologic, and genetic findings in a retrospective case series of 56 patients. Ophthalmol Retin. 2021;5:195&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oret.2020.07.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgiou M, Fujinami K, Vincent A, Nasser F, Khateb S, Vargas ME, et al. KCNV2-associated retinopathy: detailed retinal phenotype and structural endpoints-KCNV2 study group report 2. Am J Ophthalmol. 2021;230:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2021.03.004</ArticleId><ArticleId IdType="pubmed">33737031</ArticleId><ArticleId IdType="pmc">8710866</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2015.30</ArticleId><ArticleId IdType="pubmed">25741868</ArticleId><ArticleId IdType="pmc">4544753</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva RS, Arno G, Cipriani V, Pontikos N, Defoort-Dhellemmes S, Kalhoro A, et al. Unique noncoding variants upstream of PRDM13 are associated with a spectrum of developmental retinal dystrophies including progressive bifocal chorioretinal atrophy. Hum Mutat. 2019;40:578&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.23715</ArticleId><ArticleId IdType="pubmed">30710461</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasser F, Kurtenbach A, Kohl S, Obermaier C, Stingl K, Zrenner E. Retinal dystrophies with bull&#x2019;s-eye maculopathy along with negative ERGs. Doc Ophthalmol. 2019;139:45&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10633-019-09694-7</ArticleId><ArticleId IdType="pubmed">30945053</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiguchi KM, Kunikata H, Fujita K, Hashimoto K, Koyanagi Y, Akiyama M, et al. Association of CRX genotypes and retinal phenotypes confounded by variable expressivity and electronegative electroretinogram. Clin Exp Ophthalmol. 2020;48:644&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ceo.13743</ArticleId><ArticleId IdType="pubmed">32112665</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang X, Mahroo OA. Negative electroretinograms: genetic and acquired causes, diagnostic approaches and physiological insights. Eye. 2021;35:2419&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41433-021-01604-z</ArticleId><ArticleId IdType="pubmed">34127841</ArticleId><ArticleId IdType="pmc">8377097</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgiou M, Grewal PS, Narayan A, Alser M, Ali N, Fujinami K, et al. Sector retinitis pigmentosa: extending the molecular genetics basis and elucidating the natural history. Am J Ophthalmol. 2021;221:299&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2020.08.004</ArticleId><ArticleId IdType="pubmed">32795431</ArticleId><ArticleId IdType="pmc">7772805</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornelis SS, IntHout J, Runhart EH, Grunewald O, Lin S, Corradi Z, et al. Representation of women among individuals with mild variants in ABCA4-associated retinopathy: a meta-analysis. JAMA Ophthalmol. 2024;42:463&#x2013;71.</Citation></Reference><Reference><Citation>Mishra AV, Vermeirsch S, Lin S, Martin-Gutierrez MP, Simcoe M, Pontikos N, et al. Sex distributions in Non-ABCA4 autosomal macular dystrophies. Investig Ophthalmol Vis Sci. 2024;65:9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.65.5.9</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin-Casta&#xf1;o ME, Elliot SJ, Potier M, Karl M, Striker LJ, Striker GE, et al. Regulation of estrogen receptors and MMP-2 expression by estrogens in human retinal pigment epithelium. Investig Ophthalmol Vis Sci. 2003;44:50&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.01-1276</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickham LA, Gao J, Toda I, Rocha EM, Ono M, Sullivan DA. Identification of androgen, estrogen and progesterone receptor mRNAs in the eye. Acta Ophthalmol Scand. 2000;78:146&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-0420.2000.078002146.x</ArticleId><ArticleId IdType="pubmed">10794246</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull C, Scott RH, Thomas E, Jones L, Murugaesu N, Pretty FB, et al. The 100,000 Genomes Project: bringing whole genome sequencing to the NHS. BMJ. 2018;361:k1687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.k1687</ArticleId><ArticleId IdType="pubmed">29691228</ArticleId></ArticleIdList></Reference><Reference><Citation>Barwell J, Snape K, Wedderburn S. The new genomic medicine service and implications for patients. Clin Med. 2019;19:273&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmedicine.19-4-273</ArticleId></ArticleIdList></Reference><Reference><Citation>100000 Genomes Project Pilot Investigators, Smedley D, Smith KR, Martin A, Thomas EA, McDonagh EM, et al. 100,000 genomes pilot on rare-disease diagnosis in health care&#x2014;preliminary report. N Engl J Med. 2021;385:1868&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035790</ArticleId></ArticleIdList></Reference><Reference><Citation>Carss KJ, Arno G, Erwood M, Stephens J, Sanchis-Juan A, Hull S, et al. Comprehensive rare variant analysis via whole-genome sequencing to determine the molecular pathology of inherited retinal disease. Am J Hum Genet. 2016;100:75&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2016.12.003</ArticleId><ArticleId IdType="pubmed">28041643</ArticleId><ArticleId IdType="pmc">5223092</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruczek K, Qu Z, Gentry J, Fadl BR, Gieser L, Hiriyanna S, et al. Gene therapy of dominant CRX-leber congenital amaurosis using patient stem cell-derived retinal organoids. Stem Cell Rep. 2021;16:252&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2020.12.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun C, Chen S. Gene augmentation for autosomal dominant CRX-associated retinopathies. Adv Exp Med Biol. 2023;1415:135&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-031-27681-1_21</ArticleId><ArticleId IdType="pubmed">37440026</ArticleId><ArticleId IdType="pmc">11010719</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39632987</PMID><DateCompleted><Year>2024</Year><Month>12</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>04</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Development and validation of CNN-MLP models for predicting anti-VEGF therapy outcomes in diabetic macular edema.</ArticleTitle><Pagination><StartPage>30270</StartPage><MedlinePgn>30270</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-82007-4</ELocationID><Abstract><AbstractText>Diabetic macular edema (DME) is a common complication of diabetes that can lead to vision loss, and anti-vascular endothelial growth factor (anti-VEGF) therapy is the standard of care for DME, but the treatment outcomes vary widely among patients. This study collected optical coherence tomography (OCT) images and clinical data from DME patients who received anti-VEGF treatment to develop and validate deep learning (DL) models for predicting the anti-VEGF outcomes in DME patients based on convolutional neural network (CNN) and multilayer perceptron (MLP) combined architecture by using multimodal data. An Xception-MLP architecture was utilized to predict best-corrected visual acuity (BCVA), central subfield thickness (CST), cube volume (CV), and cube average thickness (CAT). Mean absolute error (MAE), mean squared error (MSE) and mean squared logarithmic error (MSLE) were employed to evaluate the model performance. In this study, both the training set and the validation set exhibited a consistent decreasing trend in MAE, MSE, and MSLE. No statistical difference was found between the actual and predicted values in all clinical indicators. This study demonstrated that the improved CNN-MLP regression models using multimodal data can accurately predict outcomes in BCVA, CST, CV, and CAT after anti-VEGF therapy in DME patients, which is valuable for ophthalmic clinical decisions and reduces the economic burden on patients.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leng</LastName><ForeName>Xiangjie</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Eye School, Chengdu University of Traditional Chinese Medicine, Chengdu, 610000, Sichuan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Ruijie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Eye School, Chengdu University of Traditional Chinese Medicine, Chengdu, 610000, Sichuan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Zhaorui</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Eye School, Chengdu University of Traditional Chinese Medicine, Chengdu, 610000, Sichuan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hai</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Eye School, Chengdu University of Traditional Chinese Medicine, Chengdu, 610000, Sichuan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Wenxuan</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Eye School, Chengdu University of Traditional Chinese Medicine, Chengdu, 610000, Sichuan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Keyin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Eye School, Chengdu University of Traditional Chinese Medicine, Chengdu, 610000, Sichuan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Xuejing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Eye School, Chengdu University of Traditional Chinese Medicine, Chengdu, 610000, Sichuan Province, China. luxuejing@cdutcm.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Ineye Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610000, Sichuan Province, China. luxuejing@cdutcm.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Key Laboratory of Sichuan Province Ophthalmopathy Prevention &amp; Cure and Visual Function Protection with TCM, Chengdu, 610000, Sichuan Province, China. luxuejing@cdutcm.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Retinal Image Technology and Chronic Vascular Disease Prevention &amp; Control and Collaborative Innovation Center, Chengdu, Sichuan, China. luxuejing@cdutcm.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2023YFC3503005</GrantID><Agency>National Key Research and Development Program of China</Agency><Country/></Grant><Grant><GrantID>XKTD2022009</GrantID><Agency>Chengdu University of Traditional Chinese Medicine</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008269" MajorTopicYN="Y">Macular Edema</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003930" MajorTopicYN="Y">Diabetic Retinopathy</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042461" MajorTopicYN="Y">Vascular Endothelial Growth Factor A</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D041623" MajorTopicYN="Y">Tomography, Optical Coherence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020533" MajorTopicYN="Y">Angiogenesis Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014792" MajorTopicYN="N">Visual Acuity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016571" MajorTopicYN="N">Neural Networks, Computer</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077321" MajorTopicYN="N">Deep Learning</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declarations. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>5</Day><Hour>4</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39632987</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-82007-4</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-82007-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Varma, R. et al. Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol. 132, 1334&#x2013;1340. https://doi.org/10.1001/jamaophthalmol.2014.2854 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2014.2854</ArticleId><ArticleId IdType="pubmed">25125075</ArticleId><ArticleId IdType="pmc">4576994</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein, R., Klein, B. E., Moss, S. E., Davis, M. D. &amp; DeMets, D. L. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 91, 1464&#x2013;1474. https://doi.org/10.1016/s0161-6420(84)34102-1 (1984).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0161-6420(84)34102-1</ArticleId><ArticleId IdType="pubmed">6521986</ArticleId></ArticleIdList></Reference><Reference><Citation>Javadzadeh, A. The effect of posterior subtenon methylprednisolone acetate in the refractory diabetic macular edema: a prospective nonrandomized interventional case series. BMC Ophthalmol. 6, 15. https://doi.org/10.1186/1471-2415-6-15 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2415-6-15</ArticleId><ArticleId IdType="pubmed">16595011</ArticleId><ArticleId IdType="pmc">1524812</ArticleId></ArticleIdList></Reference><Reference><Citation>Otani, T., Kishi, S. &amp; Maruyama, Y. Patterns of diabetic macular edema with optical coherence tomography. Am. J. Ophthalmol. 127, 688&#x2013;693. https://doi.org/10.1016/s0002-9394(99)00033-1 (1999).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0002-9394(99)00033-1</ArticleId><ArticleId IdType="pubmed">10372879</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanoff, M., Fine, B. S., Brucker, A. J. &amp; Eagle, R. C. Jr. Pathology of human cystoid macular edema. Surv. Ophthalmol. 28 Suppl, 505&#x2013;511. https://doi.org/10.1016/0039-6257(84)90233-9 (1984).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0039-6257(84)90233-9</ArticleId><ArticleId IdType="pubmed">6463850</ArticleId></ArticleIdList></Reference><Reference><Citation>Tricco, A. C. et al. Anti-vascular endothelial growth factor therapy for age-related macular degeneration: a systematic review and network meta-analysis. Syst. Rev. 10, 315. https://doi.org/10.1186/s13643-021-01864-6 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13643-021-01864-6</ArticleId><ArticleId IdType="pubmed">34930439</ArticleId><ArticleId IdType="pmc">8690960</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, T. et al. Applications of deep learning in fundus images: a review. Med. Image Anal. 69, 101971. https://doi.org/10.1016/j.media.2021.101971 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.media.2021.101971</ArticleId><ArticleId IdType="pubmed">33524824</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhillon, A. &amp; Verma, G. K. Convolutional neural network: a review of models, methodologies and applications to object detection. Progress Artif. Intell. 9, 85&#x2013;112. https://doi.org/10.1007/s13748-019-00203-0 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13748-019-00203-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzubaidi, L. et al. Review of deep learning: concepts, CNN architectures, challenges, applications, future directions. J. Big Data. 8, 53. https://doi.org/10.1186/s40537-021-00444-8 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40537-021-00444-8</ArticleId><ArticleId IdType="pubmed">33816053</ArticleId><ArticleId IdType="pmc">8010506</ArticleId></ArticleIdList></Reference><Reference><Citation>Chollet, F. in Proceedings of the IEEE conference on computer vision and pattern recognition. 1251&#x2013;1258.</Citation></Reference><Reference><Citation>Carreira, J., Madeira, H. &amp; Silva, J. G. Xception: a technique for the experimental evaluation of dependability in modern computers. IEEE Trans. Software Eng. 24, 125&#x2013;136 (1998).</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/32.666826</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramchoun, H., Ghanou, Y. &amp; Ettaouil, M. &amp; Janati Idrissi, M. A. Multilayer perceptron: Architecture optimization and training. (2016).</Citation></Reference><Reference><Citation>Taud, H. &amp; Mas, J. Multilayer perceptron (MLP). Geomatic approaches for modeling land change scenarios, 451&#x2013;455 (2018).</Citation></Reference><Reference><Citation>Zhang, S., Niu, Y. &amp; LcmUNet: A Lightweight Network combining CNN and MLP for Real-Time Medical Image Segmentation. Bioengineering 10, 712 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/bioengineering10060712</ArticleId><ArticleId IdType="pubmed">37370643</ArticleId><ArticleId IdType="pmc">10295621</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim, W. X., Chen, Z. &amp; Ahmed, A. The adoption of deep learning interpretability techniques on diabetic retinopathy analysis: a review. Med. Biol. Eng. Comput. 60, 633&#x2013;642. https://doi.org/10.1007/s11517-021-02487-8 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11517-021-02487-8</ArticleId><ArticleId IdType="pubmed">35083634</ArticleId><ArticleId IdType="pmc">8791699</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, G., Zheng, S. &amp; Li, X. in Digital TV and Wireless Multimedia Communication: 14th International Forum, IFTC 2017, Shanghai, China, November 8&#x2013;9, Revised Selected Papers 14. 193&#x2013;202 (Springer). (2017).</Citation></Reference><Reference><Citation>Kauppi, T. et al. in BMVC. 10 (Citeseer).</Citation></Reference><Reference><Citation>Giancardo, L. The Hamilton eye institute macular edema dataset (hei-med). (2012).</Citation></Reference><Reference><Citation>Mateen, M., Wen, J., Nasrullah, N., Sun, S. &amp; Hayat, S. Exudate detection for diabetic retinopathy using pretrained convolutional neural networks. Complexity 1&#x2013;11 (2020). (2020).</Citation></Reference><Reference><Citation>Bora, A. et al. Predicting the risk of developing diabetic retinopathy using deep learning. Lancet Digit. Health. 3, e10&#x2013;e19 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2589-7500(20)30250-8</ArticleId><ArticleId IdType="pubmed">33735063</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo, M., Zhang, W., Xu, Q. &amp; Chen, D. Deep personal multitask prediction of diabetes complication with attentive interactions predicting diabetes complications by multitask-learning. J. Healthcare Eng. (2022). (2022).</Citation></Reference><Reference><Citation>Lin, T. Y. et al. Deep learning to infer visual acuity from optical coherence tomography in diabetic macular edema. Front. Med. 9, 1008950 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.1008950</ArticleId></ArticleIdList></Reference><Reference><Citation>Alryalat, S. A. et al. Deep learning prediction of response to anti-VEGF among diabetic macular edema patients: treatment response analyzer system (TRAS). Diagnostics 12, 312 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics12020312</ArticleId><ArticleId IdType="pubmed">35204404</ArticleId><ArticleId IdType="pmc">8870773</ArticleId></ArticleIdList></Reference><Reference><Citation>Arcadu, F. et al. Deep learning algorithm predicts diabetic retinopathy progression in individual patients. NPJ Digit. Med. 2, 92 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-019-0172-3</ArticleId><ArticleId IdType="pubmed">31552296</ArticleId><ArticleId IdType="pmc">6754451</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka, S. et al. A deep learning-based radiomics approach to predict head and neck tumor regression for adaptive radiotherapy. Sci. Rep. 12, 8899 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-12170-z</ArticleId><ArticleId IdType="pubmed">35624113</ArticleId><ArticleId IdType="pmc">9142601</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin, A. et al. Deep learning-enabled coronary CT angiography for plaque and stenosis quantification and cardiac risk prediction: an international multicentre study. Lancet Digit. Health. 4, e256&#x2013;e265 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2589-7500(22)00022-X</ArticleId><ArticleId IdType="pubmed">35337643</ArticleId><ArticleId IdType="pmc">9047317</ArticleId></ArticleIdList></Reference><Reference><Citation>LeCun, Y. et al. Learning algorithms for classification: a comparison on handwritten digit recognition. Neural Networks: Stat. Mech. Perspective. 261, 2 (1995).</Citation></Reference><Reference><Citation>Lin, M., Chen, Q. &amp; Yan, S. Network in network. arXiv preprint arXiv:1312.4400 (2013).</Citation></Reference><Reference><Citation>Zeiler, M. D. &amp; Fergus, R. in Computer Vision&#x2013;ECCV 2014: 13th European Conference, Zurich, Switzerland, September 6&#x2013;12, Proceedings, Part I 13. 818&#x2013;833 (Springer). (2014).</Citation></Reference><Reference><Citation>Simonyan, K. &amp; Zisserman, A. Very deep convolutional networks for large-scale image recognition. arXiv preprint arXiv:1409.1556 (2014).</Citation></Reference><Reference><Citation>Szegedy, C. et al. in Proceedings of the IEEE conference on computer vision and pattern recognition. 1&#x2013;9.</Citation></Reference><Reference><Citation>Srivastava, R. K., Greff, K. &amp; Schmidhuber, J. Highway networks. arXiv preprint arXiv:1505.00387 (2015).</Citation></Reference><Reference><Citation>He, K., Zhang, X., Ren, S. &amp; Sun, J. in Proceedings of the IEEE conference on computer vision and pattern recognition. 770&#x2013;778.</Citation></Reference><Reference><Citation>Szegedy, C., Ioffe, S., Vanhoucke, V. &amp; Alemi, A. in Proceedings of the AAAI conference on artificial intelligence.</Citation></Reference><Reference><Citation>Hemelings, R. et al. Pointwise visual field estimation from optical coherence tomography in glaucoma using deep learning. Trans. Vis. Sci. Technol. 11, 22&#x2013;22 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/tvst.11.8.22</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang, N. Y. et al. Classification of pachychoroid on optical coherence tomography using deep learning. Graefe&#x2019;s Archive Clin. Exp. Ophthalmol. 259, 1803&#x2013;1809 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00417-021-05104-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim, W. S. et al. Use of multimodal dataset in AI for detecting glaucoma based on fundus photographs assessed with OCT: focus group study on high prevalence of myopia. BMC Med. Imaging. 22, 206 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12880-022-00933-z</ArticleId><ArticleId IdType="pubmed">36434508</ArticleId><ArticleId IdType="pmc">9700928</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, W. et al. Detection of Fuchs&#x2019; uveitis syndrome from slit-lamp images using deep convolutional neural networks in a Chinese population. Front. Cell. Dev. Biology. 9, 684522 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.684522</ArticleId></ArticleIdList></Reference><Reference><Citation>Raita, Y. et al. Emergency department triage prediction of clinical outcomes using machine learning models. Crit. Care. 23, 64. https://doi.org/10.1186/s13054-019-2351-7 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-019-2351-7</ArticleId><ArticleId IdType="pubmed">30795786</ArticleId><ArticleId IdType="pmc">6387562</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardak, B. &amp; Tan, M. Improving clinical outcome predictions using convolution over medical entities with multimodal learning. Artif. Intell. Med. 117, 102112. https://doi.org/10.1016/j.artmed.2021.102112 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.artmed.2021.102112</ArticleId><ArticleId IdType="pubmed">34127241</ArticleId></ArticleIdList></Reference><Reference><Citation>He, L. et al. Deep Multimodal Learning from MRI and Clinical Data for early prediction of neurodevelopmental deficits in very Preterm infants. Front. Neurosci. 15, 753033. https://doi.org/10.3389/fnins.2021.753033 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2021.753033</ArticleId><ArticleId IdType="pubmed">34675773</ArticleId><ArticleId IdType="pmc">8525883</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi, R. et al. Machine learning regression algorithms to predict short-term efficacy after anti-VEGF treatment in diabetic macular edema based on real-world data. Sci. Rep. 13, 18746 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-46021-2</ArticleId><ArticleId IdType="pubmed">37907703</ArticleId><ArticleId IdType="pmc">10618454</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen, D. et al. Deep learning-based postoperative visual acuity prediction in idiopathic epiretinal membrane. BMC Ophthalmol. 23, 361. https://doi.org/10.1186/s12886-023-03079-w (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12886-023-03079-w</ArticleId><ArticleId IdType="pubmed">37599349</ArticleId><ArticleId IdType="pmc">10440890</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins, G. S., Reitsma, J. B., Altman, D. G. &amp; Moons, K. G. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Bmj 350, g7594. https://doi.org/10.1136/bmj.g7594 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.g7594</ArticleId><ArticleId IdType="pubmed">25569120</ArticleId></ArticleIdList></Reference><Reference><Citation>Krzystolik, M. G. et al. Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. Ophthalmology 114, 1520&#x2013;1525. https://doi.org/10.1016/j.ophtha.2006.10.055 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2006.10.055</ArticleId><ArticleId IdType="pubmed">17353052</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahuja, S., Saxena, S., Meyer, C. H., Gilhotra, J. S. &amp; Akduman, L. Central subfield thickness and cube average thickness as bioimaging biomarkers for ellipsoid zone disruption in diabetic retinopathy. Int. J. Retina Vitreous. 4, 41. https://doi.org/10.1186/s40942-018-0144-9 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40942-018-0144-9</ArticleId><ArticleId IdType="pubmed">30410791</ArticleId><ArticleId IdType="pmc">6214155</ArticleId></ArticleIdList></Reference><Reference><Citation>Grading diabetic retinopathy. From stereoscopic color fundus photographs&#x2013;an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 98, 786&#x2013;806 (1991).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0161-6420(13)38012-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Han, K. et al. A survey on vision transformer. IEEE Trans. Pattern Anal. Mach. Intell. 45, 87&#x2013;110 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/TPAMI.2022.3152247</ArticleId><ArticleId IdType="pubmed">35180075</ArticleId></ArticleIdList></Reference><Reference><Citation>Muthukumar, V. et al. Classification vs regression in overparameterized regimes: does the loss function matter? J. Mach. Learn. Res. 22, 222:221&#x2013;222 (2020).</Citation></Reference><Reference><Citation>Hodson, T. O. Root-mean-square error (RMSE) or mean absolute error (MAE): when to use them or not. Geosci. Model Dev. (2022).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">39632019</PMID><DateRevised><Year>2024</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2468-6530</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>12</Issue><PubDate><Year>2024</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Ophthalmology. Retina</Title><ISOAbbreviation>Ophthalmol Retina</ISOAbbreviation></Journal><ArticleTitle>Fluid Pathways in Age-Related Macular Degeneration Elucidated with Advanced Retinal Imaging.</ArticleTitle><Pagination><StartPage>1115</StartPage><EndPage>1117</EndPage><MedlinePgn>1115-1117</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.oret.2024.08.019</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2468-6530(24)00406-8</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Feo</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Los Angeles, California, and Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarraf</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Los Angeles, California. Electronic address: dsarraf@ucla.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ophthalmol Retina</MedlineTA><NlmUniqueID>101695048</NlmUniqueID><ISSNLinking>2468-6530</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>5</Day><Hour>5</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>5</Day><Hour>5</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>4</Day><Hour>21</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39632019</ArticleId><ArticleId IdType="doi">10.1016/j.oret.2024.08.019</ArticleId><ArticleId IdType="pii">S2468-6530(24)00406-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">39632002</PMID><DateRevised><Year>2024</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1938-3207</ISSN><JournalIssue CitedMedium="Internet"><Volume>120</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The American journal of clinical nutrition</Title><ISOAbbreviation>Am J Clin Nutr</ISOAbbreviation></Journal><ArticleTitle>Impact of 25-hydroxyvitamin D and calcium on risk of age-related macular degeneration.</ArticleTitle><Pagination><StartPage>1461</StartPage><EndPage>1462</EndPage><MedlinePgn>1461-1462</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajcnut.2024.09.030</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0002-9165(24)00807-4</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xin</LastName><ForeName>Chunlian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, the Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Lidong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, the Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia, China. Electronic address: czxlld@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Clin Nutr</MedlineTA><NlmUniqueID>0376027</NlmUniqueID><ISSNLinking>0002-9165</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Conflict of interest The author declares no financial/conflicting interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>5</Day><Hour>5</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>5</Day><Hour>5</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>4</Day><Hour>21</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39632002</ArticleId><ArticleId IdType="doi">10.1016/j.ajcnut.2024.09.030</ArticleId><ArticleId IdType="pii">S0002-9165(24)00807-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39631526</PMID><DateRevised><Year>2024</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1520-6017</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Dec</Month><Day>02</Day></PubDate></JournalIssue><Title>Journal of pharmaceutical sciences</Title><ISOAbbreviation>J Pharm Sci</ISOAbbreviation></Journal><ArticleTitle>Storage Stability and Solution Binding Affinity of an Fc-Fusion Mimetic.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0022-3549(24)00539-2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.xphs.2024.11.016</ELocationID><Abstract><AbstractText>This study evaluates the storage stability and solution binding affinity of a novel Fc-fusion mimetic, receptor-PEG-receptor (RpR), designed to address limitations of the current therapeutic aflibercept, a gold-standard therapy for age-macular degeneration (AMD). Using di(bis-sulfone) PEG linker as a structural scaffold, the mimetic aims to improve the storage stability and binding efficacy of the Fc fusion protein. Mass photometry and size-exclusion chromatography demonstrated that RpR, even in an unformulated buffer, exhibits superior storage stability exceeding 10 months compared to aflibercept. Furthermore, microscale thermophoresis was employed to determine RpR's binding affinity to VEGF in solution, providing a more physiologically relevant assessment than traditional binding assays. These findings highlight RpR's potential as a therapeutic candidate for the treatment of AMD disease, warranting further investigation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Prikalkhoran</LastName><ForeName>Sama</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Medicine and Biosciences, University of West London, W55RF, UK; School of Life Sciences, University of Westminster, W1W 6UW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guiliano</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Life Sciences, University of Westminster, W1W 6UW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khalili</LastName><ForeName>Hanieh</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Medicine and Biosciences, University of West London, W55RF, UK; School of Pharmacy, University College London, WC1N 1AX, UK. Electronic address: hanieh.khalili@uwl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Pharm Sci</MedlineTA><NlmUniqueID>2985195R</NlmUniqueID><ISSNLinking>0022-3549</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Declaration of competing interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>5</Day><Hour>5</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>5</Day><Hour>5</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>4</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39631526</ArticleId><ArticleId IdType="doi">10.1016/j.xphs.2024.11.016</ArticleId><ArticleId IdType="pii">S0022-3549(24)00539-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39627894</PMID><DateRevised><Year>2024</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2326-0254</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>03</Day></PubDate></JournalIssue><Title>Eye and vision (London, England)</Title><ISOAbbreviation>Eye Vis (Lond)</ISOAbbreviation></Journal><ArticleTitle>Bilateral occlusive retinal vasculitis secondary to intravitreal faricimab injection: a case report and review of literature.</ArticleTitle><Pagination><StartPage>48</StartPage><MedlinePgn>48</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">48</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40662-024-00416-y</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This article describes a rare occurrence of bilateral retinal occlusive vasculitis secondary to intravitreal faricimab injection.</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">A 72-year-old female with age-related macular degeneration presented with bilateral retinal occlusive vasculitis following intravitreal faricimab injections. The patient was treated with 3&#xa0;days of intravenous methylprednisolone followed by oral prednisolone taper and topical steroid therapy. Resolution of retinal occlusive vasculitis was observed 2&#xa0;months post treatment.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Retinal occlusive vasculitis is a rare complication of intravitreal anti-vascular endothelial growth factor (anti-VEGF), particularly with faricimab injections. We also present a review of literature regarding retinal occlusive vasculitis following intravitreal anti-VEGF injections and propose further information regarding its pathophysiology.</AbstractText><CopyrightInformation>&#xa9; 2024. Crown.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Yong Min</ForeName><Initials>YM</Initials><Identifier Source="ORCID">0000-0003-3358-8894</Identifier><AffiliationInfo><Affiliation>Ophthalmology Department, Royal Adelaide Hospital, Port Road, Adelaide, SA, 5000, Australia. yongmin.shane.lee@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ophthalmology Department, Modbury Hospital, Adelaide, SA, 5069, Australia. yongmin.shane.lee@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, 5000, Australia. yongmin.shane.lee@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gurung</LastName><ForeName>Rajya</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Ophthalmology Department, Royal Adelaide Hospital, Port Road, Adelaide, SA, 5000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilhotra</LastName><ForeName>Jagjit Singh</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Ophthalmology Department, Royal Adelaide Hospital, Port Road, Adelaide, SA, 5000, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, 5000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Sumu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ophthalmology Department, Royal Adelaide Hospital, Port Road, Adelaide, SA, 5000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cugati</LastName><ForeName>Sudha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ophthalmology Department, Modbury Hospital, Adelaide, SA, 5069, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, 5000, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eye Vis (Lond)</MedlineTA><NlmUniqueID>101664982</NlmUniqueID><ISSNLinking>2326-0254</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Age-related macular degeneration</Keyword><Keyword MajorTopicYN="N">Faricimab</Keyword><Keyword MajorTopicYN="N">Intraocular inflammation</Keyword><Keyword MajorTopicYN="N">Intravitreal injection</Keyword><Keyword MajorTopicYN="N">Occlusive vasculitis</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee(s) and with the Helsinki Declaration (as revised in 2013). Written informed consents were obtained from the parents for publication of this case report and accompanying images. Competing interests: The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>4</Day><Hour>0</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>4</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>4</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>12</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39627894</ArticleId><ArticleId IdType="doi">10.1186/s40662-024-00416-y</ArticleId><ArticleId IdType="pii">10.1186/s40662-024-00416-y</ArticleId><ArticleId IdType="pmc">PMC11613754</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vyawahare H, Shinde P. Age-related macular degeneration: epidemiology, pathophysiology, diagnosis, and treatment. Cureus. 2022;14(9): e29583.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9595233</ArticleId><ArticleId IdType="pubmed">36312607</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhende M, Shetty S, Parthasarathy MK, Ramya S. Optical coherence tomography: a guide to interpretation of common macular diseases. Indian J Ophthalmol. 2018;66(1):20&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5778576</ArticleId><ArticleId IdType="pubmed">29283118</ArticleId></ArticleIdList></Reference><Reference><Citation>Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">35085502</ArticleId></ArticleIdList></Reference><Reference><Citation>Vabysmo Australian Government | Department of Health and Aged Care | Therapeutic Goods Administration. https://www.tga.gov.au/resources/auspmd/vabysmo.</Citation></Reference><Reference><Citation>Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399(10326):741&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">35085503</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results. Eye (Lond). 2023;37(17):3574&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10686385</ArticleId><ArticleId IdType="pubmed">37173428</ArticleId></ArticleIdList></Reference><Reference><Citation>Thangamathesvaran L, Kong J, Bressler SB, Singh M, Wenick AS, Scott AW, et al. Severe intraocular inflammation following intravitreal faricimab. JAMA Ophthalmol. 2024;142(4):365&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10905372</ArticleId><ArticleId IdType="pubmed">38421861</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Chong R, Fung AT. Association of occlusive retinal vasculitis with intravitreal faricimab. JAMA Ophthalmol. 2024;142:489.</Citation><ArticleIdList><ArticleId IdType="pubmed">38517431</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Wang X, Li X. Intra-ocular inflammation and occlusive retinal vasculitis following intravitreal injections of faricimab: a case report. Ocul Immunol Inflamm. 2024. 10.1080/09273948.2024.2361834.</Citation><ArticleIdList><ArticleId IdType="pubmed">38856728</ArticleId></ArticleIdList></Reference><Reference><Citation>Aziz AA, Khanani AM, London N, Hagen MM, Danzig CJ, Kulkarni AD, et al. Real world efficacy and safety of brolucizumab in neovascular AMD: the REBEL study. Invest Ophthalmol Vis Sci. 2021;62(8):451.</Citation></Reference><Reference><Citation>Baumal CR, Spaide RF, Vajzovic L, Freund KB, Walter SD, John V, et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology. 2020;127(10):1345&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">32344075</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxter KR, Robinson JE, Ruby AJ. Occlusive vasculitis due to hyperacute Streptococcus mitis endophthalmitis after intravitreal ranibizumab. Retin Cases Brief Rep. 2015;9(3):201&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">25764316</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodaghi B, Souied EH, Tadayoni R, Weber M, Ponthieux A, Kodjikian L. Detection and management of intraocular inflammation after brolucizumab treatment for neovascular age-related macular degeneration. Ophthalmol Retina. 2023;7(10):879&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">37343623</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillies M, Dang T, Nguyen V, Invernizzi A, Romano F, Cozzi M, et al. Six-month outcomes of brolucizumab in routine clinical practice: data from the fight retinal blindness! registry. Invest Ophthalmol Vis Sci. 2023;64(8):466.</Citation></Reference><Reference><Citation>Grewal DS, Wykoff CC, D&#x2019;Souza D, Jehl V, Alecu I, Jaffe GJ. Imaging features of retinal vasculitis and/or retinal vascular occlusion after brolucizumab treatment in the postmarketing setting. Ophthalmol Sci. 2024;4(1): 100361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10587630</ArticleId><ArticleId IdType="pubmed">37869023</ArticleId></ArticleIdList></Reference><Reference><Citation>Haug SJ, Hien DL, Uludag G, Ngoc TTT, Lajevardi S, Halim MS, et al. Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration. Am J Ophthalmol Case Rep. 2020;18: 100680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7125319</ArticleId><ArticleId IdType="pubmed">32258827</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano T, Toriyama Y, Takahashi Y, Hoshiyama K, Murata T. Retinal arterial occlusive vasculitis after multiple intravitreal brolucizumab injections for diabetic macular edema. Am J Ophthalmol Case Rep. 2023;29: 101788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9826871</ArticleId><ArticleId IdType="pubmed">36632338</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer PG, Peden MC, Suner IJ, Patel N, Dubovy SR, Albini TA. Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment:a clinicopathologic case study. Am J Ophthalmol Case Rep. 2020;20: 100989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7695942</ArticleId><ArticleId IdType="pubmed">33294727</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain A, Chea S, Matsumiya W, Halim MS, Yasar C, Kuang G, et al. Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations. Am J Ophthalmol Case Rep. 2020;18: 100687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7139151</ArticleId><ArticleId IdType="pubmed">32280811</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanani AM, Brown DM, Jaffe GJ, Wykoff CC, Adiguzel E, Wong R, et al. MERLIN: Phase 3a, multicenter, randomized, double-masked trial of brolucizumab in participants with neovascular age-related macular degeneration and persistent retinal fluid. Ophthalmology. 2022;129(9):974&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">35537533</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusuhara S, Kim KW, Miki A, Nakamura M. Angiographic findings before and after the onset of brolucizumab-associated retinal vascular occlusion and intraocular inflammation. Am J Ophthalmol Case Rep. 2022;26: 101521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9026644</ArticleId><ArticleId IdType="pubmed">35464682</ArticleId></ArticleIdList></Reference><Reference><Citation>Mones J, Srivastava SK, Jaffe GJ, Tadayoni R, Albini TA, Kaiser PK, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. 2021;128(7):1050&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">33207259</ArticleId></ArticleIdList></Reference><Reference><Citation>Witkin AJ, Hahn P, Murray TG, Arevalo JF, Blinder KJ, Choudhry N, et al. Occlusive retinal vasculitis following intravitreal brolucizumab. J Vitreoretin Dis. 2020;4(4):269&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7418897</ArticleId><ArticleId IdType="pubmed">32789284</ArticleId></ArticleIdList></Reference><Reference><Citation>Wykoff CC, Garweg JG, Regillo C, Souied E, Wolf S, Dhoot DS, et al. KESTREL and KITE Phase 3 studies: 100-week results with brolucizumab in patients with diabetic macular edema. Am J Ophthalmol. 2023;260:70&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">37460036</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubricky R, McCoy J, Donkor R, Miller DG, Sonbolian N, Heaney A, et al. Real-world frequency and management of ocular adverse events in eyes with neovascular age-related macular degeneration treated with brolucizumab. Ophthalmol Ther. 2023;12(5):2397&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10442012</ArticleId><ArticleId IdType="pubmed">37310683</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DJ, Jin KW, Han JM, Lee SH, Park YS, Lee JY, et al. Short-term safety and efficacy of intravitreal brolucizumab injections for neovascular age-related macular degeneration: a multicenter retrospective real-world study. Ophthalmologica. 2023;246(3&#x2013;4):192&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">36720210</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukushima A. Intraocular inflammation-induced visual field defect after an intravitreal brolucizumab injection. EURETINA. 2021.</Citation></Reference><Reference><Citation>Walter SD, Saba NJ. Real-world efficacy and safety of brolucizumab. Invest Ophthalmol Vis Sci. 2021;62(8):456.</Citation></Reference><Reference><Citation>Tadayoni R, Souied E, Creuzot-Garcher C, Cohen SY, Kodjikian L, Baillif S, et al. Disease control at week 16 of brolucizumab in adult patients with suboptimal anatomically controlled neovascular age related macular degeneration &#x2013; the SWIFT study. Invest Ophthalmol Vis Sci. 2023;64(8):465.</Citation></Reference><Reference><Citation>Anderson WJ, da Cruz NFS, Lima LH, Emerson GG, Rodrigues EB, Melo GB. Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review. Int J Retina Vitreous. 2021;7(1):37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8103589</ArticleId><ArticleId IdType="pubmed">33962696</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuo T, Koyama T, Morimoto N, Umezu H, Matsuo N. Retinal vasculitis as a complication of rheumatoid arthritis. Ophthalmologica. 2010;201(4):196&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">2077456</ArticleId></ArticleIdList></Reference><Reference><Citation>Macarie SS, Kadar A. Eye involvement in ANCA positive vasculitis. Rom J Ophthalmol. 2020;64(1):3&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7141924</ArticleId><ArticleId IdType="pubmed">32292850</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x130;nan&#xe7; Tekin M, &#xc7;akar &#xd6;zdal MP. Ophthalmic manifestations of ANCA-associated vasculitis. Acta Medica. 2021;52(4):257&#x2013;63.</Citation></Reference><Reference><Citation>Rothschild PR, Pagnoux C, Seror R, Br&#xe9;zin AP, Delair E, Guillevin L. Ophthalmologic manifestations of systemic necrotizing vasculitides at diagnosis: a retrospective study of 1286 patients and review of the literature. Semin Arthritis Rheum. 2013;42(5):507&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">23270762</ArticleId></ArticleIdList></Reference><Reference><Citation>Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">30986442</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A, Kumar N, Parachuri N, Singh S, Bandello F, Regillo CD, et al. Understanding retinal vasculitis associated with brolucizumab: complex pathophysiology or Occam&#x2019;s Razor? Ocul Immunol Inflamm. 2022;30(6):1508&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10919544</ArticleId><ArticleId IdType="pubmed">34014141</ArticleId></ArticleIdList></Reference><Reference><Citation>Melo GB, Figueira ACM, Batista FAH, Filho A, Rodrigues EB, Belfort R Jr, et al. Inflammatory reaction after aflibercept intravitreal injections associated with silicone oil droplets released from syringes: a case-control study. Ophthalmic Surg Lasers Imaging Retina. 2019;50(5):288&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">31100159</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchino T, Miyazaki Y, Yamazaki T, Kagawa Y. Immunogenicity of protein aggregates of a monoclonal antibody generated by forced shaking stress with siliconized and nonsiliconized syringes in BALB/c mice. J Pharm Pharmacol. 2017;69(10):1341&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">28639328</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39625442</PMID><DateCompleted><Year>2024</Year><Month>12</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1552-5783</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>14</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>02</Day></PubDate></JournalIssue><Title>Investigative ophthalmology &amp; visual science</Title><ISOAbbreviation>Invest Ophthalmol Vis Sci</ISOAbbreviation></Journal><ArticleTitle>A Novel Grid Strategy for Correlating Focal Macular Anatomic Changes With Focal Changes in Choriocapillaris Perfusion.</ArticleTitle><Pagination><StartPage>5</StartPage><MedlinePgn>5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1167/iovs.65.14.5</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">To establish the repeatability of choriocapillaris flow deficit (CCFD) measurements within a macular grid and then demonstrate the use of this registered grid strategy to follow CCFD measurements over time.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Swept-source optical coherence tomography angiography scans were acquired (nominal size of 6 &#xd7; 6&#xa0;mm). For each scan, masks of hyperreflective foci, calcified drusen, and persistent choroidal hypertransmission defects (hyperTDs) were generated. These masks were then used to exclude these prespecified regions when calculating the CCFD percentages (CCFD%). Scans were registered, and CCFD% measurements were performed within 3-mm and 5-mm fovea-centered circles and within a fovea-centered grid (one box: 74 &#xd7; 74 pixels). The 95% minimal detectable changes (MDC95) for CCFD% were calculated for each of the regions. This longitudinal grid workflow was then used to study eyes before and after drusen resolved.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Ninety eyes of 63 patients were identified: 30 normal eyes, 30 eyes with intermediate age-related macular degeneration (iAMD), and 30 eyes with hyperTDs. The MDC95 for the normal, iAMD, and hyperTD eyes within the 3-mm and 5-mm circles ranged from 0.85% to 1.96%. The MDC95 for an individual grid's box ranged from 3.35% to 4.67%, and for the total grid area, the MDC95 ranged from 0.91% to 1.40%. When tested longitudinally before and after the resolution of drusen using grid strategy, no significant differences in the CCFD% were observed.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">A grid strategy was developed to investigate targeted longitudinal changes in CCFD% associated with changes in optical coherence tomography biomarkers, and this strategy was validated using eyes in which drusen resolved.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hiya</LastName><ForeName>Farhan E</ForeName><Initials>FE</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Yuxuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, University of Washington, Seattle, Washington, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Mengxi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jianqing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berni</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Sandy Wenting</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Tan Tock Seng Hospital, National Health Group Eye Institute, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrera</LastName><ForeName>Gissel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gregori</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ruikang K</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, University of Washington, Seattle, Washington, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, University of Washington, Seattle, Washington, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenfeld</LastName><ForeName>Philip J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Invest Ophthalmol Vis Sci</MedlineTA><NlmUniqueID>7703701</NlmUniqueID><ISSNLinking>0146-0404</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D041623" MajorTopicYN="Y">Tomography, Optical Coherence</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002829" MajorTopicYN="Y">Choroid</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005451" MajorTopicYN="Y">Fluorescein Angiography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012039" MajorTopicYN="Y">Regional Blood Flow</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008266" MajorTopicYN="Y">Macula Lutea</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005654" MajorTopicYN="N">Fundus Oculi</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>3</Day><Hour>12</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>3</Day><Hour>12</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>3</Day><Hour>10</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39625442</ArticleId><ArticleId IdType="doi">10.1167/iovs.65.14.5</ArticleId><ArticleId IdType="pii">2802311</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39625016</PMID><DateCompleted><Year>2024</Year><Month>12</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2101-017X</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>La Revue du praticien</Title><ISOAbbreviation>Rev Prat</ISOAbbreviation></Journal><ArticleTitle>[Effects of air pollution on eye health].</ArticleTitle><Pagination><StartPage>947</StartPage><EndPage>949</EndPage><MedlinePgn>947-949</MedlinePgn></Pagination><Abstract><AbstractText>EFFECTS OF AIR POLLUTION ON EYE HEALTH. In addition to its well-known effects on cardio-respiratory health, air pollution could also have an impact on eye health. Indeed, certain air pollutants, especially fine particles and nitrogen dioxide, can enter the bloodstream, triggering oxidative and inflammatory mechanisms involved in the development of the major eye diseases (glaucoma, age-related macular degeneration [AMD], cataracts). Over the past 5 years, some 15 epidemiological studies carried out in Asia, Europe and Canada have consistently shown an increased risk of these diseases in individuals most exposed to air pollution at long term, particularly to fine particles. These results support the lowering of air pollution thresholds recommended by the World Health Organization (WHO) in 2021, which nevertheless continue to be exceeded in most European cities.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Delcourt</LastName><ForeName>C&#xe9;cile</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Bordeaux, Inserm, BPH, U1219, Bordeaux, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Effets de la pollution de l&#x2019;air sur la sant&#xe9; oculaire.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Rev Prat</MedlineTA><NlmUniqueID>0404334</NlmUniqueID><ISSNLinking>0035-2640</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000393">Air Pollutants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052638">Particulate Matter</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000397" MajorTopicYN="Y">Air Pollution</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005128" MajorTopicYN="Y">Eye Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000393" MajorTopicYN="N">Air Pollutants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052638" MajorTopicYN="N">Particulate Matter</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="fre"><AbstractText>EFFETS DE LA POLLUTION DE L&#x2019;AIR SUR LA SANT&#xc9; OCULAIRE. Outre ses r&#xe9;percussions bien connues sur la sant&#xe9; cardiorespiratoire, la pollution atmosph&#xe9;rique pourrait avoir des effets sur la sant&#xe9; oculaire. En effet, certains polluants atmosph&#xe9;riques, notamment les particules fines et le dioxyde d&#x2019;azote, peuvent p&#xe9;n&#xe9;trer dans la circulation sanguine, d&#xe9;clenchant des m&#xe9;canismes oxydatifs et inflammatoires impliqu&#xe9;s dans le d&#xe9;veloppement des principales maladies oculaires (glaucome, d&#xe9;g&#xe9;n&#xe9;rescence maculaire li&#xe9;e &#xe0; l&#x2019;&#xe2;ge [DMLA], cataracte). Au cours des cinq derni&#xe8;res ann&#xe9;es, une quinzaine d&#x2019;&#xe9;tudes &#xe9;pid&#xe9;miologiques, r&#xe9;alis&#xe9;es en Asie, en Europe et au Canada, ont montr&#xe9; de mani&#xe8;re tr&#xe8;s coh&#xe9;rente une augmentation du risque de ces maladies chez les personnes les plus expos&#xe9;es au long cours &#xe0; la pollution atmosph&#xe9;rique, particuli&#xe8;rement aux particules fines. Ces r&#xe9;sultats confortent la baisse des seuils de pollution atmosph&#xe9;rique recommand&#xe9;s par l&#x2019;Organisation mondiale de la sant&#xe9; (OMS) en 2021, qui continuent n&#xe9;anmoins &#xe0; &#xea;tre d&#xe9;pass&#xe9;s dans la plupart des villes europ&#xe9;ennes.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Air Pollution</Keyword><Keyword MajorTopicYN="N">Eye Diseases</Keyword></KeywordList><CoiStatement>L&#x2019;auteure d&#xe9;clare avoir particip&#xe9; &#xe0; des interventions ponctuelles pour les entreprises Allergan (travaux scientifiques), Bausch+Lomb (activit&#xe9;s de conseil, conf&#xe9;rence), Th&#xe9;a Pharma (activit&#xe9;s de conseil, conf&#xe9;rences) et Novartis (travaux scientifiques).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>3</Day><Hour>12</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>3</Day><Hour>12</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39625016</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39624796</PMID><DateRevised><Year>2024</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2666-9145</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>Ophthalmology science</Title><ISOAbbreviation>Ophthalmol Sci</ISOAbbreviation></Journal><ArticleTitle>Interplay between Lipids and Complement Proteins-How Multiomics Data Integration Can Help Unravel Age-related Macular Degeneration Pathophysiology: A&#xa0;Proof-of-concept Study.</ArticleTitle><Pagination><StartPage>100629</StartPage><MedlinePgn>100629</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100629</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.xops.2024.100629</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">Our objectives were to identify correlation patterns between complement and lipid pathways using a multiomics data integration approach and to determine how these interconnections affect age-related macular degeneration (AMD).</AbstractText><AbstractText Label="DESIGN" NlmCategory="UNASSIGNED">Nested case-control study.</AbstractText><AbstractText Label="SUBJECTS AND CONTROLS" NlmCategory="UNASSIGNED">The analyses were performed in a subset of the Singapore Indian Eye Study. We randomly selected 155 AMD cases and age- and sex-matched them with 155 controls.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Firstly, a multiomics data integration method was used to identify correlation patterns between the omics data. Then, we tested possible interactions between the lipids and complement proteins using logistic regression models.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="UNASSIGNED">Age-related macular degeneration was determined according to the Beckman classification system. We measured in serum samples 35 complement proteins and 66 lipids, and used 9 genetic variants.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Among the 155 AMD cases, 93 (60.0%) had early and 62 (40.0%) intermediate AMD. Firstly, we identified 2 clusters between complement proteins and lipids involving (1) mannan-binding lectin serine protease 1 and several different high-density lipoprotein particles, and (2) complement factor H-related protein 1, carboxypeptidase N subunit 2 and complement component C8 gamma chain, and sphingomyelin and different cholesterol. Secondly, we identified 1 interaction between complement protein 1R and sphingomyelin with an odds of AMD 2 times higher for individuals with low levels of sphingomyelin and complement protein 1R (odds ratio&#xa0;=&#xa0;2.13 [1.09, 4.17]).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">We report here, using a cutting-edge multiomics integration approach, the complex interconnections between genetic, metabolomics, and proteomic data. This method permitted us to obtain a holistic picture and identify multiomics signature of AMD pathophysiology. These results advocate for a personalized therapeutic approach that accounts for multiple pathways. However, these results need to be validated in larger studies with different ethnic groups.</AbstractText><AbstractText Label="FINANCIAL DISCLOSURES" NlmCategory="UNASSIGNED">Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</AbstractText><CopyrightInformation>&#xa9; 2024 by the American Academy of Ophthalmology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nusinovici</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ophthalmology &amp; Visual Sciences Academic Clinical Program (Eye ACP), Duke-NUS Medical School, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Applied Biology and Chemical Technology, School of Optometry, The Hong Kong Polytechnic University, Hong Kong.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Agency for Science, Technology and Research (A&#x2217;STAR), Institute of Molecular and Cell Biology, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raghavan</LastName><ForeName>Lavanya</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ophthalmology &amp; Visual Sciences Academic Clinical Program (Eye ACP), Duke-NUS Medical School, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tham</LastName><ForeName>Yih Chung</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ophthalmology &amp; Visual Sciences Academic Clinical Program (Eye ACP), Duke-NUS Medical School, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hengtong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ophthalmology &amp; Visual Sciences Academic Clinical Program (Eye ACP), Duke-NUS Medical School, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheung</LastName><ForeName>Danny</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ophthalmology &amp; Visual Sciences Academic Clinical Program (Eye ACP), Duke-NUS Medical School, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaomeng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ophthalmology &amp; Visual Sciences Academic Clinical Program (Eye ACP), Duke-NUS Medical School, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Agency for Science, Technology and Research (A&#x2217;STAR), Institute of Molecular and Cell Biology, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheung</LastName><ForeName>Chui Ming Gemmy</ForeName><Initials>CMG</Initials><AffiliationInfo><Affiliation>Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ophthalmology &amp; Visual Sciences Academic Clinical Program (Eye ACP), Duke-NUS Medical School, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Tien Yin</ForeName><Initials>TY</Initials><AffiliationInfo><Affiliation>Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ophthalmology &amp; Visual Sciences Academic Clinical Program (Eye ACP), Duke-NUS Medical School, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tsinghua Medicine, Tsinghua University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chakravarthy</LastName><ForeName>Usha</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Queen's University of Belfast, Belfast, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Ching-Yu</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ophthalmology &amp; Visual Sciences Academic Clinical Program (Eye ACP), Duke-NUS Medical School, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Innovation and Precision Eye Health, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Ophthalmol Sci</MedlineTA><NlmUniqueID>9918230896206676</NlmUniqueID><ISSNLinking>2666-9145</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Age-related macular degeneration</Keyword><Keyword MajorTopicYN="N">Complement proteins</Keyword><Keyword MajorTopicYN="N">Lipids</Keyword><Keyword MajorTopicYN="N">Multiomics data integration</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>3</Day><Hour>4</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39624796</ArticleId><ArticleId IdType="pmc">PMC11609548</ArticleId><ArticleId IdType="doi">10.1016/j.xops.2024.100629</ArticleId><ArticleId IdType="pii">S2666-9145(24)00165-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wong W.L., Su X., Li X., et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Global Health. 2014;2:e106&#x2013;e116.</Citation><ArticleIdList><ArticleId IdType="pubmed">25104651</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell P., Liew G., Gopinath B., Wong T.Y. Age-related macular degeneration. Lancet. 2018;392:1147&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">30303083</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritsche L.G., Igl W., Bailey J.N.C., et al. A&#xa0;large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet. 2016;48:134&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4745342</ArticleId><ArticleId IdType="pubmed">26691988</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunier V., Merle B.M.J., Delyfer M.N., et al. Incidence of and risk factors associated with age-related macular degeneration: four-year follow-up from the ALIENOR study. JAMA Ophthalmol. 2018;136:473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5876848</ArticleId><ArticleId IdType="pubmed">29596588</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Bedell M., Zhang K. Age-related macular degeneration: genetic and environmental factors of disease. Mol Interv. 2010;10:271&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3002218</ArticleId><ArticleId IdType="pubmed">21045241</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan P.L., Bowes Rickman C., Katsanis N. AMD and the alternative complement pathway: genetics and functional implications. Hum Genomics. 2016;10:23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4915094</ArticleId><ArticleId IdType="pubmed">27329102</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan L.X., Germer C.J., La Cunza N., Lakkaraju A. Complement activation, lipid metabolism, and mitochondrial injury: converging pathways in age-related macular degeneration. Redox Biol. 2020;37</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7767764</ArticleId><ArticleId IdType="pubmed">33162377</ArticleId></ArticleIdList></Reference><Reference><Citation>Geerlings M.J., De Jong E.K., Den Hollander A.I. The complement system in age-related macular degeneration: a review of rare genetic variants and implications for personalized treatment. Mol Immunol. 2017;84:65&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5380947</ArticleId><ArticleId IdType="pubmed">27939104</ArticleId></ArticleIdList></Reference><Reference><Citation>Khandhadia S., Cipriani V., Yates J.R.W., Lotery A.J. Age-related macular degeneration and the complement system. Immunobiology. 2012;217:127&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">21868123</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M., Jiang N., Chu Y., et al. Dysregulated metabolic pathways in age-related macular degeneration. Sci Rep. 2020;10:2464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7016007</ArticleId><ArticleId IdType="pubmed">32051464</ArticleId></ArticleIdList></Reference><Reference><Citation>Nusinovici S., Zhou L., Wang X., et al. Contributions of Lipid-Related Metabolites and Complement Proteins to Early and Intermediate Age-Related Macular Degeneration. Ophthalmol Sci. 2024;4:100538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11268342</ArticleId><ArticleId IdType="pubmed">39051044</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim R.Z.H., Tham Y.C., Betzler B.K., et al. Relationships between lipid-related metabolites and age-related macular degeneration vary with complement genotype. Ophthalmol Sci. 2022;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9755028</ArticleId><ArticleId IdType="pubmed">36531576</ArticleId></ArticleIdList></Reference><Reference><Citation>Acar &#x130;.E., Lores-Motta L., Colijn J.M., et al. Integrating metabolomics, genomics, and disease pathways in age-related&#xa0;macular degeneration. Ophthalmology. 2020;127:1693&#x2013;1709.</Citation><ArticleIdList><ArticleId IdType="pubmed">32553749</ArticleId></ArticleIdList></Reference><Reference><Citation>van Leeuwen E.M., Emri E., Merle B.M.J., et al. A&#xa0;new perspective on lipid research in age-related macular degeneration. Prog Retin Eye Res. 2018;67:56&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">29729972</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaisar T., Pennathur S., Green P.S., et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J&#xa0;Clin Invest. 2007;117:746&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1804352</ArticleId><ArticleId IdType="pubmed">17332893</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Gordon S.M., Xi H., et al. HDL subclass proteomic analysis and functional implication of protein dynamic change during HDL maturation. Redox Biol. 2019;24</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6541906</ArticleId><ArticleId IdType="pubmed">31153037</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbu A., Hamad O.A., Lind L., et al. The role of complement factor C3 in lipid metabolism. Mol Immunol. 2015;67:101&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">25746915</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee A.H., Shannon C.P., Amenyogbe N., et al. Dynamic molecular changes during the first week of human life follow a robust developmental trajectory. Nat Commun. 2019;10:1092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6414553</ArticleId><ArticleId IdType="pubmed">30862783</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan C.W., Wong T.Y., Lavanya R., et al. Prevalence and risk factors for refractive errors in Indians: the Singapore Indian eye study (SINDI) Invest Ophthalmol Vis Sci. 2011;52:3166.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296814</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferris F.L., Wilkinson C.P., Bird A., et al. Clinical classification of age-related macular degeneration. Ophthalmology. 2013;120:844&#x2013;851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11551519</ArticleId><ArticleId IdType="pubmed">23332590</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Y., Malitsky S. MetaboReport: from metabolomics data analysis to comprehensive reporting. Bioinformatics. 2024;40</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11209541</ArticleId><ArticleId IdType="pubmed">38885410</ArticleId></ArticleIdList></Reference><Reference><Citation>Soininen P., Kangas A.J., W&#xfc;rtz P., et al. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Circ Cardiovasc Genet. 2015;8:192&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">25691689</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A., Shannon C.P., Gautier B., et al. DIABLO: from multi-omics assays to biomarker discovery, an integrative approach. Bioinformatics. 2016;35:3055&#x2013;3062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6735831</ArticleId><ArticleId IdType="pubmed">30657866</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohart F., Gautier B., Singh A., L&#xea; Cao K.A. mixOmics: an R package for &#x2018;omics feature selection and multiple data integration. PLoS Comput Biol. 2017;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5687754</ArticleId><ArticleId IdType="pubmed">29099853</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao X., Starmer J., Martin E.R. A&#xa0;multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. Genet Epidemiol. 2008;32:361&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">18271029</ArticleId></ArticleIdList></Reference><Reference><Citation>Acar I.E., Willems E., Kersten E., et al. Semi-quantitative multiplex profiling of the complement system identifies associations of complement proteins with genetic variants and metabolites in age-related macular degeneration. J&#xa0;Phys Math. 2021;11:1256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8705464</ArticleId><ArticleId IdType="pubmed">34945728</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon M.V., Basu S.K., Qaladize B., et al. Sphingolipids as critical players in retinal physiology and pathology. J&#xa0;Lipid Res. 2021;62</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7933806</ArticleId><ArticleId IdType="pubmed">32948663</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M., Lee S.Y., Bae Y.S. Functional roles of sphingolipids in immunity and their implication in disease. Exp Mol Med. 2023;55:1110&#x2013;1130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10318102</ArticleId><ArticleId IdType="pubmed">37258585</ArticleId></ArticleIdList></Reference><Reference><Citation>Saini J.S., Corneo B., Miller J.D., et al. Nicotinamide ameliorates disease phenotypes in a human iPSC model of age-related macular degeneration. Cell Stem Cell. 2017;20:635&#x2013;647.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5419856</ArticleId><ArticleId IdType="pubmed">28132833</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong J., Cai H., Noggle S., et al. Stem cell-derived retinal pigment epithelium from patients with age-related macular degeneration exhibit reduced metabolism and matrix interactions. Stem Cells Transl Medicine. 2020;9:364&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7031648</ArticleId><ArticleId IdType="pubmed">31840941</ArticleId></ArticleIdList></Reference><Reference><Citation>Marneros A.G. Role of inflammasome activation in neovascular age-related macular degeneration. FEBS J. 2023;290:28&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9185667</ArticleId><ArticleId IdType="pubmed">34767301</ArticleId></ArticleIdList></Reference><Reference><Citation>Maran J.J., Adesina M.M., Green C.R., et al. The central role of the NLRP3 inflammasome pathway in the pathogenesis of age-related diseases in the eye and the brain. Ageing Res Rev. 2023;88</Citation><ArticleIdList><ArticleId IdType="pubmed">37187367</ArticleId></ArticleIdList></Reference><Reference><Citation>Trivedi V.S., Magnusen A.F., Rani R., et al. Targeting the complement&#x2013;sphingolipid system in COVID-19 and gaucher diseases: evidence for a new treatment strategy. IJMS. 2022;23</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9695449</ArticleId><ArticleId IdType="pubmed">36430817</ArticleId></ArticleIdList></Reference><Reference><Citation>Janneh A.H., Atkinson C., Tomlinson S., Ogretmen B. Sphingolipid metabolism and complement signaling in cancer progression. Trends Cancer. 2023;9:782&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10528689</ArticleId><ArticleId IdType="pubmed">37507302</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar-Singh R. The role of complement membrane attack complex in dry and wet AMD - from hypothesis to clinical trials. Exp Eye Res. 2019;184:266&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">31082363</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39624769</PMID><DateCompleted><Year>2024</Year><Month>12</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1177-8881</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Drug design, development and therapy</Title><ISOAbbreviation>Drug Des Devel Ther</ISOAbbreviation></Journal><ArticleTitle>Effects of Dexamethasone Intravitreal Implant on Multifocal Electroretinography in Diabetic Macular Oedema.</ArticleTitle><Pagination><StartPage>5367</StartPage><EndPage>5375</EndPage><MedlinePgn>5367-5375</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/DDDT.S477677</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">To evaluate the efficacy of the dexamethasone implant on the electrophysiological profile of Diabetic Macular Oedema (DMO) patients over six months.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">In this prospective, single-center study 30 eyes of 22 patients were examined using comprehensive baseline assessments including best-corrected visual acuity (BCVA), central retinal thickness (CRT), contrast sensitivity (CS) and multifocal electroretinogram (mfERG), before and after 0.7mg dexamethasone implant injection, with follow-ups at months 1, 2, 4, and 6. The study employed mixed models to analyse within-subject and between-subject correlations, considering the complexities of multiple measurements per subject.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">At baseline, BCVA was 0.66 &#xb1; 0.104 logMAR, improving to 0.568 &#xb1; 0.104 logMAR by month 6 (P &gt; 0.05). CRT significantly reduced from 521 &#xb1; 28.7&#xa0;&#x3bc;m to 336 &#xb1; 28.7&#xa0;&#x3bc;m (P &lt; 0.05). CS slightly increased from 26.8 &#xb1; 1.23 letters to 28.5 &#xb1; 1.05 letters (P &gt; 0.05). P wave amplitude saw a notable rise from 33.4 &#xb1; 5.66&#xa0;&#x3bc;V to 47.9 &#xb1; 5.43&#xa0;&#x3bc;V (P &lt; 0.05). P wave implicit time changed minimally from 47.4 &#xb1; 0.503&#xa0;seconds to 48.0 &#xb1; 0.503&#xa0;seconds (P &gt; 0.05). No severe adverse events were recorded.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">These results underscore the 0.7mg dexamethasone implant's potential in improving certain electrophysiological markers in DMO, while also highlighting the need for further investigation into its comprehensive impact on retinal function.</AbstractText><CopyrightInformation>&#xa9; 2024 Tranos et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tranos</LastName><ForeName>Paris</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Vitreoretinal Department, Ophthalmica Eye Institute, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koukoula</LastName><ForeName>Stavrenia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Vitreoretinal Department, Ophthalmica Eye Institute, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Politis</LastName><ForeName>Penelope Burle</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Vitreoretinal Department, Ophthalmica Eye Institute, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tranou</LastName><ForeName>Marianna</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0001-2992-1095</Identifier><AffiliationInfo><Affiliation>Vitreoretinal Department, Ophthalmica Eye Institute, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giamouridou</LastName><ForeName>Olympia</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Vitreoretinal Department, Ophthalmica Eye Institute, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stavrakas</LastName><ForeName>Panagiotis</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-0570-6438</Identifier><AffiliationInfo><Affiliation>Department of Ophthalmology, School of Medicine, University of Patras, Patras, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panos</LastName><ForeName>Georgios D</ForeName><Initials>GD</Initials><Identifier Source="ORCID">0000-0001-8399-7456</Identifier><AffiliationInfo><Affiliation>Division of Ophthalmology and Visual Sciences, School of Medicine, University of Nottingham, Nottingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Queen's Medical Centre, Nottingham University Hospitals, Nottingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>First Department of Ophthalmology, AHEPA University Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Des Devel Ther</MedlineTA><NlmUniqueID>101475745</NlmUniqueID><ISSNLinking>1177-8881</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>7S5I7G3JQL</RegistryNumber><NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004343">Drug Implants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003907" MajorTopicYN="Y">Dexamethasone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008269" MajorTopicYN="Y">Macular Edema</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004596" MajorTopicYN="Y">Electroretinography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003930" MajorTopicYN="Y">Diabetic Retinopathy</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004343" MajorTopicYN="Y">Drug Implants</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058449" MajorTopicYN="N">Intravitreal Injections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014792" MajorTopicYN="N">Visual Acuity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">contrast sensitivity</Keyword><Keyword MajorTopicYN="N">dexamethasone implant</Keyword><Keyword MajorTopicYN="N">diabetic macular oedema</Keyword><Keyword MajorTopicYN="N">electroretinogram</Keyword><Keyword MajorTopicYN="N">macular thickness</Keyword><Keyword MajorTopicYN="N">visual acuity</Keyword><Keyword MajorTopicYN="N">visual function</Keyword></KeywordList><CoiStatement>The authors have no other conflict of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>3</Day><Hour>4</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39624769</ArticleId><ArticleId IdType="pmc">PMC11609416</ArticleId><ArticleId IdType="doi">10.2147/DDDT.S477677</ArticleId><ArticleId IdType="pii">477677</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Leasher JL, Bourne RR, Flaxman SR, et al. Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 1990 to 2010. Diabetes Care. 2016;39(9):1643&#x2013;1649. doi:10.2337/dc15-2171</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc15-2171</ArticleId><ArticleId IdType="pubmed">27555623</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero-Aroca P. Targeting the pathophysiology of diabetic macular edema. Diabetes Care. 2010;33(11):2484&#x2013;2485. doi:10.2337/dc10-1580</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc10-1580</ArticleId><ArticleId IdType="pmc">PMC2963519</ArticleId><ArticleId IdType="pubmed">20980428</ArticleId></ArticleIdList></Reference><Reference><Citation>Browning DJ, Stewart MW, Lee C. Diabetic macular edema: evidence-based management. Indian J Ophthalmol. 2018;66(12):1736&#x2013;1750. doi:10.4103/ijo.IJO_1240_18</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijo.IJO_1240_18</ArticleId><ArticleId IdType="pmc">PMC6256891</ArticleId><ArticleId IdType="pubmed">30451174</ArticleId></ArticleIdList></Reference><Reference><Citation>Panos GD. Evolution of intravitreal therapy for retinal and macular disorders. J Int Med Res. 2020;48(1):300060518771411. doi:10.1177/0300060518771411</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0300060518771411</ArticleId><ArticleId IdType="pmc">PMC7579327</ArticleId><ArticleId IdType="pubmed">29726284</ArticleId></ArticleIdList></Reference><Reference><Citation>Grover D, Li TJ, Chong CC, Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev. 2008;1:CD005656. doi:10.1002/14651858.CD005656.pub2</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD005656.pub2</ArticleId><ArticleId IdType="pmc">PMC3804331</ArticleId><ArticleId IdType="pubmed">18254088</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz SG, Scott IU, Stewart MW, Flynn Jr. HW Jr. Update on corticosteroids for diabetic macular edema. Clin Ophthalmol. 2016;10:1723&#x2013;1730. doi:10.2147/OPTH.S115546</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OPTH.S115546</ArticleId><ArticleId IdType="pmc">PMC5019446</ArticleId><ArticleId IdType="pubmed">27660409</ArticleId></ArticleIdList></Reference><Reference><Citation>Baget-Bernaldiz M, Romero-Aroca P, Bautista-Perez A, Mercado J. Multifocal electroretinography changes at the 1-year follow-up in a cohort of diabetic macular edema patients treated with ranibizumab. Doc Ophthalmol. 2017;135(2):85&#x2013;96. doi:10.1007/s10633-017-9601-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10633-017-9601-2</ArticleId><ArticleId IdType="pmc">PMC5606940</ArticleId><ArticleId IdType="pubmed">28779336</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastropasqua R, Toto L, Borrelli E, et al. Morphology and function over a one-year follow up period after intravitreal dexamethasone implant (Ozurdex) in patients with diabetic macular edema. PLoS One. 2015;10(12):e0145663. doi:10.1371/journal.pone.0145663</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0145663</ArticleId><ArticleId IdType="pmc">PMC4697855</ArticleId><ArticleId IdType="pubmed">26720268</ArticleId></ArticleIdList></Reference><Reference><Citation>Creel DJ. Electroretinograms. Handb Clin Neurol. 2019;160:481&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">31277870</ArticleId></ArticleIdList></Reference><Reference><Citation>Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985;103(12):1796&#x2013;1806. doi:10.1001/archopht.1985.01050120030015</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archopht.1985.01050120030015</ArticleId><ArticleId IdType="pubmed">2866759</ArticleId></ArticleIdList></Reference><Reference><Citation>Zur D, Iglicki M, Loewenstein A. The role of steroids in the management of diabetic macular edema. Ophthalmic Res. 2019;62(4):231&#x2013;236. doi:10.1159/000499540</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000499540</ArticleId><ArticleId IdType="pubmed">31048580</ArticleId></ArticleIdList></Reference><Reference><Citation>Bearse MA Jr, Ozawa GY. Multifocal electroretinography in diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2014;14(9):526. doi:10.1007/s11892-014-0526-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11892-014-0526-9</ArticleId><ArticleId IdType="pubmed">25005120</ArticleId></ArticleIdList></Reference><Reference><Citation>Bearse MA Jr, Han Y, Schneck ME, Adams AJ. Retinal function in normal and diabetic eyes mapped with the slow flash multifocal electroretinogram. Invest Ophthalmol Vis Sci. 2004;45(1):296&#x2013;304. doi:10.1167/iovs.03-0424</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.03-0424</ArticleId><ArticleId IdType="pubmed">14691187</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonade D, Kern TS. Photoreceptor cells and RPE contribute to the development of diabetic retinopathy. Prog Retin Eye Res. 2021;83:100919. doi:10.1016/j.preteyeres.2020.100919</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2020.100919</ArticleId><ArticleId IdType="pmc">PMC8113320</ArticleId><ArticleId IdType="pubmed">33188897</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Lo ACY. Diabetic retinopathy: pathophysiology and treatments. Int J Mol Sci. 2018;19(6):1816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6032159</ArticleId><ArticleId IdType="pubmed">29925789</ArticleId></ArticleIdList></Reference><Reference><Citation>Panos GD, Arruti N, Patra S. The long-term efficacy and safety of fluocinolone acetonide intravitreal implant 190 mug (ILUVIEN((R))) in diabetic macular oedema in a multi-ethnic inner-city population. Eur J Ophthalmol. 2021;31(2):620&#x2013;629. doi:10.1177/1120672119898414</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1120672119898414</ArticleId><ArticleId IdType="pubmed">31906704</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulut MN, Calli U, Akcay G, Kivrak U, Bulut K, Ozerturk Y. Effects of dexamethasone implant on multifocal electroretinography in central retinal vein occlusion. J Ophthalmic Vis Res. 2018;13(1):23&#x2013;28. doi:10.4103/jovr.jovr_118_16</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/jovr.jovr_118_16</ArticleId><ArticleId IdType="pmc">PMC5782451</ArticleId><ArticleId IdType="pubmed">29403585</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39623103</PMID><DateRevised><Year>2024</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1718</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Dec</Month><Day>02</Day></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>Genome-wide association analyses identify distinct genetic architectures for age-related macular degeneration across ancestries.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41588-024-01764-0</ELocationID><Abstract><AbstractText>To effectively reduce vision loss due to age-related macular generation (AMD) on a global scale, knowledge of its genetic architecture in diverse populations is necessary. A critical element, AMD risk profiles in African and Hispanic/Latino ancestries, remains largely unknown. We combined data in the Million Veteran Program with five other cohorts to conduct the first multi-ancestry genome-wide association study of AMD and discovered 63 loci (30 novel). We observe marked cross-ancestry heterogeneity at major risk loci, especially in African-ancestry populations which demonstrate a primary signal in a major histocompatibility complex class II haplotype and reduced risk at the established CFH and ARMS2/HTRA1 loci. Dissecting local ancestry in admixed individuals, we find significantly smaller marginal effect sizes for CFH risk alleles in African ancestry haplotypes. Broadening efforts to include ancestrally distinct populations helped uncover genes and pathways that boost risk in an ancestry-dependent manner and are potential targets for corrective therapies.</AbstractText><CopyrightInformation>&#xa9; 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Gorman</LastName><ForeName>Bryan R</ForeName><Initials>BR</Initials><Identifier Source="ORCID">0000-0002-4239-4672</Identifier><AffiliationInfo><Affiliation>Center for Data and Computational Sciences (C-DACS), VA Cooperative Studies Program, VA Boston Healthcare System, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Booz Allen Hamilton, McLean, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Voloudakis</LastName><ForeName>Georgios</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-5729-632X</Identifier><AffiliationInfo><Affiliation>Center for Disease Neurogenomics, Department of Psychiatry; Friedman Brain Institute; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Precision Medicine and Translational Therapeutics, VISN 2 Mental Illness Research, Education, and Clinical Center (MIRECC), James J. Peters Veterans Affairs Medical Center, New York/New Jersey VA Health Care Network, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Igo</LastName><ForeName>Robert P</ForeName><Initials>RP</Initials><Suffix>Jr</Suffix><Identifier Source="ORCID">0000-0002-0024-1993</Identifier><AffiliationInfo><Affiliation>Research Service, VA Northeast Ohio Healthcare System, Cleveland, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kinzy</LastName><ForeName>Tyler</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Research Service, VA Northeast Ohio Healthcare System, Cleveland, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halladay</LastName><ForeName>Christopher W</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Center of Innovation in Long Term Services and Supports, VA Providence Healthcare System, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bigdeli</LastName><ForeName>Tim B</ForeName><Initials>TB</Initials><AffiliationInfo><Affiliation>Research Service, VA New York Harbor Healthcare System, Brooklyn, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, SUNY Downstate Health Sciences University, Brooklyn, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Biao</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Center for Disease Neurogenomics, Department of Psychiatry; Friedman Brain Institute; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venkatesh</LastName><ForeName>Sanan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Disease Neurogenomics, Department of Psychiatry; Friedman Brain Institute; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Precision Medicine and Translational Therapeutics, VISN 2 Mental Illness Research, Education, and Clinical Center (MIRECC), James J. Peters Veterans Affairs Medical Center, New York/New Jersey VA Health Care Network, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooke Bailey</LastName><ForeName>Jessica N</ForeName><Initials>JN</Initials><Identifier Source="ORCID">0000-0002-4001-8702</Identifier><AffiliationInfo><Affiliation>Research Service, VA Northeast Ohio Healthcare System, Cleveland, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cleveland Institute for Computational Biology, Case Western Reserve University, Cleveland, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics &amp; Genome Sciences, Case Western Reserve University, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crawford</LastName><ForeName>Dana C</ForeName><Initials>DC</Initials><Identifier Source="ORCID">0000-0002-6437-6248</Identifier><AffiliationInfo><Affiliation>Research Service, VA Northeast Ohio Healthcare System, Cleveland, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cleveland Institute for Computational Biology, Case Western Reserve University, Cleveland, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics &amp; Genome Sciences, Case Western Reserve University, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Markianos</LastName><ForeName>Kyriacos</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-0214-6014</Identifier><AffiliationInfo><Affiliation>Center for Data and Computational Sciences (C-DACS), VA Cooperative Studies Program, VA Boston Healthcare System, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Frederick</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Center for Data and Computational Sciences (C-DACS), VA Cooperative Studies Program, VA Boston Healthcare System, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Booz Allen Hamilton, McLean, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schreiner</LastName><ForeName>Patrick A</ForeName><Initials>PA</Initials><Identifier Source="ORCID">0000-0001-5391-2642</Identifier><AffiliationInfo><Affiliation>Center for Data and Computational Sciences (C-DACS), VA Cooperative Studies Program, VA Boston Healthcare System, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Booz Allen Hamilton, McLean, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Center for Disease Neurogenomics, Department of Psychiatry; Friedman Brain Institute; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>VA Million Veteran Program</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>International AMD Genomics Consortium (IAMDGC)</CollectiveName></Author><Author ValidYN="Y"><LastName>Hadi</LastName><ForeName>Tamer</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Eye Clinic, VA Northeast Ohio Healthcare System, Cleveland, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Sciences, University Hospitals Eye Institute, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anger</LastName><ForeName>Matthew D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Eye Clinic, VA Western NY Healthcare System, Buffalo, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ophthalmology, Jacobs School of Medicine and Biomedical Sciences, SUNY-University at Buffalo, Buffalo, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stockwell</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Genentech, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melles</LastName><ForeName>Ronald B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Kaiser Permanente Northern California, Redwood City, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choquet</LastName><ForeName>H&#xe9;l&#xe8;ne</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-9839-8667</Identifier><AffiliationInfo><Affiliation>Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaye</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1504-3201</Identifier><AffiliationInfo><Affiliation>Southampton Eye Unit, University Hospital Southampton National Health Service Foundation Trust, Southampton, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patasova</LastName><ForeName>Karina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Section of Ophthalmology, School of Life Course Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Twin Research and Genetic Epidemiology, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Praveen J</ForeName><Initials>PJ</Initials><Identifier Source="ORCID">0000-0001-8682-4067</Identifier><AffiliationInfo><Affiliation>National Institute for Health and Care Research Biomedical Research Centre, Moorfields Eye Hospital National Health Service Foundation Trust, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Ophthalmology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaspan</LastName><ForeName>Brian L</ForeName><Initials>BL</Initials><Identifier Source="ORCID">0000-0002-3787-2510</Identifier><AffiliationInfo><Affiliation>Department of Human Genetics, Genentech, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jorgenson</LastName><ForeName>Eric</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-5829-8191</Identifier><AffiliationInfo><Affiliation>Regeneron Genetics Center, Tarrytown, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hysi</LastName><ForeName>Pirro G</ForeName><Initials>PG</Initials><Identifier Source="ORCID">0000-0001-5752-2510</Identifier><AffiliationInfo><Affiliation>Section of Ophthalmology, School of Life Course Sciences, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Twin Research and Genetic Epidemiology, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UCL Great Ormond Street Institute of Child Health, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>S&#xf8;rlandet Sykehus Arendal, Arendal Hospital, Arendal, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lotery</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0001-5541-4305</Identifier><AffiliationInfo><Affiliation>Southampton Eye Unit, University Hospital Southampton National Health Service Foundation Trust, Southampton, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaziano</LastName><ForeName>J Michael</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Million Veteran Program Coordinating Center, VA Boston Healthcare System, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Aging, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsao</LastName><ForeName>Philip S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>VA Palo Alto Epidemiology Research and Information Center for Genomics, VA Palo Alto Health Care System, Palo Alto, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fliesler</LastName><ForeName>Steven J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Ophthalmology, Jacobs School of Medicine and Biomedical Sciences, SUNY-University at Buffalo, Buffalo, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Service, VA Western NY Healthcare System, Buffalo, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biochemistry, Jacobs School of Medicine and Biomedical Sciences, SUNY-University at Buffalo, Buffalo, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Program in Neurosciences, Jacobs School of Medicine and Biomedical Sciences, SUNY-University at Buffalo, Buffalo, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Jack M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Ophthalmology, Jacobs School of Medicine and Biomedical Sciences, SUNY-University at Buffalo, Buffalo, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Service, VA Western NY Healthcare System, Buffalo, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Program in Neurosciences, Jacobs School of Medicine and Biomedical Sciences, SUNY-University at Buffalo, Buffalo, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenberg</LastName><ForeName>Paul B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Section of Ophthalmology, VA Providence Healthcare System, Providence, RI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Ophthalmology, Alpert Medical School, Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Wen-Chih</ForeName><Initials>WC</Initials><Identifier Source="ORCID">0000-0002-2834-2024</Identifier><AffiliationInfo><Affiliation>Section of Cardiology, Medical Service, VA Providence Healthcare System, Providence, RI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Alpert Medical School, Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Assimes</LastName><ForeName>Themistocles L</ForeName><Initials>TL</Initials><Identifier Source="ORCID">0000-0003-2349-0009</Identifier><AffiliationInfo><Affiliation>VA Palo Alto Epidemiology Research and Information Center for Genomics, VA Palo Alto Health Care System, Palo Alto, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pyarajan</LastName><ForeName>Saiju</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9047-3762</Identifier><AffiliationInfo><Affiliation>Center for Data and Computational Sciences (C-DACS), VA Cooperative Studies Program, VA Boston Healthcare System, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roussos</LastName><ForeName>Panos</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4640-6239</Identifier><AffiliationInfo><Affiliation>Center for Disease Neurogenomics, Department of Psychiatry; Friedman Brain Institute; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. panagiotis.roussos@mssm.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Precision Medicine and Translational Therapeutics, VISN 2 Mental Illness Research, Education, and Clinical Center (MIRECC), James J. Peters Veterans Affairs Medical Center, New York/New Jersey VA Health Care Network, Bronx, NY, USA. panagiotis.roussos@mssm.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peachey</LastName><ForeName>Neal S</ForeName><Initials>NS</Initials><Identifier Source="ORCID">0000-0002-4419-7226</Identifier><AffiliationInfo><Affiliation>Research Service, VA Northeast Ohio Healthcare System, Cleveland, OH, USA. neal.peachey@va.gov.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA. neal.peachey@va.gov.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA. neal.peachey@va.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iyengar</LastName><ForeName>Sudha K</ForeName><Initials>SK</Initials><Identifier Source="ORCID">0000-0001-7488-250X</Identifier><AffiliationInfo><Affiliation>Research Service, VA Northeast Ohio Healthcare System, Cleveland, OH, USA. ski@case.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, USA. ski@case.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cleveland Institute for Computational Biology, Case Western Reserve University, Cleveland, OH, USA. ski@case.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics &amp; Genome Sciences, Case Western Reserve University, Cleveland, OH, USA. ski@case.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Sciences, University Hospitals Eye Institute, Cleveland, OH, USA. ski@case.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>I01BX003364</GrantID><Agency>Biomedical Laboratory Research and Development, VA Office of Research and Development (VA Biomedical Laboratory Research and Development)</Agency><Country/></Grant><Grant><GrantID>IK6BX005233</GrantID><Agency>Biomedical Laboratory Research and Development, VA Office of Research and Development (VA Biomedical Laboratory Research and Development)</Agency><Country/></Grant><Grant><GrantID>I01BX004189</GrantID><Agency>Biomedical Laboratory Research and Development, VA Office of Research and Development (VA Biomedical Laboratory Research and Development)</Agency><Country/></Grant><Grant><GrantID>I01BX004557</GrantID><Agency>Research to Prevent Blindness (RPB)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Competing interests: A.S. and B.L.Y. are employees of Genentech/Roche and hold stock and stock options in Roche. E.J. is an employee and a stockholder of Regeneron Genetics Center. The other authors declare no competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Fritsche</LastName><ForeName>Lars G</ForeName><Initials>LG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Igl</LastName><ForeName>Wilmar</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cooke Bailey</LastName><ForeName>Jessica N</ForeName><Initials>JN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grassman</LastName><ForeName>Felix</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sengupta</LastName><ForeName>Sebanti</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bragg-Gresham</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burdon</LastName><ForeName>Kathryn P</ForeName><Initials>KP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hebring</LastName><ForeName>Scott J</ForeName><Initials>SJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wen</LastName><ForeName>Cindy</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gorski</LastName><ForeName>Mathias</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Ivana K</ForeName><Initials>IK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cho</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zack</LastName><ForeName>Donald</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Souied</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scholl</LastName><ForeName>Hendrik P N</ForeName><Initials>HPN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bala</LastName><ForeName>Elisa</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Kristine E</ForeName><Initials>KE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunter</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sardell</LastName><ForeName>Rebecca J</ForeName><Initials>RJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Merriam</LastName><ForeName>Joanna E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cipriani</LastName><ForeName>Valentina</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoffman</LastName><ForeName>Joshua D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schick</LastName><ForeName>Tina</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lechanteur</LastName><ForeName>Yara T E</ForeName><Initials>YTE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guymer</LastName><ForeName>Robyn H</ForeName><Initials>RH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jiang</LastName><ForeName>Yingda</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stanton</LastName><ForeName>Chloe M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buitendijk</LastName><ForeName>Gabri&#xeb;lle H S</ForeName><Initials>GHS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhan</LastName><ForeName>Xiaowei</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kwong</LastName><ForeName>Alan M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boleda</LastName><ForeName>Alexis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brooks</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gieser</LastName><ForeName>Linn</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ratnapriya</LastName><ForeName>Rinki</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Branham</LastName><ForeName>Kari E</ForeName><Initials>KE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foerster</LastName><ForeName>Johanna R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heckenlively</LastName><ForeName>John R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Othman</LastName><ForeName>Mohammad I</ForeName><Initials>MI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vote</LastName><ForeName>Brendan J</ForeName><Initials>BJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liang</LastName><ForeName>Helena Hai</ForeName><Initials>HH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Souzeau</LastName><ForeName>Emmanuelle</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>McAllister</LastName><ForeName>Ian L</ForeName><Initials>IL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Isaacs</LastName><ForeName>Timothy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>Janette</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lake</LastName><ForeName>Stewart</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mackey</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Constable</LastName><ForeName>Ian J</ForeName><Initials>IJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Craig</LastName><ForeName>Jamie E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kitchner</LastName><ForeName>Terrie</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yang</LastName><ForeName>Zhenglin</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Su</LastName><ForeName>Zhiquang</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luo</LastName><ForeName>Hongrong</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ouyang</LastName><ForeName>Ouyang</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flagg</LastName><ForeName>Ken</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lin</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mao</LastName><ForeName>Guanping</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferreyra</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stark</LastName><ForeName>Klaus</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strachwitz</LastName><ForeName>Claudia Nvon</ForeName><Initials>CN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolf</LastName><ForeName>Armin</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brandl</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rudolph</LastName><ForeName>Guenther</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olden</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morrison</LastName><ForeName>Margaux A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morgan</LastName><ForeName>Deniste J</ForeName><Initials>DJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schu</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ahn</LastName><ForeName>Jeeyun</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silvestri</LastName><ForeName>Giuliana</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsironi</LastName><ForeName>Evangelia E</ForeName><Initials>EE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Park</LastName><ForeName>Kyu Hyung</ForeName><Initials>KH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farrer</LastName><ForeName>Lindsay A</ForeName><Initials>LA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Orlin</LastName><ForeName>Anton</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brucker</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Mingyao</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Curcio</LastName><ForeName>Christine A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mohand-Sa&#xef;d</LastName><ForeName>Saddek</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sahel</LastName><ForeName>Jos&#xe9;-Alain</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Audo</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benchaboune</LastName><ForeName>Mustapha</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cree</LastName><ForeName>Angela J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rennie</LastName><ForeName>Christina A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goverdhan</LastName><ForeName>Srinivas V</ForeName><Initials>SV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grunin</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hagbi-Levi</LastName><ForeName>Shira</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Campochiaro</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katsanis</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holz</LastName><ForeName>Frank G</ForeName><Initials>FG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blond</LastName><ForeName>Fr&#xe9;d&#xe9;ric</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blanch&#xe9;</LastName><ForeName>H&#xe9;l&#xe8;ne</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deleuze</LastName><ForeName>Jean-Fran&#xe7;ois</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Igo</LastName><ForeName>Robert P</ForeName><Initials>RP</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Truitt</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meuer</LastName><ForeName>Stacy M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Myers</LastName><ForeName>Chelsea E</ForeName><Initials>CE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moore</LastName><ForeName>Emily L</ForeName><Initials>EL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klein</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hauser</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Postel</LastName><ForeName>Eric A</ForeName><Initials>EA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Courtenay</LastName><ForeName>Monique D</ForeName><Initials>MD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Stephen G</ForeName><Initials>SG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kovach</LastName><ForeName>Jaclyn L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scott</LastName><ForeName>William K</ForeName><Initials>WK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liew</LastName><ForeName>Gerald</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tan</LastName><ForeName>Ava G</ForeName><Initials>AG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gopinath</LastName><ForeName>Bamini</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Merriam</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>R Theodore</ForeName><Initials>RT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khan</LastName><ForeName>Jane C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shahidi</LastName><ForeName>Humma</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moore</LastName><ForeName>Anthony T</ForeName><Initials>AT</Initials></Investigator><Investigator ValidYN="Y"><LastName>McGrath</LastName><ForeName>J Allie</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laux</LastName><ForeName>Rene&#xe9;</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brantley</LastName><ForeName>Milam A</ForeName><Initials>MA</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Anita</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ersoy</LastName><ForeName>Lebriz</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caramoy</LastName><ForeName>Albert</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Langmann</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saksens</LastName><ForeName>Nicole T M</ForeName><Initials>NTM</Initials></Investigator><Investigator ValidYN="Y"><LastName>deJohn</LastName><ForeName>Eiko K</ForeName><Initials>EK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoyng</LastName><ForeName>Carel B</ForeName><Initials>CB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cain</LastName><ForeName>Melinda S</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richardson</LastName><ForeName>Andrea J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Tammy M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blangero</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weeks</LastName><ForeName>Daniel E</ForeName><Initials>DE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dhillon</LastName><ForeName>Bal</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Duijn</LastName><ForeName>Cornelia M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doheny</LastName><ForeName>Kimberly F</ForeName><Initials>KF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Romm</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klaver</LastName><ForeName>Caroline C W</ForeName><Initials>CCW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hayward</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gorin</LastName><ForeName>Michael B</ForeName><Initials>MB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klein</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baird</LastName><ForeName>Paul N</ForeName><Initials>PN</Initials></Investigator><Investigator ValidYN="Y"><LastName>den Hollander</LastName><ForeName>Anneke I</ForeName><Initials>AI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fauser</LastName><ForeName>Sascha</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yates</LastName><ForeName>John R W</ForeName><Initials>JRW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Allikmets</LastName><ForeName>Rando</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>Jie Jin</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schaumberg</LastName><ForeName>Debra A</ForeName><Initials>DA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klein</LastName><ForeName>Barbara E K</ForeName><Initials>BEK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hagstrom</LastName><ForeName>Stephanie A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chowers</LastName><ForeName>Itay</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lotery</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>L&#xe9;veillard</LastName><ForeName>Thierry</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Kang</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brilliant</LastName><ForeName>Murray H</ForeName><Initials>MH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hewitt</LastName><ForeName>Alex W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swaroop</LastName><ForeName>Anand</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chew</LastName><ForeName>Emily Y</ForeName><Initials>EY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pericak-Vance</LastName><ForeName>Margaret A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeAngelis</LastName><ForeName>Margaret</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stambolian</LastName><ForeName>Dwight</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haines</LastName><ForeName>Jonathan L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iyengar</LastName><ForeName>Sudha K</ForeName><Initials>SK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weber</LastName><ForeName>Bernhard H F</ForeName><Initials>BHF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abecasis</LastName><ForeName>Gon&#xe7;alo R</ForeName><Initials>GR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heid</LastName><ForeName>Iris M</ForeName><Initials>IM</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>3</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>3</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>2</Day><Hour>23</Hour><Minute>39</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39623103</ArticleId><ArticleId IdType="doi">10.1038/s41588-024-01764-0</ArticleId><ArticleId IdType="pii">10.1038/s41588-024-01764-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fleckenstein, M. et al. Age-related macular degeneration. Nat. Rev. Dis. Primers 7, 31 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33958600</ArticleId><ArticleId IdType="doi">10.1038/s41572-021-00265-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderbeek, B. L. et al. Racial differences in age-related macular degeneration rates in the United States: a longitudinal analysis of a managed care network. Am. J. Ophthalmol. 152, 273&#x2013;282.e3 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21696700</ArticleId><ArticleId IdType="pmc">3143259</ArticleId><ArticleId IdType="doi">10.1016/j.ajo.2011.02.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahr, M. A., Hodge, D. O. &amp; Erie, J. C. Racial differences in age-related macular degeneration and associated anti-vascular endothelial growth factor intravitreal injections among Medicare beneficiaries. Ophthalmol. Retina 2, 1188&#x2013;1195 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">31047189</ArticleId><ArticleId IdType="doi">10.1016/j.oret.2018.05.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, D., Jiang, Y., He, M., Scheetz, J. &amp; Wang, W. Disparities in the global burden of age-related macular degeneration: An analysis of trends from 1990 to 2015. Curr. Eye Res. 44, 657&#x2013;663 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30703332</ArticleId><ArticleId IdType="doi">10.1080/02713683.2019.1576907</ArticleId></ArticleIdList></Reference><Reference><Citation>Haines, J. L. et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 308, 419&#x2013;421 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15761120</ArticleId><ArticleId IdType="doi">10.1126/science.1110359</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein, R. J. et al. Complement factor H polymorphism in age-related macular degeneration. Science 308, 385&#x2013;389 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15761122</ArticleId><ArticleId IdType="pmc">1512523</ArticleId><ArticleId IdType="doi">10.1126/science.1109557</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards, A. O. et al. Complement factor H polymorphism and age-related macular degeneration. Science 308, 421&#x2013;424 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15761121</ArticleId><ArticleId IdType="doi">10.1126/science.1110189</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritsche, L. G. et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat. Genet. 48, 134&#x2013;143 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26691988</ArticleId><ArticleId IdType="doi">10.1038/ng.3448</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaziano, J. M. et al. Million Veteran Program: a mega-biobank to study genetic influences on health and disease. J. Clin. Epidemiol. 70, 214&#x2013;223 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26441289</ArticleId><ArticleId IdType="doi">10.1016/j.jclinepi.2015.09.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C. A. &amp; Smoller, J. W. Polygenic prediction via Bayesian regression and continuous shrinkage priors. Nat. Commun. 10, 1776 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30992449</ArticleId><ArticleId IdType="pmc">6467998</ArticleId><ArticleId IdType="doi">10.1038/s41467-019-09718-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat. Genet. 47, 291&#x2013;295 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25642630</ArticleId><ArticleId IdType="pmc">4495769</ArticleId><ArticleId IdType="doi">10.1038/ng.3211</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietzner, M. et al. Genetic architecture of host proteins involved in SARS-CoV-2 infection. Nat. Commun. 11, 6397 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33328453</ArticleId><ArticleId IdType="pmc">7744536</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-19996-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar, P., Henikoff, S. &amp; Ng, P. C. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat. Protoc. 4, 1073&#x2013;1081 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19561590</ArticleId><ArticleId IdType="doi">10.1038/nprot.2009.86</ArticleId></ArticleIdList></Reference><Reference><Citation>Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248&#x2013;249 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20354512</ArticleId><ArticleId IdType="pmc">2855889</ArticleId><ArticleId IdType="doi">10.1038/nmeth0410-248</ArticleId></ArticleIdList></Reference><Reference><Citation>Komatsu, M. &amp; Ruoslahti, E. R-Ras is a global regulator of vascular regeneration that suppresses intimal hyperplasia and tumor angiogenesis. Nat. Med. 11, 1346&#x2013;1350 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16286923</ArticleId><ArticleId IdType="doi">10.1038/nm1324</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada, J., Li, F. &amp; Komatsu, M. R-Ras protein inhibits autophosphorylation of vascular endothelial growth factor receptor 2 in endothelial cells and suppresses receptor activation in tumor vasculature. J. Biol. Chem. 290, 8133&#x2013;8145 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25645912</ArticleId><ArticleId IdType="pmc">4375470</ArticleId><ArticleId IdType="doi">10.1074/jbc.M114.591511</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xe4;h&#xe4;tupa, M. et al. Lack of R-Ras leads to increased vascular permeability in ischemic retinopathy. Invest. Ophthalmol. Vis. Sci. 57, 4898&#x2013;4909 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27654416</ArticleId><ArticleId IdType="pmc">5032915</ArticleId><ArticleId IdType="doi">10.1167/iovs.16-19212</ArticleId></ArticleIdList></Reference><Reference><Citation>Surendran, P. et al. Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. Nat. Genet. 48, 1151&#x2013;1161 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27618447</ArticleId><ArticleId IdType="pmc">5056636</ArticleId><ArticleId IdType="doi">10.1038/ng.3654</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell, R. A. et al. Placental HTRA1 cleaves &#x3b1;1-antitrypsin to generate a NET-inhibitory peptide. Blood 138, 977&#x2013;988 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34192300</ArticleId><ArticleId IdType="pmc">9069473</ArticleId><ArticleId IdType="doi">10.1182/blood.2020009021</ArticleId></ArticleIdList></Reference><Reference><Citation>Fawcett, K. A. et al. Pleiotropic associations of heterozygosity for the SERPINA1 Z allele in the UK Biobank. ERJ Open Res. 7, 00049&#x2013;2021 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33981765</ArticleId><ArticleId IdType="pmc">8107350</ArticleId><ArticleId IdType="doi">10.1183/23120541.00049-2021</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin, X. et al. Genome-wide association studies of metabolites in Finnish men identify disease-relevant loci. Nat. Commun. 13, 1644 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35347128</ArticleId><ArticleId IdType="pmc">8960770</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-29143-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Simcoe, M. J. et al. Genome-wide association study identifies two common loci associated with pigment dispersion syndrome/pigmentary glaucoma and implicates myopia in its development. Ophthalmology 129, 626&#x2013;636 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35031440</ArticleId><ArticleId IdType="doi">10.1016/j.ophtha.2022.01.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Simcoe, M. et al. Genome-wide association study in almost 195,000 individuals identifies 50 previously unidentified genetic loci for eye color. Sci. Adv. 7, eabd1239 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33692100</ArticleId><ArticleId IdType="pmc">7946369</ArticleId><ArticleId IdType="doi">10.1126/sciadv.abd1239</ArticleId></ArticleIdList></Reference><Reference><Citation>Hysi, P. G. et al. Genome-wide association meta-analysis of individuals of European ancestry identifies new loci explaining a substantial fraction of hair color variation and heritability. Nat. Genet. 50, 652&#x2013;656 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29662168</ArticleId><ArticleId IdType="pmc">5935237</ArticleId><ArticleId IdType="doi">10.1038/s41588-018-0100-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Liyanage, U. E. et al. Combined analysis of keratinocyte cancers identifies novel genome-wide loci. Hum. Mol. Genet. 28, 3148&#x2013;3160 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31174203</ArticleId><ArticleId IdType="pmc">6737293</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddz121</ArticleId></ArticleIdList></Reference><Reference><Citation>Visconti, A. et al. Genome-wide association study in 176,678 Europeans reveals genetic loci for tanning response to sun exposure. Nat. Commun. 9, 1684 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29739929</ArticleId><ArticleId IdType="pmc">5940788</ArticleId><ArticleId IdType="doi">10.1038/s41467-018-04086-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess, S. &amp; Thompson, S. G. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur. J. Epidemiol. 32, 377&#x2013;389 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28527048</ArticleId><ArticleId IdType="pmc">5506233</ArticleId><ArticleId IdType="doi">10.1007/s10654-017-0255-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundgren, S. et al. Tissue distribution of human gp330/megalin, a putative Ca<sup>2+</sup>-sensing protein. J. Histochem. Cytochem. 45, 383&#x2013;392 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9071320</ArticleId><ArticleId IdType="doi">10.1177/002215549704500306</ArticleId></ArticleIdList></Reference><Reference><Citation>Storm, T., Heegaard, S., Christensen, E. I. &amp; Nielsen, R. Megalin-deficiency causes high myopia, retinal pigment epithelium-macromelanosomes and abnormal development of the ciliary body in mice. Cell Tissue Res. 358, 99&#x2013;107 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24980834</ArticleId><ArticleId IdType="pmc">4186978</ArticleId><ArticleId IdType="doi">10.1007/s00441-014-1919-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Noel, N. C. L. &amp; MacDonald, I. M. RP1L1 and inherited photoreceptor disease: A review. Surv. Ophthalmol. 65, 725&#x2013;739 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32360662</ArticleId><ArticleId IdType="doi">10.1016/j.survophthal.2020.04.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Han, B. &amp; Eskin, E. Random-effects model aimed at discovering associations in meta-analysis of genome-wide association studies. Am. J. Hum. Genet. 88, 586&#x2013;598 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21565292</ArticleId><ArticleId IdType="pmc">3146723</ArticleId><ArticleId IdType="doi">10.1016/j.ajhg.2011.04.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Benner, C. et al. FINEMAP: efficient variable selection using summary data from genome-wide association studies. Bioinformatics 32, 1493&#x2013;1501 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26773131</ArticleId><ArticleId IdType="pmc">4866522</ArticleId><ArticleId IdType="doi">10.1093/bioinformatics/btw018</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng, B. et al. Multi-ancestry eQTL meta-analysis of human brain identifies candidate causal variants for brain-related traits. Nat. Genet. 54, 161&#x2013;169 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35058635</ArticleId><ArticleId IdType="pmc">8852232</ArticleId><ArticleId IdType="doi">10.1038/s41588-021-00987-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Hormozdiari, F. et al. Colocalization of GWAS and eQTL signals detects target genes. Am. J. Hum. Genet. 99, 1245&#x2013;1260 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27866706</ArticleId><ArticleId IdType="pmc">5142122</ArticleId><ArticleId IdType="doi">10.1016/j.ajhg.2016.10.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Maples, B. K., Gravel, S., Kenny, E. E. &amp; Bustamante, C. D. RFMix: a discriminative modeling approach for rapid and robust local-ancestry inference. Am. J. Hum. Genet. 93, 278&#x2013;288 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23910464</ArticleId><ArticleId IdType="pmc">3738819</ArticleId><ArticleId IdType="doi">10.1016/j.ajhg.2013.06.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkinson, E. G. et al. Tractor uses local ancestry to enable the inclusion of admixed individuals in GWAS and to boost power. Nat. Genet. 53, 195&#x2013;204 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33462486</ArticleId><ArticleId IdType="pmc">7867648</ArticleId><ArticleId IdType="doi">10.1038/s41588-020-00766-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes, A. E. et al. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat. Genet. 38, 1173&#x2013;1177 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16998489</ArticleId><ArticleId IdType="doi">10.1038/ng1890</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivakumaran, T. A. et al. A 32&#x2009;kb critical region excluding Y402H in CFH mediates risk for age-related macular degeneration. PLoS ONE 6, e25598 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22022419</ArticleId><ArticleId IdType="pmc">3192039</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0025598</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes, L. V. et al. Determining the population frequency of the CFHR3/CFHR1 deletion at 1q32. PLoS ONE 8, e60352 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23613724</ArticleId><ArticleId IdType="pmc">3629053</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0060352</ArticleId></ArticleIdList></Reference><Reference><Citation>Cipriani, V. et al. Increased circulating levels of factor H-related protein 4 are strongly associated with age-related macular degeneration. Nat. Commun. 11, 778 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32034129</ArticleId><ArticleId IdType="pmc">7005798</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-14499-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Pappas, C. M. et al. Protective chromosome 1q32 haplotypes mitigate risk for age-related macular degeneration associated with the CFH-CFHR5 and ARMS2/HTRA1 loci. Hum. Genomics 15, 60 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34563268</ArticleId><ArticleId IdType="pmc">8466924</ArticleId><ArticleId IdType="doi">10.1186/s40246-021-00359-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Cipriani, V. et al. Beyond factor H: the impact of genetic-risk variants for age-related macular degeneration on circulating factor-H-like 1 and factor-H-related protein concentrations. Am. J. Hum. Genet. 108, 1385&#x2013;1400 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34260948</ArticleId><ArticleId IdType="pmc">8387294</ArticleId><ArticleId IdType="doi">10.1016/j.ajhg.2021.05.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng, X. et al. HIBAG&#x2013;HLA genotype imputation with attribute bagging. Pharmacogenomics J. 14, 192&#x2013;200 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">23712092</ArticleId><ArticleId IdType="doi">10.1038/tpj.2013.18</ArticleId></ArticleIdList></Reference><Reference><Citation>Megiorni, F. &amp; Pizzuti, A. HLA-DQA1 and HLA-DQB1 in celiac disease predisposition: practical implications of the HLA molecular typing. J. Biomed. Sci. 19, 88 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23050549</ArticleId><ArticleId IdType="pmc">3482388</ArticleId><ArticleId IdType="doi">10.1186/1423-0127-19-88</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutszegi, N. et al. HLA-DRB1*07:01-HLA-DQA1*02:01-HLA-DQB1*02:02 haplotype is associated with a high risk of asparaginase hypersensitivity in acute lymphoblastic leukemia. Haematologica 102, 1578&#x2013;1586 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28596278</ArticleId><ArticleId IdType="pmc">5685222</ArticleId><ArticleId IdType="doi">10.3324/haematol.2017.168211</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez, C. A. et al. HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. Blood 124, 1266&#x2013;1276 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24970932</ArticleId><ArticleId IdType="pmc">4141516</ArticleId><ArticleId IdType="doi">10.1182/blood-2014-03-563742</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutszegi, N. et al. Two tagging single-nucleotide polymorphisms to capture HLA-DRB1*07:01-DQA1*02:01-DQB1*02:02 haplotype associated with asparaginase hypersensitivity. Br. J. Clin. Pharmacol. 87, 2542&#x2013;2548 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33217039</ArticleId><ArticleId IdType="doi">10.1111/bcp.14664</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullins, R. F., Russell, S. R., Anderson, D. H. &amp; Hageman, G. S. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J. 14, 835&#x2013;846 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10783137</ArticleId><ArticleId IdType="doi">10.1096/fasebj.14.7.835</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, W. et al. Integrative transcriptome imputation reveals tissue-specific and shared biological mechanisms mediating susceptibility to complex traits. Nat. Commun. 10, 3834 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31444360</ArticleId><ArticleId IdType="pmc">6707297</ArticleId><ArticleId IdType="doi">10.1038/s41467-019-11874-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandal, M. J. et al. Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder. Science 362, eaat8127 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30545856</ArticleId><ArticleId IdType="pmc">6443102</ArticleId><ArticleId IdType="doi">10.1126/science.aat8127</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratnapriya, R. et al. Retinal transcriptome and eQTL analyses identify genes associated with age-related macular degeneration. Nat. Genet. 51, 606&#x2013;610 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30742112</ArticleId><ArticleId IdType="pmc">6441365</ArticleId><ArticleId IdType="doi">10.1038/s41588-019-0351-9</ArticleId></ArticleIdList></Reference><Reference><Citation>GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science 369, 1318&#x2013;1330 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaz1776</ArticleId></ArticleIdList></Reference><Reference><Citation>Franz&#xe9;n, O. et al. Cardiometabolic risk loci share downstream cis- and trans-gene regulation across tissues and diseases. Science 353, 827&#x2013;830 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27540175</ArticleId><ArticleId IdType="pmc">5534139</ArticleId><ArticleId IdType="doi">10.1126/science.aad6970</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, Y. et al. ACAT: a fast and powerful p value combination method for rare-variant analysis in sequencing studies. Am. J. Hum. Genet. 104, 410&#x2013;421 (2019).</Citation></Reference><Reference><Citation>Sj&#xf6;stedt, E. et al. An atlas of the protein-coding genes in the human, pig, and mouse brain. Science 367, eaay5947 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32139519</ArticleId><ArticleId IdType="doi">10.1126/science.aay5947</ArticleId></ArticleIdList></Reference><Reference><Citation>Strunz, T. et al. A transcriptome-wide association study based on 27 tissues identifies 106 genes potentially relevant for disease pathology in age-related macular degeneration. Sci. Rep. 10, 1584 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32005911</ArticleId><ArticleId IdType="pmc">6994629</ArticleId><ArticleId IdType="doi">10.1038/s41598-020-58510-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter-Zinck, H. et al. Genotyping array design and data quality control in the Million Veteran Program. Am. J. Hum. Genet. 106, 535&#x2013;548 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32243820</ArticleId><ArticleId IdType="pmc">7118558</ArticleId><ArticleId IdType="doi">10.1016/j.ajhg.2020.03.004</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xe9;d&#xe9;lec, Y. et al. Genetic ancestry and natural selection drive population differences in immune responses to pathogens. Cell 167, 657&#x2013;669 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27768889</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2016.09.025</ArticleId></ArticleIdList></Reference><Reference><Citation>Randolph, H. E. et al. Genetic ancestry effects on the response to viral infection are pervasive but cell type specific. Science 374, 1127&#x2013;1133 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34822289</ArticleId><ArticleId IdType="pmc">8957271</ArticleId><ArticleId IdType="doi">10.1126/science.abg0928</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein, B. E. K. et al. Sunlight exposure, pigmentation, and incident age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 55, 5855&#x2013;5861 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25125603</ArticleId><ArticleId IdType="pmc">4165367</ArticleId><ArticleId IdType="doi">10.1167/iovs.14-14602</ArticleId></ArticleIdList></Reference><Reference><Citation>Halladay, C. W. et al. Genetically-guided algorithm development and sample size optimization for age-related macular degeneration cases and controls in electronic health records from the VA Million Veteran Program. AMIA Jt Summits Transl. Sci. Proc. 2019, 153&#x2013;162 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31258967</ArticleId><ArticleId IdType="pmc">6568141</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang, H. et al. Harmonizing genetic ancestry and self-identified race/ethnicity in genome-wide association studies. Am. J. Hum. Genet. 105, 763&#x2013;772 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31564439</ArticleId><ArticleId IdType="pmc">6817526</ArticleId><ArticleId IdType="doi">10.1016/j.ajhg.2019.08.012</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy, S. et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat. Genet. 48, 1279&#x2013;1283 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27548312</ArticleId><ArticleId IdType="pmc">5388176</ArticleId><ArticleId IdType="doi">10.1038/ng.3643</ArticleId></ArticleIdList></Reference><Reference><Citation>Mbatchou, J. et al. Computationally efficient whole-genome regression for quantitative and binary traits. Nat. Genet. 53, 1097&#x2013;1103 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34017140</ArticleId><ArticleId IdType="doi">10.1038/s41588-021-00870-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, J., Zaitlen, N. A., Goddard, M. E., Visscher, P. M. &amp; Price, A. L. Advantages and pitfalls in the application of mixed-model association methods. Nat. Genet. 46, 100&#x2013;106 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24473328</ArticleId><ArticleId IdType="pmc">3989144</ArticleId><ArticleId IdType="doi">10.1038/ng.2876</ArticleId></ArticleIdList></Reference><Reference><Citation>Loh, P.-R. et al. Efficient Bayesian mixed-model analysis increases association power in large cohorts. Nat. Genet. 47, 284&#x2013;290 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25642633</ArticleId><ArticleId IdType="pmc">4342297</ArticleId><ArticleId IdType="doi">10.1038/ng.3190</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, H. et al. Control for population structure and relatedness for binary traits in genetic association studies via logistic mixed models. Am. J. Hum. Genet. 98, 653&#x2013;666 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27018471</ArticleId><ArticleId IdType="pmc">4833218</ArticleId><ArticleId IdType="doi">10.1016/j.ajhg.2016.02.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen, L. et al. Differences in the genetic susceptibility to age-related macular degeneration clinical subtypes. Invest. Ophthalmol. Vis. Sci. 56, 4290&#x2013;4299 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26176866</ArticleId><ArticleId IdType="pmc">4509058</ArticleId><ArticleId IdType="doi">10.1167/iovs.15-16533</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorgenson, E. et al. Common coding variants in the HLA-DQB1 region confer susceptibility to age-related macular degeneration. Eur. J. Hum. Genet. 24, 1049&#x2013;1055 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26733291</ArticleId><ArticleId IdType="pmc">5070898</ArticleId><ArticleId IdType="doi">10.1038/ejhg.2015.247</ArticleId></ArticleIdList></Reference><Reference><Citation>Willer, C. J., Li, Y. &amp; Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26, 2190&#x2013;2191 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20616382</ArticleId><ArticleId IdType="pmc">2922887</ArticleId><ArticleId IdType="doi">10.1093/bioinformatics/btq340</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe, K., Taskesen, E., van Bochoven, A. &amp; Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. Nat. Commun. 8, 1826 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29184056</ArticleId><ArticleId IdType="pmc">5705698</ArticleId><ArticleId IdType="doi">10.1038/s41467-017-01261-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, J., Lee, S. H., Goddard, M. E. &amp; Visscher, P. M. GCTA: a tool for genome-wide complex trait analysis. Am. J. Hum. Genet. 88, 76&#x2013;82 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21167468</ArticleId><ArticleId IdType="pmc">3014363</ArticleId><ArticleId IdType="doi">10.1016/j.ajhg.2010.11.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinze, G. &amp; Schemper, M. A solution to the problem of separation in logistic regression. Stat. Med. 21, 2409&#x2013;2419 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12210625</ArticleId><ArticleId IdType="doi">10.1002/sim.1047</ArticleId></ArticleIdList></Reference><Reference><Citation>Delaneau, O., Zagury, J.-F., Robinson, M. R., Marchini, J. L. &amp; Dermitzakis, E. T. Accurate, scalable and integrative haplotype estimation. Nat. Commun. 10, 5436 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31780650</ArticleId><ArticleId IdType="pmc">6882857</ArticleId><ArticleId IdType="doi">10.1038/s41467-019-13225-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao, X. et al. A genomewide admixture mapping panel for Hispanic/Latino populations. Am. J. Hum. Genet. 80, 1171&#x2013;1178 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17503334</ArticleId><ArticleId IdType="pmc">1867104</ArticleId><ArticleId IdType="doi">10.1086/518564</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin, A. R. et al. Human demographic history impacts genetic risk prediction across diverse populations. Am. J. Hum. Genet. 100, 635&#x2013;649 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28366442</ArticleId><ArticleId IdType="pmc">5384097</ArticleId><ArticleId IdType="doi">10.1016/j.ajhg.2017.03.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 4, 7 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25722852</ArticleId><ArticleId IdType="pmc">4342193</ArticleId><ArticleId IdType="doi">10.1186/s13742-015-0047-8</ArticleId></ArticleIdList></Reference><Reference><Citation>McInnes, L., Healy, J., Saul, N. &amp; Gro&#xdf;berger, L. UMAP: uniform manifold approximation and projection. J. Open Source Softw. 3, 861 (2018).</Citation></Reference><Reference><Citation>Das, S. et al. Next-generation genotype imputation service and methods. Nat. Genet. 48, 1284&#x2013;1287 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27571263</ArticleId><ArticleId IdType="pmc">5157836</ArticleId><ArticleId IdType="doi">10.1038/ng.3656</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi-Man, O. et al. Novel genotyping algorithms for rare variants significantly improve the accuracy of Applied Biosystems<sup>TM</sup> Axiom<sup>TM</sup> array genotyping calls: Retrospective evaluation of UK Biobank array data. PLoS ONE 17, e0277680 (2022).</Citation></Reference><Reference><Citation>Cirulli, E. T. et al. Genome-wide rare variant analysis for thousands of phenotypes in over 70,000 exomes from two cohorts. Nat. Commun. 11, 542 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31992710</ArticleId><ArticleId IdType="pmc">6987107</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-14288-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Manichaikul, A. et al. Robust relationship inference in genome-wide association studies. Bioinformatics 26, 2867&#x2013;2873 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20926424</ArticleId><ArticleId IdType="pmc">3025716</ArticleId><ArticleId IdType="doi">10.1093/bioinformatics/btq559</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu, Z. et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat. Genet. 48, 481&#x2013;487 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27019110</ArticleId><ArticleId IdType="doi">10.1038/ng.3538</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemani, G. et al. The MR-Base platform supports systematic causal inference across the human phenome. eLife 7, e34408 (2018).</Citation></Reference><Reference><Citation>Brown, B. C., Asian Genetic Epidemiology Network Type 2 Diabetes Consortium, Ye, C. J., Price, A. L. &amp; Zaitlen, N. Transethnic genetic-correlation estimates from summary statistics. Am. J. Hum. Genet. 99, 76&#x2013;88 (2016).</Citation></Reference><Reference><Citation>Carroll, R. J., Bastarache, L. &amp; Denny, J. C. R PheWAS: data analysis and plotting tools for phenome-wide association studies in the R environment. Bioinformatics 30, 2375&#x2013;2376 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24733291</ArticleId><ArticleId IdType="pmc">4133579</ArticleId><ArticleId IdType="doi">10.1093/bioinformatics/btu197</ArticleId></ArticleIdList></Reference><Reference><Citation>Fullard, J. F. et al. Single-nucleus transcriptome analysis of human brain immune response in patients with severe COVID-19. Genome Med. 13, 118 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34281603</ArticleId><ArticleId IdType="pmc">8287557</ArticleId><ArticleId IdType="doi">10.1186/s13073-021-00933-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, D. et al. Comprehensive functional genomic resource and integrative model for the human brain. Science 362, eaat8464 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30545857</ArticleId><ArticleId IdType="pmc">6413328</ArticleId><ArticleId IdType="doi">10.1126/science.aat8464</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamazon, E. R. et al. A gene-based association method for mapping traits using reference transcriptome data. Nat. Genet. 47, 1091&#x2013;1098 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26258848</ArticleId><ArticleId IdType="pmc">4552594</ArticleId><ArticleId IdType="doi">10.1038/ng.3367</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbeira, A. N. et al. Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics. Nat. Commun. 9, 1825 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29739930</ArticleId><ArticleId IdType="pmc">5940825</ArticleId><ArticleId IdType="doi">10.1038/s41467-018-03621-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini, Y. &amp; Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289&#x2013;300 (1995).</Citation></Reference><Reference><Citation>Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545&#x2013;15550 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16199517</ArticleId><ArticleId IdType="pmc">1239896</ArticleId><ArticleId IdType="doi">10.1073/pnas.0506580102</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner, M. et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25, 25&#x2013;29 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10802651</ArticleId><ArticleId IdType="pmc">3037419</ArticleId><ArticleId IdType="doi">10.1038/75556</ArticleId></ArticleIdList></Reference><Reference><Citation>Gene Ontology Consortium. The Gene Ontology resource: enriching a GOld mine. Nucleic Acids Res. 49, D325&#x2013;D334 (2021).</Citation></Reference><Reference><Citation>Zhao, C. &amp; Wang, Z. GOGO: An improved algorithm to measure the semantic similarity between gene ontology terms. Sci. Rep. 8, 15107 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30305653</ArticleId><ArticleId IdType="pmc">6180005</ArticleId><ArticleId IdType="doi">10.1038/s41598-018-33219-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Charrad, M., Ghazzali, N., Boiteau, V. &amp; Niknafs, A. NbClust: an R package for determining the relevant number of clusters in a data set. J. Stat. Softw. 61, 1&#x2013;36 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v061.i06</ArticleId></ArticleIdList></Reference><Reference><Citation>Murtagh, F. &amp; Legendre, P. Ward&#x2019;s hierarchical agglomerative clustering method: which algorithms implement ward&#x2019;s criterion? J. Classif. 31, 274&#x2013;295 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00357-014-9161-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousseeuw, P. J. Silhouettes: a graphical aid to the interpretation and validation of cluster analysis. J. Comput. Appl. Math. 20, 53&#x2013;65 (1987).</Citation></Reference><Reference><Citation>Feinerer, I., Hornik, K. &amp; Meyer, D. Text mining infrastructure in R. J. Stat. Softw. 25, 1&#x2013;54 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v025.i05</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39622926</PMID><DateCompleted><Year>2024</Year><Month>12</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>03</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Multi-spectral autofluorescence variability of the individual retinal pigmented epithelial cells in healthy aging eyes.</ArticleTitle><Pagination><StartPage>30012</StartPage><MedlinePgn>30012</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">30012</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-81433-8</ELocationID><Abstract><AbstractText>The retinal pigment epithelium (RPE) is vital for the healthy function of the retina. Cellular level changes in the RPE are not visualized with current clinical techniques due to a lack of spatial resolution. Fluorescence adaptive optics scanning light ophthalmoscopy (AOSLO) can image RPE cells by utilizing their intrinsic autofluorescence (AF). The RPE AF has been imaged with only a few discrete excitation and emission bands and the multi-spectral AF has not been interrogated systematically at the level of single cells. In this study, we imaged 16 healthy eyes (ages 20-75) with AOSLO to investigate the multi-spectral AF as a function of age and wavelength with excitation from 650 - 805 nm. Quantitative analysis showed that 720 nm light produced images with the highest SNR (65.0 dB). Spatial AF variability showed a trend to increase with aging, suggesting increased heterogeneity in RPE AF with age. Spatial variability in the multi-spectral fluorescence of RPE cells with age may be a consequence of normal age-related loss of RPE cells. Multi-spectral fluorescence AOSLO provides new insight into aging related changes to RPE cells and may be a useful tool for studying diseases that affect the RPE, such as age-related macular degeneration (AMD).</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Daniel M W</ForeName><Initials>DMW</Initials><AffiliationInfo><Affiliation>University of Pittsburgh | Swanson School of Engineering, Department of Bioengineering, Pittsburgh, 15213, USA. dal208@pitt.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Pittsburgh | School of Medicine, Department of Ophthalmology, Pittsburgh, 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>Valerie C</ForeName><Initials>VC</Initials><AffiliationInfo><Affiliation>University of Pittsburgh | School of Medicine, Department of Ophthalmology, Pittsburgh, 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossi</LastName><ForeName>Ethan A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>University of Pittsburgh | Swanson School of Engineering, Department of Bioengineering, Pittsburgh, 15213, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Pittsburgh | School of Medicine, Department of Ophthalmology, Pittsburgh, 15213, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>EY030517</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EY030517</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EY030517</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EY030517</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055213" MajorTopicYN="Y">Retinal Pigment Epithelium</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009887" MajorTopicYN="Y">Ophthalmoscopy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061848" MajorTopicYN="N">Optical Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073656" MajorTopicYN="N">Healthy Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004847" MajorTopicYN="N">Epithelial Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Declarations. Competing interests: A portion of this work include technologies that E.A.R. is an inventor of for patents that are owned by the University of Rochester (US Patent No.: US 10,123,697 and US 10,092,181). No other authors have any competing interests to disclose related to this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>3</Day><Hour>0</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>3</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>2</Day><Hour>23</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>12</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39622926</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-81433-8</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-81433-8</ArticleId><ArticleId IdType="pmc">PMC11612473</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Boulton, M. &amp; Dayhaw-Barker, P. The role of the retinal pigment epithelium: Topographical variation and ageing changes. Eye15, 384&#x2013;389. 10.1038/eye.2001.141 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11450762</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonilha, V.&#xa0;L. Age and disease-related structural changes in the retinal pigment epithelium. Clinical ophthalmology (Auckland, N.Z.)2, 413&#x2013;424 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693982</ArticleId><ArticleId IdType="pubmed">19668732</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparrow, R. J., Hicks, D. &amp; P. Hamel, C. The retinal pigment epithelium in health and disease. Current Molecular Medicine10, 802&#x2013;823. 10.2174/156652410793937813 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4120883</ArticleId><ArticleId IdType="pubmed">21091424</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, S., Zhou, J. &amp; Li, D. Functions and diseases of the retinal pigment epithelium. Frontiers in Pharmacology12, 727870. 10.3389/fphar.2021.727870 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8355697</ArticleId><ArticleId IdType="pubmed">34393803</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambati, J. &amp; Fowler, B. J. Mechanisms of age-related macular degeneration. Neuron75, 26&#x2013;39. 10.1016/j.neuron.2012.06.018 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3404137</ArticleId><ArticleId IdType="pubmed">22794258</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Zamil, W. M. &amp; Yassin, S. A. Recent developments in age-related macular degeneration: a review. Clinical Interventions in Aging12, 1313&#x2013;1330. 10.2147/CIA.S143508 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5573066</ArticleId><ArticleId IdType="pubmed">28860733</ArticleId></ArticleIdList></Reference><Reference><Citation>Ly, A., Nivison-Smith, L., Assaad, N. &amp; Kalloniatis, M. Fundus autofluorescence in age-related macular degeneration. Optometry and Vision Science94, 14 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5287441</ArticleId><ArticleId IdType="pubmed">27668639</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleckenstein, M. et al. Age-related macular degeneration. Nature Reviews Disease Primers7, 1&#x2013;25. 10.1038/s41572-021-00265-2 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33958600</ArticleId></ArticleIdList></Reference><Reference><Citation>Si, Z., Zheng, Y. &amp; Zhao, J. The role of retinal pigment epithelial cells in age-related macular degeneration: Phagocytosis and autophagy. Biomolecules13, 901. 10.3390/biom13060901 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10295839</ArticleId><ArticleId IdType="pubmed">37371481</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartong, D. T., Berson, E. L. &amp; Dryja, T. P. Retinitis pigmentosa. The Lancet368, 1795&#x2013;1809. 10.1016/S0140-6736(06)69740-7 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17113430</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakai, D. et al. Retinal pigment epithelium melanin imaging using polarization-sensitive optical coherence tomography for patients with retinitis pigmentosa. Scientific Reports12, 7115, 10.1038/s41598-022-11192-x (2022). Publisher: Nature Publishing Group.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9065024</ArticleId><ArticleId IdType="pubmed">35504937</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke, T.&#xa0;R. et al. Quantitative fundus autofluorescence in recessive stargardt disease. Investigative Ophthalmology &amp; Visual Science55, 10.1167/iovs.13-13624 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4008047</ArticleId><ArticleId IdType="pubmed">24677105</ArticleId></ArticleIdList></Reference><Reference><Citation>Jauregui, R. et al. Retinal pigment epithelium atrophy in recessive stargardt disease as measured by short-wavelength and near-infrared autofluorescence. Translational Vision Science &amp; Technology10, 3. 10.1167/tvst.10.1.3 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7794276</ArticleId><ArticleId IdType="pubmed">33505770</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas, D. &amp; Duguid, G. Optical coherence tomography-a review of the principles and contemporary uses in retinal investigation. Eye18, 561&#x2013;570, 10.1038/sj.eye.6700729 (2004). Publisher: Nature Publishing Group.</Citation><ArticleIdList><ArticleId IdType="pubmed">14765099</ArticleId></ArticleIdList></Reference><Reference><Citation>Eladawi, N. et al. Optical coherence tomography: A review. In Diabetes and Fundus OCT, 191&#x2013;221, 10.1016/B978-0-12-817440-1.00007-3 (Elsevier, 2020).</Citation></Reference><Reference><Citation>Solbach, U., Keilhauer, C., Knabben, H. &amp; Wolf, S. Imaging of retinal autofluorescence in patients with age-related macular degeneration. Retina17, 385&#x2013;389. 10.1097/00006982-199709000-00005 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9355185</ArticleId></ArticleIdList></Reference><Reference><Citation>Delori, F. C., Fleckner, M. R., Goger, D. G., Weiter, J. J. &amp; Dorey, C. K. Autofluorescence distribution associated with drusen in age-related macular degeneration. Invest Ophthalmol Vis Sci.41, 9 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10670481</ArticleId></ArticleIdList></Reference><Reference><Citation>Yung, M., Klufas, M. A. &amp; Sarraf, D. Clinical applications of fundus autofluorescence in retinal disease. International Journal of Retina and Vitreous2, 12. 10.1186/s40942-016-0035-x (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5088473</ArticleId><ArticleId IdType="pubmed">27847630</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz-Valckenberg, S., Holz, F.&#xa0;G., Bird, A.&#xa0;C. &amp; Spaide, R.&#xa0;F. Fundus autofluorescence imaging: review and perspectives. Retina (Philadelphia, Pa.)28, 385&#x2013;409, 10.1097/IAE.0b013e318164a907 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18327131</ArticleId></ArticleIdList></Reference><Reference><Citation>Keilhauer, C. N. &amp; Delori, F. C. Near-infrared autofluorescence imaging of the fundus: Visualization of ocular melanin. Invest. Ophthalmol. Vis. Sci.47, 3556. 10.1167/iovs.06-0122 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16877429</ArticleId></ArticleIdList></Reference><Reference><Citation>Delori, F. C. et al. In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Investigative Ophthalmology &amp; Visual Science36, 718&#x2013;729 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7890502</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellner, U. et al. Lipofuscin- and melanin-related fundus autofluorescence visualize different retinal pigment epithelial alterations in patients with retinitis pigmentosa. Eye23, 1349&#x2013;1359, 10.1038/eye.2008.280 (2009). Publisher: Nature Publishing Group.</Citation><ArticleIdList><ArticleId IdType="pubmed">18791550</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparrow, J.&#xa0;R. &amp; Duncker, T. Fundus autofluorescence and RPE lipofuscin in age-related macular degeneration. Journal of Clinical Medicine3, 1302&#x2013;1321, 10.3390/jcm3041302 (2014). Number: 4 Publisher: Multidisciplinary Digital Publishing Institute.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4358814</ArticleId><ArticleId IdType="pubmed">25774313</ArticleId></ArticleIdList></Reference><Reference><Citation>Taubitz, T., Fang, Y., Biesemeier, A., Julien-Schraermeyer, S. &amp; Schraermeyer, U. Age, lipofuscin and melanin oxidation affect fundus near-infrared autofluorescence. EBioMedicine48, 592&#x2013;604. 10.1016/j.ebiom.2019.09.048 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6838394</ArticleId><ArticleId IdType="pubmed">31648994</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncker, T. et al. Correlations among near-infrared and short-wavelength autofluorescence and spectral-domain optical coherence tomography in recessive stargardt disease. Investigative Ophthalmology &amp; Visual Science55, 8134. 10.1167/iovs.14-14848 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4266077</ArticleId><ArticleId IdType="pubmed">25342616</ArticleId></ArticleIdList></Reference><Reference><Citation>Roorda, A. et al. Adaptive optics scanning laser ophthalmoscopy. Optics Express10, 405. 10.1364/OE.10.000405 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">19436374</ArticleId></ArticleIdList></Reference><Reference><Citation>Roorda, A., Zhang, Y. &amp; Duncan, J. L. High-resolution in vivo imaging of the RPE mosaic in eyes with retinal disease. Invest. Ophthalmol. Vis. Sci.48, 2297. 10.1167/iovs.06-1450 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17460294</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan, J. I. W., Dubra, A., Wolfe, R., Merigan, W. H. &amp; Williams, D. R. In vivo autofluorescence imaging of the human and macaque retinal pigment epithelial cell mosaic. Invest. Ophthalmol. Vis. Sci.50, 1350. 10.1167/iovs.08-2618 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2790524</ArticleId><ArticleId IdType="pubmed">18952914</ArticleId></ArticleIdList></Reference><Reference><Citation>Scoles, D., Sulai, Y. N. &amp; Dubra, A. In vivo dark-field imaging of the retinal pigment epithelium cell mosaic. Biomed. Opt. Express4, 1710. 10.1364/BOE.4.001710 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3771842</ArticleId><ArticleId IdType="pubmed">24049692</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam, J., Liu, J., Dubra, A. &amp; Fariss, R. In vivo imaging of the human retinal pigment epithelial mosaic using adaptive optics enhanced indocyanine green ophthalmoscopy. Investigative Ophthalmology &amp; Visual Science57, 4376&#x2013;4384. 10.1167/iovs.16-19503 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5015921</ArticleId><ArticleId IdType="pubmed">27564519</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray, D. C. et al. In vivo fluorescence imaging of primate retinal ganglion cells and retinal pigment epithelial cells. Optics Express14, 7144. 10.1364/OE.14.007144 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">19529085</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, T., Jung, H., Liu, J., Droettboom, M. &amp; Tam, J. Noninvasive near infrared autofluorescence imaging of retinal pigment epithelial cells in the human retina using adaptive optics. Biomed. Opt. Express8, 4348. 10.1364/BOE.8.004348 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5654784</ArticleId><ArticleId IdType="pubmed">29082069</ArticleId></ArticleIdList></Reference><Reference><Citation>Granger, C. E. et al. Human retinal pigment epithelium: In vivo cell morphometry, multispectral autofluorescence, and relationship to cone mosaic. Invest. Ophthalmol. Vis. Sci.59, 5705. 10.1167/iovs.18-24677 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6280915</ArticleId><ArticleId IdType="pubmed">30513531</ArticleId></ArticleIdList></Reference><Reference><Citation>Grieve, K. et al. In vivo near-infrared autofluorescence imaging of retinal pigment epithelial cells with 757 nm excitation. Biomed. Opt. Express9, 5946. 10.1364/BOE.9.005946 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6490976</ArticleId><ArticleId IdType="pubmed">31065405</ArticleId></ArticleIdList></Reference><Reference><Citation>Vienola, K. V. et al. Microstructure of the retinal pigment epithelium near-infrared autofluorescence in healthy young eyes and in patients with AMD. Scientific Reports10, 9561. 10.1038/s41598-020-66581-x (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7293312</ArticleId><ArticleId IdType="pubmed">32533046</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinas, M., Dorronsoro, C., Cortes, D., Pascual, D. &amp; Marcos, S. Longitudinal chromatic aberration of the human eye in the visible and near infrared from wavefront sensing, double-pass and psychophysics. Biomed. Opt. Express6, 948. 10.1364/BOE.6.000948 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4361447</ArticleId><ArticleId IdType="pubmed">25798317</ArticleId></ArticleIdList></Reference><Reference><Citation>LIA. ANSI Z136.1-2014 for Safe Use of Lasers (Laser Institute of America, 2014).</Citation></Reference><Reference><Citation>Vienola, K. V., Holmes, J. A., Glasso, Z. &amp; Rossi, E. A. Head stabilization apparatus for high-resolution ophthalmic imaging. Applied Optics63, 940&#x2013;944. 10.1364/AO.513801 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11210293</ArticleId><ArticleId IdType="pubmed">38437390</ArticleId></ArticleIdList></Reference><Reference><Citation>Rui, Y. et al. Label-free imaging of inflammation at the level of single cells in the living human eye. Ophthalmology Science0, 10.1016/j.xops.2024.100475 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11179426</ArticleId><ArticleId IdType="pubmed">38881602</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelder, J. A. &amp; Mead, R. A simplex method for function minimization. The Computer Journal7, 308&#x2013;313. 10.1093/comjnl/7.4.308 (1965).</Citation></Reference><Reference><Citation>Zhang, M. et al. Strip-based digital image registration for distortion minimization and robust eye motion measurement from scanned ophthalmic imaging systems. Biomed. Opt. Express12, 2353. 10.1364/BOE.418070 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8086453</ArticleId><ArticleId IdType="pubmed">33996234</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, M. et al. Multi-modal automatic montaging of adaptive optics retinal images. Biomed Opt Express7, 4899&#x2013;4918. 10.1364/BOE.7.004899 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5175540</ArticleId><ArticleId IdType="pubmed">28018714</ArticleId></ArticleIdList></Reference><Reference><Citation>Guizar-Sicairos, M., Thurman, S. T. &amp; Fienup, J. R. Efficient subpixel image registration algorithms. Optics Letters33, 156. 10.1364/OL.33.000156 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18197224</ArticleId></ArticleIdList></Reference><Reference><Citation>Stringer, C., Wang, T., Michaelos, M. &amp; Pachitariu, M. Cellpose: a generalist algorithm for cellular segmentation. Nature Methods18, 100&#x2013;106. 10.1038/s41592-020-01018-x (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33318659</ArticleId></ArticleIdList></Reference><Reference><Citation>Brennan, B.&#xa0;D., Heitkotter, H., Carroll, J., Tarima, S. &amp; Cooper, R.&#xa0;F. Quantifying image quality in AOSLO images of photoreceptors. Biomedical Optics Express15, 2849&#x2013;2862, 10.1364/BOE.516477 (2024). Publisher: Optica Publishing Group.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11161361</ArticleId><ArticleId IdType="pubmed">38855680</ArticleId></ArticleIdList></Reference><Reference><Citation>von der Emde, L. et al. Histologic cell shape descriptors for the retinal pigment epithelium in age-related macular degeneration: A comparison to unaffected eyes. Translational Vision Science &amp; Technology11, 19. 10.1167/tvst.11.8.19 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9419462</ArticleId><ArticleId IdType="pubmed">35984669</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, M. et al. Retinal pigment epithelial cell multinucleation in the aging eye - a mechanism to repair damage and maintain homoeostasis. Aging Cell15, 436&#x2013;445. 10.1111/acel.12447 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4854907</ArticleId><ArticleId IdType="pubmed">26875723</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao, H. &amp; Hollyfield, J. G. Aging of the human retina. differential loss of neurons and retinal pigment epithelial cells. Investigative Ophthalmology &amp; Visual Science33, 1&#x2013;17 (1992).</Citation><ArticleIdList><ArticleId IdType="pubmed">1730530</ArticleId></ArticleIdList></Reference><Reference><Citation>Bermond, K. et al. Autofluorescent granules of the human retinal pigment epithelium: Phenotypes, intracellular distribution, and age-related topography. Investigative Ophthalmology &amp; Visual Science61, 35. 10.1167/iovs.61.5.35 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405767</ArticleId><ArticleId IdType="pubmed">32433758</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, Z., Kurokawa, K., Hammer, D. X. &amp; Miller, D. T. In vivo measurement of organelle motility in human retinal pigment epithelial cells. Biomedical Optics Express10, 4142&#x2013;4158. 10.1364/BOE.10.004142 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6701538</ArticleId><ArticleId IdType="pubmed">31453000</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero-Borja, F., Venkateswaran, K., Roorda, A. &amp; Hebert, T. Optical slicing of human retinal tissue in vivo with the adaptive optics scanning laser ophthalmoscope. Appl. Opt.44, 4032&#x2013;4040. 10.1364/AO.44.004032 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16004050</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y., Poonja, S. &amp; Roorda, A. Mems-based adaptive optics scanning laser ophthalmoscopy. Opt. Lett.31, 1268&#x2013;1270. 10.1364/OL.31.001268 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16642081</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39622437</PMID><DateRevised><Year>2024</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2162-0989</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>30</Day></PubDate></JournalIssue><Title>Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)</Title><ISOAbbreviation>Asia Pac J Ophthalmol (Phila)</ISOAbbreviation></Journal><ArticleTitle>Clinical and Anatomical Features of Myopia.</ArticleTitle><Pagination><StartPage>100114</StartPage><MedlinePgn>100114</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.apjo.2024.100114</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2162-0989(24)00134-8</ELocationID><Abstract><AbstractText>The purpose of the review is to summarize clinical and anatomically-related aspects of myopia. Recent studies have revealed macular atrophy as myopic maculopathy (MMP) stage-4 was accompanied by a central Bruch&#xb4;s membrane (BM) defect associated with a subretinal proliferation (as sign of previous macular neovascularization). Patchy atrophies (MMP-stage 3) could be differentiated into those without versus with BM defects/subretinal proliferations. BM defects and subretinal proliferations were associated with each other (OR: 78.3; P &lt; 0.001). Fundus tessellation as MMP-stage-1 correlated with visual acuity reduction, suggesting pathological changes already at MMP stage 1, in addition to a leptochoroid as risk factor. Myopic parapapillary beta zone (potentially caused by an axial elongation-related enlargement of the retinal pigment epithelium [RPE] layer opening; characterized by small or no alpha zone, few or no RPE drusen at its border, normal BM thickness) can be differentiated from glaucomatous parapapillary beta zone (characterized by alpha zone, RPE drusen, and thickened BM). The overlying retinal layers extended into the parapapillary zones, deeper than the superficial layers. Prevalence of non-glaucomatous optic neuropathy increased non-linearly with longer axial length in highly myopic eyes and was a major cause for vision loss in high myopia. In patients aged 85+ years, prevalence of MMP stage 3 or 4 in highly myopic eyes (axial length &#x2265; 26.5mm) was about 75%. Myopia was associated with a lower prevalence of diabetic retinopathy, age-related macular degeneration and angle-closure glaucoma, while high myopia, more than moderate myopia, was associated with higher prevalence and incidence of open-angle glaucoma.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jonas</LastName><ForeName>Jost B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Rothschild Foundation Hospital, Institut Fran&#xe7;ais de Myopie, Paris, France; Singapore Eye Research Institute, Singapore National Eye Center, Singapore; Privatpraxis Prof Jonas und Dr. Panda-Jonas, Heidelberg, Germany; Beijing Visual Science and Translational Eye Research Institute (BERI), Beijing Tsinghua Changgung Hospital, Tsinghua Medicine, Tsinghua University, Beijing, China; New York Eye and Ear Infirmary of Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: Jost.Jonas@medma.uni-heidelberg.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panda-Jonas</LastName><ForeName>Songhomitra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Privatpraxis Prof Jonas und Dr. Panda-Jonas, Heidelberg, Germany; f Department of Ophthalmology, University Hospital Heidelberg, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Tongren Hospital, Capital Medical University, Beijing, China; Beijing Ophthalmology &amp; Visual Sciences Key Lab, Beijing Tongren Hospital, Capital Medical University, Beijing, China; Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonas</LastName><ForeName>Rahul A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Faculty of Medicine, University of Cologne, University Hospital Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Asia Pac J Ophthalmol (Phila)</MedlineTA><NlmUniqueID>101583622</NlmUniqueID><ISSNLinking>2162-0989</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Axial elongation</Keyword><Keyword MajorTopicYN="N">Axial myopia</Keyword><Keyword MajorTopicYN="N">Bruch&#xb4;s Membrane</Keyword><Keyword MajorTopicYN="N">Retinal pigment epithelium</Keyword><Keyword MajorTopicYN="N">dome-shaped macula</Keyword><Keyword MajorTopicYN="N">glaucomatous parapapillary beta zone</Keyword><Keyword MajorTopicYN="N">high myopia</Keyword><Keyword MajorTopicYN="N">macula ridge</Keyword><Keyword MajorTopicYN="N">myopia-associated optic neuropathy</Keyword><Keyword MajorTopicYN="N">myopic maculopathy</Keyword><Keyword MajorTopicYN="N">myopic parapapillary beta zone</Keyword><Keyword MajorTopicYN="N">non-glaucomatous optic neuropathy</Keyword><Keyword MajorTopicYN="N">parapapillary scleral ridge</Keyword><Keyword MajorTopicYN="N">pathologic myopia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>3</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>3</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>2</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39622437</ArticleId><ArticleId IdType="doi">10.1016/j.apjo.2024.100114</ArticleId><ArticleId IdType="pii">S2162-0989(24)00134-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39620832</PMID><DateCompleted><Year>2024</Year><Month>12</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1552-5783</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>14</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>02</Day></PubDate></JournalIssue><Title>Investigative ophthalmology &amp; visual science</Title><ISOAbbreviation>Invest Ophthalmol Vis Sci</ISOAbbreviation></Journal><ArticleTitle>Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies.</ArticleTitle><Pagination><StartPage>1</StartPage><MedlinePgn>1</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1167/iovs.65.14.1</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">Intravitreal delivery of therapeutic transgenes to the retina via engineered viral vectors can provide sustained local concentrations of therapeutic proteins and thus potentially reduce the treatment burden and improve long-term vision outcomes for patients with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We performed directed evolution in nonhuman primates (NHP) to invent an adeno-associated viral (AAV) variant (R100) with the capacity to cross vitreoretinal barriers and transduce all regions and layers of the retina following intravitreal injection. We then engineered 4D-150, an R100-based genetic medicine carrying 2 therapeutic transgenes: a codon-optimized sequence encoding aflibercept, a recombinant protein that inhibits VEGF-A, VEGF-B, and PlGF, and a microRNA sequence that inhibits expression of VEGF-C. Transduction, transgene expression, and biological activity were characterized in human retinal cells in vitro and in NHPs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">R100 demonstrated superior retinal cell transduction in vitro and in vivo compared to AAV2, a commonly used wild-type AAV serotype in retinal gene therapies. Transduction of human retinal pigment epithelial cells in vitro by 4D-150 resulted in dose-dependent transgene expression and corresponding reductions in VEGF-A and VEGF-C. Intravitreal administration of 4D-150 to NHPs was well tolerated and led to robust retinal expression of both transgenes. In a primate model of laser-induced choroidal neovascularization, 4D-150 completely prevented clinically relevant angiogenic lesions at all tested doses.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">These findings support further development of 4D-150. Clinical trials are underway to establish the safety and efficacy of 4D-150 in individuals with wet AMD and DME.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Calton</LastName><ForeName>Melissa A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>4D Molecular Therapeutics, Emeryville, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Croze</LastName><ForeName>Roxanne H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>4D Molecular Therapeutics, Emeryville, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>4D Molecular Therapeutics, Emeryville, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beliakoff</LastName><ForeName>Ghezal</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>4D Molecular Therapeutics, Emeryville, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vazin</LastName><ForeName>Tandis</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>4D Molecular Therapeutics, Emeryville, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szymanski</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>4D Molecular Therapeutics, Emeryville, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmitt</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>4D Molecular Therapeutics, Emeryville, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Austin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>4D Molecular Therapeutics, Emeryville, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leong</LastName><ForeName>Meredith</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>4D Molecular Therapeutics, Emeryville, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quezada</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>4D Molecular Therapeutics, Emeryville, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holt</LastName><ForeName>Jenny</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>4D Molecular Therapeutics, Emeryville, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bolender</LastName><ForeName>Gabe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>4D Molecular Therapeutics, Emeryville, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barglow</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>4D Molecular Therapeutics, Emeryville, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khoday</LastName><ForeName>Devi</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>4D Molecular Therapeutics, Emeryville, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mason</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>4D Molecular Therapeutics, Emeryville, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delaria</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>4D Molecular Therapeutics, Emeryville, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassanipour</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>4D Molecular Therapeutics, Emeryville, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotterman</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>4D Molecular Therapeutics, Emeryville, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khanani</LastName><ForeName>Arshad M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Sierra Eye Associates, Reno, Nevada, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Nevada, Reno School of Medicine, Reno, Nevada, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schaffer</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University of California, Berkeley, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Francis</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>4D Molecular Therapeutics, Emeryville, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirn</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>4D Molecular Therapeutics, Emeryville, California, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of California, Berkeley, California, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Invest Ophthalmol Vis Sci</MedlineTA><NlmUniqueID>7703701</NlmUniqueID><ISSNLinking>0146-0404</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance></Chemical><Chemical><RegistryNumber>15C2VL427D</RegistryNumber><NameOfSubstance UI="C533178">aflibercept</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D040262">Receptors, Vascular Endothelial Growth Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058449" MajorTopicYN="Y">Intravitreal Injections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="Y">Genetic Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000229" MajorTopicYN="Y">Dependovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019076" MajorTopicYN="Y">Transgenes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="Y">Genetic Vectors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008253" MajorTopicYN="N">Macaca mulatta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040262" MajorTopicYN="N">Receptors, Vascular Endothelial Growth Factor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020256" MajorTopicYN="N">Choroidal Neovascularization</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055213" MajorTopicYN="N">Retinal Pigment Epithelium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057135" MajorTopicYN="N">Wet Macular Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008252" MajorTopicYN="N">Macaca fascicularis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Disclosure: <b>M.A. Calton</b>, 4DMT (E, I) and is an inventor on the following relevant international patent filings assigned to 4DMT (P): PCT/US2022/026395; <b>R.H. Croze</b>, 4DMT (E, I); <b>C. Burns</b>, 4DMT, (I); and former employee at 4DMT, and is an inventor on the following relevant international patent filings assigned to 4DMT (P): PCT/US2022/026395; <b>G. Beliakoff</b> None; <b>T. Vazin</b>, 4DMT (I) and former employee at 4DMT; <b>P. Szymanksi,</b> 4DMT, (I); and former employee at 4DMT and is an inventor on the following relevant international patent filings assigned to 4DMT (P): PCT/US2022/026395 and WO2019104279A1; <b>C. Schmitt</b>, former employee at 4DMT, has unvested stock options and is a current employee at Codexis Inc. (E, I); <b>A. Klein</b>, 4DMT (I) and former employee at 4DMT; <b>M. Leong</b>, 4DMT, (P, I) and former employee at 4DMT; <b>M. Quezada</b>, 4DMT (E, I); <b>J. Holt</b>, 4DMT (I) and former employee at 4DMT; <b>G. Bolender</b>, 4DMT (I) and former employee at 4DMT; <b>K. Barglow</b>, 4DMT (E, I); <b>D. Khoday</b>, 4DMT (E, I); <b>T. Mason</b>, 4DMT (E, I); <b>K. Delaria</b>, 4DMT (E, I); <b>M. Hassanipour,</b> is a former employee at 4DMT (I); <b>M. Kotterman</b>, former employee at 4DMT (I), and is an inventor on the following relevant international patent filings assigned to 4DMT (P): WO2017197355A2 and WO2019104279A1; <b>A.M. Khanani</b>, has served as a consultant to and/or received research support from 4DMT (C, F), AbbVie (C, F), Adverum (C, F), Alcon (C, F), Alexion (C, F), Amgen (C, F), Annexin (C, F), Annexon (C, F), Apellis Pharmaceuticals (C, F), Aviceda Therapeutics (C, F), Beacon Therapeutics (C, F), Clearside Biomedical (C, F), Complement Therapeutics (C, F), Exegenesis (C, F), EyePoint Pharmaceuticals (C, F), Fronterra Therapeutics (C, F), Genentech (C, F), Gyroscope Therapeutics (C, F), i-Lumen Scientific (C, F), Iveric Bio (C, F), Janssen Pharmaceuticals (C, F), Kodiak Sciences (C, F), Kriya Therapeutics (C, F), Nanoscope (C, F), Neurotech (C, F), Novartis (C, F), Ocular Therapeutix (C, F), Oculis (C, F), Ocuphire (C, F), OcuTerra (C, F), Olive BioPharma (C, F), Opthea (C, F), Oxular (C, F), Oxurion (C, F), Perfuse (C, F), Ray Therapeutics (C, F), Recens Medical (C, F), Regeneron Pharmaceuticals (C, F), Regenxbio (C, F), Revive (C, F), RevOpsis (C, F), Roche (C, F), Sanofi (C, F), Stealth BioTherapeutics (C, F), Thea Pharma (C, F), Unity Biotechnology (C, F), Vanotech (C, F), Vial (C, F), and Unity Biotechnology (C, F); Aviceda Therapeutics (I), Oculis (I), PolyPhotonix (I), Recens Medical (I), Perfuse (I), RevOpsis (I), and Vial (I); <b>D. Schaffer</b>, 4DMT (C, I), has received sponsored research funding from 4DMT (F), and is an inventor on the following relevant international patent filings assigned to 4DMT (P): WO2017197355A2 and WO2019104279A1; <b>P. Francis</b>, former employee at 4DMT (I), and is an inventor on the following relevant international patent filing assigned to 4DMT (P): WO2019104279A1; <b>D. Kirn</b>, is the chief executive officer at 4DMT with salary, bonus, stock and stock options, and is an inventor on the following relevant international patent filings assigned to 4DMT (P): WO2017197355A2 and WO2019104279A1</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>2</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>2</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>2</Day><Hour>9</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>12</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39620832</ArticleId><ArticleId IdType="doi">10.1167/iovs.65.14.1</ArticleId><ArticleId IdType="pii">2802302</ArticleId><ArticleId IdType="pmc">PMC11614000</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jonas JB, Cheung CMG, Panda-Jonas S.. Updates on the epidemiology of age-related macular degeneration. Asia Pac J Ophthalmol (Phila) . 2017; 6: 493&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">28906084</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong WL, Su X, Li X, et al. .. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health . 2014; 2: e106&#x2013;e116.</Citation><ArticleIdList><ArticleId IdType="pubmed">25104651</ArticleId></ArticleIdList></Reference><Reference><Citation>Hobbs SD, Pierce K.. Wet age-related macular degeneration (Wet AMD). StatPearls . Treasure Island (FL): StatPearls Publishing; 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">34283513</ArticleId></ArticleIdList></Reference><Reference><Citation>Spaide RF, Jaffe GJ, Sarraf D, et al. .. Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology . 2020; 127: 616&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11559632</ArticleId><ArticleId IdType="pubmed">31864668</ArticleId></ArticleIdList></Reference><Reference><Citation>Amoaku WM, Ghanchi F, Bailey C, et al. .. Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group. Eye (Lond) . 2020; 34: 1&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7337227</ArticleId><ArticleId IdType="pubmed">32504038</ArticleId></ArticleIdList></Reference><Reference><Citation>Amoaku WM, Ghanchi F, Bailey C, et al. .. Correction: Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group. Eye (Lond) . 2020; 34: 1941&#x2013;1942.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7608436</ArticleId><ArticleId IdType="pubmed">32699378</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakri SJ, Thorne JE, Ho AC, et al. .. Safety and efficacy of anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology . 2019; 126: 55&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">30077616</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown D, Heier JS, Boyer DS, et al. .. Current best clinical practices&#x2014;management of neovascular AMD. J Vitreoretin Dis . 2017; 1: 294&#x2013;297.</Citation></Reference><Reference><Citation>Fauser S, Schwabecker V, Muether PS.. Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am J Ophthalmol . 2014; 158: 532&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">24879948</ArticleId></ArticleIdList></Reference><Reference><Citation>Gragoudas ES, Adamis AP, Cunningham ET Jr., Feinsod M, Guyer DR, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med . 2004; 351: 2805&#x2013;2816.</Citation><ArticleIdList><ArticleId IdType="pubmed">15625332</ArticleId></ArticleIdList></Reference><Reference><Citation>Comparison of Age-related Macular Degeneration Treatments Trials Research G, &#xa0;Martin DF, Maguire MG, et al. .. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med . 2011; 364: 1897&#x2013;1908.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3157322</ArticleId><ArticleId IdType="pubmed">21526923</ArticleId></ArticleIdList></Reference><Reference><Citation>Lotery A, Griner R, Ferreira A, Milnes F, Dugel P.. Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set. Eye (Lond) . 2017; 31: 1697&#x2013;1706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5733295</ArticleId><ArticleId IdType="pubmed">28731052</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenfeld PJ, Brown DM, Heier JS, et al. .. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med . 2006; 355: 1419&#x2013;1431.</Citation><ArticleIdList><ArticleId IdType="pubmed">17021318</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Khersan H, Hussain RM, Ciulla TA, Dugel PU.. Innovative therapies for neovascular age-related macular degeneration. Expert Opin Pharmacother . 2019; 20: 1879&#x2013;1891.</Citation><ArticleIdList><ArticleId IdType="pubmed">31298960</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown DM, Kaiser PK, Michels M, et al. .. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med . 2006; 355: 1432&#x2013;1444.</Citation><ArticleIdList><ArticleId IdType="pubmed">17021319</ArticleId></ArticleIdList></Reference><Reference><Citation>Heier JS, Brown DM, Chong V, et al. .. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology . 2012; 119: 2537&#x2013;2548.</Citation><ArticleIdList><ArticleId IdType="pubmed">23084240</ArticleId></ArticleIdList></Reference><Reference><Citation>Almuhtaseb H, Johnston RL, Talks JS, Lotery AJ.. Second-year visual acuity outcomes of nAMD patients treated with aflibercept: data analysis from the UK aflibercept users group. Eye (Lond) . 2017; 31: 1582&#x2013;1588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5684449</ArticleId><ArticleId IdType="pubmed">28622328</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciulla TA, Huang F, Westby K, Williams DF, Zaveri S, Patel SC.. Real-world outcomes of anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration in the United States. Ophthalmol Retina . 2018; 2: 645&#x2013;653.</Citation><ArticleIdList><ArticleId IdType="pubmed">31047372</ArticleId></ArticleIdList></Reference><Reference><Citation>Comparison of Age-related Macular Degeneration Treatments Trials Research G, &#xa0;Maguire MG, Martin DF, et al. .. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology . 2016; 123: 1751&#x2013;1761.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4958614</ArticleId><ArticleId IdType="pubmed">27156698</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanani AM, Skelly A, Bezlyak V, Griner R, Torres LR, Sagkriotis A. SIERRA-AMD: a retrospective, real-world evidence study of patients with neovascular age-related macular degeneration in the United States. Ophthalmol Retina . 2020; 4: 122&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">31812631</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabral T, Lima LH, Mello LGM, et al. .. Bevacizumab injection in patients with neovascular age-related macular degeneration increases angiogenic biomarkers. Ophthalmol Retina . 2018; 2: 31&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5783314</ArticleId><ArticleId IdType="pubmed">29376143</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu MC, Pan MR, Hung WC.. Two birds, one stone: double hits on tumor growth and lymphangiogenesis by targeting vascular endothelial growth factor receptor 3. Cells . 2019; 8: 270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6468620</ArticleId><ArticleId IdType="pubmed">30901976</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao R, Eriksson A, Kubo H, Alitalo K, Cao Y, Thyberg J.. Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ Res . 2004; 94: 664&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pubmed">14739162</ArticleId></ArticleIdList></Reference><Reference><Citation>Pongsachareonnont P, Mak MYK, Hurst CP, Lam WC.. Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment. Clin Ophthalmol . 2018; 12: 1877&#x2013;1885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6165786</ArticleId><ArticleId IdType="pubmed">30310267</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalkara D, Kolstad KD, Caporale N, et al. .. Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol Ther . 2009; 17: 2096&#x2013;2102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2814392</ArticleId><ArticleId IdType="pubmed">19672248</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson SG, Cideciyan AV, Ratnakaram R, et al. .. Gene therapy for Leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol . 2012; 130: 9&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3600816</ArticleId><ArticleId IdType="pubmed">21911650</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLaren RE, Groppe M, Barnard AR, et al. .. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet . 2014; 383: 1129&#x2013;1137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4171740</ArticleId><ArticleId IdType="pubmed">24439297</ArticleId></ArticleIdList></Reference><Reference><Citation>Asuri P, Bartel MA, Vazin T, Jang JH, Wong TB, Schaffer DV.. Directed evolution of adeno-associated virus for enhanced gene delivery and gene targeting in human pluripotent stem cells. Mol Ther . 2012; 20: 329&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3277219</ArticleId><ArticleId IdType="pubmed">22108859</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang JH, Koerber JT, Kim JS, et al. .. An evolved adeno-associated viral variant enhances gene delivery and gene targeting in neural stem cells. Mol Ther . 2011; 19: 667&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3070092</ArticleId><ArticleId IdType="pubmed">21224831</ArticleId></ArticleIdList></Reference><Reference><Citation>Koerber JT, Jang JH, Schaffer DV.. DNA shuffling of adeno-associated virus yields functionally diverse viral progeny. Mol Ther . 2008; 16: 1703&#x2013;1709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683895</ArticleId><ArticleId IdType="pubmed">18728640</ArticleId></ArticleIdList></Reference><Reference><Citation>Koerber JT, Jang JH, Yu JH, Kane RS, Schaffer DV.. Engineering adeno-associated virus for one-step purification via immobilized metal affinity chromatography. Hum Gene Ther . 2007; 18: 367&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">17437357</ArticleId></ArticleIdList></Reference><Reference><Citation>Koerber JT, Klimczak R, Jang JH, Dalkara D, Flannery JG, Schaffer DV.. Molecular evolution of adeno-associated virus for enhanced glial gene delivery. Mol Ther . 2009; 17: 2088&#x2013;2095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2788045</ArticleId><ArticleId IdType="pubmed">19672246</ArticleId></ArticleIdList></Reference><Reference><Citation>Koerber JT, Maheshri N, Kaspar BK, Schaffer DV.. Construction of diverse adeno-associated viral libraries for directed evolution of enhanced gene delivery vehicles. Nat Protoc . 2006; 1: 701&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">17406299</ArticleId></ArticleIdList></Reference><Reference><Citation>Maheshri N, Koerber JT, Kaspar BK, Schaffer DV.. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol . 2006; 24: 198&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">16429148</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsic D, Govindasamy L, Currlin S, et al. .. Vector design Tour de Force: integrating combinatorial and rational approaches to derive novel adeno-associated virus variants. Mol Ther . 2014; 22: 1900&#x2013;1909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4429732</ArticleId><ArticleId IdType="pubmed">25048217</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalkara D, Byrne LC, Klimczak RR, et al. .. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med . 2013; 5: 189ra176.</Citation><ArticleIdList><ArticleId IdType="pubmed">23761039</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye GJ, Budzynski E, Sonnentag P, et al. .. Safety and biodistribution evaluation in cynomolgus macaques of rAAV2tYF-CB-hRS1, a recombinant adeno-associated virus vector expressing retinoschisin. Hum Gene Ther Clin Dev . 2015; 26: 165&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4788136</ArticleId><ArticleId IdType="pubmed">26390090</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin L, Greenberg K, Hunter JJ, et al. .. Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci . 2011; 52: 2775&#x2013;2783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3088562</ArticleId><ArticleId IdType="pubmed">21310920</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin L, Masella B, Dalkara D, et al. .. Imaging light responses of foveal ganglion cells in the living macaque eye. J Neurosci . 2014; 34: 6596&#x2013;6605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4012315</ArticleId><ArticleId IdType="pubmed">24806684</ArticleId></ArticleIdList></Reference><Reference><Citation>Goody RJ, Hu W, Shafiee A, et al. .. Optimization of laser-induced choroidal neovascularization in African green monkeys. Exp Eye Res . 2011; 92: 464&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">21414311</ArticleId></ArticleIdList></Reference><Reference><Citation>Grishanin R, Vuillemenot B, Sharma P, et al. .. Preclinical evaluation of ADVM-022, a novel gene therapy approach to treating wet age-related macular degeneration. Mol Ther . 2019; 27: 118&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6319194</ArticleId><ArticleId IdType="pubmed">30528929</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidman RL, Li J, Lawrence M, et al. .. The peptidomimetic Vasotide targets two retinal VEGF receptors and reduces pathological angiogenesis in murine and nonhuman primate models of retinal disease. Sci Transl Med . 2015; 7: 309ra165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4787616</ArticleId><ArticleId IdType="pubmed">26468327</ArticleId></ArticleIdList></Reference><Reference><Citation>Boye SE, Alexander JJ, Witherspoon CD, et al. .. Highly efficient delivery of adeno-associated viral vectors to the primate retina. Hum Gene Ther . 2016; 27: 580&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4991591</ArticleId><ArticleId IdType="pubmed">27439313</ArticleId></ArticleIdList></Reference><Reference><Citation>Kern A, Schmidt K, Leder C, et al. .. Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J Virol . 2003; 77: 11072&#x2013;11081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC224995</ArticleId><ArticleId IdType="pubmed">14512555</ArticleId></ArticleIdList></Reference><Reference><Citation>Opie SR, Warrington KH Jr., Agbandje-McKenna M, Zolotukhin S, Muzyczka N. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol . 2003; 77: 6995&#x2013;7006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC156206</ArticleId><ArticleId IdType="pubmed">12768018</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillay S, Meyer NL, Puschnik AS, et al. .. An essential receptor for adeno-associated virus infection. Nature . 2016; 530: 108&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4962915</ArticleId><ArticleId IdType="pubmed">26814968</ArticleId></ArticleIdList></Reference><Reference><Citation>Constable IJ, Pierce CM, Lai CM, et al. .. Phase 2a randomized clinical trial: safety and post hoc analysis of subretinal rAAV.sFLT-1 for wet age-related macular degeneration. EBioMedicine . 2016; 14: 168&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5161436</ArticleId><ArticleId IdType="pubmed">27865764</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakoczy EP, Lai CM, Magno AL, et al. .. Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial. Lancet . 2015; 386: 2395&#x2013;2403.</Citation><ArticleIdList><ArticleId IdType="pubmed">26431823</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Fortmann SD, Shen J, et al. .. AAV8-antiVEGFfab ocular gene transfer for neovascular age-related macular degeneration. Mol Ther . 2018; 26: 542&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5835120</ArticleId><ArticleId IdType="pubmed">29292162</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui JZ, Kimura H, Spee C, Thumann G, Hinton DR, Ryan SJ.. Natural history of choroidal neovascularization induced by vascular endothelial growth factor in the primate. Graefes Arch Clin Exp Ophthalmol . 2000; 238: 326&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pubmed">10853932</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossniklaus HE, Kang SJ, Berglin L.. Animal models of choroidal and retinal neovascularization. Prog Retin Eye Res . 2010; 29: 500&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2962694</ArticleId><ArticleId IdType="pubmed">20488255</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennesi ME, Neuringer M, Courtney RJ.. Animal models of age related macular degeneration. Mol Aspects Med . 2012; 33: 487&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3770531</ArticleId><ArticleId IdType="pubmed">22705444</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinores SA, Xiao WH, Aslam S, et al. .. Implication of the hypoxia response element of the Vegf promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development. J Cell Physiol . 2006; 206: 749&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">16245301</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahidatul-Adha M, Zunaina E, Aini-Amalina MN. Evaluation of vascular endothelial growth factor (VEGF) level in the tears and serum of age-related macular degeneration patients. Sci Rep . 2022; 12: 4423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8924159</ArticleId><ArticleId IdType="pubmed">35292705</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma K, Sharma NK, Singh R, Anand A.. Exploring the role of VEGF in Indian age-related macular degeneration. Ann Neurosci . 2015; 22: 232&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4627204</ArticleId><ArticleId IdType="pubmed">26526736</ArticleId></ArticleIdList></Reference><Reference><Citation>Otani A, Takagi H, Oh H, et al. .. Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res . 2002; 64: 162&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">12074642</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson TL, Slakter J, Buyse M, et al. .. A randomized controlled trial of OPT-302, a VEGF-C/D inhibitor for neovascular age-related macular degeneration. Ophthalmology . 2023; 130: 588&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pubmed">36754174</ArticleId></ArticleIdList></Reference><Reference><Citation>Wozar F, Seitz I, Reichel F, Fischer MD.. Importance of nonhuman primates as a model system for gene therapy development in ophthalmology. Klin Monbl Augenheilkd . 2022; 239: 270&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">35189657</ArticleId></ArticleIdList></Reference><Reference><Citation>Kay CN, Khanani AM, Hershberger VS, et al. .. Interim results for the phase 1/2 PRISM trial evaluating 4D-150, a dual-transgene intravitreal genetic medicine for with neovascular (wet) age-related macular degeneration. Presented at the 41st Annual Meeting of the American Society of Retina Specialists . Invest Ophthalmol Vis Sci . 2023; 64: 5055.</Citation></Reference><Reference><Citation>
Khanani AM, Hu A, Eichenbaum DA, et al. .. 
First interim results (24 weeks) from the randomized phase 2 dose expansion stage of the PRISM clinical trial evaluating 4D-150 in high need patients with neovascular (wet) age-related macular degeneration. Presented at the Angiogenesis, Exudation, and Degeneration Symposium . February 3, 2024. Available at: https://bascompalmerlearn.org/course/view.php?id=1697.</Citation></Reference><Reference><Citation>Nork TM, Dubielzig RR, Christian BJ, et al. .. Prevention of experimental choroidal neovascularization and resolution of active lesions by VEGF trap in nonhuman primates. Arch Ophthalmol . 2011; 129: 1042&#x2013;1052.</Citation><ArticleIdList><ArticleId IdType="pubmed">21825187</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39620831</PMID><DateCompleted><Year>2024</Year><Month>12</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1552-5783</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>14</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>02</Day></PubDate></JournalIssue><Title>Investigative ophthalmology &amp; visual science</Title><ISOAbbreviation>Invest Ophthalmol Vis Sci</ISOAbbreviation></Journal><ArticleTitle>The Umbra and the Penumbra: Longitudinal Effects of Geographic Atrophy in AMD on the Outer Choroid by Imaging Analysis and Histopathological Correlation.</ArticleTitle><Pagination><StartPage>2</StartPage><MedlinePgn>2</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1167/iovs.65.14.2</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">To quantitate regional changes in the outer choroidal vessels in patients with geographic atrophy (GA) in AMD and to correlate with a histopathological donor sample.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We analyzed 35 participants with GA for in vivo analysis and 1 participant with subject for histopathological analysis. Participants underwent three structural optical coherence tomography scans spaced 6 months apart over 1 year. Quantitative measurements of the outer choroidal vessels were performed in three regions: the GA region, a 150-&#xb5;m-wide border surrounding the GA, and the area beyond the border. Histopathological analysis was performed using europaeus agglutinin lectin-stained choroidal flat-mount images with the focal planes of both the choriocapillaris and the outer choroidal vessels.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">In the GA region, the median vessel area was 3390 &#xb5;m2 (interquartile range [IQR], 2821 &#xb5;m2) at baseline, 3139 &#xb5;m2 (IQR, 2888 &#xb5;m2) at the 6-month visit and 2888 &#xb5;m2 (IQR, 2617 &#xb5;m2) at the 12 month visit (P &lt; 0.001). Our cohort was divided into two subgroups based on RPE atrophy development at the GA border at the 6-month visit. This analysis showed that significant choroidal shrinking occurred only in eyes where the GA border progressed to GA at the 6-month follow-up. Histopathological analysis also demonstrated loss of the outer choroidal vessels, which were predominant in the GA region.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">The outer choroidal vessels seem to decrease with time within the area of GA. The outer vessels decrease over time in eyes where the GA progresses. This finding may suggest that these vessels are under a very tight paracrine control.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Borrelli</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, "City of Health and Science" Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cappellani</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Vickie and Jack Farber Vision Research Center, Wills Eye Hospital, Philadelphia, Pennsylvania, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Retina Service, Wills Eye Hospital, Philadelphia, Pennsylvania, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pulido</LastName><ForeName>Jose S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Vickie and Jack Farber Vision Research Center, Wills Eye Hospital, Philadelphia, Pennsylvania, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Retina Service, Wills Eye Hospital, Philadelphia, Pennsylvania, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pauleikhoff</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>St. Franziskus Hospital, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhutto</LastName><ForeName>Imran A</ForeName><Initials>IA</Initials><AffiliationInfo><Affiliation>Ophthalmology, Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLeod</LastName><ForeName>D Scott</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Ophthalmology, Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reibaldi</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, "City of Health and Science" Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edwards</LastName><ForeName>Malia M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Ophthalmology, Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Invest Ophthalmol Vis Sci</MedlineTA><NlmUniqueID>7703701</NlmUniqueID><ISSNLinking>0146-0404</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057092" MajorTopicYN="Y">Geographic Atrophy</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D041623" MajorTopicYN="Y">Tomography, Optical Coherence</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002829" MajorTopicYN="Y">Choroid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005451" MajorTopicYN="N">Fluorescein Angiography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055213" MajorTopicYN="N">Retinal Pigment Epithelium</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014792" MajorTopicYN="N">Visual Acuity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008268" MajorTopicYN="N">Macular Degeneration</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Disclosure: <b>E. Borrelli</b>, Abbvie (C), Bayer (C), Hofmann La Roche (C), Novartis (F), Zeiss (C); <b>F. Cappellani</b>, None; <b>J.S. Pulido</b>, None; <b>D. Pauleikhoff</b>, None; <b>I.A. Bhutto</b>, None; <b>D. Scott McLeod</b>, None; <b>M. Reibaldi</b>, Abbvie (C), Bayer (C), Hofmann La Roche (C), Novartis (C), Zeiss (C); <b>M.M. Edwards</b>, None</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>2</Day><Hour>12</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>2</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>2</Day><Hour>9</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>12</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39620831</ArticleId><ArticleId IdType="doi">10.1167/iovs.65.14.2</ArticleId><ArticleId IdType="pii">2802301</ArticleId><ArticleId IdType="pmc">PMC11614027</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ferris FL, Wilkinson CP, Bird A, et al. .. Clinical classification of age-related macular degeneration. Ophthalmology. 2013; 120(4): 844&#x2013;851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11551519</ArticleId><ArticleId IdType="pubmed">23332590</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein R, Klein BEK, Linton KLP.. Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 2020; 127(4S): S122&#x2013;S132.</Citation><ArticleIdList><ArticleId IdType="pubmed">32200811</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolz-Marco R, Balaratnasingam C, Messinger JD, et al. .. The border of macular atrophy in age-related macular degeneration: a clinicopathologic correlation. Am J Ophthalmol. 2018; 193: 166&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">29981740</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleckenstein M, Keenan TDL, Guymer RH, et al. .. Age-related macular degeneration. Nat Rev Dis Primers. 2021; 7(1): 31.</Citation><ArticleIdList><ArticleId IdType="pubmed">33958600</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhutto I, Lutty G.. Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris complex. Mol Aspects Med. 2012; 33(4): 295&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392421</ArticleId><ArticleId IdType="pubmed">22542780</ArticleId></ArticleIdList></Reference><Reference><Citation>McLeod DS, Grebe R, Bhutto I, Merges C, Baba T, Lutty GA.. Relationship between RPE and choriocapillaris in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009; 50(10): 4982&#x2013;4991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4829357</ArticleId><ArticleId IdType="pubmed">19357355</ArticleId></ArticleIdList></Reference><Reference><Citation>Seddon JM, McLeod DS, Bhutto IA, et al. .. Histopathological insights into choroidal vascular loss in clinically documented cases of age-related macular degeneration. JAMA Ophthalmol. 2016; 134(11): 1272&#x2013;1280. Published online September 22, 2016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6014730</ArticleId><ArticleId IdType="pubmed">27657855</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards MM, McLeod DS, Shen M, et al. .. Clinicopathologic findings in three siblings with geographic atrophy. Invest Ophthalmol Vis Sci. 2023; 64(3): 2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9983703</ArticleId><ArticleId IdType="pubmed">36862121</ArticleId></ArticleIdList></Reference><Reference><Citation>Borrelli E, Sarraf D, Freund KB, Sadda SR.. OCT angiography and evaluation of the choroid and choroidal vascular disorders. Prog Retin Eye Res. 2018; 67: 30&#x2013;55. Published online 2018.</Citation><ArticleIdList><ArticleId IdType="pubmed">30059755</ArticleId></ArticleIdList></Reference><Reference><Citation>Borrelli E, Uji A, Sarraf D, Sadda SR.. Alterations in the choriocapillaris in intermediate age-related macular degeneration. Invest Ophthalmol Vis Sci. 2017;(11): 4792&#x2013;4798.</Citation><ArticleIdList><ArticleId IdType="pubmed">28973325</ArticleId></ArticleIdList></Reference><Reference><Citation>Borrelli E, Shi Y, Uji A, et al. .. Topographical analysis of the choriocapillaris in intermediate age-related macular degeneration. Am J Ophthalmol. 2018; 196: 34&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">30118688</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman E, Smith TR, Kuwabara T. Senile choroidal vascular patterns and drusen. Arch Ophthalmol. 1963; 69: 220&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">13959793</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarks SH, Arnold JJ, Killingsworth MC, Sarks JP.. Early drusen formation in the normal and aging eye and their relation to age related maculopathy: a clinicopathological study. Br J Ophthalmol. 1999; 83(3): 358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1722952</ArticleId><ArticleId IdType="pubmed">10365048</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullins RF, Johnson MN, Faidley EA, Skeie JM, Huang J.. Choriocapillaris vascular dropout related to density of drusen in human eyes with early age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011; 52(3): 1606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3101687</ArticleId><ArticleId IdType="pubmed">21398287</ArticleId></ArticleIdList></Reference><Reference><Citation>Nassisi M, Baghdasaryan E, Borrelli E, Ip M, Sadda SR.. Choriocapillaris flow impairment surrounding geographic atrophy correlates with disease progression. PLoS One. 2019; 14(2): e0212563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6386298</ArticleId><ArticleId IdType="pubmed">30794627</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Zhang Q, Zhou H, et al. .. Correlations between choriocapillaris and choroidal measurements and the growth of geographic atrophy using swept source OCT imaging. Am J Ophthalmol. 2021; 224: 321&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8058170</ArticleId><ArticleId IdType="pubmed">33359715</ArticleId></ArticleIdList></Reference><Reference><Citation>Thulliez M, Zhang Q, Shi Y, et al. .. Correlations between choriocapillaris flow deficits around geographic atrophy and enlargement rates based on swept-source OCT imaging. Ophthalmol Retina. 2019; 3(6): 478&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11402513</ArticleId><ArticleId IdType="pubmed">31174669</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrejen S, Spaide RF.. Optical coherence tomography: Imaging of the choroid and beyond. Surv Ophthalmol. 2013; 58(5): 387&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pubmed">23916620</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorell MR, Goldhardt R, Nunes RP, et al. .. Association between subfoveal choroidal thickness, reticular pseudodrusen, and geographic atrophy in age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina. 2015; 46(5): 513&#x2013;521.</Citation><ArticleIdList><ArticleId IdType="pubmed">26057754</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindner M, Bezatis A, Czauderna J, et al. .. Choroidal thickness in geographic atrophy secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci. 2015; 56(2): 875&#x2013;882.</Citation><ArticleIdList><ArticleId IdType="pubmed">25587059</ArticleId></ArticleIdList></Reference><Reference><Citation>Borrelli E, Barresi C, Berni A, et al. .. OCT risk factors for 2-year foveal involvement in non-treated eyes with extrafoveal geographic atrophy and AMD. Graefes Arch Clin Exp Ophthalmol. 2024; 262(7): 2101&#x2013;2109. Published online February 8, 2024, doi:10.1007/s00417-024-06399-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00417-024-06399-9</ArticleId><ArticleId IdType="pmc">PMC11222248</ArticleId><ArticleId IdType="pubmed">38326629</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Gangaputra S, Lee KE, et al. .. Signal quality assessment of retinal optical coherence tomography images. Invest Ophthalmol Vis Sci. 2012; 53(4): 2133&#x2013;2141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3995569</ArticleId><ArticleId IdType="pubmed">22427567</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadda SRSR, Guymer R, Holz FGFG, et al. .. Consensus definition for atrophy associated with age-related macular degeneration on OCT: Classification of Atrophy Report 3. Ophthalmology. 2018; 125(4): 537&#x2013;548. Published online 2018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11366072</ArticleId><ArticleId IdType="pubmed">29103793</ArticleId></ArticleIdList></Reference><Reference><Citation>McLeod DS, Grebe R, Bhutto I, Merges C, Baba T, Lutty GA.. Rela between RPE and choriocapillaris in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009; 50(10): 4982&#x2013;4991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4829357</ArticleId><ArticleId IdType="pubmed">19357355</ArticleId></ArticleIdList></Reference><Reference><Citation>Hariri AH, Nittala MG, Sadda SR.. Quantitative characteristics of spectral-domain optical coherence tomography in corresponding areas of increased autofluorescence at the margin of geographic atrophy in patients with age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina. 2016; 47(6): 523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">27327281</ArticleId></ArticleIdList></Reference><Reference><Citation>Hariri AH, Tepelus TC, Akil H, Nittala MG, Sadda SR.. Retinal sensitivity at the junctional zone of eyes with geographic atrophy due to age-related macular degeneration. Am J Ophthalmol. 2016; 168: 122&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">27189929</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu Z, Shi Y, Zhou X, et al. .. Optical coherence tomography measurements of the retinal pigment epithelium to Bruch membrane thickness around geographic atrophy correlate with growth. Am J Ophthalmol. 2022; 236: 249&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8957496</ArticleId><ArticleId IdType="pubmed">34780802</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Shi Y, Shen M, et al. .. Does the outer retinal thickness around geographic atrophy represent another clinical biomarker for predicting growth? Am J Ophthalmol. 2022; 244: 79&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">36002074</ArticleId></ArticleIdList></Reference><Reference><Citation>Coulibaly LM, Reiter GS, Fuchs P, et al. .. Progression dynamics of early versus later stage atrophic lesions in nonneovascular age-related macular degeneration using quantitative OCT biomarker segmentation. Ophthalmol Retina. 2023; 7(9): 762&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">37169078</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinks J, van Dijk EHC, Klaassen I, et al. .. Exploring the choroidal vascular labyrinth and its molecular and structural roles in health and disease. Prog Retin Eye Res. 2022; 87: 100994.</Citation><ArticleIdList><ArticleId IdType="pubmed">34280556</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhutto IA, Baba T, Merges C, McLeod DS, Lutty GA.. Low nitric oxide synthases (NOSs) in eyes with age-related macular degeneration (AMD). Exp Eye Res. 2010; 90(1): 155&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789190</ArticleId><ArticleId IdType="pubmed">19836390</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39620667</PMID><DateCompleted><Year>2024</Year><Month>12</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1998-3689</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>12</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Indian journal of ophthalmology</Title><ISOAbbreviation>Indian J Ophthalmol</ISOAbbreviation></Journal><ArticleTitle>Initial experience with brolucizumab for neovascular age-related macular degeneration (nAMD) in India - Multicentric, real-world study.</ArticleTitle><Pagination><StartPage>1786</StartPage><EndPage>1794</EndPage><MedlinePgn>1786-1794</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/IJO.IJO_757_24</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To evaluate the anatomic and visual outcomes and safety profile of initial Indian eyes with neovascular age-related macular degeneration (nAMD) treated with intravitreal injection (IVI) of brolucizumab.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective multicentric, real-world study enrolled consecutive eyes with nAMD that were treated with IVI brolucizumab after it was launched in India in October 2020. Data collected for each eye included best-corrected visual acuity (BCVA), central subfield thickness (CSFT), subretinal fluid (SRF), and intraretinal fluid (IRF) status at 6, 12, and 24 months follow-up. Also recorded were the lens status, treatment protocol, number of injections received before enrollment (in switch-over cases), total number of injections, and adverse effects noticed during the study period. Primary outcomes were change in BCVA, CSFT at follow-up visits, and incidence of intraocular inflammation (IOI). Secondary outcomes were profile of macular neovascularization, treatment protocols, mean number of injections, and maximum injection-free interval observed in eyes treated by pro-re-nata (PRN) protocol.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 331 eyes received a mean of 3.55 &#xb1; 1.83 injections. Most frequent treatment protocol was PRN (53%). BCVA data was available for 100%, 96%, and 74% eyes at 6, 12, and 24 months follow-up. BCVA and CSFT improved significantly (P &lt; 0.001) at all follow-ups. Two hundred and seventy-six (83.38%) out of 331 eyes received more than one injection; out of these, 241 (87.3%) eyes that were treated by PRN protocol could achieve mean "maximum injection-free interval" of 19.43 &#xb1; 8.82 weeks. IOI and retinal vasculitis were reported in 2.11% (7/331) and 0.60% (2/331) eyes, respectively. None of the eyes with IOI or vasculitis lost any vision at the final follow-up.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study demonstrated favorable visual and anatomic outcomes and safety profile for eyes with nAMD treated by IVI brolucizumab. Mean maximum injection-free interval in eyes treated with PRN was 19 weeks.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Indian Journal of Ophthalmology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Deependra Vikram</ForeName><Initials>DV</Initials><AffiliationInfo><Affiliation>Retina Department, Vitreo-retinal Services, Eye-Q Superspecialty Eye Hospitals Gurugram, Haryana, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Aniruddha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Retina Department, The Eye Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates (UAE).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Retina Department, The Eye Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates (UAE), Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Maastricht University Medical Center, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goyal</LastName><ForeName>Anubhav</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Retina Department, Giridhar Eye Institute, Ernakulum, Kerala, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shroff</LastName><ForeName>Daraius</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Retina Department, Shroff Eye Center, Kailash Colony, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Jatinder</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Retina Department, Vitreo-retinal Services, The Eye Foundation, Coimbatore, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Pradeep</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Army Hospital Research Referral, Delhi Cantt, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reddy</LastName><ForeName>Raja Rami</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Retina Department, Neo-Retina Eyecare Institute, Chapel Road Nampally Hyderabad, Telangana, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venkatesh</LastName><ForeName>Ramesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Retina Department, Narayana Nethralaya Eye Hospital, Bengaluru, Karnataka, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Narnaware</LastName><ForeName>Shilpi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Vitreoretina Department, Sarakshi Netralaya, Nagpur, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joshi</LastName><ForeName>Shrinivas</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Retina Department, M M Joshi Eye Hospital, Gokul Road, Sadashiv Nagar Hubli, Karnataka, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Deependra V</ForeName><Initials>DV</Initials><AffiliationInfo><Affiliation>Retina Department, Vitreo-retinal Services, Eye-Q Superspecialty Eye Hospitals Gurugram, Haryana, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Narula</LastName><ForeName>Ritesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Retina Department, Smt Kanuri Santhamma Centre for Vitreo Retinal Diseases, L V Prasad Eye Institute Banjara Hills, Hyderabad, Telangana, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joshi</LastName><ForeName>Aishwarya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Retina Department, Narayana Nethralaya Eye Hospital, Bengaluru, Karnataka, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Aniruddha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Retina Department, The Eye Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates (UAE).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Retina Department, The Eye Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates (UAE), Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Maastricht University Medical Center, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goyal</LastName><ForeName>Anubhav</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Retina Department, Giridhar Eye Institute, Ernakulum, Kerala, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Charu</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Retina Department, Shroff Eye Center, Kailash Colony, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shroff</LastName><ForeName>Daraius</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Retina Department, Shroff Eye Center, Kailash Colony, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anantharaman</LastName><ForeName>Giridhar</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Retina Department, Giridhar Eye Institute, Ernakulum, Kerala, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Jatinder</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Retina Department, Vitreo-retinal Services, The Eye Foundation, Coimbatore, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Pradeep</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Army Hospital Research Referral, Delhi Cantt, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bawankule</LastName><ForeName>Prashant</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Vitreoretina Department, Sarakshi Netralaya, Nagpur, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reddy</LastName><ForeName>Raja Rami</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Retina Department, Neo-Retina Eyecare Institute, Chapel Road Nampally Hyderabad, Telangana, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Rajiv</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Retina Department, Save Sight Centre, Adarsh Nagar, Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venkatesh</LastName><ForeName>Ramesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Retina Department, Narayana Nethralaya Eye Hospital, Bengaluru, Karnataka, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tiwari</LastName><ForeName>Ruchir</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Retina Department, Vitreo-retina Services, Tewari Eye Centre, Uttar Pradesh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugumar</LastName><ForeName>Shalini</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Retina Department, Neo-Retina Eyecare Institute, Chapel Road Nampally Hyderabad, Telangana, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Shashank Rai</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Retina Department, Delhi Eye Care 4/17, Balraj Khanna Marg East Patel Nagar, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Narnaware</LastName><ForeName>Shilpi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Vitreoretina Department, Sarakshi Netralaya, Nagpur, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joshi</LastName><ForeName>Shrinivas</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Retina Department, M M Joshi Eye Hospital, Gokul Road, Sadashiv Nagar Hubli, Karnataka, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choudhary</LastName><ForeName>Somendra P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Retina Department, Complete Eye Care Centre Manish Chamber, Mayur Vihar Phase-2, Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Delhi Retina Forum Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Indian J Ophthalmol</MedlineTA><NlmUniqueID>0405376</NlmUniqueID><ISSNLinking>0301-4738</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>XSZ53G39H5</RegistryNumber><NameOfSubstance UI="C000622091">brolucizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058449" MajorTopicYN="Y">Intravitreal Injections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020533" MajorTopicYN="Y">Angiogenesis Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014792" MajorTopicYN="Y">Visual Acuity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057135" MajorTopicYN="Y">Wet Macular Degeneration</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D041623" MajorTopicYN="Y">Tomography, Optical Coherence</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="Y">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005451" MajorTopicYN="N">Fluorescein Angiography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005654" MajorTopicYN="N">Fundus Oculi</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>2</Day><Hour>12</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>2</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>2</Day><Hour>8</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39620667</ArticleId><ArticleId IdType="doi">10.4103/IJO.IJO_757_24</ArticleId><ArticleId IdType="pii">02223307-202472120-00018</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med 2008;358:2606&#x2013;17.</Citation></Reference><Reference><Citation>Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, et al.CATT Research Group Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897&#x2013;908.</Citation></Reference><Reference><Citation>Li E, Donati S, Lindsley KB, Krzystolik MG, Virgili G. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2020;5:CD012208.</Citation></Reference><Reference><Citation>Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009;116:57&#x2013;65.e5.</Citation></Reference><Reference><Citation>Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K; SEVEN&#x2013;UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: A multicenter cohort study (SEVEN-UP). Ophthalmology 2013;120:2292&#x2013;9.</Citation></Reference><Reference><Citation>Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: Year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43&#x2013;58.e1.</Citation></Reference><Reference><Citation>Busbee BG, Ho AC, Brown DM, Heier JS, Su&#xf1;er IJ, Li Z, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2013;120:1046&#x2013;56.</Citation></Reference><Reference><Citation>Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: Ninety-six-week results of the VIEW studies. Ophthalmology 2014;121:193&#x2013;201.</Citation></Reference><Reference><Citation>Dugel PU, Singh RP, Koh A, Ogura Y, Weissgerber G, Gedif K, et al. HAWK and HARRIER: Ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 2021;128:89&#x2013;99.</Citation></Reference><Reference><Citation>Ogura Y, Jaffe GJ, Cheung CMG, Kokame GT, Iida T, Takahashi K, et al. Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK. Br J Ophthalmol 2022;106:994&#x2013;9.</Citation></Reference><Reference><Citation>Mones J, Srivastava SK, Jaffe GJ, Tadayoni R, Albini TA, Kaiser PK, et al. Risk of inflammation, retinal vasculitis and retinal occlusion-related events with brolucizumab: Post hoc review of HAWK and HARRIER. Ophthalmology 2021;128:1050&#x2013;9.</Citation></Reference><Reference><Citation>Chakraborty D, Maiti A, Sheth JU, Boral S, Mondal S, Nandi K, et al. Brolucizumab in neovascular age-related macular degeneration-Indian Real-World Experience: The BRAILLE Study. Clin Ophthalmol 2021;15:3787&#x2013;95.</Citation></Reference><Reference><Citation>Mishra SK, Kumar P, Khullar S, Joshi A, Sati A, Kumar SV, et al. Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: A randomized trial in Indian patients. Int J Retina Vitreous 2022;8:51.</Citation></Reference><Reference><Citation>Moussa G, Bassilious K, Mathews N. A novel excel sheet conversion tool from Snellen fraction to LogMAR including &#x2018;counting fingers&#x2019;, &#x2018;hand movement&#x2019;, &#x2018;light perception&#x2019; and &#x2018;no light perception&#x2019; and focused review of literature of low visual acuity reference values. Acta Ophthalmol 2021;99:e963&#x2013;5.</Citation></Reference><Reference><Citation>Bodaghi B, Souied EH, Tadayoni R, Weber M, Ponthieux A, Kodjikian L. Detection and management of intraocular inflammation after brolucizumab treatment for neovascular age-related macular degeneration. Ophthalmol Retina 2023;7:879&#x2013;91.</Citation></Reference><Reference><Citation>Haug SJ, Hien DL, Uludag G, Ngoc TTT, Lajevardi S, Halim MS, et al. Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration. Am J Ophthalmol Case Rep 2020;18:100680.</Citation></Reference><Reference><Citation>Jain A, Chea S, Matsumiya W, Halim MS, Yasar C, Kuang G, et al. Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal administrations. Am J Ophthalmol Case Rep 2020;18:100687.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39620144</PMID><DateRevised><Year>2024</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-634X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in cell and developmental biology</Title><ISOAbbreviation>Front Cell Dev Biol</ISOAbbreviation></Journal><ArticleTitle>Evaluation of mesenchymal stem cells as an <i>in vitro</i> model for inherited retinal diseases.</ArticleTitle><Pagination><StartPage>1455140</StartPage><MedlinePgn>1455140</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1455140</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fcell.2024.1455140</ELocationID><Abstract><AbstractText>Retinal pathologies are major causes of vision impairment and blindness in humans, and inherited retinal diseases (IRDs), such as retinitis pigmentosa, Leber congenital amaurosis, and Stargardt disease, greatly contribute to this problem. <i>In vitro</i> disease modeling can be used for understanding the development of pathology and for screening therapeutic pharmaceutical compounds. In the preclinical research phase, <i>in vitro</i> models complement <i>in vivo</i> models by reducing animal studies, decreasing costs, and shortening research timelines. Additionally, animal models may not always accurately replicate the human disease phenotype. This review examines the types of cells that can be used to create <i>in vitro</i> IRD models, including retina-specific cell lines, primary retinal cells, induced pluripotent stem cells (iPSCs), and more. Special attention is given to mesenchymal stem cells (MSCs), which are characterized by various isolation sources, relative ease of isolation, and straightforward differentiation. MSCs derived from bone marrow (BM), adipose tissue (AT), dental tissue (DT), umbilical cord (UC), and other sources can differentiate into retinal cells, including photoreceptor cells and retinal pigment epithelial (RPE) cells, dysfunction of which is most commonly associated with IRDs. Subsequent differentiation of MSCs into retinal cells can be carried out via various methods: culturing in induction media supplemented with certain growth factors, co-culturing with retinal cells or in their conditioned media, or regulating gene expression with viral vector-delivered transcription factors (TFs) or microRNAs (miRNAs). Compared to the popular iPSCs, for example, MSC-based models are significantly cheaper and faster to obtain, making them more feasible for large-scale drug screening. Nevertheless, the existing differentiation methods need further optimization for this promising platform to receive the success it deserves.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Dodina, Gurtsieva, Karabelsky and Minskaia.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Dodina</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sirius University of Science and Technology, Krasnodar, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Gurtsieva</LastName><ForeName>Dzerassa</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Sirius University of Science and Technology, Krasnodar, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karabelsky</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sirius University of Science and Technology, Krasnodar, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minskaia</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Sirius University of Science and Technology, Krasnodar, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Cell Dev Biol</MedlineTA><NlmUniqueID>101630250</NlmUniqueID><ISSNLinking>2296-634X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IRD</Keyword><Keyword MajorTopicYN="N">MSC</Keyword><Keyword MajorTopicYN="N">in vitro disease modeling</Keyword><Keyword MajorTopicYN="N">inherited retinal diseases</Keyword><Keyword MajorTopicYN="N">mesenchymal stem cells</Keyword><Keyword MajorTopicYN="N">retinal cells</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>2</Day><Hour>5</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39620144</ArticleId><ArticleId IdType="pmc">PMC11604642</ArticleId><ArticleId IdType="doi">10.3389/fcell.2024.1455140</ArticleId><ArticleId IdType="pii">1455140</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Achberger K., Haderspeck J. C., Kleger A., Liebau S. (2019). Stem cell-based retina models. Adv. Drug Deliv. Rev. 140, 33&#x2013;50. 10.1016/j.addr.2018.05.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2018.05.005</ArticleId><ArticleId IdType="pubmed">29777757</ArticleId></ArticleIdList></Reference><Reference><Citation>Adak S., Magdalene D., Deshmukh S., Das D., Jaganathan B. G. (2021). A review on mesenchymal stem cells for treatment of retinal diseases. Stem Cell Rev. Rep. 17 (4), 1154&#x2013;1173. 10.1007/s12015-020-10090-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12015-020-10090-x</ArticleId><ArticleId IdType="pmc">PMC7787584</ArticleId><ArticleId IdType="pubmed">33410097</ArticleId></ArticleIdList></Reference><Reference><Citation>Afanasyeva T. A. V., Corral-Serrano J. C., Garanto A., Roepman R., Cheetham M. E., Collin R. W. J. (2021). A look into retinal organoids: methods, analytical techniques, and applications. Cell. Mol. Life Sci. 78 (19-20), 6505&#x2013;6532. 10.1007/s00018-021-03917-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-021-03917-4</ArticleId><ArticleId IdType="pmc">PMC8558279</ArticleId><ArticleId IdType="pubmed">34420069</ArticleId></ArticleIdList></Reference><Reference><Citation>Afflerbach A. K., Kiri M. D., Detinis T., Maoz B. M. (2020). Mesenchymal stem cells as a promising cell source for integration in novel in vitro models. Biomolecules 10 (9), 1306. 10.3390/biom10091306</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10091306</ArticleId><ArticleId IdType="pmc">PMC7565384</ArticleId><ArticleId IdType="pubmed">32927777</ArticleId></ArticleIdList></Reference><Reference><Citation>Afshari A., Shamdani S., Uzan G., Naserian S., Azarpira N. (2020). Different approaches for transformation of mesenchymal stem cells into hepatocyte-like cells. Stem Cell Res. Ther. 11 (1), 54. 10.1186/s13287-020-1555-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-020-1555-8</ArticleId><ArticleId IdType="pmc">PMC7007672</ArticleId><ArticleId IdType="pubmed">32033595</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmado A., Carr A. J., Vugler A. A., Semo M., Gias C., Lawrence J. M., et al. (2011). Induction of differentiation by pyruvate and DMEM in the human retinal pigment epithelium cell line ARPE-19. Invest. Ophthalmol. Vis. Sci. 52 (10), 7148&#x2013;7159. 10.1167/iovs.10-6374</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.10-6374</ArticleId><ArticleId IdType="pubmed">21743014</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfonsetti M., Castelli V., d'Angelo M., Benedetti E., Allegretti M., Barboni B., et al. (2021). Looking for in vitro models for retinal diseases. Int. J. Mol. Sci. 22 (19), 10334. 10.3390/ijms221910334</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms221910334</ArticleId><ArticleId IdType="pmc">PMC8508697</ArticleId><ArticleId IdType="pubmed">34638674</ArticleId></ArticleIdList></Reference><Reference><Citation>Altshuler D., Lo Turco J. J., Rush J., Cepko C. (1993). Taurine promotes the differentiation of a vertebrate retinal cell type in vitro . Development 119 (4), 1317&#x2013;1328. 10.1242/dev.119.4.1317</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.119.4.1317</ArticleId><ArticleId IdType="pubmed">8306890</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrzejewska A., Lukomska B., Janowski M. (2019). Concise review: mesenchymal stem cells: from roots to boost. Stem Cells 37 (7), 855&#x2013;864. 10.1002/stem.3016</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.3016</ArticleId><ArticleId IdType="pmc">PMC6658105</ArticleId><ArticleId IdType="pubmed">30977255</ArticleId></ArticleIdList></Reference><Reference><Citation>Aydin S., &#x15e;ahin F. (2019). Stem cells derived from dental tissues. Adv. Exp. Med. Biol. 1144, 123&#x2013;132. 10.1007/5584_2018_333</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/5584_2018_333</ArticleId><ArticleId IdType="pubmed">30635857</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballios B. G., Clarke L., Coles B. L., Shoichet M. S., Van Der Kooy D. (2012). The adult retinal stem cell is a rare cell in the ciliary epithelium whose progeny can differentiate into photoreceptors. Biol. Open 1 (3), 237&#x2013;246. 10.1242/bio.2012027</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/bio.2012027</ArticleId><ArticleId IdType="pmc">PMC3507281</ArticleId><ArticleId IdType="pubmed">23213414</ArticleId></ArticleIdList></Reference><Reference><Citation>Balse E., Tessier L. H., Fuchs C., Forster V., Sahel J. A., Picaud S. (2005). Purification of mammalian cone photoreceptors by lectin panning and the enhancement of their survival in glia-conditioned medium. Invest. Ophthalmol. Vis. Sci. 46 (1), 367&#x2013;374. 10.1167/iovs.04-0695</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.04-0695</ArticleId><ArticleId IdType="pubmed">15623797</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhardwaj A., Yadav A., Yadav M., Tanwar M. (2022). Genetic dissection of non-syndromic retinitis pigmentosa. Indian J. Ophthalmol. 70 (7), 2355&#x2013;2385. 10.4103/ijo.IJO_46_22</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijo.IJO_46_22</ArticleId><ArticleId IdType="pmc">PMC9426071</ArticleId><ArticleId IdType="pubmed">35791117</ArticleId></ArticleIdList></Reference><Reference><Citation>Blenkinsop T. A., Saini J. S., Maminishkis A., Bharti K., Wan Q., Banzon T., et al. (2015). Human adult retinal pigment epithelial stem cell-derived RPE monolayers exhibit key physiological characteristics of native tissue. Invest. Ophthalmol. Vis. Sci. 56 (12), 7085&#x2013;7099. 10.1167/iovs.14-16246</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.14-16246</ArticleId><ArticleId IdType="pmc">PMC4640474</ArticleId><ArticleId IdType="pubmed">26540654</ArticleId></ArticleIdList></Reference><Reference><Citation>Blenkinsop T. A., Salero E., Stern J. H., Temple S. (2013). The culture and maintenance of functional retinal pigment epithelial monolayers from adult human eye. Methods Mol. Biol. 945, 45&#x2013;65. 10.1007/978-1-62703-125-7_4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-62703-125-7_4</ArticleId><ArticleId IdType="pubmed">23097100</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogenmann E., Lochrie M. A., Simon M. I. (1988). Cone cell-specific genes expressed in retinoblastoma. Science 240 (4848), 76&#x2013;78. 10.1126/science.2451289</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.2451289</ArticleId><ArticleId IdType="pubmed">2451289</ArticleId></ArticleIdList></Reference><Reference><Citation>Boti M. A., Athanasopoulou K., Adamopoulos P. G., Sideris D. C., Scorilas A. (2023). Recent advances in genome-engineering strategies. Genes 14 (1), 129. 10.3390/genes14010129</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes14010129</ArticleId><ArticleId IdType="pmc">PMC9859587</ArticleId><ArticleId IdType="pubmed">36672870</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodie C., Slavin S. (2013). Mesenchymal stem cells for in vitro modeling and cell-based therapy of human diseases and banks thereof. U.S. Patent No. WO 2013/124815 A2.</Citation></Reference><Reference><Citation>Bunnell B. A. (2021). Adipose tissue-derived mesenchymal stem cells. Cells 10 (12), 3433. 10.3390/cells10123433</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10123433</ArticleId><ArticleId IdType="pmc">PMC8700397</ArticleId><ArticleId IdType="pubmed">34943941</ArticleId></ArticleIdList></Reference><Reference><Citation>Canto-Soler V., Flores-Bellver M., Vergara M. N. (2016). Stem cell sources and their potential for the treatment of retinal degenerations. Invest. Ophthalmol. Vis. Sci. 57 (5), ORSFd1&#x2013;ORSFd9. 10.1167/iovs.16-19127</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.16-19127</ArticleId><ArticleId IdType="pmc">PMC6892419</ArticleId><ArticleId IdType="pubmed">27116661</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassidy L. L., Bejjani A., Choi M., Seigel G. M. (2012). Comparison of mature retinal marker expression in Y79 and WERI-RB27 human retinoblastoma cell lines. Oncyocytology 2, 1&#x2013;5. 10.5348/ocyj-2012-2-sr-1</Citation><ArticleIdList><ArticleId IdType="doi">10.5348/ocyj-2012-2-sr-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang Y. H., Kumar V. B., Wen Y. T., Huang C. Y., Tsai R. K., Ding D. C. (2022). Induction of human umbilical mesenchymal stem cell differentiation into retinal pigment epithelial cells using a transwell-based Co-culture system. Cell Transpl. 31, 9636897221085901. 10.1177/09636897221085901</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09636897221085901</ArticleId><ArticleId IdType="pmc">PMC8961389</ArticleId><ArticleId IdType="pubmed">35321565</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Jiang Y., Duan Y., Zhang X., Li X. (2022). Mesenchymal-stem-cell-based strategies for retinal diseases. Genes 13 (10), 1901. 10.3390/genes13101901</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes13101901</ArticleId><ArticleId IdType="pmc">PMC9602395</ArticleId><ArticleId IdType="pubmed">36292786</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng L., Kuehn M. H. (2023). Human retinal organoids in therapeutic discovery: a review of applications. Handb. Exp. Pharmacol. 281, 157&#x2013;187. 10.1007/164_2023_691</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/164_2023_691</ArticleId><ArticleId IdType="pubmed">37608005</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiou S. H., Kao C. L., Peng C. H., Chen S. J., Tarng Y. W., Ku H. H., et al. (2005). A novel in vitro retinal differentiation model by co-culturing adult human bone marrow stem cells with retinal pigmented epithelium cells. Biochem. Biophys. Res. Commun. 326 (3), 578&#x2013;585. 10.1016/j.bbrc.2004.11.061</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2004.11.061</ArticleId><ArticleId IdType="pubmed">15596138</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi M. J., Lee G. W., Kim J. S., Kim H. S., Kim D., Song J. E., et al. (2019). UV-irradiated RPE cells assist differentiation of bone marrow derived mesenchymal stem cells into RPE cells under a direct Co-culture environment. Macromol. Res. 27, 781&#x2013;788. 10.1007/s13233-019-7114-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13233-019-7114-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S. W., Kim J. J., Seo M. S., Park S. B., Kang T. W., Lee J. Y., et al. (2015). miR-410 inhibition induces RPE differentiation of amniotic epithelial stem cells via overexpression of OTX2 and RPE65. Stem Cell Rev. Rep. 11 (3), 376&#x2013;386. 10.1007/s12015-014-9568-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12015-014-9568-2</ArticleId><ArticleId IdType="pubmed">25351180</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S. W., Kim J. J., Seo M. S., Park S. B., Shin T. H., Shin J. H., et al. (2017). Inhibition by miR-410 facilitates direct retinal pigment epithelium differentiation of umbilical cord blood-derived mesenchymal stem cells. J. Vet. Sci. 18 (1), 59&#x2013;65. 10.4142/jvs.2017.18.1.59</Citation><ArticleIdList><ArticleId IdType="doi">10.4142/jvs.2017.18.1.59</ArticleId><ArticleId IdType="pmc">PMC5366303</ArticleId><ArticleId IdType="pubmed">27297412</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S. W., Shin J. H., Kim J. J., Shin T. H., Seo Y., Kim H. S., et al. (2016). Direct cell fate conversion of human somatic stem cells into cone and rod photoreceptor-like cells by inhibition of microRNA-203. Oncotarget 7 (27), 42139&#x2013;42149. 10.18632/oncotarget.9882</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.9882</ArticleId><ArticleId IdType="pmc">PMC5173122</ArticleId><ArticleId IdType="pubmed">27283900</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhury R., Bayatti N., Scharff R., Szula E., Tilakaratna V., Udsen M. S., et al. (2021). FHL-1 interacts with human RPE cells through the &#x3b1;5&#x3b2;1 integrin and confers protection against oxidative stress. Sci. Rep. 11 (1), 14175. 10.1038/s41598-021-93708-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-93708-5</ArticleId><ArticleId IdType="pmc">PMC8266909</ArticleId><ArticleId IdType="pubmed">34239032</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu D. T., Phuong T. N. T., Tien N. L. B., Tran D. K., Thanh V. V., Quang T. L., et al. (2020). An update on the progress of isolation, culture, storage, and clinical application of human bone marrow mesenchymal stem/stromal cells. Int. J. Mol. Sci. 21 (3), 708. 10.3390/ijms21030708</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21030708</ArticleId><ArticleId IdType="pmc">PMC7037097</ArticleId><ArticleId IdType="pubmed">31973182</ArticleId></ArticleIdList></Reference><Reference><Citation>Cipriano M., Freyer N., Kn&#xf6;spel F., Oliveira N. G., Barcia R., Cruz P. E., et al. (2017). Self-assembled 3D spheroids and hollow-fibre bioreactors improve MSC-derived hepatocyte-like cell maturation in vitro . Arch. Toxicol. 91 (4), 1815&#x2013;1832. 10.1007/s00204-016-1838-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00204-016-1838-0</ArticleId><ArticleId IdType="pubmed">27590069</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciuffreda M. C., Malpasso G., Musar&#xf2; P., Turco V., Gnecchi M. (2016). Protocols for in vitro differentiation of human mesenchymal stem cells into osteogenic, chondrogenic and adipogenic lineages. Methods Mol. Biol. 1416, 149&#x2013;158. 10.1007/978-1-4939-3584-0_8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-3584-0_8</ArticleId><ArticleId IdType="pubmed">27236670</ArticleId></ArticleIdList></Reference><Reference><Citation>
ClinicalTrials.gov (2024). ClinicalTrials.gov. Available at: https://clinicaltrials.gov/(Accessed June 24, 2024).</Citation></Reference><Reference><Citation>Coles B. L., Ang&#xe9;nieux B., Inoue T., Del Rio-Tsonis K., Spence J. R., McInnes R. R., et al. (2004). Facile isolation and the characterization of human retinal stem cells. Proc. Natl. Acad. Sci. U. S. A. 101 (44), 15772&#x2013;15777. 10.1073/pnas.0401596101</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0401596101</ArticleId><ArticleId IdType="pmc">PMC524825</ArticleId><ArticleId IdType="pubmed">15505221</ArticleId></ArticleIdList></Reference><Reference><Citation>Collin G. B., Gogna N., Chang B., Damkham N., Pinkney J., Hyde L. F., et al. (2020). Mouse models of inherited retinal degeneration with photoreceptor cell loss. Cells 9 (4), 931. 10.3390/cells9040931</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9040931</ArticleId><ArticleId IdType="pmc">PMC7227028</ArticleId><ArticleId IdType="pubmed">32290105</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalke C., Graw J. (2005). Mouse mutants as models for congenital retinal disorders. Exp. Eye. Res. 81 (5), 503&#x2013;512. 10.1016/j.exer.2005.06.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exer.2005.06.004</ArticleId><ArticleId IdType="pubmed">16026784</ArticleId></ArticleIdList></Reference><Reference><Citation>Damasceno P. K. F., de Santana T. A., Santos G. C., Orge I. D., Silva D. N., Albuquerque J. F., et al. (2020). Genetic engineering as a strategy to improve the therapeutic efficacy of mesenchymal stem/stromal cells in regenerative medicine. Front. Cell Dev. Biol. 8, 737. 10.3389/fcell.2020.00737</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2020.00737</ArticleId><ArticleId IdType="pmc">PMC7471932</ArticleId><ArticleId IdType="pubmed">32974331</ArticleId></ArticleIdList></Reference><Reference><Citation>da Rosa N. N., Appel J. M., Irioda A. C., Mogharbel B. F., de Oliveira N. B., Perussolo M. C., et al. (2023). Three-dimensional bioprinting of an in vitro lung model. Int. J. Mol. Sci. 24 (6), 5852. 10.3390/ijms24065852</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24065852</ArticleId><ArticleId IdType="pmc">PMC10059924</ArticleId><ArticleId IdType="pubmed">36982923</ArticleId></ArticleIdList></Reference><Reference><Citation>Das A. V., Bhattacharya S., Zhao X., Hegde G., Mallya K., Eudy J. D., et al. (2008). The canonical Wnt pathway regulates retinal stem cells/progenitors in concert with Notch signaling. Dev. Neurosci. 30 (6), 389&#x2013;409. 10.1159/000178017</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000178017</ArticleId><ArticleId IdType="pubmed">19033687</ArticleId></ArticleIdList></Reference><Reference><Citation>Das A. V., James J., Rahnenf&#xfc;hrer J., Thoreson W. B., Bhattacharya S., Zhao X., et al. (2005). Retinal properties and potential of the adult mammalian ciliary epithelium stem cells. Vis. Res. 45 (13), 1653&#x2013;1666. 10.1016/j.visres.2004.12.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.visres.2004.12.017</ArticleId><ArticleId IdType="pubmed">15792841</ArticleId></ArticleIdList></Reference><Reference><Citation>Das M., Sloan A. J. (2023). Stem cell sources from human biological waste material: a role for the umbilical cord and dental pulp stem cells for regenerative medicine. Hum. Cell 36 (4), 1312&#x2013;1325. 10.1007/s13577-023-00922-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13577-023-00922-6</ArticleId><ArticleId IdType="pubmed">37273175</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Debbio C. B., Peng X., Xiong H., Ahmad I. (2013). Adult ciliary epithelial stem cells generate functional neurons and differentiate into both early and late born retinal neurons under non-cell autonomous influences. BMC Neurosci. 14, 130. 10.1186/1471-2202-14-130</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2202-14-130</ArticleId><ArticleId IdType="pmc">PMC3856605</ArticleId><ArticleId IdType="pubmed">24148749</ArticleId></ArticleIdList></Reference><Reference><Citation>Del R&#xed;o P., Irmler M., Arango-Gonz&#xe1;lez B., Favor J., Bobe C., Bartsch U., et al. (2011). GDNF-induced osteopontin from M&#xfc;ller glial cells promotes photoreceptor survival in the Pde6brd1 mouse model of retinal degeneration. Glia 59 (5), 821&#x2013;832. 10.1002/glia.21155</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.21155</ArticleId><ArticleId IdType="pubmed">21360756</ArticleId></ArticleIdList></Reference><Reference><Citation>De Silva S. R., Arno G., Robson A. G., Fakin A., Pontikos N., Mohamed M. D., et al. (2021). The X-linked retinopathies: physiological insights, pathogenic mechanisms, phenotypic features and novel therapies. Prog. Retin. Eye Res. 82, 100898. 10.1016/j.preteyeres.2020.100898</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2020.100898</ArticleId><ArticleId IdType="pubmed">32860923</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding S. L. S., Koh A. E., Kumar S., Ali Khan M. S., Alzahrani B., Mok P. L. (2019). Genetically-modified human mesenchymal stem cells to express erythropoietin enhances differentiation into retinal photoreceptors: an in-vitro study. J. Photochem. Photobiol. B 195, 33&#x2013;38. 10.1016/j.jphotobiol.2019.04.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jphotobiol.2019.04.008</ArticleId><ArticleId IdType="pubmed">31060031</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Polo A., Farber D. B. (1995). Rod photoreceptor-specific gene expression in human retinoblastoma cells. Proc. Natl. Acad. Sci. U. S. A. 92 (9), 4016&#x2013;4020. 10.1073/pnas.92.9.4016</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.92.9.4016</ArticleId><ArticleId IdType="pmc">PMC42093</ArticleId><ArticleId IdType="pubmed">7732024</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8 (4), 315&#x2013;317. 10.1080/14653240600855905</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14653240600855905</ArticleId><ArticleId IdType="pubmed">16923606</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xf6;rschmann P., B&#xf6;ser S., Isik D., Arndt C., Roider J., Selhuber-Unkel C., et al. (2022). Influence of carrier materials and coatings on retinal pigment epithelium cultivation and functions. Exp. Eye Res. 219, 109063. 10.1016/j.exer.2022.109063</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exer.2022.109063</ArticleId><ArticleId IdType="pubmed">35385758</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan P., Xu H., Zeng Y., Wang Y., Yin Z. Q. (2013). Human bone marrow stromal cells can differentiate to a retinal pigment epithelial phenotype when co-cultured with pig retinal pigment epithelium using a transwell system. Cell. Physiol. biochem. 31 (4-5), 601&#x2013;613. 10.1159/000350080</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000350080</ArticleId><ArticleId IdType="pubmed">23635912</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn K. C., Aotaki-Keen A. E., Putkey F. R., Hjelmeland L. M. (1996). ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp. Eye. Res. 62 (2), 155&#x2013;169. 10.1006/exer.1996.0020</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exer.1996.0020</ArticleId><ArticleId IdType="pubmed">8698076</ArticleId></ArticleIdList></Reference><Reference><Citation>Eberle D., Schubert S., Postel K., Corbeil D., Ader M. (2011). Increased integration of transplanted CD73-positive photoreceptor precursors into adult mouse retina. Invest. Ophthalmol. Vis. Sci. 52 (9), 6462&#x2013;6471. 10.1167/iovs.11-7399</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.11-7399</ArticleId><ArticleId IdType="pubmed">21743009</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebrahim N., James V., Rizvanov A. A., Mukhamedshina Y. (2020). Genetic modification of mesenchymal stem cells for neurological disease therapy: what effects does it have on phenotype/cell behavior, determining their effectiveness? Mol. Diagn. Ther. 24 (6), 683&#x2013;702. 10.1007/s40291-020-00491-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40291-020-00491-6</ArticleId><ArticleId IdType="pubmed">32926348</ArticleId></ArticleIdList></Reference><Reference><Citation>Eldred K. C., Hadyniak S. E., Hussey K. A., Brenerman B., Zhang P. W., Chamling X., et al. (2018). Thyroid hormone signaling specifies cone subtypes in human retinal organoids. Science 362 (6411), eaau6348. 10.1126/science.aau6348</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aau6348</ArticleId><ArticleId IdType="pmc">PMC6249681</ArticleId><ArticleId IdType="pubmed">30309916</ArticleId></ArticleIdList></Reference><Reference><Citation>Euler T., Haverkamp S., Schubert T., Baden T. (2014). Retinal bipolar cells: elementary building blocks of vision. Nat. Rev. Neurosci. 15 (8), 507&#x2013;519. 10.1038/nrn3783</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3783</ArticleId><ArticleId IdType="pubmed">25158357</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Godino R., Garland D. L., Pierce E. A. (2016). Isolation, culture and characterization of primary mouse RPE cells. Nat. Protoc. 11 (7), 1206&#x2013;1218. 10.1038/nprot.2016.065</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2016.065</ArticleId><ArticleId IdType="pmc">PMC6432639</ArticleId><ArticleId IdType="pubmed">27281648</ArticleId></ArticleIdList></Reference><Reference><Citation>Fields M. A., Del Priore L. V., Adelman R. A., Rizzolo L. J. (2020). Interactions of the choroid, Bruch's membrane, retinal pigment epithelium, and neurosensory retina collaborate to form the outer blood-retinal-barrier. Prog. Retin. Eye Res. 76, 100803. 10.1016/j.preteyeres.2019.100803</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2019.100803</ArticleId><ArticleId IdType="pubmed">31704339</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontaine V., Kinkl N., Sahel J., Dreyfus H., Hicks D. (1998). Survival of purified rat photoreceptors in vitro is stimulated directly by fibroblast growth factor-2. J. Neurosci. 18 (23), 9662&#x2013;9672. 10.1523/JNEUROSCI.18-23-09662.1998</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.18-23-09662.1998</ArticleId><ArticleId IdType="pmc">PMC6793308</ArticleId><ArticleId IdType="pubmed">9822727</ArticleId></ArticleIdList></Reference><Reference><Citation>Forouzanfar F., Shojapour M., Aghili Z. S., Asgharzade S. (2020). Growth factors as tools in photoreceptor cell regeneration and vision recovery. Curr. Drug Targets 21 (6), 573&#x2013;581. 10.2174/1389450120666191121103831</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389450120666191121103831</ArticleId><ArticleId IdType="pubmed">31755378</ArticleId></ArticleIdList></Reference><Reference><Citation>Freitas G. P., Lopes H. B., Souza A. T. P., Gomes M. P. O., Quiles G. K., Gordon J., et al. (2021). Mesenchymal stem cells overexpressing BMP-9 by CRISPR-Cas9 present high in vitro osteogenic potential and enhance in vivo bone formation. Gene Ther. 28 (12), 748&#x2013;759. 10.1038/s41434-021-00248-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41434-021-00248-8</ArticleId><ArticleId IdType="pmc">PMC8423866</ArticleId><ArticleId IdType="pubmed">33686254</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedenstein A. J., Chailakhyan R. K., Gerasimov U. V. (1987). Bone marrow osteogenic stem cells: in vitro cultivation and transplantation in diffusion chambers. Cell Tissue Kinet. 20 (3), 263&#x2013;272. 10.1111/j.1365-2184.1987.tb01309.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2184.1987.tb01309.x</ArticleId><ArticleId IdType="pubmed">3690622</ArticleId></ArticleIdList></Reference><Reference><Citation>Fr&#xf8;en R., Johnsen E. O., Nicolaissen B., Facsk&#xf3; A., Petrovski G., Moe M. C. (2013). Does the adult human ciliary body epithelium contain &#x201c;true&#x201d; retinal stem cells?. Biomed. Res. Int. 2013, 531579. 10.1155/2013/531579</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/531579</ArticleId><ArticleId IdType="pmc">PMC3826557</ArticleId><ArticleId IdType="pubmed">24286080</ArticleId></ArticleIdList></Reference><Reference><Citation>Fronk A. H., Vargis E. (2016). Methods for culturing retinal pigment epithelial cells: a review of current protocols and future recommendations. J. Tissue Eng. 7, 2041731416650838. 10.1177/2041731416650838</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2041731416650838</ArticleId><ArticleId IdType="pmc">PMC4959307</ArticleId><ArticleId IdType="pubmed">27493715</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuhrmann S., Zou C., Levine E. M. (2014). Retinal pigment epithelium development, plasticity, and tissue homeostasis. Exp. Eye. Res. 123, 141&#x2013;150. 10.1016/j.exer.2013.09.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exer.2013.09.003</ArticleId><ArticleId IdType="pmc">PMC4087157</ArticleId><ArticleId IdType="pubmed">24060344</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao H., Luodan A., Huang X., Chen X., Xu H. (2021). M&#xfc;ller glia-mediated retinal regeneration. Mol. Neurobiol. 58 (5), 2342&#x2013;2361. 10.1007/s12035-020-02274-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-020-02274-w</ArticleId><ArticleId IdType="pubmed">33417229</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xe9;l&#xe9;oc G. G. S., El-Amraoui A. (2020). Disease mechanisms and gene therapy for Usher syndrome. Hear. Res. 394, 107932. 10.1016/j.heares.2020.107932</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heares.2020.107932</ArticleId><ArticleId IdType="pubmed">32199721</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannelli S. G., Demontis G. C., Pertile G., Rama P., Broccoli V. (2011). Adult human M&#xfc;ller glia cells are a highly efficient source of rod photoreceptors. Stem Cells 29 (2), 344&#x2013;356. 10.1002/stem.579</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.579</ArticleId><ArticleId IdType="pubmed">21732491</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez A. E., Christman A. K., Van De Weghe J. C., Finn M., Doherty D. (2022). Systematic analysis of cilia characteristics and Hedgehog signaling in five immortal cell lines. PloS One 17 (12), e0266433. 10.1371/journal.pone.0266433</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0266433</ArticleId><ArticleId IdType="pmc">PMC9799305</ArticleId><ArticleId IdType="pubmed">36580465</ArticleId></ArticleIdList></Reference><Reference><Citation>Gopalakrishna K. N., Boyd K., Yadav R. P., Artemyev N. O. (2016). Aryl hydrocarbon receptor-interacting protein-like 1 is an obligate chaperone of phosphodiesterase 6 and is assisted by the &#x3b3;-subunit of its client. J. Biol. Chem. 291 (31), 16282&#x2013;16291. 10.1074/jbc.M116.737593</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M116.737593</ArticleId><ArticleId IdType="pmc">PMC4965576</ArticleId><ArticleId IdType="pubmed">27268253</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L., Zhao R. C., Wu Y. (2011). The role of microRNAs in self-renewal and differentiation of mesenchymal stem cells. Exp. Hematol. 39 (6), 608&#x2013;616. 10.1016/j.exphem.2011.01.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exphem.2011.01.011</ArticleId><ArticleId IdType="pubmed">21288479</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanany M., Rivolta C., Sharon D. (2020). Worldwide carrier frequency and genetic prevalence of autosomal recessive inherited retinal diseases. Proc. Natl. Acad. Sci. U. S. A. 117 (5), 2710&#x2013;2716. 10.1073/pnas.1913179117</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1913179117</ArticleId><ArticleId IdType="pmc">PMC7007541</ArticleId><ArticleId IdType="pubmed">31964843</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanany M., Sharon D. (2019). Allele frequency analysis of variants reported to cause autosomal dominant inherited retinal diseases question the involvement of 19% of genes and 10% of reported pathogenic variants. J. Med. Genet. 56 (8), 536&#x2013;542. 10.1136/jmedgenet-2018-105971</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmedgenet-2018-105971</ArticleId><ArticleId IdType="pubmed">30910914</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen S., McClements M. E., Corydon T. J., MacLaren R. E. (2023). Future perspectives of prime editing for the treatment of inherited retinal diseases. Cells 12 (3), 440. 10.3390/cells12030440</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells12030440</ArticleId><ArticleId IdType="pmc">PMC9913839</ArticleId><ArticleId IdType="pubmed">36766782</ArticleId></ArticleIdList></Reference><Reference><Citation>Hass R., Kasper C., B&#xf6;hm S., Jacobs R. (2011). Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun. Signal. 9, 12. 10.1186/1478-811X-9-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1478-811X-9-12</ArticleId><ArticleId IdType="pmc">PMC3117820</ArticleId><ArticleId IdType="pubmed">21569606</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauck S. M., Gloeckner C. J., Harley M. E., Schoeffmann S., Boldt K., Ekstrom P. A., et al. (2008). Identification of paracrine neuroprotective candidate proteins by a functional assay-driven proteomics approach. Mol. Cell Proteomics 7 (7), 1349&#x2013;1361. 10.1074/mcp.M700456-MCP200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.M700456-MCP200</ArticleId><ArticleId IdType="pubmed">18436526</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazim R. A., Volland S., Yen A., Burgess B. L., Williams D. S. (2019). Rapid differentiation of the human RPE cell line, ARPE-19, induced by nicotinamide. Exp. Eye. Res. 179, 18&#x2013;24. 10.1016/j.exer.2018.10.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exer.2018.10.009</ArticleId><ArticleId IdType="pmc">PMC6360117</ArticleId><ArticleId IdType="pubmed">30336127</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazrati A., Malekpour K., Soudi S., Hashemi S. M. (2022). CRISPR/Cas9-engineered mesenchymal stromal/stem cells and their extracellular vesicles: a new approach to overcoming cell therapy limitations. Biomed. Pharmacother. 156, 113943. 10.1016/j.biopha.2022.113943</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2022.113943</ArticleId><ArticleId IdType="pubmed">36411629</ArticleId></ArticleIdList></Reference><Reference><Citation>Heesterbeek T. J., Lor&#xe9;s-Motta L., Hoyng C. B., Lechanteur Y. T. E., den Hollander A. I. (2020). Risk factors for progression of age-related macular degeneration. Ophthalmic Physiol. Opt. 40 (2), 140&#x2013;170. 10.1111/opo.12675</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/opo.12675</ArticleId><ArticleId IdType="pmc">PMC7155063</ArticleId><ArticleId IdType="pubmed">32100327</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellinen L., Hagstr&#xf6;m M., Knuutila H., Ruponen M., Urtti A., Reinisalo M. (2019). Characterization of artificially re-pigmented ARPE-19 retinal pigment epithelial cell model. Sci. Rep. 9 (1), 13761. 10.1038/s41598-019-50324-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-50324-8</ArticleId><ArticleId IdType="pmc">PMC6760193</ArticleId><ArticleId IdType="pubmed">31551473</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez R., Jim&#xe9;nez-Luna C., Perales-Ad&#xe1;n J., Perazzoli G., Melguizo C., Prados J. (2020). Differentiation of human mesenchymal stem cells towards neuronal lineage: clinical trials in nervous system disorders. Biomol. Ther. 28 (1), 34&#x2013;44. 10.4062/biomolther.2019.065</Citation><ArticleIdList><ArticleId IdType="doi">10.4062/biomolther.2019.065</ArticleId><ArticleId IdType="pmc">PMC6939692</ArticleId><ArticleId IdType="pubmed">31649208</ArticleId></ArticleIdList></Reference><Reference><Citation>Hidalgo-de-Quintana J., Schwarz N., Meschede I. P., Stern-Schneider G., Powner M. B., Morrison E. E., et al. (2015). The Leber congenital amaurosis protein AIPL1 and EB proteins co-localize at the photoreceptor cilium. PloS One 10 (3), e0121440. 10.1371/journal.pone.0121440</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0121440</ArticleId><ArticleId IdType="pmc">PMC4370678</ArticleId><ArticleId IdType="pubmed">25799540</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong Y., Liang Y. P., Chen W. Q., You L. X., Ni Q. F., Gao X. Y., et al. (2021). Protective effects of upregulated HO-1 gene against the apoptosis of human retinal pigment epithelial cells in vitro . Int. J. Ophthalmol. 14 (5), 649&#x2013;655. 10.18240/ijo.2021.05.03</Citation><ArticleIdList><ArticleId IdType="doi">10.18240/ijo.2021.05.03</ArticleId><ArticleId IdType="pmc">PMC8077008</ArticleId><ArticleId IdType="pubmed">34012878</ArticleId></ArticleIdList></Reference><Reference><Citation>Hood E. M. S., Curcio C. A., Lipinski D. (2022). Isolation, culture, and cryosectioning of primary porcine retinal pigment epithelium on transwell cell culture inserts. Star. Protoc. 3 (4), 101758. 10.1016/j.xpro.2022.101758</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xpro.2022.101758</ArticleId><ArticleId IdType="pmc">PMC9576630</ArticleId><ArticleId IdType="pubmed">36227744</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C. H., Yang C. M., Yang C. H., Hou Y. C., Chen T. C. (2021). Leber's congenital amaurosis: current concepts of genotype-phenotype correlations. Genes 12 (8), 1261. 10.3390/genes12081261</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes12081261</ArticleId><ArticleId IdType="pmc">PMC8392113</ArticleId><ArticleId IdType="pubmed">34440435</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang D., Heath Jeffery R. C., Aung-Htut M. T., McLenachan S., Fletcher S., Wilton S. D., et al. (2022). Stargardt disease and progress in therapeutic strategies. Ophthalmic Genet. 43 (1), 1&#x2013;26. 10.1080/13816810.2021.1966053</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13816810.2021.1966053</ArticleId><ArticleId IdType="pubmed">34455905</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L., Liang J., Geng Y., Tsang W. M., Yao X., Jhanji V., et al. (2013). Directing adult human periodontal ligament-derived stem cells to retinal fate. Invest. Ophthalmol. Vis. Sci. 54 (6), 3965&#x2013;3974. 10.1167/iovs.13-11910</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.13-11910</ArticleId><ArticleId IdType="pubmed">23661377</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., Ng T. K., Chen C. B., Huang B., Liang J., Pang C. P., et al. (2018). Notch signaling activation enhances human adipose-derived stem cell retinal differentiation. Stem Cells Int. 2018, 9201374. 10.1155/2018/9201374</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/9201374</ArticleId><ArticleId IdType="pmc">PMC6206515</ArticleId><ArticleId IdType="pubmed">30410544</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L L., Kutluer M., Adani E., Comitato A., Marigo V. (2021). New in vitro cellular model for molecular studies of retinitis pigmentosa. Int. J. Mol. Sci. 22 (12), 6440. 10.3390/ijms22126440</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22126440</ArticleId><ArticleId IdType="pmc">PMC8235468</ArticleId><ArticleId IdType="pubmed">34208617</ArticleId></ArticleIdList></Reference><Reference><Citation>Idelson M., Alper R., Obolensky A., Ben-Shushan E., Hemo I., Yachimovich-Cohen N., et al. (2009). Directed differentiation of human embryonic stem cells into functional retinal pigment epithelium cells. Cell Stem Cell 5 (4), 396&#x2013;408. 10.1016/j.stem.2009.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2009.07.002</ArticleId><ArticleId IdType="pubmed">19796620</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishida K., Panjwani N., Cao Z., Streilein J. W. (2003). Participation of pigment epithelium in ocular immune privilege. 3. Epithelia cultured from iris, ciliary body, and retina suppress T-cell activation by partially non-overlapping mechanisms. Ocul. Immunol. Inflamm. 11 (2), 91&#x2013;105. 10.1076/ocii.11.2.91.15914</Citation><ArticleIdList><ArticleId IdType="doi">10.1076/ocii.11.2.91.15914</ArticleId><ArticleId IdType="pubmed">14533028</ArticleId></ArticleIdList></Reference><Reference><Citation>Istrate M., Vlaicu B., Poenaru M., Hasbei-Popa M., Salavat M. C., Iliescu D. A. (2020). Photoprotection role of melanin in the human retinal pigment epithelium. Imaging techniques for retinal melanin. Rom. J. Ophthalmol. 64 (2), 100&#x2013;104. 10.22336/rjo.2020.20</Citation><ArticleIdList><ArticleId IdType="doi">10.22336/rjo.2020.20</ArticleId><ArticleId IdType="pmc">PMC7339703</ArticleId><ArticleId IdType="pubmed">32685774</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadhav A. P., Mason H. A., Cepko C. L. (2006). Notch 1 inhibits photoreceptor production in the developing mammalian retina. Development 133 (5), 913&#x2013;923. 10.1242/dev.02245</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.02245</ArticleId><ArticleId IdType="pubmed">16452096</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen C., Teng Y. (2020). Is it time to start transitioning from 2D to 3D cell culture? Front. Mol. Biosci. 7, 33. 10.3389/fmolb.2020.00033</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2020.00033</ArticleId><ArticleId IdType="pmc">PMC7067892</ArticleId><ArticleId IdType="pubmed">32211418</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon S., Oh I. H. (2015). Regeneration of the retina: toward stem cell therapy for degenerative retinal diseases. BMB Rep. 48 (4), 193&#x2013;199. 10.5483/bmbrep.2015.48.4.276</Citation><ArticleIdList><ArticleId IdType="doi">10.5483/bmbrep.2015.48.4.276</ArticleId><ArticleId IdType="pmc">PMC4436854</ArticleId><ArticleId IdType="pubmed">25560700</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang X. R., Jimenez G., Chang E., Frolkis M., Kusler B., Sage M., et al. (1999). Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype. Nat. Genet. 21 (1), 111&#x2013;114. 10.1038/5056</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/5056</ArticleId><ArticleId IdType="pubmed">9916802</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H., Xiong S., Xia X. (2014). Retinitis pigmentosa-associated rhodopsin mutant T17M induces endoplasmic reticulum (ER) stress and sensitizes cells to ER stress-induced cell death. Mol. Med. Rep. 9 (5), 1737&#x2013;1742. 10.3892/mmr.2014.1987</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2014.1987</ArticleId><ArticleId IdType="pubmed">24573320</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin H. J., Bae Y. K., Kim M., Kwon S. J., Jeon H. B., Choi S. J., et al. (2013). Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy. Int. J. Mol. Sci. 14 (9), 17986&#x2013;18001. 10.3390/ijms140917986</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms140917986</ArticleId><ArticleId IdType="pmc">PMC3794764</ArticleId><ArticleId IdType="pubmed">24005862</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson T. B., Cain J. T., White K. A., Ramirez-Montealegre D., Pearce D. A., Weimer J. M. (2019). Therapeutic landscape for Batten disease: current treatments and future prospects. Nat. Rev. Neurol. 15 (3), 161&#x2013;178. 10.1038/s41582-019-0138-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-019-0138-8</ArticleId><ArticleId IdType="pmc">PMC6681450</ArticleId><ArticleId IdType="pubmed">30783219</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadkhodaeian A. H., Salati A., Lashay A. (2019a). High efficient differentiation of human adipose-derived stem cells into retinal pigment epithelium-like cells in medium containing small molecules inducers with a simple method. Tissue Cell 56, 52&#x2013;59. 10.1016/j.tice.2018.12.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tice.2018.12.003</ArticleId><ArticleId IdType="pubmed">30736904</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadkhodaeian A. H., Tiraihi T., Ahmadieh H., Ziaei H., Daftarian N., Taheri T. (2019b). Generation of retinal pigmented epithelium-like cells from pigmented spheres differentiated from bone marrow stromal cell-derived neurospheres. Tissue Eng. Regen. Med. 16 (3), 253&#x2013;263. 10.1007/s13770-019-00183-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13770-019-00183-1</ArticleId><ArticleId IdType="pmc">PMC6542896</ArticleId><ArticleId IdType="pubmed">31205854</ArticleId></ArticleIdList></Reference><Reference><Citation>Kay P., Yang Y. C., Paraoan L. (2013). Directional protein secretion by the retinal pigment epithelium: roles in retinal health and the development of age-related macular degeneration. J. Cell Mol. Med. 17 (7), 833&#x2013;843. 10.1111/jcmm.12070</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.12070</ArticleId><ArticleId IdType="pmc">PMC3822888</ArticleId><ArticleId IdType="pubmed">23663427</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley M. W., Turner J. K., Reh T. A. (1994). Retinoic acid promotes differentiation of photoreceptors in vitro . Development 120 (8), 2091&#x2013;2102. 10.1242/dev.120.8.2091</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.120.8.2091</ArticleId><ArticleId IdType="pubmed">7925013</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly J., Maumenee I. H. (1999). Hereditary macular diseases. Int. Ophthalmol. Clin. 39 (4), 83&#x2013;115. 10.1097/00004397-199903940-00008</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00004397-199903940-00008</ArticleId><ArticleId IdType="pubmed">10709584</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalili S., Ballios B. G., Belair-Hickey J., Donaldson L., Liu J., Coles B. L. K., et al. (2018). Induction of rod versus cone photoreceptor-specific progenitors from retinal precursor cells. Stem Cell Res. 33, 215&#x2013;227. 10.1016/j.scr.2018.11.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scr.2018.11.005</ArticleId><ArticleId IdType="pubmed">30453152</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanna H., Akimoto M., Siffroi-Fernandez S., Friedman J. S., Hicks D., Swaroop A. (2006). Retinoic acid regulates the expression of photoreceptor transcription factor NRL. J. Biol. Chem. 281 (37), 27327&#x2013;27334. 10.1074/jbc.M605500200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M605500200</ArticleId><ArticleId IdType="pmc">PMC1592579</ArticleId><ArticleId IdType="pubmed">16854989</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H. J., Park J. M., Lee S., Cho H. B., Park J. I., Kim J. H., et al. (2022). Efficient CRISPR-Cas9-based knockdown of RUNX2 to induce chondrogenic differentiation of stem cells. Biomater. Sci. 10 (2), 514&#x2013;523. 10.1039/d1bm01716k</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/d1bm01716k</ArticleId><ArticleId IdType="pubmed">34904600</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K., Doi A., Wen B., Ng K., Zhao R., Cahan P., et al. (2010). Epigenetic memory in induced pluripotent stem cells. Nature 467 (7313), 285&#x2013;290. 10.1038/nature09342</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09342</ArticleId><ArticleId IdType="pmc">PMC3150836</ArticleId><ArticleId IdType="pubmed">20644535</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura E., Gribanova Y. E., Farber D. B. (2011). Regulation of retinoschisin secretion in Weri-Rb1 cells by the F-actin and microtubule cytoskeleton. PloS One 6 (6), e20707. 10.1371/journal.pone.0020707</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0020707</ArticleId><ArticleId IdType="pmc">PMC3124475</ArticleId><ArticleId IdType="pubmed">21738583</ArticleId></ArticleIdList></Reference><Reference><Citation>Klettner A. K. (2020). &#x201c;Retinal pigment epithelium cell culture,&#x201d; in Retinal pigment epithelium in health and disease. Editors Klettner, A., Dithmar S. (Cham: Springer; ), 295&#x2013;305. 10.1007/978-3-030-28384-1_17</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-030-28384-1_17</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolb H., Nelson R., Ahnelt P., Cuenca N. (2001). Cellular organization of the vertebrate retina. Prog. Brain Res. 131, 3&#x2013;26. 10.1016/s0079-6123(01)31005-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0079-6123(01)31005-1</ArticleId><ArticleId IdType="pubmed">11420950</ArticleId></ArticleIdList></Reference><Reference><Citation>Komuta Y., Ishii T., Kaneda M., Ueda Y., Miyamoto K., Toyoda M., et al. (2016). In vitro transdifferentiation of human peripheral blood mononuclear cells to photoreceptor-like cells. Biol. Open 5 (6), 709&#x2013;719. 10.1242/bio.016477</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/bio.016477</ArticleId><ArticleId IdType="pmc">PMC4920181</ArticleId><ArticleId IdType="pubmed">27170256</ArticleId></ArticleIdList></Reference><Reference><Citation>Koso H., Minami C., Tabata Y., Inoue M., Sasaki E., Satoh S., et al. (2009). CD73, a novel cell surface antigen that characterizes retinal photoreceptor precursor cells. Invest. Ophthalmol. Vis. Sci. 50 (11), 5411&#x2013;5418. 10.1167/iovs.08-3246</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.08-3246</ArticleId><ArticleId IdType="pubmed">19515998</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozlowski M. R. (2015). The ARPE-19 cell line: mortality status and utility in macular degeneration research. Curr. Eye Res. 40 (5), 501&#x2013;509. 10.3109/02713683.2014.935440</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/02713683.2014.935440</ArticleId><ArticleId IdType="pubmed">24977298</ArticleId></ArticleIdList></Reference><Reference><Citation>Kravchenko S. V., Sakhnov S. N., Myasnikova V. V., Trofimenko A. I., Buzko V. Y. (2023). Bioprinting technologies in ophthalmology. Tekhnologii biopechati V. Oftal'mologii. Vestn. Oftalmol. 139 (5), 105&#x2013;112. 10.17116/oftalma2023139051105</Citation><ArticleIdList><ArticleId IdType="doi">10.17116/oftalma2023139051105</ArticleId><ArticleId IdType="pubmed">37942604</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku C. A., Wei L. W., Sieving P. A. (2023). X-linked retinoschisis. Cold Spring Harb. Perspect. Med. 13 (9), a041288. 10.1101/cshperspect.a041288</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a041288</ArticleId><ArticleId IdType="pmc">PMC10513161</ArticleId><ArticleId IdType="pubmed">36690462</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuriyan A. E., Albini T. A., Townsend J. H., Rodriguez M., Pandya H. K., Leonard R. E., et al. (2017). Vision loss after intravitreal injection of autologous &#x201c;stem cells&#x201d; for AMD. N. Engl. J. Med. 376 (11), 1047&#x2013;1053. 10.1056/NEJMoa1609583</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1609583</ArticleId><ArticleId IdType="pmc">PMC5551890</ArticleId><ArticleId IdType="pubmed">28296617</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurth I., Thompson D. A., R&#xfc;ther K., Feathers K. L., Chrispell J. D., Schroth J., et al. (2007). Targeted disruption of the murine retinal dehydrogenase gene Rdh12 does not limit visual cycle function. Mol. Cell Biol. 27 (4), 1370&#x2013;1379. 10.1128/MCB.01486-06</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.01486-06</ArticleId><ArticleId IdType="pmc">PMC1800705</ArticleId><ArticleId IdType="pubmed">17130236</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurzawa-Akanbi M., Tzoumas N., Corral-Serrano J. C., Guarascio R., Steel D. H., Cheetham M. E., et al. (2024). Pluripotent stem cell-derived models of retinal disease: elucidating pathogenesis, evaluating novel treatments, and estimating toxicity. Prog. Retin. Eye Res. 100, 101248. 10.1016/j.preteyeres.2024.101248</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2024.101248</ArticleId><ArticleId IdType="pubmed">38369182</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuse Y., Tsuruma K., Kanno Y., Shimazawa M., Hara H. (2017). CCR3 is associated with the death of a photoreceptor cell-line induced by light exposure. Front. Pharmacol. 8, 207. 10.3389/fphar.2017.00207</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2017.00207</ArticleId><ArticleId IdType="pmc">PMC5394117</ArticleId><ArticleId IdType="pubmed">28458639</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyritsis A. P., Tsokos M., Triche T. J., Chader G. J. (1986). Retinoblastoma: a primitive tumor with multipotential characteristics. Invest. Ophthalmol. Vis. Sci. 27 (12), 1760&#x2013;1764.</Citation><ArticleIdList><ArticleId IdType="pubmed">2432031</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakowski J., Welby E., Budinger D., Di Marco F., Di Foggia V., Bainbridge J. W. B., et al. (2018). Isolation of human photoreceptor precursors via a cell surface marker panel from stem cell-derived retinal organoids and fetal retinae. Stem cells 36 (5), 709&#x2013;722. 10.1002/stem.2775</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.2775</ArticleId><ArticleId IdType="pmc">PMC5947711</ArticleId><ArticleId IdType="pubmed">29327488</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb T. D. (2022). Photoreceptor physiology and evolution: cellular and molecular basis of rod and cone phototransduction. J. Physiol. 600 (21), 4585&#x2013;4601. 10.1113/JP282058</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/JP282058</ArticleId><ArticleId IdType="pmc">PMC9790638</ArticleId><ArticleId IdType="pubmed">35412676</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan L., Vitobello A., Bertacchi M., Cremisi F., Vignali R., Andreazzoli M., et al. (2009). Noggin elicits retinal fate in Xenopus animal cap embryonic stem cells. Stem Cells 27 (9), 2146&#x2013;2152. 10.1002/stem.167</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.167</ArticleId><ArticleId IdType="pubmed">19591225</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine E. M., Roelink H., Turner J., Reh T. A. (1997). Sonic hedgehog promotes rod photoreceptor differentiation in mammalian retinal cells in vitro . J. Neurosci. 17 (16), 6277&#x2013;6288. 10.1523/JNEUROSCI.17-16-06277.1997</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.17-16-06277.1997</ArticleId><ArticleId IdType="pmc">PMC6568363</ArticleId><ArticleId IdType="pubmed">9236238</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Wu Z., Zhao L., Liu Y., Su Y., Gong X., et al. (2023). The heterogeneity of mesenchymal stem cells: an important issue to be addressed in cell therapy. Stem Cell Res. Ther. 14 (1), 381. 10.1186/s13287-023-03587-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-023-03587-y</ArticleId><ArticleId IdType="pmc">PMC10734083</ArticleId><ArticleId IdType="pubmed">38124129</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Xie J., Zhai Y., Fang T., Rao N., Hu S., et al. (2019). Differentiation of stem cells from human exfoliated deciduous teeth into retinal photoreceptor-like cells and their sustainability in vivo . Stem Cells Int. 2019, 2562981. 10.1155/2019/2562981</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/2562981</ArticleId><ArticleId IdType="pmc">PMC6393909</ArticleId><ArticleId IdType="pubmed">30906327</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Zhang L., Tang F., Wei X. (2021). Retinal organoids: cultivation, differentiation, and transplantation. Front. Cell. Neurosci. 15, 638439. 10.3389/fncel.2021.638439</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2021.638439</ArticleId><ArticleId IdType="pmc">PMC8282056</ArticleId><ArticleId IdType="pubmed">34276307</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Y., Sun X., Duan C., Tang S., Chen J. (2023). Application of patient-derived induced pluripotent stem cells and organoids in inherited retinal diseases. Stem Cell Res. Ther. 14 (1), 340. 10.1186/s13287-023-03564-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-023-03564-5</ArticleId><ArticleId IdType="pmc">PMC10683306</ArticleId><ArticleId IdType="pubmed">38012786</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y., Zhang H., He D., Wang Y., Cai B., Chen J., et al. (2019). Retinal pigment epithelium cell death is associated with NLRP3 inflammasome activation by all-trans retinal. Invest. Ophthalmol. Vis. Sci. 60 (8), 3034&#x2013;3045. 10.1167/iovs.18-26360</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.18-26360</ArticleId><ArticleId IdType="pubmed">31311035</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling Q., Liang J. J., Chen S., Chen C. B., Ng T. K., Huang Y. (2023). Continuous non-adherent culture promotes transdifferentiation of human adipose-derived stem cells into retinal lineage. Open Life Sci. 18 (1), 20220760. 10.1515/biol-2022-0760</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/biol-2022-0760</ArticleId><ArticleId IdType="pmc">PMC10668113</ArticleId><ArticleId IdType="pubmed">38027227</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q., Zhang Q., Pierce E. A. (2010). Photoreceptor sensory cilia and inherited retinal degeneration. Adv. Exp. Med. Biol. 664, 223&#x2013;232. 10.1007/978-1-4419-1399-9_26</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4419-1399-9_26</ArticleId><ArticleId IdType="pmc">PMC2888132</ArticleId><ArticleId IdType="pubmed">20238021</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu W., Duan D., Ackbarkhan Z., Lu M., Huang M. L. (2017). Differentiation of human olfactory mucosa mesenchymal stem cells into photoreceptor cells in vitro . Int. J. Ophthalmol. 10 (10), 1504&#x2013;1509. 10.18240/ijo.2017.10.04</Citation><ArticleIdList><ArticleId IdType="doi">10.18240/ijo.2017.10.04</ArticleId><ArticleId IdType="pmc">PMC5638969</ArticleId><ArticleId IdType="pubmed">29062767</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y., Zhuo Y., Fukuhara M., Rizzolo L. J. (2006). Effects of culture conditions on heterogeneity and the apical junctional complex of the ARPE-19 cell line. Invest. Ophthalmol. Vis. Sci. 47 (8), 3644&#x2013;3655. 10.1167/iovs.06-0166</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.06-0166</ArticleId><ArticleId IdType="pubmed">16877439</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda A., Maeda T., Sun W., Zhang H., Baehr W., Palczewski K. (2007). Redundant and unique roles of retinol dehydrogenases in the mouse retina. Proc. Natl. Acad. Sci. U. S. A. 104 (49), 19565&#x2013;19570. 10.1073/pnas.0707477104</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0707477104</ArticleId><ArticleId IdType="pmc">PMC2148329</ArticleId><ArticleId IdType="pubmed">18048336</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahato B., Kaya K. D., Fan Y., Sumien N., Shetty R. A., Zhang W., et al. (2020). Pharmacologic fibroblast reprogramming into photoreceptors restores vision. Nature 581 (7806), 83&#x2013;88. 10.1038/s41586-020-2201-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2201-4</ArticleId><ArticleId IdType="pmc">PMC7469946</ArticleId><ArticleId IdType="pubmed">32376950</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangunsong C., Putera B., Haifa R., Suwandjaja M., Sharina A., Sasongko M. B., et al. (2019). Safety issues of peribulbar injection of umbilical cord mesenchymal stem cell (UC-MSC) in patients with retinitis pigmentosa. Cytotherapy 21 (5), S83. 10.1016/j.jcyt.2019.03.500</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcyt.2019.03.500</ArticleId></ArticleIdList></Reference><Reference><Citation>Manley A., Meshkat B. I., Jablonski M. M., Hollingsworth T. J. (2023). Cellular and molecular mechanisms of pathogenesis underlying inherited retinal dystrophies. Biomolecules 13 (2), 271. 10.3390/biom13020271</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom13020271</ArticleId><ArticleId IdType="pmc">PMC9953031</ArticleId><ArticleId IdType="pubmed">36830640</ArticleId></ArticleIdList></Reference><Reference><Citation>Maqsood M. I., Matin M. M., Bahrami A. R., Ghasroldasht M. M. (2013). Immortality of cell lines: challenges and advantages of establishment. Cell Biol. Int. 37 (10), 1038&#x2013;1045. 10.1002/cbin.10137</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbin.10137</ArticleId><ArticleId IdType="pubmed">23723166</ArticleId></ArticleIdList></Reference><Reference><Citation>Masland R. H. (2012). The neuronal organization of the retina. Neuron 76 (2), 266&#x2013;280. 10.1016/j.neuron.2012.10.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.10.002</ArticleId><ArticleId IdType="pmc">PMC3714606</ArticleId><ArticleId IdType="pubmed">23083731</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsushita T., Fujihara A., Royall L., Kagiwada S., Kosaka M., Araki M. (2014). Immediate differentiation of neuronal cells from stem/progenitor-like cells in the avian iris tissues. Exp. Eye Res. 123, 16&#x2013;26. 10.1016/j.exer.2014.04.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exer.2014.04.007</ArticleId><ArticleId IdType="pubmed">24747800</ArticleId></ArticleIdList></Reference><Reference><Citation>McFall R. C., Sery T. W., Makadon M. (1977). Characterization of a new continuous cell line derived from a human retinoblastoma. Cancer Res. 37 (4), 1003&#x2013;1010.</Citation><ArticleIdList><ArticleId IdType="pubmed">844036</ArticleId></ArticleIdList></Reference><Reference><Citation>McKay B. S., Burke J. M. (1994). Separation of phenotypically distinct subpopulations of cultured human retinal pigment epithelial cells. Exp. Cell Res. 213 (1), 85&#x2013;92. 10.1006/excr.1994.1176</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/excr.1994.1176</ArticleId><ArticleId IdType="pubmed">7517370</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon J. A., Takada S., Zimmerman L. B., Fan C. M., Harland R. M., McMahon A. P. (1998). Noggin-mediated antagonism of BMP signaling is required for growth and patterning of the neural tube and somite. Genes Dev. 12 (10), 1438&#x2013;1452. 10.1101/gad.12.10.1438</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.12.10.1438</ArticleId><ArticleId IdType="pmc">PMC316831</ArticleId><ArticleId IdType="pubmed">9585504</ArticleId></ArticleIdList></Reference><Reference><Citation>McNiece I. (2007). Subsets of mesenchymal stromal cells. Cytotherapy 9 (3), 301&#x2013;302. 10.1080/14653240701218540</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14653240701218540</ArticleId><ArticleId IdType="pubmed">17464762</ArticleId></ArticleIdList></Reference><Reference><Citation>Mencl S., Trifunovi&#x107; D., Zrenner E., Paquet-Durand F. (2018). PKG-dependent cell death in 661W cone photoreceptor-like cell cultures (experimental study). Adv. Exp. Med. Biol. 1074, 511&#x2013;517. 10.1007/978-3-319-75402-4_63</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-75402-4_63</ArticleId><ArticleId IdType="pubmed">29721983</ArticleId></ArticleIdList></Reference><Reference><Citation>Mennan C., Brown S., McCarthy H., Mavrogonatou E., Kletsas D., Garcia J., et al. (2016). Mesenchymal stromal cells derived from whole human umbilical cord exhibit similar properties to those derived from Wharton's jelly and bone marrow. FEBS Open Bio 6 (11), 1054&#x2013;1066. 10.1002/2211-5463.12104</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/2211-5463.12104</ArticleId><ArticleId IdType="pmc">PMC5095143</ArticleId><ArticleId IdType="pubmed">27833846</ArticleId></ArticleIdList></Reference><Reference><Citation>Mennan C., Wright K., Bhattacharjee A., Balain B., Richardson J., Roberts S. (2013). Isolation and characterisation of mesenchymal stem cells from different regions of the human umbilical cord. Biomed. Res. Int. 2013, 916136. 10.1155/2013/916136</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/916136</ArticleId><ArticleId IdType="pmc">PMC3741948</ArticleId><ArticleId IdType="pubmed">23984420</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelis G. A., Politi L. E., Becerra S. P. (2023). Primary retinal cell cultures as a model to study retina biology. Adv. Exp. Med. Biol. 1415, 565&#x2013;569. 10.1007/978-3-031-27681-1_82</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-031-27681-1_82</ArticleId><ArticleId IdType="pubmed">37440087</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills E. A., Goldman D. (2017). The regulation of Notch signaling in retinal development and regeneration. Curr. Pathobiol. Rep. 5 (4), 323&#x2013;331. 10.1007/s40139-017-0153-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40139-017-0153-7</ArticleId><ArticleId IdType="pmc">PMC5772988</ArticleId><ArticleId IdType="pubmed">29354328</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo M., Wang S., Zhou Y., Li H., Wu Y. (2016). Mesenchymal stem cell subpopulations: phenotype, property and therapeutic potential. Cell. Mol. Life Sci. 73 (17), 3311&#x2013;3321. 10.1007/s00018-016-2229-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-016-2229-7</ArticleId><ArticleId IdType="pmc">PMC11108490</ArticleId><ArticleId IdType="pubmed">27141940</ArticleId></ArticleIdList></Reference><Reference><Citation>Moine E., Boukhallat M., Cia D., Jacquemot N., Guillou L., Durand T., et al. (2021). New lipophenols prevent carbonyl and oxidative stresses involved in macular degeneration. Free Radic. Biol. Med. 162, 367&#x2013;382. 10.1016/j.freeradbiomed.2020.10.316</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2020.10.316</ArticleId><ArticleId IdType="pubmed">33129975</ArticleId></ArticleIdList></Reference><Reference><Citation>Moshiri A. (2021). Animals models of inherited retinal disease. Int. Ophthalmol. Clin. 61 (3), 113&#x2013;130. 10.1097/IIO.0000000000000368</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IIO.0000000000000368</ArticleId><ArticleId IdType="pmc">PMC8480535</ArticleId><ArticleId IdType="pubmed">34196320</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy A. R., Truong Y. B., O'Brien C. M., Glattauer V. (2020). Bio-inspired human in vitro outer retinal models: Bruch's membrane and its cellular interactions. Acta Biomater. 104, 1&#x2013;16. 10.1016/j.actbio.2020.01.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actbio.2020.01.013</ArticleId><ArticleId IdType="pubmed">31945506</ArticleId></ArticleIdList></Reference><Reference><Citation>Mushahary D., Spittler A., Kasper C., Weber V., Charwat V. (2018). Isolation, cultivation, and characterization of human mesenchymal stem cells. Cytom. A 93 (1), 19&#x2013;31. 10.1002/cyto.a.23242</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.23242</ArticleId><ArticleId IdType="pubmed">29072818</ArticleId></ArticleIdList></Reference><Reference><Citation>Naderi M., Nadri S. (2022). Synergistic effect of miR-9 overexpression and electrical induction on differentiation of conjunctiva mesenchymal stem cells into photoreceptor-like cells. Int. J. Artif. Organs 45 (7), 623&#x2013;630. 10.1177/03913988221103285</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/03913988221103285</ArticleId><ArticleId IdType="pubmed">35658561</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadri S., Kazemi B., Eslaminejad M. B., Yazdani S., Soleimani M. (2013). High yield of cells committed to the photoreceptor-like cells from conjunctiva mesenchymal stem cells on nanofibrous scaffolds. Mol. Biol. Rep. 40 (6), 3883&#x2013;3890. 10.1007/s11033-012-2360-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11033-012-2360-y</ArticleId><ArticleId IdType="pubmed">23588957</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadri S., Nasehi F., Barati G. (2017). Effect of parameters on the quality of core-shell fibrous scaffold for retinal differentiation of conjunctiva mesenchymal stem cells. J. Biomed. Mat. Res. A 105 (1), 189&#x2013;197. 10.1002/jbm.a.35897</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jbm.a.35897</ArticleId><ArticleId IdType="pubmed">27615413</ArticleId></ArticleIdList></Reference><Reference><Citation>Naessens S., Ruysschaert L., Lefever S., Coppieters F., De Baere E. (2019). Antisense oligonucleotide-based downregulation of the G56R pathogenic variant causing nr2e3-associated autosomal dominant retinitis pigmentosa. Genes 10 (5), 363. 10.3390/genes10050363</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes10050363</ArticleId><ArticleId IdType="pmc">PMC6562693</ArticleId><ArticleId IdType="pubmed">31083481</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagamura-Inoue T., He H. (2014). Umbilical cord-derived mesenchymal stem cells: their advantages and potential clinical utility. World J. Stem Cells 6 (2), 195&#x2013;202. 10.4252/wjsc.v6.i2.195</Citation><ArticleIdList><ArticleId IdType="doi">10.4252/wjsc.v6.i2.195</ArticleId><ArticleId IdType="pmc">PMC3999777</ArticleId><ArticleId IdType="pubmed">24772246</ArticleId></ArticleIdList></Reference><Reference><Citation>Narcisi R., Koevoet W. J. L. M., van Osch G. J. V. M. (2021). Expansion and chondrogenic differentiation of human bone marrow-derived mesenchymal stromal cells. Methods Mol. Biol. 2221, 15&#x2013;28. 10.1007/978-1-0716-0989-7_2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-0716-0989-7_2</ArticleId><ArticleId IdType="pubmed">32979195</ArticleId></ArticleIdList></Reference><Reference><Citation>Neitz M., Neitz J. (2001). The uncommon retina of the common house mouse. Trends Neurosci. 24 (5), 248&#x2013;250. 10.1016/s0166-2236(00)01773-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0166-2236(00)01773-2</ArticleId><ArticleId IdType="pubmed">11311361</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng T. K., Yung J. S., Choy K. W., Cao D., Leung C. K., Cheung H. S., et al. (2015). Transdifferentiation of periodontal ligament-derived stem cells into retinal ganglion-like cells and its microRNA signature. Sci. Rep. 5, 16429. 10.1038/srep16429</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep16429</ArticleId><ArticleId IdType="pmc">PMC4637909</ArticleId><ArticleId IdType="pubmed">26549845</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols L. L., Alur R. P., Boobalan E., Sergeev Y. V., Caruso R. C., Stone E. M., et al. (2010). Two novel CRX mutant proteins causing autosomal dominant Leber congenital amaurosis interact differently with NRL. Hum. Mutat. 31 (6), E1472&#x2013;E1483. 10.1002/humu.21268</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.21268</ArticleId><ArticleId IdType="pmc">PMC2952391</ArticleId><ArticleId IdType="pubmed">20513135</ArticleId></ArticleIdList></Reference><Reference><Citation>Nickla D. L., Wallman J. (2010). The multifunctional choroid. Prog. Retin. Eye Res. 29 (2), 144&#x2013;168. 10.1016/j.preteyeres.2009.12.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2009.12.002</ArticleId><ArticleId IdType="pmc">PMC2913695</ArticleId><ArticleId IdType="pubmed">20044062</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie J., Hashino E. (2017). Organoid technologies meet genome engineering. EMBO Rep. 18 (3), 367&#x2013;376. 10.15252/embr.201643732</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.201643732</ArticleId><ArticleId IdType="pmc">PMC5331239</ArticleId><ArticleId IdType="pubmed">28202491</ArticleId></ArticleIdList></Reference><Reference><Citation>Nithin R., Aggarwal A., Sravani A. B., Mallya P., Lewis S. (2023). Organ-on-A-chip: an emerging research platform. Organogenesis 19 (1), 2278236. 10.1080/15476278.2023.2278236</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15476278.2023.2278236</ArticleId><ArticleId IdType="pmc">PMC10653779</ArticleId><ArticleId IdType="pubmed">37965897</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;zkan B., Y&#x131;lmaz Tu&#x11f;an B., Hem&#x15f;inlio&#x11f;lu C., S&#x131;r Karaku&#x15f; G., &#x15e;ahin &#xd6;., Oval&#x131; E. (2023). Suprachoroidal spheroidal mesenchymal stem cell implantation in retinitis pigmentosa: clinical results of 6 months follow-up. Stem Cell Res. Ther. 14 (1), 252. 10.1186/s13287-023-03489-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-023-03489-z</ArticleId><ArticleId IdType="pmc">PMC10500760</ArticleId><ArticleId IdType="pubmed">37705097</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;zmert E., Arslan U. (2020a). Management of retinitis pigmentosa by Wharton's jelly derived mesenchymal stem cells: preliminary clinical results. Stem Cell Res. Ther. 11 (1), 25. 10.1186/s13287-020-1549-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-020-1549-6</ArticleId><ArticleId IdType="pmc">PMC6958670</ArticleId><ArticleId IdType="pubmed">31931872</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;zmert E., Arslan U. (2020b). Management of retinitis pigmentosa by Wharton's jelly-derived mesenchymal stem cells: prospective analysis of 1-year results. Stem Cell Res. Ther. 11 (1), 353. 10.1186/s13287-020-01870-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-020-01870-w</ArticleId><ArticleId IdType="pmc">PMC7425139</ArticleId><ArticleId IdType="pubmed">32787913</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;zmert E., Arslan U. (2023). Management of retinitis pigmentosa via wharton's jelly-derived mesenchymal stem cells or combination with magnovision: 3-year prospective results. Stem Cells Transl. Med. 12 (10), 631&#x2013;650. 10.1093/stcltm/szad051</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/stcltm/szad051</ArticleId><ArticleId IdType="pmc">PMC10552690</ArticleId><ArticleId IdType="pubmed">37713598</ArticleId></ArticleIdList></Reference><Reference><Citation>Pera E. M., Wessely O., Li S. Y., De Robertis E. M. (2001). Neural and head induction by insulin-like growth factor signals. Dev. Cell 1 (5), 655&#x2013;665. 10.1016/s1534-5807(01)00069-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1534-5807(01)00069-7</ArticleId><ArticleId IdType="pubmed">11709186</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeffer B. A., Fliesler S. J. (2022). Reassessing the suitability of ARPE-19 cells as a valid model of native RPE biology. Exp. Eye. Res. 219, 109046. 10.1016/j.exer.2022.109046</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exer.2022.109046</ArticleId><ArticleId IdType="pubmed">35314139</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilgrim M. G., Lengyel I., Lanzirotti A., Newville M., Fearn S., Emri E., et al. (2017). Subretinal pigment epithelial deposition of drusen components including hydroxyapatite in a primary cell culture model. Invest. Ophthalmol. Vis. Sci. 58 (2), 708&#x2013;719. 10.1167/iovs.16-21060</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.16-21060</ArticleId><ArticleId IdType="pmc">PMC5295770</ArticleId><ArticleId IdType="pubmed">28146236</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittenger M. F., Mackay A. M., Beck S. C., Jaiswal R. K., Douglas R., Mosca J. D., et al. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284 (5411), 143&#x2013;147. 10.1126/science.284.5411.143</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.284.5411.143</ArticleId><ArticleId IdType="pubmed">10102814</ArticleId></ArticleIdList></Reference><Reference><Citation>Pl&#xf6;ssl K., Weber B. H., Friedrich U. (2017). The X-linked juvenile retinoschisis protein retinoschisin is a novel regulator of mitogen-activated protein kinase signalling and apoptosis in the retina. J. Cell Mol. Med. 21 (4), 768&#x2013;780. 10.1111/jcmm.13019</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.13019</ArticleId><ArticleId IdType="pmc">PMC5345684</ArticleId><ArticleId IdType="pubmed">27995734</ArticleId></ArticleIdList></Reference><Reference><Citation>Poch&#xe9; R. A., Reese B. E. (2009). Retinal horizontal cells: challenging paradigms of neural development and cancer biology. Development 136 (13), 2141&#x2013;2151. 10.1242/dev.033175</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.033175</ArticleId><ArticleId IdType="pmc">PMC2729336</ArticleId><ArticleId IdType="pubmed">19502480</ArticleId></ArticleIdList></Reference><Reference><Citation>Polo J. M., Liu S., Figueroa M. E., Kulalert W., Eminli S., Tan K. Y., et al. (2010). Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat. Biotechnol. 28 (8), 848&#x2013;855. 10.1038/nbt.1667</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1667</ArticleId><ArticleId IdType="pmc">PMC3148605</ArticleId><ArticleId IdType="pubmed">20644536</ArticleId></ArticleIdList></Reference><Reference><Citation>Purwaningrum M., Jamilah N. S., Purbantoro S. D., Sawangmake C., Nantavisai S. (2021). Comparative characteristic study from bone marrow-derived mesenchymal stem cells. J. Vet. Sci. 22 (6), e74. 10.4142/jvs.2021.22.e74</Citation><ArticleIdList><ArticleId IdType="doi">10.4142/jvs.2021.22.e74</ArticleId><ArticleId IdType="pmc">PMC8636658</ArticleId><ArticleId IdType="pubmed">34697921</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabin D. M., Temple S., Stern J. H. (2011). Chronic oxidative stress up-regulates drusen-related protein synthesis in primary human RPE cells: a novel culture model for the study of age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 52 (14), 3912.</Citation></Reference><Reference><Citation>Rahmani A., Naderi M., Barati G., Arefian E., Jedari B., Nadri S. (2020). The potency of hsa-miR-9-1 overexpression in photoreceptor differentiation of conjunctiva mesenchymal stem cells on a 3D nanofibrous scaffold. Biochem. Biophys. Res. Commun. 529 (3), 526&#x2013;532. 10.1016/j.bbrc.2020.06.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.06.006</ArticleId><ArticleId IdType="pubmed">32736669</ArticleId></ArticleIdList></Reference><Reference><Citation>Rai D., Iwanami M., Takahashi Y., Komuta Y., Aoi N., Umezawa A., et al. (2022). Evaluation of photoreceptor-directed fibroblasts derived from retinitis pigmentosa patients with defects in the EYS gene: a possible cost-effective cellular model for mechanism-oriented drug. Stem Cell Res. Ther. 13 (1), 157. 10.1186/s13287-022-02827-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-022-02827-x</ArticleId><ArticleId IdType="pmc">PMC8996485</ArticleId><ArticleId IdType="pubmed">35410372</ArticleId></ArticleIdList></Reference><Reference><Citation>Rak D. J., Hardy K. M., Jaffe G. J., McKay B. S. (2006). Ca++-switch induction of RPE differentiation. Exp. Eye Res. 82 (4), 648&#x2013;656. 10.1016/j.exer.2005.09.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exer.2005.09.002</ArticleId><ArticleId IdType="pubmed">16289163</ArticleId></ArticleIdList></Reference><Reference><Citation>Ran F. A., Hsu P. D., Wright J., Agarwala V., Scott D. A., Zhang F. (2013). Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281&#x2013;2308. 10.1038/nprot.2013.143</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2013.143</ArticleId><ArticleId IdType="pmc">PMC3969860</ArticleId><ArticleId IdType="pubmed">24157548</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranjbarnejad F., Nadri S., Biglari A., Mohammadi-Yeganeh S., Paryan M. (2019). Effect of let-7a overexpression on the differentiation of conjunctiva mesenchymal stem cells into photoreceptor-like cells. Iran. J. Basic Med. 22 (8), 878&#x2013;883. 10.22038/ijbms.2019.32736.7859</Citation><ArticleIdList><ArticleId IdType="doi">10.22038/ijbms.2019.32736.7859</ArticleId><ArticleId IdType="pmc">PMC6760475</ArticleId><ArticleId IdType="pubmed">31579443</ArticleId></ArticleIdList></Reference><Reference><Citation>Reid T. W., Albert D. M., Rabson A. S., Russell P., Craft J., Chu E. W., et al. (1974). Characteristics of an established cell line of retinoblastoma. J. Natl. Cancer Inst. 53 (2), 347&#x2013;360. 10.1093/jnci/53.2.347</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/53.2.347</ArticleId><ArticleId IdType="pubmed">4135597</ArticleId></ArticleIdList></Reference><Reference><Citation>
Retinal Information Network (2024). Summaries of genes and loci causing retinal diseases. Available at: https://web.sph.uth.edu/RetNet/sum-dis.htm?csrt=11700871907574185287#A-genes (Accessed June 24, 2024).</Citation></Reference><Reference><Citation>Rezanejad H., Soheili Z. S., Haddad F., Matin M. M., Samiei S., Manafi A., et al. (2014). In vitro differentiation of adipose-tissue-derived mesenchymal stem cells into neural retinal cells through expression of human PAX6 (5a) gene. Cell Tissue Res. 356 (1), 65&#x2013;75. 10.1007/s00441-014-1795-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00441-014-1795-y</ArticleId><ArticleId IdType="pubmed">24562376</ArticleId></ArticleIdList></Reference><Reference><Citation>Roozafzoon R., Lashay A., Vasei M., Ai J., Khoshzaban A., Keshel S. H., et al. (2015). Dental pulp stem cells differentiation into retinal ganglion-like cells in a three dimensional network. Biochem. Biophys. Res. Commun. 457 (2), 154&#x2013;160. 10.1016/j.bbrc.2014.12.069</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2014.12.069</ArticleId><ArticleId IdType="pubmed">25543058</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen E. D., MacDougald O. A. (2006). Adipocyte differentiation from the inside out. Nat. Rev. Mol. Cell Biol. 7 (12), 885&#x2013;896. 10.1038/nrm2066</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2066</ArticleId><ArticleId IdType="pubmed">17139329</ArticleId></ArticleIdList></Reference><Reference><Citation>Royall L. N., Lea D., Matsushita T., Takeda T. A., Taketani S., Araki M. (2017). A novel culture method reveals unique neural stem/progenitors in mature porcine iris tissues that differentiate into neuronal and rod photoreceptor-like cells. Brain Res. 1675, 51&#x2013;60. 10.1016/j.brainres.2017.08.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2017.08.027</ArticleId><ArticleId IdType="pubmed">28866055</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell W. M. S., Burch R. L. (1959). The principles of humane experimental technique. London: Methuen.</Citation></Reference><Reference><Citation>Sahly I., Dufour E., Schietroma C., Michel V., Bahloul A., Perfettini I., et al. (2012). Localization of Usher 1 proteins to the photoreceptor calyceal processes, which are absent from mice. J. Cell Biol. 199 (2), 381&#x2013;399. 10.1083/jcb.201202012</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201202012</ArticleId><ArticleId IdType="pmc">PMC3471240</ArticleId><ArticleId IdType="pubmed">23045546</ArticleId></ArticleIdList></Reference><Reference><Citation>Saini J. S., Temple S., Stern J. H. (2016). Human retinal pigment epithelium stem cell (RPESC). Adv. Exp. Med. Biol. 854, 557&#x2013;562. 10.1007/978-3-319-17121-0_74</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-17121-0_74</ArticleId><ArticleId IdType="pubmed">26427459</ArticleId></ArticleIdList></Reference><Reference><Citation>Salero E., Blenkinsop T. A., Corneo B., Harris A., Rabin D., Stern J. H., et al. (2012). Adult human RPE can be activated into a multipotent stem cell that produces mesenchymal derivatives. Cell Stem Cell 10 (1), 88&#x2013;95. 10.1016/j.stem.2011.11.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2011.11.018</ArticleId><ArticleId IdType="pubmed">22226358</ArticleId></ArticleIdList></Reference><Reference><Citation>Salesse C. (2017). Physiology of the visual retinal signal: from phototransduction to the visual cycle. J. Fr. Ophtalmol. 40 (3), 239&#x2013;250. 10.1016/j.jfo.2016.12.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jfo.2016.12.006</ArticleId><ArticleId IdType="pubmed">28318721</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuel W., Jaworski C., Postnikova O. A., Kutty R. K., Duncan T., Tan L. X., et al. (2017). Appropriately differentiated ARPE-19 cells regain phenotype and gene expression profiles similar to those of native RPE cells. Mol. Vis. 23, 60&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5360456</ArticleId><ArticleId IdType="pubmed">28356702</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanes J. R., Masland R. H. (2015). The types of retinal ganglion cells: current status and implications for neuronal classification. Annu. Rev. Neurosci. 38, 221&#x2013;246. 10.1146/annurev-neuro-071714-034120</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-neuro-071714-034120</ArticleId><ArticleId IdType="pubmed">25897874</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos-Ferreira T., Herbig M., Otto O., Carido M., Karl M. O., Michalakis S., et al. (2019). Morpho-rheological fingerprinting of rod photoreceptors using real-time deformability cytometry. Cytom. A 95 (11), 1145&#x2013;1157. 10.1002/cyto.a.23798</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.23798</ArticleId><ArticleId IdType="pmc">PMC6900160</ArticleId><ArticleId IdType="pubmed">31107590</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar H., Moosajee M. (2019). Retinol dehydrogenase 12 (RDH12): role in vision, retinal disease and future perspectives. Exp. Eye. Res. 188, 107793. 10.1016/j.exer.2019.107793</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exer.2019.107793</ArticleId><ArticleId IdType="pubmed">31505163</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar H., Moosajee M. (2022). Choroideremia: molecular mechanisms and therapies. Trends Mol. Med. 28 (5), 378&#x2013;387. 10.1016/j.molmed.2022.02.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2022.02.011</ArticleId><ArticleId IdType="pubmed">35341685</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar H., Toms M., Moosajee M. (2021). Involvement of oxidative and endoplasmic reticulum stress in RDH12-related retinopathies. Int. J. Mol. Sci. 22 (16), 8863. 10.3390/ijms22168863</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22168863</ArticleId><ArticleId IdType="pmc">PMC8396253</ArticleId><ArticleId IdType="pubmed">34445569</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt B. P., Boehm A. E., Tuten W. S., Roorda A. (2019). Spatial summation of individual cones in human color vision. PLoS One 14 (7), e0211397. 10.1371/journal.pone.0211397</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0211397</ArticleId><ArticleId IdType="pmc">PMC6658054</ArticleId><ArticleId IdType="pubmed">31344029</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider N., Sundaresan Y., Gopalakrishnan P., Beryozkin A., Hanany M., Levanon E. Y., et al. (2022). Inherited retinal diseases: linking genes, disease-causing variants, and relevant therapeutic modalities. Prog. Retin. Eye Res. 89, 101029. 10.1016/j.preteyeres.2021.101029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2021.101029</ArticleId><ArticleId IdType="pubmed">34839010</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnichels S., Paquet-Durand F., L&#xf6;scher M., Tsai T., Hurst J., Joachim S. C., et al. (2021). Retina in a dish: cell cultures, retinal explants and animal models for common diseases of the retina. Prog. Retin. Eye Res. 81, 100880. 10.1016/j.preteyeres.2020.100880</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2020.100880</ArticleId><ArticleId IdType="pubmed">32721458</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott M. A., Nguyen V. T., Levi B., James A. W. (2011). Current methods of adipogenic differentiation of mesenchymal stem cells. Stem Cells Dev. 20 (10), 1793&#x2013;1804. 10.1089/scd.2011.0040</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/scd.2011.0040</ArticleId><ArticleId IdType="pmc">PMC3182038</ArticleId><ArticleId IdType="pubmed">21526925</ArticleId></ArticleIdList></Reference><Reference><Citation>Seah I., Goh D., Banerjee A., Su X. (2024). Modeling inherited retinal diseases using human induced pluripotent stem cell derived photoreceptor cells and retinal pigment epithelial cells. Front. Med. 11, 1328474. 10.3389/fmed.2024.1328474</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2024.1328474</ArticleId><ArticleId IdType="pmc">PMC11246861</ArticleId><ArticleId IdType="pubmed">39011458</ArticleId></ArticleIdList></Reference><Reference><Citation>Seah I., Goh D., Chan H. W., Su X. (2022). Developing non-human primate models of inherited retinal diseases. Genes 13 (2), 344. 10.3390/genes13020344</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes13020344</ArticleId><ArticleId IdType="pmc">PMC8872446</ArticleId><ArticleId IdType="pubmed">35205388</ArticleId></ArticleIdList></Reference><Reference><Citation>Seko Y., Azuma N., Ishii T., Komuta Y., Miyamoto K., Miyagawa Y., et al. (2014). Derivation of human differential photoreceptor cells from adult human dermal fibroblasts by defined combinations of CRX, RAX, OTX2 and NEUROD. Genes cells. 19 (3), 198&#x2013;208. 10.1111/gtc.12127</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/gtc.12127</ArticleId><ArticleId IdType="pmc">PMC4237506</ArticleId><ArticleId IdType="pubmed">24456169</ArticleId></ArticleIdList></Reference><Reference><Citation>Seko Y., Azuma N., Kaneda M., Nakatani K., Miyagawa Y., Noshiro Y., et al. (2012). Derivation of human differential photoreceptor-like cells from the iris by defined combinations of CRX, RX and NEUROD. PloS One 7 (4), e35611. 10.1371/journal.pone.0035611</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0035611</ArticleId><ArticleId IdType="pmc">PMC3338414</ArticleId><ArticleId IdType="pubmed">22558175</ArticleId></ArticleIdList></Reference><Reference><Citation>Seko Y., Iwanami M., Miyamoto-Matsui K., Takita S., Aoi N., Umezawa A., et al. (2018). The manner of decay of genetically defective EYS gene transcripts in photoreceptor-directed fibroblasts derived from retinitis pigmentosa patients depends on the type of mutation. Stem Cell Res. Ther. 9 (1), 279. 10.1186/s13287-018-1016-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-018-1016-9</ArticleId><ArticleId IdType="pmc">PMC6202841</ArticleId><ArticleId IdType="pubmed">30359287</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J., He J., Wang F. (2017). Isolation and culture of primary mouse retinal pigment epithelial (RPE) cells with rho-kinase and tgf&#x3b2;r-1/ALK5 inhibitor. Med. Sci. Monit. 23, 6132&#x2013;6136. 10.12659/msm.905569</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/msm.905569</ArticleId><ArticleId IdType="pmc">PMC5751728</ArticleId><ArticleId IdType="pubmed">29279601</ArticleId></ArticleIdList></Reference><Reference><Citation>Sierra-S&#xe1;nchez &#xc1;., Ord&#xf3;&#xf1;ez-Luque A., Espinosa-Ib&#xe1;&#xf1;ez O., Ruiz-Garc&#xed;a A., Arias-Santiago S. (2018). Epithelial in vitro differentiation of mesenchymal stem cells. Curr. Stem Cell Res. Ther. 13 (6), 409&#x2013;422. 10.2174/1574888X13666180501120416</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1574888X13666180501120416</ArticleId><ArticleId IdType="pubmed">29714147</ArticleId></ArticleIdList></Reference><Reference><Citation>Singhal S., Bhatia B., Jayaram H., Becker S., Jones M. F., Cottrill P. B., et al. (2012). Human M&#xfc;ller glia with stem cell characteristics differentiate into retinal ganglion cell (RGC) precursors in vitro and partially restore RGC function in vivo following transplantation. Stem Cells Transl. Med. 1 (3), 188&#x2013;199. 10.5966/sctm.2011-0005</Citation><ArticleIdList><ArticleId IdType="doi">10.5966/sctm.2011-0005</ArticleId><ArticleId IdType="pmc">PMC3659849</ArticleId><ArticleId IdType="pubmed">23197778</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaper S. D. (2012). Isolation and culture of rat cone photoreceptor cells. Methods Mol. Biol. 846, 147&#x2013;158. 10.1007/978-1-61779-536-7_13</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-61779-536-7_13</ArticleId><ArticleId IdType="pubmed">22367808</ArticleId></ArticleIdList></Reference><Reference><Citation>Slijkerman R. W., Song F., Astuti G. D., Huynen M. A., van Wijk E., Stieger K., et al. (2015). The pros and cons of vertebrate animal models for functional and therapeutic research on inherited retinal dystrophies. Prog. Retin. Eye Res. 48, 137&#x2013;159. 10.1016/j.preteyeres.2015.04.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2015.04.004</ArticleId><ArticleId IdType="pubmed">25936606</ArticleId></ArticleIdList></Reference><Reference><Citation>Solchaga L. A., Penick K. J., Welter J. F. (2011). Chondrogenic differentiation of bone marrow-derived mesenchymal stem cells: tips and tricks. Methods Mol. Biol. 698, 253&#x2013;278. 10.1007/978-1-60761-999-4_20</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-60761-999-4_20</ArticleId><ArticleId IdType="pmc">PMC3106977</ArticleId><ArticleId IdType="pubmed">21431525</ArticleId></ArticleIdList></Reference><Reference><Citation>Song J. Y., Fan B., Che L., Pan Y. R., Zhang S. M., Wang Y., et al. (2020). Suppressing endoplasmic reticulum stress-related autophagy attenuates retinal light injury. Aging 12 (16), 16579&#x2013;16596. 10.18632/aging.103846</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.103846</ArticleId><ArticleId IdType="pmc">PMC7485697</ArticleId><ArticleId IdType="pubmed">32858529</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonoi R., Kim M. H., Kino-Oka M. (2016). Facilitation of uniform maturation of human retinal pigment epithelial cells through collective movement in culture. J. Biosci. Bioeng. 121 (2), 220&#x2013;226. 10.1016/j.jbiosc.2015.05.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbiosc.2015.05.019</ArticleId><ArticleId IdType="pubmed">26134448</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalluto C., Wilson D. I., Hearn T. (2013). Evidence for reciliation of RPE1 cells in late G1 phase, and ciliary localisation of cyclin B1. FEBS Open Bio 3, 334&#x2013;340. 10.1016/j.fob.2013.08.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fob.2013.08.002</ArticleId><ArticleId IdType="pmc">PMC3821022</ArticleId><ArticleId IdType="pubmed">24251092</ArticleId></ArticleIdList></Reference><Reference><Citation>Sramk&#xf3; B., F&#xf6;ldes A., K&#xe1;d&#xe1;r K., Varga G., Zsembery &#xc1;., Pircs K. (2023). The wisdom in teeth: neuronal differentiation of dental pulp cells. Cell. Reprogr. 25 (1), 32&#x2013;44. 10.1089/cell.2022.0102</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/cell.2022.0102</ArticleId><ArticleId IdType="pmc">PMC9963504</ArticleId><ArticleId IdType="pubmed">36719998</ArticleId></ArticleIdList></Reference><Reference><Citation>Stemerdink M., Garc&#xed;a-Boh&#xf3;rquez B., Schellens R., Garcia-Garcia G., Van Wijk E., Millan J. M. (2022). Genetics, pathogenesis and therapeutic developments for Usher syndrome type 2. Hum. Genet. 141 (3-4), 737&#x2013;758. 10.1007/s00439-021-02324-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00439-021-02324-w</ArticleId><ArticleId IdType="pubmed">34331125</ArticleId></ArticleIdList></Reference><Reference><Citation>Strioga M., Viswanathan S., Darinskas A., Slaby O., Michalek J. (2012). Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells Dev. 21 (14), 2724&#x2013;2752. 10.1089/scd.2011.0722</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/scd.2011.0722</ArticleId><ArticleId IdType="pubmed">22468918</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan E., Ding X. Q., Saadi A., Agarwal N., Naash M. I., Al-Ubaidi M. R. (2004). Expression of cone-photoreceptor-specific antigens in a cell line derived from retinal tumors in transgenic mice. Invest. Ophthalmol. Vis. Sci. 45 (3), 764&#x2013;768. 10.1167/iovs.03-1114</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.03-1114</ArticleId><ArticleId IdType="pmc">PMC2937568</ArticleId><ArticleId IdType="pubmed">14985288</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao Y. X., Xu H. W., Zheng Q Y., FitzGibbon T. (2010). Noggin induces human bone marrow-derived mesenchymal stem cells to differentiate into neural and photoreceptor cells. Indian J. Exp. Biol. 48 (5), 444&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">20795361</ArticleId></ArticleIdList></Reference><Reference><Citation>Terao R., Honjo M., Ueta T., Obinata H., Izumi T., Kurano M., et al. (2019). Light stress-induced increase of sphingosine 1-phosphate in photoreceptors and its relevance to retinal degeneration. Int. J. Mol. Sci. 20 (15), 3670. 10.3390/ijms20153670</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20153670</ArticleId><ArticleId IdType="pmc">PMC6696268</ArticleId><ArticleId IdType="pubmed">31357484</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Z., Yu T., Liu J., Wang T., Higuchi A. (2023). Introduction to stem cells. Prog. Mol. Biol. Transl. Sci. 199, 3&#x2013;32. 10.1016/bs.pmbts.2023.02.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.pmbts.2023.02.012</ArticleId><ArticleId IdType="pubmed">37678976</ArticleId></ArticleIdList></Reference><Reference><Citation>Tichotov&#xe1; L., Studenovska H., Petrovski G., Popelka &#x160;., Nemesh Y., Sedl&#xe1;&#x10d;kov&#xe1; M., et al. (2022). Advantages of nanofibrous membranes for culturing of primary RPE cells compared to commercial scaffolds. Acta Ophthalmol. 100 (5), e1172&#x2013;e1185. 10.1111/aos.15034</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aos.15034</ArticleId><ArticleId IdType="pubmed">34687141</ArticleId></ArticleIdList></Reference><Reference><Citation>Traverso V., Kinkl N., Grimm L., Sahel J., Hicks D. (2003). Basic fibroblast and epidermal growth factors stimulate survival in adult porcine photoreceptor cell cultures. Invest. Ophthalmol. Vis. Sci. 44 (10), 4550&#x2013;4558. 10.1167/iovs.03-0460</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.03-0460</ArticleId><ArticleId IdType="pubmed">14507904</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang S. H., Sharma T. (2018a). Best vitelliform macular dystrophy. Adv. Exp. Med. Biol. 1085, 79&#x2013;90. 10.1007/978-3-319-95046-4_16</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-95046-4_16</ArticleId><ArticleId IdType="pubmed">30578489</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang S. H., Sharma T. (2018b). North Carolina macular dystrophy. Adv. Exp. Med. Biol. 1085, 109&#x2013;110. 10.1007/978-3-319-95046-4_21</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-95046-4_21</ArticleId><ArticleId IdType="pubmed">30578494</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuekprakhon A., Sangkitporn S., Trinavarat A., Pawestri A. R., Vamvanij V., Ruangchainikom M., et al. (2021). Intravitreal autologous mesenchymal stem cell transplantation: a non-randomized phase I clinical trial in patients with retinitis pigmentosa. Stem Cell Res. Ther. 12 (1), 52. 10.1186/s13287-020-02122-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-020-02122-7</ArticleId><ArticleId IdType="pmc">PMC7796606</ArticleId><ArticleId IdType="pubmed">33422139</ArticleId></ArticleIdList></Reference><Reference><Citation>Upadhyay U., Kumaran A., Yadav S., Majumder A., Dandekar P. (2022). &#x201c;Microfluidic retina-on-chip,&#x201d; in Microfluidics and multi organs on chip. Editor Mohanan P. V. (Singapore: Springer; ), 381&#x2013;405. 10.1007/978-981-19-1379-2_17</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-981-19-1379-2_17</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaclavik V. (2020). &#x201c;Malattia leventinese,&#x201d; in Hereditary chorioretinal disorders. Editor Cheung G. (Singapore: Springer; ), 107&#x2013;117. 10.1007/978-981-15-0414-3_9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-981-15-0414-3_9</ArticleId></ArticleIdList></Reference><Reference><Citation>van Wijk E., Kersten F. F., Kartono A., Mans D. A., Brandwijk K., Letteboer S. J., et al. (2009). Usher syndrome and Leber congenital amaurosis are molecularly linked via a novel isoform of the centrosomal ninein-like protein. Hum. Mol. Genet. 18 (1), 51&#x2013;64. 10.1093/hmg/ddn312</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddn312</ArticleId><ArticleId IdType="pmc">PMC3298862</ArticleId><ArticleId IdType="pubmed">18826961</ArticleId></ArticleIdList></Reference><Reference><Citation>Vecino E., Rodriguez F. D., Ruzafa N., Pereiro X., Sharma S. C. (2016). Glia-neuron interactions in the mammalian retina. Prog. Retin. Eye Res. 51, 1&#x2013;40. 10.1016/j.preteyeres.2015.06.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2015.06.003</ArticleId><ArticleId IdType="pubmed">26113209</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbakel S. K., van Huet R. A. C., Boon C. J. F., den Hollander A. I., Collin R. W. J., Klaver C., et al. (2018). Non-syndromic retinitis pigmentosa. Prog. Retin. Eye Res. 66, 157&#x2013;186. 10.1016/j.preteyeres.2018.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2018.03.005</ArticleId><ArticleId IdType="pubmed">29597005</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilela C. A. P., Messias A., Calado R. T., Siqueira R. C., Silva M. J. L., Covas D. T., et al. (2021). Retinal function after intravitreal injection of autologous bone marrow-derived mesenchymal stromal cells in advanced glaucoma. Doc. Ophthalmol. 143 (1), 33&#x2013;38. 10.1007/s10633-021-09817-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10633-021-09817-z</ArticleId><ArticleId IdType="pubmed">33469852</ArticleId></ArticleIdList></Reference><Reference><Citation>Volarevic V., Markovic B. S., Gazdic M., Volarevic A., Jovicic N., Arsenijevic N., et al. (2018). Ethical and safety issues of stem cell-based therapy. Int. J. Med. Sci. 15 (1), 36&#x2013;45. 10.7150/ijms.21666</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.21666</ArticleId><ArticleId IdType="pmc">PMC5765738</ArticleId><ArticleId IdType="pubmed">29333086</ArticleId></ArticleIdList></Reference><Reference><Citation>Volland S., Esteve-Rudd J., Hoo J., Yee C., Williams D. S. (2015). A comparison of some organizational characteristics of the mouse central retina and the human macula. PloS One 10 (4), e0125631. 10.1371/journal.pone.0125631</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0125631</ArticleId><ArticleId IdType="pmc">PMC4414478</ArticleId><ArticleId IdType="pubmed">25923208</ArticleId></ArticleIdList></Reference><Reference><Citation>Vossmerbaeumer U., Ohnesorge S., Kuehl S., Haapalahti M., Kluter H., Jonas J. B., et al. (2009). Retinal pigment epithelial phenotype induced in human adipose tissue-derived mesenchymal stromal cells. Cytotherapy 11 (2), 177&#x2013;188. 10.1080/14653240802714819</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14653240802714819</ArticleId><ArticleId IdType="pubmed">19241195</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G., Spencer K. L., Court B. L., Olson L. M., Scott W. K., Haines J. L., et al. (2009). Localization of age-related macular degeneration-associated ARMS2 in cytosol, not mitochondria. Invest. Ophthalmol. Vis. Sci. 50 (7), 3084&#x2013;3090. 10.1167/iovs.08-3240</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.08-3240</ArticleId><ArticleId IdType="pmc">PMC3001322</ArticleId><ArticleId IdType="pubmed">19255159</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Zhang D., Zhang Y., Ni N., Tang Z., Bai Z., et al. (2018). Insulin-like growth factor-1 regulation of retinal progenitor cell proliferation and differentiation. Cell Cycle 17 (4), 515&#x2013;526. 10.1080/15384101.2018.1431594</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15384101.2018.1431594</ArticleId><ArticleId IdType="pmc">PMC5927662</ArticleId><ArticleId IdType="pubmed">29417866</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss J. N., Benes S. C., Levy S. (2016a). Stem Cell Ophthalmology Treatment Study (Scots): improvement in serpiginous choroidopathy following autologous bone marrow derived stem cell treatment. Neural Regen. Res. 11 (9), 1512&#x2013;1516. 10.4103/1673-5374.191229</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.191229</ArticleId><ArticleId IdType="pmc">PMC5090858</ArticleId><ArticleId IdType="pubmed">27857759</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss J. N., Levy S. (2018). Stem cell ophthalmology treatment study: bone marrow derived stem cells in the treatment of retinitis pigmentosa. Stem Cell Investig. 5, 18. 10.21037/sci.2018.04.02</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/sci.2018.04.02</ArticleId><ArticleId IdType="pmc">PMC6043757</ArticleId><ArticleId IdType="pubmed">30050918</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss J. N., Levy S. (2019a). Stem cell ophthalmology treatment study (Scots): bone marrow derived stem cells in the treatment of dominant optic atrophy. Stem Cell Investig. 6, 41. 10.21037/sci.2019.11.01</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/sci.2019.11.01</ArticleId><ArticleId IdType="pmc">PMC6987313</ArticleId><ArticleId IdType="pubmed">32039263</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss J. N., Levy S. (2019b). Stem Cell Ophthalmology Treatment Study (Scots): bone marrow derived stem cells in the treatment of Usher syndrome. Stem Cell Investig. 6, 31. 10.21037/sci.2019.08.07</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/sci.2019.08.07</ArticleId><ArticleId IdType="pmc">PMC6789203</ArticleId><ArticleId IdType="pubmed">31620478</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss J. N., Levy S. (2021). Stem cell ophthalmology treatment study (Scots): bone marrow-derived stem cells in the treatment of Stargardt disease. Med. (Basel) 8 (2), 10. 10.3390/medicines8020010</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicines8020010</ArticleId><ArticleId IdType="pmc">PMC7913552</ArticleId><ArticleId IdType="pubmed">33546345</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss J. N., Levy S., Benes S. C. (2015a). Stem Cell Ophthalmology Treatment Study (Scots) for retinal and optic nerve diseases: a case report of improvement in relapsing auto-immune optic neuropathy. Neural Regen. Res. 10 (9), 1507&#x2013;1515. 10.4103/1673-5374.165525</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.165525</ArticleId><ArticleId IdType="pmc">PMC4625519</ArticleId><ArticleId IdType="pubmed">26604914</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss J. N., Levy S., Benes S. C. (2016b). Stem Cell Ophthalmology Treatment Study (Scots): bone marrow-derived stem cells in the treatment of Leber's hereditary optic neuropathy. Neural Regen. Res. 11 (10), 1685&#x2013;1694. 10.4103/1673-5374.193251</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.193251</ArticleId><ArticleId IdType="pmc">PMC5116851</ArticleId><ArticleId IdType="pubmed">27904503</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss J. N., Levy S., Benes S. C. (2017). Stem Cell Ophthalmology Treatment Study: bone marrow derived stem cells in the treatment of non-arteritic ischemic optic neuropathy (NAION). Stem Cell Investig. 4, 94. 10.21037/sci.2017.11.05</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/sci.2017.11.05</ArticleId><ArticleId IdType="pmc">PMC5723737</ArticleId><ArticleId IdType="pubmed">29270420</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss J. N., Levy S., Malkin A. (2015b). Stem Cell Ophthalmology Treatment Study (Scots) for retinal and optic nerve diseases: a preliminary report. Neural Regen. Res. 10 (6), 982&#x2013;988. 10.4103/1673-5374.158365</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.158365</ArticleId><ArticleId IdType="pmc">PMC4498363</ArticleId><ArticleId IdType="pubmed">26199618</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheway G., Nazlamova L., Turner D., Cross S. (2019). 661W photoreceptor cell line as a cell model for studying retinal ciliopathies. Front. Genet. 10, 308. 10.3389/fgene.2019.00308</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2019.00308</ArticleId><ArticleId IdType="pmc">PMC6459963</ArticleId><ArticleId IdType="pubmed">31024622</ArticleId></ArticleIdList></Reference><Reference><Citation>Woogeng I. N., Kaczkowski B., Abugessaisa I., Hu H., Tachibana A., Sahara Y., et al. (2022). Inducing human retinal pigment epithelium-like cells from somatic tissue. Stem Cell Rep. 17 (2), 289&#x2013;306. 10.1016/j.stemcr.2021.12.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2021.12.008</ArticleId><ArticleId IdType="pmc">PMC8828536</ArticleId><ArticleId IdType="pubmed">35030321</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J., Gao G., Shi F., Xie H., Yang Q., Liu D., et al. (2021). Activated microglia-induced neuroinflammatory cytokines lead to photoreceptor apoptosis in A&#x3b2;-injected mice. J. Mol. Med. (Berl.) 99 (5), 713&#x2013;728. 10.1007/s00109-021-02046-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-021-02046-6</ArticleId><ArticleId IdType="pubmed">33575853</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Y., McGhee C. N. J., Zhang J. (2024). Adult stem cells in the eye: identification, characterisation, and therapeutic application in ocular regeneration - a review. Clin. Exp. Ophthalmol. 52 (2), 148&#x2013;166. 10.1111/ceo.14309</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ceo.14309</ArticleId><ArticleId IdType="pubmed">38214071</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto H., Simon A., Eriksson U., Harris E., Berson E. L., Dryja T. P. (1999). Mutations in the gene encoding 11-cis retinol dehydrogenase cause delayed dark adaptation and fundus albipunctatus. Nat. Genet. 22 (2), 188&#x2013;191. 10.1038/9707</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/9707</ArticleId><ArticleId IdType="pubmed">10369264</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R. T., Li X., Huang J., Guidry C., Wang S. Z. (2013). Photoreceptor-like cells from reprogramming cultured mammalian RPE cells. Mol. Vis. 19, 1178&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3669535</ArticleId><ArticleId IdType="pubmed">23734087</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J. H., Gross R. L., Basinger S. F., Wu S. M. (2001). Apoptotic cell death of cultured salamander photoreceptors induced by cccp: CsA-insensitive mitochondrial permeability transition. J. Cell Sci. 114 (Pt 9), 1655&#x2013;1664. 10.1242/jcs.114.9.1655</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.114.9.1655</ArticleId><ArticleId IdType="pubmed">11309197</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeager T. R., Reddel R. R. (1999). Constructing immortalized human cell lines. Curr. Opin. Biotechnol. 10 (5), 465&#x2013;469. 10.1016/s0958-1669(99)00011-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0958-1669(99)00011-7</ArticleId><ArticleId IdType="pubmed">10508630</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshihara M., Oguchi A., Murakawa Y. (2019). Genomic instability of iPSCs and challenges in their clinical applications. Adv. Exp. Med. Biol. 1201, 23&#x2013;47. 10.1007/978-3-030-31206-0_2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-030-31206-0_2</ArticleId><ArticleId IdType="pubmed">31898780</ArticleId></ArticleIdList></Reference><Reference><Citation>Zampatti S., Peconi C., Calvino G., Ferese R., Gambardella S., Cascella R., et al. (2023). A splicing variant in RDH8 is associated with autosomal recessive Stargardt macular dystrophy. Genes 14 (8), 1659. 10.3390/genes14081659</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes14081659</ArticleId><ArticleId IdType="pmc">PMC10454646</ArticleId><ArticleId IdType="pubmed">37628710</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng Q., Zhou J., Hua X. (2023). TRIM9 promotes M&#xfc;ller cell-derived retinal stem cells to differentiate into retinal ganglion cells by regulating Atoh7. Vitro Cell. Dev. Biol. Anim. 59 (8), 586&#x2013;595. 10.1007/s11626-023-00807-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11626-023-00807-w</ArticleId><ArticleId IdType="pubmed">37792226</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerti D., Molina M. M., Dorgau B., Mearns S., Bauer R., Al-Aama J., et al. (2021). IGFBPs mediate IGF-1's functions in retinal lamination and photoreceptor development during pluripotent stem cell differentiation to retinal organoids. Stem Cells 39 (4), 458&#x2013;466. 10.1002/stem.3331</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.3331</ArticleId><ArticleId IdType="pubmed">33442906</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeviani M., Carelli V. (2021). Mitochondrial retinopathies. Int. J. Mol. Sci. 23 (1), 210. 10.3390/ijms23010210</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23010210</ArticleId><ArticleId IdType="pmc">PMC8745158</ArticleId><ArticleId IdType="pubmed">35008635</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C., McCall M. A. (2012). Receptor targets of amacrine cells. Vis. Neurosci. 29 (1), 11&#x2013;29. 10.1017/S0952523812000028</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0952523812000028</ArticleId><ArticleId IdType="pmc">PMC8991984</ArticleId><ArticleId IdType="pubmed">22310370</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Liu J., Yu B., Ma F., Ren X., Li X. (2018). Effects of mesenchymal stem cells and their exosomes on the healing of large and refractory macular holes. Graefes Arch. Clin. Exp. Ophthalmol. 256 (11), 2041&#x2013;2052. 10.1007/s00417-018-4097-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00417-018-4097-3</ArticleId><ArticleId IdType="pubmed">30167916</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Zhang D., Wei W., Shen B., Wang Y., Zhang Y., et al. (2017). Effects of RPE-conditioned medium on the differentiation of hADSCs into RPE cells, and their proliferation and migration. Exp. Ther. Med. 14 (4), 3699&#x2013;3707. 10.3892/etm.2017.4997</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2017.4997</ArticleId><ArticleId IdType="pmc">PMC5639303</ArticleId><ArticleId IdType="pubmed">29042966</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H., Yan F. (2024). Retinal organoids: a next-generation platform for high-throughput drug discovery. Stem Cell Rev. Rep. 20 (2), 495&#x2013;508. 10.1007/s12015-023-10661-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12015-023-10661-8</ArticleId><ArticleId IdType="pmc">PMC10837228</ArticleId><ArticleId IdType="pubmed">38079086</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X X., Chen Z., Wang L., Ou Q., Feng Z., Xiao H., et al. (2022). Direct conversion of human umbilical cord mesenchymal stem cells into retinal pigment epithelial cells for treatment of retinal degeneration. Cell Death Dis. 13 (9), 785. 10.1038/s41419-022-05199-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-022-05199-5</ArticleId><ArticleId IdType="pmc">PMC9468174</ArticleId><ArticleId IdType="pubmed">36096985</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y Y., Cao B., Tolone A., Yan J., Christensen G., Arango-Gonzalez B., et al. (2022). In vitro model systems for studies into retinal neuroprotection. Front. Neurosci. 16, 938089. 10.3389/fnins.2022.938089</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2022.938089</ArticleId><ArticleId IdType="pmc">PMC9301112</ArticleId><ArticleId IdType="pubmed">35873807</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39617060</PMID><DateRevised><Year>2024</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1549-4713</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>29</Day></PubDate></JournalIssue><Title>Ophthalmology</Title><ISOAbbreviation>Ophthalmology</ISOAbbreviation></Journal><ArticleTitle>Anatomic Outcomes With Faricimab vs. Aflibercept in the Head-to-Head Dosing Phase of the TENAYA/LUCERNE Trials in Neovascular AMD.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0161-6420(24)00748-6</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ophtha.2024.11.023</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To compare early anatomic outcomes following treatment with faricimab vs. aflibercept in a pooled analysis of the head-to-head dosing phase of the TENAYA/LUCERNE trials in neovascular age-related macular degeneration (nAMD).</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">TENAYA/LUCERNE (NCT03823287/NCT03823300) were identical, randomized, double-masked, active comparator-controlled phase 3 noninferiority trials.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Aged &#x2265; 50 years with treatment-na&#xef;ve nAMD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients were randomized (1:1) to intravitreal faricimab 6.0 mg up to every 16 weeks (Q16W) after 4 initial doses every 4 weeks (Q4W) or aflibercept 2.0 mg every 8 weeks (Q8W) after 3 initial doses given Q4W.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Post hoc analyses comparing faricimab with aflibercept in terms of change in central subfield thickness (CST) from baseline and proportion of patients with an absence of subretinal (SRF) and intraretinal fluid (IRF) during initial 12-week head-to-head dosing phase, when both arms received 3 injections, and time to first absence of IRF and SRF.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">1329 patients were enrolled across TENAYA/LUCERNE (n = 665 faricimab; n = 664 aflibercept). There were greater (nominal P &lt; 0.0001) reductions in adjusted mean CST from baseline with faricimab vs. aflibercept at weeks 4, 8, and 12, with comparable vision outcomes. At week 12, more patients (95% confidence interval) achieved an absence of SRF (87.9% [85.4%, 90.4%] vs. 79.0% [76.0%, 82.1%]) and both IRF and SRF (77.2% [74.0%, 80.4%] vs. 66.5% [62.9%, 70.0%]), but not IRF (88.4% [86.0%, 90.8%] vs. 85.0% [82.3%, 87.6%]), with faricimab vs. aflibercept, respectively. In patients with IRF and/or SRF at baseline (n = 581 faricimab; n = 591 aflibercept), the 75th percentile of time to first absence of IRF and SRF was reached at week 8 with faricimab and week 12 with aflibercept. At week 12, cumulative incidence of first-time absence of IRF and SRF was 85.5% (82.3%, 88.1%) with faricimab and 75.0% (71.3%, 78.3%) with aflibercept.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Faricimab resulted in greater improvement in anatomic outcomes than aflibercept during the head-to-head dosing phase and a faster time to first absence of retinal fluid.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gemmy Cheung</LastName><ForeName>Chui Ming</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Singapore Eye Research Institute, Singapore National Eye Centre, Duke-NUS Medical School, National University of Singapore, Singapore. Electronic address: gemmy.cheung.c.m@singhealth.com.sg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Jennifer I</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>University of Illinois at Chicago, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Priglinger</LastName><ForeName>Siegfried</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, LMU University Hospital, LMU Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Querques</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Vita-Salute University, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Margaron</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd., Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Shriji</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Souverain</LastName><ForeName>Audrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd., Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willis</LastName><ForeName>Jeffrey R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Ming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guymer</LastName><ForeName>Robyn</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Eye Research Australia, Royal Victorian Eye and Ear Hospital, University of Melbourne (Department of Surgery), Melbourne, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ophthalmology</MedlineTA><NlmUniqueID>7802443</NlmUniqueID><ISSNLinking>0161-6420</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>2</Day><Hour>5</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>2</Day><Hour>5</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>1</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39617060</ArticleId><ArticleId IdType="doi">10.1016/j.ophtha.2024.11.023</ArticleId><ArticleId IdType="pii">S0161-6420(24)00748-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39617059</PMID><DateRevised><Year>2024</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1549-4713</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>29</Day></PubDate></JournalIssue><Title>Ophthalmology</Title><ISOAbbreviation>Ophthalmology</ISOAbbreviation></Journal><ArticleTitle>Longitudinal Assessment of AMD using Ultrawide Field Imaging - The Optos PEripheral RetinA (OPERA) Follow-up Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0161-6420(24)00749-8</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ophtha.2024.11.024</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">With the widespread availability of ultrawide field imaging, peripheral retinal abnormalities in age-related macular degeneration (AMD) have garnered attention. However, longitudinal studies on AMD peripheral findings are limited. This study aims to characterize and quantify these features over five years.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Longitudinal ancillary study.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Optos PEripheral RetinA (OPERA) is an ancillary study of the Age-Related Eye Disease Study 2. A total of 137 OPERA participants (265 eyes) with gradable ultrawide field (UWF) color and autofluorescence imaging at year 5 (Y5) and year 10 (Y10) were included.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">UWF color and autofluorescence images were captured using Optos ultrawide field devices (Optos, Dunfermline, Scotland) and graded at the Wisconsin Reading Center for macular and peripheral AMD features using the 3-zone OPERA grid.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Presence of peripheral retinal lesions (Neovascular AMD, geographic atrophy (GA), drusen, increased pigment, decreased pigment, reticular pseudodrusen, reticular pigmentary changes, and cobblestone degeneration) and their association with central AMD progression.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">UWF color: In zone 1 at Y5, AMD severity scale (AMDSS) was &#x2264;5 in 8%, 6-8 in 49%, noncentral and central GA in 15%, and neovascular AMD in 28%. In zone 1 at Y10, AMDSS was &#x2264;5 in 6%, 6-8 in 30%, noncentral and central geographic atrophy in 27%, and neovascular AMD in 37%. In zone 2, peripheral AMD abnormalities in Y5 versus Y10 included: drusen 99% vs 99%, hyperpigmentation 11% vs 11%, and hypopigmentation 4% vs 7% respectively. Non-AMD peripheral degenerations were present in Y5 versus Y10: cobblestone 19% vs 30% and reticular pigmentary changes 25% vs 33% respectively. Among eyes with AMDSS 6-8 at Y5, progression to late AMD occurred in 41% without substantial peripheral findings and 41% with such findings, which include drusen of &#x2265;1 disc area and/or any hypo or hyperpigmentation in zones 2 or 3. UWF autofluorescence: Reticular autofluorescence pattern was present in 22% of eyes at Y5 and 39% at Y10 with 5% and 6% of cases being most prominent outside of zone 1. GA was present in 53 eyes with mean area of 3.4mm<sup>2</sup> (SD = 5.4) at Y5 and 91 eyes with mean area 7.7mm<sup>2</sup> (SD = 9.7) at Y10.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The OPERA study reveals that AMD features often extend beyond the macula, suggesting that AMD is a panretinal disease. In this study peripheral findings were not associated with increased risk of progression to late AMD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Froines</LastName><ForeName>Colin P</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pak</LastName><ForeName>Jeong W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agr&#xf3;n</LastName><ForeName>Elvira</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chew</LastName><ForeName>Emily Y</ForeName><Initials>EY</Initials><AffiliationInfo><Affiliation>Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peto</LastName><ForeName>Tunde</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Centre for Public Health, Queen's University Belfast, Belfast, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blodi</LastName><ForeName>Barbara A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Domalpally</LastName><ForeName>Amitha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin. Electronic address: domalpally@wisc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ophthalmology</MedlineTA><NlmUniqueID>7802443</NlmUniqueID><ISSNLinking>0161-6420</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Age-related macular degeneration</Keyword><Keyword MajorTopicYN="N">peripheral retinal findings</Keyword><Keyword MajorTopicYN="N">ultrawide-field photography</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>2</Day><Hour>5</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>2</Day><Hour>5</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>1</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39617059</ArticleId><ArticleId IdType="doi">10.1016/j.ophtha.2024.11.024</ArticleId><ArticleId IdType="pii">S0161-6420(24)00749-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39615827</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-0007</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>28</Day></PubDate></JournalIssue><Title>Experimental eye research</Title><ISOAbbreviation>Exp Eye Res</ISOAbbreviation></Journal><ArticleTitle>Integrative analysis and knowledgebase construction of key candidate genes and pathways in age-related macular degeneration.</ArticleTitle><Pagination><StartPage>110177</StartPage><MedlinePgn>110177</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.exer.2024.110177</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0014-4835(24)00399-3</ELocationID><Abstract><AbstractText>Age-related macular degeneration is a retinal disease that severely impacts vision in the older population. Its gene-related heterogeneity has not been fully studied, increasing the burden of precise treatment, prevention and prognosis. Genetic variation and related information were collected, annotated and expanded from multiple related websites, and all the data were integrated into the online platform AMDGKB. Users can visit this database via the following link: http://amdgd.bioinf.org.cn/for their personalized applications knowledge-guided modeling and applications. This study also explored the heterogeneity of ethnicity and AMD subtypes via genetic variation, functional enrichment analysis and protein&#x2012;protein interactions. These results suggest that VEGFA, MT2A, CCL2 and SERPINF1 play different roles in the development of AMD in different ethnic groups. The enrichment analysis also revealed differences in the pathogenesis pathways of different ethnic groups and AMD subtypes. This study highlights that genetic heterogeneity needs to be considered in the process of diagnosis and treatment. AMDGKB provides information for investigating the transformation of genetic variation during AMD progression, as well as for future personalized applications in the diagnosis and prognosis of AMD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Dongyue</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, West China Hospital, Sichuan University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Tong</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yayi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, West China Hospital, Sichuan University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Bairong</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University. Electronic address: zhangmingscu0905@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, West China Hospital, Sichuan University. Electronic address: bairong.shen@scu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Exp Eye Res</MedlineTA><NlmUniqueID>0370707</NlmUniqueID><ISSNLinking>0014-4835</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>1</Day><Hour>15</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>1</Day><Hour>15</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>30</Day><Hour>19</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39615827</ArticleId><ArticleId IdType="doi">10.1016/j.exer.2024.110177</ArticleId><ArticleId IdType="pii">S0014-4835(24)00399-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39615819</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1891</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>28</Day></PubDate></JournalIssue><Title>American journal of ophthalmology</Title><ISOAbbreviation>Am J Ophthalmol</ISOAbbreviation></Journal><ArticleTitle>The effects of pregnancy on disease progression of retinitis pigmentosa.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0002-9394(24)00548-8</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajo.2024.11.016</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Retinitis pigmentosa (RP) is the most common diagnosis in the ophthalmic genetics' clinic. Women with RP are often diagnosed during their reproductive years, posing significant challenges for family planning. The effects of pregnancy on RP progression is a frequently unanswered concern for these patients.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective cohort study.</AbstractText><AbstractText Label="SUBJECTS" NlmCategory="METHODS">Women who attended Moorfields Eye Hospital (London, UK) and met the following inclusion criteria were included in this study: (i) had their most recent visit at 30 years old or more, (ii) were diagnosed with RP, (iii) had information in their medical records about having had children, and (iv) were found to have biallelic rare or likely disease-causing variants in USH2A.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The cohort was divided into parous and nulliparous, and multivariate Cox regressions adjusting for multiple confounding effects was performed. A further analysis also included number of children as a variable.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">RP severity criteria based on visual acuity (VA) and ellipsoid zone (EZ) width, and national registration of sight impairment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">142 women were included in the study, 98 parous (69%) and 44 nulliparous (31%). In the parous group, 21% had cystoid macular oedema (CMO) requiring treatment and 46% had cataracts or were pseudophakic, versus 18% with CMO and 59% with cataracts in the nulliparous. Women had a median of 2 children. A significant association was only found in parous women having 3.04 (1.23-7.48) times increased risk of having VA worse than LogMAR 0.7 than nulliparous (p= 0.016), after adjusting for baseline age, phenotype, cataract status, and CMO.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This is the first large-scale objective study analysing the effects of pregnancy in genetically-confirmed women with RP. Women with USH2A-associated RP who had children appeared to have 3.04 times the risk of reaching VA below 6/24 than those who did not have children. It is possible that other factors besides retinal degeneration are affecting central vision and causing this increased risk. A significant association between faster or slower EZ loss and pregnancy was not present in our cohort. We believe these findings will be relevant to all women with RP considering starting a family; although further studies are needed.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Varela</LastName><ForeName>Malena Daich</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Moorfields Eye Hospital, London, United Kingdom; UCL Institute of Ophthalmology, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rashid</LastName><ForeName>Memuna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CRUK Cancer Trials Centre, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopes</LastName><ForeName>Andre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CRUK Cancer Trials Centre, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michaelides</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Moorfields Eye Hospital, London, United Kingdom; UCL Institute of Ophthalmology, University College London, London, United Kingdom. Electronic address: michel.michaelides@ucl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Ophthalmol</MedlineTA><NlmUniqueID>0370500</NlmUniqueID><ISSNLinking>0002-9394</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">genetics</Keyword><Keyword MajorTopicYN="N">inherited</Keyword><Keyword MajorTopicYN="N">motherhood</Keyword><Keyword MajorTopicYN="N">pregnancy</Keyword><Keyword MajorTopicYN="N">retina</Keyword><Keyword MajorTopicYN="N">retinitis pigmentosa</Keyword></KeywordList><CoiStatement>Declaration of competing interest None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>1</Day><Hour>15</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>1</Day><Hour>15</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>30</Day><Hour>19</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39615819</ArticleId><ArticleId IdType="doi">10.1016/j.ajo.2024.11.016</ArticleId><ArticleId IdType="pii">S0002-9394(24)00548-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39615671</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2468-6530</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>28</Day></PubDate></JournalIssue><Title>Ophthalmology. Retina</Title><ISOAbbreviation>Ophthalmol Retina</ISOAbbreviation></Journal><ArticleTitle>Insights Into Cataract Surgery Outcomes In Age-Related Macular Degeneration: Real-World Perspectives Across Severity Grades.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S2468-6530(24)00575-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.oret.2024.11.018</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Cataract and age-related macular degeneration (AMD) share age as a main risk factor and thus have a high coincidence. Both conditions substantially reduce visual acuity. This study aimed to assess the impact of cataract surgery on visual acuity, retinal morphology, and vascular-endothelial-growth-factor (VEGF) inhibitor therapy in patients with AMD.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">This study was designed as a retrospective, monocentric, real-world study.</AbstractText><AbstractText Label="SUBJECTS" NlmCategory="METHODS">Patients diagnosed with either dry AMD or neovascular AMD undergoing cataract surgery at Charit&#xe9; Campus Benjamin Franklin.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Treatment data were extracted from the Berlin Macular Registry. Best-corrected visual acuity (BCVA) and macular optical coherence tomography (OCT) parameters, including central retinal thickness (CRT), macular volume (MV), presence of macular edema, intraretinal or subretinal fluid and pigment epithelial detachment were assessed.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Primary outcome measure was the postoperative BCVA. Secondary outcomes included postoperative CRT, MV, changes in qualitative OCT parameters, alterations in anti-VEGF-therapy interval and postoperative complications.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 418 eyes of 418 patients were included in the analysis with a mean follow-up time of 18.8 (2-62) months. They were classified into a neovascular AMD (n=85) and a dry AMD (n=333) cohort. Mean BCVA improved significantly in the neovascular AMD cohort from 0.69 &#xb1;0.45 logMAR to 0.47 &#xb1;0.42 (p= &lt;0.001) and in the dry AMD cohort from 0.53 &#xb1;0.47 logMAR to 0.27 &#xb1;0.32 (p= &lt;0.001) at the two-month follow-up. Improvements in BCVA were sustained to the final visit (18.9 &#xb1;19.5 months post-surgery) with BCVA at 0.46 &#xb1; 0.38 logMAR (p= &lt;0.001) and 0.26 &#xb1; 0.34 logMAR (p= &lt;0.001), respectively. Temporary postoperative increases in CRT and MV were observed, reverting to preoperative levels by six months post-surgery. The need for anti-VEGF therapy did not change postoperatively in patients with neovascular AMD.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Within this retrospective analysis, on average patients with coincident AMD of all severity grades meeting the inclusion criteria benefited from cataract surgery. Transient increases in retinal thickness and macular volume returned to baseline within six months post-surgery. The need for intravitreal injections in neovascular AMD subjects was unchanged post-surgery. Overall, the study suggests no adverse long-term macular changes attributable to cataract surgery.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ho Ssl</LastName><ForeName>Leopold</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Charit&#xe9; University Medicine Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t Berlin, and Berlin Institute of Health.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaghefi</LastName><ForeName>Shirin Ashraf</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Charit&#xe9; University Medicine Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t Berlin, and Berlin Institute of Health.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riemer</LastName><ForeName>Tommes</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Charit&#xe9; University Medicine Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t Berlin, and Berlin Institute of Health.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kabiri</LastName><ForeName>Payam</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Charit&#xe9; University Medicine Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t Berlin, and Berlin Institute of Health.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonaventura</LastName><ForeName>Theresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Charit&#xe9; University Medicine Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t Berlin, and Berlin Institute of Health.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ru Bsam</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Charit&#xe9; University Medicine Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t Berlin, and Berlin Institute of Health; Berlin Institute of Health (BIH), Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joussen</LastName><ForeName>Antonia M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Charit&#xe9; University Medicine Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t Berlin, and Berlin Institute of Health; Berlin Institute of Health (BIH), Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeitz</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Charit&#xe9; University Medicine Berlin, corporate member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t Berlin, and Berlin Institute of Health; Berlin Institute of Health (BIH), Berlin, Germany. Electronic address: oliver.zeitz@charite.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ophthalmol Retina</MedlineTA><NlmUniqueID>101695048</NlmUniqueID><ISSNLinking>2468-6530</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>1</Day><Hour>15</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>1</Day><Hour>15</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>30</Day><Hour>19</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39615671</ArticleId><ArticleId IdType="doi">10.1016/j.oret.2024.11.018</ArticleId><ArticleId IdType="pii">S2468-6530(24)00575-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39615233</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0534</ISSN><JournalIssue CitedMedium="Internet"><Volume>184</Volume><PubDate><Year>2024</Year><Month>Nov</Month><Day>29</Day></PubDate></JournalIssue><Title>Computers in biology and medicine</Title><ISOAbbreviation>Comput Biol Med</ISOAbbreviation></Journal><ArticleTitle>Interpretable diagnostic system for multiocular diseases based on hybrid meta-heuristic feature selection.</ArticleTitle><Pagination><StartPage>109486</StartPage><MedlinePgn>109486</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.compbiomed.2024.109486</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0010-4825(24)01571-3</ELocationID><Abstract><AbstractText>Age-related Macular Degeneration (AMD), Cataract, Diabetic Retinopathy (DR) and Glaucoma are the four most common ocular conditions that affect a person's vision. Early detection in the asymptomatic stages can alleviate vision loss or slow down the progression of these diseases. However, manual diagnosis is a costly and tedious process, especially in mass screening applications. Computer aided diagnosis (CAD) systems serve as an aid to ophthalmologists in efficient diagnosis of ocular diseases. In particular, a generic CAD framework that detects multiple ocular diseases could be immensely beneficial. In the proposed work, a single framework for detection of the above-mentioned ocular diseases has been explored. Specifically, a pool of non-linear handcrafted features are extracted from fundus images, followed by feature selection using a hybrid optimization algorithm, where features are selected using JAYA algorithm (JA) first, followed sequentially by the Harris hawks optimization (HHO) algorithm. The selected features are used to train an extreme gradient boosting (XGB) model for disease classification. Unlike existing systems that restrict non-linear features to single ocular disease detection, the proposed system is the first of its kind for detection of the above-specified multiple ocular diseases in a generic framework, yielding 93&#xa0;% accuracy, 91.3&#xa0;% sensitivity, 96.4&#xa0;% specificity, 90.4&#xa0;% precision and 90.8&#xa0;% F1 score. Further, in this study, Shapley additive explanations (SHAP) analysis is employed to gain insight on the impact of the non-linear features on the model's prediction capability. This work clearly demonstrates the importance of explainability that opens the 'black box' nature of machine learning (ML) model and clearly unveils the relationships among the features and the diagnosis. Also, the explainable ML model improves transparency of the model's decision-making process. The proposed algorithm can efficiently assist physicians in diagnosing the ocular diseases using fundus images in clinical practice, and avoids the subjective difference that comes with manual assessment.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>M</LastName><ForeName>Raveenthini</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Electronics and Communication Engineering, Amrita School of Engineering, Coimbatore, Amrita Vishwa Vidyapeetham, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R</LastName><ForeName>Lavanya</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Electronics and Communication Engineering, Amrita School of Engineering, Coimbatore, Amrita Vishwa Vidyapeetham, India. Electronic address: r_lavanya@cb.amrita.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benitez</LastName><ForeName>Raul</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Automatic Control Department, Universitat Polit&#xe8;cnica de Catalunya-BarcelonaTech, 08034, Barcelona, Spain; Institut de Recerca Sant Joan de D&#xe8;u (IRSJD), 08950, Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Comput Biol Med</MedlineTA><NlmUniqueID>1250250</NlmUniqueID><ISSNLinking>0010-4825</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Age-related macular degeneration</Keyword><Keyword MajorTopicYN="N">Cataract</Keyword><Keyword MajorTopicYN="N">Diabetic retinopathy</Keyword><Keyword MajorTopicYN="N">Glaucoma</Keyword><Keyword MajorTopicYN="N">Interpretability</Keyword><Keyword MajorTopicYN="N">Machine learning</Keyword><Keyword MajorTopicYN="N">Meta-heuristic algorithm</Keyword><Keyword MajorTopicYN="N">Non-linear features</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>1</Day><Hour>15</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>1</Day><Hour>15</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>30</Day><Hour>18</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39615233</ArticleId><ArticleId IdType="doi">10.1016/j.compbiomed.2024.109486</ArticleId><ArticleId IdType="pii">S0010-4825(24)01571-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39614439</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2768-6698</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>13</Day></PubDate></JournalIssue><Title>Frontiers in bioscience (Landmark edition)</Title><ISOAbbreviation>Front Biosci (Landmark Ed)</ISOAbbreviation></Journal><ArticleTitle>Sodium Iodate: Rapid and Clinically Relevant Model of AMD.</ArticleTitle><Pagination><StartPage>380</StartPage><MedlinePgn>380</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.31083/j.fbl2911380</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Age-related macular degeneration (AMD) is the most common cause of vision loss in people above the age of 50, affecting approximately 10% of the population worldwide and the incidence is rising. Hyperreflective foci (HRF) are a major predictor of AMD progression. The purpose of this study was to use the sodium iodate mouse model to study HRF formation in retinal degeneration.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Sodium iodate (NaIO<sub>3</sub>) treated rodents were studied to characterize HRF. 3-month-old male wild-type (WT) C57Bl/6J mice were injected with phosphate-buffered saline (PBS) or varying doses of NaIO<sub>3</sub> (15-60 mg/kg). Optical Coherence Tomography (OCT) images were collected at baseline and several days post-NaIO<sub>3</sub> injection. Retinal thicknesses were measured using Bioptigen software. Seven days post-injection, eyes were prepared for either transmission electron microscopy (TEM), Hematoxylin &amp; Eosin (H&amp;E), or immunofluorescence.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">OCT imaging of the mice given higher doses of NaIO<sub>3</sub> revealed HRF formation in the neural retina (n = 4). The amount of HRF correlated with the degree of retinal tissue loss. H&amp;E and TEM imaging of the retinas seven days post-NaIO<sub>3</sub> injection revealed several pigmented bodies in multiple layers of the retina (n = 3-5). Immunofluorescence revealed that some pigmented bodies were positive for macrophage markers and an epithelial-to-mesenchymal transition marker, while all were retinal pigment epithelium (RPE) 65-negative (n = 4).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The data suggest that NaIO<sub>3</sub> induces the formation of HRF in the outer retina and their abundance correlates with retinal tissue loss. The experiments in this study highlight NaIO<sub>3</sub> as a clinically relevant model of intermediate AMD that can be used to study HRF formation and to discover new treatment targets.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s). Published by IMR Press.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Geathers</LastName><ForeName>Jasmine S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grillo</LastName><ForeName>Stephanie L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karakoleva</LastName><ForeName>Ema</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campbell</LastName><ForeName>Gregory P</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Yixuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Han</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Section of Research Resources, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barber</LastName><ForeName>Alistair J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yuanjun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sundstrom</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Bennett and Inez Chotiner Early Career Professorship in Ophthalmology endowment (JMS)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Singapore</Country><MedlineTA>Front Biosci (Landmark Ed)</MedlineTA><NlmUniqueID>101612996</NlmUniqueID><ISSNLinking>2768-6698</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>U558PCS5Z9</RegistryNumber><NameOfSubstance UI="C032285">sodium iodate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007452">Iodates</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007452" MajorTopicYN="Y">Iodates</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="Y">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D041623" MajorTopicYN="Y">Tomography, Optical Coherence</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008268" MajorTopicYN="Y">Macular Degeneration</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012160" MajorTopicYN="N">Retina</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055213" MajorTopicYN="N">Retinal Pigment Epithelium</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">epithelial-to-mesenchymal transition</Keyword><Keyword MajorTopicYN="N">hyperreflective foci</Keyword><Keyword MajorTopicYN="N">macular degeneration</Keyword><Keyword MajorTopicYN="N">retinal pigment epithelia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>30</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>30</Day><Hour>12</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>30</Day><Hour>0</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39614439</ArticleId><ArticleId IdType="doi">10.31083/j.fbl2911380</ArticleId><ArticleId IdType="pii">S2768-6701(24)01472-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39613904</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5454</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>29</Day></PubDate></JournalIssue><Title>Eye (London, England)</Title><ISOAbbreviation>Eye (Lond)</ISOAbbreviation></Journal><ArticleTitle>Prevalence and diversity of retinal disease in adults with Down syndrome.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41433-024-03508-0</ELocationID><Abstract><AbstractText>While epidemiologic data exists for some ophthalmic diseases in people with Down Syndrome (DS), like strabismus and amblyopia, no studies explore the prevalence of retinal disease in people with DS on a large scale. This study utilized a literature review and exploratory epidemiology analysis to examine patterns of retinal disease in people with DS. To evaluate previous studies on physiology and/or anatomy in retinal models representing DS or in the retinas of people with DS, all relevant terms related to Down Syndrome, retina, and retinal diseases were searched in PubMed and Scopus. Data from the health platform TriNetX was then utilized to determine the prevalence and prevalence odds ratio (POR) of retinal disorders, including diabetic retinopathy and age-related macular degeneration (AMD), within the U.S. adult population with DS. The final literature review included 28 of 535 screened studies and found that a DS diagnosis was associated with atypical retinal vascularization, retinal thickening, and abnormal neuronal development. Of 55,198,979 individuals included in the population study, 97,795 (0.18%) had a recorded DS diagnosis. Compared to the population without DS, the population with DS had significantly increased PORs for any retinal diagnosis (3.78, 95% CI 3.63-3.93), for 16 of 18 recorded individual retinal diagnoses, and for 4 of 5 major diagnostic categories, including diabetic retinopathy (2.56, 95% CI 2.33-2.82) and macular degeneration (4.01, 95% CI 3.42-4.71). The conclusion is that retinal anomalies common to people with DS likely contribute to higher rates of recorded retinal disease. However, future studies should evaluate this relationship.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Foster</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Case Western Reserve University School of Medicine, Cleveland, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Eastern Virginia Medical School, Norfolk, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0005-5306-3982</Identifier><AffiliationInfo><Affiliation>Case Western Reserve University School of Medicine, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaia</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Case Western Reserve University School of Medicine, Cleveland, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Rishi P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cleveland Clinic Martin Hospitals, Cleveland Clinic Florida, Stuart, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cleveland Clinic Cole Eye Institute, Cleveland, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talcott</LastName><ForeName>Katherine E</ForeName><Initials>KE</Initials><Identifier Source="ORCID">0000-0003-0458-4181</Identifier><AffiliationInfo><Affiliation>Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA. talcotk@ccf.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cleveland Clinic Cole Eye Institute, Cleveland, OH, USA. talcotk@ccf.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA. talcotk@ccf.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 EY024236</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30EY025585(BA-A)</GrantID><Agency>Research to Prevent Blindness (RPB)</Agency><Country/></Grant><Grant><GrantID>P30EY025585(BA-A)</GrantID><Agency>Research to Prevent Blindness (RPB)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eye (Lond)</MedlineTA><NlmUniqueID>8703986</NlmUniqueID><ISSNLinking>0950-222X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Competing interests: KT: Genentech (speaker&#x2019;s bureau, consultant), Zeiss (grant), Eyepoint (consultant), Apellis (consultant), Regenxbio (consultant). Rishi Singh reports personal fees from Genentech/Roche, Alcon, Novartis, Regeneron, Asclepix, Gyroscope, Bausch and Lomb, and Apellis. Katherine Talcott reports personal fees from Genentech/Roche, Apellis, and EyePoint and research fees from Zeiss and Regenxbio.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>30</Day><Hour>11</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>30</Day><Hour>11</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>29</Day><Hour>23</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39613904</ArticleId><ArticleId IdType="doi">10.1038/s41433-024-03508-0</ArticleId><ArticleId IdType="pii">10.1038/s41433-024-03508-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Asim A, Kumar A, Muthuswamy S, Jain S, Agarwal S. Down syndrome: an insight of the disease. J Biomed Sci. 2015;22:41. https://doi.org/10.1186/s12929-015-0138-y .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-015-0138-y</ArticleId><ArticleId IdType="pubmed">26062604</ArticleId><ArticleId IdType="pmc">4464633</ArticleId></ArticleIdList></Reference><Reference><Citation>Presson AP, Partyka G, Jensen KM, Devine OJ, Rasmussen SA, McCabe LL, et al. Current estimate of Down Syndrome population prevalence in the United States. J Pediatr. 2013;163:1163&#x2013;8. https://doi.org/10.1016/j.jpeds.2013.06.013 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2013.06.013</ArticleId><ArticleId IdType="pubmed">23885965</ArticleId><ArticleId IdType="pmc">4445685</ArticleId></ArticleIdList></Reference><Reference><Citation>Akhtar F, Bokhari SRA Down Syndrome. StatPearls. Treasure Island (FL): StatPearls Publishing; 2022. https://www.ncbi.nlm.nih.gov/books/NBK526016/ .</Citation></Reference><Reference><Citation>Driscoll DA, Gross S. Clinical practice. Prenatal screening for aneuploidy. N Engl J Med. 2009;360:2556&#x2013;62. https://doi.org/10.1056/NEJMcp0900134 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcp0900134</ArticleId><ArticleId IdType="pubmed">19516035</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrich M, Deciu C, Zwiefelhofer T, Tynan JA, Cagasan L, Tim R, et al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol. 2011;204:205.e1&#x2013;11. https://doi.org/10.1016/j.ajog.2010.12.060 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2010.12.060</ArticleId><ArticleId IdType="pubmed">21310373</ArticleId></ArticleIdList></Reference><Reference><Citation>National Human Genome Research Institute. Learning about Down syndrome. 2010. http://www.genome.gov/19517824#3 .</Citation></Reference><Reference><Citation>Landes SD, Stevens JD, Turk MA. Cause of death in adults with Down syndrome in the United States. Disabil Health J. 2020;13:100947. https://doi.org/10.1016/j.dhjo.2020.100947 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dhjo.2020.100947</ArticleId><ArticleId IdType="pubmed">32680774</ArticleId><ArticleId IdType="pmc">7655667</ArticleId></ArticleIdList></Reference><Reference><Citation>de Graaf G, Buckley F, Skotko BG. Estimation of the number of people with Down syndrome in the United States. Genet Med. 2017;19:439&#x2013;47. https://doi.org/10.1038/gim.2016.127 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2016.127</ArticleId><ArticleId IdType="pubmed">27608174</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Murphy SL, Kochanek KD, Arias E. Mortality in the United States, 2021. NCHS Data Brief. 2022. PMID: 36598387.</Citation></Reference><Reference><Citation>Sun E, Kraus CL. The ophthalmic manifestations of Down syndrome. Children. 2023;10:341. https://doi.org/10.3390/children10020341 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/children10020341</ArticleId><ArticleId IdType="pubmed">36832470</ArticleId><ArticleId IdType="pmc">9955748</ArticleId></ArticleIdList></Reference><Reference><Citation>Adio AO, Wajuihian SO. Ophthalmic manifestations of children with Down syndrome in Port Harcourt, Nigeria. Clin Ophthalmol. 2012;6:1859&#x2013;64. https://doi.org/10.2147/OPTH.S36685 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OPTH.S36685</ArticleId><ArticleId IdType="pubmed">23185113</ArticleId><ArticleId IdType="pmc">3501839</ArticleId></ArticleIdList></Reference><Reference><Citation>Liza-Sharmini AT, Azlan ZN, Zilfalil BA. Ocular findings in Malaysian children with Down syndrome. Singap Med J. 2006;47:14&#x2013;9.</Citation></Reference><Reference><Citation>Krinsky-McHale SJ, Jenkins EC, Zigman WB, Silverman W. Ophthalmic disorders in adults with Down syndrome. Curr Gerontol Geriatr Res. 2012;2012:974253. https://doi.org/10.1155/2012/974253 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/974253</ArticleId><ArticleId IdType="pubmed">22570648</ArticleId><ArticleId IdType="pmc">3337581</ArticleId></ArticleIdList></Reference><Reference><Citation>Pugazhendhi A, Hubbell M, Jairam P, Ambati B. Neovascular macular degeneration: a review of etiology, risk factors, and recent advances in research and therapy. Int J Mol Sci. 2021;22:1170. https://doi.org/10.3390/ijms22031170 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22031170</ArticleId><ArticleId IdType="pubmed">33504013</ArticleId><ArticleId IdType="pmc">7866170</ArticleId></ArticleIdList></Reference><Reference><Citation>Blank M, Fuerst PG, Stevens B, Nouri N, Kirkby L, Warrier D, et al. The Down syndrome critical region regulates retinogeniculate refinement. J Neurosci. 2011;31:5764&#x2013;76. https://doi.org/10.1523/JNEUROSCI.6015-10.2011 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6015-10.2011</ArticleId><ArticleId IdType="pubmed">21490218</ArticleId><ArticleId IdType="pmc">3230532</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu FY, Gao FJ, Xu P, Zhang SH, Wu JH. Cell development deficiency and gene expression dysregulation of trisomy 21 retina revealed by single-nucleus RNA sequencing. Front Bioeng Biotechnol. 2020;8:564057. https://doi.org/10.3389/fbioe.2020.564057 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fbioe.2020.564057</ArticleId><ArticleId IdType="pubmed">33072724</ArticleId><ArticleId IdType="pmc">7538860</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Sukeena JM, Simmons AB, Hansen EJ, Nuhn RE, Samuels IS, et al. DSCAM promotes refinement in the mouse retina through cell death and restriction of exploring dendrites. J Neurosci. 2015;35:5640&#x2013;54. https://doi.org/10.1523/JNEUROSCI.2202-14.2015 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2202-14.2015</ArticleId><ArticleId IdType="pubmed">25855178</ArticleId><ArticleId IdType="pmc">4388924</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons AB, Merrill MM, Reed JC, Deans MR, Edwards MM, Fuerst PG. Defective angiogenesis and intraretinal bleeding in mouse models with disrupted inner retinal lamination. Investig Ophthalmol Vis Sci. 2016;57:1563&#x2013;77. https://doi.org/10.1167/iovs.15-18395 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.15-18395</ArticleId></ArticleIdList></Reference><Reference><Citation>Laguna A, Barallobre MJ, Marchena M&#xc1;, Mateus C, Ram&#xed;rez E, Mart&#xed;nez-Cue C, et al. Triplication of DYRK1A causes retinal structural and functional alterations in Down syndrome. Hum Mol Genet. 2013;22:2775&#x2013;84. https://doi.org/10.1093/hmg/ddt125 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt125</ArticleId><ArticleId IdType="pubmed">23512985</ArticleId></ArticleIdList></Reference><Reference><Citation>Victorino DB, Scott-McKean JJ, Johnson MW, Costa ACS. Quantitative analysis of retinal structure and function in two chromosomally altered mouse models of Down syndrome. Investig Ophthalmol Vis Sci. 2020;61:25. https://doi.org/10.1167/iovs.61.5.25 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.61.5.25</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozen EJ, Roewenstrunk J, Barallobre MJ, Di Vona C, Jung C, Figueiredo AF, et al. DYRK1A kinase positively regulates angiogenic responses in endothelial cells. Cell Rep. 2018;23:1867&#x2013;78. https://doi.org/10.1016/j.celrep.2018.04.008 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.04.008</ArticleId><ArticleId IdType="pubmed">29742440</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott-McKean JJ, Chang B, Hurd RE, Nusinowitz S, Schmidt C, Davisson MT, et al. The mouse model of Down syndrome Ts65Dn presents visual deficits as assessed by pattern visual evoked potentials. Investig Ophthalmol Vis Sci. 2010;51:3300&#x2013;8. https://doi.org/10.1167/iovs.09-4465 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.09-4465</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad A, Pruett RC. The fundus in mongolism. Arch Ophthalmol. 1976;94:772&#x2013;6. https://doi.org/10.1001/archopht.1976.03910030378005 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archopht.1976.03910030378005</ArticleId><ArticleId IdType="pubmed">131545</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaeger EA. Ocular findings in Down&#x2019;s syndrome. Trans Am Ophthalmol Soc. 1980;78:808&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">6455003</ArticleId><ArticleId IdType="pmc">1312160</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherk MC, Williams TD. Disc vascularity in Down&#x2019;s syndrome. Am J Optom Physiol Opt. 1979;56:509&#x2013;11. https://doi.org/10.1097/00006324-197908000-00005 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006324-197908000-00005</ArticleId><ArticleId IdType="pubmed">161692</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams EJ, McCormick AQ, Tischler B. Retinal vessels in Down&#x2019;s syndrome. Arch Ophthalmol. 1973;89:269&#x2013;71. https://doi.org/10.1001/archopht.1973.01000040271001 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archopht.1973.01000040271001</ArticleId><ArticleId IdType="pubmed">4266686</ArticleId></ArticleIdList></Reference><Reference><Citation>Esteban O, Marcuello C, Martinez M, Lavilla L, Marco S, Ascaso FJ. Macular and choroidal thickness in Down syndrome by swept-source optical coherence tomography (SS-OCT). Arch Soc Esp Oftalmol 2021;96:618&#x2013;22. https://doi.org/10.1016/j.oftale.2021.01.002 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oftale.2021.01.002</ArticleId><ArticleId IdType="pubmed">34756287</ArticleId></ArticleIdList></Reference><Reference><Citation>Walpert MJ, Normando EM, Annus T, Jennings SR, Wilson LR, Watson P. et al. Age-related retinal thickness in Down's syndrome: a high-risk population for dementia. Alzheimer's Dementia Diagnosis Assessment Disease Monitoring. 2019;11:744&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dadm.2019.08.007</ArticleId><ArticleId IdType="pubmed">31909175</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafii MS, Wishnek H, Brewer JB, Donohue MC, Ness S, Mobley WC, et al. The Down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer&#x2019;s disease biomarkers in Down syndrome. Front Behav Neurosci. 2015;9:239. https://doi.org/10.3389/fnbeh.2015.00239 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnbeh.2015.00239</ArticleId><ArticleId IdType="pubmed">26441570</ArticleId><ArticleId IdType="pmc">4568340</ArticleId></ArticleIdList></Reference><Reference><Citation>da Cunha RP, Moreira JB. Ocular findings in Down&#x2019;s syndrome. Am J Ophthalmol. 1996;122:236&#x2013;44. https://doi.org/10.1016/s0002-9394(14)72015-x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0002-9394(14)72015-x</ArticleId><ArticleId IdType="pubmed">8694092</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JH, Hwang JM, Kim HJ, Yu YS. Characteristic ocular findings in Asian children with Down syndrome. Eye. 2002;16:710&#x2013;4. https://doi.org/10.1038/sj.eye.6700208 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.eye.6700208</ArticleId><ArticleId IdType="pubmed">12439664</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson R, Osborne D, Fairhead L, Beed L, Hill CM, Lee H. Segmentation of the foveal and parafoveal retinal architecture using handheld spectral-domain optical coherence tomography in children with Down syndrome. Eye. 2022;36:963&#x2013;8. https://doi.org/10.1038/s41433-021-01883-6 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41433-021-01883-6</ArticleId><ArticleId IdType="pubmed">35001092</ArticleId><ArticleId IdType="pmc">9046253</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien S, Wang J, Smith HA, Donaldson DL, Haider KM, Roberts GJ, et al. Macular structural characteristics in children with Down syndrome. Graefes Arch Clin Exp Ophthalmol. 2015;253:2317&#x2013;23. https://doi.org/10.1007/s00417-015-3088-x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00417-015-3088-x</ArticleId><ArticleId IdType="pubmed">26126584</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugurlu A, Altinkurt E. Ophthalmologic manifestations and retinal findings in children with Down syndrome. J Ophthalmol. 2020;2020:9726261. https://doi.org/10.1155/2020/9726261 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/9726261</ArticleId><ArticleId IdType="pubmed">32089873</ArticleId><ArticleId IdType="pmc">7029299</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss AH, Kelly JP, Phillips JO. Infantile nystagmus and abnormalities of conjugate eye movements in Down syndrome. Investig Ophthalmol Vis Sci. 2016;57:1301&#x2013;9. https://doi.org/10.1167/iovs.15-18532 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.15-18532</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangalesh S, Vinekar A, Jayadev C, Kemmanu V, Bhat M, Sivakumar M, et al. Spectral domain optical coherence tomography in detecting sub-clinical retinal findings in Asian Indian Children with Down Syndrome. Curr Eye Res. 2019;44:901&#x2013;7. https://doi.org/10.1080/02713683.2019.1597128 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/02713683.2019.1597128</ArticleId><ArticleId IdType="pubmed">30961422</ArticleId></ArticleIdList></Reference><Reference><Citation>Postolache L. Abnormalities of the optic nerve in Down Syndrome and associations with visual acuity. Front Neurol. 2019;10:633. https://doi.org/10.3389/fneur.2019.00633 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00633</ArticleId><ArticleId IdType="pubmed">31258511</ArticleId><ArticleId IdType="pmc">6587677</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessel L, Hamann S, Wegener M, Tong J, Fraser CL. Microcystic macular oedema in optic neuropathy: case series and literature review. Clin Exp Ophthalmol. 2018;46:1075&#x2013;86. https://doi.org/10.1111/ceo.13327 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ceo.13327</ArticleId><ArticleId IdType="pubmed">29799159</ArticleId></ArticleIdList></Reference><Reference><Citation>Haydinger CD, Ferreira LB, Williams KA, Smith JR. Mechanisms of macular edema. Front Med. 2023;10:1128811. https://doi.org/10.3389/fmed.2023.1128811 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1128811</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards MM, Lefebvre O. Laminins and retinal vascular development. Cell Adh Migr. 2013;7:82&#x2013;9. https://doi.org/10.4161/cam.22480 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/cam.22480</ArticleId><ArticleId IdType="pubmed">23154403</ArticleId><ArticleId IdType="pmc">3544790</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor D. Developmental abnormalities of the optic nerve and chiasm. Eye. 2007;21:1271&#x2013;84. https://doi.org/10.1038/sj.eye.6702851 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.eye.6702851</ArticleId><ArticleId IdType="pubmed">17914430</ArticleId></ArticleIdList></Reference><Reference><Citation>Aslam AA, Baksh RA, Pape SE, Strydom A, Gulliford MC, Chan LF. GO-DS21 consortium. diabetes and obesity in Down Syndrome across the lifespan: a retrospective cohort study using U.K. electronic health records. Diabetes Care. 2022;45:2892&#x2013;9. https://doi.org/10.2337/dc22-0482 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc22-0482</ArticleId><ArticleId IdType="pubmed">36178378</ArticleId><ArticleId IdType="pmc">7613880</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasina Z, Wang N, Wang CC. Developmental neuropathology and neurodegeneration of Down syndrome: current knowledge in humans. Front Cell Dev Biol. 2022;10:877711. https://doi.org/10.3389/fcell.2022.877711 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2022.877711</ArticleId><ArticleId IdType="pubmed">35676933</ArticleId><ArticleId IdType="pmc">9168127</ArticleId></ArticleIdList></Reference><Reference><Citation>Meharena HS, Marco A, Dileep V, Lockshin ER, Akatsu GY, Mullahoo J, et al. Down-syndrome-induced senescence disrupts the nuclear architecture of neural progenitors. Cell Stem Cell. 2022;29:116&#x2013;130.e7. https://doi.org/10.1016/j.stem.2021.12.002 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2021.12.002</ArticleId><ArticleId IdType="pubmed">34995493</ArticleId><ArticleId IdType="pmc">8805993</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39611043</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2688-2663</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>12</Issue><PubDate><Year>2024</Year><Month>Dec</Month></PubDate></JournalIssue><Title>MedComm</Title><ISOAbbreviation>MedComm (2020)</ISOAbbreviation></Journal><ArticleTitle>Ocular immune-related diseases: molecular mechanisms and therapy.</ArticleTitle><Pagination><StartPage>e70021</StartPage><MedlinePgn>e70021</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70021</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/mco2.70021</ELocationID><Abstract><AbstractText>Ocular immune-related diseases, represent a spectrum of conditions driven by immune system dysregulation, include but not limit to uveitis, diabetic retinopathy, age-related macular degeneration, Graves' ophthalmopathy, etc. The molecular and cellular mechanisms underlying these diseases are typically dysfunctioned immune responses targeting ocular tissues, resulting in inflammation and tissue damage. Recent advances have further elucidated the pivotal role of different immune responses in the development, progression, as well as management of various ocular immune diseases. However, there is currently a relative lack of connection between the cellular mechanisms and treatments of several immune-related ocular diseases. In this review, we discuss recent findings related to the immunopathogenesis of above-mentioned diseases. In particular, we summarize the different types of immune cells, inflammatory mediators, and associated signaling pathways that are involved in the pathophysiology of above-mentioned ophthalmopathies. Furthermore, we also discuss the future directions of utilizing anti-inflammatory regime in the management of these diseases. This will facilitate a better understanding of the pathogenesis of immune-related ocular diseases and provide new insights for future treatment approaches.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s). MedComm published by Sichuan International Medical Exchange &amp; Promotion Association (SCIMEA) and John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yakun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The First Affiliated Hospital of Chongqing Medical University Chongqing China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Institute of Ophthalmology Beijing Tongren Eye Center Beijing Tongren Hospital, Beijing Ophthalmology &amp; Visual Sciences Key Laboratory, Capital Medical University Beijing China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Shangze</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Beijing Institute of Ophthalmology Beijing Tongren Eye Center Beijing Tongren Hospital, Beijing Ophthalmology &amp; Visual Sciences Key Laboratory, Capital Medical University Beijing China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Beijing Institute of Ophthalmology Beijing Tongren Eye Center Beijing Tongren Hospital, Beijing Ophthalmology &amp; Visual Sciences Key Laboratory, Capital Medical University Beijing China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Beijing Institute of Ophthalmology Beijing Tongren Eye Center Beijing Tongren Hospital, Beijing Ophthalmology &amp; Visual Sciences Key Laboratory, Capital Medical University Beijing China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lei</LastName><ForeName>Fengyang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Beijing Institute of Ophthalmology Beijing Tongren Eye Center Beijing Tongren Hospital, Beijing Ophthalmology &amp; Visual Sciences Key Laboratory, Capital Medical University Beijing China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Shengping</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7796-8891</Identifier><AffiliationInfo><Affiliation>Beijing Institute of Ophthalmology Beijing Tongren Eye Center Beijing Tongren Hospital, Beijing Ophthalmology &amp; Visual Sciences Key Laboratory, Capital Medical University Beijing China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>MedComm (2020)</MedlineTA><NlmUniqueID>101769925</NlmUniqueID><ISSNLinking>2688-2663</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Graves&#x2019; ophthalmopathy</Keyword><Keyword MajorTopicYN="N">age&#x2010;related macular degeneration</Keyword><Keyword MajorTopicYN="N">diabetic retinopathy</Keyword><Keyword MajorTopicYN="N">immune</Keyword><Keyword MajorTopicYN="N">uveitis</Keyword></KeywordList><CoiStatement>The authors declare they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>29</Day><Hour>4</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39611043</ArticleId><ArticleId IdType="pmc">PMC11604294</ArticleId><ArticleId IdType="doi">10.1002/mco2.70021</ArticleId><ArticleId IdType="pii">MCO270021</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nieto&#x2010;Aristiz&#xe1;bal I, Mera JJ, Giraldo JD, Lopez&#x2010;Arevalo H, Tob&#xf3;n GJ. From ocular immune privilege to primary autoimmune diseases of the eye. Autoimmun Rev. 2022;21(8):103122.</Citation><ArticleIdList><ArticleId IdType="pubmed">35667621</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugita S. Role of ocular pigment epithelial cells in immune privilege. Arch Immunol Ther Exp (Warsz). 2009;57(4):263&#x2010;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">19568919</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Wang T, Kaneko S, et&#xa0;al. Photoreceptors inhibit pathological retinal angiogenesis through transcriptional regulation of Adam17 via c&#x2010;Fos. Angiogenesis. 2024;27(3):379&#x2010;395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11303108</ArticleId><ArticleId IdType="pubmed">38483712</ArticleId></ArticleIdList></Reference><Reference><Citation>Morohoshi K, Goodwin AM, Ohbayashi M, Ono SJ. Autoimmunity in retinal degeneration: autoimmune retinopathy and age&#x2010;related macular degeneration. J Autoimmun. 2009;33(3&#x2010;4):247&#x2010;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">19846275</ArticleId></ArticleIdList></Reference><Reference><Citation>Prete M, Dammacco R, Fatone MC, Racanelli V. Autoimmune uveitis: clinical, pathogenetic, and therapeutic features. Clin Exp Med. 2016;16(2):125&#x2010;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">25820692</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis JS, Ferreira D, Paige E, Gedye C, Boyle M. Infectious complications of biological and small molecule targeted immunomodulatory therapies. Clin Microbiol Rev. 2020;33(3):e00035&#x2010;e00119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7289788</ArticleId><ArticleId IdType="pubmed">32522746</ArticleId></ArticleIdList></Reference><Reference><Citation>Spadoni I, Fornasa G, Rescigno M. Organ&#x2010;specific protection mediated by cooperation between vascular and epithelial barriers. Nat Rev Immunol. 2017;17(12):761&#x2010;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">28869253</ArticleId></ArticleIdList></Reference><Reference><Citation>Egwuagu CE, Alhakeem SA, Mbanefo EC. Uveitis: molecular pathogenesis and emerging therapies. Front Immunol. 2021;12:623725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8119754</ArticleId><ArticleId IdType="pubmed">33995347</ArticleId></ArticleIdList></Reference><Reference><Citation>Glover K, Mishra D, Singh TRR. Epidemiology of ocular manifestations in autoimmune disease. Front Immunol. 2021;12:744396.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8593335</ArticleId><ArticleId IdType="pubmed">34795665</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy A, Liu SH, Brady CJ, Sieving PC, Palestine AG. Corticosteroid implants for chronic non&#x2010;infectious uveitis. Cochrane Database Syst Rev. 2023;8(8):CD010469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10464657</ArticleId><ArticleId IdType="pubmed">37642198</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed CM, Johnson HM, Lewin AS. Corneal application of SOCS1/3 peptides for the treatment of eye diseases mediated by inflammation and oxidative stress. Front Immunol. 2024;15:1416181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11298391</ArticleId><ArticleId IdType="pubmed">39104531</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao NA. Uveitis in developing countries. Indian J Ophthalmol. 2013;61(6):253&#x2010;254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3744776</ArticleId><ArticleId IdType="pubmed">23803475</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothova A, Suttorp&#x2010;van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80(4):332&#x2010;336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC505460</ArticleId><ArticleId IdType="pubmed">8703885</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe8;ve P, Cacoub P, Bodaghi B, et&#xa0;al. Uveitis: diagnostic work&#x2010;up. A literature review and recommendations from an expert committee. Autoimmun Rev. 2017;16(12):1254&#x2010;1264.</Citation><ArticleIdList><ArticleId IdType="pubmed">29037906</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Fang S, Li D, Zhou H, Li B, Fan X. The involvement of T cell pathogenesis in thyroid&#x2010;associated ophthalmopathy. Eye (Lond). 2019;33(2):176&#x2010;182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6367411</ArticleId><ArticleId IdType="pubmed">30531993</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong WP, Horai R, Mattapallil MJ, et&#xa0;al. IL&#x2010;27p28 inhibits central nervous system autoimmunity by concurrently antagonizing Th1 and Th17 responses. J Autoimmun. 2014;50:12&#x2010;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3975693</ArticleId><ArticleId IdType="pubmed">24021664</ArticleId></ArticleIdList></Reference><Reference><Citation>Horai R, Z&#xe1;rate&#x2010;Blad&#xe9;s CR, Dillenburg&#x2010;Pilla P, et&#xa0;al. Microbiota&#x2010;dependent activation of an autoreactive T cell receptor provokes autoimmunity in an immunologically privileged site. Immunity. 2015;43(2):343&#x2010;353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544742</ArticleId><ArticleId IdType="pubmed">26287682</ArticleId></ArticleIdList></Reference><Reference><Citation>Gholijani N, Ataollahi MR, Samiei A, Aflaki E, Shenavandeh S, Kamali&#x2010;Sarvestani E. An elevated pro&#x2010;inflammatory cytokines profile in Behcet's disease: a multiplex analysis. Immunol Lett. 2017;186:46&#x2010;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">27939191</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann U, Diedrichs&#x2010;M&#xf6;hring M, Wildner G. Dynamics of intraocular IFN&#x2010;&#x3b3;, IL&#x2010;17 and IL&#x2010;10&#x2010;producing cell populations during relapsing and monophasic rat experimental autoimmune uveitis. PLoS One. 2012;7(11):e49008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498374</ArticleId><ArticleId IdType="pubmed">23155443</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstein JE, Pepple KL. Cytokines in uveitis. Curr Opin Ophthalmol. 2018;29(3):267&#x2010;274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7199509</ArticleId><ArticleId IdType="pubmed">29521875</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Y, Han G, Shao H, Wang Y, Kaplan HJ, Sun D. Characterization of IL&#x2010;17+ interphotoreceptor retinoid&#x2010;binding protein&#x2010;specific T cells in experimental autoimmune uveitis. Invest Ophthalmol Vis Sci. 2007;48(9):4153&#x2010;41561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2567912</ArticleId><ArticleId IdType="pubmed">17724201</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan NW, Li J, Mittal SK, et&#xa0;al. Characterization of clinical and immune responses in an experimental chronic autoimmune uveitis model. Am J Pathol. 2021;191(3):425&#x2010;437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7931616</ArticleId><ArticleId IdType="pubmed">32966818</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Z, Su G, Kijlstra A, Yang P. Activation of the interleukin&#x2010;23/interleukin&#x2010;17 signalling pathway in autoinflammatory and autoimmune uveitis. Prog Retin Eye Res. 2021;80:100866.</Citation><ArticleIdList><ArticleId IdType="pubmed">32422390</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang L, Peng XY, Wang H. Th lymphocyte subsets in patients with Vogt&#x2012;Koyanagi&#x2012;Harada disease. Int J Ophthalmol. 2019;12(2):207&#x2010;211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6376230</ArticleId><ArticleId IdType="pubmed">30809474</ArticleId></ArticleIdList></Reference><Reference><Citation>Luger D, Silver PB, Tang J, et&#xa0;al. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med. 2008;205(4):799&#x2010;810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2292220</ArticleId><ArticleId IdType="pubmed">18391061</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun D, Liang D, Kaplan HJ, Shao H. The role of Th17&#x2010;associated cytokines in the pathogenesis of experimental autoimmune uveitis (EAU). Cytokine. 2015;74(1):76&#x2010;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4457592</ArticleId><ArticleId IdType="pubmed">25742774</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Zhu L, Wang R, et&#xa0;al. Aging weakens Th17 cell pathogenicity and ameliorates experimental autoimmune uveitis in mice. Protein Cell. 2022;13(6):422&#x2010;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9095810</ArticleId><ArticleId IdType="pubmed">34748200</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang P, Foster CS. Interleukin 21, interleukin 23, and transforming growth factor &#x3b2;1 in HLA&#x2010;A29&#x2010;associated birdshot retinochoroidopathy. Am J Ophthalmol. 2013;156(2):400&#x2010;406.e2.</Citation><ArticleIdList><ArticleId IdType="pubmed">23622563</ArticleId></ArticleIdList></Reference><Reference><Citation>Przepiera&#x2010;B&#x119;dzak H, Fischer K, Brzosko M. Extra&#x2010;articular symptoms in constellation with selected serum cytokines and disease activity in spondyloarthritis. Mediators Inflamm. 2016;2016:7617954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5174179</ArticleId><ArticleId IdType="pubmed">28053373</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou S, Liao D, Zhang J, et&#xa0;al. Genetic variations of IL17F and IL23A show associations with Beh&#xe7;et's disease and Vogt&#x2012;Koyanagi&#x2012;Harada syndrome. Ophthalmology. 2015;122(3):518&#x2010;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">25439430</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan W, Wang X, Zeng S, et&#xa0;al. Global lactylome reveals lactylation&#x2010;dependent mechanisms underlying T(H)17 differentiation in experimental autoimmune uveitis. Sci Adv. 2023;9(42):eadh4655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10584346</ArticleId><ArticleId IdType="pubmed">37851814</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez Krol A, Nehring HP, Krause FF, et&#xa0;al. Lactate induces metabolic and epigenetic reprogramming of pro&#x2010;inflammatory Th17 cells. EMBO Rep. 2022;23(12):e54685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9724659</ArticleId><ArticleId IdType="pubmed">36215678</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun M, Yang P, Du L, Zhou H, Ren X, Kijlstra A. Contribution of CD4+CD25+ T cells to the regression phase of experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 2010;51(1):383&#x2010;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">19696173</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Wan F, Song J, et&#xa0;al. Imbalance between Th17 cells and regulatory T cells during monophasic experimental autoimmune uveitis. Inflammation. 2016;39(1):113&#x2010;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">26296290</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanke Y, Kotake S, Goto M, Ujihara H, Matsubara M, Kamatani N. Decreased percentages of regulatory T cells in peripheral blood of patients with Behcet's disease before ocular attack: a possible predictive marker of ocular attack. Mod Rheumatol. 2008;18(4):354&#x2010;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">18427720</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert RM, Zhang X, Sampson RD, et&#xa0;al. Clinical remission of sight&#x2010;threatening non&#x2010;infectious uveitis is characterized by an upregulation of peripheral T&#x2010;regulatory cell polarized towards T&#x2010;bet and TIGIT. Front Immunol. 2018;9:907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5943505</ArticleId><ArticleId IdType="pubmed">29774027</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuang Z, Wang Y, Zhu G, et&#xa0;al. Imbalance of Th17/Treg cells in pathogenesis of patients with human leukocyte antigen B27 associated acute anterior uveitis. Sci Rep. 2017;7:40414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5238419</ArticleId><ArticleId IdType="pubmed">28091550</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin X, Liu B, Wei H, et&#xa0;al. Activation of the Notch signaling pathway disturbs the CD4(+)/CD8(+), Th17/Treg balance in rats with experimental autoimmune uveitis. Inflamm Res. 2019;68(9):761&#x2010;774.</Citation><ArticleIdList><ArticleId IdType="pubmed">31209505</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin X, Liu B, Wei H, et&#xa0;al. Activation of the Notch signaling pathway disturbs the CD4+/CD8+, Th17/Treg balance in rats with experimental autoimmune uveitis. Inflamm Res. 2019;68(9):761&#x2010;774.</Citation><ArticleIdList><ArticleId IdType="pubmed">31209505</ArticleId></ArticleIdList></Reference><Reference><Citation>LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood. 2008;112(5):1570&#x2010;1580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2518873</ArticleId><ArticleId IdType="pubmed">18725575</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Chen M. Targeting the complement system for the management of retinal inflammatory and degenerative diseases. Eur J Pharmacol. 2016;787:94&#x2010;104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5026403</ArticleId><ArticleId IdType="pubmed">26948311</ArticleId></ArticleIdList></Reference><Reference><Citation>John S, Rolnick K, Wilson L, Wong S, Van Gelder RN, Pepple KL. Bioluminescence for in vivo detection of cell&#x2010;type&#x2010;specific inflammation in a mouse model of uveitis. Sci Rep. 2020;10(1):11377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7347586</ArticleId><ArticleId IdType="pubmed">32647297</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Xu Q, Huang L. B cell depletion therapies in autoimmune diseases: monoclonal antibodies or chimeric antigen receptor&#x2010;based therapy? Front Immunol. 2023;14:1126421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9968396</ArticleId><ArticleId IdType="pubmed">36855629</ArticleId></ArticleIdList></Reference><Reference><Citation>Haruta H, Ohguro N, Fujimoto M, et&#xa0;al. Blockade of interleukin&#x2010;6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein&#x2010;specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 2011;52(6):3264&#x2010;3271.</Citation><ArticleIdList><ArticleId IdType="pubmed">21330657</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Luan H, Jiang H, et&#xa0;al. Gegen Qinlian decoction relieved DSS&#x2010;induced ulcerative colitis in mice by modulating Th17/Treg cell homeostasis via suppressing IL&#x2010;6/JAK2/STAT3 signaling. Phytomedicine. 2021;84:153519.</Citation><ArticleIdList><ArticleId IdType="pubmed">33640781</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu R, Zhao P, Zhang Q, et&#xa0;al. Adiponectin promotes fibroblast&#x2010;like synoviocytes producing IL&#x2010;6 to enhance T follicular helper cells response in rheumatoid arthritis. Clin Exp Rheumatol. 2020;38(1):11&#x2010;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">31025923</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh JG, Tawansy KA, Rao NA. Immunohistochemical study of chronic nongranulomatous anterior uveitis in juvenile idiopathic arthritis. Ophthalmology. 2008;115(10):1833&#x2010;1836.</Citation><ArticleIdList><ArticleId IdType="pubmed">18495247</ArticleId></ArticleIdList></Reference><Reference><Citation>Aziz HA, Flynn HW Jr, Young RC, Davis JL, Dubovy SR. Sympathetic ophthalmia: clinicopathologic correlation in a consecutive case series. Retina. 2015;35(8):1696&#x2010;1703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4514550</ArticleId><ArticleId IdType="pubmed">25719985</ArticleId></ArticleIdList></Reference><Reference><Citation>Wildsch&#xfc;tz L, Ackermann D, Witten A, et&#xa0;al. Transcriptomic and proteomic analysis of iris tissue and aqueous humor in juvenile idiopathic arthritis&#x2010;associated uveitis. J Autoimmun. 2019;100:75&#x2010;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">30885419</ArticleId></ArticleIdList></Reference><Reference><Citation>Gheita TA, Raafat H, Khalil H, Hussein H. Serum level of APRIL/BLyS in Beh&#xe7;et's disease patients: clinical significance in uveitis and disease activity. Mod Rheumatol. 2013;23(3):542&#x2010;546.</Citation><ArticleIdList><ArticleId IdType="pubmed">22752534</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaker OG, Tawfic SO, El&#x2010;Tawdy AM, El&#x2010;Komy MH, El Menyawi M, Heikal AA. Expression of TNF&#x2010;&#x3b1;, APRIL and BCMA in Behcet's disease. J Immunol Res. 2014;2014:380405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4236893</ArticleId><ArticleId IdType="pubmed">25759827</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan W, Huang W, Chen J, Li N, Mao L, Hou S. Retinal microglia: functions and diseases. Immunology. 2022;166(3):268&#x2010;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">35403700</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman SM, Wong WT. Microglia in the retina: roles in development, maturity, and disease. Annu Rev Vis Sci. 2018;4:45&#x2010;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">29852094</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauro C, Limatola C. Metabolic reprograming of microglia in the regulation of the innate inflammatory response. Front Immunol. 2020;11:493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7099404</ArticleId><ArticleId IdType="pubmed">32265936</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheray M, Joseph B. Epigenetics control microglia plasticity. Front Cell Neurosci. 2018;12:243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6085560</ArticleId><ArticleId IdType="pubmed">30123114</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhat SA, Sood A, Shukla R, Hanif K. AT2R activation prevents microglia pro&#x2010;inflammatory activation in a NOX&#x2010;dependent manner: inhibition of PKC activation and p47(phox) phosphorylation by PP2A. Mol Neurobiol. 2019;56(4):3005&#x2010;3023.</Citation><ArticleIdList><ArticleId IdType="pubmed">30076526</ArticleId></ArticleIdList></Reference><Reference><Citation>Perea JR, &#xc1;vila J, Bol&#xf3;s M. Dephosphorylated rather than hyperphosphorylated Tau triggers a pro&#x2010;inflammatory profile in microglia through the p38 MAPK pathway. Exp Neurol. 2018;310:14&#x2010;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">30138606</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Liao X, Li N, et&#xa0;al. Single&#x2010;cell RNA sequencing reveals inflammatory retinal microglia in experimental autoimmune uveitis. MedComm. 2024;5(4):e534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10999176</ArticleId><ArticleId IdType="pubmed">38585235</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Fan W, Li N, et&#xa0;al. YY1 lactylation in microglia promotes angiogenesis through transcription activation&#x2010;mediated upregulation of FGF2. Genome Biol. 2023;24(1):87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10120156</ArticleId><ArticleId IdType="pubmed">37085894</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J, Wang X, Li N, et&#xa0;al. YY1 lactylation aggravates autoimmune uveitis by enhancing microglial functions via inflammatory genes. Adv Sci (Weinh). 2024;11(19):e2308031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11109619</ArticleId><ArticleId IdType="pubmed">38493498</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, He S, Tan J, et&#xa0;al. Transcription factor EGR2 alleviates autoimmune uveitis via activation of GDF15 to modulate the retinal microglial phenotype. Proc Natl Acad Sci U S A. 2024;121(39):e2316161121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11441539</ArticleId><ArticleId IdType="pubmed">39298490</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Zhao C, Meng J, et&#xa0;al. Galectin&#x2010;3 regulates microglial activation and promotes inflammation through TLR4/MyD88/NF&#x2010;kB in experimental autoimmune uveitis. Clin Immunol. 2022;236:108939.</Citation><ArticleIdList><ArticleId IdType="pubmed">35121106</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, He J, Liang H, et&#xa0;al. Aryl hydrocarbon receptor regulates apoptosis and inflammation in a murine model of experimental autoimmune uveitis. Front Immunol. 2018;9:1713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6068235</ArticleId><ArticleId IdType="pubmed">30090104</ArticleId></ArticleIdList></Reference><Reference><Citation>He S, Li W, Wang G, et&#xa0;al. FTO&#x2010;mediated m6A modification alleviates autoimmune uveitis by regulating microglia phenotypes via the GPC4/TLR4/NF&#x2010;&#x3ba;B signaling axis. Genes Dis. 2023;10(5):2179&#x2010;2193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10363593</ArticleId><ArticleId IdType="pubmed">37492748</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G, Li X, Li N, et&#xa0;al. Icariin alleviates uveitis by targeting peroxiredoxin 3 to modulate retinal microglia M1/M2 phenotypic polarization. Redox Biol. 2022;52:102297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8956882</ArticleId><ArticleId IdType="pubmed">35334248</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu N, Zhang Z, Wang X, et&#xa0;al. Apigenin alleviates autoimmune uveitis by inhibiting microglia M1 pro&#x2010;inflammatory polarization. Invest Ophthalmol Vis Sci. 2023;64(5):21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10210511</ArticleId><ArticleId IdType="pubmed">37219511</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Xue Q, Chang J, et&#xa0;al. M6A methylation modification in autoimmune diseases, a promising treatment strategy based on epigenetics. Arthritis Res Ther. 2023;25(1):189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10544321</ArticleId><ArticleId IdType="pubmed">37784134</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, Ho BM, Chan HYE, et&#xa0;al. Emerging roles of cGAS&#x2010;STING signaling in mediating ocular inflammation. J Innate Immun. 2023;15(1):739&#x2010;750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10616671</ArticleId><ArticleId IdType="pubmed">37778330</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L, Chen B, Su W. A review of the various roles and participation levels of B&#x2010;cells in non&#x2010;infectious uveitis. Front Immunol. 2021;12:676046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8160461</ArticleId><ArticleId IdType="pubmed">34054864</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami Y, Ishikawa K, Nakao S, Sonoda KH. Innate immune response in retinal homeostasis and inflammatory disorders. Prog Retin Eye Res. 2020;74:100778.</Citation><ArticleIdList><ArticleId IdType="pubmed">31505218</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutolo M, Campitiello R, Gotelli E, Soldano S. The role of M1/M2 macrophage polarization in rheumatoid arthritis synovitis. Front Immunol. 2022;13:867260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9161083</ArticleId><ArticleId IdType="pubmed">35663975</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Ma C, Gong L, et&#xa0;al. Macrophage polarization and its role in liver disease. Front Immunol. 2021;12:803037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8712501</ArticleId><ArticleId IdType="pubmed">34970275</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#x151;szer T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediators Inflamm. 2015;2015:816460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4452191</ArticleId><ArticleId IdType="pubmed">26089604</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha H, Debnath B, Neamati N. Role of the CXCL8&#x2013;CXCR1/2 axis in cancer and inflammatory diseases. Theranostics. 2017;7(6):1543&#x2010;1588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5436513</ArticleId><ArticleId IdType="pubmed">28529637</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Ren L, Chen S, et&#xa0;al. Longdan Xiegan Tang attenuates liver injury and hepatic insulin resistance by regulating the angiotensin&#x2010;converting enzyme 2/Ang (1&#x2010;7)/Mas axis&#x2010;mediated anti&#x2010;inflammatory pathway in rats. J Ethnopharmacol. 2021;274:114072.</Citation><ArticleIdList><ArticleId IdType="pubmed">33781876</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu R, Peng Y, Zhou M, et&#xa0;al. MiR&#x2010;223&#x2010;3p attenuates M1 macrophage polarization via suppressing the Notch signaling pathway and NLRP3&#x2010;mediated pyroptosis in experimental autoimmune uveitis. Eur J Pharmacol. 2023;960:176139.</Citation><ArticleIdList><ArticleId IdType="pubmed">38059448</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Guo J, Bi L. Role of the NLRP3 inflammasome in autoimmune diseases. Biomed Pharmacother. 2020;130:110542.</Citation><ArticleIdList><ArticleId IdType="pubmed">32738636</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Xu W, Zhou R. NLRP3 inflammasome activation and cell death. Cell Mol Immunol. 2021;18(9):2114&#x2010;2127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8429580</ArticleId><ArticleId IdType="pubmed">34321623</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng J, Li N, Liu X, et&#xa0;al. NLRP3 attenuates intraocular inflammation by inhibiting AIM2&#x2010;mediated pyroptosis through the phosphorylated salt&#x2010;inducible kinase 1/sterol regulatory element binding transcription factor 1 pathway. Arthritis Rheumatol. 2023;75(5):842&#x2010;855.</Citation><ArticleIdList><ArticleId IdType="pubmed">36529965</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorne JE, Woreta FA, Dunn JP, Jabs DA. Risk of cataract development among children with juvenile idiopathic arthritis&#x2010;related uveitis treated with topical corticosteroids. Ophthalmology. 2010;117(7):1436&#x2010;1441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2900491</ArticleId><ArticleId IdType="pubmed">20363502</ArticleId></ArticleIdList></Reference><Reference><Citation>Jabs DA. Immunosuppression for the uveitides. Ophthalmology. 2018;125(2):193&#x2010;202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5794515</ArticleId><ArticleId IdType="pubmed">28942074</ArticleId></ArticleIdList></Reference><Reference><Citation>Gangaputra S, Newcomb CW, Liesegang TL, et&#xa0;al. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009;116(11):2188&#x2010;2198.e1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785935</ArticleId><ArticleId IdType="pubmed">19748676</ArticleId></ArticleIdList></Reference><Reference><Citation>Busto&#x2010;Iglesias M, Rodr&#xed;guez&#x2010;Mart&#xed;nez L, Rodr&#xed;guez&#x2010;Fern&#xe1;ndez CA, et&#xa0;al. Perspectives of therapeutic drug monitoring of biological agents in non&#x2010;infectious uveitis treatment: a review. Pharmaceutics. 2023;15(3):766.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10051556</ArticleId><ArticleId IdType="pubmed">36986627</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124&#x2010;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">20580421</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhary S, Zaveri J, Becker N. Proliferative diabetic retinopathy (PDR). Dis Mon. 2021;67(5):101140.</Citation><ArticleIdList><ArticleId IdType="pubmed">33546872</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang Q, Yang C. Oxidative stress and diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol. 2020;37:101799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7767789</ArticleId><ArticleId IdType="pubmed">33248932</ArticleId></ArticleIdList></Reference><Reference><Citation>ValdezGuerrero AS, Quintana&#x2010;P&#xe9;rez JC, Arellano&#x2010;Mendoza MG, Casta&#xf1;eda&#x2010;Ibarra FJ, Tamay&#x2010;Cach F, Alem&#xe1;n&#x2010;Gonz&#xe1;lez&#x2010;Duhart D. Diabetic retinopathy: important biochemical alterations and the main treatment strategies. Can J Diabetes. 2021;45(6):504&#x2010;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">33341391</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Q, Buonfiglio F, B&#xf6;hm EW, et&#xa0;al. Diabetic retinopathy: new treatment approaches targeting redox and immune mechanisms. Antioxidants (Basel). 2024;13(5):594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11117924</ArticleId><ArticleId IdType="pubmed">38790699</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunte K, Beikler T. Th17 cells and the IL&#x2010;23/IL&#x2010;17 axis in the pathogenesis of periodontitis and immune&#x2010;mediated inflammatory diseases. Int J Mol Sci. 2019;20(14):3394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6679067</ArticleId><ArticleId IdType="pubmed">31295952</ArticleId></ArticleIdList></Reference><Reference><Citation>Taguchi M, Someya H, Inada M, et&#xa0;al. Retinal changes in mice spontaneously developing diabetes by Th17&#x2010;cell deviation. Exp Eye Res. 2020;198:108155.</Citation><ArticleIdList><ArticleId IdType="pubmed">32717339</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi M, Sato T, Sakurai Y, et&#xa0;al. Association between aqueous humor and vitreous fluid levels of Th17 cell&#x2010;related cytokines in patients with proliferative diabetic retinopathy. PLoS One. 2017;12(5):e0178230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5448770</ArticleId><ArticleId IdType="pubmed">28558009</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Fang P, Yang WY, Wang H, Yang X. IL&#x2010;35, as a newly proposed homeostasis&#x2010;associated molecular pattern, plays three major functions including anti&#x2010;inflammatory initiator, effector, and blocker in cardiovascular diseases. Cytokine. 2019;122:154076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5741534</ArticleId><ArticleId IdType="pubmed">28648331</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan A, You H, Zhang X. Levels of interleukin 27 and interleukin 35 in the serum and vitreous of patients with proliferative diabetic retinopathy. Ocul Immunol Inflamm. 2018;26(2):273&#x2010;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">27537610</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Mao Y, Zhang J, et&#xa0;al. IL&#x2010;35 recombinant protein reverses inflammatory bowel disease and psoriasis through regulation of inflammatory cytokines and immune cells. J Cell Mol Med. 2018;22(2):1014&#x2010;1025.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5783847</ArticleId><ArticleId IdType="pubmed">29193791</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan A, Zhang Y, Wang X, Cui Y, Tan W. Interleukin 35 regulates interleukin 17 expression and T helper 17 in patients with proliferative diabetic retinopathy. Bioengineered. 2022;13(5):13293&#x2010;13299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9275983</ArticleId><ArticleId IdType="pubmed">35635032</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Yu ZW, Li HY, Yuan Y, Gao XY, Kuang HY. Retinal microglia polarization in diabetic retinopathy. Vis Neurosci. 2021;38:E006.</Citation><ArticleIdList><ArticleId IdType="pubmed">33934736</ArticleId></ArticleIdList></Reference><Reference><Citation>Fouda AY, Xu Z, Suwanpradid J, et&#xa0;al. Targeting proliferative retinopathy: arginase 1 limits vitreoretinal neovascularization and promotes angiogenic repair. Cell Death Dis. 2022;13(8):745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9424300</ArticleId><ArticleId IdType="pubmed">36038541</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, Luo C, Zhao J, Devarajan G, Xu H. Immune regulation in the aging retina. Prog Retin Eye Res. 2019;69:159&#x2010;172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6373845</ArticleId><ArticleId IdType="pubmed">30352305</ArticleId></ArticleIdList></Reference><Reference><Citation>Brockmann C, Dege S, Crespo&#x2010;Garcia S, et&#xa0;al. Spatial distribution of CD115(+) and CD11b(+) cells and their temporal activation during oxygen&#x2010;induced retinopathy in mice. Graefes Arch Clin Exp Ophthalmol. 2018;256(2):313&#x2010;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">29185100</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C, Liu Y, Meng J, et&#xa0;al. LGALS3BP in microglia promotes retinal angiogenesis through PI3K/AKT pathway during hypoxia. Invest Ophthalmol Vis Sci. 2022;63(8):25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9344220</ArticleId><ArticleId IdType="pubmed">35895036</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinuthia UM, Wolf A, Langmann T. Microglia and inflammatory responses in diabetic retinopathy. Front Immunol. 2020;11:564077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7681237</ArticleId><ArticleId IdType="pubmed">33240260</ArticleId></ArticleIdList></Reference><Reference><Citation>Krady JK, Basu A, Allen CM, et&#xa0;al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase&#x2010;3 activation in a rodent model of diabetic retinopathy. Diabetes. 2005;54(5):1559&#x2010;1565.</Citation><ArticleIdList><ArticleId IdType="pubmed">15855346</ArticleId></ArticleIdList></Reference><Reference><Citation>Liou GI. Diabetic retinopathy: role of inflammation and potential therapies for anti&#x2010;inflammation. World J Diabetes. 2010;1(1):12&#x2010;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083879</ArticleId><ArticleId IdType="pubmed">21537423</ArticleId></ArticleIdList></Reference><Reference><Citation>Zorena K, My&#x15b;liwska J, My&#x15b;liwiec M, et&#xa0;al. Serum TNF&#x2010;alpha level predicts nonproliferative diabetic retinopathy in children. Mediators Inflamm. 2007;2007:92196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1906713</ArticleId><ArticleId IdType="pubmed">17641733</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng S, Yu H, Yu Y, et&#xa0;al. Levels of inflammatory cytokines IL&#x2010;1&#x3b2;, IL&#x2010;6, IL&#x2010;8, IL&#x2010;17A, and TNF&#x2010;&#x3b1; in aqueous humour of patients with diabetic retinopathy. J Diabetes Res. 2018;2018:8546423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5904804</ArticleId><ArticleId IdType="pubmed">29850610</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu F, Phone A, Lamy R, et&#xa0;al. Correlation of aqueous, vitreous, and plasma cytokine levels in patients with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 2020;61(2):26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7326572</ArticleId><ArticleId IdType="pubmed">32084272</ArticleId></ArticleIdList></Reference><Reference><Citation>Doganay S, Evereklioglu C, Er H, et&#xa0;al. Comparison of serum NO, TNF&#x2010;alpha, IL&#x2010;1beta, sIL&#x2010;2R, IL&#x2010;6 and IL&#x2010;8 levels with grades of retinopathy in patients with diabetes mellitus. Eye (Lond). 2002;16(2):163&#x2010;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">11988817</ArticleId></ArticleIdList></Reference><Reference><Citation>Cs&#x151;sz &#xc9;, Boross P, Csutak A, et&#xa0;al. Quantitative analysis of proteins in the tear fluid of patients with diabetic retinopathy. J Proteomics. 2012;75(7):2196&#x2010;2204.</Citation><ArticleIdList><ArticleId IdType="pubmed">22300579</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung N, Wong IY, Wong TY. Ocular anti&#x2010;VEGF therapy for diabetic retinopathy: overview of clinical efficacy and evolving applications. Diabetes Care. 2014;37(4):900&#x2010;905.</Citation><ArticleIdList><ArticleId IdType="pubmed">24652721</ArticleId></ArticleIdList></Reference><Reference><Citation>Uemura A, Fruttiger M, D'Amore PA, et&#xa0;al. VEGFR1 signaling in retinal angiogenesis and microinflammation. Prog Retin Eye Res. 2021;84:100954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8385046</ArticleId><ArticleId IdType="pubmed">33640465</ArticleId></ArticleIdList></Reference><Reference><Citation>Peach CJ, Mignone VW, Arruda MA, et&#xa0;al. Molecular pharmacology of VEGF&#x2010;A isoforms: binding and signalling at VEGFR2. Int J Mol Sci. 2018;19(4):1264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5979509</ArticleId><ArticleId IdType="pubmed">29690653</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothhammer V, Borucki DM, Tjon EC, et&#xa0;al. Microglial control of astrocytes in response to microbial metabolites. Nature. 2018;557(7707):724&#x2010;728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6422159</ArticleId><ArticleId IdType="pubmed">29769726</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogura S, Kurata K, Hattori Y, et&#xa0;al. Sustained inflammation after pericyte depletion induces irreversible blood&#x2013;retina barrier breakdown. JCI Insight. 2017;2(3):e90905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5291729</ArticleId><ArticleId IdType="pubmed">28194443</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Xu X, Elliott MH, Zhu M, Le YZ. M&#xfc;ller cell&#x2010;derived VEGF is essential for diabetes&#x2010;induced retinal inflammation and vascular leakage. Diabetes. 2010;59(9):2297&#x2010;2305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2927953</ArticleId><ArticleId IdType="pubmed">20530741</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardona SM, Mendiola AS, Yang YC, Adkins SL, Torres V, Cardona AE. Disruption of fractalkine signaling leads to microglial activation and neuronal damage in the diabetic retina. ASN Neuro. 2015;7(5).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4641555</ArticleId><ArticleId IdType="pubmed">26514658</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Wang G, Wang Y. Intravitreous vascular endothelial growth factor and hypoxia&#x2010;inducible factor 1a in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2009;148(6):883&#x2010;889.</Citation><ArticleIdList><ArticleId IdType="pubmed">19837381</ArticleId></ArticleIdList></Reference><Reference><Citation>Blot G, Karadayi R, Przegralek L, et&#xa0;al. Perilipin 2&#x2010;positive mononuclear phagocytes accumulate in the diabetic retina and promote PPAR&#x3b3;&#x2010;dependent vasodegeneration. J Clin Invest. 2023;133(19):e161348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10702478</ArticleId><ArticleId IdType="pubmed">37781924</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen T, Lin R, Hu C, et&#xa0;al. Succinate&#x2010;induced macrophage polarization and RBP4 secretion promote vascular sprouting in ocular neovascularization. J Neuroinflammation. 2023;20(1):308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10734053</ArticleId><ArticleId IdType="pubmed">38129891</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi M, Nakao S, Wada I, et&#xa0;al. Identifying hyperreflective foci in diabetic retinopathy via VEGF&#x2010;induced local self&#x2010;renewal of CX3CR1+ vitreous resident macrophages. Diabetes. 2022;71(12):2685&#x2010;2701.</Citation><ArticleIdList><ArticleId IdType="pubmed">36203331</ArticleId></ArticleIdList></Reference><Reference><Citation>Vagaja NN, Chinnery HR, Binz N, Kezic JM, Rakoczy EP, McMenamin PG. Changes in murine hyalocytes are valuable early indicators of ocular disease. Invest Ophthalmol Vis Sci. 2012;53(3):1445&#x2010;1451.</Citation><ArticleIdList><ArticleId IdType="pubmed">22297487</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu M, Penfold PL, Madigan MC, Billson FA. Effect of human vitreous and hyalocyte&#x2010;derived factors on vascular endothelial cell growth. Aust N Z J Ophthalmol. 1997;25(1):S57&#x2010;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">9267627</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendes&#x2010;Jorge L, Ramos D, Luppo M, et&#xa0;al. Scavenger function of resident autofluorescent perivascular macrophages and their contribution to the maintenance of the blood&#x2012;retinal barrier. Invest Ophthalmol Vis Sci. 2009;50(12):5997&#x2010;6005.</Citation><ArticleIdList><ArticleId IdType="pubmed">19608545</ArticleId></ArticleIdList></Reference><Reference><Citation>Mato M, Ookawara S, Sakamoto A, et&#xa0;al. Involvement of specific macrophage&#x2010;lineage cells surrounding arterioles in barrier and scavenger function in brain cortex. Proc Natl Acad Sci U S A. 1996;93(8):3269&#x2010;3274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39595</ArticleId><ArticleId IdType="pubmed">8622926</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang NT, Nesper PL, Ong JX, Wang JM, Fawzi AA, Lavine JA. Macrophage&#x2010;like cells are increased in patients with vision&#x2010;threatening diabetic retinopathy and correlate with macular edema. Diagnostics (Basel). 2022;12(11):2793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9689296</ArticleId><ArticleId IdType="pubmed">36428853</ArticleId></ArticleIdList></Reference><Reference><Citation>Moutray T, Evans JR, Lois N, Armstrong DJ, Peto T, Azuara&#x2010;Blanco A. Different lasers and techniques for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2018;3(3):CD012314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6494342</ArticleId><ArticleId IdType="pubmed">29543992</ArticleId></ArticleIdList></Reference><Reference><Citation>Vergmann AS, Nguyen TT, Lee Torp T, et&#xa0;al. Efficacy and side effects of individualized panretinal photocoagulation. Ophthalmol Retina. 2020;4(6):642&#x2010;644.</Citation><ArticleIdList><ArticleId IdType="pubmed">32278741</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrigo A, Aragona E, Bandello F. VEGF&#x2010;targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy. Ann Med. 2022;54(1):1089&#x2010;1111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9891228</ArticleId><ArticleId IdType="pubmed">35451900</ArticleId></ArticleIdList></Reference><Reference><Citation>Bressler NM, Beaulieu WT, Glassman AR, et&#xa0;al. Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central&#x2010;involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 2018;136(3):257&#x2010;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885906</ArticleId><ArticleId IdType="pubmed">29392288</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlers JP, Yeh S, Maguire MG, et&#xa0;al. Intravitreal pharmacotherapies for diabetic macular edema: a report by the American Academy of Ophthalmology. Ophthalmology. 2022;129(1):88&#x2010;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">34446301</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang L, Xu GT, Zhang JF. Inflammation in diabetic retinopathy: possible roles in pathogenesis and potential implications for therapy. Neural Regen Res. 2023;18(5):976&#x2010;982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9827774</ArticleId><ArticleId IdType="pubmed">36254977</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai L, Xia M, Zhang F. Redox regulation of immunometabolism in microglia underpinning diabetic retinopathy. Antioxidants (Basel). 2024;13(4):423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11047590</ArticleId><ArticleId IdType="pubmed">38671871</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Y, Li J, Zhou Y, et&#xa0;al. Macrophage/microglia polarization for the treatment of diabetic retinopathy. Front Endocrinol (Lausanne). 2023;14:1276225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10569308</ArticleId><ArticleId IdType="pubmed">37842315</ArticleId></ArticleIdList></Reference><Reference><Citation>Arroba AI, Valverde &#xc1;M. Modulation of microglia in the retina: new insights into diabetic retinopathy. Acta Diabetol. 2017;54(6):527&#x2010;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">28349217</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Lu X, Hu Y, et&#xa0;al. Melatonin attenuated retinal neovascularization and neuroglial dysfunction by inhibition of HIF&#x2010;1&#x3b1;&#x2013;VEGF pathway in oxygen&#x2010;induced retinopathy mice. J Pineal Res. 2018;64(4):e12473.</Citation><ArticleIdList><ArticleId IdType="pubmed">29411894</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JH, Lin FL, Chen J, et&#xa0;al. TAK1 blockade as a therapy for retinal neovascularization. Pharmacol Res. 2023;187:106617.</Citation><ArticleIdList><ArticleId IdType="pubmed">36535572</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao F, Gao X, Ge X, Cui J, Liu X. Cyanidin&#x2010;3&#x2010;o&#x2010;glucoside (C3G) inhibits vascular leakage regulated by microglial activation in early diabetic retinopathy and neovascularization in advanced diabetic retinopathy. Bioengineered. 2021;12(2):9266&#x2010;9278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8810139</ArticleId><ArticleId IdType="pubmed">34699316</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B, Xu Y, Yu S, Huang Y, Lu L, Liang X. Anti&#x2010;angiogenic and anti&#x2010;inflammatory effect of Magnolol in the oxygen&#x2010;induced retinopathy model. Inflamm Res. 2016;65(1):81&#x2010;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">26547789</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang X, Cui K, Lu X, et&#xa0;al. A novel hypoxia&#x2010;inducible factor 1&#x3b1; inhibitor KC7F2 attenuates oxygen&#x2010;induced retinal neovascularization. Invest Ophthalmol Vis Sci. 2022;63(6):13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9202333</ArticleId><ArticleId IdType="pubmed">35695808</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Yoshida S, Nakao S, et&#xa0;al. M2 macrophages enhance pathological neovascularization in the mouse model of oxygen&#x2010;induced retinopathy. Invest Ophthalmol Vis Sci. 2015;56(8):4767&#x2010;4777.</Citation><ArticleIdList><ArticleId IdType="pubmed">26218904</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Ma L, Li X, Wang J, Li Y, Huang Z. Ferulic acid alleviates retinal neovascularization by modulating microglia/macrophage polarization through the ROS/NF&#x2010;&#x3ba;B axis. Front Immunol. 2022;13:976729.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9478033</ArticleId><ArticleId IdType="pubmed">36119027</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei X, Zhou L, Zhang T, Lu B, Sheng Y, Ji L. Corrigendum to &#x201c;Chlorogenic acid attenuates diabetic retinopathy by reducing VEGF expression and inhibiting VEGF&#x2010;mediated retinal neoangiogenesis&#x201d; [Vascul Pharmacol. 101(2018) 29&#x2010;37]. Vascul Pharmacol. 2020;130:106698.</Citation><ArticleIdList><ArticleId IdType="pubmed">29146180</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z, Zhang T, Gong C, et&#xa0;al. Erianin inhibits high glucose&#x2010;induced retinal angiogenesis via blocking ERK1/2&#x2010;regulated HIF&#x2010;1&#x3b1;&#x2013;VEGF/VEGFR2 signaling pathway. Sci Rep. 2016;6:34306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5039671</ArticleId><ArticleId IdType="pubmed">27678303</ArticleId></ArticleIdList></Reference><Reference><Citation>Connor KM, SanGiovanni JP, Lofqvist C, et&#xa0;al. Increased dietary intake of omega&#x2010;3&#x2010;polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med. 2007;13(7):868&#x2010;873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4491412</ArticleId><ArticleId IdType="pubmed">17589522</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Zhang J, Chen J, et&#xa0;al. &#x3c9;&#x2010;3PUFAs inhibit hypoxia&#x2010;induced retinal neovascularization via regulating microglial pyroptosis through METTL14&#x2010;mediated m6A modification of IFNB1 mRNA. Appl Biochem Biotechnol. 2024.</Citation><ArticleIdList><ArticleId IdType="pubmed">38175416</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Wen Z, Zhang Y, et&#xa0;al. Berberine alleviates diabetic retinopathy by regulating the Th17/Treg ratio. Immunol Lett. 2024;267:106862.</Citation><ArticleIdList><ArticleId IdType="pubmed">38702033</ArticleId></ArticleIdList></Reference><Reference><Citation>Zapadka TE, Lindstrom SI, Batoki JC, et&#xa0;al. Aryl hydrocarbon receptor agonist VAF347 impedes retinal pathogenesis in diabetic mice. Int J Mol Sci. 2021;22(9):4335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8122442</ArticleId><ArticleId IdType="pubmed">33919327</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaxel CJ, Adelman RA, Bailey ST, et&#xa0;al. Age&#x2010;related macular degeneration preferred practice pattern. Ophthalmology. 2020;127(1):p1&#x2010;p65.</Citation><ArticleIdList><ArticleId IdType="pubmed">31757502</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong WL, Su X, Li X, et&#xa0;al. Global prevalence of age&#x2010;related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta&#x2010;analysis. Lancet Glob Health. 2014;2(2):e106&#x2010;e116.</Citation><ArticleIdList><ArticleId IdType="pubmed">25104651</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferris FL 3rd, Wilkinson CP, Bird A, et&#xa0;al. Clinical classification of age&#x2010;related macular degeneration. Ophthalmology. 2013;120(4):844&#x2010;851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11551519</ArticleId><ArticleId IdType="pubmed">23332590</ArticleId></ArticleIdList></Reference><Reference><Citation>Mogi M, Ikegawa Y, Haga S, Hoshide S, Kario K. Hypertension facilitates age&#x2010;related diseases. Is hypertension associated with a wide variety of diseases? Hypertens Res. 2024;47(5):1246&#x2010;1259.</Citation><ArticleIdList><ArticleId IdType="pubmed">38491107</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogg RE, Woodside JV, McGrath A, et&#xa0;al. Mediterranean diet score and its association with age&#x2010;related macular degeneration: the European Eye Study. Ophthalmology. 2017;124(1):82&#x2010;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">27825655</ArticleId></ArticleIdList></Reference><Reference><Citation>Basyal D, Lee S, Kim HJ. Antioxidants and mechanistic insights for managing dry age&#x2010;related macular degeneration. Antioxidants (Basel). 2024;13(5):568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11117704</ArticleId><ArticleId IdType="pubmed">38790673</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Zhou L, Sun H, Yang MM. Age&#x2010;related macular degeneration: a disease of cellular senescence and dysregulated immune homeostasis. Clin Interv Aging. 2024;19:939&#x2010;951.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11130992</ArticleId><ArticleId IdType="pubmed">38807637</ArticleId></ArticleIdList></Reference><Reference><Citation>Thirunavukarasu AJ, Ross AC, Gilbert RM. Vitamin A, systemic T&#x2010;cells, and the eye: focus on degenerative retinal disease. Front Nutr. 2022;9:914457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9339908</ArticleId><ArticleId IdType="pubmed">35923205</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan W, Zou J, Yoshida S, Jiang B, Zhou Y. The role of inflammation in age&#x2010;related macular degeneration. Int J Biol Sci. 2020;16(15):2989&#x2010;3001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7545698</ArticleId><ArticleId IdType="pubmed">33061811</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambati J, Atkinson JP, Gelfand BD. Immunology of age&#x2010;related macular degeneration. Nat Rev Immunol. 2013;13(6):438&#x2010;451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3941009</ArticleId><ArticleId IdType="pubmed">23702979</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A, Subhi Y, Krogh Nielsen M, et&#xa0;al. Systemic frequencies of T helper 1 and T helper 17 cells in patients with age&#x2010;related macular degeneration: a case&#x2013;control study. Sci Rep. 2017;7(1):605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5429667</ArticleId><ArticleId IdType="pubmed">28377586</ArticleId></ArticleIdList></Reference><Reference><Citation>Raphael I, Nalawade S, Eagar TN, Forsthuber TG. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine. 2015;74(1):5&#x2010;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4416069</ArticleId><ArticleId IdType="pubmed">25458968</ArticleId></ArticleIdList></Reference><Reference><Citation>Falk M, Singh A, Faber C, Nissen M, Hviid T, S&#xf8;rensen T. Dysregulation of CXCR3 expression on peripheral blood leukocytes in patients with neovascular age&#x2010;related macular degeneration. Invest Ophthalmol Vis Sci. 2014;55:4050&#x2010;4056.</Citation><ArticleIdList><ArticleId IdType="pubmed">24812555</ArticleId></ArticleIdList></Reference><Reference><Citation>Fletcher EL. Contribution of microglia and monocytes to the development and progression of age related macular degeneration. Ophthalmic Physiol Opt. 2020;40(2):128&#x2010;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">32017190</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumaramanickavel G. Age&#x2010;related macular degeneration: genetics and biology. Asia Pac J Ophthalmol (Phila). 2016;5(4):229&#x2010;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">27488064</ArticleId></ArticleIdList></Reference><Reference><Citation>Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune&#x2010;mediated processes at the RPE&#x2010;Bruch's membrane interface in aging and age&#x2010;related macular degeneration. Prog Retin Eye Res. 2001;20(6):705&#x2010;732.</Citation><ArticleIdList><ArticleId IdType="pubmed">11587915</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson LV, Leitner WP, Staples MK, Anderson DH. Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. Exp Eye Res. 2001;73(6):887&#x2010;896.</Citation><ArticleIdList><ArticleId IdType="pubmed">11846519</ArticleId></ArticleIdList></Reference><Reference><Citation>Ao J, Wood JP, Chidlow G, Gillies MC, Casson RJ. Retinal pigment epithelium in the pathogenesis of age&#x2010;related macular degeneration and photobiomodulation as a potential therapy? Clin Exp Ophthalmol. 2018;46(6):670&#x2010;686.</Citation><ArticleIdList><ArticleId IdType="pubmed">29205705</ArticleId></ArticleIdList></Reference><Reference><Citation>Mochizuki M, Sugita S, Kamoi K. Immunological homeostasis of the eye. Prog Retin Eye Res. 2013;33:10&#x2010;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">23108335</ArticleId></ArticleIdList></Reference><Reference><Citation>Parmeggiani F, Sorrentino FS, Romano MR, et&#xa0;al. Mechanism of inflammation in age&#x2010;related macular degeneration: an up&#x2010;to&#x2010;date on genetic landmarks. Mediators Inflamm. 2013;2013:435607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3863457</ArticleId><ArticleId IdType="pubmed">24369445</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Jiang N, Chu Y, et&#xa0;al. Dysregulated metabolic pathways in age&#x2010;related macular degeneration. Sci Rep. 2020;10(1):2464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7016007</ArticleId><ArticleId IdType="pubmed">32051464</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Q, Lai K. Role of immune inflammation regulated by macrophage in the pathogenesis of age&#x2010;related macular degeneration. Exp Eye Res. 2024;239:109770.</Citation><ArticleIdList><ArticleId IdType="pubmed">38145794</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Liu F, Tang M, et&#xa0;al. Macrophage polarization in experimental and clinical choroidal neovascularization. Sci Rep. 2016;6:30933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4973249</ArticleId><ArticleId IdType="pubmed">27489096</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Yoshida S, Kubo Y, et&#xa0;al. Different distributions of M1 and M2 macrophages in a mouse model of laser&#x2010;induced choroidal neovascularization. Mol Med Rep. 2017;15(6):3949&#x2010;3956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5436148</ArticleId><ArticleId IdType="pubmed">28440413</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherepanoff S, McMenamin P, Gillies MC, Kettle E, Sarks SH. Bruch's membrane and choroidal macrophages in early and advanced age&#x2010;related macular degeneration. Br J Ophthalmol. 2010;94(7):918&#x2010;925.</Citation><ArticleIdList><ArticleId IdType="pubmed">19965817</ArticleId></ArticleIdList></Reference><Reference><Citation>Zandi S, Nakao S, Chun KH, et&#xa0;al. ROCK&#x2010;isoform&#x2010;specific polarization of macrophages associated with age&#x2010;related macular degeneration. Cell Rep. 2015;10(7):1173&#x2010;1186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5219927</ArticleId><ArticleId IdType="pubmed">25704819</ArticleId></ArticleIdList></Reference><Reference><Citation>Liew PX, Kubes P. The neutrophil's role during health and disease. Physiol Rev. 2019;99(2):1223&#x2010;1248.</Citation><ArticleIdList><ArticleId IdType="pubmed">30758246</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechner J, Chen M, Hogg RE, et&#xa0;al. Alterations in circulating immune cells in neovascular age&#x2010;related macular degeneration. Sci Rep. 2015;5:16754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4648089</ArticleId><ArticleId IdType="pubmed">26572732</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh S, Shang P, Yazdankhah M, et&#xa0;al. Activating the AKT2&#x2010;nuclear factor&#x2010;&#x3ba;B&#x2013;lipocalin&#x2010;2 axis elicits an inflammatory response in age&#x2010;related macular degeneration. J Pathol. 2017;241(5):583&#x2010;588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5357190</ArticleId><ArticleId IdType="pubmed">28026019</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritsche LG, Igl W, Bailey JN, et&#xa0;al. A large genome&#x2010;wide association study of age&#x2010;related macular degeneration highlights contributions of rare and common variants. Nat Genet. 2016;48(2):134&#x2010;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4745342</ArticleId><ArticleId IdType="pubmed">26691988</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Wang VM, Chan CC. The role of anti&#x2010;inflammatory agents in age&#x2010;related macular degeneration (AMD) treatment. Eye (Lond). 2011;25(2):127&#x2010;139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044916</ArticleId><ArticleId IdType="pubmed">21183941</ArticleId></ArticleIdList></Reference><Reference><Citation>Heesterbeek TJ, Lechanteur YTE, Lor&#xe9;s&#x2010;Motta L, et&#xa0;al. Complement activation levels are related to disease stage in AMD. Invest Ophthalmol Vis Sci. 2020;61(3):18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7401663</ArticleId><ArticleId IdType="pubmed">32176267</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds R, Hartnett ME, Atkinson JP, Giclas PC, Rosner B, Seddon JM. Plasma complement components and activation fragments: associations with age&#x2010;related macular degeneration genotypes and phenotypes. Invest Ophthalmol Vis Sci. 2009;50(12):5818&#x2010;5827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2826794</ArticleId><ArticleId IdType="pubmed">19661236</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, Wei L, Meyerle C, et&#xa0;al. Complement component C5a promotes expression of IL&#x2010;22 and IL&#x2010;17 from human T cells and its implication in age&#x2010;related macular degeneration. J Transl Med. 2011;9:1&#x2010;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3154861</ArticleId><ArticleId IdType="pubmed">21762495</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricklin D, Lambris JD. Complement&#x2010;targeted therapeutics. Nat Biotechnol. 2007;25(11):1265&#x2010;1275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2966895</ArticleId><ArticleId IdType="pubmed">17989689</ArticleId></ArticleIdList></Reference><Reference><Citation>Jermak CM, Dellacroce JT, Heffez J, Peyman GA. Triamcinolone acetonide in ocular therapeutics. Surv Ophthalmol. 2007;52(5):503&#x2010;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">17719372</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weissmann G. A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial&#x2010;leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci U S A. 1992;89(21):9991&#x2010;9995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC50263</ArticleId><ArticleId IdType="pubmed">1279685</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y&#x2010;S, Friedrichs U, Eichler W, Hoffmann S, Wiedemann P. Inhibitory effects of triamcinolone acetonide on bFGF&#x2010;induced migration and tube formation in choroidal microvascular endothelial cells. Graefe's Arch Clin Exp Ophthalmol. 2002;240(1):42&#x2010;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">11954780</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti&#x2010;inflammatory drugs in ophthalmology. Surv Ophthalmol. 2010;55(2):108&#x2010;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">20159228</ArticleId></ArticleIdList></Reference><Reference><Citation>Nussenblatt RB, Byrnes G, Sen HN, et&#xa0;al. A randomized pilot study of systemic immunosuppression in the treatment of age&#x2010;related macular degeneration with choroidal neovascularization. Retina. 2010;30(10):1579&#x2010;1587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3174007</ArticleId><ArticleId IdType="pubmed">20847709</ArticleId></ArticleIdList></Reference><Reference><Citation>Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun. 2010;11:180&#x2010;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">20173395</ArticleId></ArticleIdList></Reference><Reference><Citation>De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016;388(10047):906&#x2010;918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5014602</ArticleId><ArticleId IdType="pubmed">27038492</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor PN, Albrecht D, Scholz A, et&#xa0;al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018;14(5):301&#x2010;316.</Citation><ArticleIdList><ArticleId IdType="pubmed">29569622</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiersinga W, &#x17d;arkovi&#x107; M, Bartalena L, et&#xa0;al. Predictive score for the development or progression of Graves' orbitopathy in patients with newly diagnosed Graves' hyperthyroidism. Eur J Endocrinol. 2018;178(6):635&#x2010;643.</Citation><ArticleIdList><ArticleId IdType="pubmed">29650691</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartalena L, Baldeschi L, Dickinson A, et&#xa0;al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158(3):273&#x2010;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">18299459</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang CJ, Afifiyan N, Sand D, et&#xa0;al. Orbital fibroblasts from patients with thyroid&#x2010;associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL&#x2010;6, IL&#x2010;8, and MCP&#x2010;1. Invest Ophthalmol Vis Sci. 2009;50(5):2262&#x2010;2268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2752347</ArticleId><ArticleId IdType="pubmed">19117935</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao HJ, Wang H&#x2010;S, Zhang Y, Lin H&#x2010;Y, Phipps RP, Smith TJ. Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase&#x2010;2 expression: insights into potential pathogenic mechanisms of thyroid&#x2010;associated ophthalmopathy. J Biol Chem. 1998;273(45):29615&#x2010;29625.</Citation><ArticleIdList><ArticleId IdType="pubmed">9792671</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L&#x2010;Q, Wei R&#x2010;L, Cheng J&#x2010;W, Cai J&#x2010;P, Li Y. The expression of intercellular adhesion molecule&#x2010;1 induced by CD40&#x2010;CD40L ligand signaling in orbital fibroblasts in patients with Graves' ophthalmopathy. Invest Ophthalmol Vis Sci. 2010;51(9):4652&#x2010;4660.</Citation><ArticleIdList><ArticleId IdType="pubmed">20107176</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann GM, Feldon SE, Smith TJ, Phipps RP. Immune mechanisms in thyroid eye disease. Thyroid. 2008;18(9):959&#x2010;965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2795569</ArticleId><ArticleId IdType="pubmed">18752427</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang S, Huang Y, Wang S, et&#xa0;al. IL&#x2010;17A exacerbates fibrosis by promoting the proinflammatory and profibrotic function of orbital fibroblasts in TAO. J Clin Endocrinol Metab. 2016;101(8):2955&#x2010;2965.</Citation><ArticleIdList><ArticleId IdType="pubmed">27224264</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang S, Huang Y, Zhong S, et&#xa0;al. IL&#x2010;17A promotes RANTES expression, but not IL&#x2010;16, in orbital fibroblasts via CD40&#x2010;CD40L combination in thyroid&#x2010;associated ophthalmopathy. Invest Ophthalmol Vis Sci. 2016;57(14):6123&#x2010;6133.</Citation><ArticleIdList><ArticleId IdType="pubmed">27832278</ArticleId></ArticleIdList></Reference><Reference><Citation>Han R, Smith TJ. T helper type 1 and type 2 cytokines exert divergent influence on the induction of prostaglandin E2 and hyaluronan synthesis by interleukin&#x2010;1beta in orbital fibroblasts: implications for the pathogenesis of thyroid&#x2010;associated ophthalmopathy. Endocrinology. 2006;147(1):13&#x2010;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">16210363</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang S, Lu Y, Huang Y, Zhou H, Fan X. Mechanisms that underly T cell immunity in Graves' orbitopathy. Front Endocrinol (Lausanne). 2021;12:648732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8049604</ArticleId><ArticleId IdType="pubmed">33868176</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang S, Huang Y, Zhong S, et&#xa0;al. Regulation of orbital fibrosis and adipogenesis by pathogenic Th17 cells in Graves orbitopathy. J Clin Endocrinol Metab. 2017;102(11):4273&#x2010;4283.</Citation><ArticleIdList><ArticleId IdType="pubmed">28938397</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang S, Huang Y, Liu X, et&#xa0;al. Interaction between CCR6+ Th17 cells and CD34+ fibrocytes promotes inflammation: implications in Graves' orbitopathy in Chinese population. Invest Ophthalmol Vis Sci. 2018;59(6):2604&#x2010;2614.</Citation><ArticleIdList><ArticleId IdType="pubmed">29847667</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang S, Zhang S, Huang Y, et&#xa0;al. Evidence for associations between Th1/Th17 &#x201c;hybrid&#x201d; phenotype and altered lipometabolism in very severe Graves orbitopathy. J Clin Endocrinol Metab. 2020;105(6):dgaa124.</Citation><ArticleIdList><ArticleId IdType="pubmed">32173759</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SE, Yoon JS, Kim KH, Lee SY. Increased serum interleukin&#x2010;17 in Graves' ophthalmopathy. Graefes Arch Clin Exp Ophthalmol. 2012;250(10):1521&#x2010;1526.</Citation><ArticleIdList><ArticleId IdType="pubmed">22752189</ArticleId></ArticleIdList></Reference><Reference><Citation>Dik WA, Virakul S, van Steensel L. Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves' ophthalmopathy. Exp Eye Res. 2016;142:83&#x2010;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">26675405</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotwal A, Stan M. Thyrotropin receptor antibodies&#x2014;an overview. Ophthalmic Plast Reconstr Surg. 2018;34(4S suppl 1):S20&#x2010;S27.</Citation><ArticleIdList><ArticleId IdType="pubmed">29771756</ArticleId></ArticleIdList></Reference><Reference><Citation>Diana T, Ponto KA, Kahaly GJ. Thyrotropin receptor antibodies and Graves' orbitopathy. J Endocrinol Invest. 2021;44(4):703&#x2010;712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8310479</ArticleId><ArticleId IdType="pubmed">32749654</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizutori Y, Saitoh O, Eguchi K, Nagayama Y. Lack of effect of methimazole on dendritic cell (DC) function and DC&#x2010;induced Graves' hyperthyroidism in mice. Autoimmunity. 2007;40(5):397&#x2010;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">17612902</ArticleId></ArticleIdList></Reference><Reference><Citation>Armengol M&#x2010;P, Cardoso&#x2010;Schmidt CB, Fern&#xe1;ndez M, Ferrer X, Pujol&#x2010;Borrell R, Juan M. Chemokines determine local lymphoneogenesis and a reduction of circulating CXCR4+ T and CCR7 B and T lymphocytes in thyroid autoimmune diseases. J Immunol. 2003;170(12):6320&#x2010;6328.</Citation><ArticleIdList><ArticleId IdType="pubmed">12794165</ArticleId></ArticleIdList></Reference><Reference><Citation>Neag EJ, Smith TJ. 2021 update on thyroid&#x2010;associated ophthalmopathy. J Endocrinol Invest. 2022;45(2):235&#x2010;259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9455782</ArticleId><ArticleId IdType="pubmed">34417736</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Ji QH, Ruge F, et&#xa0;al. Reversal of pathological features of Graves' orbitopathy by activation of Forkhead transcription factors, FOXOs. J Clin Endocrinol Metab. 2016;101(1):114&#x2010;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">26502358</ArticleId></ArticleIdList></Reference><Reference><Citation>Krieger CC, Neumann S, Place RF, Marcus&#x2010;Samuels B, Gershengorn MC. Bidirectional TSH and IGF&#x2010;1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves' disease immunoglobins. J Clin Endocrinol Metab. 2015;100(3):1071&#x2010;1077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4333041</ArticleId><ArticleId IdType="pubmed">25485727</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xe4;ngericht J, Kr&#xe4;mer I, Kahaly GJ. Glucocorticoids in Graves' orbitopathy: mechanisms of action and clinical application. Ther Adv Endocrinol Metab. 2020;11:2042018820958335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745544</ArticleId><ArticleId IdType="pubmed">33403097</ArticleId></ArticleIdList></Reference><Reference><Citation>Zang S, Ponto KA, Kahaly GJ. Clinical review: intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011;96(2):320&#x2010;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">21239515</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahaly GJ, R&#xf6;sler HP, Pitz S, Hommel G. Low&#x2010; versus high&#x2010;dose radiotherapy for Graves' ophthalmopathy: a randomized, single blind trial. J Clin Endocrinol Metab. 2000;85(1):102&#x2010;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">10634372</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartalena L, Baldeschi L, Boboridis K, et&#xa0;al. The 2016 European Thyroid Association/European Group on Graves' orbitopathy guidelines for the management of graves' orbitopathy. Eur Thyroid J. 2016;5(1):9&#x2010;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4836120</ArticleId><ArticleId IdType="pubmed">27099835</ArticleId></ArticleIdList></Reference><Reference><Citation>Paridaens D, van den Bosch WA, van der Loos TL, Krenning EP, van Hagen PM. The effect of etanercept on Graves' ophthalmopathy: a pilot study. Eye (Lond). 2005;19(12):1286&#x2010;1289.</Citation><ArticleIdList><ArticleId IdType="pubmed">15550932</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Zhou H, Fan X. The effect of orbital radiation therapy on thyroid&#x2010;associated orbitopathy complicated with dysthyroid optic neuropathy. Front Med. 2017;11(3):359&#x2010;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">28500433</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez&#x2010;Moreiras JV, Alvarez&#x2010;L&#xf3;pez A, G&#xf3;mez EC. Treatment of active corticosteroid&#x2010;resistant graves' orbitopathy. Ophthalmic Plast Reconstr Surg. 2014;30(2):162&#x2010;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">24503568</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartalena L. Diagnosis and management of Graves&#x2019; disease: a global overview. Nat Rev Endocrinol. 2013;9(12):724&#x2010;734.</Citation><ArticleIdList><ArticleId IdType="pubmed">24126481</ArticleId></ArticleIdList></Reference><Reference><Citation>Turcu AF, Kumar S, Neumann S, et&#xa0;al. A small molecule antagonist inhibits thyrotropin receptor antibody&#x2010;induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy. J Clin Endocrinol Metab. 2013;98(5):2153&#x2010;2159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3644605</ArticleId><ArticleId IdType="pubmed">23482611</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Mester T, Raychaudhuri N, et&#xa0;al. Teprotumumab, an IGF&#x2010;1R blocking monoclonal antibody inhibits TSH and IGF&#x2010;1 action in fibrocytes. J Clin Endocrinol Metab. 2014;99(9):E1635&#x2010;E1640.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4154099</ArticleId><ArticleId IdType="pubmed">24878056</ArticleId></ArticleIdList></Reference><Reference><Citation>Campi I, Tosi D, Rossi S, et&#xa0;al. B cell activating factor (BAFF) and BAFF receptor expression in autoimmune and nonautoimmune thyroid diseases. Thyroid. 2015;25(9):1043&#x2010;1049.</Citation><ArticleIdList><ArticleId IdType="pubmed">26214745</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayabe R, Rootman DB, Hwang CJ, Ben&#x2010;Artzi A, Goldberg R. Adalimumab as steroid&#x2010;sparing treatment of inflammatory&#x2010;stage thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2014;30(5):415&#x2010;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">24978425</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39610566</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of a Novel Multimodal Intervention for Family Caregivers of Persons With Age-Related Macular Degeneration: A Randomized Controlled Trial.</ArticleTitle><Pagination><StartPage>e72523</StartPage><MedlinePgn>e72523</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e72523</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.72523</ELocationID><Abstract><AbstractText>Purpose Age-related macular degeneration (AMD) is a leading cause of visual impairment in older adults. Individuals affected by AMD often require regular physical and emotional support from family caregivers. Carers of people with AMD endure significant physical burdens, emotional distress, increased financial stress, and disruptions due to their lifestyle and retirement plans as a direct consequence of the AMD caregiving experience. Despite this, there are currently no interventions targeted toward family caregivers of AMD patients. We evaluated the efficacy of a novel intervention aiming to improve the burden and well-being of family carers of persons with AMD. Methods Family carers of relatives with AMD were primarily recruited through private eye clinics and randomized 1:1 to either receive a 10-week intervention of mail-delivered cognitive behavioral therapy (M-CBT) and optional telephone-delivered group counseling (n = 47) or to a wait-list control group (n = 47). Outcome measures were assessed pre-intervention (baseline) and six months post-intervention. These included treatment acceptability, caregiver burden, presence of depressive symptoms, self-efficacy, quality of life (QoL), and fatigue. Results A total of 94 participants were enrolled, with 47 randomized to each arm. Of those who completed the intervention, 30 (97%) participants reported that they were satisfied/very satisfied with the intervention. Twenty-seven (87%) participants indicated that they would recommend the program to others, and 26 (84%) thought that the program was worth their time. Intervention participants demonstrated several positive nonsignificant improvements versus the control group at six months: burden (P= 0.53), depressive symptoms (P= 0.19), general self-efficacy (P= 0.14), QoL (P= 0.17) and fatigue (P= 0.15). Conclusions Study findings demonstrate that combined M-CBT and telephone counseling intervention appear to be feasible, but did not lead to nonsignificant improvements in outcome measures such as burden in family carers of persons with AMD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024, Kha et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kha</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre for Vision Research, Westmead Institute for Medical Research, Westmead, AUS.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Centre for Vision Research, Westmead Institute for Medical Research, Westmead, AUS.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Macquarie University Hearing, Macquarie University, North Ryde, AUS.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liew</LastName><ForeName>Gerald</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre for Vision Research, Westmead Institute for Medical Research, Westmead, AUS.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Craig</LastName><ForeName>Ashley</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Macquarie University Hearing, Macquarie University, North Ryde, AUS.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burlutsky</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre for Vision Research, Westmead Institute for Medical Research, Westmead, AUS.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre for Vision Research, Westmead Institute for Medical Research, Westmead, AUS.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gopinath</LastName><ForeName>Bamini</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Macquarie University Hearing, Macquarie University, North Ryde, AUS.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">age-related macular degeneration (amd)</Keyword><Keyword MajorTopicYN="N">cognitive behavioural therapy</Keyword><Keyword MajorTopicYN="N">family caregiver</Keyword><Keyword MajorTopicYN="N">guidance and counselling</Keyword><Keyword MajorTopicYN="N">quality of life (qol)</Keyword></KeywordList><CoiStatement>Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. The University of Sydney Human Research Ethics Committee issued approval 2016/793. Ethics approval was obtained from The University of Sydney Human Research Ethics Committee (ID: 2016/793). This study was performed in accordance with the tenets of the Declaration of Helsinki. The trial registration number is ACTRN12616001461482. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: This work was supported by the Australian National Health and Medical Research Council under a Partnership Project Grant (APP1115729) and the Macular Disease Foundation Australia. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>29</Day><Hour>4</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39610566</ArticleId><ArticleId IdType="pmc">PMC11602414</ArticleId><ArticleId IdType="doi">10.7759/cureus.72523</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Wong WL, Su X, Li X, et al. Lancet Glob Health. 2014;2:106&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">25104651</ArticleId></ArticleIdList></Reference><Reference><Citation>Effectiveness of cognitive behavioral therapy for caregivers of people with dementia: a systematic review and meta-analysis. Kwon OY, Ahn HS, Kim HJ, Park KW. J Clin Neurol. 2017;13:394&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5653628</ArticleId><ArticleId IdType="pubmed">29057632</ArticleId></ArticleIdList></Reference><Reference><Citation>Age-related macular degeneration. Mitchell P, Liew G, Gopinath B, Wong TY. Lancet. 2018;392:1147&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">30303083</ArticleId></ArticleIdList></Reference><Reference><Citation>Age&#x2010;related macular degeneration&#x2014;emerging pathogenetic and therapeutic concepts. Gehrs KM, Anderson DH, Johnson LV, Hageman GS. Ann Med. 2006;38:450&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4853957</ArticleId><ArticleId IdType="pubmed">17101537</ArticleId></ArticleIdList></Reference><Reference><Citation>A study on caregiver burden: stressors, challenges, and possible solutions. Bialon LN, Coke S. Am J Hosp Palliat Care. 2012;29:210&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">21803785</ArticleId></ArticleIdList></Reference><Reference><Citation>Predictors of psychological distress in caregivers of older persons with wet age-related macular degeneration. Gopinath B, Kifley A, Cummins R, Heraghty J, Mitchell P. Aging Ment Health. 2015;19:239&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">24943714</ArticleId></ArticleIdList></Reference><Reference><Citation>Cross-sectional study evaluating burden and depressive symptoms in family carers of persons with age-related macular degeneration in Australia. Jin I, Tang D, Gengaroli J, et al. BMJ Open. 2021;11:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8438959</ArticleId><ArticleId IdType="pubmed">34497082</ArticleId></ArticleIdList></Reference><Reference><Citation>Caregiver perceptions about the impact of caring for patients with wet age-related macular degeneration. Vukicevic M, Heraghty J, Cummins R, Gopinath B, Mitchell P. Eye (Lond) 2016;30:413&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4791694</ArticleId><ArticleId IdType="pubmed">26611848</ArticleId></ArticleIdList></Reference><Reference><Citation>Improving support for family caregivers of people with a serious illness in the united states: strategic agenda and call to action. Hudson P, Morrison RS, Schulz R, Brody AA, Dahlin C, Kelly K, Meier DE. Palliat Med Rep. 2020;1:6&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8241318</ArticleId><ArticleId IdType="pubmed">34223450</ArticleId></ArticleIdList></Reference><Reference><Citation>Cognitive behavioral therapy versus general health education for family caregivers of individuals with heart failure: a pilot randomized controlled trial. Hwang B, Granger DA, Brecht ML, Doering LV. BMC Geriatr. 2022;22:281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8981676</ArticleId><ArticleId IdType="pubmed">35382758</ArticleId></ArticleIdList></Reference><Reference><Citation>Helping caregivers of persons with dementia: which interventions work and how large are their effects? Pinquart M, S&#xf6;rensen S. Int Psychogeriatr. 2006;18:577&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pubmed">16686964</ArticleId></ArticleIdList></Reference><Reference><Citation>Caring for the carer: a systematic review of pure technology-based cognitive behavioral therapy (TB-CBT) interventions for dementia carers. Scott JL, Dawkins S, Quinn MG, et al. Aging Ment Health. 2016;20:793&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pubmed">25978672</ArticleId></ArticleIdList></Reference><Reference><Citation>Family caregiver social problem-solving abilities and adjustment to caring for a relative with vision loss. Bambara JK, Owsley C, Wadley V, Martin R, Porter C, Dreer LE. Invest Ophthalmol Vis Sci. 2009;50:1585&#x2013;1592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2771396</ArticleId><ArticleId IdType="pubmed">19060279</ArticleId></ArticleIdList></Reference><Reference><Citation>One-day cognitive-behavioural therapy self-confidence workshops for people with depression: randomised controlled trial. Horrell L, Goldsmith KA, Tylee AT, et al. Br J Psychiatry. 2014;204:222&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">24357574</ArticleId></ArticleIdList></Reference><Reference><Citation>Mailed treatment to augment primary care for alcohol disorders: a randomised controlled trial. Kavanagh D, Connolly JM. Drug Alcohol Rev. 2009;28:73&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">19320679</ArticleId></ArticleIdList></Reference><Reference><Citation>The effectiveness of self-administered treatments: a practice-friendly review of the research. Mains JA, Scogin FR. J Clin Psychol. 2003;59:237&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">12552632</ArticleId></ArticleIdList></Reference><Reference><Citation>Implementing a multi-modal support service model for the family caregivers of persons with age-related macular degeneration: a study protocol for a randomised controlled trial. Gopinath B, Craig A, Kifley A, et al. BMJ Open. 2017;7:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5724127</ArticleId><ArticleId IdType="pubmed">28780563</ArticleId></ArticleIdList></Reference><Reference><Citation>Confidence intervals rather than P values: estimation rather than hypothesis testing. Gardner MJ, Altman DG. Br Med J (Clin Res Ed) 1986;292:746&#x2013;750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1339793</ArticleId><ArticleId IdType="pubmed">3082422</ArticleId></ArticleIdList></Reference><Reference><Citation>How is the minimal clinically important difference established in health-related quality of life instruments? Review of anchors and methods. Mouelhi Y, Jouve E, Castelli C, Gentile S. Health Qual Life Outcomes. 2020;18:136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7218583</ArticleId><ArticleId IdType="pubmed">32398083</ArticleId></ArticleIdList></Reference><Reference><Citation>Estimating clinically significant differences in quality of life outcomes. Wyrwich KW, Bullinger M, Aaronson N, Hays RD, Patrick DL, Symonds T. Qual Life Res. 2005;14:285&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">15892420</ArticleId></ArticleIdList></Reference><Reference><Citation>The importance of determining the clinical significance of research results in physical therapy clinical research. Armijo-Olivo S. Braz J Phys Ther. 2018;22:175&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5993947</ArticleId><ArticleId IdType="pubmed">29602714</ArticleId></ArticleIdList></Reference><Reference><Citation>Interpretation of quality of life changes. Lydick E, Epstein RS. Qual Life Res. 1993;2:221&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">8401458</ArticleId></ArticleIdList></Reference><Reference><Citation>The clinical significance of quality-of-life results: practical considerations for specific audiences. Symonds T, Berzon R, Marquis P, Rummans TA. Mayo Clin Proc. 2002;77:572&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pubmed">12059128</ArticleId></ArticleIdList></Reference><Reference><Citation>Dementia caregiver intervention research: in search of clinical significance. Schulz R, O'Brien A, Czaja S, et al. Gerontologist. 2002;42:589&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2579772</ArticleId><ArticleId IdType="pubmed">12351794</ArticleId></ArticleIdList></Reference><Reference><Citation>The efficacy of cognitive behavioral therapy: a review of meta-analyses. Hofmann SG, Asnaani A, Vonk IJ, Sawyer AT, Fang A. Cognit Ther Res. 2012;36:427&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3584580</ArticleId><ArticleId IdType="pubmed">23459093</ArticleId></ArticleIdList></Reference><Reference><Citation>Effects of a modified mindfulness-based cognitive therapy for family caregivers of people with dementia: a pilot randomized controlled trial. Kor PP, Liu JY, Chien WT. Int J Nurs Stud. 2019;98:107&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">30922609</ArticleId></ArticleIdList></Reference><Reference><Citation>A problem-solving early intervention for stroke caregivers: one year follow-up. King RB, Hartke RJ, Houle T, Lee J, Herring G, Alexander-Peterson BS, Raad J. Rehabil Nurs. 2012;37:231&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4060889</ArticleId><ArticleId IdType="pubmed">22949276</ArticleId></ArticleIdList></Reference><Reference><Citation>A systematic review of digital and face-to-face cognitive behavioral therapy for depression. Kambeitz-Ilankovic L, Rzayeva U, V&#xf6;lkel L, et al. NPJ Digit Med. 2022;5:144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9476400</ArticleId><ArticleId IdType="pubmed">36109583</ArticleId></ArticleIdList></Reference><Reference><Citation>Demographic and clinical predictors of response to internet-enabled cognitive-behavioural therapy for depression and anxiety. Catarino A, Bateup S, Tablan V, et al. BJPsych Open. 2018;4:411&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6171334</ArticleId><ArticleId IdType="pubmed">30294451</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39610324</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1754-8411</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>29</Day></PubDate></JournalIssue><Title>Disease models &amp; mechanisms</Title><ISOAbbreviation>Dis Model Mech</ISOAbbreviation></Journal><ArticleTitle>Abca4, mutated in Stargardt Disease, is required for cone outer segment structural integrity.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">dmm.052052</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1242/dmm.052052</ELocationID><Abstract><AbstractText>Stargardt Disease (STGD), the leading cause of inherited childhood blindness, is primarily caused by mutations in the ABCA4 gene, yet the underlying mechanisms of photoreceptor degeneration remain elusive, partly due to limitations in existing animal disease models. To expand our understanding, we mutated the ABCA4 paralogues, abca4a and abca4b, in zebrafish, which has a cone-rich retina. Our study unveiled striking dysmorphology and elongation of cone outer segments in abca4a;abca4b double mutants, alongside reduced phagocytosis by the retinal pigmented epithelium. We report that Abca4 protein forms a distinctive stripe along the length of cone outer segments, suggesting a potential structural role. We further show that wild-type cone outer segments constitutively present externalized phosphatidylserine, an 'eat-me' signal, and this pattern is disrupted in abca4a;abca4b double mutants, potentially contributing to reduced RPE phagocytic activity. More broadly, constitutive presentation of the "eat-me" signal by cone outer segments, if conserved in humans, has important implications for other retinal degenerative diseases, including age-related macular degeneration. This zebrafish model provides novel insights into cone dysfunction and presents a promising platform for unraveling the mechanisms of STGD pathogenesis and advancing therapeutic interventions.</AbstractText><CopyrightInformation>&#xa9; 2024. Published by The Company of Biologists Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Willoughby</LastName><ForeName>John J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Biology Department, University of Massachusetts, Amherst, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>Abbie M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-3770-4031</Identifier><AffiliationInfo><Affiliation>Biology Department, University of Massachusetts, Amherst, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1951420</GrantID><Agency>National Science Foundation</Agency><Country/></Grant><Grant><GrantID>BR-CMM-0622-0835-UMASS</GrantID><Acronym>FFB</Acronym><Agency>Foundation Fighting Blindness</Agency><Country>United States</Country></Grant><Grant><GrantID>NA</GrantID><Agency>University of Massachusetts CNS Bridge and Seed Funding grant</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Dis Model Mech</MedlineTA><NlmUniqueID>101483332</NlmUniqueID><ISSNLinking>1754-8403</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Macular degeneration</Keyword><Keyword MajorTopicYN="N">Phagocytosis</Keyword><Keyword MajorTopicYN="N">Photoreceptor</Keyword><Keyword MajorTopicYN="N">Zebrafish</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>29</Day><Hour>3</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39610324</ArticleId><ArticleId IdType="doi">10.1242/dmm.052052</ArticleId><ArticleId IdType="pii">363266</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39607311</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-7021</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>28</Day></PubDate></JournalIssue><Title>Current opinion in ophthalmology</Title><ISOAbbreviation>Curr Opin Ophthalmol</ISOAbbreviation></Journal><ArticleTitle>Artificial intelligence in ophthalmology.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1097/ICU.0000000000001111</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">To review role of artificial intelligence in medicine.</AbstractText><AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">Artificial intelligence is continuing to revolutionize access, diagnosis, personalization of medicine, and treatment in healthcare. As a matter of fact, artificial intelligence contributed to the research that resulted in 2024 Nobel Prizes in physics, chemistry, and economics. We are only at the tip of the iceberg in utilizing the abilities of artificial intelligence in medicine to improve accuracy of diagnoses and to enhance patient outcomes. Artificial intelligence has allowed better image analysis, prediction of progression of disease, personalized treatment plans, incorporations of genomics, and improved efficiency in care and follow-up utilizing home monitoring. In ocular health diagnosis and treatment of diabetic retinopathy, macular degeneration, glaucoma, corneal infections, and ectasia are only a few examples of how the power of artificial intelligence has been harnessed. Even though there are still challenges that need more work in the areas of patient privacy, Health Insurance Portability and Accountability Act (HIPAA) compliance, reliability, and development of regulatory frameworks, artificial intelligence has revolutionized and will continue to revolutionize medicine.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">Artificial intelligence is enhancing medical diagnosis and treatment, as well as access and prevention. Ocular imaging, visual outcome, optics, intraocular pressure, and data points will continue to see growth it the field of artificial intelligence.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khossravi</LastName><ForeName>Ava S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Science.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Qingyu</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Science.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Bioinformatics and Data Science, Yale School of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adelman</LastName><ForeName>Ron A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Science.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Bioinformatics and Data Science, Yale School of Medicine.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Mayo Clinic Florida, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Opin Ophthalmol</MedlineTA><NlmUniqueID>9011108</NlmUniqueID><ISSNLinking>1040-8738</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>28</Day><Hour>12</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>28</Day><Hour>12</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>28</Day><Hour>8</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39607311</ArticleId><ArticleId IdType="doi">10.1097/ICU.0000000000001111</ArticleId><ArticleId IdType="pii">00055735-990000000-00214</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Obermeyer Z, Emanuel EJ. Predicting the future - big data, machine learning, and clinical medicine. N Engl J Med 2016; 375:1216&#x2013;1219.</Citation></Reference><Reference><Citation>Esteva A, Robicquet A, Ramsundar B, et al. A guide to deep learning in healthcare. Nat Med 2019; 25:24&#x2013;29.</Citation></Reference><Reference><Citation>Rajpurkar P, Irvin J, Ball RL, et al. Deep learning for chest radiograph diagnosis: a retrospective comparison of the CheXNeXt algorithm to practicing radiologists. PLoS Med 2018; 15:e1002686.</Citation></Reference><Reference><Citation>Esteva A, Kuprel B, Novoa RA, et al. Dermatologist-level classification of skin cancer with deep neural networks. Nature 2017; 542:115&#x2013;118.</Citation></Reference><Reference><Citation>Attia ZI, Noseworthy PA, Lopez-Jimenez F, et al. An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction. Lancet 2019; 394:861&#x2013;867.</Citation></Reference><Reference><Citation>Gulshan V, Peng L, Coram M, et al. Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. JAMA 2016; 316:2402&#x2013;2410.</Citation></Reference><Reference><Citation>Ting DSW, Yanagi Y, Agrawal R, et al. Choroidal remodeling in age-related macular degeneration and polypoidal choroidal vasculopathy: a 12-month prospective study. Sci Rep 2017; 7:7868.</Citation></Reference><Reference><Citation>Wang MT, Cai YR, Jang V, et al. Establishment of a corneal ulcer prognostic model based on machine learning. Sci Rep 2024; 14:16154.</Citation></Reference><Reference><Citation>Sarayar R, Lestari YD, Setio AAA, Sitompul R. Accuracy of artificial intelligence model for infectious keratitis classification: a systematic review and meta-analysis. Front Public Health 2023; 11:1239231.</Citation></Reference><Reference><Citation>Soleimani M, Esmaili K, Rahdar A, et al. From the diagnosis of infectious keratitis to discriminating fungal subtypes; a deep learning-based study. Sci Rep 2023; 13:22200.</Citation></Reference><Reference><Citation>Maile H, Li JO, Gore D, et al. Machine learning algorithms to detect subclinical keratoconus: systematic review. JMIR Med Inform 2021; 9:e27363.</Citation></Reference><Reference><Citation>Cao K, Verspoor K, Sahebjada S, Baird PN. Accuracy of machine learning assisted detection of keratoconus: a systematic review and meta-analysis. J Clin Med 2022; 11:478.</Citation></Reference><Reference><Citation>Tognetto D, Giglio R, Vinciguerra AL, et al. Artificial intelligence applications and cataract management: a systematic review. Surv Ophthalmol 2022; 67:817&#x2013;829.</Citation></Reference><Reference><Citation>Ting DSJ, Foo VH, Yang LWY, et al. Artificial intelligence for anterior segment diseases: emerging applications in ophthalmology. Br J Ophthalmol 2021; 105:158&#x2013;168.</Citation></Reference><Reference><Citation>Lindegger DJ, Wawrzynski J, Saleh GM. Evolution and applications of artificial intelligence to cataract surgery. Ophthalmol Sci 2022; 2:100164.</Citation></Reference><Reference><Citation>Ladas J, Ladas D, Lin SR, et al. Improvement of multiple generations of intraocular lens calculation formulae with a novel approach using artificial intelligence. Transl Vis Sci Technol 2021; 10:7.</Citation></Reference><Reference><Citation>Yim KJ, Aviv R, Ianchulev T, Dvey-Aharon Z. Predicting the progression of diabetic retinopathy using machine learning. Sci Rep 2019; 11:1&#x2013;8.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39607159</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1678-2925</ISSN><JournalIssue CitedMedium="Internet"><Volume>88</Volume><Issue>3</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Arquivos brasileiros de oftalmologia</Title><ISOAbbreviation>Arq Bras Oftalmol</ISOAbbreviation></Journal><ArticleTitle>Multimodal imaging in retinitis pigmentosa related to the EYS gene.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0004-27492025000300306</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.5935/0004-2749.2024-0104</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This study aimed to characterize retinitis pigmentosa associated with the eyes shut homolog gene, which causes hereditary retinal degeneration.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The anatomical and functional findings of retinitis pigmentosa in patients with variants of the eyes shut homolog gene were characterized and compared using multimodal imaging and genetic analysis of the variants. Clinical data such as visual acuity, lens status, and refraction were obtained from medical records. Patients underwent an ophthalmic examination, including static visual field, microperimetry, optical coherence tomography, fundus autofluorescence, and fundus photography.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-two patients were included in the study. Several anatomical and functional characteristics of retinitis pigmentosa-eyes shut homolog were identified, including the presence of cataracts, cystoid macular edema, epiretinal membrane, and a tubular visual field. Genetic results revealed 26 distinct variants in the cohort, with 7 novel variants not previously documented or reported in the scientific literature or databases.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The findings demonstrate that eyes shut homolog-retinitis pigmentosa manifests in specific patterns, starting in adolescence with mild progression and advancing with age. The integration of multimodal imaging and genetic analysis has provided a detailed understanding of the anatomical and functional features of retinitis pigmentosa-eyes shut homolog. Seven novel variants of the eyes shut homolog gene have been identified. These findings enhance the understanding of eyes shut homolog-related retinitis pigmentosa characteristics of by detailing the spectrum of mutations in this gene within the Brazilian population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Ester Abigail da Silva</ForeName><Initials>EADS</Initials><Identifier Source="ORCID">0000-0001-5455-0401</Identifier><AffiliationInfo><Affiliation>Hospital S&#xe3;o Paulo, Escola Paulista de Medicina, Universidade Federal de S&#xe3;o Paulo, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodrigues</LastName><ForeName>Gabriela Don&#xe1;</ForeName><Initials>GD</Initials><Identifier Source="ORCID">0009-0008-8460-1511</Identifier><AffiliationInfo><Affiliation>Hospital S&#xe3;o Paulo, Escola Paulista de Medicina, Universidade Federal de S&#xe3;o Paulo, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ivama</LastName><ForeName>Kendy Junior</ForeName><Initials>KJ</Initials><Identifier Source="ORCID">0000-0001-5588-4462</Identifier><AffiliationInfo><Affiliation>Hospital S&#xe3;o Paulo, Escola Paulista de Medicina, Universidade Federal de S&#xe3;o Paulo, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pereira</LastName><ForeName>Mariana Costa</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0002-1450-0327</Identifier><AffiliationInfo><Affiliation>Hospital S&#xe3;o Paulo, Escola Paulista de Medicina, Universidade Federal de S&#xe3;o Paulo, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Texeira</LastName><ForeName>Caio Henrique Marques</ForeName><Initials>CHM</Initials><Identifier Source="ORCID">0000-0002-3992-6965</Identifier><AffiliationInfo><Affiliation>Hospital S&#xe3;o Paulo, Escola Paulista de Medicina, Universidade Federal de S&#xe3;o Paulo, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amaral</LastName><ForeName>Rebeca Azevedo Souza</ForeName><Initials>RAS</Initials><Identifier Source="ORCID">0000-0001-6557-0723</Identifier><AffiliationInfo><Affiliation>Hospital S&#xe3;o Paulo, Escola Paulista de Medicina, Universidade Federal de S&#xe3;o Paulo, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sallum</LastName><ForeName>Juliana Maria Ferraz</ForeName><Initials>JMF</Initials><Identifier Source="ORCID">0000-0002-7206-4447</Identifier><AffiliationInfo><Affiliation>Hospital S&#xe3;o Paulo, Escola Paulista de Medicina, Universidade Federal de S&#xe3;o Paulo, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Arq Bras Oftalmol</MedlineTA><NlmUniqueID>0400645</NlmUniqueID><ISSNLinking>0004-2749</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005136">Eye Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C533105">EYS protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012174" MajorTopicYN="Y">Retinitis Pigmentosa</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064847" MajorTopicYN="Y">Multimodal Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D041623" MajorTopicYN="Y">Tomography, Optical Coherence</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005136" MajorTopicYN="Y">Eye Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014792" MajorTopicYN="N">Visual Acuity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014794" MajorTopicYN="N">Visual Fields</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058609" MajorTopicYN="N">Visual Field Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005451" MajorTopicYN="N">Fluorescein Angiography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>28</Day><Hour>12</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>28</Day><Hour>12</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>28</Day><Hour>8</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39607159</ArticleId><ArticleId IdType="doi">10.5935/0004-2749.2024-0104</ArticleId><ArticleId IdType="pii">S0004-27492025000300306</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39606372</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>11</Day></PubDate></JournalIssue><Title>medRxiv : the preprint server for health sciences</Title><ISOAbbreviation>medRxiv</ISOAbbreviation></Journal><ArticleTitle>Diverse ancestry GWAS for advanced age-related macular degeneration in TOPMed-imputed and Ophthalmologically-confirmed 16,108 cases and 18,038 controls.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2024.11.08.24316962</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2024.11.08.24316962</ELocationID><Abstract><AbstractText>Age-related macular degeneration (AMD) is a leading cause of blindness with $344 billion dollars global costs. In 2016, the International Age-related Macular Degeneration Genomics Consortium devised genomic data on &#x223c;50,000 individuals (IAMDGC 1.0) and identified 52 variants across 34 loci associated with advanced AMD in European ancestry. We have now analyzed a more densely imputed version (IAMDGC 2.0) and performed cross-ancestry GWAS in 16,108 advanced AMD cases and 18,038 AMD-free controls. This identified 28 loci at P&lt;5&#xd7;10 <sup>-8</sup> , including two additional AMD loci compared to IAMDGC 1.0 ( <i>SERPINA1</i> and <i>CPN1</i> ). Fine-mapping supported one ancestry-shared signal around <i>HTRA1/ARMS2</i> and nine signals around <i>CFH</i> without African ancestry contribution. The 52-variant genetic risk score with and the 44-variant score without <i>CFH</i> -variants predicted advanced AMD not only in EUR, but also in AFR and ASN (AUC=0.80/0.75, 0.65/0.64, 0.80/0.79, respectively). Our results indicate that the genetic underpinning of advanced AMD is mostly shared between ancestries.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gorski</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9103-5860</Identifier></Author><Author ValidYN="Y"><LastName>Grunin</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Herold</LastName><ForeName>Janina M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Fr&#xf6;hlich</LastName><ForeName>Benedikt</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Behr</LastName><ForeName>Merle</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wheeler</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Bush</LastName><ForeName>William S</ForeName><Initials>WS</Initials><Identifier Source="ORCID">0000-0002-9729-6519</Identifier></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Yeunjoo E</ForeName><Initials>YE</Initials></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Xiaofeng</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Blanton</LastName><ForeName>Susan H</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Pericak-Vance</LastName><ForeName>Margaret A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Heid</LastName><ForeName>Iris M</ForeName><Initials>IM</Initials></Author><Author ValidYN="Y"><LastName>Haines</LastName><ForeName>Jonathan L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><CollectiveName>International Age-related Macular Degeneration Genomics Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>medRxiv</MedlineTA><NlmUniqueID>101767986</NlmUniqueID></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>28</Day><Hour>5</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39606372</ArticleId><ArticleId IdType="pmc">PMC11601516</ArticleId><ArticleId IdType="doi">10.1101/2024.11.08.24316962</ArticleId><ArticleId IdType="pii">2024.11.08.24316962</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39606340</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>11</Day></PubDate></JournalIssue><Title>medRxiv : the preprint server for health sciences</Title><ISOAbbreviation>medRxiv</ISOAbbreviation></Journal><ArticleTitle>Loss of <i>CFHR5</i> function reduces the risk for age-related macular degeneration.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2024.11.11.24317117</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2024.11.11.24317117</ELocationID><Abstract><AbstractText>Age-related macular degeneration (AMD) is a prevalent cause of vision loss in the elderly with limited therapeutic options. A single chromosomal region around the complement factor H gene ( <i>CFH</i> ) is reported to explain nearly 25% of genetic AMD risk. Here, we used association testing, statistical finemapping and conditional analyses in 12,495 AMD cases and 461,686 controls to deconvolute four major <i>CFH</i> haplotypes that convey protection from AMD. We show that beyond <i>CFH</i> , two of these are explained by Finn-enriched frameshift and missense variants in the <i>CFH</i> modulator <i>CFHR5</i> . We demonstrate through a FinnGen sample recall study that <i>CFHR5</i> variant carriers exhibit dose-dependent reductions in serum levels of the <i>CFHR5</i> gene product FHR-5 and two functionally related proteins at the locus. Genetic reduction in FHR-5 correlates with higher preserved activities of the classical and alternative complement pathways. Our results propose therapeutic downregulation of FHR-5 as promising to prevent or treat AMD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reeve</LastName><ForeName>Mary Pat</ForeName><Initials>MP</Initials><Identifier Source="ORCID">0000-0003-1788-2321</Identifier></Author><Author ValidYN="Y"><LastName>Loomis</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7478-1538</Identifier></Author><Author ValidYN="Y"><LastName>Nissil&#xe4;</LastName><ForeName>Eija</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Rausch</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-5773-5620</Identifier></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Zhili</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Briotta Parolo</LastName><ForeName>Pietro Della</ForeName><Initials>PD</Initials></Author><Author ValidYN="Y"><LastName>Ben-Isvy</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Aho</LastName><ForeName>Elias</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Cesetti</LastName><ForeName>Emilia</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Okunuki</LastName><ForeName>Yoko</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>McLaughlin</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>M&#xe4;kel&#xe4;</LastName><ForeName>Johanna</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><CollectiveName>FinnGen</CollectiveName></Author><Author ValidYN="Y"><LastName>Kurki</LastName><ForeName>Mitja</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Talkowski</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Korbel</LastName><ForeName>Jan O</ForeName><Initials>JO</Initials></Author><Author ValidYN="Y"><LastName>Connor</LastName><ForeName>Kip</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Meri</LastName><ForeName>Seppo</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Daly</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-0949-8752</Identifier></Author><Author ValidYN="Y"><LastName>Runz</LastName><ForeName>Heiko</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-2133-7345</Identifier></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>medRxiv</MedlineTA><NlmUniqueID>101767986</NlmUniqueID></MedlineJournalInfo><CoiStatement>Competing interests. SL, YO, HML, KC and HR were employees at Biogen during data generation for this study. SL is an employee of Bristol-Myers Squibb. YO and KC are employees of Johnson &amp; Johnson. HML is an employee of Moderna. JM is an employee of FinBB. MD is a co-founder of Maze Therapeutics. HR is an employee at insitro Inc. The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>28</Day><Hour>5</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39606340</ArticleId><ArticleId IdType="pmc">PMC11601675</ArticleId><ArticleId IdType="doi">10.1101/2024.11.11.24317117</ArticleId><ArticleId IdType="pii">2024.11.11.24317117</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rudnicka A. R. et al. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology 119, 571&#x2013;580 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22176800</ArticleId></ArticleIdList></Reference><Reference><Citation>Seddon J. M., George S., Rosner B. &amp; Klein M. L. CFH gene variant, Y402H, and smoking, body mass index, environmental associations with advanced age-related macular degeneration. Hum. Hered. 61, 157&#x2013;165 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16816528</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritsche L. G. et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat. Genet. 48, 134&#x2013;143 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4745342</ArticleId><ArticleId IdType="pubmed">26691988</ArticleId></ArticleIdList></Reference><Reference><Citation>He W. et al. Genome-Wide Meta-analysis Identifies Risk Loci and Improves Disease Prediction of Age-Related Macular Degeneration. Ophthalmology 131, 16&#x2013;29 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">37634759</ArticleId></ArticleIdList></Reference><Reference><Citation>Gormann B. R. et al. Distinctive cross-ancestry genetic architecture for age-related macular degeneration. medRxiv (2022) 10.1101/2022.08.16.22278855.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.08.16.22278855</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanani A. M. et al. A Phase I, Single Ascending Dose Study of GEM103 (Recombinant Human Complement Factor H) in Patients with Geographic Atrophy. Ophthalmol Sci 2, 100154 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9559901</ArticleId><ArticleId IdType="pubmed">36249705</ArticleId></ArticleIdList></Reference><Reference><Citation>Hageman G. S. et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc. Natl. Acad. Sci. U. S. A. 102, 7227&#x2013;7232 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1088171</ArticleId><ArticleId IdType="pubmed">15870199</ArticleId></ArticleIdList></Reference><Reference><Citation>Haines J. L. et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 308, 419&#x2013;421 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15761120</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein R. J. et al. Complement factor H polymorphism in age-related macular degeneration. Science 308, 385&#x2013;389 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1512523</ArticleId><ArticleId IdType="pubmed">15761122</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards A. O. et al. Complement factor H polymorphism and age-related macular degeneration. Science 308, 421&#x2013;424 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15761121</ArticleId></ArticleIdList></Reference><Reference><Citation>Maller J. et al. Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nat. Genet. 38, 1055&#x2013;1059 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16936732</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M. et al. CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration. Nat. Genet. 38, 1049&#x2013;1054 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1941700</ArticleId><ArticleId IdType="pubmed">16936733</ArticleId></ArticleIdList></Reference><Reference><Citation>Laine M. et al. Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J. Immunol. 178, 3831&#x2013;3836 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4853917</ArticleId><ArticleId IdType="pubmed">17339482</ArticleId></ArticleIdList></Reference><Reference><Citation>Kijlstra A. &amp; Berendschot T. T. J. M. Age-related macular degeneration: a complementopathy? Ophthalmic Res. 54, 64&#x2013;73 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26159686</ArticleId></ArticleIdList></Reference><Reference><Citation>Raychaudhuri S. et al. A rare penetrant mutation in CFH confers high risk of age-related macular degeneration. Nat. Genet. 43, 1232&#x2013;1236 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3225644</ArticleId><ArticleId IdType="pubmed">22019782</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes A. E. et al. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat. Genet. 38, 1173&#x2013;1177 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16998489</ArticleId></ArticleIdList></Reference><Reference><Citation>Lor&#xe9;s-Motta L. et al. Common haplotypes at the CFH locus and low-frequency variants in CFHR2 and CFHR5 associate with systemic FHR concentrations and age-related macular degeneration. Am. J. Hum. Genet. 108, 1367&#x2013;1384 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8387287</ArticleId><ArticleId IdType="pubmed">34260947</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xe4;rki&#xf6;-M&#xe4;kel&#xe4; M., Hellwage J., Tahokallio O. &amp; Meri S. Complement-regulator factor H and related proteins in otitis media with effusion. Clin. Immunol. 100, 118&#x2013;126 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11414752</ArticleId></ArticleIdList></Reference><Reference><Citation>Goicoechea de Jorge E. et al. Dimerization of complement factor H-related proteins modulates complement activation in vivo. Proc. Natl. Acad. Sci. U. S. A. 110, 4685&#x2013;4690 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3606973</ArticleId><ArticleId IdType="pubmed">23487775</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantsilieris S. et al. Recurrent structural variation, clustered sites of selection, and disease risk for the complement factor H () gene family. Proc. Natl. Acad. Sci. U. S. A. 115, E4433&#x2013;E4442 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5948961</ArticleId><ArticleId IdType="pubmed">29686068</ArticleId></ArticleIdList></Reference><Reference><Citation>Raychaudhuri S. et al. Associations of CFHR1-CFHR3 deletion and a CFH SNP to age-related macular degeneration are not independent. Nat. Genet. 42, 553&#x2013;5; author reply 555&#x2013;6 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3138072</ArticleId><ArticleId IdType="pubmed">20581873</ArticleId></ArticleIdList></Reference><Reference><Citation>Zouache M. A. et al. Levels of complement factor H-related 4 protein do not influence susceptibility to age-related macular degeneration or its course of progression. Nat. Commun. 15, 443 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10781981</ArticleId><ArticleId IdType="pubmed">38200010</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun B. B. et al. Genetic associations of protein-coding variants in human disease. Nature 603, 95&#x2013;102 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8891017</ArticleId><ArticleId IdType="pubmed">35197637</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurki M. I. et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature 613, 508&#x2013;518 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9849126</ArticleId><ArticleId IdType="pubmed">36653562</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrska-Bishop M. et al. High-coverage whole-genome sequencing of the expanded 1000 Genomes Project cohort including 602 trios. Cell 185, 3426&#x2013;3440.e19 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9439720</ArticleId><ArticleId IdType="pubmed">36055201</ArticleId></ArticleIdList></Reference><Reference><Citation>Schloissnig S. et al. Long-read sequencing and structural variant characterization in 1,019 samples from the 1000 Genomes Project. bioRxiv (2024) doi:10.1101/2024.04.18.590093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.04.18.590093</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun B. B. et al. Genomic atlas of the human plasma proteome. Nature 558, 73&#x2013;79 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697541</ArticleId><ArticleId IdType="pubmed">29875488</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhindsa R. S. et al. Rare variant associations with plasma protein levels in the UK Biobank. Nature 622, 339&#x2013;347 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10567546</ArticleId><ArticleId IdType="pubmed">37794183</ArticleId></ArticleIdList></Reference><Reference><Citation>Meri S. Self-nonself discrimination by the complement system. FEBS Lett. 590, 2418&#x2013;2434 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27393384</ArticleId></ArticleIdList></Reference><Reference><Citation>den Hollander A. I. et al. Systems genomics in age-related macular degeneration. Exp. Eye Res. 225, 109248 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10150562</ArticleId><ArticleId IdType="pubmed">36108770</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebecker M. &amp; J&#xf3;zsi M. Factor H-related protein 4 activates complement by serving as a platform for the assembly of alternative pathway C3 convertase via its interaction with C3b protein. J. Biol. Chem. 287, 19528&#x2013;19536 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365989</ArticleId><ArticleId IdType="pubmed">22518841</ArticleId></ArticleIdList></Reference><Reference><Citation>Plenge R. M., Scolnick E. M. &amp; Altshuler D. Validating therapeutic targets through human genetics. Nat. Rev. Drug Discov. 12, 581&#x2013;594 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23868113</ArticleId></ArticleIdList></Reference><Reference><Citation>Diogo D. et al. Phenome-wide association studies across large population cohorts support drug target validation. Nat. Commun. 9, 4285 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6191429</ArticleId><ArticleId IdType="pubmed">30327483</ArticleId></ArticleIdList></Reference><Reference><Citation>Heier J. S. et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet 402, 1434&#x2013;1448 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37865470</ArticleId></ArticleIdList></Reference><Reference><Citation>Seddon J. M., Cote J., Page W. F., Aggen S. H. &amp; Neale M. C. The US twin study of age-related macular degeneration: relative roles of genetic and environmental influences. Arch. Ophthalmol. 123, 321&#x2013;327 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15767473</ArticleId></ArticleIdList></Reference><Reference><Citation>Mbatchou J. et al. Computationally efficient whole-genome regression for quantitative and binary traits. Nat. Genet. 53, 1097&#x2013;1103 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34017140</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Y., Carbonetto P., Wang G. &amp; Stephens M. Fine-mapping from summary data with the &#x2018;Sum of Single Effects&#x2019; model. PLoS Genet. 18, e1010299 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9337707</ArticleId><ArticleId IdType="pubmed">35853082</ArticleId></ArticleIdList></Reference><Reference><Citation>Fauman E. B. et al. LAVAA: a lightweight association viewer across ailments. Bioinform Adv 3, vbad018 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9998102</ArticleId><ArticleId IdType="pubmed">36908397</ArticleId></ArticleIdList></Reference><Reference><Citation>Deorowicz S., Danek A. &amp; Li H. AGC: compact representation of assembled genomes with fast queries and updates. Bioinformatics 39, (2023).</Citation></Reference><Reference><Citation>Li H. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics 34, 3094&#x2013;3100 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6137996</ArticleId><ArticleId IdType="pubmed">29750242</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078&#x2013;2079 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2723002</ArticleId><ArticleId IdType="pubmed">19505943</ArticleId></ArticleIdList></Reference><Reference><Citation>Rausch T. et al. Long-read sequencing of diagnosis and post-therapy medulloblastoma reveals complex rearrangement patterns and epigenetic signatures. Cell Genom 3, 100281 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10112291</ArticleId><ArticleId IdType="pubmed">37082141</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24&#x2013;26 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3346182</ArticleId><ArticleId IdType="pubmed">21221095</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun B. B. et al. Plasma proteomic associations with genetics and health in the UK Biobank. Nature 622, 329&#x2013;338 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10567551</ArticleId><ArticleId IdType="pubmed">37794186</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39605874</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2666-9145</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>Ophthalmology science</Title><ISOAbbreviation>Ophthalmol Sci</ISOAbbreviation></Journal><ArticleTitle>ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation.</ArticleTitle><Pagination><StartPage>100628</StartPage><MedlinePgn>100628</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100628</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.xops.2024.100628</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">This study evaluated the safety and efficacy of elamipretide in dry age-related macular degeneration (AMD) with noncentral geographic atrophy (GA).</AbstractText><AbstractText Label="DESIGN" NlmCategory="UNASSIGNED">ReCLAIM-2 was a prospective, phase II, randomized, placebo-controlled, double-masked, multicenter trial (NCT03891875).</AbstractText><AbstractText Label="SUBJECTS" NlmCategory="UNASSIGNED">Patients aged &#x2265;55 years with &#x2265;1 eye with dry AMD with GA were enrolled.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Administration of daily subcutaneous elamipretide 40 mg was investigated in subjects for 48 weeks followed by a 4-week follow-up period.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="UNASSIGNED">The primary efficacy end points were the mean change from baseline (BL) in low-luminance best-corrected visual acuity (LL BCVA) and the change in square root (Sqrt) converted GA area from BL as measured by OCT. Additional predefined end points included ellipsoid zone (EZ) integrity preservation assessment and categorical changes in LL BCVA. The primary safety end point was the incidence and severity of adverse events.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Of the 176 patients randomized, there were 117 and 59 patients in the elamipretide and placebo groups, respectively. Although elamipretide did not meet statistical significance for the primary end points (mean change in LL BCVA and mean change in Sqrt converted GA area), elamipretide produced a 43% reduction in the mean progression from BL in the macular percentage of total EZ attenuation/loss (i.e., complete loss of EZ band; nominal <i>P</i>&#xa0;=&#xa0;0.0034) and 47% reduction in the mean progression of macular percentage of partial EZ attenuation/degradation (i.e., EZ-retinal pigment endothelium thickness of &#x2264;20 microns; nominal <i>P</i>&#xa0;=&#xa0;0.0040) versus placebo at week 48. Elamipretide treatment was also associated with significantly more patients experiencing a &#x2265;10 letter gain in LL BCVA versus placebo (14.6% vs. 2.1%; nominal <i>P</i>&#xa0;=&#xa0;0.0404). Adverse events were reported in 86% of those receiving elamipretide and 71% of the placebo group with the most common events being injection site reactions (e.g., pruritus, injection site pain, bruising, and erythema).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">While the primary end points were not met in this phase II study, elamipretide treatment was associated with a slowing of progressive EZ degradation/loss, a surrogate for photoreceptor damage. These findings have important clinical relevance since EZ attenuation/photoreceptor loss precedes and predicts the progressive pathological changes associated with vision loss and AMD. The EZ attenuation/loss end point will serve as the regulatory approved primary end point in the elamipretide phase III clinical development program.</AbstractText><AbstractText Label="FINANCIAL DISCLOSURES" NlmCategory="UNASSIGNED">Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</AbstractText><CopyrightInformation>&#xa9; 2024 by the American Academy of Ophthalmology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ehlers</LastName><ForeName>Justis P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Allen</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cumberland Valley Retina Consultants, Hagerstown, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyer</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Retina-Vitreous Associates Medical Group, Beverly Hills, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cousins</LastName><ForeName>Scott W</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Duke Eye Center, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waheed</LastName><ForeName>Nadia K</ForeName><Initials>NK</Initials><AffiliationInfo><Affiliation>New England Eye Center, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenfeld</LastName><ForeName>Philip J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Bascom Palmer Eye Institute, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Retina Consultants of Houston, Katy, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaiser</LastName><ForeName>Peter K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abbruscato</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Stealth BioTherapeutics, Needham, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Gui</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Stealth BioTherapeutics, Needham, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heier</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Ophthalmic Consultants of Boston, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ReCLAIM-2 (SPIAM-202) Study Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03891875</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Ophthalmol Sci</MedlineTA><NlmUniqueID>9918230896206676</NlmUniqueID><ISSNLinking>2666-9145</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Age-related macular degeneration</Keyword><Keyword MajorTopicYN="N">Elamipretide</Keyword><Keyword MajorTopicYN="N">Ellipsoid zone</Keyword><Keyword MajorTopicYN="N">Geographic atrophy</Keyword><Keyword MajorTopicYN="N">Visual acuity</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Abraham</LastName><ForeName>Prema</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Devine</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schadlu</LastName><ForeName>Anita</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Novalis</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kunimoto</LastName><ForeName>Derek Y</ForeName><Initials>DY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parchue</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moon</LastName><ForeName>Suk Jin</ForeName><Initials>SJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Segal</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marcus</LastName><ForeName>Dennis</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hahn</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suan</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Victor</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Samuel</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>Sunil</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berger</LastName><ForeName>Brian B</ForeName><Initials>BB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kwong</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pieramici</LastName><ForeName>Dante</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Eric W</ForeName><Initials>EW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shildkrot</LastName><ForeName>Yevgeniy</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Witmer</LastName><ForeName>Mathew T</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steinle</LastName><ForeName>Nathan</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gordon</LastName><ForeName>Carmelina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Learned</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Higgins</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pattar</LastName><ForeName>Guruprasad</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khetpal</LastName><ForeName>Vijay</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ross</LastName><ForeName>Robin</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barakat</LastName><ForeName>Mark R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee Sjatkowski</LastName><ForeName>Sun Young</ForeName><Initials>SY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lally</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Becker</LastName><ForeName>Troy</ForeName><Initials>T</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>28</Day><Hour>4</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39605874</ArticleId><ArticleId IdType="pmc">PMC11599447</ArticleId><ArticleId IdType="doi">10.1016/j.xops.2024.100628</ArticleId><ArticleId IdType="pii">S2666-9145(24)00164-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pennington K.L., DeAngelis M.M. Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. Eye Vis (Lond) 2016;3:34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5178091</ArticleId><ArticleId IdType="pubmed">28032115</ArticleId></ArticleIdList></Reference><Reference><Citation>Rein D.B., Wittenborn J.S., Zhang X., et al. Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. Arch Ophthalmol. 2009;127:533&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">19365036</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakravarthy U., Bailey C.C., Johnston R.L., et al. Characterizing disease burden and progression of geographic atrophy secondary. To age-related macular degeneration. Ophthalmology. 2018;125:842&#x2013;849.</Citation><ArticleIdList><ArticleId IdType="pubmed">29366564</ArticleId></ArticleIdList></Reference><Reference><Citation>Holz F.G., Strauss E.C., Schmitz-Valckenberg S., et al. Geographic atrophy: clinical features and potential therapeutic approaches. Ophthalmology. 2014;121:1079&#x2013;1091.</Citation><ArticleIdList><ArticleId IdType="pubmed">24433969</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyer D.S., Schmidt-Erfurth U., van Lookeren C.M., et al. The pathophysiology of geographic atrophy secondary to age-related macular degeneration and the complement pathway as a therapeutic target. Retina. 2017;37:819&#x2013;835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5424580</ArticleId><ArticleId IdType="pubmed">27902638</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan L.X., Germer C.J., La Cunza N., Lakkaraju A. Complement activation, lipid metabolism, and mitochondrial injury: converging pathways in age-related macular degeneration. Redox Biol. 2020;37</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7767764</ArticleId><ArticleId IdType="pubmed">33162377</ArticleId></ArticleIdList></Reference><Reference><Citation>Handa J.T., Cano M., Wang L., et al. Lipids, oxidized lipids, oxidation-specific epitopes, and Age-related Macular Degeneration. Biochim Biophys Acta Mol Cell Biol Lipids. 2017;1862:430&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5280582</ArticleId><ArticleId IdType="pubmed">27480216</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholl H.P.N., Boyer D., Giani A., Chong V. The use of neuroprotective agents in treating geographic atrophy. Ophthalmic Res. 2021;64:888&#x2013;902.</Citation><ArticleIdList><ArticleId IdType="pubmed">34153966</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham J.R., Jaffe G.J., Kaiser P.K., et al. Impact of baseline quantitative OCT features on response to risuteganib for the treatment of dry age-related macular degeneration: the importance of outer retinal integrity. Ophthalmol Retina. 2022;6:1019&#x2013;1027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9637705</ArticleId><ArticleId IdType="pubmed">35569763</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarici K., Abraham J.R., Sevgi D.D., et al. Risk classification for progression to subfoveal geographic atrophy in dry age-related macular degeneration using machine learning-enabled outer retinal feature extraction. Ophthalmic Surg Lasers Imaging Retina. 2022;53:31&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">34982004</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh Y., Vasanji A., Ehlers J.P. Volumetric ellipsoid zone mapping for enhanced visualisation of outer retinal integrity with optical coherence tomography. Br J Ophthalmol. 2016;100:295&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4936524</ArticleId><ArticleId IdType="pubmed">26201354</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasricha M.V., Tai V., Sleiman K., et al. Local anatomic precursors to new-onset geographic atrophy in age-related macular degeneration as defined on OCT. Ophthalmic Res. 2021;5:396&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8362836</ArticleId><ArticleId IdType="pubmed">33348086</ArticleId></ArticleIdList></Reference><Reference><Citation>Mai J., Riedl S., Reiter G.S., et al. Comparison of fundus autofluorescence versus optical coherence tomography&#x2013;based evaluation of the therapeutic response to pegcetacoplan in geographic atrophy. Am J Ophthalmol. 2022;244:175&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">35853489</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlers J.P., Yordi S., Cetin H., et al. 2022. Exploration of Machine Learning-Enhanced Compartmental Retinal Integrity Assessment for Progression Risk and Treatment Response in the GATHER1 Study. Presented at: Macula Society. Berlin, Germany.</Citation></Reference><Reference><Citation>Vogl W.D., Riedl S., Mai J., et al. Predicting topographic disease progression and treatment response of pegcetacoplan in geographic atrophy quantified by deep learning. Ophthalmol Retina. 2023;7:4&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">35948209</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfau M., von der Emde L., de Sisternes L., et al. Progression of photoreceptor degeneration in geographic atrophy secondary to age-related macular degeneration. JAMA Ophthalmol. 2020;138:1026&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7426886</ArticleId><ArticleId IdType="pubmed">32789526</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandramohan A., Stinnett S.S., Petrowski J.T., et al. Visual function measures in early and intermediate age-related macular degeneration. Retina. 2016;36:1021&#x2013;1031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4844847</ArticleId><ArticleId IdType="pubmed">26925551</ArticleId></ArticleIdList></Reference><Reference><Citation>Bressler N.M., Bressler S.B., Congdon N.G., et al. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol. 2003;121:1621&#x2013;1624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1473209</ArticleId><ArticleId IdType="pubmed">14609922</ArticleId></ArticleIdList></Reference><Reference><Citation>Yordi S., Cakir Y., Kalra G., et al. Ellipsoid zone integrity and visual function in dry age-related macular degeneration. J&#xa0;Pers Med. 2024;14:543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11122652</ArticleId><ArticleId IdType="pubmed">38793125</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleckenstein M., Mitchell P., Freund K.B., et al. The progression of geographic atrophy secondary to age-related macular degeneration. Opththamology. 2018;125:369&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">29110945</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunness J.S., Rubin G.S., Broman A., et al. Low luminance visual dysfunction as a predictor of subsequent visual acuity loss from geographic atrophy in age-related macular degeneration. Ophthalmology. 2008;115:1480&#x2013;1488. 1488 e1481-1482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730515</ArticleId><ArticleId IdType="pubmed">18486216</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;nzel S.H., M&#xf6;ller P.T., Lindner M., et al. Determinants of quality of life in geographic atrophy secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci. 2020;61(5):63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405807</ArticleId><ArticleId IdType="pubmed">32462198</ArticleId></ArticleIdList></Reference><Reference><Citation>Pondorfer S.G., Heinemann M., Wintergerst M.W.M., et al. Detecting vision loss in intermediate age-related macular degeneration: a comparison of visual function tests. PLoS One. 2020;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7162506</ArticleId><ArticleId IdType="pubmed">32298375</ArticleId></ArticleIdList></Reference><Reference><Citation>Min K., Smuder A.J., Kwon O.S., et al. Mitochondrial-targeted antioxidants protect skeletal muscle against immobilization-induced muscle atrophy. J&#xa0;Appl Physiol. 2011;111:1459&#x2013;1466. 1985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220313</ArticleId><ArticleId IdType="pubmed">21817113</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel M.P., Kruse S.E., Percival J.M., et al. Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell. 2013;12:763&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3772966</ArticleId><ArticleId IdType="pubmed">23692570</ArticleId></ArticleIdList></Reference><Reference><Citation>Szeto H.H. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171:2029&#x2013;2050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3976620</ArticleId><ArticleId IdType="pubmed">24117165</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbah H.N., Gupta R.C., Kohli S., et al. Chronic therapy with elamipretide (MTP-131), a novel mitochondria-targeting peptide, improves left ventricular and mitochondrial function in dogs with advanced heart failure. Circ Heart Fail. 2016;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4743543</ArticleId><ArticleId IdType="pubmed">26839394</ArticleId></ArticleIdList></Reference><Reference><Citation>Falabella M., Vernon H.J., Hanna M.G., et al. Cardiolipin, mitochondria, and neurological disease. Trends Endocrinol Metab. 2021;32:224&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8277580</ArticleId><ArticleId IdType="pubmed">33640250</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M., Liu B., Ma J., et al. Protective effect of mitochondriatargeted peptide MTP131 against oxidative stressinduced apoptosis in RGC5 cells. Mol Med Rep. 2017;15:2179&#x2013;2185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5364865</ArticleId><ArticleId IdType="pubmed">28260075</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang X., Chen F., Zhou H., et al. 2010. SS31 Protects human RPE cells from oxidative damage and reduces laser-induced choroidal neovascularization. Presented at: Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. Fort Lauderdale, FL.</Citation></Reference><Reference><Citation>Chen M., Liu B., Gao Q., et al. Mitochondria-targeted peptide MTP-131 alleviates mitochondrial dysfunction and oxidative damage in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2011;52:7027&#x2013;7037.</Citation><ArticleIdList><ArticleId IdType="pubmed">21697135</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Chen X., Xiao W., et al. Mitochondria-targeted antioxidant peptide SS31 attenuates high glucose-induced injury on human retinal endothelial cells. Biochem Biophys Res Commun. 2011;404:349&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">21134355</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J., Li X., Li M., et al. Mitochondria-targeted antioxidant peptide SS31 protects the retinas of diabetic rats. Curr Mol Med. 2013;13:935&#x2013;945.</Citation><ArticleIdList><ArticleId IdType="pubmed">23745582</ArticleId></ArticleIdList></Reference><Reference><Citation>Alam N., Mills W.C., Wong A.A., et al. A&#xa0;mitochondrial therapeutic reverses visual decline in mouse models of diabetes. Dis Model Mech. 2015;8:701&#x2013;710.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486862</ArticleId><ArticleId IdType="pubmed">26035391</ArticleId></ArticleIdList></Reference><Reference><Citation>Allingham M.J., Mettu P.S., Cousins S.W. Phase 1 clinical trial of elamipretide in intermediate age-related macular degeneration and high-risk drusen. Opththamol Sci. 2022;1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9560633</ArticleId><ArticleId IdType="pubmed">36246187</ArticleId></ArticleIdList></Reference><Reference><Citation>Mettu P.S., Allingham M.J., Cousins S.W. Phase 1 clinical trial of elamipretide in dry age-related macular degeneration and noncentral geographic atrophy. Opththalmol Sci. 2022;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9560640</ArticleId><ArticleId IdType="pubmed">36246181</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlers J.P., Lunasco L.M., Yordi S., et al. Compartmental exudative dynamics in neovascular age-related macular degeneration: volumetric outcomes and impact of volatility in a phase III clinical trial. Ophthalmol Retina. 2024;8:765&#x2013;777.</Citation><ArticleIdList><ArticleId IdType="pubmed">38403242</ArticleId></ArticleIdList></Reference><Reference><Citation>Guymer R.H., Rosenfeld P.J., Curcio C.A., et al. Incomplete retinal pigment epithelial and outer atrophy (iRORA) in age-related macular degeneration: CAM Report 4. Ophthalmology. 2020;127:394&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7218279</ArticleId><ArticleId IdType="pubmed">31708275</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabral de Guimaraes T.A., Varela M.D., Georgiou M., Michaelides M. Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions. Br J Opthalmol. 2022;106:297&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8867261</ArticleId><ArticleId IdType="pubmed">33741584</ArticleId></ArticleIdList></Reference><Reference><Citation>Csaky K., Ferris F. 3rd, Chew E.Y., et al. Report from the NEI/FDA endpoints workshop on age-related macular degeneration and inherited retinal diseases. Invest Ophthalmol Vis Sci. 2017;58:3456&#x2013;3463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5961066</ArticleId><ArticleId IdType="pubmed">28702674</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlers J.P., Uchida A., Hu M., et al. Higher-order assessment of OCT in diabetic macular edema from the VISTA study: ellipsoid zone dynamics and the retinal fluid index. Ophthalmol Retina. 2019;3:1056&#x2013;1066.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6899163</ArticleId><ArticleId IdType="pubmed">31473172</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlers J.P., Zahid R., Kaiser P.K., et al. Longitudinal assessment of ellipsoid zone integrity, subretinal hyperreflective material, and subretinal pigment epithelium disease in neovascular age-related macular degeneration. Ophthalmol Retina. 2021;5:1204&#x2013;1213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8387490</ArticleId><ArticleId IdType="pubmed">33640493</ArticleId></ArticleIdList></Reference><Reference><Citation>Heier J.S., Lad E.M., Holz F.G., et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet. 2023;402:1434&#x2013;1448.</Citation><ArticleIdList><ArticleId IdType="pubmed">37865470</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanani A.M., Patel S.S., Staurenghi G., et al. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet. 2023;402:1449&#x2013;1458.</Citation><ArticleIdList><ArticleId IdType="pubmed">37696275</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaffe G.J., Westby K., Csaky K.G., et al. C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial. Ophthalmology. 2021;128:576&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pubmed">32882310</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao D.S., Grossi F.V., El Mehdi D., et al. Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial. Ophthalmology. 2020;127:186&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">31474439</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39604206</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1755-3768</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>27</Day></PubDate></JournalIssue><Title>Acta ophthalmologica</Title><ISOAbbreviation>Acta Ophthalmol</ISOAbbreviation></Journal><ArticleTitle>Initial treatment response can predict one-year treatment outcomes in neovascular age-related macular degeneration treated according to the observe-and-plan regimen.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/aos.16801</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To investigate if the initial treatment response can predict the 1-year treatment outcomes in patients with neovascular age-related macular degeneration (nAMD) treated according to the observe-and-plan (O&amp;P) regimen.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this prospective cohort study, treatment-na&#xef;ve patients with nAMD were enrolled consecutively and followed for 1&#x2009;year while being treated according to the O&amp;P regimen. The treatment response was determined initially post-loading doses and after 1&#x2009;year. The functional treatment response (fTR) was determined by the change in best corrected visual acuity, while the morphological treatment response (mTR) was assessed by central retinal thickness and the presence of sub- and intraretinal fluid on optical coherence tomography and categorized as good, partial, and poor responders. The relative risk (RR) of the initial treatment response for predicting 1-year treatment response was assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One hundred patients were included and 94 completed the 1-year follow-up. Patients with an initial good fTR and initial poor fTR had an RR of 4.1 (95% CI 1.8-9.2) and 4.3 (95% CI 2.2-8.3), respectively, of remaining in the same response category at 1&#x2009;year. Similarly, patients with an initial good mTR and initial poor mTR had an RR of 3.0 (95% CI 1.8-4.8) and 8.7 (95% CI 3.0-25.1), respectively, of remaining in the same response category at 1&#x2009;year.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Both the anatomic and visual functional response after 3 loading doses are predictive of the anatomic and functional outcomes at 1&#x2009;year in patients with nAMD treated according to the O&amp;P regimen.</AbstractText><CopyrightInformation>&#xa9; 2024 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thomsen</LastName><ForeName>Alexander Kai</ForeName><Initials>AK</Initials><Identifier Source="ORCID">0000-0002-0214-8020</Identifier><AffiliationInfo><Affiliation>Clinical Eye Research Division, Department of Ophthalmology, Zealand University Hospital, Roskilde, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fasih-Ahmad</LastName><ForeName>Sohaib</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Doheny Eye Institute, California, Los Angeles, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadda</LastName><ForeName>SriniVas</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4939-3306</Identifier><AffiliationInfo><Affiliation>Doheny Eye Institute, California, Los Angeles, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, David Geffen School of Medicine of the University of California-Los Angeles, California, Los Angeles, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xf8;rensen</LastName><ForeName>Torben Lykke</ForeName><Initials>TL</Initials><Identifier Source="ORCID">0000-0002-6790-0199</Identifier><AffiliationInfo><Affiliation>Clinical Eye Research Division, Department of Ophthalmology, Zealand University Hospital, Roskilde, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R29-A1337</GrantID><Agency>Region Zealand</Agency><Country/></Grant><Grant><GrantID>00024226</GrantID><Agency>Velux Fonden</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Acta Ophthalmol</MedlineTA><NlmUniqueID>101468102</NlmUniqueID><ISSNLinking>1755-375X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">neovascular age&#x2010;related macular degeneration</Keyword><Keyword MajorTopicYN="N">observe&#x2010;and&#x2010;plan</Keyword><Keyword MajorTopicYN="N">prediction</Keyword><Keyword MajorTopicYN="N">treatment regimen</Keyword><Keyword MajorTopicYN="N">treatment response</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>28</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39604206</ArticleId><ArticleId IdType="doi">10.1111/aos.16801</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Amoaku, W.M., Chakravarthy, U., Gale, R., Gavin, M., Ghanchi, F., Gibson, J. et&#xa0;al. (2015) Defining response to anti&#x2010;VEGF therapies in neovascular AMD. Eye, 29(6), 721&#x2013;731. Available from: https://doi.org/10.1038/eye.2015.48</Citation></Reference><Reference><Citation>Bagi Nordsten, C., Rasmussen, B.K., Li, X., Thomsen, A.K. &amp; S&#xf8;rensen, T.L. (2024) Impact of COVID &#x2010;19 restrictions on the treatment of neovascular age&#x2010;related macular degeneration. Acta Ophthalmologica, 102(3), e404&#x2013;e405. Available from: https://doi.org/10.1111/aos.15766</Citation></Reference><Reference><Citation>Bloch, S.B., Larsen, M. &amp; Munch, I.C. (2012) Incidence of legal blindness from age&#x2010;related macular degeneration in Denmark: year 2000 to 2010. American Journal of Ophthalmology, 153(2), 209&#x2013;213.e2. Available from: https://doi.org/10.1016/j.ajo.2011.10.016</Citation></Reference><Reference><Citation>Boyer, D.S., Antoszyk, A.N., Awh, C.C., Bhisitkul, R.B., Shapiro, H. &amp; Acharya, N.R. (2007) Subgroup analysis of the MARINA study of ranibizumab in neovascular age&#x2010;related macular degeneration. Ophthalmology, 114(2), 246&#x2013;252. Available from: https://doi.org/10.1016/j.ophtha.2006.10.045</Citation></Reference><Reference><Citation>Brown, D.M., Kaiser, P.K., Michels, M., Soubrane, G., Heier, J.S., Kim, R.Y. et&#xa0;al. (2006) Ranibizumab versus verteporfin for neovascular age&#x2010;related macular degeneration. New England Journal of Medicine, 355(14), 1432&#x2013;1444. Available from: https://doi.org/10.1056/NEJMoa062655</Citation></Reference><Reference><Citation>Brown, D.M., Tuomi, L. &amp; Shapiro, H. (2013) Anatomical measures as predictors of visual outcomes in ranibizumab&#x2010;treated eyes with neovascular age&#x2010;related macular degeneration. Retina, 33(1), 23&#x2013;34. Available from: https://doi.org/10.1097/IAE.0b013e318263cedf</Citation></Reference><Reference><Citation>Eng, J. (n.d.) ROC analysis: Web&#x2010;based calculator for ROC curves. Available from http://www.jrocfit.org. n.d. [Accessed 27th June 2024]</Citation></Reference><Reference><Citation>Ferris, F.L., Wilkinson, C.P., Bird, A., Chakravarthy, U., Chew, E., Csaky, K. et&#xa0;al. (2013) Clinical classification of age&#x2010;related macular degeneration. Ophthalmology, 120(4), 844&#x2013;851. Available from: https://doi.org/10.1016/j.ophtha.2012.10.036</Citation></Reference><Reference><Citation>Finger, R.P., Wickremasinghe, S.S., Baird, P.N. &amp; Guymer, R.H. (2014) Predictors of anti&#x2010;VEGF treatment response in neovascular age&#x2010;related macular degeneration. Survey of Ophthalmology, 59(1), 1&#x2013;18. Available from: https://doi.org/10.1016/j.survophthal.2013.03.009</Citation></Reference><Reference><Citation>Gianniou, C., Dirani, A., Ferrini, W., Marchionno, L., Decugis, D., Deli, A. et&#xa0;al. (2015) Two&#x2010;year outcome of an observe&#x2010;and&#x2010;plan regimen for neovascular age&#x2010;related macular degeneration: how to alleviate the clinical burden with maintained functional results. Eye, 29(3), 342&#x2013;349. Available from: https://doi.org/10.1038/eye.2014.258</Citation></Reference><Reference><Citation>Gupta, O.P., Shienbaum, G., Patel, A.H., Fecarotta, C., Kaiser, R.S. &amp; Regillo, C.D. (2010) A treat and extend regimen using ranibizumab for neovascular age&#x2010;related macular degeneration. Ophthalmology, 117(11), 2134&#x2013;2140. Available from: https://doi.org/10.1016/j.ophtha.2010.02.032</Citation></Reference><Reference><Citation>Haji, H., Gianniou, C., Brynskov, T., S&#xf8;rensen, T.L., Olsen, R. &amp; Krogh Nielsen, M. (2023) Association between structural and functional treatment outcomes in neovascular age&#x2010;related macular degeneration. Acta Ophthalmologica, 101(2), 177&#x2013;184. Available from: https://doi.org/10.1111/aos.15233</Citation></Reference><Reference><Citation>Hariprasad, S.M., Morse, L.S., Shapiro, H., Wong, P. &amp; Tuomi, L. (2012) Fixed monthly versus less frequent ranibizumab dosing and predictors of visual response in exudative age&#x2010;related macular degeneration. Journal of Ophthalmology, 2012, 1&#x2013;8. Available from: https://doi.org/10.1155/2012/690641</Citation></Reference><Reference><Citation>Heloter&#xe4;, H., Siintamo, L., Kivinen, N., Abrahamsson, N., Aaltonen, V. &amp; Kaarniranta, K. (2024) Analysis of prognostic and predictive factors in neovascular age&#x2010;related macular degeneration Kuopio cohort. Acta Ophthalmologica, 102(6), 703&#x2013;713. Available from: https://doi.org/10.1111/aos.16681</Citation></Reference><Reference><Citation>Hollaus, M., B&#xfc;hl, W., Schmidt&#x2010;Erfurth, U. &amp; Sacu, S. (2022) The challenges of treating neovascular age&#x2010;related macular degeneration. Klinische Monatsbl&#xe4;tter f&#xfc;r Augenheilkunde, 239(8), 1033&#x2013;1042. Available from: https://doi.org/10.1055/a&#x2010;1473&#x2010;5713</Citation></Reference><Reference><Citation>Jeong, S., Ryu, G. &amp; Sagong, M. (2021) Modified observe&#x2010;and&#x2010;plan regimen using aflibercept for neovascular age&#x2010;related macular degeneration. Acta Ophthalmologica, 99(8), e1535&#x2013;e1536. Available from: https://doi.org/10.1111/aos.14803</Citation></Reference><Reference><Citation>Jyothi, S., Chowdhury, H., Elagouz, M. &amp; Sivaprasad, S. (2010) Intravitreal bevacizumab (Avastin) for age&#x2010;related macular degeneration: a critical analysis of literature. Eye, 24(5), 816&#x2013;824. Available from: https://doi.org/10.1038/eye.2009.219</Citation></Reference><Reference><Citation>Kaiser, P.K., Brown, D.M., Zhang, K., Hudson, H.L., Holz, F.G., Shapiro, H. et&#xa0;al. (2007) Ranibizumab for predominantly classic neovascular age&#x2010;related macular degeneration: subgroup analysis of first&#x2010;year ANCHOR results. American Journal of Ophthalmology, 144(6), 850&#x2013;857.e4. Available from: https://doi.org/10.1016/j.ajo.2007.08.012</Citation></Reference><Reference><Citation>Kang, S. &amp; Roh, Y.&#x2010;J. (2009) One&#x2010;year results of intravitreal ranibizumab for neovascular age&#x2010;related macular degeneration and clinical responses of various subgroups. Japanese Journal of Ophthalmology, 53(4), 389&#x2013;395. Available from: https://doi.org/10.1007/s10384&#x2010;009&#x2010;0670&#x2010;y</Citation></Reference><Reference><Citation>Krebs, I., Glittenberg, C., Ansari&#x2010;Shahrezaei, S., Hagen, S., Steiner, I. &amp; Binder, S. (2013) Non&#x2010;responders to treatment with antagonists of vascular endothelial growth factor in age&#x2010;related macular degeneration. British Journal of Ophthalmology, 97(11), 1443&#x2013;1446. Available from: https://doi.org/10.1136/bjophthalmol&#x2010;2013&#x2010;303513</Citation></Reference><Reference><Citation>Lalwani, G.A., Rosenfeld, P.J., Fung, A.E., Dubovy, S.R., Michels, S., Feuer, W. et&#xa0;al. (2009) A variable&#x2010;dosing regimen with intravitreal ranibizumab for neovascular age&#x2010;related macular degeneration: year 2 of the PrONTO study. American Journal of Ophthalmology, 148(1), 43&#x2013;58.e1. Available from: https://doi.org/10.1016/j.ajo.2009.01.024</Citation></Reference><Reference><Citation>Leth&#x2010;M&#xf8;ller Christensen, K., Kristjansen, D.B., Vergmann, A.S., Torp, T.L., Peto, T. &amp; Grauslund, J. (2024) Retinal vascular structure independently predicts the initial treatment response in neovascular age&#x2010;related macular degeneration. Acta Ophthalmologica, 102(1), 116&#x2013;121. Available from: https://doi.org/10.1111/aos.15709</Citation></Reference><Reference><Citation>Mantel, I., Niderprim, S.&#x2010;A., Gianniou, C., Deli, A. &amp; Ambresin, A. (2014) Reducing the clinical burden of ranibizumab treatment for neovascular age&#x2010;related macular degeneration using an individually planned regimen. British Journal of Ophthalmology, 98(9), 1192&#x2013;1196. Available from: https://doi.org/10.1136/bjophthalmol&#x2010;2013&#x2010;304556</Citation></Reference><Reference><Citation>Mariani, A., Deli, A., Ambresin, A. &amp; Mantel, I. (2011) Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age&#x2010;related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 249(11), 1635&#x2013;1642. Available from: https://doi.org/10.1007/s00417&#x2010;011&#x2010;1734&#x2010;5</Citation></Reference><Reference><Citation>Morken, T.S., Knutsen, C., Hanssen, M.S. &amp; Austeng, D. (2022) Patient satisfaction following a switch from treat&#x2010;and&#x2010;extend to observe&#x2010;and&#x2010;plan regimen in age&#x2010;related macular degeneration. BMJ Open Ophthalmology, 7(1), e000930. Available from: https://doi.org/10.1136/bmjophth&#x2010;2021&#x2010;000930</Citation></Reference><Reference><Citation>Parvin, P., Zola, M., Dirani, A., Ambresin, A. &amp; Mantel, I. (2017) Two&#x2010;year outcome of an observe&#x2010;and&#x2010;plan regimen for neovascular age&#x2010;related macular degeneration treated with Aflibercept. Graefe's Archive for Clinical and Experimental Ophthalmology, 255(11), 2127&#x2013;2134. Available from: https://doi.org/10.1007/s00417&#x2010;017&#x2010;3762&#x2010;2</Citation></Reference><Reference><Citation>Rosenfeld, P.J., Brown, D.M., Heier, J.S., Boyer, D.S., Kaiser, P.K., Chung, C.Y. et&#xa0;al. (2006) Ranibizumab for neovascular age&#x2010;related macular degeneration. New England Journal of Medicine, 355(14), 1419&#x2013;1431. Available from: https://doi.org/10.1056/NEJMoa054481</Citation></Reference><Reference><Citation>Rosser, D.A., Cousens, S.N., Murdoch, I.E., Fitzke, F.W. &amp; Laidlaw, D.A.H. (2003) How sensitive to clinical change are ETDRS logMAR visual acuity measurements? Investigative Opthalmology &amp; Visual Science, 44(8), 3278&#x2013;3281. Available from: https://doi.org/10.1167/iovs.02&#x2010;1100</Citation></Reference><Reference><Citation>Smailhodzic, D., Muether, P.S., Chen, J., Kwestro, A., Zhang, A.Y., Omar, A. et&#xa0;al. (2012) Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age&#x2010;related macular degeneration. Ophthalmology, 119(11), 2304&#x2013;2311. Available from: https://doi.org/10.1016/j.ophtha.2012.05.040</Citation></Reference><Reference><Citation>Soliman, M.K., Tuli, N., Lee, T.K., Britton, W.A. &amp; Tuli, R. (2021) Visual and anatomical outcomes associated with treat&#x2010;and&#x2010;extend administration of intravitreal aflibercept for neovascular age&#x2010;related macular degeneration. International Journal of Retina and Vitreous, 7(1), 54. Available from: https://doi.org/10.1186/s40942&#x2010;021&#x2010;00326&#x2010;4</Citation></Reference><Reference><Citation>Subhi, Y., Schneider, M., Hajari, J.N. &amp; La Cour, M. (2024) Injection burden and treatment intervals of aflibercept in observe&#x2010;and&#x2010;plan regimen for neovascular age&#x2010;related macular degeneration. Acta Ophthalmologica, 102(7), 821&#x2013;827. Available from: https://doi.org/10.1111/aos.16709</Citation></Reference><Reference><Citation>Thomsen, A.K., G&#xf8;ttsche, L.F., Hinnerskov, J.M.V., Falk, M.K. &amp; S&#xf8;rensen, T.L. (2024) Microperimetry and structural risk factors on OCT in intermediate age&#x2010;related macular degeneration. Ophthalmology Retina, S2468653024000885, 8(8), 786&#x2013;793. Available from: https://doi.org/10.1016/j.oret.2024.02.016</Citation></Reference><Reference><Citation>Ying, G., Maguire, M.G., Daniel, E., Ferris, F.L., Jaffe, G.J., Grunwald, J.E. et&#xa0;al. (2015) Association of baseline characteristics and early vision response with 2&#x2010;year vision outcomes in the comparison of AMD treatments trials (CATT). Ophthalmology, 122(12), 2523&#x2013;2531.e1. Available from: https://doi.org/10.1016/j.ophtha.2015.08.015</Citation></Reference><Reference><Citation>Ying, G., Maguire, M.G., Pan, W., Grunwald, J.E., Daniel, E., Jaffe, G.J. et&#xa0;al. (2018) Baseline predictors for five&#x2010;year visual acuity outcomes in the comparison of AMD treatment trials. Ophthalmology Retina, 2(6), 525&#x2013;530. Available from: https://doi.org/10.1016/j.oret.2017.10.003</Citation></Reference><Reference><Citation>Zerbib, J., Bourhis, A., Cornut, P.L., De Bats, F., Gualino, V., Halfon, J. et&#xa0;al. (2017) Prise en charge de la DMLA exsudative en France en 2015. Journal Fran&#xe7;ais d'Ophtalmologie, 40(9), 723&#x2013;730. Available from: https://doi.org/10.1016/j.jfo.2017.05.009</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39604117</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-9726</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>27</Day></PubDate></JournalIssue><Title>Aging cell</Title><ISOAbbreviation>Aging Cell</ISOAbbreviation></Journal><ArticleTitle>The Ercc1<sup>-/&#x394;</sup> mouse model of XFE progeroid syndrome undergoes accelerated retinal degeneration.</ArticleTitle><Pagination><StartPage>e14419</StartPage><MedlinePgn>e14419</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/acel.14419</ELocationID><Abstract><AbstractText>Age-related macular degeneration (AMD) is a major cause of vision loss in older adults. AMD is caused by degeneration in the macula of the retina. The retina is the highest oxygen consuming tissue in our body and is prone to oxidative damage. DNA damage is one hallmark of aging implicated in loss of organ function. Genome instability has been associated with several disorders that result in premature vision loss. We hypothesized that endogenous DNA damage plays a causal role in age-related retinal changes. To address this, we used a genetic model of systemic depletion of expression of the DNA repair enzyme ERCC1-XPF. The neural retina and retinal pigment epithelium (RPE) from Ercc1<sup>-/&#x394;</sup> mice, which models a human progeroid syndrome, were compared to age-matched wild-type (WT) and old WT mice. By 3-months-of age, Ercc1<sup>-/&#x394;</sup> mice presented abnormal optokinetic and electroretinogram responses consistent with photoreceptor dysfunction and visual impairment. Ercc1<sup>-/&#x394;</sup> mice shared many ocular characteristics with old WT mice including morphological changes, elevated DNA damage markers (&#x3b3;-H2AX and 53BP1), and increased cellular senescence in the neural retinal and RPE, as well as pathological angiogenesis. The RPE is essential for the metabolic health of photoreceptors. The RPE from Ercc1<sup>-/&#x394;</sup> mice displayed mitochondrial dysfunction causing a compensatory glycolytic shift, a characteristic feature of aging RPE. Hence, our study suggests spontaneous endogenous DNA damage promotes the hallmarks of age-related retinal degeneration.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s). Aging Cell published by Anatomical Society and John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Narasimhan</LastName><ForeName>Akilavalli</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute on the Biology of Aging and Metabolism, University of Minnesota Medical School, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Min</LastName><ForeName>Seok Hong</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Laura L</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roehrich</LastName><ForeName>Heidi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Physiology and Biophysics, Department of Ophthalmology, Center for Translational Vision Research, University of California Irvine, School of Medicine, Irvine, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Her</LastName><ForeName>Tracy K</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>Department of Integrative Biology and Physiology, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Windschitl</LastName><ForeName>Caeden</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute on the Biology of Aging and Metabolism, University of Minnesota Medical School, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Kelly</LastName><ForeName>Ryan D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Institute on the Biology of Aging and Metabolism, University of Minnesota Medical School, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angelini</LastName><ForeName>Luise</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute on the Biology of Aging and Metabolism, University of Minnesota Medical School, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yousefzadeh</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0003-2869-1029</Identifier><AffiliationInfo><Affiliation>Institute on the Biology of Aging and Metabolism, University of Minnesota Medical School, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLoon</LastName><ForeName>Linda K</ForeName><Initials>LK</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hauswirth</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robbins</LastName><ForeName>Paul D</ForeName><Initials>PD</Initials><Identifier Source="ORCID">0000-0003-1068-7099</Identifier><AffiliationInfo><Affiliation>Institute on the Biology of Aging and Metabolism, University of Minnesota Medical School, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skowronska-Krawczyk</LastName><ForeName>Dorota</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-5758-4225</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Biophysics, Department of Ophthalmology, Center for Translational Vision Research, University of California Irvine, School of Medicine, Irvine, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niedernhofer</LastName><ForeName>Laura J</ForeName><Initials>LJ</Initials><Identifier Source="ORCID">0000-0002-1074-1385</Identifier><AffiliationInfo><Affiliation>Institute on the Biology of Aging and Metabolism, University of Minnesota Medical School, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01AG063543</GrantID><Agency>Common Fund</Agency><Country/></Grant><Grant><GrantID>U19AG056278</GrantID><Agency>Common Fund</Agency><Country/></Grant><Grant><GrantID>U54AG079754</GrantID><Agency>Common Fund</Agency><Country/></Grant><Grant><GrantID>U01EY034594</GrantID><Agency>Common Fund</Agency><Country/></Grant><Grant><GrantID>P30EY034070</GrantID><Agency>Common Fund</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aging Cell</MedlineTA><NlmUniqueID>101130839</NlmUniqueID><ISSNLinking>1474-9718</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DNA damage</Keyword><Keyword MajorTopicYN="N">age&#x2010;related retinal degeneration</Keyword><Keyword MajorTopicYN="N">cellular senescence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>28</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39604117</ArticleId><ArticleId IdType="doi">10.1111/acel.14419</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Ahmad, A., Robinson, A. R., Duensing, A., van Drunen, E., Beverloo, H. B., Weisberg, D. B., Hasty, P., Hoeijmakers, J. H., &amp; Niedernhofer, L. J. (2008). ERCC1&#x2010;XPF endonuclease facilitates DNA double&#x2010;strand break repair. Molecular and Cellular Biology, 28(16), 5082&#x2013;5092. https://doi.org/10.1128/mcb.00293&#x2010;08</Citation></Reference><Reference><Citation>Benchorin, G., Calton, M. A., Beaulieu, M. O., &amp; Vollrath, D. (2017). Assessment of murine retinal function by electroretinography. Bio&#x2010;Protocol, 7(7), e2218. https://doi.org/10.21769/BioProtoc.2218</Citation></Reference><Reference><Citation>Bhagwat, N., Olsen, A. L., Wang, A. T., Hanada, K., Stuckert, P., Kanaar, R., D'Andrea, A., Niedernhofer, L. J., &amp; McHugh, P. J. (2009). XPF&#x2010;ERCC1 participates in the Fanconi anemia pathway of cross&#x2010;link repair. Molecular and Cellular Biology, 29(24), 6427&#x2013;6437. https://doi.org/10.1128/mcb.00086&#x2010;09</Citation></Reference><Reference><Citation>Blasiak, J., Glowacki, S., Kauppinen, A., &amp; Kaarniranta, K. (2013). Mitochondrial and nuclear DNA damage and repair in age&#x2010;related macular degeneration. International Journal of Molecular Sciences, 14(2), 2996&#x2013;3010. https://doi.org/10.3390/ijms14022996</Citation></Reference><Reference><Citation>Cabral, T., Mello, L. G. M., Lima, L. H., Polido, J., Regatieri, C. V., Belfort, R., Jr., &amp; Mahajan, V. B. (2017). Retinal and choroidal angiogenesis: A review of new targets. International journal of retina and vitreous, 3, 31. https://doi.org/10.1186/s40942&#x2010;017&#x2010;0084&#x2010;9</Citation></Reference><Reference><Citation>Campisi, J. (2013). Aging, cellular senescence, and cancer. Annual Review of Physiology, 75, 685&#x2013;705. https://doi.org/10.1146/annurev&#x2010;physiol&#x2010;030212&#x2010;183653</Citation></Reference><Reference><Citation>Campochiaro, P. A. (2013). Ocular neovascularization. Journal of Molecular Medicine (Berlin, Germany), 91(3), 311&#x2013;321. https://doi.org/10.1007/s00109&#x2010;013&#x2010;0993&#x2010;5</Citation></Reference><Reference><Citation>Chen, M., Rajapakse, D., Fraczek, M., Luo, C., Forrester, J. V., &amp; Xu, H. (2016). Retinal pigment epithelial cell multinucleation in the aging eye&#x2013;a mechanism to repair damage and maintain homoeostasis. Aging Cell, 15(3), 436&#x2013;445. https://doi.org/10.1111/acel.12447</Citation></Reference><Reference><Citation>Crespo&#x2010;Garcia, S., Tsuruda, P. R., Dejda, A., Ryan, R. D., Fournier, F., Chaney, S. Y., Pilon, F., Dogan, T., Cagnone, G., Patel, P., Buscarlet, M., Dasgupta, S., Girouard, G., Rao, S. R., Wilson, A. M., O'Brien, R., Juneau, R., Guber, V., Dubrac, A., &#x2026; Sapieha, P. (2021). Pathological angiogenesis in retinopathy engages cellular senescence and is amenable to therapeutic elimination via BCL&#x2010;xL inhibition. Cell Metabolism, 33(4), 818&#x2013;832.e817. https://doi.org/10.1016/j.cmet.2021.01.011</Citation></Reference><Reference><Citation>Deng, W. T., Li, J., Zhu, P., Freedman, B., Smith, W. C., Baehr, W., &amp; Hauswirth, W. W. (2019). Rescue of M&#x2010;cone function in aged Opn1mw&#x2212;/&#x2212; mice, a model for late&#x2010;stage blue cone Monochromacy. Investigative Ophthalmology &amp; Visual Science, 60(10), 3644&#x2013;3651. https://doi.org/10.1167/iovs.19&#x2010;27079</Citation></Reference><Reference><Citation>Dollfus, H., Porto, F., Caussade, P., Speeg&#x2010;Schatz, C., Sahel, J., Grosshans, E., Flament, J., &amp; Sarasin, A. (2003). Ocular manifestations in the inherited DNA repair disorders. Survey of Ophthalmology, 48(1), 107&#x2013;122. https://doi.org/10.1016/s0039&#x2010;6257(02)00400&#x2010;9</Citation></Reference><Reference><Citation>Dreyfuss, J. L., Giordano, R. J., &amp; Regatieri, C. V. (2015). Ocular Angiogenesis. Journal of Ophthalmology, 2015, 892043. https://doi.org/10.1155/2015/892043</Citation></Reference><Reference><Citation>Fang, E. F., Scheibye&#x2010;Knudsen, M., Brace, L. E., Kassahun, H., SenGupta, T., Nilsen, H., Mitchell, J. R., Croteau, D. L., &amp; Bohr, V. A. (2014). Defective mitophagy in XPA via PARP&#x2010;1 hyperactivation and NAD(+)/SIRT1 reduction. Cell, 157(4), 882&#x2013;896. https://doi.org/10.1016/j.cell.2014.03.026</Citation></Reference><Reference><Citation>Felszeghy, S., Viiri, J., Paterno, J. J., Hyttinen, J. M. T., Koskela, A., Chen, M., Leinonen, H., Tanila, H., Kivinen, N., Koistinen, A., Toropainen, E., Amadio, M., Smedowski, A., Reinisalo, M., Winiarczyk, M., Mackiewicz, J., Mutikainen, M., Ruotsalainen, A. K., Kettunen, M., &#x2026; Kaarniranta, K. (2019). Loss of NRF&#x2010;2 and PGC&#x2010;1&#x3b1; genes leads to retinal pigment epithelium damage resembling dry age&#x2010;related macular degeneration. Redox Biology, 20, 1&#x2013;12. https://doi.org/10.1016/j.redox.2018.09.011</Citation></Reference><Reference><Citation>Ferrington, D. A., Ebeling, M. C., Kapphahn, R. J., Terluk, M. R., Fisher, C. R., Polanco, J. R., Roehrich, H., Leary, M. M., Geng, Z., Dutton, J. R., &amp; Montezuma, S. R. (2017). Altered bioenergetics and enhanced resistance to oxidative stress in human retinal pigment epithelial cells from donors with age&#x2010;related macular degeneration. Redox Biology, 13, 255&#x2013;265. https://doi.org/10.1016/j.redox.2017.05.015</Citation></Reference><Reference><Citation>Fisher, C. R., &amp; Ferrington, D. A. (2018). Perspective on AMD pathobiology: A bioenergetic crisis in the RPE. Investigative Ophthalmology &amp; Visual Science, 59(4), Amd41. https://doi.org/10.1167/iovs.18&#x2010;24289</Citation></Reference><Reference><Citation>Frank, R. N. (1997). Growth factors in age&#x2010;related macular degeneration: Pathogenic and therapeutic implications. Ophthalmic Research, 29(5), 341&#x2013;353. https://doi.org/10.1159/000268032</Citation></Reference><Reference><Citation>Go, Y. M., Zhang, J., Fernandes, J., Litwin, C., Chen, R., Wensel, T. G., Jones, D. P., Cai, J., &amp; Chen, Y. (2020). MTOR&#x2010;initiated metabolic switch and degeneration in the retinal pigment epithelium. The FASEB Journal, 34(9), 12502&#x2013;12520. https://doi.org/10.1096/fj.202000612R</Citation></Reference><Reference><Citation>Golestaneh, N., Chu, Y., Xiao, Y. Y., Stoleru, G. L., &amp; Theos, A. C. (2017). Dysfunctional autophagy in RPE, a contributing factor in age&#x2010;related macular degeneration. Cell Death &amp; Disease, 8(1), e2537. https://doi.org/10.1038/cddis.2016.453</Citation></Reference><Reference><Citation>Gorgels, T. G., van der Pluijm, I., Brandt, R. M., Garinis, G. A., van Steeg, H., van den Aardweg, G., Jansen, G. H., Ruijter, J. M., Bergen, A. A., van Norren, D., Hoeijmakers, J. H., &amp; van der Horst, G. T. (2007). Retinal degeneration and ionizing radiation hypersensitivity in a mouse model for cockayne syndrome. Molecular and Cellular Biology, 27(4), 1433&#x2013;1441. https://doi.org/10.1128/mcb.01037&#x2010;06</Citation></Reference><Reference><Citation>Hyttinen, J. M. T., B&#x142;asiak, J., Niittykoski, M., Kinnunen, K., Kauppinen, A., Salminen, A., &amp; Kaarniranta, K. (2017). DNA damage response and autophagy in the degeneration of retinal pigment epithelial cells&#x2010;implications for age&#x2010;related macular degeneration (AMD). Ageing Research Reviews, 36, 64&#x2013;77. https://doi.org/10.1016/j.arr.2017.03.006</Citation></Reference><Reference><Citation>Iorio, R., Celenza, G., &amp; Petricca, S. (2021). Mitophagy: Molecular mechanisms, new concepts on Parkin activation and the emerging role of AMPK/ULK1 Axis. Cells, 11(1), 30. https://doi.org/10.3390/cells11010030</Citation></Reference><Reference><Citation>Johnson, L. L., Kueppers, R. B., Shen, E. Y., Rudell, J. C., &amp; McLoon, L. K. (2021). Development of nystagmus with the absence of MYOD expression in the extraocular muscles. Investigative Ophthalmology &amp; Visual Science, 62(13), 3. https://doi.org/10.1167/iovs.62.13.3</Citation></Reference><Reference><Citation>Kaarniranta, K., Uusitalo, H., Blasiak, J., Felszeghy, S., Kannan, R., Kauppinen, A., Salminen, A., Sinha, D., &amp; Ferrington, D. (2020). Mechanisms of mitochondrial dysfunction and their impact on age&#x2010;related macular degeneration. Progress in Retinal and Eye Research, 79, 100858. https://doi.org/10.1016/j.preteyeres.2020.100858</Citation></Reference><Reference><Citation>Kanow, M. A., Giarmarco, M. M., Jankowski, C. S., Tsantilas, K., Engel, A. L., Du, J., Linton, J. D., Farnsworth, C. C., Sloat, S. R., Rountree, A., Sweet, I. R., Lindsay, K. J., Parker, E. D., Brockerhoff, S. E., Sadilek, M., Chao, J. R., &amp; Hurley, J. B. (2017). Biochemical adaptations of the retina and retinal pigment epithelium support a metabolic ecosystem in the vertebrate eye. eLife, 6, e28899. https://doi.org/10.7554/eLife.28899</Citation></Reference><Reference><Citation>Kennedy, B. K., Berger, S. L., Brunet, A., Campisi, J., Cuervo, A. M., Epel, E. S., Franceschi, C., Lithgow, G. J., Morimoto, R. I., Pessin, J. E., Rando, T. A., Richardson, A., Schadt, E. E., Wyss&#x2010;Coray, T., &amp; Sierra, F. (2014). Geroscience: Linking aging to chronic disease. Cell, 159(4), 709&#x2013;713. https://doi.org/10.1016/j.cell.2014.10.039</Citation></Reference><Reference><Citation>Kim, Y. K., Yu, H., Summers, V. R., Donaldson, K. J., Ferdous, S., Shelton, D., Zhang, N., Chrenek, M. A., Jiang, Y., Grossniklaus, H. E., Boatright, J. H., Kong, J., &amp; Nickerson, J. M. (2021). Morphometric analysis of retinal pigment epithelial cells from C57BL/6J mice during aging. Investigative Ophthalmology &amp; Visual Science, 62(2), 32. https://doi.org/10.1167/iovs.62.2.32</Citation></Reference><Reference><Citation>Kovach, J. L., Schwartz, S. G., Flynn, H. W., Jr., &amp; Scott, I. U. (2012). Anti&#x2010;VEGF treatment strategies for wet AMD. Journal of Ophthalmology, 2012, 786870. https://doi.org/10.1155/2012/786870</Citation></Reference><Reference><Citation>Kozlowski, M. R. (2012). RPE cell senescence: A key contributor to age&#x2010;related macular degeneration. Medical Hypotheses, 78(4), 505&#x2013;510. https://doi.org/10.1016/j.mehy.2012.01.018</Citation></Reference><Reference><Citation>Kuraoka, I., Bender, C., Romieu, A., Cadet, J., Wood, R. D., &amp; Lindahl, T. (2000). Removal of oxygen free&#x2010;radical&#x2010;induced 5&#x2032;,8&#x2010;purine cyclodeoxynucleosides from DNA by the nucleotide excision&#x2010;repair pathway in human cells. Proceedings of the National Academy of Sciences of the United States of America, 97(8), 3832&#x2013;3837. https://doi.org/10.1073/pnas.070471597</Citation></Reference><Reference><Citation>Kurihara, T., Westenskow, P. D., Gantner, M. L., Usui, Y., Schultz, A., Bravo, S., Aguilar, E., Wittgrove, C., Friedlander, M., Paris, L. P., Chew, E., Siuzdak, G., &amp; Friedlander, M. (2016). Hypoxia&#x2010;induced metabolic stress in retinal pigment epithelial cells is sufficient to induce photoreceptor degeneration. eLife, 5, e14319. https://doi.org/10.7554/eLife.14319</Citation></Reference><Reference><Citation>Kvanta, A., Algvere, P. V., Berglin, L., &amp; Seregard, S. (1996). Subfoveal fibrovascular membranes in age&#x2010;related macular degeneration express vascular endothelial growth factor. Investigative Ophthalmology &amp; Visual Science, 37(9), 1929&#x2013;1934.</Citation></Reference><Reference><Citation>Lee, K. S., Lin, S., Copland, D. A., Dick, A. D., &amp; Liu, J. (2021). Cellular senescence in the aging retina and developments of senotherapies for age&#x2010;related macular degeneration. Journal of Neuroinflammation, 18(1), 32. https://doi.org/10.1186/s12974&#x2010;021&#x2010;02088&#x2010;0</Citation></Reference><Reference><Citation>Lipski, A., Endres, M., Skosyrski, S., Biniszkiewicz, D., &amp; R&#xfc;ther, K. (2007). Impaired mouse ERG caused by DNA repair deficiency and folate restriction. Investigative Ophthalmology &amp; Visual Science, 48(13), 3056.</Citation></Reference><Reference><Citation>Liu, H., Cheng, J., Zhuang, X., Qi, B., Li, F. F., &amp; Zhang, B. N. (2023). Genomic instability and eye diseases. Advances in Ophthalmology Practice and Research, 3, 103&#x2013;111. https://doi.org/10.1016/j.aopr.2023.03.002</Citation></Reference><Reference><Citation>Liu, J., Copland, D. A., Theodoropoulou, S., Chiu, H. A., Barba, M. D., Mak, K. W., Mack, M., Nicholson, L. B., &amp; Dick, A. D. (2016). Impairing autophagy in retinal pigment epithelium leads to inflammasome activation and enhanced macrophage&#x2010;mediated angiogenesis. Scientific Reports, 6, 20639. https://doi.org/10.1038/srep20639</Citation></Reference><Reference><Citation>L&#xf3;pez&#x2010;Ot&#xed;n, C., Blasco, M. A., Partridge, L., Serrano, M., &amp; Kroemer, G. (2023). Hallmarks of aging: An expanding universe. Cell, 186(2), 243&#x2013;278. https://doi.org/10.1016/j.cell.2022.11.001</Citation></Reference><Reference><Citation>Luo, C., Zhao, J., Chen, M., &amp; Xu, H. (2018). The expression of C1 inhibitor (C1INH) in macrophages is upregulated by retinal pigment epithelial cells&#x2013;implication in subretinal immune privilege in the aging eye. Aging (Albany NY), 10(6), 1380&#x2013;1389. https://doi.org/10.18632/aging.101474</Citation></Reference><Reference><Citation>Manandhar, M., Boulware, K. S., &amp; Wood, R. D. (2015). The ERCC1 and ERCC4 (XPF) genes and gene products. Gene, 569(2), 153&#x2013;161. https://doi.org/10.1016/j.gene.2015.06.026</Citation></Reference><Reference><Citation>Miranda, M., &amp; Romero, F. J. (2019). Antioxidants and retinal diseases. Antioxidants (Basel), 8(12), 604. https://doi.org/10.3390/antiox8120604</Citation></Reference><Reference><Citation>Mishima, K., Handa, J. T., Aotaki&#x2010;Keen, A., Lutty, G. A., Morse, L. S., &amp; Hjelmeland, L. M. (1999). Senescence&#x2010;associated beta&#x2010;galactosidase histochemistry for the primate eye. Investigative Ophthalmology &amp; Visual Science, 40(7), 1590&#x2013;1593.</Citation></Reference><Reference><Citation>Niedernhofer, L. J., Garinis, G. A., Raams, A., Lalai, A. S., Robinson, A. R., Appeldoorn, E., Odijk, H., Oostendorp, R., Ahmad, A., van Leeuwen, W., Theil, A. F., Vermeulen, W., van der Horst, G. T., Meinecke, P., Kleijer, W. J., Vijg, J., Jaspers, N. G., &amp; Hoeijmakers, J. H. (2006). A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. Nature, 444(7122), 1038&#x2013;1043. https://doi.org/10.1038/nature05456</Citation></Reference><Reference><Citation>Niedernhofer, L. J., Gurkar, A. U., Wang, Y., Vijg, J., Hoeijmakers, J. H. J., &amp; Robbins, P. D. (2018). Nuclear genomic instability and aging. Annual Review of Biochemistry, 87, 295&#x2013;322. https://doi.org/10.1146/annurev&#x2010;biochem&#x2010;062917&#x2010;012239</Citation></Reference><Reference><Citation>Niedernhofer, L. J., &amp; Robbins, P. D. (2018). Senotherapeutics for healthy ageing. Nature Reviews. Drug Discovery, 17(5), 377. https://doi.org/10.1038/nrd.2018.44</Citation></Reference><Reference><Citation>Nishimura, Y., Hara, H., Kondo, M., Hong, S., &amp; Matsugi, T. (2017). Oxidative stress in retinal diseases. Oxidative Medicine and Cellular Longevity, 2017, 4076518. https://doi.org/10.1155/2017/4076518</Citation></Reference><Reference><Citation>Plotegher, N., &amp; Duchen, M. R. (2017). Crosstalk between lysosomes and mitochondria in Parkinson's disease. Frontiers in Cell and Development Biology, 5, 110. https://doi.org/10.3389/fcell.2017.00110</Citation></Reference><Reference><Citation>Robinson, A. R., Yousefzadeh, M. J., Rozgaja, T. A., Wang, J., Li, X., Tilstra, J. S., Feldman, C. H., Gregg, S. Q., Johnson, C. H., Skoda, E. M., Frantz, M. C., Bell&#x2010;Temin, H., Pope&#x2010;Varsalona, H., Gurkar, A. U., Nasto, L. A., Robinson, R. A. S., Fuhrmann&#x2010;Stroissnigg, H., Czerwinska, J., McGowan, S. J., &#x2026; Niedernhofer, L. J. (2018). Spontaneous DNA damage to the nuclear genome promotes senescence, redox imbalance and aging. Redox Biology, 17, 259&#x2013;273. https://doi.org/10.1016/j.redox.2018.04.007</Citation></Reference><Reference><Citation>Selfridge, J., Hsia, K. T., Redhead, N. J., &amp; Melton, D. W. (2001). Correction of liver dysfunction in DNA repair&#x2010;deficient mice with an ERCC1 transgene. Nucleic Acids Research, 29(22), 4541&#x2013;4550. https://doi.org/10.1093/nar/29.22.4541</Citation></Reference><Reference><Citation>Shang, P., Stepicheva, N. A., Hose, S., Zigler, J. S., Jr., &amp; Sinha, D. (2018). Primary cell cultures from the mouse retinal pigment epithelium. Journal of Visualized Experiments: JoVE, 133, 56997. https://doi.org/10.3791/56997</Citation></Reference><Reference><Citation>Sijbers, A. M., de Laat, W. L., Ariza, R. R., Biggerstaff, M., Wei, Y. F., Moggs, J. G., Carter, K. C., Shell, B. K., Evans, E., de Jong, M. C., Rademakers, S., de Rooij, J., Jaspers, N. G., Hoeijmakers, J. H., &amp; Wood, R. D. (1996). Xeroderma pigmentosum group F caused by a defect in a structure&#x2010;specific DNA repair endonuclease. Cell, 86(5), 811&#x2013;822. https://doi.org/10.1016/s0092&#x2010;8674(00)80155&#x2010;5</Citation></Reference><Reference><Citation>Sinha, D., Valapala, M., Shang, P., Hose, S., Grebe, R., Lutty, G. A., Zigler, J. S., Jr., Kaarniranta, K., &amp; Handa, J. T. (2016). Lysosomes: Regulators of autophagy in the retinal pigmented epithelium. Experimental Eye Research, 144, 46&#x2013;53. https://doi.org/10.1016/j.exer.2015.08.018</Citation></Reference><Reference><Citation>Sinha, T., Naash, M. I., &amp; Al&#x2010;Ubaidi, M. R. (2020). The symbiotic relationship between the neural retina and retinal pigment epithelium is supported by utilizing differential metabolic pathways. iScience, 23(4), 101004. https://doi.org/10.1016/j.isci.2020.101004</Citation></Reference><Reference><Citation>Spivak, G. (2016). Transcription&#x2010;coupled repair: An update. Archives of Toxicology, 90(11), 2583&#x2013;2594. https://doi.org/10.1007/s00204&#x2010;016&#x2010;1820&#x2010;x</Citation></Reference><Reference><Citation>Spoor, M., Nagtegaal, A. P., Ridwan, Y., Borgesius, N. Z., van Alphen, B., van der Pluijm, I., Hoeijmakers, J. H., Frens, M. A., &amp; Borst, J. G. (2012). Accelerated loss of hearing and vision in the DNA&#x2010;repair deficient Ercc1(&#x3b4;/&#x2212;) mouse. Mechanisms of Ageing and Development, 133(2&#x2013;3), 59&#x2013;67. https://doi.org/10.1016/j.mad.2011.12.003</Citation></Reference><Reference><Citation>Strauss, O. (2005). The retinal pigment epithelium in visual function. Physiological Reviews, 85(3), 845&#x2013;881. https://doi.org/10.1152/physrev.00021.2004</Citation></Reference><Reference><Citation>Strunnikova, N., Hilmer, S., Flippin, J., Robinson, M., Hoffman, E., &amp; Csaky, K. G. (2005). Differences in gene expression profiles in dermal fibroblasts from control and patients with age&#x2010;related macular degeneration elicited by oxidative injury. Free Radical Biology &amp; Medicine, 39(6), 781&#x2013;796. https://doi.org/10.1016/j.freeradbiomed.2005.04.029</Citation></Reference><Reference><Citation>Sugita, Y., Yamamoto, H., Maeda, Y., &amp; Furukawa, T. (2020). Influence of aging on the retina and visual motion processing for optokinetic responses in mice. Frontiers in Neuroscience, 14, 586013. https://doi.org/10.3389/fnins.2020.586013</Citation></Reference><Reference><Citation>Synowiec, E., Blasiak, J., Zaras, M., Szaflik, J., &amp; Szaflik, J. P. (2012). Association between polymorphisms of the DNA base excision repair genes MUTYH and hOGG1 and age&#x2010;related macular degeneration. Experimental Eye Research, 98, 58&#x2013;66. https://doi.org/10.1016/j.exer.2012.02.008</Citation></Reference><Reference><Citation>Tong, Y., Zhang, Z., &amp; Wang, S. (2022). Role of mitochondria in retinal pigment epithelial aging and degeneration. Frontiers in Aging, 3, 926627. https://doi.org/10.3389/fragi.2022.926627</Citation></Reference><Reference><Citation>Varma, R., Vajaranant, T. S., Burkemper, B., Wu, S., Torres, M., Hsu, C., Choudhury, F., &amp; McKean&#x2010;Cowdin, R. (2016). Visual impairment and blindness in adults in the United States: Demographic and geographic variations from 2015 to 2050. JAMA Ophthalmology, 134(7), 802&#x2013;809. https://doi.org/10.1001/jamaophthalmol.2016.1284</Citation></Reference><Reference><Citation>Wang, J., Clauson, C. L., Robbins, P. D., Niedernhofer, L. J., &amp; Wang, Y. (2012). The oxidative DNA lesions 8,5&#x2032;&#x2010;cyclopurines accumulate with aging in a tissue&#x2010;specific manner. Aging Cell, 11(4), 714&#x2013;716. https://doi.org/10.1111/j.1474&#x2010;9726.2012.00828.x</Citation></Reference><Reference><Citation>Wang, Y., Liu, X., Quan, X., Qin, X., Zhou, Y., Liu, Z., Chao, Z., Jia, C., Qin, H., &amp; Zhang, H. (2022). Pigment epithelium&#x2010;derived factor and its role in microvascular&#x2010;related diseases. Biochimie, 200, 153&#x2013;171. https://doi.org/10.1016/j.biochi.2022.05.019</Citation></Reference><Reference><Citation>Wo&#x17a;niak, K., Kuc, D., B&#x142;asiak, J., Kurowska, A. K., Szaflik, J., &amp; Szaflik, J. P. (2014). Ocular manifestations in hereditary diseases with defects in DNA repair. Klinika Oczna, 116(2), 142&#x2013;145.</Citation></Reference><Reference><Citation>Ye, G. J., Budzynski, E., Sonnentag, P., Nork, T. M., Sheibani, N., Gurel, Z., Boye, S. L., Peterson, J. J., Boye, S. E., Hauswirth, W. W., &amp; Chulay, J. D. (2016). Cone&#x2010;specific promoters for gene therapy of Achromatopsia and other retinal diseases. Human Gene Therapy, 27(1), 72&#x2013;82. https://doi.org/10.1089/hum.2015.130</Citation></Reference><Reference><Citation>Yousefzadeh, M. J., Zhao, J., Bukata, C., Wade, E. A., McGowan, S. J., Angelini, L. A., Bank, M. P., Gurkar, A. U., McGuckian, C. A., Calubag, M. F., Kato, J. I., Burd, C. E., Robbins, P. D., &amp; Niedernhofer, L. J. (2020). Tissue specificity of senescent cell accumulation during physiologic and accelerated aging of mice. Aging Cell, 19(3), e13094. https://doi.org/10.1111/acel.13094</Citation></Reference><Reference><Citation>Zhang, L., Pitcher, L. E., Yousefzadeh, M. J., Niedernhofer, L. J., Robbins, P. D., &amp; Zhu, Y. (2022). Cellular senescence: A key therapeutic target in aging and diseases. The Journal of Clinical Investigation, 132(15), e158450. https://doi.org/10.1172/jci158450</Citation></Reference><Reference><Citation>Zhu, D., Wu, J., Spee, C., Ryan, S. J., &amp; Hinton, D. R. (2009). BMP4 mediates oxidative stress&#x2010;induced retinal pigment epithelial cell senescence and is overexpressed in age&#x2010;related macular degeneration. The Journal of Biological Chemistry, 284(14), 9529&#x2013;9539. https://doi.org/10.1074/jbc.M809393200</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39603590</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-1635</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>25</Day></PubDate></JournalIssue><Title>Progress in retinal and eye research</Title><ISOAbbreviation>Prog Retin Eye Res</ISOAbbreviation></Journal><ArticleTitle>Extensive Macular Atrophy with Pseudodrusen-like appearance (EMAP) Clinical characteristics, diagnostic criteria, and insights from allied Inherited Retinal Diseases and Age-related Macular Degeneration.</ArticleTitle><Pagination><StartPage>101320</StartPage><MedlinePgn>101320</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.preteyeres.2024.101320</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1350-9462(24)00085-5</ELocationID><Abstract><AbstractText>Extensive macular atrophy with pseudodrusen-like appearance (EMAP) was first described in France in 2009 as a symmetric and rapidly progressive form of macular atrophy primarily affecting middle-aged individuals. Despite the recent identification of a significant number of cases in Italy and worldwide, EMAP remains an underrecognized condition. The clinical triad typical of EMAP consists of vertically oriented macular atrophy with multilobular borders, pseudodrusen-like deposits across the posterior pole and mid-periphery, and peripheral pavingstone degeneration. Nonetheless, recent research has portrayed EMAP as a highly stage-dependent condition, allowing the identification of novel disease hallmarks, including a diffuse separation between the Bruch's membrane and the retinal pigment epithelium, along with consistent sparing of a region temporal to the macula. Additionally, retinal electrophysiology is particularly useful in distinguishing EMAP from age-related macular degeneration (AMD). Supported by unpublished data from the largest EMAP cohorts worldwide, this review aims to provide a comprehensive and updated description of EMAP, now recognized as a severely blinding disease characterized by diffuse chorioretinal atrophy and photoreceptor dysfunction. Furthermore, we propose a set of diagnostic criteria that incorporate clinical, imaging, and functional tests, to facilitate the recognition of this clinical entity. Lastly, we aim to shed light on its pathogenesis by comparing it with AMD and monogenic retinal disorders exhibiting similar phenotypes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Antropoli</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, INSERM, CNRS, Institut de la Vision, Paris, France; CHNO des Quinze-Vingts, Centre de R&#xe9;f&#xe9;rence Maladies Rares REFERET and DHU Sight Restore, INSERM-DGOS CIC1423, Paris, France; Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bianco</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, INSERM, CNRS, Institut de la Vision, Paris, France; CHNO des Quinze-Vingts, Centre de R&#xe9;f&#xe9;rence Maladies Rares REFERET and DHU Sight Restore, INSERM-DGOS CIC1423, Paris, France; Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romano</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Eye Repair Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trinco</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Eye Repair Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arrigo</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Milan, Italy; Eye Clinic, Department of Biomedical and Clinical Science, Luigi Sacco Hospital, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benadji</LastName><ForeName>Amine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CHNO des Quinze-Vingts, Centre de R&#xe9;f&#xe9;rence Maladies Rares REFERET and DHU Sight Restore, INSERM-DGOS CIC1423, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atia</LastName><ForeName>Rapha&#xeb;l</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>CHNO des Quinze-Vingts, Centre de R&#xe9;f&#xe9;rence Maladies Rares REFERET and DHU Sight Restore, INSERM-DGOS CIC1423, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palacci</LastName><ForeName>Oana</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>CHNO des Quinze-Vingts, Centre de R&#xe9;f&#xe9;rence Maladies Rares REFERET and DHU Sight Restore, INSERM-DGOS CIC1423, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dagostinoz</LastName><ForeName>Doroth&#xe9;e</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>CHNO des Quinze-Vingts, Centre de R&#xe9;f&#xe9;rence Maladies Rares REFERET and DHU Sight Restore, INSERM-DGOS CIC1423, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devisme</LastName><ForeName>C&#xe9;line</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>CHNO des Quinze-Vingts, Centre de R&#xe9;f&#xe9;rence Maladies Rares REFERET and DHU Sight Restore, INSERM-DGOS CIC1423, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Condroyer</LastName><ForeName>Christel</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, INSERM, CNRS, Institut de la Vision, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antonio</LastName><ForeName>Aline</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, INSERM, CNRS, Institut de la Vision, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bosello</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Ophthalmic Unit, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casati</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ophthalmic Unit, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvetti</LastName><ForeName>Anna Paola</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Eye Repair Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaffalon</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Eye Repair Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy; Ophthalmic Unit, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaudric</LastName><ForeName>Alain</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Ophthalmology Center for Imaging and Laser, Paris, France; Department of Ophthalmology, AP-HP, H&#xf4;pital Lariboisi&#xe8;re, Universit&#xe9; Paris Cit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sahel</LastName><ForeName>Jos&#xe9;-Alain</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, The University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staurenghi</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Eye Repair Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bandello</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sennlaub</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, INSERM, CNRS, Institut de la Vision, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeitz</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, INSERM, CNRS, Institut de la Vision, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meunier</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>National reference center for inherited sensory diseases, University Hospital of Montpellier, University of Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Battaglia Parodi</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Audo</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, INSERM, CNRS, Institut de la Vision, Paris, France; CHNO des Quinze-Vingts, Centre de R&#xe9;f&#xe9;rence Maladies Rares REFERET and DHU Sight Restore, INSERM-DGOS CIC1423, Paris, France. Electronic address: isabelle.audo@inserm.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Prog Retin Eye Res</MedlineTA><NlmUniqueID>9431859</NlmUniqueID><ISSNLinking>1350-9462</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Age-related macular degeneration</Keyword><Keyword MajorTopicYN="N">Diffuse-Trickling Geographic atrophy</Keyword><Keyword MajorTopicYN="N">Extensive macular atrophy with pseudodrusen-like appearance</Keyword><Keyword MajorTopicYN="N">Inherited retinal diseases</Keyword><Keyword MajorTopicYN="N">Multimodal imaging</Keyword><Keyword MajorTopicYN="N">Retinal electrophysiology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>28</Day><Hour>0</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>28</Day><Hour>0</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>19</Hour><Minute>31</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39603590</ArticleId><ArticleId IdType="doi">10.1016/j.preteyeres.2024.101320</ArticleId><ArticleId IdType="pii">S1350-9462(24)00085-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39603315</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1891</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>25</Day></PubDate></JournalIssue><Title>American journal of ophthalmology</Title><ISOAbbreviation>Am J Ophthalmol</ISOAbbreviation></Journal><ArticleTitle>Associations Between Contrast Sensitivity, OCT Features and Progression from Intermediate to Late Age-related Macular Degeneration.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0002-9394(24)00523-3</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajo.2024.11.006</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Establishing associations between structure, function, and clinical outcomes in intermediate age-related macular degeneration (iAMD) remains an unmet need. This study aims to (1) cross-sectionally investigate the relationships between optical coherence tomography (OCT) biomarkers and quantitative contrast sensitivity function (qCSF)-measured contrast sensitivity (CS), and (2) longitudinally assess their relationship with progression from iAMD to late stages of the disease.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Cross-sectional and cohort study.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Our study was conducted at Massachusetts Eye and Ear (Boston, MA, USA) and included eyes with (1) baseline diagnosis of iAMD, (2) same-day OCT and qCSF test, (3) visual acuity (VA) &#x2265;20/200 Snellen, and (4) 24+ months of follow-up. qCSF metrics included the area under the logCSF curve (AULCSF), contrast acuity (CA), and CS thresholds at 1-to-18 cycles per degree (cpd). Two independent graders reviewed macular OCT scans for various biomarkers, and outer nuclear layer (ONL) thickness and retinal pigment epithelium (RPE) volume were measured. Progression to wet AMD or geographic atrophy (GA) was confirmed using imaging studies. Generalized linear mixed-effects models assessed associations between qCSF and OCT biomarkers, while Cox regression models evaluated their association with progression to late AMD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We included 205 iAMD eyes from 134 patients (age: 73 [69-78] years; 63% female). Higher RPE volume in the central subfield and a greater number of intraretinal hyperreflective foci (iHRF) were associated with reduced AULCSF, CA, and CS at 6-12 cpd (p&lt;0.05). ONL thinning in the inner ring and a greater number of iHRF were associated with reduced CS at 1 and 3 cpd (p&lt;0.05). During follow-up, 35 eyes developed wet AMD (17%) and 53 progressed to GA (26%). SDD, ONL thinning in the inner ring, and reduced CS at 1.5 cpd were associated with wet AMD (p&lt;0.05). Higher RPE volume in the inner ring, hDC, SDD, higher HRF count, and reduced CS at 1 cpd were associated with GA (p&lt;0.05).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study reveals significant structure-function relationships between OCT biomarkers and qCSF-measured CS in iAMD. These findings highlight the impact of AMD alterations on CS function and offer valuable insights for patient stratification and prognostication in research and clinical settings.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>Cade</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romano</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA; Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vingopoulos</LastName><ForeName>Filippos</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA; Byers Eye Institute, Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>Mauricio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Xinyi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA; Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bannerman</LastName><ForeName>Augustine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ploumi</LastName><ForeName>Ioanna</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ntentakis</LastName><ForeName>Dimitrios</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stettler</LastName><ForeName>Isabella</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Overbey</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldwin</LastName><ForeName>Grace</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA; Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bejjani</LastName><ForeName>Romy</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garg</LastName><ForeName>Itika</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Jocelyn</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La&#xec;ns</LastName><ForeName>In&#xea;s</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA; Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Leo A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA; Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Boston, MA, USA; Byers Eye Institute, Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vavvas</LastName><ForeName>Demetrios</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Husain</LastName><ForeName>Deeba</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Joan W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>John B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA; Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Boston, MA, USA. Electronic address: john_miller@meei.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Ophthalmol</MedlineTA><NlmUniqueID>0370500</NlmUniqueID><ISSNLinking>0002-9394</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">OCT</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">contrast sensitivity function</Keyword><Keyword MajorTopicYN="N">iAMD</Keyword><Keyword MajorTopicYN="N">intermediate AMD</Keyword><Keyword MajorTopicYN="N">progression</Keyword><Keyword MajorTopicYN="N">qCSF</Keyword><Keyword MajorTopicYN="N">structure-function</Keyword></KeywordList><CoiStatement>Declaration of competing interest None relevant to this research.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>28</Day><Hour>0</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>28</Day><Hour>0</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39603315</ArticleId><ArticleId IdType="doi">10.1016/j.ajo.2024.11.006</ArticleId><ArticleId IdType="pii">S0002-9394(24)00523-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39602510</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>775</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>27</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>An mRNA-encoded dominant-negative inhibitor of transcription factor RUNX1 suppresses vitreoretinal disease in experimental models.</ArticleTitle><Pagination><StartPage>eadh0994</StartPage><MedlinePgn>eadh0994</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.adh0994</ELocationID><Abstract><AbstractText>Messenger RNA (mRNA)-based therapies are a promising approach to medical treatment. Except for infectious diseases, no other disease has mRNA-based therapies available. The eye is an ideal model for mRNA therapeutic development because it requires limited dosing. Proliferative vitreoretinopathy (PVR) is a blinding condition caused by retinal detachment that now lacks available medical treatment, with surgery as the only treatment option. We previously implicated runt-related transcription factor-1 (RUNX1) as a driver of epithelial-to-mesenchymal transition (EMT) in PVR and as a critical mediator of aberrant ocular angiogenesis when up-regulated. On the basis of these findings, an mRNA was designed to express a dominant-negative inhibitor of RUNX1 (RUNX1-Trap). We show that RUNX1-Trap delivered in polymer-lipidoid complexes or lipid nanoparticles sequestered RUNX1 in the cytosol and strongly reduced proliferation in primary cell cultures established from fibrotic membranes derived from patients with PVR. We assessed the preclinical efficacy of intraocular delivery of mRNA-encoded RUNX1-Trap in a rabbit model of PVR and in a laser-induced mouse model of aberrant angiogenesis often used to study wet age-related macular degeneration. mRNA-encoded RUNX1-Trap suppressed ocular pathology, measured as pathological scores in the rabbit PVR model and leakage and lesion size in the laser-induced choroidal neovascularization mouse model. mRNA-encoded RUNX1-Trap also strongly reduced proliferation in a human ex vivo explant model of PVR. These data demonstrate the therapeutic potential of mRNA-encoded therapeutic molecules with dominant-negative properties, highlighting the potential of mRNA-based therapies beyond standard gene supplementation approaches.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>O'Hare</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2833-3697</Identifier><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>William P</ForeName><Initials>WP</Initials><Identifier Source="ORCID">0000-0003-0157-6389</Identifier><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arevalo-Alquichire</LastName><ForeName>Said</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3366-7384</Identifier><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amarnani</LastName><ForeName>Dhanesh</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Apryani</LastName><ForeName>Evhy</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perez-Corredor</LastName><ForeName>Paula</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4327-0559</Identifier><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marino</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-2332-2163</Identifier><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shu</LastName><ForeName>Daisy Y</ForeName><Initials>DY</Initials><Identifier Source="ORCID">0000-0002-5382-6450</Identifier><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanderleest</LastName><ForeName>Timothy E</ForeName><Initials>TE</Initials><Identifier Source="ORCID">0000-0003-2929-5378</Identifier><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muriel-Torres</LastName><ForeName>Andres</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Harper B</ForeName><Initials>HB</Initials><Identifier Source="ORCID">0009-0005-9561-5706</Identifier><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gunawan</LastName><ForeName>Audrey L</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0009-0004-4884-0639</Identifier><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaplan</LastName><ForeName>Bryan A</ForeName><Initials>BA</Initials><Identifier Source="ORCID">0009-0009-2793-5539</Identifier><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barake</LastName><ForeName>Karim W</ForeName><Initials>KW</Initials><Identifier Source="ORCID">0009-0000-8912-9166</Identifier><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bejjani</LastName><ForeName>Romy P</ForeName><Initials>RP</Initials><Identifier Source="ORCID">0009-0003-1158-0506</Identifier><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doan</LastName><ForeName>Tri H</ForeName><Initials>TH</Initials><Identifier Source="ORCID">0000-0002-1365-2708</Identifier><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Rose</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delgado-Tirado</LastName><ForeName>Santiago</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez-Buendia</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossin</LastName><ForeName>Elizabeth J</ForeName><Initials>EJ</Initials><Identifier Source="ORCID">0000-0002-0052-9575</Identifier><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Guannan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eliott</LastName><ForeName>Dean</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinl-Tenbruck</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>CureVac SE, T&#xfc;bingen, 72076, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chevessier-T&#xfc;nnesen</LastName><ForeName>Fr&#xe9;d&#xe9;ric</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>CureVac SE, T&#xfc;bingen, 72076, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rejman</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CureVac SE, T&#xfc;bingen, 72076, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montrasio</LastName><ForeName>Fabio</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-6069-1937</Identifier><AffiliationInfo><Affiliation>CureVac SE, T&#xfc;bingen, 72076, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Leo A</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0001-9106-6416</Identifier><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arboleda-Velasquez</LastName><ForeName>Joseph F</ForeName><Initials>JF</Initials><Identifier Source="ORCID">0000-0002-3192-9117</Identifier><AffiliationInfo><Affiliation>Schepens Eye Research Institute of Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mass Eye and Ear and the Department of Ophthalmology at Harvard Medical School, Boston, MA 02114, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050676">Core Binding Factor Alpha 2 Subunit</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C493728">RUNX1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050676" MajorTopicYN="Y">Core Binding Factor Alpha 2 Subunit</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011817" MajorTopicYN="N">Rabbits</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="Y">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018630" MajorTopicYN="Y">Vitreoretinopathy, Proliferative</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>18</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>14</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39602510</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.adh0994</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">39602505</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1524-4636</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>12</Issue><PubDate><Year>2024</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Arteriosclerosis, thrombosis, and vascular biology</Title><ISOAbbreviation>Arterioscler Thromb Vasc Biol</ISOAbbreviation></Journal><ArticleTitle>Elucidating VEGF Biology: A Journey of Discovery and Clinical Translation.</ArticleTitle><Pagination><StartPage>2361</StartPage><EndPage>2365</EndPage><MedlinePgn>2361-2365</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1161/ATVBAHA.124.319574</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mori</LastName><ForeName>Tommaso</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Moores Cancer Center (T.M., N.K.R.N., N.F.), University of California San Diego, La Jolla.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology (T.M., N.K.R.N., N.F.), University of California San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar R N</LastName><ForeName>Naresh</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Moores Cancer Center (T.M., N.K.R.N., N.F.), University of California San Diego, La Jolla.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology (T.M., N.K.R.N., N.F.), University of California San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrara</LastName><ForeName>Napoleone</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-7029-6375</Identifier><AffiliationInfo><Affiliation>Moores Cancer Center (T.M., N.K.R.N., N.F.), University of California San Diego, La Jolla.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology (T.M., N.K.R.N., N.F.), University of California San Diego, La Jolla.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology (N.F.), University of California San Diego, La Jolla.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 EY031345</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arterioscler Thromb Vasc Biol</MedlineTA><NlmUniqueID>9505803</NlmUniqueID><ISSNLinking>1079-5642</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">angiogenesis</Keyword><Keyword MajorTopicYN="N">carcinogenesis</Keyword><Keyword MajorTopicYN="N">ischemia</Keyword><Keyword MajorTopicYN="N">macular degeneration</Keyword><Keyword MajorTopicYN="N">nutrients</Keyword></KeywordList><CoiStatement>None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>18</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>18</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>14</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39602505</ArticleId><ArticleId IdType="mid">NIHMS2030194</ArticleId><ArticleId IdType="pmc">PMC11606529</ArticleId><ArticleId IdType="doi">10.1161/ATVBAHA.124.319574</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cao Y, Langer R, Ferrara N. Targeting angiogenesis in oncology, ophthalmology and beyond. Nat Rev Drug Discov. 2023;22:476&#x2013;495. doi: 10.1038/s41573-023-00671-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-023-00671-z</ArticleId><ArticleId IdType="pubmed">37041221</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrara N VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2:795&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pubmed">12360282</ArticleId></ArticleIdList></Reference><Reference><Citation>Klagsbrun M, D&#x2019;Amore PA. Regulators of angiogenesis. Annu Rev Physiol. 1991;53:217&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">1710435</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nature Medicine. 1999;5:1359&#x2013;1364.</Citation><ArticleIdList><ArticleId IdType="pubmed">10581076</ArticleId></ArticleIdList></Reference><Reference><Citation>Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">6823562</ArticleId></ArticleIdList></Reference><Reference><Citation>Senger DR, Connolly DT, Van de Water L, Feder J, Dvorak HF. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Research. 1990;50:1774&#x2013;1778.</Citation><ArticleIdList><ArticleId IdType="pubmed">2155059</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306&#x2013;1309.</Citation><ArticleIdList><ArticleId IdType="pubmed">2479986</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Gutierrez L, Ferrara N. Biology and therapeutic targeting of vascular endothelial growth factor A. Nat Rev Mol Cell Biol. 2023;24:816&#x2013;834. doi: 10.1038/s41580-023-00631-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-023-00631-w</ArticleId><ArticleId IdType="pubmed">37491579</ArticleId></ArticleIdList></Reference><Reference><Citation>LeCouter J, Moritz DR, Li B, Phillips GL, Liang XH, Gerber HP, Hillan KJ, Ferrara N. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science. 2003;299:890&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pubmed">12574630</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">14764923</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma M, Hanahan D. Milestones in tumor vascularization and its therapeutic targeting. Nat Cancer. 2024;5:827&#x2013;843. doi: 10.1038/s43018-024-00780-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43018-024-00780-7</ArticleId><ArticleId IdType="pubmed">38918437</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature. 1993;362:841&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">7683111</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. [see comments]. New England Journal of Medicine. 1994;331:1480&#x2013;1487.</Citation><ArticleIdList><ArticleId IdType="pubmed">7526212</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15:385&#x2013;403. doi: 10.1038/nrd.2015.17</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2015.17</ArticleId><ArticleId IdType="pubmed">26775688</ArticleId></ArticleIdList></Reference><Reference><Citation>Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, Fuh G, Gerber HP, Ferrara N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol. 2007;25:911&#x2013;920.</Citation><ArticleIdList><ArticleId IdType="pubmed">17664940</ArticleId></ArticleIdList></Reference><Reference><Citation>Apte RS, Chen DS, Ferrara N. VEGF in Signaling and Disease: Beyond Discovery and Development. Cell. 2019;176:1248&#x2013;1264. doi: 10.1016/j.cell.2019.01.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.01.021</ArticleId><ArticleId IdType="pmc">PMC6410740</ArticleId><ArticleId IdType="pubmed">30849371</ArticleId></ArticleIdList></Reference><Reference><Citation>Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382:1894&#x2013;1905. doi: 10.1056/NEJMoa1915745</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1915745</ArticleId><ArticleId IdType="pubmed">32402160</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller JW, Le Couter J, Strauss EC, Ferrara N. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology. 2013;120:106&#x2013;114. doi: 10.1016/j.ophtha.2012.07.038</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2012.07.038</ArticleId><ArticleId IdType="pubmed">23031671</ArticleId></ArticleIdList></Reference><Reference><Citation>Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537&#x2013;2548. doi: 10.1016/j.ophtha.2012.09.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2012.09.006</ArticleId><ArticleId IdType="pubmed">23084240</ArticleId></ArticleIdList></Reference><Reference><Citation>Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, Hoyng CB, Hykin P, Staurenghi G, Heldner S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99:220&#x2013;226. doi: 10.1136/bjophthalmol-2014-305327</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjophthalmol-2014-305327</ArticleId><ArticleId IdType="pmc">PMC4316940</ArticleId><ArticleId IdType="pubmed">25193672</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervantes A, Adam R, Rosello S, Arnold D, Normanno N, Taieb J, Seligmann J, De Baere T, Osterlund P, Yoshino T, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:10&#x2013;32. doi: 10.1016/j.annonc.2022.10.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2022.10.003</ArticleId><ArticleId IdType="pubmed">36307056</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris VK, Kennedy EB, Baxter NN, Benson AB 3rd, Cercek A, Cho M, Ciombor KK, Cremolini C, Davis A, Deming DA, et al. Treatment of Metastatic Colorectal Cancer: ASCO Guideline. J Clin Oncol. 2023;41:678&#x2013;700. doi: 10.1200/JCO.22.01690</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.22.01690</ArticleId><ArticleId IdType="pmc">PMC10506310</ArticleId><ArticleId IdType="pubmed">36252154</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearlman JD, Hibberd MG, Chuang ML, Harada K, Lopez JJ, Gladstone SR, Friedman M, Sellke FW, Simons M. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis [see comments]. Nat-Med. 1995;1:1085&#x2013;1089 issn: 1078&#x2013;8956.</Citation><ArticleIdList><ArticleId IdType="pubmed">7489368</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK, Willerson JT, Benza RL, Berman DS, et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation. 2003;107:1359&#x2013;1365.</Citation><ArticleIdList><ArticleId IdType="pubmed">12642354</ArticleId></ArticleIdList></Reference><Reference><Citation>Yla-Herttuala S, Bridges C, Katz MG, Korpisalo P. Angiogenic gene therapy in cardiovascular diseases: dream or vision? Eur Heart J. 2017;38:1365&#x2013;1371. doi: 10.1093/eurheartj/ehw547</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehw547</ArticleId><ArticleId IdType="pmc">PMC5837788</ArticleId><ArticleId IdType="pubmed">28073865</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunewald M, Kumar S, Sharife H, Volinsky E, Glileles-Hillel A, Licht T, Permyakova A, Hinden L, Azar S, Friedmann Y, et al. Counteracting age-related VEGF signaling insufficiency promotes healthy aging and extends life span. Science. 2021;373:abc8579.</Citation><ArticleIdList><ArticleId IdType="pubmed">34326210</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">39602287</PMID><DateRevised><Year>2024</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-9235</ISSN><JournalIssue CitedMedium="Internet"><Volume>101</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Optometry and vision science : official publication of the American Academy of Optometry</Title><ISOAbbreviation>Optom Vis Sci</ISOAbbreviation></Journal><ArticleTitle>Book review: Adler's Physiology of the Eye, 12th ed.</ArticleTitle><Pagination><StartPage>644</StartPage><EndPage>645</EndPage><MedlinePgn>644-645</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/OPX.0000000000002199</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fletcher</LastName><ForeName>Erica L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Prof. Erica Fletcher is an optometrist and professor in the Department of Anatomy and Physiology at The University of Melbourne, Australia. She has over 20 years' experience evaluating the mechanisms of retinal diseases, including age-related macular degeneration and diabetic retinopathy, and has published over 150 articles on these topics. The quality and impact of Prof. Fletcher's research have been recognized by the awarding of several national and international prizes including the 2020 Nina Kondelos Prize from the Australian Neuroscience Society, the 2019 H. Barry Collin Research Medal, the 2016 Glenn A. Fry Award, and the 2006 Irvin M. and Beatrice Borish Award from the American Academy of Optometry. She has also received a Dean's award for teaching, and a service award from the Australian College of Optometry in recognition of her many years of service to leadership and education in optometry through that organization. Prof. Fletcher's original training was in optometry, where she holds an MSc degree in ocular microbiology and PhD in visual neuroscience. Prof. Fletcher's postdoctoral training was undertaken with Prof. Dr Heinz W&#xe4;ssle at the Max-Planck Institute for Brain Research in Frankfurt, Germany, funded by an NH&amp;MRC CJ Martin Award. Prof. Fletcher has been a tenured academic at The University of Melbourne since 2000 and has received considerable research funding primarily from the NH&amp;MRC but also a number of international funding agencies and published widely in a range of high-impact journals, while maintaining a teaching load and mentoring research personnel. In addition, Prof. Fletcher contributes to research leadership within the faculty and school and is passionate about mentoring young researchers.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Optom Vis Sci</MedlineTA><NlmUniqueID>8904931</NlmUniqueID><ISSNLinking>1040-5488</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39602287</ArticleId><ArticleId IdType="doi">10.1097/OPX.0000000000002199</ArticleId><ArticleId IdType="pii">00006324-202411000-00002</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39601967</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1573-7209</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>27</Day></PubDate></JournalIssue><Title>Angiogenesis</Title><ISOAbbreviation>Angiogenesis</ISOAbbreviation></Journal><ArticleTitle>Retinal pigment epithelial cells reduce vascular leak and proliferation in retinal neovessels.</ArticleTitle><Pagination><StartPage>1</StartPage><MedlinePgn>1</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10456-024-09954-4</ELocationID><Abstract><AbstractText>In multiple neurodegenerative diseases, including age-related macular degeneration, retinitis pigmentosa, and macular telangiectasia type 2 (MacTel), retinal pigment epithelial (RPE)-cells proliferate and migrate into the neuroretina, forming intraretinal pigment plaques. Though these pigmentary changes are hallmarks of disease progression, it is unknown if their presence is protective or detrimental.Here, we first evaluated the impact of pigment plaques on vascular changes and disease progression in MacTel. In a retrospective, longitudinal study, we analyzed multimodal retinal images of patients with MacTel and showed that pigment plaques were associated with decreased vascular leakage and stabilized neovascular growth. We then modeled the underlying pathomechanisms of pigment plaque formation in aberrant neovascular growth using the very-low-density lipoprotein receptor mutant (Vldlr<sup>-/-</sup>) mouse. Our data indicated that during RPE-proliferation, migration and accumulation along neovessels RPE-cells underwent epithelial-mesenchymal transition (EMT). Pharmacologic inhibition of EMT in Vldlr<sup>-/-</sup> mice decreased pigment coverage, and exacerbated neovascular growth and vascular leakage.Our findings indicate that the proliferation, migration and perivascular accumulation of RPE-cells stabilize vascular proliferation and exudation, thereby exerting a protective effect on the diseased retina. We conclude that interfering with this "natural repair mechanism" may have detrimental effects on the course of the disease and should thus be avoided.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tzaridis</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Lowy Medical Research Institute, La Jolla, CA, USA. stzaridis@scripps.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA. stzaridis@scripps.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguilar</LastName><ForeName>Edith</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorrell</LastName><ForeName>Michael I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>The Lowy Medical Research Institute, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Point Loma Nazarene University, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friedlander</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Lowy Medical Research Institute, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eade</LastName><ForeName>Kevin T</ForeName><Initials>KT</Initials><AffiliationInfo><Affiliation>The Lowy Medical Research Institute, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Angiogenesis</MedlineTA><NlmUniqueID>9814575</NlmUniqueID><ISSNLinking>0969-6970</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C036053">VLDL receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011973">Receptors, LDL</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055213" MajorTopicYN="Y">Retinal Pigment Epithelium</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="Y">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011973" MajorTopicYN="Y">Receptors, LDL</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058750" MajorTopicYN="N">Epithelial-Mesenchymal Transition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012171" MajorTopicYN="N">Retinal Vessels</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015861" MajorTopicYN="N">Retinal Neovascularization</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058456" MajorTopicYN="N">Retinal Telangiectasis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Epithelial-mesenchymal transition</Keyword><Keyword MajorTopicYN="N">Macular telangiectasia type 2</Keyword><Keyword MajorTopicYN="N">Neovascularization</Keyword><Keyword MajorTopicYN="N">Pigment migration</Keyword><Keyword MajorTopicYN="N">Retinal imaging</Keyword><Keyword MajorTopicYN="N">Vascular leakage</Keyword></KeywordList><CoiStatement>Declarations. Ethical approval: The studies were approved by the local ethics committees at each participating study site (Comit&#xe9; consultatif de protection des personnes dans la recherche biom&#xe9;dicale (CCPPRB); Human Research Ethics Committee (HREC); London City Road &amp; Hampstead Research Ethics Committee; Sterling Institutional Review Board; Ethik-Kommission der &#xc4;rztekammer Westfalen-Lippe und der Medizinischen Fakult&#xe4;t der WWU M&#xfc;nster; The State of Israel Ministry of Health; The Chaim Sheba Medical Center; Ethik-Kommission - Medizinische Fakult&#xe4;t Bonn; University of Pennsylvania Institutional Review Board; Kantonale Ethikkommission Bern (KEK); University of Miami Human Subject Research Office), and were in adherence with the Declaration of Helsinki. All participants provided informed consent prior to participation. All animal experimental procedures were approved by The Scripps Research Institute Animal Care and Use Committee. Experiments were performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals (National Academies Press, 2011). Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>12</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>11</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39601967</ArticleId><ArticleId IdType="pmc">PMC11602807</ArticleId><ArticleId IdType="doi">10.1007/s10456-024-09954-4</ArticleId><ArticleId IdType="pii">10.1007/s10456-024-09954-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>George SM, Lu F, Rao M, Leach LL, Gross JM (2021) The retinal pigment epithelium: development, injury responses, and regenerative potential in mammalian and non-mammalian systems. Prog Retin Eye Res 85:100969. 10.1016/j.preteyeres.2021.100969</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8536801</ArticleId><ArticleId IdType="pubmed">33901682</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasvoina M, Yang Q, Woods SM, Heeren T, Comer GM, C AE, Fruttiger M (2023) Intraretinal pigmented cells in retinal degenerative disease. Br J Ophthalmol 107(11):1736&#x2013;1743. 10.1136/bjophthalmol-2021-320392</Citation><ArticleIdList><ArticleId IdType="pubmed">35301216</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin M, Fialova S, Himmel T, Glosmann M, Lengheimer T, Harper DJ, Plasenzotti R, Pircher M, Hitzenberger CK, Baumann B (2016) Multi-functional OCT enables longitudinal study of retinal changes in a VLDLR knockout mouse model. PLoS ONE 11(10):e0164419. 10.1371/journal.pone.0164419</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5053493</ArticleId><ArticleId IdType="pubmed">27711217</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamiya S, Liu L, Kaplan HJ (2010) Epithelial-mesenchymal transition and proliferation of retinal pigment epithelial cells initiated upon loss of cell-cell contact. Invest Ophthalmol Vis Sci 51(5):2755&#x2013;2763. 10.1167/iovs.09-4725</Citation><ArticleIdList><ArticleId IdType="pubmed">20042656</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou M, Geathers JS, Grillo SL, Weber SR, Wang W, Zhao Y, Sundstrom JM (2020) Role of epithelial-mesenchymal transition in Retinal Pigment Epithelium Dysfunction. Front Cell Dev Biol 8:501. 10.3389/fcell.2020.00501</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7329994</ArticleId><ArticleId IdType="pubmed">32671066</ArticleId></ArticleIdList></Reference><Reference><Citation>Charbel Issa P, Gillies MC, Chew EY, Bird AC, Heeren TF, Peto T, Holz FG, Scholl HP (2013) Macular telangiectasia type 2. Prog Retin Eye Res 34:49&#x2013;77. 10.1016/j.preteyeres.2012.11.002</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3638089</ArticleId><ArticleId IdType="pubmed">23219692</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung I, Sallo FB, Bonelli R, Clemons TE, Pauleikhoff D, Chew EY, Bird AC, Peto T, MacTel Study G (2018) Characteristics of pigmented lesions in type 2 idiopathic Macular Telangiectasia. Retina 38(Suppl 1):S43&#x2013;S50. 10.1097/IAE.0000000000001842</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5726940</ArticleId><ArticleId IdType="pubmed">29095354</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzaridis S, Wintergerst MWM, Mai C, Heeren TFC, Holz FG, Charbel Issa P, Herrmann P (2019) Quantification of retinal and Choriocapillaris Perfusion in different stages of Macular Telangiectasia Type 2. Invest Ophthalmol Vis Sci 60(10):3556&#x2013;3562. 10.1167/iovs.19-27055</Citation><ArticleIdList><ArticleId IdType="pubmed">31415079</ArticleId></ArticleIdList></Reference><Reference><Citation>Breazzano MP, Yannuzzi LA, Spaide RF (2020) Characterizing retinal-choroidal anastomosis in Macular Telangiectasia Type 2 with Optical Coherence Tomography Angiography. Retina 40(1):92&#x2013;98. 10.1097/IAE.0000000000002619</Citation><ArticleIdList><ArticleId IdType="pubmed">31246676</ArticleId></ArticleIdList></Reference><Reference><Citation>Breazzano MP, Yannuzzi LA, Spaide RF (2020) Genesis of Retinal-Choroidal Anastomosis in Macular Telangiectasia Type 2: a longitudinal analysis. Retina. 10.1097/IAE.0000000000002986</Citation><ArticleIdList><ArticleId IdType="pubmed">32976212</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzaridis S, Heeren T, Mai C, Thiele S, Holz FG, Charbel Issa P, Herrmann P (2021) Right-angled vessels in macular telangiectasia type 2. Br J Ophthalmol 105(9):1289&#x2013;1296. 10.1136/bjophthalmol-2018-313364</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8380913</ArticleId><ArticleId IdType="pubmed">30808615</ArticleId></ArticleIdList></Reference><Reference><Citation>Gass JD, Blodi BA (1993) Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology 100(10):1536&#x2013;1546</Citation><ArticleIdList><ArticleId IdType="pubmed">8414413</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelbrecht NE, Aaberg TM Jr., Sung J, Lewis ML (2002) Neovascular membranes associated with idiopathic juxtafoveolar telangiectasis. Arch Ophthalmol 120(3):320&#x2013;324</Citation><ArticleIdList><ArticleId IdType="pubmed">11879135</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidorf FH, Pressman MD, Chambers RB (2004) Juxtafoveal telangiectasis-a name change? Retina 24(3):474&#x2013;478</Citation><ArticleIdList><ArticleId IdType="pubmed">15187680</ArticleId></ArticleIdList></Reference><Reference><Citation>Heeren TFC, Chew EY, Clemons T, Fruttiger M, Balaskas K, Schwartz R, Egan CA, Charbel Issa P, MacTel Study G (2020) Macular Telangiectasia Type 2: Visual Acuity, Disease End Stage, and the MacTel Area: MacTel Project Report Number 8. Ophthalmology. 10.1016/j.ophtha.2020.03.040</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8380038</ArticleId><ArticleId IdType="pubmed">32586743</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller S, Gunnemann F, Rothaus K, Book M, Faatz H, Bird A, Pauleikhoff D (2021) Incidence and phenotypical variation of outer retina-associated hyperreflectivity in macular telangiectasia type 2. Br J Ophthalmol 105(4):573&#x2013;576. 10.1136/bjophthalmol-2020-317997</Citation><ArticleIdList><ArticleId IdType="pubmed">33414243</ArticleId></ArticleIdList></Reference><Reference><Citation>Heckenlively JR, Hawes NL, Friedlander M, Nusinowitz S, Hurd R, Davisson M, Chang B (2003) Mouse model of subretinal neovascularization with choroidal anastomosis. Retina 23(4):518&#x2013;522. 10.1097/00006982-200308000-00012</Citation><ArticleIdList><ArticleId IdType="pubmed">12972764</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu W, Jiang A, Liang J, Meng H, Chang B, Gao H, Qiao X (2008) Expression of VLDLR in the retina and evolution of subretinal neovascularization in the knockout mouse model&#x2019;s retinal angiomatous proliferation. Invest Ophthalmol Vis Sci 49(1):407&#x2013;415. 10.1167/iovs.07-0870</Citation><ArticleIdList><ArticleId IdType="pubmed">18172119</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorrell MI, Aguilar E, Jacobson R, Yanes O, Gariano R, Heckenlively J, Banin E, Ramirez GA, Gasmi M, Bird A, Siuzdak G, Friedlander M (2009) Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization-associated oxidative stress. J Clin Invest 119(3):611&#x2013;623. 10.1172/JCI35977</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2648679</ArticleId><ArticleId IdType="pubmed">19188685</ArticleId></ArticleIdList></Reference><Reference><Citation>Krivosic V, Lavia C, Aubineau A, Tadayoni R, Gaudric A (2021) OCT of outer retinal hyperreflectivity, Neovascularization, and pigment in Macular Telangiectasia Type 2. Ophthalmol Retina 5(6):562&#x2013;570. 10.1016/j.oret.2020.09.012</Citation><ArticleIdList><ArticleId IdType="pubmed">32956858</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzaridis S, Hess K, Heeren TFC, Bonelli R, Holz FG, Friedlander M (2021) Hyperreflectivity on Optical Coherence Tomography in Macular Telangiectasia Type 2. Retina 41(7):1428&#x2013;1437. 10.1097/IAE.0000000000003111</Citation><ArticleIdList><ArticleId IdType="pubmed">33438900</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Lin Z, Liu CH, Gong Y, Liegl R, Fredrick TW, Meng SS, Burnim SB, Wang Z, Akula JD, Pu WT, Chen J, Smith LEH (2017) Inflammatory signals from photoreceptor modulate pathological retinal angiogenesis via c-Fos. J Exp Med 214(6):1753&#x2013;1767. 10.1084/jem.20161645</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5461000</ArticleId><ArticleId IdType="pubmed">28465464</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Huang Z, Kingsley R, Zhou X, Li F, Parke DW, Cao II W (2007) Biochemical alterations in the retinas of very low-density lipoprotein receptor knockout mice: an animal model of Retinal Angiomatous Proliferation. Arch Ophthalmol 125(6):795&#x2013;803. 10.1001/archopht.125.6.795</Citation><ArticleIdList><ArticleId IdType="pubmed">17562991</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HC, Zhu YT, Chen SY, Tseng SC (2012) Wnt signaling induces epithelial-mesenchymal transition with proliferation in ARPE-19 cells upon loss of contact inhibition. Lab Invest 92(5):676&#x2013;687. 10.1038/labinvest.2011.201</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3961713</ArticleId><ArticleId IdType="pubmed">22391957</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda Y, Nonaka Y, Futakawa S, Imai H, Akita K, Nishihata T, Fujiwara M, Ali Y, Bhisitkul RB, Nakamura Y (2019) Anti-angiogenic and Anti-scarring Dual Action of an anti-fibroblast growth factor 2 Aptamer in Animal models of Retinal Disease. Mol Ther Nucleic Acids 17:819&#x2013;828. 10.1016/j.omtn.2019.07.018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6716068</ArticleId><ArticleId IdType="pubmed">31454678</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz GS, Grant MB (1991) Neovascular growth factors. Eye (Lond) 5(Pt 2):170&#x2013;180. 10.1038/eye.1991.31</Citation><ArticleIdList><ArticleId IdType="pubmed">1712736</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang CH, Cao GF, Jiang Q, Yao J (2012) TNF-alpha promotes human retinal pigment epithelial (RPE) cell migration by inducing matrix metallopeptidase 9 (MMP-9) expression through activation of Akt/mTORC1 signaling. Biochem Biophys Res Commun 425(1):33&#x2013;38. 10.1016/j.bbrc.2012.07.044</Citation><ArticleIdList><ArticleId IdType="pubmed">22820188</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni Y, Qin Y, Huang Z, Liu F, Zhang S, Zhang Z (2020) Distinct serum and vitreous inflammation-related factor profiles in patients with proliferative vitreoretinopathy. Adv Ther 37(5):2550&#x2013;2559. 10.1007/s12325-020-01325-x</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7467460</ArticleId><ArticleId IdType="pubmed">32274748</ArticleId></ArticleIdList></Reference><Reference><Citation>Limb GA, Alam A, Earley O, Green W, Chignell AH, Dumonde DC (1994) Distribution of cytokine proteins within epiretinal membranes in proliferative vitreoretinopathy. Curr Eye Res 13(11):791&#x2013;798. 10.3109/02713689409025133</Citation><ArticleIdList><ArticleId IdType="pubmed">7851114</ArticleId></ArticleIdList></Reference><Reference><Citation>Boles NC, Fernandes M, Swigut T, Srinivasan R, Schiff L, Rada-Iglesias A, Wang Q, Saini JS, Kiehl T, Stern JH, Wysocka J, Blenkinsop TA, Temple S (2020) Epigenomic and transcriptomic changes during human RPE EMT in a stem cell model of Epiretinal Membrane Pathogenesis and Prevention by Nicotinamide. Stem Cell Rep 14(4):631&#x2013;647. 10.1016/j.stemcr.2020.03.009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7160390</ArticleId><ArticleId IdType="pubmed">32243845</ArticleId></ArticleIdList></Reference><Reference><Citation>Meleth AD, Toy BC, Nigam D, Agron E, Murphy RP, Chew EY, Wong WT (2013) Prevalence and progression of pigment clumping associated with idiopathic macular telangiectasia type 2. Retina 33(4):762&#x2013;770. 10.1097/IAE.0b013e3182695bb3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3549320</ArticleId><ArticleId IdType="pubmed">23064429</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaissle GB, May CA, van de Pavert SA, Wenzel A, Claes-May E, Giessl A, Szurman P, Wolfrum U, Wijnholds J, Fischer MD, Humphries P, Seeliger MW (2010) Bone spicule pigment formation in retinitis pigmentosa: insights from a mouse model. Graefes Arch Clin Exp Ophthalmol 248(8):1063&#x2013;1070. 10.1007/s00417-009-1253-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20012642</ArticleId></ArticleIdList></Reference><Reference><Citation>Pei D, Shu X, Gassama-Diagne A, Thiery JP (2019) Mesenchymal-epithelial transition in development and reprogramming. Nat Cell Biol 21(1):44&#x2013;53. 10.1038/s41556-018-0195-z</Citation><ArticleIdList><ArticleId IdType="pubmed">30602762</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao D, Dai C, Peng S (2011) Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation. Mol Cancer Res 9(12):1608&#x2013;1620. 10.1158/1541-7786.MCR-10-0568</Citation><ArticleIdList><ArticleId IdType="pubmed">21840933</ArticleId></ArticleIdList></Reference><Reference><Citation>Usui-Ouchi A, Usui Y, Kurihara T, Aguilar E, Dorrell MI, Ideguchi Y, Sakimoto S, Bravo S, Friedlander M (2020) Retinal microglia are critical for subretinal neovascular formation. JCI Insight 5(12). 10.1172/jci.insight.137317</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7406258</ArticleId><ArticleId IdType="pubmed">32437334</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Jiang N, Zhang Y, Ye S, Liang X, Wang X, Lin X, Zong R, Chen H, Liu Z (2020) Fenofibrate inhibits Subretinal Fibrosis through suppressing TGF-beta-Smad2/3 signaling and wnt signaling in Neovascular Age-Related Macular Degeneration. Front Pharmacol 11:580884. 10.3389/fphar.2020.580884</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7797782</ArticleId><ArticleId IdType="pubmed">33442383</ArticleId></ArticleIdList></Reference><Reference><Citation>Eade KT, Ansell BRE, Giles S, Fallon R, Harkins-Perry S, Nagasaki T, Tzaridis S, Wallace M, Mills EA, Farashi S, Johnson A, Sauer L, Hart B, Diaz-Rubio ME, Bahlo M, Metallo C, Allikmets R, Gantner ML, Bernstein PS, Friedlander M (2023) iPSC-derived retinal pigmented epithelial cells from patients with macular telangiectasia show decreased mitochondrial function. J Clin Invest 133(9). 10.1172/JCI163771</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10145939</ArticleId><ArticleId IdType="pubmed">37115691</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth T, Zeman F, Helbig H, Gamulescu MA (2018) Intravitreal anti-VEGF treatment for subretinal neovascularisation secondary to type 2 idiopathic juxtafoveolar telangiectasia. Int Ophthalmol 38(1):191&#x2013;198. 10.1007/s10792-017-0447-0</Citation><ArticleIdList><ArticleId IdType="pubmed">28108904</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayanan R, Chhablani J, Sinha M, Dave V, Tyagi M, Pappuru RR, Kuppermann BD (2012) Efficacy of anti-vascular endothelial growth factor therapy in subretinal neovascularization secondary to macular telangiectasia type 2. Retina 32(10):2001&#x2013;2005. 10.1097/IAE.0b013e3182625c1d</Citation><ArticleIdList><ArticleId IdType="pubmed">22990322</ArticleId></ArticleIdList></Reference><Reference><Citation>Roller AB, Folk JC, Patel NM, Boldt HC, Russell SR, Abramoff MD, Mahajan VB (2011) Intravitreal bevacizumab for treatment of proliferative and nonproliferative type 2 idiopathic macular telangiectasia. Retina 31(9):1848&#x2013;1855. 10.1097/IAE.0b013e31820d3feb</Citation><ArticleIdList><ArticleId IdType="pubmed">21610563</ArticleId></ArticleIdList></Reference><Reference><Citation>Charbel Issa P, Finger RP, Kruse K, Baumuller S, Scholl HP, Holz FG (2011) Monthly ranibizumab for nonproliferative macular telangiectasia type 2: a 12-month prospective study. Am J Ophthalmol 151(5):876&#x2013;886, e871. 10.1016/j.ajo.2010.11.019</Citation><ArticleIdList><ArticleId IdType="pubmed">21334595</ArticleId></ArticleIdList></Reference><Reference><Citation>Kupitz EH, Heeren TF, Holz FG, Charbel Issa P (2015) Poor long-term outcome of anti-vascular endothelial growth factor therapy in nonproliferative macular telangiectasia type 2. Retina 35(12):2619&#x2013;2626. 10.1097/IAE.0000000000000715</Citation><ArticleIdList><ArticleId IdType="pubmed">26340529</ArticleId></ArticleIdList></Reference><Reference><Citation>Clemons TE, Gillies MC, Chew EY, Bird AC, Peto T, Figueroa MJ, Harrington MW, MacTel Research G (2010) Baseline characteristics of participants in the natural history study of macular telangiectasia (MacTel) MacTel Project Report 2. Ophthalmic Epidemiol 17(1):66&#x2013;73. 10.3109/09286580903450361</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8329604</ArticleId><ArticleId IdType="pubmed">20100102</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Huang Z, Kingsley R, Zhou X, Li F, Parke DW 2nd, Cao W (2007) Biochemical alterations in the retinas of very low-density lipoprotein receptor knockout mice: an animal model of retinal angiomatous proliferation. Arch Ophthalmol 125(6):795&#x2013;803. 10.1001/archopht.125.6.795</Citation><ArticleIdList><ArticleId IdType="pubmed">17562991</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39601844</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1435-702X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>27</Day></PubDate></JournalIssue><Title>Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie</Title><ISOAbbreviation>Graefes Arch Clin Exp Ophthalmol</ISOAbbreviation></Journal><ArticleTitle>Association between the ARMS2 rs10490924 risk genotype and dry-age related macular degeneration patients with and without reticular pseudodrusen in a Turkish population: findings from a study conducted at a tertiary clinic.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00417-024-06699-0</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To evaluate the relationship between the presence of reticular pseudodrusen (RPD) and the risk allele of ARMS2 rs10490924 variation in dry-AMD patients by using multimodal imaging. Also, to compare patients with and without RPD and healthy volunteers according to the distribution of the risk allele.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this cross-sectional study, dry-AMD patients with (Group A,&#xa0;n&#x2009;=&#x2009;50) and without (Group B,&#xa0;n&#x2009;=&#x2009;50) RPD and healthy volunteers (Group C,&#xa0;n&#x2009;=&#x2009;50) were enrolled. After detailed ophthalmologic examination, confocal scanning laser ophthalmoscope (Heidelberg, Germany) was used to acquire near infra-red (NIR) imaging for RPD and the diagnosis was confirmed by Spectral Domain-Optical coherence tomography (Heidelberg, Germany). In silent choroidal neovascularization suspicion, optical coherence tomography angiography (Optovue, Fremont, CA) was performed and those were excluded. For genetic assessment, peripheric blood sampling was performed. Using next-generation sequencing technique (NGS), ARMS2 rs10490924 single nucleotide polymorphism was investigated. Groups were compared according to the distribution of the risky allele.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">150 eyes of 150 participants were included. In Group A, 42% (21) of patients were heterozygous for the T risk allele, 30% (15) were homozygous, and the risk allele was not detected in 28% (14). In Group B, 44% (22) of patients were heterozygous, 17% (8) were homozygous, and the risk allele was not detected in 39% (20). In Group C, 30% (15) of participants were heterozygous, 4% (2) were homozygous, and variation was not observed in 64% (32). Homozygous participants in Group A were significantly higher than other two groups (Group A-B: OR&#x2009;=&#x2009;2.67, 95% CI: 0.895, 8.020; Group A-C: OR&#x2009;=&#x2009;17.14, 95% CI: 3.449, 85.208) while in Group B, homozygous individuals were higher than Group C (respectively, p values 0.0039, 0.0002, 0.013). T risky allele frequencies were 51%, 38%, and 20% in Groups A, B, and C, respectively, which was significantly higher in Group A (p&#x2009;=&#x2009;0.02).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Genetic influence in AMD is inevitable while certain differences according to different ethnicities may apply. Association of genetic variations and imaging findings like RPD is lacking among literature for different populations. By the aspect of this study, the relationship between RPD and ARMS2 rs10490924 polymorphism in dry-AMD patients were highlighted among Turkish population by using multimodal imaging for the first time.</AbstractText><AbstractText Label="KEY MESSAGES" NlmCategory="CONCLUSIONS">What is Known? Pathophysiology of age-related macular degeneration is influenced from multiple factors including single nucleotide polymorphisms. The variations of ARMS2 are suspected well in the current literature. Reticular pseudodrusen is related to advanced stages of age related macular degeneration disease. What is New? The ARMS2 rs10490924 risk genotype is associated with the presence of reticular pseudodrusen in dry&#xa0;age related macular degeneration patients. Homozygous genotype of T risk allele is evaluated significantly higher in dry age related macular degeneration patients&#xa0;with reticular pseudodrusen.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Furundaoturan</LastName><ForeName>Onur</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-6929-6645</Identifier><AffiliationInfo><Affiliation>Department of Ophthalmology, Ege University, Izmir, Turkey. onurfurundaoturan@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Degirmenci</LastName><ForeName>Cumali</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-8268-536X</Identifier><AffiliationInfo><Affiliation>Department of Ophthalmology, Ege University, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Afrashi</LastName><ForeName>Filiz</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-6359-1600</Identifier><AffiliationInfo><Affiliation>Department of Ophthalmology, Ege University, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atik</LastName><ForeName>Tahir</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-1142-3872</Identifier><AffiliationInfo><Affiliation>Department of Medical Genetics, Ege University, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akkin</LastName><ForeName>Cezmi</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-7048-9599</Identifier><AffiliationInfo><Affiliation>Department of Ophthalmology, Ege University, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mentes</LastName><ForeName>Jale</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-3275-1127</Identifier><AffiliationInfo><Affiliation>Department of Ophthalmology, Ege University, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nalcaci</LastName><ForeName>Serhad</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-2785-9344</Identifier><AffiliationInfo><Affiliation>Department of Ophthalmology, Ege University, Izmir, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>TTU-2021-28871</GrantID><Agency>Ege University Research Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Graefes Arch Clin Exp Ophthalmol</MedlineTA><NlmUniqueID>8205248</NlmUniqueID><ISSNLinking>0721-832X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ARMS2</Keyword><Keyword MajorTopicYN="N">Age related macular degeneration</Keyword><Keyword MajorTopicYN="N">Reticular pseudodrusen</Keyword><Keyword MajorTopicYN="N">Rs10490924 polymorphism</Keyword></KeywordList><CoiStatement>Declarations. Ethical approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ege University Committee of Ethics (Project number: 21&#x2013;3.1&#xa0;T/76) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent: Informed consent was obtained from all individual participants included in the study. Conflict of interest: All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers&#x2019; bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>12</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>12</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>11</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39601844</ArticleId><ArticleId IdType="doi">10.1007/s00417-024-06699-0</ArticleId><ArticleId IdType="pii">10.1007/s00417-024-06699-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Guymer RH, Campbell TG (2023) Age-related macular degeneration. Lancet (London, England) 401:1459&#x2013;1472. https://doi.org/10.1016/s0140-6736(22)02609-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(22)02609-5</ArticleId><ArticleId IdType="pubmed">36996856</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, Fletcher EL, Kumar H, Greferath U, Guymer RH (2022) Reticular pseudodrusen: A critical phenotype in age-related macular degeneration. Prog Retin Eye Res 88:101017. https://doi.org/10.1016/j.preteyeres.2021.101017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2021.101017</ArticleId><ArticleId IdType="pubmed">34752916</ArticleId></ArticleIdList></Reference><Reference><Citation>Mimoun G, Soubrane G, Coscas G (1990) Macular drusen. J Fr Ophtalmol 13:511&#x2013;530</Citation><ArticleIdList><ArticleId IdType="pubmed">2081842</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritsche LG, Igl W, Bailey JN, Grassmann F, Sengupta S, Bragg-Gresham JL et al (2016) A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet 48:134&#x2013;143. https://doi.org/10.1038/ng.3448</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3448</ArticleId><ArticleId IdType="pubmed">26691988</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Q, Ding Y, Liu Y, Sun T, Fritsche LG, Clemons T, Ratnapriya R, Klein ML, Cook RJ, Liu Y, Fan R, Wei L, Abecasis GR, Swaroop A, Chew EY, Weeks DE, Chen W (2018) Genome-wide analysis of disease progression in age-related macular degeneration. Hum Mol Genet 27:929&#x2013;940. https://doi.org/10.1093/hmg/ddy002</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddy002</ArticleId><ArticleId IdType="pubmed">29346644</ArticleId><ArticleId IdType="pmc">6059197</ArticleId></ArticleIdList></Reference><Reference><Citation>Thee EF, Meester-Smoor MA, Luttikhuizen DT, Colijn JM, Enthoven CA, Haarman AEG, Rizopoulos D, Klaver CCW (2020) Performance of classification systems for age-related macular degeneration in the rotterdam study. Transl Vis Sci Technol 9:26. https://doi.org/10.1167/tvst.9.2.26</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/tvst.9.2.26</ArticleId><ArticleId IdType="pubmed">32818087</ArticleId><ArticleId IdType="pmc">7396180</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold JJ, Sarks SH, Killingsworth MC, Sarks JP (1995) Reticular pseudodrusen. A risk factor in age-related maculopathy. Retina (Philadelphia, Pa) 15:183&#x2013;191</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006982-199515030-00001</ArticleId><ArticleId IdType="pubmed">7569344</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadda SR, Guymer R, Holz FG, Schmitz-Valckenberg S, Curcio CA, Bird AC et al (2018) Consensus definition for atrophy associated with age-related macular degeneration on OCT: Classification of atrophy report 3. Ophthalmology 125:537&#x2013;548. https://doi.org/10.1016/j.ophtha.2017.09.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2017.09.028</ArticleId><ArticleId IdType="pubmed">29103793</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogg RE, Silva R, Staurenghi G, Murphy G, Santos AR, Rosina C, Chakravarthy U (2014) Clinical characteristics of reticular pseudodrusen in the fellow eye of patients with unilateral neovascular age-related macular degeneration. Ophthalmology 121:1748&#x2013;1755. https://doi.org/10.1016/j.ophtha.2014.03.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2014.03.015</ArticleId><ArticleId IdType="pubmed">24856310</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueda-Arakawa N, Ooto S, Tsujikawa A, Yamashiro K, Oishi A, Yoshimura N (2013) Sensitivity and specificity of detecting reticular pseudodrusen in multimodal imaging in Japanese patients. Retina (Philadelphia, Pa) 33:490&#x2013;497. https://doi.org/10.1097/IAE.0b013e318276e0ae</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IAE.0b013e318276e0ae</ArticleId><ArticleId IdType="pubmed">23403515</ArticleId></ArticleIdList></Reference><Reference><Citation>Joachim N, Mitchell P, Kifley A, Rochtchina E, Hong T, Wang JJ (2013) Incidence and progression of geographic atrophy: observations from a population-based cohort. Ophthalmology 120:2042&#x2013;2050. https://doi.org/10.1016/j.ophtha.2013.03.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2013.03.029</ArticleId><ArticleId IdType="pubmed">23706948</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaszubski PA, Ben Ami T, Saade C, Nabati C, Kumar V, Santos AR, Silva R, Cachulo ML, Cunha-Vaz JG, Smith RT (2018) Changes in reticular pseudodrusen area in eyes that progressed from early to late age-related macular degeneration. Int Ophthalmol 38:503&#x2013;511. https://doi.org/10.1007/s10792-017-0485-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10792-017-0485-7</ArticleId><ArticleId IdType="pubmed">28265823</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakurada Y, Sugiyama A, Kikushima W, Yoneyama S, Tanabe N, Matsubara M, Iijima H (2019) Pseudodrusen pattern and development of late age-related macular degeneration in the fellow eye of the unilateral case. Jpn J Ophthalmol 63:374&#x2013;381. https://doi.org/10.1007/s10384-019-00680-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10384-019-00680-9</ArticleId><ArticleId IdType="pubmed">31267312</ArticleId></ArticleIdList></Reference><Reference><Citation>Finger RP, Chong E, McGuinness MB, Robman LD, Aung KZ, Giles G, Baird PN, Guymer RH (2016) Reticular pseudodrusen and their association with age-related macular degeneration: The Melbourne collaborative cohort study. Ophthalmology 123:599&#x2013;608. https://doi.org/10.1016/j.ophtha.2015.10.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2015.10.029</ArticleId><ArticleId IdType="pubmed">26681391</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan H, Cougnard-Gr&#xe9;goire A, Delyfer MN, Combillet F, Rougier MB, Schweitzer C, Dartigues JF, Korobelnik JF, Delcourt C (2016) Multimodal imaging of reticular pseudodrusen in a population-based setting: The alienor study. Invest Ophthalmol Vis Sci 57:3058&#x2013;3065. https://doi.org/10.1167/iovs.16-19487</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.16-19487</ArticleId><ArticleId IdType="pubmed">27367498</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y, Qiao L, Du M, Qu C, Wan L, Li J, Huang L (2022) Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes Dis 9:62&#x2013;79. https://doi.org/10.1016/j.gendis.2021.02.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gendis.2021.02.009</ArticleId><ArticleId IdType="pubmed">35005108</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanda A, Chen W, Othman M, Branham KE, Brooks M, Khanna R, He S, Lyons R, Abecasis GR, Swaroop A (2007) A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration. Proc Natl Acad Sci USA 104:16227&#x2013;16232. https://doi.org/10.1073/pnas.0703933104</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0703933104</ArticleId><ArticleId IdType="pubmed">17884985</ArticleId><ArticleId IdType="pmc">1987388</ArticleId></ArticleIdList></Reference><Reference><Citation>Kortvely E, Hauck SM, Duetsch G, Gloeckner CJ, Kremmer E, Alge-Priglinger CS, Deeg CA, Ueffing M (2010) ARMS2 is a constituent of the extracellular matrix providing a link between familial and sporadic age-related macular degenerations. Invest Ophthalmol Vis Sci 51:79&#x2013;88. https://doi.org/10.1167/iovs.09-3850</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.09-3850</ArticleId><ArticleId IdType="pubmed">19696174</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamura H, Tsujikawa A, Yamashiro K, Akagi-Kurashige Y, Nakata I, Nakanishi H, Hayashi H, Ooto S, Otani A, Yoshimura N (2012) Association of ARMS2 genotype with bilateral involvement of exudative age-related macular degeneration. Am J Ophthalmol 154:542-548.e541. https://doi.org/10.1016/j.ajo.2012.03.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2012.03.042</ArticleId><ArticleId IdType="pubmed">22809783</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong Y, Liao J, Zhang Y, Zhou J, Zhang H, Mao M (2010) LOC387715/HTRA1 gene polymorphisms and susceptibility to age-related macular degeneration: A HuGE review and meta-analysis. Mol Vis 16:1958&#x2013;1981</Citation><ArticleIdList><ArticleId IdType="pubmed">21031019</ArticleId><ArticleId IdType="pmc">2956667</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein R, Meuer SM, Knudtson MD, Iyengar SK, Klein BE (2008) The epidemiology of retinal reticular drusen. Am J Ophthalmol 145:317&#x2013;326. https://doi.org/10.1016/j.ajo.2007.09.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2007.09.008</ArticleId><ArticleId IdType="pubmed">18045568</ArticleId></ArticleIdList></Reference><Reference><Citation>Joachim N, Mitchell P, Burlutsky G, Kifley A, Wang JJ (2015) The incidence and progression of age-related macular degeneration over 15 years: The blue mountains eye study. Ophthalmology 122:2482&#x2013;2489. https://doi.org/10.1016/j.ophtha.2015.08.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2015.08.002</ArticleId><ArticleId IdType="pubmed">26383995</ArticleId></ArticleIdList></Reference><Reference><Citation>Domalpally A, Agr&#xf3;n E, Pak JW, Keenan TD, Ferris FL, Clemons TE, Chew EY (2019) Prevalence, risk, and genetic association of reticular pseudodrusen in age-related macular degeneration: Age-related eye disease study 2 report 21. Ophthalmology 126:1659&#x2013;1666. https://doi.org/10.1016/j.ophtha.2019.07.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2019.07.022</ArticleId><ArticleId IdType="pubmed">31558345</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardak H, Gunay M, Ercalik Y, Bardak Y, Ozbas H, Bagci O (2017) Next-generation sequencing analysis of the ARMS2 gene in Turkish exudative age-related macular degeneration patients. Genetics and molecular research : GMR 16.&#xa0; https://doi.org/10.4238/gmr16019135</Citation></Reference><Reference><Citation>Soysal Y, Inan U, K&#xfc;sbeci T, Imirzalio&#x11f;lu N (2012) Age-related macular degeneration and association of CFH Y402H and LOC387715 A69S polymorphisms in a Turkish population. DNA Cell Biol 31:323&#x2013;330. https://doi.org/10.1089/dna.2011.1214</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/dna.2011.1214</ArticleId><ArticleId IdType="pubmed">21790300</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39600369</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of complement inhibitors in patients with geographic atrophy associated with age-related macular degeneration: a network meta-analysis of randomized controlled trials.</ArticleTitle><Pagination><StartPage>1410172</StartPage><MedlinePgn>1410172</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1410172</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2024.1410172</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">Clinical trials in recent years have shown significant effectiveness of complement inhibitors for geographic atrophy (GA) treatment. Two complement inhibitor drugs have been approved by the Food and Drug Administration (FDA).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">to compare and rank the different complement inhibitors in the treatment of GA secondary to age-related macular degeneration (AMD).</AbstractText><AbstractText Label="DATA SOURCES" NlmCategory="UNASSIGNED">A systematic literature search was conducted in the Cochrane Central, Web of Science Core Collection, PubMed, LWW Medical Journals, ClinicalTrials.gov, and WHO ICTRP from inception to October 2023.</AbstractText><AbstractText Label="STUDY SELECTION" NlmCategory="UNASSIGNED">All randomized clinical trials evaluating the effectiveness of complement inhibitors in patients diagnosed with secondary GA in AMD were identified.</AbstractText><AbstractText Label="DATA EXTRACTION AND SYNTHESIS" NlmCategory="UNASSIGNED">This study followed Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) network meta-analysis Checklist of Items and the Cochrane Risk of Bias Assessment Tool for assessing the study quality. Multiple authors independently coded all titles and abstracts, reviewed full-text articles against the inclusion and exclusion criteria, and resolved all discrepancies by consensus. Random-effects network meta-analyses were applied. Bayesian network meta-analysis was performed using the BUGSnet package in R (4.2.0).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="UNASSIGNED">The primary efficacy outcome was the change in GA lesion size (mm<sup>2</sup>) from baseline to month 12. The secondary efficacy outcome was the mean change in best-corrected visual acuity (BCVA) from baseline to month 12. Safety outcome measures included the number of subjects with serious adverse events (SAEs) and macular neovascularization (MNV).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Ten randomized controlled trials including 4,405 participants and five complement inhibitors were identified. Comparison with sham and SUCRA analysis showed that avacincaptad pegol 2&#xa0;mg (MD: -0.58, 95% CrI: -0.97 to -0.18, SUCRA: 93.55), pegcetacoplan monthly (MD: -0.38, 95% CrI: -0.57 to -0.20, SUCRA: 81.37), and pegcetacoplan every other month (MD: -0.30, 95% CrI: -0.49 to -0.11, SUCRA: 70.16) have significant changes in GA lesion reduction. No treatments showed significant changes in BCVA and SAE compared with sham. Pegcetacoplan monthly (OR: 4.30, 95% CrI: 1.48-16.72) increased the risk of MNV. Avacincaptad pegol 2&#xa0;mg demonstrated favorable outcomes in terms of SAE and MNV.</AbstractText><AbstractText Label="CONCLUSION AND RELEVANCE" NlmCategory="UNASSIGNED">Avacincaptad pegol 2&#xa0;mg is the most effective complement inhibitor with better safety for the treatment of GA secondary to AMD.</AbstractText><AbstractText Label="SYSTEMATIC REVIEW REGISTRATION" NlmCategory="UNASSIGNED">https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022351515, Identifier PROSPERO CRD42022351515.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Wang, Zheng, Zhang, Tian, Sun, Zhu, Bi and Zhang.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Huan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Clinical Research Center, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Jiaqi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Research Unit of Molecular Epidemiology, Helmholtz Zentrum M&#xfc;nchen, Neuherberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Clinical Research Center, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Zhongping</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yuhang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Tianyi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Clinical Research Center, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bi</LastName><ForeName>Yanlong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tongji Eye Institute, Tongji University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinical Research Center, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">age-related macular degeneration</Keyword><Keyword MajorTopicYN="N">complement inhibitors</Keyword><Keyword MajorTopicYN="N">geographic atrophy</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">network meta-analysis</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>4</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39600369</ArticleId><ArticleId IdType="pmc">PMC11589381</ArticleId><ArticleId IdType="doi">10.3389/fphar.2024.1410172</ArticleId><ArticleId IdType="pii">1410172</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anderson D. H., Radeke M. J., Gallo N. B., Chapin E. A., Johnson P. T., Curletti C. R., et al. (2010). The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog. Retin Eye Res. 29 (2), 95&#x2013;112. 10.1016/j.preteyeres.2009.11.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2009.11.003</ArticleId><ArticleId IdType="pmc">PMC3641842</ArticleId><ArticleId IdType="pubmed">19961953</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey I. L., Lovie-Kitchin J. E. (2013). Visual acuity testing. From the laboratory to the clinic. Vis. Res. 90, 2&#x2013;9. 10.1016/j.visres.2013.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.visres.2013.05.004</ArticleId><ArticleId IdType="pubmed">23685164</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe9;liveau A., Boyne D. J., Slater J., Brenner D., Arora P. (2019). BUGSnet: an R package to facilitate the conduct and reporting of Bayesian network meta-analyses. BMC Med. Res. Methodol. 19 (1), 196. 10.1186/s12874-019-0829-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-019-0829-2</ArticleId><ArticleId IdType="pmc">PMC6805536</ArticleId><ArticleId IdType="pubmed">31640567</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett C. R., Bex P. J., Bauer C. M., Merabet L. B. (2019). The assessment of visual function and functional vision. Semin. Pediatr. Neurol. 31, 30&#x2013;40. 10.1016/j.spen.2019.05.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.spen.2019.05.006</ArticleId><ArticleId IdType="pmc">PMC6761988</ArticleId><ArticleId IdType="pubmed">31548022</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyer D. S., Schmidt-Erfurth U., van Lookeren Campagne M., Henry E. C., Brittain C. (2017). The pathophysiology of geographic atrophy secondary to age-related macular degeneration and the complement pathway as a therapeutic target. Retina 37 (5), 819&#x2013;835. 10.1097/iae.0000000000001392</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/iae.0000000000001392</ArticleId><ArticleId IdType="pmc">PMC5424580</ArticleId><ArticleId IdType="pubmed">27902638</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang D. S., Callaway N. F., Steffen V., Csaky K., Guymer R. H., Birch D. G., et al. (2024). Macular sensitivity endpoints in geographic atrophy: exploratory analysis of chroma and spectri clinical trials. Ophthalmol. Sci. 4 (1), 100351. 10.1016/j.xops.2023.100351</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xops.2023.100351</ArticleId><ArticleId IdType="pmc">PMC10587617</ArticleId><ArticleId IdType="pubmed">37869030</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung D. C., McCague S., Yu Z. F., Thill S., DiStefano-Pappas J., Bennett J., et al. (2018). Novel mobility test to assess functional vision in patients with inherited retinal dystrophies. Clin. Exp. Ophthalmol. 46 (3), 247&#x2013;259. 10.1111/ceo.13022</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ceo.13022</ArticleId><ArticleId IdType="pmc">PMC5764825</ArticleId><ArticleId IdType="pubmed">28697537</ArticleId></ArticleIdList></Reference><Reference><Citation>Colijn J. M., Liefers B., Joachim N., Verzijden T., Meester-Smoor M. A., Biarn&#xe9;s M., et al. (2021). Enlargement of geographic atrophy from first diagnosis to end of life. JAMA Ophthalmol. 139 (7), 743&#x2013;750. 10.1001/jamaophthalmol.2021.1407</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2021.1407</ArticleId><ArticleId IdType="pmc">PMC8138753</ArticleId><ArticleId IdType="pubmed">34014262</ArticleId></ArticleIdList></Reference><Reference><Citation>Csaky K. G., Miller J. M. L., Martin D. F., Johnson M. W. (2024). Drug approval for the treatment of geographic atrophy: how we got here and where we need to go. Am. J. Ophthalmol. 263, 231&#x2013;239. 10.1016/j.ajo.2024.02.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2024.02.021</ArticleId><ArticleId IdType="pmc">PMC11162935</ArticleId><ArticleId IdType="pubmed">38387826</ArticleId></ArticleIdList></Reference><Reference><Citation>El Chehab H., Agard E., Russo A., Boujnah Y., Dot C. (2016). Intraocular pressure spikes after aflibercept intravitreal injections. Ophthalmologica 236 (1), 43&#x2013;47. 10.1159/000446878</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000446878</ArticleId><ArticleId IdType="pubmed">27409826</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaxel C. J., Adelman R. A., Bailey S. T., Fawzi A., Lim J. I., Vemulakonda G. A., et al. Age-related macular degeneration preferred practice pattern&#xae;. Ophthalmology (2020) 127(1):P1-p65. 10.1016/j.ophtha.2019.09.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2019.09.024</ArticleId><ArticleId IdType="pubmed">31757502</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg A., Nanji K., Tai F., Phillips M., Zeraatkar D., Garg S. J., et al. (2023). The effect of complement C3 or C5 inhibition on geographic atrophy secondary to age-related macular degeneration: a living systematic review and meta-analysis. Surv. Ophthalmol. 69, 349&#x2013;361. 10.1016/j.survophthal.2023.11.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.survophthal.2023.11.008</ArticleId><ArticleId IdType="pubmed">38008405</ArticleId></ArticleIdList></Reference><Reference><Citation>Girgis S., Lee L. R. (2023). Treatment of dry age-related macular degeneration: a review. Clin. Exp. Ophthalmol. 51 (8), 835&#x2013;852. 10.1111/ceo.14294</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ceo.14294</ArticleId><ArticleId IdType="pubmed">37737509</ArticleId></ArticleIdList></Reference><Reference><Citation>Heier J. S., Lad E. M., Holz F. G., Rosenfeld P. J., Guymer R. H., Boyer D., et al. (2023). Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet 402 (10411), 1434&#x2013;1448. 10.1016/s0140-6736(23)01520-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(23)01520-9</ArticleId><ArticleId IdType="pubmed">37865470</ArticleId></ArticleIdList></Reference><Reference><Citation>
Higgins J. P. T. G. S. (2011). Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration. Available at: www.handbook.cochrane.org.
</Citation></Reference><Reference><Citation>Holz F. G., Sadda S. R., Busbee B., Chew E. Y., Mitchell P., Tufail A., et al. (2018). Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: chroma and spectri phase 3 randomized clinical trials. JAMA Ophthalmol. 136 (6), 666&#x2013;677. 10.1001/jamaophthalmol.2018.1544</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2018.1544</ArticleId><ArticleId IdType="pmc">PMC6145777</ArticleId><ArticleId IdType="pubmed">29801123</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton B., Salanti G., Caldwell D. M., Chaimani A., Schmid C. H., Cameron C., et al. (2015). The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann. Intern Med. 162 (11), 777&#x2013;784. 10.7326/m14-2385</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/m14-2385</ArticleId><ArticleId IdType="pubmed">26030634</ArticleId></ArticleIdList></Reference><Reference><Citation>Holz F. G., Sadda S. R., Busbee B, Chew E. Y., Mitchell P., Tufail A., et al. (2018). Efficacy and safety of lampalizumab for geographic atrophy due to a ge-related macular degeneration: chroma and spectri phase 3 randomized clinical trials. JAMA Ophthalmol. 136 (6), 666&#x2013;677. 10.1001/jamaophthalmol.2018.1544</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2018.1544</ArticleId><ArticleId IdType="pmc">PMC6145777</ArticleId><ArticleId IdType="pubmed">29801123</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaffe G. J., Westby K., Csaky K. G., Mon&#xe9;s J., Pearlman J. A., Patel S. S., et al. (2021). C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial. Ophthalmology 128 (4), 576&#x2013;586. 10.1016/j.ophtha.2020.08.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2020.08.027</ArticleId><ArticleId IdType="pubmed">32882310</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonas J. B., Cheung C. M. G., Panda-Jonas S. (2017). Updates on the epidemiology of age-related macular degeneration. Asia Pac J. Ophthalmol. (Phila) 6 (6), 493&#x2013;497. 10.22608/apo.2017251</Citation><ArticleIdList><ArticleId IdType="doi">10.22608/apo.2017251</ArticleId><ArticleId IdType="pubmed">28906084</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang C. (2023). Avacincaptad pegol: first approval. Drugs 83 (15), 1447&#x2013;1453. 10.1007/s40265-023-01948-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-023-01948-8</ArticleId><ArticleId IdType="pubmed">37814173</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanani A. M., Patel S. S., Staurenghi G., Tadayoni R., Danzig C. J., Eichenbaum D. A., et al. (2023). Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet 402 (10411), 1449&#x2013;1458. 10.1016/s0140-6736(23)01583-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(23)01583-0</ArticleId><ArticleId IdType="pubmed">37696275</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim B. J., Liu T., Mastellos D. C., Lambris J. D. (2022). Emerging opportunities for C3 inhibition in the eye. Semin. Immunol. 59, 101633. 10.1016/j.smim.2022.101633</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2022.101633</ArticleId><ArticleId IdType="pubmed">35787973</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim B. J., Mastellos D. C., Li Y., Dunaief J. L., Lambris J. D. (2021). Targeting complement components C3 and C5 for the retina: key concepts and lingering questions. Prog. Retin Eye Res. 83, 100936. 10.1016/j.preteyeres.2020.100936</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2020.100936</ArticleId><ArticleId IdType="pmc">PMC8197769</ArticleId><ArticleId IdType="pubmed">33321207</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambris J. D., Lao Z., Oglesby T. J., Atkinson J. P., Hack C. E., Becherer J. D. (1996). Dissection of CR1, factor H, membrane cofactor protein, and factor B binding and functional sites in the third complement component. J. Immunol. 156 (12), 4821&#x2013;4832. 10.4049/jimmunol.156.12.4821</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.156.12.4821</ArticleId><ArticleId IdType="pubmed">8648130</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao D. S., Grossi F. V., El Mehdi D., Gerber M. R., Brown D. M., Heier J. S., et al. (2020). Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial. Ophthalmology 127 (2), 186&#x2013;195. 10.1016/j.ophtha.2019.07.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2019.07.011</ArticleId><ArticleId IdType="pubmed">31474439</ArticleId></ArticleIdList></Reference><Reference><Citation>Maguire A. M., Russell S., Wellman J. A., Chung D. C., Yu Z. F., Tillman A., et al. (2019). Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials. Ophthalmology 126 (9), 1273&#x2013;1285. 10.1016/j.ophtha.2019.06.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2019.06.017</ArticleId><ArticleId IdType="pubmed">31443789</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannes M., Dopler A., Huber-Lang M., Schmidt C. Q. (2020). Tuning the functionality by splicing: factor H and its alternative splice variant FHL-1 share a gene but not all functions. Front. Immunol. 11, 596415. 10.3389/fimmu.2020.596415</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.596415</ArticleId><ArticleId IdType="pmc">PMC7593401</ArticleId><ArticleId IdType="pubmed">33178228</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastellos D. C., Hajishengallis G., Lambris J. D. (2023). A guide to complement biology, pathology and therapeutic opportunity. Nat. Rev. Immunol. 24, 118&#x2013;141. 10.1038/s41577-023-00926-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-023-00926-1</ArticleId><ArticleId IdType="pubmed">37670180</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer C. H., Melo G. B., Khanani A. M. (2023). Can intravitreal injections with higher volume cause higher intraocular eye pressure? Considerations for anti-complement injections in normal and glaucomatous eyes. Int. J. Retina Vitr. 9 (1), 80. 10.1186/s40942-023-00517-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40942-023-00517-1</ArticleId><ArticleId IdType="pmc">PMC10722703</ArticleId><ArticleId IdType="pubmed">38098108</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullins R. F., Russell S. R., Anderson D. H., Hageman G. S. (2000). Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. Faseb J. 14 (7), 835&#x2013;846. 10.1096/fasebj.14.7.835</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fasebj.14.7.835</ArticleId><ArticleId IdType="pubmed">10783137</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadeem A., Malik I. A., Shariq F., Afridi E. K., Taha M., Raufi N., et al. (2023). Advancements in the treatment of geographic atrophy: focus on pegcetacoplan in age-related macular degeneration. Ann. Med. Surg. (Lond) 85 (12), 6067&#x2013;6077. 10.1097/ms9.0000000000001466</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ms9.0000000000001466</ArticleId><ArticleId IdType="pmc">PMC10718344</ArticleId><ArticleId IdType="pubmed">38098608</ArticleId></ArticleIdList></Reference><Reference><Citation>Nittala M. G., Metlapally R., Ip M., Chakravarthy U., Holz F. G., Staurenghi G., et al. (2022). Association of pegcetacoplan with progression of incomplete retinal pigment epithelium and outer retinal atrophy in age-related macular degeneration: a post hoc analysis of the filly randomized clinical trial. JAMA Ophthalmol. 140 (3), 243&#x2013;249. 10.1001/jamaophthalmol.2021.6067</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2021.6067</ArticleId><ArticleId IdType="pmc">PMC8814977</ArticleId><ArticleId IdType="pubmed">35113137</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel P. N., Patel P. A., Land M. R., Bakerkhatib-Taha I., Ahmed H., Sheth V. (2022). Targeting the complement cascade for treatment of dry age-related macular degeneration. Biomedicines 10, 1884. 10.3390/biomedicines10081884</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10081884</ArticleId><ArticleId IdType="pmc">PMC9405256</ArticleId><ArticleId IdType="pubmed">36009430</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfau M., von der Emde L., de Sisternes L., Hallak J. A., Leng T., Schmitz-Valckenberg S., et al. (2020). Progression of photoreceptor degeneration in geographic atrophy secondary to age-related macular degeneration. JAMA Ophthalmol. 138 (10), 1026&#x2013;1034. 10.1001/jamaophthalmol.2020.2914</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2020.2914</ArticleId><ArticleId IdType="pmc">PMC7426886</ArticleId><ArticleId IdType="pubmed">32789526</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin S., Dong N., Yang M., Wang J., Feng X., Wang Y. (2021). Complement inhibitors in age-related macular degeneration: a potential therapeutic option. J. Immunol. Res. 2021, 9945725. 10.1155/2021/9945725</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/9945725</ArticleId><ArticleId IdType="pmc">PMC8346298</ArticleId><ArticleId IdType="pubmed">34368372</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathi S., Hasan R., Ueffing M., Clark S. J. (2023). Therapeutic targeting of the complement system in ocular disease. Drug Discov. Today 28 (11), 103757. 10.1016/j.drudis.2023.103757</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2023.103757</ArticleId><ArticleId IdType="pubmed">37657753</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis E. S., Mastellos D. C., Hajishengallis G., Lambris J. D. (2019). New insights into the immune functions of complement. Nat. Rev. Immunol. 19 (8), 503&#x2013;516. 10.1038/s41577-019-0168-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-019-0168-x</ArticleId><ArticleId IdType="pmc">PMC6667284</ArticleId><ArticleId IdType="pubmed">31048789</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley-Gillis B., Huh H., Shen J., den Hollander A. I. (2023). Genetic and molecular biomarkers for geographic atrophy. Acta Ophthalmol. 101(8):869&#x2013;880. 10.1111/aos.15803</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aos.15803</ArticleId><ArticleId IdType="pubmed">37933607</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadda S. R., Chakravarthy U., Birch D. G., Staurenghi G., Henry E. C., Brittain C. (2016). Clinical endpoints for the study of geographic atrophy secondary to age-related macular degeneration. Retina 36 (10), 1806&#x2013;1822. 10.1097/iae.0000000000001283</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/iae.0000000000001283</ArticleId><ArticleId IdType="pmc">PMC5384792</ArticleId><ArticleId IdType="pubmed">27652913</ArticleId></ArticleIdList></Reference><Reference><Citation>Schachar I. H. (2023). Concerning syfovre approval for geographic atrophy. JAMA Ophthalmol. 142, 85&#x2013;86. 10.1001/jamaophthalmol.2023.5584</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2023.5584</ArticleId><ArticleId IdType="pubmed">38060249</ArticleId></ArticleIdList></Reference><Reference><Citation>Schramm E. C., Clark S. J., Triebwasser M. P., Raychaudhuri S., Seddon J., Atkinson J. P. (2014). Genetic variants in the complement system predisposing to age-related macular degeneration: a review. Mol. Immunol. 61 (2), 118&#x2013;125. 10.1016/j.molimm.2014.06.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2014.06.032</ArticleId><ArticleId IdType="pmc">PMC4149817</ArticleId><ArticleId IdType="pubmed">25034031</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweighoffer R., Schumacher A. M., Blaese R., Walter S., Eckstein S. (2022). A systematic review and bayesian network meta-analysis investigating the effectiveness of psychological short-term interventions in inpatient palliative care settings. Int. J. Environ. Res. Public Health 19 (13), 7711. 10.3390/ijerph19137711</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19137711</ArticleId><ArticleId IdType="pmc">PMC9265936</ArticleId><ArticleId IdType="pubmed">35805365</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzoumas N., Riding G., Williams M. A., Steel D. H. (2023). Complement inhibitors for age-related macular degeneration. Cochrane Database Syst. Rev. 6 (6), Cd009300. 10.1002/14651858.CD009300.pub3</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD009300.pub3</ArticleId><ArticleId IdType="pmc">PMC10266126</ArticleId><ArticleId IdType="pubmed">37314061</ArticleId></ArticleIdList></Reference><Reference><Citation>US Department of Health and Human Services FaDA. Gene therapy for retinal disorders: guidance for industry. (2020).</Citation></Reference><Reference><Citation>Vangsted A., Thinggaard B. S., Nissen A. H. K., Hajari J. N., Klefter O. N., Krogh N. M., et al. (2023). Prevalence of geographic atrophy in Nordic countries and number of patients potentially eligible for intravitreal complement inhibitor treatment: a systematic review with meta-analyses and forecasting study. Acta Ophthalmol. 101 (8), 857&#x2013;868. 10.1111/aos.15768</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aos.15768</ArticleId><ArticleId IdType="pubmed">37680141</ArticleId></ArticleIdList></Reference><Reference><Citation>Vujosevic S., Alovisi C., Chakravarthy U. (2023). Epidemiology of geographic atrophy and its precursor features of intermediate age-related macular degeneration. Acta Ophthalmol. 101 (8), 839&#x2013;856. 10.1111/aos.15767</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aos.15767</ArticleId><ArticleId IdType="pubmed">37933608</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Zhong Y., Zhang L., Wu Q., Tham Y., Rim T. H., et al. (2022). Global incidence, progression, and risk factors of age-related macular degeneration and projection of disease statistics in 30 Years: a modeling study. Gerontology 68 (7), 721&#x2013;735. 10.1159/000518822</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000518822</ArticleId><ArticleId IdType="pubmed">34569526</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitmore S. S., Sohn E. H., Chirco K. R., Drack A. V., Stone E. M., Tucker B. A., et al. (2015). Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy. Prog. Retin Eye Res. 45, 1&#x2013;29. 10.1016/j.preteyeres.2014.11.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2014.11.005</ArticleId><ArticleId IdType="pmc">PMC4339497</ArticleId><ArticleId IdType="pubmed">25486088</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong W. L., Su X., Li X., Cheung C. M., Klein R., Cheng C. Y., et al. (2014). Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob. Health 2 (2), e106&#x2013;e116. 10.1016/s2214-109x(13)70145-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2214-109x(13)70145-1</ArticleId><ArticleId IdType="pubmed">25104651</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaspan B. L., Williams D. F., Holz F. G., Regillo C. D., Li Z., Dressen A., et al. (2017). Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration. Sci. Transl. Med. 9 (395), eaaf1443. 10.1126/scitranslmed.aaf1443</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf1443</ArticleId><ArticleId IdType="pubmed">28637922</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng R., Zhang Y., Zhang K., Yuan Y., Jia S., Liu J. (2022). The complement system, aging, and aging-related diseases. Int. J. Mol. Sci. 23 (15), 8689. 10.3390/ijms23158689</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23158689</ArticleId><ArticleId IdType="pmc">PMC9369321</ArticleId><ArticleId IdType="pubmed">35955822</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39599758</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2072-6643</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>22</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>20</Day></PubDate></JournalIssue><Title>Nutrients</Title><ISOAbbreviation>Nutrients</ISOAbbreviation></Journal><ArticleTitle>Beneficial Effects of Micronutrient Supplementation in Restoring the Altered Microbiota and Gut-Retina Axis in Patients with Neovascular Age-Related Macular Degeneration-A Randomized Clinical Trial.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">3971</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nu16223971</ELocationID><Abstract><AbstractText><b>Background/Objectives:</b> Age-related macular degeneration (AMD) is a leading cause of visual impairment in the elderly and is characterized by a multifactorial etiology. Emerging evidence points to the potential involvement of the gut-retina axis in AMD pathogenesis, prompting exploration into novel therapeutic strategies. This study aims to investigate the effects of some micronutrients (such as lutein and zeaxanthin) and saffron (as a supplement)-known for their anti-inflammatory properties-on ophthalmological and microbial parameters in neovascular AMD (nAMD) patients. <b>Methods:</b> Thirty naive nAMD patients were randomized to receive daily micronutrient supplementation alongside anti-VEGF (vascular endothelial growth factor) therapy, or anti-VEGF treatment alone, over a 6-month period, with comparisons made to a healthy control (HC) group (N = 15). Ophthalmological assessments, biochemical measurements, and stool samples were obtained before and after treatment. Gut microbiota (GM) characterization was performed using 16S rRNA sequencing, while short-chain fatty acids (SCFAs), medium-chain fatty acids (MCFAs), and long-chain fatty acids (LCFAs) were analyzed with a gas chromatography-mass spectrometry protocol. <b>Results:</b> Compared to HC, nAMD patients exhibited reduced GM alpha diversity, altered taxonomic composition, and decreased total SCFA levels, in addition to elevated levels of proinflammatory octanoic and nonanoic acids. Micronutrient supplementation was associated with improved visual acuity relative to the group treated with anti-VEGF alone, along with a decrease in the total amount of MCFAs, which are metabolites known to have adverse ocular effects. <b>Conclusions:</b> In conclusion, despite certain limitations-such as the limited sample size and the low taxonomic resolution of 16S rRNA sequencing-this study highlights compositional and functional imbalances in the GM of nAMD patients and demonstrates that micronutrient supplementation may help restore the gut-retina axis. These findings suggest the therapeutic potential of micronutrients in enhancing ocular outcomes for nAMD patients, underscoring the complex interaction between GM and ocular health.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baldi</LastName><ForeName>Simone</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5151-2618</Identifier><AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pagliai</LastName><ForeName>Giuditta</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-2177-2857</Identifier><AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Gloria</LastName><ForeName>Leandro</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-8630-8166</Identifier><AffiliationInfo><Affiliation>Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, 50134 Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pallecchi</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0057-6531</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Psychology, Drug Research and Child Health NEUROFARBA, University of Florence, 50139 Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barca</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-8835-9381</Identifier><AffiliationInfo><Affiliation>Complex Operative Unit of Ophthalmology, Palagi Hospital, USL Toscana Centro, 50122 Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pieri</LastName><ForeName>Benedetta</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Complex Operative Unit of Ophthalmology, Palagi Hospital, USL Toscana Centro, 50122 Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartolucci</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-5631-8769</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Psychology, Drug Research and Child Health NEUROFARBA, University of Florence, 50139 Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramazzotti</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6862-9409</Identifier><AffiliationInfo><Affiliation>Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, 50134 Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amedei</LastName><ForeName>Amedeo</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6797-9343</Identifier><AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palendri</LastName><ForeName>Gianna</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Complex Operative Unit of Ophthalmology, Palagi Hospital, USL Toscana Centro, 50122 Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sofi</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-7113-7424</Identifier><AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit of Clinical Nutrition, Careggi University Hospital, 50134 Florence, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nutrients</MedlineTA><NlmUniqueID>101521595</NlmUniqueID><ISSNLinking>2072-6643</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018977">Micronutrients</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance></Chemical><Chemical><RegistryNumber>X72A60C9MT</RegistryNumber><NameOfSubstance UI="D014975">Lutein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065146">Zeaxanthins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019587" MajorTopicYN="Y">Dietary Supplements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018977" MajorTopicYN="Y">Micronutrients</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008268" MajorTopicYN="Y">Macular Degeneration</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012160" MajorTopicYN="N">Retina</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014975" MajorTopicYN="N">Lutein</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014792" MajorTopicYN="N">Visual Acuity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D027622" MajorTopicYN="N">Crocus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065146" MajorTopicYN="N">Zeaxanthins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">gut microbiota</Keyword><Keyword MajorTopicYN="N">gut&#x2013;retina axis</Keyword><Keyword MajorTopicYN="N">lutein</Keyword><Keyword MajorTopicYN="N">nAMD</Keyword><Keyword MajorTopicYN="N">saffron</Keyword><Keyword MajorTopicYN="N">short-chain fatty acids</Keyword><Keyword MajorTopicYN="N">zeaxanthin</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>12</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>1</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39599758</ArticleId><ArticleId IdType="pmc">PMC11597754</ArticleId><ArticleId IdType="doi">10.3390/nu16223971</ArticleId><ArticleId IdType="pii">nu16223971</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pennington K.L., DeAngelis M.M. Epidemiology of age-related macular degeneration (AMD): Associations with cardiovascular disease phenotypes and lipid factors. Eye Vis. 2016;3:34. doi: 10.1186/s40662-016-0063-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40662-016-0063-5</ArticleId><ArticleId IdType="pmc">PMC5178091</ArticleId><ArticleId IdType="pubmed">28032115</ArticleId></ArticleIdList></Reference><Reference><Citation>Rein D.B., Wittenborn J.S., Zhang X., Honeycutt A.A., Lesesne S.B., Saaddine J., Vision Health Cost-Effectiveness Study Group Forecasting age-related macular degeneration through the year 2050: The potential impact of new treatments. Arch. Ophthalmol. 2009;127:533&#x2013;540. doi: 10.1001/archophthalmol.2009.58.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archophthalmol.2009.58</ArticleId><ArticleId IdType="pubmed">19365036</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman D.S., O&#x2019;Colmain B.J., Mu&#xf1;oz B., Tomany S.C., McCarty C., de Jong P.T., Nemesure B., Mitchell P., Kempen J. Eye Diseases Prevalence Research Group.Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 2004;122:564&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">15078675</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman N.A., Jacobs R.J., Braakhuis A.J. Role of diet and food intake in age-related macular degeneration: A systematic review. Clin. Exp. Ophthalmol. 2019;47:106&#x2013;127. doi: 10.1111/ceo.13343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ceo.13343</ArticleId><ArticleId IdType="pubmed">29927057</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinninella E., Mele M.C., Merendino N., Cintoni M., Anselmi G., Caporossi A., Gasbarrini A., Minnella A.M. The Role of Diet, Micronutrients and the Gut Microbiota in Age-Related Macular Degeneration: New Perspectives from the Gut&#x207b;Retina Axis. Nutrients. 2018;10:1677. doi: 10.3390/nu10111677.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu10111677</ArticleId><ArticleId IdType="pmc">PMC6267253</ArticleId><ArticleId IdType="pubmed">30400586</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Zamil W.M., Yassin S.A. Recent developments in age-related macular degeneration: A review. Clin. Interv. Aging. 2017;12:1313&#x2013;1330. doi: 10.2147/CIA.S143508.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CIA.S143508</ArticleId><ArticleId IdType="pmc">PMC5573066</ArticleId><ArticleId IdType="pubmed">28860733</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell P., Liew G., Gopinath B., Wong T.Y. Age-related macular degeneration. Lancet. 2018;392:1147&#x2013;1159. doi: 10.1016/S0140-6736(18)31550-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)31550-2</ArticleId><ArticleId IdType="pubmed">30303083</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin A.J., Scholl S., Kirchhof J. Treatment of neovascular age-related macular degeneration: Current therapies. Clin. Ophthalmol. 2009;3:175&#x2013;182. doi: 10.2147/OPTH.S3926.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OPTH.S3926</ArticleId><ArticleId IdType="pmc">PMC2708986</ArticleId><ArticleId IdType="pubmed">19668562</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q.Y., Tie L.J., Wu S.S., Lv P.L., Huang H.W., Wang W.Q., Wang H., Ma L. Overweight, Obesity, and Risk of Age-Related Macular Degeneration. Investig. Ophthalmol. Vis. Sci. 2016;57:1276&#x2013;1283. doi: 10.1167/iovs.15-18637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.15-18637</ArticleId><ArticleId IdType="pubmed">26990164</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan Y., Jiang S., Gericke A. Age-Related Macular Degeneration: Role of Oxidative Stress and Blood Vessels. Int. J. Mol. Sci. 2021;22:1296. doi: 10.3390/ijms22031296.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22031296</ArticleId><ArticleId IdType="pmc">PMC7866075</ArticleId><ArticleId IdType="pubmed">33525498</ArticleId></ArticleIdList></Reference><Reference><Citation>Age-Related Eye Disease Study Research Group A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch. Ophthalmol. 2001;119:1417&#x2013;1436. doi: 10.1001/archopht.119.10.1417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archopht.119.10.1417</ArticleId><ArticleId IdType="pmc">PMC1462955</ArticleId><ArticleId IdType="pubmed">11594942</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew E.Y., Clemons T.E., SanGiovanni J.P., Danis R.P., Ferris F.L., Elman M.J., Antoszyk A.N., Ruby A.J., Orth D., Bressler S.B., et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmol. 2014;132:142&#x2013;149. doi: 10.1001/jamaophthalmol.2013.7376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2013.7376</ArticleId><ArticleId IdType="pmc">PMC4636082</ArticleId><ArticleId IdType="pubmed">24310343</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L., Dou H.L., Wu Y.Q., Huang Y.M., Huang Y.B., Xu X.R., Zou Z.Y., Lin X.M. Lutein and zeaxanthin intake and the risk of age-related macular degeneration: A systematic review and meta-analysis. Br. J. Nutr. 2012;107:350&#x2013;359. doi: 10.1017/S0007114511004260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0007114511004260</ArticleId><ArticleId IdType="pubmed">21899805</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew E.Y., Clemons T.E., Agr&#xf3;n E., Domalpally A., Keenan T.D.L., Vitale S., Weber C., Smith D.C., Christen W., AREDS2 Research Group Long-term Outcomes of Adding Lutein/Zeaxanthin and &#x3c9;-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28. JAMA Ophthalmol. 2022;140:692&#x2013;698. doi: 10.1001/jamaophthalmol.2022.1640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2022.1640</ArticleId><ArticleId IdType="pmc">PMC9164119</ArticleId><ArticleId IdType="pubmed">35653117</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L., Liu R., Du J.H., Liu T., Wu S.S., Liu X.H. Lutein, Zeaxanthin and Meso-zeaxanthin Supplementation Associated with Macular Pigment Optical Density. Nutrients. 2016;8:426. doi: 10.3390/nu8070426.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu8070426</ArticleId><ArticleId IdType="pmc">PMC4963902</ArticleId><ArticleId IdType="pubmed">27420092</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki A., Inoue M., Nguyen E., Obata R., Kadonosono K., Shinkai S., Hashimoto H., Sasaki S., Yanagi Y. Dietary n-3 Fatty Acid, &#x3b1;-Tocopherol, Zinc, vitamin D, vitamin C, and &#x3b2;-carotene are Associated with Age-Related Macular Degeneration in Japan. Sci. Rep. 2016;6:20723. doi: 10.1038/srep20723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep20723</ArticleId><ArticleId IdType="pmc">PMC4742947</ArticleId><ArticleId IdType="pubmed">26846575</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X.Y., Meng L., Shen L., Ji H.F. Regulation of gut microbiota by vitamin C, vitamin E and &#x3b2;-carotene. Food Res. Int. 2023;169:112749. doi: 10.1016/j.foodres.2023.112749.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.foodres.2023.112749</ArticleId><ArticleId IdType="pubmed">37254375</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng S., Hern&#xe1;ndez J., Mullins R.F. Effects of antioxidant components of AREDS vitamins and zinc ions on endothelial cell activation: Implications for macular degeneration. Investig. Ophthalmol. Vis. Sci. 2012;53:1041&#x2013;1047. doi: 10.1167/iovs.11-8531.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.11-8531</ArticleId><ArticleId IdType="pmc">PMC3317404</ArticleId><ArticleId IdType="pubmed">22247465</ArticleId></ArticleIdList></Reference><Reference><Citation>Broadhead G.K., Grigg J.R., McCluskey P., Hong T., Schlub T.E., Chang A.A. Saffron therapy for the treatment of mild/moderate age-related macular degeneration: A randomised clinical trial. Graefes Arch. Clin. Exp. Ophthalmol. 2019;257:31&#x2013;40. doi: 10.1007/s00417-018-4163-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00417-018-4163-x</ArticleId><ArticleId IdType="pubmed">30343354</ArticleId></ArticleIdList></Reference><Reference><Citation>Abedi A., Ghobadi H., Sharghi A., Iranpour S., Fazlzadeh M., Aslani M.R. Effect of saffron supplementation on oxidative stress markers (MDA, TAC, TOS, GPx, SOD, and pro-oxidant/antioxidant balance): An updated systematic review and meta-analysis of randomized placebo-controlled trials. Front. Med. 2023;10:1071514. doi: 10.3389/fmed.2023.1071514.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1071514</ArticleId><ArticleId IdType="pmc">PMC9928952</ArticleId><ArticleId IdType="pubmed">36817799</ArticleId></ArticleIdList></Reference><Reference><Citation>Lashay A., Sadough G., Ashrafi E., Lashay M., Movassat M., Akhondzadeh S. Short-term Outcomes of Saffron Supplementation in Patients with Age-related Macular Degeneration: A Double-blind, Placebo-controlled, Randomized Trial. Med. Hypothesis Discov. Innov. Ophthalmol. 2016;5:32&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5342880</ArticleId><ArticleId IdType="pubmed">28289690</ArticleId></ArticleIdList></Reference><Reference><Citation>Scuderi G., Troiani E., Minnella A.M. Gut Microbiome in Retina Health: The Crucial Role of the Gut-Retina Axis. Front. Microbiol. 2021;12:726792. doi: 10.3389/fmicb.2021.726792.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.726792</ArticleId><ArticleId IdType="pmc">PMC8795667</ArticleId><ArticleId IdType="pubmed">35095780</ArticleId></ArticleIdList></Reference><Reference><Citation>Boem F., Amedei A. Healthy axis: Towards an integrated view of the gut-brain health. World J. Gastroenterol. 2019;25:3838&#x2013;3841. doi: 10.3748/wjg.v25.i29.3838.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v25.i29.3838</ArticleId><ArticleId IdType="pmc">PMC6689813</ArticleId><ArticleId IdType="pubmed">31413521</ArticleId></ArticleIdList></Reference><Reference><Citation>Andriessen E.M., Wilson A.M., Mawambo G., Dejda A., Miloudi K., Sennlaub F., Sapieha P. Gut microbiota influences pathological angiogenesis in obesity-driven choroidal neovascularization. EMBO Mol. Med. 2016;8:1366&#x2013;1379. doi: 10.15252/emmm.201606531.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201606531</ArticleId><ArticleId IdType="pmc">PMC5167134</ArticleId><ArticleId IdType="pubmed">27861126</ArticleId></ArticleIdList></Reference><Reference><Citation>Noailles A., Maneu V., Campello L., Lax P., Cuenca N. Systemic inflammation induced by lipopolysaccharide aggravates inherited retinal dystrophy. Cell Death Dis. 2018;9:350. doi: 10.1038/s41419-018-0355-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-018-0355-x</ArticleId><ArticleId IdType="pmc">PMC5834451</ArticleId><ArticleId IdType="pubmed">29500424</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinkernagel M.S., Zysset-Burri D.C., Keller I., Berger L.E., Leichtle A.B., Largiad&#xe8;r C.R., Fiedler G.M., Wolf S. Association of the intestinal microbiome with the development of neovascular age-related macular degeneration. Sci. Rep. 2017;17:40826. doi: 10.1038/srep40826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep40826</ArticleId><ArticleId IdType="pmc">PMC5240106</ArticleId><ArticleId IdType="pubmed">28094305</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolyen E., Rideout J.R., Dillon M.R., Bokulich N.A., Abnet C.C., Al-Ghalith G.A., Alexander H., Alm E.J., Arumugam M., Asnicar F. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat. Biotechnol. 2019;37:852&#x2013;857. doi: 10.1038/s41587-019-0209-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-019-0209-9</ArticleId><ArticleId IdType="pmc">PMC7015180</ArticleId><ArticleId IdType="pubmed">31341288</ArticleId></ArticleIdList></Reference><Reference><Citation>Callahan B.J., McMurdie P.J., Rosen M.J., Han A.W., Johnson A.J.A., Holmes S.P. DADA2: High-resolution sample inference from Illumina amplicon data. Nat. Methods. 2016;13:581&#x2013;583. doi: 10.1038/nmeth.3869.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.3869</ArticleId><ArticleId IdType="pmc">PMC4927377</ArticleId><ArticleId IdType="pubmed">27214047</ArticleId></ArticleIdList></Reference><Reference><Citation>Bokulich N.A., Subramanian S., Faith J.J., Gevers D., Gordon J.I., Knight R., Mills D.A., Caporaso J.G. Quality-filtering vastly improves diversity estimates from Illumina amplicon sequencing. Nat. Methods. 2013;10:57&#x2013;59. doi: 10.1038/nmeth.2276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2276</ArticleId><ArticleId IdType="pmc">PMC3531572</ArticleId><ArticleId IdType="pubmed">23202435</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Q., Sun X., Rajesh K., Chalasani N., Gelow K., Katz B., Shah V.H., Sanyal A.J., Smirnova E. Effects of Rare Microbiome Taxa Filtering on Statistical Analysis. Front. Microbiol. 2020;11:607325. doi: 10.3389/fmicb.2020.607325.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.607325</ArticleId><ArticleId IdType="pmc">PMC7835481</ArticleId><ArticleId IdType="pubmed">33510727</ArticleId></ArticleIdList></Reference><Reference><Citation>Niccolai E., Baldi S., Ricci F., Russo E., Nannini G., Menicatti M., Poli G., Taddei A., Bartolucci G., Calabr&#xf2; A.S., et al. Evaluation and comparison of short chain fatty acids composition in gut diseases. World J. Gastroenterol. 2019;25:5543&#x2013;5558. doi: 10.3748/wjg.v25.i36.5543.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v25.i36.5543</ArticleId><ArticleId IdType="pmc">PMC6767983</ArticleId><ArticleId IdType="pubmed">31576099</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong W.L., Su X., Li X., Cheung C.M., Klein R., Cheng C.Y., Wong T.Y. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. Lancet Glob. Health. 2014;2:e106&#x2013;e116. doi: 10.1016/S2214-109X(13)70145-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(13)70145-1</ArticleId><ArticleId IdType="pubmed">25104651</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams M.K., Simpson J.A., Aung K.Z., Makeyeva G.A., Giles G.G., English D.R., Hopper J., Guymer R.H., Baird P.N., Robman L.D. Abdominal obesity and age-related macular degeneration. Am. J. Epidemiol. 2011;173:1246&#x2013;1255. doi: 10.1093/aje/kwr005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwr005</ArticleId><ArticleId IdType="pubmed">21422060</ArticleId></ArticleIdList></Reference><Reference><Citation>Brockhaus K., Melkonyan H., Prokosch-Willing V., Liu H., Thanos S. Alterations in Tight- and Adherens-Junction Proteins Related to Glaucoma Mimicked in the Organotypically Cultivated Mouse Retina Under Elevated Pressure. Investig. Ophthalmol. Vis. Sci. 2020;61:46. doi: 10.1167/iovs.61.3.46.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.61.3.46</ArticleId><ArticleId IdType="pmc">PMC7401456</ArticleId><ArticleId IdType="pubmed">32207812</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N., Wu J., Wang J., Piri N., Chen F., Xiao T., Zhao Y., Sun D., Kaplan H.J., Shao H. Short chain fatty acids inhibit endotoxin-induced uveitis and inflammatory responses of retinal astrocytes. Exp. Eye Res. 2021;206:108520. doi: 10.1016/j.exer.2021.108520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exer.2021.108520</ArticleId><ArticleId IdType="pmc">PMC8489808</ArticleId><ArticleId IdType="pubmed">33617852</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Wang T., Wan Z., Bai J., Xue Y., Dai R., Wang M., Peng Q. Alterations of the intestinal microbiota in age-related macular degeneration. Front. Microbiol. 2023;14:1069325. doi: 10.3389/fmicb.2023.1069325.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2023.1069325</ArticleId><ArticleId IdType="pmc">PMC10113553</ArticleId><ArticleId IdType="pubmed">37089564</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue W., Peng P., Wen X., Meng H., Qin Y., Deng T., Guo S., Chen T., Li X., Liang J., et al. Metagenomic Sequencing Analysis Identifies Cross-Cohort Gut Microbial Signatures Associated with Age-Related Macular Degeneration. Invest Ophthalmol. Vis. Sci. 2023;64:11. doi: 10.1167/iovs.64.5.11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.64.5.11</ArticleId><ArticleId IdType="pmc">PMC10202153</ArticleId><ArticleId IdType="pubmed">37195657</ArticleId></ArticleIdList></Reference><Reference><Citation>Juste C., G&#xe9;rard P. Cholesterol-to-Coprostanol Conversion by the Gut Microbiota: What We Know, Suspect, and Ignore. Microorganisms. 2021;9:1881. doi: 10.3390/microorganisms9091881.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms9091881</ArticleId><ArticleId IdType="pmc">PMC8468837</ArticleId><ArticleId IdType="pubmed">34576776</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie X., Chen J., Ma X., Ni Y., Shen Y., Yu H., Panagiotou G., Bao Y. A metagenome-wide association study of gut microbiome and visceral fat accumulation. Comput. Struct. Biotechnol. J. 2020;18:2596&#x2013;2609. doi: 10.1016/j.csbj.2020.09.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2020.09.026</ArticleId><ArticleId IdType="pmc">PMC7528071</ArticleId><ArticleId IdType="pubmed">33033580</ArticleId></ArticleIdList></Reference><Reference><Citation>Yassour M., Lim M.Y., Yun H.S., Tickle T.L., Sung J., Song Y.M., Lee K., Franzosa E.A., Morgan X.C., Gevers D., et al. Sub-clinical detection of gut microbial biomarkers of obesity and type 2 diabetes. Genome Med. 2016;8:17. doi: 10.1186/s13073-016-0271-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13073-016-0271-6</ArticleId><ArticleId IdType="pmc">PMC4756455</ArticleId><ArticleId IdType="pubmed">26884067</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin P. The role of the intestinal microbiome in ocular inflammatory disease. Curr. Opin. Ophthalmol. 2018;29:261&#x2013;266. doi: 10.1097/ICU.0000000000000465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ICU.0000000000000465</ArticleId><ArticleId IdType="pubmed">29538183</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu F., Guo X., Zhang J., Zhang M., Ou Z., Peng Y. Phascolarctobacterium faecium abundant colonization in human gastrointestinal tract. Exp. Ther. Med. 2017;14:3122&#x2013;3126. doi: 10.3892/etm.2017.4878.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2017.4878</ArticleId><ArticleId IdType="pmc">PMC5585883</ArticleId><ArticleId IdType="pubmed">28912861</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui Y., Zhang L., Wang X., Yi Y., Shan Y., Liu B., Zhou Y., L&#xfc; X. Roles of intestinal Parabacteroides in human health and diseases. FEMS Microbiol. Lett. 2022;369:fnac072. doi: 10.1093/femsle/fnac072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/femsle/fnac072</ArticleId><ArticleId IdType="pubmed">35945336</ArticleId></ArticleIdList></Reference><Reference><Citation>Fusco W., Lorenzo M.B., Cintoni M., Porcari S., Rinninella E., Kaitsas F., Lener E., Mele M.C., Gasbarrini A., Collado M.C. Short-Chain Fatty-Acid-Producing Bacteria: Key Components of the Human Gut Microbiota. Nutrients. 2023;15:2211. doi: 10.3390/nu15092211.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu15092211</ArticleId><ArticleId IdType="pmc">PMC10180739</ArticleId><ArticleId IdType="pubmed">37432351</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanayakkara U., Khan M.A., Hargun D.K., Sivagnanam S., Samarawickrama C. Ocular streptococcal infections: A clinical and microbiological review. Surv. Ophthalmol. 2023;68:678&#x2013;696. doi: 10.1016/j.survophthal.2023.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.survophthal.2023.02.001</ArticleId><ArticleId IdType="pubmed">36764397</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan H., Qin Q., Chen J., Yan S., Li T., Gao X., Yang Y., Li A., Ding S. Gut Microbiome Alterations in Patients with Visceral Obesity Based on Quantitative Computed Tomography. Front. Cell Infect. Microbiol. 2021;11:823262. doi: 10.3389/fcimb.2021.823262.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2021.823262</ArticleId><ArticleId IdType="pmc">PMC8811355</ArticleId><ArticleId IdType="pubmed">35127566</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva Y.P., Bernardi A., Frozza R.L. The Role of Short-Chain Fatty Acids from Gut Microbiota in Gut-Brain Communication. Front. Endocrinol. 2020;11:25. doi: 10.3389/fendo.2020.00025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2020.00025</ArticleId><ArticleId IdType="pmc">PMC7005631</ArticleId><ArticleId IdType="pubmed">32082260</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaefer L., Hernandez H., Coats R.A., Yu Z., Pflugfelder S.C., Britton R.A., de Paiva C.S. Gut-derived butyrate suppresses ocular surface inflammation. Sci. Rep. 2022;12:4512. doi: 10.1038/s41598-022-08442-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-08442-3</ArticleId><ArticleId IdType="pmc">PMC8927112</ArticleId><ArticleId IdType="pubmed">35296712</ArticleId></ArticleIdList></Reference><Reference><Citation>Panova I.G., Yakovleva M.A., Tatikolov A.S., Kononikhin A.S., Feldman T.B., Poltavtseva R.A., Nikolaev E.N., Sukhikh G.T., Ostrovsky M.A. Lutein and its oxidized forms in eye structures throughout prenatal human development. Exp. Eye Res. 2017;160:31&#x2013;37. doi: 10.1016/j.exer.2017.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exer.2017.04.008</ArticleId><ArticleId IdType="pubmed">28454979</ArticleId></ArticleIdList></Reference><Reference><Citation>Murillo A.G., Hu S., Fernandez M.L. Zeaxanthin: Metabolism, Properties, and Antioxidant Protection of Eyes, Heart, Liver, and Skin. Antioxidants. 2019;8:390. doi: 10.3390/antiox8090390.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox8090390</ArticleId><ArticleId IdType="pmc">PMC6770730</ArticleId><ArticleId IdType="pubmed">31514298</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrowicka M., Mrowicki J., Kucharska E., Majsterek I. Lutein and Zeaxanthin and Their Roles in Age-Related Macular Degeneration-Neurodegenerative Disease. Nutrients. 2022;14:827. doi: 10.3390/nu14040827.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu14040827</ArticleId><ArticleId IdType="pmc">PMC8874683</ArticleId><ArticleId IdType="pubmed">35215476</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Marco S., Carnicelli V., Franceschini N., Di Paolo M., Piccardi M., Bisti S., Falsini B. Saffron: A Multitask Neuroprotective Agent for Retinal Degenerative Diseases. Antioxidants. 2019;8:224. doi: 10.3390/antiox8070224.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox8070224</ArticleId><ArticleId IdType="pmc">PMC6681062</ArticleId><ArticleId IdType="pubmed">31319529</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y.M., Dou H.L., Huang F.F., Xu X.R., Zou Z.Y., Lin X.M. Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration. Biomed. Res. Int. 2015;2015:564738. doi: 10.1155/2015/564738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/564738</ArticleId><ArticleId IdType="pmc">PMC4359817</ArticleId><ArticleId IdType="pubmed">25815324</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng L., Nie K., Jiang H., Fan W. Effects of lutein supplementation in age-related macular degeneration. PLoS ONE. 2019;14:e0227048. doi: 10.1371/journal.pone.0227048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0227048</ArticleId><ArticleId IdType="pmc">PMC6936877</ArticleId><ArticleId IdType="pubmed">31887124</ArticleId></ArticleIdList></Reference><Reference><Citation>Maqbool Z., Arshad M.S., Ali A., Aziz A., Khalid W., Afzal M.F., Bangar S.P., Addi M., Hano C. Potential Role of Phytochemical Extract from Saffron in Development of Functional Foods and Protection of Brain-Related Disorders. Oxid. Med. Cell Longev. 2022;2022:6480590. doi: 10.1155/2022/6480590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/6480590</ArticleId><ArticleId IdType="pmc">PMC9526642</ArticleId><ArticleId IdType="pubmed">36193081</ArticleId></ArticleIdList></Reference><Reference><Citation>Riazi A., Panahi Y., Alishiri A.A., Hosseini M.A., Karimi Zarchi A.A., Sahebkar A. The impact of saffron (Crocus sativus) supplementation on visual function in patients with dry age-related macular degeneration. Ital. J. Med. 2017;11:196&#x2013;201. doi: 10.4081/itjm.2016.758.</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/itjm.2016.758</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai Z., Li Z., Shi E., Nie M., Feng L., Chen G., Gao R., Zeng X., Li D. Study on the Interaction between Four Typical Carotenoids and Human Gut Microflora Using an in Vitro Fermentation Model. J. Agric. Food Chem. 2022;70:13592&#x2013;13601. doi: 10.1021/acs.jafc.2c03464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jafc.2c03464</ArticleId><ArticleId IdType="pubmed">36214842</ArticleId></ArticleIdList></Reference><Reference><Citation>Beld J., Blatti J.L., Behnke C., Mendez M., Burkart M.D. Evolution of acyl-ACP-thioesterases and &#x3b2;-ketoacyl-ACP-synthases revealed by protein-protein interactions. J. Appl. Phycol. 2014;26:1619&#x2013;1629. doi: 10.1007/s10811-013-0203-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10811-013-0203-4</ArticleId><ArticleId IdType="pmc">PMC4125210</ArticleId><ArticleId IdType="pubmed">25110394</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;nfeld P., Wojtczak L. Short- and medium-chain fatty acids in energy metabolism: The cellular perspective. J. Lipid Res. 2016;57:943&#x2013;954. doi: 10.1194/jlr.R067629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.R067629</ArticleId><ArticleId IdType="pmc">PMC4878196</ArticleId><ArticleId IdType="pubmed">27080715</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki M., Takaishi S., Nagasaki M., Onozawa Y., Iino I., Maeda H., Komai T., Oda T. Medium-chain fatty acid-sensing receptor, GPR84, is a proinflammatory receptor. J. Biol. Chem. 2013;288:10684&#x2013;10691. doi: 10.1074/jbc.M112.420042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.420042</ArticleId><ArticleId IdType="pmc">PMC3624448</ArticleId><ArticleId IdType="pubmed">23449982</ArticleId></ArticleIdList></Reference><Reference><Citation>Heckel E., Cagnone G., Agnihotri T., Cakir B., Das A., Kim J.S., Kim N., Lavoie G., Situ A., Pundir S. Triglyceride-derived fatty acids reduce autophagy in a model of retinal angiomatous proliferation. JCI Insight. 2022;7:e154174. doi: 10.1172/jci.insight.154174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.154174</ArticleId><ArticleId IdType="pmc">PMC8986067</ArticleId><ArticleId IdType="pubmed">35167498</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39598522</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1999-4923</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>30</Day></PubDate></JournalIssue><Title>Pharmaceutics</Title><ISOAbbreviation>Pharmaceutics</ISOAbbreviation></Journal><ArticleTitle>Revolutionizing Eye Care: Exploring the Potential of Microneedle Drug Delivery.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1398</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pharmaceutics16111398</ELocationID><Abstract><AbstractText>Microneedle technology revolutionizes ocular drug delivery by addressing challenges in treating ocular diseases. This review explores its potential impact, recent advancements, and clinical uses. This minimally invasive technique offers precise control of drug delivery to the eye, with various microneedle types showing the potential to penetrate barriers in the cornea and sclera, ensuring effective drug delivery. Recent advancements have improved safety and efficacy, offering sustained and controlled drug delivery for conditions like age-related macular degeneration and glaucoma. While promising, challenges such as regulatory barriers and long-term biocompatibility persist. Overcoming these through interdisciplinary research is crucial. Ultimately, microneedle drug delivery presents a revolutionary method with the potential to significantly enhance ocular disease treatment, marking a new era in eye care.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rojekar</LastName><ForeName>Satish</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3301-5941</Identifier><AffiliationInfo><Affiliation>Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parit</LastName><ForeName>Swapnali</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Chemical Technology, Marathwada Campus, Jalna 431203, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gholap</LastName><ForeName>Amol D</ForeName><Initials>AD</Initials><Identifier Source="ORCID">0000-0003-4145-4060</Identifier><AffiliationInfo><Affiliation>Department of Pharmaceutics, St. John Institute of Pharmacy and Research, Palghar 401404, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manchare</LastName><ForeName>Ajit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Chemical Technology, Marathwada Campus, Jalna 431203, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nangare</LastName><ForeName>Sopan N</ForeName><Initials>SN</Initials><Identifier Source="ORCID">0000-0002-6513-3336</Identifier><AffiliationInfo><Affiliation>Department of Pharmaceutics, H. R. Patel Institute of Pharmaceutical Education and Research, Shirpur 425405, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hatvate</LastName><ForeName>Navnath</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-3388-3247</Identifier><AffiliationInfo><Affiliation>Institute of Chemical Technology, Marathwada Campus, Jalna 431203, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugandhi</LastName><ForeName>Vrashabh V</ForeName><Initials>VV</Initials><Identifier Source="ORCID">0000-0001-7072-5910</Identifier><AffiliationInfo><Affiliation>College of Pharmacy &amp; Health Sciences, St. John's University, 8000 Utopia Parkway, Queens, NY 11439, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paudel</LastName><ForeName>Keshav Raj</ForeName><Initials>KR</Initials><Identifier Source="ORCID">0000-0002-3591-2080</Identifier><AffiliationInfo><Affiliation>Centre for Inflammation, School of Life Sciences, Faculty of Science, Centenary Institute and University of Technology Sydney, Sydney, NSW 2007, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ingle</LastName><ForeName>Rahul G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>Datta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education and Research (Deemed to Be University)-DMIHER, Wardha 442107, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceutics</MedlineTA><NlmUniqueID>101534003</NlmUniqueID><ISSNLinking>1999-4923</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">biocompatibility</Keyword><Keyword MajorTopicYN="N">eye care</Keyword><Keyword MajorTopicYN="N">glaucoma</Keyword><Keyword MajorTopicYN="N">microneedles</Keyword><Keyword MajorTopicYN="N">ocular drug delivery</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>1</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39598522</ArticleId><ArticleId IdType="pmc">PMC11597228</ArticleId><ArticleId IdType="doi">10.3390/pharmaceutics16111398</ArticleId><ArticleId IdType="pii">pharmaceutics16111398</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Urtti A. Challenges and Obstacles of Ocular Pharmacokinetics and Drug Delivery. Adv. Drug Deliv. Rev. 2006;58:1131&#x2013;1135. doi: 10.1016/j.addr.2006.07.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2006.07.027</ArticleId><ArticleId IdType="pubmed">17097758</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilochonwu B.C., van der Lugt S.A., Annala A., Di Marco G., Sampon T., Siepmann J., Siepmann F., Hennink W.E., Vermonden T. Thermo-Responsive Diels-Alder Stabilized Hydrogels for Ocular Drug Delivery of a Corticosteroid and an Anti-VEGF Fab Fragment. J. Control. Release. 2023;361:334&#x2013;349. doi: 10.1016/j.jconrel.2023.07.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2023.07.052</ArticleId><ArticleId IdType="pubmed">37532147</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang J.C. Ocular Drug Delivery Conventional Ocular Formulations. Adv. Drug Deliv. Rev. 1995;16:39&#x2013;43. doi: 10.1016/0169-409X(95)00012-V.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0169-409X(95)00012-V</ArticleId></ArticleIdList></Reference><Reference><Citation>Reardon G., Kotak, Schwartz G. Objective Assessment of Compliance and Persistence among Patients Treated for Glaucoma and Ocular Hypertension: A Systematic Review. Patient Prefer. Adherence. 2011;5:441&#x2013;463. doi: 10.2147/PPA.S23780.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/PPA.S23780</ArticleId><ArticleId IdType="pmc">PMC3191921</ArticleId><ArticleId IdType="pubmed">22003282</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheive M., Yazdani S., Hajrasouliha A.R. The Utility and Risks of Therapeutic Nanotechnology in the Retina. Ther. Adv. Ophthalmol. 2021;13:251584142110033. doi: 10.1177/25158414211003381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/25158414211003381</ArticleId><ArticleId IdType="pmc">PMC7989128</ArticleId><ArticleId IdType="pubmed">33817552</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar D., Sharma R., Singh P., Verma V., Karkhur S., Verma S., Soni D., Sharma B. Age-Related Cataract&#x2014;Prevalence, Epidemiological Pattern and Emerging Risk Factors in a Cross-Sectional Study from Central India. Indian. J. Ophthalmol. 2023;71:1905&#x2013;1912. doi: 10.4103/ijo.IJO_2020_22.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijo.IJO_2020_22</ArticleId><ArticleId IdType="pmc">PMC10391463</ArticleId><ArticleId IdType="pubmed">37203054</ArticleId></ArticleIdList></Reference><Reference><Citation>Allison K., Patel D., Alabi O. Epidemiology of Glaucoma: The Past, Present, and Predictions for the Future. Cureus. 2020;12:e11686. doi: 10.7759/cureus.11686.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.11686</ArticleId><ArticleId IdType="pmc">PMC7769798</ArticleId><ArticleId IdType="pubmed">33391921</ArticleId></ArticleIdList></Reference><Reference><Citation>Vyawahare H., Shinde P. Age-Related Macular Degeneration: Epidemiology, Pathophysiology, Diagnosis, and Treatment. Cureus. 2022;14:e29583. doi: 10.7759/cureus.29583.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.29583</ArticleId><ArticleId IdType="pmc">PMC9595233</ArticleId><ArticleId IdType="pubmed">36312607</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee R., Wong T.Y., Sabanayagam C. Epidemiology of Diabetic Retinopathy, Diabetic Macular Edema and Related Vision Loss. Eye Vis. 2015;2:17. doi: 10.1186/s40662-015-0026-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40662-015-0026-2</ArticleId><ArticleId IdType="pmc">PMC4657234</ArticleId><ArticleId IdType="pubmed">26605370</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y.C., Chiang B., Wu X., Prausnitz M.R. Ocular Delivery of Macromolecules. J. Control. Release. 2014;190:172&#x2013;181. doi: 10.1016/j.jconrel.2014.06.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2014.06.043</ArticleId><ArticleId IdType="pmc">PMC4142116</ArticleId><ArticleId IdType="pubmed">24998941</ArticleId></ArticleIdList></Reference><Reference><Citation>Glover K., Mishra D., Gade S., Vora L.K., Wu Y., Paredes A.J., Donnelly R.F., Singh T.R.R. Microneedles for Advanced Ocular Drug Delivery. Adv. Drug Deliv. Rev. 2023;201:115082. doi: 10.1016/j.addr.2023.115082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2023.115082</ArticleId><ArticleId IdType="pubmed">37678648</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadzi&#x144;ski P., Froelich A., Wojty&#x142;ko M., Bia&#x142;ek A., Krysztofiak J., Osma&#x142;ek T. Microneedle-Based Ocular Drug Delivery Systems&#x2014;Recent Advances and Challenges. Beilstein J. Nanotechnol. 2022;13:1167&#x2013;1184. doi: 10.3762/bjnano.13.98.</Citation><ArticleIdList><ArticleId IdType="doi">10.3762/bjnano.13.98</ArticleId><ArticleId IdType="pmc">PMC9623140</ArticleId><ArticleId IdType="pubmed">36348935</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaudana R., Ananthula H.K., Parenky A., Mitra A.K. Ocular Drug Delivery. AAPS J. 2010;12:348&#x2013;360. doi: 10.1208/s12248-010-9183-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12248-010-9183-3</ArticleId><ArticleId IdType="pmc">PMC2895432</ArticleId><ArticleId IdType="pubmed">20437123</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunha-Vaz J., Marques F.B., Fernandes R., Alves C., Velpandian T. Pharmacology of Ocular Therapeutics. Springer International Publishing; Cham, Switzerland: 2016. Drug Transport Across Blood-Ocular Barriers and Pharmacokinetics; pp. 37&#x2013;63.</Citation></Reference><Reference><Citation>Rzhevskiy A.S., Singh T.R.R., Donnelly R.F., Anissimov Y.G. Microneedles as the Technique of Drug Delivery Enhancement in Diverse Organs and Tissues. J. Control. Release. 2018;270:184&#x2013;202. doi: 10.1016/j.jconrel.2017.11.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2017.11.048</ArticleId><ArticleId IdType="pubmed">29203415</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan S., Li J., Ruan H., Xia Q., Hou X., Wang Z., Guo T., Zhu C., Feng N., Zhang Y. Microneedle-Mediated Nose-to-Brain Drug Delivery for Improved Alzheimer&#x2019;s Disease Treatment. J. Control. Release. 2024;366:712&#x2013;731. doi: 10.1016/j.jconrel.2024.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2024.01.013</ArticleId><ArticleId IdType="pubmed">38219911</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao Z., Dong C., Fang H. Current Perspective on Microneedles for Ocular Drug Delivery. Saudi J. Med. Pharm. Sci. 2017;4929:772&#x2013;776. doi: 10.36348/sjmps.2017.v03i07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.36348/sjmps.2017.v03i07.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi H., Zhou J., Wang Y., Zhu Y., Lin D., Lei L., Vakal S., Wang J., Li X. A Rapid Corneal Healing Microneedle for Efficient Ocular Drug Delivery. Small. 2022;18:2104657. doi: 10.1002/smll.202104657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/smll.202104657</ArticleId><ArticleId IdType="pubmed">35083856</ArticleId></ArticleIdList></Reference><Reference><Citation>Jathar J., Mahajan H., Nerkar P. Microneedles: A Minimally Invasive Delivery System for Ocular Treatment. Ann. Pharm. Fr. 2024 doi: 10.1016/j.pharma.2024.05.007. in press .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharma.2024.05.007</ArticleId><ArticleId IdType="pubmed">38821480</ArticleId></ArticleIdList></Reference><Reference><Citation>Alrbyawi H., Annaji M., Fasina O., Palakurthi S., Boddu S.H.S., Hassan N., Tiwari A.K., Suryawanshi A., Babu R.J. Rapidly Dissolving Trans-Scleral Microneedles for Intraocular Delivery of Cyclosporine A. AAPS PharmSciTech. 2024;25:28. doi: 10.1208/s12249-024-02738-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12249-024-02738-5</ArticleId><ArticleId IdType="pubmed">38302687</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Nimry S., Abu Dayah A. Implication of Microneedles for Ocular Drug Delivery Systems. J. Drug Deliv. Sci. Technol. 2024;98:105841. doi: 10.1016/j.jddst.2024.105841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jddst.2024.105841</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni D., Damiri F., Rojekar S., Zehravi M., Ramproshad S., Dhoke D., Musale S., Mulani A.A., Modak P., Paradhi R., et al. Recent Advancements in Microneedle Technology for Multifaceted Biomedical Applications. Pharmaceutics. 2022;14:1097. doi: 10.3390/pharmaceutics14051097.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics14051097</ArticleId><ArticleId IdType="pmc">PMC9144002</ArticleId><ArticleId IdType="pubmed">35631683</ArticleId></ArticleIdList></Reference><Reference><Citation>An H., Gu Z., Huang Z., Huo T., Xu Y., Dong Y., Wen Y. Novel Microneedle Platforms for the Treatment of Wounds by Drug Delivery: A Review. Colloids Surf. B Biointerfaces. 2024;233:113636. doi: 10.1016/j.colsurfb.2023.113636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.colsurfb.2023.113636</ArticleId><ArticleId IdType="pubmed">37979482</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojekar S., Vora L.K., Tekko I.A., Volpe-Zanutto F., McCarthy H.O., Vavia P.R., Donnelly R.F. Etravirine-Loaded Dissolving Microneedle Arrays for Long-Acting Delivery. Eur. J. Pharm. Biopharm. 2021;165:41&#x2013;51. doi: 10.1016/j.ejpb.2021.04.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpb.2021.04.024</ArticleId><ArticleId IdType="pubmed">33971273</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta P., Yadav K.S. Applications of Microneedles in Delivering Drugs for Various Ocular Diseases. Life Sci. 2019;237:116907. doi: 10.1016/j.lfs.2019.116907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2019.116907</ArticleId><ArticleId IdType="pubmed">31606378</ArticleId></ArticleIdList></Reference><Reference><Citation>Mdanda S., Ubanako P., Kondiah P.P.D., Kumar P., Choonara Y.E. Recent Advances in Microneedle Platforms for Transdermal Drug Delivery Technologies. Polymers. 2021;13:2405. doi: 10.3390/polym13152405.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/polym13152405</ArticleId><ArticleId IdType="pmc">PMC8348894</ArticleId><ArticleId IdType="pubmed">34372008</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitore J.G., Pagar S., Singh N., Karunakaran B., Salve S., Hatvate N., Rojekar S., Benival D. A Comprehensive Review of Nanosuspension Loaded Microneedles: Fabrication Methods, Applications, and Recent Developments. J. Pharm. Investig. 2023;53:475&#x2013;504. doi: 10.1007/s40005-023-00622-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40005-023-00622-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Moffatt K., Wang Y., Raj Singh T.R., Donnelly R.F. Microneedles for Enhanced Transdermal and Intraocular Drug Delivery. Curr. Opin. Pharmacol. 2017;36:14&#x2013;21. doi: 10.1016/j.coph.2017.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2017.07.007</ArticleId><ArticleId IdType="pubmed">28780407</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraji Rad Z., Prewett P.D., Davies G.J. An Overview of Microneedle Applications, Materials, and Fabrication Methods. Beilstein J. Nanotechnol. 2021;12:1034&#x2013;1046. doi: 10.3762/bjnano.12.77.</Citation><ArticleIdList><ArticleId IdType="doi">10.3762/bjnano.12.77</ArticleId><ArticleId IdType="pmc">PMC8450954</ArticleId><ArticleId IdType="pubmed">34621614</ArticleId></ArticleIdList></Reference><Reference><Citation>Song H.B., Lee K.J., Seo I.H., Lee J.Y., Lee S.-M., Kim J.H., Kim J.H., Ryu W. Impact Insertion of Transfer-Molded Microneedle for Localized and Minimally Invasive Ocular Drug Delivery. J. Control. Release. 2015;209:272&#x2013;279. doi: 10.1016/j.jconrel.2015.04.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2015.04.041</ArticleId><ArticleId IdType="pubmed">25937320</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakur Singh R.R., Tekko I., McAvoy K., McMillan H., Jones D., Donnelly R.F. Minimally Invasive Microneedles for Ocular Drug Delivery. Expert. Opin. Drug Deliv. 2017;14:525&#x2013;537. doi: 10.1080/17425247.2016.1218460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17425247.2016.1218460</ArticleId><ArticleId IdType="pubmed">27485251</ArticleId></ArticleIdList></Reference><Reference><Citation>Chopra H., Priyanka, Choudhary O.P., Emran T.B. Microneedles for Ophthalmic Drug Delivery: Recent Developments. Int. J. Surg. 2023;109:551&#x2013;552. doi: 10.1097/JS9.0000000000000133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JS9.0000000000000133</ArticleId><ArticleId IdType="pmc">PMC10389204</ArticleId><ArticleId IdType="pubmed">36912803</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf6;nk&#xe4;re J., Pontier M., van Kampen E.E.M., Du G., Leone M., Romeijn S., Nejadnik M.R., O&#x2019;Mahony C., Sl&#xfc;tter B., Jiskoot W., et al. Development of PLGA Nanoparticle Loaded Dissolving Microneedles and Comparison with Hollow Microneedles in Intradermal Vaccine Delivery. Eur. J. Pharm. Biopharm. 2018;129:111&#x2013;121. doi: 10.1016/j.ejpb.2018.05.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpb.2018.05.031</ArticleId><ArticleId IdType="pubmed">29803720</ArticleId></ArticleIdList></Reference><Reference><Citation>Loh J.M., Lim Y.J.L., Tay J.T., Cheng H.M., Tey H.L., Liang K. Design and Fabrication of Customizable Microneedles Enabled by 3D Printing for Biomedical Applications. Bioact. Mater. 2024;32:222&#x2013;241. doi: 10.1016/j.bioactmat.2023.09.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bioactmat.2023.09.022</ArticleId><ArticleId IdType="pmc">PMC10589728</ArticleId><ArticleId IdType="pubmed">37869723</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., Vora L.K., Wang Y., Adrianto M.F., Tekko I.A., Waite D., Donnelly R.F., Thakur R.R.S. Long-Acting Nanoparticle-Loaded Bilayer Microneedles for Protein Delivery to the Posterior Segment of the Eye. Eur. J. Pharm. Biopharm. 2021;165:306&#x2013;318. doi: 10.1016/j.ejpb.2021.05.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpb.2021.05.022</ArticleId><ArticleId IdType="pubmed">34048879</ArticleId></ArticleIdList></Reference><Reference><Citation>Migalska K., Morrow D.I.J., Garland M.J., Thakur R., Woolfson A.D., Donnelly R.F. Laser-Engineered Dissolving Microneedle Arrays for Transdermal Macromolecular Drug Delivery. Pharm. Res. 2011;28:1919&#x2013;1930. doi: 10.1007/s11095-011-0419-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-011-0419-4</ArticleId><ArticleId IdType="pubmed">21437789</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakur R.R.S., Tekko I.A., Al-Shammari F., Ali A.A., McCarthy H., Donnelly R.F. Rapidly Dissolving Polymeric Microneedles for Minimally Invasive Intraocular Drug Delivery. Drug Deliv. Transl. Res. 2016;6:800&#x2013;815. doi: 10.1007/s13346-016-0332-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13346-016-0332-9</ArticleId><ArticleId IdType="pmc">PMC5097091</ArticleId><ArticleId IdType="pubmed">27709355</ArticleId></ArticleIdList></Reference><Reference><Citation>Amer M., Chen R.K. Self-Adhesive Microneedles with Interlocking Features for Sustained Ocular Drug Delivery. Macromol. Biosci. 2020;20:2000089. doi: 10.1002/mabi.202000089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mabi.202000089</ArticleId><ArticleId IdType="pubmed">32538528</ArticleId></ArticleIdList></Reference><Reference><Citation>McAllister D.V., Wang P.M., Davis S.P., Park J.H., Canatella P.J., Allen M.G., Prausnitz M.R. Microfabricated Needles for Transdermal Delivery of Macromolecules and Nanoparticles: Fabrication Methods and Transport Studies. Proc. Natl. Acad. Sci. USA. 2003;100:13755&#x2013;13760. doi: 10.1073/pnas.2331316100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2331316100</ArticleId><ArticleId IdType="pmc">PMC283494</ArticleId><ArticleId IdType="pubmed">14623977</ArticleId></ArticleIdList></Reference><Reference><Citation>Makhijani S., Elossaily G.M., Rojekar S., Ingle R.G. MRNA-Based Vaccines&#x2014;Global Approach, Challenges, and Could Be a Promising Wayout for Future Pandemics. Pharm. Dev. Technol. 2024;29:559&#x2013;565. doi: 10.1080/10837450.2024.2361656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10837450.2024.2361656</ArticleId><ArticleId IdType="pubmed">38814266</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariq N., Ashraf M.W., Tayyaba S. A Review on Solid Microneedles for Biomedical Applications. J. Pharm. Innov. 2022;17:1464&#x2013;1483. doi: 10.1007/s12247-021-09586-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12247-021-09586-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei-ze L., Mei-rong H., Jian-ping Z., Yong-qiang Z., Bao-hua H. Super-Short Solid Silicon Microneedles for Transdermal Drug Delivery Applications. Int. J. Pharm. 2010;389:122&#x2013;129. doi: 10.1016/j.ijpharm.2010.01.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2010.01.024</ArticleId><ArticleId IdType="pubmed">20096759</ArticleId></ArticleIdList></Reference><Reference><Citation>Waghule T., Singhvi G., Kumar S., Monohar M. Microneedles: A Smart Approach and Increasing Potential for Transdermal Drug Delivery System. Biomed. Pharmacother. 2019;109:1249&#x2013;1258. doi: 10.1016/j.biopha.2018.10.078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2018.10.078</ArticleId><ArticleId IdType="pubmed">30551375</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanjay S.T., Zhou W., Dou M., Tavakoli H., Ma L., Xu F., Li X. Recent Advances of Controlled Drug Delivery Using Microfluidic Platforms. Adv. Drug Deliv. Rev. 2018;128:3&#x2013;28. doi: 10.1016/j.addr.2017.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2017.09.013</ArticleId><ArticleId IdType="pmc">PMC5854505</ArticleId><ArticleId IdType="pubmed">28919029</ArticleId></ArticleIdList></Reference><Reference><Citation>Ita K. Ceramic Microneedles and Hollow Microneedles for Transdermal Drug Delivery: Two Decades of Research. J. Drug Deliv. Sci. Technol. 2018;44:314&#x2013;322. doi: 10.1016/j.jddst.2018.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jddst.2018.01.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Aich K., Singh T., Dang S. Advances in Microneedle-Based Transdermal Delivery for Drugs and Peptides. Drug Deliv. Transl. Res. 2022;12:1556&#x2013;1568. doi: 10.1007/s13346-021-01056-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13346-021-01056-8</ArticleId><ArticleId IdType="pubmed">34564827</ArticleId></ArticleIdList></Reference><Reference><Citation>Bal S.M., Ding Z., van Riet E., Jiskoot W., Bouwstra J.A. Advances in Transcutaneous Vaccine Delivery: Do All Ways Lead to Rome? J. Control. Release. 2010;148:266&#x2013;282. doi: 10.1016/j.jconrel.2010.09.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2010.09.018</ArticleId><ArticleId IdType="pubmed">20869998</ArticleId></ArticleIdList></Reference><Reference><Citation>Norman J.J., Gupta J., Patel S.R., Park S., Jarrahian C., Zehrung D., Prausnitz M.R. Reliability and Accuracy of Intradermal Injection by Mantoux Technique, Hypodermic Needle Adapter, and Hollow Microneedle in Pigs. Drug Deliv. Transl. Res. 2014;4:126&#x2013;130. doi: 10.1007/s13346-013-0184-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13346-013-0184-5</ArticleId><ArticleId IdType="pubmed">25786726</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J.D., Kim M., Yang H., Lee K., Jung H. Droplet-Born Air Blowing: Novel Dissolving Microneedle Fabrication. J. Control. Release. 2013;170:430&#x2013;436. doi: 10.1016/j.jconrel.2013.05.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2013.05.026</ArticleId><ArticleId IdType="pubmed">23742882</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K., Lee C.Y., Jung H. Dissolving Microneedles for Transdermal Drug Administration Prepared by Stepwise Controlled Drawing of Maltose. Biomaterials. 2011;32:3134&#x2013;3140. doi: 10.1016/j.biomaterials.2011.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2011.01.014</ArticleId><ArticleId IdType="pubmed">21292317</ArticleId></ArticleIdList></Reference><Reference><Citation>Leone M., M&#xf6;nk&#xe4;re J., Bouwstra J.A., Kersten G. Dissolving Microneedle Patches for Dermal Vaccination. Pharm. Res. 2017;34:2223&#x2013;2240. doi: 10.1007/s11095-017-2223-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-017-2223-2</ArticleId><ArticleId IdType="pmc">PMC5643353</ArticleId><ArticleId IdType="pubmed">28718050</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., Vora L.K., Donnelly R.F., Singh T.R.R. Rapidly Dissolving Bilayer Microneedles Enabling Minimally Invasive and Efficient Protein Delivery to the Posterior Segment of the Eye. Drug Deliv. Transl. Res. 2023;13:2142&#x2013;2158. doi: 10.1007/s13346-022-01190-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13346-022-01190-x</ArticleId><ArticleId IdType="pmc">PMC10315354</ArticleId><ArticleId IdType="pubmed">35713782</ArticleId></ArticleIdList></Reference><Reference><Citation>Vora L.K., Vavia P.R., Larra&#xf1;eta E., Bell S.E.J., Donnelly R.F. Novel Nanosuspension-based Dissolving Microneedle Arrays for Transdermal Delivery of a Hydrophobic Drug. J. Interdiscip. Nanomed. 2018;3:89&#x2013;101. doi: 10.1002/jin2.41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jin2.41</ArticleId><ArticleId IdType="pmc">PMC6055884</ArticleId><ArticleId IdType="pubmed">30069310</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill H.S., Prausnitz M.R. Coated Microneedles for Transdermal Delivery. J. Control. Release. 2007;117:227&#x2013;237. doi: 10.1016/j.jconrel.2006.10.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2006.10.017</ArticleId><ArticleId IdType="pmc">PMC1853346</ArticleId><ArticleId IdType="pubmed">17169459</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarbox T.N., Watts A.B., Cui Z., Williams R.O. An Update on Coating/Manufacturing Techniques of Microneedles. Drug Deliv. Transl. Res. 2018;8:1828&#x2013;1843. doi: 10.1007/s13346-017-0466-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13346-017-0466-4</ArticleId><ArticleId IdType="pubmed">29288358</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingrole R.S.J., Gill H.S. Microneedle Coating Methods: A Review with a Perspective. J. Pharmacol. Exp. Ther. 2019;370:555&#x2013;569. doi: 10.1124/jpet.119.258707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.119.258707</ArticleId><ArticleId IdType="pmc">PMC6806358</ArticleId><ArticleId IdType="pubmed">31175217</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapoor Y., Milewski M., Dick L., Zhang J., Bothe J.R., Gehrt M., Manser K., Nissley B., Petrescu I., Johnson P., et al. Coated Microneedles for Transdermal Delivery of a Potent Pharmaceutical Peptide. Biomed. Microdevices. 2020;22:7. doi: 10.1007/s10544-019-0462-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10544-019-0462-1</ArticleId><ArticleId IdType="pubmed">31845070</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo X., Yang L., Cui Y. Microneedles: Materials, Fabrication, and Biomedical Applications. Biomed. Microdevices. 2023;25:20. doi: 10.1007/s10544-023-00658-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10544-023-00658-y</ArticleId><ArticleId IdType="pmc">PMC10242236</ArticleId><ArticleId IdType="pubmed">37278852</ArticleId></ArticleIdList></Reference><Reference><Citation>Khandan O., Famili A., Kahook M.Y., Rao M.P. Titanium-Based, Fenestrated, in-Plane Microneedles for Passive Ocular Drug Delivery; Proceedings of the 2012 Annual International Conference of the IEEE Engineering in Medicine and Biology Society; San Diego, CA, USA. 28 August&#x2013;1 September 2012; pp. 6572&#x2013;6575.</Citation><ArticleIdList><ArticleId IdType="pubmed">23367435</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Mamun A., Zhao F. In-Plane Si Microneedles: Fabrication, Characterization, Modeling and Applications. Micromachines. 2022;13:657. doi: 10.3390/mi13050657.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/mi13050657</ArticleId><ArticleId IdType="pmc">PMC9146885</ArticleId><ArticleId IdType="pubmed">35630124</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed Saeed AL-Japairai K., Mahmood S., Hamed Almurisi S., Reddy Venugopal J., Rebhi Hilles A., Azmana M., Raman S. Current Trends in Polymer Microneedle for Transdermal Drug Delivery. Int. J. Pharm. 2020;587:119673. doi: 10.1016/j.ijpharm.2020.119673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2020.119673</ArticleId><ArticleId IdType="pmc">PMC7392082</ArticleId><ArticleId IdType="pubmed">32739388</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakka D., Matadh A.V., Shankar V.K., Shivakumar H.N., Narasimha Murthy S. Polymer Coated Polymeric (PCP) Microneedles for Controlled Delivery of Drugs (Dermal and Intravitreal) J. Pharm. Sci. 2022;111:2867&#x2013;2878. doi: 10.1016/j.xphs.2022.05.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2022.05.023</ArticleId><ArticleId IdType="pmc">PMC10775835</ArticleId><ArticleId IdType="pubmed">35662543</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner J.G., White L.R., Estrela P., Leese H.S. Hydrogel-Forming Microneedles: Current Advancements and Future Trends. Macromol. Biosci. 2021;21:2000307. doi: 10.1002/mabi.202000307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mabi.202000307</ArticleId><ArticleId IdType="pubmed">33241641</ArticleId></ArticleIdList></Reference><Reference><Citation>Migdadi E.M., Courtenay A.J., Tekko I.A., McCrudden M.T.C., Kearney M.C., McAlister E., McCarthy H.O., Donnelly R.F. Hydrogel-Forming Microneedles Enhance Transdermal Delivery of Metformin Hydrochloride. J. Control. Release. 2018;285:142&#x2013;151. doi: 10.1016/j.jconrel.2018.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2018.07.009</ArticleId><ArticleId IdType="pmc">PMC6141810</ArticleId><ArticleId IdType="pubmed">29990526</ArticleId></ArticleIdList></Reference><Reference><Citation>Damiri F., Rojekar S., Bachra Y., Varma R.S., Andra S., Balu S., Pardeshi C.V., Patel P.J., Patel H.M., Paiva-Santos A.C., et al. Polysaccharide-Based Nanogels for Biomedical Applications: A Comprehensive Review. J. Drug Deliv. Sci. Technol. 2023;84:104447. doi: 10.1016/j.jddst.2023.104447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jddst.2023.104447</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly R.F., McCrudden M.T.C., Alkilani A.Z., Larra&#xf1;eta E., McAlister E., Courtenay A.J., Kearney M.C., Raj Singh T.R., McCarthy H.O., Kett V.L., et al. Hydrogel-Forming Microneedles Prepared from &#x201c;Super Swelling&#x201d; Polymers Combined with Lyophilised Wafers for Transdermal Drug Delivery. PLoS ONE. 2014;9:e111547. doi: 10.1371/journal.pone.0111547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0111547</ArticleId><ArticleId IdType="pmc">PMC4216095</ArticleId><ArticleId IdType="pubmed">25360806</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kasasbeh R., Brady A.J., Courtenay A.J., Larra&#xf1;eta E., McCrudden M.T.C., O&#x2019;Kane D., Liggett S., Donnelly R.F. Evaluation of the Clinical Impact of Repeat Application of Hydrogel-Forming Microneedle Array Patches. Drug Deliv. Transl. Res. 2020;10:690&#x2013;705. doi: 10.1007/s13346-020-00727-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13346-020-00727-2</ArticleId><ArticleId IdType="pmc">PMC7228965</ArticleId><ArticleId IdType="pubmed">32103450</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly R.F., Singh T.R.R., Garland M.J., Migalska K., Majithiya R., McCrudden C.M., Kole P.L., Mahmood T.M.T., McCarthy H.O., Woolfson A.D. Hydrogel-Forming Microneedle Arrays for Enhanced Transdermal Drug Delivery. Adv. Funct. Mater. 2012;22:4879&#x2013;4890. doi: 10.1002/adfm.201200864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adfm.201200864</ArticleId><ArticleId IdType="pmc">PMC3627464</ArticleId><ArticleId IdType="pubmed">23606824</ArticleId></ArticleIdList></Reference><Reference><Citation>Castilla-Casadiego D.A., Miranda-Mu&#xf1;oz K.A., Roberts J.L., Crowell A.D., Gonzalez-Nino D., Choudhury D., Aparicio-Solis F.O., Servoss S.L., Rosales A.M., Prinz G., et al. Biodegradable Microneedle Patch for Delivery of Meloxicam for Managing Pain in Cattle. PLoS ONE. 2022;17:e0272169. doi: 10.1371/journal.pone.0272169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0272169</ArticleId><ArticleId IdType="pmc">PMC9345335</ArticleId><ArticleId IdType="pubmed">35917312</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan W., Hong X., Wu Z., Chen L., Liu Z., Wu F., Wei L. Dissolving and Biodegradable Microneedle Technologies for Transdermal Sustained Delivery of Drug and Vaccine. Drug Des. Devel Ther. 2013;7:945&#x2013;952. doi: 10.2147/DDDT.S44401.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S44401</ArticleId><ArticleId IdType="pmc">PMC3771849</ArticleId><ArticleId IdType="pubmed">24039404</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q.Y., Zhang J.N., Chen B.Z., Wang Q.L., Guo X.D. A Solid Polymer Microneedle Patch Pretreatment Enhances the Permeation of Drug Molecules into the Skin. RSC Adv. 2017;7:15408&#x2013;15415. doi: 10.1039/C6RA26759A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C6RA26759A</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S., Kim M., Baek S.-K., Park J.-H., Choi S.-O. Spray-Formed Layered Polymer Microneedles for Controlled Biphasic Drug Delivery. Polymers. 2019;11:369. doi: 10.3390/polym11020369.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/polym11020369</ArticleId><ArticleId IdType="pmc">PMC6419157</ArticleId><ArticleId IdType="pubmed">30960353</ArticleId></ArticleIdList></Reference><Reference><Citation>He X., Sun J., Zhuang J., Xu H., Liu Y., Wu D. Microneedle System for Transdermal Drug and Vaccine Delivery: Devices, Safety, and Prospects. Dose-Response. 2019;17:155932581987858. doi: 10.1177/1559325819878585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1559325819878585</ArticleId><ArticleId IdType="pmc">PMC6794664</ArticleId><ArticleId IdType="pubmed">31662709</ArticleId></ArticleIdList></Reference><Reference><Citation>Kompella U.B., Edelhauser H.F., editors. Drug Product Development for the Back of the Eye. Volume 2. Springer; Boston, MA, USA: 2011.</Citation></Reference><Reference><Citation>Haj-Ahmad R., Khan H., Arshad M., Rasekh M., Hussain A., Walsh S., Li X., Chang M.-W., Ahmad Z. Microneedle Coating Techniques for Transdermal Drug Delivery. Pharmaceutics. 2015;7:486&#x2013;502. doi: 10.3390/pharmaceutics7040486.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics7040486</ArticleId><ArticleId IdType="pmc">PMC4695830</ArticleId><ArticleId IdType="pubmed">26556364</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J., Gill H.S., Ghate D., McCarey B.E., Patel S.R., Edelhauser H.F., Prausnitz M.R. Coated Microneedles for Drug Delivery to the Eye. Investig. Opthalmology Vis. Sci. 2007;48:4038. doi: 10.1167/iovs.07-0066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.07-0066</ArticleId><ArticleId IdType="pubmed">17724185</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucak A., Sirbubalo M., Hindija L., Rahi&#x107; O., Had&#x17e;iabdi&#x107; J., Muhamedagi&#x107; K., &#x10c;eki&#x107; A., Vrani&#x107; E. Microneedles: Characteristics, Materials, Production Methods and Commercial Development. Micromachines. 2020;11:961. doi: 10.3390/mi11110961.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/mi11110961</ArticleId><ArticleId IdType="pmc">PMC7694032</ArticleId><ArticleId IdType="pubmed">33121041</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardano P., Cali&#xf2; A., Di Palma V., Bevilacqua M., Di Matteo A., De Stefano L. A Photolithographic Approach to Polymeric Microneedles Array Fabrication. Materials. 2015;8:8661&#x2013;8673. doi: 10.3390/ma8125484.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ma8125484</ArticleId><ArticleId IdType="pmc">PMC5458808</ArticleId><ArticleId IdType="pubmed">28793736</ArticleId></ArticleIdList></Reference><Reference><Citation>Albadr A.A., Tekko I.A., Vora L.K., Ali A.A., Laverty G., Donnelly R.F., Thakur R.R.S. Rapidly Dissolving Microneedle Patch of Amphotericin B for Intracorneal Fungal Infections. Drug Deliv. Transl. Res. 2022;12:931&#x2013;943. doi: 10.1007/s13346-021-01032-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13346-021-01032-2</ArticleId><ArticleId IdType="pmc">PMC8888497</ArticleId><ArticleId IdType="pubmed">34302273</ArticleId></ArticleIdList></Reference><Reference><Citation>Defelippi K.M., Kwong A.Y.S., Appleget J.R., Altay R., Matheny M.B., Dubus M.M., Eribes L.M., Mobed-Miremadi M. An Integrated Approach to Control the Penetration Depth of 3D-Printed Hollow Microneedles. Appl. Mech. 2024;5:233&#x2013;260. doi: 10.3390/applmech5020015.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/applmech5020015</ArticleId></ArticleIdList></Reference><Reference><Citation>Gade S., Glover K., Mishra D., Sharma S., Guy O., Donnelly R.F., Vora L.K., Thakur R.R.S. Hollow Microneedles for Ocular Drug Delivery. J. Control. Release. 2024;371:43&#x2013;66. doi: 10.1016/j.jconrel.2024.05.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2024.05.013</ArticleId><ArticleId IdType="pubmed">38735395</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J., Moore J.S., Edelhauser H.F., Prausnitz M.R. Intrascleral Drug Delivery to the Eye Using Hollow Microneedles. Pharm. Res. 2009;26:395&#x2013;403. doi: 10.1007/s11095-008-9756-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-008-9756-3</ArticleId><ArticleId IdType="pmc">PMC2900774</ArticleId><ArticleId IdType="pubmed">18979189</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Bi D., Hu Z., Yang Y., Liu Y., Leung W.K. Hydrogel-Forming Microneedles with Applications in Oral Diseases Management. Materials. 2023;16:4805. doi: 10.3390/ma16134805.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ma16134805</ArticleId><ArticleId IdType="pmc">PMC10343795</ArticleId><ArticleId IdType="pubmed">37445119</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakur R.R.S., Fallows S.J., McMillan H.L., Donnelly R.F., Jones D.S. Microneedle-Mediated Intrascleral Delivery of in Situ Forming Thermoresponsive Implants for Sustained Ocular Drug Delivery. J. Pharm. Pharmacol. 2014;66:584&#x2013;595. doi: 10.1111/jphp.12152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jphp.12152</ArticleId><ArticleId IdType="pmc">PMC7938837</ArticleId><ArticleId IdType="pubmed">24127904</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelley H., Annaji M., Grant M., Fasina O., Babu R.J. Sustained Release Biodegradable Microneedles of Difluprednate for Delivery to Posterior Eye. J. Ocul. Pharmacol. Ther. 2022;38:449&#x2013;458. doi: 10.1089/jop.2021.0089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jop.2021.0089</ArticleId><ArticleId IdType="pubmed">35167767</ArticleId></ArticleIdList></Reference><Reference><Citation>Park W., Nguyen V.P., Jeon Y., Kim B., Li Y., Yi J., Kim H., Leem J.W., Kim Y.L., Kim D.R., et al. Biodegradable Silicon Nanoneedles for Ocular Drug Delivery. Sci. Adv. 2022;8:eabn1772. doi: 10.1126/sciadv.abn1772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abn1772</ArticleId><ArticleId IdType="pmc">PMC8967230</ArticleId><ArticleId IdType="pubmed">35353558</ArticleId></ArticleIdList></Reference><Reference><Citation>Chae J.J., Jung J.H., Zhu W., Gerberich B.G., Bahrani Fard M.R., Grossniklaus H.E., Ethier C.R., Prausnitz M.R. Drug-Free, Nonsurgical Reduction of Intraocular Pressure for Four Months after Suprachoroidal Injection of Hyaluronic Acid Hydrogel. Adv. Sci. 2021;8:2001908. doi: 10.1002/advs.202001908.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202001908</ArticleId><ArticleId IdType="pmc">PMC7816721</ArticleId><ArticleId IdType="pubmed">33511001</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel S.R., Lin A.S.P., Edelhauser H.F., Prausnitz M.R. Suprachoroidal Drug Delivery to the Back of the Eye Using Hollow Microneedles. Pharm. Res. 2011;28:166&#x2013;176. doi: 10.1007/s11095-010-0271-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-010-0271-y</ArticleId><ArticleId IdType="pmc">PMC3038673</ArticleId><ArticleId IdType="pubmed">20857178</ArticleId></ArticleIdList></Reference><Reference><Citation>Dabholkar N., Gorantla S., Waghule T., Rapalli V.K., Kothuru A., Goel S., Singhvi G. Biodegradable Microneedles Fabricated with Carbohydrates and Proteins: Revolutionary Approach for Transdermal Drug Delivery. Int. J. Biol. Macromol. 2021;170:602&#x2013;621. doi: 10.1016/j.ijbiomac.2020.12.177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2020.12.177</ArticleId><ArticleId IdType="pubmed">33387545</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K., Song H.B., Cho W., Kim J.H., Kim J.H., Ryu W. Intracorneal Injection of a Detachable Hybrid Microneedle for Sustained Drug Delivery. Acta Biomater. 2018;80:48&#x2013;57. doi: 10.1016/j.actbio.2018.09.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actbio.2018.09.039</ArticleId><ArticleId IdType="pubmed">30267886</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y., Thiele J., Abdelmohsen L., Xu J., Huck W.T.S. Biocompatible Macro-Initiators Controlling Radical Retention in Microfluidic on-Chip Photo-Polymerization of Water-in-Oil Emulsions. Chem. Commun. 2014;50:112&#x2013;114. doi: 10.1039/C3CC46733C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C3CC46733C</ArticleId><ArticleId IdType="pubmed">24217172</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran K.T.M., Nguyen T.D. Lithography-Based Methods to Manufacture Biomaterials at Small Scales. J. Sci. Adv. Mater. Devices. 2017;2:1&#x2013;14. doi: 10.1016/j.jsamd.2016.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsamd.2016.12.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Rassaei L., Singh P.S., Lemay S.G. Lithography-Based Nanoelectrochemistry. Anal. Chem. 2011;83:3974&#x2013;3980. doi: 10.1021/ac200307n.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ac200307n</ArticleId><ArticleId IdType="pubmed">21510648</ArticleId></ArticleIdList></Reference><Reference><Citation>del Campo A., Arzt E. Fabrication Approaches for Generating Complex Micro- and Nanopatterns on Polymeric Surfaces. Chem. Rev. 2008;108:911&#x2013;945. doi: 10.1021/cr050018y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cr050018y</ArticleId><ArticleId IdType="pubmed">18298098</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P.-C., Wester B.A., Rajaraman S., Paik S.-J., Kim S.-H., Allen M.G. Hollow Polymer Microneedle Array Fabricated by Photolithography Process Combined with Micromolding Technique; Proceedings of the 2009 Annual International Conference of the IEEE Engineering in Medicine and Biology Society; Minneapolis, MN, USA. 3&#x2013;6 September 2009; pp. 7026&#x2013;7029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9050966</ArticleId><ArticleId IdType="pubmed">19964192</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J., Mayes R.H., Chen G., Xie H., Chan P.S. Effects of Process Parameters on the Micro Molding Process. Polym. Eng. Sci. 2003;43:1542&#x2013;1554. doi: 10.1002/pen.10130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pen.10130</ArticleId></ArticleIdList></Reference><Reference><Citation>Alireza S.S. Ph.D. Thesis. McMaster University; Hamilton, ON, Canada: 2020. Development of Biofabrication Techniques to Engineer 3D In Vitro Avatars Development of Biofabrication Techniques to Engineer 3D In Vitro Avatars.</Citation></Reference><Reference><Citation>Katoh T., Tokuno R., Zhang Y., Abe M., Akita K., Akamatsu M. Micro Injection Molding for Mass Production Using LIGA Mold Inserts. Microsyst. Technol. 2008;14:1507&#x2013;1514. doi: 10.1007/s00542-007-0533-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00542-007-0533-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon S., Lee N., Kang S. Fabrication of a Microlens Array Using Micro-Compression Molding with an Electroformed Mold Insert. J. Micromech. Microeng. 2003;13:98&#x2013;103. doi: 10.1088/0960-1317/13/1/314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1088/0960-1317/13/1/314</ArticleId></ArticleIdList></Reference><Reference><Citation>Han G., Wan W., Zhang Z., Xu L., Liu F., Zhang H. Experimental Investigation into Effects of Different Ultrasonic Vibration Modes in Micro-Extrusion Process. J. Manuf. Process. 2021;67:427&#x2013;437. doi: 10.1016/j.jmapro.2021.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmapro.2021.05.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshmukh S.S., Goswami A. Recent Developments in Hot Embossing&#x2014;A Review. Mater. Manuf. Process. 2021;36:501&#x2013;543. doi: 10.1080/10426914.2020.1832691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10426914.2020.1832691</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C.-Y., Yang S.-Y., Huang L.-S., Jeng T.-M. A Novel Method for Rapid Fabrication of Microlens Arrays Using Micro-Transfer Molding with Soft Mold. J. Micromech. Microeng. 2006;16:999&#x2013;1005. doi: 10.1088/0960-1317/16/5/017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1088/0960-1317/16/5/017</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon J., Lee S., Kang D., Meitl M.A., Bower C.A., Rogers J.A. Heterogeneously Integrated Optoelectronic Devices Enabled by Micro-Transfer Printing. Adv. Opt. Mater. 2015;3:1313&#x2013;1335. doi: 10.1002/adom.201500365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adom.201500365</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Y., Whitesides G.M. Soft Lithography. Annu. Rev. Mater. Sci. 1998;28:153&#x2013;184. doi: 10.1146/annurev.matsci.28.1.153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.matsci.28.1.153</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahadevan G., Sheardown H., Selvaganapathy P. PDMS Embedded Microneedles as a Controlled Release System for the Eye. J. Biomater. Appl. 2013;28:20&#x2013;27. doi: 10.1177/0885328211433778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0885328211433778</ArticleId><ArticleId IdType="pubmed">22262574</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentili E., Tabaglio L., Aggogeri F. Review on Micromachining Techniques. CISM Int. Cent. Mech. Sci. Courses Lect. 2005;486:387&#x2013;396. doi: 10.1007/3-211-38053-1_37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/3-211-38053-1_37</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L.J. Nanoimprint Lithography: Methods and Material Requirements. Adv. Mater. 2007;19:495&#x2013;513. doi: 10.1002/adma.200600882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adma.200600882</ArticleId></ArticleIdList></Reference><Reference><Citation>Dabbagh S.R., Sarabi M.R., Rahbarghazi R., Sokullu E., Yetisen A.K., Tasoglu S. 3D-Printed Microneedles in Biomedical Applications. iScience. 2021;24:102012. doi: 10.1016/j.isci.2020.102012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2020.102012</ArticleId><ArticleId IdType="pmc">PMC7814162</ArticleId><ArticleId IdType="pubmed">33506186</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal A., Rastogi C.K., Rani S., Singh G.P., Saxena S., Shukla S. Two Decades of Two-Photon Lithography: Materials Science Perspective for Additive Manufacturing of 2D/3D Nano-Microstructures. iScience. 2023;26:106374. doi: 10.1016/j.isci.2023.106374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2023.106374</ArticleId><ArticleId IdType="pmc">PMC10121806</ArticleId><ArticleId IdType="pubmed">37096047</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupone F., Padovano E., Casamento F., Badini C. Process Phenomena and Material Properties in Selective Laser Sintering of Polymers: A Review. Materials. 2021;15:183. doi: 10.3390/ma15010183.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ma15010183</ArticleId><ArticleId IdType="pmc">PMC8746045</ArticleId><ArticleId IdType="pubmed">35009332</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitaihi R., Abukhamees S., Chung S.H., Craig D.Q.M. Optimization of Stereolithography 3D Printing of Microneedle Micro-Molds for Ocular Drug Delivery. Int. J. Pharm. 2024;658:124195. doi: 10.1016/j.ijpharm.2024.124195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2024.124195</ArticleId><ArticleId IdType="pubmed">38703935</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilal M., Mehmood S., Raza A., Hayat U., Rasheed T., Iqbal H.M.N. Microneedles in Smart Drug Delivery. Adv. Wound Care. 2021;10:204&#x2013;219. doi: 10.1089/wound.2019.1122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/wound.2019.1122</ArticleId><ArticleId IdType="pmc">PMC7906867</ArticleId><ArticleId IdType="pubmed">32320365</ArticleId></ArticleIdList></Reference><Reference><Citation>You J., Yang C., Han J., Wang H., Zhang W., Zhang Y., Lu Z., Wang S., Cai R., Li H., et al. Ultrarapid-Acting Microneedles for Immediate Delivery of Biotherapeutics. Adv. Mater. 2023;35:e2304582. doi: 10.1002/adma.202304582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adma.202304582</ArticleId><ArticleId IdType="pubmed">37547966</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearney M.-C., McKenna P.E., Quinn H.L., Courtenay A.J., Larra&#xf1;eta E., Donnelly R.F. Design and Development of Liquid Drug Reservoirs for Microneedle Delivery of Poorly Soluble Drug Molecules. Pharmaceutics. 2019;11:605. doi: 10.3390/pharmaceutics11110605.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics11110605</ArticleId><ArticleId IdType="pmc">PMC6920785</ArticleId><ArticleId IdType="pubmed">31766145</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumbhar P.S., Jadhav T.P., Chopade S.S., Gavade T.T., Sorate R.C., Shinde T.U., Maske P.P., Disouza J.I., Manjappa A.S. Microneedles: An Advanced Approach for Transdermal Delivery of Biologics. Asian J. Pharm. Res. 2021;11:46&#x2013;54. doi: 10.5958/2231-5691.2021.00010.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.5958/2231-5691.2021.00010.1</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B.Z., He Y.T., Zhao Z.Q., Feng Y.H., Liang L., Peng J., Yang C.Y., Uyama H., Shahbazi M.-A., Guo X.D. Strategies to Develop Polymeric Microneedles for Controlled Drug Release. Adv. Drug Deliv. Rev. 2023;203:115109. doi: 10.1016/j.addr.2023.115109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2023.115109</ArticleId><ArticleId IdType="pubmed">39492421</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Z., Yu J., Quek Y.J., Bai B., Li X., Shou Y., Myint B., Xu C., Tay A. Design Principles of Microneedles for Drug Delivery and Sampling Applications. Mater. Today. 2023;63:137&#x2013;169. doi: 10.1016/j.mattod.2022.10.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mattod.2022.10.025</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B.Z., Yang Y., Wang B.B., Ashfaq M., Guo X.D. Self-Implanted Tiny Needles as Alternative to Traditional Parenteral Administrations for Controlled Transdermal Drug Delivery. Int. J. Pharm. 2019;556:338&#x2013;348. doi: 10.1016/j.ijpharm.2018.12.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2018.12.019</ArticleId><ArticleId IdType="pubmed">30553955</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J., Liu X., Fu Y., Song Y. Recent Advances of Microneedles for Biomedical Applications: Drug Delivery and Beyond. Acta Pharm. Sin. B. 2019;9:469&#x2013;483. doi: 10.1016/j.apsb.2019.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2019.03.007</ArticleId><ArticleId IdType="pmc">PMC6543086</ArticleId><ArticleId IdType="pubmed">31193810</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh P., Carrier A., Chen Y., Lin S., Wang J., Cui S., Zhang X. Polymeric Microneedles for Controlled Transdermal Drug Delivery. J. Control. Release. 2019;315:97&#x2013;113. doi: 10.1016/j.jconrel.2019.10.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2019.10.022</ArticleId><ArticleId IdType="pubmed">31644938</ArticleId></ArticleIdList></Reference><Reference><Citation>Senapati S., Mahanta A.K., Kumar S., Maiti P. Controlled Drug Delivery Vehicles for Cancer Treatment and Their Performance. Signal Transduct. Target. Ther. 2018;3:7. doi: 10.1038/s41392-017-0004-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-017-0004-3</ArticleId><ArticleId IdType="pmc">PMC5854578</ArticleId><ArticleId IdType="pubmed">29560283</ArticleId></ArticleIdList></Reference><Reference><Citation>Park K. Controlled Drug Delivery Systems: Past Forward and Future Back. J. Control. Release. 2014;190:3&#x2013;8. doi: 10.1016/j.jconrel.2014.03.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2014.03.054</ArticleId><ArticleId IdType="pmc">PMC4142099</ArticleId><ArticleId IdType="pubmed">24794901</ArticleId></ArticleIdList></Reference><Reference><Citation>Petlin D.G., Tverdokhlebov S.I., Anissimov Y.G. Plasma Treatment as an Efficient Tool for Controlled Drug Release from Polymeric Materials: A Review. J. Control. Release. 2017;266:57&#x2013;74. doi: 10.1016/j.jconrel.2017.09.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2017.09.023</ArticleId><ArticleId IdType="pubmed">28935595</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B.Z., Zhang L.Q., Xia Y.Y., Zhang X.P., Guo X.D. A Basal-Bolus Insulin Regimen Integrated Microneedle Patch for Intraday Postprandial Glucose Control. Sci. Adv. 2020;6:eaba7260. doi: 10.1126/sciadv.aba7260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aba7260</ArticleId><ArticleId IdType="pmc">PMC7439566</ArticleId><ArticleId IdType="pubmed">32832606</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T., Chen M., Fu J., Sun Y., Lu C., Quan G., Pan X., Wu C. Recent Advances in Microneedles-Mediated Transdermal Delivery of Protein and Peptide Drugs. Acta Pharm. Sin. B. 2021;11:2326&#x2013;2343. doi: 10.1016/j.apsb.2021.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2021.03.003</ArticleId><ArticleId IdType="pmc">PMC8424228</ArticleId><ArticleId IdType="pubmed">34522590</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganeson K., Alias A.H., Murugaiyah V., Amirul A.-A.A., Ramakrishna S., Vigneswari S. Microneedles for Efficient and Precise Drug Delivery in Cancer Therapy. Pharmaceutics. 2023;15:744. doi: 10.3390/pharmaceutics15030744.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics15030744</ArticleId><ArticleId IdType="pmc">PMC10057903</ArticleId><ArticleId IdType="pubmed">36986606</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y., Park J., Prausnitz M.R. Microneedles for Drug and Vaccine Delivery. Adv. Drug Deliv. Rev. 2012;64:1547&#x2013;1568. doi: 10.1016/j.addr.2012.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2012.04.005</ArticleId><ArticleId IdType="pmc">PMC3419303</ArticleId><ArticleId IdType="pubmed">22575858</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin W., Quan G., Sun Y., Chen M., Yang P., Feng D., Wen T., Hu X., Pan X., Wu C. Dissolving Microneedles with Spatiotemporally Controlled Pulsatile Release Nanosystem for Synergistic Chemo-Photothermal Therapy of Melanoma. Theranostics. 2020;10:8179&#x2013;8196. doi: 10.7150/thno.44194.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.44194</ArticleId><ArticleId IdType="pmc">PMC7381723</ArticleId><ArticleId IdType="pubmed">32724465</ArticleId></ArticleIdList></Reference><Reference><Citation>Dangol M., Yang H., Li C.G., Lahiji S.F., Kim S., Ma Y., Jung H. Innovative Polymeric System (IPS) for Solvent-Free Lipophilic Drug Transdermal Delivery via Dissolving Microneedles. J. Control. Release. 2016;223:118&#x2013;125. doi: 10.1016/j.jconrel.2015.12.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2015.12.038</ArticleId><ArticleId IdType="pubmed">26732554</ArticleId></ArticleIdList></Reference><Reference><Citation>Tekko I.A., Permana A.D., Vora L., Hatahet T., McCarthy H.O., Donnelly R.F. Localised and Sustained Intradermal Delivery of Methotrexate Using Nanocrystal-Loaded Microneedle Arrays: Potential for Enhanced Treatment of Psoriasis. Eur. J. Pharm. Sci. 2020;152:105469. doi: 10.1016/j.ejps.2020.105469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2020.105469</ArticleId><ArticleId IdType="pmc">PMC7417809</ArticleId><ArticleId IdType="pubmed">32679177</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao G., Quan G., Lin S., Peng T., Wang Q., Ran H., Chen H., Zhang Q., Wang L., Pan X., et al. Novel Dissolving Microneedles for Enhanced Transdermal Delivery of Levonorgestrel: In Vitro and in Vivo Characterization. Int. J. Pharm. 2017;534:378&#x2013;386. doi: 10.1016/j.ijpharm.2017.10.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2017.10.035</ArticleId><ArticleId IdType="pubmed">29051119</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin S., Quan G., Hou A., Yang P., Peng T., Gu Y., Qin W., Liu R., Ma X., Pan X., et al. Strategy for Hypertrophic Scar Therapy: Improved Delivery of Triamcinolone Acetonide Using Mechanically Robust Tip-Concentrated Dissolving Microneedle Array. J. Control. Release. 2019;306:69&#x2013;82. doi: 10.1016/j.jconrel.2019.05.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2019.05.038</ArticleId><ArticleId IdType="pubmed">31145948</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpe-Zanutto F., Ferreira L.T., Permana A.D., Kirkby M., Paredes A.J., Vora L.K., Bonfanti A.P., Charlie-Silva I., Raposo C., Figueiredo M.C., et al. Artemether and Lumefantrine Dissolving Microneedle Patches with Improved Pharmacokinetic Performance and Antimalarial Efficacy in Mice Infected with Plasmodium Yoelii. J. Control. Release. 2021;333:298&#x2013;315. doi: 10.1016/j.jconrel.2021.03.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2021.03.036</ArticleId><ArticleId IdType="pubmed">33794272</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan H., Ma F., Huang Y., Zhang J., Jiang X., Qian Y. Application of Composite Dissolving Microneedles with High Drug Loading Ratio for Rapid Local Anesthesia. Eur. J. Pharm. Sci. 2018;121:330&#x2013;337. doi: 10.1016/j.ejps.2018.06.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2018.06.014</ArticleId><ArticleId IdType="pubmed">29908904</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaric M., Lyubomska O., Touzelet O., Poux C., Al-Zahrani S., Fay F., Wallace L., Terhorst D., Malissen B., Henri S., et al. Skin Dendritic Cell Targeting via Microneedle Arrays Laden with Antigen-Encapsulated Poly-d, l-Lactide-Co-Glycolide Nanoparticles Induces Efficient Antitumor and Antiviral Immune Responses. ACS Nano. 2013;7:2042&#x2013;2055. doi: 10.1021/nn304235j.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/nn304235j</ArticleId><ArticleId IdType="pmc">PMC3936823</ArticleId><ArticleId IdType="pubmed">23373658</ArticleId></ArticleIdList></Reference><Reference><Citation>Vora L.K., Donnelly R.F., Larra&#xf1;eta E., Gonz&#xe1;lez-V&#xe1;zquez P., Thakur R.R.S., Vavia P.R. Novel Bilayer Dissolving Microneedle Arrays with Concentrated PLGA Nano-Microparticles for Targeted Intradermal Delivery: Proof of Concept. J. Control. Release. 2017;265:93&#x2013;101. doi: 10.1016/j.jconrel.2017.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2017.10.005</ArticleId><ArticleId IdType="pubmed">29037785</ArticleId></ArticleIdList></Reference><Reference><Citation>Permana A.D., Tekko I.A., McCrudden M.T.C., Anjani Q.K., Ramadon D., McCarthy H.O., Donnelly R.F. Solid Lipid Nanoparticle-Based Dissolving Microneedles: A Promising Intradermal Lymph Targeting Drug Delivery System with Potential for Enhanced Treatment of Lymphatic Filariasis. J. Control. Release. 2019;316:34&#x2013;52. doi: 10.1016/j.jconrel.2019.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2019.10.004</ArticleId><ArticleId IdType="pubmed">31655132</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan X., She J., Lin D., Xu Y., Li X., Yang W., Lui V.W.Y., Jin L., Xie X., Su Y. Microneedle-Mediated Delivery of Lipid-Coated Cisplatin Nanoparticles for Efficient and Safe Cancer Therapy. ACS Appl. Mater. Interfaces. 2018;10:33060&#x2013;33069. doi: 10.1021/acsami.8b12926.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsami.8b12926</ArticleId><ArticleId IdType="pubmed">30204401</ArticleId></ArticleIdList></Reference><Reference><Citation>Permana A.D., Paredes A.J., Volpe-Zanutto F., Anjani Q.K., Utomo E., Donnelly R.F. Dissolving Microneedle-Mediated Dermal Delivery of Itraconazole Nanocrystals for Improved Treatment of Cutaneous Candidiasis. Eur. J. Pharm. Biopharm. 2020;154:50&#x2013;61. doi: 10.1016/j.ejpb.2020.06.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpb.2020.06.025</ArticleId><ArticleId IdType="pubmed">32649991</ArticleId></ArticleIdList></Reference><Reference><Citation>Mc Crudden M.T.C., Larra&#xf1;eta E., Clark A., Jarrahian C., Rein-Weston A., Creelman B., Moyo Y., Lachau-Durand S., Niemeijer N., Williams P., et al. Design, Formulation, and Evaluation of Novel Dissolving Microarray Patches Containing Rilpivirine for Intravaginal Delivery. Adv. Health Mater. 2019;8:e1801510. doi: 10.1002/adhm.201801510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adhm.201801510</ArticleId><ArticleId IdType="pubmed">30838804</ArticleId></ArticleIdList></Reference><Reference><Citation>Giffen P.S., Bhuiya R., Brackenborough K., Hobbs M.J., Qian L., Burke M.D. Controlled Delivery of Dutasteride Using Dissolvable Microarrays: Initial Formulation and In Vivo Evaluation. J. Pharm. Sci. 2020;109:1303&#x2013;1311. doi: 10.1016/j.xphs.2019.11.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2019.11.012</ArticleId><ArticleId IdType="pubmed">31751565</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelghany S., Tekko I.A., Vora L., Larra&#xf1;eta E., Permana A.D., Donnelly R.F. Nanosuspension-Based Dissolving Microneedle Arrays for Intradermal Delivery of Curcumin. Pharmaceutics. 2019;11:308. doi: 10.3390/pharmaceutics11070308.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics11070308</ArticleId><ArticleId IdType="pmc">PMC6681049</ArticleId><ArticleId IdType="pubmed">31269648</ArticleId></ArticleIdList></Reference><Reference><Citation>Permana A.D., McCrudden M.T.C., Donnelly R.F. Enhanced Intradermal Delivery of Nanosuspensions of Antifilariasis Drugs Using Dissolving Microneedles: A Proof of Concept Study. Pharmaceutics. 2019;11:346. doi: 10.3390/pharmaceutics11070346.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics11070346</ArticleId><ArticleId IdType="pmc">PMC6680801</ArticleId><ArticleId IdType="pubmed">31319602</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong H.-R., Kim J.-Y., Kim S.-N., Park J.-H. Local Dermal Delivery of Cyclosporin A, a Hydrophobic and High Molecular Weight Drug, Using Dissolving Microneedles. Eur. J. Pharm. Biopharm. 2018;127:237&#x2013;243. doi: 10.1016/j.ejpb.2018.02.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpb.2018.02.014</ArticleId><ArticleId IdType="pubmed">29432892</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn H.L., Bonham L., Hughes C.M., Donnelly R.F. Design of a Dissolving Microneedle Platform for Transdermal Delivery of a Fixed-Dose Combination of Cardiovascular Drugs. J. Pharm. Sci. 2015;104:3490&#x2013;3500. doi: 10.1002/jps.24563.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jps.24563</ArticleId><ArticleId IdType="pubmed">26149914</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito Y., Murano H., Hamasaki N., Fukushima K., Takada K. Incidence of Low Bioavailability of Leuprolide Acetate after Percutaneous Administration to Rats by Dissolving Microneedles. Int. J. Pharm. 2011;407:126&#x2013;131. doi: 10.1016/j.ijpharm.2011.01.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2011.01.039</ArticleId><ArticleId IdType="pubmed">21277965</ArticleId></ArticleIdList></Reference><Reference><Citation>Jing Q., Ruan H., Li J., Wang Z., Pei L., Hu H., He Z., Wu T., Ruan S., Guo T., et al. Keratinocyte Membrane-Mediated Nanodelivery System with Dissolving Microneedles for Targeted Therapy of Skin Diseases. Biomaterials. 2021;278:121142. doi: 10.1016/j.biomaterials.2021.121142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2021.121142</ArticleId><ArticleId IdType="pubmed">34571433</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao S., Wang Y., Wang M., Yang X., Tang Y., Pang M., Wang W., Chen L., Wu C., Xu Y. Microneedles Mediated Bioinspired Lipid Nanocarriers for Targeted Treatment of Alopecia. J. Control. Release. 2021;329:1&#x2013;15. doi: 10.1016/j.jconrel.2020.11.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2020.11.038</ArticleId><ArticleId IdType="pubmed">33227337</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., Peng T., Hu W., Gao X., Chen Y., Zhang Q., Wu C., Pan X. Fully Armed Photodynamic Therapy with Spear and Shear for Topical Deep Hypertrophic Scar Treatment. J. Control. Release. 2022;343:408&#x2013;419. doi: 10.1016/j.jconrel.2022.01.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2022.01.043</ArticleId><ArticleId IdType="pubmed">35104572</ArticleId></ArticleIdList></Reference><Reference><Citation>Du H., Liu P., Zhu J., Lan J., Li Y., Zhang L., Zhu J., Tao J. Hyaluronic Acid-Based Dissolving Microneedle Patch Loaded with Methotrexate for Improved Treatment of Psoriasis. ACS Appl. Mater. Interfaces. 2019;11:43588&#x2013;43598. doi: 10.1021/acsami.9b15668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsami.9b15668</ArticleId><ArticleId IdType="pubmed">31651148</ArticleId></ArticleIdList></Reference><Reference><Citation>Dugam S., Tade R., Dhole R., Nangare S. Emerging Era of Microneedle Array for Pharmaceutical and Biomedical Applications: Recent Advances and Toxicological Perspectives. Futur. J. Pharm. Sci. 2021;7:19. doi: 10.1186/s43094-020-00176-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43094-020-00176-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardeshi S., Damiri F., Zehravi M., Joshi R., Kapare H., Prajapati M.K., Munot N., Berrada M., Giram P.S., Rojekar S., et al. Functional Thermoresponsive Hydrogel Molecule to Material Design for Biomedical Applications. Polymers. 2022;14:3126. doi: 10.3390/polym14153126.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/polym14153126</ArticleId><ArticleId IdType="pmc">PMC9371082</ArticleId><ArticleId IdType="pubmed">35956641</ArticleId></ArticleIdList></Reference><Reference><Citation>Damiri F., Rahman M.H., Zehravi M., Awaji A.A., Nasrullah M.Z., Gad H.A., Bani-Fwaz M.Z., Varma R.S., Germoush M.O., Al-Malky H.S., et al. MXene (Ti3C2Tx)-Embedded Nanocomposite Hydrogels for Biomedical Applications: A Review. Materials. 2022;15:1666. doi: 10.3390/ma15051666.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ma15051666</ArticleId><ArticleId IdType="pmc">PMC8911478</ArticleId><ArticleId IdType="pubmed">35268907</ArticleId></ArticleIdList></Reference><Reference><Citation>Podoleanu A.G. Optical Coherence Tomography. J. Microsc. 2012;247:209&#x2013;219. doi: 10.1111/j.1365-2818.2012.03619.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2818.2012.03619.x</ArticleId><ArticleId IdType="pmc">PMC3563006</ArticleId><ArticleId IdType="pubmed">22708800</ArticleId></ArticleIdList></Reference><Reference><Citation>Babalola O., Mamalis A., Lev-Tov H., Jagdeo J. Optical Coherence Tomography (OCT) of Collagen in Normal Skin and Skin Fibrosis. Arch. Dermatol. Res. 2014;306:1&#x2013;9. doi: 10.1007/s00403-013-1417-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00403-013-1417-7</ArticleId><ArticleId IdType="pmc">PMC4043183</ArticleId><ArticleId IdType="pubmed">24113905</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung J.H., Jin S.G. Microneedle for Transdermal Drug Delivery: Current Trends and Fabrication. J. Pharm. Investig. 2021;51:503&#x2013;517. doi: 10.1007/s40005-021-00512-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40005-021-00512-4</ArticleId><ArticleId IdType="pmc">PMC7931162</ArticleId><ArticleId IdType="pubmed">33686358</ArticleId></ArticleIdList></Reference><Reference><Citation>Dul M., Alali M., Ameri M., Burke M.D., Craig C.M., Creelman B.P., Dick L., Donnelly R.F., Eakins M.N., Frivold C., et al. Assessing the Risk of a Clinically Significant Infection from a Microneedle Array Patch (MAP) Product. J. Control. Release. 2023;361:236&#x2013;245. doi: 10.1016/j.jconrel.2023.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2023.07.001</ArticleId><ArticleId IdType="pubmed">37437849</ArticleId></ArticleIdList></Reference><Reference><Citation>McCrudden M.T.C., Alkilani A.Z., Courtenay A.J., McCrudden C.M., McCloskey B., Walker C., Alshraiedeh N., Lutton R.E.M., Gilmore B.F., Woolfson A.D., et al. Considerations in the Sterile Manufacture of Polymeric Microneedle Arrays. Drug Deliv. Transl. Res. 2015;5:3&#x2013;14. doi: 10.1007/s13346-014-0211-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13346-014-0211-1</ArticleId><ArticleId IdType="pubmed">25787335</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong S.-Y., Park J.-H., Lee Y.-S., Kim Y.-S., Park J.-Y., Kim S.-Y. The Current Status of Clinical Research Involving Microneedles: A Systematic Review. Pharmaceutics. 2020;12:1113. doi: 10.3390/pharmaceutics12111113.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics12111113</ArticleId><ArticleId IdType="pmc">PMC7699365</ArticleId><ArticleId IdType="pubmed">33228098</ArticleId></ArticleIdList></Reference><Reference><Citation>Li A.D.R., Plott J., Chen L., Montgomery J.S., Shih A. Needle Deflection and Tissue Sampling Length in Needle Biopsy. J. Mech. Behav. Biomed. Mater. 2020;104:103632. doi: 10.1016/j.jmbbm.2020.103632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmbbm.2020.103632</ArticleId><ArticleId IdType="pmc">PMC7078072</ArticleId><ArticleId IdType="pubmed">32174391</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellin A. Estimating the Needle Area from Geometric Measurements: Application of Different Calculation Methods to Norway Spruce. Trees&#x2014;Struct. Funct. 2000;14:215&#x2013;222. doi: 10.1007/PL00009765.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/PL00009765</ArticleId></ArticleIdList></Reference><Reference><Citation>Moffatt K., Donnelly R.F. Drug Delivery Devices and Therapeutic Systems. Elsevier; Amsterdam, The Netherlands: 2020. Microneedle Technology; pp. 345&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-819838-4.00004-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore J.Z., McLaughlin P.W., Shih A.J. Novel Needle Cutting Edge Geometry for End-Cut Biopsy. Med. Phys. 2012;39:99&#x2013;108. doi: 10.1118/1.3665253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1118/1.3665253</ArticleId><ArticleId IdType="pubmed">22225279</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan G., Warner K.S., Zhang J., Sharma S., Gale B.K. Evaluation Needle Length and Density of Microneedle Arrays in the Pretreatment of Skin for Transdermal Drug Delivery. Int. J. Pharm. 2010;391:7&#x2013;12. doi: 10.1016/j.ijpharm.2010.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2010.02.007</ArticleId><ArticleId IdType="pubmed">20188808</ArticleId></ArticleIdList></Reference><Reference><Citation>Avcil M., &#xc7;elik A. Microneedles in Drug Delivery: Progress and Challenges. Micromachines. 2021;12:1321. doi: 10.3390/mi12111321.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/mi12111321</ArticleId><ArticleId IdType="pmc">PMC8623547</ArticleId><ArticleId IdType="pubmed">34832733</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu S., Dong Z., Xu X., Bei H.-P., Yuen H.-Y., James Cheung C.-W., Wong M.-S., He Y., Zhao X. Going below and beyond the Surface: Microneedle Structure, Materials, Drugs, Fabrication, and Applications for Wound Healing and Tissue Regeneration. Bioact. Mater. 2023;27:303&#x2013;326. doi: 10.1016/j.bioactmat.2023.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bioactmat.2023.04.003</ArticleId><ArticleId IdType="pmc">PMC10140753</ArticleId><ArticleId IdType="pubmed">37122902</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill H.S., Denson D.D., Burris B.A., Prausnitz M.R. Effect of Microneedle Design on Pain in Human Volunteers. Clin. J. Pain. 2008;24:585&#x2013;594. doi: 10.1097/AJP.0b013e31816778f9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/AJP.0b013e31816778f9</ArticleId><ArticleId IdType="pmc">PMC2917250</ArticleId><ArticleId IdType="pubmed">18716497</ArticleId></ArticleIdList></Reference><Reference><Citation>Alimardani V., Abolmaali S.S., Yousefi G., Rahiminezhad Z., Abedi M., Tamaddon A., Ahadian S. Microneedle Arrays Combined with Nanomedicine Approaches for Transdermal Delivery of Therapeutics. J. Clin. Med. 2021;10:181. doi: 10.3390/jcm10020181.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10020181</ArticleId><ArticleId IdType="pmc">PMC7825522</ArticleId><ArticleId IdType="pubmed">33419118</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang D., Tang J., Schwendeman S.P., Prausnitz M.R. Effect of Surface Interactions on Microsphere Loading in Dissolving Microneedle Patches. ACS Appl. Mater. Interfaces. 2022;14:29577&#x2013;29587. doi: 10.1021/acsami.2c05795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsami.2c05795</ArticleId><ArticleId IdType="pmc">PMC9264316</ArticleId><ArticleId IdType="pubmed">35732055</ArticleId></ArticleIdList></Reference><Reference><Citation>Fakhraei Lahiji S., Jang Y., Ma Y., Dangol M., Yang H., Jang M., Jung H. Effects of Dissolving Microneedle Fabrication Parameters on the Activity of Encapsulated Lysozyme. Eur. J. Pharm. Sci. 2018;117:290&#x2013;296. doi: 10.1016/j.ejps.2018.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2018.03.003</ArticleId><ArticleId IdType="pubmed">29505815</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S., Miyazaki T., Itoh M., Matsumoto H., Moro-oka Y., Tanaka M., Miyahara Y., Suganami T., Matsumoto A. A Porous Reservoir-Backed Boronate Gel Microneedle for Efficient Skin Penetration and Sustained Glucose-Responsive Insulin Delivery. Gels. 2022;8:74. doi: 10.3390/gels8020074.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/gels8020074</ArticleId><ArticleId IdType="pmc">PMC8871697</ArticleId><ArticleId IdType="pubmed">35200456</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu D.D., Zhang X.P., Yu H.L., Liu R.X., Shen C.B., Zhang W.F., Cui Y., Guo X.D. Kinetic Stability Studies of HBV Vaccine in a Microneedle Patch. Int. J. Pharm. 2019;567:118489. doi: 10.1016/j.ijpharm.2019.118489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2019.118489</ArticleId><ArticleId IdType="pubmed">31276760</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldawood F.K., Andar A., Desai S. A Comprehensive Review of Microneedles: Types, Materials, Processes, Characterizations and Applications. Polymers. 2021;13:2815. doi: 10.3390/polym13162815.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/polym13162815</ArticleId><ArticleId IdType="pmc">PMC8400269</ArticleId><ArticleId IdType="pubmed">34451353</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Liu S., Xu J., Gao M., Qu Y., Liu Y., Yang Y., Cui X. Dissolvable Microneedles Based on Panax Notoginseng Polysaccharide for Transdermal Drug Delivery and Skin Dendritic Cell Activation. Carbohydr. Polym. 2021;268:118211. doi: 10.1016/j.carbpol.2021.118211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carbpol.2021.118211</ArticleId><ArticleId IdType="pubmed">34127215</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchiya K., Jinnin S., Yamamoto H., Uetsuji Y., Nakamachi E. Design and Development of a Biocompatible Painless Microneedle by the Ion Sputtering Deposition Method. Precis. Eng. 2010;34:461&#x2013;466. doi: 10.1016/j.precisioneng.2010.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.precisioneng.2010.01.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y.C., Grossniklaus H.E., Edelhauser H.F., Prausnitz M.R. Intrastromal Delivery of Bevacizumab Using Microneedles to Treat Corneal Neovascularization. Investig. Opthalmology Vis. Sci. 2014;55:7376. doi: 10.1167/iovs.14-15257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.14-15257</ArticleId><ArticleId IdType="pmc">PMC4231993</ArticleId><ArticleId IdType="pubmed">25212779</ArticleId></ArticleIdList></Reference><Reference><Citation>Varela-Fern&#xe1;ndez R., D&#xed;az-Tom&#xe9; V., Luaces-Rodr&#xed;guez A., Conde-Penedo A., Garc&#xed;a-Otero X., Luzardo-&#xc1;lvarez A., Fern&#xe1;ndez-Ferreiro A., Otero-Espinar F. Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations. Pharmaceutics. 2020;12:269. doi: 10.3390/pharmaceutics12030269.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics12030269</ArticleId><ArticleId IdType="pmc">PMC7151081</ArticleId><ArticleId IdType="pubmed">32188045</ArticleId></ArticleIdList></Reference><Reference><Citation>Peyman G.A., Hosseini K., Cormier M. A Minimally Invasive Jet Injector for Intravitreal and Subconjunctival Injection. Ophthalmic Surg. Lasers Imaging Retin. 2012;43:57&#x2013;62. doi: 10.3928/15428877-20111129-05.</Citation><ArticleIdList><ArticleId IdType="doi">10.3928/15428877-20111129-05</ArticleId><ArticleId IdType="pubmed">22251846</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K.Y., Fujioka J.K., Gholamian T., Zaharia M., Tran S.D. Suprachoroidal Injection: A Novel Approach for Targeted Drug Delivery. Pharmaceuticals. 2023;16:1241. doi: 10.3390/ph16091241.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph16091241</ArticleId><ArticleId IdType="pmc">PMC10535603</ArticleId><ArticleId IdType="pubmed">37765048</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y.C., Edelhauser H.F., Prausnitz M.R. Targeted Delivery of Antiglaucoma Drugs to the Supraciliary Space Using Microneedles. Investig. Opthalmology Vis. Sci. 2014;55:7387. doi: 10.1167/iovs.14-14651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.14-14651</ArticleId><ArticleId IdType="pmc">PMC4232008</ArticleId><ArticleId IdType="pubmed">25212782</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly R.F., Raghu T., Singh R., Woolfson A.D., Donnelly R.F., Raghu T., Singh R., Woolfson A.D. Microneedle-Based Drug Delivery Systems: Microfabrication, Drug Delivery, and Safety. Drug Deliv. 2010;14:187&#x2013;207. doi: 10.3109/10717541003667798.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10717541003667798</ArticleId><ArticleId IdType="pmc">PMC2906704</ArticleId><ArticleId IdType="pubmed">20297904</ArticleId></ArticleIdList></Reference><Reference><Citation>Tun K., Shurko J.F., Ryan L., Lee G.C. Age-Based Health and Economic Burden of Skin and Soft Tissue Infections in the United States, 2000 and 2012. PLoS ONE. 2018;13:e0206893. doi: 10.1371/journal.pone.0206893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0206893</ArticleId><ArticleId IdType="pmc">PMC6211756</ArticleId><ArticleId IdType="pubmed">30383858</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo J.-H., Harkins C.P., Schwardt N.H., Portillo J.A., Zimmerman M.D., Carter C.L., Hossen M.A., Peer C.J., Polley E.C., Dartois V., et al. Alterations of Human Skin Microbiome and Expansion of Antimicrobial Resistance after Systemic Antibiotics. Sci. Transl. Med. 2021;13:eabd8077. doi: 10.1126/scitranslmed.abd8077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abd8077</ArticleId><ArticleId IdType="pmc">PMC8878148</ArticleId><ArticleId IdType="pubmed">34936382</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuan-Mahmood T.-M., McCrudden M.T.C., Torrisi B.M., McAlister E., Garland M.J., Singh T.R.R., Donnelly R.F. Microneedles for Intradermal and Transdermal Drug Delivery. Eur. J. Pharm. Sci. 2013;50:623&#x2013;637. doi: 10.1016/j.ejps.2013.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2013.05.005</ArticleId><ArticleId IdType="pmc">PMC4119996</ArticleId><ArticleId IdType="pubmed">23680534</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-V&#xe1;zquez P., Larra&#xf1;eta E., McCrudden M.T.C., Jarrahian C., Rein-Weston A., Quintanar-Solares M., Zehrung D., McCarthy H., Courtenay A.J., Donnelly R.F. Transdermal Delivery of Gentamicin Using Dissolving Microneedle Arrays for Potential Treatment of Neonatal Sepsis. J. Control. Release. 2017;265:30&#x2013;40. doi: 10.1016/j.jconrel.2017.07.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2017.07.032</ArticleId><ArticleId IdType="pmc">PMC5736097</ArticleId><ArticleId IdType="pubmed">28754611</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J., Danehy R., Cai H., Ao Z., Pu M., Nusawardhana A., Rowe-Magnus D., Guo F. Microneedle Patch-Mediated Treatment of Bacterial Biofilms. ACS Appl. Mater. Interfaces. 2019;11:14640&#x2013;14646. doi: 10.1021/acsami.9b02578.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsami.9b02578</ArticleId><ArticleId IdType="pubmed">30933463</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsioris K., Raja W.K., Pritchard E.M., Panilaitis B., Kaplan D.L., Omenetto F.G. Fabrication of Silk Microneedles for Controlled-Release Drug Delivery. Adv. Funct. Mater. 2012;22:330&#x2013;335. doi: 10.1002/adfm.201102012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adfm.201102012</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaware S.A., Rokade K.A., Bala P., Kale S.N. Microneedles of Chitosan-porous Carbon Nanocomposites: Stimuli (PH and Electric Field)-initiated Drug Delivery and Toxicological Studies. J. Biomed. Mater. Res. A. 2019;107:1582&#x2013;1596. doi: 10.1002/jbm.a.36672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jbm.a.36672</ArticleId><ArticleId IdType="pubmed">30884173</ArticleId></ArticleIdList></Reference><Reference><Citation>Permana A.D., Mir M., Utomo E., Donnelly R.F. Bacterially Sensitive Nanoparticle-Based Dissolving Microneedles of Doxycycline for Enhanced Treatment of Bacterial Biofilm Skin Infection: A Proof of Concept Study. Int. J. Pharm. X. 2020;2:100047. doi: 10.1016/j.ijpx.2020.100047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpx.2020.100047</ArticleId><ArticleId IdType="pmc">PMC7168771</ArticleId><ArticleId IdType="pubmed">32322819</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Chen G., Yu Y., Sun L., Zhao Y. Bioinspired Adhesive and Antibacterial Microneedles for Versatile Transdermal Drug Delivery. Research. 2020;2020:3672120. doi: 10.34133/2020/3672120.</Citation><ArticleIdList><ArticleId IdType="doi">10.34133/2020/3672120</ArticleId><ArticleId IdType="pmc">PMC7231261</ArticleId><ArticleId IdType="pubmed">32490376</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziesmer J., Tajpara P., Hempel N., Ehrstr&#xf6;m M., Melican K., Eidsmo L., Sotiriou G.A. Vancomycin-Loaded Microneedle Arrays against Methicillin-Resistant Staphylococcus Aureus Skin Infections. Adv. Mater. Technol. 2021;6:2001307. doi: 10.1002/admt.202001307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/admt.202001307</ArticleId><ArticleId IdType="pmc">PMC8281827</ArticleId><ArticleId IdType="pubmed">34307835</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Feng P., Yu J., Yang J., Zhao J., Wang J., Shen Q., Gu Z. ROS-Responsive Microneedle Patch for Acne Vulgaris Treatment. Adv. Ther. 2018;1:1800035. doi: 10.1002/adtp.201800035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adtp.201800035</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziesmer J., Venckute Larsson J., Sotiriou G.A. Hybrid Microneedle Arrays for Antibiotic and Near-IR Photothermal Synergistic Antimicrobial Effect against Methicillin-Resistant Staphylococcus Aureus. Chem. Eng. J. 2023;462:142127. doi: 10.1016/j.cej.2023.142127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cej.2023.142127</ArticleId><ArticleId IdType="pmc">PMC7615096</ArticleId><ArticleId IdType="pubmed">37719675</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner J.G., Laabei M., Li S., Estrela P., Leese H.S. Antimicrobial Releasing Hydrogel Forming Microneedles. Biomater. Adv. 2023;151:213467. doi: 10.1016/j.bioadv.2023.213467.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bioadv.2023.213467</ArticleId><ArticleId IdType="pubmed">37236117</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatnagar S., Saju A., Cheerla K.D., Gade S.K., Garg P., Venuganti V.V.K. Corneal Delivery of Besifloxacin Using Rapidly Dissolving Polymeric Microneedles. Drug Deliv. Transl. Res. 2018;8:473&#x2013;483. doi: 10.1007/s13346-017-0470-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13346-017-0470-8</ArticleId><ArticleId IdType="pubmed">29288357</ArticleId></ArticleIdList></Reference><Reference><Citation>Shetty K., Sherje A.P. Nano Intervention in Topical Delivery of Corticosteroid for Psoriasis and Atopic Dermatitis&#x2014;A Systematic Review. J. Mater. Sci. Mater. Med. 2021;32:88. doi: 10.1007/s10856-021-06558-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10856-021-06558-y</ArticleId><ArticleId IdType="pmc">PMC8325647</ArticleId><ArticleId IdType="pubmed">34331599</ArticleId></ArticleIdList></Reference><Reference><Citation>Dey V. Misuse of Topical Corticosteroids: A Clinical Study of Adverse Effects. Indian Dermatol. Online J. 2014;5:436. doi: 10.4103/2229-5178.142486.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2229-5178.142486</ArticleId><ArticleId IdType="pmc">PMC4228636</ArticleId><ArticleId IdType="pubmed">25396124</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawud H., Abu Ammar A.A. Rapidly Dissolving Microneedles for the Delivery of Steroid-Loaded Nanoparticles Intended for the Treatment of Inflammatory Skin Diseases. Pharmaceutics. 2023;15:526. doi: 10.3390/pharmaceutics15020526.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics15020526</ArticleId><ArticleId IdType="pmc">PMC9967926</ArticleId><ArticleId IdType="pubmed">36839849</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang M., Kang B.M., Yang H., Ohn J., Kwon O., Jung H. High-Dose Steroid Dissolving Microneedle for Relieving Atopic Dermatitis. Adv. Health Mater. 2021;10:526. doi: 10.1002/adhm.202001691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adhm.202001691</ArticleId><ArticleId IdType="pubmed">33586358</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin J.U., Kim J.D., Kim H.K., Kang H.K., Joo C., Lee J.H., Jeong D.H., Song S., Chu H., Lee J.S., et al. The Use of Biodegradable Microneedle Patches to Increase Penetration of Topical Steroid for Prurigo Nodularis. Eur. J. Dermatol. 2018;28:71&#x2013;77. doi: 10.1684/ejd.2017.3164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1684/ejd.2017.3164</ArticleId><ArticleId IdType="pubmed">29521638</ArticleId></ArticleIdList></Reference><Reference><Citation>Penn J.S., Madan A., Caldwell R.B., Bartoli M., Caldwell R.W., Hartnett M.E. Vascular Endothelial Growth Factor in Eye Disease. Prog. Retin. Eye Res. 2008;27:331&#x2013;371. doi: 10.1016/j.preteyeres.2008.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2008.05.001</ArticleId><ArticleId IdType="pmc">PMC3682685</ArticleId><ArticleId IdType="pubmed">18653375</ArticleId></ArticleIdList></Reference><Reference><Citation>Rieke E.R., Amaral J., Becerra S.P., Lutz R.J. Sustained Subconjunctival Protein Delivery Using a Thermosetting Gel Delivery System. J. Ocul. Pharmacol. Ther. 2010;26:55&#x2013;64. doi: 10.1089/jop.2009.0059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jop.2009.0059</ArticleId><ArticleId IdType="pmc">PMC3096542</ArticleId><ArticleId IdType="pubmed">20148655</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyne J., Davis B., Kauffman D., Zhao N., Wang Y. Polymer Microneedle Mediated Local Aptamer Delivery for Blocking the Function of Vascular Endothelial Growth Factor. ACS Biomater. Sci. Eng. 2017;3:3395&#x2013;3403. doi: 10.1021/acsbiomaterials.7b00718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsbiomaterials.7b00718</ArticleId><ArticleId IdType="pmc">PMC5912260</ArticleId><ArticleId IdType="pubmed">29707631</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S.J., Flach A.J., Jampol L.M. Nonsteroidal Anti-Inflammatory Drugs in Ophthalmology. Surv. Ophthalmol. 2010;55:108&#x2013;133. doi: 10.1016/j.survophthal.2009.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.survophthal.2009.07.005</ArticleId><ArticleId IdType="pubmed">20159228</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker G., Huitema D., Aerts J.C.J.H. Prescriptions for Adaptive Comanagement: The Case of Flood Management in the German Rhine Basin. Ecol. Soc. 2015;20:1. doi: 10.5751/ES-07562-200301.</Citation><ArticleIdList><ArticleId IdType="doi">10.5751/ES-07562-200301</ArticleId></ArticleIdList></Reference><Reference><Citation>Garhofer G., Datlinger P., Tittl M., Geyer W., Maar N., Schmetterer L. Qualitative Assessment of Visual Impairment in Patients with Age-Related Macular Degeneration Using Standardized, Image-Based Questionnaires. Br. J. Vis. Impair. 2019;37:174&#x2013;182. doi: 10.1177/0264619619833718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0264619619833718</ArticleId></ArticleIdList></Reference><Reference><Citation>Gholap A.D., Kapare H.S., Pagar S., Kamandar P., Bhowmik D., Vishwakarma N., Raikwar S., Garkal A., Mehta T.A., Rojekar S., et al. Exploring Modified Chitosan-Based Gene Delivery Technologies for Therapeutic Advancements. Int. J. Biol. Macromol. 2024;260:129581. doi: 10.1016/j.ijbiomac.2024.129581.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2024.129581</ArticleId><ArticleId IdType="pubmed">38266848</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozyurt A., Kocak N., Akan P., Calan O., Ozturk T., Kaya M., Karahan E., Kaynak S. Comparison of Macular Pigment Optical Density in Patients with Dry and Wet Age-Related Macular Degeneration. Indian. J. Ophthalmol. 2017;65:477. doi: 10.4103/ijo.IJO_365_16.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijo.IJO_365_16</ArticleId><ArticleId IdType="pmc">PMC5508458</ArticleId><ArticleId IdType="pubmed">28643712</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta S. Age-Related Macular Degeneration. Prim. Care: Clin. Off. Pract. 2015;42:377&#x2013;391. doi: 10.1016/j.pop.2015.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pop.2015.05.009</ArticleId><ArticleId IdType="pubmed">26319344</ArticleId></ArticleIdList></Reference><Reference><Citation>Serener A., Serte S. Dry and Wet Age-Related Macular Degeneration Classification Using OCT Images and Deep Learning; Proceedings of the 2019 Scientific Meeting on Electrical-Electronics &amp; Biomedical Engineering and Computer Science (EBBT); Istanbul, Turkey. 24&#x2013;26 April 2019; pp. 1&#x2013;4.</Citation></Reference><Reference><Citation>Apte R.S. Age-Related Macular Degeneration. N. Engl. J. Med. 2021;385:539&#x2013;547. doi: 10.1056/NEJMcp2102061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcp2102061</ArticleId><ArticleId IdType="pmc">PMC9369215</ArticleId><ArticleId IdType="pubmed">34347954</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans J.R., Lawrenson J.G. Antioxidant Vitamin and Mineral Supplements for Slowing the Progression of Age-Related Macular Degeneration. Cochrane Database Syst. Rev. 2023;2023:CD000254. doi: 10.1002/14651858.CD000254.pub5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD000254.pub5</ArticleId><ArticleId IdType="pmc">PMC10498493</ArticleId><ArticleId IdType="pubmed">37702300</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramin S., Soheilian M., Habibi G., Ghazavi R., Gharebaghi R., Heidary F. Age-Related Macular Degeneration: A Scientometric Analysis. Med. Hypothesis Discov. Innov. Ophthalmol. 2015;4:39&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4458325</ArticleId><ArticleId IdType="pubmed">26060829</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley J., Ju M., Robinson G.S. Combination Therapy for the Treatment of Ocular Neovascularization. Angiogenesis. 2007;10:141&#x2013;148. doi: 10.1007/s10456-007-9069-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10456-007-9069-x</ArticleId><ArticleId IdType="pubmed">17372853</ArticleId></ArticleIdList></Reference><Reference><Citation>Cougnard-Gr&#xe9;goire A., Delyfer M.-N., Korobelnik J.-F., Rougier M.-B., Malet F., Le Goff M., Dartigues J.-F., Colin J., Barberger-Gateau P., Delcourt C. Long-Term Blood Pressure and Age-Related Macular Degeneration: The ALIENOR Study. Investig. Opthalmology Vis. Sci. 2013;54:1905. doi: 10.1167/iovs.12-10192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.12-10192</ArticleId><ArticleId IdType="pubmed">23404120</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos T., Barber R.M., Bell B., Bertozzi-Villa A., Biryukov S., Bolliger I., Charlson F., Davis A., Degenhardt L., Dicker D., et al. Global, Regional, and National Incidence, Prevalence, and Years Lived with Disability for 301 Acute and Chronic Diseases and Injuries in 188 Countries, 1990&#x2013;2013: A Systematic Analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:743&#x2013;800. doi: 10.1016/S0140-6736(15)60692-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(15)60692-4</ArticleId><ArticleId IdType="pmc">PMC4561509</ArticleId><ArticleId IdType="pubmed">26063472</ArticleId></ArticleIdList></Reference><Reference><Citation>Maller J., George S., Purcell S., Fagerness J., Altshuler D., Daly M.J., Seddon J.M. Common Variation in Three Genes, Including a Noncoding Variant in CFH, Strongly Influences Risk of Age-Related Macular Degeneration. Nat. Genet. 2006;38:1055&#x2013;1059. doi: 10.1038/ng1873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1873</ArticleId><ArticleId IdType="pubmed">16936732</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham J. Recognizing Age-Related Macular Degeneration in Primary Care. J. Am. Acad. Physician Assist. 2017;30:18&#x2013;22. doi: 10.1097/01.JAA.0000512227.85313.05.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.JAA.0000512227.85313.05</ArticleId><ArticleId IdType="pubmed">28151737</ArticleId></ArticleIdList></Reference><Reference><Citation>Thornton J., Edwards R., Mitchell P., Harrison R.A., Buchan I., Kelly S.P. Smoking and Age-Related Macular Degeneration: A Review of Association. Eye. 2005;19:935&#x2013;944. doi: 10.1038/sj.eye.6701978.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.eye.6701978</ArticleId><ArticleId IdType="pubmed">16151432</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarwar S., Clearfield E., Soliman M.K., Sadiq M.A., Baldwin A.J., Hanout M., Agarwal A., Sepah Y.J., Do D.V., Nguyen Q.D. Aflibercept for Neovascular Age-Related Macular Degeneration. Cochrane Database Syst. Rev. 2016;2016:CD011346. doi: 10.1002/14651858.CD011346.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD011346.pub2</ArticleId><ArticleId IdType="pmc">PMC5030844</ArticleId><ArticleId IdType="pubmed">26857947</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jong E.K., Geerlings M.J., den Hollander A.I. Genetics and Genomics of Eye Disease. Elsevier; Amsterdam, The Netherlands: 2020. Age-Related Macular Degeneration; pp. 155&#x2013;180.</Citation></Reference><Reference><Citation>Ghasemi Falavarjani K., Nguyen Q.D. Adverse Events and Complications Associated with Intravitreal Injection of Anti-VEGF Agents: A Review of Literature. Eye. 2013;27:787&#x2013;794. doi: 10.1038/eye.2013.107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/eye.2013.107</ArticleId><ArticleId IdType="pmc">PMC3709385</ArticleId><ArticleId IdType="pubmed">23722722</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratnapriya R., Chew E.Y. Age-related Macular Degeneration&#x2014;Clinical Review and Genetics Update. Clin. Genet. 2013;84:160&#x2013;166. doi: 10.1111/cge.12206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cge.12206</ArticleId><ArticleId IdType="pmc">PMC3732788</ArticleId><ArticleId IdType="pubmed">23713713</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding X., Patel M., Chan C.-C. Molecular Pathology of Age-Related Macular Degeneration. Prog. Retin. Eye Res. 2009;28:1&#x2013;18. doi: 10.1016/j.preteyeres.2008.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2008.10.001</ArticleId><ArticleId IdType="pmc">PMC2715284</ArticleId><ArticleId IdType="pubmed">19026761</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavakoli S., Peynshaert K., Lajunen T., Devoldere J., del Amo E.M., Ruponen M., De Smedt S.C., Remaut K., Urtti A. Ocular Barriers to Retinal Delivery of Intravitreal Liposomes: Impact of Vitreoretinal Interface. J. Control. Release. 2020;328:952&#x2013;961. doi: 10.1016/j.jconrel.2020.10.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2020.10.028</ArticleId><ArticleId IdType="pubmed">33091527</ArticleId></ArticleIdList></Reference><Reference><Citation>van Lookeren Campagne M., LeCouter J., Yaspan B.L., Ye W. Mechanisms of Age-related Macular Degeneration and Therapeutic Opportunities. J. Pathol. 2014;232:151&#x2013;164. doi: 10.1002/path.4266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.4266</ArticleId><ArticleId IdType="pubmed">24105633</ArticleId></ArticleIdList></Reference><Reference><Citation>Amer M., Chen R.K. Hydrogel-Forming Microneedle Arrays for Sustained and Controlled Ocular Drug Delivery. J. Eng. Sci. Med. Diagn. Ther. 2020;3:041003. doi: 10.1115/1.4048481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1115/1.4048481</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales-Canton V., Fromow-Guerra J., Salinas Longoria S., Romero Vera R., Widmann M., Patel S., Yerxa B. Suprachoroidal Microinjection of Bevacizumab Is Well Tolerated in Human Patients. Investig. Ophthalmol. Vis. Sci. 2013;54:3299.</Citation></Reference><Reference><Citation>Klein R. Prevalence of Age-Related Macular Degeneration in the US Population. Arch. Ophthalmol. 2011;129:75. doi: 10.1001/archophthalmol.2010.318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archophthalmol.2010.318</ArticleId><ArticleId IdType="pubmed">21220632</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoub T., Patel N. Age-Related Macular Degeneration. J. R. Soc. Med. 2009;102:56&#x2013;61. doi: 10.1258/jrsm.2009.080298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1258/jrsm.2009.080298</ArticleId><ArticleId IdType="pmc">PMC2642874</ArticleId><ArticleId IdType="pubmed">19208869</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Quintanilla L., Luaces-Rodr&#xed;guez A., Gil-Mart&#xed;nez M., Mondelo-Garc&#xed;a C., Maro&#xf1;as O., Mangas-Sanjuan V., Gonz&#xe1;lez-Barcia M., Zarra-Ferro I., Aguiar P., Otero-Espinar F.J., et al. Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration. Pharmaceutics. 2019;11:365. doi: 10.3390/pharmaceutics11080365.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics11080365</ArticleId><ArticleId IdType="pmc">PMC6723750</ArticleId><ArticleId IdType="pubmed">31370346</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakravarthy U., Wong T.Y., Fletcher A., Piault E., Evans C., Zlateva G., Buggage R., Pleil A., Mitchell P. Clinical Risk Factors for Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis. BMC Ophthalmol. 2010;10:31. doi: 10.1186/1471-2415-10-31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2415-10-31</ArticleId><ArticleId IdType="pmc">PMC3009619</ArticleId><ArticleId IdType="pubmed">21144031</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhary S., Zaveri J., Becker N. Proliferative Diabetic Retinopathy (PDR) Disease-a-Month. 2021;67:101140. doi: 10.1016/j.disamonth.2021.101140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.disamonth.2021.101140</ArticleId><ArticleId IdType="pubmed">33546872</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong D.S., Aiello L., Gardner T.W., King G.L., Blankenship G., Cavallerano J.D., Ferris F.L., Klein R. Diabetic Retinopathy. Diabetes Care. 2003;26:226&#x2013;229. doi: 10.2337/diacare.26.1.226.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diacare.26.1.226</ArticleId><ArticleId IdType="pubmed">12502685</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferris F.L. How Effective Are Treatments for Diabetic Retinopathy? JAMA J. Am. Med. Assoc. 1993;269:1290. doi: 10.1001/jama.1993.03500100088034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1993.03500100088034</ArticleId><ArticleId IdType="pubmed">8437309</ArticleId></ArticleIdList></Reference><Reference><Citation>Stitt A.W., Curtis T.M., Chen M., Medina R.J., McKay G.J., Jenkins A., Gardiner T.A., Lyons T.J., Hammes H.-P., Sim&#xf3; R., et al. The Progress in Understanding and Treatment of Diabetic Retinopathy. Prog. Retin. Eye Res. 2016;51:156&#x2013;186. doi: 10.1016/j.preteyeres.2015.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2015.08.001</ArticleId><ArticleId IdType="pubmed">26297071</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiello L.M. Perspectives on Diabetic Retinopathy. Am. J. Ophthalmol. 2003;136:122&#x2013;135. doi: 10.1016/S0002-9394(03)00219-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9394(03)00219-8</ArticleId><ArticleId IdType="pubmed">12834680</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim&#xf3; R., Sundstrom J.M., Antonetti D.A. Ocular Anti-VEGF Therapy for Diabetic Retinopathy: The Role of VEGF in the Pathogenesis of Diabetic Retinopathy. Diabetes Care. 2014;37:893&#x2013;899. doi: 10.2337/dc13-2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc13-2002</ArticleId><ArticleId IdType="pubmed">24652720</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferris F.L., Davis M.D., Aiello L.M. Treatment of Diabetic Retinopathy. N. Engl. J. Med. 1999;341:667&#x2013;678. doi: 10.1056/NEJM199908263410907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199908263410907</ArticleId><ArticleId IdType="pubmed">10460819</ArticleId></ArticleIdList></Reference><Reference><Citation>Osaadon P., Fagan X.J., Lifshitz T., Levy J. A Review of Anti-VEGF Agents for Proliferative Diabetic Retinopathy. Eye. 2014;28:510&#x2013;520. doi: 10.1038/eye.2014.13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/eye.2014.13</ArticleId><ArticleId IdType="pmc">PMC4017101</ArticleId><ArticleId IdType="pubmed">24525867</ArticleId></ArticleIdList></Reference><Reference><Citation>Duh E.J., Sun J.K., Stitt A.W. Diabetic Retinopathy: Current Understanding, Mechanisms, and Treatment Strategies. JCI Insight. 2017;2:e93751. doi: 10.1172/jci.insight.93751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.93751</ArticleId><ArticleId IdType="pmc">PMC5518557</ArticleId><ArticleId IdType="pubmed">28724805</ArticleId></ArticleIdList></Reference><Reference><Citation>Pieramici D.J., Rabena M.D. Anti-VEGF Therapy: Comparison of Current and Future Agents. Eye. 2008;22:1330&#x2013;1336. doi: 10.1038/eye.2008.88.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/eye.2008.88</ArticleId><ArticleId IdType="pubmed">18497829</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh S., Khurana R.N., Shah M., Henry C.R., Wang R.C., Kissner J.M., Ciulla T.A., Noronha G. Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis. Ophthalmology. 2020;127:948&#x2013;955. doi: 10.1016/j.ophtha.2020.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2020.01.006</ArticleId><ArticleId IdType="pubmed">32173113</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy G., Galigama R.D., Thorat V.S., Garg P., Venuganti V.V.K. Microneedle Ocular Patch: Fabrication, Characterization, and Ex-Vivo Evaluation Using Pilocarpine as Model Drug. Drug Dev. Ind. Pharm. 2020;46:1114&#x2013;1122. doi: 10.1080/03639045.2020.1776317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03639045.2020.1776317</ArticleId><ArticleId IdType="pubmed">32468863</ArticleId></ArticleIdList></Reference><Reference><Citation>Khandan O., Kahook M.Y., Rao M.P. Fenestrated Microneedles for Ocular Drug Delivery. Sens. Actuators B Chem. 2016;223:15&#x2013;23. doi: 10.1016/j.snb.2015.09.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.snb.2015.09.071</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadonosono K., Yamane S., Arakawa A., Inoue M., Yamakawa T., Uchio E., Yanagi Y., Amano S. Endovascular Cannulation With a Microneedle for Central Retinal Vein Occlusion. JAMA Ophthalmol. 2013;131:783. doi: 10.1001/jamaophthalmol.2013.2585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2013.2585</ArticleId><ArticleId IdType="pubmed">23764703</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronday M.J.H., Stilma J.S., Barbe R.F., McElroy W.J., Luyendijk L., Kolk A.H.J., Bakker M., Kijlstra A., Rothova A. Aetiology of Uveitis in Sierra Leone, West Africa. Br. J. Ophthalmol. 1996;80:956&#x2013;961. doi: 10.1136/bjo.80.11.956.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjo.80.11.956</ArticleId><ArticleId IdType="pmc">PMC505671</ArticleId><ArticleId IdType="pubmed">8976721</ArticleId></ArticleIdList></Reference><Reference><Citation>de Smet M.D., Taylor S.R.J., Bodaghi B., Miserocchi E., Murray P.I., Pleyer U., Zierhut M., Barisani-Asenbauer T., LeHoang P., Lightman S. Understanding Uveitis: The Impact of Research on Visual Outcomes. Prog. Retin. Eye Res. 2011;30:452&#x2013;470. doi: 10.1016/j.preteyeres.2011.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2011.06.005</ArticleId><ArticleId IdType="pubmed">21807112</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q. Retinitis Pigmentosa. Asia-Pac. J. Ophthalmol. 2016;5:265&#x2013;271. doi: 10.1097/APO.0000000000000227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/APO.0000000000000227</ArticleId><ArticleId IdType="pubmed">27488069</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalkara D., Goureau O., Marazova K., Sahel J.-A. Let There Be Light: Gene and Cell Therapy for Blindness. Hum. Gene Ther. 2016;27:134&#x2013;147. doi: 10.1089/hum.2015.147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2015.147</ArticleId><ArticleId IdType="pmc">PMC4779297</ArticleId><ArticleId IdType="pubmed">26751519</ArticleId></ArticleIdList></Reference><Reference><Citation>Buch P., MacLaren R., Ali R. Neuroprotective Gene Therapy for the Treatment of Inherited Retinal Degeneration. Curr. Gene Ther. 2007;7:434&#x2013;445. doi: 10.2174/156652307782793531.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156652307782793531</ArticleId><ArticleId IdType="pubmed">18045103</ArticleId></ArticleIdList></Reference><Reference><Citation>Azari A.A., Arabi A. Conjunctivitis: A Systematic Review. J. Ophthalmic Vis. Res. 2020;15:372&#x2013;395. doi: 10.18502/jovr.v15i3.7456.</Citation><ArticleIdList><ArticleId IdType="doi">10.18502/jovr.v15i3.7456</ArticleId><ArticleId IdType="pmc">PMC7431717</ArticleId><ArticleId IdType="pubmed">32864068</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel A. Ocular Drug Delivery Systems: An Overview. World J. Pharmacol. 2013;2:47. doi: 10.5497/wjp.v2.i2.47.</Citation><ArticleIdList><ArticleId IdType="doi">10.5497/wjp.v2.i2.47</ArticleId><ArticleId IdType="pmc">PMC4289909</ArticleId><ArticleId IdType="pubmed">25590022</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharif Z., Sharif W. Corneal Neovascularization: Updates on Pathophysiology, Investigations &amp; Management. Rom. J. Ophthalmol. 2019;63:15&#x2013;22. doi: 10.22336/rjo.2019.4.</Citation><ArticleIdList><ArticleId IdType="doi">10.22336/rjo.2019.4</ArticleId><ArticleId IdType="pmc">PMC6531773</ArticleId><ArticleId IdType="pubmed">31198893</ArticleId></ArticleIdList></Reference><Reference><Citation>Irimia T., Ghica M., Popa L., Anu&#x163;a V., Arsene A.-L., Dinu-P&#xee;rvu C.-E. Strategies for Improving Ocular Drug Bioavailability and Corneal Wound Healing with Chitosan-Based Delivery Systems. Polymers. 2018;10:1221. doi: 10.3390/polym10111221.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/polym10111221</ArticleId><ArticleId IdType="pmc">PMC6290606</ArticleId><ArticleId IdType="pubmed">30961146</ArticleId></ArticleIdList></Reference><Reference><Citation>Clearside Biomedical, Inc . Suprachoroidal Injection of CLS-TA in Subjects with Macular Edema Associated with Non-Infectious Uveitis (PEACHTREE) Clearside Biomedical, Inc.; Alpharetta, GA, USA: 2019.</Citation></Reference><Reference><Citation>Lampen S.I., Khurana R.N., Brown D.M., Wykoff C.C. Suprachoroidal Space Alterations after Delivery of Triamcinolone Acetonide: Post-Hoc Analysis of the Phase 1/2 HULK Study of Patients with Diabetic Macular Edema. Investig. Ophthalmol. Vis. Sci. 2018;59:1096.</Citation><ArticleIdList><ArticleId IdType="pubmed">30222804</ArticleId></ArticleIdList></Reference><Reference><Citation>Zakaria Y.G., Salman A.G., Said A., Abdelatif M.K. Suprachoroidal versus Intravitreal Triamcinolone Acetonide for the Treatment of Diabetic Macular Edema. Clin. Ophthalmol. 2022;16:733&#x2013;746. doi: 10.2147/OPTH.S351853.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OPTH.S351853</ArticleId><ArticleId IdType="pmc">PMC8923681</ArticleId><ArticleId IdType="pubmed">35300032</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein D.A., Do D., Noronha G., Kissner J.M., Srivastava S.K., Nguyen Q.D. Suprachoroidal Corticosteroid Administration: A Novel Route for Local Treatment of Noninfectious Uveitis. Transl. Vis. Sci. Technol. 2016;5:14. doi: 10.1167/tvst.5.6.14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/tvst.5.6.14</ArticleId><ArticleId IdType="pmc">PMC5156441</ArticleId><ArticleId IdType="pubmed">27980877</ArticleId></ArticleIdList></Reference><Reference><Citation>Willekens K., Gijbels A., Smits J., Schoevaerdts L., Blanckaert J., Feyen J.H.M., Reynaerts D., Stalmans P. Phase I Trial on Robot Assisted Retinal Vein Cannulation with Ocriplasmin Infusion for Central Retinal Vein Occlusion. Acta Ophthalmol. 2021;99:90&#x2013;96. doi: 10.1111/aos.14480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aos.14480</ArticleId><ArticleId IdType="pubmed">32701225</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas J., Kim L., Albini T., Yeh S. Triamcinolone Acetonide Injectable Suspension for Suprachoroidal Use in the Treatment of Macular Edema Associated with Uveitis. Expert. Rev. Ophthalmol. 2022;17:165&#x2013;173. doi: 10.1080/17469899.2022.2114456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17469899.2022.2114456</ArticleId><ArticleId IdType="pmc">PMC9438525</ArticleId><ArticleId IdType="pubmed">36060305</ArticleId></ArticleIdList></Reference><Reference><Citation>Boote C., Sigal I.A., Grytz R., Hua Y., Nguyen T.D., Girard M.J.A. Scleral Structure and Biomechanics. Prog. Retin. Eye Res. 2020;74:100773. doi: 10.1016/j.preteyeres.2019.100773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2019.100773</ArticleId><ArticleId IdType="pmc">PMC7187923</ArticleId><ArticleId IdType="pubmed">31412277</ArticleId></ArticleIdList></Reference><Reference><Citation>McClements D.J. Encapsulation, Protection, and Delivery of Bioactive Proteins and Peptides Using Nanoparticle and Microparticle Systems: A Review. Adv. Colloid. Interface Sci. 2018;253:1&#x2013;22. doi: 10.1016/j.cis.2018.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cis.2018.02.002</ArticleId><ArticleId IdType="pubmed">29478671</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez A., Lam H. Microneedle Delivery of Ophthalmic Macromolecules. University of California San Diego; San Diego, CA, USA: 2014. pp. 1&#x2013;19.</Citation></Reference><Reference><Citation>Zhao Y., Voyer J., Li Y., Kang X., Chen X. Laser Microporation Facilitates Topical Drug Delivery: A Comprehensive Review about Preclinical Development and Clinical Application. Expert. Opin. Drug Deliv. 2023;20:31&#x2013;54. doi: 10.1080/17425247.2023.2152002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17425247.2023.2152002</ArticleId><ArticleId IdType="pmc">PMC9825102</ArticleId><ArticleId IdType="pubmed">36519356</ArticleId></ArticleIdList></Reference><Reference><Citation>Salahshoori I., Golriz M., Nobre M.A.L., Mahdavi S., Eshaghi Malekshah R., Javdani-Mallak A., Namayandeh Jorabchi M., Ali Khonakdar H., Wang Q., Mohammadi A.H., et al. Simulation-Based Approaches for Drug Delivery Systems: Navigating Advancements, Opportunities, and Challenges. J. Mol. Liq. 2024;395:123888. doi: 10.1016/j.molliq.2023.123888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molliq.2023.123888</ArticleId></ArticleIdList></Reference><Reference><Citation>Truckenm&#xfc;ller R., Giselbrecht S., Rivron N., Gottwald E., Saile V., van den Berg A., Wessling M., van Blitterswijk C. Thermoforming of Film-Based Biomedical Microdevices. Adv. Mater. 2011;23:1311&#x2013;1329. doi: 10.1002/adma.201003538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adma.201003538</ArticleId><ArticleId IdType="pubmed">21400590</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly R.F., Woolfson A.D. Patient Safety and beyond: What Should We Expect from Microneedle Arrays in the Transdermal Delivery Arena? Ther. Deliv. 2014;5:653&#x2013;662. doi: 10.4155/tde.14.29.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/tde.14.29</ArticleId><ArticleId IdType="pubmed">25090279</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S.-C. Factors Affecting Therapeutic Compliance: A Review from the Patient&#x2019;s Perspective. Ther. Clin. Risk Manag. 2008;4:269&#x2013;286. doi: 10.2147/TCRM.S1458.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/TCRM.S1458</ArticleId><ArticleId IdType="pmc">PMC2503662</ArticleId><ArticleId IdType="pubmed">18728716</ArticleId></ArticleIdList></Reference><Reference><Citation>Gholap A.D., Rojekar S., Kapare H.S., Vishwakarma N., Raikwar S., Garkal A., Mehta T.A., Jadhav H., Prajapati M.K., Annapure U. Chitosan Scaffolds: Expanding Horizons in Biomedical Applications. Carbohydr. Polym. 2024;323:121394. doi: 10.1016/j.carbpol.2023.121394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carbpol.2023.121394</ArticleId><ArticleId IdType="pubmed">37940287</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohr A., Memarzadeh K. Artificial Intelligence in Healthcare. Elsevier; Amsterdam, The Netherlands: 2020. The Rise of Artificial Intelligence in Healthcare Applications; pp. 25&#x2013;60.</Citation></Reference><Reference><Citation>Shajari S., Kuruvinashetti K., Komeili A., Sundararaj U. The Emergence of AI-Based Wearable Sensors for Digital Health Technology: A Review. Sensors. 2023;23:9498. doi: 10.3390/s23239498.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/s23239498</ArticleId><ArticleId IdType="pmc">PMC10708748</ArticleId><ArticleId IdType="pubmed">38067871</ArticleId></ArticleIdList></Reference><Reference><Citation>Horspool K. Conference Report: Out of This World&#x2014;Sound Bites from the Excipient World Conference &amp; Expo, May 13&#x2013;15, 2024.  [(accessed on 10 July 2024)];Int. J. Pharm. Excip. 2024 1:5&#x2013;9. Available online:  https://jefc.scholasticahq.com/article/120608-conference-report-out-of-this-world-sound-bites-from-the-excipient-world-conference-expo-may-13-15-2024.</Citation></Reference><Reference><Citation>Hu F., Gao Q., Liu J., Chen W., Zheng C., Bai Q., Sun N., Zhang W., Zhang Y., Lu T. Smart Microneedle Patches for Wound Healing and Management. J. Mater. Chem. B. 2023;11:2830&#x2013;2851. doi: 10.1039/D2TB02596E.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D2TB02596E</ArticleId><ArticleId IdType="pubmed">36916631</ArticleId></ArticleIdList></Reference><Reference><Citation>Papangkorn K., Prendergast E., Higuchi J.W., Brar B., Higuchi W.I. Noninvasive Ocular Drug Delivery System of Dexamethasone Sodium Phosphate in the Treatment of Experimental Uveitis Rabbit. J. Ocul. Pharmacol. Ther. 2017;33:753&#x2013;762. doi: 10.1089/jop.2017.0053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jop.2017.0053</ArticleId><ArticleId IdType="pmc">PMC5733740</ArticleId><ArticleId IdType="pubmed">29022761</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39598433</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1424-8247</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>12</Day></PubDate></JournalIssue><Title>Pharmaceuticals (Basel, Switzerland)</Title><ISOAbbreviation>Pharmaceuticals (Basel)</ISOAbbreviation></Journal><ArticleTitle>Rutin-Activated Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Attenuates Corneal and Heart Damage in Mice.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1523</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ph17111523</ELocationID><Abstract><AbstractText><b>Background:</b> Corneal degeneration is a form of progressive cell death caused by multiple factors, such as diabetic retinopathy. It is the most well-known neural degenerative disease caused by macular degeneration in the aged and those with retinitis pigmentosa. Myocardial infarction is becoming a more common burden, causing cardiomyocyte degeneration, ischemia, and heart tissue death. This study examined the preventive effects of rutin on isoproterenol (ISO)-induced oxidative damage (that is, inflammation) on rabbit corneal epithelial cells and mouse heart injuries. <b>Methods:</b> These investigations involved a cytotoxicity test, biochemical analysis, qRT-PCR, Western blotting, and mouse cardiac histopathology. <b>Results:</b> The results showed that rutin enhanced ADH7 and ALDH1A1, retinoic acid signaling components in SIRC1 rabbit corneal cell lines. The production of NO by ocular epithelial cells was significantly reduced. It reduced cTnT and cTnI, CK-MB, and LDH contents in mouse cardiac tissue. The nuclear expressions of Nrf2, Sirt, and HO-1 were all increased by rutin. Docking studies revealed a good interaction between rutin and the Keap protein, enhancing Nrf2 nuclear activity. <b>Conclusions:</b> This showed that rutin can potentially enhance ADH7 and ALDH1A1 corneal signaling components, preventing corneal degeneration and mitigating ISO-induced myocardial infarction (MI) via Keap/Nrf2 expressions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Emeka</LastName><ForeName>Promise M</ForeName><Initials>PM</Initials><Identifier Source="ORCID">0000-0003-1943-1874</Identifier><AffiliationInfo><Affiliation>Department of Pharmaceutical Science, College of Clinical Pharmacy, King Faisal University, Al Ahsa 31982, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badger-Emeka</LastName><ForeName>Lorina I</ForeName><Initials>LI</Initials><Identifier Source="ORCID">0000-0002-9201-6215</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Science, College of Medicine, King Faisal University, Al Ahsa 31982, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thirugnanasambantham</LastName><ForeName>Krishnaraj</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-5340-8806</Identifier><AffiliationInfo><Affiliation>Pondicherry Centre for Biological Science and Educational Trust, Sundararaja Nagar, Puducherry 605004, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alatawi</LastName><ForeName>Abdulaziz S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Science, College of Clinical Pharmacy, King Faisal University, Al Ahsa 31982, Saudi Arabia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>KSRG-2023-107</GrantID><Agency>King Salman Center for Disability Research</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceuticals (Basel)</MedlineTA><NlmUniqueID>101238453</NlmUniqueID><ISSNLinking>1424-8247</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antioxidants</Keyword><Keyword MajorTopicYN="N">corneal injuries</Keyword><Keyword MajorTopicYN="N">isoproterenol</Keyword><Keyword MajorTopicYN="N">nuclear factor erythroid 2-related factor</Keyword><Keyword MajorTopicYN="N">oxidative stress</Keyword><Keyword MajorTopicYN="N">reactive oxygen species</Keyword><Keyword MajorTopicYN="N">rutin</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>1</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39598433</ArticleId><ArticleId IdType="pmc">PMC11597448</ArticleId><ArticleId IdType="doi">10.3390/ph17111523</ArticleId><ArticleId IdType="pii">ph17111523</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alkatan H., Alkheraiji N., Alzahem, Corneal T. Frontiers in Ophthalmology and Ocular Imaging. IntechOpen; London, UK: 2019. Dystrophies and Degenerations.</Citation></Reference><Reference><Citation>Kumaravel S. Short Cases in Orthopaedics for PG Practical Examination. Jaypee Brothers Medical Publishers; New Delhi, India: 2013.</Citation></Reference><Reference><Citation>Tavakoli M., Kallinikos P.A., Efron N., Boulton A.J., Malik R.A. Corneal Sensitivity Is Reduced and Relates to the Severity of Neuropathy in Patients with Diabetes. Diabetes Care. 2007;30:1895&#x2013;1897. doi: 10.2337/dc07-0175.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc07-0175</ArticleId><ArticleId IdType="pubmed">17372147</ArticleId></ArticleIdList></Reference><Reference><Citation>Batliwala S., Xavier C., Liu Y., Wu H., Pang I.-H. Involvement of Nrf2 in Ocular Diseases. Oxidative Med. Cell. Longev. 2017;2017:1703810. doi: 10.1155/2017/1703810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/1703810</ArticleId><ArticleId IdType="pmc">PMC5394909</ArticleId><ArticleId IdType="pubmed">28473877</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth G.A., Mensah G.A., Johnson C.O., Addolorato G., Ammirati E., Baddour L.M., Barengo N.C., Beaton A.Z., Benjamin E.J., Benziger C.P., et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990&#x2013;2019: Update from the GBD 2019 Study. J. Am. Coll. Cardiol. 2020;76:2982&#x2013;3021. doi: 10.1016/j.jacc.2020.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.11.010</ArticleId><ArticleId IdType="pmc">PMC7755038</ArticleId><ArticleId IdType="pubmed">33309175</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaziano T.A. Reducing the Growing Burden of Cardiovascular Disease in the Developing World. Health Aff. 2007;26:13&#x2013;24. doi: 10.1377/hlthaff.26.1.13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1377/hlthaff.26.1.13</ArticleId><ArticleId IdType="pmc">PMC2365905</ArticleId><ArticleId IdType="pubmed">17211010</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed G.W., Rossi J.E., Cannon C.P. Acute myocardial infarction. Lancet. 2017;389:197&#x2013;210. doi: 10.1016/S0140-6736(16)30677-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)30677-8</ArticleId><ArticleId IdType="pubmed">27502078</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu H., Tan Y., Yang L., Dong H., Liao Y., Cao S., Fu S. Cardioprotective Efficiency of Tangeretin Against Heart Failure Induced by Isoproterenol in Rats. Int. J. Pharmacol. 2018;14:1145&#x2013;1152. doi: 10.3923/ijp.2018.1145.1152.</Citation><ArticleIdList><ArticleId IdType="doi">10.3923/ijp.2018.1145.1152</ArticleId></ArticleIdList></Reference><Reference><Citation>Aodah A.H., Devi S., Alkholifi F.K., Yusufoglu H.S., Foudah A.I., Alam A. Effects of Taraxerol on Oxidative and Inflammatory Mediators in Isoproterenol-Induced Cardiotoxicity in an Animal Model. Molecules. 2023;28:4089. doi: 10.3390/molecules28104089.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules28104089</ArticleId><ArticleId IdType="pmc">PMC10224333</ArticleId><ArticleId IdType="pubmed">37241830</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokkinaki M., Abu-Asab M., Gunawardena N., Ahern G., Javidnia M., Young J., Golestaneh N. Klotho Regulates Retinal Pigment Epithelial Functions and Protects Against Oxidative Stress. J. Neurosci. 2013;33:16346&#x2013;16359. doi: 10.1523/JNEUROSCI.0402-13.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0402-13.2013</ArticleId><ArticleId IdType="pmc">PMC3810551</ArticleId><ArticleId IdType="pubmed">24107965</ArticleId></ArticleIdList></Reference><Reference><Citation>Nahar K., Kabir F., Islam P., Rahman M., Al Mamun A., Faruk M., Rahman G.S., Reza H.M., Alam A. Cardioprotective effect of Amaranthus tricolor extract in isoprenaline induced myocardial damage in ovariectomized rats. Biomed. Pharmacother. 2018;103:1154&#x2013;1162. doi: 10.1016/j.biopha.2018.04.151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2018.04.151</ArticleId><ArticleId IdType="pubmed">29715759</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B., Lu Y., Chen Y., Cheng J. The role of Nrf2 in oxidative stress-induced endothelial injuries. J. Endocrinol. 2015;225:R83&#x2013;R99. doi: 10.1530/JOE-14-0662.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/JOE-14-0662</ArticleId><ArticleId IdType="pubmed">25918130</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu L., Lin J., Wang Q., Li C., Peng X., Fan Y., Lu C., Lin H., Niu Y., Zhu G., et al. Dimethyl itaconate protects against fungal keratitis by activating the Nrf2/HO-1 signaling pathway. Immunol. Cell Biol. 2020;98:229&#x2013;241. doi: 10.1111/imcb.12316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imcb.12316</ArticleId><ArticleId IdType="pmc">PMC7065235</ArticleId><ArticleId IdType="pubmed">31943336</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Q. Role of Nrf2 in Oxidative Stress and Toxicity. Annu. Rev. Pharmacol. Toxicol. 2013;53:401&#x2013;426. doi: 10.1146/annurev-pharmtox-011112-140320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pharmtox-011112-140320</ArticleId><ArticleId IdType="pmc">PMC4680839</ArticleId><ArticleId IdType="pubmed">23294312</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X.-F., Zhou D.-D., Xie T., Malik T.H., Lu C.-B., Li H.-J., Wang F., Shu C., Liu C., Lu C.-W., et al. Nrf2, a Potential Therapeutic Target against Oxidative Stress in Corneal Diseases. Oxid. Med. Cell. Longev. 2017;2017:2326178. doi: 10.1155/2017/2326178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/2326178</ArticleId><ArticleId IdType="pmc">PMC5676473</ArticleId><ArticleId IdType="pubmed">29209447</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganeshpurkar A., Saluja A.K. The Pharmacological Potential of Rutin. Saudi Pharm. J. 2016;25:149&#x2013;164. doi: 10.1016/j.jsps.2016.04.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsps.2016.04.025</ArticleId><ArticleId IdType="pmc">PMC5355559</ArticleId><ArticleId IdType="pubmed">28344465</ArticleId></ArticleIdList></Reference><Reference><Citation>Niture S.K., Khatri R., Jaiswal A.K. Regulation of Nrf2&#x2014;An update. Free. Radic. Biol. Med. 2014;66:36&#x2013;44. doi: 10.1016/j.freeradbiomed.2013.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2013.02.008</ArticleId><ArticleId IdType="pmc">PMC3773280</ArticleId><ArticleId IdType="pubmed">23434765</ArticleId></ArticleIdList></Reference><Reference><Citation>Karthick M., Prince P.S.M. Preventive effect of rutin, a bioflavonoid, on lipid peroxides and antioxidants in isoproterenol-induced myocardial infarction in rats. J. Pharm. Pharmacol. 2006;58:701&#x2013;707. doi: 10.1211/jpp.58.5.0016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1211/jpp.58.5.0016</ArticleId><ArticleId IdType="pubmed">16640840</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanely Mainzen Prince P., Priya S. Preventive Effects of Rutin on Lysosomal Enzymes in Isoproterenol Induced Cardio Toxic Rats: Biochemical, Histological and in Vitro Evidences. Eur. J. Pharmacol. 2010;649:229&#x2013;235. doi: 10.1016/j.ejphar.2010.08.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2010.08.054</ArticleId><ArticleId IdType="pubmed">20851115</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghorbani A. Mechanisms of antidiabetic effects of flavonoid rutin. Biomed. Pharmacother. 2017;96:305&#x2013;312. doi: 10.1016/j.biopha.2017.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2017.10.001</ArticleId><ArticleId IdType="pubmed">29017142</ArticleId></ArticleIdList></Reference><Reference><Citation>Budzynska B., Faggio C., Kruk-Slomka M., Samec D., Nabavi S.F., Sureda A., Devi K.P., Nabavi S.M. Rutin as neuroprotective agent: From bench to bedside. Curr. Med. Chem. 2019;26:5152&#x2013;5164. doi: 10.2174/0929867324666171003114154.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867324666171003114154</ArticleId><ArticleId IdType="pubmed">28971760</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Ma X., Gao C., Luo Y., Fei X., Zheng Q., Ma X., Kuai L., Li B., Wang R., et al. Rutin attenuates inflammation by downregulating AGE-RAGE signaling pathway in psoriasis: Network pharmacology analysis and experimental evidence. Int. Immunopharmacol. 2023;125:111033. doi: 10.1016/j.intimp.2023.111033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2023.111033</ArticleId><ArticleId IdType="pubmed">38149569</ArticleId></ArticleIdList></Reference><Reference><Citation>Sui C., Wu Y., Zhang R., Zhang T., Zhang Y., Xi J., Ding Y., Wen J., Hu Y. Rutin Inhibits the Progression of Osteoarthritis Through CBS-Mediated RhoA/ROCK Signaling. DNA Cell Biol. 2022;41:617&#x2013;630. doi: 10.1089/dna.2021.1182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/dna.2021.1182</ArticleId><ArticleId IdType="pubmed">35588172</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y., Jia K., Zhou Y., Chen L., Wang F., Yi X., Huang Y., Ge Y., Chen X., Liao D., et al. Rutin hydrate relieves neuroinflammation in zebrafish models: Involvement of NF-&#x3ba;B pathway as a central network. Fish. Shellfish. Immunol. 2023;141:109062. doi: 10.1016/j.fsi.2023.109062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fsi.2023.109062</ArticleId><ArticleId IdType="pubmed">37678480</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji Y., Ma Y., Ma Y., Wang Y., Zhao X., Jin D., Xu L., Ge S. Rutin prevents pyroptosis and M1 microglia via Nrf2/Mac-1/caspase-1-mediated inflammasome axis to improve POCD. Int. Immunopharmacol. 2023;127:111290. doi: 10.1016/j.intimp.2023.111290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2023.111290</ArticleId><ArticleId IdType="pubmed">38064815</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupasco T., He Z., Cassagne M., Sagnial T., Brion L., Fourni&#xe9; P., Gain P., Thuret G., Allouche M., Malecaze F., et al. Corneal epithelium in keratoconus underexpresses active NRF2 and a subset of oxidative stress-related genes. PLoS ONE. 2022;17:e0273807. doi: 10.1371/journal.pone.0273807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0273807</ArticleId><ArticleId IdType="pmc">PMC9565379</ArticleId><ArticleId IdType="pubmed">36240204</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayir Y., Cadirci E., Suleyman H., Halici Z., Keles M.S. Effects of Lacidipine, Ramipril and Valsartan on Serum BNP Levels in Acute and Chronic Periods Following Isoproterenol-Induced Myocardial Infarction in Rats. Eurasian J. Med. 2009;41:44&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4261647</ArticleId><ArticleId IdType="pubmed">25610063</ArticleId></ArticleIdList></Reference><Reference><Citation>Cejka C., Cejkova J. Oxidative Stress to the Cornea, Changes in Corneal Optical Properties, and Advances in Treatment of Corneal Oxidative Injuries. Oxidative Med. Cell. Longev. 2015;2015:591530. doi: 10.1155/2015/591530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/591530</ArticleId><ArticleId IdType="pmc">PMC4377462</ArticleId><ArticleId IdType="pubmed">25861412</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Seshadri V.D., Jiang Q. Ameliorative Effects of Ponicidin Against the Isoproterenol-induced Acute Myocardial Infarction in Rats. Pharmacogn. Mag. 2023;19:427&#x2013;438. doi: 10.1177/09731296221139010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09731296221139010</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurtul B.E., Kurtul A., Ergashev K. Is there a relationship between statin use and corneal specular microscopy and topography findings? Beyoglu Eye. J. 2021;6:280&#x2013;284. doi: 10.14744/bej.2021.28190.</Citation><ArticleIdList><ArticleId IdType="doi">10.14744/bej.2021.28190</ArticleId><ArticleId IdType="pmc">PMC8759549</ArticleId><ArticleId IdType="pubmed">35059574</ArticleId></ArticleIdList></Reference><Reference><Citation>Thirunavukarasu A.J., Ross A.C., Gilbert R.M. Vitamin A, systemic T-cells, and the eye: Focus on degenerative retinal disease. Front. Nutr. 2022;9:914457. doi: 10.3389/fnut.2022.914457.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2022.914457</ArticleId><ArticleId IdType="pmc">PMC9339908</ArticleId><ArticleId IdType="pubmed">35923205</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardag-Gorce F., Diaz A., Niihara R., Stark J., Cortez D., Lee A., Hoft R., Niihara Y. Aldehyde Dehydrogenases Expression in Corneal Epithelial Cells with Limbal Stem Cell Deficiency. Int. J. Mol. Sci. 2022;23:4032. doi: 10.3390/ijms23074032.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23074032</ArticleId><ArticleId IdType="pmc">PMC8999523</ArticleId><ArticleId IdType="pubmed">35409392</ArticleId></ArticleIdList></Reference><Reference><Citation>Juli&#xe0; P., Farr&#xe9;s J., Par&#xe9;s X. Ocular alcohol dehydrogenase in the rat: Regional distribution and kinetics of the ADH-1 isoenzyme with retinol and retinal. Exp. Eye Res. 1986;42:305&#x2013;314. doi: 10.1016/0014-4835(86)90023-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-4835(86)90023-0</ArticleId><ArticleId IdType="pubmed">2940107</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertinchant J., Robert E., Polge A., Marty-Double C., Fabbro-Peray P., Poirey S., Aya G., Juan J., Ledermann B., de la Coussaye J., et al. Comparison of the diagnostic value of cardiac troponin I and T determinations for detecting early myocardial damage and the relationship with histological findings after isoprenaline-induced cardiac injury in rats. Clin. Chim. Acta. 2000;298:13&#x2013;28. doi: 10.1016/S0009-8981(00)00223-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0009-8981(00)00223-0</ArticleId><ArticleId IdType="pubmed">10876001</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Song F., Duan L.-R., Sheng J.-J., Xie Y.-H., Yang Q., Chen Y., Dong Q.-Q., Zhang B.-L., Wang S.-W. Paeonol and danshensu combination attenuates apoptosis in myocardial infarcted rats by inhibiting oxidative stress: Roles of Nrf2/HO-1 and PI3K/Akt pathway. Sci. Rep. 2016;6:23693. doi: 10.1038/srep23693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep23693</ArticleId><ArticleId IdType="pmc">PMC4810373</ArticleId><ArticleId IdType="pubmed">27021411</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng G., Zhang J., Jia S., Feng P., Chang F., Yan L., Gupta P., Wu H. Cardioprotective Effect of Gossypin Against Myocardial Ischemic/Reperfusion in Rats via Alteration of Oxidative Stress, Inflammation and Gut Microbiota. J. Inflamm. Res. 2022;15:1637&#x2013;1651. doi: 10.2147/JIR.S348883.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S348883</ArticleId><ArticleId IdType="pmc">PMC8906873</ArticleId><ArticleId IdType="pubmed">35282267</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Q., Liu S., Sun Y., Chen C., Yang S., Lin M., Long J., Yao J., Lin Y., Yi F., et al. Targeting oxidative stress as a preventive and therapeutic approach for cardiovascular disease. J. Transl. Med. 2023;21:1&#x2013;35. doi: 10.1186/s12967-023-04361-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-023-04361-7</ArticleId><ArticleId IdType="pmc">PMC10394930</ArticleId><ArticleId IdType="pubmed">37533007</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Rejaie S.S., Aleisa A.M., Sayed-Ahmed M.M., Al-Shabanah O.A., Abuohashish H.M., Ahmed M.M., Al-Hosaini K.A., Hafez M.M. Protective effect of rutin on the antioxidant genes expression in hypercholestrolemic male Westar rat. BMC Complement. Altern. Med. 2013;13:136. doi: 10.1186/1472-6882-13-136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6882-13-136</ArticleId><ArticleId IdType="pmc">PMC3717094</ArticleId><ArticleId IdType="pubmed">23773725</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S.-S., Park H.-R., Lee K.-A. A Comparative Study of Rutin and Rutin Glycoside: Antioxidant Activity, Anti-Inflammatory Effect, Effect on Platelet Aggregation and Blood Coagulation. Antioxidants. 2021;10:1696. doi: 10.3390/antiox10111696.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10111696</ArticleId><ArticleId IdType="pmc">PMC8614652</ArticleId><ArticleId IdType="pubmed">34829567</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L., Wu D., Sang M., Xu Y., Liu Z., Wu Q. Stachydrine ameliorates isoproterenol-induced cardiac hypertrophy and fibrosis by suppressing inflammation and oxidative stress through inhibiting NF-&#x3ba;B and JAK/STAT signaling pathways in rats. Int. Immunopharmacol. 2017;48:102&#x2013;109. doi: 10.1016/j.intimp.2017.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2017.05.002</ArticleId><ArticleId IdType="pubmed">28499193</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsujimoto Y. Role of Bcl-2 family proteins in apoptosis: Apoptosomes or mitochondria? Genes. Cells. 1998;3:697&#x2013;707. doi: 10.1046/j.1365-2443.1998.00223.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2443.1998.00223.x</ArticleId><ArticleId IdType="pubmed">9990505</ArticleId></ArticleIdList></Reference><Reference><Citation>Korshunova A.Y., Blagonravov M.L., Neborak E.V., Syatkin S.P., Sklifasovskaya A.P., Semyatov S.M., Agostinelli E. BCL2-regulated apoptotic process in myocardial ischemia-reperfusion injury (Review) Int. J. Mol. Med. 2020;47:23&#x2013;36. doi: 10.3892/ijmm.2020.4781.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm.2020.4781</ArticleId><ArticleId IdType="pmc">PMC7723511</ArticleId><ArticleId IdType="pubmed">33155658</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelzaher W.Y., Ahmed S.M., Welson N.N., Alsharif K.F., Batiha G.E.-S., Labib D.A.A. Dapsone Ameliorates Isoproterenol-Induced Myocardial Infarction via Nrf2/ HO-1; TLR4/ TNF-&#x3b1; Signaling Pathways and the Suppression of Oxidative Stress, Inflammation, and Apoptosis in Rats. Front. Pharmacol. 2021;12:669679. doi: 10.3389/fphar.2021.669679.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.669679</ArticleId><ArticleId IdType="pmc">PMC8170324</ArticleId><ArticleId IdType="pubmed">34093197</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalaf H.M., Abdalla A.M., Ahmed A.F., Abdel-Aziz A.M. Role of nitric oxide in mediating the cardioprotective effect of agomelatine against isoproterenol-induced myocardial injury in rats. Naunyn-Schmiedeberg&#x2019;s Arch. Pharmacol. 2020;393:1809&#x2013;1823. doi: 10.1007/s00210-020-01860-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00210-020-01860-y</ArticleId><ArticleId IdType="pubmed">32399613</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad R., Prasad S. Histoprotective effect of rutin against cisplatin-induced toxicities in tumor-bearing mice: Rutin lessens cisplatin-induced toxicities. Hum. Exp. Toxicol. 2021;40:245&#x2013;258. doi: 10.1177/0960327120947793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0960327120947793</ArticleId><ArticleId IdType="pubmed">32787450</ArticleId></ArticleIdList></Reference><Reference><Citation>Arjumand W., Seth A., Sultana S. Rutin attenuates cisplatin induced renal inflammation and apoptosis by reducing NF&#x3ba;B, TNF-&#x3b1; and caspase-3 expression in wistar rats. Food Chem. Toxicol. 2011;49:2013&#x2013;2021. doi: 10.1016/j.fct.2011.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fct.2011.05.012</ArticleId><ArticleId IdType="pubmed">21605616</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X.-Y., Li L.-J., Dong Q.-X., Zhu J., Huang Y.-R., Hou S.-J., Yu X.-L., Liu R.-T. Rutin prevents tau pathology and neuroinflammation in a mouse model of Alzheimer&#x2019;s disease. J. Neuroinflammation. 2021;18:131. doi: 10.1186/s12974-021-02182-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-021-02182-3</ArticleId><ArticleId IdType="pmc">PMC8196535</ArticleId><ArticleId IdType="pubmed">34116706</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., He X., Lv S. Notoginsenoside-R1 ameliorates palmitic acid-induced insulin resistance and oxidative stress in HUVEC via Nrf2/ARE pathway. Food Sci. Nutr. 2023;11:7791&#x2013;7802. doi: 10.1002/fsn3.3696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/fsn3.3696</ArticleId><ArticleId IdType="pmc">PMC10724591</ArticleId><ArticleId IdType="pubmed">38107110</ArticleId></ArticleIdList></Reference><Reference><Citation>Unni S., Deshmukh P., Krishnappa G., Kommu P., Padmanabhan B. Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1. FEBS J. 2020;288:1599&#x2013;1613. doi: 10.1111/febs.15485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.15485</ArticleId><ArticleId IdType="pubmed">32672401</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Cheng Y., Liu J., Zuo J., Yan L., Thring R.W., Ba X., Qi D., Wu M., Gao Y., et al. Tauroursodeoxycholic acid functions as a critical effector mediating insulin sensitization of metformin in obese mice. Redox Biol. 2022;57:102481. doi: 10.1016/j.redox.2022.102481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2022.102481</ArticleId><ArticleId IdType="pmc">PMC9493383</ArticleId><ArticleId IdType="pubmed">36148770</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou S., Sun W., Zhang Z., Zheng Y. The Role of Nrf2-Mediated Pathway in Cardiac Remodeling and Heart Failure. Oxidative Med. Cell. Longev. 2014;2014:260429. doi: 10.1155/2014/260429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/260429</ArticleId><ArticleId IdType="pmc">PMC4102082</ArticleId><ArticleId IdType="pubmed">25101151</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones R.M., Desai C., Darby T.M., Luo L., Wolfarth A.A., Scharer C.D., Ardita C.S., Reedy A.R., Keebaugh E.S., Neish A.S. Lactobacilli Modulate Epithelial Cytoprotection through the Nrf2 Pathway. Cell Rep. 2015;12:1217&#x2013;1225. doi: 10.1016/j.celrep.2015.07.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.07.042</ArticleId><ArticleId IdType="pmc">PMC4640184</ArticleId><ArticleId IdType="pubmed">26279578</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi R., Himori N., Taguchi K., Ishikawa Y., Uesugi K., Ito M., Duncan T., Tsujikawa M., Nakazawa T., Yamamoto M., et al. The role of the Nrf2-mediated defense system in corneal epithelial wound healing. Free. Radic. Biol. Med. 2013;61:333&#x2013;342. doi: 10.1016/j.freeradbiomed.2013.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2013.04.008</ArticleId><ArticleId IdType="pubmed">23587556</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabolacci E., Tringali G., Nobile V., Duca S., Pizzoferrato M., Bottoni P., Clementi M.E. Rutin Protects Fibroblasts from UVA Radiation through Stimulation of Nrf2 Pathway. Antioxidants. 2023;12:820. doi: 10.3390/antiox12040820.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox12040820</ArticleId><ArticleId IdType="pmc">PMC10135198</ArticleId><ArticleId IdType="pubmed">37107196</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovac S., Angelova P.R., Holmstr&#xf6;m K.M., Zhang Y., Dinkova-Kostova A.T., Abramov A.Y. Nrf2 regulates ROS production by mitochondria and NADPH oxidase. Biochim. Biophys. Acta (BBA) Gen. Subj. 2015;1850:794&#x2013;801. doi: 10.1016/j.bbagen.2014.11.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbagen.2014.11.021</ArticleId><ArticleId IdType="pmc">PMC4471129</ArticleId><ArticleId IdType="pubmed">25484314</ArticleId></ArticleIdList></Reference><Reference><Citation>Florento L., Matias R., Tuano E., Santiago K., Cruz F., Tuazon A. Comparison of Cytotoxic Activity of Anticancer Drugs against Various Human Tumor Cell Lines Using In Vitro Cell-Based Approach. Int. J. Biomed. Sci. 2012;8:76&#x2013;80. doi: 10.59566/IJBS.2012.8076.</Citation><ArticleIdList><ArticleId IdType="doi">10.59566/IJBS.2012.8076</ArticleId><ArticleId IdType="pmc">PMC3614850</ArticleId><ArticleId IdType="pubmed">23675259</ArticleId></ArticleIdList></Reference><Reference><Citation>Repetto G., del Peso A., Zurita J.L. Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat. Protoc. 2008;3:1125&#x2013;1131. doi: 10.1038/nprot.2008.75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2008.75</ArticleId><ArticleId IdType="pubmed">18600217</ArticleId></ArticleIdList></Reference><Reference><Citation>Grisham M.B., Johnson G.G., Lancaster J.R., Jr. Quantitation of nitrate and nitrite in extracellular fluids. Methods Enzymol. 1996;268:237&#x2013;246. doi: 10.1016/s0076-6879(96)68026-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0076-6879(96)68026-4</ArticleId><ArticleId IdType="pubmed">8782590</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu P., Cai M., Liu J., Wang X. Catecholamine Surges Cause Cardiomyocyte Necroptosis via a RIPK1&#x2013;RIPK3-Dependent Pathway in Mice. Front. Cardiovasc. Med. 2021;8:740839. doi: 10.3389/fcvm.2021.740839.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.740839</ArticleId><ArticleId IdType="pmc">PMC8481609</ArticleId><ArticleId IdType="pubmed">34604361</ArticleId></ArticleIdList></Reference><Reference><Citation>Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2&#x2212;&#x394;&#x394;CT Method. Methods. 2001;25:402&#x2013;408. doi: 10.1006/meth.2001.1262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/meth.2001.1262</ArticleId><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference><Reference><Citation>Gado A.M., Nasser A., Adam I., Aldahmash B.A. Cardiotoxicity Induced by Cyclophosphamide in Rats: Protective Effect of Curcumin. J. Res. Environ. Sci. Toxicol. 2013;2:2315&#x2013;5698.</Citation></Reference><Reference><Citation>Sanner M.F. Python: A programming language for software integration and development. J. Mol. Graph. Model. 1999;17:57&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">10660911</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39598352</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1424-8247</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>28</Day></PubDate></JournalIssue><Title>Pharmaceuticals (Basel, Switzerland)</Title><ISOAbbreviation>Pharmaceuticals (Basel)</ISOAbbreviation></Journal><ArticleTitle>Application of Artificial Intelligence Models to Predict the Onset or Recurrence of Neovascular Age-Related Macular Degeneration.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1440</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ph17111440</ELocationID><Abstract><AbstractText>Neovascular age-related macular degeneration (nAMD) is one of the major causes of vision impairment that affect millions of people worldwide. Early detection of nAMD is crucial because, if untreated, it can lead to blindness. Software and algorithms that utilize artificial intelligence (AI) have become valuable tools for early detection, assisting doctors in diagnosing and facilitating differential diagnosis. AI is particularly important for remote or isolated communities, as it allows patients to endure tests and receive rapid initial diagnoses without the necessity of extensive travel and long wait times for medical consultations. Similarly, AI is notable also in big hubs because cutting-edge technologies and networking help and speed processes such as detection, diagnosis, and follow-up times. The automatic detection of retinal changes might be optimized by AI, allowing one to choose the most effective treatment for nAMD. The complex retinal tissue is well-suited for scanning and easily accessible by modern AI-assisted multi-imaging techniques. AI enables us to enhance patient management by effectively evaluating extensive data, facilitating timely diagnosis and long-term prognosis. Novel applications of AI to nAMD have focused on image analysis, specifically for the automated segmentation, extraction, and quantification of imaging-based features included within optical coherence tomography (OCT) pictures. To date, we cannot state that AI could accurately forecast the therapy that would be necessary for a single patient to achieve the best visual outcome. A small number of large datasets with high-quality OCT, lack of data about alternative treatment strategies, and absence of OCT standards are the challenges for the development of AI models for nAMD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sorrentino</LastName><ForeName>Francesco Saverio</ForeName><Initials>FS</Initials><Identifier Source="ORCID">0000-0002-7691-8980</Identifier><AffiliationInfo><Affiliation>Unit of Ophthalmology, Department of Surgical Sciences, Ospedale Maggiore, 40100 Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeppieri</LastName><ForeName>Marco</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0999-5545</Identifier><AffiliationInfo><Affiliation>Department of Ophthalmology, University Hospital of Udine, 33100 Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Culiersi</LastName><ForeName>Carola</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-3221-3791</Identifier><AffiliationInfo><Affiliation>Unit of Ophthalmology, Department of Surgical Sciences, Ospedale Maggiore, 40100 Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Florido</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4921-5830</Identifier><AffiliationInfo><Affiliation>Unit of Ophthalmology, Department of Surgical Sciences, Ospedale Maggiore, 40100 Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Nadai</LastName><ForeName>Katia</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Translational Medicine and for Romagna, University of Ferrara, 44121 Ferrara, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ERN-EYE Network-Center for Retinitis Pigmentosa of Veneto Region, Camposampiero Hospital, 35012 Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adamo</LastName><ForeName>Ginevra Giovanna</ForeName><Initials>GG</Initials><AffiliationInfo><Affiliation>Department of Translational Medicine and for Romagna, University of Ferrara, 44121 Ferrara, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit of Ophthalmology, Azienda Ospedaliero Universitaria di Ferrara, 44100 Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pellegrini</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Translational Medicine and for Romagna, University of Ferrara, 44121 Ferrara, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit of Ophthalmology, Azienda Ospedaliero Universitaria di Ferrara, 44100 Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nasini</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-7618-7308</Identifier><AffiliationInfo><Affiliation>Unit of Ophthalmology, Azienda Ospedaliero Universitaria di Ferrara, 44100 Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vivarelli</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><Identifier Source="ORCID">0009-0004-5139-254X</Identifier><AffiliationInfo><Affiliation>Department of Translational Medicine and for Romagna, University of Ferrara, 44121 Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mura</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Translational Medicine and for Romagna, University of Ferrara, 44121 Ferrara, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>King Khaled Eye Specialist Hospital, Riyadh 12211, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parmeggiani</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-9296-0986</Identifier><AffiliationInfo><Affiliation>Department of Translational Medicine and for Romagna, University of Ferrara, 44121 Ferrara, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ERN-EYE Network-Center for Retinitis Pigmentosa of Veneto Region, Camposampiero Hospital, 35012 Padua, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceuticals (Basel)</MedlineTA><NlmUniqueID>101238453</NlmUniqueID><ISSNLinking>1424-8247</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">artificial intelligence</Keyword><Keyword MajorTopicYN="N">deep learning</Keyword><Keyword MajorTopicYN="N">neovascular age-related macular degeneration</Keyword><Keyword MajorTopicYN="N">retinal biomarkers</Keyword><Keyword MajorTopicYN="N">therapy prediction</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>1</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39598352</ArticleId><ArticleId IdType="pmc">PMC11597877</ArticleId><ArticleId IdType="doi">10.3390/ph17111440</ArticleId><ArticleId IdType="pii">ph17111440</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wong W.L., Su X., Li X., Cheung C.M., Klein R., Cheng C.Y., Wong T.Y. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. Lancet Glob. Health. 2014;2:e106&#x2013;e116. doi: 10.1016/S2214-109X(13)70145-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(13)70145-1</ArticleId><ArticleId IdType="pubmed">25104651</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamura H., Goto R., Akune Y., Hiratsuka Y., Hiragi S., Yamada M. The clinical effectiveness and cost-effectiveness of screening for age-related macular degeneration in Japan: A markov modeling study. PLoS ONE. 2015;10:e0133628. doi: 10.1371/journal.pone.0133628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0133628</ArticleId><ArticleId IdType="pmc">PMC4516236</ArticleId><ArticleId IdType="pubmed">26214804</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorrentino F.S., Gardini L., Fontana L., Musa M., Gabai A., Maniaci A., Lavalle S., D&#x2019; Esposito F., Russo A., Longo A., et al. Novel approaches for early detection of retinal diseases using artificial intelligence. J. Pers. Med. 2024;14:690. doi: 10.3390/jpm14070690.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm14070690</ArticleId><ArticleId IdType="pmc">PMC11278069</ArticleId><ArticleId IdType="pubmed">39063944</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogunovi&#x107; H., Mares V., Reiter G.S., Schmidt-Erfurth U. Predicting treat-and-extend outcomes and treatment intervals in neovascular age-related macular degeneration from retinal optical coherence tomography using artificial intelligence. Front. Med. 2022;9:958469. doi: 10.3389/fmed.2022.958469.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.958469</ArticleId><ArticleId IdType="pmc">PMC9396241</ArticleId><ArticleId IdType="pubmed">36017006</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodfellow I., Bengio Y., Courville A. Deep Learning. MIT Press; Cambridge, MA, USA: 2016.</Citation></Reference><Reference><Citation>Fabre M., Mateo L., Lamaa D., Baillif S., Pag&#xe8;s G., Demange L., Ronco C., Benhida R. Recent advances in age-related macular degeneration therapies. Molecules. 2022;27:5089. doi: 10.3390/molecules27165089.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27165089</ArticleId><ArticleId IdType="pmc">PMC9414333</ArticleId><ArticleId IdType="pubmed">36014339</ArticleId></ArticleIdList></Reference><Reference><Citation>Girgis S., Lee L.R. Treatment of dry age-related macular degeneration: A review. Clin. Exp. Ophthalmol. 2023;51:835&#x2013;852. doi: 10.1111/ceo.14294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ceo.14294</ArticleId><ArticleId IdType="pubmed">37737509</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang M.A., Kapre A., Kaufman D., Kardatzke D.R., Rabena M., Patel S., Bobbala A., Gune S., Fung A., Wallenstein G. Patient preference and treatment satisfaction with a port delivery system for ranibizumab vs intravitreal injections in patients with neovascular age-related macular degeneration: A randomized clinical trial. JAMA Ophthalmol. 2022;140:771&#x2013;778. doi: 10.1001/jamaophthalmol.2022.1091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2022.1091</ArticleId><ArticleId IdType="pmc">PMC9204622</ArticleId><ArticleId IdType="pubmed">35708706</ArticleId></ArticleIdList></Reference><Reference><Citation>Holekamp N.M., Campochiaro P.A., Chang M. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2022;129:295&#x2013;307. doi: 10.1016/j.ophtha.2021.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2021.09.016</ArticleId><ArticleId IdType="pubmed">34597713</ArticleId></ArticleIdList></Reference><Reference><Citation>Braithwaite T., Calvert M., Gray A., Pesudovs K., Denniston A.K. The use of patient-reported outcome research in modern ophthalmology: Impact on clinical trials and routine clinical practice. Patient Relat. Outcome Meas. 2019;10:9&#x2013;24. doi: 10.2147/PROM.S162802.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/PROM.S162802</ArticleId><ArticleId IdType="pmc">PMC6352858</ArticleId><ArticleId IdType="pubmed">30774489</ArticleId></ArticleIdList></Reference><Reference><Citation>Stahl A. The diagnosis and treatment of age-related macular degeneration. Dtsch. Arztebl. Int. 2020;117:513&#x2013;520. doi: 10.3238/arztebl.2020.0513.</Citation><ArticleIdList><ArticleId IdType="doi">10.3238/arztebl.2020.0513</ArticleId><ArticleId IdType="pmc">PMC7588619</ArticleId><ArticleId IdType="pubmed">33087239</ArticleId></ArticleIdList></Reference><Reference><Citation>Riedl S., Vogl W.D., Waldstein S.M., Schmidt-Erfurth U., Bogunovi&#x107; H. Impact of intra- and subretinal fluid on vision based on volume quantification in the HARBOR trial. Ophthalmol. Retin. 2022;6:291&#x2013;297. doi: 10.1016/j.oret.2021.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oret.2021.12.007</ArticleId><ArticleId IdType="pubmed">34922038</ArticleId></ArticleIdList></Reference><Reference><Citation>Maunz A., Barras L., Kawczynski M.G., Dai J., Lee A.Y., Spaide R.F., Sahni J., Ferrara D. Machine learning to predict response to ranibizumab in neovascular age-related macular degeneration. Ophthalmol. Sci. 2023;3:100319. doi: 10.1016/j.xops.2023.100319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xops.2023.100319</ArticleId><ArticleId IdType="pmc">PMC10251067</ArticleId><ArticleId IdType="pubmed">37304043</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldstein S.M., Vogl W.D., Bogunovi&#x107; H., Sadeghipour A., Riedl S., Schmidt-Erfurth U. Characterization of drusen and hyperreflective foci as biomarkers for disease progression in age-related macular degeneration using artificial intelligence in optical coherence tomography. JAMA Ophthalmol. 2020;138:740&#x2013;747. doi: 10.1001/jamaophthalmol.2020.1376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2020.1376</ArticleId><ArticleId IdType="pmc">PMC7206537</ArticleId><ArticleId IdType="pubmed">32379287</ArticleId></ArticleIdList></Reference><Reference><Citation>LeCun Y., Bengio Y., Hinton G. Deep learning. Nature. 2015;521:436&#x2013;444. doi: 10.1038/nature14539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14539</ArticleId><ArticleId IdType="pubmed">26017442</ArticleId></ArticleIdList></Reference><Reference><Citation>Ting D.S.W., Lin H., Ruamviboonsuk P., Wong T.Y., Sim D.A. Artificial intelligence, the internet of things, and virtual clinics: Ophthalmology at the digital translation forefront. Lancet Digit. Health. 2020;2:e8&#x2013;e9. doi: 10.1016/S2589-7500(19)30217-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2589-7500(19)30217-1</ArticleId><ArticleId IdType="pubmed">33328040</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashidi H.H., Tran N.K., Betts E.V., Howell L.P., Green R. Artificial intelligence and machine learning in pathology: The present landscape of supervised methods. Acad. Pathol. 2019;6:2374289519873088. doi: 10.1177/2374289519873088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2374289519873088</ArticleId><ArticleId IdType="pmc">PMC6727099</ArticleId><ArticleId IdType="pubmed">31523704</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassmann F., Mengelkamp J., Brandl C., Harsch S., Zimmermann M.E., Linkohr B., Peters A., Heid I.M., Palm C., Weber B.H.F. A Deep learning algorithm for prediction of age-related eye disease study severity scale for age-related macular degeneration from color fundus photography. Ophthalmology. 2018;125:1410&#x2013;1420. doi: 10.1016/j.ophtha.2018.02.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2018.02.037</ArticleId><ArticleId IdType="pubmed">29653860</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J.Q., Welchowski T., Schmid M. Prevalence and incidence of age-related macular degeneration in Europe: A systematic review and meta-analysis. Br. J. Ophthalmol. 2020;104:1077&#x2013;1084. doi: 10.1136/bjophthalmol-2019-314422.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjophthalmol-2019-314422</ArticleId><ArticleId IdType="pubmed">31712255</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell P., Liew G., Gopinath B. Age-related macular degeneration. Lancet. 2018;392:1147&#x2013;1159. doi: 10.1016/S0140-6736(18)31550-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)31550-2</ArticleId><ArticleId IdType="pubmed">30303083</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahr T., Vu T.A., Tuttle J.J., Iezzi R. Deep learning and machine learning algorithms for retinal image analysis in neurodegenerative disease: Systematic review of datasets and models. Transl. Vis. Sci. Technol. 2024;13:16. doi: 10.1167/tvst.13.2.16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/tvst.13.2.16</ArticleId><ArticleId IdType="pmc">PMC10893898</ArticleId><ArticleId IdType="pubmed">38381447</ArticleId></ArticleIdList></Reference><Reference><Citation>Vujosevic S., Parra M.M., Hartnett M.E. Optical coherence tomography as retinal imaging biomarker of neuroinflammation/neurodegeneration in systemic disorders in adults and children. Eye. 2023;37:203&#x2013;219. doi: 10.1038/s41433-022-02056-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41433-022-02056-9</ArticleId><ArticleId IdType="pmc">PMC9012155</ArticleId><ArticleId IdType="pubmed">35428871</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Khersan H., Hussain R.M., Ciulla T.A., Dugel P.U. Innovative therapies for neovascular age-related macular degeneration. Expert. Opin. Pharmacother. 2019;20:1879&#x2013;1891. doi: 10.1080/14656566.2019.1636031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14656566.2019.1636031</ArticleId><ArticleId IdType="pubmed">31298960</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrara D., Newton E.M., Lee A.Y. Artificial intelligence-based predictions in neovascular age-related macular degeneration. Curr. Opin. Ophthalmol. 2021;32:389&#x2013;396. doi: 10.1097/ICU.0000000000000782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ICU.0000000000000782</ArticleId><ArticleId IdType="pmc">PMC8373444</ArticleId><ArticleId IdType="pubmed">34265783</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho A.C., Busbee B.G., Regillo C.D. HARBOR Study Group. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014;121:2181&#x2013;2192. doi: 10.1016/j.ophtha.2014.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2014.05.009</ArticleId><ArticleId IdType="pubmed">25015215</ArticleId></ArticleIdList></Reference><Reference><Citation>Fasler K., Moraes G., Wagner S. One- and two-year visual outcomes from the Moorfields age-related macular degeneration database: A retrospective cohort study and an open science resource. BMJ Open. 2019;9:e027441. doi: 10.1136/bmjopen-2018-027441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2018-027441</ArticleId><ArticleId IdType="pmc">PMC6596999</ArticleId><ArticleId IdType="pubmed">31230012</ArticleId></ArticleIdList></Reference><Reference><Citation>Moraes G., Fu D.J., Wilson M. Quantitative analysis of OCT for neovascular age-related macular degeneration using deep learning. Ophthalmology. 2021;128:693&#x2013;705. doi: 10.1016/j.ophtha.2020.09.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2020.09.025</ArticleId><ArticleId IdType="pmc">PMC8528155</ArticleId><ArticleId IdType="pubmed">32980396</ArticleId></ArticleIdList></Reference><Reference><Citation>De Fauw J., Ledsam J.R., Romera-Paredes B. Clinically applicable deep learning for diagnosis and referral in retinal disease. Nat. Med. 2018;24:1342&#x2013;1350. doi: 10.1038/s41591-018-0107-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0107-6</ArticleId><ArticleId IdType="pubmed">30104768</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu D.J., Faes L., Wagner S.K., Moraes G., Chopra R., Patel P.J., Balaskas K., Keenan T.D.L., Bachmann L.M., Keane P.A. Predicting incremental and future visual change in neovascular age-related macular degeneration using deep learning. Ophthalmol. Retin. 2021;5:1074&#x2013;1084. doi: 10.1016/j.oret.2021.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oret.2021.01.009</ArticleId><ArticleId IdType="pubmed">33516917</ArticleId></ArticleIdList></Reference><Reference><Citation>Liefers B., Taylor P., Alsaedi A. Quantification of key retinal features in early and late age-related macular degeneration using deep learning. Am. J. Ophthalmol. 2021;226:1&#x2013;12. doi: 10.1016/j.ajo.2020.12.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2020.12.034</ArticleId><ArticleId IdType="pubmed">33422464</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakravarthy U., Goldenberg D., Young G., Havilio M., Rafaeli O., Benyamini G., Loewenstein A. Automated identification of lesion activity in neovascular age-related macular degeneration. Ophthalmology. 2016;123:1731&#x2013;1736.</Citation><ArticleIdList><ArticleId IdType="pubmed">27206840</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlegl T., Waldstein S.M., Bogunovi&#x107; H., Endstra&#xdf;er F., Sadeghipour A., Philip A.M., Podkowinski D., Gerendas B.S., Langs G., Schmidt-Erfurth U. Fully automated detection and quantification of macular fluid in OCT using deep learning. Ophthalmology. 2018;125:549&#x2013;558. doi: 10.1016/j.ophtha.2017.10.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2017.10.031</ArticleId><ArticleId IdType="pubmed">29224926</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt-Erfurth U., Vogl W.D., Jampol L.M., Bogunovi&#x107; H. Application of automated quantification of fluid volumes to anti-VEGF therapy of neovascular age-related macular degeneration. Ophthalmology. 2020;127:1211&#x2013;1219. doi: 10.1016/j.ophtha.2020.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2020.03.010</ArticleId><ArticleId IdType="pubmed">32327254</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakravarthy U., Havilio M., Syntosi A. Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD. Eye. 2021;35:2983&#x2013;2990. doi: 10.1038/s41433-020-01354-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41433-020-01354-4</ArticleId><ArticleId IdType="pmc">PMC8526705</ArticleId><ArticleId IdType="pubmed">33414525</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawczynski M.G., Bengtsson T., Dai J., Hopkins J.J., Gao S.S., Willis J.R. Development of deep learning models to predict best-corrected visual acuity from optical coherence tomography. Transl. Vis. Sci. Technol. 2020;9:51. doi: 10.1167/tvst.9.2.51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/tvst.9.2.51</ArticleId><ArticleId IdType="pmc">PMC7488630</ArticleId><ArticleId IdType="pubmed">32974088</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng D., Chen X., Zhou Z.A. preliminary study of predicting effectiveness of anti-VEGF injection using OCT images based on deep learning; Proceedings of the 42nd Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC); Montreal, QC, Canada. 20&#x2013;24 July 2020; pp. 5428&#x2013;5431.</Citation><ArticleIdList><ArticleId IdType="pubmed">33019208</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H., Kim S., Kim M.A. Post-treatment prediction of optical coherence tomography using a conditional generative adversarial network in age-related macular degeneration. Retina. 2021;41:572&#x2013;580. doi: 10.1097/IAE.0000000000002898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IAE.0000000000002898</ArticleId><ArticleId IdType="pubmed">32568984</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W., Southern J., Zhu K., Li Y., Cordeiro M.F., Veselkov K. Deep learning to detect macular atrophy in wet age-related macular degeneration using optical coherence tomography. Sci. Rep. 2023;13:8296. doi: 10.1038/s41598-023-35414-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-35414-y</ArticleId><ArticleId IdType="pmc">PMC10203346</ArticleId><ArticleId IdType="pubmed">37217770</ArticleId></ArticleIdList></Reference><Reference><Citation>Crincoli E., Sacconi R., Querques L., Querques G. Artificial intelligence in age-related macular degeneration: State of the art and recent updates. BMC Ophthalmol. 2024;24:121. doi: 10.1186/s12886-024-03381-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12886-024-03381-1</ArticleId><ArticleId IdType="pmc">PMC10943791</ArticleId><ArticleId IdType="pubmed">38491380</ArticleId></ArticleIdList></Reference><Reference><Citation>Romo-Bucheli D., Erfurth U.S., Bogunovi&#x107; H. End-to-end deep learning model for predicting treatment requirements in neovascular AMD from longitudinal retinal OCT imaging. IEEE J. Biomed. Health Inf. 2020;24:3456&#x2013;3465. doi: 10.1109/JBHI.2020.3000136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/JBHI.2020.3000136</ArticleId><ArticleId IdType="pubmed">32750929</ArticleId></ArticleIdList></Reference><Reference><Citation>Daich Varela M., Sen S., De Guimaraes T.A.C. Artificial intelligence in retinal disease: Clinical application, challenges, and future directions. Graefes. Arch. Clin. Exp. Ophthalmol. 2023;261:3283&#x2013;3297. doi: 10.1007/s00417-023-06052-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00417-023-06052-x</ArticleId><ArticleId IdType="pmc">PMC10169139</ArticleId><ArticleId IdType="pubmed">37160501</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee A.Y., Campbell J.P., Hwang T.S. American Academy of Ophthalmology. Recommendations for standardization of images in ophthalmology. Ophthalmology. 2021;128:969&#x2013;970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8335850</ArticleId><ArticleId IdType="pubmed">33832778</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas D.S., Lee A.Y., M&#xfc;ller P.L. UK AMD EMR Users Group. Contextualizing single-arm trials with real-world data: An emulated target trial comparing therapies for neovascular age-related macular degeneration. Clin. Transl. Sci. 2021;14:1166&#x2013;1175. doi: 10.1111/cts.12974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.12974</ArticleId><ArticleId IdType="pmc">PMC8212729</ArticleId><ArticleId IdType="pubmed">33421321</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C.S., Lee A.Y. How artificial intelligence can transform randomized controlled trials. Transl. Vis. Sci. Technol. 2020;9:9. doi: 10.1167/tvst.9.2.9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/tvst.9.2.9</ArticleId><ArticleId IdType="pmc">PMC7346875</ArticleId><ArticleId IdType="pubmed">32704415</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C.S., Tyring A.J., Wu Y. Generating retinal flow maps from structural optical coherence tomography with artificial intelligence. Sci. Rep. 2019;9:5694. doi: 10.1038/s41598-019-42042-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-42042-y</ArticleId><ArticleId IdType="pmc">PMC6450899</ArticleId><ArticleId IdType="pubmed">30952891</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Yang J., Zhou Y., Wang W., Zhao J., Yu W., Zhang D., Ding D., Li X., Chen Y. Prediction of OCT images of short-term response to anti-VEGF treatment for neovascular age-related macular degeneration using generative adversarial network. Br. J. Ophthalmol. 2020;104:1735&#x2013;1740. doi: 10.1136/bjophthalmol-2019-315338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjophthalmol-2019-315338</ArticleId><ArticleId IdType="pubmed">32217538</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohm M., Tresp V., M&#xfc;ller M. Predicting visual acuity by using machine learning in patients treated for neovascular age-related macular degeneration. Ophthalmology. 2018;125:1028&#x2013;1036. doi: 10.1016/j.ophtha.2017.12.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2017.12.034</ArticleId><ArticleId IdType="pubmed">29454659</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh T.C., Luo A.C., Deng Y.S., Lee Y.H., Chen S.J., Chang P.H., Chou Y.B. Prediction of treatment outcome in neovascular age-related macular degeneration using a novel convolutional neural network. Sci. Rep. 2022;12:5871. doi: 10.1038/s41598-022-09642-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-09642-7</ArticleId><ArticleId IdType="pmc">PMC8989893</ArticleId><ArticleId IdType="pubmed">35393449</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X., Zhang X., Lv B., Meng L., Zhang C., Liu Y., Lv C., Xie G., Chen Y. Optical coherence tomography-based short-term effect prediction of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration using sensitive structure guided network. Graefes. Arch. Clin. Exp. Ophthalmol. 2021;259:3261&#x2013;3269. doi: 10.1007/s00417-021-05247-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00417-021-05247-4</ArticleId><ArticleId IdType="pubmed">34097114</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon S., Lee Y., Hwang J. Prediction of anti-vascular endothelial growth factor agent-specific treatment outcomes in neovascular age-related macular degeneration using a generative adversarial network. Sci. Rep. 2023;13:5639. doi: 10.1038/s41598-023-32398-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-32398-7</ArticleId><ArticleId IdType="pmc">PMC10079864</ArticleId><ArticleId IdType="pubmed">37024576</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohji M., Okada A.A., Sasaki K., Moon S.C., Machewitz T., Takahashi K. ALTAIR Investigators. Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: Subgroup and post-hoc analyses from the ALTAIR study. Graefes. Arch. Clin. Exp. Ophthalmol. 2021;259:3637&#x2013;3647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8589769</ArticleId><ArticleId IdType="pubmed">34283294</ArticleId></ArticleIdList></Reference><Reference><Citation>Jhaveri C., Wykoff C.C., Khanani A.M., Eandi C.M., Chang B.G., Gedif K.A., Singer M. Early residual fluid-free status and long-term BCVA outcomes: A treatment agnostic, post hoc analysis of pooled HAWK and HARRIER data. Am J. Ophthalmol. 2022;236:12&#x2013;19. doi: 10.1016/j.ajo.2021.10.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2021.10.017</ArticleId><ArticleId IdType="pubmed">34695400</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogunovi&#x107; H., Waldstein S.M., Schlegl T., Langs G., Sadeghipour A., Liu X., Gerendas B.S., Osborne A., Schmidt-Erfurth U. Prediction of anti-VEGF treatment requirements in neovascular AMD using a machine learning approach. Investig. Ophthalmol. Vis. Sci. 2017;58:3240&#x2013;3248. doi: 10.1167/iovs.16-21053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.16-21053</ArticleId><ArticleId IdType="pubmed">28660277</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfau M., Sahu S., Rupnow R.A., Romond K., Millet D., Holz F.G., Schmitz-Valckenberg S., Fleckenstein M., Lim J.I., de Sisternes L. Probabilistic forecasting of anti-VEGF treatment frequency in neovascular age-related macular degeneration. Transl Vis. Sci. Technol. 2021;10:30. doi: 10.1167/tvst.10.7.30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/tvst.10.7.30</ArticleId><ArticleId IdType="pmc">PMC8254013</ArticleId><ArticleId IdType="pubmed">34185055</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallardo M., Munk M.R., Kurmann T., De Zanet S., Mosinska A., Karagoz I.K., Zinkernagel M.S., Wolf S., Sznitman R. Machine learning can predict anti-VEGF treatment demand in a treat-and-extend regimen for patients with neovascular AMD, DME, and RVO associated macular edema. Ophthalmo. Retina. 2021;5:604&#x2013;624. doi: 10.1016/j.oret.2021.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oret.2021.05.002</ArticleId><ArticleId IdType="pubmed">33971352</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma D., Kumar M., Khetan V., Sen P., Bhende M., Chen S., Timothy T., Lee S., Navajas E.V., Matsubara J.A., et al. Clinical explainable differential diagnosis of polypoidal choroidal vasculopathy and age-related macular degeneration using deep learning. Comput. Biol. Med. 2022;143:105319. doi: 10.1016/j.compbiomed.2022.105319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.compbiomed.2022.105319</ArticleId><ArticleId IdType="pubmed">35220077</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang S., Zou B., Xiao X. A novel approach for automatic classification of macular degeneration OCT images. Sci. Rep. 2024;14:19285. doi: 10.1038/s41598-024-70175-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-70175-2</ArticleId><ArticleId IdType="pmc">PMC11335908</ArticleId><ArticleId IdType="pubmed">39164445</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorrentino F.S., Jurman G., De Nadai K., Campa C., Furlanello C., Parmeggiani F. Application of artificial intelligence in targeting retinal diseases. Curr. Drug Targets. 2020;21:1208&#x2013;1215. doi: 10.2174/1389450121666200708120646.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389450121666200708120646</ArticleId><ArticleId IdType="pubmed">32640954</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiao C., Edupuganti N.R., Patel P.A., Bui T., Sheth V. Evaluating the artificial intelligence performance growth in ophthalmic knowledge. Cureus. 2023;15:e45700. doi: 10.7759/cureus.45700.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.45700</ArticleId><ArticleId IdType="pmc">PMC10590143</ArticleId><ArticleId IdType="pubmed">37868408</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.T., Lin T.Y., Lin C.J., Hwang D.K. The future application of artificial intelligence and telemedicine in the retina: A perspective. Taiwan J. Ophthalmol. 2023;13:133&#x2013;141. doi: 10.4103/tjo.TJO-D-23-00028.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/tjo.TJO-D-23-00028</ArticleId><ArticleId IdType="pmc">PMC10361422</ArticleId><ArticleId IdType="pubmed">37484624</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39596978</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1648-9144</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Medicina (Kaunas, Lithuania)</Title><ISOAbbreviation>Medicina (Kaunas)</ISOAbbreviation></Journal><ArticleTitle>Advances in Imaging-Based Machine Learning and Therapeutic Technology in the Management of Retinal Diseases.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1794</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/medicina60111794</ELocationID><Abstract><AbstractText>Retinal conditions like age-related macular degeneration (AMD), diabetic retinopathy, central serous chorioretinopathy (CSCR), and retinal vein occlusion can drastically affect a patient's quality of life [...].</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ong</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4860-827X</Identifier><AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Sciences, University of Michigan Kellogg Eye Center, Ann Arbor, MI 48105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chhablani</LastName><ForeName>Jay</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1772-3558</Identifier><AffiliationInfo><Affiliation>Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Medicina (Kaunas)</MedlineTA><NlmUniqueID>9425208</NlmUniqueID><ISSNLinking>1010-660X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="Y">Machine Learning</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012164" MajorTopicYN="Y">Retinal Diseases</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056833" MajorTopicYN="N">Central Serous Chorioretinopathy</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>1</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39596978</ArticleId><ArticleId IdType="pmc">PMC11596187</ArticleId><ArticleId IdType="doi">10.3390/medicina60111794</ArticleId><ArticleId IdType="pii">medicina60111794</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Grzybowski A., Brona P. Analysis and Comparison of Two Artificial Intelligence Diabetic Retinopathy Screening Algorithms in a Pilot Study: IDx-DR and Retinalyze. J. Clin. Med. 2021;10:2352. doi: 10.3390/jcm10112352.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10112352</ArticleId><ArticleId IdType="pmc">PMC8199438</ArticleId><ArticleId IdType="pubmed">34071990</ArticleId></ArticleIdList></Reference><Reference><Citation>Borrelli E., Serafino S., Ricardi F., Coletto A., Neri G., Olivieri C., Ulla L., Foti C., Marolo P., Toro M.D., et al. Deep Learning in Neovascular Age-Related Macular Degeneration. Medicina. 2024;60:990. doi: 10.3390/medicina60060990.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina60060990</ArticleId><ArticleId IdType="pmc">PMC11205843</ArticleId><ArticleId IdType="pubmed">38929607</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee I., de Sisternes L., Hallak J.A., Leng T., Osborne A., Rosenfeld P.J., Gregori G., Durbin M., Rubin D. Prediction of age-related macular degeneration disease using a sequential deep learning approach on longitudinal SD-OCT imaging biomarkers. Sci. Rep. 2020;10:15434. doi: 10.1038/s41598-020-72359-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-72359-y</ArticleId><ArticleId IdType="pmc">PMC7508843</ArticleId><ArticleId IdType="pubmed">32963300</ArticleId></ArticleIdList></Reference><Reference><Citation>Borrelli E., Oakley J.D., Iaccarino G., Russakoff D.B., Battista M., Grosso D., Borghesan F., Barresi C., Sacconi R., Bandello F., et al. Deep-learning based automated quantification of critical optical coherence tomography features in neovascular age-related macular degeneration. Eye. 2024;38:537&#x2013;544. doi: 10.1038/s41433-023-02720-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41433-023-02720-8</ArticleId><ArticleId IdType="pmc">PMC10858028</ArticleId><ArticleId IdType="pubmed">37670143</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez-Zulueta J., Bolanos-Chang A.J., Santa Cruz-Pavlovich F.J., Valero Rodriguez A.D., Lizarraga Madrigal A., Del Rio-Murillo X.I., Navarro-Partida J., Gonzalez-De la Rosa A. Microbial Dynamics in Ophthalmic Health: Exploring the Interplay Between Human Microbiota and Glaucoma Pathogenesis. Medicina. 2024;60:592. doi: 10.3390/medicina60040592.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina60040592</ArticleId><ArticleId IdType="pmc">PMC11051970</ArticleId><ArticleId IdType="pubmed">38674238</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh M., Negi R., Alka. Vinayagam R., Kang S.G., Shukla P. Age-Related Macular Degeneration (AMD): Pathophysiology, Drug Targeting Approaches, and Recent Developments in Nanotherapeutics. Medicina. 2024;60:1647. doi: 10.3390/medicina60101647.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina60101647</ArticleId><ArticleId IdType="pmc">PMC11509623</ArticleId><ArticleId IdType="pubmed">39459435</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruggeri M.L., Di Nicola M., Passamonti M., Lorenzi C., Quarta A., Mastropasqua R., Toto L. Choroidal and Choriocapillaris Changes after Photodynamic Therapy and Subthreshold Micropulse Laser Treatment for Central Serous Chorioretinopathy. Medicina. 2024;60:1674. doi: 10.3390/medicina60101674.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina60101674</ArticleId><ArticleId IdType="pmc">PMC11509465</ArticleId><ArticleId IdType="pubmed">39459461</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39595533</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2218-273X</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>24</Day></PubDate></JournalIssue><Title>Biomolecules</Title><ISOAbbreviation>Biomolecules</ISOAbbreviation></Journal><ArticleTitle>Selected Trace Elements and Their Impact on Redox Homeostasis in Eye Health.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1356</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biom14111356</ELocationID><Abstract><AbstractText>Oxidative stress plays a crucial role in the pathogenesis of various ocular degenerative diseases, leading to structural and functional changes in eye tissues. This imbalance between reactive oxygen species (ROS) and antioxidants significantly contributes to conditions such as age-related macular degeneration, diabetic retinopathy, cataracts, and glaucoma. Both enzymatic and nonenzymatic antioxidants are vital for maintaining ocular health by neutralizing ROS and restoring cellular redox balance. Essential trace elements, including iron, zinc, copper, and selenium, are fundamental for the proper functioning of these antioxidant systems. Iron is indispensable for enzymatic activity and cellular energy production, zinc supports numerous proteins involved in visual functions and antioxidant defense, copper is essential for various enzymatic reactions preventing oxidative stress, and selenium is critical for the activity of antioxidant enzymes such as glutathione peroxidase (GPX) and thioredoxin reductase (TrxR). This review summarizes current research on the complex interactions between oxidative stress and trace elements in ocular diseases, highlighting the therapeutic potential of antioxidant supplementation to mitigate oxidative damage and improve eye health. By integrating insights from studies on oxidative stress, trace elements, and eye physiology, this article underscores new diagnostic and therapeutic strategies that could lead to more effective prevention and treatment of ocular diseases, aiming to enhance clinical outcomes and guide future research in optimizing therapeutic strategies for eye health.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wr&#xf3;blewska</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8188-8296</Identifier><AffiliationInfo><Affiliation>Department of Medical Biology and Biochemistry, Faculty of Medicine, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toru&#x144;, 24 Kar&#x142;owicza St., 85-092 Bydgoszcz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nuszkiewicz</LastName><ForeName>Jaros&#x142;aw</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1378-5065</Identifier><AffiliationInfo><Affiliation>Department of Medical Biology and Biochemistry, Faculty of Medicine, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toru&#x144;, 24 Kar&#x142;owicza St., 85-092 Bydgoszcz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wr&#xf3;blewski</LastName><ForeName>Marcin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7887-132X</Identifier><AffiliationInfo><Affiliation>Department of Medical Biology and Biochemistry, Faculty of Medicine, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toru&#x144;, 24 Kar&#x142;owicza St., 85-092 Bydgoszcz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wr&#xf3;blewska</LastName><ForeName>Weronika</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Student Research Club of Medical Biology and Biochemistry, Department of Medical Biology and Biochemistry, Faculty of Medicine, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toru&#x144;, 85-092 Bydgoszcz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wo&#x17a;niak</LastName><ForeName>Alina</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4492-4796</Identifier><AffiliationInfo><Affiliation>Department of Medical Biology and Biochemistry, Faculty of Medicine, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toru&#x144;, 24 Kar&#x142;owicza St., 85-092 Bydgoszcz, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomolecules</MedlineTA><NlmUniqueID>101596414</NlmUniqueID><ISSNLinking>2218-273X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014131">Trace Elements</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014131" MajorTopicYN="Y">Trace Elements</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010084" MajorTopicYN="Y">Oxidation-Reduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="Y">Oxidative Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006706" MajorTopicYN="Y">Homeostasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="Y">Antioxidants</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005123" MajorTopicYN="N">Eye</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005128" MajorTopicYN="N">Eye Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antioxidants</Keyword><Keyword MajorTopicYN="N">copper</Keyword><Keyword MajorTopicYN="N">eye</Keyword><Keyword MajorTopicYN="N">iron</Keyword><Keyword MajorTopicYN="N">oxidative stress</Keyword><Keyword MajorTopicYN="N">redox balance</Keyword><Keyword MajorTopicYN="N">selenium</Keyword><Keyword MajorTopicYN="N">trace elements</Keyword><Keyword MajorTopicYN="N">vision health</Keyword><Keyword MajorTopicYN="N">zinc</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>12</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39595533</ArticleId><ArticleId IdType="pmc">PMC11591929</ArticleId><ArticleId IdType="doi">10.3390/biom14111356</ArticleId><ArticleId IdType="pii">biom14111356</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hsueh Y.-J., Chen Y.-N., Tsao Y.-T., Cheng C.-M., Wu W.-C., Chen H.-C. The Pathomechanism, Antioxidant Biomarkers, and Treatment of Oxidative Stress-Related Eye Diseases. Int. J. Mol. Sci. 2022;23:1255. doi: 10.3390/ijms23031255.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23031255</ArticleId><ArticleId IdType="pmc">PMC8835903</ArticleId><ArticleId IdType="pubmed">35163178</ArticleId></ArticleIdList></Reference><Reference><Citation>Daruich A., Sauvain J.-J., Matet A., Eperon S., Schweizer C., Berthet A., Danuser B., Behar-Cohen F. Levels of the Oxidative Stress Biomarker Malondialdehyde in Tears of Patients with Central Serous Chorioretinopathy Relate to Disease Activity. Mol. Vis. 2020;26:722&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7655974</ArticleId><ArticleId IdType="pubmed">33209015</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaluzhny Y., Kinuthia M.W., Lapointe A.M., Truong T., Klausner M., Hayden P. Oxidative Stress in Corneal Injuries of Different Origin: Utilization of 3D Human Corneal Epithelial Tissue Model. Exp. Eye Res. 2020;190:107867. doi: 10.1016/j.exer.2019.107867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exer.2019.107867</ArticleId><ArticleId IdType="pubmed">31705899</ArticleId></ArticleIdList></Reference><Reference><Citation>Vona R., Gambardella L., Cittadini C., Straface E., Pietraforte D. Biomarkers of Oxidative Stress in Metabolic Syndrome and Associated Diseases. Oxid. Med. Cell. Longev. 2019;2019:8267234. doi: 10.1155/2019/8267234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/8267234</ArticleId><ArticleId IdType="pmc">PMC6525823</ArticleId><ArticleId IdType="pubmed">31191805</ArticleId></ArticleIdList></Reference><Reference><Citation>Picard E., Ranchon-Cole I., Jonet L., Beaumont C., Behar-Cohen F., Courtois Y., Jeanny J.C. Light-Induced Retinal Degeneration Correlates with Changes in Iron Metabolism Gene Expression, Ferritin Level, and Aging. Investig. Ophthalmol. Vis. Sci. 2011;52:1261&#x2013;1274. doi: 10.1167/iovs.10-5705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.10-5705</ArticleId><ArticleId IdType="pubmed">20881284</ArticleId></ArticleIdList></Reference><Reference><Citation>Moussa Z., Judeh Z.M.A., Ahmed S.A. Free Radical Medicine and Biology. IntechOpen; London, UK: 2020. Nonenzymatic Exogenous and Endogenous Antioxidants.</Citation></Reference><Reference><Citation>Wills N.K., Sadagopa Ramanujam V.M., Kalariya N., Lewis J.R., van Kuijk F.J.G.M. Copper and Zinc Distribution in the Human Retina: Relationship to Cadmium Accumulation, Age, and Gender. Exp. Eye Res. 2008;87:80&#x2013;88. doi: 10.1016/j.exer.2008.04.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exer.2008.04.013</ArticleId><ArticleId IdType="pubmed">18579132</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorusupudi A., Nelson K., Bernstein P.S. The Age-Related Eye Disease 2 Study: Micronutrients in the Treatment of Macular Degeneration. Adv. Nutr. 2017;8:40&#x2013;53. doi: 10.3945/an.116.013177.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/an.116.013177</ArticleId><ArticleId IdType="pmc">PMC5227975</ArticleId><ArticleId IdType="pubmed">28096126</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Bassam L., Shearman G.C., Brocchini S., Alany R.G., Williams G.R. The Potential of Selenium-Based Therapies for Ocular Oxidative Stress. Pharmaceutics. 2024;16:631. doi: 10.3390/pharmaceutics16050631.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics16050631</ArticleId><ArticleId IdType="pmc">PMC11125443</ArticleId><ArticleId IdType="pubmed">38794293</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Meo S., Reed T.T., Venditti P., Victor V.M. Role of ROS and RNS Sources in Physiological and Pathological Conditions. Oxid. Med. Cell. Longev. 2016;2016:1245049. doi: 10.1155/2016/1245049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/1245049</ArticleId><ArticleId IdType="pmc">PMC4960346</ArticleId><ArticleId IdType="pubmed">27478531</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;hm E.W., Buonfiglio F., Voigt A.M., Bachmann P., Safi T., Pfeiffer N., Gericke A. Oxidative Stress in the Eye and Its Role in the Pathophysiology of Ocular Diseases. Redox Biol. 2023;68:102967. doi: 10.1016/j.redox.2023.102967.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2023.102967</ArticleId><ArticleId IdType="pmc">PMC10701459</ArticleId><ArticleId IdType="pubmed">38006824</ArticleId></ArticleIdList></Reference><Reference><Citation>Konno T., Melo E.P., Chambers J.E., Avezov E. Intracellular Sources of ROS/H2O2 in Health and Neurodegeneration: Spotlight on Endoplasmic Reticulum. Cells. 2021;10:233. doi: 10.3390/cells10020233.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10020233</ArticleId><ArticleId IdType="pmc">PMC7912550</ArticleId><ArticleId IdType="pubmed">33504070</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x15a;wi&#x105;tkiewicz I., Wr&#xf3;blewski M., Nuszkiewicz J., Sutkowy P., Wr&#xf3;blewska J., Wo&#x17a;niak A. The Role of Oxidative Stress Enhanced by Adiposity in Cardiometabolic Diseases. Int. J. Mol. Sci. 2023;24:6382. doi: 10.3390/ijms24076382.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24076382</ArticleId><ArticleId IdType="pmc">PMC10094567</ArticleId><ArticleId IdType="pubmed">37047352</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermot A., Petit-H&#xe4;rtlein I., Smith S.M.E., Fieschi F. NADPH Oxidases (NOX): An Overview from Discovery, Molecular Mechanisms to Physiology and Pathology. Antioxidants. 2021;10:890. doi: 10.3390/antiox10060890.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10060890</ArticleId><ArticleId IdType="pmc">PMC8228183</ArticleId><ArticleId IdType="pubmed">34205998</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng M., Ho H., Wu Y., Chiu D.T.-Y. Glucose-6-Phosphate Dehydrogenase-Deficient Cells Show an Increased Propensity for Oxidant-Induced Senescence. Free Radic. Biol. Med. 2004;36:580&#x2013;591. doi: 10.1016/j.freeradbiomed.2003.11.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2003.11.031</ArticleId><ArticleId IdType="pubmed">14980702</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xf3;brega-Pereira S., Fernandez-Marcos P.J., Brioche T., Gomez-Cabrera M.C., Salvador-Pascual A., Flores J.M., Vi&#xf1;a J., Serrano M. G6PD Protects from Oxidative Damage and Improves Healthspan in Mice. Nat. Commun. 2016;7:10894. doi: 10.1038/ncomms10894.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms10894</ArticleId><ArticleId IdType="pmc">PMC4796314</ArticleId><ArticleId IdType="pubmed">26976705</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsubai T., Matsuo M. Ultraviolet Light-Induced Changes in the Glucose-6-Phosphate Dehydrogenase Activity of Porcine Corneas. Cornea. 2002;21:495&#x2013;500. doi: 10.1097/00003226-200207000-00011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003226-200207000-00011</ArticleId><ArticleId IdType="pubmed">12072725</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu I.M.-J., Lai R.K.-H., Lin S.-H., Tse A.P.-W., Chiu D.K.-C., Koh H.-Y., Law C.-T., Wong C.-M., Cai Z., Wong C.C.-L., et al. Transketolase Counteracts Oxidative Stress to Drive Cancer Development. Proc. Natl. Acad. Sci. USA. 2016;113:E725&#x2013;E734. doi: 10.1073/pnas.1508779113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1508779113</ArticleId><ArticleId IdType="pmc">PMC4760787</ArticleId><ArticleId IdType="pubmed">26811478</ArticleId></ArticleIdList></Reference><Reference><Citation>Dr&#xf6;ge W. Free Radicals in the Physiological Control of Cell Function. Physiol. Rev. 2002;82:47&#x2013;95. doi: 10.1152/physrev.00018.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00018.2001</ArticleId><ArticleId IdType="pubmed">11773609</ArticleId></ArticleIdList></Reference><Reference><Citation>Dammak A., Pastrana C., Martin-Gil A., Carpena-Torres C., Peral Cerda A., Simovart M., Alarma P., Huete-Toral F., Carracedo G. Oxidative Stress in the Anterior Ocular Diseases: Diagnostic and Treatment. Biomedicines. 2023;11:292. doi: 10.3390/biomedicines11020292.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines11020292</ArticleId><ArticleId IdType="pmc">PMC9952931</ArticleId><ArticleId IdType="pubmed">36830827</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Mehta G., Vasiliou V. Antioxidant Defenses in the Ocular Surface. Ocul. Surf. 2009;7:176&#x2013;185. doi: 10.1016/S1542-0124(12)70185-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1542-0124(12)70185-4</ArticleId><ArticleId IdType="pmc">PMC4104792</ArticleId><ArticleId IdType="pubmed">19948101</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xc1;lvarez-Barrios A., &#xc1;lvarez L., Garc&#xed;a M., Artime E., Pereiro R., Gonz&#xe1;lez-Iglesias H. Antioxidant Defenses in the Human Eye: A Focus on Metallothioneins. Antioxidants. 2021;10:89. doi: 10.3390/antiox10010089.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10010089</ArticleId><ArticleId IdType="pmc">PMC7826537</ArticleId><ArticleId IdType="pubmed">33440661</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaschler M.M., Stockwell B.R. Lipid Peroxidation in Cell Death. Biochem. Biophys. Res. Commun. 2017;482:419&#x2013;425. doi: 10.1016/j.bbrc.2016.10.086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2016.10.086</ArticleId><ArticleId IdType="pmc">PMC5319403</ArticleId><ArticleId IdType="pubmed">28212725</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala A., Mu&#xf1;oz M.F., Arg&#xfc;elles S. Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal. Oxid. Med. Cell. Longev. 2014;2014:360438. doi: 10.1155/2014/360438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/360438</ArticleId><ArticleId IdType="pmc">PMC4066722</ArticleId><ArticleId IdType="pubmed">24999379</ArticleId></ArticleIdList></Reference><Reference><Citation>Janicka M., Kot-Wasik A., Kot J., Namie&#x15b;nik J. Isoprostanes-Biomarkers of Lipid Peroxidation: Their Utility in Evaluating Oxidative Stress and Analysis. Int. J. Mol. Sci. 2010;11:4631&#x2013;4659. doi: 10.3390/ijms11114631.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms11114631</ArticleId><ArticleId IdType="pmc">PMC3000105</ArticleId><ArticleId IdType="pubmed">21151461</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahandeh A., Bui B.V., Finkelstein D.I., Nguyen C.T.O. Effects of Excess Iron on the Retina: Insights From Clinical Cases and Animal Models of Iron Disorders. Front. Neurosci. 2022;15:794809. doi: 10.3389/fnins.2021.794809.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2021.794809</ArticleId><ArticleId IdType="pmc">PMC8851357</ArticleId><ArticleId IdType="pubmed">35185447</ArticleId></ArticleIdList></Reference><Reference><Citation>Loh A., Hadziahmetovic M., Dunaief J.L. Iron Homeostasis and Eye Disease. Biochim. Biophys. Acta-Gen. Subj. 2009;1790:637&#x2013;649. doi: 10.1016/j.bbagen.2008.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbagen.2008.11.001</ArticleId><ArticleId IdType="pmc">PMC2718721</ArticleId><ArticleId IdType="pubmed">19059309</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Li M., Geng Z., Khattak S., Ji X., Wu D., Dang Y. Role of Oxidative Stress in Retinal Disease and the Early Intervention Strategies: A Review. Oxid. Med. Cell. Longev. 2022;2022:7836828. doi: 10.1155/2022/7836828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/7836828</ArticleId><ArticleId IdType="pmc">PMC9586758</ArticleId><ArticleId IdType="pubmed">36275903</ArticleId></ArticleIdList></Reference><Reference><Citation>Kushwah N., Bora K., Maurya M., Pavlovich M.C., Chen J. Oxidative Stress and Antioxidants in Age-Related Macular Degeneration. Antioxidants. 2023;12:1379. doi: 10.3390/antiox12071379.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox12071379</ArticleId><ArticleId IdType="pmc">PMC10376043</ArticleId><ArticleId IdType="pubmed">37507918</ArticleId></ArticleIdList></Reference><Reference><Citation>Abokyi S., To C.-H., Lam T.T., Tse D.Y. Central Role of Oxidative Stress in Age-Related Macular Degeneration: Evidence from a Review of the Molecular Mechanisms and Animal Models. Oxid. Med. Cell. Longev. 2020;2020:7901270. doi: 10.1155/2020/7901270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/7901270</ArticleId><ArticleId IdType="pmc">PMC7035553</ArticleId><ArticleId IdType="pubmed">32104539</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao T., Guo X., Sun Y. Iron Accumulation and Lipid Peroxidation in the Aging Retina: Implication of Ferroptosis in Age-Related Macular Degeneration. Aging Dis. 2021;12:529. doi: 10.14336/AD.2020.0912.</Citation><ArticleIdList><ArticleId IdType="doi">10.14336/AD.2020.0912</ArticleId><ArticleId IdType="pmc">PMC7990372</ArticleId><ArticleId IdType="pubmed">33815881</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghaffarieh A., Ciolino J.B. Potential of Application of Iron Chelating Agents in Ophthalmic Diseases. Semin. Ophthalmol. 2021;36:157&#x2013;161. doi: 10.1080/08820538.2021.1887900.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08820538.2021.1887900</ArticleId><ArticleId IdType="pmc">PMC8554538</ArticleId><ArticleId IdType="pubmed">33621147</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemeth E., Ganz T. Hepcidin-Ferroportin Interaction Controls Systemic Iron Homeostasis. Int. J. Mol. Sci. 2021;22:6493. doi: 10.3390/ijms22126493.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22126493</ArticleId><ArticleId IdType="pmc">PMC8235187</ArticleId><ArticleId IdType="pubmed">34204327</ArticleId></ArticleIdList></Reference><Reference><Citation>Glorieux C., Calderon P.B. Catalase, a Remarkable Enzyme: Targeting the Oldest Antioxidant Enzyme to Find a New Cancer Treatment Approach. Biol. Chem. 2017;398:1095&#x2013;1108. doi: 10.1515/hsz-2017-0131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/hsz-2017-0131</ArticleId><ArticleId IdType="pubmed">28384098</ArticleId></ArticleIdList></Reference><Reference><Citation>Nandi A., Yan L.-J., Jana C.K., Das N. Role of Catalase in Oxidative Stress- and Age-Associated Degenerative Diseases. Oxid. Med. Cell. Longev. 2019;2019:9613090. doi: 10.1155/2019/9613090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/9613090</ArticleId><ArticleId IdType="pmc">PMC6885225</ArticleId><ArticleId IdType="pubmed">31827713</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Z., Ju Y., Dai X., Ni N., Liu Y., Zhang D., Gao H., Sun H., Zhang J., Gu P. HO-1-Mediated Ferroptosis as a Target for Protection against Retinal Pigment Epithelium Degeneration. Redox Biol. 2021;43:101971. doi: 10.1016/j.redox.2021.101971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2021.101971</ArticleId><ArticleId IdType="pmc">PMC8099560</ArticleId><ArticleId IdType="pubmed">33895485</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson, Rasmussen H. Nutrients for the Aging Eye. Clin. Interv. Aging. 2013;8:741. doi: 10.2147/CIA.S45399.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CIA.S45399</ArticleId><ArticleId IdType="pmc">PMC3693724</ArticleId><ArticleId IdType="pubmed">23818772</ArticleId></ArticleIdList></Reference><Reference><Citation>Marreiro D., Cruz K., Morais J., Beserra J., Severo J., De Oliveira A. Zinc and Oxidative Stress: Current Mechanisms. Antioxidants. 2017;6:24. doi: 10.3390/antiox6020024.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox6020024</ArticleId><ArticleId IdType="pmc">PMC5488004</ArticleId><ArticleId IdType="pubmed">28353636</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodella U., Honisch C., Gatto C., Ruzza P., D&#x2019;Amato T&#xf3;thov&#xe1; J. Antioxidant Nutraceutical Strategies in the Prevention of Oxidative Stress Related Eye Diseases. Nutrients. 2023;15:2283. doi: 10.3390/nu15102283.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu15102283</ArticleId><ArticleId IdType="pmc">PMC10221444</ArticleId><ArticleId IdType="pubmed">37242167</ArticleId></ArticleIdList></Reference><Reference><Citation>Si M., Lang J. The Roles of Metallothioneins in Carcinogenesis. J. Hematol. Oncol. 2018;11:107. doi: 10.1186/s13045-018-0645-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13045-018-0645-x</ArticleId><ArticleId IdType="pmc">PMC6108115</ArticleId><ArticleId IdType="pubmed">30139373</ArticleId></ArticleIdList></Reference><Reference><Citation>Cobine P.A., Moore S.A., Leary S.C. Getting out What You Put in: Copper in Mitochondria and Its Impacts on Human Disease. Biochim. Biophys. Acta-Mol. Cell Res. 2021;1868:118867. doi: 10.1016/j.bbamcr.2020.118867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2020.118867</ArticleId><ArticleId IdType="pmc">PMC7680424</ArticleId><ArticleId IdType="pubmed">32979421</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin J., Fu P.P., Lutterodt H., Zhou Y., Antholine W.E., Wamer W. Dual Role of Selected Antioxidants Found in Dietary Supplements: Crossover between Anti- and Pro-Oxidant Activities in the Presence of Copper. J. Agric. Food Chem. 2012;60:2554&#x2013;2561. doi: 10.1021/jf204724w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jf204724w</ArticleId><ArticleId IdType="pmc">PMC3971523</ArticleId><ArticleId IdType="pubmed">22339379</ArticleId></ArticleIdList></Reference><Reference><Citation>Suntres Z.E., Lui E.M.K. Prooxidative Effect of Copper&#x2013;Metallothionein in the Acute Cytotoxicity of Hydrogen Peroxide in Ehrlich Ascites Tumour Cells. Toxicology. 2006;217:155&#x2013;168. doi: 10.1016/j.tox.2005.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tox.2005.09.004</ArticleId><ArticleId IdType="pubmed">16221516</ArticleId></ArticleIdList></Reference><Reference><Citation>Jomova K., Valko M. Advances in Metal-Induced Oxidative Stress and Human Disease. Toxicology. 2011;283:65&#x2013;87. doi: 10.1016/j.tox.2011.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tox.2011.03.001</ArticleId><ArticleId IdType="pubmed">21414382</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Bayati M.A., Jamil D.A., Al-Aubaidy H.A. Cardiovascular Effects of Copper Deficiency on Activity of Superoxide Dismutase in Diabetic Nephropathy. N. Am. J. Med. Sci. 2015;7:41&#x2013;46. doi: 10.4103/1947-2714.152077.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1947-2714.152077</ArticleId><ArticleId IdType="pmc">PMC4358047</ArticleId><ArticleId IdType="pubmed">25789247</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabi S.U., Jan A., Muzamil S., Razaq R., Muhee A., Ashraf T., Ahmad S., Makhdoomi D.M., Shah N.N., Syed Q. Role of Biometals in Activation of Immune Cum Inflammatory Response in Ovine Ageing Eye: A Potential Model for Understanding Human Geriatric Eye Diseases. BioMetals. 2021;34:1081&#x2013;1098. doi: 10.1007/s10534-021-00331-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10534-021-00331-y</ArticleId><ArticleId IdType="pubmed">34297243</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadrup N., Ravn-Haren G. Acute Human Toxicity and Mortality after Selenium Ingestion: A Review. J. Trace Elem. Med. Biol. 2020;58:126435. doi: 10.1016/j.jtemb.2019.126435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtemb.2019.126435</ArticleId><ArticleId IdType="pubmed">31775070</ArticleId></ArticleIdList></Reference><Reference><Citation>Labunskyy V.M., Hatfield D.L., Gladyshev V.N. Selenoproteins: Molecular Pathways and Physiological Roles. Physiol. Rev. 2014;94:739&#x2013;777. doi: 10.1152/physrev.00039.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00039.2013</ArticleId><ArticleId IdType="pmc">PMC4101630</ArticleId><ArticleId IdType="pubmed">24987004</ArticleId></ArticleIdList></Reference><Reference><Citation>Dogaru C.B., Muscurel C., Du&#x21b;&#x103; C., Stoian I. &#x201c;Alphabet&#x201d; Selenoproteins: Their Characteristics and Physiological Roles. Int. J. Mol. Sci. 2023;24:15992. doi: 10.3390/ijms242115992.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms242115992</ArticleId><ArticleId IdType="pmc">PMC10650576</ArticleId><ArticleId IdType="pubmed">37958974</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi A., Takahashi K., Hirashima M., Kawakita T., Tsubota K. Selenoprotein P Controls Oxidative Stress in Cornea. PLoS ONE. 2010;5:e9911. doi: 10.1371/journal.pone.0009911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0009911</ArticleId><ArticleId IdType="pmc">PMC2847950</ArticleId><ArticleId IdType="pubmed">20360971</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade I.G.A., Suano-Souza F.I., Fonseca F.L.A., Lago C.S.A., Sarni R.O.S. Selenium Levels and Glutathione Peroxidase Activity in Patients with Ataxia-Telangiectasia: Association with Oxidative Stress and Lipid Status Biomarkers. Orphanet J. Rare Dis. 2021;16:83. doi: 10.1186/s13023-021-01732-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-021-01732-5</ArticleId><ArticleId IdType="pmc">PMC7881534</ArticleId><ArticleId IdType="pubmed">33579341</ArticleId></ArticleIdList></Reference><Reference><Citation>Maia L.B., Maiti B.K., Moura I., Moura J.J.G. Selenium&#x2014;More than Just a Fortuitous Sulfur Substitute in Redox Biology. Molecules. 2023;29:120. doi: 10.3390/molecules29010120.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules29010120</ArticleId><ArticleId IdType="pmc">PMC10779653</ArticleId><ArticleId IdType="pubmed">38202704</ArticleId></ArticleIdList></Reference><Reference><Citation>Ighodaro O.M., Akinloye O.A. First Line Defence Antioxidants-Superoxide Dismutase (SOD), Catalase (CAT) and Glutathione Peroxidase (GPX): Their Fundamental Role in the Entire Antioxidant Defence Grid. Alex. J. Med. 2018;54:287&#x2013;293. doi: 10.1016/j.ajme.2017.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajme.2017.09.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Bj&#xf8;rklund G., Shanaida M., Lysiuk R., Antonyak H., Klishch I., Shanaida V., Peana M. Selenium: An Antioxidant with a Critical Role in Anti-Aging. Molecules. 2022;27:6613. doi: 10.3390/molecules27196613.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27196613</ArticleId><ArticleId IdType="pmc">PMC9570904</ArticleId><ArticleId IdType="pubmed">36235150</ArticleId></ArticleIdList></Reference><Reference><Citation>Ananth S., Miyauchi S., Thangaraju M., Jadeja R.N., Bartoli M., Ganapathy V., Martin P.M. Selenomethionine (Se-Met) Induces the Cystine/Glutamate Exchanger SLC7A11 in Cultured Human Retinal Pigment Epithelial (RPE) Cells: Implications for Antioxidant Therapy in Aging Retina. Antioxidants. 2021;10:9. doi: 10.3390/antiox10010009.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10010009</ArticleId><ArticleId IdType="pmc">PMC7823377</ArticleId><ArticleId IdType="pubmed">33374239</ArticleId></ArticleIdList></Reference><Reference><Citation>Wr&#xf3;blewski M., Wr&#xf3;blewska J., Nuszkiewicz J., Paw&#x142;owska M., Weso&#x142;owski R., Wo&#x17a;niak A. The Role of Selected Trace Elements in Oxidoreductive Homeostasis in Patients with Thyroid Diseases. Int. J. Mol. Sci. 2023;24:4840. doi: 10.3390/ijms24054840.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24054840</ArticleId><ArticleId IdType="pmc">PMC10003705</ArticleId><ArticleId IdType="pubmed">36902266</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi A., Inoue H., Kaneko Y., Oonishi E., Tsubota K. Selenium-Binding Lactoferrin Is Taken into Corneal Epithelial Cells by a Receptor and Prevents Corneal Damage in Dry Eye Model Animals. Sci. Rep. 2016;6:36903. doi: 10.1038/srep36903.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep36903</ArticleId><ArticleId IdType="pmc">PMC5105079</ArticleId><ArticleId IdType="pubmed">27833152</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi A. Autologous Serum and Serum Components. Investig. Opthalmology Vis. Sci. 2018;59:DES121. doi: 10.1167/iovs.17-23760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.17-23760</ArticleId><ArticleId IdType="pubmed">30481816</ArticleId></ArticleIdList></Reference><Reference><Citation>Genchi G., Lauria G., Catalano A., Sinicropi M.S., Carocci A. Biological Activity of Selenium and Its Impact on Human Health. Int. J. Mol. Sci. 2023;24:2633. doi: 10.3390/ijms24032633.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24032633</ArticleId><ArticleId IdType="pmc">PMC9917223</ArticleId><ArticleId IdType="pubmed">36768955</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian J., Liu J., Li J., Zheng J., Chen L., Wang Y., Liu Q., Ni J. The Interaction of Selenoprotein F (SELENOF) with Retinol Dehydrogenase 11 (RDH11) Implied a Role of SELENOF in Vitamin A Metabolism. Nutr. Metab. 2018;15:7. doi: 10.1186/s12986-017-0235-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12986-017-0235-x</ArticleId><ArticleId IdType="pmc">PMC5778809</ArticleId><ArticleId IdType="pubmed">29410696</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasaikina M.V., Fomenko D.E., Labunskyy V.M., Lachke S.A., Qiu W., Moncaster J.A., Zhang J., Wojnarowicz M.W., Natarajan S.K., Malinouski M., et al. Roles of the 15-KDa Selenoprotein (Sep15) in Redox Homeostasis and Cataract Development Revealed by the Analysis of Sep 15 Knockout Mice. J. Biol. Chem. 2011;286:33203&#x2013;33212. doi: 10.1074/jbc.M111.259218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.259218</ArticleId><ArticleId IdType="pmc">PMC3190948</ArticleId><ArticleId IdType="pubmed">21768092</ArticleId></ArticleIdList></Reference><Reference><Citation>Han S.-J., Lee B.C., Yim S.H., Gladyshev V.N., Lee S.-R. Characterization of Mammalian Selenoprotein O: A Redox-Active Mitochondrial Protein. PLoS ONE. 2014;9:e95518. doi: 10.1371/journal.pone.0095518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0095518</ArticleId><ArticleId IdType="pmc">PMC3994087</ArticleId><ArticleId IdType="pubmed">24751718</ArticleId></ArticleIdList></Reference><Reference><Citation>Floh&#xe9; L. Nutrition and the Eye. Volume 38. KARGER; Basel, Switzerland: 2005. Selenium, Selenoproteins and Vision; pp. 89&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">15604619</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F., Li X., Wei Y. Selenium and Selenoproteins in Health. Biomolecules. 2023;13:799. doi: 10.3390/biom13050799.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom13050799</ArticleId><ArticleId IdType="pmc">PMC10216560</ArticleId><ArticleId IdType="pubmed">37238669</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano S., Lobanov A.V., Chapple C., Novoselov S.V., Albrecht M., Hua D., Lescure A., Lengauer T., Krol A., Gladyshev V.N., et al. Diversity and Functional Plasticity of Eukaryotic Selenoproteins: Identification and Characterization of the SelJ Family. Proc. Natl. Acad. Sci. USA. 2005;102:16188&#x2013;16193. doi: 10.1073/pnas.0505146102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0505146102</ArticleId><ArticleId IdType="pmc">PMC1283428</ArticleId><ArticleId IdType="pubmed">16260744</ArticleId></ArticleIdList></Reference><Reference><Citation>Alaunyte I., Stojceska V., Plunkett A. Iron and the Female Athlete: A Review of Dietary Treatment Methods for Improving Iron Status and Exercise Performance. J. Int. Soc. Sports Nutr. 2015;12:1. doi: 10.1186/s12970-015-0099-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12970-015-0099-2</ArticleId><ArticleId IdType="pmc">PMC4596414</ArticleId><ArticleId IdType="pubmed">26448737</ArticleId></ArticleIdList></Reference><Reference><Citation>Milman N.T. Dietary Iron Intakes in Men in Europe Are Distinctly Above the Recommendations: A Review of 39 National Studies From 20 Countries in the Period 1995&#x2013;2016. Gastroenterol. Res. 2020;13:233&#x2013;245. doi: 10.14740/gr1344.</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/gr1344</ArticleId><ArticleId IdType="pmc">PMC7781270</ArticleId><ArticleId IdType="pubmed">33447302</ArticleId></ArticleIdList></Reference><Reference><Citation>Frydrych A., Kro&#x15b;niak M., Jurowski K. The Role of Chosen Essential Elements (Zn, Cu, Se, Fe, Mn) in Food for Special Medical Purposes (FSMPs) Dedicated to Oncology Patients&#x2014;Critical Review: State-of-the-Art. Nutrients. 2023;15:1012. doi: 10.3390/nu15041012.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu15041012</ArticleId><ArticleId IdType="pmc">PMC9961387</ArticleId><ArticleId IdType="pubmed">36839370</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie R.F., Palomaki G.E., Neveux L.M., Navolotskaia O., Ledue T.B., Craig W.Y. Reference Distributions for Serum Iron and Transferrin Saturation: A Practical, Simple, and Clinically Relevant Approach in a Large Cohort. J. Clin. Lab. Anal. 2002;16:237&#x2013;245. doi: 10.1002/jcla.10048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcla.10048</ArticleId><ArticleId IdType="pmc">PMC6807751</ArticleId><ArticleId IdType="pubmed">12357453</ArticleId></ArticleIdList></Reference><Reference><Citation>Basuli D., Stevens R.G., Torti F.M., Torti S.V. Epidemiological Associations between Iron and Cardiovascular Disease and Diabetes. Front. Pharmacol. 2014;5:117. doi: 10.3389/fphar.2014.00117.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2014.00117</ArticleId><ArticleId IdType="pmc">PMC4033158</ArticleId><ArticleId IdType="pubmed">24904420</ArticleId></ArticleIdList></Reference><Reference><Citation>Picard E., Daruich A., Youale J., Courtois Y., Behar-Cohen F. From Rust to Quantum Biology: The Role of Iron in Retina Physiopathology. Cells. 2020;9:705. doi: 10.3390/cells9030705.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9030705</ArticleId><ArticleId IdType="pmc">PMC7140613</ArticleId><ArticleId IdType="pubmed">32183063</ArticleId></ArticleIdList></Reference><Reference><Citation>Ataide R., Fielding K., Pasricha S.R., Bennett C. Iron Deficiency, Pregnancy, and Neonatal Development. Int. J. Gynecol. Obstet. 2023;162:14&#x2013;22. doi: 10.1002/ijgo.14944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijgo.14944</ArticleId><ArticleId IdType="pubmed">37538017</ArticleId></ArticleIdList></Reference><Reference><Citation>Moriarty-Craige S.E., Ha K.-N., Sternberg P., Lynn M., Bressler S., Gensler G., Jones D.P. Effects of Long-Term Zinc Supplementation on Plasma Thiol Metabolites and Redox Status in Patients with Age-Related Macular Degeneration. Am. J. Ophthalmol. 2007;143:206&#x2013;211.e2. doi: 10.1016/j.ajo.2006.09.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2006.09.056</ArticleId><ArticleId IdType="pmc">PMC1993812</ArticleId><ArticleId IdType="pubmed">17157802</ArticleId></ArticleIdList></Reference><Reference><Citation>Biesemeier A., Kokkinou D., Julien S., Heiduschka P., Berneburg M., Bartz-Schmidt K.U., Schraermeyer U. UV-A Induced Oxidative Stress Is More Prominent in Naturally Pigmented Aged Human RPE Cells Compared to Non-Pigmented Human RPE Cells Independent of Zinc Treatment. J. Photochem. Photobiol. B Biol. 2008;90:113&#x2013;120. doi: 10.1016/j.jphotobiol.2007.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jphotobiol.2007.11.005</ArticleId><ArticleId IdType="pubmed">18203614</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood J.P., Osborne N.N. The Influence of Zinc on Caspase-3 and DNA Breakdown in Cultured Human Retinal Pigment Epithelial Cells. Arch. Ophthalmol. 2001;119:81&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">11146730</ArticleId></ArticleIdList></Reference><Reference><Citation>Miceli M.V., Tate D.J., Alcock N.W., Newsome D.A. Zinc Deficiency and Oxidative Stress in the Retina of Pigmented Rats. Investig. Ophthalmol. Vis. Sci. 1999;40:1238&#x2013;1244.</Citation><ArticleIdList><ArticleId IdType="pubmed">10235558</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan A., Yacoubian C., Watson N., Morrison I. The Risk of Copper Deficiency in Patients Prescribed Zinc Supplements. J. Clin. Pathol. 2015;68:723&#x2013;725. doi: 10.1136/jclinpath-2014-202837.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jclinpath-2014-202837</ArticleId><ArticleId IdType="pubmed">26085547</ArticleId></ArticleIdList></Reference><Reference><Citation>Satarug S., Kikuchi M., Wisedpanichkij R., Li B., Takeda K., Na-Bangchang K., Moore M.R., Hirayama K., Shibahara S. Prevention of Cadmium Accumulation in Retinal Pigment Epithelium with Manganese and Zinc. Exp. Eye Res. 2008;87:587&#x2013;593. doi: 10.1016/j.exer.2008.09.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exer.2008.09.014</ArticleId><ArticleId IdType="pubmed">18948096</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozdemir G., Inanc F. Zinc May Protect Remote Ocular Injury Caused by Intestinal Ischemia Reperfusion in Rats. Tohoku J. Exp. Med. 2005;206:247&#x2013;251. doi: 10.1620/tjem.206.247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1620/tjem.206.247</ArticleId><ArticleId IdType="pubmed">15942153</ArticleId></ArticleIdList></Reference><Reference><Citation>Newsome D.A., Miceli M.V., Tate D.J., Alcock N.W., Oliver P.D. Zinc Content of Human Retinal Pigment Epithelium Decreases with Age and Macular Degeneration, but Superoxide Dismutase Activity Increases. J. Trace Elem. Exp. Med. 1996;8:193&#x2013;199. doi: 10.1002/(SICI)1520-670X(199605)8:4&lt;193::AID-JTRA1&gt;3.0.CO;2-O.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1520-670X(199605)8:4&lt;193::AID-JTRA1&gt;3.0.CO;2-O</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha K.-N., Chen Y., Cai J., Sternberg P. Increased Glutathione Synthesis through an ARE-Nrf2&#x2013;Dependent Pathway by Zinc in the RPE: Implication for Protection against Oxidative Stress. Investig. Opthalmology Vis. Sci. 2006;47:2709. doi: 10.1167/iovs.05-1322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.05-1322</ArticleId><ArticleId IdType="pubmed">16723490</ArticleId></ArticleIdList></Reference><Reference><Citation>Mano F., Sakata S., Chang K.-C., Mano T. Effects of Zinc Acetate Hydrate Treatment on Serum Oxidative Stress Markers in Patients with Macular Drusen. J. Ocul. Pharmacol. Ther. 2021;37:518&#x2013;524. doi: 10.1089/jop.2021.0031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jop.2021.0031</ArticleId><ArticleId IdType="pubmed">34558962</ArticleId></ArticleIdList></Reference><Reference><Citation>Satyam S.M., Bairy L.K., Pirasanthan R., Vaishnav R.L. Grape Seed Extract and Zinc Containing Nutritional Food Supplement Prevents Onset and Progression of Age-Related Cataract in Wistar Rats. J. Nutr. Health Aging. 2014;18:524&#x2013;530. doi: 10.1007/s12603-014-0020-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12603-014-0020-8</ArticleId><ArticleId IdType="pubmed">24886740</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Miao J. An Emerging Role of Defective Copper Metabolism in Heart Disease. Nutrients. 2022;14:700. doi: 10.3390/nu14030700.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu14030700</ArticleId><ArticleId IdType="pmc">PMC8838622</ArticleId><ArticleId IdType="pubmed">35277059</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz L.M., Libedinsky A., Elorza A.A. Role of Copper on Mitochondrial Function and Metabolism. Front. Mol. Biosci. 2021;8:711227. doi: 10.3389/fmolb.2021.711227.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2021.711227</ArticleId><ArticleId IdType="pmc">PMC8421569</ArticleId><ArticleId IdType="pubmed">34504870</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlatic S., Comstra H.S., Gokhale A., Petris M.J., Faundez V. Molecular Basis of Neurodegeneration and Neurodevelopmental Defects in Menkes Disease. Neurobiol. Dis. 2015;81:154&#x2013;161. doi: 10.1016/j.nbd.2014.12.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2014.12.024</ArticleId><ArticleId IdType="pmc">PMC4499018</ArticleId><ArticleId IdType="pubmed">25583185</ArticleId></ArticleIdList></Reference><Reference><Citation>Galhardi C.M., Diniz Y.S., Faine L.A., Rodrigues H.G., Burneiko R.C.M., Ribas B.O., Novelli E.L.B. Toxicity of Copper Intake: Lipid Profile, Oxidative Stress and Susceptibility to Renal Dysfunction. Food Chem. Toxicol. 2004;42:2053&#x2013;2060. doi: 10.1016/j.fct.2004.07.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fct.2004.07.020</ArticleId><ArticleId IdType="pubmed">15500942</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardak H., U&#x11f;uz A.C., Bardak Y., Rocha-Pimienta J., Delgado-Ad&#xe1;mez J., Espino J. Selenium Protects ARPE-19 and ACBRI 181 Cells against High Glucose-Induced Oxidative Stress. Molecules. 2023;28:5961. doi: 10.3390/molecules28165961.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules28165961</ArticleId><ArticleId IdType="pmc">PMC10459791</ArticleId><ArticleId IdType="pubmed">37630213</ArticleId></ArticleIdList></Reference><Reference><Citation>Yazici A., Aksit H., Sari E.S., Yay A., Erken H.A., Aksit D., Cakmak H., Seyrek K., Ermis S.S. Comparison of Pre-Treatment and Post-Treatment Use of Selenium in Retinal Ischemia Reperfusion Injury. Int. J. Ophthalmol. 2015;8:263&#x2013;268. doi: 10.3980/j.issn.2222-3959.2015.02.09.</Citation><ArticleIdList><ArticleId IdType="doi">10.3980/j.issn.2222-3959.2015.02.09</ArticleId><ArticleId IdType="pmc">PMC4413567</ArticleId><ArticleId IdType="pubmed">25938038</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao M., Hu J., Zhu Y., Wang X., Zeng S., Hong Y., Zhao G. Ferroptosis and Apoptosis Are Involved in the Formation of L-Selenomethionine-Induced Ocular Defects in Zebrafish Embryos. Int. J. Mol. Sci. 2022;23:4783. doi: 10.3390/ijms23094783.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23094783</ArticleId><ArticleId IdType="pmc">PMC9100823</ArticleId><ArticleId IdType="pubmed">35563172</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou L., Wu Z., Hu X., Huang J., Yi Z., Gong Z., Li H., Peng K., Shu C., Koole L.H. A Tissue-Adhesive F127 Hydrogel Delivers Antioxidative Copper-Selenide Nanoparticles for the Treatment of Dry Eye Disease. Acta Biomater. 2024;175:353&#x2013;368. doi: 10.1016/j.actbio.2023.12.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actbio.2023.12.021</ArticleId><ArticleId IdType="pubmed">38110136</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Bras M., Cl&#xe9;ment M.V., Pervaiz S., Brenner C. Reactive Oxygen Species and the Mitochondrial Signaling Pathway of Cell Death. Histol. Histopathol. 2005;20:205&#x2013;220. doi: 10.14670/HH-20.205.</Citation><ArticleIdList><ArticleId IdType="doi">10.14670/HH-20.205</ArticleId><ArticleId IdType="pubmed">15578439</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39595213</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9059</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>20</Day></PubDate></JournalIssue><Title>Biomedicines</Title><ISOAbbreviation>Biomedicines</ISOAbbreviation></Journal><ArticleTitle>Involvement of <i>Lgals3</i>/Galectin-3 in Choroidal Neovascularization and Subretinal Fibrosis Formation.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2649</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biomedicines12112649</ELocationID><Abstract><AbstractText><b>Background:</b><i>Lgals3</i>/galectin-3 plays a pivotal role in many vascular diseases. However, the involvement of <i>Lgals3</i>/galectin-3 in eyes with neovascular age-related macular degeneration (nAMD) remains unknown. <b>Methods:</b> In the laser-induced CNV model, a whole mount retina stained with Isolectin B4 and collagen type I revealed the vascular bed and CNV-associated subretinal fibrosis on day 7 after laser treatment. <b>Results:</b> We show that the expression levels of <i>Lgals3</i>/galectin-3 were significantly increased in the RPE/choroidal complex of CNV mice. An intravitreal injection of <i>Lgals3</i>-siRNA significantly suppressed the area of CNV and subretinal fibrosis, together with <i>Mcp-1</i> decline. The mixture of <i>Lgals3</i>-siRNA and Ranibizumab showed more efficiency than each drug used separately. Hypoxia induced <i>Lgals3</i>/galectin-3 production in ARPE-19 cells, which was reduced by the silencing hypoxia-inducible factor -1&#x3b1; (<i>Hif-1a</i>). <b>Conclusions:</b> Our data indicated that <i>Lgals3</i>/galectin-3 is involved in the pathogenesis of CNV and subretinal fibrosis, and <i>Lgals3</i>/galectin-3 could be a potential therapeutic target for nAMD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Di</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Eye Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial Key Laboratory of Ophthalmology, Zhejiang Provincial Clinical Research Center for Eye Diseases, Zhejiang Provincial Engineering Institute on Eye Diseases, Hangzhou 310051, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ye</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Eye Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial Key Laboratory of Ophthalmology, Zhejiang Provincial Clinical Research Center for Eye Diseases, Zhejiang Provincial Engineering Institute on Eye Diseases, Hangzhou 310051, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Xiaogang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Eye Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial Key Laboratory of Ophthalmology, Zhejiang Provincial Clinical Research Center for Eye Diseases, Zhejiang Provincial Engineering Institute on Eye Diseases, Hangzhou 310051, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zhiqing</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Eye Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial Key Laboratory of Ophthalmology, Zhejiang Provincial Clinical Research Center for Eye Diseases, Zhejiang Provincial Engineering Institute on Eye Diseases, Hangzhou 310051, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Qiuli</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Eye Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial Key Laboratory of Ophthalmology, Zhejiang Provincial Clinical Research Center for Eye Diseases, Zhejiang Provincial Engineering Institute on Eye Diseases, Hangzhou 310051, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Ke</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-6764-7365</Identifier><AffiliationInfo><Affiliation>Eye Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial Key Laboratory of Ophthalmology, Zhejiang Provincial Clinical Research Center for Eye Diseases, Zhejiang Provincial Engineering Institute on Eye Diseases, Hangzhou 310051, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>LQ21H120003</GrantID><Agency>Zhejiang Provincial Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>82301207</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>2024ZY01057</GrantID><Agency>Central guidance for local scientific and technological development funding projects</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomedicines</MedlineTA><NlmUniqueID>101691304</NlmUniqueID><ISSNLinking>2227-9059</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Lgals3/galectin-3</Keyword><Keyword MajorTopicYN="N">age-related macular degeneration</Keyword><Keyword MajorTopicYN="N">choroidal neovascularization</Keyword><Keyword MajorTopicYN="N">hypoxia-inducible factor</Keyword><Keyword MajorTopicYN="N">subretinal fibrosis</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>1</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39595213</ArticleId><ArticleId IdType="pmc">PMC11592115</ArticleId><ArticleId IdType="doi">10.3390/biomedicines12112649</ArticleId><ArticleId IdType="pii">biomedicines12112649</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wong W.L., Su X., Li X., Cheung C.M., Klein R., Cheng C.Y., Wong T.Y. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. Lancet Glob. Health. 2014;2:e106&#x2013;e116. doi: 10.1016/S2214-109X(13)70145-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(13)70145-1</ArticleId><ArticleId IdType="pubmed">25104651</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenbrock L., Wolf J., Boneva S., Schlecht A., Agostini H., Wieghofer P., Schlunck G., Lange C. Subretinal fibrosis in neovascular age-related macular degeneration: Current concepts, therapeutic avenues, and future perspectives. Cell Tissue Res. 2022;387:361&#x2013;375. doi: 10.1007/s00441-021-03514-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00441-021-03514-8</ArticleId><ArticleId IdType="pmc">PMC8975778</ArticleId><ArticleId IdType="pubmed">34477966</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncel D., Oncel D., Mishra K., Oncel M., Arevalo J.F. Current Management of Subretinal Hemorrhage in Neovascular Age-Related Macular Degeneration. Ophthalmologica. 2023;246:295&#x2013;305. doi: 10.1159/000534440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000534440</ArticleId><ArticleId IdType="pubmed">37806303</ArticleId></ArticleIdList></Reference><Reference><Citation>Mettu P.S., Allingham M.J., Cousins S.W. Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. Prog. Retin. Eye Res. 2021;82:100906. doi: 10.1016/j.preteyeres.2020.100906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2020.100906</ArticleId><ArticleId IdType="pmc">PMC10368393</ArticleId><ArticleId IdType="pubmed">33022379</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheridan C.M., Pate S., Hiscott P., Wong D., Pattwell D.M., Kent D. Expression of hypoxia-inducible factor-1alpha and -2alpha in human choroidal neovascular membranes. Graefes Arch. Clin. Exp. Ophthalmol. 2009;247:1361&#x2013;1367. doi: 10.1007/s00417-009-1133-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00417-009-1133-3</ArticleId><ArticleId IdType="pubmed">19590888</ArticleId></ArticleIdList></Reference><Reference><Citation>Mammadzada P., Corredoira P.M., Andre H. The role of hypoxia-inducible factors in neovascular age-related macular degeneration: A gene therapy perspective. Cell Mol. Life Sci. 2020;77:819&#x2013;833. doi: 10.1007/s00018-019-03422-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-019-03422-9</ArticleId><ArticleId IdType="pmc">PMC7058677</ArticleId><ArticleId IdType="pubmed">31893312</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanani A.M., Russell M.W., Aziz A.A., Danzig C.J., Weng C.Y., Eichenbaum D.A., Singh R.P. Angiopoietins as Potential Targets in Management of Retinal Disease. Clin. Ophthalmol. 2021;15:3747&#x2013;3755. doi: 10.2147/OPTH.S231801.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OPTH.S231801</ArticleId><ArticleId IdType="pmc">PMC8427682</ArticleId><ArticleId IdType="pubmed">34511878</ArticleId></ArticleIdList></Reference><Reference><Citation>Biasella F., Strunz T., Kiel C., On Behalf Of The International Amd Genomics Consortium, I. Weber B.H.F., Friedrich U. Vitronectin and Its Interaction with PAI-1 Suggests a Functional Link to Vascular Changes in AMD Pathobiology. Cells. 2022;11:1766. doi: 10.3390/cells11111766.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11111766</ArticleId><ArticleId IdType="pmc">PMC9179922</ArticleId><ArticleId IdType="pubmed">35681461</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K., Sakurai E., Itaya M., Yamasaki S., Ogura Y. Inhibition of laser-induced choroidal neovascularization by atorvastatin by downregulation of monocyte chemotactic protein-1 synthesis in mice. Investig. Ophthalmol. Vis. Sci. 2007;48:1839&#x2013;1843. doi: 10.1167/iovs.06-1085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.06-1085</ArticleId><ArticleId IdType="pubmed">17389519</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambati J., Anand A., Fernandez S., Sakurai E., Lynn B.C., Kuziel W.A., Rollins B.J., Ambati B.K. An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat. Med. 2003;9:1390&#x2013;1397. doi: 10.1038/nm950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm950</ArticleId><ArticleId IdType="pubmed">14566334</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D., Kanda A., Liu Y., Kase S., Noda K., Ishida S. Galectin-1 promotes choroidal neovascularization and subretinal fibrosis mediated via epithelial-mesenchymal transition. FASEB J. 2019;33:2498&#x2013;2513. doi: 10.1096/fj.201801227R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201801227R</ArticleId><ArticleId IdType="pubmed">30277820</ArticleId></ArticleIdList></Reference><Reference><Citation>Verkerke H., Dias-Baruffi M., Cummings R.D., Arthur C.M., Stowell S.R. Galectins: An Ancient Family of Carbohydrate Binding Proteins with Modern Functions. Methods Mol. Biol. 2022;2442:1&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">35320517</ArticleId></ArticleIdList></Reference><Reference><Citation>Johannes L., Jacob R., Leffler H. Galectins at a glance. J. Cell Sci. 2018;131:jcs208884. doi: 10.1242/jcs.208884.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.208884</ArticleId><ArticleId IdType="pubmed">29717004</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S., Pritchard D.M., Yu L.G. Galectin-3 promotes secretion of proteases that decrease epithelium integrity in human colon cancer cells. Cell Death Dis. 2023;14:268. doi: 10.1038/s41419-023-05789-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-023-05789-x</ArticleId><ArticleId IdType="pmc">PMC10102123</ArticleId><ArticleId IdType="pubmed">37055381</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Z., Liu Z., Wang R., Zheng Y., Li H., Yang L. Galectin-3 Is a Potential Mediator for Atherosclerosis. J. Immunol. Res. 2020;2020:5284728. doi: 10.1155/2020/5284728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/5284728</ArticleId><ArticleId IdType="pmc">PMC7042544</ArticleId><ArticleId IdType="pubmed">32149158</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanda V., Bracale U.M., Di Taranto M.D., Fortunato G. Galectin-3 in Cardiovascular Diseases. Int. J. Mol. Sci. 2020;21:9232. doi: 10.3390/ijms21239232.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21239232</ArticleId><ArticleId IdType="pmc">PMC7731136</ArticleId><ArticleId IdType="pubmed">33287402</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Moreno E., Oyanadel C., de la Pena A., Hernandez R., Perez-Molina F., Metz C., Gonzalez A., Soza A. Galectins in epithelial-mesenchymal transition: Roles and mechanisms contributing to tissue repair, fibrosis and cancer metastasis. Biol. Res. 2024;57:14. doi: 10.1186/s40659-024-00490-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40659-024-00490-5</ArticleId><ArticleId IdType="pmc">PMC10993482</ArticleId><ArticleId IdType="pubmed">38570874</ArticleId></ArticleIdList></Reference><Reference><Citation>Saravanan C., Liu F.T., Gipson I.K., Panjwani N. Galectin-3 promotes lamellipodia formation in epithelial cells by interacting with complex N-glycans on alpha3beta1 integrin. J. Cell Sci. 2009;122:3684&#x2013;3693. doi: 10.1242/jcs.045674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.045674</ArticleId><ArticleId IdType="pmc">PMC2758802</ArticleId><ArticleId IdType="pubmed">19755493</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade F.E.C., Correa M.P., Gimenes A.D., Dos Santos M.S., Campos M., Chammas R., Gomes J.A.P., Gil C.D. Galectin-3: Role in ocular allergy and potential as a predictive biomarker. Br. J. Ophthalmol. 2018;102:1003&#x2013;1010. doi: 10.1136/bjophthalmol-2017-311473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjophthalmol-2017-311473</ArticleId><ArticleId IdType="pubmed">29502069</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito N.J., Mazzoni F., Vargas J.A., Finnemann S.C. Diurnal Photoreceptor Outer Segment Renewal in Mice Is Independent of Galectin-3. Investig. Ophthalmol. Vis. Sci. 2021;62:7. doi: 10.1167/iovs.62.2.7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.62.2.7</ArticleId><ArticleId IdType="pmc">PMC7862728</ArticleId><ArticleId IdType="pubmed">33538769</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitts K.M., Neeson C.E., Hall N.E., Lin J.B., Falah H.K., Wang S.L., Lo K.T., Song C.E., Margeta M.A., Sola-Del Valle D.A. Neurodegeneration Markers Galectin-3 and Apolipoprotein E Are Elevated in the Aqueous Humor of Eyes With Glaucoma. Transl. Vis. Sci. Technol. 2022;11:1. doi: 10.1167/tvst.11.11.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/tvst.11.11.1</ArticleId><ArticleId IdType="pmc">PMC9639679</ArticleId><ArticleId IdType="pubmed">36318198</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Zhao C., Meng J., Li N., Xu Z., Liu X., Hou S. Galectin-3 regulates microglial activation and promotes inflammation through TLR4/MyD88/NF-kB in experimental autoimmune uveitis. Clin. Immunol. 2022;236:108939. doi: 10.1016/j.clim.2022.108939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2022.108939</ArticleId><ArticleId IdType="pubmed">35121106</ArticleId></ArticleIdList></Reference><Reference><Citation>Canning P., Glenn J.V., Hsu D.K., Liu F.T., Gardiner T.A., Stitt A.W. Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes. Exp. Diabetes Res. 2007;2007:51837. doi: 10.1155/2007/51837.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2007/51837</ArticleId><ArticleId IdType="pmc">PMC1880865</ArticleId><ArticleId IdType="pubmed">17641742</ArticleId></ArticleIdList></Reference><Reference><Citation>An E., Lu X., Flippin J., Devaney J.M., Halligan B., Hoffman E.P., Strunnikova N., Csaky K., Hathout Y. Secreted proteome profiling in human RPE cell cultures derived from donors with age related macular degeneration and age matched healthy donors. J. Proteome Res. 2006;5:2599&#x2013;2610. doi: 10.1021/pr060121j.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr060121j</ArticleId><ArticleId IdType="pubmed">17022631</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Kanda A., Wu D., Ishizuka E.T., Kase S., Noda K., Ichihara A., Ishida S. Suppression of Choroidal Neovascularization and Fibrosis by a Novel RNAi Therapeutic Agent against (Pro)renin Receptor. Mol. Ther. Nucleic Acids. 2019;17:113&#x2013;125. doi: 10.1016/j.omtn.2019.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2019.05.012</ArticleId><ArticleId IdType="pmc">PMC6599885</ArticleId><ArticleId IdType="pubmed">31254924</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang Y.H., Hsing C.H., Chiu C.J., Wu Y.R., Hsu S.M., Hsu Y.H. Protective role of IL-17-producing gammadelta T cells in a laser-induced choroidal neovascularization mouse model. J. Neuroinflamm. 2023;20:279. doi: 10.1186/s12974-023-02952-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-023-02952-1</ArticleId><ArticleId IdType="pmc">PMC10676594</ArticleId><ArticleId IdType="pubmed">38007487</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Wu D., Fu Q., Hao S., Gu Y., Zhao W., Chen S., Sheng F., Xu Y., Chen Z., et al. CHAC1 as a Novel Contributor of Ferroptosis in Retinal Pigment Epithelial Cells with Oxidative Damage. Int. J. Mol. Sci. 2023;24:1582. doi: 10.3390/ijms24021582.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24021582</ArticleId><ArticleId IdType="pmc">PMC9861460</ArticleId><ArticleId IdType="pubmed">36675091</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki M., Tsujikawa M., Itabe H., Du Z.J., Xie P., Matsumura N., Fu X., Zhang R., Sonoda K.H., Egashira K., et al. Chronic photo-oxidative stress and subsequent MCP-1 activation as causative factors for age-related macular degeneration. Pt 10J. Cell Sci. 2012;125:2407&#x2013;2415. doi: 10.1242/jcs.097683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.097683</ArticleId><ArticleId IdType="pmc">PMC3383257</ArticleId><ArticleId IdType="pubmed">22357958</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenfeld P.J., Brown D.M., Heier J.S., Boyer D.S., Kaiser P.K., Chung C.Y., Kim R.Y., Group M.S. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2006;355:1419&#x2013;1431. doi: 10.1056/NEJMoa054481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa054481</ArticleId><ArticleId IdType="pubmed">17021318</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrado C., Fontana S. Hypoxia and HIF Signaling: One Axis with Divergent Effects. Int. J. Mol. Sci. 2020;21:5611. doi: 10.3390/ijms21165611.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21165611</ArticleId><ArticleId IdType="pmc">PMC7460602</ArticleId><ArticleId IdType="pubmed">32764403</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukurba K.R., Montgomery S.B. RNA Sequencing and Analysis. Cold Spring Harb. Protoc. 2015;2015:951&#x2013;969. doi: 10.1101/pdb.top084970.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/pdb.top084970</ArticleId><ArticleId IdType="pmc">PMC4863231</ArticleId><ArticleId IdType="pubmed">25870306</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonsack F., Sukumari-Ramesh S. Differential Cellular Expression of Galectin-1 and Galectin-3 After Intracerebral Hemorrhage. Front. Cell Neurosci. 2019;13:157. doi: 10.3389/fncel.2019.00157.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2019.00157</ArticleId><ArticleId IdType="pmc">PMC6530358</ArticleId><ArticleId IdType="pubmed">31156388</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z.Y., Chang T.F., Lin Z.B., Jing Y.T., Wen L.S., Niu Y.L., Bai Q., Guo C.M., Sun J.X., Wang Y.S., et al. Microglial Galectin3 enhances endothelial metabolism and promotes pathological angiogenesis via Notch inhibition by competitively binding to Jag1. Cell Death Dis. 2023;14:380. doi: 10.1038/s41419-023-05897-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-023-05897-8</ArticleId><ArticleId IdType="pmc">PMC10300109</ArticleId><ArticleId IdType="pubmed">37369647</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade F.E.C., Correia-Silva R.D., Covre J.L., Lice I., Gomes J.A.P., Gil C.D. Effects of galectin-3 protein on UVA-induced damage in retinal pigment epithelial cells. Photochem. Photobiol. Sci. 2023;22:21&#x2013;32. doi: 10.1007/s43630-022-00294-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43630-022-00294-0</ArticleId><ArticleId IdType="pubmed">36036336</ArticleId></ArticleIdList></Reference><Reference><Citation>Abreu C.A., De Lima S.V., Mendonca H.R., Goulart C.O., Martinez A.M. Absence of galectin-3 promotes neuroprotection in retinal ganglion cells after optic nerve injury. Histol. Histopathol. 2017;32:253&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">27255346</ArticleId></ArticleIdList></Reference><Reference><Citation>Sedlar A., Travnickova M., Bojarova P., Vlachova M., Slamova K., Kren V., Bacakova L. Interaction between Galectin-3 and Integrins Mediates Cell-Matrix Adhesion in Endothelial Cells and Mesenchymal Stem Cells. Int. J. Mol. Sci. 2021;22:5144. doi: 10.3390/ijms22105144.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22105144</ArticleId><ArticleId IdType="pmc">PMC8152275</ArticleId><ArticleId IdType="pubmed">34067978</ArticleId></ArticleIdList></Reference><Reference><Citation>Markowska A.I., Jefferies K.C., Panjwani N. Galectin-3 protein modulates cell surface expression and activation of vascular endothelial growth factor receptor 2 in human endothelial cells. J. Biol. Chem. 2011;286:29913&#x2013;29921. doi: 10.1074/jbc.M111.226423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.226423</ArticleId><ArticleId IdType="pmc">PMC3191032</ArticleId><ArticleId IdType="pubmed">21715322</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W.S., Cao Z., Leffler H., Nilsson U.J., Panjwani N. Galectin-3 Inhibition by a Small-Molecule Inhibitor Reduces Both Pathological Corneal Neovascularization and Fibrosis. Investig. Ophthalmol. Vis. Sci. 2017;58:9&#x2013;20. doi: 10.1167/iovs.16-20009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.16-20009</ArticleId><ArticleId IdType="pmc">PMC5225999</ArticleId><ArticleId IdType="pubmed">28055102</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan X., Gu X., Crabb J.S., Yue X., Shadrach K., Hollyfield J.G., Crabb J.W. Quantitative proteomics: Comparison of the macular Bruch membrane/choroid complex from age-related macular degeneration and normal eyes. Mol. Cell Proteom. 2010;9:1031&#x2013;1046. doi: 10.1074/mcp.M900523-MCP200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.M900523-MCP200</ArticleId><ArticleId IdType="pmc">PMC2877969</ArticleId><ArticleId IdType="pubmed">20177130</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie P., Kamei M., Suzuki M., Matsumura N., Nishida K., Sakimoto S., Sakaguchi H., Nishida K. Suppression and regression of choroidal neovascularization in mice by a novel CCR2 antagonist, INCB3344. PLoS ONE. 2011;6:e28933. doi: 10.1371/journal.pone.0028933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0028933</ArticleId><ArticleId IdType="pmc">PMC3242774</ArticleId><ArticleId IdType="pubmed">22205983</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan W., Zou J., Yoshida S., Jiang B., Zhou Y. The Role of Inflammation in Age-Related Macular Degeneration. Int. J. Biol. Sci. 2020;16:2989&#x2013;3001. doi: 10.7150/ijbs.49890.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.49890</ArticleId><ArticleId IdType="pmc">PMC7545698</ArticleId><ArticleId IdType="pubmed">33061811</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Revilla J., Boza-Serrano A., Espinosa-Oliva A.M., Soto M.S., Deierborg T., Ruiz R., de Pablos R.M., Burguillos M.A., Venero J.L. Galectin-3, a rising star in modulating microglia activation under conditions of neurodegeneration. Cell Death Dis. 2022;13:628. doi: 10.1038/s41419-022-05058-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-022-05058-3</ArticleId><ArticleId IdType="pmc">PMC9300700</ArticleId><ArticleId IdType="pubmed">35859075</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauppinen A., Paterno J.J., Blasiak J., Salminen A., Kaarniranta K. Inflammation and its role in age-related macular degeneration. Cell Mol. Life Sci. 2016;73:1765&#x2013;1786. doi: 10.1007/s00018-016-2147-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-016-2147-8</ArticleId><ArticleId IdType="pmc">PMC4819943</ArticleId><ArticleId IdType="pubmed">26852158</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Cui X., Han Y., Park K.S., Gao X., Zhang X., Yuan Z., Hu Y., Hsu C.W., Li X., et al. Hypoxic drive caused type 3 neovascularization in a preclinical model of exudative age-related macular degeneration. Hum. Mol. Genet. 2019;28:3475&#x2013;3485. doi: 10.1093/hmg/ddz159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddz159</ArticleId><ArticleId IdType="pmc">PMC7275777</ArticleId><ArticleId IdType="pubmed">31518400</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu X., Meng H., Wang J., Wang R., Cao M., Liu S., Chen H., Xu Y. Hypoxia contributes to galectin-3 expression in renal carcinoma cells. Eur. J. Pharmacol. 2021;890:173637. doi: 10.1016/j.ejphar.2020.173637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2020.173637</ArticleId><ArticleId IdType="pubmed">33065093</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumic J., Dabelic S., Flogel M. Galectin-3: An open-ended story. Biochim. Biophys. Acta. 2006;1760:616&#x2013;635. doi: 10.1016/j.bbagen.2005.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbagen.2005.12.020</ArticleId><ArticleId IdType="pubmed">16478649</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39594655</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>22</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>18</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Thrombospondin 1 Mediates Autophagy Upon Inhibition of the Rho-Associated Protein Kinase Inhibitor.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1907</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells13221907</ELocationID><Abstract><AbstractText>Age-related macular degeneration (AMD) is a degenerative eye disease leading to central vision loss and is characterized by dysregulated autophagy of the retinal pigment epithelium (RPE) layer. Recent studies have suggested that rho-associated protein kinase (ROCK) inhibitors may enhance autophagy in neurodegenerative diseases and promote the survival of RPE cells. This study investigated the effect of ROCK inhibitors on autophagy gene expression and autophagic vacuole formation in a human RPE (ARPE-19) cell line. The highly selective and potent ROCK inhibitor Y-39983 enhanced the expression of autophagy genes in ARPE-19 cells and increased autophagic vacuole formation. A proteomic analysis using mass spectrometry was performed to further characterize the effects of ROCK inhibition at the protein level. Y-39983 downregulated thrombospondin-1 (THBS1), and suppression of THBS1 in ARPE-19 cells resulted in an increase in autophagic vacuole formation. Our data showed that ROCK inhibitor-induced autophagy was mediated by THBS1 downregulation. We identified ROCK and THBS1 as potential novel therapeutic targets in AMD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Catral</LastName><ForeName>Kirk Patrick Carreon</ForeName><Initials>KPC</Initials><Identifier Source="ORCID">0000-0001-6458-4875</Identifier><AffiliationInfo><Affiliation>School of Optometry, The Hong Kong Polytechnic University, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tse</LastName><ForeName>Choi-Yee</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>School of Optometry, The Hong Kong Polytechnic University, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Wei-Ying</ForeName><Initials>WY</Initials><Identifier Source="ORCID">0009-0008-1392-3011</Identifier><AffiliationInfo><Affiliation>School of Optometry, The Hong Kong Polytechnic University, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ling</LastName><ForeName>Choi-Ying</ForeName><Initials>CY</Initials><Identifier Source="ORCID">0009-0006-4472-3202</Identifier><AffiliationInfo><Affiliation>School of Optometry, The Hong Kong Polytechnic University, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwok</LastName><ForeName>Oi-Lam</ForeName><Initials>OL</Initials><AffiliationInfo><Affiliation>School of Optometry, The Hong Kong Polytechnic University, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choy</LastName><ForeName>Kit-Ying</ForeName><Initials>KY</Initials><Identifier Source="ORCID">0000-0001-8696-4246</Identifier><AffiliationInfo><Affiliation>School of Optometry, The Hong Kong Polytechnic University, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Eye and Vision Research (CEVR), 17W Hong Kong Science Park, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Da-Qian</ForeName><Initials>DQ</Initials><Identifier Source="ORCID">0000-0003-2804-2424</Identifier><AffiliationInfo><Affiliation>School of Optometry, The Hong Kong Polytechnic University, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bian</LastName><ForeName>Jing-Fang</ForeName><Initials>JF</Initials><Identifier Source="ORCID">0000-0003-0464-1705</Identifier><AffiliationInfo><Affiliation>School of Optometry, The Hong Kong Polytechnic University, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Eye and Vision Research (CEVR), 17W Hong Kong Science Park, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Centre for SHARP Vision (RCSV), The Hong Kong Polytechnic University, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Thomas Chuen</ForeName><Initials>TC</Initials><Identifier Source="ORCID">0000-0002-3511-5620</Identifier><AffiliationInfo><Affiliation>School of Optometry, The Hong Kong Polytechnic University, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Eye and Vision Research (CEVR), 17W Hong Kong Science Park, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Centre for SHARP Vision (RCSV), The Hong Kong Polytechnic University, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Centre for Chinese Medicine (RCMI), The Hong Kong Polytechnic University, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tse</LastName><ForeName>Dennis Yan-Yin</ForeName><Initials>DY</Initials><Identifier Source="ORCID">0000-0001-7561-9121</Identifier><AffiliationInfo><Affiliation>School of Optometry, The Hong Kong Polytechnic University, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Eye and Vision Research (CEVR), 17W Hong Kong Science Park, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Centre for SHARP Vision (RCSV), The Hong Kong Polytechnic University, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shan</LastName><ForeName>Samantha Sze-Wan</ForeName><Initials>SS</Initials><Identifier Source="ORCID">0000-0001-6876-9914</Identifier><AffiliationInfo><Affiliation>School of Optometry, The Hong Kong Polytechnic University, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Eye and Vision Research (CEVR), 17W Hong Kong Science Park, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Centre for SHARP Vision (RCSV), The Hong Kong Polytechnic University, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Centre for Chinese Medicine (RCMI), The Hong Kong Polytechnic University, Hong Kong, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1-BD6R</GrantID><Agency>Hong Kong Polytechnic University</Agency><Country/></Grant><Grant><GrantID>1-BBDL</GrantID><Agency>Hong Kong Polytechnic University</Agency><Country/></Grant><Grant><GrantID>U-ZEZ2</GrantID><Agency>University Grants Committee (UGC)</Agency><Country/></Grant><Grant><GrantID>The InnoHK initiative of the Hong Kong Special Administrative Region Government</GrantID><Agency>The InnoHK initiative of the Hong Kong Special Administrative Region Government</Agency><Country/></Grant><Grant><GrantID>08191556</GrantID><Agency>Health and Medical Research Fund</Agency><Country/></Grant><Grant><GrantID>09200276</GrantID><Agency>Health and Medical Research Fund</Agency><Country/></Grant><Grant><GrantID>1-BBDA</GrantID><Agency>Research Centre for SHARP Vision</Agency><Country/></Grant><Grant><GrantID>1-BBC0</GrantID><Agency>Research Centre for SHARP Vision</Agency><Country/></Grant><Grant><GrantID>PolyU Research Postgraduate Studentship</GrantID><Agency>Hong Kong Polytechnic University</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D054460">rho-Associated Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019700">Thrombospondin 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000611726">thrombospondin-1, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="Y">Autophagy</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054460" MajorTopicYN="Y">rho-Associated Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019700" MajorTopicYN="Y">Thrombospondin 1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055213" MajorTopicYN="Y">Retinal Pigment Epithelium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="Y">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014617" MajorTopicYN="N">Vacuoles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AMD</Keyword><Keyword MajorTopicYN="N">ROCK inhibitor</Keyword><Keyword MajorTopicYN="N">Thrombospondin-1</Keyword><Keyword MajorTopicYN="N">autophagy</Keyword><Keyword MajorTopicYN="N">signaling pathway</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>1</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39594655</ArticleId><ArticleId IdType="pmc">PMC11593289</ArticleId><ArticleId IdType="doi">10.3390/cells13221907</ArticleId><ArticleId IdType="pii">cells13221907</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bourne R.R., Stevens G.A., White R.A., Smith J.L., Flaxman S.R., Price H., Jonas J.B., Keeffe J., Leasher J., Naidoo K., et al. Causes of vision loss worldwide, 1990&#x2013;2010: A systematic analysis. Lancet Glob. Health. 2013;1:e339&#x2013;e349. doi: 10.1016/S2214-109X(13)70113-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(13)70113-X</ArticleId><ArticleId IdType="pubmed">25104599</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong W.L., Su X., Li X., Cheung C.M.G., Klein R., Cheng C.Y., Wong T.Y. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. Lancet Glob. Health. 2014;2:e106&#x2013;e116. doi: 10.1016/S2214-109X(13)70145-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(13)70145-1</ArticleId><ArticleId IdType="pubmed">25104651</ArticleId></ArticleIdList></Reference><Reference><Citation>National Eye Institute  AREDS/AREDS2 Clinical Trials.  [(accessed on 26 January 2024)];2020  Available online:  https://www.nei.nih.gov/research/clinical-trials/age-related-eye-disease-studies-aredsareds2/about-areds-and-areds2.</Citation></Reference><Reference><Citation>Age-Related Eye Disease Study Research Group The Age-Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: The Age-Related Eye Disease Study Report Number 6. Am. J. Ophthalmol. 2001;132:668&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pubmed">11704028</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhutto I., Lutty G. Understanding age-related macular degeneration (AMD): Relationships between the photoreceptor/retinal pigment epithelium/Bruch&#x2019;s membrane/choriocapillaris complex. Mol. Asp. Med. 2012;33:295&#x2013;317. doi: 10.1016/j.mam.2012.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mam.2012.04.005</ArticleId><ArticleId IdType="pmc">PMC3392421</ArticleId><ArticleId IdType="pubmed">22542780</ArticleId></ArticleIdList></Reference><Reference><Citation>Lois N., Forrester J.V. Fundus Autofluorescence. Lippincott Williams &amp; Wilkins; Baltimore, MD, USA: 2009.</Citation></Reference><Reference><Citation>Kaarniranta K., Sinha D., Blasiak J., Kauppinen A., Ver&#xe9;b Z., Salminen A., Boulton M.E., Petrovski G. Autophagy and heterophagy dysregulation leads to retinal pigment epithelium dysfunction and development of age-related macular degeneration. Autophagy. 2013;9:973&#x2013;984. doi: 10.4161/auto.24546.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.24546</ArticleId><ArticleId IdType="pmc">PMC3722332</ArticleId><ArticleId IdType="pubmed">23590900</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitter S.K., Song C., Qi X., Mao H., Rao H., Akin D., Lewin A., Grant M., Dunn W., Jr., Ding J., et al. Dysregulated autophagy in the RPE is associated with increased susceptibility to oxidative stress and AMD. Autophagy. 2014;10:1989&#x2013;2005. doi: 10.4161/auto.36184.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.36184</ArticleId><ArticleId IdType="pmc">PMC4502658</ArticleId><ArticleId IdType="pubmed">25484094</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuervo A.M., Bergamini E., Brunk U.T., Dr&#xf6;ge W., Ffrench M., Terman A. Autophagy and aging: The importance of maintaining &#x201c;clean&#x201d; cells. Autophagy. 2005;1:131&#x2013;140. doi: 10.4161/auto.1.3.2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.1.3.2017</ArticleId><ArticleId IdType="pubmed">16874025</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Roso A., Vittorini S., Cavallini G., Donati A., Gori Z., Masini M., Pollera M., Bergamini E. Ageing-related changes in the in vivo function of rat liver macroautophagy and proteolysis. Exp. Gerontol. 2003;38:519&#x2013;527. doi: 10.1016/S0531-5565(03)00002-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0531-5565(03)00002-0</ArticleId><ArticleId IdType="pubmed">12742529</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaarniranta K., Hyttinen J., Ryhanen T., Viiri J., Paimela T., Toropainen E., Sorri I., Salminen A. Mechanisms of protein aggregation in the retinal pigment epithelial cells. Front. Biosci. 2010;2:1374&#x2013;1384. doi: 10.2741/e198.</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/e198</ArticleId><ArticleId IdType="pubmed">20515810</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciarretta S., Maejima Y., Zablocki D., Sadoshima J. The Role of Autophagy in the Heart. Annu. Rev. Physiol. 2018;80:1&#x2013;26. doi: 10.1146/annurev-physiol-021317-121427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-physiol-021317-121427</ArticleId><ArticleId IdType="pubmed">29068766</ArticleId></ArticleIdList></Reference><Reference><Citation>Mleczak A., Millar S., Tooze S.A., Olson M.F., Chan E.Y. Regulation of autophagosome formation by Rho kinase. Cell. Signal. 2013;25:1&#x2013;11. doi: 10.1016/j.cellsig.2012.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2012.09.010</ArticleId><ArticleId IdType="pubmed">22975682</ArticleId></ArticleIdList></Reference><Reference><Citation>Preau S., Delguste F., Yu Y., Remy-Jouet I., Richard V., Saulnier F., Boulanger E., Neviere R. Endotoxemia Engages the RhoA Kinase Pathway to Impair Cardiac Function by Altering Cytoskeleton, Mitochondrial Fission, and Autophagy. Antioxid. Redox Signal. 2016;24:529&#x2013;542. doi: 10.1089/ars.2015.6421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2015.6421</ArticleId><ArticleId IdType="pubmed">26602979</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Chac&#xf3;n G., Vela F.J., Campos J.L., Abell&#xe1;n E., Yakhine-Diop S.M.S., Ballest&#xed;n A. Autophagy modulation in animal models of corneal diseases: A systematic review. Mol. Cell. Biochem. 2020;474:41&#x2013;55. doi: 10.1007/s11010-020-03832-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11010-020-03832-5</ArticleId><ArticleId IdType="pubmed">32710189</ArticleId></ArticleIdList></Reference><Reference><Citation>Moskal N., Riccio V., Bashkurov M., Taddese R., Datti A., Lewis P.N., McQuibban G.A. ROCK inhibitors upregulate the neuroprotective Parkin-mediated mitophagy pathway. Nat. Commun. 2020;11:88. doi: 10.1038/s41467-019-13781-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-13781-3</ArticleId><ArticleId IdType="pmc">PMC6941965</ArticleId><ArticleId IdType="pubmed">31900402</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamano T., Shirafuji N., Yen S.-H., Yoshida H., Kanaan N.M., Hayashi K., Ikawa M., Yamamura O., Fujita Y., Kuriyama M., et al. Rho-kinase ROCK inhibitors reduce oligomeric tau protein. Neurobiol. Aging. 2020;89:41&#x2013;54. doi: 10.1016/j.neurobiolaging.2019.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2019.12.009</ArticleId><ArticleId IdType="pmc">PMC7183001</ArticleId><ArticleId IdType="pubmed">31982202</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z., Li T., Li P., Wei N., Zhao Z., Liang H., Ji X., Chen W., Xue M., Wei J. The Ambiguous Relationship of Oxidative Stress, Tau Hyperphosphorylation, and Autophagy Dysfunction in Alzheimer&#x2019;s Disease. Oxid. Med. Cell. Longev. 2015;2015:352723. doi: 10.1155/2015/352723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/352723</ArticleId><ArticleId IdType="pmc">PMC4485995</ArticleId><ArticleId IdType="pubmed">26171115</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin D.D., Ladha S., Ehrnhoefer D.E., Hayden M.R. Autophagy in Huntington disease and huntingtin in autophagy. Trends Neurosci. 2015;38:26&#x2013;35. doi: 10.1016/j.tins.2014.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2014.09.003</ArticleId><ArticleId IdType="pubmed">25282404</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollanders K., Van Bergen T., Kindt N., Castermans K., Leysen D., Vandewalle E., Moons L., Stalmans I. The effect of AMA0428, a novel and potent ROCK inhibitor, in a model of neovascular age-related macular degeneration. Investig. Opthalmology Vis. Sci. 2015;56:1335&#x2013;1348. doi: 10.1167/iovs.14-15681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.14-15681</ArticleId><ArticleId IdType="pubmed">25626969</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni Y., Qin Y., Fang Z., Zhang Z. ROCK Inhibitor Y-27632 Promotes Human Retinal Pigment Epithelium Survival by Altering Cellular Biomechanical Properties. Curr. Mol. Med. 2017;17:637&#x2013;646. doi: 10.2174/1566524018666180316150936.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1566524018666180316150936</ArticleId><ArticleId IdType="pmc">PMC6040175</ArticleId><ArticleId IdType="pubmed">29546834</ArticleId></ArticleIdList></Reference><Reference><Citation>Okumura N., Nakano S., Kay E.P., Numata R., Ota A., Sowa Y., Sakai T., Ueno M., Kinoshita S., Koizumi N. Involvement of cyclin D and p27 in cell proliferation mediated by ROCK inhibitors Y-27632 and Y-39983 during corneal endothelium wound healing. Investig. Opthalmology Vis. Sci. 2014;55:318&#x2013;329. doi: 10.1167/iovs.13-12225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.13-12225</ArticleId><ArticleId IdType="pubmed">24106120</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokushige H., Inatani M., Nemoto S., Sakaki H., Katayama K., Uehata M., Tanihara H. Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Investig. Opthalmology Vis. Sci. 2007;48:3216&#x2013;3222. doi: 10.1167/iovs.05-1617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.05-1617</ArticleId><ArticleId IdType="pubmed">17591891</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W., Lin Y., Huang Y., Chan J., Terrillon S., Rosenbaum A.I., Contrepois K. Robust and High-Throughput Analytical Flow Proteomics Analysis of Cynomolgus Monkey and Human Matrices with Zeno SWATH Data-Independent Acquisition. Mol. Cell. Proteom. 2023;22:100562. doi: 10.1016/j.mcpro.2023.100562.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcpro.2023.100562</ArticleId><ArticleId IdType="pmc">PMC10267596</ArticleId><ArticleId IdType="pubmed">37142056</ArticleId></ArticleIdList></Reference><Reference><Citation>Abokyi S., Shan S.-W., Lam C.H.-I., Catral K.P., Pan F., Chan H.H.-L., To C.-H., Tse D.Y.-Y. Targeting Lysosomes to Reverse Hydroquinone-Induced Autophagy Defects and Oxidative Damage in Human Retinal Pigment Epithelial Cells. Int. J. Mol. Sci. 2021;22:9042. doi: 10.3390/ijms22169042.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22169042</ArticleId><ArticleId IdType="pmc">PMC8396439</ArticleId><ArticleId IdType="pubmed">34445748</ArticleId></ArticleIdList></Reference><Reference><Citation>Zougman A., Selby P.J., Banks R.E. Suspension trapping (STrap) sample preparation method for bottom-up proteomics analysis. Proteomics. 2014;14:1000&#x2013;1006. doi: 10.1002/pmic.201300553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmic.201300553</ArticleId><ArticleId IdType="pubmed">24678027</ArticleId></ArticleIdList></Reference><Reference><Citation>HaileMariam M., Eguez R.V., Singh H., Bekele S., Ameni G., Pieper R., Yu Y. S-Trap, an Ultrafast Sample-Preparation Approach for Shotgun Proteomics. J. Proteome Res. 2018;17:2917&#x2013;2924. doi: 10.1021/acs.jproteome.8b00505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.8b00505</ArticleId><ArticleId IdType="pubmed">30114372</ArticleId></ArticleIdList></Reference><Reference><Citation>Demichev V., Messner C.B., Vernardis S.I., Lilley K.S., Ralser M. DIA-NN: Neural networks and interference correction enable deep proteome coverage in high throughput. Nat. Methods. 2020;17:41&#x2013;44. doi: 10.1038/s41592-019-0638-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-019-0638-x</ArticleId><ArticleId IdType="pmc">PMC6949130</ArticleId><ArticleId IdType="pubmed">31768060</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphries E.M., Xavier D., Ashman K., Hains P.G., Robinson P.J. High-Throughput Proteomics and Phosphoproteomics of Rat Tissues Using Microflow Zeno SWATH. J. Proteome Res. 2024;23:2355&#x2013;2366. doi: 10.1021/acs.jproteome.4c00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.4c00010</ArticleId><ArticleId IdType="pubmed">38819404</ArticleId></ArticleIdList></Reference><Reference><Citation>Sze Y.H., Tse D.Y.Y., Zuo B., Li K.K., Zhao Q., Jiang X., Kurihara T., Tsubota K., Lam T.C. Deep Spectral Library of Mice Retina for Myopia Research: Proteomics Dataset generated by SWATH and DIA-NN. Sci. Data. 2024;11:1115. doi: 10.1038/s41597-024-03958-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41597-024-03958-x</ArticleId><ArticleId IdType="pmc">PMC11467338</ArticleId><ArticleId IdType="pubmed">39389962</ArticleId></ArticleIdList></Reference><Reference><Citation>Donato M., Xu Z., Tomoiaga A., Granneman J.G., Mackenzie R.G., Bao R., Than N.G., Westfall P.H., Romero R., Draghici S. Analysis and correction of crosstalk effects in pathway analysis. Genome Res. 2013;23:1885&#x2013;1893. doi: 10.1101/gr.153551.112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.153551.112</ArticleId><ArticleId IdType="pmc">PMC3814888</ArticleId><ArticleId IdType="pubmed">23934932</ArticleId></ArticleIdList></Reference><Reference><Citation>Draghici S., Khatri P., Tarca A.L., Amin K., Done A., Voichita C., Georgescu C., Romero R. A systems biology approach for pathway level analysis. Genome Res. 2007;17:1537&#x2013;1545. doi: 10.1101/gr.6202607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.6202607</ArticleId><ArticleId IdType="pmc">PMC1987343</ArticleId><ArticleId IdType="pubmed">17785539</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarau I.-S., Berlin A., Curcio C.A., Ach T. The Cytoskeleton of the Retinal Pigment Epithelium: From Normal Aging to Age-Related Macular Degeneration. Int. J. Mol. Sci. 2019;20:3578. doi: 10.3390/ijms20143578.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20143578</ArticleId><ArticleId IdType="pmc">PMC6678077</ArticleId><ArticleId IdType="pubmed">31336621</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjorkoy G., Lamark T., Pankiv S., &#xd8;vervatn A., Brech A., Johansen T. Monitoring autophagic degradation of p62/SQSTM1. Methods Enzymol. 2009;452:181&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">19200883</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatti M., Motta M., Di Bartolomeo S., Cianfanelli V., Salvioli R. Cathepsin-mediated regulation of autophagy in saposin C deficiency. Autophagy. 2013;9:241&#x2013;243. doi: 10.4161/auto.22557.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.22557</ArticleId><ArticleId IdType="pmc">PMC3552889</ArticleId><ArticleId IdType="pubmed">23108186</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahani M.H., Itakura E., Mizushima N. Expression of the autophagy substrate SQSTM1/p62 is restored during prolonged starvation depending on transcriptional upregulation and autophagy-derived amino acids. Autophagy. 2014;10:431&#x2013;441. doi: 10.4161/auto.27344.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.27344</ArticleId><ArticleId IdType="pmc">PMC4077882</ArticleId><ArticleId IdType="pubmed">24394643</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur S., Martin-Manso G., Pendrak M.L., Garfield S.H., Isenberg J.S., Roberts D.D. Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J. Biol. Chem. 2010;285:38923&#x2013;38932. doi: 10.1074/jbc.M110.172304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.172304</ArticleId><ArticleId IdType="pmc">PMC2998110</ArticleId><ArticleId IdType="pubmed">20923780</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaslavsky A., Baek K.-H., Lynch R.C., Short S., Grillo J., Folkman J., Italiano J.E., Ryeom S. Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood. 2010;115:4605&#x2013;4613. doi: 10.1182/blood-2009-09-242065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-09-242065</ArticleId><ArticleId IdType="pmc">PMC2881490</ArticleId><ArticleId IdType="pubmed">20086246</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorenson C.M., Wang S., Darjatmoko S.R., Gurel Z., Liu B., Sheibani N. Targeted Thrombospondin-1 Expression in Ocular Vascular Development and Neovascularization. Front. Cell Dev. Biol. 2021;9:671989. doi: 10.3389/fcell.2021.671989.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.671989</ArticleId><ArticleId IdType="pmc">PMC8097095</ArticleId><ArticleId IdType="pubmed">33968943</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Wang S., Sheibani N. Enhanced proangiogenic signaling in thrombospondin-1-deficient retinal endothelial cells. Microvasc. Res. 2006;71:143&#x2013;151. doi: 10.1016/j.mvr.2006.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mvr.2006.02.004</ArticleId><ArticleId IdType="pubmed">16624339</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39594569</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-3921</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>20</Day></PubDate></JournalIssue><Title>Antioxidants (Basel, Switzerland)</Title><ISOAbbreviation>Antioxidants (Basel)</ISOAbbreviation></Journal><ArticleTitle>(Photo)toxicity of Partially Oxidized Docosahexaenoate and Its Effect on the Formation of Lipofuscin in Cultured Human Retinal Pigment Epithelial Cells.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1428</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/antiox13111428</ELocationID><Abstract><AbstractText>Docosahexaenoate is a cytoprotective &#x3c9;-3 polyunsaturated lipid that is abundant in the retina and is essential for its function. Due to its six unsaturated double bonds, docosahexaenoate is highly susceptible to oxidation and the formation of products with photosensitizing properties. This study aimed to test on cultured human retinal pigment epithelial cells ARPE-19 the (photo)cytotoxic potential of partly oxidized docosahexaenoate and its effect on the formation of lipofuscin from phagocytosed photoreceptor outer segments (POSs). The results demonstrate that the cytoprotective effects of docosahexaenoate do not counteract the deleterious effects of its oxidation products, leading to the concentration-dependent loss of cell metabolic activity, which is exacerbated by concomitant exposure to visible light. Partly oxidized docosahexaenoate does not cause permeability of the cell plasma membrane but does cause apoptosis. While vitamin E can provide partial protection from the (photo)toxicity of partly oxidized docosahexaenoate, zeaxanthin undergoes rapid photodegradation and can exacerbate the (photo)toxicity. Feeding cells with POSs enriched in partly oxidized docosahexaenoate results in a greater accumulation of intracellular fluorescent lipofuscin than in cells fed POSs without the addition. In conclusion, partly oxidized docosahexaenoate increases the accumulation of lipofuscin-like intracellular deposits, is cytotoxic, and its toxicity increases during exposure to light. These effects may contribute to the increased progression of geographic atrophy observed after long-term supplementation with docosahexaenoate in age-related macular degeneration patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bakker</LastName><ForeName>Linda M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>School of Optometry and Vision Sciences, Cardiff University, Cardiff CF24 4HQ, Wales, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boulton</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0002-0796-1766</Identifier><AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Sciences, University of Alabama at Birmingham, Birmingham, AL 35294, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R&#xf3;&#x17c;anowska</LastName><ForeName>Ma&#x142;gorzata B</ForeName><Initials>MB</Initials><Identifier Source="ORCID">0000-0003-2913-8954</Identifier><AffiliationInfo><Affiliation>School of Optometry and Vision Sciences, Cardiff University, Cardiff CF24 4HQ, Wales, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiff Institute for Tissue Engineering and Repair (CITER), Cardiff University, Cardiff CF10 3AX, Wales, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>SCIAD 048</GrantID><Agency>National Eye Research Centre</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Antioxidants (Basel)</MedlineTA><NlmUniqueID>101668981</NlmUniqueID><ISSNLinking>2076-3921</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">(photo)toxicity</Keyword><Keyword MajorTopicYN="N">AREDS2</Keyword><Keyword MajorTopicYN="N">age-related macular degeneration</Keyword><Keyword MajorTopicYN="N">apoptosis</Keyword><Keyword MajorTopicYN="N">docosahexaenoic acid</Keyword><Keyword MajorTopicYN="N">lipid peroxidation</Keyword><Keyword MajorTopicYN="N">lipofuscin</Keyword><Keyword MajorTopicYN="N">omega-3 fatty acid</Keyword><Keyword MajorTopicYN="N">photoreceptor outer segments</Keyword><Keyword MajorTopicYN="N">retina</Keyword><Keyword MajorTopicYN="N">retinal pigment epithelium</Keyword><Keyword MajorTopicYN="N">zeaxanthin</Keyword><Keyword MajorTopicYN="N">&#x3b1;-tocopherol</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>1</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39594569</ArticleId><ArticleId IdType="pmc">PMC11591205</ArticleId><ArticleId IdType="doi">10.3390/antiox13111428</ArticleId><ArticleId IdType="pii">antiox13111428</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bazan H.E., Bazan N.G., Feeney-Burns L., Berman E.R. Lipids in human lipofuscin-enriched subcellular fractions of two age populations. Comparison with rod outer segments and neural retina. Investig. Ophthalmol. Vis. Sci. 1990;31:1433&#x2013;1443.</Citation><ArticleIdList><ArticleId IdType="pubmed">2387677</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinkels D., Baes M. The essential role of docosahexaenoic acid and its derivatives for retinal integrity. Pharmacol. Ther. 2023;247:108440. doi: 10.1016/j.pharmthera.2023.108440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2023.108440</ArticleId><ArticleId IdType="pubmed">37201739</ArticleId></ArticleIdList></Reference><Reference><Citation>Longoni B., Demontis G.C. Polyunsaturated Lipids in the Light-Exposed and Prooxidant Retinal Environment. Antioxidants. 2023;12:617. doi: 10.3390/antiox12030617.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox12030617</ArticleId><ArticleId IdType="pmc">PMC10044808</ArticleId><ArticleId IdType="pubmed">36978865</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewandowski D., Sander C.L., Tworak A., Gao F., Xu Q., Skowronska-Krawczyk D. Dynamic lipid turnover in photoreceptors and retinal pigment epithelium throughout life. Prog. Retin. Eye Res. 2022;89:101037. doi: 10.1016/j.preteyeres.2021.101037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2021.101037</ArticleId><ArticleId IdType="pmc">PMC10361839</ArticleId><ArticleId IdType="pubmed">34971765</ArticleId></ArticleIdList></Reference><Reference><Citation>Senapati S., Gragg M., Samuels I.S., Parmar V.M., Maeda A., Park P.S. Effect of dietary docosahexaenoic acid on rhodopsin content and packing in photoreceptor cell membranes. Biochim. Biophys. Acta Biomembr. 2018;1860:1403&#x2013;1413. doi: 10.1016/j.bbamem.2018.03.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamem.2018.03.030</ArticleId><ArticleId IdType="pmc">PMC5912654</ArticleId><ArticleId IdType="pubmed">29626443</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice D.S., Calandria J.M., Gordon W.C., Jun B., Zhou Y., Gelfman C.M., Li S., Jin M., Knott E.J., Chang B., et al. Adiponectin receptor 1 conserves docosahexaenoic acid and promotes photoreceptor cell survival. Nat. Commun. 2015;6:6228. doi: 10.1038/ncomms7228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms7228</ArticleId><ArticleId IdType="pmc">PMC4351799</ArticleId><ArticleId IdType="pubmed">25736573</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Martin M.J., Ramon E., Torrent-Burgues J., Garriga P. Improved conformational stability of the visual G protein-coupled receptor rhodopsin by specific interaction with docosahexaenoic acid phospholipid. Chembiochem. 2013;14:639&#x2013;644. doi: 10.1002/cbic.201200687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbic.201200687</ArticleId><ArticleId IdType="pubmed">23447332</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell D.C., Niu S.L., Litman B.J. Quantifying the differential effects of DHA and DPA on the early events in visual signal transduction. Chem. Phys. Lipids. 2012;165:393&#x2013;400. doi: 10.1016/j.chemphyslip.2012.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chemphyslip.2012.02.008</ArticleId><ArticleId IdType="pubmed">22405878</ArticleId></ArticleIdList></Reference><Reference><Citation>Dornstauder B., Suh M., Kuny S., Gaillard F., Macdonald I.M., Clandinin M.T., Sauve Y. Dietary docosahexaenoic acid supplementation prevents age-related functional losses and A2E accumulation in the retina. Investig. Ophthalmol. Vis. Sci. 2012;53:2256&#x2013;2265. doi: 10.1167/iovs.11-8569.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.11-8569</ArticleId><ArticleId IdType="pubmed">22427551</ArticleId></ArticleIdList></Reference><Reference><Citation>Calder P.C. Eicosapentaenoic and docosahexaenoic acid derived specialised pro-resolving mediators: Concentrations in humans and the effects of age, sex, disease and increased omega-3 fatty acid intake. Biochimie. 2020;178:105&#x2013;123. doi: 10.1016/j.biochi.2020.08.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biochi.2020.08.015</ArticleId><ArticleId IdType="pubmed">32860894</ArticleId></ArticleIdList></Reference><Reference><Citation>Christie W.W., Harwood J.L. Oxidation of polyunsaturated fatty acids to produce lipid mediators. Essays Biochem. 2020;64:401&#x2013;421. doi: 10.1042/EBC20190082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/EBC20190082</ArticleId><ArticleId IdType="pmc">PMC7517362</ArticleId><ArticleId IdType="pubmed">32618335</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazan N.G., Molina M.F., Gordon W.C. Docosahexaenoic acid signalolipidomics in nutrition: Significance in aging, neuroinflammation, macular degeneration, Alzheimer&#x2019;s, and other neurodegenerative diseases. Annu. Rev. Nutr. 2011;31:321&#x2013;351. doi: 10.1146/annurev.nutr.012809.104635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.nutr.012809.104635</ArticleId><ArticleId IdType="pmc">PMC3406932</ArticleId><ArticleId IdType="pubmed">21756134</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcheselli V.L., Mukherjee P.K., Arita M., Hong S., Antony R., Sheets K., Winkler J.W., Petasis N.A., Serhan C.N., Bazan N.G. Neuroprotectin D1/protectin D1 stereoselective and specific binding with human retinal pigment epithelial cells and neutrophils. Prostaglandins Leukot. Essent. Fat. Acids. 2010;82:27&#x2013;34. doi: 10.1016/j.plefa.2009.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.plefa.2009.10.010</ArticleId><ArticleId IdType="pmc">PMC2822836</ArticleId><ArticleId IdType="pubmed">19931440</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee P.K., Marcheselli V.L., de Rivero Vaccari J.C., Gordon W.C., Jackson F.E., Bazan N.G. Photoreceptor outer segment phagocytosis attenuates oxidative stress-induced apoptosis with concomitant neuroprotectin D1 synthesis. Proc. Natl. Acad. Sci. USA. 2007;104:13158&#x2013;13163. doi: 10.1073/pnas.0705963104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0705963104</ArticleId><ArticleId IdType="pmc">PMC1941804</ArticleId><ArticleId IdType="pubmed">17670935</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee P.K., Marcheselli V.L., Barreiro S., Hu J., Bok D., Bazan N.G. Neurotrophins enhance retinal pigment epithelial cell survival through neuroprotectin D1 signaling. Proc. Natl. Acad. Sci. USA. 2007;104:13152&#x2013;13157. doi: 10.1073/pnas.0705949104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0705949104</ArticleId><ArticleId IdType="pmc">PMC1941803</ArticleId><ArticleId IdType="pubmed">17670936</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee P.K., Chawla A., Loayza M.S., Bazan N.G. Docosanoids are multifunctional regulators of neural cell integrity and fate: Significance in aging and disease. Prostaglandins Leukot. Essent. Fat. Acids. 2007;77:233&#x2013;238. doi: 10.1016/j.plefa.2007.10.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.plefa.2007.10.022</ArticleId><ArticleId IdType="pmc">PMC2696125</ArticleId><ArticleId IdType="pubmed">18060755</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee P.K., Marcheselli V.L., Serhan C.N., Bazan N.G. Neuroprotectin D1: A docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc. Natl. Acad. Sci. USA. 2004;101:8491&#x2013;8496. doi: 10.1073/pnas.0402531101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0402531101</ArticleId><ArticleId IdType="pmc">PMC420421</ArticleId><ArticleId IdType="pubmed">15152078</ArticleId></ArticleIdList></Reference><Reference><Citation>Schebb N.H., Kuhn H., Kahnt A.S., Rund K.M., O&#x2019;Donnell V.B., Flamand N., Peters-Golden M., Jakobsson P.J., Weylandt K.H., Rohwer N., et al. Formation, Signaling and Occurrence of Specialized Pro-Resolving Lipid Mediators-What is the Evidence so far? Front. Pharmacol. 2022;13:838782. doi: 10.3389/fphar.2022.838782.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.838782</ArticleId><ArticleId IdType="pmc">PMC8924552</ArticleId><ArticleId IdType="pubmed">35308198</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J., Cho E., Giovannucci E.L., Rosner B.A., Sastry S.M., Willett W.C., Schaumberg D.A. Dietary Intakes of Eicosapentaenoic Acid and Docosahexaenoic Acid and Risk of Age-Related Macular Degeneration. Ophthalmology. 2017;124:634&#x2013;643. doi: 10.1016/j.ophtha.2016.12.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2016.12.033</ArticleId><ArticleId IdType="pmc">PMC5401792</ArticleId><ArticleId IdType="pubmed">28153441</ArticleId></ArticleIdList></Reference><Reference><Citation>Feher J., Kovacs B., Kovacs I., Schveoller M., Papale A., Balacco Gabrieli C. Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10. Ophthalmologica. 2005;219:154&#x2013;166. doi: 10.1159/000085248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000085248</ArticleId><ArticleId IdType="pubmed">15947501</ArticleId></ArticleIdList></Reference><Reference><Citation>Querques G., Benlian P., Chanu B., Leveziel N., Coscas G., Soubrane G., Souied E.H. DHA supplementation for late onset Stargardt disease: NAT-3 study. Clin. Ophthalmol. 2010;4:575&#x2013;580. doi: 10.2147/OPTH.S10049.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OPTH.S10049</ArticleId><ArticleId IdType="pmc">PMC2909886</ArticleId><ArticleId IdType="pubmed">20668719</ArticleId></ArticleIdList></Reference><Reference><Citation>Group A.R., Chew E.Y., Clemons T., SanGiovanni J.P., Danis R., Domalpally A., McBee W., Sperduto R., Ferris F.L. The Age-Related Eye Disease Study 2 (AREDS2): Study design and baseline characteristics (AREDS2 report number 1) Ophthalmology. 2012;119:2282&#x2013;2289. doi: 10.1016/j.ophtha.2012.05.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2012.05.027</ArticleId><ArticleId IdType="pmc">PMC3485447</ArticleId><ArticleId IdType="pubmed">22840421</ArticleId></ArticleIdList></Reference><Reference><Citation>Age-Related Eye Disease Study 2 Research G. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: The Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013;309:2005&#x2013;2015. doi: 10.1001/jama.2013.4997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.4997</ArticleId><ArticleId IdType="pubmed">23644932</ArticleId></ArticleIdList></Reference><Reference><Citation>Souied E.H., Delcourt C., Querques G., Bassols A., Merle B., Zourdani A., Smith T., Benlian P., Nutritional A.M.D.T.S.G. Oral docosahexaenoic acid in the prevention of exudative age-related macular degeneration: The Nutritional AMD Treatment 2 study. Ophthalmology. 2013;120:1619&#x2013;1631. doi: 10.1016/j.ophtha.2013.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2013.01.005</ArticleId><ArticleId IdType="pubmed">23395546</ArticleId></ArticleIdList></Reference><Reference><Citation>Merle B.M., Richard F., Benlian P., Puche N., Delcourt C., Souied E.H. CFH Y402H and ARMS2 A69S Polymorphisms and Oral Supplementation with Docosahexaenoic Acid in Neovascular Age-Related Macular Degeneration Patients: The NAT2 Study. PLoS ONE. 2015;10:e0130816. doi: 10.1371/journal.pone.0130816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0130816</ArticleId><ArticleId IdType="pmc">PMC4489493</ArticleId><ArticleId IdType="pubmed">26132079</ArticleId></ArticleIdList></Reference><Reference><Citation>Querques G., Merle B.M., Pumariega N.M., Benlian P., Delcourt C., Zourdani A., Leisy H.B., Lee M.D., Smith R.T., Souied E.H. Dynamic Drusen Remodelling in Participants of the Nutritional AMD Treatment-2 (NAT-2) Randomized Trial. PLoS ONE. 2016;11:e0149219. doi: 10.1371/journal.pone.0149219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0149219</ArticleId><ArticleId IdType="pmc">PMC4762680</ArticleId><ArticleId IdType="pubmed">26901353</ArticleId></ArticleIdList></Reference><Reference><Citation>Semeraro F., Gambicordi E., Cancarini A., Morescalchi F., Costagliola C., Russo A. Treatment of exudative age-related macular degeneration with aflibercept combined with pranoprofen eye drops or nutraceutical support with omega-3: A randomized trial. Br. J. Clin. Pharmacol. 2019;85:908&#x2013;913. doi: 10.1111/bcp.13871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.13871</ArticleId><ArticleId IdType="pmc">PMC6475693</ArticleId><ArticleId IdType="pubmed">30680768</ArticleId></ArticleIdList></Reference><Reference><Citation>Piatti A., Croce A., Mazzacane D., Traina G., Ambrosino L., Boni L., Lisi L., Cascella M.C., Grunberger A. Effect of 2-year nutritional supplementation on progression of age-related macular degeneration. Eur. J. Ophthalmol. 2020;30:376&#x2013;381. doi: 10.1177/1120672119836007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1120672119836007</ArticleId><ArticleId IdType="pubmed">30880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Christen W.G., Cook N.R., Manson J.E., Buring J.E., Chasman D.I., Lee I.M., Bubes V., Li C., Haubourg M., Schaumberg D.A., et al. Effect of Vitamin D and omega-3 Fatty Acid Supplementation on Risk of Age-Related Macular Degeneration: An Ancillary Study of the VITAL Randomized Clinical Trial. JAMA Ophthalmol. 2020;138:1280&#x2013;1289. doi: 10.1001/jamaophthalmol.2020.4409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2020.4409</ArticleId><ArticleId IdType="pmc">PMC7596682</ArticleId><ArticleId IdType="pubmed">33119047</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz S.G., Wang X., Chavis P., Kuriyan A.E., Abariga S.A. Vitamin A and fish oils for preventing the progression of retinitis pigmentosa. Cochrane Database Syst. Rev. 2020;6:CD008428. doi: 10.1002/14651858.CD008428.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD008428.pub3</ArticleId><ArticleId IdType="pmc">PMC7388842</ArticleId><ArticleId IdType="pubmed">32573764</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Layana A., Recalde S., Hernandez M., Abraldes M.J., Nascimento J., Hernandez-Galilea E., Olmedilla-Alonso B., Escobar-Barranco J.J., Zapata M.A., Silva R., et al. A Randomized Study of Nutritional Supplementation in Patients with Unilateral Wet Age-Related Macular Degeneration. Nutrients. 2021;13:1253. doi: 10.3390/nu13041253.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13041253</ArticleId><ArticleId IdType="pmc">PMC8069087</ArticleId><ArticleId IdType="pubmed">33920232</ArticleId></ArticleIdList></Reference><Reference><Citation>Keenan T.D.L., Agron E., Keane P.A., Domalpally A., Chew E.Y., Age-Related Eye Disease Study Research G., Age-Related Eye Disease Study 2 Research G. Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration. Ophthalmology. 2024 doi: 10.1016/j.ophtha.2024.07.014. in press .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2024.07.014</ArticleId><ArticleId IdType="pubmed">39025435</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf3;zanowska M.B. Lipofuscin, Its Origin, Properties, and Contribution to Retinal Fluorescence as a Potential Biomarker of Oxidative Damage to the Retina. Antioxidants. 2023;12:2111. doi: 10.3390/antiox12122111.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox12122111</ArticleId><ArticleId IdType="pmc">PMC10740933</ArticleId><ArticleId IdType="pubmed">38136230</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliwell B., Gutteridge J.M.C. Free Radicals in Biology and Medicine. 4th ed. Oxford University Press Inc.; New York, NY, USA: 2007.</Citation></Reference><Reference><Citation>He X., Hahn P., Iacovelli J., Wong R., King C., Bhisitkul R., Massaro-Giordano M., Dunaief J.L. Iron homeostasis and toxicity in retinal degeneration. Prog. Retin. Eye Res. 2007;26:649&#x2013;673. doi: 10.1016/j.preteyeres.2007.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2007.07.004</ArticleId><ArticleId IdType="pmc">PMC2093950</ArticleId><ArticleId IdType="pubmed">17921041</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn P., Milam A.H., Dunaief J.L. Maculas affected by age-related macular degeneration contain increased chelatable iron in the retinal pigment epithelium and Bruch&#x2019;s membrane. Arch. Ophthalmol. 2003;121:1099&#x2013;1105. doi: 10.1001/archopht.121.8.1099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archopht.121.8.1099</ArticleId><ArticleId IdType="pubmed">12912686</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaschler M.M., Stockwell B.R. Lipid peroxidation in cell death. Biochem. Biophys. Res. Commun. 2017;482:419&#x2013;425. doi: 10.1016/j.bbrc.2016.10.086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2016.10.086</ArticleId><ArticleId IdType="pmc">PMC5319403</ArticleId><ArticleId IdType="pubmed">28212725</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanito M., Elliott M.H., Kotake Y., Anderson R.E. Protein modifications by 4-hydroxynonenal and 4-hydroxyhexenal in light-exposed rat retina. Investig. Ophthalmol. Vis. Sci. 2005;46:3859&#x2013;3868. doi: 10.1167/iovs.05-0672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.05-0672</ArticleId><ArticleId IdType="pubmed">16186375</ArticleId></ArticleIdList></Reference><Reference><Citation>Crabb J.W., Miyagi M., Gu X., Shadrach K., West K.A., Sakaguchi H., Kamei M., Hasan A., Yan L., Rayborn M.E., et al. Drusen proteome analysis: An approach to the etiology of age-related macular degeneration. Proc. Natl. Acad. Sci. USA. 2002;99:14682&#x2013;14687. doi: 10.1073/pnas.222551899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.222551899</ArticleId><ArticleId IdType="pmc">PMC137479</ArticleId><ArticleId IdType="pubmed">12391305</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu X., Meer S.G., Miyagi M., Rayborn M.E., Hollyfield J.G., Crabb J.W., Salomon R.G. Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-related macular degeneration. J. Biol. Chem. 2003;278:42027&#x2013;42035. doi: 10.1074/jbc.M305460200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M305460200</ArticleId><ArticleId IdType="pubmed">12923198</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng K.P., Gugiu B., Renganathan K., Davies M.W., Gu X., Crabb J.S., Kim S.R., Rozanowska M.B., Bonilha V.L., Rayborn M.E., et al. Retinal pigment epithelium lipofuscin proteomics. Mol. Cell Proteom. 2008;7:1397&#x2013;1405. doi: 10.1074/mcp.M700525-MCP200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.M700525-MCP200</ArticleId><ArticleId IdType="pmc">PMC2493379</ArticleId><ArticleId IdType="pubmed">18436525</ArticleId></ArticleIdList></Reference><Reference><Citation>Handa J.T., Cano M., Wang L., Datta S., Liu T. Lipids, oxidized lipids, oxidation-specific epitopes, and Age-related Macular Degeneration. Biochim. Biophys. Acta Mol. Cell Biol. Lipids. 2017;1862:430&#x2013;440. doi: 10.1016/j.bbalip.2016.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbalip.2016.07.013</ArticleId><ArticleId IdType="pmc">PMC5280582</ArticleId><ArticleId IdType="pubmed">27480216</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta S., Cano M., Ebrahimi K., Wang L., Handa J.T. The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD. Prog. Retin. Eye Res. 2017;60:201&#x2013;218. doi: 10.1016/j.preteyeres.2017.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2017.03.002</ArticleId><ArticleId IdType="pmc">PMC5600827</ArticleId><ArticleId IdType="pubmed">28336424</ArticleId></ArticleIdList></Reference><Reference><Citation>Linetsky M., Guo J., Udeigwe E., Ma D., Chamberlain A.S., Yu A.O., Solovyova K., Edgar E., Salomon R.G. 4-Hydroxy-7-oxo-5-heptenoic acid (HOHA) lactone induces apoptosis in retinal pigment epithelial cells. Free Radic. Biol. Med. 2020;152:280&#x2013;294. doi: 10.1016/j.freeradbiomed.2020.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2020.03.017</ArticleId><ArticleId IdType="pmc">PMC7276294</ArticleId><ArticleId IdType="pubmed">32222470</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y.S., Linetsky M., Li H., Ayyash N., Gardella A., Salomon R.G. 4-Hydroxy-7-oxo-5-heptenoic acid lactone can induce mitochondrial dysfunction in retinal pigmented epithelial cells. Free Radic. Biol. Med. 2020;160:719&#x2013;733. doi: 10.1016/j.freeradbiomed.2020.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2020.09.009</ArticleId><ArticleId IdType="pmc">PMC7704664</ArticleId><ArticleId IdType="pubmed">32920040</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y.S., Linetsky M., Gu X., Ayyash N., Gardella A., Salomon R.G. Light-induced generation and toxicity of docosahexaenoate-derived oxidation products in retinal pigmented epithelial cells. Exp. Eye Res. 2019;181:325&#x2013;345. doi: 10.1016/j.exer.2018.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exer.2018.09.012</ArticleId><ArticleId IdType="pmc">PMC6443467</ArticleId><ArticleId IdType="pubmed">30296412</ArticleId></ArticleIdList></Reference><Reference><Citation>Linetsky M., Bondelid K.S., Losovskiy S., Gabyak V., Rullo M.J., Stiadle T.I., Munjapara V., Saxena P., Ma D.M., Cheng Y.S., et al. 4-Hydroxy-7-oxo-5-heptenoic Acid Lactone Is a Potent Inducer of the Complement Pathway in Human Retinal Pigmented Epithelial Cells. Chem. Res. Toxicol. 2018;31:666&#x2013;679. doi: 10.1021/acs.chemrestox.8b00028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrestox.8b00028</ArticleId><ArticleId IdType="pmc">PMC6102073</ArticleId><ArticleId IdType="pubmed">29883119</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Linetsky M., Guo J.H., Yu A.O., Salomon R.G. Metabolism of 4-Hydroxy-7-oxo-5-heptenoic Acid (HOHA) Lactone by Retinal Pigmented, Epithelial Cells. Chem. Res. Toxicol. 2016;29:1198&#x2013;1210. doi: 10.1021/acs.chemrestox.6b00153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrestox.6b00153</ArticleId><ArticleId IdType="pmc">PMC5008261</ArticleId><ArticleId IdType="pubmed">27355557</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J.H., Linetsky M., Yu A.O., Zhang L., Howell S.J., Folkwein H.J., Wang H., Salomon R.G. 4-Hydroxy-7-oxo-5-heptenoic Acid Lactone Induces Angiogenesis through Several Different Molecular Pathways. Chem. Res. Toxicol. 2016;29:2125&#x2013;2135. doi: 10.1021/acs.chemrestox.6b00233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrestox.6b00233</ArticleId><ArticleId IdType="pmc">PMC5349710</ArticleId><ArticleId IdType="pubmed">27806561</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Linetsky M., Guo J.H., Choi J., Hong L., Chamberlain A.S., Howell S.J., Howes A.M., Salomon R.G. 4-Hydroxy-7-oxo-5-heptenoic Acid (HOHA) Lactone is a Biologically Active Precursor for the Generation of 2-(&#x3c9;-Carboxyethyl)pyrrole (CEP) Derivatives of Proteins and Ethanolamine Phospholipids. Chem. Res. Toxicol. 2015;28:967&#x2013;977. doi: 10.1021/acs.chemrestox.5b00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrestox.5b00001</ArticleId><ArticleId IdType="pmc">PMC4437860</ArticleId><ArticleId IdType="pubmed">25793308</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Guo J.H., West X.X.Z., Bid H.K., Lu L., Hong L., Jang G.F., Zhang L., Crabb J.W., Linetsky M., et al. Detection and Biological Activities of Carboxyethylpyrrole Ethanolamine Phospholipids (CEP-EPs) Chem. Res. Toxicol. 2014;27:2015&#x2013;2022. doi: 10.1021/tx500216a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/tx500216a</ArticleId><ArticleId IdType="pmc">PMC4269404</ArticleId><ArticleId IdType="pubmed">25380349</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf3;zanowska M.B., Pawlak A., R&#xf3;zanowski B. Products of docosahexaenoate oxidation as contributors to photosensitising properties of retinal lipofuscin. Int. J. Mol. Sci. 2021;22:3525. doi: 10.3390/ijms22073525.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22073525</ArticleId><ArticleId IdType="pmc">PMC8037991</ArticleId><ArticleId IdType="pubmed">33805370</ArticleId></ArticleIdList></Reference><Reference><Citation>Folch J., Lees M., Sloane Stanley G.H. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 1957;226:497&#x2013;509. doi: 10.1016/S0021-9258(18)64849-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)64849-5</ArticleId><ArticleId IdType="pubmed">13428781</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozanowska M., Pawlak A., Rozanowski B., Skumatz C., Zareba M., Boulton M.E., Burke J.M., Sarna T., Simon J.D. Age-related changes in the photoreactivity of retinal lipofuscin granules: Role of chloroform-insoluble components. Investig. Ophthalmol. Vis. Sci. 2004;45:1052&#x2013;1060. doi: 10.1167/iovs.03-0277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.03-0277</ArticleId><ArticleId IdType="pubmed">15037568</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMar J.C., Jr., Wensel T.G., Anderson R.E. Biosynthesis of the unsaturated 14-carbon fatty acids found on the N termini of photoreceptor-specific proteins. J. Biol. Chem. 1996;271:5007&#x2013;5016. doi: 10.1074/jbc.271.9.5007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.271.9.5007</ArticleId><ArticleId IdType="pubmed">8617777</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim R.S., LaBella F.S. Comparison of analytical methods for monitoring autoxidation profiles of authentic lipids. J. Lipid Res. 1987;28:1110&#x2013;1117. doi: 10.1016/S0022-2275(20)38624-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-2275(20)38624-7</ArticleId><ArticleId IdType="pubmed">3655563</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrona M., Rozanowska M., Sarna T. Zeaxanthin in combination with ascorbic acid or alpha-tocopherol protects ARPE-19 cells against photosensitized peroxidation of lipids. Free Radic. Biol. Med. 2004;36:1094&#x2013;1101. doi: 10.1016/j.freeradbiomed.2004.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2004.02.005</ArticleId><ArticleId IdType="pubmed">15082063</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn K.C., Aotaki-Keen A.E., Putkey F.R., Hjelmeland L.M. ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp. Eye Res. 1996;62:155&#x2013;169. doi: 10.1006/exer.1996.0020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exer.1996.0020</ArticleId><ArticleId IdType="pubmed">8698076</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozanowska M.B., Rozanowski B. Photodegradation of Lipofuscin in Suspension and in ARPE-19 Cells and the Similarity of Fluorescence of the Photodegradation Product with Oxidized Docosahexaenoate. Int. J. Mol. Sci. 2022;23:922. doi: 10.3390/ijms23020922.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23020922</ArticleId><ArticleId IdType="pmc">PMC8778276</ArticleId><ArticleId IdType="pubmed">35055111</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozanowska M.B., Czuba-Pelech B., Rozanowski B. Is There an Optimal Combination of AREDS2 Antioxidants Zeaxanthin, Vitamin E and Vitamin C on Light-Induced Toxicity of Vitamin A Aldehyde to the Retina? Antioxidants. 2022;11:1132. doi: 10.3390/antiox11061132.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox11061132</ArticleId><ArticleId IdType="pmc">PMC9220409</ArticleId><ArticleId IdType="pubmed">35740030</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozanowska M., Handzel K., Boulton M.E., Rozanowski B. Cytotoxicity of all-trans-retinal increases upon photodegradation. Photochem. Photobiol. 2012;88:1362&#x2013;1372. doi: 10.1111/j.1751-1097.2012.01161.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1751-1097.2012.01161.x</ArticleId><ArticleId IdType="pmc">PMC3644973</ArticleId><ArticleId IdType="pubmed">22515697</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosmann T. Rapid colorimetric assay for cellular growth and survival&#x2014;application to proliferation and cytotoxicity assays. J. Immunol. Methods. 1983;65:55&#x2013;63. doi: 10.1016/0022-1759(83)90303-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-1759(83)90303-4</ArticleId><ArticleId IdType="pubmed">6606682</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavrieli Y., Sherman Y., Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 1992;119:493&#x2013;501. doi: 10.1083/jcb.119.3.493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.119.3.493</ArticleId><ArticleId IdType="pmc">PMC2289665</ArticleId><ArticleId IdType="pubmed">1400587</ArticleId></ArticleIdList></Reference><Reference><Citation>Papermaster D.S. Preparation of retinal rod outer segments. Methods Enzymol. 1982;81:48&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">6212746</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulton M., Marshall J. Effects of increasing numbers of phagocytic inclusions on human retinal pigment epithelial cells in culture: A model for aging. Br. J. Ophthalmol. 1986;70:808&#x2013;815. doi: 10.1136/bjo.70.11.808.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjo.70.11.808</ArticleId><ArticleId IdType="pmc">PMC1040833</ArticleId><ArticleId IdType="pubmed">3790481</ArticleId></ArticleIdList></Reference><Reference><Citation>Recknagel R.O., Glende E.A. Spectrophotometric detection of lipid conjugated dienes. Methods Enzymol. 1984;105:331&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">6727673</ArticleId></ArticleIdList></Reference><Reference><Citation>Pryor W.A., Castle L. Chemical methods for the detection of lipid hydroperoxides. Methods Enzymol. 1984;105:293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">6727667</ArticleId></ArticleIdList></Reference><Reference><Citation>Corongiu F.P., Banni S., Dess M.A. Conjugated dienes detected in tissue lipid extracts by second derivative spectrophotometry. Free Radic. Biol. Med. 1989;7:183&#x2013;186. doi: 10.1016/0891-5849(89)90012-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0891-5849(89)90012-9</ArticleId><ArticleId IdType="pubmed">2806943</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovich I.A., Lukyanova S.M., Bachmann C. Dihydroxydocosahexaenoic acids of the neuroprotectin D family: Synthesis, structure, and inhibition of human 5-lipoxygenase. J. Lipid Res. 2006;47:2462&#x2013;2474. doi: 10.1194/jlr.M600280-JLR200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.M600280-JLR200</ArticleId><ArticleId IdType="pubmed">16899822</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovich I.A. On the structure and synthesis of neuroprotectin D1, a novel anti-inflammatory compound of the docosahexaenoic acid family. J. Lipid Res. 2005;46:2311&#x2013;2314. doi: 10.1194/jlr.C500015-JLR200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.C500015-JLR200</ArticleId><ArticleId IdType="pubmed">16150835</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight J., Taylor G.W., Wright P., Clare A.S., Rowley A.F. Eicosanoid biosynthesis in an advanced deuterostomate invertebrate, the sea squirt (Ciona intestinalis) Biochim. Biophys. Acta Mol. Cell Biol. Lipids. 1999;1436:467&#x2013;478. doi: 10.1016/S0005-2760(98)00153-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0005-2760(98)00153-2</ArticleId><ArticleId IdType="pubmed">9989276</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuklev D.V., Smith W.L. Synthesis of long chain n-3 and n-6 fatty acids having a photoactive conjugated tetraene group. Chem. Phys. Lipids. 2004;130:145&#x2013;158. doi: 10.1016/j.chemphyslip.2004.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chemphyslip.2004.02.006</ArticleId><ArticleId IdType="pubmed">15172831</ArticleId></ArticleIdList></Reference><Reference><Citation>Artigas J.M., Felipe A., Navea A., Fandino A., Artigas C. Spectral transmission of the human crystalline lens in adult and elderly persons: Color and total transmission of visible light. Investig. Ophthalmol. Vis. Sci. 2012;53:4076&#x2013;4084. doi: 10.1167/iovs.12-9471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.12-9471</ArticleId><ArticleId IdType="pubmed">22491402</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozanowska M., Edge R., Land E.J., Navaratnam S., Sarna T., Truscott T.G. Scavenging of Cation Radicals of the Visual Cycle Retinoids by Lutein, Zeaxanthin, Taurine, and Melanin. Int. J. Mol. Sci. 2023;25:506. doi: 10.3390/ijms25010506.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms25010506</ArticleId><ArticleId IdType="pmc">PMC10779001</ArticleId><ArticleId IdType="pubmed">38203675</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozanowska M.B., Czuba-Pelech B., Landrum J.T., Rozanowski B. Comparison of Antioxidant Properties of Dehydrolutein with Lutein and Zeaxanthin, and their Effects on Cultured Retinal Pigment Epithelial Cells. Antioxidants. 2021;10:753. doi: 10.3390/antiox10050753.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10050753</ArticleId><ArticleId IdType="pmc">PMC8151661</ArticleId><ArticleId IdType="pubmed">34068492</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrona M., Korytowski W., Rozanowska M., Sarna T., Truscott T.G. Cooperation of antioxidants in protection against photosensitized oxidation. Free Radic. Biol. Med. 2003;35:1319&#x2013;1329. doi: 10.1016/j.freeradbiomed.2003.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2003.07.005</ArticleId><ArticleId IdType="pubmed">14607531</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozanowska M., Bakker L., Boulton M.E., Rozanowski B. Concentration dependence of vitamin C in combinations with vitamin E and zeaxanthin on light-induced toxicity to retinal pigment epithelial cells. Photochem. Photobiol. 2012;88:1408&#x2013;1417. doi: 10.1111/j.1751-1097.2012.01228.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1751-1097.2012.01228.x</ArticleId><ArticleId IdType="pmc">PMC3484246</ArticleId><ArticleId IdType="pubmed">22924673</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsung Y.C., Chung C.Y., Wan H.C., Chang Y.Y., Shih P.C., Hsu H.S., Kao M.C., Huang C.J. Dimethyl Sulfoxide Attenuates Acute Lung Injury Induced by Hemorrhagic Shock/Resuscitation in Rats. Inflammation. 2017;40:555&#x2013;565. doi: 10.1007/s10753-016-0502-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-016-0502-4</ArticleId><ArticleId IdType="pubmed">28028757</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf3;&#x17c;anowska M., R&#xf3;&#x17c;anowski B. Uptake and photoprotection in cultured RPE cells. In: Landrum J.T., editor. Carotenoids: Physical, Chemical, and Biological Functions and Properties. CRC Press; Boca Raton, FL, USA: 2010. pp. 309&#x2013;364.</Citation></Reference><Reference><Citation>Kalariya N.M., Ramana K.V., Srivastava S.K., van Kuijk F.J. Genotoxic effects of carotenoid breakdown products in human retinal pigment epithelial cells. Curr. Eye Res. 2009;34:737&#x2013;747. doi: 10.1080/02713680903046855.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/02713680903046855</ArticleId><ArticleId IdType="pmc">PMC2796437</ArticleId><ArticleId IdType="pubmed">19839867</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalariya N.M., Ramana K.V., Srivastava S.K., van Kuijk F.J. Carotenoid derived aldehydes-induced oxidative stress causes apoptotic cell death in human retinal pigment epithelial cells. Exp. Eye Res. 2008;86:70&#x2013;80. doi: 10.1016/j.exer.2007.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exer.2007.09.010</ArticleId><ArticleId IdType="pmc">PMC2786271</ArticleId><ArticleId IdType="pubmed">17977529</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaemmerer E., Schutt F., Krohne T.U., Holz F.G., Kopitz J. Effects of lipid peroxidation-related protein modifications on RPE lysosomal functions and POS phagocytosis. Investig. Ophthalmol. Vis. Sci. 2007;48:1342&#x2013;1347. doi: 10.1167/iovs.06-0549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.06-0549</ArticleId><ArticleId IdType="pubmed">17325182</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson S.E., Sundelin S.P., Wihlmark U., Brunk U.T. Aging of cultured retinal pigment epithelial cells: Oxidative reactions, lipofuscin formation and blue light damage. Doc. Ophthalmol. 2003;106:13&#x2013;16. doi: 10.1023/A:1022419606629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1022419606629</ArticleId><ArticleId IdType="pubmed">12675480</ArticleId></ArticleIdList></Reference><Reference><Citation>Wihlmark U., Wrigstad A., Roberg K., Brunk U.T., Nilsson S.E. Lipofuscin formation in cultured retinal pigment epithelial cells exposed to photoreceptor outer segment material under different oxygen concentrations. APMIS. 1996;104:265&#x2013;271. doi: 10.1111/j.1699-0463.1996.tb00716.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1699-0463.1996.tb00716.x</ArticleId><ArticleId IdType="pubmed">8645465</ArticleId></ArticleIdList></Reference><Reference><Citation>Wihlmark U., Wrigstad A., Roberg K., Brunk U.T., Nilsson S.E. Formation of lipofuscin in cultured retinal pigment epithelial cells exposed to pre-oxidized photoreceptor outer segments. APMIS. 1996;104:272&#x2013;279. doi: 10.1111/j.1699-0463.1996.tb00717.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1699-0463.1996.tb00717.x</ArticleId><ArticleId IdType="pubmed">8645466</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Zhang D., Wu Y., Ji B. Docosahexaenoic acid aggravates photooxidative damage in retinal pigment epithelial cells via lipid peroxidation. J. Photochem. Photobiol. B. 2014;140:85&#x2013;93. doi: 10.1016/j.jphotobiol.2014.07.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jphotobiol.2014.07.016</ArticleId><ArticleId IdType="pubmed">25108204</ArticleId></ArticleIdList></Reference><Reference><Citation>Neiteler A., Palakkan A.A., Gallagher K.M., Ross J.A. Oxidative stress and docosahexaenoic acid injury lead to increased necroptosis and ferroptosis in retinal pigment epithelium. Sci. Rep. 2023;13:21143. doi: 10.1038/s41598-023-47721-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-47721-5</ArticleId><ArticleId IdType="pmc">PMC10689458</ArticleId><ArticleId IdType="pubmed">38036571</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozanowska M., Sarna T. Light-induced damage to the retina: Role of rhodopsin chromophore revisited. Photochem. Photobiol. 2005;81:1305&#x2013;1330. doi: 10.1562/2004-11-13-IR-371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1562/2004-11-13-IR-371</ArticleId><ArticleId IdType="pubmed">16120006</ArticleId></ArticleIdList></Reference><Reference><Citation>Stubbs G.W., Litman B.J. Effect of alterations in the amphipathic microenvironment on the conformational stability of bovine opsin. 1. Mechanism of solubilization of disk membranes by the nonionic detergent, octyl glucoside. Biochemistry. 1978;17:215&#x2013;219. doi: 10.1021/bi00595a003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi00595a003</ArticleId><ArticleId IdType="pubmed">619986</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Liu J., Ma X., Bai X. Maresin-1 inhibits high glucose induced ferroptosis in ARPE-19 cells by activating the Nrf2/HO-1/GPX4 pathway. BMC Ophthalmol. 2023;23:368. doi: 10.1186/s12886-023-03115-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12886-023-03115-9</ArticleId><ArticleId IdType="pmc">PMC10481498</ArticleId><ArticleId IdType="pubmed">37674121</ArticleId></ArticleIdList></Reference><Reference><Citation>Calandria J.M., Do K.V., Kala-Bhattacharjee S., Obenaus A., Belayev L., Bazan N.G. cRel and Wnt5a/Frizzled 5 Receptor-Mediated Inflammatory Regulation Reveal Novel Neuroprotectin D1 Targets for Neuroprotection. Cell Mol. Neurobiol. 2023;43:1077&#x2013;1096. doi: 10.1007/s10571-022-01231-6. Erratum in 2023, 43, 1097&#x2013;1103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-022-01231-6</ArticleId><ArticleId IdType="pmc">PMC10006067</ArticleId><ArticleId IdType="pubmed">35622188</ArticleId></ArticleIdList></Reference><Reference><Citation>Antony R., Lukiw W.J., Bazan N.G. Neuroprotectin D1 induces dephosphorylation of Bcl-xL in a PP2A-dependent manner during oxidative stress and promotes retinal pigment epithelial cell survival. J. Biol. Chem. 2010;285:18301&#x2013;18308. doi: 10.1074/jbc.M109.095232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.095232</ArticleId><ArticleId IdType="pmc">PMC2881755</ArticleId><ArticleId IdType="pubmed">20363734</ArticleId></ArticleIdList></Reference><Reference><Citation>Calandria J.M., Bazan N.G. Neuroprotectin D1 Modulates the Induction of Pro-Inflammatory Signaling and Promotes Retinal Pigment Epithelial Cell Survival DuringOxidative Stress. Adv. Exp. Med. Biol. 2010;664:663&#x2013;670. doi: 10.1007/978-1-4419-1399-9_76.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4419-1399-9_76</ArticleId><ArticleId IdType="pubmed">20238071</ArticleId></ArticleIdList></Reference><Reference><Citation>Calandria J.M., Marcheselli V.L., Mukherjee P.K., Uddin J., Winkler J.W., Petasis N.A., Bazan N.G. Selective survival rescue in 15-lipoxygenase-1-deficient retinal pigment epithelial cells by the novel docosahexaenoic acid-derived mediator, neuroprotectin D1. J. Biol. Chem. 2009;284:17877&#x2013;17882. doi: 10.1074/jbc.M109.003988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.003988</ArticleId><ArticleId IdType="pmc">PMC2719426</ArticleId><ArticleId IdType="pubmed">19403949</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim&#xf3;n M.V., Agnolazza D.L., German O.L., Garelli A., Politi L.E., Agbaga M.P., Anderson R.E., Rotstein N.P. Synthesis of docosahexaenoic acid from eicosapentaenoic acid in retina neurons protects photoreceptors from oxidative stress. J. Neurochem. 2016;136:931&#x2013;946. doi: 10.1111/jnc.13487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13487</ArticleId><ArticleId IdType="pmc">PMC4755815</ArticleId><ArticleId IdType="pubmed">26662863</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanito M., Brush R.S., Elliott M.H., Wicker L.D., Henry K.R., Anderson R.E. High levels of retinal membrane docosahexaenoic acid increase susceptibility to stress-induced degeneration. J. Lipid Res. 2009;50:807&#x2013;819. doi: 10.1194/jlr.M800170-JLR200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.M800170-JLR200</ArticleId><ArticleId IdType="pmc">PMC2666167</ArticleId><ArticleId IdType="pubmed">19023138</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun M., Finnemann S.C., Febbraio M., Shan L., Annangudi S.P., Podrez E.A., Hoppe G., Darrow R., Organisciak D.T., Salomon R.G., et al. Light-induced oxidation of photoreceptor outer segment phospholipids generates ligands for CD36-mediated phagocytosis by retinal pigment epithelium: A potential mechanism for modulating outer segment phagocytosis under oxidant stress conditions. J. Biol. Chem. 2006;281:4222&#x2013;4230. doi: 10.1074/jbc.M509769200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M509769200</ArticleId><ArticleId IdType="pmc">PMC3627732</ArticleId><ArticleId IdType="pubmed">16354659</ArticleId></ArticleIdList></Reference><Reference><Citation>Organisciak D.T., Darrow R.M., Jiang Y.L., Blanks J.C. Retinal light damage in rats with altered levels of rod outer segment docosahexaenoate. Investig. Ophthalmol. Vis. Sci. 1996;37:2243&#x2013;2257.</Citation><ArticleIdList><ArticleId IdType="pubmed">8843911</ArticleId></ArticleIdList></Reference><Reference><Citation>Orban T., Johnson W.M., Dong Z., Maeda T., Maeda A., Sakai T., Tsuneoka H., Mieyal J.J., Palczewski K. Serum levels of lipid metabolites in age-related macular degeneration. FASEB J. 2015;29:4579&#x2013;4588. doi: 10.1096/fj.15-275289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.15-275289</ArticleId><ArticleId IdType="pmc">PMC4608905</ArticleId><ArticleId IdType="pubmed">26187344</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal E., Jun B., Gordon W.C., Maire M.A., Martine L., Gregoire S., Khoury S., Cabaret S., Berdeaux O., Acar N., et al. Bioavailability and spatial distribution of fatty acids in the rat retina after dietary omega-3 supplementation. J. Lipid Res. 2020;61:1733&#x2013;1746. doi: 10.1194/jlr.RA120001057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.RA120001057</ArticleId><ArticleId IdType="pmc">PMC7707163</ArticleId><ArticleId IdType="pubmed">33127836</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugasini D., Yalagala P.C.R., Subbaiah P.V. Efficient Enrichment of Retinal DHA with Dietary Lysophosphatidylcholine-DHA: Potential Application for Retinopathies. Nutrients. 2020;12:3114. doi: 10.3390/nu12103114. Erratum in 2021, 13, 2166.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12103114</ArticleId><ArticleId IdType="pmc">PMC7601701</ArticleId><ArticleId IdType="pubmed">33053841</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnebelen-Berthier C., Acar N., Pouillart P., Thabuis C., Rodriguez B., Depeint F., Clerc E., Mathiaud A., Bourdillon A., Baert B., et al. Incorporation of lutein and docosahexaenoic acid from dietary microalgae into the retina in quail. Int. J. Food Sci. Nutr. 2015;66:222&#x2013;229. doi: 10.3109/09637486.2014.971227.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/09637486.2014.971227</ArticleId><ArticleId IdType="pubmed">25657100</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramchani-Ben Othman K., Cercy C., Amri M., Doly M., Ranchon-Cole I. Dietary Supplement Enriched in Antioxidants and Omega-3 Protects from Progressive Light-Induced Retinal Degeneration. PLoS ONE. 2015;10:e0128395. doi: 10.1371/journal.pone.0128395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0128395</ArticleId><ArticleId IdType="pmc">PMC4455991</ArticleId><ArticleId IdType="pubmed">26042773</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnebelen C., Gregoire S., Pasquis B., Joffre C., Creuzot-Garcher C.P., Bron A.M., Bretillon L., Acar N. Dietary n-3 and n-6 PUFA enhance DHA incorporation in retinal phospholipids without affecting PGE(1) and PGE (2) levels. Lipids. 2009;44:465&#x2013;470. doi: 10.1007/s11745-009-3289-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11745-009-3289-3</ArticleId><ArticleId IdType="pubmed">19242743</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnebelen C., Viau S., Gregoire S., Joffre C., Creuzot-Garcher C.P., Bron A.M., Bretillon L., Acar N. Nutrition for the eye: Different susceptibility of the retina and the lacrimal gland to dietary omega-6 and omega-3 polyunsaturated fatty acid incorporation. Ophthalmic Res. 2009;41:216&#x2013;224. doi: 10.1159/000217726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000217726</ArticleId><ArticleId IdType="pubmed">19451735</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J.Y., Sekine S., Saito M. Effect of docosahexaenoic acid and ascorbate on peroxidation of retinal membranes of ODS rats. Free Radic. Res. 2003;37:419&#x2013;424. doi: 10.1080/1071576031000070084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1071576031000070084</ArticleId><ArticleId IdType="pubmed">12747736</ArticleId></ArticleIdList></Reference><Reference><Citation>Prokopiou E., Kolovos P., Kalogerou M., Neokleous A., Nicolaou O., Sokratous K., Kyriacou K., Georgiou T. Omega-3 Fatty Acids Supplementation: Therapeutic Potential in a Mouse Model of Stargardt Disease. Investig. Ophthalmol. Vis. Sci. 2018;59:2757&#x2013;2767. doi: 10.1167/iovs.17-23523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.17-23523</ArticleId><ArticleId IdType="pubmed">29860462</ArticleId></ArticleIdList></Reference><Reference><Citation>Prokopiou E., Kolovos P., Georgiou C., Kalogerou M., Potamiti L., Sokratous K., Kyriacou K., Georgiou T. Omega-3 fatty acids supplementation protects the retina from age-associated degeneration in aged C57BL/6J mice. BMJ Open Ophthalmol. 2019;4:e000326. doi: 10.1136/bmjophth-2019-000326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjophth-2019-000326</ArticleId><ArticleId IdType="pmc">PMC6861077</ArticleId><ArticleId IdType="pubmed">31799410</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun G.Y., Appenteng M.K., Li R., Woo T., Yang B., Qin C., Pan M., Cieslik M., Cui J., Fritsche K.L., et al. Docosahexaenoic Acid (DHA) Supplementation Alters Phospholipid Species and Lipid Peroxidation Products in Adult Mouse Brain, Heart, and Plasma. Neuromolecular Med. 2021;23:118&#x2013;129. doi: 10.1007/s12017-020-08616-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12017-020-08616-0</ArticleId><ArticleId IdType="pmc">PMC9555299</ArticleId><ArticleId IdType="pubmed">32926329</ArticleId></ArticleIdList></Reference><Reference><Citation>Miralles-Perez B., Mendez L., Nogues M.R., Sanchez-Martos V., Fortuno-Mar A., Ramos-Romero S., Hereu M., Medina I., Romeu M. Effects of a Fish Oil Rich in Docosahexaenoic Acid on Cardiometabolic Risk Factors and Oxidative Stress in Healthy Rats. Mar. Drugs. 2021;19:555. doi: 10.3390/md19100555.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/md19100555</ArticleId><ArticleId IdType="pmc">PMC8539050</ArticleId><ArticleId IdType="pubmed">34677454</ArticleId></ArticleIdList></Reference><Reference><Citation>Starcevic K., Filipovic N., Galan A., Micek V., Gudan Kurilj A., Masek T. Hepatic Lipogenesis and Brain Fatty Acid Profile in Response to Different Dietary n6/n3 Ratios and DHA/EPA Supplementation in Streptozotocin Treated Rats. Mol. Nutr. Food Res. 2018;62:e1701007. doi: 10.1002/mnfr.201701007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mnfr.201701007</ArticleId><ArticleId IdType="pubmed">29579359</ArticleId></ArticleIdList></Reference><Reference><Citation>Allard J.P., Kurian R., Aghdassi E., Muggli R., Royall D. Lipid peroxidation during n-3 fatty acid and vitamin E supplementation in humans. Lipids. 1997;32:535&#x2013;541. doi: 10.1007/s11745-997-0068-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11745-997-0068-2</ArticleId><ArticleId IdType="pubmed">9168460</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaloga G.P. Narrative Review of n-3 Polyunsaturated Fatty Acid Supplementation upon Immune Functions, Resolution Molecules and Lipid Peroxidation. Nutrients. 2021;13:662. doi: 10.3390/nu13020662.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13020662</ArticleId><ArticleId IdType="pmc">PMC7922327</ArticleId><ArticleId IdType="pubmed">33670710</ArticleId></ArticleIdList></Reference><Reference><Citation>Mane S., Kumari P., Singh A., Taneja N.K., Chopra R. Amelioration for oxidative stability and bioavailability of N-3 PUFA enriched microalgae oil: An overview. Crit. Rev. Food Sci. Nutr. 2024;64:2579&#x2013;2600. doi: 10.1080/10408398.2022.2124505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10408398.2022.2124505</ArticleId><ArticleId IdType="pubmed">36128949</ArticleId></ArticleIdList></Reference><Reference><Citation>Hands J.M., Anderson M.L., Cooperman T., Frame L.A. A Multi-Year Rancidity Analysis of 72 Marine and Microalgal Oil Omega-3 Supplements. J. Diet. Suppl. 2024;21:195&#x2013;206. doi: 10.1080/19390211.2023.2252064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19390211.2023.2252064</ArticleId><ArticleId IdType="pubmed">37712532</ArticleId></ArticleIdList></Reference><Reference><Citation>Jairoun A.A., Shahwan M., Zyoud S.H. Fish oil supplements, oxidative status, and compliance behaviour: Regulatory challenges and opportunities. PLoS ONE. 2020;15:e0244688. doi: 10.1371/journal.pone.0244688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0244688</ArticleId><ArticleId IdType="pmc">PMC7774961</ArticleId><ArticleId IdType="pubmed">33382790</ArticleId></ArticleIdList></Reference><Reference><Citation>Ismail A., Bannenberg G., Rice H.B., Schutt E., MacKay D. Oxidation in EPA- and DHA-rich oils: An overview. Lipid Technol. 2016;28:55&#x2013;59. doi: 10.1002/lite.201600013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lite.201600013</ArticleId></ArticleIdList></Reference><Reference><Citation>Beltrame G., Ahonen E., Damerau A., Gudmundsson H.G., Haraldsson G.G., Linderborg K.M. Lipid Structure Influences the Digestion and Oxidation Behavior of Docosahexaenoic and Eicosapentaenoic Acids in the Simulated Digestion System. J. Agric. Food Chem. 2023;71:10087&#x2013;10096. doi: 10.1021/acs.jafc.3c02207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jafc.3c02207</ArticleId><ArticleId IdType="pmc">PMC10326875</ArticleId><ArticleId IdType="pubmed">37338276</ArticleId></ArticleIdList></Reference><Reference><Citation>Floros S., Toskas A., Pasidi E., Vareltzis P. Bioaccessibility and Oxidative Stability of Omega-3 Fatty Acids in Supplements, Sardines and Enriched Eggs Studied Using a Static In Vitro Gastrointestinal Model. Molecules. 2022;27:415. doi: 10.3390/molecules27020415.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27020415</ArticleId><ArticleId IdType="pmc">PMC8780033</ArticleId><ArticleId IdType="pubmed">35056730</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew E.Y., Clemons T.E., Agron E., Domalpally A., Keenan T.D.L., Vitale S., Weber C., Smith D.C., Christen W., Group A.R. Long-term Outcomes of Adding Lutein/Zeaxanthin and omega-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28. JAMA Ophthalmol. 2022;140:692&#x2013;698. doi: 10.1001/jamaophthalmol.2022.1640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2022.1640</ArticleId><ArticleId IdType="pmc">PMC9164119</ArticleId><ArticleId IdType="pubmed">35653117</ArticleId></ArticleIdList></Reference><Reference><Citation>Sliney D.H. Eye protective techniques for bright light. Ophthalmology. 1983;90:937&#x2013;944. doi: 10.1016/S0161-6420(83)80021-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0161-6420(83)80021-9</ArticleId><ArticleId IdType="pubmed">6634078</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozanowska M., Rozanowski B., Boulton M.  Photobiology of the retina: Light damage to the retina. In: Smith K.C., editor. Photobiological Sciences. American Society for Photobiology; Herndon, VA, USA: 2009.  [(accessed on 16 September 2024)].  Available online:  http://photobiology.info/Rozanowska.html.</Citation></Reference><Reference><Citation>Ham W.T., Jr., Ruffolo J.J., Jr., Mueller H.A., Clarke A.M., Moon M.E. Histologic analysis of photochemical lesions produced in rhesus retina by short-wave-length light. Investig. Ophthalmol. Vis. Sci. 1978;17:1029&#x2013;1035.</Citation><ArticleIdList><ArticleId IdType="pubmed">100464</ArticleId></ArticleIdList></Reference><Reference><Citation>Buettner G.R. The pecking order of free radicals and antioxidants: Lipid peroxidation, &#x3b1;-tocopherol, and ascorbate. Arch. Biochem. Biophys. 1993;300:535&#x2013;543. doi: 10.1006/abbi.1993.1074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/abbi.1993.1074</ArticleId><ArticleId IdType="pubmed">8434935</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouchi A., Ishikura M., Konishi K., Nagaoka S., Mukai K. Kinetic study of the prooxidant effect of alpha-tocopherol. Hydrogen abstraction from lipids by alpha-tocopheroxyl radical. Lipids. 2009;44:935&#x2013;943. doi: 10.1007/s11745-009-3339-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11745-009-3339-x</ArticleId><ArticleId IdType="pubmed">19763654</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamberson C.R., Xu L., Muchalski H., Montenegro-Burke J.R., Shmanai V.V., Bekish A.V., McLean J.A., Clarke C.F., Shchepinov M.S., Porter N.A. Unusual kinetic isotope effects of deuterium reinforced polyunsaturated fatty acids in tocopherol-mediated free radical chain oxidations. J. Am. Chem. Soc. 2014;136:838&#x2013;841. doi: 10.1021/ja410569g.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja410569g</ArticleId><ArticleId IdType="pmc">PMC4578730</ArticleId><ArticleId IdType="pubmed">24380377</ArticleId></ArticleIdList></Reference><Reference><Citation>Firsov A.M., Franco M.S.F., Chistyakov D.V., Goriainov S.V., Sergeeva M.G., Kotova E.A., Fomich M.A., Bekish A.V., Sharko O.L., Shmanai V.V., et al. Deuterated polyunsaturated fatty acids inhibit photoirradiation-induced lipid peroxidation in lipid bilayers. J. Photochem. Photobiol. B. 2022;229:112425. doi: 10.1016/j.jphotobiol.2022.112425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jphotobiol.2022.112425</ArticleId><ArticleId IdType="pubmed">35276579</ArticleId></ArticleIdList></Reference><Reference><Citation>Jerzykiewicz M., Cwielag-Piasecka I., Witwicki M., Jezierski A. a-Tocopherol impact on oxy-radical induced free radical decomposition of DMSO: Spin trapping EPR and theoretical studies. Chem. Phys. 2011;383:27&#x2013;34. doi: 10.1016/j.chemphys.2011.03.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chemphys.2011.03.028</ArticleId></ArticleIdList></Reference><Reference><Citation>Edge R., Truscott T.G. Singlet Oxygen and Free Radical Reactions of Retinoids and Carotenoids-A Review. Antioxidants. 2018;7:5. doi: 10.3390/antiox7010005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox7010005</ArticleId><ArticleId IdType="pmc">PMC5789315</ArticleId><ArticleId IdType="pubmed">29301252</ArticleId></ArticleIdList></Reference><Reference><Citation>Black H.S., Boehm F., Edge R., Truscott T.G. The Benefits and Risks of Certain Dietary Carotenoids that Exhibit both Anti- and Pro-Oxidative Mechanisms-A Comprehensive Review. Antioxidants. 2020;9:264. doi: 10.3390/antiox9030264.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox9030264</ArticleId><ArticleId IdType="pmc">PMC7139534</ArticleId><ArticleId IdType="pubmed">32210038</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehm F., Edge R., Truscott T.G. Anti- and pro-oxidative mechanisms comparing the macular carotenoids zeaxanthin and lutein with other dietary carotenoids&#x2014;A singlet oxygen, free-radical in vitro and ex vivo study. Photochem. Photobiol. Sci. 2020;19:1001&#x2013;1009. doi: 10.1039/d0pp00120a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/d0pp00120a</ArticleId><ArticleId IdType="pubmed">32589182</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapp L.M., Maple S.S., Choi J.H. Lutein and zeaxanthin concentrations in rod outer segment membranes from perifoveal and peripheral human retina. Investig. Ophthalmol. Vis. Sci. 2000;41:1200&#x2013;1209.</Citation><ArticleIdList><ArticleId IdType="pubmed">10752961</ArticleId></ArticleIdList></Reference><Reference><Citation>Sommerburg O.G., Siems W.G., Hurst J.S., Lewis J.W., Kliger D.S., van Kuijk F.J. Lutein and zeaxanthin are associated with photoreceptors in the human retina. Curr. Eye Res. 1999;19:491&#x2013;495. doi: 10.1076/ceyr.19.6.491.5276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1076/ceyr.19.6.491.5276</ArticleId><ArticleId IdType="pubmed">10550790</ArticleId></ArticleIdList></Reference><Reference><Citation>Finnemann S.C., Silverstein R.L. Differential roles of CD36 and alphavbeta5 integrin in photoreceptor phagocytosis by the retinal pigment epithelium. J. Exp. Med. 2001;194:1289&#x2013;1298. doi: 10.1084/jem.194.9.1289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.194.9.1289</ArticleId><ArticleId IdType="pmc">PMC2195987</ArticleId><ArticleId IdType="pubmed">11696594</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunk U.T., Wihlmark U., Wrigstad A., Roberg K., Nilsson S.E. Accumulation of lipofuscin within retinal pigment epithelial cells results in enhanced sensitivity to photo-oxidation. Gerontology. 1995;41((Suppl. 2)):201&#x2013;212. doi: 10.1159/000213743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000213743</ArticleId><ArticleId IdType="pubmed">8821332</ArticleId></ArticleIdList></Reference><Reference><Citation>Krohne T.U., Stratmann N.K., Kopitz J., Holz F.G. Effects of lipid peroxidation products on lipofuscinogenesis and autophagy in human retinal pigment epithelial cells. Exp. Eye Res. 2010;90:465&#x2013;471. doi: 10.1016/j.exer.2009.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exer.2009.12.011</ArticleId><ArticleId IdType="pubmed">20059996</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei L., Tzekov R., McDowell J.H., Smith W.C., Tang S., Kaushal S. Formation of lipofuscin-like material in the RPE Cell by different components of rod outer segments. Exp. Eye Res. 2013;112:57&#x2013;67. doi: 10.1016/j.exer.2013.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exer.2013.04.006</ArticleId><ArticleId IdType="pmc">PMC4069600</ArticleId><ArticleId IdType="pubmed">23603319</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C.L., Chen Y.H., Liang C.M., Tai M.C., Lu D.W., Chen J.T. Glucosamine-Induced Autophagy through AMPK(-)mTOR Pathway Attenuates Lipofuscin-Like Autofluorescence in Human Retinal Pigment Epithelial Cells In Vitro. Int. J. Mol. Sci. 2018;19:1416. doi: 10.3390/ijms19051416.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19051416</ArticleId><ArticleId IdType="pmc">PMC5983587</ArticleId><ArticleId IdType="pubmed">29747425</ArticleId></ArticleIdList></Reference><Reference><Citation>Naash M.I., Anderson R.E. Glutathione-dependent enzymes in intact rod outer segments. Exp. Eye Res. 1989;48:309&#x2013;318. doi: 10.1016/S0014-4835(89)80080-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-4835(89)80080-6</ArticleId><ArticleId IdType="pubmed">2924815</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozanowska M. Properties and Functions of Ocular Melanins and Melanosomes. In: Borovansky J., Riley P.A., editors. Melanins and Melanosomes; Biosynthesis, Biogenesis, Physiological and Pathological Functions. Wiley-Blackwell; Weinheim, Germany: 2011.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39593115</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2662-2211</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>26</Day></PubDate></JournalIssue><Title>Implementation science communications</Title><ISOAbbreviation>Implement Sci Commun</ISOAbbreviation></Journal><ArticleTitle>Intervention design for artificial intelligence-enabled macular service implementation: a primary qualitative study.</ArticleTitle><Pagination><StartPage>131</StartPage><MedlinePgn>131</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">131</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s43058-024-00667-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Neovascular age-related macular degeneration (nAMD) is one of the largest single-disease contributors to hospital outpatient appointments. Challenges in finding the clinical capacity to meet this demand can lead to sight-threatening delays in the macular services that provide treatment. Clinical artificial intelligence (AI) technologies pose one opportunity to rebalance demand and capacity in macular services. However, there is a lack of evidence to guide early-adopters seeking to use AI as a solution to demand-capacity imbalance. This study aims to provide guidance for these early adopters on how AI-enabled macular services may best be implemented by exploring what will influence the outcome of AI implementation and why.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Thirty-six semi-structured interviews were conducted with participants. Data were analysed with the Nonadoption, Abandonment, Scale-up, Spread and Sustainability (NASSS) framework to identify factors likely to influence implementation outcomes. These factors and the primary data then underwent a secondary analysis using the Fit between Individuals, Technology and Task (FITT) framework to propose an actionable intervention.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">nAMD treatment should be initiated at face-to-face appointments with clinicians who recommend year-long periods of AI-enabled scheduling of treatments. This aims to maintain or enhance the quality of patient communication, whilst reducing consultation frequency. Appropriately trained photographers should take on the additional roles of inputting retinal imaging into the AI device and overseeing its communication to clinical colleagues, while ophthalmologists assume clinical oversight and consultation roles. Interoperability to facilitate this intervention would best be served by imaging equipment that can send images to the cloud securely for analysis by AI tools. Picture Archiving and Communication Software (PACS) should have the capability to output directly into electronic medical records (EMR) familiar to clinical and administrative staff.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">There are many enablers to implementation and few of the remaining barriers relate directly to the AI technology itself. The proposed intervention requires local tailoring and prospective evaluation but can support early adopters in optimising the&#xa0;chances of success from initial efforts to implement AI-enabled macular services.</AbstractText><AbstractText Label="PROTOCOL REGISTRATION" NlmCategory="BACKGROUND">Hogg HDJ, Brittain K, Teare D, Talks J, Balaskas K, Keane P, Maniatopoulos G. Safety and efficacy of an artificial intelligence-enabled decision tool for treatment decisions in neovascular age-related macular degeneration and an exploration of clinical pathway integration and implementation: protocol for a multi-methods validation study. BMJ Open. 2023 Feb 1;13(2):e069443. https://doi.org/10.1136/bmjopen-2022-069443 . PMID: 36725098; PMCID: PMC9896175.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hogg</LastName><ForeName>Henry David Jeffry</ForeName><Initials>HDJ</Initials><Identifier Source="ORCID">0000-0001-8044-7790</Identifier><AffiliationInfo><Affiliation>Research, Development and Innovation, University Hospitals Birmingham NHS Foundation Trust, Level 2 ITM, Queen Elizabeth HospitalMindelsohn Way, Birmingham, B15 2GW, UK. J.Hogg.1@bham.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Applied Health Research, School of Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK. J.Hogg.1@bham.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Moorfields Eye Hospital NHS Foundation Trust, London, UK. J.Hogg.1@bham.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brittain</LastName><ForeName>Katie</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talks</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Newcastle Eye Centre, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keane</LastName><ForeName>Pearse Andrew</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Moorfields Eye Hospital NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Ophthalmology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Technology Enhanced Macular Services Study Reference Group</CollectiveName></Author><Author ValidYN="Y"><LastName>Maniatopoulos</LastName><ForeName>Gregory</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Business, Leicester University, Leicester, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NIHR301467</GrantID><Agency>Research Trainees Coordinating Centre</Agency><Country/></Grant><Grant><GrantID>MR/T019050/1</GrantID><Agency>UK Research and Innovation</Agency><Country/></Grant><Grant><GrantID>R190028A</GrantID><Agency>Moorfields Eye Charity</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Implement Sci Commun</MedlineTA><NlmUniqueID>101764360</NlmUniqueID><ISSNLinking>2662-2211</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Artificial intelligence</Keyword><Keyword MajorTopicYN="N">Clinical decision support</Keyword><Keyword MajorTopicYN="N">Implementation</Keyword><Keyword MajorTopicYN="N">Machine learning</Keyword><Keyword MajorTopicYN="N">Neovascular age-related macular degeneration</Keyword><Keyword MajorTopicYN="N">Ophthalmology</Keyword><Keyword MajorTopicYN="N">Qualitative research</Keyword><Keyword MajorTopicYN="N">Retina</Keyword><Keyword MajorTopicYN="N">Theoretical approach</Keyword><Keyword MajorTopicYN="N">Theory</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: Ethical approval was granted for this work by the Greater Manchester South Research Ethics Committee, reference 21/NW/0138. All interview participants were consented with study-specific ink or digitally signed consent forms. Consent for publication: Participant consent included pseudonymised publication of interview extracts. All authors have reviewed the manuscript and give their consent for publication. Competing interests: No authors have competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Kumar</LastName><ForeName>Rashmi</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lunn</LastName><ForeName>Janet</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lunn</LastName><ForeName>Trevor</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nicholls</LastName><ForeName>Rosemary</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quilley</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sinnett</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>27</Day><Hour>0</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39593115</ArticleId><ArticleId IdType="pmc">PMC11600873</ArticleId><ArticleId IdType="doi">10.1186/s43058-024-00667-9</ArticleId><ArticleId IdType="pii">10.1186/s43058-024-00667-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bourne R, Steinmetz JD, Flaxman S, Briant PS, Taylor HR, Resnikoff S, et al. Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9(2):e130&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7820390</ArticleId><ArticleId IdType="pubmed">33275950</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JQ, Welchowski T, Schmid M, Mauschitz MM, Holz FG, Finger RP. Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis. Br J Ophthalmol. 2020;104(8):1077&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">31712255</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu DJ, Keenan TD, Faes L, Lim E, Wagner SK, Moraes G, et al. Insights from survival analyses during 12 years of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration. JAMA Ophthalmology. 2021;139(1):57&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7677877</ArticleId><ArticleId IdType="pubmed">33211064</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross AH, Downey L, Devonport H, Gale RP, Kotagiri A, Mahmood S, et al. Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration. Eye. 2020;34(10):1825&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7608090</ArticleId><ArticleId IdType="pubmed">31900438</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogg J, et al. The prevalence and impact of treatment delays in exudative age-related macular degeneration. Invest Ophthalmol Vis Sci. 2021;62:2941.</Citation></Reference><Reference><Citation>Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">25104651</ArticleId></ArticleIdList></Reference><Reference><Citation>Varma D, Talks J, de Salvo G, et al. Real-world treatment patterns and outcomes in the first 6 and 12 months of faricimab use among eyes with neovascular age-related macular degeneration (nAMD) in the UK: FARWIDE-nAMD. Invest Ophthalmol Vis Sci. 2024;65(7):4905.</Citation></Reference><Reference><Citation>Zhang J, Whebell S, Gallifant J, Budhdeo S, Mattie H, Lertvittayakumjorn P, et al. An interactive dashboard to track themes, development maturity, and global equity in clinical artificial intelligence research. Lancet Digital Health. 2022;4(4):e212&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9150439</ArticleId><ArticleId IdType="pubmed">35337638</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Ethics and Governance team WHO. Ethics and governance of artificial intelligence for health. 2021.</Citation></Reference><Reference><Citation>Yin J, Ngiam KY, Teo HH. Role of artificial intelligence applications in real-life clinical practice: systematic review. J Med Internet Res. 2021;23(4):e25759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8103304</ArticleId><ArticleId IdType="pubmed">33885365</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenderott K, Krups J, Luetkens JA, Gambashidze N, Weigl M. Prospective effects of an artificial intelligence-based computer-aided detection system for prostate imaging on routine workflow and radiologists&#x2019; outcomes. Eur J Radiol. 2024;170:111252.</Citation><ArticleIdList><ArticleId IdType="pubmed">38096741</ArticleId></ArticleIdList></Reference><Reference><Citation>van Leeuwen KG, de Rooij M, Schalekamp S, van Ginneken B, Rutten M. How does artificial intelligence in radiology improve efficiency and health outcomes? Pediatr Radiol. 2022;52(11):2087&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9537124</ArticleId><ArticleId IdType="pubmed">34117522</ArticleId></ArticleIdList></Reference><Reference><Citation>Beede E, Baylor E, Hersch F, et al. A human-centered evaluation of a deep learning system deployed in clinics for the detection of diabetic retinopathy. Proceedings of the 2020 CHI conference on human factors in computing systems.&#xa0;Honolulu, HI, USA. p. 1&#x2013;12.&#xa0;https://www.mdpi.com/2075-4426/14/10/1062.</Citation></Reference><Reference><Citation>Ong AY HH, Kale AU, Taribagil P, Kras A, Dow E, Macdonald T, Liu X, Keane PA, Denniston AK. Artificial intelligence as a medical device for ophthalmic imaging in Europe, Australia, and the United States: protocol for a systematic scoping review of regulated devices.&#xa0;JMIR Res Protoc. 2024;13:e52602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10979335</ArticleId><ArticleId IdType="pubmed">38483456</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogg HDJ, Al-Zubaidy M, Talks J, Denniston AK, Kelly CJ, Malawana J, et al. Stakeholder perspectives of clinical artificial intelligence implementation: systematic review of qualitative evidence. J Med Internet Res. 2023;25:e39742.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9875023</ArticleId><ArticleId IdType="pubmed">36626192</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogg HDJ, Sendak MP, Denniston AK, Keane PA, Maniatopoulos G. Unlocking the potential of qualitative research for the implementation of artificial intelligence-enabled healthcare. J Med Artif Intell. 2023;6. 10.21037/jmai-23-28.</Citation></Reference><Reference><Citation>Taribagil P, Hogg HDJ, Balaskas K, Keane PA. Integrating artificial intelligence into an ophthalmologist&#x2019;s workflow: obstacles and opportunities. Expert Rev Ophthalmol. 2023;18(1):45&#x2013;56.</Citation></Reference><Reference><Citation>Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687.</Citation><ArticleIdList><ArticleId IdType="pubmed">24609605</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">17872937</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogg HDJ, Brittain K, Teare D, Talks SJ, Balaskas K, Keane PA, et al. Safety and efficacy of an artificial intelligence-enabled decision tool for treatment decisions in neovascular age-related macular degeneration and an exploration of clinical pathway integration and implementation: protocol for a multi-methods validation study. BMJ Open. 2023;13(2):e069443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9896175</ArticleId><ArticleId IdType="pubmed">36725098</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T, Wherton J, Papoutsi C, Lynch J, Hughes G, A&#x2019;Court C, et al. Beyond adoption: a new framework for theorizing and evaluating nonadoption, abandonment, and challenges to the scale-up, spread, and sustainability of health and care technologies. J Med Internet Res. 2017;19(11):e367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5688245</ArticleId><ArticleId IdType="pubmed">29092808</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsen P. Making sense of implementation theories, models and frameworks. Implement Sci. 2015;10(1):53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4406164</ArticleId><ArticleId IdType="pubmed">25895742</ArticleId></ArticleIdList></Reference><Reference><Citation>Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;7(4):50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2736161</ArticleId><ArticleId IdType="pubmed">19664226</ArticleId></ArticleIdList></Reference><Reference><Citation>Cresswell K, Williams R, Sheikh A. Developing and applying a formative evaluation framework for health information technology implementations: qualitative investigation. J Med Internet Res. 2020;22(6):e15068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7315366</ArticleId><ArticleId IdType="pubmed">32519968</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogg HDJ, Al-Zubaidy M, Keane PA, Hughes G, Beyer FR, Maniatopoulos G. Evaluating the translation of implementation science to clinical artificial intelligence: a bibliometric study of qualitative research. Front Health Serv. 2023;3:1161822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10364639</ArticleId><ArticleId IdType="pubmed">37492632</ArticleId></ArticleIdList></Reference><Reference><Citation>Ammenwerth E, Iller C, Mahler C. IT-adoption and the interaction of task, technology and individuals: a fit framework and a case study. BMC Med Inform Decis Mak. 2006;6(1):3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1352353</ArticleId><ArticleId IdType="pubmed">16401336</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis FD. Perceived usefulness, perceived ease of use, and user acceptance of information technology. MIS Q. 1989;13(3):319&#x2013;40.</Citation></Reference><Reference><Citation>Sittig DF, Singh H. A new sociotechnical model for studying health information technology in complex adaptive healthcare systems. Qual Saf Health Care. 2010;19 Suppl 3(Suppl 3):i68&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3120130</ArticleId><ArticleId IdType="pubmed">20959322</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders B, Sim J, Kingstone T, Baker S, Waterfield J, Bartlam B, Burroughs H, Jinks C. Saturation in qualitative research: exploring its conceptualization and operationalization. Qual Quant. 2018;52(4):1893&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5993836</ArticleId><ArticleId IdType="pubmed">29937585</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai Y, Yu Z, Zhang Q, Zhang Y. Barriers and facilitators to implementing a nursing clinical decision support system in a tertiary hospital setting: a qualitative study using the FITT framework. Int J Med Inform. 2022;166:104841.</Citation><ArticleIdList><ArticleId IdType="pubmed">36027798</ArticleId></ArticleIdList></Reference><Reference><Citation>Talks SJ, Daien V, Mitchell P, Aslam T, Barratt J, Biberger A, et al. The patient voice in neovascular age-related macular degeneration: findings from a qualitative study. Ophthalmol Ther. 2023;12(1):561&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9756919</ArticleId><ArticleId IdType="pubmed">36525220</ArticleId></ArticleIdList></Reference><Reference><Citation>Coulibaly LM, Sacu S, Fuchs P, Bogunovic H, Faustmann G, Unterrainer C, et al. Personalized treatment supported by automated quantitative fluid analysis in active neovascular age-related macular degeneration (nAMD)&#x2014;a phase III, prospective, multicentre, randomized study: design and methods. Eye. 2023;37(7):1464&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9255834</ArticleId><ArticleId IdType="pubmed">35790835</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebovitz S, Lifshitz-Assaf H, Levina N. To engage or not to engage with AI for critical judgments: how professionals deal with opacity when using AI for medical diagnosis. Organ Sci. 2022;33(1):126&#x2013;48.</Citation></Reference><Reference><Citation>Cai CJ, Winter S, Steiner D, Wilcox L, Terry M. &#x201c;Hello AI&#x201d;: uncovering the onboarding needs of medical practitioners for human-AI collaborative decision-making. Proc ACM Hum-Comput Interact. 2019;3(CSCW):Article 104.</Citation></Reference><Reference><Citation>Pawson R, Tilley N. Realistic evaluation.&#xa0;London: Sage; 1997.&#xa0;</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39589947</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2079-9721</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases (Basel, Switzerland)</Title><ISOAbbreviation>Diseases</ISOAbbreviation></Journal><ArticleTitle>Frailty and Visual Impairment in Elderly Individuals: Improving Outcomes and Modulating Cognitive Decline Through Collaborative Care Between Geriatricians and Ophthalmologists.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">273</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/diseases12110273</ELocationID><Abstract><AbstractText><b>Introduction</b>: As life expectancy increases, the prevalence of frailty and eye diseases (cataracts, glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy) in the elderly global population is rising. Eye diseases and visual impairment not only contribute to a high incidence of falls, fractures, depression, and social isolation but they also herald cognitive decline and frailty (vision-cognitive impairment). <b>Methods</b>: This narrative review explores the relationship between eye diseases, visual impairment, and frailty, their association with cognitive decline, the current approaches in identifying and managing these conditions and the potential role of interdisciplinary care models. Relevant articles were identified by searching the major databases. <b>Result</b>: Eye diseases are common in elderly individuals and can lead to visual impairment and subsequently contribute to falls, fractures, depression, and social isolation. Visual impairment is strongly linked to cognitive decline, which is a key component of frailty. Reduced sensory input from vision loss leads to decreased cognitive stimulation, reduced engagement in activities such as reading, problem-solving, executive function, attention, and social interactions, which are crucial for maintaining cognitive health. This can lead to a form of "sensory deprivation", which accelerates neurodegenerative processes. As cognitive decline progresses, it creates a feedback loop where individuals may struggle to manage their health, adhere to treatment regimens, or seek timely medical care, exacerbating both cognitive impairment and frailty. Additionally, subjective cognitive decline (SCD) is common in older adults with vision loss and may precede clinical dementia. This sense of declining cognitive ability can worsen anxiety and depression, further contributing to frailty. Early intervention has the potential to mitigate the cognitive effects of vision loss (vision-cognitive impairment). <b>Conclusions</b>: Ophthalmologists should play an important role in detecting frailty associated with vision loss. Incorporating frailty assessments into ophthalmic practice can facilitate referrals to geriatric care and early interventions, improving patient outcomes. Geriatricians should be vigilant in identifying visual impairment and referring patients for appropriate ophthalmic investigation and management. Regular vision assessments should be part of comprehensive geriatric evaluations. Future research will assess the beneficial role of community geriatricians in detecting frailty and vision-cognitive impairment. An interdisciplinary and collaborative approach between ophthalmologists and geriatricians can lead to earlier detection, comprehensive management, and improved outcomes in frailty, eye diseases, and cognitive function.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dinarvand</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0009-0006-9590-1726</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Ashford and St. Peter's Hospital NHS Foundation Trust, Surrey KT16 0PZ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panthakey</LastName><ForeName>Johann</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, Royal Surrey County Hospital NHS Foundation Trust, Surrey GU2 7XX, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassan</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Alexandria University, Alexandria 21563, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Mohamed H</ForeName><Initials>MH</Initials><Identifier Source="ORCID">0000-0001-8045-6996</Identifier><AffiliationInfo><Affiliation>Department of Medicine and HIV Metabolic Clinic, Milton Keynes University Hospital NHS Foundation Trust, Eaglestone, Milton Keynes MK6 5LD, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Geriatric Medicine, Milton Keynes University Hospital NHS Foundation Trust, Eaglestone, Milton Keynes MK6 5LD, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Honorary Senior Lecturer of the Faculty of Medicine and Health Sciences, University of Buckingham, Buckinghham MK18 1EG, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Diseases</MedlineTA><NlmUniqueID>101636232</NlmUniqueID><ISSNLinking>2079-9721</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cognitive function</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">eye disease</Keyword><Keyword MajorTopicYN="N">frailty</Keyword><Keyword MajorTopicYN="N">old age</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>18</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>12</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39589947</ArticleId><ArticleId IdType="pmc">PMC11593253</ArticleId><ArticleId IdType="doi">10.3390/diseases12110273</ArticleId><ArticleId IdType="pii">diseases12110273</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>United Nations  . World Population Ageing, 2019 Highlights. United Nations; New York, NY, USA: 2020.  [(accessed on 5 August 2024)].  Available online:  https://www.un.org/en/development/desa/population/publications/pdf/ageing/WorldPopulationAgeing2019-Highlights.pdf.</Citation></Reference><Reference><Citation>O&#x2019;Caoimh R., Sezgin D., O&#x2019;Donovan M.R., Molloy D.W., Clegg A., Rockwood K., Liew A. Prevalence of frailty in 62 countries across the world: A systematic review and meta-analysis of population-level studies. Age Ageing. 2021;50:96&#x2013;104. doi: 10.1093/ageing/afaa219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/afaa219</ArticleId><ArticleId IdType="pubmed">33068107</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinmetz J.D., Bourne R.R.A., Briant P.S., Flaxman S.R., Taylor H.R.B., Jonas J.B., Abdoli A.A., Abrha W.A., Abualhasan A., Abu-Gharbieh E.G., et al. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: The Right to Sight: An analysis for the Global Burden of Disease Study. Lancet Glob. Health. 2021;9:e144&#x2013;e160. doi: 10.1016/S2214-109X(20)30489-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(20)30489-7</ArticleId><ArticleId IdType="pmc">PMC7820391</ArticleId><ArticleId IdType="pubmed">33275949</ArticleId></ArticleIdList></Reference><Reference><Citation>Tham Y.-C., Li X., Wong T.Y., Quigley H.A., Aung T., Cheng C.-Y. Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040. Ophthalmology. 2014;121:2081&#x2013;2090. doi: 10.1016/j.ophtha.2014.05.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2014.05.013</ArticleId><ArticleId IdType="pubmed">24974815</ArticleId></ArticleIdList></Reference><Reference><Citation>Clegg A., Young J., Iliffe S., Rikkert M.O., Rockwood K. Frailty in elderly people. Lancet. 2013;381:752&#x2013;762. doi: 10.1016/S0140-6736(12)62167-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(12)62167-9</ArticleId><ArticleId IdType="pmc">PMC4098658</ArticleId><ArticleId IdType="pubmed">23395245</ArticleId></ArticleIdList></Reference><Reference><Citation>Crews J.E., Campbell V.A. Vision Impairment and Hearing Loss Among Community-Dwelling Older Americans: Implications for Health and Functioning. Am. J. Public Health. 2004;94:823&#x2013;829. doi: 10.2105/AJPH.94.5.823.</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/AJPH.94.5.823</ArticleId><ArticleId IdType="pmc">PMC1448344</ArticleId><ArticleId IdType="pubmed">15117707</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong T., Mitchell P., Burlutsky G., Samarawickrama C., Wang J.J. Visual Impairment and the Incidence of Falls and Fractures Among Older People: Longitudinal Findings From the Blue Mountains Eye Study. Investig. Ophthalmol. Vis. Sci. 2014;55:7589. doi: 10.1167/iovs.14-14262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.14-14262</ArticleId><ArticleId IdType="pubmed">25370514</ArticleId></ArticleIdList></Reference><Reference><Citation>Fried L.P., Tangen C.M., Walston J., Newman A.B., Hirsch C., Gottdiener J., Seeman T., Tracy R., Kop W.J., Burke G., et al. Frailty in Older Adults: Evidence for a Phenotype. J. Gerontol. Ser. A Biol. Sci. Med. Sci. 2001;56:M146&#x2013;M157. doi: 10.1093/gerona/56.3.M146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/56.3.M146</ArticleId><ArticleId IdType="pubmed">11253156</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue Q.-L. The Frailty Syndrome: Definition and Natural History. Clin. Geriatr. Med. 2011;27:1&#x2013;15. doi: 10.1016/j.cger.2010.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cger.2010.08.009</ArticleId><ArticleId IdType="pmc">PMC3028599</ArticleId><ArticleId IdType="pubmed">21093718</ArticleId></ArticleIdList></Reference><Reference><Citation>Swenor B.K., Lee M.J., Tian J., Varadaraj V., Bandeen-Roche K. Visual Impairment and Frailty: Examining an Understudied Relationship. J. Gerontol. Ser. A. 2020;75:596&#x2013;602. doi: 10.1093/gerona/glz182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glz182</ArticleId><ArticleId IdType="pmc">PMC7328203</ArticleId><ArticleId IdType="pubmed">31419280</ArticleId></ArticleIdList></Reference><Reference><Citation>Liljas A.E.M., Carvalho L.A., Papachristou E., De Oliveira C., Wannamethee S.G., Ramsay S.E., Walters K. Vision impairment and risk of frailty: The English Longitudinal Study of Ageing. Lancet. 2016;388:S70. doi: 10.1016/S0140-6736(16)32306-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)32306-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Lord S.R., Dayhew J. Visual Risk Factors for Falls in Older People. J. Am. Geriatr. Soc. 2001;49:508&#x2013;515. doi: 10.1046/j.1532-5415.2001.49107.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1532-5415.2001.49107.x</ArticleId><ArticleId IdType="pubmed">11380741</ArticleId></ArticleIdList></Reference><Reference><Citation>Varadaraj V., Munoz B., Deal J.A., An Y., Albert M.S., Resnick S.M., Ferrucci L., Swenor B.K. Association of Vision Impairment With Cognitive Decline Across Multiple Domains in Older Adults. JAMA Netw. Open. 2021;4:e2117416. doi: 10.1001/jamanetworkopen.2021.17416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.17416</ArticleId><ArticleId IdType="pmc">PMC8285732</ArticleId><ArticleId IdType="pubmed">34269806</ArticleId></ArticleIdList></Reference><Reference><Citation>Tetteh J., Fordjour G., Ekem-Ferguson G., Yawson A.O., Boima V., Entsuah-Mensah K., Biritwum R., Essuman A., Mensah G., Yawson A.E. Visual impairment and social isolation, depression and life satisfaction among older adults in Ghana: Analysis of the WHO&#x2019;s Study on global AGEing and adult health (SAGE) Wave 2. BMJ Open Ophthalmol. 2020;5:e000492. doi: 10.1136/bmjophth-2020-000492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjophth-2020-000492</ArticleId><ArticleId IdType="pmc">PMC7326267</ArticleId><ArticleId IdType="pubmed">32626826</ArticleId></ArticleIdList></Reference><Reference><Citation>Crews J.E., Chou C.-F., Zack M.M., Zhang X., Bullard K.M., Morse A.R., Saaddine J.B. The Association of Health-Related Quality of Life with Severity of Visual Impairment among People Aged 40&#x2013;64 Years: Findings from the 2006&#x2013;2010 Behavioral Risk Factor Surveillance System. Ophthalmic Epidemiol. 2016;23:145&#x2013;153. doi: 10.3109/09286586.2016.1168851.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/09286586.2016.1168851</ArticleId><ArticleId IdType="pmc">PMC4924343</ArticleId><ArticleId IdType="pubmed">27159347</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin M.Y., Gutierrez P.R., Stone K.L., Yaffe K., Ensrud K.E., Fink H.A., Sarkisian C.A., Coleman A.L., Mangione C.M. Vision Impairment and Combined Vision and Hearing Impairment Predict Cognitive and Functional Decline in Older Women. J. Am. Geriatr. Soc. 2004;52:1996&#x2013;2002. doi: 10.1111/j.1532-5415.2004.52554.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2004.52554.x</ArticleId><ArticleId IdType="pubmed">15571533</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitson H.E., Cronin-Golomb A., Cruickshanks K.J., Gilmore G.C., Owsley C., Peelle J.E., Recanzone G., Sharma A., Swenor B., Yaffe K., et al. American Geriatrics Society and National Institute on Aging Bench-to-Bedside Conference: Sensory Impairment and Cognitive Decline in Older Adults. J. Am. Geriatr. Soc. 2018;66:2052&#x2013;2058. doi: 10.1111/jgs.15506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.15506</ArticleId><ArticleId IdType="pmc">PMC6410371</ArticleId><ArticleId IdType="pubmed">30248173</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston G., Huntley J., Liu K.Y., Costafreda S.G., Selb&#xe6;k G., Alladi S., Ames D., Banerjee S., Burns A., Brayne C., et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404:572&#x2013;628. doi: 10.1016/S0140-6736(24)01296-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(24)01296-0</ArticleId><ArticleId IdType="pubmed">39096926</ArticleId></ArticleIdList></Reference><Reference><Citation>Zijlmans J.L., Lamballais S., Lahousse L., Vernooij M.W., Ikram M.K., Ikram M.A., Luik A.I. The interaction of cognitive and brain reserve with frailty in the association with mortality: An observational cohort study. Lancet Healthy Longev. 2021;2:e194&#x2013;e201. doi: 10.1016/S2666-7568(21)00028-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-7568(21)00028-3</ArticleId><ArticleId IdType="pubmed">36098120</ArticleId></ArticleIdList></Reference><Reference><Citation>Petermann-Rocha F., Lyall D.M., Gray S.R., Esteban-Cornejo I., Quinn T.J., Ho F.K., Pell J.P., Celis-Morales C. Associations between physical frailty and dementia incidence: A prospective study from UK Biobank. Lancet Healthy Longev. 2020;1:e58&#x2013;e68. doi: 10.1016/S2666-7568(20)30007-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-7568(20)30007-6</ArticleId><ArticleId IdType="pubmed">36094146</ArticleId></ArticleIdList></Reference><Reference><Citation>Soysal P., Veronese N., Thompson T., Kahl K.G., Fernandes B.S., Prina A.M., Solmi M., Schofield P., Koyanagi A., Tseng P.-T., et al. Relationship between depression and frailty in older adults: A systematic review and meta-analysis. Ageing Res. Rev. 2017;36:78&#x2013;87. doi: 10.1016/j.arr.2017.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2017.03.005</ArticleId><ArticleId IdType="pubmed">28366616</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou T., Liu M., Zhang J. Bidirectional association between visual impairment and frailty among community-dwelling older adults: A longitudinal study. BMC Geriatr. 2022;22:672. doi: 10.1186/s12877-022-03365-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12877-022-03365-0</ArticleId><ArticleId IdType="pmc">PMC9377125</ArticleId><ArticleId IdType="pubmed">35971062</ArticleId></ArticleIdList></Reference><Reference><Citation>Liesegang T., Lee A.G., Liesegang T. Increasing geriatrics expertise in ophthalmology. Ophthalmology. 2002;109:635&#x2013;636. doi: 10.1016/S0161-6420(01)01056-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0161-6420(01)01056-9</ArticleId><ArticleId IdType="pubmed">11927417</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkateswaran N., Gillespie S., Ramchandran R., Gearinger M., Hindman H. Assessing Educational Needs in Geriatric Care in Ophthalmology: A Single Academic Institution Study. J. Clin. Acad. Ophthalmol. 2016;8:e30&#x2013;e38. doi: 10.1055/s-0036-1581112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0036-1581112</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandeen-Roche K., Seplaki C.L., Huang J., Buta B., Kalyani R.R., Varadhan R., Xue Q.-L., Walston J.D., Kasper J.D. Frailty in Older Adults: A Nationally Representative Profile in the United States. J. Gerontol. Ser. A Biomed. Sci. Med. Sci. 2015;70:1427&#x2013;1434. doi: 10.1093/gerona/glv133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glv133</ArticleId><ArticleId IdType="pmc">PMC4723664</ArticleId><ArticleId IdType="pubmed">26297656</ArticleId></ArticleIdList></Reference><Reference><Citation>Dent E., Martin F.C., Bergman H., Woo J., Romero-Ortuno R., Walston J.D. Management of frailty: Opportunities, challenges, and future directions. Lancet. 2019;394:1376&#x2013;1386. doi: 10.1016/S0140-6736(19)31785-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)31785-4</ArticleId><ArticleId IdType="pubmed">31609229</ArticleId></ArticleIdList></Reference><Reference><Citation>Veronese N., Cereda E., Stubbs B., Solmi M., Luchini C., Manzato E., Sergi G., Manu P., Harris T., Fontana L., et al. Risk of cardiovascular disease morbidity and mortality in frail and pre-frail older adults: Results from a meta-analysis and exploratory meta-regression analysis. Ageing Res. Rev. 2017;35:63&#x2013;73. doi: 10.1016/j.arr.2017.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2017.01.003</ArticleId><ArticleId IdType="pmc">PMC6047747</ArticleId><ArticleId IdType="pubmed">28143778</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoogendijk E.O., Afilalo J., Ensrud K.E., Kowal P., Onder G., Fried L.P. Frailty: Implications for clinical practice and public health. Lancet. 2019;394:1365&#x2013;1375. doi: 10.1016/S0140-6736(19)31786-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)31786-6</ArticleId><ArticleId IdType="pubmed">31609228</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima G., Iliffe S., Jivraj S., Walters K. Association between frailty and quality of life among community-dwelling older people: A systematic review and meta-analysis. J. Epidemiol. Community Health. 2016;70:716&#x2013;721. doi: 10.1136/jech-2015-206717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jech-2015-206717</ArticleId><ArticleId IdType="pubmed">26783304</ArticleId></ArticleIdList></Reference><Reference><Citation>Congdon N., O&#x2019;Colmain B., Klaver C.C.W., Klein R., Mu&#xf1;oz B., Friedman D.S., Kempen J., Taylor H.R., Mitchell P. Causes and prevalence of visual impairment among adults in the United States. Arch. Ophthalmol. 2004;122:477&#x2013;485. doi: 10.1001/archopht.122.4.477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archopht.122.4.477</ArticleId><ArticleId IdType="pubmed">15078664</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourne R.R.A., Flaxman S.R., Braithwaite T., Cicinelli M.V., Das A., Jonas J.B., Keeffe J., Kempen J.H., Leasher J., Limburg H., et al. Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: A systematic review and meta-analysis. Lancet Glob. Health. 2017;5:e888&#x2013;e897. doi: 10.1016/S2214-109X(17)30293-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(17)30293-0</ArticleId><ArticleId IdType="pubmed">28779882</ArticleId></ArticleIdList></Reference><Reference><Citation>Swenor B.K., Lee M.J., Varadaraj V., Whitson H.E., Ramulu P.Y. Aging With Vision Loss: A Framework for Assessing the Impact of Visual Impairment on Older Adults. Gerontologist. 2020;60:989&#x2013;995. doi: 10.1093/geront/gnz117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geront/gnz117</ArticleId><ArticleId IdType="pmc">PMC7427480</ArticleId><ArticleId IdType="pubmed">31504483</ArticleId></ArticleIdList></Reference><Reference><Citation>Welp A., Woodbury R.B., McCoy M.A., Teutsch S.M. Making Eye Health a Population Health Imperative Vision for Tomorrow. National Academies Press; Washington, DC, USA: 2017.</Citation><ArticleIdList><ArticleId IdType="pubmed">27656731</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta P., Man R.E.K., Fenwick E.K., Qian C., Sim R., Majithia S., Tham Y.C., Sabanayagam C., Wong T.Y., Cheng C.-Y., et al. Associations between visual impairment, incident falls and fall frequency among older asians: Longitudinal findings from the Singapore Epidemiology of Eye Diseases study. Br. J. Ophthalmol. 2023;107:1590&#x2013;1596. doi: 10.1136/bjo-2021-320873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjo-2021-320873</ArticleId><ArticleId IdType="pubmed">35914927</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouyang S., Zheng C., Lin Z., Zhang X., Li H., Fang Y., Hu Y., Yu H., Wu G. Risk factors of falls in elderly patients with visual impairment. Front. Public Health. 2022;10:984199. doi: 10.3389/fpubh.2022.984199.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.984199</ArticleId><ArticleId IdType="pmc">PMC9441862</ArticleId><ArticleId IdType="pubmed">36072374</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin H., Zhou Y., Stagg B.C., Ehrlich J.R. Association between vision impairment and increased prevalence of falls in older US adults. J. Am. Geriatr. Soc. 2024;72:1373&#x2013;1383. doi: 10.1111/jgs.18879.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.18879</ArticleId><ArticleId IdType="pmc">PMC11090722</ArticleId><ArticleId IdType="pubmed">38514075</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., Ge S., Yin Y., Tian C., Mei Y., Han P. Frailty is associated with worse cognitive functioning in older adults. Front. Psychiatry. 2023;14:1108902. doi: 10.3389/fpsyt.2023.1108902.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2023.1108902</ArticleId><ArticleId IdType="pmc">PMC9928943</ArticleId><ArticleId IdType="pubmed">36816402</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao G.-Y., Chen Z.-S., Yao S.-S., Wang K., Huang Z.-T., Su H.-X., Luo Y., De Fries C.M., Hu Y.-H., Xu B. The association between vision impairment and cognitive outcomes in older adults: A systematic review and meta-analysis. Aging Ment. Health. 2023;27:350&#x2013;356. doi: 10.1080/13607863.2022.2077303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13607863.2022.2077303</ArticleId><ArticleId IdType="pubmed">35583075</ArticleId></ArticleIdList></Reference><Reference><Citation>Jessen F., Amariglio R.E., Buckley R.F., Van Der Flier W.M., Han Y., Molinuevo J.L., Rabin L., Rentz D.M., Rodriguez-Gomez O., Saykin A.J., et al. The characterisation of subjective cognitive decline. Lancet Neurol. 2020;19:271&#x2013;278. doi: 10.1016/S1474-4422(19)30368-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(19)30368-0</ArticleId><ArticleId IdType="pmc">PMC7062546</ArticleId><ArticleId IdType="pubmed">31958406</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack C.R., Bennett D.A., Blennow K., Carrillo M.C., Dunn B., Haeberlein S.B., Holtzman D.M., Jagust W., Jessen F., Karlawish J., et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Amp. Dement. 2018;14:535&#x2013;562. doi: 10.1016/j.jalz.2018.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley R.F., Saling M.M., Frommann I., Wolfsgruber S., Wagner M. Subjective Cognitive Decline from a Phenomenological Perspective: A Review of the Qualitative Literature. J. Alzheimer&#x2019;s Dis. 2015;48:S125&#x2013;S140. doi: 10.3233/JAD-150095.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-150095</ArticleId><ArticleId IdType="pubmed">26402078</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo L., Jiang N., Zheng X., Wang P., Bi J., Xu F., Xie Z., Yang L. Effect of visual impairment on subjective cognitive decline in older adults: A cross-sectional study in China. BMJ Open. 2024;14:e072626. doi: 10.1136/bmjopen-2023-072626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2023-072626</ArticleId><ArticleId IdType="pmc">PMC11086556</ArticleId><ArticleId IdType="pubmed">38688669</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagarajan N., Assi L., Varadaraj V., Motaghi M., Sun Y., Couser E., Ehrlich J.R., Whitson H., Swenor B.K. Vision impairment and cognitive decline among older adults: A systematic review. BMJ Open. 2022;12:e047929. doi: 10.1136/bmjopen-2020-047929.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-047929</ArticleId><ArticleId IdType="pmc">PMC8739068</ArticleId><ArticleId IdType="pubmed">34992100</ArticleId></ArticleIdList></Reference><Reference><Citation>Aubin G., Phillips N., Jaiswal A., Johnson A.P., Joubert S., Bachir V., Kehayia E., Wittich W. Visual and cognitive functioning among older adults with low vision before vision rehabilitation: A pilot study. Front. Psychol. 2023;14:1058951. doi: 10.3389/fpsyg.2023.1058951.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2023.1058951</ArticleId><ArticleId IdType="pmc">PMC10075203</ArticleId><ArticleId IdType="pubmed">37034930</ArticleId></ArticleIdList></Reference><Reference><Citation>Ripa M., Schipa C., Rizzo S., Sollazzi L., Aceto P. Is the visual impairment a risk factor for frailty in older adults? A systematic review and meta-analysis of 10-year clinical studies. Aging Clin. Exp. Res. 2022;35:227&#x2013;244. doi: 10.1007/s40520-022-02296-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40520-022-02296-5</ArticleId><ArticleId IdType="pubmed">36367632</ArticleId></ArticleIdList></Reference><Reference><Citation>Gbessemehlan A., Kehoua G., Helmer C., Delcourt C., Tchalla A., Mbelesso P., Ndamba-Bandzouzi B., Dartigues J.-F., Houinato D., Preux P.-M., et al. Self-Reported Vision Impairment and Frailty among Older People with Low Cognitive Performance in Central Africa: EPIDEMCA Population-Based Study. Dement. Geriatr. Cogn. Disord. 2021;50:326&#x2013;332. doi: 10.1159/000518601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000518601</ArticleId><ArticleId IdType="pubmed">34808622</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh R.R., Maurya P. Visual impairment and falls among older adults and elderly: Evidence from longitudinal study of ageing in India. BMC Public Health. 2022;22:2324. doi: 10.1186/s12889-022-14697-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-022-14697-2</ArticleId><ArticleId IdType="pmc">PMC9746100</ArticleId><ArticleId IdType="pubmed">36510173</ArticleId></ArticleIdList></Reference><Reference><Citation>Guti&#xe9;rrez-Robledo L.M., Villas&#xed;s-Keever M.A., Avila-Avila A., Medina-Campos R.H., Castrej&#xf3;n-P&#xe9;rez R.C., Garc&#xed;a-Pe&#xf1;a C. Effect of Cataract Surgery on Frequency of Falls among Older Persons: A Systematic Review and Meta-Analysis. J. Ophthalmol. 2021;2021:2169571. doi: 10.1155/2021/2169571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/2169571</ArticleId><ArticleId IdType="pmc">PMC7987466</ArticleId><ArticleId IdType="pubmed">33815834</ArticleId></ArticleIdList></Reference><Reference><Citation>Rokach A., Berman D., Rose A. Loneliness of the Blind and the Visually Impaired. Front. Psychol. 2021;12:641711. doi: 10.3389/fpsyg.2021.641711.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2021.641711</ArticleId><ArticleId IdType="pmc">PMC8267375</ArticleId><ArticleId IdType="pubmed">34248743</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang A.R., Cudjoe T.K.M., Rebok G.W., Swenor B.K., Deal J.A. Hearing and vision impairment and social isolation over 8 years in community-dwelling older adults. BMC Public Health. 2024;24:779. doi: 10.1186/s12889-024-17730-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-024-17730-8</ArticleId><ArticleId IdType="pmc">PMC10936068</ArticleId><ArticleId IdType="pubmed">38475742</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunes A.B., Hansen M., Heir T. Loneliness among adults with visual impairment: Prevalence, associated factors, and relationship to life satisfaction. Health Qual. Life Outcomes. 2019;17:24. doi: 10.1186/s12955-019-1096-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-019-1096-y</ArticleId><ArticleId IdType="pmc">PMC6359849</ArticleId><ArticleId IdType="pubmed">30709406</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang E., Lee K.H. Association between Visual Impairment and Nutritional Risk among Older Adults with Diabetes: A Population-Based Cross-Sectional Study. J. Korean Acad. Nurs. 2023;53:167. doi: 10.4040/jkan.22141.</Citation><ArticleIdList><ArticleId IdType="doi">10.4040/jkan.22141</ArticleId><ArticleId IdType="pubmed">37164345</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirone K.D., Pur D.R., Malvankar-Mehta M.S. Overlooked dietary insufficiencies impacting visual impairment: A systematic review and meta-analysis. JFO Open Ophthalmol. 2023;3:100036. doi: 10.1016/j.jfop.2023.100036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jfop.2023.100036</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou C.-H., Pu C. Association Between Visual Impairment and Health Care Use. Am. J. Ophthalmol. 2022;234:166&#x2013;173. doi: 10.1016/j.ajo.2021.07.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2021.07.033</ArticleId><ArticleId IdType="pubmed">34407430</ArticleId></ArticleIdList></Reference><Reference><Citation>Cupples M.E., Hart P.M., Johnston A., Jackson A.J. Improving healthcare access for people with visual impairment and blindness. BMJ. 2012;344:e542. doi: 10.1136/bmj.e542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.e542</ArticleId><ArticleId IdType="pubmed">22290101</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupetina R. The Braille System: The Writing and Reading System that Brings Independence to the Blind Person. EJSE. May 15, 2022.  [(accessed on 23 October 2024)].  Available online:  https://oapub.org/edu/index.php/ejse/article/view/4288.</Citation></Reference><Reference><Citation>Timilsina A., Neupane P., Pandey J., Subedi A., Thapa S. Exploring the healthcare access challenges faced by visually impaired young women in Nepal: Navigating sexual harassment and stigma within healthcare settings. Dialogues Health. 2024;4:100171. doi: 10.1016/j.dialog.2024.100171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dialog.2024.100171</ArticleId><ArticleId IdType="pmc">PMC10953973</ArticleId><ArticleId IdType="pubmed">38516223</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang X., Wu G., Wang W., Zhu Z., Zhang X., Huang Y., Hu Y., He M., Yu H. Associations of vision impairment and eye diseases with frailty in community-dwelling older adults: A nationwide longitudinal study in China. Br. J. Ophthalmol. 2024;108:310&#x2013;316. doi: 10.1136/bjo-2022-322048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjo-2022-322048</ArticleId><ArticleId IdType="pubmed">36535748</ArticleId></ArticleIdList></Reference><Reference><Citation>Halawa O.A., Kang J., Parikh A.A., Oh G., Glynn R.J., Friedman D.S., Kim D.H., Zebardast N. Relationship between Claims-Based Frailty Index and Eye Care Utilization among Medicare Beneficiaries with Glaucoma. Ophthalmology. 2023;130:646&#x2013;654. doi: 10.1016/j.ophtha.2023.01.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2023.01.015</ArticleId><ArticleId IdType="pmc">PMC10614114</ArticleId><ArticleId IdType="pubmed">36731798</ArticleId></ArticleIdList></Reference><Reference><Citation>Davuluru S.S., Jess A.T., Kim J.S.B., Yoo K., Nguyen V., Xu B.Y. Identifying, Understanding, and Addressing Disparities in Glaucoma Care in the United States. Trans. Vis. Sci. Technol. 2023;12:18. doi: 10.1167/tvst.12.10.18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/tvst.12.10.18</ArticleId><ArticleId IdType="pmc">PMC10617640</ArticleId><ArticleId IdType="pubmed">37889504</ArticleId></ArticleIdList></Reference><Reference><Citation>Palagyi A., Morlet N., McCluskey P., White A., Meuleners L., Ng J.Q., Lamoureux E., Pesudovs K., Stapleton F., Ivers R.Q., et al. Visual and refractive associations with falls after first-eye cataract surgery. J. Cataract. Refract. Surg. 2017;43:1313&#x2013;1321. doi: 10.1016/j.jcrs.2017.07.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrs.2017.07.029</ArticleId><ArticleId IdType="pubmed">29056303</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharifi A., Jahanshahlou F., Gol Mohammadi Senji A., Hamzezadeh S., Zarei M., Hosseini M.-S. Enhanced Recovery After Surgery Protocols and Procedures in Geriatric Surgery. Int. J. Aging. 2024;2:e2. doi: 10.34172/ija.2024.e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.34172/ija.2024.e2</ArticleId></ArticleIdList></Reference><Reference><Citation>Liljas A.E.M., Carvalho L.A., Papachristou E., De Oliveira C., Wannamethee S.G., Ramsay S.E., Walters K.R. Self-reported vision impairment and incident prefrailty and frailty in English community-dwelling older adults: Findings from a 4-year follow-up study. J. Epidemiol. Community Health. 2017;71:1053&#x2013;1058. doi: 10.1136/jech-2017-209207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jech-2017-209207</ArticleId><ArticleId IdType="pmc">PMC5847099</ArticleId><ArticleId IdType="pubmed">28798152</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicinelli M.V., Buchan J.C., Nicholson M., Varadaraj V., Khanna R.C. Cataracts. Lancet. 2023;401:377&#x2013;389. doi: 10.1016/S0140-6736(22)01839-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01839-6</ArticleId><ArticleId IdType="pubmed">36565712</ArticleId></ArticleIdList></Reference><Reference><Citation>Takefuji Y. Frailty and eye diseases: A review of the literature. Eye. 2024;38:648. doi: 10.1038/s41433-023-02770-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41433-023-02770-y</ArticleId><ArticleId IdType="pmc">PMC10920872</ArticleId><ArticleId IdType="pubmed">37770528</ArticleId></ArticleIdList></Reference><Reference><Citation>Guymer R.H., Campbell T.G. Age-related macular degeneration. Lancet. 2023;401:1459&#x2013;1472. doi: 10.1016/S0140-6736(22)02609-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)02609-5</ArticleId><ArticleId IdType="pubmed">36996856</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayaram H., Kolko M., Friedman D.S., Gazzard G. Glaucoma: Now and beyond. Lancet. 2023;402:1788&#x2013;1801. doi: 10.1016/S0140-6736(23)01289-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(23)01289-8</ArticleId><ArticleId IdType="pubmed">37742700</ArticleId></ArticleIdList></Reference><Reference><Citation>Bidwai P., Gite S., Pahuja K., Kotecha K. A Systematic Literature Review on Diabetic Retinopathy Using an Artificial Intelligence Approach. Big Data Cogn. Comput. 2022;6:152. doi: 10.3390/bdcc6040152.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/bdcc6040152</ArticleId></ArticleIdList></Reference><Reference><Citation>Leley S.P., Ciulla T.A., Bhatwadekar A. Diabetic Retinopathy in the Aging Population: A Perspective of Pathogenesis and Treatment. Clin. Interv. Aging. 2021;16:1367&#x2013;1378. doi: 10.2147/CIA.S297494.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CIA.S297494</ArticleId><ArticleId IdType="pmc">PMC8289197</ArticleId><ArticleId IdType="pubmed">34290499</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham A.G., Ervin A., Swenor B., Ramulu P., Channa R., Kong X., Stosor V., Friedman M.R., Detels R., Plankey M. Prevalence and Consequences of Perceived Vision Difficulty in Aging Adults with HIV Infection. Am. J. Ophthalmol. 2020;218:268&#x2013;278. doi: 10.1016/j.ajo.2020.06.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2020.06.018</ArticleId><ArticleId IdType="pmc">PMC9230650</ArticleId><ArticleId IdType="pubmed">32621897</ArticleId></ArticleIdList></Reference><Reference><Citation>Poh A.W.Y., Teo S.P. Utility of Frailty Screening Tools in Older Surgical Patients. Ann. Geriatr. Med. Res. 2020;24:75&#x2013;82. doi: 10.4235/agmr.20.0023.</Citation><ArticleIdList><ArticleId IdType="doi">10.4235/agmr.20.0023</ArticleId><ArticleId IdType="pmc">PMC7370792</ArticleId><ArticleId IdType="pubmed">32743327</ArticleId></ArticleIdList></Reference><Reference><Citation>Varadaraj V., Chung S.-E., Sheehan O.C., Roth D., Schein O.D., Bandeen-Roche K., Swenor B.K. Post-cataract surgery health outcomes in frail older patients. Investig. Ophthalmol. Vis. Sci. 2021;62:63</Citation></Reference><Reference><Citation>Cesari M., Marzetti E., Thiem U., P&#xe9;rez-Zepeda M.U., Abellan Van Kan G., Landi F., Petrovic M., Cherubini A., Bernabei R. The geriatric management of frailty as paradigm of &#x201c;The end of the disease era&#x201d;. Eur. J. Intern. Med. 2016;31:11&#x2013;14. doi: 10.1016/j.ejim.2016.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2016.03.005</ArticleId><ArticleId IdType="pubmed">26997416</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockwood K. A global clinical measure of fitness and frailty in elderly people. Can. Med. Assoc. J. 2005;173:489&#x2013;495. doi: 10.1503/cmaj.050051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.050051</ArticleId><ArticleId IdType="pmc">PMC1188185</ArticleId><ArticleId IdType="pubmed">16129869</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinarvand D., Panthakey J., Heidari A., Hassan A., Ahmed M.H. The Intersection between Frailty, Diabetes, and Hypertension: The Critical Role of Community Geriatricians and Pharmacists in Deprescribing. J. Pers. Med. 2024;14:924. doi: 10.3390/jpm14090924.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm14090924</ArticleId><ArticleId IdType="pmc">PMC11433409</ArticleId><ArticleId IdType="pubmed">39338179</ArticleId></ArticleIdList></Reference><Reference><Citation>Searle S.D., Mitnitski A., Gahbauer E.A., Gill T.M., Rockwood K. A standard procedure for creating a frailty index. BMC Geriatr. 2008;8:24. doi: 10.1186/1471-2318-8-24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2318-8-24</ArticleId><ArticleId IdType="pmc">PMC2573877</ArticleId><ArticleId IdType="pubmed">18826625</ArticleId></ArticleIdList></Reference><Reference><Citation>Church S., Rogers E., Rockwood K., Theou O. A scoping review of the Clinical Frailty Scale. BMC Geriatr. 2020;20:393. doi: 10.1186/s12877-020-01801-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12877-020-01801-7</ArticleId><ArticleId IdType="pmc">PMC7540438</ArticleId><ArticleId IdType="pubmed">33028215</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappe M., Laterre P.-F., Dechamps M. Preoperative frailty screening, assessment and management. Curr. Opin. Anaesthesiol. 2023;36:83&#x2013;88. doi: 10.1097/ACO.0000000000001221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ACO.0000000000001221</ArticleId><ArticleId IdType="pmc">PMC9794163</ArticleId><ArticleId IdType="pubmed">36476726</ArticleId></ArticleIdList></Reference><Reference><Citation>Forn&#xe6;ss K.M., Nome P.L., Aakre E.K., Hegvik T., Jammer I. Clinical frailty scale: Inter-rater reliability of retrospective scoring in emergency abdominal surgery. Acta Anaesthesiol. Scand. 2022;66:25&#x2013;29. doi: 10.1111/aas.13974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aas.13974</ArticleId><ArticleId IdType="pubmed">34425015</ArticleId></ArticleIdList></Reference><Reference><Citation>Nissen S.K., Fournaise A., Lauridsen J.T., Ryg J., Nickel C.H., Gudex C., Brabrand M., Andersen-Ranberg K. Cross-sectoral inter-rater reliability of the clinical frailty scale&#x2013;a Danish translation and validation study. BMC Geriatr. 2020;20:443. doi: 10.1186/s12877-020-01850-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12877-020-01850-y</ArticleId><ArticleId IdType="pmc">PMC7640648</ArticleId><ArticleId IdType="pubmed">33143651</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;rlin E., Munir Ehrlington S., Henricson J., John R.T., Wilhelms D. Inter-rater reliability of the Clinical Frailty Scale by staff members in a Swedish emergency department setting. Acad. Emerg. Med. 2022;29:1431&#x2013;1437. doi: 10.1111/acem.14603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acem.14603</ArticleId><ArticleId IdType="pmc">PMC10092290</ArticleId><ArticleId IdType="pubmed">36200372</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis G., Whitehead M.A., O&#x2019;Neill D., Langhorne P., Robinson D.  Comprehensive Geriatric Assessment for Older Adults Admitted to Hospital. In: The Cochrane Collaboration, editor. Cochrane Database of Systematic Reviews. John Wiley &amp; Sons, Ltd.; Chichester, UK: 2011.  [(accessed on 23 July 2024)]. p. CD006211.pub2. Available online:  https://doi.wiley.com/10.1002/14651858.CD006211.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD006211.pub2</ArticleId><ArticleId IdType="pmc">PMC4164377</ArticleId><ArticleId IdType="pubmed">21735403</ArticleId></ArticleIdList></Reference><Reference><Citation>Briggs R., McDonough A., Ellis G., Bennett K., O&#x2019;Neill D., Robinson D. Comprehensive Geriatric Assessment for Community-Dwelling, High-Risk, Frail, Older People. Cochrane Effective Practice and Organisation of Care Group, editor. Cochrane Database of Systematic Reviews. May 6, 2022.  [(accessed on 15 September 2024)].  Available online:  http://doi.wiley.com/10.1002/14651858.CD012705.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD012705.pub2</ArticleId><ArticleId IdType="pmc">PMC9074104</ArticleId><ArticleId IdType="pubmed">35521829</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39589346</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1552-5783</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>13</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>04</Day></PubDate></JournalIssue><Title>Investigative ophthalmology &amp; visual science</Title><ISOAbbreviation>Invest Ophthalmol Vis Sci</ISOAbbreviation></Journal><ArticleTitle>Small Extracellular Vesicle-Associated MiRNAs in Polarized Retinal Pigmented Epithelium.</ArticleTitle><Pagination><StartPage>57</StartPage><MedlinePgn>57</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">57</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1167/iovs.65.13.57</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">Oxidative stress in the retinal pigmented epithelium (RPE) has been implicated in age-related macular degeneration by impacting endocytic trafficking, including the formation, content, and secretion of extracellular vesicles (EVs). Using our model of polarized primary porcine RPE (pRPE) cells under chronic subtoxic oxidative stress, we tested the hypothesis that RPE miRNAs packaged into EVs are secreted in a polarized manner and contribute to maintaining RPE homeostasis.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Small EVs (sEVs) enriched for exosomes were isolated from apical and basal conditioned media from pRPE cells grown for up to four weeks with or without low concentrations of hydrogen peroxide using two sEV isolation methods, leading to eight experimental groups. The sEV miRNA expression was profiled using miRNA-Seq with Illumina MiSeq, followed by quality control and bioinformatics analysis for differential expression using the R computing environment. Expression of selected miRNAs were validated using qRT-PCR.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">We identified miRNA content differences carried by sEVs isolated using two ultracentrifugation-based methods. Regardless of the sEV isolation method, miR-182 and miR-183 were enriched in the cargo of apically secreted sEVs, and miR-122 in the cargo of basally secreted sEVs from RPE cells during normal homeostatic conditions. After oxidative stress, miR-183 levels were significantly decreased in the cargo of apically released sEVs from stressed RPE cells.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">We curated RPE sEV miRNA datasets based on cell polarity and oxidative stress. Unbiased miRNA analysis identified differences based on polarity, stress, and sEV isolation methods. These findings suggest that miRNAs in sEVs may contribute to RPE homeostasis and function in a polarized manner.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Belinda J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Duke University School of Medicine, Durham, North Carolina, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strain</LastName><ForeName>Madison</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Duke Molecular Physiology Institute, Department of Medicine, Duke University, Durham, North Carolina, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suarez</LastName><ForeName>Maria Fernanda</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Duke University School of Medicine, Durham, North Carolina, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stamer</LastName><ForeName>W Daniel</ForeName><Initials>WD</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Duke University School of Medicine, Durham, North Carolina, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Duke University, Durham, North Carolina, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashley-Koch</LastName><ForeName>Allison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Duke Molecular Physiology Institute, Department of Medicine, Duke University, Durham, North Carolina, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yutao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cellular Biology and Anatomy, James and Jean Culver Vision Discovery Institute, Augusta University, Augusta, Georgia, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klingeborn</LastName><ForeName>Mikael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>McLaughlin Research Institute, Great Falls, Montana, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Touro College of Osteopathic Medicine Montana, Great Falls, Montana, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowes Rickman</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Duke University School of Medicine, Durham, North Carolina, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Biology, Duke University, Durham, North Carolina, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P20 GM152335</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EY023242</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 EY033057</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EY031748</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EY032960</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 EY033170</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 EY031631</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 EY033961</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 EY028671</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 EY005722</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Invest Ophthalmol Vis Sci</MedlineTA><NlmUniqueID>7703701</NlmUniqueID><ISSNLinking>0146-0404</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D055213" MajorTopicYN="Y">Retinal Pigment Epithelium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013552" MajorTopicYN="N">Swine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067128" MajorTopicYN="Y">Extracellular Vesicles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="Y">Oxidative Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060888" MajorTopicYN="N">Real-Time Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016764" MajorTopicYN="N">Cell Polarity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Disclosure: <b>B.J. Hernandez</b>, None; <b>M. Strain</b>, None; <b>M.F. Suarez</b>, None; <b>W.D. Stamer</b>, None; <b>A. Ashley-Koch</b>, None; <b>Y. Liu</b>, None; <b>M. Klingeborn</b>, None; <b>C. Bowes Rickman</b>, None</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>10</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39589346</ArticleId><ArticleId IdType="pmc">PMC11601136</ArticleId><ArticleId IdType="doi">10.1167/iovs.65.13.57</ArticleId><ArticleId IdType="pii">2802291</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Strauss O. The retinal pigment epithelium in visual function. Physiol Rev. 2005; 85: 845&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pubmed">15987797</ArticleId></ArticleIdList></Reference><Reference><Citation>Klingeborn M, Dismuke WM, Bowes Rickman C, Stamer WD.. Roles of exosomes in the normal and diseased eye. Prog Retinal Eye Res. 2017; 59: 158&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5537591</ArticleId><ArticleId IdType="pubmed">28465248</ArticleId></ArticleIdList></Reference><Reference><Citation>Klingeborn M, Dismuke WM, Skiba NP, Kelly U, Stamer WD, Bowes Rickman C. Directional exosome proteomes reflect polarity-specific functions in retinal pigmented epithelium monolayers. Sci Rep. 2017; 7: 4901.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5501811</ArticleId><ArticleId IdType="pubmed">28687758</ArticleId></ArticleIdList></Reference><Reference><Citation>Marmorstein AD. The polarity of the retinal pigment epithelium. Traffic. 2001; 2: 867&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">11737824</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta S, Cano M, Ebrahimi K, Wang L, Handa JT.. The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD. Progress in retinal and eye research. 2017; 60: 201&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5600827</ArticleId><ArticleId IdType="pubmed">28336424</ArticleId></ArticleIdList></Reference><Reference><Citation>Toomey CB, Johnson LV, Bowes Rickman C. Complement factor H in AMD: bridging genetic associations and pathobiology. Prog Retinal Eye Res. 2018; 62: 38&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5776047</ArticleId><ArticleId IdType="pubmed">28928087</ArticleId></ArticleIdList></Reference><Reference><Citation>Congdon N, O'Colmain B, Klaver CC, et al. .. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004; 122: 477&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pubmed">15078664</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong WL, Su X, Li X, et al. .. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014; 2: e106&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">25104651</ArticleId></ArticleIdList></Reference><Reference><Citation>Jager RD, Mieler WF, Miller JW.. Age-related macular degeneration. N Engl J Med. 2008; 358: 2606&#x2013;2617.</Citation><ArticleIdList><ArticleId IdType="pubmed">18550876</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein R, Klein BE, Linton KL.. Prevalence of age-related maculopathy. The beaver dam eye study. Ophthalmology. 1992; 99: 933&#x2013;943.</Citation><ArticleIdList><ArticleId IdType="pubmed">1630784</ArticleId></ArticleIdList></Reference><Reference><Citation>Vingerling JR, Dielemans I, Hofman A, et al. .. The prevalence of age-related maculopathy in the rotterdam study. Ophthalmology. 1995; 102: 205&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">7862408</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Zibetti C, Shang P, et al. .. ATAC-Seq analysis reveals a widespread decrease of chromatin accessibility in age-related macular degeneration. Nat Commun. 2018; 9: 1364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5893535</ArticleId><ArticleId IdType="pubmed">29636475</ArticleId></ArticleIdList></Reference><Reference><Citation>Alipoor SD, Mortaz E, Garssen J, Movassaghi M, Mirsaeidi M, Adcock IM.. Exosomes and exosomal miRNA in respiratory diseases. Mediators Inflamm. 2016; 2016: 5628404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5055958</ArticleId><ArticleId IdType="pubmed">27738390</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Z, Batagov AO, Schinelli S, et al. .. Coding and noncoding landscape of extracellular RNA released by human glioma stem cells. Nat Commun. 2017; 8: 1145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5658400</ArticleId><ArticleId IdType="pubmed">29074968</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng L, Sharples RA, Scicluna BJ, Hill AF.. Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. J Extracell Vesicles. 2014; 3: 23743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3968297</ArticleId><ArticleId IdType="pubmed">24683445</ArticleId></ArticleIdList></Reference><Reference><Citation>Zayakin P, Sadovska L, Eglitis K, et al. .. Extracellular vesicles&#x2014;a source of RNA biomarkers for the detection of breast cancer in liquid biopsies. Cancers. 2023; 15: 4329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10487078</ArticleId><ArticleId IdType="pubmed">37686605</ArticleId></ArticleIdList></Reference><Reference><Citation>Raposo G, Stoorvogel W.. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013; 200: 373&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575529</ArticleId><ArticleId IdType="pubmed">23420871</ArticleId></ArticleIdList></Reference><Reference><Citation>ELA S, Mager I, Breakefield XO, Wood MJ.. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013; 12: 347&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">23584393</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Pol E, Boing AN, Harrison P, Sturk A, Nieuwland R.. Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol Rev. 2012; 64: 676&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">22722893</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanez-Mo M, Siljander PR, Andreu Z, et al. .. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015; 4: 27066.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4433489</ArticleId><ArticleId IdType="pubmed">25979354</ArticleId></ArticleIdList></Reference><Reference><Citation>Howitt J, Hill AF.. Exosomes in the Pathology of Neurodegenerative Diseases. J Biol Chem. 2016; 291: 26589&#x2013;26597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5207170</ArticleId><ArticleId IdType="pubmed">27852825</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalluri R, LeBleu VS.. The biology, function, and biomedical applications of exosomes. Science. 2020; 367(6478): eaau6977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7717626</ArticleId><ArticleId IdType="pubmed">32029601</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadvina R, Lotfy Khaled M, Akoto T, Zhi W, Karamichos D, Liu Y. Exosomes and their miRNA/protein profile in keratoconus-derived corneal stromal cells. Exp Eye Res. 2023; 236: 109642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10842962</ArticleId><ArticleId IdType="pubmed">37714423</ArticleId></ArticleIdList></Reference><Reference><Citation>Du SW, Palczewski K.. MicroRNA regulation of critical retinal pigment epithelial functions. Trends Neurosci. 2022; 45: 78&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9066699</ArticleId><ArticleId IdType="pubmed">34753606</ArticleId></ArticleIdList></Reference><Reference><Citation>Ying SY, Chang DC, Lin SL.. The microRNA (miRNA): overview of the RNA genes that modulate gene function. Mol Biotechnol. 2008; 38: 257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7091389</ArticleId><ArticleId IdType="pubmed">17999201</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozniak T, Shcharbin D, Bryszewska M.. Circulating microRNAs in medicine. Int J Mol Sci. 2022; 23(7): 3996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8999557</ArticleId><ArticleId IdType="pubmed">35409354</ArticleId></ArticleIdList></Reference><Reference><Citation>Pogue AI, Lukiw WJ.. Up-regulated Pro-inflammatory MicroRNAs (miRNAs) in Alzheimer's disease (AD) and Age-Related Macular Degeneration (AMD). Cell Mol Neurobiol. 2018; 38: 1021&#x2013;1031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11481951</ArticleId><ArticleId IdType="pubmed">29302837</ArticleId></ArticleIdList></Reference><Reference><Citation>Szemraj M, Bielecka-Kowalska A, Oszajca K, et al. .. Serum MicroRNAs as Potential Biomarkers of AMD. Med Sci Monit. 2015; 21: 2734&#x2013;2742.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4576928</ArticleId><ArticleId IdType="pubmed">26366973</ArticleId></ArticleIdList></Reference><Reference><Citation>ElShelmani H, Wride MA, Saad T, Rani S, Kelly DJ, Keegan D. Identification of novel serum microRNAs in age-related macular degeneration. Transl Vis Sci Technol. 2020; 9: 28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7396178</ArticleId><ArticleId IdType="pubmed">32818115</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren C, Liu Q, Wei Q, et al. .. Circulating miRNAs as potential biomarkers of age-related macular degeneration. Cell Physiol Biochem. 2017; 41: 1413&#x2013;1423.</Citation><ArticleIdList><ArticleId IdType="pubmed">28315863</ArticleId></ArticleIdList></Reference><Reference><Citation>Oltra M, Vidal-Gil L, Maisto R, Sancho-Pelluz J, Barcia JM.. Oxidative stress-induced angiogenesis is mediated by miR-205-5p. J Cell Mol Med. 2020; 24: 1428&#x2013;1436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6991635</ArticleId><ArticleId IdType="pubmed">31863632</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang FE, Zhang C, Maminishkis A, et al. .. MicroRNA-204/211 alters epithelial physiology. FASEB J. 2010; 24: 1552&#x2013;1571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3231816</ArticleId><ArticleId IdType="pubmed">20056717</ArticleId></ArticleIdList></Reference><Reference><Citation>Li WB, Zhang YS, Lu ZY, et al. .. Development of retinal pigment epithelium from human parthenogenetic embryonic stem cells and microRNA signature. Invest Ophthalmol Vis Sci. 2012; 53: 5334&#x2013;5343.</Citation><ArticleIdList><ArticleId IdType="pubmed">22736612</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Lee AY, Wigg JP, Peshavariya H, Liu P, Zhang H.. MiR-126 regulation of angiogenesis in age-related macular degeneration in CNV mouse model. Int J Mol Sci. 2016; 17(6): 895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4926429</ArticleId><ArticleId IdType="pubmed">27338342</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren C, Hu W, Wei Q, et al. .. MicroRNA-27a promotes oxidative-induced RPE cell death through targeting FOXO1. Biomed Res Int. 2021; 2021: 6666506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8575620</ArticleId><ArticleId IdType="pubmed">34761005</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez BJ, Skiba NP, Plossl K, et al. .. Polarized desmosome and hemidesmosome shedding via small extracellular vesicles is an early indicator of outer blood-retina barrier dysfunction. J Extracell Biol. 2023; 2(10): e116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10720597</ArticleId><ArticleId IdType="pubmed">38108061</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann GL, Benedicto I, Philp NJ, Rodriguez-Boulan E.. Plasma membrane protein polarity and trafficking in RPE cells: past, present and future. Exp Eye Res. 2014; 126: 5&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4502961</ArticleId><ArticleId IdType="pubmed">25152359</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzolo LJ. Barrier properties of cultured retinal pigment epithelium. Exp Eye Res. 2014; 126: 16&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">24731966</ArticleId></ArticleIdList></Reference><Reference><Citation>Ablonczy Z, Crosson CE.. VEGF modulation of retinal pigment epithelium resistance. Exp Eye Res. 2007; 85: 762&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2199266</ArticleId><ArticleId IdType="pubmed">17915218</ArticleId></ArticleIdList></Reference><Reference><Citation>Ablonczy Z, Dahrouj M, Tang PH, et al. .. Human retinal pigment epithelium cells as functional models for the RPE in vivo. Invest Ophthalmol Vis Sci. 2011; 52: 8614&#x2013;8620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3208409</ArticleId><ArticleId IdType="pubmed">21960553</ArticleId></ArticleIdList></Reference><Reference><Citation>Ablonczy Z, Prakasam A, Fant J, Fauq A, Crosson C, Sambamurti K.. Pigment epithelium-derived factor maintains retinal pigment epithelium function by inhibiting vascular endothelial growth factor-R2 signaling through gamma-secretase. J Biol Chem. 2009; 284: 30177&#x2013;30186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2781573</ArticleId><ArticleId IdType="pubmed">19723623</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn KC, Aotaki-Keen AE, Putkey FR, Hjelmeland LM.. ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp Eye Res. 1996; 62: 155&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">8698076</ArticleId></ArticleIdList></Reference><Reference><Citation>Thery C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006; Chapter 3: Unit 3 22.</Citation><ArticleIdList><ArticleId IdType="pubmed">18228490</ArticleId></ArticleIdList></Reference><Reference><Citation>Thery C, Witwer KW, Aikawa E, et al. .. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018; 7: 1535750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6322352</ArticleId><ArticleId IdType="pubmed">30637094</ArticleId></ArticleIdList></Reference><Reference><Citation>Wik L, Klingeborn M, Willander H, Linne T.. Separate mechanisms act concurrently to shed and release the prion protein from the cell. Prion. 2012; 6: 498&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3510861</ArticleId><ArticleId IdType="pubmed">23093798</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J . 2011; 17: 3.</Citation></Reference><Reference><Citation>Smith T, Heger A, Sudbery I.. UMI-tools: modeling sequencing errors in unique molecular identifiers to improve quantification accuracy. Genome Res. 2017; 27: 491&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5340976</ArticleId><ArticleId IdType="pubmed">28100584</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayers EW, Bolton EE, Brister JR, et al. .. Database resources of the national center for biotechnology information. Nucleic Acids Res. 2022; 50: D20&#x2013;D26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8728269</ArticleId><ArticleId IdType="pubmed">34850941</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozomara A, Griffiths-Jones S.. MiRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2014; 42: D68&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3965103</ArticleId><ArticleId IdType="pubmed">24275495</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead B, Salzberg SL.. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012; 9: 357&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322381</ArticleId><ArticleId IdType="pubmed">22388286</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinlan AR, Hall IM.. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010; 26: 841&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2832824</ArticleId><ArticleId IdType="pubmed">20110278</ArticleId></ArticleIdList></Reference><Reference><Citation>Team RC. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2023.</Citation></Reference><Reference><Citation>Jain N, Thatte J, Braciale T, et al. . Local-Pooled-Error test for identifying differentially expressed genes with a small number of replicated microarrays. Bioinformatics. 2003; 19: 1945&#x2013;1951.</Citation><ArticleIdList><ArticleId IdType="pubmed">14555628</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME, Phipson B, Wu D, et al. .. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43: e47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4402510</ArticleId><ArticleId IdType="pubmed">25605792</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickham H. ggplot2: Elegant Graphics for Data Analysis . 2nd ed. New York: Springer Cham; 2016.</Citation></Reference><Reference><Citation>Schmittgen TD, Livak KJ.. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3: 1101&#x2013;1108.</Citation><ArticleIdList><ArticleId IdType="pubmed">18546601</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal V, Bell GW, Nam JW, Bartel DP.. Predicting effective microRNA target sites in mammalian mRNAs. Elifev 2015; 4: e05005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4532895</ArticleId><ArticleId IdType="pubmed">26267216</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlachos IS, Paraskevopoulou MD, Karagkouni D, et al. .. DIANA-TarBase v7.0: indexing more than half a million experimentally supported miRNA:mRNA interactions. Nucleic Acids Res. 2015; 43: D153&#x2013;D159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4383989</ArticleId><ArticleId IdType="pubmed">25416803</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T.. miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res. 2009; 37: D105&#x2013;D110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2686554</ArticleId><ArticleId IdType="pubmed">18996891</ArticleId></ArticleIdList></Reference><Reference><Citation>Caceres PS, Rodriguez-Boulan E.. Retinal pigment epithelium polarity in health and blinding diseases. Curr Opin Cell Biol. 2020; 62: 37&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7035989</ArticleId><ArticleId IdType="pubmed">31518914</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma X, Li H, Chen Y, et al. .. The transcription factor MITF in RPE function and dysfunction. Prog Retin Eye Res. 2019; 73: 100766.</Citation><ArticleIdList><ArticleId IdType="pubmed">31242455</ArticleId></ArticleIdList></Reference><Reference><Citation>Han S, Chen J, Hua J, et al. .. MITF protects against oxidative damage-induced retinal degeneration by regulating the NRF2 pathway in the retinal pigment epithelium. Redox Biol. 2020; 34: 101537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7191850</ArticleId><ArticleId IdType="pubmed">32361183</ArticleId></ArticleIdList></Reference><Reference><Citation>Busch C, Annamalai B, Abdusalamova K, et al. .. Anaphylatoxins activate Ca(2+), Akt/PI3-kinase, and FOXO1/FoxP3 in the retinal pigment epithelium. Front Immunol. 2017; 8: 703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5472091</ArticleId><ArticleId IdType="pubmed">28663750</ArticleId></ArticleIdList></Reference><Reference><Citation>Du J, Yanagida A, Knight K, et al. .. Reductive carboxylation is a major metabolic pathway in the retinal pigment epithelium. Proc Natl Acad Sci USA. 2016; 113: 14710&#x2013;14715.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5187684</ArticleId><ArticleId IdType="pubmed">27911769</ArticleId></ArticleIdList></Reference><Reference><Citation>Markitantova Y, Simirskii V.. Endogenous and exogenous regulation of redox homeostasis in retinal pigment epithelium cells: an updated antioxidant perspective. Int J Mol Sci. 2023; 24(13): 10776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10341664</ArticleId><ArticleId IdType="pubmed">37445953</ArticleId></ArticleIdList></Reference><Reference><Citation>Korthagen NM, van Bilsen K, Swagemakers SM, et al. .. Retinal pigment epithelial cells display specific transcriptional responses upon TNF-alpha stimulation. Br J Ophthalmol. 2015; 99: 700&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pubmed">25680620</ArticleId></ArticleIdList></Reference><Reference><Citation>Touhami S, Beguier F, Augustin S, et al. .. Chronic exposure to tumor necrosis factor alpha induces retinal pigment epithelium cell dedifferentiation. J Neuroinflammation. 2018; 15: 85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5857126</ArticleId><ArticleId IdType="pubmed">29548329</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris DR, Bounds SE, Liu H, et al. .. Exosomal MiRNA transfer between retinal microglia and RPE. Int J Mol Sci. 2020; 21: 3541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7279010</ArticleId><ArticleId IdType="pubmed">32429541</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukai A, Otsuki Y, Ito E, et al. .. Mitochondrial miRNA494-3p in extracellular vesicles participates in cellular interplay of iPS-Derived human retinal pigment epithelium with macrophages. Exp Eye Res. 2021; 208: 108621.</Citation><ArticleIdList><ArticleId IdType="pubmed">34000275</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Wang K, Pan J, et al. .. Exosomes mediate an epithelial-mesenchymal transition cascade in retinal pigment epithelial cells: implications for proliferative vitreoretinopathy. J Cell Mol Med. 2020; 24: 13324&#x2013;13335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7701536</ArticleId><ArticleId IdType="pubmed">33047885</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene WA, Muniz A, Plamper ML, Kaini RR, Wang HC.. MicroRNA expression profiles of human iPS cells, retinal pigment epithelium derived from iPS, and fetal retinal pigment epithelium. J Vis Exp. 2014;(88): e51589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4204998</ArticleId><ArticleId IdType="pubmed">24999033</ArticleId></ArticleIdList></Reference><Reference><Citation>Soundara Pandi SP, Chen M, Guduric-Fuchs J, Xu H, Simpson DA. Extremely complex populations of small RNAs in the mouse retina and RPE/choroid. Invest Ophthalmol Vis Sci. 2013; 54: 8140&#x2013;8151.</Citation><ArticleIdList><ArticleId IdType="pubmed">24235016</ArticleId></ArticleIdList></Reference><Reference><Citation>Intartaglia D, Giamundo G, Conte I.. The impact of miRNAs in health and disease of retinal pigment epithelium. Front Cell Dev Biol. 2020; 8: 589985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7844312</ArticleId><ArticleId IdType="pubmed">33520981</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu G, Huang K, Yu J, et al. .. Identification of miRNA signatures during the differentiation of hESCs into retinal pigment epithelial cells. PLoS One. 2012; 7: e37224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3407211</ArticleId><ArticleId IdType="pubmed">22848339</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Z, Mao K.. Oxidative stress-responsive small extracellular vesicles and microRNAs in age-related macular degeneration: biomarkers and therapeutic tools. Discov Med. 2022; 34: 33&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">36320090</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Liang H, Zhang J, Zen K, Zhang CY.. Horizontal transfer of microRNAs: molecular mechanisms and clinical applications. Protein Cell. 2012; 3: 28&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4875218</ArticleId><ArticleId IdType="pubmed">22314808</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu Z, Tan J, Miao Y, Zhang Q.. The role of microvesicles containing microRNAs in vascular endothelial dysfunction. J Cell Mol Med. 2019; 23: 7933&#x2013;7945.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6850938</ArticleId><ArticleId IdType="pubmed">31576661</ArticleId></ArticleIdList></Reference><Reference><Citation>Zernecke A, Bidzhekov K, Noels H, et al. .. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal. 2009; 2: ra81.</Citation><ArticleIdList><ArticleId IdType="pubmed">19996457</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu S, Liu Y, Zou J, et al. .. Retinal pigment epithelial cells secrete miR-202-5p-containing exosomes to protect against proliferative diabetic retinopathy. Exp Eye Res. 2020; 201: 108271.</Citation><ArticleIdList><ArticleId IdType="pubmed">33007305</ArticleId></ArticleIdList></Reference><Reference><Citation>Welsh JA, Goberdhan DCI, O'Driscoll L, et al. .. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles. 2024; 13: e12404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10850029</ArticleId><ArticleId IdType="pubmed">38326288</ArticleId></ArticleIdList></Reference><Reference><Citation>Doyle LM, Wang MZ.. Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis. Cells. 2019; 8: 727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6678302</ArticleId><ArticleId IdType="pubmed">31311206</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaborowski MP, Balaj L, Breakefield XO, Lai CP.. Extracellular vesicles: composition, biological relevance, and methods of study. Bioscience. 2015; 65: 783&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4776721</ArticleId><ArticleId IdType="pubmed">26955082</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori MA, Ludwig RG, Garcia-Martin R, Brandao BB, Kahn CR.. Extracellular miRNAs: from biomarkers to mediators of physiology and disease. Cell Metab. 2019; 30: 656&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6774861</ArticleId><ArticleId IdType="pubmed">31447320</ArticleId></ArticleIdList></Reference><Reference><Citation>Yakubovich EI, Polischouk AG, Evtushenko VI.. Principles and problems of exosome isolation from biological fluids. Biochem (Mosc) Suppl Ser A Membr Cell Biol. 2022; 16: 115&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9202659</ArticleId><ArticleId IdType="pubmed">35730027</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig N, Whiteside TL, Reichert TE.. Challenges in exosome isolation and analysis in health and disease. Int J Mol Sci. 2019; 20: 4684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6801453</ArticleId><ArticleId IdType="pubmed">31546622</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, Xu R, Rai A, et al. .. Distinct shed microvesicle and exosome microRNA signatures reveal diagnostic markers for colorectal cancer. PLoS One. 2019; 14: e0210003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6319712</ArticleId><ArticleId IdType="pubmed">30608951</ArticleId></ArticleIdList></Reference><Reference><Citation>Royo F, Diwan I, Tackett MR, et al. .. Comparative miRNA analysis of urine extracellular vesicles isolated through five different methods. Cancers (Basel). 2016; 8: 112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5187510</ArticleId><ArticleId IdType="pubmed">27973407</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S, Lee K, Park IB, et al. .. The profiles of microRNAs from urinary extracellular vesicles (EVs) prepared by various isolation methods and their correlation with serum EV microRNAs. Diabetes Res Clin Pract. 2020; 160: 108010.</Citation><ArticleIdList><ArticleId IdType="pubmed">31987752</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathieu M, Martin-Jaular L, Lavieu G, Thery C.. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol. 2019; 21: 9&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">30602770</ArticleId></ArticleIdList></Reference><Reference><Citation>Michell DL, Vickers KC.. Lipoprotein carriers of microRNAs. Biochim Biophys Acta. 2016; 1861: 2069&#x2013;2074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4959968</ArticleId><ArticleId IdType="pubmed">26825691</ArticleId></ArticleIdList></Reference><Reference><Citation>Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT.. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011; 13: 423&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3074610</ArticleId><ArticleId IdType="pubmed">21423178</ArticleId></ArticleIdList></Reference><Reference><Citation>Amini-Farsani Z, Asgharzade S.. The impact of miR-183/182/96 gene regulation on the maturation, survival, and function of photoreceptor cells in the retina. J Comp Neurol. 2020; 528: 1616&#x2013;1625.</Citation><ArticleIdList><ArticleId IdType="pubmed">31785157</ArticleId></ArticleIdList></Reference><Reference><Citation>Busskamp V, Krol J, Nelidova D, et al. .. miRNAs 182 and 183 are necessary to maintain adult cone photoreceptor outer segments and visual function. Neuron. 2014; 83: 586&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">25002228</ArticleId></ArticleIdList></Reference><Reference><Citation>Shanbagh S, Gadde SG, Shetty R, et al. .. Hyperglycemia-induced miR182-5p drives glycolytic and angiogenic response in Proliferative Diabetic Retinopathy and RPE cells via depleting FoxO1. Exp Eye Res. 2023; 238: 109713.</Citation><ArticleIdList><ArticleId IdType="pubmed">37952722</ArticleId></ArticleIdList></Reference><Reference><Citation>Oltra M, Vidal-Gil L, Maisto R, et al. .. miR302a and 122 are deregulated in small extracellular vesicles from ARPE-19 cells cultured with H(2)O(2). Sci Rep. 2019; 9: 17954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6884596</ArticleId><ArticleId IdType="pubmed">31784665</ArticleId></ArticleIdList></Reference><Reference><Citation>Wooff Y, Cioanca AV, Chu-Tan JA, Aggio-Bruce R, Schumann U, Natoli R.. Small-medium extracellular vesicles and their mirna cargo in retinal health and degeneration: mediators of homeostasis, and vehicles for targeted gene therapy. Front Cell Neurosci. 2020; 14: 160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7330137</ArticleId><ArticleId IdType="pubmed">32670023</ArticleId></ArticleIdList></Reference><Reference><Citation>Murad N, Kokkinaki M, Gunawardena N, et al. .. miR-184 regulates ezrin, LAMP-1 expression, affects phagocytosis in human retinal pigment epithelium and is downregulated in age-related macular degeneration. FEBS J. 2014; 281: 5251&#x2013;5264.</Citation><ArticleIdList><ArticleId IdType="pubmed">25251993</ArticleId></ArticleIdList></Reference><Reference><Citation>Roblain Q, Louis T, Yip C, et al. .. Intravitreal injection of anti-miRs against miR-142-3p reduces angiogenesis and microglia activation in a mouse model of laser-induced choroidal neovascularization. Aging (Albany NY). 2021; 13: 12359&#x2013;12377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8148470</ArticleId><ArticleId IdType="pubmed">33952723</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Ye S, Xiao W, Luo L, Liu Y. Differentially expressed microRNAs in TGFbeta2-induced epithelial-mesenchymal transition in retinal pigment epithelium cells. Int J Mol Med. 2014; 33: 1195&#x2013;1200.</Citation><ArticleIdList><ArticleId IdType="pubmed">24604358</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu-Tan JA, Cioanca AV, Feng ZP, et al. .. Functional microRNA targetome undergoes degeneration-induced shift in the retina. Mol Neurodegener. 2021; 16: 60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8406976</ArticleId><ArticleId IdType="pubmed">34465369</ArticleId></ArticleIdList></Reference><Reference><Citation>Krol J, Busskamp V, Markiewicz I, et al. .. Characterizing light-regulated retinal microRNAs reveals rapid turnover as a common property of neuronal microRNAs. Cell. 2010; 141: 618&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pubmed">20478254</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39588880</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1755-3768</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>26</Day></PubDate></JournalIssue><Title>Acta ophthalmologica</Title><ISOAbbreviation>Acta Ophthalmol</ISOAbbreviation></Journal><ArticleTitle>Major sight-threatening eye disorders and mental disorders.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/aos.16800</ELocationID><Abstract><AbstractText>The purpose of this study was to: (a) investigate the comorbidities of major sight-threatening eye disorders with mental disorders, (b) investigate the associations and prevalence of reported comorbidities and (c) identify potential influencing factors. A systematic review of the PubMed, Embase, Web of Science and Cochrane Library databases was conducted from inception to 30 December 2023. Studies that presented only laboratory results or used non-representative sampling methods were excluded. Meta-analyses were performed using the inverse variance method with a random-effects model. A total of 67 studies were included in the analysis. The most prevalent comorbidities were diabetic retinopathy (DR) and depression (pooled prevalence of 30%) and DR and anxiety (pooled prevalence of 29%). Significant associations were found between glaucoma and depression (odds ratio [OR]&#x2009;=&#x2009;1.42, 95% confidence interval [CI]&#x2009;=&#x2009;1.21-1.66), glaucoma and anxiety (OR&#x2009;=&#x2009;2.11, 95% CI&#x2009;=&#x2009;1.22-3.66), glaucoma and schizophrenia (OR&#x2009;=&#x2009;1.38, 95% CI&#x2009;=&#x2009;1.28-1.50), age-related macular degeneration (AMD) and depression (OR&#x2009;=&#x2009;1.36, 95% CI&#x2009;=&#x2009;1.18-1.57), and DR and depression (OR&#x2009;=&#x2009;1.03, 95% CI&#x2009;=&#x2009;1.01-1.06). Income was identified as a significant contributing factor to the prevalence of comorbidity between glaucoma and depression. Major sight-threatening eye disorders were significantly associated with mental disorders, particularly depression and anxiety. The burden of comorbidity between major sight-threatening eye disorders and mental disorders is not optimistic and may be influenced by income disparities. Healthcare providers are encouraged to assess and manage potential comorbidities to optimize patient outcomes.</AbstractText><CopyrightInformation>&#xa9; 2024 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Xing-Xuan</ForeName><Initials>XX</Initials><AffiliationInfo><Affiliation>School of Public Health; The Fourth Affiliated Hospital of Soochow University, Suzhou Medical College of Soochow University, Suzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Hui-Hui</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>School of Public Health; The Fourth Affiliated Hospital of Soochow University, Suzhou Medical College of Soochow University, Suzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ying</LastName><ForeName>Zhi-Qi</ForeName><Initials>ZQ</Initials><AffiliationInfo><Affiliation>School of Public Health; The Fourth Affiliated Hospital of Soochow University, Suzhou Medical College of Soochow University, Suzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Dong-Ling</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>School of Public Health; The Fourth Affiliated Hospital of Soochow University, Suzhou Medical College of Soochow University, Suzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Jia-Yu</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>School of Public Health; The Fourth Affiliated Hospital of Soochow University, Suzhou Medical College of Soochow University, Suzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Dan-Lin</ForeName><Initials>DL</Initials><Identifier Source="ORCID">0000-0003-0800-4308</Identifier><AffiliationInfo><Affiliation>School of Public Health; The Fourth Affiliated Hospital of Soochow University, Suzhou Medical College of Soochow University, Suzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Dan-Ning</ForeName><Initials>DN</Initials><AffiliationInfo><Affiliation>New York eye and ear Infirmary of Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, New York City, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanca</LastName><ForeName>Carla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Science, New York University Abu Dhabi, Abu Dhabi, UAE.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Health Research Center (CHRC), Escola Nacional de Sa&#xfa;de P&#xfa;blica, Universidade Nova de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grzybowski</LastName><ForeName>Andrzej</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3724-2391</Identifier><AffiliationInfo><Affiliation>Institute for Research in Ophthalmology, Foundation for Ophthalmology Development, Poznan, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Chen-Wei</ForeName><Initials>CW</Initials><Identifier Source="ORCID">0000-0003-3362-4613</Identifier><AffiliationInfo><Affiliation>School of Public Health; The Fourth Affiliated Hospital of Soochow University, Suzhou Medical College of Soochow University, Suzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>82122059</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Acta Ophthalmol</MedlineTA><NlmUniqueID>101468102</NlmUniqueID><ISSNLinking>1755-375X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">association</Keyword><Keyword MajorTopicYN="N">comorbidity</Keyword><Keyword MajorTopicYN="N">major sight&#x2010;threatening eye disorder</Keyword><Keyword MajorTopicYN="N">mental disorder</Keyword><Keyword MajorTopicYN="N">prevalence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>7</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39588880</ArticleId><ArticleId IdType="doi">10.1111/aos.16800</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Abe, R.Y., Silva, T.C., Dantas, I., Curado, S.X., Madeira, M.S., de Sousa, L.B. et&#xa0;al. (2020) Can psychologic stress elevate intraocular pressure in healthy individuals? Ophthalmol Glaucoma, 3, 426&#x2013;433.</Citation></Reference><Reference><Citation>Ajith, B.S., Najeeb, N., John, A. &amp; Anima, V.N. (2022) Cross sectional study of depression, anxiety and quality of life in glaucoma patients at a tertiary centre in North Kerala. Indian Journal of Ophthalmology, 70, 546&#x2013;551.</Citation></Reference><Reference><Citation>Bigger, S.E. &amp; Vo, T. (2022) Self&#x2010;perceived burden: a critical evolutionary concept analysis. Journal of Hospice and Palliative Nursing, 24, 40&#x2013;49.</Citation></Reference><Reference><Citation>Chu, E.M., Kolappan, M., Barnes, T.R., Joyce, E.M. &amp; Ron, M.A. (2012) A window into the brain: an in&#xa0;vivo study of the retina in schizophrenia using optical coherence tomography. Psychiatry Research, 203, 89&#x2013;94.</Citation></Reference><Reference><Citation>Cimarolli, V.R., Casten, R.J., Rovner, B.W., Heyl, V., S&#xf6;rensen, S. &amp; Horowitz, A. (2016) Anxiety and depression in patients with advanced macular degeneration: current perspectives. Clinical Ophthalmology, 10, 55&#x2013;63.</Citation></Reference><Reference><Citation>Dawson, S.R., Mallen, C.D., Gouldstone, M.B., Yarham, R. &amp; Mansell, G. (2014) The prevalence of anxiety and depression in people with age&#x2010;related macular degeneration: a systematic review of observational study data. BMC Ophthalmology, 14, 78.</Citation></Reference><Reference><Citation>Eramudugolla, R., Wood, J. &amp; Anstey, K.J. (2013) Co&#x2010;morbidity of depression and anxiety in common age&#x2010;related eye diseases: a population&#x2010;based study of 662 adults. Frontiers in Aging Neuroscience, 5, 56.</Citation></Reference><Reference><Citation>Evans, J.R., Fletcher, A.E. &amp; Wormald, R.P. (2007) Depression and anxiety in visually impaired older people. Ophthalmology, 114, 283&#x2013;288.</Citation></Reference><Reference><Citation>Feinstein, A.R. (1970) The pre&#x2010;therapeutic classification of CO&#x2010;morbidity in chronic disease. Journal of Chronic Diseases, 23, 455&#x2013;468.</Citation></Reference><Reference><Citation>Ferry, F., Rosato, M. &amp; Leavey, G. (2023) Severe mental illness and ophthalmic health: a linked administrative data study. PLoS One, 18, e0286860.</Citation></Reference><Reference><Citation>Fonteh, C.N., Mathias, M.T., Mandava, N., Manoharan, N., Lynch, A.M., Navo, R. et&#xa0;al. (2022) Mental health and visual acuity in patients with age&#x2010;related macular degeneration. BMC Ophthalmology, 22, 391.</Citation></Reference><Reference><Citation>Ford, D.M., Budworth, L., Lawton, R., Teale, E.A. &amp; O'Connor, D.B. (2023) In&#x2010;hospital stress and patient outcomes: a systematic review and meta&#x2010;analysis. PLoS One, 18, e0282789.</Citation></Reference><Reference><Citation>Fraunfelder, F.W. (2004) Twice&#x2010;yearly exams unnecessary for patients taking quetiapine. American Journal of Ophthalmology, 138, 870&#x2013;871.</Citation></Reference><Reference><Citation>Friedman, D.S., Okeke, C.O., Jampel, H.D., Ying, G.S., Plyler, R.J., Jiang, Y. et&#xa0;al. (2009) Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma. Ophthalmology, 116, 1097&#x2013;1105.</Citation></Reference><Reference><Citation>Gale, R.P., Finger, R.P., Eldem, B., Aslam, T., Barratt, J., Daien, V. et&#xa0;al. (2023) The management of neovascular age&#x2010;related macular degeneration: a systematic literature review of patient&#x2010;reported outcomes, patient mental health and caregiver burden. Acta Ophthalmologica, 101, e26&#x2013;e42.</Citation></Reference><Reference><Citation>Gaynes, B.I. (2005) Twice&#x2010;yearly exams unnecessary for patients taking quetiapine. American Journal of Ophthalmology, 140, 348&#x2013;349 author reply 349.</Citation></Reference><Reference><Citation>Ghanbarnia, M.J., Hosseini, S.R., Ghasemi, M., Roustaei, G.A., Mekaniki, E., Ghadimi, R. et&#xa0;al. (2023) Association of age&#x2010;related eye diseases with cognitive frailty in older adults: a population&#x2010;based study. Aging Clinical and Experimental Research, 35, 1731&#x2013;1740.</Citation></Reference><Reference><Citation>Golden, S.H. (2007) A review of the evidence for a neuroendocrine link between stress, depression and diabetes mellitus. Current Diabetes Reviews, 3, 252&#x2013;259.</Citation></Reference><Reference><Citation>Gonzalez, J.S., Peyrot, M., McCarl, L.A., Collins, E.M., Serpa, L., Mimiaga, M.J. et&#xa0;al. (2008) Depression and diabetes treatment nonadherence: a meta&#x2010;analysis. Diabetes Care, 31, 2398&#x2013;2403.</Citation></Reference><Reference><Citation>Hayman, K.J., Kerse, N.M., La Grow, S.J., Wouldes, T., Robertson, M.C. &amp; Campbell, A.J. (2007) Depression in older people: visual impairment and subjective ratings of health. Optometry and Vision Science, 84, 1024&#x2013;1030.</Citation></Reference><Reference><Citation>Holl&#xf3;, G., K&#xf3;thy, P., G&#xe9;czy, A. &amp; Vargha, P. (2009) Personality traits, depression, and objectively measured adherence to once&#x2010;daily prostaglandin analog medication in glaucoma. Journal of Glaucoma, 18, 288&#x2013;292.</Citation></Reference><Reference><Citation>Hwang, S., Kang, S.W., Kim, S.J., Han, K., Kim, B.S., Jung, W. et&#xa0;al. (2023) Impact of age&#x2010;related macular degeneration and related visual disability on the risk of depression: a Nationwide cohort study. Ophthalmology, 130, 615&#x2013;623.</Citation></Reference><Reference><Citation>Jayawant, S.S., Bhosle, M.J., Anderson, R.T. &amp; Balkrishnan, R. (2007) Depressive symptomatology, medication persistence, and associated healthcare costs in older adults with glaucoma. Journal of Glaucoma, 16, 513&#x2013;520.</Citation></Reference><Reference><Citation>Jung, K.I. &amp; Park, C.K. (2016) Mental health status and quality of life in undiagnosed glaucoma patients: a Nationwide population&#x2010;based study. Medicine (Baltimore), 95, e3523.</Citation></Reference><Reference><Citation>Kim, E.S., Kim, Y., Yu, S.Y. &amp; Kim, M. (2016) Depression and anxiety in age&#x2010;related macular degeneration. Patient Preference and Adherence, 10, 1853&#x2013;1854.</Citation></Reference><Reference><Citation>Knudtson, M.D., Klein, B.E., Klein, R., Cruickshanks, K.J. &amp; Lee, K.E. (2005) Age&#x2010;related eye disease, quality of life, and functional activity. Archives of Ophthalmology, 123, 807&#x2013;814.</Citation></Reference><Reference><Citation>Large, M.M. &amp; Kapur, N. (2018) Psychiatric hospitalisation and the risk of suicide. The British Journal of Psychiatry, 212, 269&#x2013;273.</Citation></Reference><Reference><Citation>Lee, W.W., Tajunisah, I., Sharmilla, K., Peyman, M. &amp; Subrayan, V. (2013) Retinal nerve fiber layer structure abnormalities in schizophrenia and its relationship to disease state: evidence from optical coherence tomography. Investigative Ophthalmology &amp; Visual Science, 54, 7785&#x2013;7792.</Citation></Reference><Reference><Citation>Li, X. (2021) Application of evidence&#x2010;based nursing in patients after cataract surgery and its impacts on visual acuity recovery and psychological status. American Journal of Translational Research, 13, 9784&#x2013;9789.</Citation></Reference><Reference><Citation>Li, X., Lin, J., Chen, Z., Jin, G. &amp; Zheng, D. (2021) The impact of cataract surgery on vision&#x2010;related quality of life and psychological distress in monocular patients. Journal of Ophthalmology, 2021, 4694577.</Citation></Reference><Reference><Citation>Liu, W., Ge, T., Leng, Y., Pan, Z., Fan, J., Yang, W. et&#xa0;al. (2017) The role of neural plasticity in depression: from hippocampus to prefrontal cortex. Neural Plasticity, 2017, 6871089.</Citation></Reference><Reference><Citation>London, A., Benhar, I. &amp; Schwartz, M. (2013) The retina as a window to the brain&#x2010;from eye research to CNS disorders. Nature Reviews. Neurology, 9, 44&#x2013;53.</Citation></Reference><Reference><Citation>Malhi, G.S. &amp; Mann, J.J. (2018) Depression. Lancet, 392, 2299&#x2013;2312.</Citation></Reference><Reference><Citation>Manderson, L. &amp; Kokanovic, R. (2009) &#x201c;Worried all the time&#x201d;: distress and the circumstances of everyday life among immigrant Australians with type 2 diabetes. Chronic Illness, 5, 21&#x2013;32.</Citation></Reference><Reference><Citation>Moussavi, S., Chatterji, S., Verdes, E., Tandon, A., Patel, V. &amp; Ustun, B. (2007) Depression, chronic diseases, and decrements in health: results from the world health surveys. Lancet, 370, 851&#x2013;858.</Citation></Reference><Reference><Citation>Musich, S., Wang, S.S., Ruiz, J., Hawkins, K. &amp; Wicker, E. (2018) The impact of mobility limitations on health outcomes among older adults. Geriatric Nursing, 39, 162&#x2013;169.</Citation></Reference><Reference><Citation>Musselman, D.L., Betan, E., Larsen, H. &amp; Phillips, L.S. (2003) Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biological Psychiatry, 54, 317&#x2013;329.</Citation></Reference><Reference><Citation>Ohrnberger, J., Fichera, E. &amp; Sutton, M. (2017) The relationship between physical and mental health: a mediation analysis. Social Science &amp; Medicine, 195, 42&#x2013;49.</Citation></Reference><Reference><Citation>Owens, D.K., Lohr, K.N., Atkins, D., Treadwell, J.R., Reston, J.T., Bass, E.B. et&#xa0;al. (2010) AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions&#x2010;&#x2010;agency for healthcare research and quality and the effective health&#x2010;care program. Journal of Clinical Epidemiology, 63, 513&#x2013;523.</Citation></Reference><Reference><Citation>Page, M.J., McKenzie, J.E., Bossuyt, P.M., Boutron, I., Hoffmann, T.C., Mulrow, C.D. et&#xa0;al. (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 372, n71.</Citation></Reference><Reference><Citation>Pedersen, F.N., Stokholm, L., Andersen, N., Andresen, J., Bek, T., Hajari, J.N. et&#xa0;al. (2023) Longitudinal bidirectional associations between diabetic retinopathy and diagnosed depression: results from a Danish nationwide registry&#x2010;based cohort study. Journal of Diabetes and its Complications, 37, 108589.</Citation></Reference><Reference><Citation>Purola, P.K.M., N&#xe4;ttinen, J.E., Ojamo, M.U.I., Koskinen, S.V.P., Rissanen, H.A., Sainio, P.R.J. et&#xa0;al. (2021) Prevalence and 11&#x2010;year incidence of common eye diseases and their relation to health&#x2010;related quality of life, mental health, and visual impairment. Quality of Life Research, 30, 2311&#x2013;2327.</Citation></Reference><Reference><Citation>Rees, G., Xie, J., Fenwick, E.K., Sturrock, B.A., Finger, R., Rogers, S.L. et&#xa0;al. (2016) Association between diabetes&#x2010;related eye complications and symptoms of anxiety and depression. JAMA Ophthalmol, 134, 1007&#x2013;1014.</Citation></Reference><Reference><Citation>Rezapour, J., Nickels, S., Schuster, A.K., Michal, M., M&#xfc;nzel, T., Wild, P.S. et&#xa0;al. (2018) Prevalence of depression and anxiety among participants with glaucoma in a population&#x2010;based cohort study: the Gutenberg health study. BMC Ophthalmology, 18, 157.</Citation></Reference><Reference><Citation>Rezapour, J., Schuster, A.K., Nickels, S., Korb, C.A., Elbaz, H., Peto, T. et&#xa0;al. (2020) Prevalence and new onset of depression and anxiety among participants with AMD in a European cohort. Scientific Reports, 10, 4816.</Citation></Reference><Reference><Citation>Riva, I., Legramandi, L., Rulli, E., Konstas, A.G., Katsanos, A., Oddone, F. et&#xa0;al. (2019) Vision&#x2010;related quality of life and symptom perception change over time in newly&#x2010;diagnosed primary open angle glaucoma patients. Scientific Reports, 9, 6735.</Citation></Reference><Reference><Citation>Rose, M.A., Vukicevic, M., Koklanis, K., Rees, G., Sandhu, S. &amp; Itsiopoulos, C. (2019) Experiences and perceptions of patients undergoing treatment and quality of life impact of diabetic macular edema: a systematic review. Psychology, Health &amp; Medicine, 24, 383&#x2013;401.</Citation></Reference><Reference><Citation>Sabel, B.A., Wang, J., C&#xe1;rdenas&#x2010;Morales, L., Faiq, M. &amp; Heim, C. (2018) Mental stress as consequence and cause of vision loss: the dawn of psychosomatic ophthalmology for preventive and personalized medicine. The EPMA Journal, 9, 133&#x2013;160.</Citation></Reference><Reference><Citation>Saji, A., Oishi, A. &amp; Harding, R. (2023) Self&#x2010;perceived burden for people with life&#x2010;threatening illness: a qualitative systematic review. Journal of Pain and Symptom Management, 65, e207&#x2013;e217.</Citation></Reference><Reference><Citation>Serbin, M., Devine, B., Campbell, J. &amp; Basu, A. (2020) Assessing health care burden in glaucoma patients with and without physical or mental comorbidities. Journal of Managed Care &amp; Specialty Pharmacy, 26, 325&#x2013;331.</Citation></Reference><Reference><Citation>Shin, D.Y., Jung, K.I., Park, H.Y.L. &amp; Park, C.K. (2021) The effect of anxiety and depression on progression of glaucoma. Scientific Reports, 11, 1769.</Citation></Reference><Reference><Citation>Stahl, A. (2020) The diagnosis and treatment of age&#x2010;related macular degeneration. Deutsches &#xc4;rzteblatt International, 117, 513&#x2013;520.</Citation></Reference><Reference><Citation>Stang, A. (2010) Critical evaluation of the Newcastle&#x2010;Ottawa scale for the assessment of the quality of nonrandomized studies in meta&#x2010;analyses. European Journal of Epidemiology, 25, 603&#x2013;605.</Citation></Reference><Reference><Citation>Stroup, D.F., Berlin, J.A., Morton, S.C., Olkin, I., Williamson, G.D., Rennie, D. et&#xa0;al. (2000) Meta&#x2010;analysis of observational studies in epidemiology: a proposal for reporting. Meta&#x2010;analysis of observational studies in epidemiology (MOOSE) group. JAMA, 283, 2008&#x2013;2012.</Citation></Reference><Reference><Citation>Vera, J., Redondo, B., &#xc1;lvarez&#x2010;Rodr&#xed;guez, M., Molina, R. &amp; Jim&#xe9;nez, R. (2020) The intraocular pressure responses to oral academic examination: the influence of perceived levels of public speaking anxiety. Applied Ergonomics, 88, 103158.</Citation></Reference><Reference><Citation>Voleti, V.B. &amp; Hubschman, J.P. (2013) Age&#x2010;related eye disease. Maturitas, 75, 29&#x2013;33.</Citation></Reference><Reference><Citation>Wang, S.Y., Singh, K. &amp; Lin, S.C. (2012) Prevalence and predictors of depression among participants with glaucoma in a nationally representative population sample. American Journal of Ophthalmology, 154, 436&#x2013;444.e432.</Citation></Reference><Reference><Citation>Wang, W. &amp; Lo, A.C.Y. (2018) Diabetic retinopathy: pathophysiology and treatments. International Journal of Molecular Sciences, 19, 1816.</Citation></Reference><Reference><Citation>Wei, X., Cho, K.S., Thee, E.F., Jager, M.J. &amp; Chen, D.F. (2019) Neuroinflammation and microglia in glaucoma: time for a paradigm shift. Journal of Neuroscience Research, 97, 70&#x2013;76.</Citation></Reference><Reference><Citation>Weinreb, R.N., Aung, T. &amp; Medeiros, F.A. (2014) The pathophysiology and treatment of glaucoma: a review. JAMA, 311, 1901&#x2013;1911.</Citation></Reference><Reference><Citation>Weinstein, O., Cohen, A.D., Levy, J., Zloto, O., Freud, T., Krieger, I. et&#xa0;al. (2023) Anxiety in patients with Neovascular age&#x2010;related macular degeneration. Ophthalmic Epidemiology, 30, 286&#x2013;292.</Citation></Reference><Reference><Citation>Whitehorn, D., Gallant, J., Woodley, H., Rui, Q., Milliken, H. &amp; Kopala, L. (2004) Quetiapine treatment in early psychosis: no evidence of cataracts. Schizophrenia Research, 71, 511&#x2013;512.</Citation></Reference><Reference><Citation>Wilson, M.R., Coleman, A.L., Yu, F., Fong Sasaki, I., Bing, E.G. &amp; Kim, M.H. (2002) Depression in patients with glaucoma as measured by self&#x2010;report surveys. Ophthalmology, 109, 1018&#x2013;1022.</Citation></Reference><Reference><Citation>Zhang, X., Olson, D.J., Le, P., Lin, F.C., Fleischman, D. &amp; Davis, R.M. (2017) The association between glaucoma, anxiety, and depression in a Large population. American Journal of Ophthalmology, 183, 37&#x2013;41.</Citation></Reference><Reference><Citation>Zhou, C., Qian, S., Wu, P. &amp; Qiu, C. (2013) Anxiety and depression in Chinese patients with glaucoma: sociodemographic, clinical, and self&#x2010;reported correlates. Journal of Psychosomatic Research, 75, 75&#x2013;82.</Citation></Reference><Reference><Citation>Zhou, F., Liu, Z., Guo, Y. &amp; Xu, H. (2021) Association of short sleep with risk of periodontal disease: a meta&#x2010;analysis and Mendelian randomization study. Journal of Clinical Periodontology, 48, 1076&#x2013;1084.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39588040</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>27</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-861X</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in nutrition</Title><ISOAbbreviation>Front Nutr</ISOAbbreviation></Journal><ArticleTitle>Association between dietary consumption of multiple vitamins and age-related macular degeneration: a cross-sectional observational study in the National Health and Nutrition Examination Survey 2005-2008.</ArticleTitle><Pagination><StartPage>1504081</StartPage><MedlinePgn>1504081</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1504081</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fnut.2024.1504081</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">Age-related macular degeneration (AMD) is one of the common causes of blindness in the elderly worldwide. Its prevention and monitoring indicators remain a key area of research. This study aims to examine the association between vitamin intake and AMD prevalence.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Data from the National Health and Nutrition Examination Survey (NHANES) from 2005 to 2008 were used for cross-sectional analysis. Logistic regression models, subgroup analyses and multicollinearity regression were employed to assess the association between vitamin intake and AMD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 1,627 participants were included, with 54.5% (weighted) males and 45.5% (weighted) females. Significant differences were observed in the intake of vitamins B (B1, B2, B6, and B12), E, and folic acid between the AMD and Non-AMD groups. The Non-AMD group had higher average intakes (weighted) of vitamin B1 (1.71&#x2009;&#xb1;&#x2009;1.10 vs. 1.37&#x2009;&#xb1;&#x2009;0.64), B2 (2.42&#x2009;&#xb1;&#x2009;1.22 vs. 1.86&#x2009;&#xb1;&#x2009;0.70), B6 (2.05&#x2009;&#xb1;&#x2009;1.25 vs. 1.71&#x2009;&#xb1;&#x2009;0.85), B12 (5.73&#x2009;&#xb1;&#x2009;6.18 vs. 4.54&#x2009;&#xb1;&#x2009;3.27), E (7.93&#x2009;&#xb1;&#x2009;5.47 vs. 6.39&#x2009;&#xb1;&#x2009;2.86), and folic acid (181.87&#x2009;&#xb1;&#x2009;178.04 vs. 140.72&#x2009;&#xb1;&#x2009;124.60). Logistic regression and subgroup analyses further supported these findings.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">This study found that higher vitamin intakes B and E were associated with a lower prevalence of AMD in the U.S. population. Eating a healthy diet rich in vitamins B and E, particularly B2 (eggs, green vegetables, meat, mushrooms, and almonds) may help to reduce vision loss due to AMD. However, since this is a cross-sectional study, causal associations between vitamin intake and AMD cannot be established. Further randomized clinical trials are needed to confirm these findings.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Liu, Wang, Li and Cai.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Liu</LastName><ForeName>Zhao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Aier Eye Hospital of Guizhou Province, Guiyang, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zunyi Medical University, Zunyi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Qiuyuan</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Zunyi Medical University, Zunyi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guizhou Branch of the Affiliated Hospital of Zunyi Medical University, National Clinical Research Center of the Eye Hospital of Guizhou Province, Key Laboratory of Eye Disease Characteristics of Guizhou Province, Zunyi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Zunyi Medical University, Zunyi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guizhou Branch of the Affiliated Hospital of Zunyi Medical University, National Clinical Research Center of the Eye Hospital of Guizhou Province, Key Laboratory of Eye Disease Characteristics of Guizhou Province, Zunyi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>ShanJun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Aier Eye Hospital of Guizhou Province, Guiyang, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Zunyi Medical University, Zunyi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guizhou Branch of the Affiliated Hospital of Zunyi Medical University, National Clinical Research Center of the Eye Hospital of Guizhou Province, Key Laboratory of Eye Disease Characteristics of Guizhou Province, Zunyi, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Nutr</MedlineTA><NlmUniqueID>101642264</NlmUniqueID><ISSNLinking>2296-861X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">NHANES</Keyword><Keyword MajorTopicYN="N">causality</Keyword><Keyword MajorTopicYN="N">dietary intake</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">macular degeneration</Keyword><Keyword MajorTopicYN="N">vitamin</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>11</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>11</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>4</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39588040</ArticleId><ArticleId IdType="pmc">PMC11587902</ArticleId><ArticleId IdType="doi">10.3389/fnut.2024.1504081</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, et al. . Age-related macular degeneration preferred practice pattern. Ophthalmology. (2020) 127:P1&#x2013;P65. doi: 10.1016/j.ophtha.2019.09.024, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2019.09.024</ArticleId><ArticleId IdType="pubmed">31757502</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinese Vitreo-Retina Society of Chinese Medical Association, Fundus Disease Group of Chinese Ophthalmologist Association . Evidence-based guidelines for diagnosis and treatment of age-related macular degeneration in China. Zhonghua Yan Ke Za Zhi. (2023) 59:347&#x2013;66. doi: 10.3760/cma.j.cn112142-20221222-00649, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn112142-20221222-00649</ArticleId><ArticleId IdType="pubmed">37032564</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H, Wang L, Li J, Fan Y, Li Z, Ma M, et al. . Dietary vitamins, carotenoids and their sources in relation to age-related macular degeneration risk in China: a population-based case-control study. Br J Nutr. (2023) 129:1804&#x2013;11. doi: 10.1017/S0007114522002161, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0007114522002161</ArticleId><ArticleId IdType="pubmed">35894297</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Pan W, Xu Y, Zhang J, Wan J, Jiang H. Microglia-mediated Neuroinflammation: a potential target for the treatment of cardiovascular diseases. J Inflamm Res. (2022) 15:3083&#x2013;94. doi: 10.2147/JIR.S350109, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S350109</ArticleId><ArticleId IdType="pmc">PMC9148574</ArticleId><ArticleId IdType="pubmed">35642214</ArticleId></ArticleIdList></Reference><Reference><Citation>Keenan TDL, Agr&#xf3;n E, Chew EY, for the AREDS and AREDS2 Research Groups . Dietary nutrient intake and cognitive function in the age-related eye disease studies 1 and 2. Alzheimers Dement. (2023) 19:4311&#x2013;24. doi: 10.1002/alz.13033, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.13033</ArticleId><ArticleId IdType="pmc">PMC10509327</ArticleId><ArticleId IdType="pubmed">36939084</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev. (2023) 9:CD000254. doi: 10.1002/14651858.CD000254.pub5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD000254.pub5</ArticleId><ArticleId IdType="pmc">PMC10498493</ArticleId><ArticleId IdType="pubmed">37702300</ArticleId></ArticleIdList></Reference><Reference><Citation>Pameijer EM, Heus P, Damen JAA, Spijker R, Hooft L, Ringens PJ, et al. . What did we learn in 35&#x2009;years of research on nutrition and supplements for age-related macular degeneration: a systematic review. Acta Ophthalmol. (2022) 100:e1541&#x2013;52. doi: 10.1111/aos.15191</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aos.15191</ArticleId><ArticleId IdType="pmc">PMC9796889</ArticleId><ArticleId IdType="pubmed">35695158</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Andrew N, LaHood BR. Evidence-based vitamin supplements for age-related macular degeneration: an analysis of available products. Clin Exp Optom. (2022) 105:836&#x2013;41. doi: 10.1080/08164622.2021.1989264</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08164622.2021.1989264</ArticleId><ArticleId IdType="pubmed">34780311</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Liang J, Lu L, Liu L, Wang L. Effect of ferulic acid incorporation on structural, rheological, and digestive properties of hot-extrusion 3D-printed rice starch. Int J Biol Macromol. (2024) 266:131279. doi: 10.1016/j.ijbiomac.2024.131279</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2024.131279</ArticleId><ArticleId IdType="pubmed">38561115</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuan V, Warwick A, Hingorani A, Tufail A, Cipriani V, Burgess S, et al. . Association of smoking, alcohol consumption, blood pressure, body mass index, and glycemic risk factors with age-related macular degeneration: a mendelian randomization study. JAMA Ophthalmol. (2021) 139:1299&#x2013;306. doi: 10.1001/jamaophthalmol.2021.4601, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2021.4601</ArticleId><ArticleId IdType="pmc">PMC8569599</ArticleId><ArticleId IdType="pubmed">34734970</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Zhong Y, Zhang L, Wu Q, Tham Y, Rim TH, et al. . Global incidence, progression, and risk factors of age-related macular degeneration and projection of disease statistics in 30 years: a modeling study. Gerontology. (2022) 68:721&#x2013;35. doi: 10.1159/000518822, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000518822</ArticleId><ArticleId IdType="pubmed">34569526</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Y, Chen X, Luo S, Jiang S, Mao Y, Xiao W. Serum 25-Hydroxyvitamin D is differentially associated with early and late age-related macular degeneration in the United States population. Nutrients. (2023) 15:1216. doi: 10.3390/nu15051216, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu15051216</ArticleId><ArticleId IdType="pmc">PMC10005371</ArticleId><ArticleId IdType="pubmed">36904215</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong J, Chen F, Zhang J, Ao W, Zhou X, Yang H, et al. . Occurrence of aflatoxin M1 in three types of Milk from Xinjiang, China, and the risk of exposure for Milk consumers in different age-sex groups. Food Secur. (2022) 11:3922. doi: 10.3390/foods11233922, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/foods11233922</ArticleId><ArticleId IdType="pmc">PMC9738243</ArticleId><ArticleId IdType="pubmed">36496730</ArticleId></ArticleIdList></Reference><Reference><Citation>Agr&#xf3;n E, Mares J, Clemons TE, Swaroop A, Chew EY, Keenan TDL, et al. . Dietary nutrient intake and progression to late age-related macular degeneration in the age-related eye disease studies 1 and 2. Ophthalmology. (2021) 128:425&#x2013;42. doi: 10.1016/j.ophtha.2020.08.018, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2020.08.018</ArticleId><ArticleId IdType="pmc">PMC7902480</ArticleId><ArticleId IdType="pubmed">32858063</ArticleId></ArticleIdList></Reference><Reference><Citation>Merle BMJ, Barthes S, F&#xe9;art C, Cougnard-Gr&#xe9;goire A, Korobelnik JF, Rougier MB, et al. . B vitamins and incidence of advanced age-related macular degeneration: the Alienor study. Nutrients. (2022) 14:2821. doi: 10.3390/nu14142821, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu14142821</ArticleId><ArticleId IdType="pmc">PMC9318446</ArticleId><ArticleId IdType="pubmed">35889778</ArticleId></ArticleIdList></Reference><Reference><Citation>Millen AE, Nie J, Mares JA, Lutsey PL, LaMonte MJ, Meuer SM, et al. . Serum 25-Hydroxyvitamin D concentrations and incidence of age-related macular degeneration: the atherosclerosis risk in communities study. Invest Ophthalmol Vis Sci. (2019) 60:1362&#x2013;71. doi: 10.1167/iovs.18-25945, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.18-25945</ArticleId><ArticleId IdType="pmc">PMC6892376</ArticleId><ArticleId IdType="pubmed">30934055</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibuki M, Lee D, Shinojima A, Miwa Y, Tsubota K, Kurihara T. Rice bran and vitamin B6 suppress pathological neovascularization in a murine model of age-related macular degeneration as novel HIF inhibitors. Int J Mol Sci. (2020) 21:8940. doi: 10.3390/ijms21238940, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21238940</ArticleId><ArticleId IdType="pmc">PMC7728083</ArticleId><ArticleId IdType="pubmed">33255657</ArticleId></ArticleIdList></Reference><Reference><Citation>Icel E, Ucak T, Ugurlu A, Erdol H. Changes in optical coherence tomography angiography in patients with vitamin D deficiency. Eur J Ophthalmol. (2022) 32:3514&#x2013;21. doi: 10.1177/11206721221086240</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/11206721221086240</ArticleId><ArticleId IdType="pubmed">35253469</ArticleId></ArticleIdList></Reference><Reference><Citation>Christen WG, Chasman DI, Cook NR, Chiuve SE, Ridker PM, Buring JE. Homocysteine, B vitamins, MTHFR genotype, and incident age-related macular degeneration. Ophthalmol Retina. (2018) 2:508&#x2013;10. doi: 10.1016/j.oret.2017.10.001, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oret.2017.10.001</ArticleId><ArticleId IdType="pmc">PMC6022858</ArticleId><ArticleId IdType="pubmed">29963648</ArticleId></ArticleIdList></Reference><Reference><Citation>Christen WG, Cook NR, Chiuve SE, Ridker PM, Gaziano JM. Prospective study of plasma homocysteine, its dietary determinants, and risk of age-related macular degeneration in men. Ophthalmic Epidemiol. (2018) 25:79&#x2013;88. doi: 10.1080/09286586.2017.1362009, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09286586.2017.1362009</ArticleId><ArticleId IdType="pmc">PMC6204217</ArticleId><ArticleId IdType="pubmed">29035128</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention . National center for health Statistics national health and nutrition examination survey MEC in-person dietary interviewers procedures manual. Available at: https://wwwn.cdc.gov/nchs/data/nhanes/2005-2006/manuals/DIETARY_MEC.pdf</Citation></Reference><Reference><Citation>U.S. Department of Agriculture . Agricultural research service what we eat in America food categories 2009&#x2013;2010. Available at: https://www.ars.usda.gov/ARSUserFiles/80400530/pdf/0910/wweia_2009_2010_data.pdf</Citation></Reference><Reference><Citation>U.S. Department of Agriculture . Agricultural research service vitamin D addendum to USDA food and nutrient database for dietary studies 3.0. Available at: https://www.ars.usda.gov/ARSUserFiles/80400530/pdf/fndds/VitDaddendumFNDDS3.pdf</Citation></Reference><Reference><Citation>Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U. Age-related macular degeneration: a review. JAMA. (2024) 331:147&#x2013;57. doi: 10.1001/jama.2023.26074</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.26074</ArticleId><ArticleId IdType="pubmed">38193957</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahendra CK, Tan LTH, Pusparajah P, Htar TT, Chuah LH, Lee VS, et al. . Detrimental effects of UVB on retinal pigment epithelial cells and its role in age-related macular degeneration. Oxidative Med Cell Longev. (2020) 2020:1&#x2013;29. doi: 10.1155/2020/1904178</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/1904178</ArticleId><ArticleId IdType="pmc">PMC7443017</ArticleId><ArticleId IdType="pubmed">32855763</ArticleId></ArticleIdList></Reference><Reference><Citation>Callaghan B, Vallabh NA, Willoughby CE. Deuterated polyunsaturated fatty acids provided protection against oxidative stress in ocular fibroblasts derived from glaucoma patients. Mech Ageing Dev. (2023) 211:111778. doi: 10.1016/j.mad.2023.111778</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mad.2023.111778</ArticleId><ArticleId IdType="pubmed">36716826</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon J, Freeman SA. Phagocytosis by the retinal pigment epithelium: recognition, resolution, recycling. Front Immunol. (2020) 11:604205. doi: 10.3389/fimmu.2020.604205, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.604205</ArticleId><ArticleId IdType="pmc">PMC7691529</ArticleId><ArticleId IdType="pubmed">33281830</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Chen Y, Li J, Wu E, Tang T, Singla RK, et al. . Natural products for the treatment of age-related macular degeneration. Phytomedicine. (2024) 130:155522. doi: 10.1016/j.phymed.2024.155522, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phymed.2024.155522</ArticleId><ArticleId IdType="pubmed">38820665</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanus J, Anderson C, Wang S. RPE necroptosis in response to oxidative stress and in AMD. Ageing Res Rev. (2015) 24:286&#x2013;98. doi: 10.1016/j.arr.2015.09.002, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2015.09.002</ArticleId><ArticleId IdType="pmc">PMC4661094</ArticleId><ArticleId IdType="pubmed">26369358</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellyer JA, Padda SK, Diehn M, Wakelee HA. Clinical implications of KEAP1-NFE2L2 mutations in NSCLC. J Thorac Oncol. (2021) 16:395&#x2013;403. doi: 10.1016/j.jtho.2020.11.015, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtho.2020.11.015</ArticleId><ArticleId IdType="pubmed">33307193</ArticleId></ArticleIdList></Reference><Reference><Citation>Keenan TDL, Agr&#xf3;n E, Keane PA, Domalpally A, Chew EY. Oral antioxidant and lutein/zeaxanthin supplements slow geographic atrophy progression to the fovea in age-related macular degeneration. Ophthalmology. S0161-6420(24)00425-1. doi: 10.1016/j.ophtha.2024.07.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2024.07.014</ArticleId><ArticleId IdType="pubmed">39025435</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S, Mason AM, Carter P, Burgess S, Larsson SC. Homocysteine, B vitamins, and cardiovascular disease: a Mendelian randomization study. BMC Med. (2021) 19:97. doi: 10.1186/s12916-021-01977-8, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-01977-8</ArticleId><ArticleId IdType="pmc">PMC8063383</ArticleId><ArticleId IdType="pubmed">33888102</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergandi L, Palladino G, Meduri A, de Luca L, Silvagno F. Vitamin D and Sulforaphane decrease inflammatory oxidative stress and restore the markers of epithelial integrity in an in vitro model of age-related macular degeneration. Int J Mol Sci. (2024) 25:6404. doi: 10.3390/ijms25126404, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms25126404</ArticleId><ArticleId IdType="pmc">PMC11203625</ArticleId><ArticleId IdType="pubmed">38928111</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinna A, Zaccheddu F, Boscia F, Carru C, Solinas G. Homocysteine and risk of age-related macular degeneration: a systematic review and meta-analysis. Acta Ophthalmol. (2018) 96:e269 e276. doi: 10.1111/aos.13343</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aos.13343</ArticleId><ArticleId IdType="pubmed">27966830</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali MA, Hafez HA, Kamel MA, Ghamry HI, Shukry M, Farag MA. Dietary vitamin B complex: orchestration in human nutrition throughout life with sex differences. Nutrients. (2022) 14:3940. doi: 10.3390/nu14193940</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu14193940</ArticleId><ArticleId IdType="pmc">PMC9573099</ArticleId><ArticleId IdType="pubmed">36235591</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Q, Shen T, Xu M, Tan L, Shen Z, Hong C. Association between dietary consumption of vitamin B1 and advanced age-related macular degeneration: a cross-sectional observational study in NHANES 2005-2008. Ophthalmic Res. (2023) 66:1353&#x2013;61. doi: 10.1159/000534819, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000534819</ArticleId><ArticleId IdType="pubmed">37926095</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanna M, Jaqua E, Nguyen V, Clay J. B vitamins: functions and uses in medicine. Perm J. (2022) 26:89&#x2013;97. doi: 10.7812/TPP/21.204, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.7812/TPP/21.204</ArticleId><ArticleId IdType="pmc">PMC9662251</ArticleId><ArticleId IdType="pubmed">35933667</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodati S, Sen HN. Uveitis and the gut microbiota. Best Pract Res Clin Rheumatol. (2019) 33:101500. doi: 10.1016/j.berh.2020.101500, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.berh.2020.101500</ArticleId><ArticleId IdType="pmc">PMC7299813</ArticleId><ArticleId IdType="pubmed">32278666</ArticleId></ArticleIdList></Reference><Reference><Citation>Kammoun S, Rekik M, Dlensi A, Aloulou S, Smaoui W, Sellami S, et al. . The gut-eye axis: the retinal/ocular degenerative diseases and the emergent therapeutic strategies. Front Cell Neurosci. (2024) 18:1468187. doi: 10.3389/fncel.2024.1468187, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2024.1468187</ArticleId><ArticleId IdType="pmc">PMC11464360</ArticleId><ArticleId IdType="pubmed">39391760</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin P. Importance of the intestinal microbiota in ocular inflammatory diseases: a review. Clin Experiment Ophthalmol. (2019) 47:418&#x2013;22. doi: 10.1111/ceo.13493, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ceo.13493</ArticleId><ArticleId IdType="pubmed">30834680</ArticleId></ArticleIdList></Reference><Reference><Citation>Handa JT, Bowes Rickman C, Dick AD, Gorin MB, Miller JW, Toth CA, et al. . A systems biology approach towards understanding and treating non-neovascular age-related macular degeneration. Nat Commun. (2019) 10:3347. doi: 10.1038/s41467-019-11262-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-11262-1</ArticleId><ArticleId IdType="pmc">PMC6659646</ArticleId><ArticleId IdType="pubmed">31350409</ArticleId></ArticleIdList></Reference><Reference><Citation>Attaluri P, Castillo A, Edriss H, Nugent K. Thiamine deficiency: an important consideration in critically ill patients. Am J Med Sci. (2018) 356:382&#x2013;90. doi: 10.1016/j.amjms.2018.06.015, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjms.2018.06.015</ArticleId><ArticleId IdType="pubmed">30146080</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto-Martin EC, Warnke I, Farquharson FM, Christodoulou M, Horgan G, Derrien M, et al. . Vitamin biosynthesis by human gut butyrate-producing Bacteria and cross-feeding in synthetic microbial communities. MBio. (2020) 11:e00886&#x2013;20. doi: 10.1128/mBio.00886-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00886-20</ArticleId><ArticleId IdType="pmc">PMC7360928</ArticleId><ArticleId IdType="pubmed">32665271</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, Hosomi K, Kawashima H, Chen YA, Mohsen A, Ohno H, et al. . Dietary vitamin B1 intake influences gut microbial community and the consequent production of Short-chain fatty acids. Nutrients. (2022) 14:2078. doi: 10.3390/nu14102078, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu14102078</ArticleId><ArticleId IdType="pmc">PMC9147846</ArticleId><ArticleId IdType="pubmed">35631219</ArticleId></ArticleIdList></Reference><Reference><Citation>Suwannasom N, Kao I, Pru&#xdf; A, Georgieva R, B&#xe4;umler H. Riboflavin: the health benefits of a forgotten natural vitamin. Int J Mol Sci. (2020) 21:950. doi: 10.3390/ijms21030950, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21030950</ArticleId><ArticleId IdType="pmc">PMC7037471</ArticleId><ArticleId IdType="pubmed">32023913</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu YY, Thakur K, Feng JY, Zhang JG, Hu F, Cespedes-Acu&#xf1;a CL, et al. . Riboflavin bioenriched soymilk alleviates oxidative stress mediated liver injury, intestinal inflammation, and gut microbiota modification in B2 depletion-repletion mice. J Agric Food Chem. (2022) 70:3818&#x2013;31. doi: 10.1021/acs.jafc.2c00117, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jafc.2c00117</ArticleId><ArticleId IdType="pubmed">35302755</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Sadaghian Sadabad M, Gabarrini G, Lisotto P, von Martels J, Wardill HR, et al. . Riboflavin supplementation promotes butyrate production in the absence of Gross compositional changes in the gut microbiota. Antioxid Redox Signal. (2023) 38:282&#x2013;97. doi: 10.1089/ars.2022.0033, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2022.0033</ArticleId><ArticleId IdType="pmc">PMC9986023</ArticleId><ArticleId IdType="pubmed">35943883</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham VT, Fehlbaum S, Seifert N, Richard N, Bruins MJ, Sybesma W, et al. . Effects of colon-targeted vitamins on the composition and metabolic activity of the human gut microbiome-a pilot study. Gut Microbes. (2021) 13:1&#x2013;20. doi: 10.1080/19490976.2021.1875774, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2021.1875774</ArticleId><ArticleId IdType="pmc">PMC7899684</ArticleId><ArticleId IdType="pubmed">33615992</ArticleId></ArticleIdList></Reference><Reference><Citation>Stach K, Stach W, Augoff K. Vitamin B6 in health and disease. Nutrients. (2021) 13:3229. doi: 10.3390/nu13093229, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13093229</ArticleId><ArticleId IdType="pmc">PMC8467949</ArticleId><ArticleId IdType="pubmed">34579110</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan Z, Zheng J, Zhu Z, Sang L, Zhu J, Luo S, et al. . Intermediate role of gut microbiota in vitamin B nutrition and its influences on human health. Front Nutr. (2022) 9:1031502. doi: 10.3389/fnut.2022.1031502</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnut.2022.1031502</ArticleId><ArticleId IdType="pmc">PMC9792504</ArticleId><ArticleId IdType="pubmed">36583209</ArticleId></ArticleIdList></Reference><Reference><Citation>Luong JHT, Vashist SK. Chemistry of biotin-streptavidin and the growing concern of an emerging biotin interference in clinical immunoassays. ACS Omega. (2019) 5:10&#x2013;8. doi: 10.1021/acsomega.9b03013</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsomega.9b03013</ArticleId><ArticleId IdType="pmc">PMC6963918</ArticleId><ArticleId IdType="pubmed">31956746</ArticleId></ArticleIdList></Reference><Reference><Citation>Hibberd MC, Wu M, Rodionov DA, Li X, Cheng J, Griffin NW, et al. . The effects of micronutrient deficiencies on bacterial species from the human gut microbiota. Sci Transl Med. (2017) 9:eaal 4069. doi: 10.1126/scitranslmed.aal4069, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aal4069</ArticleId><ArticleId IdType="pmc">PMC5524138</ArticleId><ArticleId IdType="pubmed">28515336</ArticleId></ArticleIdList></Reference><Reference><Citation>Malinowska AM, Schmidt M, Kok DE, Chmurzynska A. Ex vivo folate production by fecal bacteria does not predict human blood folate status: associations between dietary patterns, gut microbiota, and folate metabolism. Food Res Int. (2022) 156:111290. doi: 10.1016/j.foodres.2022.111290</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.foodres.2022.111290</ArticleId><ArticleId IdType="pubmed">35651056</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurwara S, Ajami NJ, Jang A, Hessel FC, Chen L, Plew S, et al. . Dietary nutrients involved in one-carbon metabolism and colonic mucosa-associated gut microbiome in individuals with an endoscopically Normal Colon. Nutrients. (2019) 11:613. doi: 10.3390/nu11030613, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11030613</ArticleId><ArticleId IdType="pmc">PMC6470629</ArticleId><ArticleId IdType="pubmed">30871224</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohd Zaffarin AS, Ng SF, Ng MH, Hassan H, Alias E. Pharmacology and pharmacokinetics of vitamin E: Nanoformulations to enhance bioavailability. Int J Nanomedicine. (2020) 15:9961&#x2013;74. doi: 10.2147/IJN.S276355, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJN.S276355</ArticleId><ArticleId IdType="pmc">PMC7733471</ArticleId><ArticleId IdType="pubmed">33324057</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva YP, Bernardi A, Frozza RL. The role of Short-chain fatty acids from gut microbiota in gut-brain communication. Front Endocrinol (Lausanne). (2020) 11:25. doi: 10.3389/fendo.2020.00025, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2020.00025</ArticleId><ArticleId IdType="pmc">PMC7005631</ArticleId><ArticleId IdType="pubmed">32082260</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank RN. Of age-related macular degeneration and vitamins. JAMA Ophthalmol. (2020) 138:1290. doi: 10.1001/jamaophthalmol.2020.4417</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2020.4417</ArticleId><ArticleId IdType="pubmed">33119041</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong XX, Chen DL, Miao YF, Li DL, Kai JY, Hu DN, et al. . The impact of 25-hydroxyvitamin D and calcium on risk of age-related macular degeneration: a Mendelian randomization study. Am J Clin Nutr. (2024) 120:727&#x2013;36. doi: 10.1016/j.ajcnut.2024.06.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajcnut.2024.06.018</ArticleId><ArticleId IdType="pubmed">38964658</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Li Y, Hou Y, Fan Y, Jiang H, Li B, et al. . Association of Plasma Vitamins and Carotenoids, DNA methylation of LCAT, and risk of age-related macular degeneration. Nutrients. (2023) 15:2985. doi: 10.3390/nu15132985, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu15132985</ArticleId><ArticleId IdType="pmc">PMC10347047</ArticleId><ArticleId IdType="pubmed">37447314</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabata&#x15f; N, Do&#x11f;an A&#x15e;, Y&#x131;lmaz M, Kabata&#x15f; EU, Bi&#xe7;er T, &#xc7;al&#x131;&#x15f;kan S, et al. . Association between age-related macular degeneration and 25(OH) vitamin D levels in the Turkish population. Arq Bras Oftalmol. (2022) 85:7&#x2013;12. doi: 10.5935/0004-2749.20220002</Citation><ArticleIdList><ArticleId IdType="doi">10.5935/0004-2749.20220002</ArticleId><ArticleId IdType="pubmed">34586223</ArticleId></ArticleIdList></Reference><Reference><Citation>Keenan TD, Agr&#xf3;n E, Domalpally A, Clemons TE, van Asten F, Wong WT, et al. . Progression of geographic atrophy in age-related macular degeneration: AREDS2 report number 16. Ophthalmology. (2018) 125:1913&#x2013;28. doi: 10.1016/j.ophtha.2018.05.028, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2018.05.028</ArticleId><ArticleId IdType="pmc">PMC6246813</ArticleId><ArticleId IdType="pubmed">30060980</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">39587629</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>25</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>A novel AAV Vector for gene therapy of RPE-related retinal degenerative diseases via intravitreal delivery.</ArticleTitle><Pagination><StartPage>89</StartPage><MedlinePgn>89</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">89</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13024-024-00777-x</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Gong</LastName><ForeName>Yajun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, 54 Xianlie South Rd, Guangzhou, 510060, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Sun Yat-Sen University, Guangzhou, 510060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Huang</LastName><ForeName>Xianyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Shanghai EmayGene Biotech Co. Ltd, Shanghai, 201203, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tu</LastName><ForeName>Tianxiang</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, 54 Xianlie South Rd, Guangzhou, 510060, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Sun Yat-Sen University, Guangzhou, 510060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Cenfeng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>iHuman Institute, ShanghaiTech University, Shanghai, 201210, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xian</LastName><ForeName>Chunrui</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>iHuman Institute, ShanghaiTech University, Shanghai, 201210, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Yushun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Shanghai EmayGene Biotech Co. Ltd, Shanghai, 201203, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, 54 Xianlie South Rd, Guangzhou, 510060, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Sun Yat-Sen University, Guangzhou, 510060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ruobi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, 54 Xianlie South Rd, Guangzhou, 510060, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Sun Yat-Sen University, Guangzhou, 510060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Guisheng</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>iHuman Institute, ShanghaiTech University, Shanghai, 201210, China. zhongsh@shanghaitech.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, China. zhongsh@shanghaitech.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xiaolai</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-4531-4658</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, 54 Xianlie South Rd, Guangzhou, 510060, China. zhouxiaolai@gzzoc.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Sun Yat-Sen University, Guangzhou, 510060, China. zhouxiaolai@gzzoc.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2022YFF1202901</GrantID><Agency>Key Research and Development Program of the Ministry of Science and Technology</Agency><Country/></Grant><Grant><GrantID>82171404</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>2023A1515011529</GrantID><Agency>Natural Science Foundation of Guangdong Province</Agency><Country/></Grant><Grant><GrantID>2023A03J0181, 2024A04J6481</GrantID><Agency>Science and Technology Planning Project of Guangzhou City</Agency><Country/></Grant><Grant><GrantID>22yklj04</GrantID><Agency>the Fundamental Research Funds for the Central Universities</Agency><Country/></Grant><Grant><GrantID>Funded Talent[2020]18</GrantID><Agency>the Research Start-up Founds of Sun Yat-sen University</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adeno-associated virus (AAV)</Keyword><Keyword MajorTopicYN="N">Age-related macular degeneration (AMD)</Keyword><Keyword MajorTopicYN="N">Gene therapy</Keyword><Keyword MajorTopicYN="N">Retinal degenerative diseases</Keyword><Keyword MajorTopicYN="N">Retinal pigment epithelium (RPE)</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: All animal experiments were carried out with the approval of the Institutional Animal Care and Use Committee of Sun Yat-Sen University (Permit Number: SYSU-IACUC-2024-002111) and in compliance with the ARVO statement for the use of animals in ophthalmic and vision research. Consent for publication: All authors have reviewed the final manuscript and consented to publication. Competing interests: The authors have declared that no competing interests exists.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>1</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39587629</ArticleId><ArticleId IdType="pmc">PMC11590224</ArticleId><ArticleId IdType="doi">10.1186/s13024-024-00777-x</ArticleId><ArticleId IdType="pii">10.1186/s13024-024-00777-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zarbin M. Cell-based therapy for degenerative retinal disease. Trends Mol Med. 2016;22(2):115&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">26791247</ArticleId></ArticleIdList></Reference><Reference><Citation>DiCarlo JE, Mahajan VB, Tsang SH. Gene therapy and genome surgery in the retina. J Clin Invest. 2018;128(6):2177&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5983345</ArticleId><ArticleId IdType="pubmed">29856367</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleckenstein M, Keenan TDL, Guymer RH, Chakravarthy U, Schmitz-Valckenberg S, Klaver CC, Wong WT, Chew EY. Age-related macular degeneration. Nat Rev Dis Primer. 2021;7(1):1&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">33958600</ArticleId></ArticleIdList></Reference><Reference><Citation>Heier JS, Kherani S, Desai S, Dugel P, Kaushal S, Cheng SH, Delacono C, Purvis A, Richards S, Le-Halpere A, Connelly J, Wadsworth SC, Varona R, Buggage R, Scaria A, Campochiaro PA. Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. Lancet. 2017;390(10089):50&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">28526489</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39587331</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5454</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>25</Day></PubDate></JournalIssue><Title>Eye (London, England)</Title><ISOAbbreviation>Eye (Lond)</ISOAbbreviation></Journal><ArticleTitle>Non-exudative OCT findings in neovascular AMD.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41433-024-03461-y</ELocationID><Abstract><AbstractText>In this narrative review we describe the main optical coherence tomography biomarkers appearing in eyes with neovascular age-related macular degeneration (AMD) that do not directly correspond to exudation. We highlight those signs that may mimic exudation and therefore do not require active treatment, such as outer retinal tubulations, pseudocysts, lipid globules, or hyporeflective wedges. Other signs may indicate impending exudation such as hyperreflective foci or shallow irregular retinal pigment epithelium elevation, and therefore should be carefully monitored. We also review and summarize the different origins of subretinal hyperreflective material and describe the main signs of degeneration seen in eyes with AMD, such as outer retinal tubulation, thinning of the retinal layers, outer retinal atrophy, and choroidal changes.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vidal-Oliver</LastName><ForeName>Lourdes</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Unit of Macula, Oftalvist Clinic, Valencia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ophthalmology Department, University Hospital Mannheim, University of Heidelberg, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Avellaneda</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Ophthalmology Department, Basurto Hospital, Bilbao, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fragiotta</LastName><ForeName>Serena</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-6214-6270</Identifier><AffiliationInfo><Affiliation>Ophthalmology Unit, Department NESMOS, S. Andrea Hospital, University of Rome "La Sapienza", Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corradetti</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-9213-5575</Identifier><AffiliationInfo><Affiliation>Doheny Eye Institute, Pasadena, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, University of California Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borrelli</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-2815-5031</Identifier><AffiliationInfo><Affiliation>Department of Surgical Sciences, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, "City of Health and Science" Hospital, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dolz-Marco</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-2963-2541</Identifier><AffiliationInfo><Affiliation>Unit of Macula, Oftalvist Clinic, Valencia, Spain. rosadolzmarco@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eye (Lond)</MedlineTA><NlmUniqueID>8703986</NlmUniqueID><ISSNLinking>0950-222X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Competing interests: LVO reports travel expenses from Bayer; PFA is a consultant for Bayer and Roche; SF reports personal fees from Bayer (Advisor) outside the submitted work; GC none; EB is consultant to Abbvie, Bayer, Hofmann La Roche, Zeiss; RDM is consultant to Heidelberg Engineering and receives research funding from Roche, and Abbvie. The current manuscript received no funding.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>0</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>0</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39587331</ArticleId><ArticleId IdType="doi">10.1038/s41433-024-03461-y</ArticleId><ArticleId IdType="pii">10.1038/s41433-024-03461-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Keenan T, Cukras C, Chew E. Age-related macular degeneration: epidemiology and clinical aspects. Adv Exp Med Biol. 2021;1256:1&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-030-66014-7_1</ArticleId><ArticleId IdType="pubmed">33847996</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferris FL, Wilkinson CP, Bird A, Chakravarthy U, Chew E, Csaky K, et al. Clinical classification of age-related macular degeneration. Ophthalmology. 2013;120:844&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2012.10.036</ArticleId><ArticleId IdType="pubmed">23332590</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal-Oliver L, Montol&#xed;o-Marzo E, Gallego-Pinazo R, Dolz-Marco R. Optical coherence tomography biomarkers in early and intermediate age-related macular degeneration: a clinical guide. Clin Exp Ophthalmol. 2024;52:207&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ceo.14337</ArticleId><ArticleId IdType="pubmed">38214056</ArticleId></ArticleIdList></Reference><Reference><Citation>Borrelli E, Barresi C, Lari G, Berni A, Battista M, Reibaldi M et al. Capturing the transition from intermediate to neovascular AMD: longitudinal inner retinal thinning and factors associated with neuronal loss. Invest Ophthalmol Vis Sci. 2023;64:21.</Citation></Reference><Reference><Citation>Rudas A, Chiang JN, Corradetti G, Rakocz N, Avram O, Halperin E, et al. Automated large-scale prediction of exudative AMD progression using machine-read OCT biomarkers. PLoS Digit Heal. 2023;2:e0000106. https://doi.org/10.1371/journal.pdig.0000106 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pdig.0000106</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakatsuki Y, Hirabayashi K, Yu HJ, Marion KM, Corradetti G, Wykoff CC, et al. Optical coherence tomography biomarkers for conversion to exudative neovascular age-related macular degeneration. Am J Ophthalmol. 2023;247:137&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2022.09.018</ArticleId><ArticleId IdType="pubmed">36228779</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Mrejen S, Jung JJ, Gallego-Pinazo R, Thompson D, Marsiglia M, et al. Geographic atrophy in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Retina. 2015;35:176&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IAE.0000000000000374</ArticleId><ArticleId IdType="pubmed">25387047</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrejen S, Jung JJ, Chen C, Patel SN, Gallego-Pinazo R, Yannuzzi N, et al. Long-term visual outcomes for a treat and extend anti-vascular endothelial growth factor regimen in eyes with neovascular age-related macular degeneration. J Clin Med. 2015;4:1380&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pmc">4519796</ArticleId><ArticleId IdType="doi">10.3390/jcm4071380</ArticleId><ArticleId IdType="pubmed">26239682</ArticleId></ArticleIdList></Reference><Reference><Citation>Kar SS, Cetin H, Lunasco L, Le TK, Zahid R, Meng X, et al. OCT-derived radiomic features predict anti&#x2013;VEGF response and durability in neovascular age-related macular degeneration. Ophthalmol Sci. 2022;2:100171. https://doi.org/10.1016/j.xops.2022.100171 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xops.2022.100171</ArticleId><ArticleId IdType="pmc">9754979</ArticleId><ArticleId IdType="pubmed">36531588</ArticleId></ArticleIdList></Reference><Reference><Citation>Pugazhendhi A, Hubbell M, Jairam P, Ambati B. Neovascular macular degeneration: a review of etiology, risk factors, and recent advances in research and therapy. Int J Mol Sci. 2021;22:1&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22031170</ArticleId></ArticleIdList></Reference><Reference><Citation>Monje-Fern&#xe1;ndez L, Gallego-Pinazo R, Cordero-Coma M, Donate-L&#xf3;pez J, Coco-Mart&#xed;n RM, Dolz-Marco R. Evaluation of non-exudative tomographic signs in cases of exudative age-related macular degeneration. Arch Soc Esp Oftalmol. 2023;98:276&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">37037324</ArticleId></ArticleIdList></Reference><Reference><Citation>Zatreanu L, Freund K, Leong B, Yu H, Teke M, Yzer S, et al. Serous macular detachment in Best disease: a Masquerade Syndrome. Retina. 2020;40:1456&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IAE.0000000000002659</ArticleId><ArticleId IdType="pubmed">31613838</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacconi R, Fragiotta S, Sarraf D, Sadda SVR, Freund KB, Parravano M, et al. Towards a better understanding of non-exudative choroidal and macular neovascularization. Prog Retin Eye Res. 2023;92:101113. https://doi.org/10.1016/j.preteyeres.2022.101113 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2022.101113</ArticleId><ArticleId IdType="pubmed">35970724</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirabayashi K, Yu H, Wakatsuki Y, Marion K, Wykoff CC, Sadda S. OCT risk factors for development of atrophy in eyes with intermediate age-related macular degeneration. Ophthalmol Retin. 2023;7:253&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oret.2022.09.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricardi F, Borrelli E, Boscia G, Gelormini F, Marica V, Conte F, et al. Relationship of topographic distribution of macular atrophy secondary to neovascular AMD and reading performance. Invest Ophthalmol Vis Sci. 2024;65:44.</Citation><ArticleIdList><ArticleId IdType="pmc">10833051</ArticleId><ArticleId IdType="doi">10.1167/iovs.65.1.44</ArticleId><ArticleId IdType="pubmed">38289615</ArticleId></ArticleIdList></Reference><Reference><Citation>Querques G, Coscas F, Forte R, Massamba N, Sterkers M, Souied EH. Cystoid macular degeneration in exudative age-related macular degeneration. Am J Ophthalmol. 2011;152:100&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2011.01.027</ArticleId><ArticleId IdType="pubmed">21570056</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen SY, Dubois L, Nghiem-Buffet S, Ayrault S, Fajnkuchen F, Guiberteau B, et al. Retinal pseudocysts in age-related geographic atrophy. Am J Ophthalmol. 2010;150:211&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2010.02.019</ArticleId><ArticleId IdType="pubmed">20537310</ArticleId></ArticleIdList></Reference><Reference><Citation>Servillo A, Kesim C, Sacconi R, Battist M, Capuano V, Fragiotta S, et al. Non-exudative intraretinal fluid in intermediate age-related macular degeneration. Retina. 2024. https://doi.org/10.1097/IAE.0000000000004054 .</Citation></Reference><Reference><Citation>Berlin A, Messinger JD, Balaratnasingam C, Mendis R, Ferrara D, Freund KB, et al. Imaging histology correlations of intraretinal fluid in neovascular age-related macular degeneration. Transl Vis Sci Technol. 2023;12:1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/tvst.12.11.13</ArticleId></ArticleIdList></Reference><Reference><Citation>Fragiotta S, Abdolrahimzadeh S, Dolz-Marco R, Sakurada Y, Gal-Or O, Scuderi G. Significance of hyperreflective foci as an optical coherence tomography biomarker in retinal diseases: characterization and clinical implications. J Ophthalmol. 2021;2021:6096017.</Citation><ArticleIdList><ArticleId IdType="pmc">8709761</ArticleId><ArticleId IdType="doi">10.1155/2021/6096017</ArticleId><ArticleId IdType="pubmed">34956669</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao D, Leong B, Messinger JD, Kar D, Ach T, Yannuzzi LA, et al. Hyperreflective foci, optical coherence tomography progression indicators in age-related macular degeneration, include transdifferentiated retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2021;62:34.</Citation><ArticleIdList><ArticleId IdType="pmc">8399556</ArticleId><ArticleId IdType="doi">10.1167/iovs.62.10.34</ArticleId><ArticleId IdType="pubmed">34448806</ArticleId></ArticleIdList></Reference><Reference><Citation>Goh KL, Wintergerst MWM, Abbott CJ, Hadoux X, Jannaud M, Kumar H, et al. Hyperreflective foci not seen as hyperpigmentary abnormalities on color fundus photographs in age-related macular degeneration. Retina. 2024;44:214&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">37831941</ArticleId></ArticleIdList></Reference><Reference><Citation>Duic C, Pfau K, Keenan T, Wiley H, Thavikulwat A, Chew E, et al. Hyperreflective foci in age-related macular degeneration are associated with disease severity and functional impairment. Ophthalmol Retin. 2023;7:307&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oret.2022.11.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Balaratnasingam C, Messinger JD, Sloan KR, Yannuzzi LA, Freund KB, Curcio CA. Histologic and optical coherence tomographic correlates in drusenoid pigment epithelium detachment in age-related macular degeneration. Ophthalmology. 2017;124:644&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2016.12.034</ArticleId><ArticleId IdType="pubmed">28153442</ArticleId></ArticleIdList></Reference><Reference><Citation>Bousquet E, Santina A, Corradetti G, Sacconi R, Ramtohul P, Bijon J, et al. From drusen to type 3 macular neovascularization. Retina. 2024;44:189&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">37756671</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacconi R, Sarraf D, Garrity S, Freund K, Yanuzzi L, Gal-Or O, et al. Nascent type 3 neovascularization in age-related macular degeneration. Ophthalmol Retina. 2018;2:1097&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oret.2018.04.016</ArticleId><ArticleId IdType="pubmed">31047548</ArticleId></ArticleIdList></Reference><Reference><Citation>Segal O, Barayev E, Nemet AY, Geffen N, Vainer I, Mimouni M. Prognostic value of hyperreflective foci in neovascular age-related macular degeneration treated with Bevacizumab. Retina. 2016;36:2175&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IAE.0000000000001033</ArticleId><ArticleId IdType="pubmed">27078799</ArticleId></ArticleIdList></Reference><Reference><Citation>Moraes G, Fu DJ, Wilson M, Khalid H, Wagner SK, Korot E, et al. Quantitative analysis of OCT for neovascular age-related macular degeneration using deep learning. Ophthalmology. 2021;128:693&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2020.09.025</ArticleId><ArticleId IdType="pubmed">32980396</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg NR, Greenberg JP, Laud K, Tsang S, Freund KB. Outer retinal tubulation in degenerative retinal disorders. Retina. 2013;33:1871&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">4291318</ArticleId><ArticleId IdType="doi">10.1097/IAE.0b013e318296b12f</ArticleId><ArticleId IdType="pubmed">23676993</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrigo A, Aragona E, Battaglia O, Saladino A, Amato A, Borghesan F, et al. Outer retinal tubulation formation and clinical course of advanced age-related macular degeneration. Sci Rep. 2021;11:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-94310-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Janse Van Rensburg E, Ryu CL, Rampakakis E, Vila N, Chan EW, Chen JC. Outer retinal tubulation may result from fibrosed type 2 neovascularization: clinical observations and model of pathogenesis. Retina. 2021;41:1930&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">8384246</ArticleId><ArticleId IdType="doi">10.1097/IAE.0000000000003127</ArticleId><ArticleId IdType="pubmed">33492078</ArticleId></ArticleIdList></Reference><Reference><Citation>Zweifel S, Engelbert M, Laud K, Margolis R, Spaide R, Freund KB. Outer retinal tubulation: a novel optical coherence tomography finding. Arch Opthalmol. 2009;127:1596&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archophthalmol.2009.326</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaal KB, Freund KB, Litts KM, Zhang Y, Messinger JD, Curcio CA. Outer retinal tubulation in advanced age-related macular degeneration optical coherence tomographic findings correspond to histology. Retina. 2015;35:1339&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">4478232</ArticleId><ArticleId IdType="doi">10.1097/IAE.0000000000000471</ArticleId><ArticleId IdType="pubmed">25635579</ArticleId></ArticleIdList></Reference><Reference><Citation>Litts KM, Ach T, Hammack KM, Sloan KR, Zhang Y, Freund KB, et al. Quantitative analysis of outer retinal tubulation in age-related macular degeneration from spectral-domain optical coherence tomography and histology. Invest Ophthalmol Vis Sci. 2016;57:2647&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">4868096</ArticleId><ArticleId IdType="doi">10.1167/iovs.16-19262</ArticleId><ArticleId IdType="pubmed">27177321</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolff B, Matet A, Vasseur V, Sahel JA, Mauget-Fa&#xff;sse M. En face OCT imaging for the diagnosis of outer retinal tubulations in age-related macular degeneration. J Ophthalmol. 2012;2012:542417. https://doi.org/10.1155/2012/542417 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/542417</ArticleId><ArticleId IdType="pmc">3437289</ArticleId><ArticleId IdType="pubmed">22970349</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolz-Marco R, Litts KM, Tan ACS, Freund KB, Curcio CA. The evolution of outer retinal tubulation, a neurodegeneration and gliosis prominent in macular diseases. Ophthalmology. 2017;124:1353&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2017.03.043</ArticleId><ArticleId IdType="pubmed">28456420</ArticleId></ArticleIdList></Reference><Reference><Citation>Iaculli C, Barone A, Scudieri M, Palumbo MG, Noci ND. Outer retinal tubulation: characteristics in patients with neovascular age-related macular degeneration. Retina. 2015;35:1979&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IAE.0000000000000609</ArticleId><ArticleId IdType="pubmed">26079476</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs A, Kiss T, Rarosi F, Somfai GM, Facsko A, Degi R. The effect of ranibizumab and aflibercept treatment on the prevalence of outer retinal tubulation and its influence on retreatment in neovascular age-related macular degeneration. BMC Ophthalmol. 2018;18:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12886-018-0960-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah VP, Shah SA, Mrejen S, Freund KB. Subretinal hyperreflective exudation associated with neovascular age-related macular degeneration. Retina. 2014;34:1281&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IAE.0000000000000166</ArticleId><ArticleId IdType="pubmed">24695062</ArticleId></ArticleIdList></Reference><Reference><Citation>Montol&#xed;o-Marzo S, Gallego-Pinazo R, Palacios-Pozo E, Dolz-Marco R. Advantages of optical coherence tomography as a high dynamic range imaging modality in subretinal hyperreflective material. Retina. 2023;43:641&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IAE.0000000000003705</ArticleId><ArticleId IdType="pubmed">36729623</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar JB, Stinnett S, Han JIL, Jaffe GJ. Correlation of subretinal hyperreflective material morphology and visual acuity in neovascular age-related macular degeneration. Retina. 2020;40:845&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IAE.0000000000002552</ArticleId><ArticleId IdType="pubmed">31305505</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawashima Y, Hata M, Oishi A, Ooto S, Yamashiro K, Tamura H, et al. Association of vascular versus avascular subretinal hyperreflective material with aflibercept response in age-related macular degeneration. Am J Ophthalmol. 2017;181:61&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2017.06.015</ArticleId><ArticleId IdType="pubmed">28669776</ArticleId></ArticleIdList></Reference><Reference><Citation>Dansingani KK, Tan ACS, Gilani F, Phasukkijwatana N, Novais E, Querques L, et al. Subretinal hyperreflective material imaged with optical coherence tomography angiography. Am J Ophthalmol. 2016;169:235&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2016.06.031</ArticleId><ArticleId IdType="pubmed">27349411</ArticleId></ArticleIdList></Reference><Reference><Citation>Willoughby AS, Ying GS, Toth CA, Maguire MG, Burns RE, Grunwald JE, et al. Subretinal hyperreflective material in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2015;122:1846&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2015.05.042</ArticleId><ArticleId IdType="pubmed">26143666</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolz-Marco R, Phasukkijwatana N, Sarraf D, Freund KB. Regression of type 2 neovascularization into a type 1 pattern after intravitreal anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration. Retina. 2017;37:222&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IAE.0000000000001279</ArticleId><ArticleId IdType="pubmed">27627752</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacconi R, Mullins RF, Lutty GA, Borrelli E, Bandello F, Querques G. Subretinal pseudocyst: a novel optical coherence tomography finding in age-related macular degeneration. Eur J Ophthalmol. 2020;30:NP24&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1120672119846437</ArticleId><ArticleId IdType="pubmed">31018677</ArticleId></ArticleIdList></Reference><Reference><Citation>Menean M, Sacconi R, Vujosevic S, Kesim C, Quarta A, Ribarich N, et al. Subretinal pseudocysts: a comprehensive analysis of this novel OCT finding. Ophthalmol Ther. 2023;12:2035&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">10287866</ArticleId><ArticleId IdType="doi">10.1007/s40123-023-00727-8</ArticleId><ArticleId IdType="pubmed">37198519</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Avellaneda P, Freund KB, Wang RK, He Q, Zhang Q, Fragiotta S, et al. Multimodal imaging features and clinical relevance of subretinal lipid globules. Am J Ophthalmol. 2021;222:112&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2020.09.003</ArticleId><ArticleId IdType="pubmed">32918902</ArticleId></ArticleIdList></Reference><Reference><Citation>Mon&#xe9;s J, Biarn&#xe9;s M, Trindade F. Hyporeflective wedge-shaped band in geographic atrophy secondary to age-related macular degeneration: an underreported finding. Ophthalmology. 2012;119:1412&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2012.01.026</ArticleId><ArticleId IdType="pubmed">22440276</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacconi R, Sarraf D, Sadda S, Freund K, Servillo A, Fogel Levin M, et al. Nascent geographic atrophy as a predictor of type 3 macular neovascularization development. Ophthalmol Retin. 2023;7:586&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oret.2023.01.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Dolz-Marco R, Huisingh C, Messinger JD, Feist RM, Ferrara D, et al. Clinicopathologic correlation of geographic atrophy secondary to age-related macular degeneration. Retina. 2019;39:802&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">6445604</ArticleId><ArticleId IdType="doi">10.1097/IAE.0000000000002461</ArticleId><ArticleId IdType="pubmed">30839495</ArticleId></ArticleIdList></Reference><Reference><Citation>Capuano GQ, Frascio V, Zweifel P, Georges S, Souied A. E. Wedge-shaped subretinal hyporeflectivity in geographic atrophy. Retina. 2015;35:1735&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IAE.0000000000000553</ArticleId><ArticleId IdType="pubmed">25923956</ArticleId></ArticleIdList></Reference><Reference><Citation>Fragiotta S, Parravano M, Sacconi R, Costanzo E, Viggiano P, Prascina F, et al. A common finding in foveal-sparing extensive macular atrophy with pseudodrusen implicated basal laminar deposits. Retina. 2022;42:1319&#x2013;29.</Citation></Reference><Reference><Citation>Tan ACS, Astroz P, Dansingani KK, Slakter JS, Yannuzzi LA, Curcio CA, et al. The evolution of the plateau, an optical coherence tomography signature seen in geographic atrophy. Invest Ophthalmol Vis Sci. 2017;58:2349&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">5413303</ArticleId><ArticleId IdType="doi">10.1167/iovs.16-21237</ArticleId><ArticleId IdType="pubmed">28437524</ArticleId></ArticleIdList></Reference><Reference><Citation>Querques G, Costanzo E, Miere A, Capuano V, Souied EH. Choroidal caverns: a novel optical coherence tomography finding in geographic atrophy. Invest Ophthalmol Vis Sci. 2016;57:2578&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">4868100</ArticleId><ArticleId IdType="doi">10.1167/iovs.16-19083</ArticleId><ArticleId IdType="pubmed">27163770</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolz-Marco R, Glover JP, Gal-Or O, Litts KM, Messinger JD, Zhang Y, et al. Choroidal and sub-retinal pigment epithelium caverns: multimodal imaging and correspondence with friedman lipid globules. Ophthalmology. 2018;125:1287&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2018.02.036</ArticleId><ArticleId IdType="pubmed">29625839</ArticleId></ArticleIdList></Reference><Reference><Citation>Fragiotta S, Parravano M, Costanzo E, De Geronimo D, Varano M, Fernandez-Avellaneda P, et al. Subretinal lipid globules an early biomarker of macular neovascularization in eyes with intermediate age-related macular degeneration. Retina. 2023;44:913&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IAE.0000000000003760</ArticleId></ArticleIdList></Reference><Reference><Citation>Querques G, Srour M, Massamba N, Georges A, Ben Moussa N, Rafaeli O, et al. Functional characterization and multimodal imaging of treatment-naive &#x201c;quiescent&#x201d; choroidal neovascularization. Invest Ophthalmol Vis Sci. 2013;54:6886&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.13-11665</ArticleId><ArticleId IdType="pubmed">24084095</ArticleId></ArticleIdList></Reference><Reference><Citation>Narita C, Wu Z, Rosenfeld PJ, Yang J, Lyu C, Caruso E, et al. Structural OCT signs suggestive of subclinical nonexudative macular neovascularization in eyes with large drusen. Ophthalmology. 2020;127:637&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2019.11.007</ArticleId><ArticleId IdType="pubmed">31899036</ArticleId></ArticleIdList></Reference><Reference><Citation>de Oliveira Dias JR, Zhang Q, Garcia JMB, Zheng F, Motulsky EH, Roisman L, et al. Natural history of subclinical neovascularization in nonexudative age-related macular degeneration using swept-source OCT angiography. Ophthalmology. 2018;125:255&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2017.08.030</ArticleId><ArticleId IdType="pubmed">28964581</ArticleId></ArticleIdList></Reference><Reference><Citation>Csincsik L, Muldrew KA, Bettiol A, Wright DM, Rosenfeld PJ, Waheed NK, et al. The double layer sign is highly predictive of progression to exudation in age-related macular degeneration. Ophthalmol Retina. 2024;8:234&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oret.2023.10.006</ArticleId><ArticleId IdType="pubmed">37839548</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Sun J, Wu J, Jia H, Feng J, Chen J, et al. Growth of nonexudative macular neovascularization in age-related macular degeneration: an indicator of biological lesion activity. Eye. 2023;37:2048&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41433-022-02282-1</ArticleId><ArticleId IdType="pubmed">36434285</ArticleId></ArticleIdList></Reference><Reference><Citation>Carnevali A, Cicinelli MV, Capuano V, Corvi F, Mazzaferro A, Querques L, et al. Optical coherence tomography angiography: a useful tool for diagnosis of treatment-na&#xef;ve quiescent choroidal neovascularization. Am J Ophthalmol. 2016;169:189&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2016.06.042</ArticleId><ArticleId IdType="pubmed">27394033</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahimy E, Freund KB, Larsen M, Spaide RF, Costa RA, Hoang Q, et al. Multilayered pigment epithelial detachment in neovascular age-related macular degeneration. Retina. 2014;34:1289&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IAE.0000000000000130</ArticleId><ArticleId IdType="pubmed">24675391</ArticleId></ArticleIdList></Reference><Reference><Citation>Soman M, Sheth JU, Indurkar A, Meleth P, Nair U. De-novo multilayering in fibrovascular pigment epithelial detachment. Sci Rep. 2021;11:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-96746-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukai R, Sato T, Kishi S A. hyporeflective space between hyperreflective materials in pigment epithelial detachment and Bruch&#x2019;s membrane in neovascular age-related macular degeneration. BMC Ophthalmol. 2014;14:159.</Citation></Reference><Reference><Citation>Kredi G, Iglicki M, Gomel N, Hilely A, Loewenstein A, Habot-Wilner Z, et al. Risk factors and clinical significance of prechoroidal cleft in eyes with neovascular age-related macular degeneration in Caucasian patients. Acta Ophthalmol. 2023;101:e338&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aos.15273</ArticleId><ArticleId IdType="pubmed">36259092</ArticleId></ArticleIdList></Reference><Reference><Citation>Pece A, Borrelli E, Sacconi R, Maione G, Bandello F, Querques G. Choroidal cleft simulating choroidal caverns in neovascular age-related macular degeneration. Eur J Ophthalmol. 2019;29:471&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1120672119855540</ArticleId><ArticleId IdType="pubmed">31353948</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Kang S, Son D, Bae K. Risk factors and clinical significance of prechoroidal cleft in neovascular age-related macular degeneration. Retina. 2017;37:2047&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IAE.0000000000001435</ArticleId><ArticleId IdType="pubmed">28114175</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Kim J, Kim C, Lee D. Long-term course and visual outcomes of prechoroidal cleft in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Retina. 2021;41:2436&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IAE.0000000000003242</ArticleId><ArticleId IdType="pubmed">34173365</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Kim KT, Kim DY, Chae JB, Seo EJ. Outer nuclear layer recovery as a predictor of visual prognosis in type 1 choroidal neovascularization of neovascular age-related macular degeneration. Sci Rep. 2023;13:1&#x2013;10.</Citation></Reference><Reference><Citation>Pfau M, von der Emde L, de Sisternes L, Hallak J, Leng T, Schmitz-Valckenberg S, et al. Progression of photoreceptor degeneration in geographic atrophy secondary to age-related macular degeneration. JAMA Ophthalmol. 2020;138:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">7582226</ArticleId><ArticleId IdType="doi">10.1001/jamaophthalmol.2020.2914</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheong KX, Li H, Tham YC, Teo KYC, Tan ACS, Schmetterer L, et al. Relationship between retinal layer thickness and genetic susceptibility to age-related macular degeneration in Asian populations. Ophthalmol Sci. 2023;3:100396.</Citation><ArticleIdList><ArticleId IdType="pmc">10630670</ArticleId><ArticleId IdType="doi">10.1016/j.xops.2023.100396</ArticleId><ArticleId IdType="pubmed">38025159</ArticleId></ArticleIdList></Reference><Reference><Citation>Zekavat SM, Sekimitsu S, Ye Y, Raghu V, Zhao H, Elze T, et al. Photoreceptor layer thinning is an early biomarker for age-related macular degeneration: epidemiologic and genetic evidence from UK Biobank OCT Data. Ophthalmology. 2022;129:694&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2022.02.001</ArticleId><ArticleId IdType="pubmed">35149155</ArticleId></ArticleIdList></Reference><Reference><Citation>Farinha C, Silva AL, Coimbra R, Nunes S, Cachulo ML, Marques JP, et al. Retinal layer thicknesses and neurodegeneration in early age-related macular degeneration: insights from the Coimbra Eye Study. Graefes Arch Clin Exp Ophthalmol. 2021;259:2545&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00417-021-05140-0</ArticleId><ArticleId IdType="pubmed">33738626</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandl C, Br&#xfc;cklmayer C, G&#xfc;nther F, Zimmermann ME, K&#xfc;chenhoff H, Helbig H, et al. Retinal layer thicknesses in early age-related macular degeneration: results from the German AugUR study. Invest Ophthalmol Vis Sci. 2019;60:1581&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">6892378</ArticleId><ArticleId IdType="doi">10.1167/iovs.18-25332</ArticleId><ArticleId IdType="pubmed">30995315</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucchiatti I, Parodi MB, Pierro L, Cicinelli MV, Gagliardi M, Castellino N, et al. Macular ganglion cell complex and retinal nerve fiber layer comparison in different stages of age-related macular degeneration. Am J Ophthalmol. 2015;160:602&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2015.05.030</ArticleId><ArticleId IdType="pubmed">26052088</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SW, Sim HE, Park JY, Kim JS, Chang IB, Park YS, et al. Changes in inner retinal layer thickness in patients with exudative age-related macular degeneration during treatment with anti-vascular endothelial growth factor. Medicine. 2020;99:E19955.</Citation><ArticleIdList><ArticleId IdType="pmc">7220743</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000019955</ArticleId><ArticleId IdType="pubmed">32332680</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadda SR, Guymer R, Holz FG, Schmitz-Valckenberg S, Curcio CA, Bird AC, et al. Consensus definition for atrophy associated with age-related macular degeneration on OCT: classification of atrophy report 3. Ophthalmology. 2018;125:537&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2017.09.028</ArticleId><ArticleId IdType="pubmed">29103793</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitamura Y, Mitamura-Aizawa S, Katome T, Naito T, Hagiwara A, Kumagai K, et al. Photoreceptor impairment and restoration on optical coherence tomographic image. J Ophthalmol. 2013;2013:518170.</Citation><ArticleIdList><ArticleId IdType="pmc">3649344</ArticleId><ArticleId IdType="doi">10.1155/2013/518170</ArticleId><ArticleId IdType="pubmed">23691278</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadda SVR, Abdelfattah NS, Lei J, Shi Y, Marion KM, Morgenthien E, et al. Spectral-domain OCT analysis of risk factors for macular atrophy development in the HARBOR study for neovascular age-related macular degeneration. Ophthalmology. 2020;127:1360&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2020.03.031</ArticleId><ArticleId IdType="pubmed">32402555</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindner M, Bezatis A, Czauderna J, Becker E, Brinkmann CK, Schmitz-Valckenberg S, et al. Choroidal thickness in geographic atrophy secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci. 2015;56:875&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.14-14933</ArticleId><ArticleId IdType="pubmed">25587059</ArticleId></ArticleIdList></Reference><Reference><Citation>Foss A, Rotsos T, Empeslidis T, Chong V. Development of macular atrophy in patients with wet age-related macular degeneration receiving anti-VEGF treatment. Ophthalmologica. 2022;245:204&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000520171</ArticleId><ArticleId IdType="pubmed">34695835</ArticleId></ArticleIdList></Reference><Reference><Citation>Siedlecki J, Fischer C, Schworm B, Kreutzer TC, Luft N, Kortuem KU, et al. Impact of sub-retinal fluid on the long-term incidence of macular atrophy in neovascular age-related macular degeneration under treat &amp; extend anti-vascular endothelial growth factor inhibitors. Sci Rep. 2020;10:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-64901-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Toth CA, Tai V, Pistilli M, Chiu SJ, Winter KP, Daniel E, et al. Distribution of OCT features within areas of macular atrophy or scar after 2 years of anti-VEGF treatment for neovascular AMD in CATT. Ophthalmol Retin. 2019;3:316&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oret.2018.11.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Eshtiaghi A, Issa M, Popovic M, Muni R, Kertes P. Geographic atrophy incidence and progression after intravitreal injections of anti-vascular endothelial growth factor agents for age-related macular degeneration: a meta-analysis. Retina. 2021;41:2424&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IAE.0000000000003207</ArticleId><ArticleId IdType="pubmed">34101693</ArticleId></ArticleIdList></Reference><Reference><Citation>Christakis PG, Agr&#xf3;n E, Klein ML, Clemons TE, Campbell JP, Ferris FL, et al. Incidence of macular atrophy after untreated neovascular age-related macular degeneration: age-related eye disease study report 40. Ophthalmology. 2020;127:784&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2019.11.016</ArticleId><ArticleId IdType="pubmed">31899035</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhisitkul RB, Mendes TS, Rofagha S, Enanoria W, Boyer DS, Sadda SVR, et al. Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: The SEVEN-UP study. Am J Ophthalmol. 2015;159:915&#x2013;24.e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2015.01.032</ArticleId><ArticleId IdType="pubmed">25640411</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2012.03.053</ArticleId><ArticleId IdType="pubmed">22555112</ArticleId></ArticleIdList></Reference><Reference><Citation>Gune S, Abdelfattah NS, Karamat A, Balasubramanian S, Marion KM, Morgenthien E, et al. Spectral-domain OCT&#x2013;based prevalence and progression of macular atrophy in the HARBOR study for neovascular age-related macular degeneration. Ophthalmology. 2020;127:523&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2019.09.030</ArticleId><ArticleId IdType="pubmed">31718842</ArticleId></ArticleIdList></Reference><Reference><Citation>Querques G, Capuano V, Costanzo E, Corvi F, Querques L, Introini U, et al. Retinal pigment epithelium aperture: A previously unreported finding in the evolution of avascular pigment epithelium detachment. Retina. 2016;36:S65&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IAE.0000000000001231</ArticleId><ArticleId IdType="pubmed">28005664</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakaki-Zimmermann H, Querques G, Munch IC, Shroff D, Sarraf D, Chen X, et al. Atypical retinal pigment epithelial defects with retained photoreceptor layers: a so far disregarded finding in age related macular degeneration. BMC Ophthalmol. 2017;17:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12886-017-0452-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Molina-Pallete R, Andreu-Fenoll M, Gallego-Pinazo R, Dolz-Marco R. Atypical healing in a case with retinal pigment epithelium apertures. Retin Cases Brief Rep. 2021;15:294&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ICB.0000000000000789</ArticleId><ArticleId IdType="pubmed">30015776</ArticleId></ArticleIdList></Reference><Reference><Citation>Girgis J, Liu Y, Liang M, Baumal C, Duker J, Waheed N. Retinal pigment epithelium aperture preceding collapse of vascular and avascular pigment epithelial detachments secondary to AMD. Retin Cases Brief Rep. 2023. https://doi.org/10.1097/ICB.0000000000001435 .</Citation></Reference><Reference><Citation>Ersoz MG, Karacorlu M, Arf S, Sayman Muslubas I, Hocaoglu M. Retinal pigment epithelium tears: classification, pathogenesis, predictors, and management. Surv Ophthalmol. 2017;62:493&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.survophthal.2017.03.004</ArticleId><ArticleId IdType="pubmed">28336128</ArticleId></ArticleIdList></Reference><Reference><Citation>Iovino C, Chhablani J, Parameswarappa DC, Pellegrini M, Giannaccare G, Peiretti E. Retinal pigment epithelium apertures as a late complication of longstanding serous pigment epithelium detachments in chronic central serous chorioretinopathy. Eye. 2019;33:1871&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">7002443</ArticleId><ArticleId IdType="doi">10.1038/s41433-019-0505-0</ArticleId><ArticleId IdType="pubmed">31267093</ArticleId></ArticleIdList></Reference><Reference><Citation>Clemens CR, Alten F, Eter N. Reading the signs: microrips as a prognostic sign for impending RPE tear development. Acta Ophthalmol. 2015;93:e600&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aos.12683</ArticleId><ArticleId IdType="pubmed">25752471</ArticleId></ArticleIdList></Reference><Reference><Citation>Fragiotta S, Scuderi L, Iodice CM, Rullo D, Di Pippo M, Maugliani E, et al. Choroidal vasculature changes in age-related macular degeneration: from a molecular to a clinical perspective. Int J Mol Sci. 2022;23:12010.</Citation><ArticleIdList><ArticleId IdType="pmc">9570412</ArticleId><ArticleId IdType="doi">10.3390/ijms231912010</ArticleId><ArticleId IdType="pubmed">36233311</ArticleId></ArticleIdList></Reference><Reference><Citation>Invernizzi A, Benatti E, Cozzi M, Erba S, Vaishnavi S, Vupparaboina KK, et al. Choroidal structural changes correlate with neovascular activity in neovascular age related macular degeneration. Invest Ophthalmol Vis Sci. 2018;59:3836&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.18-23960</ArticleId><ArticleId IdType="pubmed">30073357</ArticleId></ArticleIdList></Reference><Reference><Citation>Borrelli E, Souied EH, Bailey Freund K, Querques G, Miere A, Gal-Or O, et al. Reduced choriocapillaris flow in eyes with type 3 neovascularization and age-related macular degeneration. Retina. 2018;38:1968&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IAE.0000000000002198</ArticleId><ArticleId IdType="pubmed">29746411</ArticleId></ArticleIdList></Reference><Reference><Citation>Salehi MA, Mohammadi S, Gouravani M, Rezagholi F, Arevalo JF. Retinal and choroidal changes in AMD: a systematic review and meta-analysis of spectral-domain optical coherence tomography studies. Surv Ophthalmol. 2023;68:54&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.survophthal.2022.07.006</ArticleId><ArticleId IdType="pubmed">35908660</ArticleId></ArticleIdList></Reference><Reference><Citation>Ting DSW, Ng WY, Ng SR, Tan SP, Yeo IYS, Mathur R, et al. Choroidal thickness changes in age-related macular degeneration and polypoidal choroidal vasculopathy: a 12-month prospective study. Am J Ophthalmol. 2016;164:128&#x2013;36.e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2015.12.024</ArticleId><ArticleId IdType="pubmed">26743619</ArticleId></ArticleIdList></Reference><Reference><Citation>Boscia G, Pozharitskiy N, Grassi MO, Borrelli E, D&#x2019;Addario M, Alessio G, et al. Choroidal remodeling following different anti-VEGF therapies in neovascular AMD. Sci Rep. 2024;14:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-52315-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Scharf JM, Corradetti G, Alagorie AR, Grondin C, Hilely A, Wang D, et al. Choriocapillaris flow deficits and treatment-na&#xef;ve macular neovascularization secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci. 2020;61:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.61.11.11</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39586847</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1435-702X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>25</Day></PubDate></JournalIssue><Title>Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie</Title><ISOAbbreviation>Graefes Arch Clin Exp Ophthalmol</ISOAbbreviation></Journal><ArticleTitle>Real-world therapy and persistence of patients with neovascular age-related macular degeneration and diabetic retinopathy or diabetic macular edema: a German claims data analysis.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00417-024-06690-9</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Vascular endothelial growth factor (VEGF) inhibition is the current and high-volume standard-of-care for patients with neovascular age-related macular degeneration (nAMD) and diabetic retinopathy (DR) with diabetic macular edema (DME). This study assessed the impact of non-persistence in anti-VEGF treatment using claims data from two German states.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study identified adults with nAMD or DR/DME and incident anti-VEGF treatment (=&#x2009;index) in January 2015-June 2019 using the German AOK PLUS claims database (January 2014-June 2021,&#x2009;~&#x2009;3.5 million insured). Baseline characteristics were observed within 12&#xa0;months before index. Patient follow-up lasted&#x2009;&#x2265;&#x2009;24&#xa0;months or until death. Non-persistence (gap of&#x2009;&#x2265;&#x2009;180&#xa0;days) was calculated using Kaplan-Meier estimation. Cox regression identified variables linked to non- persistence. The study analysed reimbursed anti-VEGF treatments, thus excluding off-label use of bevacizumab.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">5,498 patients diagnosed with nAMD (mean age, 80.09&#xa0;years; male, 37.50%; mean Charlson Comorbidity Index [CCI] score, 3.07) and 484 patients with DR/DME (mean age, 67.14; male, 58.88%; mean CCI score, 4.54) were identified. Non-persistence to anti-VEGF treatment within 12&#xa0;months after index occurred in 51.38% of nAMD patients and 62.60% of DR/DME patients, with mean times to first gap of 11.28 and 8.98&#xa0;months, respectively. Cox regression revealed factors associated with non-persistence, including higher age, female gender, higher care needs, longer AMD history, and the use of ranibizumab.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Epidemiologic and ophthalmologic factors associated with anti-VEGF non-persistence were successfully identified in the first year of therapy. The analyzed dataset can potentially be enriched with additional health insurance database sets under the used criteria to gain more understanding of anti-VEGF non-persistence.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krieger</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cytel Inc., Potsdamer Stra&#xdf;e 58, 10785, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cox</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-2308-7837</Identifier><AffiliationInfo><Affiliation>F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070, Basel, Switzerland. oliver.cox@roche.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flacke</LastName><ForeName>Jan-Paul</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Roche Pharma AG, Emil-Barell-Stra&#xdf;e 1, 79639, Grenzach-Wyhlen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beilschmidt</LastName><ForeName>Lena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Roche Pharma AG, Emil-Barell-Stra&#xdf;e 1, 79639, Grenzach-Wyhlen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mueller</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>IPAM E.V., Alter Holzhafen 19, 23966, Wismar, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maywald</LastName><ForeName>Ulf</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Payers GmbH, Heilwigstra&#xdf;e 34, 20249, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koss</LastName><ForeName>Michael Janusz</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Eye Center Nymphenburger H&#xf6;fe, Augenklinik Herzog Carl Theodor, Nymphenburger Str. 4, 80335, Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Graefes Arch Clin Exp Ophthalmol</MedlineTA><NlmUniqueID>8205248</NlmUniqueID><ISSNLinking>0721-832X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adherence</Keyword><Keyword MajorTopicYN="N">Administrative data</Keyword><Keyword MajorTopicYN="N">Anti-vascular endothelial growth factor</Keyword><Keyword MajorTopicYN="N">Diabetic retinopathy</Keyword><Keyword MajorTopicYN="N">Neovascular age-related macular degeneration</Keyword><Keyword MajorTopicYN="N">Persistence</Keyword></KeywordList><CoiStatement>Declarations. Ethical approval: Due to the non-interventional, retrospective nature of the analyzed data and because our analysis involved an anonymized dataset, neither ethical review nor informed consent of the patients was required according to German national legislation (&#xa7; 75 SGB X). As the responsible authority, the involved sickness fund (AOK PLUS) approved the use of the data for the purpose of this study. Conflict of interest: Oliver Cox, Jan-Paule Flacke, and Lena Beilschmidt are employees of Roche. Julia Krieger was an employee of Cytel. Sabrina Mueller is an employee of IPAM. Cytel and IPAM work was financially supported by Roche. Ulf Maywald has no potential conflict of interest, except those potentially related to his employer, AOK PLUS. Michael Janusz Koss is an employee of the Augenklinik Herzog Carl Theodor and has declared no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>0</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>0</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>25</Day><Hour>23</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39586847</ArticleId><ArticleId IdType="doi">10.1007/s00417-024-06690-9</ArticleId><ArticleId IdType="pii">10.1007/s00417-024-06690-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ricci F, Bandello F, Navarra P, Staurenghi G, Stumpp M, Zarbin M (2020) Neovascular age-related macular degeneration: Therapeutic management and new-upcoming approaches. Int J Mol Sci 21(21):8242. https://doi.org/10.3390/ijms21218242</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21218242</ArticleId><ArticleId IdType="pubmed">33153227</ArticleId><ArticleId IdType="pmc">7662479</ArticleId></ArticleIdList></Reference><Reference><Citation>Gheorghe A, Mahdi L, Musat O (2015) Age-related macular degeneration. Rom J Ophthalmol 59(2):74&#x2013;77</Citation><ArticleIdList><ArticleId IdType="pubmed">26978865</ArticleId><ArticleId IdType="pmc">5712933</ArticleId></ArticleIdList></Reference><Reference><Citation>Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G et al (2020) Consensus nomenclature for reporting neovascular age-related macular degeneration data: Consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology 127(5):616&#x2013;636. https://doi.org/10.1016/j.ophtha.2019.11.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2019.11.004</ArticleId><ArticleId IdType="pubmed">31864668</ArticleId></ArticleIdList></Reference><Reference><Citation>Michels S, Schmidt-Erfurth U, Rosenfeld PJ (2006) Promising new treatments for neovascular age-related macular degeneration. Expert Opin Investig Drugs 15(7):779&#x2013;793. https://doi.org/10.1517/13543784.15.7.779</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/13543784.15.7.779</ArticleId><ArticleId IdType="pubmed">16787141</ArticleId></ArticleIdList></Reference><Reference><Citation>Stahl A (2020) The diagnosis and treatment of age-related macular degeneration. Dtsch Arztebl Int 117(29&#x2013;30):513&#x2013;520. https://doi.org/10.3238/arztebl.2020.0513</Citation><ArticleIdList><ArticleId IdType="doi">10.3238/arztebl.2020.0513</ArticleId><ArticleId IdType="pubmed">33087239</ArticleId><ArticleId IdType="pmc">7588619</ArticleId></ArticleIdList></Reference><Reference><Citation>Knauer C, Pfeiffer N (2006) Blindness in Germany&#x2013;today and in 2030. Ophthalmologe 103(9):735&#x2013;741. https://doi.org/10.1007/s00347-006-1411-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00347-006-1411-y</ArticleId><ArticleId IdType="pubmed">16924449</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster AK, Wolfram C, Pfeiffer N, Finger RP (2019) Ophthalmology 2019-where do we stand?&#x202f;: An analysis of the treatment situation in Germany. Ophthalmologe 116(9):829&#x2013;837. https://doi.org/10.1007/s00347-019-0894-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00347-019-0894-2</ArticleId><ArticleId IdType="pubmed">31053964</ArticleId></ArticleIdList></Reference><Reference><Citation>Browning DJ, Stewart MW, Lee C (2018) Diabetic macular edema: Evidence-based management. Indian J Ophthalmol 66(12):1736&#x2013;1750. https://doi.org/10.4103/ijo.IJO_1240_18</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijo.IJO_1240_18</ArticleId><ArticleId IdType="pubmed">30451174</ArticleId><ArticleId IdType="pmc">6256891</ArticleId></ArticleIdList></Reference><Reference><Citation>Holekamp NM (2016) Overview of diabetic macular edema. Am J Manag Care 22(10 Suppl):s284&#x2013;s291</Citation><ArticleIdList><ArticleId IdType="pubmed">27668630</ArticleId></ArticleIdList></Reference><Reference><Citation>Ting DSW, Cheung GCM, Wong TY (2016) Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clin Experiment Ophthalmol 44(4):260&#x2013;277. https://doi.org/10.1111/ceo.12696</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ceo.12696</ArticleId><ArticleId IdType="pubmed">26716602</ArticleId></ArticleIdList></Reference><Reference><Citation>Happich M, Falkenstein P, Reitberger U, Eichmann F, J C (2006) Diabetic retinopathy including macular edema in Germany: epidemiology and burden of disease</Citation></Reference><Reference><Citation>ElSheikh RH, Chauhan MZ, Sallam AB (2022) Current and novel therapeutic approaches for treatment of neovascular age-related macular degeneration. Biomolecules. 12(11):1629. https://doi.org/10.3390/biom12111629</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom12111629</ArticleId><ArticleId IdType="pubmed">36358978</ArticleId><ArticleId IdType="pmc">9688017</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan MZ, Rather PA, Samarah SM, Elhusseiny AM, Sallam AB (2022) Current and novel therapeutic approaches for treatment of diabetic macular edema. Cells 11(12):1950</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11121950</ArticleId><ArticleId IdType="pubmed">35741079</ArticleId><ArticleId IdType="pmc">9221813</ArticleId></ArticleIdList></Reference><Reference><Citation>Angermann R, Huber AL, Nowosielski Y, Salcher S, Gasser T, Seifarth C et al (2022) Changes in systemic levels of vascular endothelial growth factor after intravitreal injection of aflibercept or brolucizumab for neovascular age-related macular degeneration. Retina. 42(3):503&#x2013;510</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IAE.0000000000003344</ArticleId><ArticleId IdType="pubmed">34731094</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS et al (2017) Guidelines for the management of diabetic macular edema by the european society of retina specialists (EURETINA). Ophthalmologica 237(4):185&#x2013;222. https://doi.org/10.1159/000458539</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000458539</ArticleId><ArticleId IdType="pubmed">28423385</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R et al (2014) Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 98(9):1144&#x2013;1167. https://doi.org/10.1136/bjophthalmol-2014-305702</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjophthalmol-2014-305702</ArticleId><ArticleId IdType="pubmed">25136079</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency (EMA): Eylea (aflibercept) - An overview of Eylea and why it is authorised in the EU. https://www.ema.europa.eu/en/documents/overview/eylea-epar-medicine-overview_en.pdf . Accessed Aug 2023</Citation></Reference><Reference><Citation>European Medicines Agency (EMA): Beovu (brolucizumab) - An overview of Eylea and why it is authorised in the EU. https://www.ema.europa.eu/en/documents/overview/beovu-epar-medicine-overview_en-0.pdf . Accessed Aug 2023</Citation></Reference><Reference><Citation>European Medicines Agency (EMA): Lucentis (ranibizumab) - An overview of Lucentis and why it is authorised in the EU. https://www.ema.europa.eu/en/documents/overview/lucentis-epar-medicine-overview_en.pdf . Accessed Aug 2023</Citation></Reference><Reference><Citation>European Medicines Agency (EMA): Vabysmo (faricimab) - An overview of Vabysmo and why it is authorised in the EU. file:///C:/Users/Julia.Krieger/Downloads/vabysmo-epar-product-information_en.pdf. Accessed Nov 2023</Citation></Reference><Reference><Citation>Bro T, Derebecka M, J&#xf8;rstad &#xd8;K, Grzybowski A (2020) Off-label use of bevacizumab for wet age-related macular degeneration in Europe. Graefes Arch Clin Exp Ophthalmol 258(3):503&#x2013;511. https://doi.org/10.1007/s00417-019-04569-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00417-019-04569-8</ArticleId><ArticleId IdType="pubmed">31889214</ArticleId></ArticleIdList></Reference><Reference><Citation>Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, MaA Nasir et al (2006) Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113(10):1695&#x2013;705.e6. https://doi.org/10.1016/j.ophtha.2006.05.064</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2006.05.064</ArticleId></ArticleIdList></Reference><Reference><Citation>Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C et al (2022) Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. The Lancet 399(10326):729&#x2013;740. https://doi.org/10.1016/S0140-6736(22)00010-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00010-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD et al (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119(12):2537&#x2013;2548. https://doi.org/10.1016/j.ophtha.2012.09.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2012.09.006</ArticleId><ArticleId IdType="pubmed">23084240</ArticleId></ArticleIdList></Reference><Reference><Citation>Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM et al (2020) HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127(1):72&#x2013;84. https://doi.org/10.1016/j.ophtha.2019.04.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2019.04.017</ArticleId><ArticleId IdType="pubmed">30986442</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419&#x2013;1431. https://doi.org/10.1056/NEJMoa054481</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa054481</ArticleId><ArticleId IdType="pubmed">17021318</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlken C, Ziemssen F, Eter N, Lanzl I, Kaymak H, Lommatzsch A et al (2020) Systematic review: non-adherence and non-persistence in intravitreal treatment. Graefes Arch Clin Exp Ophthalmol 258(10):2077&#x2013;2090. https://doi.org/10.1007/s00417-020-04798-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00417-020-04798-2</ArticleId><ArticleId IdType="pubmed">32572607</ArticleId><ArticleId IdType="pmc">7550304</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahzad H, Mahmood S, McGee S, Hubbard J, Haque S, Paudyal V et al (2023) Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic review and meta-analysis. Syst Rev 12(1):92. https://doi.org/10.1186/s13643-023-02261-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13643-023-02261-x</ArticleId><ArticleId IdType="pubmed">37269003</ArticleId><ArticleId IdType="pmc">10237080</ArticleId></ArticleIdList></Reference><Reference><Citation>Wintergerst MWM, Bouws J, Loss J, Heimes B, Pauleikhoff D, Holz FG et al (2018) Reasons for delayed and discontinued therapy in age-related macular degeneration. Ophthalmologe 115(12):1035&#x2013;1041. https://doi.org/10.1007/s00347-017-0610-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00347-017-0610-z</ArticleId><ArticleId IdType="pubmed">29138977</ArticleId></ArticleIdList></Reference><Reference><Citation>Lommatzsch A, Eter N, Ehlken C, Lanzl I, Kaymak H, Schuster AK et al (2021) Adherence to anti-VEGF treatment-Considerations and practical recommendations. Ophthalmologe 118(8):801&#x2013;809. https://doi.org/10.1007/s00347-020-01273-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00347-020-01273-5</ArticleId><ArticleId IdType="pubmed">33270147</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada M, Mitchell P, Finger RP, Eldem B, Talks SJ, Hirst C et al (2021) Non-adherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review. Ophthalmology 128(2):234&#x2013;247. https://doi.org/10.1016/j.ophtha.2020.07.060</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2020.07.060</ArticleId><ArticleId IdType="pubmed">32763265</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed R, Aslani P (2014) What is patient adherence? A terminology overview. Int J Clin Pharm 36(1):4&#x2013;7. https://doi.org/10.1007/s11096-013-9856-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11096-013-9856-y</ArticleId><ArticleId IdType="pubmed">24104760</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozturk M, Harris ML, Nguyen V, Barthelmes D, Gillies MC, Mehta H (2018) Real-world visual outcomes in patients with neovascular age-related macular degeneration receiving aflibercept at fixed intervals as per UK licence. Clin Exp Ophthalmol 46(4):407&#x2013;411. https://doi.org/10.1111/ceo.13085</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ceo.13085</ArticleId><ArticleId IdType="pubmed">29044979</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlken C, Helms M, B&#xf6;hringer D, Agostini HT, Stahl A (2018) Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Clin Ophthalmol 12:13&#x2013;20. https://doi.org/10.2147/opth.S151611</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/opth.S151611</ArticleId><ArticleId IdType="pubmed">29339917</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlken C, Wilke T, Bauer-Steinhusen U, Agostini HT, Hasanbasic Z, M&#xfc;ller S (2018) Treatment of neovascular age-related macular degeneration patients with vascular endothelial growth factor inhibitors in everyday practice: Identification of health care constraints in Germany-The PONS study. Retina 38(6):1134&#x2013;1144. https://doi.org/10.1097/iae.0000000000001681</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/iae.0000000000001681</ArticleId><ArticleId IdType="pubmed">28489692</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel PJ, Devonport H, Sivaprasad S, Ross AH, Walters G, Gale RP et al (2017) Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update. Clin Ophthalmol 11(null):1957&#x2013;66. https://doi.org/10.2147/OPTH.S145732</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OPTH.S145732</ArticleId><ArticleId IdType="pubmed">29184385</ArticleId><ArticleId IdType="pmc">5685136</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Vigo JI, Contreras I, Crespo MJ, Beckford C, Flores-Moreno I, Cobo-Soriano R et al (2022) Expert panel consensus for addressing Anti-VEGF treatment challenges of diabetic macular edema in Spain. Clin Ophthalmol 16:3097&#x2013;3106. https://doi.org/10.2147/opth.S374763</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/opth.S374763</ArticleId><ArticleId IdType="pubmed">36164581</ArticleId><ArticleId IdType="pmc">9507974</ArticleId></ArticleIdList></Reference><Reference><Citation>Augsburger M, Sarra G-M, Imesch P (2019) Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study. Graefes Arch Clin Exp Ophthalmol 257(9):1889&#x2013;1895. https://doi.org/10.1007/s00417-019-04404-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00417-019-04404-0</ArticleId><ArticleId IdType="pubmed">31256237</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollaus M, B&#xfc;hl W, Schmidt-Erfurth U, Sacu S (2022) The challenges of treating neovascular age-related macular degeneration. Klin Monbl Augenheilkd 239(8):1033&#x2013;1042. https://doi.org/10.1055/a-1473-5713</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1473-5713</ArticleId><ArticleId IdType="pubmed">34198354</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes D, Cowell W, Koncz T, Cramer J (2007) Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. Value in Health 10(6):498&#x2013;509. https://doi.org/10.1111/j.1524-4733.2007.00205.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1524-4733.2007.00205.x</ArticleId><ArticleId IdType="pubmed">17970932</ArticleId></ArticleIdList></Reference><Reference><Citation>Mevius A, Brandes A, Hardtstock F, Wilke T, Ratsch Boris A, Orzechowski H-D et al (2019) Persistence with biologic treatment in patients with inflammatory bowel disease: A German claims data analysis. Digestion 102(2):216&#x2013;226. https://doi.org/10.1159/000503859</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000503859</ArticleId><ArticleId IdType="pubmed">31639807</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller S, Wilke T, Fuchs A, Maywald U, Flacke JP, Heinisch H et al (2017) Non-persistence and non-adherence to MTX therapy in patients with rheumatoid arthritis: a retrospective cohort study based on German RA patients. Patient Prefer Adherence 11:1253&#x2013;1264. https://doi.org/10.2147/ppa.S134924</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/ppa.S134924</ArticleId><ArticleId IdType="pubmed">28790807</ArticleId><ArticleId IdType="pmc">5530851</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilke T, Mueller S, Groth A, Berg B, Fuchs A, Sikirica M et al (2016) Non-persistence and non-adherence of patients with type 2 diabetes mellitus in therapy with GLP-1 receptor agonists: A retrospective analysis. Diabetes Ther 7(1):105&#x2013;124. https://doi.org/10.1007/s13300-015-0149-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13300-015-0149-4</ArticleId><ArticleId IdType="pubmed">26695499</ArticleId></ArticleIdList></Reference><Reference><Citation>Bundesministerium f&#xfc;r Gesundheit: Pflegebed&#xfc;rftig - was nun? https://www.bundesgesundheitsministerium.de/themen/pflege/online-ratgeber-pflege/pflegebeduerftig-was-nun.html . Accessed Aug 2023</Citation></Reference><Reference><Citation>Heimes B, Gunnemann F, Ziegler M, Gutfleisch M, Spital G, Pauleikhoff D et al (2016) Compliance of age related macular degeneration patients undergoing anti-VEGF therapy&#x202f;: Analysis and suggestions for improvement. Ophthalmologe 113(11):925&#x2013;932. https://doi.org/10.1007/s00347-016-0275-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00347-016-0275-z</ArticleId><ArticleId IdType="pubmed">27272633</ArticleId></ArticleIdList></Reference><Reference><Citation>Angermann R, Rauchegger T, Nowosielski Y, Casazza M, Bilgeri A, Ulmer H et al (2019) Treatment compliance and adherence among patients with diabetic retinopathy and age-related macular degeneration treated by anti-vascular endothelial growth factor under universal health coverage. Graefes Arch Clin Exp Ophthalmol 257(10):2119&#x2013;2125. https://doi.org/10.1007/s00417-019-04414-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00417-019-04414-y</ArticleId><ArticleId IdType="pubmed">31286206</ArticleId></ArticleIdList></Reference><Reference><Citation>Busch C, Katzmann JL, Jochmann C, Unterlauft JD, Vollhardt D, Wiedemann P et al (2021) General health of patients with diabetic macular edema-The LIPSIA study. PLoS ONE 16(6):e0252321. https://doi.org/10.1371/journal.pone.0252321</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0252321</ArticleId><ArticleId IdType="pubmed">34115786</ArticleId><ArticleId IdType="pmc">8195383</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss M, Sim DA, Herold T, Schumann RG, Liegl R, Kern C et al (2018) Compliance and adherence of patients with diabetic macular edema to intravitreal anti-vascular endothelial growth factor therapy in daily practice. Retina 38(12):2293&#x2013;2300. https://doi.org/10.1097/iae.0000000000001892</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/iae.0000000000001892</ArticleId><ArticleId IdType="pubmed">29068914</ArticleId></ArticleIdList></Reference><Reference><Citation>Korva-Gurung I, Kubin AM, Ohtonen P, Hautala N (2023) Incidence and prevalence of neovascular age-related macular degeneration: 15-year epidemiological study in a population-based cohort in Finland. Ann Med 55(1):2222545. https://doi.org/10.1080/07853890.2023.2222545</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2023.2222545</ArticleId><ArticleId IdType="pubmed">37306515</ArticleId><ArticleId IdType="pmc">10262804</ArticleId></ArticleIdList></Reference><Reference><Citation>Binkley MS, Rauf MS, Milgrom SA, Pinnix CC, Tsang R, Dickinson M et al (2020) Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood 135(26):2365&#x2013;74</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2019003877</ArticleId><ArticleId IdType="pubmed">32211877</ArticleId></ArticleIdList></Reference><Reference><Citation>Gesetzliche Krankenversicherung (GKV): Statutory health insurance. https://www.gkv-spitzenverband.de/english/statutory_health_insurance/statutory_health_insurance.jsp . Accessed Jan 2024</Citation></Reference><Reference><Citation>Schultz NM, Bhardwaj S, Barclay C, Gaspar L, Schwartz J (2021) Global burden of dry age-related macular degeneration: a targeted literature review. Clin Ther 43(10):1792&#x2013;1818. https://doi.org/10.1016/j.clinthera.2021.08.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2021.08.011</ArticleId><ArticleId IdType="pubmed">34548176</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39586833</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-5094</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>25</Day></PubDate></JournalIssue><Title>Ophthalmic genetics</Title><ISOAbbreviation>Ophthalmic Genet</ISOAbbreviation></Journal><ArticleTitle>Distinguishing <i>ABCA4</i> from <i>PRPH2</i>-related disease: qualitative analysis of examination and imaging features.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>7</EndPage><MedlinePgn>1-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/13816810.2024.2432064</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED"><i>ABCA4</i> and <i>PRPH2</i>-related diseases are both phenotypically heterogeneous and clinically difficult to differentiate. There may be examination and imaging features that can aid in establishing a clinical diagnosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A single-center, retrospective, consecutive case series including patients with a molecular confirmation of pathologic variants in either the ABCA4 or PRPH2 were included. Chi-square analysis, Fisher exact test, and Student's t-test comparing prevalence of specific examination and imaging features between ABCA4 and PRPH2.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Of the 127 eyes from 64 patients included, the ABCA4 group was more significantly associated with peripapillary sparing on both fundus imaging (73% vs. 40%; <i>p</i>&#x2009;=&#x2009;0.006) and FAF (71% vs. 44%; <i>p</i> = 0.025), macular (64% vs. 12%; <i>p</i>&#x2009;&lt;&#x2009;0.001) and peripheral pisciform flecks (22% vs. 3.6%; <i>p</i>&#x2009;=&#x2009;0.025). The PRPH2 group was more highly associated with macular chorioretinal atrophy (86% vs. 55%; <i>p</i>&#x2009;=&#x2009;0.003).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Peripapillary sparing and pisciform flecks are more highly associated with <i>ABCA4</i>-related disease, while macular chorioretinal atrophy is more highly associated with <i>PRPH2</i>-related disease. Logistic regression demonstrates that bull's eye maculopathy and macular flecks are predictive of the <i>ABCA4</i> genotype.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Kenneth C</ForeName><Initials>KC</Initials><Identifier Source="ORCID">0000-0002-4453-9337</Identifier><AffiliationInfo><Affiliation>Retina Consultants of America, Retina Consultants of Texas, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Calvin W</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nichols</LastName><ForeName>Braden A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Retina Consultants of America, Retina Consultants of Texas, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadat</LastName><ForeName>Roa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Retina Consultants of America, Retina Consultants of Texas, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>Troy C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Retina Consultants of America, Retina Consultants of Texas, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Retina Consultants of America, Retina Consultants of Texas, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wykoff</LastName><ForeName>Charles C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Retina Consultants of America, Retina Consultants of Texas, Houston, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Blanton Eye Institute, Houston Methodist Hospital, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ophthalmic Genet</MedlineTA><NlmUniqueID>9436057</NlmUniqueID><ISSNLinking>1381-6810</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ABCA4</Keyword><Keyword MajorTopicYN="N">PRPH2</Keyword><Keyword MajorTopicYN="N">imaging</Keyword><Keyword MajorTopicYN="N">inherited retinal disease</Keyword><Keyword MajorTopicYN="N">stargardt disease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>0</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>0</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>25</Day><Hour>23</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39586833</ArticleId><ArticleId IdType="doi">10.1080/13816810.2024.2432064</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39586714</PMID><DateRevised><Year>2024</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1549-5469</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>25</Day></PubDate></JournalIssue><Title>Genome research</Title><ISOAbbreviation>Genome Res</ISOAbbreviation></Journal><ArticleTitle>A deconvolution framework that uses single-cell sequencing plus a small benchmark dataset for accurate analysis of cell type ratios in complex tissue samples.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">gr.278822.123</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/gr.278822.123</ELocationID><Abstract><AbstractText>Bulk deconvolution with single-cell/nucleus RNA-seq data is critical for understanding heterogeneity in complex biological samples, yet the technological discrepancy across sequencing platforms limits deconvolution accuracy. To address this, we utilize an experimental design to match inter-platform biological signals, hence revealing the technological discrepancy, and then develop a deconvolution framework called DeMixSC using this well-matched, i.e., benchmark, data. Built upon a novel weighted nonnegative least-squares framework, DeMixSC identifies and adjusts genes with high technological discrepancy and aligns the benchmark data with large patient cohorts of matched-tissue-type for large-scale deconvolution. Our results using two benchmark datasets of healthy retinas and ovarian cancer tissues suggest much-improved deconvolution accuracy. Leveraging tissue-specific benchmark datasets, we applied DeMixSC to a large cohort of 453 age-related macular degeneration patients and a cohort of 30 ovarian cancer patients with various responses to neoadjuvant chemotherapy. Only DeMixSC successfully unveiled biologically meaningful differences across patient groups, demonstrating its broad applicability in diverse real-world clinical scenarios. Our findings reveal the impact of technological discrepancy on deconvolution performance and underscore the importance of a well-matched dataset to resolve this challenge. The developed DeMixSC framework is generally applicable for accurately deconvolving large cohorts of disease tissues, including cancers, when a well-matched benchmark dataset is available.</AbstractText><CopyrightInformation>Published by Cold Spring Harbor Laboratory Press.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Shuai</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The University of Texas MD Anderson Cancer Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiaoqian</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>The University of Texas MD Anderson Cancer Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Xuesen</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Baylor College of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Yujie</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The University of Texas MD Anderson Cancer Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Shuangxi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The University of Texas MD Anderson Cancer Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Qingnan</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Baylor College of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koval</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The University of Texas MD Anderson Cancer Center, Rice University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yumei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Baylor College of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Owen</LastName><ForeName>Leah A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>SUNY University at Buffalo, University of Utah School of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ivana K</ForeName><Initials>IK</Initials><AffiliationInfo><Affiliation>Harvard Medical School.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aparicio</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The University of Texas MD Anderson Cancer Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sanghoon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The University of Texas MD Anderson Cancer Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sood</LastName><ForeName>Anil K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>The University of Texas MD Anderson Cancer Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kopetz</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The University of Texas MD Anderson Cancer Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>John Paul</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>The University of Texas MD Anderson Cancer Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinstein</LastName><ForeName>John N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>The University of Texas MD Anderson Cancer Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeAngelis</LastName><ForeName>Margaret M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>SUNY University at Buffalo, University of Utah School of Medicine, VA Western New York Healthcare System.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Baylor College of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wenyi</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0003-0617-9438</Identifier><AffiliationInfo><Affiliation>The University of Texas MD Anderson Cancer Center; wwang7@mdanderson.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Genome Res</MedlineTA><NlmUniqueID>9518021</NlmUniqueID><ISSNLinking>1088-9051</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>bioRxiv. 2023 Nov 11:2023.10.10.561733. doi: 10.1101/2023.10.10.561733</RefSource><PMID Version="1">37873318</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>0</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>26</Day><Hour>0</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>25</Day><Hour>21</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39586714</ArticleId><ArticleId IdType="doi">10.1101/gr.278822.123</ArticleId><ArticleId IdType="pii">gr.278822.123</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39585864</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>27</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>11</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Predicting long-term functional anti-VEGF treatment outcomes in neovascular AMD in a real-world setting.</ArticleTitle><Pagination><StartPage>e0314167</StartPage><MedlinePgn>e0314167</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0314167</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0314167</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To test to what degree retinal fluid (RF) after the loading phase and at the end of year 1 predicts long-term functional outcomes in neovascular macular degeneration (nAMD), as do macular (MA) atrophy, treatment density and treatment interval extension.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this retrospective single-center cohort study, a consecutive series of eyes with treatment-na&#xef;ve nAMD followed under a treat-and-extend (T&amp;E) protocol followed over &#x2265;2 years. Best-corrected visual acuity (BCVA), presence of retinal fluid (RF) and macular atrophy (MA) were registered along with central retinal thickness (CRT) and treatment density over time. The relationship between these variables was tested by regression analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 433 eyes were followed for 4.9 &#xb1; 2.2 years. A series of univariate analyses were run to select the covariates for the final multivariate regression model. CRT after loading, time to dryness, intraretinal fluid and MA after one year were found to predict visual function over 2 to 5 years. A final regression model was adjusted for visual acuity (VA) at baseline and showed that CRT after loading was predictive only in the short term (2 years) and that MA had the greatest predictive value for VA after 2 to 5 years. Intraretinal fluid (IRF) significantly predicted VA only after 4 years. The final regression model explained 21 to 32% of the variation in VA.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this large retrospective cohort, the presence of MA after one year was the strongest predictor of VA after 2 to 5 years, explaining a vision loss of 13 to 20 letters. The presence of IRF and SRF at any point of time had a comparably weak predictive potential for the outcomes over 5 and more years.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2024 Pfister et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pfister</LastName><ForeName>Isabel B</ForeName><Initials>IB</Initials><Identifier Source="ORCID">0000-0001-8752-8390</Identifier><AffiliationInfo><Affiliation>Swiss Eye Institute and Clinic for Vitreoretinal Diseases, Berner Augenklinik, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schild</LastName><ForeName>Christin</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-7705-1103</Identifier><AffiliationInfo><Affiliation>Swiss Eye Institute and Clinic for Vitreoretinal Diseases, Berner Augenklinik, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garweg</LastName><ForeName>Justus G</ForeName><Initials>JG</Initials><Identifier Source="ORCID">0000-0003-3973-5082</Identifier><AffiliationInfo><Affiliation>Swiss Eye Institute and Clinic for Vitreoretinal Diseases, Berner Augenklinik, Bern, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>ZL1R02VT79</RegistryNumber><NameOfSubstance UI="D000069579">Ranibizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014792" MajorTopicYN="Y">Visual Acuity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042461" MajorTopicYN="Y">Vascular Endothelial Growth Factor A</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020533" MajorTopicYN="N">Angiogenesis Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057135" MajorTopicYN="N">Wet Macular Degeneration</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D041623" MajorTopicYN="N">Tomography, Optical Coherence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069579" MajorTopicYN="N">Ranibizumab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>None of the authors received direct or indirect support for this investigator-initiated study or have any conflicting interests with the data that are presented in this report.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>25</Day><Hour>18</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>25</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>25</Day><Hour>13</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39585864</ArticleId><ArticleId IdType="pmc">PMC11588237</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0314167</ArticleId><ArticleId IdType="pii">PONE-D-24-23017</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Finger RP, Wickremasinghe SS, Baird PN, Guymer RH (2014) Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration. Surv Ophthalmol 59: 1&#x2013;18. doi: 10.1016/j.survophthal.2013.03.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.survophthal.2013.03.009</ArticleId><ArticleId IdType="pubmed">24332379</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen SY, Mimoun G, Oubraham H, Zourdani A, Malbrel C, et al.. (2013) Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study. Retina 33: 474&#x2013;481. doi: 10.1097/IAE.0b013e31827b6324</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IAE.0b013e31827b6324</ArticleId><ArticleId IdType="pubmed">23266880</ArticleId></ArticleIdList></Reference><Reference><Citation>Muether PS, Hoerster R, Hermann MM, Kirchhof B, Fauser S (2013) Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 251: 453&#x2013;458. doi: 10.1007/s00417-012-2038-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00417-012-2038-0</ArticleId><ArticleId IdType="pubmed">22573410</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloch SB, la Cour M, Sander B, Hansen LK, Fuchs J, et al.. (2013) Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment. Acta Ophthalmol 91: 42&#x2013;47. doi: 10.1111/j.1755-3768.2011.02268.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1755-3768.2011.02268.x</ArticleId><ArticleId IdType="pubmed">22008284</ArticleId></ArticleIdList></Reference><Reference><Citation>Real JP, Luna JD, Urrets-Zavalia JA, De Santis MO, Palma SD, et al.. (2013) Accessibility as a conditioning factor in treatment for exudative age-related macular degeneration. Eur J Ophthalmol 23: 857&#x2013;864. doi: 10.5301/ejo.5000299</Citation><ArticleIdList><ArticleId IdType="doi">10.5301/ejo.5000299</ArticleId><ArticleId IdType="pubmed">23661541</ArticleId></ArticleIdList></Reference><Reference><Citation>Muether PS, Hermann MM, Koch K, Fauser S (2011) Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity. Graefes Arch Clin Exp Ophthalmol 249: 633&#x2013;637. doi: 10.1007/s00417-010-1520-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00417-010-1520-9</ArticleId><ArticleId IdType="pubmed">20865421</ArticleId></ArticleIdList></Reference><Reference><Citation>Real JP, Granero GE, De Santis MO, Juarez CP, Palma SD, et al.. (2015) Rate of vision loss in neovascular age-related macular degeneration explored. Graefes Arch Clin Exp Ophthalmol 253: 1859&#x2013;1865. doi: 10.1007/s00417-014-2885-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00417-014-2885-y</ArticleId><ArticleId IdType="pubmed">25491161</ArticleId></ArticleIdList></Reference><Reference><Citation>Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, et al.. (2013) Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 120: 122&#x2013;129. doi: 10.1016/j.ophtha.2012.07.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2012.07.042</ArticleId><ArticleId IdType="pmc">PMC3536921</ArticleId><ArticleId IdType="pubmed">23047002</ArticleId></ArticleIdList></Reference><Reference><Citation>Ying GS, Maguire MG, Daniel E, Ferris FL, Jaffe GJ, et al.. (2015) Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology 122: 2523&#x2013;2531.e2521. doi: 10.1016/j.ophtha.2015.08.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2015.08.015</ArticleId><ArticleId IdType="pmc">PMC4658285</ArticleId><ArticleId IdType="pubmed">26383996</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee AY, Lee CS, Butt T, Xing W, Johnston RL, et al.. (2015) UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12. Br J Ophthalmol 99: 1045&#x2013;1050. doi: 10.1136/bjophthalmol-2014-306229</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjophthalmol-2014-306229</ArticleId><ArticleId IdType="pmc">PMC4560462</ArticleId><ArticleId IdType="pubmed">25680619</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillies MC, Campain A, Barthelmes D, Simpson JM, Arnold JJ, et al.. (2015) Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study. Ophthalmology 122: 1837&#x2013;1845. doi: 10.1016/j.ophtha.2015.05.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2015.05.010</ArticleId><ArticleId IdType="pubmed">26096346</ArticleId></ArticleIdList></Reference><Reference><Citation>Reznicek L, Muhr J, Ulbig M, Kampik A, Mayer WJ, et al.. (2014) Visual acuity and central retinal thickness: fulfilment of retreatment criteria for recurrent neovascular AMD in routine clinical care. Br J Ophthalmol 98: 1333&#x2013;1337. doi: 10.1136/bjophthalmol-2013-304399</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjophthalmol-2013-304399</ArticleId><ArticleId IdType="pubmed">24903670</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen A, Bloch SB, Fuchs J, Hansen LH, Larsen M, et al.. (2013) A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmology 120: 2630&#x2013;2636. doi: 10.1016/j.ophtha.2013.05.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2013.05.018</ArticleId><ArticleId IdType="pubmed">23830760</ArticleId></ArticleIdList></Reference><Reference><Citation>Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, et al.. (2015) Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 99: 220&#x2013;226. doi: 10.1136/bjophthalmol-2014-305327</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjophthalmol-2014-305327</ArticleId><ArticleId IdType="pmc">PMC4316940</ArticleId><ArticleId IdType="pubmed">25193672</ArticleId></ArticleIdList></Reference><Reference><Citation>Zandi S, Weisskopf F, Garweg JG, Pfister IB, Pruente C, et al.. (2017) Pre-Existing RPE Atrophy and Defects in the External Limiting Membrane Predict Early Poor Visual Response to Ranibizumab in Neovascular Age-Related Macular Degeneration. Ophthalmic Surg Lasers Imaging Retina 48: 326&#x2013;332. doi: 10.3928/23258160-20170329-07</Citation><ArticleIdList><ArticleId IdType="doi">10.3928/23258160-20170329-07</ArticleId><ArticleId IdType="pubmed">28419398</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CS, Lim LW, Ngo WK, Pannirselvam P, See C, et al.. (2020) Predictors of persistent disease activity following anti-VEGF loading dose for nAMD patients in Singapore: the DIALS study. BMC Ophthalmol 20: 324. doi: 10.1186/s12886-020-01582-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12886-020-01582-y</ArticleId><ArticleId IdType="pmc">PMC7409440</ArticleId><ArticleId IdType="pubmed">32762659</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarraf D, London NJ, Khurana RN, Dugel PU, Gune S, et al.. (2016) Ranibizumab Treatment for Pigment Epithelial Detachment Secondary to Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the HARBOR Study. Ophthalmology 123: 2213&#x2013;2224. doi: 10.1016/j.ophtha.2016.07.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2016.07.007</ArticleId><ArticleId IdType="pubmed">27566855</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, et al.. (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364: 1897&#x2013;1908. doi: 10.1056/NEJMoa1102673</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1102673</ArticleId><ArticleId IdType="pmc">PMC3157322</ArticleId><ArticleId IdType="pubmed">21526923</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al.. (2020) Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results. Ophthalmology 127: S135&#x2013;s145. doi: 10.1016/j.ophtha.2020.01.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2020.01.029</ArticleId><ArticleId IdType="pubmed">32200813</ArticleId></ArticleIdList></Reference><Reference><Citation>Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, et al.. (2016) Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 123: 1751&#x2013;1761. doi: 10.1016/j.ophtha.2016.03.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2016.03.045</ArticleId><ArticleId IdType="pmc">PMC4958614</ArticleId><ArticleId IdType="pubmed">27156698</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen M, Schmidt-Erfurth U, Lanzetta P, Wolf S, Simader C, et al.. (2012) Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results. Ophthalmology 119: 992&#x2013;1000. doi: 10.1016/j.ophtha.2012.02.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2012.02.002</ArticleId><ArticleId IdType="pubmed">22424834</ArticleId></ArticleIdList></Reference><Reference><Citation>Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K (2013) Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 120: 2292&#x2013;2299. doi: 10.1016/j.ophtha.2013.03.046</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2013.03.046</ArticleId><ArticleId IdType="pubmed">23642856</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, et al.. (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419&#x2013;1431. doi: 10.1056/NEJMoa054481</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa054481</ArticleId><ArticleId IdType="pubmed">17021318</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadda SR, Tuomi LL, Ding B, Fung AE, Hopkins JJ (2018) Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration. Ophthalmology 125: 878&#x2013;886. doi: 10.1016/j.ophtha.2017.12.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2017.12.026</ArticleId><ArticleId IdType="pubmed">29477692</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, et al.. (2014) Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 121: 193&#x2013;201. doi: 10.1016/j.ophtha.2013.08.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2013.08.011</ArticleId><ArticleId IdType="pubmed">24084500</ArticleId></ArticleIdList></Reference><Reference><Citation>Garweg JG, Gerhardt C (2021) Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) - a meta-analysis. Graefes Arch Clin Exp Ophthalmol 259: 2181&#x2013;2192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8352813</ArticleId><ArticleId IdType="pubmed">33528645</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadda SR, Guymer R, Holz FG, Schmitz-Valckenberg S, Curcio CA, et al.. (2018) Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT: Classification of Atrophy Report 3. Ophthalmology 125: 537&#x2013;548. doi: 10.1016/j.ophtha.2017.09.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2017.09.028</ArticleId><ArticleId IdType="pmc">PMC11366072</ArticleId><ArticleId IdType="pubmed">29103793</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue K, Hua P, Maguire MG, Daniel E, Jaffe GJ, et al.. (2023) Prediction for 2-Year Vision Outcomes Using Early Morphologic and Functional Responses in the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmol Retina 7: 564&#x2013;572. doi: 10.1016/j.oret.2023.02.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oret.2023.02.008</ArticleId><ArticleId IdType="pmc">PMC10330060</ArticleId><ArticleId IdType="pubmed">36803692</ArticleId></ArticleIdList></Reference><Reference><Citation>Foss A, Rotsos T, Empeslidis T, Chong V (2022) Development of Macular Atrophy in Patients with Wet Age-Related Macular Degeneration Receiving Anti-VEGF Treatment. Ophthalmologica 245: 204&#x2013;217. doi: 10.1159/000520171</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000520171</ArticleId><ArticleId IdType="pubmed">34695835</ArticleId></ArticleIdList></Reference><Reference><Citation>Gemenetzi M, Lotery AJ, Patel PJ (2017) Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents. Eye (Lond) 31: 1&#x2013;9. doi: 10.1038/eye.2016.208</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/eye.2016.208</ArticleId><ArticleId IdType="pmc">PMC5233933</ArticleId><ArticleId IdType="pubmed">27716750</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39585675</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1552-5783</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>13</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>04</Day></PubDate></JournalIssue><Title>Investigative ophthalmology &amp; visual science</Title><ISOAbbreviation>Invest Ophthalmol Vis Sci</ISOAbbreviation></Journal><ArticleTitle>Adult Onset Foveomacular Vitelliform Dystrophy Shows Genetic Overlap With Age-Related Macular Degeneration.</ArticleTitle><Pagination><StartPage>53</StartPage><MedlinePgn>53</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">53</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1167/iovs.65.13.53</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">Adult-onset foveomacular vitelliform dystrophy (AFVD) shares phenotypic similarities with age-related macular degeneration (AMD). The genetic factors associated with AFVD are unknown in &gt;80% of cases. This study evaluated the association of known AMD genetic risk variants with AFVD and compared systemic complement activation in these conditions.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Clinical, imaging, and genetic data were collected from 50 patients with AFVD (men/women = 25/25, mean age &#xb1; SD 73 &#xb1; 10 years), 917 patients with AMD (men/women = 377/540, mean age &#xb1; SD 77 &#xb1; 9 years), and 432 unaffected healthy controls (men/women = 202/230, mean age &#xb1; SD 71 &#xb1; 8 years). Genotyping focused on 52 single nucleotide polymorphisms (SNPs) linked to AMD. Weighted genetic risk scores (GRS) for 19 complement system associated variants, 7 lipid metabolism associated variants, the remaining 26 variants (other pathways GRS), and for all 52 variants (global score) were derived and correlated with phenotype.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Of the 52 SNPs evaluated, CFH (rs570618) and C2/CFB/SKIV2L (rs116503776 and rs114254831) were associated with AFVD compared with healthy controls (odds ratio [OR] = 2.73, 95% confidence interval [CI] = 1.32-5.73, P = 0.01; OR = 0.31, 95% CI = 0.14-0.71, P = 0.0036; and OR = 0.41, 95% CI = 0.22-0.74, P = 0.0025, respectively). MIR6130/RORB (rs10781182) was negatively associated with AFVD compared with the healthy controls (OR = 0.13, CI = 0.06-0.25, P &lt; 0.0001) and AMD (OR = 0.19, CI = 0.10-0.34, P &lt; 0.0001). Regression analysis showed complement GRS was positively associated with AFVD compared with controls (OR = 1.42, 95% CI = 1.04-1.95, P = 0.03), whereas the other pathways' GRS was negatively associated (OR = 0.46, 95% CI = 0.21-0.98, P = 0.04). AMD was positively associated with the complement score, global score, and ARMS2/HTRA1 compared with controls.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Non-monogenic AFVD is associated with AMD risk alleles in the complement cascade, but not in other pathways. Further research is needed to explore complement inhibition for AFVD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jaskoll</LastName><ForeName>Shlomit</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Hadassah-Hebrew University Medical Center, and the Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Military Medicine and "Tzameret", Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel, and Medical Corps, Israel Defense Forces, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Adi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Hadassah-Hebrew University Medical Center, and the Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elbaz-Hayoun</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Hadassah-Hebrew University Medical Center, and the Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rinsky</LastName><ForeName>Batya</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Hadassah-Hebrew University Medical Center, and the Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eandi</LastName><ForeName>Chiara M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences, University of Torino, Torino, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, Department of Ophthalmology, University of Lausanne, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grunin</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Hadassah-Hebrew University Medical Center, and the Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Braun School of Public Health and Community Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shwartz</LastName><ForeName>Yahel</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Hadassah-Hebrew University Medical Center, and the Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tiosano</LastName><ForeName>Liran</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Hadassah-Hebrew University Medical Center, and the Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heid</LastName><ForeName>Iris M</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>Department of Genetic Epidemiology, University of Regensburg, Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winkler</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Genetic Epidemiology, University of Regensburg, Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chowers</LastName><ForeName>Itay</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Hadassah-Hebrew University Medical Center, and the Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 EY022310</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Invest Ophthalmol Vis Sci</MedlineTA><NlmUniqueID>7703701</NlmUniqueID><ISSNLinking>0146-0404</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>80295-65-4</RegistryNumber><NameOfSubstance UI="D017242">Complement Factor H</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057826" MajorTopicYN="Y">Vitelliform Macular Dystrophy</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008268" MajorTopicYN="Y">Macular Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017242" MajorTopicYN="N">Complement Factor H</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D041623" MajorTopicYN="N">Tomography, Optical Coherence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Disclosure: <b>S. Jaskoll</b>, None; <b>A. Kramer</b>, None; <b>S. Elbaz-Hayoun</b>, None; <b>B. Rinsky</b>, None; <b>C.M. Eandi</b>, None; <b>M. Grunin</b>, None; <b>Y. Shwartz</b>, None; <b>L. Tiosano</b>, None; <b>I.M. Heid</b>, None; <b>T. Winkler</b>, None; <b>I. Chowers</b>, None</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>25</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>25</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>25</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39585675</ArticleId><ArticleId IdType="pmc">PMC11601137</ArticleId><ArticleId IdType="doi">10.1167/iovs.65.13.53</ArticleId><ArticleId IdType="pii">2802284</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chowers I, Tiosano L, Audo I, Grunin M, Boon CJF.. Adult-onset foveomacular vitelliform dystrophy: a fresh perspective. Prog Retin Eye Res. 2015; 47: 64&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">25681578</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess DB, Olk RJ, Uniat LM.. Macular disease resembling adult foveomacular vitelliform dystrophy in older adults. Ophthalmology. 1987; 94(4): 362&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">3587917</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalvin LA, Pulido JS, Marmorstein AD.. Vitelliform dystrophies: prevalence in Olmsted County, Minnesota, United States. Ophthalmic Genet. 2017; 38(2): 143&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5638045</ArticleId><ArticleId IdType="pubmed">27120116</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis PJ, Schultz DW, Gregory AM, et al. .. Genetic and phenotypic heterogeneity in pattern dystrophy. Br J Ophthalmol. 2005; 89(9): 1115&#x2013;1119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1772799</ArticleId><ArticleId IdType="pubmed">16113362</ArticleId></ArticleIdList></Reference><Reference><Citation>Meunier I, Manes G, Bocquet B, et al. .. Frequency and clinical pattern of vitelliform macular dystrophy caused by mutations of interphotoreceptor matrix IMPG1 and IMPG2 genes. Ophthalmology. 2014; 121(12): 2406&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">25085631</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiosano L, Grunin M, Hagbi-Levi S, Banin E, Averbukh E, Chowers I.. Characterising the phenotype and progression of sporadic adult-onset foveomacular vitelliform dystrophy. Br J Ophthalmol. 2016; 100(11): 1476&#x2013;1481.</Citation><ArticleIdList><ArticleId IdType="pubmed">26802173</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaouni T, Averbukh E, Burstyn-Cohen T, et al. .. Association of pattern dystrophy with an HTRA1 single-nucleotide polymorphism. Arch Ophthalmol. 2012; 130(8): 987&#x2013;991.</Citation><ArticleIdList><ArticleId IdType="pubmed">22893068</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson LV., Ozaki S, Staples MK, Erickson PA, Anderson DH.. A potential role for immune complex pathogenesis in drusen formation. Exp Eye Res. 2000; 70(4): 441&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pubmed">10865992</ArticleId></ArticleIdList></Reference><Reference><Citation>Freund KB, Laud K, Lima LH, Spaide RF, Zweifel S, Yannuzzi LA.. Acquired vitelliform lesions: correlation of clinical findings and multiple imaging analyses. Retina. 2011; 31(1): 13&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">21102371</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritsche LG, Igl W, Cooke Bailey JN, et al. .. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet. 2016; 48(2): 134&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4745342</ArticleId><ArticleId IdType="pubmed">26691988</ArticleId></ArticleIdList></Reference><Reference><Citation>Micklisch S, Lin Y, Jacob S, et al. .. Age-related macular degeneration associated polymorphism rs10490924 in ARMS2 results in deficiency of a complement activator. J Neuroinflammation. 2017; 14(1): 4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5234120</ArticleId><ArticleId IdType="pubmed">28086806</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero-Vazquez S, Llorens V, Soler-Boronat A, Figueras-Roca M, Adan A, Molins B. Interlink between inflammation and oxidative stress in age-related macular degeneration: role of complement factor H. Biomedicines. 2021; 9(7): 763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8301356</ArticleId><ArticleId IdType="pubmed">34209418</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolgin E. Age-related macular degeneration foils drugmakers. Nat Biotechnol. 2017; 35(11): 1000&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pubmed">29121027</ArticleId></ArticleIdList></Reference><Reference><Citation>Smailhodzic D, Klaver CCW, Klevering BJ, et al. .. Risk alleles in CFH and ARMS2 are independently associated with systemic complement activation in age-related macular degeneration. Ophthalmology. 2012; 119(2): 339&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pubmed">22133792</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechner J, Chen M, Hogg RE, et al. .. Higher plasma levels of complement C3a, C4a and C5a increase the risk of subretinal fibrosis in neovascular age-related macular degeneration. Immun Ageing. 2016; 13: 4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4754842</ArticleId><ArticleId IdType="pubmed">26884800</ArticleId></ArticleIdList></Reference><Reference><Citation>Ristau T, Paun C, Ersoy L, et al. .. Impact of the common genetic associations of age-related macular degeneration upon systemic complement component C3d levels. PLoS One. 2014; 9(3): e93459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3968152</ArticleId><ArticleId IdType="pubmed">24675670</ArticleId></ArticleIdList></Reference><Reference><Citation>Gass JD. A clinicopathologic study of a peculiar foveomacular dystrophy. Trans Am Ophthalmol Soc. 1974; 72: 139&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1311393</ArticleId><ArticleId IdType="pubmed">4142662</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferris FL, Davis MD, Clemons TE, et al. .. A simplified severity scale for age-related macular degeneration: AREDS report no. 18. Arch Ophthalmol. 2005; 123(11): 1570&#x2013;1574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1473206</ArticleId><ArticleId IdType="pubmed">16286620</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaffe GJ, Chakravarthy U, Freund KB, et al. .. Imaging features associated with progression to geographic atrophy in age-related macular degeneration: Classification of Atrophy Meeting Report 5. Ophthalmol Retina. 2021; 5: 855&#x2013;867.</Citation><ArticleIdList><ArticleId IdType="pubmed">33348085</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmann M, Bacci T, Kar D, et al. .. Histology and clinical lifecycle of acquired vitelliform lesion, a pathway to advanced age-related macular degeneration. Am J Ophthalmol. 2022; 240: 99&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9592119</ArticleId><ArticleId IdType="pubmed">35192790</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold JJ, Sarks JP, Killingsworth MC, Kettle EK, Sarks SH.. Adult vitelliform macular degeneration: a clinicopathological study. Eye. 2003; 17(6): 717&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">12928683</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen DT, Tran TTH, Tran MH, et al. .. A comprehensive evaluation of polygenic score and genotype imputation performances of human SNP arrays in diverse populations. Sci Rep. 2022; 12(1): 17556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9585077</ArticleId><ArticleId IdType="pubmed">36266455</ArticleId></ArticleIdList></Reference><Reference><Citation>Das S, Forer L, Sch&#xf6;nherr S, et al. .. Next-generation genotype imputation service and methods. Nat Genet. 2016; 48(10): 1284&#x2013;1287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5157836</ArticleId><ArticleId IdType="pubmed">27571263</ArticleId></ArticleIdList></Reference><Reference><Citation>Taliun D, Harris DN, Kessler MD, et al. .. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. Nature. 2021; 590(7845): 290&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7875770</ArticleId><ArticleId IdType="pubmed">33568819</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchsberger C, Abecasis GR, Hinds DA.. Minimac2: faster genotype imputation. Bioinformatics. 2015; 31(5): 782&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4341061</ArticleId><ArticleId IdType="pubmed">25338720</ArticleId></ArticleIdList></Reference><Reference><Citation>He W, Han X, Ong JS, et al. .. Genome-wide meta-analysis identifies risk loci and improves disease prediction of age-related macular degeneration. Ophthalmology. 2024; 131(1): 16&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">37634759</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, Gharahkhani P, Mitchell P, Liew G, Hewitt AW, MacGregor S.. Genome-wide meta-analysis identifies novel loci associated with age-related macular degeneration. J Hum Genet. 2020; 65(8): 657&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pubmed">32277175</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xfc;ls A, Kr&#xe4;mer U, Carlsten C, Schikowski T, Ickstadt K, Schwender H.. Comparison of weighting approaches for genetic risk scores in gene-environment interaction studies. BMC Genet. 2017; 18(1): 115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5732390</ArticleId><ArticleId IdType="pubmed">29246113</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee PH, O'Dushlaine C, Thomas B, Purcell SM. INRICH: interval-based enrichment analysis for genome-wide association studies. Bioinformatics. 2012; 28(13): 1797&#x2013;1799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3381960</ArticleId><ArticleId IdType="pubmed">22513993</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandwijk RJMGE, Michels MAHM, van Rossum M, et al. .. Pitfalls in complement analysis: a systematic literature review of assessing complement activation. Front Immunol. 2022; 13: 1007102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9623276</ArticleId><ArticleId IdType="pubmed">36330514</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathak A, Agrawal A.. Evolution of C-reactive protein. Front Immunol. 2019; 10: 943.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6503050</ArticleId><ArticleId IdType="pubmed">31114584</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowers I, Meir T, Lederman M, et al. .. Sequence variants in HTRA1 and LOC387715/ARMS2 and phenotype and response to photodynamic therapy in neovascular age-related macular degeneration in populations from Israel. Mol Vis. 2008; 14: 2263&#x2013;2271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2596748</ArticleId><ArticleId IdType="pubmed">19065273</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Wang X.. miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res. 2020; 48(D1): D127&#x2013;D131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6943051</ArticleId><ArticleId IdType="pubmed">31504780</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholl HPN, Issa PC, Walier M, et al. .. Systemic complement activation in age-related macular degeneration. PLoS One. 2008; 3(7): e2593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2440421</ArticleId><ArticleId IdType="pubmed">18596911</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivaprasad S, Adewoyin T, Bailey TA, et al. .. Estimation of systemic complement C3 activity in age-related macular degeneration. Arch Ophthalmol. 2007; 125(4): 515&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">17420372</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds R, Hartnett ME, Atkinson JP, Giclas PC, Rosner B, Seddon JM.. Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest Ophthalmol Vis Sci. 2009; 50(12): 5818&#x2013;5827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2826794</ArticleId><ArticleId IdType="pubmed">19661236</ArticleId></ArticleIdList></Reference><Reference><Citation>Thee EF, Colijn JM, Cougnard-Gr&#xe9;goire A, et al. .. The phenotypic course of age-related macular degeneration for ARMS2/HTRA1: the EYE-RISK Consortium. Ophthalmology. 2022; 129(7): 752&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pubmed">35240203</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39584280</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2083</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>25</Day></PubDate></JournalIssue><Title>Human molecular genetics</Title><ISOAbbreviation>Hum Mol Genet</ISOAbbreviation></Journal><ArticleTitle>The role of complement factor I rare genetic variants in age related macular degeneration in Finland.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ddae165</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/hmg/ddae165</ELocationID><Abstract><AbstractText>Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. The alternative pathway (AP) of complement has been linked to the pathogenesis of AMD. In particular, rare variants (RVs) in the complement factor I (CFI) gene encoding the Factor I (FI) protein confer increased AMD risk. The prevalence of CFI RVs are well characterised in European AMD, however little is known about other populations. The Finnish population underwent genetic restriction events which have skewed allele frequencies in unexpected ways. A series of novel or enriched CFI RVs were identified in individuals with dry AMD from the Finnish Biobank Cooperative (FINBB), but the relationship between these genotypes and contribution to disease was unclear. Understanding how RVs impact the ability of FI to regulate the complement system is important to inform mechanistic understanding for how different genotypes contribute to disease development. To explore this a series of in vitro assays were used to functionally characterise the protein products of 3 CFI RVs enriched in FINBB dry AMD, where no prior data were available. The G547R variant resulted in almost complete loss of both classical pathway and AP regulatory potential. The c.982 g&gt;a variant encoding G328R FI perturbed an exon splice enhancer site which resulted in exon skipping and a premature stop codon in vitro and low levels of FI in vivo. Despite detailed analysis no defect in levels or function was demonstrated in T107A. Functional characterization of all Finnish CFI RVs in the cohort allowed us to demonstrate that in Finnish dry AMD, collectively the type 1 CFI RVs (associated with FI haploinsufficiency) were significantly enriched with odds ratio (ORs) of 72.6 (95% confidence interval; CI 16.92 to 382.1). Meanwhile, type 2 CFI RVs (associated with FI dysfunction) collectively conferred a significant OR of 4.97 (95% CI 1.522 to 15.74), and non-impaired or normal CFI RV collectively conferred an of OR 3.19 (95% CI 2.410 to 4.191) although this was driven primarily by G261D. Overall, this study for the first time determined the ORs and functional effect for all CFI RVs within a Geographic Atrophy (GA) cohort, enabling calculations of combined risk scores that underline the risk conferred by type 1 and 2 CFI RVs in GA/AMD.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2024. Published by Oxford University Press.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Andreadi</LastName><ForeName>Anneliza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Framlington Place Newcastle upon Tyne, NE2 4HH, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Renal Complement Therapeutics Centre, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hallam</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials><Identifier Source="ORCID">0000-0002-4632-9640</Identifier><AffiliationInfo><Affiliation>Gyroscope Therapeutics Limited, A Novartis Company, Rolling Stock Yard, 188 York Way, London, N7 9AS, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brocklebank</LastName><ForeName>Vicky</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Framlington Place Newcastle upon Tyne, NE2 4HH, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Renal Complement Therapeutics Centre, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharp</LastName><ForeName>Scott J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Gyroscope Therapeutics Limited, A Novartis Company, Rolling Stock Yard, 188 York Way, London, N7 9AS, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Patrick R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Framlington Place Newcastle upon Tyne, NE2 4HH, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Renal Complement Therapeutics Centre, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Southerington</LastName><ForeName>Tom</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Finnish Biobank Cooperative Regus, Yliopistonkatu 31, 20100 Turku, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Turku, Hospital District of Southwest Finland, Finnish Biobank Cooperative - FINBB, Turku, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hautalahti</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Finnish Biobank Cooperative Regus, Yliopistonkatu 31, 20100 Turku, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steel</LastName><ForeName>David H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Biosciences Institute, Newcastle University, International Centre for Life, Central Parkway, Newcastle upon Tyne, NE1 3BZ, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sunderland Eye Infirmary, Queen Alexandra Rd, Sunderland, SR2 9HP, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lotery</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Clinical and Experimental Sciences, Faculty of Medicine, Southampton General Hospital, University of Southampton, Southampton, SO17 1BJ, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Claire L</ForeName><Initials>CL</Initials><Identifier Source="ORCID">0000-0003-0845-1730</Identifier><AffiliationInfo><Affiliation>Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Framlington Place Newcastle upon Tyne, NE2 4HH, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gyroscope Therapeutics Limited, A Novartis Company, Rolling Stock Yard, 188 York Way, London, N7 9AS, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marchbank</LastName><ForeName>Kevin J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>National Renal Complement Therapeutics Centre, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gyroscope Therapeutics Limited, A Novartis Company, Rolling Stock Yard, 188 York Way, London, N7 9AS, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kavanagh</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-4718-0072</Identifier><AffiliationInfo><Affiliation>Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Framlington Place Newcastle upon Tyne, NE2 4HH, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Renal Complement Therapeutics Centre, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Amy V</ForeName><Initials>AV</Initials><Identifier Source="ORCID">0000-0003-3467-6765</Identifier><AffiliationInfo><Affiliation>Gyroscope Therapeutics Limited, A Novartis Company, Rolling Stock Yard, 188 York Way, London, N7 9AS, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>NIHR Newcastle Biomedical Research Centre at Newcastle upon Tyne Hospitals NHS Foundation Trust</Agency><Country/></Grant><Grant><GrantID>R01-EY028602</GrantID><Agency>US National Institutes of Health</Agency><Country/></Grant><Grant><GrantID>RES/0248/7836</GrantID><Agency>Wellcome Trust: 4Ward North Academy</Agency><Country/></Grant><Grant><GrantID>MR/X020975/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/R000913/1</GrantID><Agency>Medical Research Council/Kidney Research UK Clinical Research Training Fellow</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hum Mol Genet</MedlineTA><NlmUniqueID>9208958</NlmUniqueID><ISSNLinking>0964-6906</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FINBB</Keyword><Keyword MajorTopicYN="N">Finland</Keyword><Keyword MajorTopicYN="N">aHUS</Keyword><Keyword MajorTopicYN="N">age related macular degeneration</Keyword><Keyword MajorTopicYN="N">complement</Keyword><Keyword MajorTopicYN="N">factor I</Keyword><Keyword MajorTopicYN="N">rare genetic variants</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>25</Day><Hour>11</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>25</Day><Hour>11</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>25</Day><Hour>5</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39584280</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddae165</ArticleId><ArticleId IdType="pii">7907879</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39584184</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2666-9145</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>Ophthalmology science</Title><ISOAbbreviation>Ophthalmol Sci</ISOAbbreviation></Journal><ArticleTitle>An Eye on Extracellular Vesicles: Trends and Clinical Translations in Vision Research.</ArticleTitle><Pagination><StartPage>100619</StartPage><MedlinePgn>100619</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100619</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.xops.2024.100619</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">To perform a review of research, funding, and clinical translation efforts for extracellular vesicles (EVs) within vision science.</AbstractText><AbstractText Label="DESIGN" NlmCategory="UNASSIGNED">Retrospective analysis of publication, funding, and clinical trials data.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A pretrained large language model (Jina2) was used to create semantic embeddings for 41&#xa0;282 abstracts from articles related to EVs archived on EMBASE and published between January 1966 and January 2024. The articles were projected and clustered according to semantic embedding similarity, and research subdomains for EVs were determined through inspection of term frequency-inverse document frequency weighted word clouds. Mann-Kendall trend analysis was performed to identify current areas of growth within EV research. Additionally, National Institutes of Health funding data from RePORT Expenditures and Results and clinical trials data from ClinicalTrials.gov were analyzed to correlate publication trends with funding support and clinical translation efforts.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Unsupervised clustering and Mann-Kendall trend analysis identified wound healing/regeneration (<i>P</i>&#xa0;=&#xa0;0.030) and neurodegenerative disease (<i>P</i>&#xa0;=&#xa0;0.049) as significantly accelerating in growth of publication over time. Ophthalmology-restricted subset analysis identified that publications in age-related macular degeneration (<i>P</i>&#xa0;=&#xa0;0.191) and clinical applications (<i>P</i>&#xa0;=&#xa0;0.086) are no longer growing at a significant rate. Analysis of funding data identified that the National Cancer Institute was the top funding institution overall, but that the National Institute on Aging is rapidly advancing in terms of funding EV research and trials. Analysis of ClinicalTrials.gov data highlights a dearth of clinical trials within ophthalmology despite a growing number of studies in other medical subfields.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Extracellular vesicles remain a promising substrate for both the identification and treatment of vision-threatening diseases. A better understanding of the current landscape of research and funding trends should help to inform future funding and translational efforts.</AbstractText><AbstractText Label="FINANCIAL DISCLOSURES" NlmCategory="UNASSIGNED">Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</AbstractText><CopyrightInformation>&#xa9; 2024 by the American Academy of Ophthalmology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dhodapkar</LastName><ForeName>Rahul M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sun Young</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology and Neuroscience, Keck School of Medicine, University of Southern California, Los Angeles, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Ophthalmol Sci</MedlineTA><NlmUniqueID>9918230896206676</NlmUniqueID><ISSNLinking>2666-9145</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Diagnostics</Keyword><Keyword MajorTopicYN="N">Extracellular vesicle</Keyword><Keyword MajorTopicYN="N">Survey</Keyword><Keyword MajorTopicYN="N">Therapeutics</Keyword><Keyword MajorTopicYN="N">Vision research</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>25</Day><Hour>11</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>25</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>25</Day><Hour>5</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39584184</ArticleId><ArticleId IdType="pmc">PMC11585720</ArticleId><ArticleId IdType="doi">10.1016/j.xops.2024.100619</ArticleId><ArticleId IdType="pii">S2666-9145(24)00155-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Buzas E.I. The roles of extracellular vesicles in the immune system. Nat Rev Immunol. 2023;23:236&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9361922</ArticleId><ArticleId IdType="pubmed">35927511</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Liu Y., Liu H., Tang W.H. Exosomes: biogenesis, biologic function and clinical potential. Cell Biosci. 2019;9:1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6377728</ArticleId><ArticleId IdType="pubmed">30815248</ArticleId></ArticleIdList></Reference><Reference><Citation>Welsh J.A., Goberdhan D.C., O'Driscoll L., et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J&#xa0;Extracell Vesicles. 2024;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10850029</ArticleId><ArticleId IdType="pubmed">38326288</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalluri R., LeBleu V.S. The biology, function, and biomedical applications of exosomes. Science. 2020;367</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7717626</ArticleId><ArticleId IdType="pubmed">32029601</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng W., He C., Hao Y., et al. Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source. Drug Deliv. 2020;27:585&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7178886</ArticleId><ArticleId IdType="pubmed">32264719</ArticleId></ArticleIdList></Reference><Reference><Citation>Claridge B., Lozano J., Poh Q.H., Greening D.W. Development of extracellular vesicle therapeutics: challenges, considerations, and opportunities. Front Cell Dev Biol. 2021;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8488228</ArticleId><ArticleId IdType="pubmed">34616741</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouma B.E., de Boer J.F., Huang D., et al. Optical coherence tomography. Nat Rev Methods Prim. 2022;2:79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9901537</ArticleId><ArticleId IdType="pubmed">36751306</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas D., Duguid G. Optical coherence tomography&#x2014;a review of the principles and contemporary uses in retinal investigation. Eye. 2004;18:561&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pubmed">14765099</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell S., Bennett J., Wellman J.A., et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390:849&#x2013;860.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5726391</ArticleId><ArticleId IdType="pubmed">28712537</ArticleId></ArticleIdList></Reference><Reference><Citation>Humayun M.S., Lee S.Y. Advanced retina implants. Ophthalmol Retina. 2022;6:899&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pubmed">35436597</ArticleId></ArticleIdList></Reference><Reference><Citation>McKay T.B., Yeung V., Hutcheon A.E., et al. Extracellular vesicles in the cornea: insights from other tissues. Anal Cell Pathol. 2021;2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8324376</ArticleId><ArticleId IdType="pubmed">34336556</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun F., Xu W., Qian H. The emerging role of extracellular vesicles in retinal diseases. Am J Transl Res. 2021;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8748154</ArticleId><ArticleId IdType="pubmed">35035672</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurzawa-Akanbi M., Whitfield P., Burt&#xe9; F., et al. Retinal pigment epithelium extracellular vesicles are potent inducers of age-related macular degeneration disease phenotype in the outer retina. J&#xa0;Extracell Vesicles. 2022;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9772497</ArticleId><ArticleId IdType="pubmed">36544284</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores-Bellver M., Mighty J., Aparicio-Domingo S., et al. Extracellular vesicles released by human retinal pigment epithelium mediate increased polarised secretion of drusen proteins in response to AMD stressors. J&#xa0;Extracell Vesicles. 2021;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8575963</ArticleId><ArticleId IdType="pubmed">34750957</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike S., Peng C.C., Neviani P., et al. CD63/81 small extracellular vesicles in the aqueous humor are retinoblastoma associated. Invest Ophthalmol Vis Sci. 2023;64:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10337798</ArticleId><ArticleId IdType="pubmed">37410475</ArticleId></ArticleIdList></Reference><Reference><Citation>McKay T.B., Hutcheon A.E., Zieske J.D., Ciolino J.B. Extracellular vesicles secreted by corneal epithelial cells promote myofibroblast differentiation. Cells. 2020;9:1080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7290736</ArticleId><ArticleId IdType="pubmed">32357574</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng S.X., Dos Santos A., Gee S. Therapeutic potential of extracellular vesicles for the treatment of corneal injuries and scars. Transl Vis Sci Technol. 2020;9:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7645240</ArticleId><ArticleId IdType="pubmed">33200043</ArticleId></ArticleIdList></Reference><Reference><Citation>Dismuke W.M., Challa P., Navarro I., et al. Human aqueous humor exosomes. Exp Eye Res. 2015;132:73&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4352394</ArticleId><ArticleId IdType="pubmed">25619138</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanghani A., Andriesei P., Kafetzis K.N., et al. Advances in exosome therapies in ophthalmology&#x2013;From bench to clinical trial. Acta Ophthalmol. 2022;100:243&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">34114746</ArticleId></ArticleIdList></Reference><Reference><Citation>Arel-Bundock V., Enevoldsen N., Yetman C. Countrycode: an R package to convert country names and country codes. J&#xa0;Open Source Softw. 2018;3:848.</Citation></Reference><Reference><Citation>Zhao W.X., Zhou K., Li J., et al. A&#xa0;survey of large language models. arXiv. 2023 doi: 10.48550/arXiv.2303.18223.</Citation><ArticleIdList><ArticleId IdType="doi">10.48550/arXiv.2303.18223</ArticleId></ArticleIdList></Reference><Reference><Citation>Guesmi M., Chatti M.A., Kadhim L., et al. Semantic interest modeling and content-based scientific publication recommendation using word embeddings and sentence encoders. Multimodal Technol Interact. 2023;7:91.</Citation></Reference><Reference><Citation>Alexandrov M., Gelbukh A., Rosso P. Springer; Berlin, Germany: 2005. An approach to clustering abstracts; pp. 275&#x2013;285.</Citation></Reference><Reference><Citation>G&#xfc;nther M., Ong J., Mohr I., et al. Jina embeddings 2: 8192-token general-purpose text embeddings for long documents. arXiv. 2023 doi: 10.48550/arXiv.2310.19923.</Citation><ArticleIdList><ArticleId IdType="doi">10.48550/arXiv.2310.19923</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf T., Debut L., Sanh V., et al. Huggingface's transformers: state-of-the-art natural language processing. arXiv. 2019 doi: 10.48550/arXiv.1910.03771.</Citation><ArticleIdList><ArticleId IdType="doi">10.48550/arXiv.1910.03771</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinerer I., Hornik K., Meyer D. Text mining infrastructure in R. J&#xa0;Stat Software. 2008;25:1&#x2013;54.</Citation></Reference><Reference><Citation>Beel J., Gipp B., Langer S., Breitinger C. Paper recommender systems: a literature survey. Int J Digit Libr. 2016;17:305&#x2013;338.</Citation></Reference><Reference><Citation>Fellows I., Fellows M.I., Rcpp L., Rcpp L. Package &#x2018;wordcloud&#x2019;. R&#xa0;package version. 2018;2:331.</Citation></Reference><Reference><Citation>Neuwirth E. Package &#x2018;RColorBrewer&#x2019;, 2014, ColorBrewer.</Citation><ArticleIdList><ArticleId IdType="doi">10.32614/CRAN.package.RColorBrewer</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilke C.O. Package &#x2018;cowplot&#x2019;, In: Streamlined plot theme and plot annotations for &#x2019;ggplot2, 2019, 1.</Citation><ArticleIdList><ArticleId IdType="doi">10.32614/CRAN.package.cowplot</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson L. Oxford University Press; Oxford, United Kingdom: 2011. ggplot2: Elegant Graphics for Data Analysis by Wickham, H.</Citation></Reference><Reference><Citation>Armstrong R.A. When to use the Bonferroni correction. Ophthalmic Physiol Opt. 2014;34:502&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">24697967</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginn S.L., Amaya A.K., Alexander I.E., et al. Gene therapy clinical trials worldwide to 2017: an update. J&#xa0;Gene Med. 2018;20</Citation><ArticleIdList><ArticleId IdType="pubmed">29575374</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M., Yang F., Xu Y. Global trends of stem cell precision medicine research (2018&#x2013;2022): a bibliometric analysis. Front Surg. 2022;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9260221</ArticleId><ArticleId IdType="pubmed">35813047</ArticleId></ArticleIdList></Reference><Reference><Citation>Mead B., Amaral J., Tomarev S. Mesenchymal stem cell&#x2013;derived small extracellular vesicles promote neuroprotection in rodent models of glaucoma. Invest Ophthalmol Vis Sci. 2018;59:702&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5795911</ArticleId><ArticleId IdType="pubmed">29392316</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleckenstein M., Keenan T.D., Guymer R.H., et al. Age-related macular degeneration. Nat Rev Dis Prim. 2021;7:31.</Citation><ArticleIdList><ArticleId IdType="pubmed">33958600</ArticleId></ArticleIdList></Reference><Reference><Citation>ekar R., Wooff Y., Cioanca A.V., et al. Impairing Gasdermin D-mediated pyroptosis is protective against retinal degeneration. J&#xa0;Neuroinflammation. 2023;20:239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10588253</ArticleId><ArticleId IdType="pubmed">37864169</ArticleId></ArticleIdList></Reference><Reference><Citation>Atienzar-Aroca S., Flores-Bellver M., Serrano-Heras G., et al. Oxidative stress in retinal pigment epithelium cells increases exosome secretion and promotes angiogenesis in endothelial cells. J&#xa0;Cell Mol Med. 2016;20:1457&#x2013;1466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4956947</ArticleId><ArticleId IdType="pubmed">26999719</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris D.R., Bounds S.E., Liu H., et al. Exosomal MiRNA transfer between retinal microglia and RPE. Int J Mol Sci. 2020;21:3541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7279010</ArticleId><ArticleId IdType="pubmed">32429541</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung V., Boychev N., Farhat W., et al. Extracellular vesicles in corneal fibrosis/scarring. Int J Mol Sci. 2022;23:5921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9180085</ArticleId><ArticleId IdType="pubmed">35682600</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H., Liu S., Zhao X., et al. Role of tear exosomes in the spread of herpes simplex virus type 1 in recurrent herpes simplex keratitis. Eye. 2023;37:3180&#x2013;3185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10564740</ArticleId><ArticleId IdType="pubmed">36894762</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi E., Saruwatari J., Fujimoto T., et al. The effects of exosomes derived from trabecular meshwork cells on Schlemm's canal endothelial cells. Sci Rep. 2021;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8578291</ArticleId><ArticleId IdType="pubmed">34754027</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y., Li H., Qin C., et al. Embryonic stem cells-derived exosomes enhance retrodifferentiation of retinal M&#xfc;ller cells by delivering BDNF protein to activate Wnt pathway. Immunobiology. 2022;227</Citation><ArticleIdList><ArticleId IdType="pubmed">35390666</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke Y., Fan X., Hao R., et al. Human embryonic stem cell-derived extracellular vesicles alleviate retinal degeneration by upregulating Oct4 to promote retinal M&#xfc;ller cell retrodifferentiation via HSP90. Stem Cell Res Ther. 2021;12:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7792097</ArticleId><ArticleId IdType="pubmed">33413616</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang M.F. The 2021 national eye institute strategic plan: driving innovation in eye and vision research. Invest Ophthalmol Vis Sci. 2021;62:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8572467</ArticleId><ArticleId IdType="pubmed">34724539</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39584182</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2666-9145</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>Ophthalmology science</Title><ISOAbbreviation>Ophthalmol Sci</ISOAbbreviation></Journal><ArticleTitle>OCT Changes Observed during the Progression of Early Age-Related Macular Degeneration.</ArticleTitle><Pagination><StartPage>100615</StartPage><MedlinePgn>100615</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100615</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.xops.2024.100615</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">Automated retinal cell layer segmentation empowers OCT as a precise tool for characterizing morphologic features of retinal health throughout age-related macular degeneration (AMD) progression, particularly in advance of more visible biomarkers such as drusen and macular pigmentary changes. Few studies have examined OCT changes in eyes progressing from early to intermediate disease, or combined examinations of cell layer thickness, reflectivity, and heterogeneity. Therefore, this study analyzed OCTs from eyes progressing from early to intermediate AMD to identify changes in retinal morphology and reflectivity that may serve as biomarkers of early progression.</AbstractText><AbstractText Label="DESIGN" NlmCategory="UNASSIGNED">Retrospective cohort study.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="UNASSIGNED">Patients &#x2265;50 years with a diagnosis of AMD and with high-quality ipsilateral OCTs in both early and intermediate stage disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Fifty OCTs from 25 patients were automatically segmented using a previously validated artificial intelligence-driven algorithm. Changes in the mean and standard deviation of cell layer thickness and reflectivity with progression through stages were calculated for 90 retinal volumes with the help of a novel Python-based analysis tool.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="UNASSIGNED">The primary outcomes were significant changes to cell layer thickness, reflectivity, and heterogeneity with progression of AMD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">With progression from early to intermediate disease, photoreceptor outer segments diffusely thinned. Within the ellipsoid zone, the fovea and parafovea were thinned with a simultaneous increase in thickness variability and a decrease in parafoveal reflectivity. The retinal pigment epithelium-Bruch's membrane complex underwent diffuse thickening and increased thickness variability alongside a decrease in foveal and parafoveal reflectivity.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">These findings correlate with the known histopathology of early AMD and identify measurable OCT trends through the earliest stages of disease.</AbstractText><AbstractText Label="FINANCIAL DISCLOSURES" NlmCategory="UNASSIGNED">Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</AbstractText><CopyrightInformation>&#xa9; 2024 by the American Academy of Ophthalmology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Heckenlaible</LastName><ForeName>Nicolas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toomey</LastName><ForeName>Christopher B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Shiley Eye Institute, University of California San Diego School of Medicine, San Diego, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Handa</LastName><ForeName>James T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Ophthalmol Sci</MedlineTA><NlmUniqueID>9918230896206676</NlmUniqueID><ISSNLinking>2666-9145</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Age-related macular degeneration</Keyword><Keyword MajorTopicYN="N">Artificial intelligence</Keyword><Keyword MajorTopicYN="N">Biomarkers</Keyword><Keyword MajorTopicYN="N">OCT</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>25</Day><Hour>11</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>25</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>25</Day><Hour>5</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39584182</ArticleId><ArticleId IdType="pmc">PMC11584586</ArticleId><ArticleId IdType="doi">10.1016/j.xops.2024.100615</ArticleId><ArticleId IdType="pii">S2666-9145(24)00151-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Klein R. Prevalence of age-related macular degeneration in the US population. Arch Ophthalmol. 2011;129:75.</Citation><ArticleIdList><ArticleId IdType="pubmed">21220632</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores R., Carneiro &#xc2;., Vieira M., et al. Age-related macular degeneration: pathophysiology, management, and future perspectives. Ophthalmologica. 2021;244:495&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">34130290</ArticleId></ArticleIdList></Reference><Reference><Citation>The age-related eye disease study (AREDS) Control Clin Trials. 1999;20:573&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1473211</ArticleId><ArticleId IdType="pubmed">10588299</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores R., Carneiro &#xc2;., Tenreiro S., Seabra M.C. Retinal progression biomarkers of early and intermediate age-related macular degeneration. Life. 2021;12:36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8779095</ArticleId><ArticleId IdType="pubmed">35054429</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramoff M.D., Garvin M.K., Sonka M. Retinal imaging and image analysis. IEEE Rev Biomed Eng. 2010;3:169&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3131209</ArticleId><ArticleId IdType="pubmed">22275207</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Kang, Wu Xiaodong, Chen D.Z., Sonka M. Optimal surface segmentation in volumetric images-A graph-theoretic approach. IEEE Trans Pattern Anal Mach Intell. 2006;28:119&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2646122</ArticleId><ArticleId IdType="pubmed">16402624</ArticleId></ArticleIdList></Reference><Reference><Citation>Garvin M.K., Abramoff M.D., Xiaodong Wu, et al. Automated 3-D intraretinal layer segmentation of macular spectral-domain optical coherence tomography images. IEEE Trans Med Imaging. 2009;28:1436&#x2013;1447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2911837</ArticleId><ArticleId IdType="pubmed">19278927</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollreisz A., Reiter G.S., Bogunovic H., et al. Topographic distribution and progression of soft drusen volume in age-related macular degeneration implicate neurobiology of fovea. Invest Ophthalmol Vis Sci. 2021;62:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7900846</ArticleId><ArticleId IdType="pubmed">33605982</ArticleId></ArticleIdList></Reference><Reference><Citation>Yehoshua Z., Wang F., Rosenfeld P.J., et al. Natural history of drusen morphology in age-related macular degeneration using spectral domain optical coherence tomography. Ophthalmology. 2011;118:2434&#x2013;2441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3189426</ArticleId><ArticleId IdType="pubmed">21724264</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlanitz F.G., Baumann B., Kundi M., et al. Drusen volume development over time and its relevance to the course of age-related macular degeneration. Br J Ophthalmol. 2017;101:198&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5293844</ArticleId><ArticleId IdType="pubmed">27044341</ArticleId></ArticleIdList></Reference><Reference><Citation>Farsiu S., Chiu S.J., O'Connell R.V., et al. Quantitative classification of eyes with and without intermediate age-related macular degeneration using optical coherence tomography. Ophthalmology. 2014;121:162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3901571</ArticleId><ArticleId IdType="pubmed">23993787</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J.Q., McGeehan B., Firn K., et al. Comparison of the Iowa Reference Algorithm to the Heidelberg Spectralis optical coherence tomography segmentation algorithm. J&#xa0;Biophotonics. 2020;13</Citation><ArticleIdList><ArticleId IdType="pubmed">32057191</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldstein S.M., Vogl W.D., Bogunovic H., et al. Characterization of drusen and hyperreflective foci as biomarkers for disease progression in age-related macular degeneration using artificial intelligence in optical coherence tomography. JAMA Ophthalmol. 2020;138:740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7206537</ArticleId><ArticleId IdType="pubmed">32379287</ArticleId></ArticleIdList></Reference><Reference><Citation>Muntean G.A., Marginean A., Groza A., et al. The predictive capabilities of artificial intelligence-based OCT analysis for age-related macular degeneration progression&#x2014;a systematic review. Diagnostics. 2023;13:2464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10378064</ArticleId><ArticleId IdType="pubmed">37510207</ArticleId></ArticleIdList></Reference><Reference><Citation>Romond K., Alam M., Kravets S., et al. Imaging and artificial intelligence for progression of age-related macular degeneration. Exp Biol Med. 2021;246:2159&#x2013;2169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8718252</ArticleId><ArticleId IdType="pubmed">34404252</ArticleId></ArticleIdList></Reference><Reference><Citation>Curcio C., Medeiros N.E., Millican C.L. Photoreceptor loss in age-related macular degeneration. Invest Ophthalmol Vis Sci. 1996;37:1236&#x2013;1249.</Citation><ArticleIdList><ArticleId IdType="pubmed">8641827</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandl C., Br&#xfc;cklmayer C., G&#xfc;nther F., et al. Retinal layer thicknesses in early age-related macular degeneration: results from the German AugUR study. Invest Ophthalmol Vis Sci. 2019;60:1581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6892378</ArticleId><ArticleId IdType="pubmed">30995315</ArticleId></ArticleIdList></Reference><Reference><Citation>Nivison-Smith L., Wang H., Assaad N., Kalloniatis M. Retinal thickness changes throughout the natural history of drusen in age-related macular degeneration. Optom Vis Sci. 2018;95:648&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pubmed">30063666</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuman S.G., Koreishi A.F., Farsiu S., et al. Photoreceptor layer thinning over drusen in eyes with age-related macular degeneration imaged in&#xa0;vivo with spectral-domain optical coherence tomography. Ophthalmology. 2009;116:488&#x2013;496.e2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2695995</ArticleId><ArticleId IdType="pubmed">19167082</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogala J., Zangerl B., Assaad N., et al. In&#xa0;vivo quantification of retinal changes associated with drusen in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2015;56:1689&#x2013;1700.</Citation><ArticleIdList><ArticleId IdType="pubmed">25670493</ArticleId></ArticleIdList></Reference><Reference><Citation>Reumueller A., Schmidt-Erfurth U., Salas M., et al. Three-dimensional adaptive optics&#x2013;assisted visualization of photoreceptors in healthy and pathologically aged eyes. Invest Ophthalmol Vis Sci. 2019;60:1144.</Citation><ArticleIdList><ArticleId IdType="pubmed">30901772</ArticleId></ArticleIdList></Reference><Reference><Citation>Spaide R.F., Curcio C.A. Drusen characterization with multimodal imaging. Retina. 2010;30:1441&#x2013;1454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2952278</ArticleId><ArticleId IdType="pubmed">20924263</ArticleId></ArticleIdList></Reference><Reference><Citation>Litts K.M., Zhang Y., Freund K.B., Curcio C.A. Optical coherence tomography and histology of age-related macular degeneration Support mitochondria as reflectivity sources. Retina. 2018;38:445&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6230433</ArticleId><ArticleId IdType="pubmed">29210936</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrara D., Silver R.E., Louzada R.N., et al. Optical coherence tomography features preceding the onset of advanced age-related macular degeneration. Invest Ophthalmol Vis Sci. 2017;58:3519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5512971</ArticleId><ArticleId IdType="pubmed">28715590</ArticleId></ArticleIdList></Reference><Reference><Citation>Curcio C.A., Zanzottera E.C., Ach T., et al. Activated retinal pigment epithelium, an optical coherence tomography biomarker for progression in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2017;58:BIO211&#x2013;BIO226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5557213</ArticleId><ArticleId IdType="pubmed">28785769</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta S., Cano M., Satyanarayana G., et al. Mitophagy initiates retrograde mitochondrial-nuclear signaling to guide retinal pigment cell heterogeneity. Autophagy. 2023;19:966&#x2013;983.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9980637</ArticleId><ArticleId IdType="pubmed">35921555</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevilla M.B., McGwin G., Lad E.M., et al. Relating retinal morphology and function in aging and early to intermediate age-related macular degeneration subjects. Am J Ophthalmol. 2016;165:65&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567819</ArticleId><ArticleId IdType="pubmed">26940163</ArticleId></ArticleIdList></Reference><Reference><Citation>Pondorfer S.G., Wintergerst M.W.M., Gorgi Zadeh S., et al. Association of visual function measures with drusen volume in early stages of age-related macular degeneration. Invest Ophthalmol Vis Sci. 2020;61:55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7401419</ArticleId><ArticleId IdType="pubmed">32232348</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoshal R., Sharanjeet-Kaur S., Mohamad Fadzil N., et al. Correlation between visual functions and retinal morphology in eyes with early and intermediate age-related macular degeneration. Int J Environ Res Public Health. 2020;17:6379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7503555</ArticleId><ArticleId IdType="pubmed">32887214</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39581910</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2576</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>25</Day></PubDate></JournalIssue><Title>Inflammation</Title><ISOAbbreviation>Inflammation</ISOAbbreviation></Journal><ArticleTitle>IL-6 Exacerbates Oxidative Damage of RPE Cells by Indirectly Destabilizing the mRNA of DNA Repair Genes.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10753-024-02192-2</ELocationID><Abstract><AbstractText>Chronic inflammation has been associated with the progression of age-related macular degeneration (AMD) and diabetic retinopathy (DR), and the levels of various inflammatory factors are significantly increased in intraocular fluids of patients with AMD and DR. Therefore, elucidating the roles of inflammatory factors in the oxidative damage of RPE cells will help uncover the pathogenesis of AMD and DR. We have previously demonstrated that E2F1 plays an important role in the antioxidant capacity of RPE cells. Here, our transcriptome analysis shows that E2F1 affected the expressions of DNA repair genes in RPE cells. In addition, we found that E2F1 transactivated the splicing factor SRSF1. SRSF1 knockdown promoted DNA oxidative damage and apoptosis and decreased the mRNA stability of DNA repair genes XRCC2, POLK and LIG4 in RPE cells. Moreover, we found that SRSF1 could bind to the RNA stabilizing factor MATR3, and knockdown of the latter affected the mRNA stability of these DNA repair genes. Notably, interleukin-6 (IL-6), an inflammatory factor upregulated in intraocular fluids of patients with AMD and DR, decreased SRSF1 expression by inducing acetylation of E2F1 at the K125 position. Consistently, SRSF1 overexpression relieved IL-6-induced DNA oxidative damage and apoptosis in RPE cells. In vivo experiment results also confirmed that IL-6 could aggravate retinal oxidative damage. In conclusion, high levels of IL-6 in the eyes of patients with AMD and DR destabilize the mRNAs of DNA repair genes by disrupting the expression of SRSF1, leading to abnormal repair of DNA oxidative damage in RPE cells.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Huirong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Xuzhou Key Laboratory of Ophthalmology, The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou First People's Hospital, Eye Institute of Xuzhou, Xuzhou, 221100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Yucong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Xuzhou Key Laboratory of Ophthalmology, The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou First People's Hospital, Eye Institute of Xuzhou, Xuzhou, 221100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Haiyu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Xuzhou Key Laboratory of Ophthalmology, The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou First People's Hospital, Eye Institute of Xuzhou, Xuzhou, 221100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Meiling</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Xuzhou Key Laboratory of Ophthalmology, The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou First People's Hospital, Eye Institute of Xuzhou, Xuzhou, 221100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Xuzhou Key Laboratory of Ophthalmology, The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou First People's Hospital, Eye Institute of Xuzhou, Xuzhou, 221100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Chaoju</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Xuzhou Key Laboratory of Ophthalmology, The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou First People's Hospital, Eye Institute of Xuzhou, Xuzhou, 221100, China. gongcj@zju.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Suyan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Xuzhou Key Laboratory of Ophthalmology, The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou First People's Hospital, Eye Institute of Xuzhou, Xuzhou, 221100, China. lisuyan_med@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou First People's Hospital, Eye Institute of Xuzhou, Xuzhou, 221100, China. lisuyan_med@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>202210313031Z</GrantID><Agency>Jiangsu Training Program of Innovation and Entrepreneurship for Undergraduates</Agency><Country/></Grant><Grant><GrantID>202210313031Z</GrantID><Agency>Jiangsu Training Program of Innovation and Entrepreneurship for Undergraduates</Agency><Country/></Grant><Grant><GrantID>202210313031Z</GrantID><Agency>Jiangsu Training Program of Innovation and Entrepreneurship for Undergraduates</Agency><Country/></Grant><Grant><GrantID>82103334</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>KC23071</GrantID><Agency>Basic Research Plan of Xuzhou Science and Technology Project</Agency><Country/></Grant><Grant><GrantID>BK20211052</GrantID><Agency>Natural Science Foundation of Jiangsu Province</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Inflammation</MedlineTA><NlmUniqueID>7600105</NlmUniqueID><ISSNLinking>0360-3997</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DNA Repair</Keyword><Keyword MajorTopicYN="N">Interleukin-6</Keyword><Keyword MajorTopicYN="N">Retinal Pigment Epithelium</Keyword><Keyword MajorTopicYN="N">Serine and Arginine Rich Splicing Factor 1</Keyword><Keyword MajorTopicYN="N">Transcription Factor E2F1</Keyword></KeywordList><CoiStatement>Declarations. Ethics Approval and Consent to Participate: The animal studies were approved by the Animal Ethics Committee of Xuzhou Medical University (approval number: 202303T030). Conflict of interest: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>25</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>25</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>24</Day><Hour>23</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39581910</ArticleId><ArticleId IdType="doi">10.1007/s10753-024-02192-2</ArticleId><ArticleId IdType="pii">10.1007/s10753-024-02192-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kang, Q., and C. Yang. 2020. Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biology 37: 101799.</Citation><ArticleIdList><ArticleId IdType="pubmed">33248932</ArticleId><ArticleId IdType="pmc">7767789</ArticleId><ArticleId IdType="doi">10.1016/j.redox.2020.101799</ArticleId></ArticleIdList></Reference><Reference><Citation>Kushwah, N., et al. 2023. Oxidative Stress and Antioxidants in Age-Related Macular Degeneration. Antioxidants 12 (7): 1379.</Citation><ArticleIdList><ArticleId IdType="pubmed">37507918</ArticleId><ArticleId IdType="pmc">10376043</ArticleId><ArticleId IdType="doi">10.3390/antiox12071379</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan, W., et al. 2020. The Role of Inflammation in Age-Related Macular Degeneration. International Journal of Biological Sciences 16 (15): 2989&#x2013;3001.</Citation><ArticleIdList><ArticleId IdType="pubmed">33061811</ArticleId><ArticleId IdType="pmc">7545698</ArticleId><ArticleId IdType="doi">10.7150/ijbs.49890</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, W., and A.C.Y. Lo. 2018. Diabetic Retinopathy: Pathophysiology and Treatments. International Journal of Molecular Sciences 19 (6): 1816.</Citation><ArticleIdList><ArticleId IdType="pubmed">29925789</ArticleId><ArticleId IdType="pmc">6032159</ArticleId><ArticleId IdType="doi">10.3390/ijms19061816</ArticleId></ArticleIdList></Reference><Reference><Citation>Subhi, Y., et al. 2019. The transcriptome of peripheral blood mononuclear cells in patients with clinical subtypes of late age-related macular degeneration. Immunity &amp; Ageing 16: 20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12979-019-0160-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Krogh Nielsen, M., et al. 2019. Systemic Levels of Interleukin-6 Correlate With Progression Rate of Geographic Atrophy Secondary to Age-Related Macular Degeneration. Investigative Ophthalmology &amp; Visual Science 60 (1): 202&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.18-25878</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal, R., et al. 2019. Cytokine Profiling in Patients With Exudative Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy. Investigative Ophthalmology &amp; Visual science 60 (1): 376&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.18-24387</ArticleId></ArticleIdList></Reference><Reference><Citation>Nahavandipour, A., et al. 2020. Systemic levels of interleukin-6 in patients with age-related macular degeneration: A systematic review and meta-analysis. Acta Ophthalmologica 98 (5): 434&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pubmed">32180348</ArticleId><ArticleId IdType="doi">10.1111/aos.14402</ArticleId></ArticleIdList></Reference><Reference><Citation>Zorena, K., et al. 2007. Serum TNF-alpha level predicts nonproliferative diabetic retinopathy in children. Mediators of Inflammation 2007: 92196.</Citation><ArticleIdList><ArticleId IdType="pubmed">17641733</ArticleId><ArticleId IdType="pmc">1906713</ArticleId><ArticleId IdType="doi">10.1155/2007/92196</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, J.H., et al. 2008. Cytokine profile of peripheral blood in type 2 diabetes mellitus patients with diabetic retinopathy. Annals of Clinical and Laboratory Science 38 (4): 361&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">18988929</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuuki, T., et al. 2001. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. Journal of Diabetes and its Complications 15 (5): 257&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">11522500</ArticleId><ArticleId IdType="doi">10.1016/S1056-8727(01)00155-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng, S., et al. 2018. Levels of Inflammatory Cytokines IL-1beta, IL-6, IL-8, IL-17A, and TNF-alpha in Aqueous Humour of Patients with Diabetic Retinopathy. Journal of Diabetes Research 2018: 8546423.</Citation><ArticleIdList><ArticleId IdType="pubmed">29850610</ArticleId><ArticleId IdType="pmc">5904804</ArticleId><ArticleId IdType="doi">10.1155/2018/8546423</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao, Y., et al. 2019. Interleukin-6 and Diabetic Retinopathy: A Systematic Review and Meta-Analysis. Current Eye Research 44 (5): 564&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">30644770</ArticleId><ArticleId IdType="doi">10.1080/02713683.2019.1570274</ArticleId></ArticleIdList></Reference><Reference><Citation>Putzer, B.M., and D. Engelmann. 2013. E2F1 apoptosis counterattacked: Evil strikes back. Trends in Molecular Medicine 19 (2): 89&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">23219173</ArticleId><ArticleId IdType="doi">10.1016/j.molmed.2012.10.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertosun, M.G., et al. 2020. Regulation of E2F1 activity via PKA-mediated phosphorylations. Turkish Journal of Biology = Turk Biyoloji Dergisi 44 (5): 215&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">33110360</ArticleId><ArticleId IdType="pmc">7585165</ArticleId><ArticleId IdType="doi">10.3906/biy-2003-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswas, A.K., D.L. Mitchell, and D.G. Johnson. 2014. E2F1 responds to ultraviolet radiation by directly stimulating DNA repair and suppressing carcinogenesis. Cancer Research 74 (12): 3369&#x2013;3377.</Citation><ArticleIdList><ArticleId IdType="pubmed">24741006</ArticleId><ArticleId IdType="pmc">4083823</ArticleId><ArticleId IdType="doi">10.1158/0008-5472.CAN-13-3216</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong, C., et al. 2020. IL-6-induced acetylation of E2F1 aggravates oxidative damage of retinal pigment epithelial cell line. Experimental Eye Research 200: 108219.</Citation><ArticleIdList><ArticleId IdType="pubmed">32910941</ArticleId><ArticleId IdType="doi">10.1016/j.exer.2020.108219</ArticleId></ArticleIdList></Reference><Reference><Citation>Udayakumar, T., et al. 2010. The E2F1/Rb and p53/MDM2 pathways in DNA repair and apoptosis: Understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy. Seminars in Radiation Oncology 20 (4): 258&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">20832018</ArticleId><ArticleId IdType="doi">10.1016/j.semradonc.2010.05.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozaki, T., et al. 2009. Acetylation status of E2F&#x2013;1 has an important role in the regulation of E2F-1-mediated transactivation of tumor suppressor p73. Biochemical and Biophysical Research Communications 386 (1): 207&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">19523927</ArticleId><ArticleId IdType="doi">10.1016/j.bbrc.2009.06.035</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa, Y., et al. 2002. Apaf-1 is a mediator of E2F-1-induced apoptosis. The Journal of Biological Chemistry 277 (42): 39760&#x2013;39768.</Citation><ArticleIdList><ArticleId IdType="pubmed">12149244</ArticleId><ArticleId IdType="doi">10.1074/jbc.M200805200</ArticleId></ArticleIdList></Reference><Reference><Citation>Han, R., et al. 2021. Tiliroside as a CAXII inhibitor suppresses liver cancer development and modulates E2Fs/Caspase-3 axis. Scientific Reports 11 (1): 8626.</Citation><ArticleIdList><ArticleId IdType="pubmed">33883691</ArticleId><ArticleId IdType="pmc">8060393</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-88133-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Manickavinayaham, S., et al. 2019. E2F1 acetylation directs p300/CBP-mediated histone acetylation at DNA double-strand breaks to facilitate repair. Nature Communications 10 (1): 4951.</Citation><ArticleIdList><ArticleId IdType="pubmed">31666529</ArticleId><ArticleId IdType="pmc">6821830</ArticleId><ArticleId IdType="doi">10.1038/s41467-019-12861-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Balbas, M.A., et al. 2000. Regulation of E2F1 activity by acetylation. The EMBO Journal 19 (4): 662&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pubmed">10675335</ArticleId><ArticleId IdType="pmc">305604</ArticleId><ArticleId IdType="doi">10.1093/emboj/19.4.662</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Den Broeck, A., et al. 2012. Activation of a Tip60/E2F1/ERCC1 network in human lung adenocarcinoma cells exposed to cisplatin. Carcinogenesis 33 (2): 320&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">22159227</ArticleId><ArticleId IdType="doi">10.1093/carcin/bgr292</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng, J., et al. 2017. Bioinformatics analysis of SRSF1-controlled gene networks in colorectal cancer. Oncology Letters 14 (5): 5393&#x2013;5399.</Citation><ArticleIdList><ArticleId IdType="pubmed">29113173</ArticleId><ArticleId IdType="pmc">5656040</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Terroba, E., et al. 2018. The oncogenic RNA-binding protein SRSF1 regulates LIG1 in non-small cell lung cancer. Laboratory Investigation 98 (12): 1562&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">30181552</ArticleId><ArticleId IdType="doi">10.1038/s41374-018-0128-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Salton, M., et al. 2011. Matrin 3 binds and stabilizes mRNA. PLoS One 6 (8): e23882.</Citation><ArticleIdList><ArticleId IdType="pubmed">21858232</ArticleId><ArticleId IdType="pmc">3157474</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0023882</ArticleId></ArticleIdList></Reference><Reference><Citation>Coelho, M.B., et al. 2015. Nuclear matrix protein Matrin3 regulates alternative splicing and forms overlapping regulatory networks with PTB. The EMBO Journal 34 (5): 653&#x2013;668.</Citation><ArticleIdList><ArticleId IdType="pubmed">25599992</ArticleId><ArticleId IdType="pmc">4365034</ArticleId><ArticleId IdType="doi">10.15252/embj.201489852</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao, X., et al. 2023. SRSF1 is essential for primary follicle development by regulating granulosa cell survival via mRNA alternative splicing. Cellular and Molecular Life Sciences&#x202f;: CMLS 80 (11): 343.</Citation><ArticleIdList><ArticleId IdType="pubmed">37907803</ArticleId><ArticleId IdType="pmc">11072053</ArticleId><ArticleId IdType="doi">10.1007/s00018-023-04979-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma, V., et al. 2016. Oxidative stress at low levels can induce clustered DNA lesions leading to NHEJ mediated mutations. Oncotarget 7 (18): 25377&#x2013;25390.</Citation><ArticleIdList><ArticleId IdType="pubmed">27015367</ArticleId><ArticleId IdType="pmc">5041911</ArticleId><ArticleId IdType="doi">10.18632/oncotarget.8298</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreassen, P.R., and H. Hanenberg. 2019. XRCC2 (X-ray repair cross complementing 2). Atlas of Genetics and Cytogenetics in Oncology and Haematology 23 (1): 1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">31275435</ArticleId><ArticleId IdType="pmc">6604853</ArticleId></ArticleIdList></Reference><Reference><Citation>Pannunzio, N.R., G. Watanabe, and M.R. Lieber. 2018. Nonhomologous DNA end-joining for repair of DNA double-strand breaks. The Journal of Biological Chemistry 293 (27): 10512&#x2013;10523.</Citation><ArticleIdList><ArticleId IdType="pubmed">29247009</ArticleId><ArticleId IdType="doi">10.1074/jbc.TM117.000374</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedberg, E.C. 2005. Suffering in silence: The tolerance of DNA damage. Nature Reviews Molecular Cell Biology 6 (12): 943&#x2013;953.</Citation><ArticleIdList><ArticleId IdType="pubmed">16341080</ArticleId><ArticleId IdType="doi">10.1038/nrm1781</ArticleId></ArticleIdList></Reference><Reference><Citation>Nohmi, T., and K. Matsumoto. 2020. Effects of DNA polymerase kappa and mismatch repair on dose-responses of chromosome aberrations induced by three oxidative genotoxins in human cells. Environmental and Molecular Mutagenesis 61 (1): 193&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">31294882</ArticleId><ArticleId IdType="doi">10.1002/em.22315</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, X., et al. 2013. Mouse DNA polymerase kappa has a functional role in the repair of DNA strand breaks. DNA Repair 12 (5): 377&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">23522793</ArticleId><ArticleId IdType="pmc">3636179</ArticleId><ArticleId IdType="doi">10.1016/j.dnarep.2013.02.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Zegeye, M.M., et al. 2018. Activation of the JAK/STAT3 and PI3K/AKT pathways are crucial for IL-6 trans-signaling-mediated pro-inflammatory response in human vascular endothelial cells. Cell Communication and Signaling 16 (1): 55.</Citation><ArticleIdList><ArticleId IdType="pubmed">30185178</ArticleId><ArticleId IdType="pmc">6125866</ArticleId><ArticleId IdType="doi">10.1186/s12964-018-0268-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, Q., et al. 2019. Oxidative stress mediated by lipid metabolism contributes to high glucose-induced senescence in retinal pigment epithelium. Free Radical Biology &amp; Medicine 130: 48&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2018.10.419</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang, Y., et al. 2021. Mingmu Xiaomeng Tablets Restore Autophagy and Alleviate Diabetic Retinopathy by Inhibiting PI3K/Akt/mTOR Signaling. Frontiers in Pharmacology 12: 632040.</Citation><ArticleIdList><ArticleId IdType="pubmed">33927618</ArticleId><ArticleId IdType="pmc">8077025</ArticleId><ArticleId IdType="doi">10.3389/fphar.2021.632040</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, X., et al. 2021. Combination therapy with semaglutide and rosiglitazone as a synergistic treatment for diabetic retinopathy in rodent animals. Life Sciences 269: 119013.</Citation><ArticleIdList><ArticleId IdType="pubmed">33417950</ArticleId><ArticleId IdType="doi">10.1016/j.lfs.2020.119013</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, Y.C., et al. 2023. Inhibition of oxidative stress-induced epithelial-mesenchymal transition in retinal pigment epithelial cells of age-related macular degeneration model by suppressing ERK activation. Journal of Advanced Research 60: 14&#x2013;157.</Citation></Reference><Reference><Citation>Anderson, B.D., et al. 2024. Optimizing the sodium iodate model: Effects of dose, gender, and age. Experimental Eye Research 239: 109772.</Citation><ArticleIdList><ArticleId IdType="pubmed">38158173</ArticleId><ArticleId IdType="doi">10.1016/j.exer.2023.109772</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, J., et al. 2014. Direct effect of sodium iodate on neurosensory retina. Investigative Ophthalmology &amp; Visual Science 55 (3): 1941&#x2013;1953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.13-13075</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39581330</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1549-4713</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>22</Day></PubDate></JournalIssue><Title>Ophthalmology</Title><ISOAbbreviation>Ophthalmology</ISOAbbreviation></Journal><ArticleTitle>Visual Loss in Geographic Atrophy: Learnings From the Lampalizumab Trials.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0161-6420(24)00742-5</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ophtha.2024.11.017</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To assess the correlation of lesion growth rate and baseline factors, including foveal involvement and focality, on visual loss as measured by best-corrected visual acuity (BCVA) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective analysis of the lampalizumab phase 3 (NCT02247479 and NCT02247531) and prospective observational (NCT02479386) trials.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Patients with bilateral GA.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Monthly BCVA and fundus autofluorescence (FAF) at baseline and every 6 months for 2 years were analyzed. Baseline GA area from FAF images was correlated to baseline BCVA and change in BCVA. The lesion growth rate was calculated as the slope of a linear fit from all available GA area measurements of a patient. Association between GA growth rate quartiles and BCVA changes were assessed, subgrouped by GA foveal involvement and/or focality. Time-to-event analysis for BCVA loss of &#x2265; 5, &#x2265; 10, and &#x2265;15 letters was performed. A Cox regression model adjusted for baseline factors was performed on these outcomes. Kaplan-Meier (KM) curves are provided for each baseline factor and GA growth rate.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Correlations of baseline BCVA, GA area, and growth rate with change in BCVA, and time to &#x2265; 5, &#x2265; 10, and &#x2265; 15-letter loss by foveal involvement and/or focality.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">BCVA and GA area at baseline did not correlate with BCVA change at any visit. GA growth rate showed a weak correlation with BCVA loss, which increased over time. The 2 highest GA growth rate quartiles had accelerated BCVA loss in eyes with subfoveal, unifocal lesions. Approximately 75%, 50%, and 25% of study eyes experienced a &#x2265; 5-, &#x2265; 10-, and &#x2265; 15-letter loss by 2 years, respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">BCVA and GA area at baseline did not correlate with BCVA loss, but faster GA growth rates appeared to be associated with faster BCVA loss. GA foveal involvement and focality correlated with the rate of BCVA loss with subfoveal lesions at high risk of vision loss over time, especially when the GA lesion was unifocal.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Anegondi</LastName><ForeName>Neha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steffen</LastName><ForeName>Verena</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadda</LastName><ForeName>Srinivas R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Doheny Image Reading Center, Doheny Eye Institute, Pasadena, California; Department of Ophthalmology, University of California - Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmitz-Valckenberg</LastName><ForeName>Steffen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>John A. Moran Eye Center, University of Utah, Salt Lake City, Utah; GRADE Reading Center and Department of Ophthalmology, University of Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tufail</LastName><ForeName>Adnan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Ophthalmology, University College London, London, United Kingdom; Moorfields Eye Hospital, NHS Trust, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Csaky</LastName><ForeName>Karl</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Retina Foundation of the Southwest, Dallas, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lad</LastName><ForeName>Eleonora M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaiser</LastName><ForeName>Peter K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrara</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Genentech, Inc., South San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chakravarthy</LastName><ForeName>Usha</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Queens University of Belfast, Belfast, United Kingdom. Electronic address: u.chakravarthy@qub.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02479386</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ophthalmology</MedlineTA><NlmUniqueID>7802443</NlmUniqueID><ISSNLinking>0161-6420</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BCVA</Keyword><Keyword MajorTopicYN="N">Best-corrected visual acuity</Keyword><Keyword MajorTopicYN="N">Fundus autofluorescence</Keyword><Keyword MajorTopicYN="N">Geographic atrophy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>25</Day><Hour>1</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>25</Day><Hour>1</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>24</Day><Hour>19</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39581330</ArticleId><ArticleId IdType="doi">10.1016/j.ophtha.2024.11.017</ArticleId><ArticleId IdType="pii">S0161-6420(24)00742-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39581257</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-0295</ISSN><JournalIssue CitedMedium="Internet"><Volume>155</Volume><PubDate><Year>2024</Year><Month>Nov</Month><Day>22</Day></PubDate></JournalIssue><Title>Regulatory toxicology and pharmacology : RTP</Title><ISOAbbreviation>Regul Toxicol Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Considerations and derivations of permitted daily exposure limits for impurities from intravitreal pharmaceutical products.</ArticleTitle><Pagination><StartPage>105745</StartPage><MedlinePgn>105745</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.yrtph.2024.105745</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0273-2300(24)00186-7</ELocationID><Abstract><AbstractText>Intravitreal (IVT) injection is an uncommon route of parenteral administration for therapeutic medications, but one of the most important for the treatment of ocular diseases, especially those related to macular degeneration. Nonetheless, there are currently no regulatory guidelines that specifically address how to establish a permitted daily exposure (PDE) for impurities and residual process reagents in IVT pharmaceutical drug products given the unique vulnerability of ocular tissues. The establishment of PDEs for IVT administration is complicated by the limited understanding of metabolism and clearance of small molecular weight chemicals from the human vitreous humor (VH), a problem compounded by the limited IVT-specific toxicological data. In this paper, we describe a feasible and comprehensive methodology for deriving PDE limits for impurities and residual process reagents from IVT drug products, as exemplified by five case studies, including inorganic elements, formic acid, polyethylene glycols, acetic acid, and caprolactam. The five case studies were selected to cover compounds with a wide range of impurity sources and toxicological data availability. The proposed framework considers both local ocular and systemic toxicity endpoints and advances the goal of a harmonized, science-based approach for deriving IVT PDE limits.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yu Rice</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Amgen Inc., Thousand Oaks, CA, 93010, USA. Electronic address: yyurice@amgen.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dolan</LastName><ForeName>David G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Amgen Inc., Thousand Oaks, CA, 93010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bandara</LastName><ForeName>Suren B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Amgen Inc., Thousand Oaks, CA, 93010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>Ryan E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Amgen Inc., Thousand Oaks, CA, 93010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garry</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Exponent, Inc., Bellevue, WA, 98007, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsuji</LastName><ForeName>Joyce</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Exponent, Inc., Bellevue, WA, 98007, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Regul Toxicol Pharmacol</MedlineTA><NlmUniqueID>8214983</NlmUniqueID><ISSNLinking>0273-2300</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acetic acid</Keyword><Keyword MajorTopicYN="N">Caprolactam</Keyword><Keyword MajorTopicYN="N">Formic acid</Keyword><Keyword MajorTopicYN="N">Inorganic elements</Keyword><Keyword MajorTopicYN="N">Intravitreal (IVT) administration</Keyword><Keyword MajorTopicYN="N">Permitted daily exposure (PDE)</Keyword><Keyword MajorTopicYN="N">Polyethylene glycols</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>25</Day><Hour>1</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>25</Day><Hour>1</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>24</Day><Hour>19</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39581257</ArticleId><ArticleId IdType="doi">10.1016/j.yrtph.2024.105745</ArticleId><ArticleId IdType="pii">S0273-2300(24)00186-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39580658</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1742-4658</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>24</Day></PubDate></JournalIssue><Title>The FEBS journal</Title><ISOAbbreviation>FEBS J</ISOAbbreviation></Journal><ArticleTitle>Antioxidant properties of the soluble carotenoprotein AstaP and its feasibility for retinal protection against oxidative stress.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/febs.17335</ELocationID><Abstract><AbstractText>Photodamage to the outer segments of photoreceptor cells and their impaired utilization by retinal pigment epithelium (RPE) cells contribute to the development of age-related macular degeneration (AMD) leading to blindness. Degeneration of photoreceptor cells and RPE cells is triggered by reactive oxygen species (ROS) produced by photochemical reactions involving bisretinoids, by-products of the visual cycle, which accumulate in photoreceptor discs and lipofuscin granules of RPE. Carotenoids, natural antioxidants with high potential efficacy against a wide range of ROS, may protect against the cytotoxic properties of lipofuscin. To solve the problem of high hydrophobicity of carotenoids and increase their bioaccessibility, specialized proteins can ensure their targeted delivery to the affected tissues. In this study, we present new capabilities of the recombinant water-soluble protein AstaP from Coelastrella astaxanthina Ki-4 (Scenedesmaceae) for protein-mediated carotenoid delivery and demonstrate how zeaxanthin delivery suppresses oxidative stress in a lipofuscin-enriched model of photoreceptor and pigment epithelium cells. AstaP in complex with zeaxanthin can effectively scavenge various ROS (singlet oxygen, free radical cations, hydrogen peroxide) previously reported to be generated in AMD. In addition, we explore the potential of optimizing the structure of AstaP to enhance its thermal stability and resistance to proteolytic activity in the ocular media. This optimization aims to maximize the prevention of retinal degenerative changes in AMD.</AbstractText><CopyrightInformation>&#xa9; 2024 Federation of European Biochemical Societies.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lunegova</LastName><ForeName>Daria A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Faculty of Biology, M.V. Lomonosov Moscow State University, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Federal Research Center of Biotechnology, Russian Academy of Sciences, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gvozdev</LastName><ForeName>Danil A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Faculty of Biology, M.V. Lomonosov Moscow State University, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Senin</LastName><ForeName>Ivan I</ForeName><Initials>II</Initials><AffiliationInfo><Affiliation>Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gudkova</LastName><ForeName>Victoria R</ForeName><Initials>VR</Initials><AffiliationInfo><Affiliation>Faculty of Biology, M.V. Lomonosov Moscow State University, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sidorenko</LastName><ForeName>Svetlana V</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>Faculty of Biology, M.V. Lomonosov Moscow State University, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tiulina</LastName><ForeName>Veronika V</ForeName><Initials>VV</Initials><AffiliationInfo><Affiliation>Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shebardina</LastName><ForeName>Natalia G</ForeName><Initials>NG</Initials><AffiliationInfo><Affiliation>Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yakovleva</LastName><ForeName>Marina A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Tatiana B</ForeName><Initials>TB</Initials><AffiliationInfo><Affiliation>Faculty of Biology, M.V. Lomonosov Moscow State University, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramonova</LastName><ForeName>Alla A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Faculty of Biology, M.V. Lomonosov Moscow State University, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moysenovich</LastName><ForeName>Anastasia M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Faculty of Biology, M.V. Lomonosov Moscow State University, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Semenov</LastName><ForeName>Alexey N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Faculty of Biology, M.V. Lomonosov Moscow State University, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zernii</LastName><ForeName>Evgeni Yu</ForeName><Initials>EY</Initials><Identifier Source="ORCID">0000-0002-3013-7863</Identifier><AffiliationInfo><Affiliation>Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maksimov</LastName><ForeName>Eugene G</ForeName><Initials>EG</Initials><Identifier Source="ORCID">0000-0001-6767-1501</Identifier><AffiliationInfo><Affiliation>Faculty of Biology, M.V. Lomonosov Moscow State University, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sluchanko</LastName><ForeName>Nikolai N</ForeName><Initials>NN</Initials><Identifier Source="ORCID">0000-0002-8608-1416</Identifier><AffiliationInfo><Affiliation>Federal Research Center of Biotechnology, Russian Academy of Sciences, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirpichnikov</LastName><ForeName>Mikhail P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Faculty of Biology, M.V. Lomonosov Moscow State University, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostrovsky</LastName><ForeName>Mikhail A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Faculty of Biology, M.V. Lomonosov Moscow State University, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, Moscow, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>23-SH04-09</GrantID><Agency>Interdisciplinary Scientific and Educational School of Lomonosov Moscow State University 'Molecular Technologies of the Living Systems and Synthetic Biology'</Agency><Country/></Grant><Grant><GrantID>24-15-00171</GrantID><Agency>Russian Science Foundation</Agency><Country/></Grant><Grant><Agency>Program of the Ministry of Science and Higher Education of the Russian Federation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>FEBS J</MedlineTA><NlmUniqueID>101229646</NlmUniqueID><ISSNLinking>1742-464X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ROS</Keyword><Keyword MajorTopicYN="N">carotenoids</Keyword><Keyword MajorTopicYN="N">lipofuscin</Keyword><Keyword MajorTopicYN="N">photoreceptors</Keyword><Keyword MajorTopicYN="N">retinal pigment epithelium</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>25</Day><Hour>1</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>25</Day><Hour>1</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>24</Day><Hour>7</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39580658</ArticleId><ArticleId IdType="doi">10.1111/febs.17335</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Fleckenstein M, Keenan TDL, Guymer RH, Chakravarthy U, Schmitz&#x2010;Valckenberg S, Klaver CC, Wong WT &amp; Chew EY (2021) Age&#x2010;related macular degeneration. Nat Rev Dis Primers 7, 1&#x2013;25.</Citation></Reference><Reference><Citation>Beatty S, Koh H, Phil M, Henson D &amp; Boulton M (2000) The role of oxidative stress in the pathogenesis of age&#x2010;related macular degeneration. Surv Ophthalmol 45, 115&#x2013;134.</Citation></Reference><Reference><Citation>Quazi F, Lenevich S &amp; Molday RS (2012) ABCA4 is an N&#x2010;retinylidene&#x2010;phosphatidylethanolamine and phosphatidylethanolamine importer. Nat Commun 3, 925.</Citation></Reference><Reference><Citation>Scortecci JF, Molday LL, Curtis SB, Garces FA, Panwar P, Van Petegem F &amp; Molday RS (2021) Cryo&#x2010;EM structures of the ABCA4 importer reveal mechanisms underlying substrate binding and Stargardt disease. Nat Commun 12, 5902.</Citation></Reference><Reference><Citation>Quazi F &amp; Molday RS (2014) ATP&#x2010;binding cassette transporter ABCA4 and chemical isomerization protect photoreceptor cells from the toxic accumulation of excess 11&#x2010;cis&#x2010;retinal. Proc Natl Acad Sci USA 111, 5024&#x2013;5029.</Citation></Reference><Reference><Citation>Boyer NP, Higbee D, Currin MB, Blakeley LR, Chen C, Ablonczy Z, Crouch RK &amp; Koutalos Y (2012) Lipofuscin and N&#x2010;retinylidene&#x2010;N&#x2010;retinylethanolamine (A2E) accumulate in retinal pigment epithelium in absence of light exposure: their origin is 11&#x2010;cis&#x2010;retinal. J Biol Chem 287, 22276&#x2013;22286.</Citation></Reference><Reference><Citation>Mata NL, Weng J &amp; Travis GH (2000) Biosynthesis of a major lipofuscin fluorophore in mice and humans with ABCR&#x2010;mediated retinal and macular degeneration. Proc Natl Acad Sci USA 97, 7154&#x2013;7159.</Citation></Reference><Reference><Citation>Weng J, Mata NL, Azarian SM, Tzekov RT, Birch DG &amp; Travis GH (1999) Insights into the function of Rim protein in photoreceptors and etiology of Stargardt's disease from the phenotype in abcr knockout mice. Cell 98, 13&#x2013;23.</Citation></Reference><Reference><Citation>Hunter JJ, Morgan JIW, Merigan WH, Sliney DH, Sparrow JR &amp; Williams DR (2012) The susceptibility of the retina to photochemical damage from visible light. Prog Retin Eye Res 31, 28&#x2013;42.</Citation></Reference><Reference><Citation>Maeda T, Golczak M &amp; Maeda A (2012) Retinal photodamage mediated by all&#x2010;trans&#x2010;retinal. Photochem Photobiol 88, 1309&#x2013;1319.</Citation></Reference><Reference><Citation>Baksheeva VE, Tiulina VV, Tikhomirova NK, Gancharova OS, Komarov SV, Philippov PP, Zamyatnin AA, Senin II &amp; Zernii EY (2019) Suppression of light&#x2010;induced oxidative stress in the retina by mitochondria&#x2010;targeted antioxidant. Antioxidants 8, 3.</Citation></Reference><Reference><Citation>Hall MO &amp; Hall DO (1975) Superoxide dismutase of bovine and frog rod outer segments. Biochem Biophys Res Commun 67, 1199&#x2013;1204.</Citation></Reference><Reference><Citation>Organisciak DT &amp; Vaughan DK (2010) Retinal light damage: mechanisms and protection. Prog Retin Eye Res 29, 113&#x2013;134.</Citation></Reference><Reference><Citation>Fritsche LG, Fleckenstein M, Fiebig BS, Schmitz&#x2010;Valckenberg S, Bindewald&#x2010;Wittich A, Keilhauer CN, Renner AB, Mackensen F, M&#xf6;&#xdf;ner A, Pauleikhoff D et&#xa0;al. (2012) A subgroup of age&#x2010;related macular degeneration is associated with mono&#x2010;allelic sequence variants in the ABCA4 gene. Invest Ophthalmol Vis Sci 53, 2112&#x2013;2118.</Citation></Reference><Reference><Citation>Caceres PS &amp; Rodriguez&#x2010;Boulan E (2020) Retinal pigment epithelium polarity in health and blinding diseases. Curr Opin Cell Biol 62, 37&#x2013;45.</Citation></Reference><Reference><Citation>Lakkaraju A, Umapathy A, Tan LX, Daniele L, Philp NJ, Boesze&#x2010;Battaglia K &amp; Williams DS (2020) The cell biology of the retinal pigment epithelium. Prog Retin Eye Res 78, 100846.</Citation></Reference><Reference><Citation>Strauss O (2005) The retinal pigment epithelium in visual function. Physiol Rev 85, 845&#x2013;881.</Citation></Reference><Reference><Citation>Boulton M, Dontsov A, Jarvis&#x2010;Evans J, Ostrovsky M &amp; Svistunenko D (1993) Lipofuscin is a photoinducible free radical generator. J Photochem Photobiol B Biol 19, 201&#x2013;204.</Citation></Reference><Reference><Citation>Wassell J, Davies S, Bardsley W &amp; Boulton M (1999) The photoreactivity of the retinal age pigment lipofuscin. J Biol Chem 274, 23828&#x2013;23832.</Citation></Reference><Reference><Citation>Sch&#xfc;tt F, Davies S, Kopitz J, Holz FG &amp; Boulton ME (2000) Photodamage to human RPE cells by A2&#x2010;E, a retinoid component of lipofuscin. Invest Ophthalmol Vis Sci 41, 2303&#x2013;2308.</Citation></Reference><Reference><Citation>Sparrow JR, Zhou J &amp; Cai B (2003) DNA is a target of the photodynamic effects elicited in A2E&#x2010;laden RPE by blue&#x2010;light illumination. Invest Ophthalmol Vis Sci 44, 2245&#x2013;2251.</Citation></Reference><Reference><Citation>Britton G, ed. (2004) Carotenoids: Handbook. Birkh&#xe4;user, Basel; Boston, MA; Berlin.</Citation></Reference><Reference><Citation>Pishchalnikov RY, Yaroshevich IA, Slastnikova TA, Ashikhmin AA, Stepanov AV, Slutskaya EA, Friedrich T, Sluchanko NN &amp; Maksimov EG (2019) Structural peculiarities of keto&#x2010;carotenoids in water&#x2010;soluble proteins revealed by simulation of linear absorption. Phys Chem Chem Phys 21, 25707&#x2013;25719.</Citation></Reference><Reference><Citation>Maksimov EG, Zamaraev AV, Parshina EY, Slonimskiy YB, Slastnikova TA, Abdrakhmanov AA, Babaev PA, Efimova SS, Ostroumova OS, Stepanov AV et&#xa0;al. (2020) Soluble cyanobacterial carotenoprotein as a robust antioxidant nanocarrier and delivery module. Antioxidants 9, 869.</Citation></Reference><Reference><Citation>Sluchanko NN, Slonimskiy YB, Egorkin NA, Varfolomeeva LA, Faletrov YV, Moysenovich AM, Parshina EY, Friedrich T, Maksimov EG, Boyko KM et&#xa0;al. (2022) Silkworm carotenoprotein as an efficient carotenoid extractor, solubilizer and transporter. Int J Biol Macromol 223, 1381&#x2013;1393.</Citation></Reference><Reference><Citation>Sluchanko NN, Slonimskiy YB, Egorkin NA, Varfolomeeva LA, Kleymenov SY, Minyaev ME, Faletrov YV, Moysenovich AM, Parshina EY, Friedrich T et&#xa0;al. (2022) Structural basis for the carotenoid binding and transport function of a START domain. Structure 30, 1647&#x2013;1659.e4.</Citation></Reference><Reference><Citation>Slonimskiy YB, Egorkin NA, Ashikhmin AA, Friedrich T, Maksimov EG &amp; Sluchanko NN (2022) Reconstitution of the functional carotenoid&#x2010;binding protein from silkworm in E. coli. Int J Biol Macromol 214, 664&#x2013;671.</Citation></Reference><Reference><Citation>Semenov AN, Maksimov EG, Moysenovich AM, Yakovleva MA, Tsoraev GV, Ramonova AA, Shirshin EA, Sluchanko NN, Feldman TB, Rubin AB et&#xa0;al. (2023) Protein&#x2010;mediated carotenoid delivery suppresses the photoinducible oxidation of lipofuscin in retinal pigment epithelial cells. Antioxidants 12, 413.</Citation></Reference><Reference><Citation>M&#xfc;nch M &amp; Kawasaki A (2013) Intrinsically photosensitive retinal ganglion cells: classification, function and clinical implications. Curr Opin Neurol 26, 45&#x2013;51.</Citation></Reference><Reference><Citation>Slonimskiy YB, Egorkin NA, Friedrich T, Maksimov EG &amp; Sluchanko NN (2022) Microalgal protein AstaP is a potent carotenoid solubilizer and delivery module with a broad carotenoid binding repertoire. FEBS J 289, 999&#x2013;1022.</Citation></Reference><Reference><Citation>Kawasaki S, Mizuguchi K, Sato M, Kono T &amp; Shimizu H (2013) A novel astaxanthin&#x2010;binding photooxidative stress&#x2010;inducible aqueous carotenoprotein from a eukaryotic microalga isolated from asphalt in midsummer. Plant Cell Physiol 54, 1027&#x2013;1040.</Citation></Reference><Reference><Citation>Kornilov FD, Slonimskiy YB, Lunegova DA, Egorkin NA, Savitskaya AG, Kleymenov SY, Maksimov EG, Goncharuk SA, Mineev KS &amp; Sluchanko NN (2023) Structural basis for the ligand promiscuity of the neofunctionalized, carotenoid&#x2010;binding fasciclin domain protein AstaP. Commun Biol 6, 1&#x2013;14.</Citation></Reference><Reference><Citation>Feldman TB, Dontsov AE, Yakovleva MA &amp; Ostrovsky MA (2022) Photobiology of lipofuscin granules in the retinal pigment epithelium cells of the eye: norm, pathology, age. Biophys Rev 14, 1051&#x2013;1065.</Citation></Reference><Reference><Citation>Halat M, Zaj&#x105;c G, Kaczor A &amp; Baranska M (2017) Resonance Raman optical activity of zeaxanthin aggregates. J Raman Spectrosc 48, 673&#x2013;679.</Citation></Reference><Reference><Citation>Gvozdev DA, Ramonova AA, Maksimov EG &amp; Paschenko VZ (2020) Specific features of the interaction between chemical traps and phthalocyanine dyes affecting the measurement of the yield of reactive oxygen species. Dyes Pigm 181, 108538.</Citation></Reference><Reference><Citation>Lam LA, Mehta S, Lad EM, Emerson GG, Jumper JM, Awh CC &amp; Task Force on Intravitreal Injection Supplemental Services (2021) Intravitreal injection therapy: current techniques and supplemental services. J Vitreoretin Dis 5, 438&#x2013;447.</Citation></Reference><Reference><Citation>Toomey MB &amp; Corbo JC (2017) Evolution, development and function of vertebrate cone oil droplets. Front Neural Circuits 11, 97.</Citation></Reference><Reference><Citation>Grudzinski W, Luchowski R, Ostrowski J, S&#x119;k A, Mendes Pinto MM, Welc&#x2010;Stanowska R, Zubik&#x2010;Duda M, Teresi&#x144;ski G, Rejdak R &amp; Gruszecki WI (2023) Physiological significance of the heterogeneous distribution of zeaxanthin and lutein in the retina of the human eye. Int J Mol Sci 24, 10702.</Citation></Reference><Reference><Citation>Vaughan&#x2010;Thomas A, Gilbert SJ &amp; Duance VC (2000) Elevated levels of proteolytic enzymes in the aging human vitreous. Invest Ophthalmol Vis Sci 41, 3299&#x2013;3304.</Citation></Reference><Reference><Citation>Garc&#xed;a&#x2010;Quintanilla L, Luaces&#x2010;Rodr&#xed;guez A, Gil&#x2010;Mart&#xed;nez M, Mondelo&#x2010;Garc&#xed;a C, Maro&#xf1;as O, Mangas&#x2010;Sanjuan V, Gonz&#xe1;lez&#x2010;Barcia M, Zarra&#x2010;Ferro I, Aguiar P, Otero&#x2010;Espinar FJ et&#xa0;al. (2019) Pharmacokinetics of intravitreal anti&#x2010;VEGF drugs in age&#x2010;related macular degeneration. Pharmaceutics 11, 365.</Citation></Reference><Reference><Citation>Rose RC, Gogia R &amp; Richer SP (1997) Properties of electrochemically active components in mammalian vitreous humor. Exp Eye Res 64, 807&#x2013;812.</Citation></Reference><Reference><Citation>Trevithick&#x2010;Sutton CC, Foote CS, Collins M &amp; Trevithick JR (2006) The retinal carotenoids zeaxanthin and lutein scavenge superoxide and hydroxyl radicals: a chemiluminescence and ESR study. Mol Vis 12, 1127&#x2013;1135.</Citation></Reference><Reference><Citation>G&#xfc;rol I, Durmu&#x15f; M, Ahsen V &amp; Nyokong T (2007) Synthesis, photophysical and photochemical properties of substituted zinc phthalocyanines. Dalton Trans 3782&#x2013;3791.</Citation></Reference><Reference><Citation>Groeneveld I, Kanelli M, Ariese F &amp; van Bommel MR (2023) Parameters that affect the photodegradation of dyes and pigments in solution and on substrate &#x2013; an overview. Dyes Pigm 210, 110999.</Citation></Reference><Reference><Citation>Gvozdev DA, Maksimov EG &amp; Paschenko VZ (2020) Photobleaching of phthalocyanine molecules within a complex with colloidal quantum dots. Moscow Univ Biol Sci Bull 75, 7&#x2013;12.</Citation></Reference><Reference><Citation>Ilyasov IR, Beloborodov VL, Selivanova IA &amp; Terekhov RP (2020) ABTS/PP decolorization assay of antioxidant capacity reaction pathways. Int J Mol Sci 21, 1131.</Citation></Reference><Reference><Citation>Re R, Pellegrini N, Proteggente A, Pannala A, Yang M &amp; Rice&#x2010;Evans C (1999) Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radic Biol Med 26, 1231&#x2013;1237.</Citation></Reference><Reference><Citation>Feldman TB, Yakovleva MA, Arbukhanova PM, Borzenok SA, Kononikhin AS, Popov IA, Nikolaev EN &amp; Ostrovsky MA (2015) Changes in spectral properties and composition of lipofuscin fluorophores from human&#x2010;retinal&#x2010;pigment epithelium with age and pathology. Anal Bioanal Chem 407, 1075&#x2013;1088.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39580292</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">0219-3108</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>22</Day></PubDate></JournalIssue><Title>Asian journal of surgery</Title><ISOAbbreviation>Asian J Surg</ISOAbbreviation></Journal><ArticleTitle>Identification of a novel mutation in the PROM1 gene associated with autosomal dominant Stargardt disease.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1015-9584(24)02598-3</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.asjsur.2024.10.264</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Weiguang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine and Clinical Laboratory, Shaoxing Second Hospital, Shaoxing, 312000, China. Electronic address: zwgisme@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tu</LastName><ForeName>Yongtao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine and Clinical Laboratory, Shaoxing Second Hospital, Shaoxing, 312000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Pingyu</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Shaoxing Second Hospital, Shaoxing, 312000, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Asian J Surg</MedlineTA><NlmUniqueID>8900600</NlmUniqueID><ISSNLinking>1015-9584</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Declaration of competing interest The authors declare no potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>24</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>24</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>23</Day><Hour>21</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39580292</ArticleId><ArticleId IdType="doi">10.1016/j.asjsur.2024.10.264</ArticleId><ArticleId IdType="pii">S1015-9584(24)02598-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39579046</PMID><DateCompleted><Year>2024</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0970</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>14</Issue><PubDate><Year>2024</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Multiple sclerosis (Houndmills, Basingstoke, England)</Title><ISOAbbreviation>Mult Scler</ISOAbbreviation></Journal><ArticleTitle>Homonymous hemi-macular atrophy in multiple sclerosis.</ArticleTitle><Pagination><StartPage>1802</StartPage><EndPage>1814</EndPage><MedlinePgn>1802-1814</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/13524585241297816</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Retrograde trans-synaptic degeneration (TSD) following retro-chiasmal pathology, typically retro-geniculate in multiple sclerosis (MS), may manifest as homonymous hemi-macular atrophy (HHMA) of the ganglion cell/inner plexiform layer (GCIPL).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To determine the frequency, association with clinical outcomes, and retinal and radiological features of HHMA in people with MS (PwMS).</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">In this cross-sectional study, healthy controls (HC) and PwMS underwent retinal optical coherence tomography scanning. For quantitative identification of HHMA, a normalized asymmetry ratio was used, and its normative cutoffs were established from the HC. HHMA PwMS were propensity score matched 1:2 to non-HHMA PwMS. Mixed-effects linear regression models were used in analyses.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Based on normative data from 238 HC (466 eyes), 79 out of 942 PwMS exhibited HHMA (8.4%; 143 eyes). Compared to non-HHMA eyes from matched PwMS (158 PwMS; 308 eyes), HHMA eyes had lower average GCIPL (diff: -5.7 &#x3bc;m (95% CI -7.6 to -3.8); <i>p</i> &lt; 0.001) but also inner nuclear layer (diff: -0.9 &#x3bc;m (95% CI -1.6 to -0.1); <i>p</i> = 0.02), and outer nuclear layer (diff: -1.9 &#x3bc;m (95% CI -3.4 to -0.4); <i>p</i> = 0.02) thicknesses; in further analyses, these differences were exclusive to the homonymous side of HHMA. HHMA participants also exhibited higher expanded disability status scale scores (diff: 0.5 (95% CI 0.1 to 0.9); <i>p</i> = 0.02), worse 100% and 2.5% visual acuity scores (diff: -3.2 (95% CI -4.1 to -1.0); <i>p</i> = 0.002, -5.4 (95% CI -7.5 to -3.5); <i>p</i> &lt; 0.001), and higher frequency of microcystoid macular changes (10.1% vs. 3.2%; <i>p</i> = 0.03) compared to non-HHMA participants.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">HHMA, possibly as a marker of TSD, may signify higher disability in MS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kalaitzidis</LastName><ForeName>Grigorios</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-7680-3609</Identifier><AffiliationInfo><Affiliation>Division of Neuroimmunology and Neurological Infections, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Boston University Chobanian &amp; Avedisian School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ezzedin</LastName><ForeName>Omar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Division of Neuroimmunology and Neurological Infections, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bacchetti</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Neuroimmunology and Neurological Infections, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moussa</LastName><ForeName>Hussein</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Neuroimmunology and Neurological Infections, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Olwen C</ForeName><Initials>OC</Initials><Identifier Source="ORCID">0000-0001-7880-8948</Identifier><AffiliationInfo><Affiliation>Division of Neuroimmunology and Neurological Infections, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Filippatou</LastName><ForeName>Angeliki G</ForeName><Initials>AG</Initials><Identifier Source="ORCID">0000-0003-0419-233X</Identifier><AffiliationInfo><Affiliation>Division of Neuroimmunology and Neurological Infections, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ehrhardt</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Neuroimmunology and Neurological Infections, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasileiou</LastName><ForeName>Eleni</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Neuroimmunology and Neurological Infections, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pellegrini</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Neuroimmunology and Neurological Infections, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Simidele</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Neuroimmunology and Neurological Infections, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Douglas</LastName><ForeName>Morgan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Neuroimmunology and Neurological Infections, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fitzgerald</LastName><ForeName>Kathryn C</ForeName><Initials>KC</Initials><Identifier Source="ORCID">0000-0003-3137-0322</Identifier><AffiliationInfo><Affiliation>Division of Neuroimmunology and Neurological Infections, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DuVal</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Neuroimmunology and Neurological Infections, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Douglas Newsome</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Neuroimmunology and Neurological Infections, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sotirchos</LastName><ForeName>Elias S</ForeName><Initials>ES</Initials><Identifier Source="ORCID">0000-0002-8812-1637</Identifier><AffiliationInfo><Affiliation>Division of Neuroimmunology and Neurological Infections, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nourbakhsh</LastName><ForeName>Bardia</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-6617-2003</Identifier><AffiliationInfo><Affiliation>Division of Neuroimmunology and Neurological Infections, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dewey</LastName><ForeName>Blake E</ForeName><Initials>BE</Initials><Identifier Source="ORCID">0000-0003-4554-5058</Identifier><AffiliationInfo><Affiliation>Division of Neuroimmunology and Neurological Infections, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prince</LastName><ForeName>Jerry</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Electrical and Computer Engineering, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saidha</LastName><ForeName>Shiv</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6387-0714</Identifier><AffiliationInfo><Affiliation>Division of Neuroimmunology and Neurological Infections, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calabresi</LastName><ForeName>Peter A</ForeName><Initials>PA</Initials><Identifier Source="ORCID">0000-0002-7776-6472</Identifier><AffiliationInfo><Affiliation>Division of Neuroimmunology and Neurological Infections, Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mult Scler</MedlineTA><NlmUniqueID>9509185</NlmUniqueID><ISSNLinking>1352-4585</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D041623" MajorTopicYN="Y">Tomography, Optical Coherence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="Y">Atrophy</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="Y">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012165" MajorTopicYN="N">Retinal Ganglion Cells</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008266" MajorTopicYN="N">Macula Lutea</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012183" MajorTopicYN="N">Retrograde Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Trans-synaptic degeneration</Keyword><Keyword MajorTopicYN="N">ganglion cell/inner plexiform layer</Keyword><Keyword MajorTopicYN="N">homonymous hemi-macular atrophy</Keyword><Keyword MajorTopicYN="N">microcystoid macular pathology</Keyword><Keyword MajorTopicYN="N">multiple sclerosis</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">optical coherence tomography</Keyword></KeywordList><CoiStatement>Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: OCM receives funding from the Race to Erase MS Foundation.KCF reports research funding from NIH, NMSS, and the DoD. She has served on Data and Safety Monitoring Boards for trials funded by the NIH and NMSS, and has received honorarium for serving as an external thesis committee reviewer.SDN reports grants or contracts from Biogen, Roche, Genentech, National Multiple Sclerosis Society, Department of Defense, and Patient Centered Outcomes Research Institute; personal compensation for consulting from Biogen, Roche, Genentech, Bristol Myers Squibb, EMD Serono, Greenwich Biosciences, Novartis, and Horizon Therapeutics; and participation on a Data Safety Monitoring Board or Advisory Board for MedDay Pharmaceuticals. SDN also reports support from the Stiff Person Syndrome Research Foundation.ESS reports scientific advisory boards and/or consulting for Alexion, Viela Bio, Horizon Therapeutics, Genentech, and Ad Scientiam; speaking honoraria from Alexion, Viela Bio, and Biogen.BN has received research funding from the NMSS, DoD, NIH, PCORI, and Genentech.JP is a founder of Sonovex, Inc. and serves on its Board of Directors, and has received consulting fees from JuneBrain LLC and is PI on research grants to Johns Hopkins from Genentech and Biogen.SS has received consulting fees from Medical Logix for the development of CME programs in neurology and has served on scientific advisory boards for Biogen, Genzyme, Genentech Corporation, EMD Serono, and Celgene. He is the PI of investigator-initiated studies funded by Genentech and Biogen, was the site investigator of a trial sponsored by MedDay Pharmaceuticals and received support from the Race to Erase MS foundation. He has consulted for Carl Zeiss Meditec, and has received equity compensation for consulting from JuneBrain LLC, a retinal imaging device developer.PAC has received consulting fees from Disarm, Nervgen, and Biogen and is Principal Investigator on grants to JHU from Biogen, Genentech, Prinicpia, and Annexon.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>24</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>23</Day><Hour>7</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>12</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39579046</ArticleId><ArticleId IdType="doi">10.1177/13524585241297816</ArticleId><ArticleId IdType="pmc">PMC11617262</ArticleId><ArticleId IdType="mid">NIHMS2031223</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dutta R, Trapp BD. Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol. 2011;93(1):1&#x2013;12. doi:10.1016/j.pneurobio.2010.09.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2010.09.005</ArticleId><ArticleId IdType="pmc">PMC3030928</ArticleId><ArticleId IdType="pubmed">20946934</ArticleId></ArticleIdList></Reference><Reference><Citation>Azevedo CJ, Cen SY, Khadka S, et al. Thalamic atrophy in multiple sclerosis: A magnetic resonance imaging marker of neurodegeneration throughout disease. Ann Neurol. 2018;83(2):223&#x2013;234. doi:10.1002/ana.25150</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25150</ArticleId><ArticleId IdType="pmc">PMC6317847</ArticleId><ArticleId IdType="pubmed">29328531</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy OC, Calabresi PA, Saidha S. Trans-synaptic degeneration as a mechanism of neurodegeneration in multiple sclerosis. Neural Regen Res. 2023;18(12):2682&#x2013;2684. doi:10.4103/1673-5374.373661</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.373661</ArticleId><ArticleId IdType="pmc">PMC10358689</ArticleId><ArticleId IdType="pubmed">37449621</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy OC, Sotirchos ES, Kalaitzidis G, et al. Trans-Synaptic Degeneration Following Acute Optic Neuritis in Multiple Sclerosis. Ann Neurol. 2023;93(1):76&#x2013;87. doi:10.1002/ana.26529</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26529</ArticleId><ArticleId IdType="pmc">PMC9933774</ArticleId><ArticleId IdType="pubmed">36218157</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Louzi O, Button J, Newsome SD, Calabresi PA, Saidha S. Retrograde trans-synaptic visual pathway degeneration in multiple sclerosis: A case series. Mult Scler. 2017;23(7):1035&#x2013;1039. doi:10.1177/1352458516679035</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458516679035</ArticleId><ArticleId IdType="pmc">PMC5451303</ArticleId><ArticleId IdType="pubmed">28385128</ArticleId></ArticleIdList></Reference><Reference><Citation>Jindahra P, Petrie A, Plant GT. The time course of retrograde trans-synaptic degeneration following occipital lobe damage in humans. Brain. 2012;135(Pt 2):534&#x2013;541. doi:10.1093/brain/awr324</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr324</ArticleId><ArticleId IdType="pubmed">22300877</ArticleId></ArticleIdList></Reference><Reference><Citation>Klistorner A, Graham EC, Yiannikas C, et al. Progression of retinal ganglion cell loss in multiple sclerosis is associated with new lesions in the optic radiations. Eur J Neurol. 2017;24(11):1392&#x2013;1398. doi:10.1111/ene.13404</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13404</ArticleId><ArticleId IdType="pubmed">28799222</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinnecker T, Oberwahrenbrock T, Metz I, et al. Optic radiation damage in multiple sclerosis is associated with visual dysfunction and retinal thinning--an ultrahigh-field MR pilot study. Eur Radiol. 2015;25(1):122&#x2013;131. doi:10.1007/s00330-014-3358-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00330-014-3358-8</ArticleId><ArticleId IdType="pubmed">25129119</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell JR, Oliveira C, Tsiouris AJ, Dinkin MJ. Corresponding Ganglion Cell Atrophy in Patients With Postgeniculate Homonymous Visual Field Loss. J Neuroophthalmol. 2015;35(4):353&#x2013;359. doi:10.1097/WNO.0000000000000268</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WNO.0000000000000268</ArticleId><ArticleId IdType="pubmed">26035806</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;hlemann F, Grabe H, Fok A, et al. Homonymous hemiatrophy of ganglion cell layer from retrochiasmal lesions in the visual pathway. Neurology. 2020;94(3):e323&#x2013;e329. doi:10.1212/WNL.0000000000008738</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008738</ArticleId><ArticleId IdType="pubmed">31848256</ArticleId></ArticleIdList></Reference><Reference><Citation>Saidha S, Sotirchos ES, Ibrahim MA, et al. Relationships of the inner nuclear layer of the retina with clinicoradiologic disease characteristics in multiple sclerosis; Aretrospective study. Lancet Neurol. 2012;11(11):963&#x2013;972. doi:10.1016/S1474-4422(12)70213-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70213-2</ArticleId><ArticleId IdType="pmc">PMC3533139</ArticleId><ArticleId IdType="pubmed">23041237</ArticleId></ArticleIdList></Reference><Reference><Citation>Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292&#x2013;302. doi:10.1002/ana.22366</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22366</ArticleId><ArticleId IdType="pmc">PMC3084507</ArticleId><ArticleId IdType="pubmed">21387374</ArticleId></ArticleIdList></Reference><Reference><Citation>Syc SB, Warner CV, Hiremath GS, et al. Reproducibility of high-resolution optical coherence tomography in multiple sclerosis. Mult Scler. 2010;16(7):829&#x2013;839. doi:10.1177/1352458510371640</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458510371640</ArticleId><ArticleId IdType="pubmed">20530512</ArticleId></ArticleIdList></Reference><Reference><Citation>Tewarie P, Balk L, Costello F, et al. The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS One. 2012;7(4):e34823. doi:10.1371/journal.pone.0034823</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0034823</ArticleId><ArticleId IdType="pmc">PMC3334941</ArticleId><ArticleId IdType="pubmed">22536333</ArticleId></ArticleIdList></Reference><Reference><Citation>Schippling S, Balk LJ, Costello F, et al. Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria. Mult Scler. 2015;21(2):163&#x2013;170. doi:10.1177/1352458514538110</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458514538110</ArticleId><ArticleId IdType="pubmed">24948688</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang A, Carass A, Al-Louzi O, et al. Combined registration and motion correction of longitudinal retinal OCT data. Proc SPIE Int Soc Opt Eng. 2016;9784:97840X. doi:10.1117/12.2217157</Citation><ArticleIdList><ArticleId IdType="doi">10.1117/12.2217157</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Louzi O, Sotirchos ES, Vidal-Jordana A, et al. Characteristics of morphologic macular abnormalities in neuroimmunology practice. Mult Scler. 2019;25(3):361&#x2013;371. doi:10.1177/1352458517741206</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458517741206</ArticleId><ArticleId IdType="pmc">PMC6929206</ArticleId><ArticleId IdType="pubmed">29125422</ArticleId></ArticleIdList></Reference><Reference><Citation>Aytulun A, Cruz-Herranz A, Aktas O, et al. APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies. Neurology. 2021;97(2):68&#x2013;79. doi:10.1212/WNL.0000000000012125</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000012125</ArticleId><ArticleId IdType="pmc">PMC8279566</ArticleId><ArticleId IdType="pubmed">33910937</ArticleId></ArticleIdList></Reference><Reference><Citation>A C, Lj B, T O, et al. The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurology. 2016;86(24). doi:10.1212/WNL.0000000000002774</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002774</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolan-Kenney RC, Liu M, Akhand O, et al. Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study. Ann Neurol. 2019;85(5):618&#x2013;629. doi:10.1002/ana.25462</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25462</ArticleId><ArticleId IdType="pubmed">30851125</ArticleId></ArticleIdList></Reference><Reference><Citation>Davion J, Kuchcinski G, Viard R, et al. A Fully Automatic Method for Optic Radiation Tractography Applicable to Multiple Sclerosis Patients. Brain Topogr. 2020;33(4):533&#x2013;544. doi:10.1007/s10548-020-00771-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10548-020-00771-8</ArticleId><ArticleId IdType="pubmed">32303949</ArticleId></ArticleIdList></Reference><Reference><Citation>Davion J, Lopes R, Drumez E, et al. Asymptomatic optic nerve lesions: An underestimated cause of silent retinal atrophy in MS. Neurology. 2020;94(23):e2468&#x2013;e2478. doi:10.1212/WNL.0000000000009504</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009504</ArticleId><ArticleId IdType="pubmed">32434868</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallin MT, Culpepper WJ, Campbell JD, et al. The prevalence of MS in the United States: A population-based estimate using health claims data. Neurology. 2019;92(10):e1029&#x2013;e1040. doi:10.1212/WNL.0000000000007035</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007035</ArticleId><ArticleId IdType="pmc">PMC6442006</ArticleId><ArticleId IdType="pubmed">30770430</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich DS, Lucchinetti CF, Calabresi PA. Multiple Sclerosis. N Engl J Med. 2018;378(2):169&#x2013;180. doi:10.1056/NEJMra1401483</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1401483</ArticleId><ArticleId IdType="pmc">PMC6942519</ArticleId><ArticleId IdType="pubmed">29320652</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinkin M Trans-synaptic Retrograde Degeneration in the Human Visual System: Slow, Silent, and Real. Curr Neurol Neurosci Rep. 2017;17(2):16. doi:10.1007/s11910-017-0725-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11910-017-0725-2</ArticleId><ArticleId IdType="pubmed">28229400</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin T, Chien C, Kuchling J, et al. Interactions of optic radiation lesions with retinal and brain atrophy in early multiple sclerosis. Ann Clin Transl Neurol. 2024;11(1):45&#x2013;56. doi:10.1002/acn3.51931</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51931</ArticleId><ArticleId IdType="pmc">PMC10791029</ArticleId><ArticleId IdType="pubmed">37903651</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaglia V, Dubey M, Malpede MA, et al. Complement-associated loss of CA2 inhibitory synapses in the demyelinated hippocampus impairs memory. Acta Neuropathol. 2021;142(4):643&#x2013;667. doi:10.1007/s00401-021-02338-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-021-02338-8</ArticleId><ArticleId IdType="pmc">PMC8423657</ArticleId><ArticleId IdType="pubmed">34170374</ArticleId></ArticleIdList></Reference><Reference><Citation>Michailidou I, Willems JGP, Kooi E, et al. Complement C1q-C3-associated synaptic changes in multiple sclerosis hippocampus. Ann Neurol. 2015;77(6):1007&#x2013;1026. doi:10.1002/ana.24398</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24398</ArticleId><ArticleId IdType="pubmed">25727254</ArticleId></ArticleIdList></Reference><Reference><Citation>Absinta M, Maric D, Gharagozloo M, et al. A lymphocyte-microglia-astrocyte axis in chronic active multiple sclerosis. Nature. 2021;597(7878):709&#x2013;714. doi:10.1038/s41586-021-03892-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03892-7</ArticleId><ArticleId IdType="pmc">PMC8719282</ArticleId><ArticleId IdType="pubmed">34497421</ArticleId></ArticleIdList></Reference><Reference><Citation>Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. 2019;365(6460):eaav7188. doi:10.1126/science.aav7188</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aav7188</ArticleId><ArticleId IdType="pmc">PMC7241648</ArticleId><ArticleId IdType="pubmed">31604244</ArticleId></ArticleIdList></Reference><Reference><Citation>Colom-Cadena M, Davies C, Sirisi S, et al. Synaptic oligomeric tau in Alzheimer&#x2019;s disease - A potential culprit in the spread of tau pathology through the brain. Neuron. 2023;111(14):2170&#x2013;2183.e6. doi:10.1016/j.neuron.2023.04.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2023.04.020</ArticleId><ArticleId IdType="pubmed">37192625</ArticleId></ArticleIdList></Reference><Reference><Citation>Petzold A, Balcer LJ, Calabresi PA, et al. Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. 2017;16(10):797&#x2013;812. doi:10.1016/S1474-4422(17)30278-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30278-8</ArticleId><ArticleId IdType="pubmed">28920886</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotirchos ES, Gonzalez Caldito N, Filippatou A, et al. Progressive Multiple Sclerosis Is Associated with Faster and Specific Retinal Layer Atrophy. Ann Neurol. 2020;87(6):885&#x2013;896. doi:10.1002/ana.25738</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25738</ArticleId><ArticleId IdType="pmc">PMC8682917</ArticleId><ArticleId IdType="pubmed">32285484</ArticleId></ArticleIdList></Reference><Reference><Citation>Lujan BJ, Horton JC. Microcysts in the inner nuclear layer from optic atrophy are caused by retrograde trans-synaptic degeneration combined with vitreous traction on the retinal surface. Brain. 2013;136(Pt 11):e260. doi:10.1093/brain/awt154</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt154</ArticleId><ArticleId IdType="pmc">PMC3808684</ArticleId><ArticleId IdType="pubmed">23872368</ArticleId></ArticleIdList></Reference><Reference><Citation>Saidha S, Sotirchos ES, Ibrahim MA, et al. Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. Lancet Neurol. 2012;11(11):963&#x2013;972. doi:10.1016/S1474-4422(12)70213-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70213-2</ArticleId><ArticleId IdType="pmc">PMC3533139</ArticleId><ArticleId IdType="pubmed">23041237</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelfand JM, Nolan R, Schwartz DM, Graves J, Green AJ. Microcystic macular oedema in multiple sclerosis is associated with disease severity. Brain. 2012;135(6):1786&#x2013;1793. doi:10.1093/brain/aws098</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws098</ArticleId><ArticleId IdType="pmc">PMC3359753</ArticleId><ArticleId IdType="pubmed">22539259</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39579005</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1475-1313</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>23</Day></PubDate></JournalIssue><Title>Ophthalmic &amp; physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)</Title><ISOAbbreviation>Ophthalmic Physiol Opt</ISOAbbreviation></Journal><ArticleTitle>Extracting full information from OCT scans-signs of early age-related macular degeneration within inner retinal layers by local neighbourhood statistics. Part II: Results.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/opo.13393</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="OBJECTIVE">Associations between the occurrence of early age related macular degeneration (AMD) and alterations in retinal layer thicknesses have been reported, based on classical processing of optical coherence tomography (OCT) data by noise removal and subsequent image segmentation. However, speckle noise within OCT data itself bears a substantial part of the total information. For this reason, we designed an omics-type approach for full exploitation of OCT data, which was able to identify signs of early AMD throughout the retina as a whole.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A nested case-control study was designed with 200 early AMD cases and 200 healthy controls. For each participant, within a randomly selected OCT scan and a randomly selected column therein, manual grading was performed for 26 retinal feature positions. At every position, a total of 3792 descriptors were computed, based on nonlinear transformations of OCT data, first-order neighbourhood statistics and Haralick features. Equivalence and differences between cases and controls were tested for each descriptor at every graded position. Results of multiple testing were expressed in terms of false and true discovery rates controlled by the Benjamini-Yekutieli procedure.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In terms of the amount and disparity of true discoveries, overall non-equivalence was found for early AMD and healthy groups. Strong difference signals were observed at the internal limiting membrane and two central retinal positions, particularly for descriptors emphasising speckle noise.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Between the retinae of healthy controls and early AMD patients, significant differences were observed at the level of local neighbourhood statistics within OCT data. Thus, independent evidence was obtained for AMD affecting not only the outer retinal layers but the retina as a whole, even in the early stages of the disease. Within OCT data, both cartoon and speckle bear essential parts of the total information. We pursued a constructive, completely documented, traceable and repeatable approach without invoking artificial intelligence methods.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s). Ophthalmic and Physiological Optics published by John Wiley &amp; Sons Ltd on behalf of College of Optometrists.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9063-1452</Identifier><AffiliationInfo><Affiliation>Institute for Medical Informatics Statistics and Epidemiology (IMISE), Leipzig University, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sommerer</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics Statistics and Epidemiology (IMISE), Leipzig University, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rauscher</LastName><ForeName>Franziska G</ForeName><Initials>FG</Initials><Identifier Source="ORCID">0000-0003-0183-0340</Identifier><AffiliationInfo><Affiliation>Institute for Medical Informatics Statistics and Epidemiology (IMISE), Leipzig University, Leipzig, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leipzig Research Centre for Civilisation Diseases (LIFE), Leipzig University, Leipzig, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>497989466</GrantID><Agency>Deutsche Forschungsgemeinschaft</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ophthalmic Physiol Opt</MedlineTA><NlmUniqueID>8208839</NlmUniqueID><ISSNLinking>0275-5408</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">age&#x2010;related macular degeneration</Keyword><Keyword MajorTopicYN="N">computer&#x2010;generated endpoints</Keyword><Keyword MajorTopicYN="N">inner retina</Keyword><Keyword MajorTopicYN="N">local neighbourhood statistics</Keyword><Keyword MajorTopicYN="N">nested case&#x2010;control study</Keyword><Keyword MajorTopicYN="N">optical coherence tomography</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>23</Day><Hour>11</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>23</Day><Hour>11</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>23</Day><Hour>5</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39579005</ArticleId><ArticleId IdType="doi">10.1111/opo.13393</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Chakravarthy U, Peto T. Current perspective on age&#x2010;related macular degeneration. JAMA. 2020;324:794&#x2013;795.</Citation></Reference><Reference><Citation>Finger RP, Fimmers R, Holz FG, Scholl HP. Incidence of blindness and severe visual impairment in Germany: projections for 2030. Invest Opthalmol Vis Sci. 2011;52:4381&#x2013;4389.</Citation></Reference><Reference><Citation>Fleckenstein M, Schmitz&#x2010;Valckenberg S, Chakravarthy U. Age&#x2010;related macular degeneration. A review. JAMA. 2024;331:147&#x2013;157.</Citation></Reference><Reference><Citation>Li JQ, Welchowski T, Schmid M, Mauschitz MM, Holz FG, Finger RP. Prevalence and incidence of age&#x2010;related macular degeneration in Europe: a systematic review and meta&#x2010;analysis. Br J Ophthalmol. 2020;104:1077&#x2013;1084.</Citation></Reference><Reference><Citation>Spaide RF, Ooto S, Curcio CA. Subretinal drusenoid deposits AKA pseudodrusen. Surv Ophthalmol. 2018;63:782&#x2013;815.</Citation></Reference><Reference><Citation>Pead E, Megaw R, Cameron J, Fleming A, Dhillon B, Trucco E, et&#xa0;al. Automated detection of age&#x2010;related macular degeneration in color fundus photography: a systematic review. Surv Ophthalmol. 2019;64:498&#x2013;511.</Citation></Reference><Reference><Citation>Brandl C, Br&#xfc;cklmayer C, G&#xfc;nther F, Zimmermann ME, K&#xfc;chenhoff H, Helbig H, et&#xa0;al. Retinal layer thicknesses in early age&#x2010;related macular degeneration: results from the German AugUR study. Invest Ophthalmol Vis Sci. 2019;60:1581&#x2013;1594.</Citation></Reference><Reference><Citation>Nusinowitz S, Wang Y, Kim P, Habib S, Baron R, Conley Y, et&#xa0;al. Retinal structure in pre&#x2010;clinical age&#x2010;related macular degeneration. Curr Eye Res. 2018;43:376&#x2013;382.</Citation></Reference><Reference><Citation>Trinh M, Kalloniatis M, Alonso&#x2010;Caneiro D, Nivison&#x2010;Smith L. High&#x2010;density optical coherence tomography analysis provides insights into early/intermediate age&#x2010;related macular degeneration retinal layer changes. Invest Ophthalmol Vis Sci. 2022;63:36. https://doi.org/10.1167/iovs.63.5.36</Citation></Reference><Reference><Citation>Wolf&#x2010;Schnurrbusch UE, Ceklic L, Brinkmann CK, Iliev ME, Frey M, Rothenbuehler SP, et&#xa0;al. Macular thickness measurements in healthy eyes using six different optical coherence tomography instruments. Invest Ophthalmol Vis Sci. 2009;50:3432&#x2013;3437.</Citation></Reference><Reference><Citation>Wagner M, Sommerer J, Rauscher FG. Extracting full information from OCT scans&#x2014;signs of early age&#x2010;related macular degeneration within inner retinal layers by local neighbourhood statistics. Part I: Methodology. Ophthalmic Physiol Opt. 2025; In press.</Citation></Reference><Reference><Citation>Walker E, Nowacki AS. Understanding equivalence and noninferiority testing. J Gen Intern Med. 2011;26:192&#x2013;196.</Citation></Reference><Reference><Citation>Korthauer K, Kimes PK, Duvallet C, Reyes A, Subramanian A, Teng M, et&#xa0;al. A practical guide to methods controlling false discoveries in computational biology. Genome Biol. 2019;20:118. https://doi.org/10.1186/s13059&#x2010;019&#x2010;1716&#x2010;1</Citation></Reference><Reference><Citation>Klein R, Meuer SM, Myers CE, Buitendijk GHS, Rochtchina E, Choudhury F, et&#xa0;al. Harmonizing the classification of age&#x2010;related macular degeneration in the three&#x2010;continent AMD consortium. Ophthalmic Epidemiol. 2014;21:14&#x2013;23.</Citation></Reference><Reference><Citation>Loeffler M, Engel C, Ahnert P, Alfermann D, Arelin K, Baber R, et&#xa0;al. The LIFE&#x2010;Adult&#x2010;Study: objectives and design of a population&#x2010;based cohort study with 10,000 deeply phenotyped adults in Germany. BMC Public Health. 2015;15:691. https://doi.org/10.1186/s12889&#x2010;015&#x2010;1983&#x2010;z</Citation></Reference><Reference><Citation>Engel C, Wirkner K, Zeylanova S, Baber R, Binder H, Ceglarek U, et&#xa0;al. Cohort profile: the LIFE&#x2010;adult&#x2010;study. Int J Epidemiol. 2023;52:e66&#x2013;e79.</Citation></Reference><Reference><Citation>Heidelberg Engineering GmbH. Spectralis, Spectralis Viewing Module, Software Version 4.0. Special Function: Exporting Raw Data, Document Revision 4.0&#x2010;1E. Heidelberg 2008.</Citation></Reference><Reference><Citation>Staurenghi G, Sadda S, Chakravarthy U, Spaide RF, International Nomenclature for Optical Coherence Tomography (IN&#x2022;OCT) Panel. Proposed lexicon for anatomic landmarks in normal posterior segment spectral&#x2010;domain optical coherence tomography: the IN&#x2022;OCT consensus. Ophthalmology. 2014;121:1572&#x2013;1578.</Citation></Reference><Reference><Citation>Rudin LI, Osher S, Fatemi E. Nonlinear total variation based noise removal algorithms. Phys D. 1992;60:259&#x2013;268.</Citation></Reference><Reference><Citation>Bredies K, Wagner M, Schubert C, Ahnelt PK. Computer&#x2010;assisted counting of retinal cells by automatic segmentation after TV denoising. BMC Ophthalmol. 2013;13:59. https://doi.org/10.1186/1471&#x2010;2415&#x2010;13&#x2010;59</Citation></Reference><Reference><Citation>Haralick RM, Shanmugam K, Dinstein I. Textural features for image classification. IEEE Trans Syst Man Cybernet. 1973;3:610&#x2013;621.</Citation></Reference><Reference><Citation>Larue RT, Defraene G, De Ruysscher D, Lambin P, van Elmpt W. Quantitative radiomics studies for tissue characterization: a review of technology and methodological procedures. Br J Radiol. 2017;90:20160665. https://doi.org/10.1259/bjr.20160665</Citation></Reference><Reference><Citation>Schuirmann DJ. A comparison of the two one&#x2010;sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987;15:657&#x2013;680.</Citation></Reference><Reference><Citation>Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Ann Stat. 2001;29:1165&#x2013;1188.</Citation></Reference><Reference><Citation>Sawilowsky SS, Blair RC. A more realistic look at the robustness and type II error properties of the t test to departures from population normality. Psychol Bull. 1992;111:352&#x2013;360.</Citation></Reference><Reference><Citation>Posten HO. The robustness of the one&#x2010;sample t&#x2010;test over the pearson system. J Stat Comput Simul. 1979;9:133&#x2013;149.</Citation></Reference><Reference><Citation>Diabetic Retinography Study Research Group. Report 7. A modification of the Airlie House classification of diabetic retinopathy. Invest Ophthalmol Vis Sci. 1981;21:210&#x2013;226.</Citation></Reference><Reference><Citation>Kaye RA, Patasova K, Patel PJ, Hysi P, Lotery AJ, Patel PJ, et&#xa0;al. Macular thickness varies with age&#x2010;related macular degeneration genetic risk variants in the UK Biobank cohort. Sci Rep. 2021;11:23255. https://doi.org/10.1038/s41598&#x2010;021&#x2010;02631&#x2010;2</Citation></Reference><Reference><Citation>Zekavat SM, Sekimitsu S, Ye Y, Raghu V, Zhao H, Elze T, et&#xa0;al. Photoreceptor layer thinning is an early biomarker for age&#x2010;related macular degeneration: epidemiologic and genetic evidence from UK Biobank OCT data. Ophthalmology. 2022;129:694&#x2013;707.</Citation></Reference><Reference><Citation>Zouache MA, Bennion A, Hageman JL, Pappas C, Richards BT, Hageman GS. Macular retinal thickness differs markedly in age&#x2010;related macular degeneration driven by risk polymorphisms on chromosomes 1 and 10. Sci Rep. 2020;10:21093. https://doi.org/10.1038/s41598&#x2010;020&#x2010;78059&#x2010;x</Citation></Reference><Reference><Citation>Lamin A, Oakley JD, Dubis AM, Russakoff DB, Sivaprasad S. Changes in volume of various retinal layers over time in early and intermediate age&#x2010;related macular degeneration. Eye. 2019;33:428&#x2013;434.</Citation></Reference><Reference><Citation>Abdolrahimzadeh S, Di Pippo M, Sordi E, Zweifel SA. Inner retinal layer thickness alterations in early age related macular degeneration in eyes with subretinal drusenoid deposits or conventional drusen. J Clin Med. 2021;31:5136. https://doi.org/10.3390/jcm10215136</Citation></Reference><Reference><Citation>Muftuoglu IK, Ramkumar HL, Bartsch DU, Meshi A, Gaber R, Freeman WR. Quantitative analysis of the inner retinal layer thicknesses in age&#x2010;related macular degeneration using corrected optical coherence tomography segmentation. Retina. 2018;38:1478&#x2013;1484.</Citation></Reference><Reference><Citation>Wang M, Elze T, Franksen ML, Cannavo E, Leutloff CJ, Wong RC, et&#xa0;al. The impact of age&#x2010;related macular degeneration (AMD) on the retinal layer thickness maps (RLTMs). Invest Ophthalmol Vis Sci. 2020;61:ARVO E&#x2010;Abstract PP0020.</Citation></Reference><Reference><Citation>Nam KT, Yun C, Seo M, Ahn S, Oh J. Comparison of retinal thickness measurements among four different optical coherence tomography devices. Sci Rep. 2024;14:3560. https://doi.org/10.1038/s41598&#x2010;024&#x2010;54109&#x2010;6</Citation></Reference><Reference><Citation>Sommerer J. Comparative neighbourhood statistics within OCTs from healthy and early AMD patients (M.Sc. thesis). Leipzig University, iv&#x2009;+&#x2009;130 pp. 2022.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39579003</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1475-1313</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>23</Day></PubDate></JournalIssue><Title>Ophthalmic &amp; physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)</Title><ISOAbbreviation>Ophthalmic Physiol Opt</ISOAbbreviation></Journal><ArticleTitle>Extracting full information from OCT scans-signs of early age-related macular degeneration within inner retinal layers by local neighbourhood statistics. Part I: Methodology.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/opo.13392</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="OBJECTIVE">Associations between the occurrence of early age-related macular degeneration (AMD) and alterations in retinal layer thicknesses have been reported based on classical processing of optical coherence tomography (OCT) data by noise removal and subsequent image segmentation. However, speckle noise within OCT data itself bears a substantial part of the total information. For this reason, an omics-type approach was designed for full exploitation of OCT data, which was able to identify signs of early AMD throughout the retina as a whole.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A nested case-control study was designed with 200 early AMD cases and 200 healthy controls. For every participant, within a randomly selected OCT scan and a randomly selected column therein, manual grading was performed for 26 retinal feature positions. At each position, a total of 3792 descriptors were computed, based on nonlinear transformations of OCT data, first-order neighbourhood statistics and Haralick features. Equivalence and differences between cases and controls were tested for every descriptor at each graded position. Results of multiple testing were expressed in terms of false and true discovery rates controlled by the Benjamini-Yekutieli procedure.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In terms of the amount and disparity of true discoveries, overall non-equivalence of early AMD and healthy groups was found. Strong difference signals were observed at the internal limiting membrane and two central retinal positions, particularly for descriptors emphasising speckle noise.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Between retinae of healthy controls and early AMD patients, significant differences were observed at the level of local neighbourhood statistics within the OCT data. Thus, independent evidence was obtained for AMD affecting not only the outer retinal layers but also the retina as a whole, even in the early stages of the disease. Within OCT data, both cartoons and speckle bear essential parts of total information. A constructive, completely documented, traceable and repeatable approach was pursued without invoking artificial intelligence methods.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s). Ophthalmic and Physiological Optics published by John Wiley &amp; Sons Ltd on behalf of College of Optometrists.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9063-1452</Identifier><AffiliationInfo><Affiliation>Institute for Medical Informatics, Statistics and Epidemiology (IMISE), Leipzig University, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sommerer</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics, Statistics and Epidemiology (IMISE), Leipzig University, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rauscher</LastName><ForeName>Franziska G</ForeName><Initials>FG</Initials><Identifier Source="ORCID">0000-0003-0183-0340</Identifier><AffiliationInfo><Affiliation>Institute for Medical Informatics, Statistics and Epidemiology (IMISE), Leipzig University, Leipzig, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leipzig Research Centre for Civilization Diseases (LIFE), Leipzig University, Leipzig, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>497989466</GrantID><Agency>Deutsche Forschungsgemeinschaft</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ophthalmic Physiol Opt</MedlineTA><NlmUniqueID>8208839</NlmUniqueID><ISSNLinking>0275-5408</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">age&#x2010;related macular degeneration</Keyword><Keyword MajorTopicYN="N">computer&#x2010;generated endpoints</Keyword><Keyword MajorTopicYN="N">inner retina</Keyword><Keyword MajorTopicYN="N">local neighbourhood statistics</Keyword><Keyword MajorTopicYN="N">nested case&#x2013;control study</Keyword><Keyword MajorTopicYN="N">optical coherence tomography</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>23</Day><Hour>11</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>23</Day><Hour>11</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>23</Day><Hour>5</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39579003</ArticleId><ArticleId IdType="doi">10.1111/opo.13392</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Chakravarthy U, Peto T. Current perspective on age&#x2010;related macular degeneration. JAMA. 2020;324:794&#x2013;795.</Citation></Reference><Reference><Citation>Finger RP, Fimmers R, Holz FG, Scholl HP. Incidence of blindness and severe visual impairment in Germany: projections for 2030. Invest Opthalmol Vis Sci. 2011;52:4381&#x2013;4389.</Citation></Reference><Reference><Citation>Fleckenstein M, Schmitz&#x2010;Valckenberg S, Chakravarthy U. Age&#x2010;related macular degeneration. A review. JAMA. 2024;331:147&#x2013;157.</Citation></Reference><Reference><Citation>Li JQ, Welchowski T, Schmid M, Mauschitz MM, Holz FG, Finger RP. Prevalence and incidence of age&#x2010;related macular degeneration in Europe: a systematic review and meta&#x2010;analysis. Br J Ophthalmol. 2020;104:1077&#x2013;1084.</Citation></Reference><Reference><Citation>Cheung CMG, Wong TY. Is age&#x2010;related macular degeneration a manifestation of systemic disease? New prospects for early intervention and treatment. J Intern Med. 2014;276:140&#x2013;153.</Citation></Reference><Reference><Citation>DeAngelis MM, Owen LA, Morrison MA, Morgan DJ, Li M, Shakoor A, et&#xa0;al. Genetics of age&#x2010;related macular degeneration (AMD). Hum Mol Genet. 2017;26(R1):R45&#x2013;R50.</Citation></Reference><Reference><Citation>Winkler TW, Grassmann F, Brandl C, Kiel C, G&#xfc;nther F, Strunz T, et&#xa0;al. Genome&#x2010;wide association meta&#x2010;analysis for early age&#x2010;related macular degeneration highlights novel loci and insights for advanced disease. BMC Med Genet. 2020;13:120. https://doi.org/10.1186/s12920&#x2010;020&#x2010;00760&#x2010;7</Citation></Reference><Reference><Citation>Spaide RF, Ooto S, Curcio CA. Subretinal drusenoid deposits AKA pseudodrusen. Surv Ophthalmol. 2018;63:782&#x2013;815.</Citation></Reference><Reference><Citation>Pead E, Megaw R, Cameron J, Fleming A, Dhillon B, Trucco E, et&#xa0;al. Automated detection of age&#x2010;related macular degeneration in color fundus photography: a systematic review. Surv Ophthalmol. 2019;64:498&#x2013;511.</Citation></Reference><Reference><Citation>Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, et&#xa0;al. Optical coherence tomography. Science. 1991;254:1178&#x2013;1181.</Citation></Reference><Reference><Citation>Wakabayashi T, Oshima Y, Gomi F, Tano Y. Principles and applications of modern optical coherence tomography. In: Coscas G, Coscas F, Vismara S, Zourdani A, Calzi CIL, editors. Optical coherence tomography in age&#x2010;related macular degeneration. Heidelberg: Springer Medizin Verlag; 2009. p. 67&#x2013;84.</Citation></Reference><Reference><Citation>Brandl C, Br&#xfc;cklmayer C, G&#xfc;nther F, Zimmermann ME, K&#xfc;chenhoff H, Helbig H, et&#xa0;al. Retinal layer thicknesses in early age&#x2010;related macular degeneration: results from the German AugUR study. Invest Ophthalmol Vis Sci. 2019;60:1581&#x2013;1594.</Citation></Reference><Reference><Citation>Nusinowitz S, Wang Y, Kim P, Habib S, Baron R, Conley Y, et&#xa0;al. Retinal structure in pre&#x2010;clinical age&#x2010;related macular degeneration. Curr Eye Res. 2018;43:376&#x2013;382.</Citation></Reference><Reference><Citation>Trinh M, Kalloniatis M, Alonso&#x2010;Caneiro D, Nivison&#x2010;Smith L. High&#x2010;density optical coherence tomography analysis provides insights into early/intermediate age&#x2010;related macular degeneration retinal layer changes. Invest Ophthalmol Vis Sci. 2022;63:36. https://doi.org/10.1167/iovs.63.5.36</Citation></Reference><Reference><Citation>Wagner M, Sommerer J, Rauscher FG. Extracting full information from OCT scans&#x2014;signs of early age&#x2010;related macular degeneration within inner retinal layers by local neighbourhood statistics. Part II: Results. Ophthalmic Physiol Opt. 2025; in press.</Citation></Reference><Reference><Citation>Haralick RM, Shanmugam K, Dinstein I. Textural features for image classification. IEEE Trans Systems, Man, Cybernet. 1973;SMC&#x2010;3:610&#x2013;621.</Citation></Reference><Reference><Citation>Larue RT, Defraene G, De Ruysscher D, Lambin P, van Elmpt W. Quantitative radiomics studies for tissue characterization: a review of technology and methodological procedures. Br J Radiol. 2017;90:20160665. https://doi.org/10.1259/bjr.20160665</Citation></Reference><Reference><Citation>Schmitt JM, Xiang SH, Yung KM. Speckle in optical coherence tomography. J Biomed Opt. 1999;4:95&#x2013;105.</Citation></Reference><Reference><Citation>Bredies K, Wagner M, Schubert C, Ahnelt PK. Computer&#x2010;assisted counting of retinal cells by automatic segmentation after TV denoising. BMC Ophthalmol. 2013;13:59. https://doi.org/10.1186/1471&#x2010;2415&#x2010;13&#x2010;59</Citation></Reference><Reference><Citation>Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Ann Stat. 2001;29:1165&#x2013;1188.</Citation></Reference><Reference><Citation>Walker E, Nowacki AS. Understanding equivalence and noninferiority testing. J Gen Intern Med. 2011;26:192&#x2013;196.</Citation></Reference><Reference><Citation>Loeffler M, Engel C, Ahnert P, Alfermann D, Arelin K, Baber R, et&#xa0;al. The LIFE&#x2010;Adult&#x2010;Study: objectives and design of a population&#x2010;based cohort study with 10,000 deeply phenotyped adults in Germany. BMC Public Health. 2015;15:691. https://doi.org/10.1186/s12889&#x2010;015&#x2010;1983&#x2010;z</Citation></Reference><Reference><Citation>Engel C, Wirkner K, Zeylanova S, Baber R, Binder H, Ceglarek U, et&#xa0;al. Cohort profile: the LIFE&#x2010;Adult&#x2010;Study. Int J Epidemiol. 2023;52:e66&#x2013;e79.</Citation></Reference><Reference><Citation>Klein R, Meuer SM, Myers CE, Buitendijk GHS, Rochtchina E, Choudhury F, et&#xa0;al. Harmonizing the classification of age&#x2010;related macular degeneration in the three&#x2010;continent AMD consortium. Ophthalmic Epidemiol. 2014;21:14&#x2013;23.</Citation></Reference><Reference><Citation>WHO Consultation on Obesity (1999: Geneva, Switzerland), World Health Organization. Obesity: preventing and managing the global epidemic: report of a WHO consultation (WHO Technical Report Series 894). Geneva: World Health Organization; 2000. p. 253.</Citation></Reference><Reference><Citation>Lampert T, Kroll L, M&#xfc;ters S, Stolzenberg H. Measurement of socioeconomic status in the German Health Interview and Examination Survey for Adults (DEGS1) (English version). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56:631&#x2013;636.</Citation></Reference><Reference><Citation>American Diabetes Association. Standards of medical care in diabetes&#x2010;021. Abridged for primary care providers. Clin Diabetes. 2021;39:14&#x2013;43.</Citation></Reference><Reference><Citation>Heidelberg Engineering GmbH. Spectralis HRA + OCT, user manual software version 5.4. Heidelberg: Heidelberg Engineering GmbH; 2011.</Citation></Reference><Reference><Citation>Heidelberg Engineering GmbH. Spectralis, Spectralis viewing module, software version 4.0. special function: exporting raw data, document revision 4.0&#x2010;1E. Heidelberg: Heidelberg Engineering GmbH; 2008.</Citation></Reference><Reference><Citation>Staurenghi G, Sadda S, Chakravarthy U, Spaide RF. International Nomenclature for Optical Coherence Tomography (IN&#x2022;OCT) Panel. Proposed lexicon for anatomic landmarks in normal posterior segment spectral&#x2010;domain optical coherence tomography: the IN&#x2022;OCT consensus. Ophthalmology. 2014;121:1572&#x2013;1578.</Citation></Reference><Reference><Citation>Rudin LI, Osher S, Fatemi E. Nonlinear total variation based noise removal algorithms. Physica D. 1992;60:259&#x2013;268.</Citation></Reference><Reference><Citation>Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, et&#xa0;al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006. https://doi.org/10.1038/ncomms5006</Citation></Reference><Reference><Citation>Baroni M, Diciotti S, Evangelisti A, Fortunato P, la Torre A. Texture classification of retinal layers in optical coherence tomography. In: Jarm T, Kramar P, &#x17d;upani&#x10d; A, editors. 11th Mediterranean Conference on Medical and Biomedical Engineering and Computing 2007. IFMBE Proceedings, Volume 16. Berlin&#x2010;Heidelberg: Springer; 2007. p. 847&#x2013;850.</Citation></Reference><Reference><Citation>Quellec G, Lee K, Dolejsi M, Garvin MK, Abramoff MD, Sonka M. Three&#x2010;dimensional analysis of retinal layer texture: identification of fluid&#x2010;filled regions in SD&#x2010;OCT of the macula. IEEE Trans Med Imaging. 2010;29:1321&#x2013;1330.</Citation></Reference><Reference><Citation>Raupov DS, Myakinin OO, Bratchenko IA, Zakharov V, Khramov A. Multimodal texture analysis of OCT images as a diagnostic application for skin tumors. J Biomed Photonics Eng. 2017;3:10307. https://doi.org/10.18287/JBPE17.03.010307</Citation></Reference><Reference><Citation>L&#xf6;fstedt T, Brynolfsson P, Asklund T, Nyholm T, Garpebring A. Gray&#x2010;level invariant Haralick texture features. PLoS One. 2019;14:e0212110. https://doi.org/10.1371/journal.pone.0212110</Citation></Reference><Reference><Citation>Chambolle A, Pock T. A first&#x2010;order primal&#x2010;dual algorithm for convex problems with applications to imaging. J Math Imaging Vision. 2011;40:120&#x2013;145.</Citation></Reference><Reference><Citation>Sommerer J. Comparative neighbourhood statistics within OCTs from healthy and early AMD patients. M.Sc. thesis. Leipzig University. 2022 iv + 130 pp.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39578919</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2056-9920</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>22</Day></PubDate></JournalIssue><Title>International journal of retina and vitreous</Title><ISOAbbreviation>Int J Retina Vitreous</ISOAbbreviation></Journal><ArticleTitle>Self-reported visual function and in-depth swept-source optical coherence tomography features of cystoid macular edema in retinitis pigmentosa.</ArticleTitle><Pagination><StartPage>89</StartPage><MedlinePgn>89</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">89</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40942-024-00608-7</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To evaluate self-reported visual function in retinitis pigmentosa (RP) patients with and without cystoid macular edema (CME) and to explore associations between cystoid spaces (CS), retinal morphometric parameters, and clinical data using swept-source optical coherence tomography (SS-OCT).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this cross-sectional case-control study (1:3) conducted at an Inherited Retinal Degenerations referral center in Portugal, RP patients with and without CME (matched for age and gender) completed the Michigan Retinal Degeneration Questionnaire (MRDQ) and underwent SS-OCT. Morphometric analysis, including ellipsoid zone area (EZA), was performed by two independent graders. In the CME group, detailed CS analysis was conducted. Correlations between clinical data - age, gender, best-corrected visual acuity (BCVA) - and MRDQ domains were evaluated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The study included 23 RP patients with CME (60.87% male, mean age 44.65&#x2009;&#xb1;&#x2009;13.58 years) and 69 without CME (49.28% male, mean age 47.94&#x2009;&#xb1;&#x2009;14.39 years). No significant differences were found between groups in almost all MRDQ domains, BCVA, or EZA. Age positively correlated with 4 MRDQ domains in both groups. BCVA negatively correlated with nearly all MRDQ domains. While EZA showed a negative correlation in both groups, it was significant only in RP without CME. In the CME group, centrally located, outer nuclear layer-involving and large CS were associated with worse BCVA but better EZA.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">MRDQ responses strongly correlated with clinical parameters. CME does not seem to affect self-reported visual function in RP patients, and CS may not worsen visual function. Thus, aggressive treatment of CME in RP may not be necessary.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Costa</LastName><ForeName>Celso</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Ophthalmology Department, Unidade Local de Sa&#xfa;de de Coimbra (ULS Coimbra), Coimbra, 3004-561, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nogueira</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Ophthalmology Department, Unidade Local de Sa&#xfa;de de Coimbra (ULS Coimbra), Coimbra, 3004-561, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soares</LastName><ForeName>M&#xe1;rio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Ophthalmology Department, Unidade Local de Sa&#xfa;de de Coimbra (ULS Coimbra), Coimbra, 3004-561, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sim&#xe3;o</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ophthalmology Department, Unidade Local de Sa&#xfa;de de Coimbra (ULS Coimbra), Coimbra, 3004-561, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melo</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Ophthalmology Department, Unidade Local de Sa&#xfa;de de Coimbra (ULS Coimbra), Coimbra, 3004-561, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Rufino</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Ophthalmology Department, Unidade Local de Sa&#xfa;de de Coimbra (ULS Coimbra), Coimbra, 3004-561, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Coimbra (FMUC), Coimbra, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Academic Center of Coimbra (CACC), Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murta</LastName><ForeName>Joaquim</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Ophthalmology Department, Unidade Local de Sa&#xfa;de de Coimbra (ULS Coimbra), Coimbra, 3004-561, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Coimbra (FMUC), Coimbra, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Academic Center of Coimbra (CACC), Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marques</LastName><ForeName>Jo&#xe3;o Pedro</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0000-0002-1014-0483</Identifier><AffiliationInfo><Affiliation>Ophthalmology Department, Unidade Local de Sa&#xfa;de de Coimbra (ULS Coimbra), Coimbra, 3004-561, Portugal. marquesjoaopedro@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Coimbra (FMUC), Coimbra, Portugal. marquesjoaopedro@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Academic Center of Coimbra (CACC), Coimbra, Portugal. marquesjoaopedro@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Retina Vitreous</MedlineTA><NlmUniqueID>101677897</NlmUniqueID><ISSNLinking>2056-9920</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cystoid macular edema</Keyword><Keyword MajorTopicYN="N">Inherited-retinal degenerations</Keyword><Keyword MajorTopicYN="N">Michigan retinal degeneration questionnaire</Keyword><Keyword MajorTopicYN="N">Retinitis pigmentosa</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: The authors declare no competing interests. Conflict of interest: The authors have no conflicts of interest to declare. Protection of human and animal subjects: The authors declare that the procedures followed were in accord-ance with the regulations of the relevant clinical research ethics committee and with those of the Code of Ethics of the World Medical Association (Declaration of Helsinki as revised in 2013). Provenance and peer review: Not commissioned; externally peer reviewed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>23</Day><Hour>11</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>23</Day><Hour>11</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>23</Day><Hour>3</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39578919</ArticleId><ArticleId IdType="pmc">PMC11583574</ArticleId><ArticleId IdType="doi">10.1186/s40942-024-00608-7</ArticleId><ArticleId IdType="pii">10.1186/s40942-024-00608-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dias MF, Joo K, Kemp JA, Fialho SL, da Silva Cunha A Jr, Woo SJ, et al. Molecular genetics and emerging therapies for retinitis pigmentosa: basic research and clinical perspectives. Prog Retin Eye Res. 2018;63:107&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">29097191</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques JP, Ferreira N, Moreno N, Marta A, Vaz-Pereira S, Estrela-Silva S, et al. Current management of inherited retinal degenerations in Portugal (IRD-PT survey). Sci Rep. 2024;14:21473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11401845</ArticleId><ArticleId IdType="pubmed">39277603</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos T, Warren LH, Santos AR, Marques IP, Kubach S, Mendes LG, et al. Swept-source OCTA quantification of capillary closure predicts ETDRS severity staging of NPDR. Br J Ophthalmol. 2022;106:712&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9046755</ArticleId><ArticleId IdType="pubmed">33355147</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogino K, Oishi A, Oishi M, Gotoh N, Morooka S, Sugahara M, et al. Efficacy of column scatter plots for presenting retinitis pigmentosa phenotypes in a Japanese cohort. Transl Vis Sci Technol. 2016;5:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4782824</ArticleId><ArticleId IdType="pubmed">26966640</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorrentino FS, Gallenga CE, Bonifazzi C, Perri P. A challenge to the striking genotypic heterogeneity of retinitis pigmentosa: a better understanding of the pathophysiology using the newest genetic strategies. Eye. 2016;30:1542&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5177762</ArticleId><ArticleId IdType="pubmed">27564722</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006;368:1795&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">17113430</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen X-T-A, Moekotte L, Plomp AS, Bergen AA, van Genderen MM, Boon CJF. Retinitis pigmentosa: current clinical management and emerging therapies. Int J Mol Sci. 2023;24. 10.3390/ijms24087481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10139437</ArticleId><ArticleId IdType="pubmed">37108642</ArticleId></ArticleIdList></Reference><Reference><Citation>Fishman GA, Maggiano JM, Fishman M. Foveal lesions seen in retinitis pigmentosa. Arch Ophthalmol. 1977;95:1993&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">921578</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques JP, Neves E, Geada S, Carvalho AL, Murta J, Saraiva J, et al. Frequency of cystoid macular edema and vitreomacular interface disorders in genetically solved syndromic and non-syndromic retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol. 2022;260:2859&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">35389060</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Liu X, Peng X. Management of cystoid macular edema in retinitis pigmentosa: a systematic review and meta-analysis. Front Med. 2022;9:895208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9149278</ArticleId><ArticleId IdType="pubmed">35652079</ArticleId></ArticleIdList></Reference><Reference><Citation>Kal M, Brzd&#x119;k M, Winiarczyk M, Mackiewicz J, Kozie&#x142; D, Odrobina D, et al. Retinal thickness in patients with elevated D-dimer and interleukin-6 levels as a result of SARS-CoV-2 infection. Med Stud. 2023;39:342&#x2013;51.</Citation></Reference><Reference><Citation>Kal M, P&#x142;atkowska-Adamska B, Zar&#x119;bska-Michaluk D, Rzymski P. Reduced vessel density and enlarged foveal avascular zone in the macula as a result of systemic hypoxia caused by SARS-CoV-2 infection. J Pers Med. 2023;13. 10.3390/jpm13060926.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10301350</ArticleId><ArticleId IdType="pubmed">37373915</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J-Y, Kim JP, Jang H, Kim J, Kang SH, Kim JS, et al. Optical coherence tomography angiography as a potential screening tool for cerebral small vessel diseases. Alzheimers Res Ther. 2020;12:73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7291486</ArticleId><ArticleId IdType="pubmed">32527301</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo JH, Kim YJ, Yoon YH, Optical coherence tomography, angiography in patients with retinitis pigmentosa-associated cystoid macular Edema. Retina. 2020;40:2385&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">31923123</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorovoy IR, Gallagher DS, Eller AW, Mayercik VA, Friberg TR, Schuman JS. Cystoid macular edema in retinitis pigmentosa patients without associated macular thickening. Semin Ophthalmol. 2013;28:79&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5536830</ArticleId><ArticleId IdType="pubmed">23448561</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong SA, Hirji N, Quartilho A, Kalitzeos A, Michaelides M. Retrospective cohort study exploring whether an association exists between spatial distribution of cystoid spaces in cystoid macular oedema secondary to retinitis pigmentosa and response to treatment with carbonic anhydrase inhibitors. Br J Ophthalmol. 2019;103:233&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">29706600</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong S, Liew G, Michaelides M. Retinitis pigmentosa-associated cystoid macular oedema: pathogenesis and avenues of intervention. Br J Ophthalmol. 2017;101:31&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5256121</ArticleId><ArticleId IdType="pubmed">27913439</ArticleId></ArticleIdList></Reference><Reference><Citation>Karuntu JS, Nguyen XT, Boon CJF. Correlations between the Michigan Retinal Degeneration Questionnaire and visual function parameters in patients with retinitis pigmentosa. Acta Ophthalmol. 2024;102:555&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">38158751</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy GD, Abalem MF, Andrews CA, Popova LT, Santos EP, Yu G, et al. The Michigan Retinal Degeneration Questionnaire: a patient-reported outcome instrument for inherited retinal degenerations. Am J Ophthalmol. 2021;222:60&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7907279</ArticleId><ArticleId IdType="pubmed">32858027</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques JP, Bernardes L, Oliveira C, Fonseca G, Quadrado Gil J, Sotero L, et al. Portuguese translation and linguistic validation of the Michigan Retinal Degeneration Questionnaire and the Michigan Vision-related anxiety questionnaire in a cohort with inherited retinal degenerations. Ophthalmic Genet. 2022;43:137&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">35021937</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques JP, Carvalho AL, Henriques J, Murta JN, Saraiva J, Silva R. Design, development and deployment of a web-based interoperable registry for inherited retinal dystrophies in Portugal: the IRD-PT. Orphanet J Rare Dis. 2020;15:304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7590677</ArticleId><ArticleId IdType="pubmed">33109251</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544753</ArticleId><ArticleId IdType="pubmed">25741868</ArticleId></ArticleIdList></Reference><Reference><Citation>Govetto A, Lalane RA, Sarraf D, Figueroa MS, Hubschman JP. Insights into epiretinal membranes: presence of ectopic inner foveal layers and a new optical coherence tomography staging scheme. Am J Ophthalmol. 2017;175:99&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">27993592</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques JP, Machado Soares R, Sim&#xe3;o S, Abuzaitoun R, Andrews C, Alves CH, et al. Self-reported visual function and psychosocial impact of visual loss in EYS-associated retinal degeneration in a Portuguese population. Ophthalmic Genet. 2023;44:334&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">36946380</ArticleId></ArticleIdList></Reference><Reference><Citation>Bambara JK, Wadley V, Owsley C, Martin RC, Porter C, Dreer LE. Family functioning and low vision: a systematic review. J Vis Impair Blind. 2009;103:137&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2798155</ArticleId><ArticleId IdType="pubmed">20046836</ArticleId></ArticleIdList></Reference><Reference><Citation>Leroy BP, Daly A, H&#xe9;on E, Sahel J-A, Dollfus H, IRD Study Group. Therapies for inherited retinal dystrophies: what is enough? Drug Discov Today. 2024;29:104095.</Citation><ArticleIdList><ArticleId IdType="pubmed">38992419</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouveia N, Chukwunalu O, Oliveira C, Alves CH, Silva R, Murta J, et al. Exploring self-reported visual function and vision-related anxiety in patients with RPGR-associated retinal degeneration. Sci Rep. 2024;14:15189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11220147</ArticleId><ArticleId IdType="pubmed">38956231</ArticleId></ArticleIdList></Reference><Reference><Citation>Parekh B, Duncan JL, Samarakoon L, Melia M, Abalem MF, Andrews CA, et al. Self-reported functional vision in USH2A-associated retinal degeneration as measured by the Michigan Retinal Degeneration Questionnaire. Invest Ophthalmol Vis Sci. 2024;65:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11156206</ArticleId><ArticleId IdType="pubmed">38833260</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrigo A, Aragona E, Perra C, Bianco L, Antropoli A, Saladino A, et al. Characterizing macular edema in retinitis pigmentosa through a combined structural and microvascular optical coherence tomography investigation. Sci Rep. 2023;13:800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9842653</ArticleId><ArticleId IdType="pubmed">36646739</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YJ, Joe SG, Lee D-H, Lee JY, Kim J-G, Yoon YH. Correlations between spectral-domain OCT measurements and visual acuity in cystoid macular edema associated with retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2013;54:1303&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23329664</ArticleId></ArticleIdList></Reference><Reference><Citation>Eichenbaum D, Brown DM, Ip M, Khanani AM, Figueroa MS, McAllister IL, et al. Impact of retinal fluid-free months on outcomes in neovascular age-related macular degeneration: a treatment agnostic analysis of the HAWK and HARRIER studies. Retina. 2023;43:632&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10035657</ArticleId><ArticleId IdType="pubmed">36705252</ArticleId></ArticleIdList></Reference><Reference><Citation>Zur D, Guymer R, Korobelnik J-F, Wu L, Viola F, Eter N et al. Impact of residual retinal fluid on treatment outcomes in neovascular age-related macular degeneration. Br J Ophthalmol. 2024:bjo-2024-325640. 10.1136/bjo-2024-325640</Citation><ArticleIdList><ArticleId IdType="pubmed">39033013</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JH, Sagong M, Woo SJ, Kim YC, Cho H, Lee YH, et al. A real-world study assessing the impact of retinal fluid on visual acuity outcomes in patients with neovascular age-related macular degeneration in Korea. Sci Rep. 2022;12:14166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9391430</ArticleId><ArticleId IdType="pubmed">35986074</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalur A, Iyer AI, Muste JC, Talcott KE, Singh RP. Impact of retinal fluid in patients with diabetic macular edema treated with anti-VEGF in routine clinical practice. Can J Ophthalmol. 2023;58:271&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">35395214</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlers JP, Uchida A, Sevgi DD, Hu M, Reed K, Berliner A, et al. Retinal fluid volatility associated with interval tolerance and visual outcomes in diabetic macular edema in the VISTA phase III trial. Am J Ophthalmol. 2021;224:217&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307417</ArticleId><ArticleId IdType="pubmed">33253664</ArticleId></ArticleIdList></Reference><Reference><Citation>Stitt AW, Curtis TM, Chen M, Medina RJ, McKay GJ, Jenkins A, et al. The progress in understanding and treatment of diabetic retinopathy. Prog Retin Eye Res. 2016;51:156&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">26297071</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe9;lair M-L, Kim SJ, Thorne JE, Dunn JP, Kedhar SR, Brown DM, et al. Incidence of cystoid macular edema after cataract surgery in patients with and without uveitis using optical coherence tomography. Am J Ophthalmol. 2009;148:128&#x2013;e352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722753</ArticleId><ArticleId IdType="pubmed">19403110</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SJ, Belair M-L, Bressler NM, Dunn JP, Thorne JE, Kedhar SR, et al. A method of reporting macular edema after cataract surgery using optical coherence tomography. Retina. 2008;28:870&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">18536605</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossniklaus HE, Green WR. Choroidal neovascularization. Am J Ophthalmol. 2004;137:496&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">15013874</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakthavatchalam M, Lai FHP, Rong SS, Ng DS, Brelen ME. Treatment of cystoid macular edema secondary to retinitis pigmentosa: a systematic review. Surv Ophthalmol. 2018;63:329&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">28987613</ArticleId></ArticleIdList></Reference><Reference><Citation>Heutinck PAT, van den Born LI, van Laar JAM, van Hagen PM, Smailhodzic D, Meester-Smoor MA et al. Somatostatin analogues as a treatment option for cystoid maculopathy in retinitis pigmentosa. BMJ Open Ophthalmol. 2024;9: e001722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11331938</ArticleId><ArticleId IdType="pubmed">39134323</ArticleId></ArticleIdList></Reference><Reference><Citation>Veritti D, Sarao V, De Nadai K, Chizzolini M, Parmeggiani F, Perissin L, et al. Dexamethasone implant produces better outcomes than oral acetazolamide in patients with cystoid macular edema secondary to retinitis pigmentosa. J Ocul Pharmacol Ther. 2020;36:190&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">31886707</ArticleId></ArticleIdList></Reference><Reference><Citation>Catal&#xe0;-Mora J, Santamar&#xed;a &#xc1;lvarez JF, Kyriakou D, Alforja S, Barraso Rodrigo M, Blasco Palacio PB, et al. Protocol for the treatment of cystoid macular edema secondary to retinitis pigmentosa and other inherited retinal dystrophies. Arch Soc Esp Oftalmol (Engl Ed). 2024;99:67&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">37940089</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombo L, Montesano G, Di Domenico A, Colizzi B, Rissotto R, Maltese P, et al. Dexamethasone implant versus topical carbonic anhydrase inhibitors in patients with bilateral retinitis pigmentosa-related cystoid macular edema: a prospective, paired-eye pilot study. Retina. 2024;44:852&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11027988</ArticleId><ArticleId IdType="pubmed">38166238</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Q, Chen R, Lin X, Xiang Z. Efficacy of carbonic anhydrase inhibitors in management of cystoid macular edema in retinitis pigmentosa: a meta-analysis. PLoS ONE. 2017;12: e0186180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5638411</ArticleId><ArticleId IdType="pubmed">29023491</ArticleId></ArticleIdList></Reference><Reference><Citation>Mimouni M, Nahum Y, Levant A, Levant B, Weinberger D. Cystoid macular edema: a correlation between macular volumetric parameters and visual acuity. Can J Ophthalmol. 2014;49:183&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24767226</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruff A, Tezel A, Tezel TH. Anatomical and functional correlates of cystic macular edema in retinitis pigmentosa. PLoS ONE. 2022;17:e0276629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9586413</ArticleId><ArticleId IdType="pubmed">36269735</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida N, Ikeda Y, Notomi S, Ishikawa K, Murakami Y, Hisatomi T, et al. Clinical evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology. 2013;120:100&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">22986109</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39578549</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5454</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>22</Day></PubDate></JournalIssue><Title>Eye (London, England)</Title><ISOAbbreviation>Eye (Lond)</ISOAbbreviation></Journal><ArticleTitle>Photoreceptor assessment in age-related macular degeneration.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41433-024-03462-x</ELocationID><Abstract><AbstractText>Clinical trials investigating drugs for various stages of age-related macular degeneration (AMD) are actively underway and there is a strong interest in outcomes that demonstrate a structure-function-correlation. The ellipsoid zone (EZ), a crucial anatomical feature affected in this disease, has emerged as a strong contender. There is significant interest in evaluating EZ metrics on Optical Coherence Tomography (OCT), such as integrity and reflectivity, as disruption of this photoreceptor-rich layer may indicate disease progression. Loss of photoreceptor integrity in the junctional zone of geographic atrophy (GA) has been shown to exceed the areas of retinal pigment epithelial (RPE) atrophy, thus predicting future GA expansion. Furthermore, reduced visual acuity and retinal sensitivity have been correlated with loss of EZ integrity, underscoring a structure-function relationship. Photoreceptor integrity has also recently been acknowledged by the Food and Drug Administration (FDA), supporting its use as a primary endpoint in clinical trials investigating treatments for GA. However, the segmentation of this EZ still poses challenges. Continuous enhancements in OCT resolution and advancements in automated segmentation algorithms contribute to improved assessment of the EZ, strengthening its potential as an imaging biomarker for assessing photoreceptor function. It remains to be seen whether the EZ will serve as a surrogate marker for intermediate AMD. This article aims to provide an overview of the current understanding and knowledge of the EZ, while addressing ongoing challenges encountered in its assessment and interpretation.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Domalpally</LastName><ForeName>Amitha</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8145-9619</Identifier><AffiliationInfo><Affiliation>Wisconsin Reading Center, Dept of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, USA. domalpally@wisc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haas</LastName><ForeName>Anna-Maria</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Wisconsin Reading Center, Dept of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Karl Landsteiner Institute for Retinal Research and Imaging, Juchgasse 25, 1030, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Clinic Landstra&#xdf;e, Vienna Healthcare Group, Juchgasse 25, 1030, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandra</LastName><ForeName>Shruti</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-2634-9775</Identifier><AffiliationInfo><Affiliation>Moorfields Clinical Research Facility, NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>VanderZee</LastName><ForeName>Brandon</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Wisconsin Reading Center, Dept of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S Dimopoulos</LastName><ForeName>Ioannis</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>National Eye Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D L Keenan</LastName><ForeName>Tiarnan</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-2253-1772</Identifier><AffiliationInfo><Affiliation>National Eye Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>W Pak</LastName><ForeName>Jeong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Wisconsin Reading Center, Dept of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G Csaky</LastName><ForeName>Karl</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Retina Foundation of the Southwest, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>A Blodi</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Wisconsin Reading Center, Dept of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sivaprasad</LastName><ForeName>Sobha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Moorfields Clinical Research Facility, NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eye (Lond)</MedlineTA><NlmUniqueID>8703986</NlmUniqueID><ISSNLinking>0950-222X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Competing interests: SS is the editor-in-chief and SC and TK are members of the Eye editorial board. DA, HAM, VZB, DIS, KTDL, PJW, BBA and CS have no financial disclosures. KGC received consultancy fees from NGM Biopharmaceuticals, Novartis, Johnson &amp; Johnson, Genentech/Roche, EyeBio, Annexon Biosciences, Boehringer Ingelheim, Heidelberg Engineering and is on Data Monitoring Committee for Adverum Biotechnologies, Ocular Therapeutix and PYC Therapeutics. SS received consultancy fees from Bayer, Allergan, Novartis Pharma AG, Roche, Boehringer Ingelheim, Optos, Apellis, Oxurion, Oculis and Heidelberg Engineering and is a member of the Eye editorial board.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>23</Day><Hour>11</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>23</Day><Hour>11</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>23</Day><Hour>2</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39578549</ArticleId><ArticleId IdType="doi">10.1038/s41433-024-03462-x</ArticleId><ArticleId IdType="pii">10.1038/s41433-024-03462-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Danis RP, Lavine JA, Domalpally A. Geographic atrophy in patients with advanced dry age-related macular degeneration: current challenges and future prospects. Clin Ophthalmol. 2015;9:2159&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">26640366</ArticleId><ArticleId IdType="pmc">4662367</ArticleId><ArticleId IdType="doi">10.2147/OPTH.S92359</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaal KB, Rosenfeld PJ, Gregori G, Yehoshua Z, Feuer WJ. Anatomic clinical trial endpoints for nonexudative age-related macular degeneration. Ophthalmology. 2016;123:1060&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">26952592</ArticleId><ArticleId IdType="doi">10.1016/j.ophtha.2016.01.034</ArticleId></ArticleIdList></Reference><Reference><Citation>Bird AC, Phillips RL, Hageman GS. Geographic atrophy: a histopathological assessment. JAMA Ophthalmol. 2014;132:338&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">24626824</ArticleId><ArticleId IdType="pmc">4853921</ArticleId><ArticleId IdType="doi">10.1001/jamaophthalmol.2013.5799</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleh M, Flores M, Gauthier AS, Elphege E, Delbosc B. Quantitative analysis of photoreceptor layer reflectivity on en-face optical coherence tomography as an estimator of cone density. Graefes Arch Clin Exp Ophthalmol. 2017;255:2119&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">28791546</ArticleId><ArticleId IdType="doi">10.1007/s00417-017-3761-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Cideciyan AV, Papastergiou GI, Banin E, Semple-Rowland SL, Milam AH, et al. Relation of optical coherence tomography to microanatomy in normal and rd chickens. Invest Ophthalmol Vis Sci. 1998;39:2405&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">9804149</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross DH, Clark ME, Godara P, Huisingh C, McGwin G, Owsley C, et al. RefMoB, a reflectivity feature model-based automated method for measuring four outer retinal hyperreflective bands in optical coherence tomography. Invest Ophthalmol Vis Sci. 2015;56:4166&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">26132776</ArticleId><ArticleId IdType="pmc">4495810</ArticleId><ArticleId IdType="doi">10.1167/iovs.14-15256</ArticleId></ArticleIdList></Reference><Reference><Citation>Spaide RF, Curcio CA. Anatomical correlates to the bands seen in the outer retina by optical coherence tomography: literature review and model. Retina. 2011;31:1609&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">21844839</ArticleId><ArticleId IdType="pmc">3619110</ArticleId><ArticleId IdType="doi">10.1097/IAE.0b013e3182247535</ArticleId></ArticleIdList></Reference><Reference><Citation>Litts KM, Zhang Y, Freund KB, Curcio CA. Optical coherence tomography and histology of age-related macular degeneration support mitochondria as reflectivity sources. Retina. 2018;38:445&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">29210936</ArticleId><ArticleId IdType="pmc">6230433</ArticleId><ArticleId IdType="doi">10.1097/IAE.0000000000001946</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonnal RS, Kocaoglu OP, Zawadzki RJ, Lee SH, Werner JS, Miller DT. The cellular origins of the outer retinal bands in optical coherence tomography images. Invest Ophthalmol Vis Sci. 2014;55:7904&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">25324288</ArticleId><ArticleId IdType="pmc">4261632</ArticleId><ArticleId IdType="doi">10.1167/iovs.14-14907</ArticleId></ArticleIdList></Reference><Reference><Citation>Staurenghi G, Sadda S, Chakravarthy U, Spaide RF. Proposed lexicon for anatomic landmarks in normal posterior segment spectral-domain optical coherence tomography: the IN*OCT consensus. Ophthalmology. 2014;121:1572&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24755005</ArticleId><ArticleId IdType="doi">10.1016/j.ophtha.2014.02.023</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KE, Heitkotter H, Carroll J. Challenges associated with ellipsoid zone intensity measurements using optical coherence tomography. Transl Vis Sci Technol. 2021;10:27.</Citation><ArticleIdList><ArticleId IdType="pubmed">34665233</ArticleId><ArticleId IdType="pmc">8543396</ArticleId><ArticleId IdType="doi">10.1167/tvst.10.12.27</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann KI, Gomez ML, Bartsch DU, Schuster AK, Freeman WR. Effect of change in drusen evolution on photoreceptor inner segment/outer segment junction. Retina. 2012;32:1492&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22481478</ArticleId><ArticleId IdType="pmc">3792858</ArticleId><ArticleId IdType="doi">10.1097/IAE.0b013e318242b949</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrejen S, Sato T, Curcio CA, Spaide RF. Assessing the cone photoreceptor mosaic in eyes with pseudodrusen and soft Drusen in vivo using adaptive optics imaging. Ophthalmology. 2014;121:545&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">24183341</ArticleId><ArticleId IdType="doi">10.1016/j.ophtha.2013.09.026</ArticleId></ArticleIdList></Reference><Reference><Citation>Oster SF, Mojana F, Brar M, Yuson RM, Cheng L, Freeman WR. Disruption of the photoreceptor inner segment/outer segment layer on spectral domain-optical coherence tomography is a predictor of poor visual acuity in patients with epiretinal membranes. Retina. 2010;30:713&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">20038861</ArticleId><ArticleId IdType="doi">10.1097/IAE.0b013e3181c596e3</ArticleId></ArticleIdList></Reference><Reference><Citation>Maheshwary AS, Oster SF, Yuson RM, Cheng L, Mojana F, Freeman WR. The association between percent disruption of the photoreceptor inner segment-outer segment junction and visual acuity in diabetic macular edema. Am J Ophthalmol. 2010;150:63&#x2013;7 e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">20451897</ArticleId><ArticleId IdType="pmc">2900476</ArticleId><ArticleId IdType="doi">10.1016/j.ajo.2010.01.039</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizawa S, Mitamura Y, Baba T, Hagiwara A, Ogata K, Yamamoto S. Correlation between visual function and photoreceptor inner/outer segment junction in patients with retinitis pigmentosa. Eye. 2009;23:304&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18188175</ArticleId><ArticleId IdType="doi">10.1038/sj.eye.6703076</ArticleId></ArticleIdList></Reference><Reference><Citation>Baba T, Yamamoto S, Arai M, Arai E, Sugawara T, Mitamura Y, et al. Correlation of visual recovery and presence of photoreceptor inner/outer segment junction in optical coherence images after successful macular hole repair. Retina. 2008;28:453&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18327138</ArticleId><ArticleId IdType="doi">10.1097/IAE.0b013e3181571398</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlers JP, Zahid R, Kaiser PK, Heier JS, Brown DM, Meng X, et al. Longitudinal Assessment of Ellipsoid Zone Integrity, Subretinal Hyperreflective Material, and Subretinal Pigment Epithelium Disease in Neovascular Age-Related Macular Degeneration. Ophthalmol Retin. 2021;5:1204&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oret.2021.02.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Pauleikhoff D, Bonelli R, Dubis AM, Gunnemann F, Rothaus K, Charbel Issa P, et al. Progression characteristics of ellipsoid zone loss in macular telangiectasia type 2. Acta Ophthalmol. 2019;97:e998&#x2013;e1005.</Citation><ArticleIdList><ArticleId IdType="pubmed">30968592</ArticleId><ArticleId IdType="pmc">6785352</ArticleId><ArticleId IdType="doi">10.1111/aos.14110</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano F, Arrigo A, Leone PP, Saladino A, Bandello F, Battaglia Parodi M. Altered ellipsoid zone reflectivity and deep capillary plexus rarefaction correlate with progression in Best disease. Br J Ophthalmol. 2020;104:461&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">31358498</ArticleId><ArticleId IdType="doi">10.1136/bjophthalmol-2019-313980</ArticleId></ArticleIdList></Reference><Reference><Citation>Etheridge T, Dobson ETA, Wiedenmann M, Oden N, VanVeldhuisen P, Scott IU, et al. Ellipsoid Zone Defects in Retinal Vein Occlusion Correlates With Visual Acuity Prognosis: SCORE2 Report 14. Transl Vis Sci Technol. 2021;10:31.</Citation><ArticleIdList><ArticleId IdType="pubmed">34003964</ArticleId><ArticleId IdType="pmc">7998009</ArticleId><ArticleId IdType="doi">10.1167/tvst.10.3.31</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon YH, Lee DK, Kim HE, Kwon OW. Predictive findings of visual outcome in spectral domain optical coherence tomography after ranibizumab treatment in age-related macular degeneration. Korean J Ophthalmol. 2014;28:386&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">25276080</ArticleId><ArticleId IdType="pmc">4179115</ArticleId><ArticleId IdType="doi">10.3341/kjo.2014.28.5.386</ArticleId></ArticleIdList></Reference><Reference><Citation>Oishi A, Shimozono M, Mandai M, Hata M, Nishida A, Kurimoto Y. Recovery of photoreceptor outer segments after anti-VEGF therapy for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2013;251:435&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">22576370</ArticleId><ArticleId IdType="doi">10.1007/s00417-012-2034-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Ren C, Huang L, Lin B, Pu M, Pickard GE, et al. The Dorsal Raphe Nucleus Receives Afferents From Alpha-Like Retinal Ganglion Cells and Intrinsically Photosensitive Retinal Ganglion Cells in the Rat. Investigative Ophthalmol Vis Sci. 2015;56:8373&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.15-16614</ArticleId></ArticleIdList></Reference><Reference><Citation>Gin TJ, Wu Z, Chew SK, Guymer RH, Luu CD. Quantitative Analysis of the Ellipsoid Zone Intensity in Phenotypic Variations of Intermediate Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2017;58:2079&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">28388704</ArticleId><ArticleId IdType="doi">10.1167/iovs.16-20105</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele S, Wu Z, Isselmann B, Pfau M, Guymer RH, Luu CD. Natural History of the Relative Ellipsoid Zone Reflectivity in Age-Related Macular Degeneration. Ophthalmol Retin. 2022;6:1165&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oret.2022.06.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao LW, Wu Z, Guymer RH, Luu CD. Ellipsoid zone on optical coherence tomography: a review. Clin Exp Ophthalmol. 2016;44:422&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">26590363</ArticleId><ArticleId IdType="doi">10.1111/ceo.12685</ArticleId></ArticleIdList></Reference><Reference><Citation>Berkowitz BA, Podolsky RH, Childers KL, Burgoyne T, De Rossi G, Qian H, et al. Functional Changes Within the Rod Inner Segment Ellipsoid in Wildtype Mice: An Optical Coherence Tomography and Electron Microscopy Study. Invest Ophthalmol Vis Sci. 2022;63:8.</Citation><ArticleIdList><ArticleId IdType="pubmed">35816042</ArticleId><ArticleId IdType="pmc">9284466</ArticleId><ArticleId IdType="doi">10.1167/iovs.63.8.8</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal M, Haelterman NA, Sandoval H, Xiong B, Donti T, Kalsotra A, et al. Correction: Impaired Mitochondrial Energy Production Causes Light-Induced Photoreceptor Degeneration Independent of Oxidative Stress. PLoS Biol. 2018;16:e1002622.</Citation><ArticleIdList><ArticleId IdType="pubmed">29509758</ArticleId><ArticleId IdType="pmc">5839534</ArticleId><ArticleId IdType="doi">10.1371/journal.pbio.1002622</ArticleId></ArticleIdList></Reference><Reference><Citation>Sassmannshausen M, Behning C, Isselmann B, Schmid M, Finger RP, Holz FG, et al. Relative ellipsoid zone reflectivity and its association with disease severity in age-related macular degeneration: a MACUSTAR study report. Sci Rep. 2022;12:14933.</Citation><ArticleIdList><ArticleId IdType="pubmed">36056113</ArticleId><ArticleId IdType="pmc">9440143</ArticleId><ArticleId IdType="doi">10.1038/s41598-022-18875-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Toprak I, Yaylali V, Yildirim C. Early deterioration in ellipsoid zone in eyes with non-neovascular age-related macular degeneration. Int Ophthalmol. 2017;37:801&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">27591785</ArticleId><ArticleId IdType="doi">10.1007/s10792-016-0331-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcos S, Burns SA. Cone spacing and waveguide properties from cone directionality measurements. J Opt Soc Am A Opt Image Sci Vis. 1999;16:995&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pubmed">10234854</ArticleId><ArticleId IdType="pmc">2882181</ArticleId><ArticleId IdType="doi">10.1364/JOSAA.16.000995</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao W, Cense B, Zhang Y, Jonnal RS, Miller DT. Measuring retinal contributions to the optical Stiles-Crawford effect with optical coherence tomography. Opt Express. 2008;16:6486&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">18516251</ArticleId><ArticleId IdType="doi">10.1364/OE.16.006486</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin SM, Jia Y, Johnson AJ, Antony BJ, McDonald HR, Johnson RN, et al. Directional Reflectivity of the Ellipsoid Zone in Dry Age-Related Macular Degeneration. Ophthalmic Surg Lasers Imaging Retin. 2021;52:145&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="doi">10.3928/23258160-20210302-05</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele S, Isselmann B, Pfau M, Holz FG, Schmitz-Valckenberg S, Wu Z, et al. Validation of an Automated Quantification of Relative Ellipsoid Zone Reflectivity on Spectral Domain-Optical Coherence Tomography Images. Transl Vis Sci Technol. 2020;9:17.</Citation><ArticleIdList><ArticleId IdType="pubmed">33133775</ArticleId><ArticleId IdType="pmc">7581490</ArticleId><ArticleId IdType="doi">10.1167/tvst.9.11.17</ArticleId></ArticleIdList></Reference><Reference><Citation>Heitkotter H, Vang K, Gaffney M, Carroll J. Evaluation of EZ reflectivity normalization across different OCT devices. Investigative Ophthalmol Vis Sci. 2022;63:4086&#x2013;F0050.</Citation></Reference><Reference><Citation>Wolf-Schnurrbusch UEK, Ceklic L, Brinkmann CK, Iliev ME, Frey M, Rothenbuehler SP, et al. Macular Thickness Measurements in Healthy Eyes Using Six Different Optical Coherence Tomography Instruments. Investigative Ophthalmol Vis Sci. 2009;50:3432&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.08-2970</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierro L, Gagliardi M, Iuliano L, Ambrosi A, Bandello F. Retinal Nerve Fiber Layer Thickness Reproducibility Using Seven Different OCT Instruments. Investigative Ophthalmol Vis Sci. 2012;53:5912&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.11-8644</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucchiatti I, Parodi MB, Pierro L, Cicinelli MV, Gagliardi M, Castellino N, et al. Macular Ganglion Cell Complex and Retinal Nerve Fiber Layer Comparison in Different Stages of Age-Related Macular Degeneration. Am J Ophthalmol. 2015;160:602&#x2013;7.e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">26052088</ArticleId><ArticleId IdType="doi">10.1016/j.ajo.2015.05.030</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlanitz FG, Baumann B, Kundi M, Sacu S, Baratsits M, Scheschy U, et al. Drusen volume development over time and its relevance to the course of age-related macular degeneration. Br J Ophthalmol. 2017;101:198&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">27044341</ArticleId><ArticleId IdType="doi">10.1136/bjophthalmol-2016-308422</ArticleId></ArticleIdList></Reference><Reference><Citation>Folgar FA, Yuan EL, Sevilla MB, Chiu SJ, Farsiu S, Chew EY, et al. Drusen Volume and Retinal Pigment Epithelium Abnormal Thinning Volume Predict 2-Year Progression of Age-Related Macular Degeneration. Ophthalmology. 2016;123:39&#x2013;50.e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">26578448</ArticleId><ArticleId IdType="doi">10.1016/j.ophtha.2015.09.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Maloca PM, Lee AY, de Carvalho ER, Okada M, Fasler K, Leung I, et al. Validation of automated artificial intelligence segmentation of optical coherence tomography images. PLoS One. 2019;14:e0220063.</Citation><ArticleIdList><ArticleId IdType="pubmed">31419240</ArticleId><ArticleId IdType="pmc">6697318</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0220063</ArticleId></ArticleIdList></Reference><Reference><Citation>Pekala M, Joshi N, Liu TYA, Bressler NM, DeBuc DC, Burlina P. Deep learning based retinal OCT segmentation. Computers Biol Med. 2019;114:103445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.compbiomed.2019.103445</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh Y, Vasanji A, Ehlers JP. Volumetric ellipsoid zone mapping for enhanced visualisation of outer retinal integrity with optical coherence tomography. Br J Ophthalmol. 2016;100:295&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">26201354</ArticleId><ArticleId IdType="doi">10.1136/bjophthalmol-2015-307105</ArticleId></ArticleIdList></Reference><Reference><Citation>Giocanti-Auregan A, Tadayoni R, Fajnkuchen F, Dourmad P, Magazzeni S, Cohen SY. Predictive Value of Outer Retina En Face OCT Imaging for Geographic Atrophy Progression. Investigative Ophthalmol Vis Sci. 2015;56:8325&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.14-15480</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunes RP, Gregori G, Yehoshua Z, Stetson PF, Feuer W, Moshfeghi AA, et al. Predicting the progression of geographic atrophy in age-related macular degeneration with SD-OCT en face imaging of the outer retina. Ophthalmic Surg Lasers Imaging Retin. 2013;44:344&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="doi">10.3928/23258160-20130715-06</ArticleId></ArticleIdList></Reference><Reference><Citation>Orlando JI, Gerendas BS, Riedl S, Grechenig C, Breger A, Ehler M, et al. Automated Quantification of Photoreceptor alteration in macular disease using Optical Coherence Tomography and Deep Learning. Sci Rep. 2020;10:5619.</Citation><ArticleIdList><ArticleId IdType="pubmed">32221349</ArticleId><ArticleId IdType="pmc">7101374</ArticleId><ArticleId IdType="doi">10.1038/s41598-020-62329-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra Z, Ganegoda A, Selicha J, Wang Z, Sadda SR, Hu Z. Automated Retinal Layer Segmentation Using Graph-based Algorithm Incorporating Deep-learning-derived Information. Sci Rep. 2020;10:9541.</Citation><ArticleIdList><ArticleId IdType="pubmed">32533120</ArticleId><ArticleId IdType="pmc">7293300</ArticleId><ArticleId IdType="doi">10.1038/s41598-020-66355-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Fasih-Ahmad S, Wang Z, Mishra Z, Vatanatham C, Clark ME, Swain TA, et al. Potential Structural Biomarkers in 3D Images Validated by the First Functional Biomarker for Early Age-Related Macular Degeneration - ALSTAR2 Baseline. Invest Ophthalmol Vis Sci. 2024;65:1.</Citation><ArticleIdList><ArticleId IdType="pubmed">38300559</ArticleId><ArticleId IdType="pmc">10846345</ArticleId><ArticleId IdType="doi">10.1167/iovs.65.2.1</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalra G, Cetin H, Whitney J, Yordi S, Cakir Y, McConville C, et al. Automated Identification and Segmentation of Ellipsoid Zone At-Risk Using Deep Learning on SD-OCT for Predicting Progression in Dry AMD. Diagnostics. 2023;13:1178.</Citation></Reference><Reference><Citation>Lu J, Cheng Y, Hiya FE, Shen M, Herrera G, Zhang Q, et al. Deep-learning-based automated measurement of outer retinal layer thickness for use in the assessment of age-related macular degeneration, applicable to both swept-source and spectral-domain OCT imaging. Biomed Opt Express. 2024;15:413&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">38223170</ArticleId><ArticleId IdType="doi">10.1364/BOE.512359</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YX, Pan Z, Xue CC, Xie H, Wu X, Jonas JB. Macular outer nuclear layer, ellipsoid zone and outer photoreceptor segment band thickness, axial length and other determinants. Sci Rep. 2023;13:5386.</Citation><ArticleIdList><ArticleId IdType="pubmed">37012316</ArticleId><ArticleId IdType="pmc">10070240</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-32629-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsui Y, Mizuochi M, Uchiyama E, Kondo M. Ellipsoid Zone Thickness Measured by Ultrahigh Resolution Spectral-Domain Optical Coherence Tomography. Investigative Ophthalmol Vis Sci. 2016;57:465. -</Citation></Reference><Reference><Citation>Westheimer G. Directional sensitivity of the retina: 75 years of Stiles-Crawford effect. Proc Biol Sci. 2008;275:2777&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">18765346</ArticleId><ArticleId IdType="pmc">2572678</ArticleId></ArticleIdList></Reference><Reference><Citation>Curcio CA, Medeiros NE, Millican CL. Photoreceptor loss in age-related macular degeneration. Invest Ophthalmol Vis Sci. 1996;37:1236&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">8641827</ArticleId></ArticleIdList></Reference><Reference><Citation>Lujan BJ, Griffin SM, Makhijani VS, Antony BJ, Chew EY, Roorda A, et al. Directional optical coherence tomography imaging of macular pathology. RETINA. 2024;44:1124&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">38564762</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson PT, Lewis GP, Talaga KC, Brown MN, Kappel PJ, Fisher SK, et al. Drusen-associated degeneration in the retina. Invest Ophthalmol Vis Sci. 2003;44:4481&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">14507896</ArticleId><ArticleId IdType="doi">10.1167/iovs.03-0436</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Messinger JD, Ferrara D, Freund KB, Curcio CA. Stages of Drusen-Associated Atrophy in Age-Related Macular Degeneration Visible via Histologically Validated Fundus Autofluorescence. Ophthalmol Retin. 2021;5:730&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oret.2020.11.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Hariri AH, Zhang HY, Ho A, Francis P, Weleber RG, Birch DG, et al. Quantification of Ellipsoid Zone Changes in Retinitis Pigmentosa Using en Face Spectral Domain-Optical Coherence Tomography. JAMA Ophthalmol. 2016;134:628&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">27031504</ArticleId><ArticleId IdType="pmc">5317200</ArticleId><ArticleId IdType="doi">10.1001/jamaophthalmol.2016.0502</ArticleId></ArticleIdList></Reference><Reference><Citation>Bearelly S, Chau FY, Koreishi A, Stinnett SS, Izatt JA, Toth CA. Spectral Domain Optical Coherence Tomography Imaging of Geographic Atrophy Margins. Ophthalmology. 2009;116:1762&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19643488</ArticleId><ArticleId IdType="doi">10.1016/j.ophtha.2009.04.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleland SC, Konda SM, Danis RP, Huang Y, Myers DJ, Blodi BA, et al. Quantification of Geographic Atrophy Using Spectral Domain OCT in Age-Related Macular Degeneration. Ophthalmol Retin. 2021;5:41&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oret.2020.07.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Gromniak M, Gessert N, Saathoff T, Schlaefer A. Needle tip force estimation by deep learning from raw spectral OCT data. Int J Computer Assist Radiol Surg. 2020;15:1699&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11548-020-02224-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Abu-Qamar O, Kar D, Messinger JD, Hwang Y, Moult EM, et al. Ultrahigh Resolution OCT Markers of Normal Aging and Early Age-related Macular Degeneration. Ophthalmol Sci. 2023;3:100277.</Citation><ArticleIdList><ArticleId IdType="pubmed">36970115</ArticleId><ArticleId IdType="pmc">10034509</ArticleId><ArticleId IdType="doi">10.1016/j.xops.2023.100277</ArticleId></ArticleIdList></Reference><Reference><Citation>Roorda A. Optoretinography is coming of age. Proc Natl Acad Sci. 2021;118:e2119737118.</Citation><ArticleIdList><ArticleId IdType="pubmed">34907020</ArticleId><ArticleId IdType="pmc">8713980</ArticleId><ArticleId IdType="doi">10.1073/pnas.2119737118</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu J, Velaga SB, Hariri AH, Nittala MG, Sadda S. Classification and Quantitative Analysis Of Geographic Atrophy Junctional Zone Using Spectral Domain Optical Coherance Tomography. Retina. 2018;38:1456&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">28834947</ArticleId><ArticleId IdType="doi">10.1097/IAE.0000000000001824</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayegh RG, Kiss CG, Simader C, Kroisamer J, Montuoro A, Mittermuller TJ, et al. A systematic correlation of morphology and function using spectral domain optical coherence tomography and microperimetry in patients with geographic atrophy. Br J Ophthalmol. 2014;98:1050&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">24711655</ArticleId><ArticleId IdType="doi">10.1136/bjophthalmol-2014-305195</ArticleId></ArticleIdList></Reference><Reference><Citation>Amine R, Yordi S, Cetin H, McConville CA, Kalra G, Cakir Y, et al. Baseline Characterization of Advanced Ellipsoid Zone Integrity Features in the GATHER1 Phase 2/3 Clinical Trial for AMD with Geographic Atrophy. Investigative Ophthalmol Vis Sci. 2023;64:2265.</Citation></Reference><Reference><Citation>Reiter GS, Told R, Schranz M, Baumann L, Mylonas G, Sacu S, et al. Subretinal Drusenoid Deposits and Photoreceptor Loss Detecting Global and Local Progression of Geographic Atrophy by SD-OCT Imaging. Invest Ophthalmol Vis Sci. 2020;61:11.</Citation><ArticleIdList><ArticleId IdType="pubmed">32503052</ArticleId><ArticleId IdType="pmc">7415285</ArticleId><ArticleId IdType="doi">10.1167/iovs.61.6.11</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfau M, von der Emde L, de Sisternes L, Hallak JA, Leng T, Schmitz-Valckenberg S, et al. Progression of Photoreceptor Degeneration in Geographic Atrophy Secondary to Age-related Macular Degeneration. JAMA Ophthalmol. 2020;138:1026&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">32789526</ArticleId><ArticleId IdType="doi">10.1001/jamaophthalmol.2020.2914</ArticleId></ArticleIdList></Reference><Reference><Citation>Riedl S, Vogl WD, Mai J, Reiter GS, Lachinov D, Grechenig C, et al. The Effect of Pegcetacoplan Treatment on Photoreceptor Maintenance in Geographic Atrophy Monitored by Artificial Intelligence-Based OCT Analysis. Ophthalmol Retin. 2022;6:1009&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oret.2022.05.030</ArticleId></ArticleIdList></Reference><Reference><Citation>Mai J, Riedl S, Reiter GS, Lachinov D, Vogl WD, Bogunovic H, et al. Comparison of Fundus Autofluorescence Versus Optical Coherence Tomography-based Evaluation of the Therapeutic Response to Pegcetacoplan in Geographic Atrophy. Am J Ophthalmol. 2022;244:175&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">35853489</ArticleId><ArticleId IdType="doi">10.1016/j.ajo.2022.06.023</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt-Erfurth U, Mai J, Reiter GS, Vogl W-D, Sadeghipour A, McKeown AS, et al. Therapeutic effect of pegcetacoplan on retinal pigment epithelium (RPE) and photoreceptor (PR) integrity in geographic atrophy (GA) in the phase III OAKS and DERBY trials. Investigative Ophthalmol Vis Sci. 2023;64:919.</Citation></Reference><Reference><Citation>ReCLAIM-2 Study to Evaluate Safety,Efficacy &amp; Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA (ReCLAIM-2). 2019. www.Clinicaltrials.gov .</Citation></Reference><Reference><Citation>BioSpace. Stealth BioTherapeutics Announces Positive End-of-Phase 2 Meeting with FDA on the Development of Elamipretide in Patients with Dry Age-related Macular Degeneration Needham, Mass: Stealth Biotherapeutics; 2023 [updated 6/12/2023]. Available from: https://stealthbt.com/stealth-biotherapeutics-announces-positive-end-of-phase-2-meeting-with-fda-on-the-development-of-elamipretide-in-patients-with-dry-age-related-macular-degeneration/ .</Citation></Reference><Reference><Citation>Ehlers JP, Cetin H, Hanumanthu A, Le TK, Kaiser P, Reese J, et al. Association of Ellipsoid Zone Integrity and Treatment Response in Subjects with Non-neovascular AMD Treated with Subcutaneous Elamipretide: Post Hoc Analysis of the Phase 1 ReCLAIM Study. Investigative Ophthalmol Vis Sci. 2021;62:1942.</Citation></Reference><Reference><Citation>Lally D, Abbruscato A, Yordi S, Cetin H, Whitmore VE, Kalra G, et al. Elamipretide-Mediated Visual Function Improvements Are Associated With Ellipsoid Zone Integrity in Patients With Geographic Atrophy. Investigative Ophthalmol Vis Sci. 2023;64:2261.</Citation></Reference><Reference><Citation>Borrelli E, Sacconi R, Zuccaro B, Cavalleri M, Bordato A, Zucchiatti I, et al. Photoreceptor alteration in intermediate age-related macular degeneration. Sci Rep. 2020;10:21036.</Citation><ArticleIdList><ArticleId IdType="pubmed">33273666</ArticleId><ArticleId IdType="pmc">7713116</ArticleId><ArticleId IdType="doi">10.1038/s41598-020-78201-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlers JP, Patel N, Kaiser PK, Heier JS, Brown DM, Meng X, et al. The Association of Fluid Volatility With Subretinal Hyperreflective Material and Ellipsoid Zone Integrity in Neovascular AMD. Investigative Ophthalmol Vis Sci. 2022;63:17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.63.6.17</ArticleId></ArticleIdList></Reference><Reference><Citation>Song X, Xu Q, Li H, Fan Q, Zheng Y, Zhang Q, et al. Automatic quantification of retinal photoreceptor integrity to predict persistent disease activity in neovascular age-related macular degeneration using deep learning. Front Neurosci. 2022;16:952735.</Citation></Reference><Reference><Citation>Chew EY, Clemons TE, Jaffe GJ, Johnson CA, Farsiu S, Lad EM, et al. Effect of Ciliary Neurotrophic Factor on Retinal Neurodegeneration in Patients with Macular Telangiectasia Type 2: A Randomized Clinical Trial. Ophthalmology. 2019;126:540&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">30292541</ArticleId><ArticleId IdType="doi">10.1016/j.ophtha.2018.09.041</ArticleId></ArticleIdList></Reference><Reference><Citation>Sallo FB, Peto T, Egan C, Wolf-Schnurrbusch UE, Clemons TE, Gillies MC, et al. The IS/OS junction layer in the natural history of type 2 idiopathic macular telangiectasia. Invest Ophthalmol Vis Sci. 2012;53:7889&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">23092925</ArticleId><ArticleId IdType="pmc">4606792</ArticleId><ArticleId IdType="doi">10.1167/iovs.12-10765</ArticleId></ArticleIdList></Reference><Reference><Citation>Birch DG, Locke KG, Wen Y, Locke KI, Hoffman DR, Hood DC. Spectral-domain optical coherence tomography measures of outer segment layer progression in patients with X-linked retinitis pigmentosa. JAMA Ophthalmol. 2013;131:1143&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">23828615</ArticleId><ArticleId IdType="pmc">4111937</ArticleId><ArticleId IdType="doi">10.1001/jamaophthalmol.2013.4160</ArticleId></ArticleIdList></Reference><Reference><Citation>Lad EM, Duncan JL, Liang W, Maguire MG, Ayala AR, Audo I, et al. Baseline Microperimetry and OCT in the RUSH2A Study: Structure-Function Association and Correlation With Disease Severity. Am J Ophthalmol. 2022;244:98&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">36007554</ArticleId><ArticleId IdType="pmc">9712171</ArticleId><ArticleId IdType="doi">10.1016/j.ajo.2022.08.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Zada M, Cornish EE, Fraser CL, Jamieson RV, Grigg JR. Natural history and clinical biomarkers of progression in X-linked retinitis pigmentosa: a systematic review. Acta Ophthalmol. 2021;99:499&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">33258268</ArticleId><ArticleId IdType="doi">10.1111/aos.14662</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong X, Ho A, Munoz B, West S, Strauss RW, Jha A, et al. Reproducibility of Measurements of Retinal Structural Parameters Using Optical Coherence Tomography in Stargardt Disease. Transl Vis Sci Technol. 2019;8:46.</Citation><ArticleIdList><ArticleId IdType="pubmed">31259091</ArticleId><ArticleId IdType="pmc">6590092</ArticleId><ArticleId IdType="doi">10.1167/tvst.8.3.46</ArticleId></ArticleIdList></Reference><Reference><Citation>Campochiaro PA, Iftikhar M, Hafiz G, Akhlaq A, Tsai G, Wehling D, et al. Oral N-acetylcysteine improves cone function in retinitis pigmentosa patients in phase I trial. J Clin Investig. 2020;130:1527&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">31805012</ArticleId><ArticleId IdType="pmc">7269599</ArticleId><ArticleId IdType="doi">10.1172/JCI132990</ArticleId></ArticleIdList></Reference><Reference><Citation>Oral N-acetylcysteine for Retinitis Pigmentosa (NAC Attack). 2022. www.Clinicaltrials.gov .</Citation></Reference><Reference><Citation>Sunness JS, Rubin GS, Broman A, Applegate CA, Bressler NM, Hawkins BS. Low luminance visual dysfunction as a predictor of subsequent visual acuity loss from geographic atrophy in age-related macular degeneration. Ophthalmology. 2008;115:1480&#x2013;8.</Citation></Reference><Reference><Citation>Cheung SH, Legge GE. Functional and cortical adaptations to central vision loss. Vis Neurosci. 2005;22:187&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">15935111</ArticleId><ArticleId IdType="pmc">1255967</ArticleId><ArticleId IdType="doi">10.1017/S0952523805222071</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleckenstein M, Charbel Issa P, Helb HM, Schmitz-Valckenberg S, Finger RP, Scholl HP, et al. High-resolution spectral domain-OCT imaging in geographic atrophy associated with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49:4137&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">18487363</ArticleId><ArticleId IdType="doi">10.1167/iovs.08-1967</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi A, Ooto S, Yamashiro K, Oishi A, Tamura H, Nakanishi H, et al. Photoreceptor Damage and Reduction of Retinal Sensitivity Surrounding Geographic Atrophy in Age-Related Macular Degeneration. Am J Ophthalmol. 2016;168:260&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">27296489</ArticleId><ArticleId IdType="doi">10.1016/j.ajo.2016.06.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanzottera EC, Messinger JD, Ach T, Smith RT, Freund KB, Curcio CA. The Project MACULA Retinal Pigment Epithelium Grading System for Histology and Optical Coherence Tomography in Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2015;56:3253&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">25813989</ArticleId><ArticleId IdType="pmc">4455313</ArticleId><ArticleId IdType="doi">10.1167/iovs.15-16431</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Messinger JD, Zhang Y, Spaide RF, Freund KB, Curcio CA. Subretinal Drusenoid Deposit in Age-Related Macular Degeneration: Histologic Insights Into Initiation, Progression to Atrophy, and Imaging. Retina. 2020;40:618&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">31599795</ArticleId><ArticleId IdType="pmc">7103566</ArticleId><ArticleId IdType="doi">10.1097/IAE.0000000000002657</ArticleId></ArticleIdList></Reference><Reference><Citation>Grewal MK, Chandra S, Gurudas S, Rasheed R, Sen P, Menon D, et al. Functional clinical endpoints and their correlations in eyes with AMD with and without subretinal drusenoid deposits-a pilot study. Eye. 2022;36:398&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">33750892</ArticleId><ArticleId IdType="doi">10.1038/s41433-021-01488-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooto S, Suzuki M, Vongkulsiri S, Sato T, Spaide RF. Multimodal Visual Function Testing in Eyes with Nonexudative Age-Related Macular Degeneration. Retina. 2015;35:1726&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">25932557</ArticleId><ArticleId IdType="doi">10.1097/IAE.0000000000000608</ArticleId></ArticleIdList></Reference><Reference><Citation>Landa G, Su E, Garcia PM, Seiple WH, Rosen RB. Inner segment-outer segment junctional layer integrity and corresponding retinal sensitivity in dry and wet forms of age-related macular degeneration. Retina. 2011;31:364&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">21221051</ArticleId><ArticleId IdType="doi">10.1097/IAE.0b013e3181e91132</ArticleId></ArticleIdList></Reference><Reference><Citation>Heier JS, Pieramici D, Chakravarthy U, Patel SS, Gupta S, Lotery A, et al. Visual Function Decline Resulting from Geographic Atrophy: Results from the Chroma and Spectri Phase 3 Trials. Ophthalmol Retin. 2020;4:673&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oret.2020.01.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanzottera EC, Ach T, Huisingh C, Messinger JD, Freund KB, Curcio CA. Visualizing Retinal Pigment Epithelium Phenotypes in the Transition to Atrophy in Neovascular Age-Related Macular Degeneration. Retina. 2016;36:S26&#x2013;S39.</Citation><ArticleIdList><ArticleId IdType="pubmed">28005661</ArticleId><ArticleId IdType="pmc">5542007</ArticleId><ArticleId IdType="doi">10.1097/IAE.0000000000001330</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunness JS, Schuchard RA, Shen N, Rubin GS, Dagnelie G, Haselwood DM. Landmark-driven fundus perimetry using the scanning laser ophthalmoscope. Invest Ophthalmol Vis Sci. 1995;36:1863&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">7635660</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, Hadoux X, Jannaud M, Glover EK, Gee EE, Hodgson LAB, et al. Visual Sensitivity Loss in Geographic Atrophy: Structure-Function Evaluation Using Defect-Mapping Microperimetry. Invest Ophthalmol Vis Sci. 2024;65:36.</Citation><ArticleIdList><ArticleId IdType="pubmed">39028975</ArticleId><ArticleId IdType="pmc">11262543</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogl W-D, Riedl S, Mai J, Reiter GS, Lachinov D, Bogunovi&#x107; H, et al. Predicting Topographic Disease Progression and Treatment Response of Pegcetacoplan in Geographic Atrophy Quantified by Deep Learning. Ophthalmol Retin. 2023;7:4&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oret.2022.08.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Mettu PS, Allingham MJ, Cousins SW. Phase 1 Clinical Trial of Elamipretide in Dry Age-Related Macular Degeneration and Noncentral Geographic Atrophy: ReCLAIM NCGA Study. Ophthalmol Sci. 2022;2:100086.</Citation><ArticleIdList><ArticleId IdType="pubmed">36246181</ArticleId><ArticleId IdType="doi">10.1016/j.xops.2021.100086</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansari G, Scharer N, Camenzind Zuche H, Gabrani C, Anders P, Pfau K, et al. The Optical Coherence Tomography and Microperimetry Biomarker Evaluation in Patients with Geographic Atrophy (OMEGA) Study: Design and Baseline Characteristics - OMEGA Report 1. Ophthalmic Res. 2023;66:1392&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">38016431</ArticleId><ArticleId IdType="doi">10.1159/000535375</ArticleId></ArticleIdList></Reference><Reference><Citation>Cocce KJ, Stinnett SS, Luhmann UFO, Vajzovic L, Horne A, Schuman SG, et al. Visual Function Metrics in Early and Intermediate Dry Age-related Macular Degeneration for Use as Clinical Trial Endpoints. Am J Ophthalmol. 2018;189:127&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">29477964</ArticleId><ArticleId IdType="pmc">6043161</ArticleId><ArticleId IdType="doi">10.1016/j.ajo.2018.02.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, Ayton LN, Luu CD, Guymer RH. Relationship between retinal microstructures on optical coherence tomography and microperimetry in age-related macular degeneration. Ophthalmology. 2014;121:1445&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">24629618</ArticleId><ArticleId IdType="doi">10.1016/j.ophtha.2014.01.025</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwama D, Tsujikawa A, Ojima Y, Nakanishi H, Yamashiro K, Tamura H, et al. Relationship between retinal sensitivity and morphologic changes in eyes with confluent soft drusen. Clin Exp Ophthalmol. 2010;38:483&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">20584018</ArticleId><ArticleId IdType="doi">10.1111/j.1442-9071.2010.02294.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, Ayton LN, Luu CD, Guymer RH. Microperimetry of nascent geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2014;56:115&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">25515578</ArticleId><ArticleId IdType="doi">10.1167/iovs.14-15614</ArticleId></ArticleIdList></Reference><Reference><Citation>Lains I, Miller JB, Park DH, Tsikata E, Davoudi S, Rahmani S, et al. Structural Changes Associated with Delayed Dark Adaptation in Age-Related Macular Degeneration. Ophthalmology. 2017;124:1340&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">28501377</ArticleId><ArticleId IdType="doi">10.1016/j.ophtha.2017.03.061</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee AY, Lee CS, Blazes MS, Owen JP, Bagdasarova Y, Wu Y, et al. Exploring a Structural Basis for Delayed Rod-Mediated Dark Adaptation in Age-Related Macular Degeneration Via Deep Learning. Transl Vis Sci Technol. 2020;9:62.</Citation><ArticleIdList><ArticleId IdType="pubmed">33344065</ArticleId><ArticleId IdType="pmc">7745629</ArticleId><ArticleId IdType="doi">10.1167/tvst.9.2.62</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyer DS, Gonzalez VH, Kunimoto DY, Maturi RK, Roe RH, Singer MA, et al. Safety and Efficacy of Intravitreal Risuteganib for Non-Exudative AMD: A Multicenter, Phase 2a, Randomized, Clinical Trial. Ophthalmic Surg Lasers Imaging Retin. 2021;52:327&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="doi">10.3928/23258160-20210528-05</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra S, Gurudas S, Burton BJL, Menon G, Pearce I, McKibbin M, et al. Associations of presenting visual acuity with morphological changes on OCT in neovascular age-related macular degeneration: PRECISE Study Report 2. Eye. 2024;38:757&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">37853106</ArticleId><ArticleId IdType="doi">10.1038/s41433-023-02769-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho CYD, Wu Z, Turpin A, Lawson DJ, Luu CD, McKendrick AM, et al. A Tablet-Based Retinal Function Test in Neovascular Age-Related Macular Degeneration Eyes and At-Risk Fellow Eye. Transl Vis Sci Technol. 2018;7:2.</Citation><ArticleIdList><ArticleId IdType="pubmed">29520334</ArticleId><ArticleId IdType="pmc">5837668</ArticleId><ArticleId IdType="doi">10.1167/tvst.7.2.2</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T, Suzuki M, Ooto S, Spaide RF. Multimodal Imaging Findings and Multimodal Vision Testing in Neovascular Age-Related Macular Degeneration. Retina. 2015;35:1292&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">25830697</ArticleId><ArticleId IdType="doi">10.1097/IAE.0000000000000505</ArticleId></ArticleIdList></Reference><Reference><Citation>Csaky K, Ferris F 3rd, Chew EY, Nair P, Cheetham JK, Duncan JL. Report From the NEI/FDA Endpoints Workshop on Age-Related Macular Degeneration and Inherited Retinal Diseases. Invest Ophthalmol Vis Sci. 2017;58:3456&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">28702674</ArticleId><ArticleId IdType="doi">10.1167/iovs.17-22339</ArticleId></ArticleIdList></Reference><Reference><Citation>Csaky KG, Richman EA, Ferris FL. III Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium*. Invest Ophthalmol Vis Sci. 2008;49:479&#x2013;89.</Citation></Reference><Reference><Citation>Agency EM Syfovre. 2024. https://www.ema.europa.eu/en/medicines/human/EPAR/syfovre .</Citation></Reference><Reference><Citation>McLeod C, Norman R, Litton E, Saville BR, Webb S, Snelling TL. Choosing primary endpoints for clinical trials of health care interventions. Contemp Clin Trials Commun. 2019;16:100486.</Citation><ArticleIdList><ArticleId IdType="pubmed">31799474</ArticleId><ArticleId IdType="pmc">6881606</ArticleId><ArticleId IdType="doi">10.1016/j.conctc.2019.100486</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong V. Endpoints: The Beginning of a New Treatment? Ophthalmologica. 2021;244:365&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">34348339</ArticleId><ArticleId IdType="doi">10.1159/000518459</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmetterer L, Scholl H, Garhofer G, Janeschitz-Kriegl L, Corvi F, Sadda SR, et al. Endpoints for clinical trials in ophthalmology. Prog Retin Eye Res. 2023;97:101160.</Citation><ArticleIdList><ArticleId IdType="pubmed">36599784</ArticleId><ArticleId IdType="doi">10.1016/j.preteyeres.2022.101160</ArticleId></ArticleIdList></Reference><Reference><Citation>Acton JH, Smith RT, Hood DC, Greenstein VC. Relationship between retinal layer thickness and the visual field in early age-related macular degeneration. Invest Ophthalmol Vis Sci. 2012;53:7618&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">23074210</ArticleId><ArticleId IdType="pmc">3495604</ArticleId><ArticleId IdType="doi">10.1167/iovs.12-10361</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadda SR. GA: Alternative Endpoints. 2023. Available from: https://theophthalmologist.com/subspecialties/ga-alternative-endpoints .</Citation></Reference><Reference><Citation>Spaide RF, Vavvas DG. Complement Inhibition for Geographic Atrophy: Review of Salient Functional Outcomes and Perspective. Retina. 2023;43:1064&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">36996460</ArticleId></ArticleIdList></Reference><Reference><Citation>Inc. AP IZERVAY&#x2122; (avacincaptad pegol intravitreal solution) Monthly or Every Other Month Reduced Geographic Atrophy Lesion Growth Through 2 Years 2023. Available from: https://www.astellas.com/en/news/28646 .</Citation></Reference><Reference><Citation>Csaky KG, Miller JML, Martin DF, Johnson MW. Drug Approval for the Treatment of Geographic Atrophy: How We Got Here and Where We Need to Go. Am J Ophthalmol. 2024;263:231&#x2013;9.</Citation></Reference><Reference><Citation>Charters L. Photoreceptor viability may be a more promising target than GA in AMD. Modern Retina. 2023;3 https://www.modernretina.com/view/photoreceptor-viability-may-be-a-more-promising-target-than-ga-in-amd .</Citation></Reference><Reference><Citation>Biotherapeutics S, editor. ReCLAIM-2 Study Topline Results: A Phase 2 Study of Elamipretide Safety and Efficacy in Geographic Atrophy. Clinical Trials at the Summit; 2022 21 May, 2022; Lake Tahoe, Nevada: American Society of Retina Specialists.</Citation></Reference><Reference><Citation>Cimberle M. Mitochondrial stabilizers may play a role in treatment of dry AMD 2023 [updated 12 December, 2023]. Available from: https://www.healio.com/news/ophthalmology/20231212/mitochondrial-stabilizers-may-play-a-role-in-treatment-of-dry-amd .</Citation></Reference><Reference><Citation>Kaiser P. Elamipretide Update &#x2013; Entering Phase 3 2024. Available from: https://www.ophthalmologytimes.com/view/stealth-biotherapeutics-enrolls-first-patient-in-global-phase-3-clinical-program-for-elamipretide-in-patients-diagnosed-with-dry-amd .</Citation></Reference><Reference><Citation>EN. Allegro Ophthalmics receives approval from FDA for design of phase 2b/3 clinical trial of Risuteganib for the treatment of intermediate dry AMD: Eyewire; 2023 [updated 4/12/2023]. Available from: https://eyewire.news/news/allegro-ophthalmics-receives-approval-from-fda-for-design-of-phase-2b3-clinical-trial-of-risuteganib-for-the-treatment-of-intermediate-dry-amd?c4src=article:infinite-scroll .</Citation></Reference><Reference><Citation>Reche J, Stocker AB, Henchoz V, Habra O, Escher P, Wolf S, et al. High-Resolution Optical Coherence Tomography in Healthy Individuals Provides Resolution at the Cellular and Subcellular Levels. Transl Vis Sci Technol. 2023;12:12.</Citation><ArticleIdList><ArticleId IdType="pubmed">37428129</ArticleId><ArticleId IdType="pmc">10341292</ArticleId><ArticleId IdType="doi">10.1167/tvst.12.7.12</ArticleId></ArticleIdList></Reference><Reference><Citation>Lad EM, Chakravarthy U. The Issue of End Point Discordance in Dry Age-Related Macular Degeneration: How Might Clinical Trials Demonstrate a Functional Benefit? Ophthalmology. 2023;130:890&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">37278678</ArticleId><ArticleId IdType="doi">10.1016/j.ophtha.2023.05.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Mares V, Nehemy MB, Bogunovic H, Frank S, Reiter GS, Schmidt-Erfurth U. AI-based support for optical coherence tomography in age-related macular degeneration. Int J Retin Vitreous. 2024;10:31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40942-024-00549-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Vujosevic S, Loewenstein A, O&#x2019;Toole L, Schmidt-Erfurth UM, Zur D, Chakravarthy U. Imaging geographic atrophy: integrating structure and function to better understand the effects of new treatments. Br J Ophthalmol. 2024:108;773&#x2013;8.</Citation></Reference><Reference><Citation>Mai J, Lachinov D, Riedl S, Reiter GS, Vogl WD, Bogunovic H, et al. Clinical validation for automated geographic atrophy monitoring on OCT under complement inhibitory treatment. Sci Rep. 2023;13:7028.</Citation><ArticleIdList><ArticleId IdType="pubmed">37120456</ArticleId><ArticleId IdType="pmc">10148818</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-34139-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Csaky KG. The use of high density focal photopic microperimetry to follow response to anti-complement therapy in patients with geographic atrophy. [Conference Presentation]. Angiogenesis, exudation and degeneration. 2024. https://umiamihealth.org/-/media/Bascom-Palmer-Eye-Institute/PDFs/CME/Angiogenesis/Program_Agenda_Angiogenesis-2024_19.pdf .</Citation></Reference><Reference><Citation>Heidelberg Engineering. Heidelberg AppWay gives unprecedented access to GA Monitor, the first and only CE-marked AI-based GA-algorithm for clinical use 2023 [updated 28 November, 2023]. Available from: https://www.heidelbergengineering.com/int/press-releases/heidelberg-appway-gives-unprecedented-access-to-ga-monitor-the-first-and-only-ce-marked-ai-based-ga-algorithm-for-clinical-use/#:~:text=The%20GA%20Monitor%20analyzes%20SPECTRALIS,of%20visual%20impairment%20and%20blindness .</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39578546</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5454</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>22</Day></PubDate></JournalIssue><Title>Eye (London, England)</Title><ISOAbbreviation>Eye (Lond)</ISOAbbreviation></Journal><ArticleTitle>Gene therapy for geographic atrophy in age-related macular degeneration: current insights.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41433-024-03463-w</ELocationID><Abstract><AbstractText>Geographic atrophy (GA) is the advanced stage of non-neovascular (dry) age-related macular degeneration, defined by the presence of sharply demarcated atrophic lesions of the outer retina. The complement system is integral to the body's natural immune response, and hence its overactivation can lead to tissue damage and inflammation. It has been shown to play a significant role in GA lesion development and progression, and therefore, complement inhibition is emerging as a promising avenue for therapeutic intervention. With the recent approval by the Food and Drug Administration of drugs like SYFOVRE&#x2122; (pegcetacoplan injection) and IZERVAY&#x2122; (avacincaptad pegol intravitreal solution), there is hope for the development of interventions capable of slowing down or arresting the progression of GA. In particular, gene therapy intervention is gaining traction for halting GA atrophy at the source of our genes. The concept is to insert a gene into the eye that will act as an ocular "bio-factory," producing a desired protein. This can either lead to overproduction of an already available protein or produce a substance not typically generated in the eye. This review aims to provide an overview of the present understanding of GA, encompassing risk factors, prevalence, pathophysiology, and genetic associations. It will also highlight the current landscape of GA treatment, with particular emphasis on gene therapy intervention.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jamil</LastName><ForeName>Muhammad Usman</ForeName><Initials>MU</Initials><Identifier Source="ORCID">0000-0001-9642-1886</Identifier><AffiliationInfo><Affiliation>New England Eye Center, Tufts Medical Center, Boston, MA, 02116, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waheed</LastName><ForeName>Nadia K</ForeName><Initials>NK</Initials><Identifier Source="ORCID">0000-0002-8229-7519</Identifier><AffiliationInfo><Affiliation>New England Eye Center, Tufts Medical Center, Boston, MA, 02116, USA. nadiakwaheed@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eye (Lond)</MedlineTA><NlmUniqueID>8703986</NlmUniqueID><ISSNLinking>0950-222X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Competing interests: MUJ, None; NKW, Zeiss (F), Topcon (C,F) Nidek (C,F), Regeneron (F), Complement Therapeutics (C), OliX Pharmaceuticals (C), Iolyx Pharmaceuticals (C,I), Aavantgarde Bio (C), Samsung Bioepis (C), Alkeus Pharmaceuticals (C), Ocular Therapeutix (S), Valitor (I), Ocudyne (I), Beacon Therapeutics (I).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>23</Day><Hour>11</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>23</Day><Hour>11</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>23</Day><Hour>2</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39578546</ArticleId><ArticleId IdType="doi">10.1038/s41433-024-03463-w</ArticleId><ArticleId IdType="pii">10.1038/s41433-024-03463-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2. Available from: https://pubmed.ncbi.nlm.nih.gov/25104651/</Citation></Reference><Reference><Citation>Ferris FL, Wilkinson CP, Bird A, Chakravarthy U, Chew E, Csaky K, et al. Clinical classification of age-related macular degeneration. Ophthalmology. 2013;120:844&#x2013;51.</Citation></Reference><Reference><Citation>Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol. 1988;32:375&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">2457955</ArticleId><ArticleId IdType="doi">10.1016/0039-6257(88)90052-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudnicka AR, Kapetanakis VV, Jarrar Z, Wathern AK, Wormald R, Fletcher AE, et al. Incidence of Late-Stage Age-Related Macular Degeneration in American Whites: Systematic Review and Meta-analysis. Am J Ophthalmol. 2015;160:85&#x2013;93.e3.</Citation><ArticleIdList><ArticleId IdType="pubmed">25857680</ArticleId><ArticleId IdType="doi">10.1016/j.ajo.2015.04.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Holz FG, Strauss EC, Schmitz-Valckenberg S, Van Lookeren Campagne M. Geographic atrophy: clinical features and potential therapeutic approaches. Ophthalmology. 2014;121:1079&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">24433969</ArticleId><ArticleId IdType="doi">10.1016/j.ophtha.2013.11.023</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindblad AS, Lloyd PC, Clemons TE, Gensler GR, Ferris FL, Klein ML, et al. Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26. Arch Ophthalmol. 2009;127:1168&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">19752426</ArticleId><ArticleId IdType="doi">10.1001/archophthalmol.2009.198</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown MM, Brown GC, Sharma S, Stein JD, Roth Z, Campanella J, et al. The burden of age-related macular degeneration: a value-based analysis. Curr Opin Ophthalmol. 2006;17:257&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">16794438</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyer DS, Schmidt-Erfurth U, Van Lookeren Campagne M, Henry EC, Brittain C. The Pathophysiology Of Geographic Atrophy Secondary To Age-Related Macular Degeneration And The Complement Pathway As A Therapeutic Target. Retin. 2017;37:819&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IAE.0000000000001392</ArticleId></ArticleIdList></Reference><Reference><Citation>Sastre-Ib&#xe1;&#xf1;ez M, Barreiro-Gonz&#xe1;lez A, Gallego-Pinazo R, Dolz-Marco R, Garc&#xed;a-Armendariz B. Geographic atrophy: Etiopathogenesis and current therapies. Arch Soc Esp Oftalmol. 2018;93:22&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">28886928</ArticleId><ArticleId IdType="doi">10.1016/j.oftal.2017.07.004</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA Approves SYFOVRETM (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness - Apellis Pharmaceuticals, Inc. 2024. Available from: https://investors.apellis.com/news-releases/news-release-details/fda-approves-syfovretm-pegcetacoplan-injection-first-and-only .</Citation></Reference><Reference><Citation>News. Astellas Pharma Inc. 2024. Available from: https://www.astellas.com/en/news/28281 .</Citation></Reference><Reference><Citation>FDA Approves Spark Therapeutics&#x2019; LUXTURNA<sup>TM</sup> (voretigene neparvovec-rzyl), a One-time Gene Therapy for Patients with Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy &#x2013; Spark Therapeutics. 2024. Available from: https://sparktx.com/press_releases/fda-approves-spark-therapeutics-luxturna-voretigene-neparvovec-rzyl-a-one-time-gene-therapy-for-patients-with-confirmed-biallelic-rpe65-mutation-associated-retinal-dystrophy/ .</Citation></Reference><Reference><Citation>Rudnicka AR, Jarrar Z, Wormald R, Cook DG, Fletcher A, Owen CG. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology. 2012;119:571&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">22176800</ArticleId><ArticleId IdType="doi">10.1016/j.ophtha.2011.09.027</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahid H, Khan JC, Cipriani V, Sepp T, Matharu BK, Bunce C, et al. Age-related macular degeneration: the importance of family history as a risk factor. Br J Ophthalmol. 2012;96:427&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">21865200</ArticleId><ArticleId IdType="doi">10.1136/bjophthalmol-2011-300193</ArticleId></ArticleIdList></Reference><Reference><Citation>Priya RR, Chew EY, Swaroop A. Genetic studies of age-related macular degeneration: lessons, challenges, and opportunities for disease management. Ophthalmology. 2012;119:2526&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">23009893</ArticleId><ArticleId IdType="doi">10.1016/j.ophtha.2012.06.042</ArticleId></ArticleIdList></Reference><Reference><Citation>Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE, et al. Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2016;123:1751&#x2013;61.</Citation></Reference><Reference><Citation>Seddon JM, George S, Rosner B. Cigarette smoking, fish consumption, omega-3 fatty acid intake, and associations with age-related macular degeneration: the US Twin Study of Age-Related Macular Degeneration. Arch Ophthalmol. 2006;124:995&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pubmed">16832023</ArticleId><ArticleId IdType="doi">10.1001/archopht.124.7.995</ArticleId></ArticleIdList></Reference><Reference><Citation>Vingerling JR, Hofman A, Grobbee DE, De Jong PTVM. Age-related macular degeneration and smoking. The Rotterdam Study. Arch Ophthalmol. 1996;114:1193&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">8859077</ArticleId><ArticleId IdType="doi">10.1001/archopht.1996.01100140393005</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennington KL, DeAngelis MM. Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. Eye Vis. 2016;3. Available from: https://pubmed.ncbi.nlm.nih.gov/28032115/ .</Citation></Reference><Reference><Citation>Zhang QY, Tie LJ, Wu SS, Lv PL, Huang HW, Wang WQ, et al. Overweight, Obesity, and Risk of Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2016;57:1276&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">26990164</ArticleId><ArticleId IdType="doi">10.1167/iovs.15-18637</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakravarthy U, Bailey CC, Johnston RL, McKibbin M, Khan RS, Mahmood S, et al. Characterizing Disease Burden and Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration. Ophthalmology. 2018;125:842&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">29366564</ArticleId><ArticleId IdType="doi">10.1016/j.ophtha.2017.11.036</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2. Available from: https://pubmed.ncbi.nlm.nih.gov/25104651/ .</Citation></Reference><Reference><Citation>Varma R, Fraser-Bell S, Tan S, Klein R, Azen SP. Prevalence of age-related macular degeneration in Latinos: the Los Angeles Latino eye study. Ophthalmology. 2004;111:1288&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">15234128</ArticleId><ArticleId IdType="doi">10.1016/j.ophtha.2004.01.023</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman DS, O&#x2019;Colmain BJ, Mu&#xf1;oz B, Tomany SC, McCarty C, DeJong PTVM, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">15078675</ArticleId><ArticleId IdType="doi">10.1001/archopht.122.4.564</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanani AM, Kim JE, Singer M, Singh RP. Expanding The Understanding Of Geographic Atrophy. Retina. 2022;42:S1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.iae.0000890488.00508.7b</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritsche LG, Igl W, Bailey JNC, Grassmann F, Sengupta S, Bragg-Gresham JL, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet. 2016;48:134&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">26691988</ArticleId><ArticleId IdType="doi">10.1038/ng.3448</ArticleId></ArticleIdList></Reference><Reference><Citation>Gehrs KM, Anderson DH, Johnson LV, Hageman GS. Age-related macular degeneration-emerging pathogenetic and therapeutic concepts. Ann Med. 2006;38:450&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">17101537</ArticleId><ArticleId IdType="doi">10.1080/07853890600946724</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritsche LG, Chen W, Schu M, Yaspan BL, Yu Y, Thorleifsson G, et al. Seven New Loci Associated with Age-Related Macular Degeneration. Nat Genet. 2013;45:433.</Citation><ArticleIdList><ArticleId IdType="pubmed">23455636</ArticleId><ArticleId IdType="doi">10.1038/ng.2578</ArticleId></ArticleIdList></Reference><Reference><Citation>Sardell RJ, Persad PJ, Pan SS, Whitehead P, Adams LD, Laux RA, et al. Progression Rate From Intermediate to Advanced Age-Related Macular Degeneration Is Correlated With the Number of Risk Alleles at the CFH Locus. Invest Ophthalmol Vis Sci. 2016;57:6107&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">27832277</ArticleId><ArticleId IdType="pmc">5104418</ArticleId><ArticleId IdType="doi">10.1167/iovs.16-19519</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobrin L, Seddon JM. Nature and nurture- genes and environment- predict onset and progression of macular degeneration. Prog Retin Eye Res. 2014;40:1&#x2013;15.</Citation></Reference><Reference><Citation>Seddon JM, Francis PJ, George S, Schultz DW, Rosner B, Klein ML. Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration. JAMA. 2007;297:1793&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">17456821</ArticleId><ArticleId IdType="doi">10.1001/jama.297.16.1793</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Geng P, Zhang Y, Zhang M. Association between complement factor H Val62Ile polymorphism and age-related macular degeneration susceptibility: a meta-analysis. Gene. 2014;538:306&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">24440287</ArticleId><ArticleId IdType="doi">10.1016/j.gene.2014.01.032</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Chen M. Targeting the complement system for the management of retinal inflammatory and degenerative diseases. Eur J Pharm. 2016;787:94&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2016.03.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res. 2010;20:34&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">20010915</ArticleId><ArticleId IdType="doi">10.1038/cr.2009.139</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H. Complement regulation: physiology and disease relevance. Korean J Pediatr. 2015;58:239&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">26300937</ArticleId><ArticleId IdType="pmc">4543182</ArticleId><ArticleId IdType="doi">10.3345/kjp.2015.58.7.239</ArticleId></ArticleIdList></Reference><Reference><Citation>Nebbioso M, Lambiase A, Cerini A, Limoli PG, La Cava M, Greco A. Therapeutic Approaches with Intravitreal Injections in Geographic Atrophy Secondary to Age-Related Macular Degeneration: Current Drugs and Potential Molecules. Int J Mol Sci. 2019;20. Available from: https://pubmed.ncbi.nlm.nih.gov/30987401/ .</Citation></Reference><Reference><Citation>Kawa MP, Machalinska A, Roginska D, Machalinski B. Complement System in Pathogenesis of AMD: Dual Player in Degeneration and Protection of Retinal Tissue. J Immunol Res. 2014;2014;483960.</Citation></Reference><Reference><Citation>Drag S, Dotiwala F, Upadhyay AK. Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions. Invest Ophthalmol Vis Sci. 2023;64:39.</Citation><ArticleIdList><ArticleId IdType="pubmed">37389545</ArticleId><ArticleId IdType="pmc">10318594</ArticleId><ArticleId IdType="doi">10.1167/iovs.64.7.39</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedmann T, Roblin R. Gene Therapy for Human Genetic Disease? Science. 1972;175:949&#x2013;55.</Citation></Reference><Reference><Citation>Ma CC, Wang ZL, Xu T, He ZY, Wei YQ. The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnol Adv. 2020;40:107502.</Citation><ArticleIdList><ArticleId IdType="pubmed">31887345</ArticleId><ArticleId IdType="doi">10.1016/j.biotechadv.2019.107502</ArticleId></ArticleIdList></Reference><Reference><Citation>Walters L. The ethics of human gene therapy. Nature. 1986;320:6059.</Citation></Reference><Reference><Citation>Jenks S. Gene therapy death-&#x201c;everyone has to share in the guilt&#x201d;. J Natl Cancer Inst. 2000;92:98&#x2013;100.</Citation></Reference><Reference><Citation>Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, Sadelain M. Gene therapy comes of age. Science. 2018;359. Available from: https://www.science.org/doi/10.1126/science.aan4672 .</Citation></Reference><Reference><Citation>Naldini L. Gene therapy returns to centre stage. Nature. 2015;526:351&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">26469046</ArticleId><ArticleId IdType="doi">10.1038/nature15818</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni R, Zhou J, Hossain N, Chau Y. Virus-inspired nucleic acid delivery system: Linking virus and viral mimicry. Adv Drug Deliv Rev. 2016;106:3&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">27473931</ArticleId><ArticleId IdType="doi">10.1016/j.addr.2016.07.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoraba HH, Akhavanrezayat A, Karaca I, Yavari N, Lajevardi S, Hwang J, et al. Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses. Clin Ophthalmol. 2022;16:1753.</Citation><ArticleIdList><ArticleId IdType="pubmed">35685379</ArticleId><ArticleId IdType="pmc">9173725</ArticleId><ArticleId IdType="doi">10.2147/OPTH.S364200</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang P, Narendran S, Pereira F, Fukuda S, Nagasaka Y, Apicella I, et al. The Learning Curve of Murine Subretinal Injection Among Clinically Trained Ophthalmic Surgeons. Transl Vis Sci Technol. 2022;11. Available from: https://pubmed.ncbi.nlm.nih.gov/35275207/ .</Citation></Reference><Reference><Citation>Ramlogan-Steel CA, Murali A, Andrzejewski S, Dhungel B, Steel JC, Layton CJ. Gene therapy and the adeno-associated virus in the treatment of genetic and acquired ophthalmic diseases in humans: Trials, future directions and safety considerations. Clin Exp Ophthalmol. 2019;47:521&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">30345694</ArticleId><ArticleId IdType="doi">10.1111/ceo.13416</ArticleId></ArticleIdList></Reference><Reference><Citation>Boye SL, Bennett A, Scalabrino ML, McCullough KT, Van Vliet K, Choudhury S, et al. Impact of Heparan Sulfate Binding on Transduction of Retina by Recombinant Adeno-Associated Virus Vectors. J Virol. 2016;90:4215.</Citation><ArticleIdList><ArticleId IdType="pubmed">26865709</ArticleId><ArticleId IdType="pmc">4810560</ArticleId><ArticleId IdType="doi">10.1128/JVI.00200-16</ArticleId></ArticleIdList></Reference><Reference><Citation>Planul A, Dalkara D. Vectors and Gene Delivery to the Retina. Annu Rev Vis Sci. 2017;3:121&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">28937950</ArticleId><ArticleId IdType="doi">10.1146/annurev-vision-102016-061413</ArticleId></ArticleIdList></Reference><Reference><Citation>Varin J, Morival C, Maillard N, Adjali O, Cronin T. Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy. Int J Mol Sci. 2021;22. Available from: https://pubmed.ncbi.nlm.nih.gov/34884622/ .</Citation></Reference><Reference><Citation>Bucher K, Rodr&#xed;guez-Bocanegra E, Dauletbekov D, Fischer MD. Immune responses to retinal gene therapy using adeno-associated viral vectors - Implications for treatment success and safety. Prog Retin Eye Res. 2021;83. Available from: https://pubmed.ncbi.nlm.nih.gov/33069860/ .</Citation></Reference><Reference><Citation>Wirth T, Parker N, Yl&#xe4;-Herttuala S. History of gene therapy. Gene. 2013;525:162&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23618815</ArticleId><ArticleId IdType="doi">10.1016/j.gene.2013.03.137</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowsky T, Gianni D, Pieracci J, Suh J. AAV manufacturing for clinical use: Insights on current challenges from the upstream process perspective. Curr Opin Biomed Eng. 2021;20:100353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cobme.2021.100353</ArticleId></ArticleIdList></Reference><Reference><Citation>Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59. 2024. Available from: https://clinicaltrials.gov/study/NCT03144999 .</Citation></Reference><Reference><Citation>Janssen Acquires Rights to Novel Gene Therapy, Pioneering Treatment Solutions for Late-Stage Age-Related Macular Degeneration. 2024. Available from: https://www.jnj.com/media-center/press-releases/janssen-acquires-rights-to-novel-gene-therapy-pioneering-treatment-solutions-for-late-stage-age-related-macular-degeneration .</Citation></Reference><Reference><Citation>AAO 2022 Retina Subspecialty Day &#x2013; JNJ-81201887 Gene Therapy in Geographic Atrophy &#x2013; Retina Round Up. 2024. Available from: https://retinaroundup.com/2022/10/05/aao-2022-retina-subspecialty-day-jnj-81201887-gene-therapy-in-geographic-atrophy/ .</Citation></Reference><Reference><Citation>Lad EM, Chao DL, Pepio A, Zhang W, Capuano G, Rogers A, et al. Pooled safety analysis of a single intravitreal injection of JNJ-1887 (gene therapy, AAVCAGsCD59) in patients with age-related macular degeneration (AMD). Invest Ophthalmol Vis Sci. 2023;64:732&#x2013;732.</Citation></Reference><Reference><Citation>A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD). 2024. Available from: https://clinicaltrials.gov/study/NCT05811351 .</Citation></Reference><Reference><Citation>JNJ-1887 by Johnson &amp; Johnson for Dry (Atrophic) Macular Degeneration: Likelihood of Approval. 2024. Available from: https://www.pharmaceutical-technology.com/data-insights/jnj-1887-johnson-johnson-dry-atrophic-macular-degeneration-likelihood-of-approval/ .</Citation></Reference><Reference><Citation>FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD. 2024. Available from: https://www.clinicaltrials.gov/study/NCT03846193 .</Citation></Reference><Reference><Citation>HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005. 2024. Available from: https://clinicaltrials.gov/study/NCT04566445 .</Citation></Reference><Reference><Citation>EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005. 2024. Available from: https://clinicaltrials.gov/study/NCT04437368 .</Citation></Reference><Reference><Citation>Nielsen J, MacLaren RE, Heier JS, Steel D, Ivanova T, Sivaprasad S, et al. Preliminary Results from a First-in-human Phase I/II Gene Therapy Study (FOCUS) of Subretinally Delivered GT005, an Investigational AAV2 Vector, in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration. Invest Ophthalmol Vis Sci. 2022;63:1504&#x2013;1504.</Citation></Reference><Reference><Citation>Gyroscope Therapeutics Announces Presentation of Positive Interim Phase I/II Data for Investigational Gene Therapy GT005 at Retina Society Annual Scientific Meeting | BioSpace. 2024. Available from: https://www.biospace.com/article/releases/gyroscope-therapeutics-announces-presentation-of-positive-interim-phase-i-ii-data-for-investigational-gene-therapy-gt005-at-retina-society-annual-scientific-meeting/ .</Citation></Reference><Reference><Citation>GT005 (PPY988): Development Program in Geographic Atrophy. Novartis. 2024. Available from: https://www.novartis.com/news/gt005-ppy988-development-program-geographic-atrophy .</Citation></Reference><Reference><Citation>4DMT Highlights Recent Clinical Pipeline Progress. 2024. Available from: https://www.globenewswire.com/news-release/2024/01/04/2803939/0/en/4DMT-Highlights-Recent-Clinical-Pipeline-Progress-Near-Term-Milestones-and-Organizational-Updates.html .</Citation></Reference><Reference><Citation>Calton MA. Targeting the Complement Pathway with AAV-Based Gene Therapy for Geographic Atrophy. 2021. Available from: https://4dmoleculartherapeutics.com/wp-content/uploads/Presentation_Gene-Tx-for-Ophthalmic-Disorders-Summit-2023_4D-175_Calton_FINAL.pdf</Citation></Reference><Reference><Citation>Adverum Biotechnologies, Inc. - Adverum Biotechnologies Introduces an Intravitreal Gene Therapy Program for Geographic Atrophy and Presents Data on Its Ocular Gene Therapy Platform. 2024. Available from: https://investors.adverum.com/news/news-details/2023/Adverum-Biotechnologies-Introduces-an-Intravitreal-Gene-Therapy-Program-for-Geographic-Atrophy-and-Presents-Data-on-Its-Ocular-Gene-Therapy-Platform/default.aspx .</Citation></Reference><Reference><Citation>Opthalmology: Gene Therapy for Geographic Atrophy. 2024. Available from: https://kriyatherapeutics.com/pipeline/ophthalmology/ .</Citation></Reference><Reference><Citation>SYFOVRE&#xae; (pegcetacoplan injection). 2023. Available from: https://syfovre.com/ .</Citation></Reference><Reference><Citation>Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration | ClinicalTrials.gov. 2024. Available from: https://clinicaltrials.gov/study/NCT03525600 .</Citation></Reference><Reference><Citation>A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration. 2024. Available from: https://clinicaltrials.gov/study/NCT03525613 .</Citation></Reference><Reference><Citation>Heier JS, Lad EM, Holz FG, Rosenfeld PJ, Guymer RH, Boyer D, et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet. 2023;402:1434&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">37865470</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(23)01520-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration. 2024. Available from: https://clinicaltrials.gov/study/NCT02686658 .</Citation></Reference><Reference><Citation>Patel SS, Lally DR, Hsu J, Wykoff CC, Eichenbaum D, Heier JS, et al. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial. Eye. 2023;37:3551&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">36964259</ArticleId><ArticleId IdType="pmc">10686386</ArticleId><ArticleId IdType="doi">10.1038/s41433-023-02497-w</ArticleId></ArticleIdList></Reference><Reference><Citation>A Study of NGM621 in Participants With Geographic Atrophy. 2024. Available from: https://clinicaltrials.gov/study/NCT04465955 .</Citation></Reference><Reference><Citation>NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration | NGM Biopharmaceuticals, Inc. 2024. Available from: https://ir.ngmbio.com/news-releases/news-release-details/ngm-bio-announces-topline-results-catalina-phase-2-trial-ngm621 .</Citation></Reference><Reference><Citation>A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy. 2024. Available from: https://clinicaltrials.gov/study/NCT04656561?intr=ANX007&amp;rank=2 .</Citation></Reference><Reference><Citation>Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD). 2024. Available from: https://clinicaltrials.gov/study/NCT00658619 .</Citation></Reference><Reference><Citation>A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration. 2024. Available from: https://clinicaltrials.gov/study/NCT02087085 .</Citation></Reference><Reference><Citation>Freeman WR, Bandello F, Souied E, Guymer RH, Garg SJ, Chen FK, et al. Randomized Phase IIb Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-Related Macular Degeneration. Ophthalmol. Retin. 2023;7:573&#x2013;85.</Citation></Reference><Reference><Citation>Du H, Lim SL, Grob S, Zhang K. Induced pluripotent stem cell therapies for geographic atrophy of age-related macular degeneration. Semin Ophthalmol. 2011;26:216&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">21609235</ArticleId><ArticleId IdType="pmc">3805047</ArticleId><ArticleId IdType="doi">10.3109/08820538.2011.577498</ArticleId></ArticleIdList></Reference><Reference><Citation>Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration. 2024. Available from: https://clinicaltrials.gov/study/NCT01344993 .</Citation></Reference><Reference><Citation>Schwartz SD, Regillo CD, Lam BL, Eliott D, Rosenfeld PJ, Gregori NZ, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt&#x2019;s macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet. 2015;385:509&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">25458728</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(14)61376-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Study of Subretinal Implantation of Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry AMD. 2024. Available from: https://clinicaltrials.gov/study/NCT02590692 .</Citation></Reference><Reference><Citation>Kashani AH, Lebkowski JS, Rahhal FM, Avery RL, Salehi-Had H, Chen S, et al. One-Year Follow-Up in a Phase 1/2a Clinical Trial of an Allogeneic RPE Cell Bioengineered Implant for Advanced Dry Age-Related Macular Degeneration. Transl Vis Sci Technol. 2021;10:13.</Citation></Reference><Reference><Citation>Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration. 2024. Available from: https://clinicaltrials.gov/study/NCT02286089 .</Citation></Reference><Reference><Citation>Banin E, Barak A, Boyer DS, Ehrlich R, Ho A, Jaouni T, et al. Exploratory optical coherence tomography (OCT) analysis in patients with geographic atrophy (GA) treated by OpRegen: Results from the Phase 1/2a trial. Invest Ophthalmol Vis Sci. 2023;64:2826&#x2013;2826.</Citation></Reference><Reference><Citation>Transpalpebral Micro-Current Electrical Stimulation for the Treatment of Dry Age-Related Macular Degeneration. 2024. Available from: https://clinicaltrials.gov/study/NCT02540148 .</Citation></Reference><Reference><Citation>Parkinson KM, Sayre EC, Tobe SW. Evaluation of visual acuity in dry AMD patients after microcurrent electrical stimulation. Int J Retina Vitreous. 2023;9. Available from: https://pubmed.ncbi.nlm.nih.gov/37331928/ .</Citation></Reference><Reference><Citation>Phase 3 Study of ALK-001 in Geographic Atrophy. 2024. Available from: https://clinicaltrials.gov/study/NCT03845582 .</Citation></Reference><Reference><Citation>Karaa A, Haas R, Goldstein A, Vockley J, Douglas Weaver W, Cohen BH. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurol. 2018;90:E1212&#x2013;21.</Citation></Reference><Reference><Citation>An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration. 2024. Available from: https://clinicaltrials.gov/study/NCT02848313 .</Citation></Reference><Reference><Citation>ReCLAIM-2 Study to Evaluate Safety,Efficacy &amp; Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA. 2024. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT03891875 .</Citation></Reference><Reference><Citation>Stealth Biotherapeutics Announces Data from ReCLAIM-2 Phase 2 Trial of Elamipretide in Geographic Atrophy - Stealth BioTherapeutics Inc. 2024. Available from: https://stealthbt.com/stealth-biotherapeutics-announces-data-from-reclaim-2-phase-2-trial-of-elamipretide-in-geographic-atrophy/ .</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39578251</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1573-2630</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>23</Day></PubDate></JournalIssue><Title>International ophthalmology</Title><ISOAbbreviation>Int Ophthalmol</ISOAbbreviation></Journal><ArticleTitle>Carbonic anhydrase inhibitor alleviates retinal barrier toxicity in paclitaxel-induced retinopathy and macular edema by inhibiting CAXIV.</ArticleTitle><Pagination><StartPage>437</StartPage><MedlinePgn>437</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">437</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10792-024-03362-9</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To investigate the mechanism of paclitaxel (PTX)-induced macular edema and the therapeutic effect of carbonic anhydrase inhibitors (CAI) on this condition.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The effect of PTX on cell morphology was detected by immunofluorescence. Cell barrier was measured by measuring cell resistance across the epithelium. Western blotting analysis and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) were performed to investigate the effects of PTX or PTX&#x2009;+&#x2009;CAI on the expression of carbonic anhydrase XIV (CAXIV), aquaporin 4 (AQP4) and inflammatory factors. After intraperitoneal injection of PTX in vivo, retinal electrophysiology (ERG) was used to evaluate the effects of drugs on visual electrophysiology.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">PTX inhibited the proliferation of ARPE-19 and M&#xfc;ller cells, promoting their apoptosis, changing their morphology and cell cycle, reducing the transepithelial resistance of ARPE-19 cells and promoting the expression of inflammatory factors; This process was alleviated after temporary withdrawal. CAI inhibited the upregulation of inflammatory factors. Following treatment with PTX, the expression levels of AQP4 and CAXIV were higher than control group; nevertheless, the levels of ZO-1 and OCLN were lower than control group. In vivo, the ERG analysis showed that the light- and dark-adapted 3.0 ERG, and dark-adapted 3.0 oscillatory potentials decreased to different degrees following treatment with PTX.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">PTX-induced macular edema is mainly due to M&#xfc;ller cell toxicity. The condition can be alleviated by regulating water channels and enhancing subretinal fluid absorption. Thus, CAI may provide a new therapeutic approach for PTX-induced macular edema.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Ya-Ting</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>College of Life Sciences, Northwest University, Xi'an, 710069, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, The First Affiliated Hospital of Northwest University (Xi'an First Hospital), Xi'an, 710002, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niu</LastName><ForeName>Ya-Li</ForeName><Initials>YL</Initials><AffiliationInfo><Affiliation>College of Life Sciences, Northwest University, Xi'an, 710069, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Eye Institute of Chinese PLA, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Zi-Yi</ForeName><Initials>ZY</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Eye Institute of Chinese PLA, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>College of Life Sciences, Northwest University, Xi'an, 710069, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Tian-Fang</ForeName><Initials>TF</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Eye Institute of Chinese PLA, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jing</LastName><ForeName>Yu-Tong</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Eye Institute of Chinese PLA, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>The Hospital of 26, Base of PLA Strategic Support Force, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Zhao-Jie</ForeName><Initials>ZJ</Initials><AffiliationInfo><Affiliation>College of Life Sciences, Northwest University, Xi'an, 710069, China. chuzhaojie2009@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, The First Affiliated Hospital of Northwest University (Xi'an First Hospital), Xi'an, 710002, China. chuzhaojie2009@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int Ophthalmol</MedlineTA><NlmUniqueID>7904294</NlmUniqueID><ISSNLinking>0165-5701</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>P88XT4IS4D</RegistryNumber><NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002257">Carbonic Anhydrase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008269" MajorTopicYN="Y">Macular Edema</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017239" MajorTopicYN="Y">Paclitaxel</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002257" MajorTopicYN="Y">Carbonic Anhydrase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001813" MajorTopicYN="N">Blood-Retinal Barrier</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004596" MajorTopicYN="N">Electroretinography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000972" MajorTopicYN="N">Antineoplastic Agents, Phytogenic</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012164" MajorTopicYN="N">Retinal Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D041623" MajorTopicYN="N">Tomography, Optical Coherence</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055213" MajorTopicYN="N">Retinal Pigment Epithelium</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aquaporin 4 (AQP4)</Keyword><Keyword MajorTopicYN="N">Carbonic anhydrase XIV (CAXIV)</Keyword><Keyword MajorTopicYN="N">Carbonic anhydrase inhibitors (CAI)</Keyword><Keyword MajorTopicYN="N">Macular edema</Keyword><Keyword MajorTopicYN="N">Paclitaxel</Keyword></KeywordList><CoiStatement>Declarations. Conflict of interest: The authors declare no competing interests. Ethical approval: In this study, we used ARPE-19 cells (CRL-2302), Which were purchased from the American Type Culture Collection (Manassas, VA, USA). The number of cell line is 1&#xa0;ml suspension, but we don&#x2019;t know the cell batch. This study was approved by the Laboratory Animal Management and Ethics Committee, Northwestern University. Informed consent: Informed consent was obtained from all individual participants included in the study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>23</Day><Hour>11</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>23</Day><Hour>11</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>23</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39578251</ArticleId><ArticleId IdType="pmc">PMC11584476</ArticleId><ArticleId IdType="doi">10.1007/s10792-024-03362-9</ArticleId><ArticleId IdType="pii">10.1007/s10792-024-03362-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alqahtani FY, Aleanizy FS, El Tahir E, Alkahtani HM, AlQuadeib BT (2019) Paclitaxel. Profiles Drug Subst Excip Relat Methodol 44:205&#x2013;238. 10.1016/bs.podrm.2018.11.001</Citation><ArticleIdList><ArticleId IdType="pubmed">31029218</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagiwara H, Sunada Y (2004) Mechanism of taxane neurotoxicity. Breast Cancer 11:82&#x2013;85. 10.1007/BF02968008</Citation><ArticleIdList><ArticleId IdType="pubmed">14718798</ArticleId></ArticleIdList></Reference><Reference><Citation>Gore ME, Rustin G, Slevin M, Gallagher C, Penson R, Osborne R, Ledermann J, Cameron T, Thompson JM (1997) Single-agent paclitaxel in patients with previously untreated stage IV epithelial ovarian cancer. London gynaecological oncology and north thames gynaecological oncology groups. Br J Cancer 75:710&#x2013;714. 10.1038/bjc.1997.126</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2063326</ArticleId><ArticleId IdType="pubmed">9043029</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang JCB, Goldstein D, Trinh T, Au K, Park SB, Krishnan AV, Markoulli M (2021) A cross-sectional study of ocular surface discomfort and corneal nerve dysfunction after paclitaxel treatment for cancer. Sci Rep 11:1786. 10.1038/s41598-021-81398-y</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7815840</ArticleId><ArticleId IdType="pubmed">33469093</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan A, Su C, de Boer RH, Gajdatsy A (2013) Prevalence of excessive tearing in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy. J Clin Oncol 31:2123&#x2013;2127. 10.1200/JCO.2012.45.6574</Citation><ArticleIdList><ArticleId IdType="pubmed">23650421</ArticleId></ArticleIdList></Reference><Reference><Citation>Esmaeli B, Burnstine MA, Ahmadi MA, Prieto VG (2003) Docetaxel-induced histologic changes in the lacrimal sac and the nasal mucosa. Ophthalmic Plast Reconstr Surg 19:305&#x2013;308. 10.1097/01.IOP.0000075016.29682.E0</Citation><ArticleIdList><ArticleId IdType="pubmed">12878879</ArticleId></ArticleIdList></Reference><Reference><Citation>Esmaeli B, Hidaji L, Adinin RB, Faustina M, Coats C, Arbuckle R, Rivera E, Valero V, Tu SM, Ahmadi MA (2003) Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer 98:504&#x2013;507. 10.1002/cncr.11527</Citation><ArticleIdList><ArticleId IdType="pubmed">12879466</ArticleId></ArticleIdList></Reference><Reference><Citation>Skolnick CA, Doughman DJ (2003) Erosive conjunctivitis and punctal stenosis secondary to docetaxel (taxotere). Eye Contact Lens 29:134&#x2013;135. 10.1097/01.ICL.0000062464.79558.5A</Citation><ArticleIdList><ArticleId IdType="pubmed">12695719</ArticleId></ArticleIdList></Reference><Reference><Citation>del Pilar Bernal M, Loftfield K, Nussdorf JD (2000) Taxane-induced glaucoma. Lancet 355:577. 10.1016/S0140-6736(05)73228-1</Citation><ArticleIdList><ArticleId IdType="pubmed">10683031</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabre-Guillevin E, Tchen N, Anibali-Charpiat MF, Calluaud L, Ravaud A (1999) Taxane-induced glaucoma. Lancet 354:1181&#x2013;1182. 10.1016/S0140-6736(99)03019-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10513720</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidman AD, Barrett S, Canezo S (1994) Photopsia during 3&#xa0;hour paclitaxel administration at doses &gt; or = 250&#xa0;mg/m2. J Clin Oncol 12:1741&#x2013;1742. 10.1200/JCO.1994.12.8.1741</Citation><ArticleIdList><ArticleId IdType="pubmed">7913722</ArticleId></ArticleIdList></Reference><Reference><Citation>Noguchi Y, Kawashima Y, Kawara H, Kaneko M, Nakauchi H, Tokuyama Y (2016) An undeniable case of optic neuropathy due to cabazitaxel. Gan To Kagaku Ryoho 43:777&#x2013;779</Citation><ArticleIdList><ArticleId IdType="pubmed">27306820</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan X, Feng Y, Li D, Li M (2019) Unilateral visual impairment in a patient undergoing chemotherapy: a case report and clinical findings. BMC Ophthalmol 19:236. 10.1186/s12886-019-1246-3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6873404</ArticleId><ArticleId IdType="pubmed">31752765</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaya M, Atas F, Guc ZG, Oztop I, Durak I, Saatci AO (2020) A cross-sectional optical coherence tomography study in patients on taxane-based therapy and a case report with the literature review. Cutan Ocul Toxicol 39(3):287&#x2013;293. 10.1080/15569527.2020.1790592</Citation><ArticleIdList><ArticleId IdType="pubmed">32619362</ArticleId></ArticleIdList></Reference><Reference><Citation>Nomi N, Ota M, Fukumura M, Nuno Y, Hatano M, Wakuta M, Yanai R, Kimura K (2018) Indocyanine green angiography findings of cystoid macular edema secondary to paclitaxel therapy. Jpn J Ophthalmol 62:163&#x2013;167. 10.1007/s10384-017-0552-7</Citation><ArticleIdList><ArticleId IdType="pubmed">29270811</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira SA, Vale C, Moreira J, Sampaio F (2022) Macular cystoid edema induced by nab-paclitaxel. Acta Med Port 35(4):294&#x2013;297. 10.20344/amp.13421</Citation><ArticleIdList><ArticleId IdType="pubmed">34287143</ArticleId></ArticleIdList></Reference><Reference><Citation>Otsubo M, Kinouchi R, Kamiya T, Yoshida A (2021) Regression of taxane-related cystoid macular edema after topical dorzolamide treatment: two case reports. J Med Case Rep 15:355. 10.1186/s13256-021-02954-8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8293476</ArticleId><ArticleId IdType="pubmed">34284818</ArticleId></ArticleIdList></Reference><Reference><Citation>Browning DJ, Stewart MW, Lee C (2018) Diabetic macular edema: evidence-based management. Indian J Ophthalmol 66:1736&#x2013;1750. 10.4103/ijo.IJO_1240_18</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6256891</ArticleId><ArticleId IdType="pubmed">30451174</ArticleId></ArticleIdList></Reference><Reference><Citation>Noma H, Yasuda K, Shimura M (2021) Involvement of cytokines in the pathogenesis of diabetic macular edema. Int J Mol Sci. 10.3390/ijms22073427</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8036935</ArticleId><ArticleId IdType="pubmed">33810434</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassi E, Loizzi V, Furino C, Martino R, Alessio G, Ettore C, Cormio G (2017) Cystoid macular edema secondary to paclitaxel therapy for ovarian cancer: a case report. Mol Clin Oncol 7:285&#x2013;287. 10.3892/mco.2017.1296</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5532694</ArticleId><ArticleId IdType="pubmed">28781803</ArticleId></ArticleIdList></Reference><Reference><Citation>Sibaud V, Leb&#x153;uf NR, Roche H, Belum VR, Gladieff L, Deslandres M, Montastruc M, Eche A, Vigarios E, Dalenc F, Lacouture ME (2016) Dermatological adverse events with taxane chemotherapy. Eur J Dermatol 26:427&#x2013;443. 10.1684/ejd.2016.2833</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5526115</ArticleId><ArticleId IdType="pubmed">27550571</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholl S, Kirchhof J, Augustin AJ (2010) Pathophysiology of macular edema. Ophthalmologica 224(Suppl 1):8&#x2013;15. 10.1159/000315155</Citation><ArticleIdList><ArticleId IdType="pubmed">20714176</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi MM, Garretson BR (2007) Paclitaxel maculopathy. Arch Ophthalmol 125:709&#x2013;710. 10.1001/archopht.125.5.709</Citation><ArticleIdList><ArticleId IdType="pubmed">17502517</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo NK, Kim YC (2012) A case of paclitaxel-induced maculopathy treated with methazolamide. Korean J Ophthalmol 26:394&#x2013;397. 10.3341/kjo.2012.26.5.394</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3464326</ArticleId><ArticleId IdType="pubmed">23060729</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfensberger TJ (1999) The role of carbonic anhydrase inhibitors in the management of macular edema. Doc Ophthalmol 97:387&#x2013;397. 10.1023/a:1002143802926</Citation><ArticleIdList><ArticleId IdType="pubmed">10896355</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih CH, Lee YC (2018) Impaired retinal pigment epithelium in paclitaxel-induced macular edema: a case report. Medicine (Baltimore) 97(26):e11229. 10.1097/MD.0000000000011229</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6039693</ArticleId><ArticleId IdType="pubmed">29952984</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagelhus EA, Horio Y, Inanobe A, Fujita A, Haug FM, Nielsen S, Kurachi Y, Ottersen OP (1999) Immunogold evidence suggests that coupling of K+ siphoning and water transport in rat retinal M&#xfc;ller cells is mediated by a coenrichment of Kir4.1 and AQP4 in specific membrane domains. Glia 26:47&#x2013;54</Citation><ArticleIdList><ArticleId IdType="pubmed">10088671</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadopoulos MC, Manley GT, Krishna S, Verkman AS (2004) Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema. Faseb J 18:1291&#x2013;1293. 10.1096/fj.04-1723fje</Citation><ArticleIdList><ArticleId IdType="pubmed">15208268</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye YT (2022) Damage of retinal pigment epithelial cells function by paclitaxel and its potential mechanism [J]. Int Eye Sci 5:194&#x2013;199</Citation></Reference><Reference><Citation>Dwivedi R, Tiroumal S (2018) Possible efficacy of topical dorzolamide in the treatment of paclitaxel-related cystoid macular edema. Retin Cases Brief Rep 12:75&#x2013;79. 10.1097/ICB.0000000000000433</Citation><ArticleIdList><ArticleId IdType="pubmed">27749791</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlers JP, Rayess H, Steinle N (2013) Topical dorzolamide therapy for taxane-related macular oedema. Eye (Lond) 27:102&#x2013;104. 10.1038/eye.2012.228</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3545372</ArticleId><ArticleId IdType="pubmed">23154489</ArticleId></ArticleIdList></Reference><Reference><Citation>Supuran CT (2020) An update on drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors. Expert Opin Drug Metab Toxicol 16:297&#x2013;307</Citation><ArticleIdList><ArticleId IdType="pubmed">32172611</ArticleId></ArticleIdList></Reference><Reference><Citation>Scozzafava A, Supuran CT (2014) Glaucoma and the applications of carbonic anhydrase inhibitors. Subcell Biochem 75:349&#x2013;359. 10.1007/978-94-007-7359-2_17</Citation><ArticleIdList><ArticleId IdType="pubmed">24146387</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong SA, Hirji N, Quartilho A, Kalitzeos A, Michaelides M (2019) Retrospective cohort study exploring whether an association exists between spatial distribution of cystoid spaces in cystoid macular oedema secondary to retinitis pigmentosa and response to treatment with carbonic anhydrase inhibitors. Br J Ophthalmol 103:233&#x2013;237. 10.1136/bjophthalmol-2017-311392</Citation><ArticleIdList><ArticleId IdType="pubmed">29706600</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y, Wang L, Zhang W, Xu H, Chang X (2012) Transgenic mice over-expressing carbonic anhydrase I showed aggravated joint inflammation and tissue destruction. BMC Musculoskelet Disord 13:256. 10.1186/1471-2474-13-256</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575273</ArticleId><ArticleId IdType="pubmed">23256642</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuang GZ, Keeler B, Grant J, Bianchi L, Fu ES, Zhang YP, Erasso DM, Cui JG, Wiltshire T, Li Q, Hao S, Sarantopoulos KD, Candiotti K, Wishnek SM, Smith SB, Maixner W, Diatchenko L, Martin ER, Levitt RC (2015) Carbonic anhydrase-8 regulates inflammatory pain by inhibiting the ITPR1-cytosolic free calcium pathway. PLoS ONE 10:e0118273. 10.1371/journal.pone.0118273</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4347988</ArticleId><ArticleId IdType="pubmed">25734498</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfensberger TJ, Mahieu I, Jarvis-Evans J, Boulton M, Carter ND, N&#xf3;gr&#xe1;di A, Hollande E, Bird AC (1994) Membrane-bound carbonic anhydrase in human retinal pigment epithelium. Invest Ophthalmol Vis Sci 35:3401&#x2013;3407</Citation><ArticleIdList><ArticleId IdType="pubmed">8056514</ArticleId></ArticleIdList></Reference><Reference><Citation>Ochrietor JD, Clamp MF, Moroz TP, Grubb JH, Shah GN, Waheed A, Sly WS, Linser PJ (2005) Carbonic anhydrase XIV identified as the membrane CA in mouse retina: strong expression in M&#xfc;ller cells and the RPE. Exp Eye Res 81:492&#x2013;500. 10.1016/j.exer.2005.03.010</Citation><ArticleIdList><ArticleId IdType="pubmed">16126196</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfensberger TJ, Chiang RK, Takeuchi A, Marmor MF (2000) Inhibition of membrane-bound carbonic anhydrase enhances subretinal fluid absorption and retinal adhesiveness. Graefes Arch Clin Exp Ophthalmol 238:76&#x2013;80. 10.1007/s004170050013</Citation><ArticleIdList><ArticleId IdType="pubmed">10664057</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfensberger TJ, Dmitriev AV, Govardovskii VI (1999) Inhibition of membrane-bound carbonic anhydrase decreases subretinal pH and volume. Doc Ophthalmol 97:261&#x2013;271. 10.1023/a:1002496223131</Citation><ArticleIdList><ArticleId IdType="pubmed">10896339</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagelhus EA, Mathiisen TM, Bateman AC, Haug FM, Ottersen OP, Grubb JH, Waheed A, Sly WS (2005) Carbonic anhydrase XIV is enriched in specific membrane domains of retinal pigment epithelium, Muller cells, and astrocytes. Proc Natl Acad Sci U S A 102:8030&#x2013;8035. 10.1073/pnas.0503021102</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1142392</ArticleId><ArticleId IdType="pubmed">15901897</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39577606</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-0007</ISSN><JournalIssue CitedMedium="Internet"><Volume>250</Volume><PubDate><Year>2024</Year><Month>Nov</Month><Day>20</Day></PubDate></JournalIssue><Title>Experimental eye research</Title><ISOAbbreviation>Exp Eye Res</ISOAbbreviation></Journal><ArticleTitle>Choroidal macrophages in homeostasis, aging and age-related macular degeneration.</ArticleTitle><Pagination><StartPage>110159</StartPage><MedlinePgn>110159</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.exer.2024.110159</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0014-4835(24)00381-6</ELocationID><Abstract><AbstractText>With increasing age, the optimal functioning of the choroid is essential for efficient removal of waste products formed from photoreceptor renewal. A decline in regulatory elements of the immune system, termed immunosenescence, and the failure of para-inflammation to restore tissue homeostasis can result in the progression of healthy aging to sight-threatening inflammation of the choroid. Macrophages are uniquely situated between the innate and adaptive immune systems, with a high capacity for phagocytosis, recognition of complement components, as well as antigen presentation. In this review, we provide an overview of macrophages and their properties in the healthy choroid and cover the impact of aging, immunosenescence and inflammaging on the function of choroidal macrophages. We will discuss the impact of age on macrophage phenotype and behaviour in the pathophysiology of age-related macular degeneration.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Adnan H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Institute for Vision Research, University of Iowa, Iowa City, IA, USA; Department of Ophthalmology &amp; Visual Sciences, University of Iowa, Iowa City, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mulfaul</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute for Vision Research, University of Iowa, Iowa City, IA, USA; Department of Ophthalmology &amp; Visual Sciences, University of Iowa, Iowa City, IA, USA. Electronic address: kelly-mulfaul@uiowa.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Exp Eye Res</MedlineTA><NlmUniqueID>0370707</NlmUniqueID><ISSNLinking>0014-4835</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Age-related macular degeneration</Keyword><Keyword MajorTopicYN="N">Choroid</Keyword><Keyword MajorTopicYN="N">Immunosenescence</Keyword><Keyword MajorTopicYN="N">Inflammaging</Keyword><Keyword MajorTopicYN="N">Macrophage</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>23</Day><Hour>11</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>23</Day><Hour>11</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>19</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39577606</ArticleId><ArticleId IdType="doi">10.1016/j.exer.2024.110159</ArticleId><ArticleId IdType="pii">S0014-4835(24)00381-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39575904</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-0193</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>17</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Human brain mapping</Title><ISOAbbreviation>Hum Brain Mapp</ISOAbbreviation></Journal><ArticleTitle>Impact of Deprivation and Preferential Usage on Functional Connectivity Between Early Visual Cortex and Category-Selective Visual Regions.</ArticleTitle><Pagination><StartPage>e70064</StartPage><MedlinePgn>e70064</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70064</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/hbm.70064</ELocationID><Abstract><AbstractText>Human behavior can be remarkably shaped by experience, such as the removal of sensory input. Many studies of conditions such as stroke, limb amputation, and vision loss have examined how removal of input changes brain function. However, an important question yet to be answered is: when input is lost, does the brain change its connectivity to preferentially use some remaining inputs over others? In individuals with healthy vision, the central portion of the retina is preferentially used for everyday visual tasks, due to its ability to discriminate fine details. When central vision is lost in conditions like macular degeneration, peripheral vision must be relied upon for those everyday tasks, with some portions receiving "preferential" usage over others. Using resting-state fMRI collected during total darkness, we examined how deprivation and preferential usage influence the intrinsic functional connectivity of sensory cortex by studying individuals with selective vision loss due to late stages of macular degeneration. Specifically, we examined functional connectivity between category-selective visual areas and the cortical representation of three areas of the retina: the lesioned area, a preferentially used region of the intact retina, and a non-preferentially used region. We found that cortical regions representing spared portions of the peripheral retina, regardless of whether they are preferentially used, exhibit plasticity of intrinsic functional connectivity in macular degeneration. Cortical representations of spared peripheral retinal locations showed stronger connectivity to MT, a region involved in processing motion. These results suggest that the long-term loss of central vision can produce widespread effects throughout spared representations in early visual cortex, regardless of whether those representations are preferentially used. These findings support the idea that connections to visual cortex maintain the capacity for change well after critical periods of visual development.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s). Human Brain Mapping published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fleming</LastName><ForeName>Leland L</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Defenderfer</LastName><ForeName>Matthew K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demirayak</LastName><ForeName>Pinar</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-7159-5457</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Decarlo</LastName><ForeName>Dawn K</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Visscher</LastName><ForeName>Kristina M</ForeName><Initials>KM</Initials><Identifier Source="ORCID">0000-0003-0737-4024</Identifier><AffiliationInfo><Affiliation>Department of Neurobiology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F99 NS113424</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 EY025858</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NINDS F99NS113424</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NEI U01EY025858</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Brain Mapp</MedlineTA><NlmUniqueID>9419065</NlmUniqueID><ISSNLinking>1065-9471</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>bioRxiv. 2024 May 17:2024.05.17.593020. doi: 10.1101/2024.05.17.593020</RefSource><PMID Version="1">38798355</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014793" MajorTopicYN="Y">Visual Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008268" MajorTopicYN="N">Macular Degeneration</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014795" MajorTopicYN="N">Visual Pathways</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012683" MajorTopicYN="N">Sensory Deprivation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014796" MajorTopicYN="N">Visual Perception</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FFA</Keyword><Keyword MajorTopicYN="N">MT</Keyword><Keyword MajorTopicYN="N">V1</Keyword><Keyword MajorTopicYN="N">fMRI</Keyword><Keyword MajorTopicYN="N">functional connectivity</Keyword><Keyword MajorTopicYN="N">lesion projection zone</Keyword><Keyword MajorTopicYN="N">macular degeneration</Keyword><Keyword MajorTopicYN="N">plasticity</Keyword><Keyword MajorTopicYN="N">sensory deprivation</Keyword><Keyword MajorTopicYN="N">visual cortex</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>12</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>7</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39575904</ArticleId><ArticleId IdType="pmc">PMC11583081</ArticleId><ArticleId IdType="doi">10.1002/hbm.70064</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andrews&#x2010;Hanna, J. R. , Snyder A. Z., Vincent J. L., et&#xa0;al. 2007. &#x201c;Disruption of Large&#x2010;Scale Brain Systems in Advanced Aging.&#x201d; Neuron 56: 924&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2709284</ArticleId><ArticleId IdType="pubmed">18054866</ArticleId></ArticleIdList></Reference><Reference><Citation>Arcaro, M. J. , Honey C. J., Mruczek R. E. B., Kastner S., and Hasson U.. 2015. &#x201c;Widespread Correlation Patterns of fMRI Signal Across Visual Cortex Reflect Eccentricity Organization.&#x201d; eLife 4: e03952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4337732</ArticleId><ArticleId IdType="pubmed">25695154</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker, C. I. , Dilks D. D., Peli E., and Kanwisher N.. 2008. &#x201c;Reorganization of Visual Processing in Macular Degeneration: Replication and Clues About the Role of Foveal Loss.&#x201d; Vision Research 48: 1910&#x2013;1919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2572262</ArticleId><ArticleId IdType="pubmed">18620725</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker, C. I. , Peli E., Knouf N., and Kanwisher N. G.. 2005. &#x201c;Reorganization of Visual Processing in Macular Degeneration.&#x201d; Journal of Neuroscience 25: 614&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725316</ArticleId><ArticleId IdType="pubmed">15659597</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldassano, C. , Fei&#x2010;Fei L., and Beck D. M.. 2016. &#x201c;Pinpointing the Peripheral Bias in Neural Scene&#x2010;Processing Networks During Natural Viewing.&#x201d; Journal of Vision 16: 9.</Citation><ArticleIdList><ArticleId IdType="pubmed">27187606</ArticleId></ArticleIdList></Reference><Reference><Citation>Baseler, H. A. , Gouws A., Haak K. V., et&#xa0;al. 2011. &#x201c;Large&#x2010;Scale Remapping of Visual Cortex Is Absent in Adult Humans With Macular Degeneration.&#x201d; Nature Neuroscience 14: 649&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pubmed">21441924</ArticleId></ArticleIdList></Reference><Reference><Citation>Benson, N. C. , Butt O. H., Datta R., Radoeva P. D., Brainard D. H., and Aguirre G. K.. 2012. &#x201c;The Retinotopic Organization of Striate Cortex Is Well Predicted by Surface Topology.&#x201d; Current Biology 22: 2081&#x2013;2085.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3494819</ArticleId><ArticleId IdType="pubmed">23041195</ArticleId></ArticleIdList></Reference><Reference><Citation>Benson, N. C. , and Winawer J.. 2018. &#x201c;Bayesian Analysis of Retinotopic Maps.&#x201d; eLife 7: e40224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6340702</ArticleId><ArticleId IdType="pubmed">30520736</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswal, B. , Yetkin F. Z., Haughton V. M., and Hyde J. S.. 1995. &#x201c;Functional Connectivity in the Motor Cortex of Resting Human Brain Using Echo&#x2010;Planar MRI.&#x201d; Magnetic Resonance in Medicine 34: 537&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pubmed">8524021</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewer, A. A. , Liu J., Wade A. R., and Wandell B. A.. 2005. &#x201c;Visual Field Maps and Stimulus Selectivity in Human Ventral Occipital Cortex.&#x201d; Nature Neuroscience 8: 1102&#x2013;1109.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025108</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullimore, M. A. , Bailey I. L., and Wacker R. T.. 1991. &#x201c;Face Recognition in Age&#x2010;Related Maculopathy.&#x201d; Investigative Ophthalmology &amp; Visual Science 32: 2020&#x2013;2029.</Citation><ArticleIdList><ArticleId IdType="pubmed">2055696</ArticleId></ArticleIdList></Reference><Reference><Citation>Burge, W. K. , Griffis J. C., Nenert R., et&#xa0;al. 2016. &#x201c;Cortical Thickness in Human V1 Associated With Central Vision Loss.&#x201d; Scientific Reports 6: 23268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4806312</ArticleId><ArticleId IdType="pubmed">27009536</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnat, K. , Hu T.&#x2010;T., Kossut M., Eysel U. T., and Arckens L.. 2017. &#x201c;Plasticity Beyond V1: Reinforcement of Motion Perception Upon Binocular Central Retinal Lesions in Adulthood.&#x201d; Journal of Neuroscience 37: 8989&#x2013;8999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6596799</ArticleId><ArticleId IdType="pubmed">28821647</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan, M. Y. , Park D. C., Savalia N. K., Petersen S. E., and Wig G. S.. 2014. &#x201c;Decreased Segregation of Brain Systems Across the Healthy Adult Lifespan.&#x201d; Proceedings of the National Academy of Sciences 111: E4997&#x2013;E5006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4246293</ArticleId><ArticleId IdType="pubmed">25368199</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciric, R. , Rosen A. F. G., Erus G., et&#xa0;al. 2018. &#x201c;Mitigating Head Motion Artifact in Functional Connectivity MRI.&#x201d; Nature Protocols 13: 2801&#x2013;2826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8161527</ArticleId><ArticleId IdType="pubmed">30446748</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole, M. W. , Ito T., Cocuzza C., and Sanchez&#x2010;Romero R.. 2021. &#x201c;The Functional Relevance of Task&#x2010;State Functional Connectivity.&#x201d; Journal of Neuroscience 41: 2684&#x2013;2702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8018740</ArticleId><ArticleId IdType="pubmed">33542083</ArticleId></ArticleIdList></Reference><Reference><Citation>Cramer, S. C. , Sur M., Dobkin B. H., et&#xa0;al. 2011. &#x201c;Harnessing Neuroplasticity for Clinical Applications.&#x201d; Brain 134: 1591&#x2013;1609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102236</ArticleId><ArticleId IdType="pubmed">21482550</ArticleId></ArticleIdList></Reference><Reference><Citation>Crossland, M. D. , Crabb D. P., and Rubin G. S.. 2011. &#x201c;Task&#x2010;Specific Fixation Behavior in Macular Disease.&#x201d; Investigative Ophthalmology &amp; Visual Science 52: 411&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">20811056</ArticleId></ArticleIdList></Reference><Reference><Citation>Dacey, D. M. 1993. &#x201c;The Mosaic of Midget Ganglion Cells in the Human Retina.&#x201d; Journal of Neuroscience 13: 5334&#x2013;5355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576399</ArticleId><ArticleId IdType="pubmed">8254378</ArticleId></ArticleIdList></Reference><Reference><Citation>Defenderfer, M. , Demirayak P., and Visscher K. M.. 2021. &#x201c;A Method for Mapping Retinal Images in Early Visual Cortical Areas.&#x201d; NeuroImage 245: 118737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9807285</ArticleId><ArticleId IdType="pubmed">34798232</ArticleId></ArticleIdList></Reference><Reference><Citation>Defenderfer, M. K. , Demirayak P., Fleming L. L., DeCarlo D. K., Stewart P., and Visscher K. M.. 2023. &#x201c;Cortical Plasticity in Central Vision Loss: Cortical Thickness and Neurite Structure.&#x201d; Human Brain Mapping 44: 4120&#x2013;4135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10258531</ArticleId><ArticleId IdType="pubmed">37195035</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xe9;ruaz, A. , Whatham A. R., Mermoud C., and Safran A. B.. 2002. &#x201c;Reading With Multiple Preferred Retinal Loci: Implications for Training a More Efficient Reading Strategy.&#x201d; Vision Research 42: 2947&#x2013;2957.</Citation><ArticleIdList><ArticleId IdType="pubmed">12450504</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickie, E. W. , Anticevic A., Smith D. E., et&#xa0;al. 2019. &#x201c;Ciftify: A Framework for Surface&#x2010;Based Analysis of Legacy MR Acquisitions.&#x201d; NeuroImage 197: 818&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675413</ArticleId><ArticleId IdType="pubmed">31091476</ArticleId></ArticleIdList></Reference><Reference><Citation>Dilks, D. D. , Baker C. I., Peli E., and Kanwisher N.. 2009. &#x201c;Reorganization of Visual Processing in Macular Degeneration Is Not Specific to the &#x201c;Preferred Retinal Locus&#x201d;.&#x201d; Journal of Neuroscience 29: 2768&#x2013;2773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2672419</ArticleId><ArticleId IdType="pubmed">19261872</ArticleId></ArticleIdList></Reference><Reference><Citation>Dosenbach, N. U. F. , Nardos B., Cohen A. L., et&#xa0;al. 2010. &#x201c;Prediction of Individual Brain Maturity Using fMRI.&#x201d; Science 329: 1358&#x2013;1361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135376</ArticleId><ArticleId IdType="pubmed">20829489</ArticleId></ArticleIdList></Reference><Reference><Citation>Duret, F. , Issenhuth M., and Safran A. B.. 1999. &#x201c;Combined Use of Several Preferred Retinal Loci in Patients With Macular Disorders When Reading Single Words.&#x201d; Vision Research 39: 873&#x2013;879.</Citation><ArticleIdList><ArticleId IdType="pubmed">10341972</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkhetali, A. S. , Fleming L. L., Vaden R. J., Nenert R., Mendle J. E., and Visscher K. M.. 2019. &#x201c;Background Connectivity Between Frontal and Sensory Cortex Depends on Task State, Independent of Stimulus Modality.&#x201d; NeuroImage 184: 790&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8415012</ArticleId><ArticleId IdType="pubmed">30237034</ArticleId></ArticleIdList></Reference><Reference><Citation>Esteban, O. , Birman D., Schaer M., Koyejo O. O., Poldrack R. A., and Gorgolewski K. J.. 2017. &#x201c;MRIQC: Advancing the Automatic Prediction of Image Quality in MRI From Unseen Sites.&#x201d; PLoS One 12: e0184661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5612458</ArticleId><ArticleId IdType="pubmed">28945803</ArticleId></ArticleIdList></Reference><Reference><Citation>Esteban, O. , Markiewicz C. J., Blair R. W., et&#xa0;al. 2019. &#x201c;fMRIPrep: A Robust Preprocessing Pipeline for Functional MRI.&#x201d; Nature Methods 16: 111&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6319393</ArticleId><ArticleId IdType="pubmed">30532080</ArticleId></ArticleIdList></Reference><Reference><Citation>Fair, D. A. , Dosenbach N. U. F., Church J. A., et&#xa0;al. 2007. &#x201c;Development of Distinct Control Networks Through Segregation and Integration.&#x201d; Proceedings of the National Academy of Sciences 104: 13507&#x2013;13512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1940033</ArticleId><ArticleId IdType="pubmed">17679691</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferris, F. L. , Kassoff A., Bresnick G. H., and Bailey I.. 1982. &#x201c;New Visual Acuity Charts for Clinical Research.&#x201d; American Journal of Ophthalmology 94: 91&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">7091289</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleming, L. L. , Harnett N. G., and Ressler K. J.. 2024. &#x201c;Sensory Alterations in Post&#x2010;Traumatic Stress Disorder.&#x201d; Current Opinion in Neurobiology 84: 102821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10922208</ArticleId><ArticleId IdType="pubmed">38096758</ArticleId></ArticleIdList></Reference><Reference><Citation>Geerligs, L. , Renken R. J., Saliasi E., Maurits N. M., and Lorist M. M.. 2015. &#x201c;A Brain&#x2010;Wide Study of Age&#x2010;Related Changes in Functional Connectivity.&#x201d; Cerebral Cortex 25: 1987&#x2013;1999.</Citation><ArticleIdList><ArticleId IdType="pubmed">24532319</ArticleId></ArticleIdList></Reference><Reference><Citation>Gen&#xe7;, E. , Sch&#xf6;lvinck M. L., Bergmann J., Singer W., and Kohler A.. 2016. &#x201c;Functional Connectivity Patterns of Visual Cortex Reflect Its Anatomical Organization.&#x201d; Cerebral Cortex 26: 3719&#x2013;3731.</Citation><ArticleIdList><ArticleId IdType="pubmed">26271111</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert, C. D. , and Li W.. 2012. &#x201c;Adult Visual Cortical Plasticity.&#x201d; Neuron 75: 250&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3408614</ArticleId><ArticleId IdType="pubmed">22841310</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasser, M. F. , Coalson T. S., Robinson E. C., et&#xa0;al. 2016. &#x201c;A Multi&#x2010;Modal Parcellation of Human Cerebral Cortex.&#x201d; Nature 536: 171&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4990127</ArticleId><ArticleId IdType="pubmed">27437579</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasser, M. F. , Smith S. M., Marcus D. S., et&#xa0;al. 2016. &#x201c;The Human Connectome Project's Neuroimaging Approach.&#x201d; Nature Neuroscience 19: 1175&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6172654</ArticleId><ArticleId IdType="pubmed">27571196</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorgolewski, K. J. , Auer T., Calhoun V. D., et&#xa0;al. 2016. &#x201c;The Brain Imaging Data Structure, a Format for Organizing and Describing Outputs of Neuroimaging Experiments.&#x201d; Scientific Data 3: 160044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4978148</ArticleId><ArticleId IdType="pubmed">27326542</ArticleId></ArticleIdList></Reference><Reference><Citation>Gratton, C. , Laumann T. O., Nielsen A. N., et&#xa0;al. 2018. &#x201c;Functional Brain Networks Are Dominated by Stable Group and Individual Factors, Not Cognitive or Daily Variation.&#x201d; Neuron 98: 439&#x2013;452.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5912345</ArticleId><ArticleId IdType="pubmed">29673485</ArticleId></ArticleIdList></Reference><Reference><Citation>Grefkes, C. , and Fink G. R.. 2014. &#x201c;Connectivity&#x2010;Based Approaches in Stroke and Recovery of Function.&#x201d; Lancet Neurology 13: 206&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">24457190</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffis, J. C. , Elkhetali A. S., Burge W. K., et&#xa0;al. 2017. &#x201c;Retinotopic Patterns of Functional Connectivity Between V1 and Large&#x2010;Scale Brain Networks During Resting Fixation.&#x201d; NeuroImage 146: 1071&#x2013;1083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5318284</ArticleId><ArticleId IdType="pubmed">27554527</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagan, M. A. , Chaplin T. A., Huxlin K. R., Rosa M. G. P., and Lui L. L.. 2020. &#x201c;Altered Sensitivity to Motion of Area MT Neurons Following Long&#x2010;Term V1 Lesions.&#x201d; Cerebral Cortex 30: 451&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7444738</ArticleId><ArticleId IdType="pubmed">31211357</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahamy, A. , Behrmann M., and Malach R.. 2015. &#x201c;The Idiosyncratic Brain: Distortion of Spontaneous Connectivity Patterns in Autism Spectrum Disorder.&#x201d; Nature Neuroscience 18: 302&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">25599222</ArticleId></ArticleIdList></Reference><Reference><Citation>Harmelech, T. , and Malach R.. 2013. &#x201c;Neurocognitive Biases and the Patterns of Spontaneous Correlations in the Human Cortex.&#x201d; Trends in Cognitive Sciences 17: 606&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pubmed">24182697</ArticleId></ArticleIdList></Reference><Reference><Citation>Harnett, N. G. , Fleming L. L., Clancy K. J., Ressler K. J., and Rosso I. M.. 2024. &#x201c;Affective Visual Circuit Dysfunction in Trauma and Stress&#x2010;Related Disorders.&#x201d; Biological Psychiatry. Published ahead of print, July 10, 2024.</Citation><ArticleIdList><ArticleId IdType="pubmed">38996901</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasson, U. , Levy I., Behrmann M., Hendler T., and Malach R.. 2002. &#x201c;Eccentricity Bias as an Organizing Principle for Human High&#x2010;Order Object Areas.&#x201d; Neuron 34: 479&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pubmed">11988177</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebb, D. 1949. &#x201c;The Organization of Behavior.&#x201d;</Citation></Reference><Reference><Citation>Heinzle, J. , Kahnt T., and Haynes J.&#x2010;D.. 2011. &#x201c;Topographically Specific Functional Connectivity Between Visual Field Maps in the Human Brain.&#x201d; NeuroImage 56: 1426&#x2013;1436.</Citation><ArticleIdList><ArticleId IdType="pubmed">21376818</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubel, D. H. , and Wiesel T. N.. 1962. &#x201c;Receptive Fields, Binocular Interaction and Functional Architecture in the cat's Visual Cortex.&#x201d; Journal of Physiology (London) 160: 106&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1359523</ArticleId><ArticleId IdType="pubmed">14449617</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubel, D. H. , and Wiesel T. N.. 1963. &#x201c;Receptive Fields Of Cells In Striate Cortex Of Very Young, Visually Inexperienced Kittens.&#x201d; Journal of Neurophysiology 26: 994&#x2013;1002.</Citation><ArticleIdList><ArticleId IdType="pubmed">14084171</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubel, D. H. , and Wiesel T. N.. 1970. &#x201c;The Period of Susceptibility to the Physiological Effects of Unilateral Eye Closure in Kittens.&#x201d; Journal of Physiology (London) 206: 419&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1348655</ArticleId><ArticleId IdType="pubmed">5498493</ArticleId></ArticleIdList></Reference><Reference><Citation>Koba, C. , Notaro G., Tamm S., Nilsonne G., and Hasson U.. 2021. &#x201c;Spontaneous Eye Movements During Eyes&#x2010;Open Rest Reduce Resting&#x2010;State&#x2010;Network Modularity by Increasing Visual&#x2010;Sensorimotor Connectivity.&#x201d; Network Neuroscience 5: 451&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233114</ArticleId><ArticleId IdType="pubmed">34189373</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreichman, O. , and Gilaie&#x2010;Dotan S.. 2024. &#x201c;Parafoveal Vision Reveals Qualitative Differences Between Fusiform Face Area and Parahippocampal Place Area.&#x201d; Human Brain Mapping 45: e26616.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10879909</ArticleId><ArticleId IdType="pubmed">38379465</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei, H. , and Schuchard R. A.. 1997. &#x201c;Using Two Preferred Retinal Loci for Different Lighting Conditions in Patients With Central Scotomas.&#x201d; Investigative Ophthalmology &amp; Visual Science 38: 1812&#x2013;1818.</Citation><ArticleIdList><ArticleId IdType="pubmed">9286270</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy, I. , Hasson U., Avidan G., Hendler T., and Malach R.. 2001. &#x201c;Center&#x2010;Periphery Organization of Human Object Areas.&#x201d; Nature Neuroscience 4: 533&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11319563</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis, C. M. , Baldassarre A., Committeri G., Romani G. L., and Corbetta M.. 2009. &#x201c;Learning Sculpts the Spontaneous Activity of the Resting Human Brain.&#x201d; National Academy of Sciences 106: 17558&#x2013;17563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2762683</ArticleId><ArticleId IdType="pubmed">19805061</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, L. D. , and Pack C. C.. 2017. &#x201c;The Contribution of Area MT to Visual Motion Perception Depends on Training.&#x201d; Neuron 95: 436&#x2013;446.e3.</Citation><ArticleIdList><ArticleId IdType="pubmed">28689980</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, T. , Cheung S.&#x2010;H., Schuchard R. A., et&#xa0;al. 2010. &#x201c;Incomplete cortical reorganization in macular degeneration.&#x201d; Investigative Ophthalmology &amp; Visual Science 51: 6826&#x2013;6834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3055781</ArticleId><ArticleId IdType="pubmed">20631240</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcus, D. S. , Harms M. P., Snyder A. Z., et&#xa0;al. 2013. &#x201c;Human Connectome Project Informatics: Quality Control, Database Services, and Data Visualization.&#x201d; NeuroImage 80: 202&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3845379</ArticleId><ArticleId IdType="pubmed">23707591</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcus, D. S. , Harwell J., Olsen T., et&#xa0;al. 2011. &#x201c;Informatics and Data Mining Tools and Strategies for the Human Connectome Project.&#x201d; Frontiers in Neuroinformatics 5: 4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3127103</ArticleId><ArticleId IdType="pubmed">21743807</ArticleId></ArticleIdList></Reference><Reference><Citation>Masri, R. A. , Gr&#xfc;nert U., and Martin P. R.. 2020. &#x201c;Analysis of Parvocellular and Magnocellular Visual Pathways in Human Retina.&#x201d; Journal of Neuroscience 40: 8132&#x2013;8148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7574660</ArticleId><ArticleId IdType="pubmed">33009001</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda, Y. , Dumoulin S. O., Nakadomari S., and Wandell B. A.. 2008. &#x201c;V1 Projection Zone Signals in Human Macular Degeneration Depend on Task, Not Stimulus.&#x201d; Cerebral Cortex 18: 2483&#x2013;2493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2733314</ArticleId><ArticleId IdType="pubmed">18250083</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda, Y. , Takemura H., Terao M., et&#xa0;al. 2021. &#x201c;V1 Projection Zone Signals in Human Macular Degeneration Depend on Task Despite Absence of Visual Stimulus.&#x201d; Current Biology 31: 406&#x2013;412.e3.</Citation><ArticleIdList><ArticleId IdType="pubmed">33157025</ArticleId></ArticleIdList></Reference><Reference><Citation>Merabet, L. B. , Hamilton R., Schlaug G., et&#xa0;al. 2008. &#x201c;Rapid and Reversible Recruitment of Early Visual Cortex for Touch.&#x201d; PLoS One 3: e3046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2516172</ArticleId><ArticleId IdType="pubmed">18728773</ArticleId></ArticleIdList></Reference><Reference><Citation>Meunier, D. , Achard S., Morcom A., and Bullmore E.. 2009. &#x201c;Age&#x2010;Related Changes in Modular Organization of Human Brain Functional Networks.&#x201d; NeuroImage 44: 715&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pubmed">19027073</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell, P. , Liew G., Gopinath B., and Wong T. Y.. 2018. &#x201c;Age&#x2010;Related Macular Degeneration.&#x201d; Lancet 392: 1147&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">30303083</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller, S. , Wang D., Fox M. D., et&#xa0;al. 2013. &#x201c;Individual Variability in Functional Connectivity Architecture of the Human Brain.&#x201d; Neuron 77: 586&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3746075</ArticleId><ArticleId IdType="pubmed">23395382</ArticleId></ArticleIdList></Reference><Reference><Citation>Newbold, D. J. , Laumann T. O., Hoyt C. R., et&#xa0;al. 2020. &#x201c;Plasticity and Spontaneous Activity Pulses in Disused Human Brain Circuits.&#x201d; Neuron 107: 580&#x2013;589.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7419711</ArticleId><ArticleId IdType="pubmed">32778224</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer, S. M. , and Rosa M. G. P.. 2006. &#x201c;A Distinct Anatomical Network of Cortical Areas for Analysis of Motion in Far Peripheral Vision.&#x201d; European Journal of Neuroscience 24: 2389&#x2013;2405.</Citation><ArticleIdList><ArticleId IdType="pubmed">17042793</ArticleId></ArticleIdList></Reference><Reference><Citation>Park, B.&#x2010;Y. , Tark K.&#x2010;J., Shim W. M., and Park H.. 2018. &#x201c;Functional Connectivity Based Parcellation of Early Visual Cortices.&#x201d; Human Brain Mapping 39: 1380&#x2013;1390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6866351</ArticleId><ArticleId IdType="pubmed">29250855</ArticleId></ArticleIdList></Reference><Reference><Citation>Raemaekers, M. , Schellekens W., van Wezel R. J. A., Petridou N., Kristo G., and Ramsey N. F.. 2014. &#x201c;Patterns of Resting State Connectivity in Human Primary Visual Cortical Areas: A 7T fMRI Study.&#x201d; NeuroImage 84: 911&#x2013;921.</Citation><ArticleIdList><ArticleId IdType="pubmed">24099850</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramachandran, V. S. , and Hirstein W.. 1998. &#x201c;The Perception of Phantom Limbs. The D. O. Hebb Lecture.&#x201d; Brain: A Journal of Neurology 121, no. Pt 9: 1603&#x2013;1630.</Citation><ArticleIdList><ArticleId IdType="pubmed">9762952</ArticleId></ArticleIdList></Reference><Reference><Citation>Romei, V. , Chiappini E., Hibbard P. B., and Avenanti A.. 2016. &#x201c;Empowering Reentrant Projections From V5 to V1 Boosts Sensitivity to Motion.&#x201d; Current Biology 26: 2155&#x2013;2160.</Citation><ArticleIdList><ArticleId IdType="pubmed">27524488</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbah, N. , Sanda N., Authi&#xe9; C. N., et&#xa0;al. 2017. &#x201c;Reorganization of Early Visual Cortex Functional Connectivity Following Selective Peripheral and Central Visual Loss.&#x201d; Scientific Reports 7: 43223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5324137</ArticleId><ArticleId IdType="pubmed">28233790</ArticleId></ArticleIdList></Reference><Reference><Citation>Satterthwaite, T. D. , Wolf D. H., Erus G., et&#xa0;al. 2013. &#x201c;Functional Maturation of the Executive System During Adolescence.&#x201d; Journal of Neuroscience 33: 16249&#x2013;16261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3792462</ArticleId><ArticleId IdType="pubmed">24107956</ArticleId></ArticleIdList></Reference><Reference><Citation>Sele, S. , Liem F., M&#xe9;rillat S., and J&#xe4;ncke L.. 2021. &#x201c;Age&#x2010;Related Decline in the Brain: A Longitudinal Study on Inter&#x2010;Individual Variability of Cortical Thickness, Area, Volume, and Cognition.&#x201d; NeuroImage 240: 118370.</Citation><ArticleIdList><ArticleId IdType="pubmed">34245866</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen, S. , Khalsa N. N., Tong N., et&#xa0;al. 2022. &#x201c;The Role of Visual Experience in Individual Differences of Brain Connectivity.&#x201d; Journal of Neuroscience 42: 5070&#x2013;5084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9233442</ArticleId><ArticleId IdType="pubmed">35589393</ArticleId></ArticleIdList></Reference><Reference><Citation>Slotnick, S. D. , and White R. C.. 2013. &#x201c;The Fusiform Face Area Responds Equivalently to Faces and Abstract Shapes in the Left and Central Visual Fields.&#x201d; NeuroImage 83: 408&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">23777758</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparling, T. , Iyer L., Pasquina P., and Petrus E.. 2024. &#x201c;Cortical Reorganization After Limb Loss: Bridging the Gap Between Basic Science and Clinical Recovery.&#x201d; Journal of Neuroscience 44: e1051232024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10851691</ArticleId><ArticleId IdType="pubmed">38171645</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinman, R. M. 1965. &#x201c;Effect of Target Size, Luminance, and Color on Monocular Fixation*.&#x201d; Journal of the Optical Society of America 55: 1158.</Citation></Reference><Reference><Citation>Striem&#x2010;Amit, E. , Ovadia&#x2010;Caro S., Caramazza A., Margulies D. S., Villringer A., and Amedi A.. 2015. &#x201c;Functional Connectivity of Visual Cortex in the Blind Follows Retinotopic Organization Principles.&#x201d; Brain 138: 1679&#x2013;1695.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4614142</ArticleId><ArticleId IdType="pubmed">25869851</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunness, J. S. , Liu T., and Yantis S.. 2004. &#x201c;Retinotopic Mapping of the Visual Cortex Using Functional Magnetic Resonance Imaging in a Patient With Central Scotomas From Atrophic Macular Degeneration.&#x201d; Ophthalmology 111: 1595&#x2013;1598.</Citation><ArticleIdList><ArticleId IdType="pubmed">15288993</ArticleId></ArticleIdList></Reference><Reference><Citation>Timberlake, G. T. , Peli E., Essock E. A., and Augliere R. A.. 1987. &#x201c;Reading With a Macular Scotoma. II. Retinal Locus for Scanning Text.&#x201d; Investigative Ophthalmology &amp; Visual Science 28: 1268&#x2013;1274.</Citation><ArticleIdList><ArticleId IdType="pubmed">3610545</ArticleId></ArticleIdList></Reference><Reference><Citation>Tootell, R. B. , Reppas J. B., Dale A. M., et&#xa0;al. 1995. &#x201c;Visual Motion Aftereffect in Human Cortical Area MT Revealed by Functional Magnetic Resonance Imaging.&#x201d; Nature 375: 139&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">7753168</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyoizumi, T. , Kaneko M., Stryker M. P., and Miller K. D.. 2014. &#x201c;Modeling the Dynamic Interaction of Hebbian and Homeostatic Plasticity.&#x201d; Neuron 84: 497&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4223656</ArticleId><ArticleId IdType="pubmed">25374364</ArticleId></ArticleIdList></Reference><Reference><Citation>Tropea, D. , Kreiman G., Lyckman A., et&#xa0;al. 2006. &#x201c;Gene Expression Changes and Molecular Pathways Mediating Activity&#x2010;Dependent Plasticity in Visual Cortex.&#x201d; Nature Neuroscience 9: 660&#x2013;668.</Citation><ArticleIdList><ArticleId IdType="pubmed">16633343</ArticleId></ArticleIdList></Reference><Reference><Citation>Turrigiano, G. G. 1999. &#x201c;Homeostatic Plasticity in Neuronal Networks: The More Things Change, the More They Stay the Same.&#x201d; Trends in Neurosciences 22: 221&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">10322495</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner, K. S. , Barnett M. A., Witthoft N., et&#xa0;al. 2018. &#x201c;Defining the Most Probable Location of the Parahippocampal Place Area Using Cortex&#x2010;Based Alignment and Cross&#x2010;Validation.&#x201d; NeuroImage 170: 373&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6330657</ArticleId><ArticleId IdType="pubmed">28435097</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan, W. , Peng Y.&#x2010;R., van Zyl T., et&#xa0;al. 2020. &#x201c;Cell Atlas of the Human Fovea and Peripheral Retina.&#x201d; Scientific Reports 10: 9802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299956</ArticleId><ArticleId IdType="pubmed">32555229</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu, H.&#x2010;H. , Verma R., Yang Y., et&#xa0;al. 2010. &#x201c;Spatial and Temporal Frequency Tuning in Striate Cortex: Functional Uniformity and Specializations Related to Receptive Field Eccentricity.&#x201d; European Journal of Neuroscience 31: 1043&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pubmed">20377618</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarbin, M. A. 2004. &#x201c;Current Concepts in the Pathogenesis of Age&#x2010;Related Macular Degeneration.&#x201d; Archives of Ophthalmology 122: 598&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pubmed">15078679</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhen, Z. , Kong X.&#x2010;Z., Huang L., et&#xa0;al. 2017. &#x201c;Quantifying the Variability of Scene&#x2010;Selective Regions: Interindividual, Interhemispheric, and Sex Differences.&#x201d; Human Brain Mapping 38: 2260&#x2013;2275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6866930</ArticleId><ArticleId IdType="pubmed">28117508</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39575534</PMID><DateCompleted><Year>2024</Year><Month>12</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1473-0189</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>24</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>03</Day></PubDate></JournalIssue><Title>Lab on a chip</Title><ISOAbbreviation>Lab Chip</ISOAbbreviation></Journal><ArticleTitle>Applying low levels of strain to model nascent phenomenon of retinal pathologies.</ArticleTitle><Pagination><StartPage>5338</StartPage><EndPage>5346</EndPage><MedlinePgn>5338-5346</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1039/d4lc00205a</ELocationID><Abstract><AbstractText>Age-related macular degeneration (AMD) is a leading cause of vision loss in aging populations. A better understanding of the mechanisms of the disease, especially at early stages, could elucidate new treatment targets. One characteristic of AMD is strain on the retinal pigment epithelium (RPE), a crucial layer of the retina. This strain can be caused by physical phenomena like waste aggregation underneath the RPE, drusen formation, or leaky blood vessels that infiltrate the retina during choroidal neovascularization (CNV). It is not well understood how strain affects RPE cell function. Most models generate equibiaxial strain or higher levels of strain that are not representative of early stages of AMD. To overcome these issues, we engineered a device to cause controlled, low amounts of localized, radial strain (maximum &#x223c;1.4%). This strain level is more mimetic to what occurs during aging or at the beginning of physical disruptions experienced during AMD. To evaluate how RPE cells respond to this physical stimulus, primary porcine RPE cells were exposed to low levels of strain applied by our custom-made device. Cell secretions and genetic expression were analyzed to determine how proteins linked to drusen and CNV are affected. The results indicate that this low amount of strain does not immediately initiate angiogenesis but causes changes in mRNA expression of amyloid precursor protein (APP), which plays a role in retinal health and drusen accumulation. This research offers insight into AMD progression as well as the health of other organs, including the brain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Paterson</LastName><ForeName>Chase</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4522-437X</Identifier><AffiliationInfo><Affiliation>Biological Engineering, Utah State University College of Engineering, 4105 Old Main Hill, ENGR 402, Logan, Utah, USA. vargis@usu.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vargis</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-3141-9317</Identifier><AffiliationInfo><Affiliation>Biological Engineering, Utah State University College of Engineering, 4105 Old Main Hill, ENGR 402, Logan, Utah, USA. vargis@usu.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lab Chip</MedlineTA><NlmUniqueID>101128948</NlmUniqueID><ISSNLinking>1473-0189</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055213" MajorTopicYN="Y">Retinal Pigment Epithelium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013552" MajorTopicYN="N">Swine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008268" MajorTopicYN="Y">Macular Degeneration</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013314" MajorTopicYN="N">Stress, Mechanical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020256" MajorTopicYN="N">Choroidal Neovascularization</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>3</Day><Hour>12</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>4</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39575534</ArticleId><ArticleId IdType="doi">10.1039/d4lc00205a</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39574566</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2692-8205</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>06</Day></PubDate></JournalIssue><Title>bioRxiv : the preprint server for biology</Title><ISOAbbreviation>bioRxiv</ISOAbbreviation></Journal><ArticleTitle>Restoring and sustaining human postmortem retinal light responses with scalable methods for testing degenerative disease therapies.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2024.11.04.621932</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2024.11.04.621932</ELocationID><Abstract><AbstractText>Neuro- and retinal degenerative diseases rob millions of aging individuals of their independence. Researching these diseases in human tissue has been hindered by the immediate loss of electric activity in neurons after the circulation ceases. Recent studies indicate that limited neuronal activity can be revived postmortem, even in the retina. We capitalized on this discovery by successfully restoring and maintaining <i>in vivo</i> -like light responses in eyes recovered up to four hours and stored for up to 48 hours postmortem. This breakthrough significantly increases the availability of functionally viable human retinas for research. Our AI-based postmortem retinal imaging platform identifies retinal structures and allows us to compare light responses in the healthy central and peripheral retina with <i>ex vivo</i> electroretinography. We use this platform to measure the dark adaptation of human macular cones from controls and donors with age-related macular degeneration for the first time in the absence of the retinal pigment epithelium. We developed increased throughput technology and a model to simulate disease-associated acute ischemia-reperfusion. In this model, we demonstrate the protective or toxic effects of several drugs targeting oxidative stress or glutamate excitotoxicity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>Silke</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Jordan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Morison</LastName><ForeName>Zia L'Ecuyer</ForeName><Initials>ZL</Initials></Author><Author ValidYN="Y"><LastName>Saeid</LastName><ForeName>Sama</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Koskelainen</LastName><ForeName>Ari</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Vinberg</LastName><ForeName>Frans</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-3439-4979</Identifier></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>bioRxiv</MedlineTA><NlmUniqueID>101680187</NlmUniqueID><ISSNLinking>2692-8205</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>4</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39574566</ArticleId><ArticleId IdType="pmc">PMC11580909</ArticleId><ArticleId IdType="doi">10.1101/2024.11.04.621932</ArticleId><ArticleId IdType="pii">2024.11.04.621932</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39572858</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1442-9071</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>21</Day></PubDate></JournalIssue><Title>Clinical &amp; experimental ophthalmology</Title><ISOAbbreviation>Clin Exp Ophthalmol</ISOAbbreviation></Journal><ArticleTitle>Utilisation of patient-centred outcome measures in age-related macular degeneration research and clinical practice: A systematic review.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/ceo.14466</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To identify the utilisation, type, and psychometric properties of patient-centered outcome measures (PCOMs) associated with the performance-based assessment of visual function (VF) in age-related macular degeneration (AMD) in clinical care and research.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic literature search identified studies, available in English, that used PCOMs to assess VF in patients with any AMD severity, published from January 2015 to November 2023. Two researchers screened studies for quality using the Mixed Methods Appraisal Tool (MMAT) 2018 and assessed the psychometric properties of the PCOMs with the guidance of Consensus-based Standards for the selection of health Measurement Instruments (COSMIN).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 514 studies shortlisted in the literature, 31 were eligible with the majority (77.4%) fulfilling all the MMAT criteria, indicating good quality. The most used PCOM was reading (14/31&#x2009;=&#x2009;45.1%), with 5 of the 14 studies (35.7%) showing that the increasing severity and/or progression of AMD were associated with a worsening reading ability. AMD also negatively affected mobility and physical activity levels (7/31&#x2009;=&#x2009;22.6%), and visual search and exploration (4/31&#x2009;=&#x2009;12.9%). Based on the COSMIN checklist, apart from reading and physical activity measured with the accelerometer, the other PCOMs had 'inadequate' psychometric properties.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Limited published studies include PCOMs as an assessment of VF in AMD patients. Apart from reading, there is a lack of robust validation data to support the widespread use of other PCOMs. Hence, well-designed, robustly validated, and simple to use PCOMs are required for more widespread implementation in AMD clinical care and research.</AbstractText><CopyrightInformation>&#xa9; 2024 Royal Australian and New Zealand College of Ophthalmologists.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Loo</LastName><ForeName>Cheng Yi</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Singapore National Eye Centre, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fenwick</LastName><ForeName>Eva K</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>Singapore Eye Research Institute, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Duke-NUS Medical School, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Man</LastName><ForeName>Ryan E K</ForeName><Initials>REK</Initials><AffiliationInfo><Affiliation>Singapore National Eye Centre, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Singapore Eye Research Institute, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Duke-NUS Medical School, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamoureux</LastName><ForeName>Ecosse L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Singapore Eye Research Institute, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Duke-NUS Medical School, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Anna C S</ForeName><Initials>ACS</Initials><Identifier Source="ORCID">0000-0001-9266-3589</Identifier><AffiliationInfo><Affiliation>Singapore National Eye Centre, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Singapore Eye Research Institute, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Duke-NUS Medical School, Singapore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>05/FY2016/P2/20-A47</GrantID><Agency>SingHealth</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Clin Exp Ophthalmol</MedlineTA><NlmUniqueID>100896531</NlmUniqueID><ISSNLinking>1442-6404</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">age&#x2010;related macular degeneration</Keyword><Keyword MajorTopicYN="N">outcome measures</Keyword><Keyword MajorTopicYN="N">reading</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>21</Day><Hour>23</Hour><Minute>51</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39572858</ArticleId><ArticleId IdType="doi">10.1111/ceo.14466</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Chaudhuri M, Hassan Y, Bakka Vemana PPS, Bellary Pattanashetty MS, Abdin ZU, Siddiqui HF. Age&#x2010;related macular degeneration: an exponentially emerging imminent threat of visual impairment and irreversible blindness. Cureus. 2023;15(5):e39624.</Citation></Reference><Reference><Citation>Wong WL, Su X, Li X, et al. Global prevalence of age&#x2010;related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta&#x2010;analysis. Lancet Glob Health. 2014;2(2):e106&#x2010;e116.</Citation></Reference><Reference><Citation>Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age&#x2010;related maculopathy and age&#x2010;related macular degeneration. The international ARM epidemiological study group. Surv Ophthalmol. 1995;39(5):367&#x2010;374.</Citation></Reference><Reference><Citation>Ferris FL, Wilkinson CP, Bird A, et al. Clinical classification of age&#x2010;related macular degeneration. Ophthalmology. 2013;120(4):844&#x2010;851.</Citation></Reference><Reference><Citation>Yuzawa M, Fujita K, Tanaka E, Wang EC. Assessing quality of life in the treatment of patients with age&#x2010;related macular degeneration: clinical research findings and recommendations for clinical practice. Clin Ophthalmol. 2013;7:1325&#x2010;1332.</Citation></Reference><Reference><Citation>Hochberg C, Maul E, Chan ES, et al. Association of vision loss in glaucoma and age&#x2010;related macular degeneration with IADL disability. Invest Ophthalmol vis Sci. 2012;53(6):3201&#x2010;3206.</Citation></Reference><Reference><Citation>Finger RP, Fleckenstein M, Holz FG, Scholl HP. Quality of life in age&#x2010;related macular degeneration: a review of available vision&#x2010;specific psychometric tools. Qual Life Res. 2008;17(4):559&#x2010;574.</Citation></Reference><Reference><Citation>Lotery A, Xu X, Zlatava G, Loftus J. Burden of illness, visual impairment and health resource utilisation of patients with neovascular age&#x2010;related macular degeneration: results from the UK cohort of a five&#x2010;country cross&#x2010;sectional study. Br J Ophthalmol. 2007;91(10):1303&#x2010;1307.</Citation></Reference><Reference><Citation>Lamoureux EL, Mitchell P, Rees G, et al. Impact of early and late age&#x2010;related macular degeneration on vision&#x2010;specific functioning. Br J Ophthalmol. 2011;95(5):666&#x2010;670.</Citation></Reference><Reference><Citation>Gopinath B, Liew G, Burlutsky G, Mitchell P. Age&#x2010;related macular degeneration and 5&#x2010;year incidence of impaired activities of daily living. Maturitas. 2014;77(3):263&#x2010;266.</Citation></Reference><Reference><Citation>Scilley K, DeCarlo DK, Wells J, Owsley C. Vision&#x2010;specific health&#x2010;related quality of life in age&#x2010;related maculopathy patients presenting for low vision services. Ophthalmic Epidemiol. 2004;11(2):131&#x2010;146.</Citation></Reference><Reference><Citation>Hassell JB, Lamoureux EL, Keeffe JE. Impact of age related macular degeneration on quality of life. Br J Ophthalmol. 2006;90(5):593&#x2010;596.</Citation></Reference><Reference><Citation>Mitchell J, Bradley C. Quality of life in age&#x2010;related macular degeneration: a review of the literature. Health Qual Life Outcomes. 2006;4:97.</Citation></Reference><Reference><Citation>Morel T, Cano SJ. Measuring what matters to rare disease patients &#x2010; reflections on the work by the IRDiRC taskforce on patient&#x2010;centered outcome measures. Orphanet J Rare Dis. 2017;12(1):171.</Citation></Reference><Reference><Citation>Taylor D, Hobby A, Binns A, Crabb D. How does age&#x2010;related macular degeneration affect realworld visual ability and quality of life? A systematic review. BMJ Open. 2016;6:e011504.</Citation></Reference><Reference><Citation>Mokkink LB, Boers M, van der Vleuten CPM, et al. COSMIN risk of bias tool to assess the quality of studies on reliability or measurement error of outcome measurement instruments: a Delphi study. BMC Med Res Methodol. 2020;20(1):293.</Citation></Reference><Reference><Citation>Prinsen CAC, Mokkink LB, Bouter LM, et al. COSMIN guideline for systematic reviews of patient&#x2010;reported outcome measures. Qual Life Res. 2018;27(5):1147&#x2010;1157.</Citation></Reference><Reference><Citation>Leonardi NT, Kawakami DMO, Hurst JR, Cruz J, Mendes RG. Performance&#x2010;based outcome measures to assess functionality in hospitalised patients with COPD exacerbations: a systematic review of the measurement properties. Eur Respir Rev. 2023;32(169):230013.</Citation></Reference><Reference><Citation>Barry Walsh C, Cahalan R, Hinman RS. K OS: psychometric properties of performance&#x2010;based measures of physical function administered via telehealth among people with chronic conditions: a systematic review. PLoS One. 2022;17(9):e0274349.</Citation></Reference><Reference><Citation>Hong QN, Pluye P, F&#xe0;bregues S, et al. Mixed Methods Appraisal Tool (MMAT), version 2018. Registration of Copyright (#1148552), Canadian Intellectual Property Office, Industry Canada. 2018.</Citation></Reference><Reference><Citation>Trauzettel&#x2010;Klosinski S, Dietz K. Standardized assessment of reading performance: the new international Reading speed texts IReST. Invest Ophthalmol Vis Sci. 2012;53(9):5452&#x2010;5461.</Citation></Reference><Reference><Citation>Stifter E, K&#xf6;nig F, Lang T, et al. Reliability of a standardized reading chart system: variance component analysis, test&#x2010;retest and inter&#x2010;chart reliability. Graefes Arch Clin Exp Ophthalmol. 2004;242(1):31&#x2010;39.</Citation></Reference><Reference><Citation>Radner W. Reading charts in ophthalmology. Graefes Arch Clin Exp Ophthalmol. 2017;255(8):1465&#x2010;1482.</Citation></Reference><Reference><Citation>Bailey JE, Lakshminaryanan V. Assessing Reading ability in normal and low vision using the Mnread reading acuity chart: preliminary results. In: Lakshminarayanan V, ed. Basic and Clinical Applications of Vision Science: the Professor Jay M Enoch Festschrift Volume. Springer Netherlands; 1997:247&#x2010;250.</Citation></Reference><Reference><Citation>Patel PJ, Chen FK, Da Cruz L, Rubin GS, Tufail A. Test&#x2010;retest variability of reading performance metrics using MNREAD in patients with age&#x2010;related macular degeneration. Invest Ophthalmol Vis Sci. 2011;52(6):3854&#x2010;3859.</Citation></Reference><Reference><Citation>Hedlich C, Barstow E, Vogtle LK. Age&#x2010;related macular degeneration and Reading performance: does font style make a difference? J Visual Impair Blin. 2018;112(4):398&#x2010;403.</Citation></Reference><Reference><Citation>Hern&#xe1;ndez&#x2010;Moreno L, Senra H, Lewis P, et al. Cost&#x2010;effectiveness of basic vision rehabilitation (the basic VRS&#x2010;effect study): study protocol for a randomised controlled trial. Ophthalmic Physiol Opt. 2020;40(3):350&#x2010;364.</Citation></Reference><Reference><Citation>Kaltenegger K, Kuester S, Altpeter&#x2010;Ott E, et al. Effects of home reading training on reading and quality of life in AMD&#x2010;a randomized and controlled study. Graefes Arch Clin Exp Ophthalmol. 2019;257(7):1499&#x2010;1512.</Citation></Reference><Reference><Citation>Taylor DJ, Smith N, Binns A, Crabb D. Searching for objects in everyday scenes and recognising faces: measuring performance in people with dry age&#x2010;related macular degeneration (AMD). Invest Ophthalmol vis Sci. 2016;57(12):1887&#x2010;1892.</Citation></Reference><Reference><Citation>Taylor DJ. Everyday Visual Function and the Visual Experience in Dry Age&#x2010;Related Macular Degeneration. University of London; 2018.</Citation></Reference><Reference><Citation>Verghese P, Tyson TL, Ghahghaei S, Fletcher DC. Depth perception and grasp in central field loss. Invest Ophthalmol vis Sci. 2016;57(3):1476&#x2010;1487.</Citation></Reference><Reference><Citation>Vottonen P, Kaarniranta K, P&#xe4;&#xe4;kk&#xf6;nen A, Tarkka IM. Visual processing in patients with age&#x2010;related macular degeneration performing a face detection test. Clin Ophthalmol. 2017;11:1245&#x2010;1252.</Citation></Reference><Reference><Citation>Dunbar HM, Behning C, Abdirahman A, et al. Repeatability and discriminatory power of chart&#x2010;based visual function tests in individuals with age&#x2010;related macular degeneration: a MACUSTAR study report. JAMA Ophthalmol. 2022;140(8):780&#x2010;789.</Citation></Reference><Reference><Citation>Hahn GA, Penka D, Gehrlich C, et al. New standardised texts for assessing reading performance in four European languages. Br J Ophthalmol. 2006;90(4):480&#x2010;484.</Citation></Reference><Reference><Citation>Kelly LA, McMillan DGE, Anderson A, Fippinger M, Fillerup G, Rider J. Validity of actigraphs uniaxial and triaxial accelerometers for assessment of physical activity in adults in laboratory conditions. BMC Med Phys. 2013;13(1):5.</Citation></Reference><Reference><Citation>Aadland E, Ylvis&#xe5;ker E. Reliability of the Actigraph GT3X+ accelerometer in adults under free&#x2010;living conditions. PLoS One. 2015;10(8):e0134606.</Citation></Reference><Reference><Citation>Timmis MA, Pardhan S. The effect of central visual impairment on manual prehension when tasked with transporting&#x2010;to&#x2010;place an object accurately to a new location. Invest Ophthalmol vis Sci. 2012;53(6):2812&#x2010;2822.</Citation></Reference><Reference><Citation>Varma R, Souied EH, Tufail A, et al. Maximum Reading speed in patients with geographic atrophy secondary to age&#x2010;related macular degeneration. Invest Ophthalmol vis Sci. 2018;59(4):AMD195&#x2010;amd201.</Citation></Reference><Reference><Citation>Heier J, Pieramici D, Chakravarthy U, et al. Visual function decline resulting from geographic atrophy: results from the chroma and spectri phase 3 trials. Ophthalmol Retin. 2020;4:673&#x2010;688.</Citation></Reference><Reference><Citation>K&#xfc;nzel SH, Lindner M, Sassen J, et al. Association of reading performance in geographic atrophy secondary to age&#x2010;related macular degeneration with visual function and structural biomarkers. JAMA Ophthalmol. 2021;139(11):1191&#x2010;1199.</Citation></Reference><Reference><Citation>Akuffo KO, Nolan JM, Peto T, et al. Relationship between Macular pigment and visual function in subjects with early age&#x2010;related macular degeneration. Br J Ophthalmol. 2016;101:190&#x2010;197.</Citation></Reference><Reference><Citation>Akuffo KO, Beatty S, Peto T, et al. The impact of supplemental antioxidants on visual function in nonadvanced age&#x2010;related macular degeneration: a head&#x2010;to&#x2010;head randomized clinical trial. Invest Ophthalmol vis Sci. 2017;58(12):5347&#x2010;5360.</Citation></Reference><Reference><Citation>Kimel M, Leidy NK, Tschosik E, et al. Functional Reading Independence (FRI) index: a new patient&#x2010;reported outcome measure for patients with geographic atrophy. Invest Ophthalmol vis Sci. 2016;57(14):6298&#x2010;6304.</Citation></Reference><Reference><Citation>Pondorfer SG, Heinemann M, Wintergerst MWM, et al. Detecting vision loss in intermediate age&#x2010;related macular degeneration: a comparison of visual function tests. PLoS One. 2020;15(4):e0231748.</Citation></Reference><Reference><Citation>Sivaprasad S, Tschosik E, Kapre A, et al. Reliability and construct validity of the NEI VFQ&#x2010;25 in a subset of patients with geographic atrophy from the phase 2 Mahalo study. Am J Ophthalmol. 2018;190:1&#x2010;8.</Citation></Reference><Reference><Citation>Heier JS, Lad EM, Holz FG, et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age&#x2010;related macular degeneration (OAKS and DERBY): two multicentre, randomised, double&#x2010;masked, sham&#x2010;controlled, phase 3 trials. Lancet. 2023;402(10411):1434&#x2010;1448.</Citation></Reference><Reference><Citation>Dev MK. Low Luminance Vision and Function in Older Adults with Visual Impairment from Age&#x2010;Related Macular Degeneration. Queensland University of Technology; 2021.</Citation></Reference><Reference><Citation>Higgins BE, Taylor DJ, Bi W, Binns AM, Crabb DP. Novel computer&#x2010;based tests for assessing performance in visually guided tasks in people with age&#x2010;related macular degeneration: searching for everyday objects and detecting road signs. Invest Ophthalmol vis Sci. 2019;60(9):5922.</Citation></Reference><Reference><Citation>Thibaut M, Delerue C, Boucart M, Tran TH. Visual exploration of objects and scenes in patients with age&#x2010;related macular degeneration. J Fr Ophtalmol. 2016;39(1):82&#x2010;89.</Citation></Reference><Reference><Citation>Thibaut M, Tran TH, Szaffarczyk S, Boucart M. Impact of age&#x2010;related macular degeneration on object searches in realistic panoramic scenes. Clin Exp Optom. 2018;101(3):372&#x2010;379.</Citation></Reference><Reference><Citation>Higgins BE, Taylor DJ, Bi W, Binns AM, Crabb DP. Novel computer&#x2010;based assessments of everyday visual function in people with age&#x2010;related macular degeneration. PLoS One. 2020;15(12):e0243578.</Citation></Reference><Reference><Citation>Wood JM, Black AA, Mallon K, Kwan A, Owsley C. Driving performance in early and intermediate age&#x2010;related macular degeneration. Invest Ophthalmol vis Sci. 2016;57(12):1963.</Citation></Reference><Reference><Citation>Taylor DJ, Smith ND, Jones PR, Binns AM, Crabb DP. Measuring dynamic levels of self&#x2010;perceived anxiety and concern during simulated mobility tasks in people with non&#x2010;neovascular age&#x2010;related macular degeneration. Br J Ophthalmol. 2020;104(4):529&#x2010;534.</Citation></Reference><Reference><Citation>Brown GC, Brown MM, Sharma S. Difference between ophthalmologists' and patients' perceptions of quality of life associated with age&#x2010;related macular degeneration. Can J Ophthalmol. 2000;35(3):127&#x2010;133.</Citation></Reference><Reference><Citation>Stein JD, Brown MM, Brown GC, Hollands H, Sharma S. Quality of life with macular degeneration: perceptions of patients, clinicians, and community members. Br J Ophthalmol. 2003;87(1):8&#x2010;12.</Citation></Reference><Reference><Citation>Subramanian A, Pardhan S. The repeatability of MNREAD acuity charts and variability at different test distances. Optom vis Sci. 2006;83(8):572&#x2010;576.</Citation></Reference><Reference><Citation>Hassan SE, Lovie&#x2010;Kitchin JE, Woods RL. Vision and mobility performance of subjects with age&#x2010;related macular degeneration. Optom vis Sci. 2002;79(11):697&#x2010;707.</Citation></Reference><Reference><Citation>Chung STL. Reading in the presence of macular disease: a mini&#x2010;review. Ophthalmic Physiol Opt. 2020;40(2):171&#x2010;186.</Citation></Reference><Reference><Citation>Haymes SA, Johnston AW, Heyes AD. The development of the Melbourne low&#x2010;vision ADL index: a measure of vision disability. Invest Ophthalmol vis Sci. 2001;42(6):1215&#x2010;1225.</Citation></Reference><Reference><Citation>Haymes SA, Johnston AW, Heyes AD. Preliminary investigation of the responsiveness of the Melbourne low vision ADL index to low&#x2010;vision rehabilitation. Optom vis Sci. 2001;78(6):373&#x2010;380.</Citation></Reference><Reference><Citation>Ueta T, Iriyama A, Francis J, et al. Development of typical age&#x2010;related macular degeneration and polypoidal choroidal vasculopathy in fellow eyes of Japanese patients with exudative age&#x2010;related macular degeneration. Am J Ophthalmol. 2008;146(1):96&#x2010;101.</Citation></Reference><Reference><Citation>Yanagi Y, Mohla A, Lee WK, et al. Prevalence and risk factors for nonexudative neovascularization in fellow eyes of patients with unilateral age&#x2010;related macular degeneration and polypoidal choroidal vasculopathy. Invest Ophthalmol vis Sci. 2017;58(9):3488&#x2010;3495.</Citation></Reference><Reference><Citation>Peterson CL, Yap CL, Tan TF, et al. Monocular and binocular visual function assessments and activities of daily living performance in age&#x2010;related macular degeneration. Ophthalmol Retina. 2023;8:32&#x2010;41.</Citation></Reference><Reference><Citation>Peterson CL, Htoon HM, Man R, et al. Development and validation of performance&#x2010;based assessments of daily living tasks for age&#x2010;related macular degeneration. Invest Ophthalmol vis Sci. 2023;64(8):5042.</Citation></Reference><Reference><Citation>Tsai LT, Hsu JL, Wu CT, Chen CC, Su YC. A new visual stimulation program for improving visual acuity in children with visual impairment: a pilot study. Front Hum Neurosci. 2016;10:157.</Citation></Reference><Reference><Citation>Kinateder M, Gualtieri J, Dunn MJ, Jarosz W, Yang XD, Cooper EA. Using an augmented reality device as a distance&#x2010;based vision aid&#x2010;promise and limitations. Optom vis Sci. 2018;95(9):727&#x2010;737.</Citation></Reference><Reference><Citation>Pur DR, Lee&#x2010;Wing N, Bona MD. The use of augmented reality and virtual reality for visual field expansion and visual acuity improvement in low vision rehabilitation: a systematic review. Graefes Arch Clin Exp Ophthalmol. 2023;261(6):1743&#x2010;1755.</Citation></Reference><Reference><Citation>Li T, Li C, Zhang X, et al. Augmented reality in ophthalmology: applications and challenges. Front Med (Lausanne). 2021;8:733241.</Citation></Reference><Reference><Citation>Corveleyn X, Lenoble Q, Szaffarczyk S. What is the nature of the reach and grasp deficit in wet age&#x2010;related macular degeneration? Optom vis Sci. 2018;95(6):554.</Citation></Reference><Reference><Citation>Pardhan S, Scarfe A, Bourne R, Timmis M. A comparison of reach&#x2010;to&#x2010;grasp and transport&#x2010;to&#x2010;place performance in participants with age&#x2010;related macular degeneration and glaucoma. Invest Ophthalmol vis Sci. 2017;58(3):1560&#x2010;1569.</Citation></Reference><Reference><Citation>Chatard H, Tepenier L, Jankowski O, et al. Effects of age&#x2010;related macular degeneration on postural sway. Front Hum Neurosci. 2017;11:158.</Citation></Reference><Reference><Citation>Zult T, Smith L, Stringer C, Pardhan S. Levels of self&#x2010;reported and objective physical activity in individuals with age&#x2010;related macular degeneration. BMC Public Health. 2020;20(1):1144.</Citation></Reference><Reference><Citation>Loprinzi PD, Swenor BK, Ramulu PY. Age&#x2010;related macular degeneration is associated with less physical activity among US adults: cross&#x2010;sectional study. PLoS One. 2015;10(5):e0125394.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39572693</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>21</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Soluble endoglin as a biomarker of successful rheopheresis treatment in patients with age-related macular degeneration.</ArticleTitle><Pagination><StartPage>28902</StartPage><MedlinePgn>28902</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">28902</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-80375-5</ELocationID><Abstract><AbstractText>Age-related macular degeneration (AMD) is a progressive chronic disease causing visual impairment or central vision loss in the elderly. We hypothesized that successful rheopheresis would be associated with positive changes in soluble endoglin (sENG), PSCK9, alpha-2-macroglobulin (A2M), and hs-CRP levels. 31 elderly patients with the dry form of AMD, treated with rheopheresis with a follow-up period of at least 5&#xa0;years and an average age of 68&#x2009;&#xb1;&#x2009;4&#xa0;years, were evaluated. Each treated patient received a series of 8 procedures in 10&#xa0;weeks and, after the 2-year period, another 2 procedures within 1&#xa0;week. Then, the patients were followed up every 6&#xa0;months and divided into the successfully treated and therapeutic failure group according to best-corrected visual acuity (BCVA), size of the drusen area, and the drusenoid pigment epithelium detachment (DPED). Based on the ophthalmological assessment, rheopheresis treatment was successful in 73% of AMD patients. The therapy was associated with a significant decrease in total cholesterol, LDL-C, HDL-C, apoprotein B, lipoprotein (a) levels, and rheologically important parameters, irrespective of the therapy's success or failure. The success of rheopheresis therapy was exclusively related to a significant decrease in sENG and A2M levels. Over the long term, rheopheresis prevented the decline of BCVA, reduced the DPED and area of macular drusen, and improved the preservation of an intact photoreceptor ellipsoid zone in most patients. Moreover, we showed for the first time that sENG and A2M could be potentially sensitive biomarkers of successful rheopheresis procedure, irrespective of lipid parameters changes.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Blaha</LastName><ForeName>Vladimir</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Faculty of Medicine in Hradec Kralove, 3rd Department of Internal Medicine - Metabolism and Gerontology, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Rathouska</LastName><ForeName>Jana Urbankova</ForeName><Initials>JU</Initials><AffiliationInfo><Affiliation>Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Heyrovskeho 1203, 500 05, Hradec Kralove, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langrova</LastName><ForeName>Hana</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Faculty of Medicine in Hradec Kralove, Department of Ophthalmology, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blaha</LastName><ForeName>Milan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Medicine in Hradec Kralove, 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Studnicka</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Faculty of Medicine in Hradec Kralove, Department of Ophthalmology, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrys</LastName><ForeName>Ctirad</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Immunology and Allergology, Faculty of Medicine in Hradec Kralove, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loefflerova</LastName><ForeName>Veronika</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Regional Hospital Liberec, Liberec, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanska</LastName><ForeName>Miriam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Medicine in Hradec Kralove, 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vejrazkova</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Faculty of Medicine in Hradec Kralove, 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nachtigal</LastName><ForeName>Petr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Heyrovskeho 1203, 500 05, Hradec Kralove, Czech Republic. petr.nachtigal@faf.cuni.cz.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stepanov</LastName><ForeName>Alexandr</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine in Hradec Kralove, Department of Ophthalmology, University Hospital Hradec Kralove and Charles University, Hradec Kralove, Czech Republic.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>17-29241A</GrantID><Agency>Ministerstvo Zdravotnictv&#xed; Cesk&#xe9; Republiky</Agency><Country/></Grant><Grant><GrantID>CZ.02.01.01/00/22_008/0004607</GrantID><Agency>European Union</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071063">Endoglin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008268" MajorTopicYN="Y">Macular Degeneration</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071063" MajorTopicYN="Y">Endoglin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014792" MajorTopicYN="N">Visual Acuity</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Age-related macular degeneration</Keyword><Keyword MajorTopicYN="N">Alpha-2-macroglobulin</Keyword><Keyword MajorTopicYN="N">Rheopheresis</Keyword><Keyword MajorTopicYN="N">Soluble endoglin</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: The protocol was carried out according to the Declaration of Helsinki. All participants gave written informed consent, which, together with the protocol of the study, were approved by the institute&#x2019;s ethics committee (approval number 201607 S03P). The study has been registered under Clinical Trial Registration number NCT01943396 (17/09/2013). https://classic.clinicaltrials.gov/ct2/show/NCT01943396?cond=Age-Related+Macular+Degeneration&amp;cntry=CZ&amp;draw=2&amp;rank=1</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>21</Day><Hour>23</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39572693</ArticleId><ArticleId IdType="pmc">PMC11582623</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-80375-5</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-80375-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jager, R. D., Mieler, W. F. &amp; Miller, J. W. Age-related macular degeneration. N. Engl. J. Med.358, 2606&#x2013;2617 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18550876</ArticleId></ArticleIdList></Reference><Reference><Citation>Roizenblatt, M., Naranjit, N., Maia, M. &amp; Gehlbach, P. L. The question of a role for statins in age-related macular degeneration. Int. J. Mol. Sci.19, 3688 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6274767</ArticleId><ArticleId IdType="pubmed">30469381</ArticleId></ArticleIdList></Reference><Reference><Citation>Tserentsoodol, N. et al. Uptake of cholesterol by the retina occurs primarily via a low density lipoprotein receptor-mediated process. Mol. Vis.12, 1306&#x2013;1318 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17110914</ArticleId></ArticleIdList></Reference><Reference><Citation>Fliesler, S. J., Florman, R., Rapp, L. M., Pittler, S. J. &amp; Keller, R. K. In vivo biosynthesis of cholesterol in the rat retina. FEBS Lett.335, 234&#x2013;238 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8253203</ArticleId></ArticleIdList></Reference><Reference><Citation>Tserentsoodol, N. et al. Intraretinal lipid transport is dependent on high density lipoprotein-like particles and class B scavenger receptors. Mol. Vis.12, 1319&#x2013;1333 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17110915</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein, R. et al. Markers of inflammation, oxidative stress, and endothelial dysfunction and the 20-year cumulative incidence of early age-related macular degeneration: the Beaver Dam Eye Study. JAMA Ophthalmol.132, 446&#x2013;455 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4076038</ArticleId><ArticleId IdType="pubmed">24481424</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann, G. L. et al. Retinal pigment epithelium-secreted VEGF-A induces alpha-2-macroglobulin expression in endothelial cells. Cells11, 2975 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9564307</ArticleId><ArticleId IdType="pubmed">36230937</ArticleId></ArticleIdList></Reference><Reference><Citation>Blazquez-Medela, A. M. et al. Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients. BMC Med.8, 86 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3012013</ArticleId><ArticleId IdType="pubmed">21171985</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaitu&#x2019;u-Lino, T. J. et al. MMP-14 is expressed in preeclamptic placentas and mediates release of soluble endoglin. Am. J. Pathol.180, 888&#x2013;894 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22296769</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaha, M. et al. Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familiar hypercholesterolemia. Atherosclerosis197, 264&#x2013;270 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">17540382</ArticleId></ArticleIdList></Reference><Reference><Citation>Blann, A. D., Wang, J. M., Wilson, P. B. &amp; Kumar, S. Serum levels of the TGF-beta receptor are increased in atherosclerosis. Atherosclerosis120, 221&#x2013;226 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8645363</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhotra, R. et al. Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension. Pulm. Circ.3, 369&#x2013;380 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3757832</ArticleId><ArticleId IdType="pubmed">24015338</ArticleId></ArticleIdList></Reference><Reference><Citation>Leanos-Miranda, A. et al. Soluble endoglin as a marker for preeclampsia, its severity, and the occurrence of adverse outcomes. Hypertension74, 991&#x2013;997 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31446801</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathouska, J., Jezkova, K., Nemeckova, I. &amp; Nachtigal, P. Soluble endoglin, hypercholesterolemia and endothelial dysfunction. Atherosclerosis243, 383&#x2013;388 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26520890</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitverova, B. et al. Soluble endoglin and hypercholesterolemia aggravate endothelial and vessel wall dysfunction in mouse aorta. Atherosclerosis271, 15&#x2013;25 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29459262</ArticleId></ArticleIdList></Reference><Reference><Citation>Klingel, R., Fassbender, C., Fassbender, T. &amp; Gohlen, B. Clinical studies to implement Rheopheresis for age-related macular degeneration guided by evidence-based-medicine. Transfus. Apher. Sci.29, 71&#x2013;84 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12877897</ArticleId></ArticleIdList></Reference><Reference><Citation>Borberg, H. &amp; Tauchert, M. Rheohaemapheresis of ophthalmological diseases and diseases of the microcirculation. Transfus. Apher. Sci.34, 41&#x2013;49 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16343990</ArticleId></ArticleIdList></Reference><Reference><Citation>Zion, I. B. et al. Pulsatile ocular blood flow: relationship with flow velocities in vessels supplying the retina and choroid. Br. J. Ophthalmol.91, 882&#x2013;884 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1955661</ArticleId><ArticleId IdType="pubmed">17576711</ArticleId></ArticleIdList></Reference><Reference><Citation>Klingel, R. et al. RheoNet registry analysis of rheopheresis for microcirculatory disorders with a focus on age-related macular degeneration. Ther. Apher. Dial.14, 276&#x2013;286 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20609179</ArticleId></ArticleIdList></Reference><Reference><Citation>Langrova, H. et al. Rheopheresis in the treatment of age-related macular degeneration. Cesk. Slov. Oftalmol.79, 8&#x2013;24 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36858957</ArticleId></ArticleIdList></Reference><Reference><Citation>Rencova, E. et al. Reduction in the drusenoid retinal pigment epithelium detachment area in the dry form of age-related macular degeneration 2.5 years after rheohemapheresis. Acta Ophthalmol.91, e406-408 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">22971248</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz, J. et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American society for apheresis: the sixth special issue. J. Clin. Apher.28, 145&#x2013;284 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23868759</ArticleId></ArticleIdList></Reference><Reference><Citation>Studnicka, J. et al. Long-term outcomes of rheohaemapheresis in the treatment of dry form of age-related macular degeneration. J. Ophthalmol,2013, 135798 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3880698</ArticleId><ArticleId IdType="pubmed">24455194</ArticleId></ArticleIdList></Reference><Reference><Citation>Visek, J. et al. Monitoring of up to 15 years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients. Orphanet. J. Rare Dis.16, 110 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7913462</ArticleId><ArticleId IdType="pubmed">33640001</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaha, M. et al. Changes of the complement system and rheological indicators after therapy with rheohemapheresis. Atheroscler. Suppl.18, 140&#x2013;145 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25936318</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavori, H., Giunzioni, I., Linton, M. F. &amp; Fazio, S. Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis. Circ. Res.113, 1290&#x2013;1295 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3939022</ArticleId><ArticleId IdType="pubmed">24122718</ArticleId></ArticleIdList></Reference><Reference><Citation>Augood, C. et al. Methods for a population-based study of the prevalence of and risk factors for age-related maculopathy and macular degeneration in elderly European populations: the EUREYE study. Ophthalmic Epidemiol.11, 117&#x2013;129 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15255027</ArticleId></ArticleIdList></Reference><Reference><Citation>Rencova, E. et al. Haemorheopheresis could block the progression of the dry form of age-related macular degeneration with soft drusen to the neovascular form. Acta Ophthalmol.89, 463&#x2013;471 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">20102350</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaha, M. et al. Rheohaemapheresis in the treatment of nonvascular age-related macular degeneration. Atheroscler. Suppl.14, 179&#x2013;184 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23357162</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz, J. et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American society for apheresis: The seventh special issue. J. Clin. Apher.31, 149&#x2013;162 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27322218</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaha, V. et al. Antioxidant defense system in familial hypercholesterolemia and the effects of lipoprotein apheresis. Atheroscler. Suppl.30, 159&#x2013;165 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29096832</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulido, J. S., Multicenter Investigation of Rheopheresis for AMDSG. Multicenter prospective, randomized, double-masked, placebo-controlled study of Rheopheresis to treat nonexudative age-related macular degeneration: interim analysis. Trans. Am. Ophthalmol. Soc.100, 85&#x2013;106 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1358951</ArticleId><ArticleId IdType="pubmed">12545682</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaha, M. et al. Extracorporeal LDL cholesterol elimination (25 years of experience in CZ). Atheroscler. Suppl.10, 17&#x2013;20 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">20129368</ArticleId></ArticleIdList></Reference><Reference><Citation>Rencova, E. et al. Preservation of the photoreceptor inner/outer segment junction in dry age-related macular degeneration treated by rheohemapheresis. J. Ophthalmol.2015, 359747 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4553324</ArticleId><ArticleId IdType="pubmed">26351571</ArticleId></ArticleIdList></Reference><Reference><Citation>Snow, K. K. &amp; Seddon, J. M. Do age-related macular degeneration and cardiovascular disease share common antecedents?. Ophthalmic Epidemiol.6, 125&#x2013;143 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10420212</ArticleId></ArticleIdList></Reference><Reference><Citation>Connelly-Smith, L. et al. Guidelines on the use of therapeutic apheresis in clinical practice&#x2014;evidence-based approach from the writing committee of the American society for apheresis: The ninth special issue. J. Clin. Apher.38, 77&#x2013;278 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37017433</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennington, K. L. &amp; DeAngelis, M. M. Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. Eye Vis.3, 34 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5178091</ArticleId><ArticleId IdType="pubmed">28032115</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaha, M. et al. Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia. Atherosclerosis197, 264&#x2013;270 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">17540382</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicen, M. et al. Regulation and role of endoglin in cholesterol-induced endothelial and vascular dysfunction in vivo and in vitro. FASEB J.33, 6099&#x2013;6114 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30753095</ArticleId></ArticleIdList></Reference><Reference><Citation>Strasky, Z. et al. Cholesterol effects on endoglin and its downstream pathways in ApoE/LDLR double knockout mice. Circ. J.75, 1747&#x2013;1755 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21576826</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabro, P., Golia, E. &amp; Yeh, E. T. CRP and the risk of atherosclerotic events. Semin. Immunopathol.31, 79&#x2013;94 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19415283</ArticleId></ArticleIdList></Reference><Reference><Citation>Shijo, T. et al. Association of CRP levels with ARMS2 and CFH variants in age-related macular degeneration. Int. Ophthalmol.40, 2735&#x2013;2742 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32507953</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandooren, J. &amp; Itoh, Y. Alpha-2-macroglobulin in inflammation immunity and infections. Front. Immunol.12, 803244 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8712716</ArticleId><ArticleId IdType="pubmed">34970276</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantuano, E. et al. LDL receptor-related protein-1 regulates NFkappaB and microRNA-155 in macrophages to control the inflammatory response. Proc. Natl. Acad. Sci. U. S. A.113, 1369&#x2013;1374 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4747752</ArticleId><ArticleId IdType="pubmed">26787872</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39572070</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1757-790X</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>20</Day></PubDate></JournalIssue><Title>BMJ case reports</Title><ISOAbbreviation>BMJ Case Rep</ISOAbbreviation></Journal><ArticleTitle>Cystoid macular oedema: a rare complication following selective laser trabeculoplasty.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e262307</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bcr-2024-262307</ELocationID><Abstract><AbstractText>A female patient with previous vitrectomy for epiretinal membrane in the left eye underwent bilateral selective laser trabeculoplasty (SLT) for pigmentary glaucoma and subsequently developed cystoid macular oedema (CMO) in the vitrectomised eye. This resolved fully with treatment with topical steroids and non-steroidal anti-inflammatory drug (NSAID) drops. This complication has been very rarely reported in the literature, and a subsequent internal audit found a very low rate of CMO temporally related to SLT of 0.07%. We suggest close follow-up and 'red flag' follow-up instructions to patients with previous vitrectomy or epiretinal membrane to watch for this complication, and clinicians may consider covering higher risk patients with an NSAID post-laser.</AbstractText><CopyrightInformation>&#xa9; BMJ Publishing Group Limited 2024. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Richardson-May</LastName><ForeName>James</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8223-3101</Identifier><AffiliationInfo><Affiliation>Ophthalmology, University Hospital Southampton NHS Foundation Trust, Southampton, UK jamesrichardsonmay@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ophthalmology, Salisbury District Hospital NHS Foundation Trust, Salisbury, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Salisbury District Hospital NHS Foundation Trust, Salisbury, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pandey</LastName><ForeName>Shweta</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ophthalmology, Salisbury District Hospital NHS Foundation Trust, Salisbury, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Karinya</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Ophthalmology, Salisbury District Hospital, Salisbury, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Case Rep</MedlineTA><NlmUniqueID>101526291</NlmUniqueID><ISSNLinking>1757-790X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005902" MajorTopicYN="N">Glaucoma, Open-Angle</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053685" MajorTopicYN="N">Laser Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008269" MajorTopicYN="Y">Macular Edema</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014130" MajorTopicYN="Y">Trabeculectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014821" MajorTopicYN="N">Vitrectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Glaucoma</Keyword><Keyword MajorTopicYN="N">Retina</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>21</Day><Hour>20</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39572070</ArticleId><ArticleId IdType="doi">10.1136/bcr-2024-262307</ArticleId><ArticleId IdType="pii">17/11/e262307</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39571776</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-0007</ISSN><JournalIssue CitedMedium="Internet"><Volume>250</Volume><PubDate><Year>2024</Year><Month>Nov</Month><Day>20</Day></PubDate></JournalIssue><Title>Experimental eye research</Title><ISOAbbreviation>Exp Eye Res</ISOAbbreviation></Journal><ArticleTitle>Conditioned media from dental pulp stem cells to counteract age-related macular degeneration.</ArticleTitle><Pagination><StartPage>110167</StartPage><MedlinePgn>110167</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.exer.2024.110167</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0014-4835(24)00389-0</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly. To date, there are no effective therapies to counteract AMD towards the most severe stages characterised by a progressive loss of photoreceptors triggered by retinal pigmented epithelium dysfunction. Given their easy source and their high proliferative potential, Dental Pulp Stem Cells (DPSCs) are considered promising for regenerative medicine. The main advantage of DPSCs is related to their paracrine immunosuppressive and immunoregulatory abilities, including the capability to promote regeneration of damaged tissues. Recent studies demonstrated the therapeutic potential of DPSCs-conditioned media (CM) in neurodegenerative diseases. In addition, we have already shown a differential expression of some growth factors and cytokines in CM derived from DPSCs cultured in hypoxia and normoxia conditions.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">In this study we evaluated the capability of DPSCs-CM to counteract retinal degeneration in an animal model of AMD. DPSCs-CM were intravitreally injected the day before the exposure of albino rats to high intensity light (LD).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We evaluated the retinal function, and we performed morphological and molecular analysis a week after the LD, in accordance with the well-established protocol of our light damage model. DPSCs-CM obtained from hypoxia (HYPO-CM) or normoxia (NORM-CM), were able to preserve the retinal function, to reduce the damaged area and to counteract the upregulation of key factors involved in retinal degeneration, like FGF-2. Furthermore, we demonstrated that neither conditioned media modified inflammatory activation, as shown by both microglia activation and GFAP upregulation, but in vitro studies demonstrated a significant effect of both CM to counteract oxidative stress, one of the main causes of AMD.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Taken together, our study demonstrated that NORM-CM and HYPO-CM, albeit with a different chemical composition, could represent eligible candidates to counteract retinal degeneration in an animal model of AMD. Further studies are needed to obtain conditioned media with the best performance in term of retinal protection.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carozza</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100, L'Aquila, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zerti</LastName><ForeName>Darin</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100, L'Aquila, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pulcini</LastName><ForeName>Fanny</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100, L'Aquila, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lancia</LastName><ForeName>Loreto</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100, L'Aquila, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delle Monache</LastName><ForeName>Simona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100, L'Aquila, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattei</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Life Science, Health and Health Professions, Link Campus University, 00165, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maccarone</LastName><ForeName>Rita</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100, L'Aquila, Italy. Electronic address: rita.maccarone@univaq.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Exp Eye Res</MedlineTA><NlmUniqueID>0370707</NlmUniqueID><ISSNLinking>0014-4835</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Age-related macular degeneration</Keyword><Keyword MajorTopicYN="N">Conditioned media</Keyword><Keyword MajorTopicYN="N">Dental pulp stem cells</Keyword><Keyword MajorTopicYN="N">Light damage</Keyword><Keyword MajorTopicYN="N">Oxidative stress</Keyword><Keyword MajorTopicYN="N">Retina</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>21</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39571776</ArticleId><ArticleId IdType="doi">10.1016/j.exer.2024.110167</ArticleId><ArticleId IdType="pii">S0014-4835(24)00389-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39571557</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1423-0259</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>21</Day></PubDate></JournalIssue><Title>Ophthalmic research</Title><ISOAbbreviation>Ophthalmic Res</ISOAbbreviation></Journal><ArticleTitle>Patient Preferences with Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Multinational Discrete Choice Experiment Study.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>17</EndPage><MedlinePgn>1-17</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000541349</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">New anti-vascular endothelial growth factor (VEGF) treatments are emerging for the treatment of diabetic macular edema (DME)/neovascular age-related macular degeneration (nAMD). This study aimed to explore the treatment attributes patients find important when deciding on treatment options.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This noninterventional survey study assessed treatment preferences through a discrete choice experiment (DCE) among patients with DME/nAMD in the United States, Canada, France, Italy, Spain, and the United Kingdom. The DCE design was informed by a targeted literature review and qualitative interview research and included five treatment attributes: mode of administration, frequency of examinations, frequency of injections or refills, likely change in visual acuity, and eye-related side effects. Conditional logit models were used to analyze the choice data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 537 patients completed the DCE (DME, n = 173; nAMD, n = 364). Patients reported preferring "injection" over "implant surgery and refills" and better visual outcomes over "stabilization", which were also the most important attributes driving preference (35.1% and 31.5%, respectively). They also showed a preference for less-frequent treatment and examinations and for "mild-moderate, frequent" over "severe, rare" side effects. These findings were generally consistent across the two conditions, although significant differences were found depending on anti-VEGF treatment duration (nAMD, DME) and number of reported barriers (nAMD).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Patient preferences for treatment are driven by several factors. Considering these is essential when designing/introducing new therapies. Individual treatment preferences should be identified and given key consideration when helping patients select from an expanding array of treatment options.</AbstractText><CopyrightInformation>The Author(s). Published by S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garc&#xed;a-Layana</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Chi</LastName><ForeName>Gloria C</ForeName><Initials>GC</Initials></Author><Author ValidYN="Y"><LastName>Kodjikian</LastName><ForeName>Laurent</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Parravano</LastName><ForeName>Mariacristina</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Timothy L</ForeName><Initials>TL</Initials></Author><Author ValidYN="Y"><LastName>Danzig</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Paris</LastName><ForeName>Liliana P</ForeName><Initials>LP</Initials></Author><Author ValidYN="Y"><LastName>Mirt</LastName><ForeName>Mirela</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Henry-Szatkowski</LastName><ForeName>Mickael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Hannah B</ForeName><Initials>HB</Initials></Author><Author ValidYN="Y"><LastName>Gentile</LastName><ForeName>Brittany</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Ophthalmic Res</MedlineTA><NlmUniqueID>0267442</NlmUniqueID><ISSNLinking>0030-3747</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>22</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>21</Day><Hour>18</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39571557</ArticleId><ArticleId IdType="doi">10.1159/000541349</ArticleId><ArticleId IdType="pii">000541349</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39569789</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0042-465X</ISSN><JournalIssue CitedMedium="Print"><Volume>140</Volume><Issue>5</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Vestnik oftalmologii</Title><ISOAbbreviation>Vestn Oftalmol</ISOAbbreviation></Journal><ArticleTitle>[Efficacy of brolucizumab in the treatment of retinal pathologies: a review of post-marketing studies].</ArticleTitle><Pagination><StartPage>154</StartPage><EndPage>161</EndPage><MedlinePgn>154-161</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.17116/oftalma2024140051154</ELocationID><Abstract><AbstractText>Brolucizumab, an angiogenesis inhibitor, is a single-chain fragment of a humanized antibody used to treat neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Although registration studies are the primary source of information on the new drug, post-marketing studies allow for further exploration and expansion of previous knowledge about its effectiveness, safety, and dosing regimens. This study summarizes the experience with brolucizumab from real-world clinical practice studies. A systematic literature review was conducted to identify articles published up to April 2024 that investigated the use of brolucizumab in the treatment of retinal vasogenic diseases, revealing the high effectiveness of brolucizumab compared to other angiogenesis inhibitors in the treatment of patients with nAMD and DME, including those who were treatment-na&#xef;ve and those resistant to ongoing therapy, as well as patients with changes in the vitreoretinal interface. A significant advantage of brolucizumab is its ability to reduce the number of injections and extend the intervals between them up to 16 weeks. Study results demonstrate substantial improvements in anatomical and functional outcomes compared to previously existing and newly emerging angiogenesis inhibitors. Its ability to stabilize disease progression, achieve better disease control, and reduce injection frequency makes brolucizumab an attractive option for both first-line therapy and as a switching drug, highlighting its potential for expanded indications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kulikov</LastName><ForeName>A N</ForeName><Initials>AN</Initials><Identifier Source="ORCID">0000-0002-5274-6993</Identifier><AffiliationInfo><Affiliation>S.M. Kirov Military Medical Academy, Saint Petersburg, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalinicheva</LastName><ForeName>Y A</ForeName><Initials>YA</Initials><Identifier Source="ORCID">0000-0002-9033-3276</Identifier><AffiliationInfo><Affiliation>S.M. Kirov Military Medical Academy, Saint Petersburg, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maltsev</LastName><ForeName>D S</ForeName><Initials>DS</Initials><Identifier Source="ORCID">0000-0001-6598-3982</Identifier><AffiliationInfo><Affiliation>S.M. Kirov Military Medical Academy, Saint Petersburg, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>rus</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType></PublicationTypeList><VernacularTitle>Effektivnost' brolutsizumaba v lechenii retinal'noi patologii: obzor postmarketingovykh issledovanii.</VernacularTitle></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Vestn Oftalmol</MedlineTA><NlmUniqueID>0415216</NlmUniqueID><ISSNLinking>0042-465X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>XSZ53G39H5</RegistryNumber><NameOfSubstance UI="C000622091">brolucizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020533" MajorTopicYN="Y">Angiogenesis Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="Y">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003930" MajorTopicYN="Y">Diabetic Retinopathy</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058449" MajorTopicYN="N">Intravitreal Injections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011358" MajorTopicYN="N">Product Surveillance, Postmarketing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008269" MajorTopicYN="N">Macular Edema</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057135" MajorTopicYN="N">Wet Macular Degeneration</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="rus"><AbstractText>&#x411;&#x440;&#x43e;&#x43b;&#x443;&#x446;&#x438;&#x437;&#x443;&#x43c;&#x430;&#x431; &#x2014; &#x438;&#x43d;&#x433;&#x438;&#x431;&#x438;&#x442;&#x43e;&#x440; &#x430;&#x43d;&#x433;&#x438;&#x43e;&#x433;&#x435;&#x43d;&#x435;&#x437;&#x430;, &#x43e;&#x434;&#x43d;&#x43e;&#x446;&#x435;&#x43f;&#x43e;&#x447;&#x435;&#x447;&#x43d;&#x44b;&#x439; &#x444;&#x440;&#x430;&#x433;&#x43c;&#x435;&#x43d;&#x442; &#x433;&#x443;&#x43c;&#x430;&#x43d;&#x438;&#x437;&#x438;&#x440;&#x43e;&#x432;&#x430;&#x43d;&#x43d;&#x43e;&#x433;&#x43e; &#x430;&#x43d;&#x442;&#x438;&#x442;&#x435;&#x43b;&#x430;, &#x43f;&#x440;&#x438;&#x43c;&#x435;&#x43d;&#x44f;&#x435;&#x43c;&#x44b;&#x439; &#x434;&#x43b;&#x44f; &#x43b;&#x435;&#x447;&#x435;&#x43d;&#x438;&#x44f; &#x43d;&#x435;&#x43e;&#x432;&#x430;&#x441;&#x43a;&#x443;&#x43b;&#x44f;&#x440;&#x43d;&#x43e;&#x439; &#x432;&#x43e;&#x437;&#x440;&#x430;&#x441;&#x442;&#x43d;&#x43e;&#x439; &#x43c;&#x430;&#x43a;&#x443;&#x43b;&#x44f;&#x440;&#x43d;&#x43e;&#x439; &#x434;&#x435;&#x433;&#x435;&#x43d;&#x435;&#x440;&#x430;&#x446;&#x438;&#x438; (&#x43d;&#x412;&#x41c;&#x414;) &#x438; &#x434;&#x438;&#x430;&#x431;&#x435;&#x442;&#x438;&#x447;&#x435;&#x441;&#x43a;&#x43e;&#x433;&#x43e; &#x43c;&#x430;&#x43a;&#x443;&#x43b;&#x44f;&#x440;&#x43d;&#x43e;&#x433;&#x43e; &#x43e;&#x442;&#x435;&#x43a;&#x430; (&#x414;&#x41c;&#x41e;). &#x420;&#x435;&#x433;&#x438;&#x441;&#x442;&#x440;&#x430;&#x446;&#x438;&#x43e;&#x43d;&#x43d;&#x44b;&#x435; &#x438;&#x441;&#x441;&#x43b;&#x435;&#x434;&#x43e;&#x432;&#x430;&#x43d;&#x438;&#x44f; &#x44f;&#x432;&#x43b;&#x44f;&#x44e;&#x442;&#x441;&#x44f; &#x43e;&#x441;&#x43d;&#x43e;&#x432;&#x43d;&#x44b;&#x43c; &#x438;&#x441;&#x442;&#x43e;&#x447;&#x43d;&#x438;&#x43a;&#x43e;&#x43c; &#x438;&#x43d;&#x444;&#x43e;&#x440;&#x43c;&#x430;&#x446;&#x438;&#x438; &#x43e; &#x43d;&#x43e;&#x432;&#x43e;&#x43c; &#x43f;&#x440;&#x435;&#x43f;&#x430;&#x440;&#x430;&#x442;&#x435;, &#x43e;&#x434;&#x43d;&#x430;&#x43a;&#x43e; &#x43f;&#x43e;&#x441;&#x442;&#x43c;&#x430;&#x440;&#x43a;&#x435;&#x442;&#x438;&#x43d;&#x433;&#x43e;&#x432;&#x44b;&#x435; &#x438;&#x441;&#x441;&#x43b;&#x435;&#x434;&#x43e;&#x432;&#x430;&#x43d;&#x438;&#x44f; &#x43f;&#x43e;&#x437;&#x432;&#x43e;&#x43b;&#x44f;&#x44e;&#x442; &#x443;&#x433;&#x43b;&#x443;&#x431;&#x438;&#x442;&#x44c; &#x438; &#x434;&#x43e;&#x43f;&#x43e;&#x43b;&#x43d;&#x438;&#x442;&#x44c; &#x43f;&#x43e;&#x43b;&#x443;&#x447;&#x435;&#x43d;&#x43d;&#x44b;&#x435; &#x440;&#x430;&#x43d;&#x435;&#x435; &#x441;&#x432;&#x435;&#x434;&#x435;&#x43d;&#x438;&#x44f; &#x43e; &#x435;&#x433;&#x43e; &#x44d;&#x444;&#x444;&#x435;&#x43a;&#x442;&#x438;&#x432;&#x43d;&#x43e;&#x441;&#x442;&#x438;, &#x431;&#x435;&#x437;&#x43e;&#x43f;&#x430;&#x441;&#x43d;&#x43e;&#x441;&#x442;&#x438; &#x438; &#x440;&#x435;&#x436;&#x438;&#x43c;&#x435; &#x434;&#x43e;&#x437;&#x438;&#x440;&#x43e;&#x432;&#x430;&#x43d;&#x438;&#x44f;. &#x41f;&#x43e;&#x44d;&#x442;&#x43e;&#x43c;&#x443; &#x446;&#x435;&#x43b;&#x44c;&#x44e; &#x440;&#x430;&#x431;&#x43e;&#x442;&#x44b; &#x441;&#x442;&#x430;&#x43b;&#x43e; &#x43e;&#x431;&#x43e;&#x431;&#x449;&#x435;&#x43d;&#x438;&#x435; &#x43e;&#x43f;&#x44b;&#x442;&#x430; &#x43f;&#x440;&#x438;&#x43c;&#x435;&#x43d;&#x435;&#x43d;&#x438;&#x44f; &#x431;&#x440;&#x43e;&#x43b;&#x443;&#x446;&#x438;&#x437;&#x443;&#x43c;&#x430;&#x431;&#x430; &#x432; &#x438;&#x441;&#x441;&#x43b;&#x435;&#x434;&#x43e;&#x432;&#x430;&#x43d;&#x438;&#x44f;&#x445; &#x440;&#x435;&#x430;&#x43b;&#x44c;&#x43d;&#x43e;&#x439; &#x43a;&#x43b;&#x438;&#x43d;&#x438;&#x447;&#x435;&#x441;&#x43a;&#x43e;&#x439; &#x43f;&#x440;&#x430;&#x43a;&#x442;&#x438;&#x43a;&#x438;. &#x412; &#x445;&#x43e;&#x434;&#x435; &#x440;&#x430;&#x431;&#x43e;&#x442;&#x44b; &#x43f;&#x440;&#x43e;&#x432;&#x435;&#x434;&#x435;&#x43d; &#x441;&#x438;&#x441;&#x442;&#x435;&#x43c;&#x430;&#x442;&#x438;&#x447;&#x435;&#x441;&#x43a;&#x438;&#x439; &#x43e;&#x431;&#x437;&#x43e;&#x440; &#x43b;&#x438;&#x442;&#x435;&#x440;&#x430;&#x442;&#x443;&#x440;&#x44b; &#x434;&#x43b;&#x44f; &#x432;&#x44b;&#x44f;&#x432;&#x43b;&#x435;&#x43d;&#x438;&#x44f; &#x43e;&#x43f;&#x443;&#x431;&#x43b;&#x438;&#x43a;&#x43e;&#x432;&#x430;&#x43d;&#x43d;&#x44b;&#x445; &#x434;&#x43e; &#x430;&#x43f;&#x440;&#x435;&#x43b;&#x44f; 2024 &#x433;. &#x441;&#x442;&#x430;&#x442;&#x435;&#x439;, &#x432; &#x43a;&#x43e;&#x442;&#x43e;&#x440;&#x44b;&#x445; &#x438;&#x441;&#x441;&#x43b;&#x435;&#x434;&#x43e;&#x432;&#x430;&#x43b;&#x43e;&#x441;&#x44c; &#x43f;&#x440;&#x438;&#x43c;&#x435;&#x43d;&#x435;&#x43d;&#x438;&#x435; &#x431;&#x440;&#x43e;&#x43b;&#x443;&#x446;&#x438;&#x437;&#x443;&#x43c;&#x430;&#x431;&#x430; &#x434;&#x43b;&#x44f; &#x43b;&#x435;&#x447;&#x435;&#x43d;&#x438;&#x44f; &#x432;&#x430;&#x437;&#x43e;&#x433;&#x435;&#x43d;&#x43d;&#x44b;&#x445; &#x437;&#x430;&#x431;&#x43e;&#x43b;&#x435;&#x432;&#x430;&#x43d;&#x438;&#x439; &#x441;&#x435;&#x442;&#x447;&#x430;&#x442;&#x43a;&#x438;. &#x41d;&#x430; &#x43e;&#x441;&#x43d;&#x43e;&#x432;&#x430;&#x43d;&#x438;&#x438; &#x430;&#x43d;&#x430;&#x43b;&#x438;&#x437;&#x430; &#x43b;&#x438;&#x442;&#x435;&#x440;&#x430;&#x442;&#x443;&#x440;&#x44b; &#x432;&#x44b;&#x44f;&#x432;&#x43b;&#x435;&#x43d;&#x430; &#x432;&#x44b;&#x441;&#x43e;&#x43a;&#x430;&#x44f; &#x44d;&#x444;&#x444;&#x435;&#x43a;&#x442;&#x438;&#x432;&#x43d;&#x43e;&#x441;&#x442;&#x44c; &#x431;&#x440;&#x43e;&#x43b;&#x443;&#x446;&#x438;&#x437;&#x443;&#x43c;&#x430;&#x431;&#x430; &#x432; &#x441;&#x440;&#x430;&#x432;&#x43d;&#x435;&#x43d;&#x438;&#x438; &#x441; &#x434;&#x440;&#x443;&#x433;&#x438;&#x43c;&#x438; &#x438;&#x43d;&#x433;&#x438;&#x431;&#x438;&#x442;&#x43e;&#x440;&#x430;&#x43c;&#x438; &#x430;&#x43d;&#x433;&#x438;&#x43e;&#x433;&#x435;&#x43d;&#x435;&#x437;&#x430; &#x432; &#x43b;&#x435;&#x447;&#x435;&#x43d;&#x438;&#x438; &#x43f;&#x430;&#x446;&#x438;&#x435;&#x43d;&#x442;&#x43e;&#x432; &#x441; &#x43d;&#x412;&#x41c;&#x414; &#x438; &#x414;&#x41c;&#x41e;, &#x43a;&#x430;&#x43a; &#x440;&#x430;&#x43d;&#x435;&#x435; &#x43d;&#x435; &#x43f;&#x43e;&#x43b;&#x443;&#x447;&#x430;&#x432;&#x448;&#x438;&#x445; &#x43b;&#x435;&#x447;&#x435;&#x43d;&#x438;&#x435;, &#x442;&#x430;&#x43a; &#x438; &#x440;&#x435;&#x437;&#x438;&#x441;&#x442;&#x435;&#x43d;&#x442;&#x43d;&#x44b;&#x445; &#x43a; &#x43f;&#x440;&#x43e;&#x432;&#x43e;&#x434;&#x438;&#x43c;&#x43e;&#x43c;&#x443; &#x43b;&#x435;&#x447;&#x435;&#x43d;&#x438;&#x44e;, &#x432; &#x442;&#x43e;&#x43c; &#x447;&#x438;&#x441;&#x43b;&#x435; &#x43f;&#x430;&#x446;&#x438;&#x435;&#x43d;&#x442;&#x43e;&#x432; &#x441; &#x438;&#x437;&#x43c;&#x435;&#x43d;&#x435;&#x43d;&#x438;&#x44f;&#x43c;&#x438; &#x432;&#x438;&#x442;&#x440;&#x435;&#x43e;&#x440;&#x435;&#x442;&#x438;&#x43d;&#x430;&#x43b;&#x44c;&#x43d;&#x43e;&#x433;&#x43e; &#x438;&#x43d;&#x442;&#x435;&#x440;&#x444;&#x435;&#x439;&#x441;&#x430;. &#x412;&#x430;&#x436;&#x43d;&#x44b;&#x43c; &#x43f;&#x440;&#x435;&#x438;&#x43c;&#x443;&#x449;&#x435;&#x441;&#x442;&#x432;&#x43e;&#x43c; &#x431;&#x440;&#x43e;&#x43b;&#x443;&#x446;&#x438;&#x437;&#x443;&#x43c;&#x430;&#x431;&#x430; &#x44f;&#x432;&#x43b;&#x44f;&#x435;&#x442;&#x441;&#x44f; &#x432;&#x43e;&#x437;&#x43c;&#x43e;&#x436;&#x43d;&#x43e;&#x441;&#x442;&#x44c; &#x441;&#x43e;&#x43a;&#x440;&#x430;&#x449;&#x435;&#x43d;&#x438;&#x44f; &#x447;&#x438;&#x441;&#x43b;&#x430; &#x438;&#x43d;&#x44a;&#x435;&#x43a;&#x446;&#x438;&#x439; &#x438; &#x443;&#x434;&#x43b;&#x438;&#x43d;&#x435;&#x43d;&#x438;&#x44f; &#x438;&#x43d;&#x442;&#x435;&#x440;&#x432;&#x430;&#x43b;&#x43e;&#x432; &#x43c;&#x435;&#x436;&#x434;&#x443; &#x43d;&#x438;&#x43c;&#x438; &#x434;&#x43e; 16 &#x43d;&#x435;&#x434;. &#x420;&#x435;&#x437;&#x443;&#x43b;&#x44c;&#x442;&#x430;&#x442;&#x44b; &#x438;&#x441;&#x441;&#x43b;&#x435;&#x434;&#x43e;&#x432;&#x430;&#x43d;&#x438;&#x439; &#x441;&#x432;&#x438;&#x434;&#x435;&#x442;&#x435;&#x43b;&#x44c;&#x441;&#x442;&#x432;&#x443;&#x44e;&#x442; &#x43e; &#x441;&#x443;&#x449;&#x435;&#x441;&#x442;&#x432;&#x435;&#x43d;&#x43d;&#x43e;&#x43c; &#x443;&#x43b;&#x443;&#x447;&#x448;&#x435;&#x43d;&#x438;&#x438; &#x430;&#x43d;&#x430;&#x442;&#x43e;&#x43c;&#x43e;-&#x444;&#x443;&#x43d;&#x43a;&#x446;&#x438;&#x43e;&#x43d;&#x430;&#x43b;&#x44c;&#x43d;&#x44b;&#x445; &#x43f;&#x43e;&#x43a;&#x430;&#x437;&#x430;&#x442;&#x435;&#x43b;&#x435;&#x439; &#x432; &#x441;&#x440;&#x430;&#x432;&#x43d;&#x435;&#x43d;&#x438;&#x438; &#x441; &#x440;&#x430;&#x43d;&#x435;&#x435; &#x441;&#x443;&#x449;&#x435;&#x441;&#x442;&#x432;&#x443;&#x44e;&#x449;&#x438;&#x43c;&#x438; &#x438; &#x441; &#x432;&#x43d;&#x43e;&#x432;&#x44c; &#x43f;&#x43e;&#x44f;&#x432;&#x438;&#x432;&#x448;&#x438;&#x43c;&#x438;&#x441;&#x44f; &#x438;&#x43d;&#x433;&#x438;&#x431;&#x438;&#x442;&#x43e;&#x440;&#x430;&#x43c;&#x438; &#x430;&#x43d;&#x433;&#x438;&#x43e;&#x433;&#x435;&#x43d;&#x435;&#x437;&#x430;. &#x412;&#x43e;&#x437;&#x43c;&#x43e;&#x436;&#x43d;&#x43e;&#x441;&#x442;&#x44c; &#x441;&#x442;&#x430;&#x431;&#x438;&#x43b;&#x438;&#x437;&#x430;&#x446;&#x438;&#x438; &#x442;&#x435;&#x447;&#x435;&#x43d;&#x438;&#x44f; &#x437;&#x430;&#x431;&#x43e;&#x43b;&#x435;&#x432;&#x430;&#x43d;&#x438;&#x44f;, &#x435;&#x433;&#x43e; &#x43b;&#x443;&#x447;&#x448;&#x430;&#x44f; &#x43a;&#x43e;&#x43d;&#x442;&#x440;&#x43e;&#x43b;&#x438;&#x440;&#x443;&#x435;&#x43c;&#x43e;&#x441;&#x442;&#x44c;, &#x430; &#x442;&#x430;&#x43a;&#x436;&#x435; &#x432;&#x43e;&#x437;&#x43c;&#x43e;&#x436;&#x43d;&#x43e;&#x441;&#x442;&#x44c; &#x432;&#x44b;&#x43f;&#x43e;&#x43b;&#x43d;&#x435;&#x43d;&#x438;&#x44f; &#x431;&#x43e;&#x43b;&#x435;&#x435; &#x440;&#x435;&#x434;&#x43a;&#x438;&#x445; &#x438;&#x43d;&#x44a;&#x435;&#x43a;&#x446;&#x438;&#x439; &#x434;&#x435;&#x43b;&#x430;&#x44e;&#x442; &#x431;&#x440;&#x43e;&#x43b;&#x443;&#x446;&#x438;&#x437;&#x443;&#x43c;&#x430;&#x431; &#x43f;&#x440;&#x438;&#x432;&#x43b;&#x435;&#x43a;&#x430;&#x442;&#x435;&#x43b;&#x44c;&#x43d;&#x44b;&#x43c; &#x43f;&#x440;&#x438; &#x432;&#x44b;&#x431;&#x43e;&#x440;&#x435; &#x441;&#x440;&#x435;&#x434;&#x441;&#x442;&#x432;&#x430; &#x441;&#x442;&#x430;&#x440;&#x442;&#x43e;&#x432;&#x43e;&#x439; &#x442;&#x435;&#x440;&#x430;&#x43f;&#x438;&#x438; &#x438;&#x43b;&#x438; &#x43f;&#x440;&#x435;&#x43f;&#x430;&#x440;&#x430;&#x442;&#x430; &#x43f;&#x435;&#x440;&#x435;&#x43a;&#x43b;&#x44e;&#x447;&#x435;&#x43d;&#x438;&#x44f; &#x438; &#x43e;&#x43f;&#x440;&#x435;&#x434;&#x435;&#x43b;&#x44f;&#x44e;&#x442; &#x432;&#x43e;&#x437;&#x43c;&#x43e;&#x436;&#x43d;&#x43e;&#x441;&#x442;&#x44c; &#x440;&#x430;&#x441;&#x448;&#x438;&#x440;&#x435;&#x43d;&#x438;&#x44f; &#x43f;&#x43e;&#x43a;&#x430;&#x437;&#x430;&#x43d;&#x438;&#x439; &#x43a; &#x435;&#x433;&#x43e; &#x43f;&#x440;&#x438;&#x43c;&#x435;&#x43d;&#x435;&#x43d;&#x438;&#x44e;.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antiangiogenic therapy</Keyword><Keyword MajorTopicYN="N">brolucizumab</Keyword><Keyword MajorTopicYN="N">central serous chorioretinopathy</Keyword><Keyword MajorTopicYN="N">diabetic macular edema</Keyword><Keyword MajorTopicYN="N">neovascular age-related macular degeneration</Keyword><Keyword MajorTopicYN="N">optical coherence tomography</Keyword><Keyword MajorTopicYN="N">polypoidal choroidal vasculopathy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>21</Day><Hour>12</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>21</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>21</Day><Hour>7</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39569789</ArticleId><ArticleId IdType="doi">10.17116/oftalma2024140051154</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39569781</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0042-465X</ISSN><JournalIssue CitedMedium="Print"><Volume>140</Volume><Issue>5</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Vestnik oftalmologii</Title><ISOAbbreviation>Vestn Oftalmol</ISOAbbreviation></Journal><ArticleTitle>[Objective structural and functional monitoring of polypeptide retinal neuroprotective therapy in diabetic retinopathy].</ArticleTitle><Pagination><StartPage>97</StartPage><EndPage>104</EndPage><MedlinePgn>97-104</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.17116/oftalma202414005197</ELocationID><Abstract><AbstractText Label="UNLABELLED">In recent years, there has been a growing interest in the contribution of neuroretinal degeneration to the pathogenesis of diabetic retinopathy (DR), preceding the classic vascular changes associated with DR.</AbstractText><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This study evaluated the impact of the polypeptide drug Retinalamin on the structural and functional condition of the retina in patients with DR using optical coherence tomography (OCT) (Topcon OCT 2000 FA, Japan) and the Diopsys Nova vision testing system for electrophysiological studies of the visual organ.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">The clinical study included 56 patients (112 eyes) with type 1 and type 2 diabetes and DR without macular edema. Of these, 28 patients (56 eyes) comprised the main group receiving intramuscular Retinalamin. The control group consisted of 28 patients (56 eyes) who did not receive Retinalamin treatment. The thickness of the ganglion cell complex was analyzed by OCT imaging performed on the Topcon OCT 2000 FA. Electrophysiological studies of the visual organ were conducted using the Diopsys Nova vision testing system, following the Diopsys PERG24 (pattern ERG) and Diopsys ffERG/Multi-Luminance Flicker (full-field ERG, or flash ERG) protocols.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The study demonstrated convincing objective evidence of positive changes in the main observation group.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The emergence of two pathogenetically oriented neurodegenerative vectors of DR, involving both the inner and outer retina, significantly expands our understanding of this diabetic complication. This includes the potential for retinal neuroprotective treatment with peptide bioregulators in clinical practice, especially in the early stages of DR.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Malakhova</LastName><ForeName>A I</ForeName><Initials>AI</Initials><Identifier Source="ORCID">0000-0002-0181-9873</Identifier><AffiliationInfo><Affiliation>Smolensk Regional Clinical Hospital, Smolensk, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strakhov</LastName><ForeName>V V</ForeName><Initials>VV</Initials><Identifier Source="ORCID">0009-0002-6337-5208</Identifier><AffiliationInfo><Affiliation>Yaroslavl State Medical University, Yaroslavl, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malakhova</LastName><ForeName>Yu A</ForeName><Initials>YA</Initials><Identifier Source="ORCID">0009-0003-1472-6806</Identifier><AffiliationInfo><Affiliation>I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>rus</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Ob"ektivnyi strukturno-funktsional'nyi kontrol' polipeptidnoi retinoprotektornoi terapii pri diabeticheskoi retinopatii.</VernacularTitle></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Vestn Oftalmol</MedlineTA><NlmUniqueID>0415216</NlmUniqueID><ISSNLinking>0042-465X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003930" MajorTopicYN="Y">Diabetic Retinopathy</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D041623" MajorTopicYN="Y">Tomography, Optical Coherence</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004596" MajorTopicYN="Y">Electroretinography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012160" MajorTopicYN="N">Retina</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014792" MajorTopicYN="N">Visual Acuity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012165" MajorTopicYN="N">Retinal Ganglion Cells</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="rus"><AbstractText Label="UNLABELLED">&#x412; &#x43f;&#x43e;&#x441;&#x43b;&#x435;&#x434;&#x43d;&#x438;&#x435; &#x433;&#x43e;&#x434;&#x44b; &#x43d;&#x430;&#x431;&#x43b;&#x44e;&#x434;&#x430;&#x435;&#x442;&#x441;&#x44f; &#x440;&#x430;&#x441;&#x442;&#x443;&#x449;&#x438;&#x439; &#x438;&#x43d;&#x442;&#x435;&#x440;&#x435;&#x441; &#x43a; &#x432;&#x43a;&#x43b;&#x430;&#x434;&#x443; &#x43d;&#x435;&#x439;&#x440;&#x43e;&#x440;&#x435;&#x442;&#x438;&#x43d;&#x430;&#x43b;&#x44c;&#x43d;&#x43e;&#x439; &#x434;&#x435;&#x433;&#x435;&#x43d;&#x435;&#x440;&#x430;&#x446;&#x438;&#x438; &#x432; &#x43f;&#x430;&#x442;&#x43e;&#x433;&#x435;&#x43d;&#x435;&#x437; &#x434;&#x438;&#x430;&#x431;&#x435;&#x442;&#x438;&#x447;&#x435;&#x441;&#x43a;&#x43e;&#x439; &#x440;&#x435;&#x442;&#x438;&#x43d;&#x43e;&#x43f;&#x430;&#x442;&#x438;&#x438; (&#x414;&#x420;), &#x43f;&#x440;&#x435;&#x434;&#x448;&#x435;&#x441;&#x442;&#x432;&#x443;&#x44e;&#x449;&#x435;&#x439; &#x43a;&#x43b;&#x430;&#x441;&#x441;&#x438;&#x447;&#x435;&#x441;&#x43a;&#x438;&#x43c; &#x441;&#x43e;&#x441;&#x443;&#x434;&#x438;&#x441;&#x442;&#x44b;&#x43c; &#x438;&#x437;&#x43c;&#x435;&#x43d;&#x435;&#x43d;&#x438;&#x44f;&#x43c; &#x43f;&#x440;&#x438; &#x414;&#x420;.</AbstractText><AbstractText Label="&#x426;&#x415;&#x41b;&#x42c; &#x418;&#x421;&#x421;&#x41b;&#x415;&#x414;&#x41e;&#x412;&#x410;&#x41d;&#x418;&#x42f;" NlmCategory="UNASSIGNED">&#x421; &#x43f;&#x43e;&#x43c;&#x43e;&#x449;&#x44c;&#x44e; &#x43e;&#x43f;&#x442;&#x438;&#x447;&#x435;&#x441;&#x43a;&#x43e;&#x439; &#x43a;&#x43e;&#x433;&#x435;&#x440;&#x435;&#x43d;&#x442;&#x43d;&#x43e;&#x439; &#x442;&#x43e;&#x43c;&#x43e;&#x433;&#x440;&#x430;&#x444;&#x438;&#x438; (&#x41e;&#x41a;&#x422;) (Topcon OCT 2000 FA, &#x42f;&#x43f;&#x43e;&#x43d;&#x438;&#x44f;) &#x438; &#x441;&#x438;&#x441;&#x442;&#x435;&#x43c;&#x44b; &#x434;&#x43b;&#x44f; &#x44d;&#x43b;&#x435;&#x43a;&#x442;&#x440;&#x43e;&#x444;&#x438;&#x437;&#x438;&#x43e;&#x43b;&#x43e;&#x433;&#x438;&#x447;&#x435;&#x441;&#x43a;&#x438;&#x445; &#x438;&#x441;&#x441;&#x43b;&#x435;&#x434;&#x43e;&#x432;&#x430;&#x43d;&#x438;&#x439; (&#x42d;&#x424;&#x418;) &#x43e;&#x440;&#x433;&#x430;&#x43d;&#x430; &#x437;&#x440;&#x435;&#x43d;&#x438;&#x44f; Diopsys Nova &#x43e;&#x446;&#x435;&#x43d;&#x438;&#x442;&#x44c; &#x432;&#x43b;&#x438;&#x44f;&#x43d;&#x438;&#x435; &#x43f;&#x43e;&#x43b;&#x438;&#x43f;&#x435;&#x43f;&#x442;&#x438;&#x434;&#x43d;&#x43e;&#x433;&#x43e; &#x43f;&#x440;&#x435;&#x43f;&#x430;&#x440;&#x430;&#x442;&#x430; &#xab;&#x420;&#x435;&#x442;&#x438;&#x43d;&#x430;&#x43b;&#x430;&#x43c;&#x438;&#x43d;&#xbb; &#x43d;&#x430; &#x441;&#x442;&#x440;&#x443;&#x43a;&#x442;&#x443;&#x440;&#x43d;&#x43e;&#x435; &#x438; &#x444;&#x443;&#x43d;&#x43a;&#x446;&#x438;&#x43e;&#x43d;&#x430;&#x43b;&#x44c;&#x43d;&#x43e;&#x435; &#x441;&#x43e;&#x441;&#x442;&#x43e;&#x44f;&#x43d;&#x438;&#x435; &#x441;&#x435;&#x442;&#x447;&#x430;&#x442;&#x43a;&#x438; &#x443; &#x43f;&#x430;&#x446;&#x438;&#x435;&#x43d;&#x442;&#x43e;&#x432; &#x441; &#x414;&#x420;.</AbstractText><AbstractText Label="&#x41c;&#x410;&#x422;&#x415;&#x420;&#x418;&#x410;&#x41b; &#x418; &#x41c;&#x415;&#x422;&#x41e;&#x414;&#x42b;" NlmCategory="UNASSIGNED">&#x41f;&#x440;&#x43e;&#x432;&#x435;&#x434;&#x435;&#x43d;&#x43e; &#x43a;&#x43b;&#x438;&#x43d;&#x438;&#x447;&#x435;&#x441;&#x43a;&#x43e;&#x435; &#x438;&#x441;&#x441;&#x43b;&#x435;&#x434;&#x43e;&#x432;&#x430;&#x43d;&#x438;&#x435; 56 &#x43f;&#x430;&#x446;&#x438;&#x435;&#x43d;&#x442;&#x43e;&#x432; (112 &#x433;&#x43b;&#x430;&#x437;) &#x441; &#x441;&#x430;&#x445;&#x430;&#x440;&#x43d;&#x44b;&#x43c; &#x434;&#x438;&#x430;&#x431;&#x435;&#x442;&#x43e;&#x43c; 1-&#x433;&#x43e; &#x438; 2-&#x433;&#x43e; &#x442;&#x438;&#x43f;&#x430; &#x441; &#x414;&#x420; &#x431;&#x435;&#x437; &#x43c;&#x430;&#x43a;&#x443;&#x43b;&#x44f;&#x440;&#x43d;&#x43e;&#x433;&#x43e; &#x43e;&#x442;&#x435;&#x43a;&#x430;. &#x418;&#x437; &#x43d;&#x438;&#x445; 28 &#x447;&#x435;&#x43b;&#x43e;&#x432;&#x435;&#x43a; (56 &#x433;&#x43b;&#x430;&#x437;) &#x432;&#x43e;&#x448;&#x43b;&#x438; &#x432; &#x43e;&#x441;&#x43d;&#x43e;&#x432;&#x43d;&#x443;&#x44e; &#x433;&#x440;&#x443;&#x43f;&#x43f;&#x443;, &#x438;&#x43c; &#x43d;&#x430;&#x437;&#x43d;&#x430;&#x447;&#x430;&#x43b;&#x441;&#x44f; &#x43f;&#x440;&#x435;&#x43f;&#x430;&#x440;&#x430;&#x442; &#xab;&#x420;&#x435;&#x442;&#x438;&#x43d;&#x430;&#x43b;&#x430;&#x43c;&#x438;&#x43d;&#xbb; &#x432;&#x43d;&#x443;&#x442;&#x440;&#x438;&#x43c;&#x44b;&#x448;&#x435;&#x447;&#x43d;&#x43e;. &#x413;&#x440;&#x443;&#x43f;&#x43f;&#x443; &#x43a;&#x43e;&#x43d;&#x442;&#x440;&#x43e;&#x43b;&#x44f; &#x441;&#x43e;&#x441;&#x442;&#x430;&#x432;&#x438;&#x43b;&#x438; 28 &#x43f;&#x430;&#x446;&#x438;&#x435;&#x43d;&#x442;&#x43e;&#x432; (56 &#x433;&#x43b;&#x430;&#x437;) &#x431;&#x435;&#x437; &#x43b;&#x435;&#x447;&#x435;&#x43d;&#x438;&#x44f; &#x43f;&#x440;&#x435;&#x43f;&#x430;&#x440;&#x430;&#x442;&#x43e;&#x43c; &#xab;&#x420;&#x435;&#x442;&#x438;&#x43d;&#x430;&#x43b;&#x430;&#x43c;&#x438;&#x43d;&#xbb;. &#x421; &#x43f;&#x43e;&#x43c;&#x43e;&#x449;&#x44c;&#x44e; &#x43f;&#x440;&#x438;&#x431;&#x43e;&#x440;&#x430; Topcon OCT 2000 FA &#x43f;&#x440;&#x43e;&#x432;&#x43e;&#x434;&#x438;&#x43b;&#x43e;&#x441;&#x44c; &#x41e;&#x41a;&#x422;-&#x438;&#x441;&#x441;&#x43b;&#x435;&#x434;&#x43e;&#x432;&#x430;&#x43d;&#x438;&#x435; &#x441;&#x442;&#x440;&#x443;&#x43a;&#x442;&#x443;&#x440;&#x44b; &#x441;&#x435;&#x442;&#x447;&#x430;&#x442;&#x43a;&#x438;. &#x41f;&#x440;&#x43e;&#x438;&#x437;&#x432;&#x43e;&#x434;&#x438;&#x43b;&#x441;&#x44f; &#x430;&#x43d;&#x430;&#x43b;&#x438;&#x437; &#x442;&#x43e;&#x43b;&#x449;&#x438;&#x43d;&#x44b; &#x433;&#x430;&#x43d;&#x433;&#x43b;&#x438;&#x43e;&#x437;&#x43d;&#x43e;&#x433;&#x43e; &#x43a;&#x43e;&#x43c;&#x43f;&#x43b;&#x435;&#x43a;&#x441;&#x430; &#x441;&#x435;&#x442;&#x447;&#x430;&#x442;&#x43a;&#x438;. &#x42d;&#x424;&#x418; &#x43e;&#x440;&#x433;&#x430;&#x43d;&#x430; &#x437;&#x440;&#x435;&#x43d;&#x438;&#x44f; &#x43f;&#x440;&#x43e;&#x432;&#x43e;&#x434;&#x438;&#x43b;&#x438;&#x441;&#x44c; &#x43d;&#x430; &#x43f;&#x440;&#x438;&#x431;&#x43e;&#x440;&#x435; Diopsys Nova &#x43f;&#x43e; &#x43f;&#x440;&#x43e;&#x442;&#x43e;&#x43a;&#x43e;&#x43b;&#x443; Diopsys PERG24 (&#x43f;&#x430;&#x442;&#x442;&#x435;&#x440;&#x43d;-&#x42d;&#x420;&#x413;) &#x438; Diopsys ffERG/Multi-Luminance Flicker (&#x43f;&#x43e;&#x43b;&#x43d;&#x43e;&#x43f;&#x43e;&#x43b;&#x435;&#x432;&#x430;&#x44f; &#x42d;&#x420;&#x413;, &#x438;&#x43b;&#x438; &#x444;&#x43b;&#x435;&#x448;-&#x42d;&#x420;&#x413;).</AbstractText><AbstractText Label="&#x420;&#x415;&#x417;&#x423;&#x41b;&#x42c;&#x422;&#x410;&#x422;&#x42b;" NlmCategory="UNASSIGNED">&#x412; &#x438;&#x441;&#x441;&#x43b;&#x435;&#x434;&#x43e;&#x432;&#x430;&#x43d;&#x438;&#x438; &#x43f;&#x43e;&#x43b;&#x443;&#x447;&#x435;&#x43d;&#x44b; &#x443;&#x431;&#x435;&#x434;&#x438;&#x442;&#x435;&#x43b;&#x44c;&#x43d;&#x44b;&#x435; &#x43e;&#x431;&#x44a;&#x435;&#x43a;&#x442;&#x438;&#x432;&#x43d;&#x44b;&#x435; &#x434;&#x43e;&#x43a;&#x430;&#x437;&#x430;&#x442;&#x435;&#x43b;&#x44c;&#x441;&#x442;&#x432;&#x430; &#x43f;&#x43e;&#x43b;&#x43e;&#x436;&#x438;&#x442;&#x435;&#x43b;&#x44c;&#x43d;&#x44b;&#x445; &#x438;&#x437;&#x43c;&#x435;&#x43d;&#x435;&#x43d;&#x438;&#x439; &#x443; &#x43f;&#x430;&#x446;&#x438;&#x435;&#x43d;&#x442;&#x43e;&#x432; &#x43e;&#x441;&#x43d;&#x43e;&#x432;&#x43d;&#x43e;&#x439; &#x433;&#x440;&#x443;&#x43f;&#x43f;&#x44b; &#x43d;&#x430;&#x431;&#x43b;&#x44e;&#x434;&#x435;&#x43d;&#x438;&#x44f;.</AbstractText><AbstractText Label="&#x417;&#x410;&#x41a;&#x41b;&#x42e;&#x427;&#x415;&#x41d;&#x418;&#x415;" NlmCategory="UNASSIGNED">&#x41f;&#x43e;&#x44f;&#x432;&#x43b;&#x435;&#x43d;&#x438;&#x435; &#x434;&#x432;&#x443;&#x445; &#x43f;&#x430;&#x442;&#x43e;&#x433;&#x435;&#x43d;&#x435;&#x442;&#x438;&#x447;&#x435;&#x441;&#x43a;&#x438; &#x43e;&#x440;&#x438;&#x435;&#x43d;&#x442;&#x438;&#x440;&#x43e;&#x432;&#x430;&#x43d;&#x43d;&#x44b;&#x445; &#x43d;&#x435;&#x439;&#x440;&#x43e;&#x434;&#x435;&#x433;&#x435;&#x43d;&#x435;&#x440;&#x430;&#x442;&#x438;&#x432;&#x43d;&#x44b;&#x445; &#x432;&#x435;&#x43a;&#x442;&#x43e;&#x440;&#x43e;&#x432; &#x414;&#x420; &#x432; &#x432;&#x438;&#x434;&#x435; &#x432;&#x43e;&#x432;&#x43b;&#x435;&#x447;&#x435;&#x43d;&#x438;&#x44f; &#x432; &#x43f;&#x430;&#x442;&#x43e;&#x43b;&#x43e;&#x433;&#x438;&#x44e; &#x43d;&#x435; &#x442;&#x43e;&#x43b;&#x44c;&#x43a;&#x43e; &#x432;&#x43d;&#x443;&#x442;&#x440;&#x435;&#x43d;&#x43d;&#x435;&#x439;, &#x43d;&#x43e; &#x438; &#x43d;&#x430;&#x440;&#x443;&#x436;&#x43d;&#x43e;&#x439; &#x441;&#x435;&#x442;&#x447;&#x430;&#x442;&#x43a;&#x438; &#x43f;&#x43e;&#x437;&#x432;&#x43e;&#x43b;&#x44f;&#x435;&#x442; &#x441;&#x443;&#x449;&#x435;&#x441;&#x442;&#x432;&#x435;&#x43d;&#x43d;&#x43e; &#x440;&#x430;&#x441;&#x448;&#x438;&#x440;&#x438;&#x442;&#x44c; &#x43d;&#x430;&#x448;&#x438; &#x43f;&#x440;&#x435;&#x434;&#x441;&#x442;&#x430;&#x432;&#x43b;&#x435;&#x43d;&#x438;&#x44f; &#x43e;&#x431; &#x44d;&#x442;&#x43e;&#x43c; &#x43e;&#x441;&#x43b;&#x43e;&#x436;&#x43d;&#x435;&#x43d;&#x438;&#x438; &#x434;&#x438;&#x430;&#x431;&#x435;&#x442;&#x430;, &#x432; &#x442;&#x43e;&#x43c; &#x447;&#x438;&#x441;&#x43b;&#x435; &#x441; &#x446;&#x435;&#x43b;&#x44c;&#x44e; &#x43f;&#x440;&#x438;&#x43c;&#x435;&#x43d;&#x435;&#x43d;&#x438;&#x44f; &#x43d;&#x435;&#x439;&#x440;&#x43e;&#x440;&#x435;&#x442;&#x438;&#x43d;&#x43e;&#x43f;&#x440;&#x43e;&#x442;&#x435;&#x43a;&#x442;&#x43e;&#x440;&#x43d;&#x43e;&#x433;&#x43e; &#x43b;&#x435;&#x447;&#x435;&#x43d;&#x438;&#x44f; &#x43f;&#x435;&#x43f;&#x442;&#x438;&#x434;&#x43d;&#x44b;&#x43c;&#x438; &#x431;&#x438;&#x43e;&#x440;&#x435;&#x433;&#x443;&#x43b;&#x44f;&#x442;&#x43e;&#x440;&#x430;&#x43c;&#x438; &#x432; &#x43a;&#x43b;&#x438;&#x43d;&#x438;&#x447;&#x435;&#x441;&#x43a;&#x43e;&#x439; &#x43f;&#x440;&#x430;&#x43a;&#x442;&#x438;&#x43a;&#x435;, &#x432; &#x447;&#x430;&#x441;&#x442;&#x43d;&#x43e;&#x441;&#x442;&#x438; &#x43d;&#x430; &#x440;&#x430;&#x43d;&#x43d;&#x438;&#x445; &#x441;&#x442;&#x430;&#x434;&#x438;&#x44f;&#x445; &#x414;&#x420;.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Diopsys</Keyword><Keyword MajorTopicYN="N">Retinalamin</Keyword><Keyword MajorTopicYN="N">diabetic retinopathy</Keyword><Keyword MajorTopicYN="N">electrophysiological studies</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">optical coherence tomography</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>21</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>21</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>21</Day><Hour>7</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39569781</ArticleId><ArticleId IdType="doi">10.17116/oftalma202414005197</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39568745</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Exploring the relationship between cathepsin and age-related macular degeneration using Mendelian randomization.</ArticleTitle><Pagination><StartPage>1460779</StartPage><MedlinePgn>1460779</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1460779</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2024.1460779</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">Age-related macular degeneration (AMD) is the leading cause of low vision and even blindness in the elderly population worldwide. However, no studies have been conducted to analyze the causal relationship between the cathepsin family and AMD. The present study aimed to explore and analyze this potential association using Mendelian randomization (MR).</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">In this study, AMD was classified into two types: exudative AMD and atrophic AMD. Inverse-variance weighting (IVW) was used as the main analysis method. The association between nine cathepsins and the two classifications of AMD were analyzed using multivariable Mendelian randomization (MVMR). Sensitivity analysis included Cochran's Q-test and the MR-Egger intercept test.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Two-sample MR analysis showed that higher levels of cathepsin L2 were associated with a delay in the development of atrophic AMD (IVW: <i>p</i>&#x2009;=&#x2009;0.017; OR&#x2009;=&#x2009;0.885; 95% CI&#x2009;=&#x2009;0.799-0.979). Reverse MR analysis indicated that cathepsin E levels were increased in individuals with atrophic (IVW: <i>p</i>&#x2009;=&#x2009;0.023; OR&#x2009;=&#x2009;1.058; 95% CI&#x2009;=&#x2009;1.007-1.111) and exudative AMD (IVW: <i>p</i>&#x2009;=&#x2009;0.018; OR&#x2009;=&#x2009;1.061; 95% CI 1&#x2009;=&#x2009;1.010-1.115). MVMR analysis indicated a causal relationship between cathepsin G (IVW: <i>p</i>&#x2009;=&#x2009;0.025; OR&#x2009;=&#x2009;1.124; 95% CI&#x2009;=&#x2009;1.014-1.245), cathepsin O (IVW: <i>p</i>&#x2009;=&#x2009;0.043, OR&#x2009;=&#x2009;1.158, 95% CI&#x2009;=&#x2009;1.004-1.336), and exudative AMD after coordinating for other types of cathepsin.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">This study demonstrated a potential link between the cathepsin family and the onset of AMD. Elevated serum concentrations of cathepsin L2 may serve as a protective factor for atrophic AMD, while increased levels of serum cathepsin G and O concentrations may promote the development of exudative AMD. Besides, the development of AMD may be associated with elevated serum concentrations of cathepsin E.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Wang and Cai.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qiuyuan</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Guizhou Branch of the Affiliated Hospital of Zunyi Medical University, National Clinical Research Center of the Eye Hospital of Guizhou Province, Key Laboratory of Eye Disease Characteristics of Guizhou Province, Zunyi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, The First Clinical College, Zunyi Medical University, Zunyi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Shanjun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Guizhou Branch of the Affiliated Hospital of Zunyi Medical University, National Clinical Research Center of the Eye Hospital of Guizhou Province, Key Laboratory of Eye Disease Characteristics of Guizhou Province, Zunyi, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Mendelian randomization</Keyword><Keyword MajorTopicYN="N">age-related macular degeneration</Keyword><Keyword MajorTopicYN="N">cathepsins</Keyword><Keyword MajorTopicYN="N">causal analysis</Keyword><Keyword MajorTopicYN="N">multivariable Mendelian randomization</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>21</Day><Hour>4</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39568745</ArticleId><ArticleId IdType="pmc">PMC11576310</ArticleId><ArticleId IdType="doi">10.3389/fmed.2024.1460779</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, et al. . Age-related macular degeneration preferred practice pattern&#xae;. Ophthalmology. (2020) 127:P1&#x2013;P65. doi: 10.1016/j.ophtha.2019.09.024, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2019.09.024</ArticleId><ArticleId IdType="pubmed">31757502</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinese Vitreo-Retina Society of Chinese Medical Association; Fundus Disease Group of Chinese Ophthalmologist Association . [Evidence-based guidelines for diagnosis and treatment of age-related macular degeneration in China (2023)]. Zhonghua Yan Ke Za Zhi. (2023) 59:347&#x2013;66. doi: 10.3760/cma.j.cn112142-20221222-00649</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn112142-20221222-00649</ArticleId><ArticleId IdType="pubmed">37032564</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert NG, ElShelmani H, Singh MK, Mansergh FC, Wride MA, Padilla M, et al. . Risk factors and biomarkers of age-related macular degeneration. Prog Retin Eye Res. (2016) 54:64&#x2013;102. doi: 10.1016/j.preteyeres.2016.04.003, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2016.04.003</ArticleId><ArticleId IdType="pmc">PMC4992630</ArticleId><ArticleId IdType="pubmed">27156982</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H, Han KD, Shin J. Association between glycemic status and age-related macular degeneration: a nationwide population-based cohort study. Diabetes Metab. (2023) 49:101442. doi: 10.1016/j.diabet.2023.101442, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabet.2023.101442</ArticleId><ArticleId IdType="pubmed">36931431</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiser J, Adair B, Reinheckel T. Specialized roles for cysteine cathepsins in health and disease. J Clin Invest. (2010) 120:3421&#x2013;31. doi: 10.1172/JCI42918, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI42918</ArticleId><ArticleId IdType="pmc">PMC2947230</ArticleId><ArticleId IdType="pubmed">20921628</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonovi&#x107; M, Turk B. Cysteine cathepsins and extracellular matrix degradation. Biochim Biophys Acta. (2014) 1840:2560&#x2013;70. doi: 10.1016/j.bbagen.2014.03.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbagen.2014.03.017</ArticleId><ArticleId IdType="pubmed">24680817</ArticleId></ArticleIdList></Reference><Reference><Citation>Conus S, Simon HU. Cathepsins: key modulators of cell death and inflammatory responses. Biochem Pharmacol. (2008) 76:1374&#x2013;82. doi: 10.1016/j.bcp.2008.07.041, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2008.07.041</ArticleId><ArticleId IdType="pubmed">18762176</ArticleId></ArticleIdList></Reference><Reference><Citation>Cipriani V, Tierney A, Griffiths JR, Zuber V, Sergouniotis PI, Yates JRW, et al. . Beyond factor H: the impact of genetic-risk variants for age-related macular degeneration on circulating factor-H-like 1 and factor-H-related protein concentrations. Am J Hum Genet. (2021) 108:1385&#x2013;400. doi: 10.1016/j.ajhg.2021.05.015, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2021.05.015</ArticleId><ArticleId IdType="pmc">PMC8387294</ArticleId><ArticleId IdType="pubmed">34260948</ArticleId></ArticleIdList></Reference><Reference><Citation>Julian TH, Cooper-Knock J, MacGregor S, Guo H, Aslam T, Sanderson E, et al. . Phenome-wide Mendelian randomisation analysis identifies causal factors for age-related macular degeneration. eLife. (2023) 12:e82546. doi: 10.7554/eLife.82546, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.82546</ArticleId><ArticleId IdType="pmc">PMC9883012</ArticleId><ArticleId IdType="pubmed">36705323</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, et al. . Guidelines for performing Mendelian randomization investigations: update for summer 2023. Wellcome Open Res. (2023) 4:186. doi: 10.12688/wellcomeopenres.15555.3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/wellcomeopenres.15555.3</ArticleId><ArticleId IdType="pmc">PMC7384151</ArticleId><ArticleId IdType="pubmed">32760811</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, et al. . Genomic atlas of the human plasma proteome. Nature. (2018) 558:73&#x2013;9. doi: 10.1038/s41586-018-0175-2, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0175-2</ArticleId><ArticleId IdType="pmc">PMC6697541</ArticleId><ArticleId IdType="pubmed">29875488</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Ren Q, Zheng Q, Bai Y, He S, Zhang Y, et al. . Causal associations between gastroesophageal reflux disease and lung cancer risk: a Mendelian randomization study. Cancer Med. (2023) 12:7552&#x2013;9. doi: 10.1002/cam4.5498, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.5498</ArticleId><ArticleId IdType="pmc">PMC10067102</ArticleId><ArticleId IdType="pubmed">36479899</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U. Age-related macular degeneration: a review. JAMA. (2024) 331:147&#x2013;57. doi: 10.1001/jama.2023.26074</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.26074</ArticleId><ArticleId IdType="pubmed">38193957</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor AE, Davies NM, Ware JJ, VanderWeele T, Smith GD, Munaf&#xf2; MR. Mendelian randomization in health research: using appropriate genetic variants and avoiding biased estimates. Econ Hum Biol. (2014) 13:99&#x2013;106. doi: 10.1016/j.ehb.2013.12.002, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ehb.2013.12.002</ArticleId><ArticleId IdType="pmc">PMC3989031</ArticleId><ArticleId IdType="pubmed">24388127</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekula P, Del Greco MF, Pattaro C, K&#xf6;ttgen A. Mendelian randomization as an approach to assess causality using observational data. J Am Soc Nephrol. (2016) 27:3253&#x2013;65. doi: 10.1681/ASN.2016010098, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2016010098</ArticleId><ArticleId IdType="pmc">PMC5084898</ArticleId><ArticleId IdType="pubmed">27486138</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess S, Thompson SG. Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. Am J Epidemiol. (2015) 181:251&#x2013;60. doi: 10.1093/aje/kwu283, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwu283</ArticleId><ArticleId IdType="pmc">PMC4325677</ArticleId><ArticleId IdType="pubmed">25632051</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings. Int J Epidemiol. (2019) 48:713&#x2013;27. doi: 10.1093/ije/dyy262, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyy262</ArticleId><ArticleId IdType="pmc">PMC6734942</ArticleId><ArticleId IdType="pubmed">30535378</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanderson E. Multivariable Mendelian randomization and mediation. Cold Spring Harb Perspect Med. (2021) 11:a038984. doi: 10.1101/cshperspect.a038984, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a038984</ArticleId><ArticleId IdType="pmc">PMC7849347</ArticleId><ArticleId IdType="pubmed">32341063</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Tang M, Gao X, Tian S, Liu W. Mendelian randomization analyses explore the relationship between cathepsins and lung cancer. Commun Biol. (2023) 6:1019. doi: 10.1038/s42003-023-05408-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-023-05408-7</ArticleId><ArticleId IdType="pmc">PMC10560205</ArticleId><ArticleId IdType="pubmed">37805623</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-egger method. Eur J Epidemiol. (2017) 32:377&#x2013;89. doi: 10.1007/s10654-017-0255-x, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-017-0255-x</ArticleId><ArticleId IdType="pmc">PMC5506233</ArticleId><ArticleId IdType="pubmed">28527048</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess S, Scott RA, Timpson NJ, Davey Smith G, Thompson SG, EPIC- InterAct Consortium . Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. Eur J Epidemiol. (2015) 30:543&#x2013;52. doi: 10.1007/s10654-015-0011-z, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-015-0011-z</ArticleId><ArticleId IdType="pmc">PMC4516908</ArticleId><ArticleId IdType="pubmed">25773750</ArticleId></ArticleIdList></Reference><Reference><Citation>Greco MFD, Minelli C, Sheehan NA, Thompson JR. Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. Stat Med. (2015) 34:2926&#x2013;40. doi: 10.1002/sim.6522, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.6522</ArticleId><ArticleId IdType="pubmed">25950993</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through egger regression. Int J Epidemiol. (2015) 44:512&#x2013;25. doi: 10.1093/ije/dyv080, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyv080</ArticleId><ArticleId IdType="pmc">PMC4469799</ArticleId><ArticleId IdType="pubmed">26050253</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol. (2016) 40:304&#x2013;14. doi: 10.1002/gepi.21965, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gepi.21965</ArticleId><ArticleId IdType="pmc">PMC4849733</ArticleId><ArticleId IdType="pubmed">27061298</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. (2018) 50:693&#x2013;8. doi: 10.1038/s41588-018-0099-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0099-7</ArticleId><ArticleId IdType="pmc">PMC6083837</ArticleId><ArticleId IdType="pubmed">29686387</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlstetter M, Scholz R, Rutar M, Wong WT, Provis JM, Langmann T. Retinal microglia: just bystander or target for therapy? Prog Retin Eye Res. (2015) 45:30&#x2013;57. doi: 10.1016/j.preteyeres.2014.11.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2014.11.004</ArticleId><ArticleId IdType="pubmed">25476242</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashid K, Akhtar-Schaefer I, Langmann T. Microglia in Retinal Degeneration. Front Immunol. (2019) 10:1975. doi: 10.3389/fimmu.2019.01975, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01975</ArticleId><ArticleId IdType="pmc">PMC6710350</ArticleId><ArticleId IdType="pubmed">31481963</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasiak J, Sobczuk P, Pawlowska E, Kaarniranta K. Interplay between aging and other factors of the pathogenesis of age-related macular degeneration. Ageing Res Rev. (2022) 81:101735. doi: 10.1016/j.arr.2022.101735, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2022.101735</ArticleId><ArticleId IdType="pubmed">36113764</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman-Martinez L, Maccioni RB, Andrade V, Navarrete LP, Pastor MG, Ramos-Escobar N. Neuroinflammation as a common feature of neurodegenerative disorders. Front Pharmacol. (2019) 10:1008. doi: 10.3389/fphar.2019.01008, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2019.01008</ArticleId><ArticleId IdType="pmc">PMC6751310</ArticleId><ArticleId IdType="pubmed">31572186</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves CH, Fernandes R, Santiago AR, Ambr&#xf3;sio AF. Microglia contribution to the regulation of the retinal and choroidal vasculature in age-related macular degeneration. Cells. (2020) 9:1217. doi: 10.3390/cells9051217, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9051217</ArticleId><ArticleId IdType="pmc">PMC7290930</ArticleId><ArticleId IdType="pubmed">32423062</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma W, Lee SE, Guo J, Qu W, Hudson BI, Schmidt AM, et al. . RAGE ligand upregulation of VEGF secretion in ARPE-19 cells. Invest Ophthalmol Vis Sci. (2007) 48:1355&#x2013;61. doi: 10.1167/iovs.06-0738, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.06-0738</ArticleId><ArticleId IdType="pubmed">17325184</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadati T, Houben T, Bitorina A, Shiri-Sverdlov R. The ins and outs of cathepsins: physiological function and role in disease management. Cells. (2020) 9:1679. doi: 10.3390/cells9071679, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9071679</ArticleId><ArticleId IdType="pmc">PMC7407943</ArticleId><ArticleId IdType="pubmed">32668602</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakanishi H. Microglial cathepsin B as a key driver of inflammatory brain diseases and brain aging. Neural Regen Res. (2020) 15:25&#x2013;9. doi: 10.4103/1673-5374.264444, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.264444</ArticleId><ArticleId IdType="pmc">PMC6862407</ArticleId><ArticleId IdType="pubmed">31535638</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Inoue A, Lei Y, Wu H, Hong L, Cheng XW. Cathepsins in the extracellular space: focusing on non-lysosomal proteolytic functions with clinical implications. Cell Signal. (2023) 103:110531. doi: 10.1016/j.cellsig.2022.110531, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2022.110531</ArticleId><ArticleId IdType="pubmed">36417977</ArticleId></ArticleIdList></Reference><Reference><Citation>Zurdel J, Finckh U, Menzer G, Nitsch RM, Richard G. CST3 genotype associated with exudative age-related macular degeneration. Br J Ophthalmol. (2002) 86:214&#x2013;9. doi: 10.1136/bjo.86.2.214, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjo.86.2.214</ArticleId><ArticleId IdType="pmc">PMC1771004</ArticleId><ArticleId IdType="pubmed">11815350</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Z, Meng J, Kong W, Wu Z, Lan F, Narengaowa, et al. . Microglial cathepsin E plays a role in neuroinflammation and amyloid &#x3b2; production in Alzheimer's disease. Aging Cell. (2022) 21:e13565. doi: 10.1111/acel.13565, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.13565</ArticleId><ArticleId IdType="pmc">PMC8920437</ArticleId><ArticleId IdType="pubmed">35181976</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39567706</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5454</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>21</Day></PubDate></JournalIssue><Title>Eye (London, England)</Title><ISOAbbreviation>Eye (Lond)</ISOAbbreviation></Journal><ArticleTitle>Intravitreal Faricimab in treatment-na&#xef;ve neovascular age-related macular degeneration: real-world outcome of 12-week extension after the loading dose from a UK centre.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41433-024-03487-2</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To assess the visual outcome of extension to 12-weekly intervals (Q12W) following 4 loading doses of intravitreal Faricimab injections as described in the TENAYA and LUCERENE trials for the management of treatment-na&#xef;ve neovascular Age-related Macular Degeneration (nAMD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective analysis was carried out on all treatment-na&#xef;ve nAMD patients who started Faricimab intravitreal injections in the period between 1<sup>st</sup> September 2022 and 31<sup>st</sup> January 2023. The data collection included best corrected visual acuity (BCVA) at baseline, 12 weeks, 24 weeks and 52 weeks; Central Subfield Thickness (CST) at baseline, 24 weeks and 52 weeks; Number of injections at 52 weeks; treatment intervals at 52 weeks. Descriptive and correlational analysis, independent and Paired-sample T-tests were used to analyse the data.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Patwardhan</LastName><ForeName>Ashish</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0003-6514-7548</Identifier><AffiliationInfo><Affiliation>Royal Cornwall Hospitals NHS Trust, Treliske, Truro, Cornwall, TR1 3LJ, England. a.patwardhan@nhs.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Nadir</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-9718-5571</Identifier><AffiliationInfo><Affiliation>Royal Cornwall Hospitals NHS Trust, Treliske, Truro, Cornwall, TR1 3LJ, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Law</LastName><ForeName>Stacey</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Royal Cornwall Hospitals NHS Trust, Treliske, Truro, Cornwall, TR1 3LJ, England.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eye (Lond)</MedlineTA><NlmUniqueID>8703986</NlmUniqueID><ISSNLinking>0950-222X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>21</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>21</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>20</Day><Hour>23</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39567706</ArticleId><ArticleId IdType="doi">10.1038/s41433-024-03487-2</ArticleId><ArticleId IdType="pii">10.1038/s41433-024-03487-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bourne RR, Jonas JB, Flaxman SR, Keeffe J, Leasher J, Naidoo K, et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990-2010. Br J Ophthalmol. 2014;98:629&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjophthalmol-2013-304033</ArticleId><ArticleId IdType="pubmed">24665132</ArticleId></ArticleIdList></Reference><Reference><Citation>Colijn JM, Buitendijk GHS, Prokofyeva E, Alves D, Cachulo ML, Khawaja AP, et al. Prevalence of Age-Related Macular Degeneration in Europe: The Past and the Future. Ophthalmology. 2017;124:1753&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2017.05.035</ArticleId><ArticleId IdType="pubmed">28712657</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen CG, Jarrar Z, Wormald R, Cook DG, Fletcher AE, Rudnicka AR. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol. 2012;96:752&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjophthalmol-2011-301109</ArticleId><ArticleId IdType="pubmed">22329913</ArticleId></ArticleIdList></Reference><Reference><Citation>Pezzullo L, Streatfeild J, Simkiss P, Shickle D. The economic impact of sight loss and blindness in the UK adult population. BMC Health Serv Res. 2018;18:63.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12913-018-2836-0</ArticleId><ArticleId IdType="pubmed">29382329</ArticleId><ArticleId IdType="pmc">5791217</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamis AP, Brittain CJ, Dandekar A, Hopkins JJ. Building on the success of antivascular endothelial growth factor therapy: a vision for the next decade. Eye. 2020;34:1966&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41433-020-0895-z</ArticleId><ArticleId IdType="pubmed">32541890</ArticleId><ArticleId IdType="pmc">7784857</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanani AM, Guymer RH, Basu K, Boston H, Heier JS, Korobelnik JF, et al. TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration. Ophthalmol Sci. 2021;1:100076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xops.2021.100076</ArticleId><ArticleId IdType="pubmed">36246941</ArticleId><ArticleId IdType="pmc">9559073</ArticleId></ArticleIdList></Reference><Reference><Citation>Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00010-1</ArticleId><ArticleId IdType="pubmed">35085502</ArticleId></ArticleIdList></Reference><Reference><Citation>Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399:741&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00018-6</ArticleId><ArticleId IdType="pubmed">35085503</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung EH, Oh DJ, Alderson SE, Bracy J, McLeod M, Perez LI, et al. Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration. Clin Ophthalmol. 2023;17:1287&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OPTH.S409822</ArticleId><ArticleId IdType="pubmed">37181079</ArticleId><ArticleId IdType="pmc">10167970</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results. Eye. 2023;37:3574&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41433-023-02553-5</ArticleId><ArticleId IdType="pubmed">37173428</ArticleId><ArticleId IdType="pmc">10686385</ArticleId></ArticleIdList></Reference><Reference><Citation>Rush RB, Rush SW. Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration. Clin Ophthalmol. 2022;16:4041&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OPTH.S395279</ArticleId><ArticleId IdType="pubmed">36532820</ArticleId><ArticleId IdType="pmc">9747838</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto H, Hoshino J, Nakamura K, Nagashima T, Akiyama H. Short-term outcomes of intravitreal faricimab for treatment-na&#xef;ve neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2023;261:2945&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00417-023-06116-y</ArticleId><ArticleId IdType="pubmed">37195339</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanga PE, Valent&#xed;n-Bravo FJ, Stanga SEF, Reinstein UI, Pastor-Idoate S, Downes SM. Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic. Eye. 2023;37:3282&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41433-023-02505-z</ArticleId><ArticleId IdType="pubmed">36959312</ArticleId><ArticleId IdType="pmc">10564726</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng AM, Joshi S, Banoub RG, Saddemi J, Chalam KV. Faricimab Effectively Resolves Intraretinal Fluid and Preserves Vision in Refractory, Recalcitrant, and Nonresponsive Neovascular Age-Related Macular Degeneration. Cureus. 2023;15:e40100.</Citation><ArticleIdList><ArticleId IdType="pubmed">37425528</ArticleId><ArticleId IdType="pmc">10328548</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39566885</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2468-6530</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>18</Day></PubDate></JournalIssue><Title>Ophthalmology. Retina</Title><ISOAbbreviation>Ophthalmol Retina</ISOAbbreviation></Journal><ArticleTitle>Type 3 MNV in AMD: baseline predictors of 3-year macular atrophy development.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S2468-6530(24)00541-4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.oret.2024.11.011</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To identify baseline optical coherence tomography (OCT) predictors of the 3-year macular atrophy (MA) development for type 3 macular neovascularization (MNV) secondary to neovascular age-related macular degeneration (nAMD) treated by anti-VEGF therapy.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Multicenter, retrospective, longitudinal study.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">We included patients with treatment-na&#xef;ve type 3 MNV secondary to nAMD at baseline, treated with anti-VEGF during a 3-year follow-up.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients were identified from six retinal referral institutions: 1) San Raffaele University, Milan, Italy 2) University of Genova, Genova, Italy; 3) Doheny Eye Institute, Los Angeles, USA; 4) Stein Eye Institute, Los Angeles, USA; 5) University of Paris Est, Creteil, France; 6) IRCCS Bietti Foundation, Rome, Italy. Several baseline predictors of 3-year MA area were analyzed based on structural OCT and demographics.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Multivariate analysis in order to identify baseline independent predictors of the 3-year MA development for type 3 MNV secondary to nAMD treated by anti-VEGF therapy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We included 131 eyes of 131 patients (mean age 80&#xb1;6-year-old, 81% females). Best-corrected visual acuity was 0.49&#xb1;0.40 LogMAR at the baseline and significantly decreased to 0.59&#xb1;0.43 LogMAR at the end of 3-year follow-up (p&lt;0.001). Patients were treated with 11&#xb1;6 anti-VEGF injections and developed atrophy in 75% of cases (from 18% at the baseline). Eyes that developed 3-year MA were treated with a significantly lower number of injections compared to eyes without MA (9.9&#xb1;5.5 vs 14.7&#xb1;7.2 injections, p&lt;0.001). The most relevant independent predictors at baseline of MA area at 3-year follow-up were: area of MA at baseline (p&lt;0.001), AMD phenotype (presence of reticular pseudodrusen) (p=0.017), baseline presence of nascent geographic atrophy (p=0.008), and the baseline presence of subretinal hyper-reflective material (p=0.002).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Macular atrophy development is a frequent complication of type 3 MNV treated with anti-VEGF injections. Several factors could be considered as baseline predictors of atrophy development during the anti-VEGF treatment.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sacconi</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Medicine, Vita-Salute San Raffaele University, Milan, Italy; Division of head and neck, Ophthalmology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forte</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>IRCCS Ospedale Policlinico San Martino, Eye Unit, Genoa, Italy; University of Genoa, Dipartimento di Neuroscienze, riabilitazione, oftalmologia, genetica e scienze materno-infantili (DINOGMI), Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corradetti</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Doheny Eye Institute, University of California, Los Angeles, California, United States; Retinal Disorders and Ophthalmic Genetics Division, Stein Eye Institute, University of California, Los Angeles, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costanzo</LastName><ForeName>Eliana</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>IRCCS-Fondazione Bietti, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capuano</LastName><ForeName>Vittorio</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Hospital Intercommunal de Creteil, University Paris Est Creteil, Creteil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bousquet</LastName><ForeName>Elodie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Retinal Disorders and Ophthalmic Genetics Division, Stein Eye Institute, University of California, Los Angeles, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beretta</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Medicine, Vita-Salute San Raffaele University, Milan, Italy; Division of head and neck, Ophthalmology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iannuzzi</LastName><ForeName>Serena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polito</LastName><ForeName>Maria Sole</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>IRCCS-Fondazione Bietti, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicolo'</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>IRCCS Ospedale Policlinico San Martino, Eye Unit, Genoa, Italy; University of Genoa, Dipartimento di Neuroscienze, riabilitazione, oftalmologia, genetica e scienze materno-infantili (DINOGMI), Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parravano</LastName><ForeName>Mariacristina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>IRCCS-Fondazione Bietti, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Souied</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Hospital Intercommunal de Creteil, University Paris Est Creteil, Creteil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarraf</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Retinal Disorders and Ophthalmic Genetics Division, Stein Eye Institute, University of California, Los Angeles, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadda</LastName><ForeName>SriniVas</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Doheny Eye Institute, University of California, Los Angeles, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bandello</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Medicine, Vita-Salute San Raffaele University, Milan, Italy; Division of head and neck, Ophthalmology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Querques</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>School of Medicine, Vita-Salute San Raffaele University, Milan, Italy; Division of head and neck, Ophthalmology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy. Electronic address: giuseppe.querques@hotmail.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ophthalmol Retina</MedlineTA><NlmUniqueID>101695048</NlmUniqueID><ISSNLinking>2468-6530</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">OCT</Keyword><Keyword MajorTopicYN="N">RAP</Keyword><Keyword MajorTopicYN="N">age-related macular degeneration</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">macular neovascularization</Keyword><Keyword MajorTopicYN="N">multimodal imaging</Keyword><Keyword MajorTopicYN="N">nascent type 3</Keyword><Keyword MajorTopicYN="N">predictor</Keyword><Keyword MajorTopicYN="N">type 3 neovascularization</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>21</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>21</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>20</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39566885</ArticleId><ArticleId IdType="doi">10.1016/j.oret.2024.11.011</ArticleId><ArticleId IdType="pii">S2468-6530(24)00541-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39566751</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9130</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>18</Day></PubDate></JournalIssue><Title>Methods (San Diego, Calif.)</Title><ISOAbbreviation>Methods</ISOAbbreviation></Journal><ArticleTitle>Optimizing retinal Imaging: Evaluation of ultrasmall TiO<sub>2</sub> Nanoparticle- fluorescein conjugates for improved Fundus fluorescein angiography.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1046-2023(24)00249-4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ymeth.2024.11.012</ELocationID><Abstract><AbstractText>Fundus Fluorescein Angiography (FFA) has been extensively used for the identification, management, and diagnosis of various retinal and choroidal diseases, such as age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity, among others. This exam enables clinicians to evaluate retinal morphology and the pathophysiology of retinal vasculature. However, adverse events, including from mild to severe reactions to sodium fluorescein, have been reported. Titanium dioxide nanoparticles (NPTiO<sub>2</sub>) have shown significant potential in numerous biological applications. Coating or conjugating these nanoparticles with small molecules can enhance their stability, photochemical properties, and biocompatibility, as well as increase the hydrophilicity of the nanoparticles, making them more suitable for biomedical applications. This work demonstrates the potential use of ultrasmall titanium dioxide nanoparticles conjugated with sodium fluorescein to improve the quality of angiography exams. The strategy of conjugating fluorescein with NPTiO<sub>2</sub> successfully enhanced the fluorescence photostability of the contrast agent and increased its retention time in the retina. Preliminary in vivo and in vitro safety tests suggest that these nanoparticles are safe for the intended application demonstrating low tendency to hemolysis, and no significant changes in the retina thickness or in the electroretinography a-wave and b-wave amplitudes. Overall, the conjugation of fluorescein to NPTiO<sub>2</sub> has produced a nanomaterial with favorable properties for use as an innovative contrast agent in FFA examinations. By providing a clear description of our methodology of analysis, we also aim to offer better perspectives and reproducible conditions for future research.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fran&#xe7;a Dias</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pharmaceutical Research and Development, Ezequiel Dias Foundation, R. Conde Pereira Carneiro 80, Gameleira, 30510-010 Belo Horizonte, MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ken Kawassaki</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Chemistry, University of S&#xe3;o Paulo, Av. Prof. Lineu Prestes 748, Butant&#xe3;, 05508-000 S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amaral de Melo</LastName><ForeName>Lutiana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Pharmaceutical Research and Development, Ezequiel Dias Foundation, R. Conde Pereira Carneiro 80, Gameleira, 30510-010 Belo Horizonte, MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Araki</LastName><ForeName>Koiti</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Chemistry, University of S&#xe3;o Paulo, Av. Prof. Lineu Prestes 748, Butant&#xe3;, 05508-000 S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raphael Guimar&#xe3;es</LastName><ForeName>Robson</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Chemistry, University of S&#xe3;o Paulo, Av. Prof. Lineu Prestes 748, Butant&#xe3;, 05508-000 S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lig&#xf3;rio Fialho</LastName><ForeName>S&#xed;lvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Pharmaceutical Research and Development, Ezequiel Dias Foundation, R. Conde Pereira Carneiro 80, Gameleira, 30510-010 Belo Horizonte, MG, Brazil. Electronic address: silvia.fialho@funed.mg.gov.br.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Methods</MedlineTA><NlmUniqueID>9426302</NlmUniqueID><ISSNLinking>1046-2023</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Angiography</Keyword><Keyword MajorTopicYN="N">Fluorescein</Keyword><Keyword MajorTopicYN="N">Imaging</Keyword><Keyword MajorTopicYN="N">Ocular</Keyword><Keyword MajorTopicYN="N">Retina</Keyword><Keyword MajorTopicYN="N">TiO(2) nanoparticles</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>21</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>21</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>20</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39566751</ArticleId><ArticleId IdType="doi">10.1016/j.ymeth.2024.11.012</ArticleId><ArticleId IdType="pii">S1046-2023(24)00249-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39565329</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2164-2591</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>04</Day></PubDate></JournalIssue><Title>Translational vision science &amp; technology</Title><ISOAbbreviation>Transl Vis Sci Technol</ISOAbbreviation></Journal><ArticleTitle>Automated Detection of Drusenoid Pigment Epithelial Detachments From Spectral-Domain Optical Coherence Tomography in Patients With AMD.</ArticleTitle><Pagination><StartPage>25</StartPage><MedlinePgn>25</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">25</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1167/tvst.13.11.25</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">This study aimed to develop an algorithm for automated detection of drusenoid pigment epithelial detachments (DPEDs) in optical coherence tomography (OCT) volumes of patients with age-related macular degeneration (AMD) and to compare its performance against traditional reading center grading on color-fundus photographs (CFPs).</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Eyes with a range of AMD severities, excluding neovascular disease, were imaged using spectral-domain OCT (SD-OCT) and paired CFPs and were followed annually for up to 5&#xa0;years. DPEDs were automatically identified by segmenting the retinal pigment epithelium (RPE) and Bruch's membrane (BM) layers from the SD-OCT volumes and imposing both a minimum RPE BM height (&gt;75 &#xb5;m) and a two-dimensional length requirement (&gt;433 &#xb5;m). Comparisons in detection rates and contoured areas were made between the algorithmic SD-OCT detections and manually graded and contoured CFPs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Of the 1602 visits for the 323 eyes, the automated OCT algorithm identified 139 visits (8.7%) from 50 eyes with DPED, but a reading center review of paired CFPs identified 23 visits (1.4%) from nine eyes as having DPEDs. Eyes identified with DPEDs on OCT received nine-step AMD severity scores ranging from 6 to 10, and those scores had occurrence ratios of 23/160 (14%), 89/226 (39%), 24/99 (24%), 2/63 (3%), and 1/29 (3%), respectively. On a subset of 25 visits that also underwent manual contouring of DPED lesions in CFP, the Pearson correlation coefficient for DPED areas observed by OCT and CFP was 0.85.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Our analysis shows the feasibility of using OCT scans to objectively detect features that historically have been detected qualitatively by expert graders on CFPs.</AbstractText><AbstractText Label="TRANSLATIONAL RELEVANCE" NlmCategory="UNASSIGNED">Automated detection and quantitation of high-risk features can facilitate screening patients for clinical-trial enrollment and could serve as an outcome metric [T1 (Translation-to-Humans) and T4 (Translation-to-Population-Health)].</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mukherjee</LastName><ForeName>Souvick</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Trials Branch, Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duic</LastName><ForeName>Cameron</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinical Trials Branch, Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Silva</LastName><ForeName>Tharindu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Clinical Trials Branch, Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keenan</LastName><ForeName>Tiarnan D L</ForeName><Initials>TDL</Initials><AffiliationInfo><Affiliation>Clinical Trials Branch, Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thavikulwat</LastName><ForeName>Alisa T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Clinical Trials Branch, Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chew</LastName><ForeName>Emily Y</ForeName><Initials>EY</Initials><AffiliationInfo><Affiliation>Clinical Trials Branch, Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cukras</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinical Trials Branch, Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transl Vis Sci Technol</MedlineTA><NlmUniqueID>101595919</NlmUniqueID><ISSNLinking>2164-2591</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D041623" MajorTopicYN="Y">Tomography, Optical Coherence</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012163" MajorTopicYN="Y">Retinal Detachment</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="Y">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055213" MajorTopicYN="Y">Retinal Pigment Epithelium</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015593" MajorTopicYN="Y">Retinal Drusen</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008268" MajorTopicYN="Y">Macular Degeneration</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016570" MajorTopicYN="N">Bruch Membrane</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Disclosure: <b>S. Mukherjee</b>, None; <b>C. Duic</b>, None; <b>T. De Silva</b>, None; <b>T.D.L. Keenan</b>, None; <b>A.T. Thavikulwat</b>, None; <b>E.Y. Chew</b>, None; <b>C. Cukras</b>, None</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>20</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>20</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>20</Day><Hour>10</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39565329</ArticleId><ArticleId IdType="pmc">PMC11583990</ArticleId><ArticleId IdType="doi">10.1167/tvst.13.11.25</ArticleId><ArticleId IdType="pii">2802262</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Flaxman SR, Bourne RRA, Resnikoff S, et al. .. Global causes of blindness and distance vision impairment 1990&#x2013;2020: a systematic review and meta-analysis. Lancet Glob Health. 2017; 5(12): e1221&#x2013;e1234.</Citation><ArticleIdList><ArticleId IdType="pubmed">29032195</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman DS, O'Colmain BJ, Mu&#xf1;oz B, et al. .. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004; 122(4): 564&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">15078675</ArticleId></ArticleIdList></Reference><Reference><Citation>Chappelow AV, Kaiser PK.. Neovascular age-related macular degeneration. Drugs. 2008; 68(8): 1029&#x2013;1036.</Citation><ArticleIdList><ArticleId IdType="pubmed">18484796</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamin A, Oakley JD, Dubis AM, Russakoff DB, Sivaprasad S.. Changes in volume of various retinal layers over time in early and intermediate age-related macular degeneration. Eye (Lond). 2019; 33(3): 428&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6460706</ArticleId><ArticleId IdType="pubmed">30310161</ArticleId></ArticleIdList></Reference><Reference><Citation>Salehi MA, Mohammadi S, Gouravani M, Rezagholi F, Arevalo JF.. Retinal and choroidal changes in AMD: a systematic review and meta-analysis of spectral-domain optical coherence tomography studies. Surv Ophthalmol. 2023; 68(1): 54&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">35908660</ArticleId></ArticleIdList></Reference><Reference><Citation>Spaide RF, Curcio CA.. Drusen characterization with multimodal imaging. Retina. 2010; 30(9): 1441&#x2013;1454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2952278</ArticleId><ArticleId IdType="pubmed">20924263</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein R, Klein BEK, Linton KLP.. Prevalence of age-related maculopathy. Ophthalmology. 1992; 99(6): 933&#x2013;943.</Citation><ArticleIdList><ArticleId IdType="pubmed">1630784</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell P, Smith W, Attebo K, Wang JJ.. Prevalence of age-related maculopathy in Australia. Ophthalmology. 1995; 102(10): 1450&#x2013;1460.</Citation><ArticleIdList><ArticleId IdType="pubmed">9097791</ArticleId></ArticleIdList></Reference><Reference><Citation>Age-Related Eye Disease Study Group. The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1. Control Clin Trials. 1999; 20(6): 573&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1473211</ArticleId><ArticleId IdType="pubmed">10588299</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew EY, Clemons T, SanGiovanni JP, et al. .. The Age-Related Eye Disease Study 2 (AREDS2). Ophthalmology. 2012; 119(11): 2282&#x2013;2289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3485447</ArticleId><ArticleId IdType="pubmed">22840421</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofman A, Breteler MMB, van Duijn CM, et al. .. The Rotterdam Study: objectives and design update. Eur J Epidemiol. 2007; 22(11): 819&#x2013;829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2071967</ArticleId><ArticleId IdType="pubmed">17955331</ArticleId></ArticleIdList></Reference><Reference><Citation>Cukras C, Agr&#xf3;n E, Klein ML, et al. .. Natural history of drusenoid pigment epithelial detachment in age-related macular degeneration: Age-Related Eye Disease Study Report No. 28. Ophthalmology. 2010; 117(3): 489&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947750</ArticleId><ArticleId IdType="pubmed">20079925</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu JJ, Agr&#xf3;n E, Clemons TE, et al. .. Natural history of drusenoid pigment epithelial detachment associated with age-related macular degeneration. Ophthalmology. 2019; 126(2): 261&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6348044</ArticleId><ArticleId IdType="pubmed">30142373</ArticleId></ArticleIdList></Reference><Reference><Citation>Danis RP, Domalpally A, Chew EY, et al. .. Methods and reproducibility of grading optimized digital color fundus photographs in the Age-Related Eye Disease Study 2 (AREDS2 Report Number 2). Invest Ophthalmol Vis Sci. 2013; 54(7): 4548&#x2013;4554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3706107</ArticleId><ArticleId IdType="pubmed">23620429</ArticleId></ArticleIdList></Reference><Reference><Citation>Shijo T, Sakurada Y, Tanaka K, et al. .. Incidence and risk of advanced age-related macular degeneration in eyes with drusenoid pigment epithelial detachment. Sci Rep. 2022; 12(1): 4715.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8933473</ArticleId><ArticleId IdType="pubmed">35304557</ArticleId></ArticleIdList></Reference><Reference><Citation>Roquet W. Clinical features of drusenoid pigment epithelial detachment in age related macular degeneration. Br J Ophthalmol. 2004; 88(5): 638&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1772148</ArticleId><ArticleId IdType="pubmed">15090415</ArticleId></ArticleIdList></Reference><Reference><Citation>Thavikulwat AT, De Silva T, Agr&#xf3;n E, et al. .. Multimodal assessments of drusenoid pigment epithelial detachments in the Age-Related Eye Disease Study 2 ancillary spectral-domain optical coherence tomography study cohort. Retina. 2022; 42(5): 842&#x2013;851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11550875</ArticleId><ArticleId IdType="pubmed">35174809</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith RT. A method of drusen measurement based on reconstruction of fundus background reflectance. Br J Ophthalmol. 2005; 89(1): 87&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1772480</ArticleId><ArticleId IdType="pubmed">15615753</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalid S, Akram MU, Hassan T, Jameel A, Khalil T.. Automated segmentation and quantification of drusen in fundus and optical coherence tomography images for detection of ARMD. J Digit Imaging. 2018; 31(4): 464&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6113158</ArticleId><ArticleId IdType="pubmed">29204763</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee S, De Silva T, Grisso P, et al. .. Retinal layer segmentation in optical coherence tomography (OCT) using a 3D deep-convolutional regression network for patients with age-related macular degeneration. Biomed Opt Express. 2022; 13(6): 3195&#x2013;3210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9208604</ArticleId><ArticleId IdType="pubmed">35781941</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain N, Farsiu S, Khanifar AA, et al. .. Quantitative comparison of drusen segmented on SD-OCT versus drusen delineated on color fundus photographs. Invest Ophthalmol Vis Sci. 2010; 51(10): 4875&#x2013;4883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2939301</ArticleId><ArticleId IdType="pubmed">20393117</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung CMG, Shi Y, Tham YC, et al. .. Correlation of color fundus photograph grading with risks of early age-related macular degeneration by using automated OCT-derived drusen measurements. Sci Rep. 2018; 8(1): 12937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6113205</ArticleId><ArticleId IdType="pubmed">30154521</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregori G, Wang F, Rosenfeld PJ, et al. .. Spectral domain optical coherence tomography imaging of drusen in nonexudative age-related macular degeneration. Ophthalmology. 2011; 118(7): 1373&#x2013;1379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3129493</ArticleId><ArticleId IdType="pubmed">21388687</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee S, de Silva T, Duic C, et al. .. Automated detection of drusenoid pigment epithelial detachments (DPEDs) on OCTs in patients with age related macular degeneration (AMD). Invest Ophthalmol Vis Sci. 2022; 63(7): 1035.</Citation></Reference><Reference><Citation>Mukherjee S, De Silva TS, Jayakar G, et al. .. Retinal layer segmentation for age-related macular degeneration patients with 3D-UNet. In: Iftekharuddin KM, Drukker K, Mazurowski MA, Lu H, Muramatsu C, Samala RK, eds. Medical Imaging 2022: Computer-Aided Diagnosis. Bellingham, WA: SPIE; 2022: 70.</Citation></Reference><Reference><Citation>Au A, Santina A, Abraham N, et al. .. Relationship between drusen height and OCT biomarkers of atrophy in non-neovascular AMD. Invest Ophthalmol Vis Sci. 2022; 63(11): 24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9624265</ArticleId><ArticleId IdType="pubmed">36306145</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis MD, Gangnon RE, Lee LY, et al. .. The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS report no. 17. Arch Ophthalmol. 2005; 123(11): 1484&#x2013;1498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1472813</ArticleId><ArticleId IdType="pubmed">16286610</ArticleId></ArticleIdList></Reference><Reference><Citation>Jolesz FA, ed. Intraoperative Imaging and Image-Guided Therapy. New York: Springer; 2014.</Citation></Reference><Reference><Citation>Fedorov A, Beichel R, Kalpathy-Cramer J, et al. .. 3D Slicer as an image computing platform for the Quantitative Imaging Network. Magn Reson Imaging. 2012; 30(9): 1323&#x2013;1341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3466397</ArticleId><ArticleId IdType="pubmed">22770690</ArticleId></ArticleIdList></Reference><Reference><Citation>De Silva T, Chew EY, Hotaling N, Cukras CA.. Deep-learning based multi-modal retinal image registration for the longitudinal analysis of patients with age-related macular degeneration. Biomed Opt Express. 2021; 12(1): 619&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7818952</ArticleId><ArticleId IdType="pubmed">33520392</ArticleId></ArticleIdList></Reference><Reference><Citation>Yehoshua Z, Gregori G, Sadda SR, et al. .. Comparison of drusen area detected by spectral domain optical coherence tomography and color fundus imaging. Invest Ophthalmol Vis Sci. 2013; 54(4): 2429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3623598</ArticleId><ArticleId IdType="pubmed">23471895</ArticleId></ArticleIdList></Reference><Reference><Citation>Sa&#xdf;mannshausen M, Behning C, Weinz J, et al. .. Characteristics and spatial distribution of structural features in age-related macular degeneration. Ophthalmology Retina. 2023; 7(5): 420&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">36563964</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Leng T, Zheng L, et al. .. Automated drusen segmentation and quantification in SD-OCT images. Med Image Anal. 2013; 17(8): 1058&#x2013;1072.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3795829</ArticleId><ArticleId IdType="pubmed">23880375</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SY, Stetson PF, Ruiz-Garcia H, Heussen FM, Sadda SR.. Automated characterization of pigment epithelial detachment by optical coherence tomography. Invest Ophthalmol Vis Sci. 2012; 53(1): 164.</Citation><ArticleIdList><ArticleId IdType="pubmed">22159019</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlanitz FG, Ahlers C, Sacu S, et al. .. Performance of drusen detection by spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2010; 51(12): 6715.</Citation><ArticleIdList><ArticleId IdType="pubmed">21123769</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleiman K, Veerappan M, Winter KP, et al. .. Optical coherence tomography predictors of risk for progression to non-neovascular atrophic age-related macular degeneration. Ophthalmology. 2017; 124(12): 1764&#x2013;1777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5768932</ArticleId><ArticleId IdType="pubmed">28847641</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeannette JY, Agr&#xf3;n E, Clemons TE, et al. .. Natural history of drusenoid pigment epithelial detachment associated with age-related macular degeneration: Age-Related Eye Disease Study 2 Report No. 17. Ophthalmology. 2019; 126(2): 261&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6348044</ArticleId><ArticleId IdType="pubmed">30142373</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirabayashi K, Hannah JY, Wakatsuki Y, Marion KM, Wykoff CC, Sadda SR. OCT risk factors for development of atrophy in eyes with intermediate age-related macular degeneration. Ophthalmol Retina. 2023; 7(3): 253&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">36208726</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalra G, Cetin H, Whitney J, et al. .. Automated identification and segmentation of ellipsoid zone at-risk using deep learning on SD-OCT for predicting progression in dry AMD. Diagnostics (Basel). 2023; 13(6): 1178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10047385</ArticleId><ArticleId IdType="pubmed">36980486</ArticleId></ArticleIdList></Reference><Reference><Citation>Laiginhas R, Shi Y, Shen M, et al. .. Persistent hypertransmission defects detected on en face swept source optical computed tomography images predict the formation of geographic atrophy in age-related macular degeneration. Am J Ophthalmol. 2022; 237: 58&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9035026</ArticleId><ArticleId IdType="pubmed">34785169</ArticleId></ArticleIdList></Reference><Reference><Citation>Corradetti G, Tiosano L, Nassisi M, et al. .. Scotopic microperimetric sensitivity and inner choroid flow deficits as predictors of progression to nascent geographic atrophy. Br J Ophthalmol. 2021; 105(11): 1584&#x2013;1590.</Citation><ArticleIdList><ArticleId IdType="pubmed">33172861</ArticleId></ArticleIdList></Reference><Reference><Citation>Grisso P, Pak JW, De Silva T, et al. .. Correlations between AMD severity and OCT thickness. Invest Ophthalmol Vis Sci. 2021; 62(8): 313.</Citation></Reference><Reference><Citation>Oncel D, Corradetti G, Wakatsuki Y, et al. .. Drusen morphometrics on optical coherence tomography in eyes with age-related macular degeneration and normal aging. Graefes Arch Clin Exp Ophthalmol. 2023; 261(9): 2525&#x2013;2533.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10527978</ArticleId><ArticleId IdType="pubmed">37133500</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39563963</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1179-2752</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Clinical optometry</Title><ISOAbbreviation>Clin Optom (Auckl)</ISOAbbreviation></Journal><ArticleTitle>A Novel Optometry-Led Decision-Making Community Referral Refinement Scheme for Neovascular Age-Related Macular Degeneration Screening.</ArticleTitle><Pagination><StartPage>293</StartPage><EndPage>299</EndPage><MedlinePgn>293-299</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/OPTO.S470577</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The prevalence of neovascular age-related macular degeneration (nAMD) continues to increase. Hospital Eye Services are operating above capacity, innovative solutions to minimise the high proportion of false negative referrals, improve the care pathway and increase capacity for those patients who need ongoing care are essential are essential.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A two-phase retrospective longitudinal analysis of all patients referred and assessed for nAMD between; April 2019 to March 2020 (Phase 1) n=394, and April 2020 to March 2021 (Phase 2) n= 414, within Swansea Bay University Health Board (SBUHB). All patients with suspect nAMD were referred to the hospital based nAMD clinic in phase 1, and a community optometry nAMD decision making pathway in phase 2. All clinical records were reviewed, and data collated for subsequent analysis. Age, sex, date of referral, diagnosis, and treatment date were all recorded and analysed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">During phase 1, 104 new nAMD cases needing treatment were diagnosed with 85% (n=88) receiving treatment within 2&#xa0;weeks of initial referral. During phase 2, 230 new nAMD cases requiring treatment were diagnosed with 94% (n=216) receiving treatment within 2&#xa0;weeks of initial referral. Both the proportion of nAMD cases diagnosed (&#x3c7;&#xb2; = 70.8; p&lt;0.001) and proportion of those treated within 2&#xa0;weeks of initial diagnosis (&#x3c7;&#xb2; = 7.57; p&lt;0.05) were significantly higher during phase 2.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">There are advantages to a community optometry nAMD decision-making pathway with regard to 1) decreasing the number of patients requiring HES attendance, 2) increasing the number of patients able to access treatment for nAMD within 2&#xa0;weeks of initial referral 3) an increased rate of diagnosis confirmation of nAMD and 4) a decrease in the rate of false-positive referrals.</AbstractText><CopyrightInformation>&#xa9; 2024 Sanders et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sanders</LastName><ForeName>Francis W B</ForeName><Initials>FWB</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Singleton Hospital, Swansea, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>John</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-9785-5520</Identifier><AffiliationInfo><Affiliation>Primary Care Services, NHS Wales Shared Services Partnership, Cardiff, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Optometry Division, Specsavers Opticians, Swansea, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Gwyn Samuel</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Singleton Hospital, Swansea, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Clin Optom (Auckl)</MedlineTA><NlmUniqueID>101730504</NlmUniqueID><ISSNLinking>1179-2752</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">age-related-macular-degeneration</Keyword><Keyword MajorTopicYN="N">primary care</Keyword><Keyword MajorTopicYN="N">public health</Keyword><Keyword MajorTopicYN="N">shared care</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>20</Day><Hour>11</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>20</Day><Hour>11</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>20</Day><Hour>4</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39563963</ArticleId><ArticleId IdType="pmc">PMC11573688</ArticleId><ArticleId IdType="doi">10.2147/OPTO.S470577</ArticleId><ArticleId IdType="pii">470577</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bourne RRA, Jonas JB, Flaxman SR, et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990-2010. Br J Ophthalmol. 2014;98(5):629&#x2013;638. doi:10.1136/bjophthalmol-2013-304033</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjophthalmol-2013-304033</ArticleId><ArticleId IdType="pubmed">24665132</ArticleId></ArticleIdList></Reference><Reference><Citation>Colijn JM, Buitendijk GHS, Meester MA, Vingerling JR, Hofman A, Klaver CCW. The prevalence of Age-related Macular Degeneration in Europe. The E3 Consortium. Invest Ophthalmol Visual Sci. 2016;57(12).</Citation></Reference><Reference><Citation>Li JQ, Welchowski T, Schmid M, Mauschitz MM, Holz FG, F RP. Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis. Br J Ophthalmol. 2020;104(8):1077&#x2013;1084. doi:10.1136/bjophthalmol-2019-314422</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjophthalmol-2019-314422</ArticleId><ArticleId IdType="pubmed">31712255</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419&#x2013;1431. doi:10.1056/NEJMoa054481</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa054481</ArticleId><ArticleId IdType="pubmed">17021318</ArticleId></ArticleIdList></Reference><Reference><Citation>Claessen H, Genz J, Bertram B, et al. Evidence for a considerable decrease in total and cause-specific incidences of blindness in Germany. Eur j epidemiol. 2012;27(7):519&#x2013;524. doi:10.1007/s10654-012-9705-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-012-9705-7</ArticleId><ArticleId IdType="pubmed">22711586</ArticleId></ArticleIdList></Reference><Reference><Citation>Delcourt C, Korobelnik J-F, Buitendijk GHS, Foster PJ, Hammond CJ, P S. Ophthalmic epidemiology in Europe: the &#x201c;European Eye Epidemiology&#x201d; (E3) consortium. Eur J Epidemiol. 2016;31(2):197&#x2013;210. doi:10.1007/s10654-015-0098-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-015-0098-2</ArticleId><ArticleId IdType="pubmed">26686680</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao J, Choudhary MM, S AP. Neovascular age-related macular degeneration. Dev Ophthalmol. 2016;55:125&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">26501146</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas CJ, Mirza RG, Gill MK. Age-Related Macular Degeneration. Med Clin North Am. 2021;105(3):473&#x2013;491. doi:10.1016/j.mcna.2021.01.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcna.2021.01.003</ArticleId><ArticleId IdType="pubmed">33926642</ArticleId></ArticleIdList></Reference><Reference><Citation>Das A, McGuire PG. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retinal Eye Res. 2003;22(6):721&#x2013;748. doi:10.1016/j.preteyeres.2003.08.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preteyeres.2003.08.001</ArticleId><ArticleId IdType="pubmed">14575722</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricci F, Bandello F, Navarra P, Staurenghi G, Stumpp M, Zarbin M. Neovascular age-related macular degeneration: therapeutic management and new-upcoming approaches. Int J Mol Sci. 2020;21(21):8242. doi:10.3390/ijms21218242</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21218242</ArticleId><ArticleId IdType="pmc">PMC7662479</ArticleId><ArticleId IdType="pubmed">33153227</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong V. Ranibizumab for the treatment of wet AMD: a summary of real-world studies vol 30, pg 270, 2016). Eye. 2016;30(11):1526. doi:10.1038/eye.2016.202</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/eye.2016.202</ArticleId><ArticleId IdType="pmc">PMC5108026</ArticleId><ArticleId IdType="pubmed">27612184</ArticleId></ArticleIdList></Reference><Reference><Citation>Gualino V, Tadayoni R, Cohen SY, et al. Optical coherence tomography, fluorescein angiography, and diagnosis of choroidal neovascularization in age-related macular degeneration. Retina-the Journal of Retinal and Vitreous Diseases. 2019;39(9):1664&#x2013;1671. doi:10.1097/iae.0000000000002220</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/iae.0000000000002220</ArticleId><ArticleId IdType="pmc">PMC6727912</ArticleId><ArticleId IdType="pubmed">30045134</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra S, McKibbin M, Mahmood S, Downey L, Barnes B, S S. The Royal college of ophthalmologists commissioning guidelines on age macular degeneration: executive summary. Eye. 2022;36(11):2078&#x2013;2083. doi:10.1038/s41433-022-02095-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41433-022-02095-2</ArticleId><ArticleId IdType="pmc">PMC9582190</ArticleId><ArticleId IdType="pubmed">35624304</ArticleId></ArticleIdList></Reference><Reference><Citation>RCOphthal. The Way Forward Options to Help Meet Demand for the Current and Future Care of Patients with Eye Disease. The Royal College of Ophthalmologists; 2016.</Citation></Reference><Reference><Citation>Kelly SP, Wallwork I, Haider D, Q K. Teleophthalmology with optical coherence tomography imaging in community optometry. Evaluation of a quality improvement for macular patients. Clin Ophthalmol. 2011;1673&#x2013;1678. doi:10.2147/OPTH.S26753</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OPTH.S26753</ArticleId><ArticleId IdType="pmc">PMC3236713</ArticleId><ArticleId IdType="pubmed">22174576</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor J, Scott LJ, Rogers CA, et al. The design and implementation of a study to investigate the effectiveness of community vs hospital eye service follow-up for patients with neovascular age-related macular degeneration with quiescent disease. Eye. 2016;30(1):68&#x2013;78. doi:10.1038/eye.2015.170</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/eye.2015.170</ArticleId><ArticleId IdType="pmc">PMC4707499</ArticleId><ArticleId IdType="pubmed">26449197</ArticleId></ArticleIdList></Reference><Reference><Citation>Reeves BC, Scott LJ, Taylor J, et al. Effectiveness of community versus hospital eye service follow-up for patients with neovascular age-related macular degeneration with quiescent disease (ECHoES): a virtual non-inferiority trial. BMJ Open. 2016;6(7):e010685. doi:10.1136/bmjopen-2015-010685</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2015-010685</ArticleId><ArticleId IdType="pmc">PMC4947830</ArticleId><ArticleId IdType="pubmed">27401357</ArticleId></ArticleIdList></Reference><Reference><Citation>Reeves BC, Scott LJ, Taylor J, et al. The Effectiveness, cost-effectiveness and acceptability of community versus hospital eye service follow-up for patients with neovascular age-related macular degeneration with quiescent disease (ECHoES): a virtual randomised balanced incomplete block triald. Health Technol Assess. 2016;20(80):1&#x2013;+. doi:10.3310/hta20800</Citation><ArticleIdList><ArticleId IdType="doi">10.3310/hta20800</ArticleId><ArticleId IdType="pmc">PMC5107885</ArticleId><ArticleId IdType="pubmed">27809956</ArticleId></ArticleIdList></Reference><Reference><Citation>Violato M, Dakin H, Chakravarthy U, et al. Cost-effectiveness of community versus hospital eye service follow-up for patients with quiescent treated age-related macular degeneration alongside the ECHoES randomised trial. BMJ Open. 2016;6(10):e011121. doi:10.1136/bmjopen-2016-011121</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2016-011121</ArticleId><ArticleId IdType="pmc">PMC5093395</ArticleId><ArticleId IdType="pubmed">27797985</ArticleId></ArticleIdList></Reference><Reference><Citation>Gale RP, Mahmood S, Devonport H, et al. Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service. Eye. 2019:33. doi: 10.1038/s41433-018-0300-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41433-018-0300-3</ArticleId><ArticleId IdType="pmc">PMC6474281</ArticleId><ArticleId IdType="pubmed">30926932</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan AA, Mustafa MZ, Sanders R. Improving patient access to prevent sight loss: ophthalmic electronic referrals and communication (Scotland). Public Health. 2015;129(2):117&#x2013;123. doi:10.1016/j.puhe.2014.10.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.puhe.2014.10.010</ArticleId><ArticleId IdType="pubmed">25515043</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsaousis KT, Empeslidis T, Konidaris VE, Kapoor B, Deane J. The concept of virtual clinics in monitoring patients with age-related macular degeneration. Acta Ophthalmologica. 2016;94(5):e353&#x2013;e355. doi:10.1111/aos.12832</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aos.12832</ArticleId><ArticleId IdType="pubmed">26385270</ArticleId></ArticleIdList></Reference><Reference><Citation>North R, Anderson P, Harris S, Kenkre J, Wallace S, W C. Wet age related macular degeneration services in the community: a pathfinder evaluation - Final Report 2019. 2019.</Citation></Reference><Reference><Citation>COptom. Professional Certificate in Medical Retina. College of Optometrists; 2022.</Citation></Reference><Reference><Citation>Consultant Connect. Available from: https://www.consultantconnect.org.uk. Accessed December
28, 2022.</Citation></Reference><Reference><Citation>Owen CG, Jarrar Z, Wormald R, Cook DG, Fletcher AE, Rudnicka AR. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol. 2012;96(5):752&#x2013;756. doi:10.1136/bjophthalmol-2011-301109</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjophthalmol-2011-301109</ArticleId><ArticleId IdType="pmc">PMC3329633</ArticleId><ArticleId IdType="pubmed">22329913</ArticleId></ArticleIdList></Reference><Reference><Citation>RCOphth. Ophthalmology &#x2013; The Hospital Eye Service in Crisis. Royal College of Ophthalmologists; 2018.</Citation></Reference><Reference><Citation>Pyott A. External Review of Eye Care Services in Wales. Royal College of Ophthalmologists; 2021.</Citation></Reference><Reference><Citation>Government Welsh. A Healthier Wales: Our Plan for Health and Social Care. Available from: https://www.gov.wales/sites/default/files/publications/2021-09/a-healthier-wales-our-plan-for-health-and-social-care.pdf. Accessed 8
October 2024.</Citation></Reference><Reference><Citation>Welsh Government. NHS wales eye health care, future approach for optometry services. Welsh Government. 2021.</Citation></Reference><Reference><Citation>Varano M, Eter N, Winyard S, et al. Current barriers to treatment for wet age-related macular degeneration (wAMD): findings from the wAMD patient and caregiver survey. Clin Ophthalmol. 2015;9:2243&#x2013;2250. doi:10.2147/opth.s92548</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/opth.s92548</ArticleId><ArticleId IdType="pmc">PMC4671808</ArticleId><ArticleId IdType="pubmed">26664038</ArticleId></ArticleIdList></Reference><Reference><Citation>Parfitt A, Boxell E, Amoaku WM, Bradley C. Patient-reported reasons for delay in diagnosis of age-related macular degeneration: a national survey. BMJ Open Ophthalmol. 2019;4(1):e000276. doi:10.1136/bmjophth-2019-000276</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjophth-2019-000276</ArticleId><ArticleId IdType="pmc">PMC6830468</ArticleId><ArticleId IdType="pubmed">31750395</ArticleId></ArticleIdList></Reference><Reference><Citation>Skelly A, Taylor N, Fasser C, Malkowski JP, Goswami P, Downey L. PATIENT PREFERENCES IN THE MANAGEMENT OF WET AGE-RELATED MACULAR DEGENERATION: a CONJOINT ANALYSIS. Value Health. 2022;25(1):S235&#x2013;S236. doi:10.1016/j.jval.2021.11.1150</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2021.11.1150</ArticleId><ArticleId IdType="pmc">PMC9464751</ArticleId><ArticleId IdType="pubmed">35995894</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C, Rees G. Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychol Health Med. 2018;23(2):127&#x2013;140. doi:10.1080/13548506.2016.1274040</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13548506.2016.1274040</ArticleId><ArticleId IdType="pubmed">28064517</ArticleId></ArticleIdList></Reference><Reference><Citation>Obeid A, Gao XX, Ali FS, et al. Loss to follow-up among patients with neovascular age-related macular degeneration who received intravitreal anti-vascular endothelial growth factor injections. JAMA Ophthalmol. 2018;136(11):1251&#x2013;1259. doi:10.1001/jamaophthalmol.2018.3578</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2018.3578</ArticleId><ArticleId IdType="pmc">PMC6583857</ArticleId><ArticleId IdType="pubmed">30352121</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend D, Reeves BC, Taylor J, et al. Health professionals&#x2019; and service users&#x2019; perspectives of shared care for monitoring wet age-related macular degeneration: a qualitative study alongside the ECHoES trial. BMJ Open. 2015;5(4):e007400. doi:10.1136/bmjopen-2014-007400</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2014-007400</ArticleId><ArticleId IdType="pmc">PMC4410127</ArticleId><ArticleId IdType="pubmed">25900465</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Connor PM, Harper CA, Brunton CL, Clews SJ, Haymes SA, Keeffe JE. Shared care for chronic eye diseases: perspectives of ophthalmologists, optometrists and patients. Med j Aust. 2012;196(10):646&#x2013;650. doi:10.5694/mja11.10856</Citation><ArticleIdList><ArticleId IdType="doi">10.5694/mja11.10856</ArticleId><ArticleId IdType="pubmed">22676881</ArticleId></ArticleIdList></Reference><Reference><Citation>Creer RC, Roberts SA, Aslam TM, et al. Treatment decisions of UK hospital optometrists and ophthalmologists in patients with nAMD: a vignette study. Ophthalmic Physiol Opt. 2019;39(6):432&#x2013;440. doi:10.1111/opo.12644</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/opo.12644</ArticleId><ArticleId IdType="pubmed">31602674</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39563807</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1948-5875</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>14</Day></PubDate></JournalIssue><Title>ACS medicinal chemistry letters</Title><ISOAbbreviation>ACS Med Chem Lett</ISOAbbreviation></Journal><ArticleTitle>Novel Plasma Kallikrein Inhibitors for Treating Multiple Diseases.</ArticleTitle><Pagination><StartPage>1808</StartPage><EndPage>1809</EndPage><MedlinePgn>1808-1809</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acsmedchemlett.4c00484</ELocationID><Abstract><AbstractText>Provided herein are novel plasma kallikrein inhibitors, pharmaceutical compositions, use of such compounds in treating hereditary angioedema, uveitis, posterior uveitis, wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy and retinal vein occlusion and processes for preparing such compounds.</AbstractText><CopyrightInformation>Published 2024 by American Chemical Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sabnis</LastName><ForeName>Ram W</ForeName><Initials>RW</Initials><Identifier Source="ORCID">0000-0001-7289-0581</Identifier><AffiliationInfo><Affiliation>Smith, Gambrell &amp; Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ACS Med Chem Lett</MedlineTA><NlmUniqueID>101521073</NlmUniqueID><ISSNLinking>1948-5875</ISSNLinking></MedlineJournalInfo><CoiStatement>The author declares no competing financial interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>20</Day><Hour>11</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>20</Day><Hour>11</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>20</Day><Hour>4</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39563807</ArticleId><ArticleId IdType="pmc">PMC11571081</ArticleId><ArticleId IdType="doi">10.1021/acsmedchemlett.4c00484</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Smith T. D.; Riedl M. A. The future of therapeutic options for hereditary angioedem. Ann. Allergy, Asthma Immunol. 2024, 133, 380&#x2013;390. 10.1016/j.anai.2024.04.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.anai.2024.04.029</ArticleId><ArticleId IdType="pubmed">38679158</ArticleId></ArticleIdList></Reference><Reference><Citation>Valerieva A.; Caballero T.; Magerl M.; Frade J. P.; Audhya P. K.; Craig T. Advent of oral medications for the treatment of hereditary angioedema. Clin. Transl. Allergy 2024, 14, e12391.10.1002/clt2.12391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/clt2.12391</ArticleId><ArticleId IdType="pmc">PMC11431061</ArticleId><ArticleId IdType="pubmed">39331535</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar A.; Nwagwu C.; Craig T. An Overview of Hereditary Angioedema for the Primary Care Physician. Med. Clin. North Am. 2024, 108, 747&#x2013;755. 10.1016/j.mcna.2023.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcna.2023.08.005</ArticleId><ArticleId IdType="pubmed">38816115</ArticleId></ArticleIdList></Reference><Reference><Citation>Fei X.; Jung S.; Kwon S.; Kim J.; Corson T. W.; Seo S&#x2013;Y. Challenges and opportunities of developing small-molecule therapies for age-related macular degeneration. Arch. Pharm. Res. 2024, 47, 538&#x2013;557. 10.1007/s12272-024-01503-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12272-024-01503-3</ArticleId><ArticleId IdType="pubmed">38902481</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabnis R. W. Novel Plasma Kallikrein Inhibitors for Treating Hereditary Angioedema, Diabetic Macular Edema, and Diabetic Retinopathy. ACS Med. Chem. Lett. 2023, 14, 1491&#x2013;1492. 10.1021/acsmedchemlett.3c00441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsmedchemlett.3c00441</ArticleId><ArticleId IdType="pmc">PMC10641894</ArticleId><ArticleId IdType="pubmed">37974944</ArticleId></ArticleIdList></Reference><Reference><Citation>Do T.; Riedl M. A. Current and Emerging Therapeutics in Hereditary Angioedema. Immunol. Allergy Clin. North Am. 2024, 44, 561&#x2013;576. 10.1016/j.iac.2024.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.iac.2024.03.009</ArticleId><ArticleId IdType="pubmed">38937016</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>